PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HILLE, R; NISHINO, T				HILLE, R; NISHINO, T			FLAVOPROTEIN STRUCTURE AND MECHANISM .4. XANTHINE-OXIDASE AND XANTHINE DEHYDROGENASE	FASEB JOURNAL			English	Review						ENZYME KINETICS; ELECTRON TRANSFER; ISCHEMIA REPERFUSION	DINUCLEOTIDE-BINDING-SITE; REDUCTIVE HALF-REACTION; AMINO-ACID-SEQUENCE; ELECTRON-TRANSFER; DROSOPHILA-MELANOGASTER; O-2-DEPENDENT TYPES; MOLECULAR-OXYGEN; PULSE-RADIOLYSIS; MOLYBDENUM; FLAVIN	Xanthine oxidase and xanthine dehydrogenase are enzymes involved in the metabolism of purines and pyrimidines in various organisms. Their relationship to one another has been the subject of considerable debate, primarily because of their proposed roles in ischemia/reperfusion damage in tissues. Differences in the kinetics and oxidation-reduction behavior of the two forms are accounted for by the presence in the dehydrogenase of a binding site for NAD(+), as well as a substantially lower reduction potential for the flavin FADH ./FADH(2) couple of the dehydrogenase relative to the oxidase. This review presents recent advances of our understanding of the biochemistry and molecular biology of these systems, including a model for the overall morphology of xanthine oxidizing enzymes. The evidence that the two enzymes represent alternate forms of the same gene product, in some cases reversibly interconvertible between one another, is discussed.	NIPPON MED COLL,DEPT BIOCHEM & MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	Nippon Medical School	HILLE, R (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.				NIAMS NIH HHS [AR 38917] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAYA Y, 1990, J BIOL CHEM, V265, P14170; [Anonymous], 1993, ADV INORGANIC CHEM, DOI DOI 10.1016/S0898-8838(08)60181-6; BARBER MJ, 1977, BIOCHEM J, V163, P279, DOI 10.1042/bj1630279; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8522, DOI 10.1021/bi00099a004; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1993, J BIOL CHEM, V268, P18685; HUNT J, 1994, J BIOL CHEM, V269, P18914; ICHIDA K, 1993, GENE, V133, P279; KEITH TP, 1987, GENETICS, V116, P67; KIM JH, 1993, J BIOL CHEM, V268, P44; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1994, J BIOCHEM, V116, P1; NISHINO T, 1982, J BIOL CHEM, V257, P7348; NISHINO T, 1987, BIOCHEMISTRY-US, V26, P3068, DOI 10.1021/bi00385a018; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; RATNAM K, 1993, BIOCHEM BIOPH RES CO, V194, P1097, DOI 10.1006/bbrc.1993.1934; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOUENES U, 1994, EUR J BIOCHEM, V220, P901; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690	42	336	346	3	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					995	1003		10.1096/fasebj.9.11.7649415	http://dx.doi.org/10.1096/fasebj.9.11.7649415			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649415				2022-12-28	WOS:A1995RP99600003
J	SCHWIMMER, S				SCHWIMMER, S			DEPOLYMERASE AMYLO-CHAIN REACTION - UNTYING THE GORDIAN-KNOT OF RAW STARCH DIGESTION	FASEB JOURNAL			English	Article							GLUCOAMYLASE				SCHWIMMER, S (corresponding author), USDA ARS, WESTERN REG RES CTR, 800 BUCHANAN ST, ALBANY, CA 94710 USA.							ANNISON G, 1994, ANNU REV NUTR, V14, P297, DOI 10.1146/annurev.nu.14.070194.001501; HAN IY, 1987, BIOTECHNOL BIOENG, V30, P225, DOI 10.1002/bit.260300212; HASSID WZ, 1970, BIOGRAPHICAL MEMOIRS, V10, P1; HAYASHIDA S, 1989, AGR BIOL CHEM TOKYO, V53, P135, DOI 10.1080/00021369.1989.10869272; HSKA N, 1994, STARCH, V46, P480; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MONMA M, 1989, STARCH-STARKE, V41, P382, DOI 10.1002/star.19890411005; Northrop J. H., 1939, CRYSTALLINE ENZYMES; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; SCHWIMMER S, 1945, J BIOL CHEM, V161, P219; SCHWIMMER S, 1945, FED PROC, V4, P102; SIGURSKJOLD BW, 1994, EUR J BIOCHEM, V225, P133, DOI 10.1111/j.1432-1033.1994.00133.x; SISSONS MJ, 1994, J CEREAL SCI, V19, P161, DOI 10.1006/jcrs.1994.1022; Sumner JB, 1926, J BIOL CHEM, V69, P435; TANAKA A, 1995, J BIOCHEM-TOKYO, V117, P1024, DOI 10.1093/oxfordjournals.jbchem.a124801; WAHLBERG J, 1948, NORD MED, V40, P1831, DOI 10.1002/hlca.19480310648; WELLER CL, 1984, T AM SOC AGR ENG, V7, P1911	17	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1118	1119		10.1096/fasebj.9.11.7649412	http://dx.doi.org/10.1096/fasebj.9.11.7649412			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649412				2022-12-28	WOS:A1995RP99600018
J	CHANCE, B				CHANCE, B			THEOS LABORATORY	FASEB JOURNAL			English	Item About an Individual											CHANCE, B (corresponding author), UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,D501 RICHARDS BLDG,PHILADELPHIA,PA 19104, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					692	693		10.1096/fasebj.9.8.7768363	http://dx.doi.org/10.1096/fasebj.9.8.7768363			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768363				2022-12-28	WOS:A1995RC10600018
J	LELKES, PI; RAMOS, EM; CHICK, DM; LIU, JD; UNSWORTH, BR				LELKES, PI; RAMOS, EM; CHICK, DM; LIU, JD; UNSWORTH, BR			MICROGRAVITY DECREASES TYROSINE-HYDROXYLASE EXPRESSION IN RAT ADRENALS	FASEB JOURNAL			English	Article						SPACE BIOLOGY; CHROMAFFIN CELLS; CATECHOLAMINES; ADRENAL MEDULLA	DOPAMINE-BETA-HYDROXYLASE; REPEATED IMMOBILIZATION STRESS; MESSENGER-RNA LEVELS; PROTEIN-KINASE-C; MEDULLARY CELLS; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; GENE-EXPRESSION; FOS; TRANSCRIPTION	During spaceflight, alterations in blood and urinary catecholamine (CA) levels have been observed, yet the cellular/molecular mechanisms leading to these changes are not known. We used molecular, immunological, and biochemical approaches to analyze in situ the expression of catecholamine enzymes in adrenal medullary chromaffin cells of rats flown for 6 days on board Space Shuttle mission STS-54. Exposure to microgravity (10(-6) g) resulted in a 35% inhibition of both the expression and the specific activity of tyrosine hydroxylase (TH), the rate-limiting step in the cascade of CA synthesis. By contrast, the expression, specific activity, and immunoreactivity of other catecholamine-synthesizing enzymes, e.g., phenylethanolamine-N-methyl-transferase (PNMT), were not altered. The total tissue CA contents were reduced, concomitant with a decrease in the epinephrine:norepinephrine ratio. These results are in line with reports of other gravity-sensitive cellular effects and suggest that the inhibition of TH expression might be due to a direct effect of microgravity on PKC-dependent signal transduction pathways in chromaffin cells.	MARQUETTE UNIV,DEPT BIOL,MILWAUKEE,WI 53201	Marquette University	LELKES, PI (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,DEPT MED,CELL BIOL LAB,MILWAUKEE CLIN CAMPUS,MILWAUKEE,WI 53201, USA.		Lelkes, Peter I/S-1751-2019; Lelkes, Peter/HGA-2907-2022					Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BARUCHIN A, 1990, J NEUROCHEM, V54, P1769, DOI 10.1111/j.1471-4159.1990.tb01232.x; COGOLI A, 1993, J LEUKOCYTE BIOL, V53, P569, DOI 10.1002/jlb.53.5.569; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; DEGROOT RP, 1990, J CELL SCI, V97, P33; DEGROOT RP, 1991, AVIAT SPACE ENVIR MD, V62, P37; Ferre F, 1992, PCR Methods Appl, V2, P1; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GRINDELAND R, 1987, AM J PHYSIOL, V252, pR209, DOI 10.1152/ajpregu.1987.252.2.R209; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; HOLLEY DC, 1991, AVIAT SPACE ENVIR MD, V62, P953; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ILYIN EA, 1983, AVIAT SPACE ENVIR MD, V54, pS9; KEIL L, 1992, J APPL PHYSIOL, V73, pS166, DOI 10.1152/jappl.1992.73.2.S166; KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7; KILBOURNE EJ, 1991, J NEUROSCI METH, V40, P193, DOI 10.1016/0165-0270(91)90068-B; KIM KS, 1993, J BIOL CHEM, V268, P15689; LEACH CS, 1976, AVIAT SPACE ENVIR MD, V47, P402; LEVINE RA, 1984, ANAL BIOCHEM, V143, P205, DOI 10.1016/0003-2697(84)90577-3; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERZEY M, 1989, NUCLEIC ACIDS RES, V17, P2125; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; NANKOVA B, 1993, J NEUROCHEM, V61, P776; POLLARD HB, 1979, ANAL BIOCHEM, V99, P281, DOI 10.1016/S0003-2697(79)80007-X; ROSENHECK K, 1987, STIMULUS SECRETION C; SCHMITT DA, 1993, J CELL SCI, V104, P805; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; STACHOWIAK MK, 1990, ONCOGENE, V5, P69; STACHOWIAK MK, 1990, J BIOL CHEM, V265, P4694; TAKIYYUDDIN MA, 1993, HYPERTENSION, V21, P674, DOI 10.1161/01.HYP.21.5.674; TISCHLER ME, 1992, AM I AERONAUT AUSTRO, V92, P1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; ZHU YS, 1993, MOL PHARMACOL, V44, P328; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	42	16	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1177	1182		10.1096/fasebj.8.14.7958625	http://dx.doi.org/10.1096/fasebj.8.14.7958625			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958625				2022-12-28	WOS:A1994PT12800014
J	DEDUVE, C				DEDUVE, C			BORN-AGAIN GLUCAGON .41.	FASEB JOURNAL			English	Article											DEDUVE, C (corresponding author), INT INST CELLULAR & MOLEC PATHOL, 75 AVE HIPPOCRATE, B-1200 BRUSSELS, BELGIUM.							Abel JJ, 1926, P NATL ACAD SCI USA, V12, P132, DOI 10.1073/pnas.12.2.132; BOUCKAERT JP, 1947, PHYSIOL REV, V27, P39, DOI 10.1152/physrev.1947.27.1.39; Bridge EM, 1938, B JOHNS HOPKINS HOSP, V62, P408; BROMER WW, 1957, J AM CHEM SOC, V79, P2807, DOI 10.1021/ja01568a038; Cori CF, 1928, J BIOL CHEM, V76, P755; DEDUVE C, 1947, CR SOC BIOL, V141, P1147; DEDUVE C, 1953, LANCET, V265, P99; DEDUVE C, 1945, GLUCOSE INSULINE DIA; DEDUVE C, 1969, LYSOSOMES BIOLOGY PA, V1, P1; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; FIESSINGER N., 1937, COMPT REND SOC BIOL, V124, P952; Geiling EMK, 1930, J PHARMACOL EXP THER, V39, P369; Lundsgaard E, 1939, SKAND ARCH PHYSIOL, V81, P11, DOI 10.1111/j.1748-1716.1939.tb01310.x; Scott DA, 1934, BIOCHEM J, V28, P1592, DOI 10.1042/bj0281592; SHIPLEY RA, 1945, AM J PHYSIOL, V144, P51, DOI 10.1152/ajplegacy.1945.144.1.51; STAUB A., 1955, JOUR BIOL CHEM, V214, P619; SUTHERLAND EW, 1948, J BIOL CHEM, V175, P663; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; SUTHERLAND EW, 1948, J BIOL CHEM, V172, P737	19	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					979	981		10.1096/fasebj.8.12.8088464	http://dx.doi.org/10.1096/fasebj.8.12.8088464			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088464				2022-12-28	WOS:A1994PG29300011
J	KUBOHARA, Y; OKAMOTO, K				KUBOHARA, Y; OKAMOTO, K			CYTOPLASMIC CA2+ AND H+ CONCENTRATIONS DETERMINE CELL FATE IN DICTYOSTELIUM-DISCOIDEUM	FASEB JOURNAL			English	Article						THAPSIGARGIN; CALCIUM; DIFFERENTIATION-INDUCING FACTOR; STALK DIFFERENTIATION	PRESPORE-SPECIFIC GENE; INTRACELLULAR PH; FREE CALCIUM; PRESTALK CELLS; CYCLIC-AMP; TUMOR PROMOTER; SLIME-MOLD; ACID LOAD; DIFFERENTIATION; THAPSIGARGIN	A putative morphogen, called differentiation-inducing factor (DIF), is essential for stalk cell differentiation in the cellular slime mold, Dictyostelium discoideum. To investigate the relationship between the signal molecule (DIF) and the concentrations of cytoplasmic calcium ions and proton, we have examined the effects of thapsigargin (Tg) and 5,5-dimethyl-2,4-oxazolidinedione (DMO) on cell differentiation of a mutant strain HM44, which is defective in DIF production. Tg is a specific inhibitor of the Ca2+-ATPase present in endoplasmic and sarcoplasmic reticula, and raises the cytoplasmic calcium concentration. DMO is a reagent that decreases intracellular pH. When HM44 cells were incubated with Tg or DMO in the absence of DIF, a fraction of the cells was induced to stalk cells. If added together, these reagents induced stalk cell differentiation at high efficiency (70-80%), comparable to that attained with exogenous DIF. In the presence of the reagents, the efficiency was not much affected by lowering cell density, which suggests that the effect (stalk induction) of these reagents was not exerted through the stimulation of DIF production. Thus, these results indicate that a rise in cytoplasmic calcium and proton concentrations triggers stalk cell differentiation possibly by mimicking the roles of DIF.	KYOTO UNIV, FAC SCI, DEPT BOT, KYOTO 60601, JAPAN	Kyoto University								ABE T, 1989, PROTOPLASMA, V151, P175, DOI 10.1007/BF01403457; AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; BEATTY DM, 1993, ENDOCRINOLOGY, V133, P972, DOI 10.1210/en.133.3.972; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BONNER JT, 1970, P NATL ACAD SCI USA, V65, P110; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; EARLY AE, 1988, DEVELOPMENT, V103, P519; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRIDOLF T, 1992, BIOCHEM BIOPH RES CO, V184, P878, DOI 10.1016/0006-291X(92)90672-8; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; GERSON DF, 1977, J CELL PHYSIOL, V91, P297, DOI 10.1002/jcp.1040910214; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HORN F, 1993, P INT DICTYOSTELIUM; INOUYE K, 1988, J CELL SCI, V91, P109; INOUYE K, 1988, DEVELOPMENT, V104, P669; INOUYE K, 1985, J CELL SCI, V76, P235; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JEMYN KA, 1987, DEVELOPMENT, V100, P745; KAY RR, 1986, J CELL SCI, V83, P165; KAY RR, 1989, DEVELOPMENT, V107, P81; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KUBOHARA Y, 1993, EXP CELL RES, V204, P382, DOI 10.1006/excr.1993.1047; KUBOHARA Y, 1993, FEBS LETT, V322, P73, DOI 10.1016/0014-5793(93)81114-F; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MAEDA Y, 1989, DIFFERENTIATION, V41, P169, DOI 10.1111/j.1432-0436.1989.tb00744.x; MAEDA Y, 1973, EXP CELL RES, V82, P125, DOI 10.1016/0014-4827(73)90253-X; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MORLEY P, 1992, CELL CALCIUM, V13, P263, DOI 10.1016/0143-4160(92)90014-J; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; NUCCITELLI R, 1982, INTRACELLULAR PH ITS, P1; RAMESH KW, 1990, J CLIN INVEST, V85, P1296; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SARAN S, 1994, IN PRESS FEBS LETT; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/0167-4889(88)90200-5; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SHEN SS, 1978, NATURE, V272, P253, DOI 10.1038/272253a0; SOBOLEWSKI A, 1988, DEV BIOL, V127, P296, DOI 10.1016/0012-1606(88)90316-8; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIRLAPUR UK, 1991, DIFFERENTIATION, V48, P137, DOI 10.1111/j.1432-0436.1991.tb00252.x; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VANDUIJN B, 1991, P NATL ACAD SCI USA, V88, P4951, DOI 10.1073/pnas.88.11.4951; WANG M, 1989, DEVELOPMENT, V105, P569; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WEIJER CJ, 1984, J CELL SCI, V70, P133; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WILLIAMS JG, 1989, DEVELOPMENT, V107, P91; YAMADA Y, 1992, DEV BIOL, V149, P235, DOI 10.1016/0012-1606(92)90280-T; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119	66	83	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					869	874		10.1096/fasebj.8.11.8070636	http://dx.doi.org/10.1096/fasebj.8.11.8070636			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070636				2022-12-28	WOS:A1994PC88500010
J	STARE, FJ				STARE, FJ			WHEAT-GERM, CORN GERM AND OAT PROTEINS REVISITED - AND MORE FROM ABOUT 50 YEARS AGO	FASEB JOURNAL			English	Editorial Material											STARE, FJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.							Hegsted DM, 1944, J NUTR, V27, P141, DOI 10.1093/jn/27.2.141; HEGSTED DM, 1946, J LAB CLIN MED, V31, P261; HEGSTED DM, 1944, AM ANN, P1; McKibbin John M., 1943, JOUR AMER DIETETIC ASSOC, V19, P331; STARE F. J., 1944, Federation Proceedings. Federation of American Societies for Experimental Biology, V3, P120; Stare FJ, 1943, NEW ENGL J MED, V228, P809, DOI 10.1056/NEJM194306242282501; STARE FJ, 1945, JAMA-J AM MED ASSOC, V127, P1120; STARE FJ, 1945, JAMA-J AM MED ASSOC, V127, P985; Stare FJ, 1943, ANN INTERN MED, V19, P735, DOI 10.7326/0003-4819-19-5-735; STARE FJ, 1991, ADV NUTRITION; Stare FJ, 1943, AM J PUBLIC HEALTH N, V33, P1444, DOI 10.2105/AJPH.33.12.1444	11	0	0	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					551	552		10.1096/fasebj.8.8.8181675	http://dx.doi.org/10.1096/fasebj.8.8.8181675			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181675				2022-12-28	WOS:A1994NM36400014
J	TEPLY, LJ				TEPLY, LJ			BIOCHEMICAL TEAMWORK - REVEALING THE NIACIN-TRYPTOPHAN RELATIONSHIP .31.	FASEB JOURNAL			English	Editorial Material																		Krehl W. A., 1946, JOUR NUTRITION, V31, P85; KREHL WA, 1945, SCIENCE, V101, P283, DOI 10.1126/science.101.2620.283; KREHL WA, 1945, SCIENCE, V101, P489, DOI 10.1126/science.101.2628.489; PERLZWEIG WA, 1947, J BIOL CHEM, V167, P511; ROSEN F, 1946, J BIOL CHEM, V163, P343; SARRETT HP, 1947, J BIOL CHEM, V167, P293; SARRETT HP, 1992, FASEB J, V6, P2487	7	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1300	1300		10.1096/fasebj.7.13.8405816	http://dx.doi.org/10.1096/fasebj.7.13.8405816			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405816				2022-12-28	WOS:A1993MB37600015
J	ANGLISTER, J; SCHERF, T; ZILBER, B; LEVY, R; ZVI, A; HILLER, R; FEIGELSON, D				ANGLISTER, J; SCHERF, T; ZILBER, B; LEVY, R; ZVI, A; HILLER, R; FEIGELSON, D			2-DIMENSIONAL NMR INVESTIGATIONS OF THE INTERACTIONS OF ANTIBODIES WITH PEPTIDE ANTIGENS	FASEB JOURNAL			English	Article						PROTEIN STRUCTURE; FAB FRAGMENT; NOE SPECTROSCOPY	HUMAN IMMUNODEFICIENCY VIRUS; CHOLERA-TOXIN; SYNTHETIC PEPTIDES; MONOCLONAL-ANTIBODY; COMBINING SITE; FV FRAGMENT; 3-DIMENSIONAL STRUCTURE; ANTIPEPTIDE ANTIBODIES; HYPERVARIABLE REGIONS; B-SUBUNIT	To increase our understanding of the molecular basis for antibody specificity and for the cross-reactivity of anti-peptide antibodies with native proteins it is important to study the three-dimensional structure of antibody complexes with their peptide antigens. For this purpose it may not be necessary to solve the structure of the whole antibody complex but rather to concentrate on elucidating the combining site structure, the interactions of the antibody with its antigen and the bound peptide conformation. We have developed an NMR methodology based on two-dimensional difference spectrum measurements which extract the information concerning antibody-peptide interactions and intramolecular interactions in the bound ligand from the crowded and unresolved spectrum of the Fab complex. These measurements yield restraints on interproton distances in the complex which are used to dock the peptide into calculated models for the antibodies' combining sites. Comparison of the interactions of three antibodies against a cholera toxin peptide (CTP3), which differ in their cross-reactivity with the toxin, yields information about the size and conformation of antigenic determinants recognized by antibodies, the structure of their combining sites and relationships between antibodies' primary structure, and their interactions with peptide antigens.			ANGLISTER, J (corresponding author), WEIZMANN INST SCI, DEPT STRUCT BIOL, IL-76100 REHOVOT, ISRAEL.							ALBRAND JP, 1979, INT J BIOL MACROMOL, V1, P37, DOI 10.1016/0141-8130(79)90008-4; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANGLISTER J, 1985, NATURE, V315, P65, DOI 10.1038/315065a0; ANGLISTER J, 1989, BIOCHEMISTRY-US, V28, P3360, DOI 10.1021/bi00434a035; ANGLISTER J, 1990, Q REV BIOPHYS, V23, P175, DOI 10.1017/S0033583500005539; ANGLISTER J, 1988, BIOCHEMISTRY-US, V27, P717, DOI 10.1021/bi00402a034; ANGLISTER J, 1990, BIOCHEMISTRY-US, V29, P921, DOI 10.1021/bi00456a011; ARNON R, 1986, TRENDS BIOCHEM SCI, V11, P521, DOI 10.1016/0968-0004(86)90088-5; BOTHNERB.AA, 1973, ANN NY ACAD SCI, V222, P668, DOI 10.1111/j.1749-6632.1973.tb15293.x; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CUNG MT, 1991, BIOPOLYMERS, V31, P769, DOI 10.1002/bip.360310622; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GIVOL D, 1991, MOL IMMUNOL, V28, P1379, DOI 10.1016/0161-5890(91)90040-Q; GLAUDEMANS CPJ, 1990, BIOCHEMISTRY-US, V29, P10906, DOI 10.1021/bi00501a007; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JACOB CO, 1983, P NATL ACAD SCI-BIOL, V80, P7611, DOI 10.1073/pnas.80.24.7611; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SHOHAM M, 1993, IN PRESS J MOL BIOL; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWARD MW, 1987, IMMUNOL TODAY, V8, P51, DOI 10.1016/0167-5699(87)90239-8; TAKAHASHI H, 1991, BIOCHEMISTRY-US, V30, P2840, DOI 10.1021/bi00225a016; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TSANG P, 1992, BIOCHEMISTRY-US, V31, P3862, DOI 10.1021/bi00130a018; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZILBER B, 1990, BIOCHEMISTRY-US, V29, P10032, DOI 10.1021/bi00495a004	45	14	15	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1154	1162		10.1096/fasebj.7.12.8375614	http://dx.doi.org/10.1096/fasebj.7.12.8375614			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375614				2022-12-28	WOS:A1993LW81700010
J	GERSHONI, JM; DENISOVA, G; RAVIV, D; SMORODINSKY, NI; BUYANER, D				GERSHONI, JM; DENISOVA, G; RAVIV, D; SMORODINSKY, NI; BUYANER, D			HIV BINDING TO ITS RECEPTOR CREATES SPECIFIC EPITOPES FOR THE CD4/GP120 COMPLEX	FASEB JOURNAL			English	Article						AIDS; HIV; RECEPTOR LIGAND INTERACTIONS; VACCINE	AIDS PATHOGENESIS; VIRUS BINDING; FUSION; CD4; ENVELOPE; IDENTIFICATION; RECOGNIZES; ANTIBODIES; INFECTION; CELLS	Effective vaccines against the human immunodeficiency virus (HIV) must cope with the genetic variation of the viral envelope (gp120) to combat or prevent acquired immunodeficiency syndrome (AIDS). Here we describe novel epitopes that are accentuated when gp120 complexes with its receptor (CD4). The presentation of these epitopes results through conformational rearrangements in the CD4/gp120 complex. Monoclonal antibodies directed to these epitopes inhibit syncytium formation, thus indicating the potential use of these epitopes as subunit vaccines.			GERSHONI, JM (corresponding author), TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL.							ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; GERSHONI JM, 1988, P NATL ACAD SCI USA, V85, P4087, DOI 10.1073/pnas.85.11.4087; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HILLMAN K, 1990, J IMMUNOL, V144, P2131; OHNO T, 1991, P NATL ACAD SCI USA, V88, P10726, DOI 10.1073/pnas.88.23.10726; PROFY AT, 1990, J IMMUNOL, V144, P4641; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0	14	62	75	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1185	1187		10.1096/fasebj.7.12.7690724	http://dx.doi.org/10.1096/fasebj.7.12.7690724			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	7690724				2022-12-28	WOS:A1993LW81700014
J	WRIGHT, SC; ZHONG, J; ZHENG, H; LARRICK, JW				WRIGHT, SC; ZHONG, J; ZHENG, H; LARRICK, JW			NICOTINE INHIBITION OF APOPTOSIS SUGGESTS A ROLE IN TUMOR PROMOTION	FASEB JOURNAL			English	Article						APOPTOSIS; DNA FRAGMENTATION; TUMOR NECROSIS FACTOR; NICOTINE	PROGRAMMED CELL-DEATH; PROTEIN-KINASE-C; DNA FRAGMENTATION; NECROSIS FACTOR; LEUKEMIA-CELLS; N-NITROSAMINES; PHORBOL ESTERS; INDUCTION; LYMPHOCYTES; ACTIVATION	Recent evidence indicates that cell death through apoptosis may be an important mechanism to prevent tumor development. Therefore, agents that inhibit apoptosis may function as tumor promotors. The purpose of this study was to determine the effects of nicotine on the process of apoptosis. The results demonstrate that nicotine inhibits apoptosis induced by diverse stimuli including tumor necrosis factor (TNF), UV light, chemotherapeutic drugs, and calcium ionophore. This phenomenon was observed in normal and transformed cells derived from a variety of species and tissues, including tumor cell types related to tobacco use. The major nicotine metabolite, cotinine, also inhibited apoptosis, whereas N-nitrosodiethylamine, a carcinogen found in tobacco, was without effect. Therefore, nicotine-mediated inhibition of apoptosis may contribute to the pathogenesis of tobacco-related cancer as well as decrease the efficacy of cancer therapies.			WRIGHT, SC (corresponding author), PALO ALTO INST MOLEC MED,MT VIEW,CA 94043, USA.				NCI NIH HHS [CA47669] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BURSCH W, 1992, TIPS, V13, P243; DAVIES BD, 1982, MOL CELL BIOCHEM, V44, P23, DOI 10.1007/BF00573842; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; HALEY NJ, 1985, CLIN CHEM, V31, P1598; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; HOFFMANN D, 1981, CANCER RES, V41, P4305; HOFFMANN D, 1985, CANCER RES, V45, P935; KANTER P, 1984, BIOCHEM BIOPH RES CO, V118, P392, DOI 10.1016/0006-291X(84)91315-9; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KIZAKI H, 1989, J IMMUNOL, V143, P1790; LASTER SM, 1988, J IMMUNOL, V141, P2629; LUCAS M, 1991, FEBS LETT, V279, P19, DOI 10.1016/0014-5793(91)80239-Y; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; MELTZER LT, 1980, PSYCHOPHARMACOLOGY, V68, P283, DOI 10.1007/BF00428116; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RUSSELL MAH, 1975, BRIT MED J, V2, P414, DOI 10.1136/bmj.2.5968.414; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SELLINS KS, 1987, J IMMUNOL, V139, P3199; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; TUOMINEN RK, 1992, J NEUROCHEM, V58, P1652, DOI 10.1111/j.1471-4159.1992.tb10037.x; VINCEK WC, 1981, J PHARM SCI, V70, P1292, DOI 10.1002/jps.2600701131; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WIN DM, 1981, NEW ENGL J MED, V304, P745; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WU JM, 1990, FASEB J, V4, pA1975; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; 1986, TOBACCO SMOKING, V38, P199	41	163	170	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1045	1051		10.1096/fasebj.7.11.8370474	http://dx.doi.org/10.1096/fasebj.7.11.8370474			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370474				2022-12-28	WOS:A1993LT83900010
J	GRAY, MW; CEDERGREN, R				GRAY, MW; CEDERGREN, R			THE NEW AGE OF RNA	FASEB JOURNAL			English	Editorial Material									UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal	GRAY, MW (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,DEPT BIOCHEM,PROGRAM EVOLUT BIOL,HALIFAX B3H 4H7,NS,CANADA.			Gray, Michael/0000-0001-7125-2625				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BURKE JM, 1993, FASEB J, V7, P106, DOI 10.1096/fasebj.7.1.8422956; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; GAUTHERET D, 1993, FASEB J, V7, P97, DOI 10.1096/fasebj.7.1.7678567; GRAY MW, 1993, FASEB J, V7, P64, DOI 10.1096/fasebj.7.1.8422976; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MCCLAIN WH, 1993, FASEB J, V7, P72, DOI 10.1096/fasebj.7.1.8422977; NOLLER HF, 1993, FASEB J, V7, P87, DOI 10.1096/fasebj.7.1.8422979; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; ORGEL LE, 1993, FASEB J, V7, P238, DOI 10.1096/fasebj.7.1.7678564; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	16	11	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					4	6		10.1096/fasebj.7.1.7678565	http://dx.doi.org/10.1096/fasebj.7.1.7678565			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678565				2022-12-28	WOS:A1993KH88000002
J	SCHNEIDER, D; GOLD, L; PLATT, T				SCHNEIDER, D; GOLD, L; PLATT, T			SELECTIVE ENRICHMENT OF RNA SPECIES FOR TIGHT-BINDING TO ESCHERICHIA-COLI RHO-FACTOR	FASEB JOURNAL			English	Article						RHO-FACTOR; RNA BINDING; RNA STRUCTURE; SELEX; TRANSCRIPTION TERMINATION	DEPENDENT TRANSCRIPTION TERMINATION; CONSENSUS SEQUENCE; BASE-PAIRS; PROTEIN; SITE; POLYMERASE	We have applied the SELEX procedure (systematic evolution of ligands by exponential enrichment) to obtain RNA molecules that bind tightly to the Escherichia coli transcription termination factor rho. The starting pool was a population of RNA molecules 77 nucleotides (nt) long, in which was embedded a cassette of 30 nt of randomized sequence. The apparent dissociation constant of this RNA pool for hexameric rho factor was about 1 muM. After eight rounds of selection by filter binding, with RNA in either 10-fold or 40 to 100-fold excess at each step, the dissociation constant of the selected RNA had dropped by more than 500-fold to about 1 nm. Analysis of 29 clonal isolates from the population revealed that five had K(D)S substantially weaker than 10 nM (presumably background carryover), 40% were C-rich (as might have been predicted from rho's known substrate binding), and 40% had a strikingly preserved potential hairpin, in most cases of 6 base pairs with a 3 nt CAA loop and preceded by a CCCCA consensus. The rho-dependent trp t' terminator region includes a related potential hairpin structure; however, it is energetically unfavorable. The implications of the sequence findings for elucidating both static and dynamic aspects of rho factor recognition and response to its RNA target site are discussed.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Rochester; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM 35658, GM 28685, GM 19963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035658, R01GM019963, R37GM019963, R01GM028685] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; HART CM, 1991, J BIOL CHEM, V266, P24140; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; SCHNEIDER D, 1992, IN PRESS J MOL BIOL; SHARP JA, 1986, J BIOL CHEM, V261, P2524; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1992, POLYM CHAIN REACTION; ZALATAN F, 1992, J BIOL CHEM, V267, P19082	21	55	67	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					201	207		10.1096/fasebj.7.1.7678562	http://dx.doi.org/10.1096/fasebj.7.1.7678562			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678562				2022-12-28	WOS:A1993KH88000031
J	ESMON, CT				ESMON, CT			THROMBOMODULIN AS A MODEL OF MOLECULAR MECHANISMS THAT MODULATE PROTEASE SPECIFICITY AND FUNCTION AT THE VESSEL SURFACE	FASEB JOURNAL			English	Review						THROMBIN; PROTEIN; ENDOTHELIUM; CALCIUM	CARBOXYGLUTAMIC ACID RESIDUES; FACTOR-LIKE DOMAINS; BLOOD-COAGULATION; COFACTOR ACTIVITY; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; FACTOR-X; THROMBIN; BINDING; SITE	The protein C anticoagulant system generates an ''on demand'' physiologic anticoagulant response, The pathway is initiated when thrombin binds to the endothelial cell thrombin binding protein, thrombomodulin. The complex exhibits dramatically altered macromolecular specificity, It rapidly cleaves the protein C zymogen to form the anticoagulant, activated protein C, Complex formation between thrombin and thrombomodulin also prevents thrombin, the enzyme responsible for clot formation and a potent platelet activator, from being able to clot fibrinogen or to activate platelets, Structural, kinetic, and competition studies suggest that thrombomodulin blocks these clotting reactions by masking the binding sites for fibrinogen and the platelet thrombin receptor. Stimulation of protein C activation appears to occur through conformational changes in the extended binding pocket of thrombin, This prevents repulsive interactions with protein C that exist when the free enzyme attempts to dock with this substrate, In addition to protein-protein interactions, thrombomodulin has a covalently associated chondroitin sulfate moiety, Chondroitin sulfate binds to a basic surface on thrombin that is also involved in heparin interaction. The chondroitin sulfate enhances the affinity of thrombin for thrombomodulin approximately 10- to 20-fold, making thrombomodulin a more potent inhibitor of coagulation, altering thrombin's conformation and specificity, and accelerating thrombin inhibition by the serpin, antithrombin. These properties make thrombomodulin a molecular switch ideally suited to trigger an anticoagulant response when too much thrombin is generated. The importance of the system is documented by the clinical observation that patients deficient in protein C often die of massive thrombotic complications that can be reversed or prevented by infusion of protein C.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	ESMON, CT (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [R37 HL 30340, R01 HL 29807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; CREY ST, 1994, J IMMUNOL, V153, P3664; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEMUNK GAW, 1993, BIOCHEM J, V290, P655, DOI 10.1042/bj2900655; DITTMAN WA, 1991, TRENDS CARDIOVAS MED, V1, P331, DOI 10.1016/1050-1738(91)90070-U; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; HEEB MJ, 1989, BLOOD, V73, P446; HOGG PJ, 1992, J BIOL CHEM, V267, P703; HOOPER WC, 1994, BLOOD, V84, P483, DOI 10.1182/blood.V84.2.483.bloodjournal842483; HORIE S, 1994, BIOCHEM J, V301, P683, DOI 10.1042/bj3010683; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; LASZIK Z, 1994, LAB INVEST, V70, P862; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIN JH, 1994, J BIOL CHEM, V269, P25021; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MOLINARI A, 1992, THROMB HAEMOSTASIS, V67, P226; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PERSSON E, 1991, J BIOL CHEM, V266, P2444; QIU XY, 1992, BIOCHEMISTRY-US, V31, P11689, DOI 10.1021/bi00162a004; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1994, BLOOD, V83, P2526, DOI 10.1182/blood.V83.9.2526.bloodjournal8392526; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RIVARD GE, 1993, THROMB HAEMOSTASIS, V69, P2338; SCULLY MF, 1993, THROMB HAEMOSTASIS, V69, P448; SEMERARO N, 1993, THROMB RES, V71, P479, DOI 10.1016/0049-3848(93)90121-4; SMIRNOV MD, 1995, J CLIN INVEST, V95, P309, DOI 10.1172/JCI117657; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; TSIANG M, 1992, J BIOL CHEM, V267, P6164; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1994, J BIOL CHEM, V269, P17965; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1994, J BIOL CHEM, V269, P3590; ZHANG L, 1992, BLOOD, V80, P942; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	57	335	347	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					946	955		10.1096/fasebj.9.10.7615164	http://dx.doi.org/10.1096/fasebj.9.10.7615164			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615164				2022-12-28	WOS:A1995RK89900017
J	GALIS, ZS; SUKHOVA, GK; LIBBY, P				GALIS, ZS; SUKHOVA, GK; LIBBY, P			MICROSCOPIC LOCALIZATION OF ACTIVE PROTEASES BY IN-SITU ZYMOGRAPHY - DETECTION OF MATRIX METALLOPROTEINASE ACTIVITY IN VASCULAR TISSUE	FASEB JOURNAL			English	Article						EXTRACELLULAR MATRIX DEGRADATION; FLUORESCENT ASSAY; ATHEROSCLEROSIS	DEGRADING METALLOPROTEINASES; ATHEROSCLEROTIC PLAQUES; EXPRESSION; PROCOLLAGENASE; THROMBOSIS; METASTASIS	Many physiological and pathological processes involve tissue remodeling due in part to degradation of extracellular matrix, Several factors limit current approaches used for detection of matrix-degrading enzymes in tissues, Matrix metalloproteinases (MMPs), enzymes specialized in catabolism of extracellular matrix constituents, require processing from inactive zymogen precursors to gain enzymatic function, Presently available antibodies do not distinguish between precursor and proteolytically processed forms of MMPs. Also, ubiquitous tissue inhibitors of metalloproteinases (TIMPs) could prevent matrix degradation by MMPs even if the enzymes were in an active form, For these reasons immunocytochemistry does not provide information regarding the functional state of these enzymes, Biochemical studies of tissue extracts preclude localization and entail the possibility of artifactual activation of the enzymes consequent to tissue disruption, To obviate these problems, we have adapted substrate zymography to frozen tissue sections to assess net proteolytic activity in situ, We report here the details and the validation of this methodology, Initial experiments defined casein fluorescently labeled with resorufin as a useful substrate for detecting stromelysin, and fluoresceinated gelatin or autoradiographic emulsion as suitable for detecting gelatinolytic activity by this approach, Either TIMP-1 or the Zn chelator 1,10-phenanthroline reduced the zymographic activity in cryosections of atheroma from humans or rabbits, Inhibitors of serine proteases did not reduce the extent of substrate lysis substantially. In situ zymography preserves the fine morphological details of the tissue and can complement the study of enzyme expression by other microscopic techniques, such as immunocytochemistry, This approach may prove generally applicable for the detection of protease activity in tissue sections permitting exploration of the roles of these enzymes in pathobiology.	BRIGHAM & WOMENS HOSP,VASC MED & ATHEROSCLEROSIS UNIT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034636, R37HL034636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34636-10] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; CONSTANTINIDES P, 1989, PATHOBIOLOGY HUMAN A, P393; DAVIES MJ, 1993, BRIT HEART J, V69, P377; EISEN AZ, 1970, J INVEST DERMATOL, V55, P359, DOI 10.1111/1523-1747.ep12260483; FUSTER V, 1990, CIRCULATION, V82, P47; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2810; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P1434; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	20	239	251	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					974	980		10.1096/fasebj.9.10.7615167	http://dx.doi.org/10.1096/fasebj.9.10.7615167			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615167				2022-12-28	WOS:A1995RK89900021
J	SISODIA, SS; PRICE, DL				SISODIA, SS; PRICE, DL			ROLE OF THE BETA-AMYLOID PROTEIN IN ALZHEIMERS-DISEASE	FASEB JOURNAL			English	Review						APP PROCESSING; FAD MUTATIONS; TOXICITY; APOE	PAIRED HELICAL FILAMENTS; HEREDITARY CEREBRAL-HEMORRHAGE; PLAQUE CORE PROTEIN; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; CULTURED-CELLS; MESSENGER-RNA; GENETIC-LINKAGE; SECRETED FORM; CLEAVAGE SITE	A major histopathological hallmark of Alzheimer's disease (AD) is the presence of amyloid deposits in the parenchyma of the amygdala, hippocampus, and neocortex. The principal component of amyloid is the beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), APP occurs as several A beta-containing isoforms of 695, 751, and 770 amino acids, with the latter two APP containing a domain that shares structural and functional homologies with Kunitz serine protease inhibitors. In cultured cells, APP mature through the constitutive secretory pathway, and some cell surface-bound APP are cleaved by an enzyme, designated as alpha-secretase, within the A beta domain, an event that precludes A beta amyloidogenesis. Several studies have delineated two additional pathways of APP processing: first, an endosomal/lysosomal pathway generates a complex set of APP-related membrane-bound fragments, some of which contain the entire A beta sequence; and, second, by mechanisms which are not fully understood, A beta 1-40 is secreted into the conditioned medium in vitro and is present in cerebrospinal fluid in vivo. The intracellular sites of enzymes responsible for proteolytic cleavage at the NH2 and COOH termini of A beta, termed gamma- and beta-secretase, respectively, have not been identified. Finally, recent molecular genetic investigations have identified a variety of mutations in APP that segregate with early-onset familial AD and with hereditary cerebral hemorrhage with amyloid, Dutch type (HCHWA-D), Several of these mutations appear to influence APP processing and result in the production of higher levels or longer A beta-related peptides that are inherently more fibrillogenic, Although a variety of lines of evidence implicates APP/A beta in AD, the mechanisms by which A beta influences the biology and vulnerability of neural cells are not fully understood but are very active areas of investigation. This review focuses on the present state of our understanding of APP and A beta in the context of AD.	JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	SISODIA, SS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, 558 ROSS RES BLDG, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.				NIA NIH HHS [AG 07914, AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146, R35AG007914] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, IN PRESS J BIOL CHEM; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; IWATSUBO T, 1994, IN PRESS NEURON; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1994, IN PRESS J BIOL CHEM; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PASTERNACK JM, 1992, BIOCHEMISTRY-US, V31, P10936, DOI 10.1021/bi00159a038; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WANG R, 1991, J BIOL CHEM, V266, P16960; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	77	227	237	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					366	370		10.1096/fasebj.9.5.7896005	http://dx.doi.org/10.1096/fasebj.9.5.7896005			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896005				2022-12-28	WOS:A1995QP45100008
J	KAPPEL, CA; BIEBERICH, CJ; JAY, G				KAPPEL, CA; BIEBERICH, CJ; JAY, G			EVOLVING CONCEPTS IN MOLECULAR PATHOLOGY	FASEB JOURNAL			English	Review						TRANSGENIC MICE; GENE EXPRESSION; HUMAN DISEASE; ANIMAL MODELS	EPIDERMOLYSIS-BULLOSA SIMPLEX; AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MICE; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL BREAKPOINT; APOLIPOPROTEIN-E; VIRUS-INFECTION; KERATIN CDNAS; GENES; ATHEROSCLEROSIS	During the last decade, an understanding of the causes of many human diseases has progressed rapidly, in large measure because of the development of technologies that allow us to identify the genes that are involved. Identification of a gene that is suspected to play an important role in a particular disease opens up a whole new dimension of research to understand the molecular events that underlie the cause of that disorder. A crucial step in this process is often the development of an animal model of the disease. Again, the last decade has seen rapid advances in our ability to create such models, particularly in mice. Technologies that allow for the addition, alteration, of elimination of individual genes from the genome to create a transgenic mouse are now routine. The advantages of having a transgenic mouse model of a human disease are many. These animals often provide the first unequivocal proof that a particular gene is responsible for causing the pathological changes that occur with disease. They also can provide a system to carefully dissect the successive events that lead to the disease state, and can provide a custom-designed whole animal system to test potential therapies to treat and eventually cure the disease. Most important, new concepts relating to gene expression and gene function in disease often emerge from such transgenic studies. This review will illustrate several examples in which transgenic animals have contributed significantly to the evolution of concepts of the underlying mechanisms of human disease.	AMER RED CROSS, JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	American Red Cross			Jay, Gregory/C-6346-2013					ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRESLOW JL, 1993, CIRCULATION, V87, P16; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RYYNANEN M, 1991, AM J HUM GENET, V49, P978; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	8	9	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					583	592		10.1096/fasebj.8.9.8005386	http://dx.doi.org/10.1096/fasebj.8.9.8005386			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005386				2022-12-28	WOS:A1994NR90600005
J	KINSCHERF, R; FISCHBACH, T; MIHM, S; ROTH, S; HOHENHAUSSIEVERT, E; WEISS, C; EDLER, L; BARTSCH, P; DROGE, W				KINSCHERF, R; FISCHBACH, T; MIHM, S; ROTH, S; HOHENHAUSSIEVERT, E; WEISS, C; EDLER, L; BARTSCH, P; DROGE, W			EFFECT OF GLUTATHIONE DEPLETION AND ORAL N-ACETYL-CYSTEINE TREATMENT ON CD4(+) AND CD8(+) CELLS	FASEB JOURNAL			English	Article						GLUTATHIONE DISULFIDE; MONONUCLEAR CELLS; LYMPHOCYTES	IMMUNODEFICIENCY-VIRUS-INFECTION; BLOOD; LYMPHOCYTES; ACTIVATION; DEFICIENCY; PLASMA; ACETYLCYSTEINE; EXERCISE; CYSTINE	HIV-infected individuals and SIV-infected rhesus macaques have, on the average, decreased plasma cysteine and cystine concentrations and decreased intracellular glutathione levels. We show that the cysteine supply and the intracellular glutathione levels have a strong influence on the T cell system. A study of healthy human subjects revealed that persons with intracellular glutathione levels of 20-30 nmol/mg protein had significantly higher numbers of CD4(+) T cells than persons with either lower or higher glutathione levels. Persons who moved during a 4-week observation period from the optimal to the suboptimal range (10-20 nmol/mg) experienced, on the average, a 30% decrease in CD4(+) T cell numbers. This decrease was prevented by treatment with N-acetyl-cysteine (NAC). NAC caused this relative increase of CD4(+) T cell numbers in spite of decreasing glutathione levels and not by increasing the glutathione level. Our studies suggest that the immune system may be exquisitely sensitive not only against a cysteine and glutathione deficiency but also against an excess of cysteine.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT IMMUNOCHEM, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV BIOMED STAT ANAL, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT SPORT MED, HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Kinscherf, Ralf/AAV-7164-2021					BUHL R, 1990, LANCET, V336, P1294; DEQUAY B, 1992, AIDS, V6, P815, DOI 10.1097/00002030-199208000-00008; DROGE W, 1986, IMMUNOBIOLOGY, V172, P151; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DUTHIE GG, 1990, ARCH BIOCHEM BIOPHYS, V282, P78, DOI 10.1016/0003-9861(90)90089-H; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ECK HP, 1992, INT IMMUNOL, V4, P7, DOI 10.1093/intimm/4.1.7; GMUNDER H, 1991, EUR J BIOCHEM, V201, P113, DOI 10.1111/j.1432-1033.1991.tb16263.x; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GMUNDER H, 1991, CELL IMMUNOL, V138, P229, DOI 10.1016/0008-8749(91)90147-4; GOHIL K, 1988, J APPL PHYSIOL, V64, P115, DOI 10.1152/jappl.1988.64.1.115; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; LEW H, 1985, FEBS LETT, V185, P262, DOI 10.1016/0014-5793(85)80919-4; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROTH S, 1991, CELL IMMUNOL, V136, P95, DOI 10.1016/0008-8749(91)90384-N; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5	22	99	107	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					448	451		10.1096/fasebj.8.6.7909525	http://dx.doi.org/10.1096/fasebj.8.6.7909525			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	7909525				2022-12-28	WOS:A1994NH25000013
J	CIECHANOVER, A; SCHWARTZ, AL				CIECHANOVER, A; SCHWARTZ, AL			THE UBIQUITIN-MEDIATED PROTEOLYTIC PATHWAY - MECHANISMS OF RECOGNITION OF THE PROTEOLYTIC SUBSTRATE AND INVOLVEMENT IN THE DEGRADATION OF NATIVE CELLULAR PROTEINS	FASEB JOURNAL			English	Review						UBIQUITIN; PROTEIN DEGRADATION; ENERGY DEPENDENCE; 26S PROTEASE COMPLEX; MCP (MULTICATALYTIC PROTEINASE COMPLEX PROTEASOME); ATP; N-ALPHA ACETYLATED PROTEINS	N-END RULE; HUMAN PAPILLOMAVIRUS TYPE-16; MOLECULAR-WEIGHT PROTEASES; CONJUGATING ENZYME; TRANSCRIPTIONAL REGULATOR; TARGETED DEGRADATION; ANTIGEN PRESENTATION; RETICULOCYTE LYSATE; SYSTEM; COMPLEX	Ubiquitin modification of a variety of protein targets within the cell plays important roles in many cellular processes. Among these are regulation of gene expression, regulation of cell cycle and division, involvement in the cellular stress response, modification of cell surface receptors, DNA repair, import of proteins into mitochondria, uptake of precursors into neurons, and biog- enesis of mitochondria, ribosomes, and peroxisomes. The best studied modification occurs in the ubiquitin-mediated proteolytic pathway. Degradation of a protein via the ubiquitin system involves two discrete steps. Initially, multiple ubiquitin molecules are covalently linked in an ATP-dependent mode to the protein substrate. The targeted protein is then degraded by a specific and energy-dependent high molecular mass protease into free amino acids, and free and reutilizable ubiquitin is released. In addition, stable mono-ubiquitin adducts are also found in the cell, for example, those involving nucleosomal histones. Despite the considerable progress that has been made in elucidating the mode of action and roles of the ubiquitin system, many problems remain unsolved. For example, little is known on the signals that target proteins for degradation. Although mechanistic aspects of recognition via the N-terminal residue have been studied thoroughly, it is clear that the vast majority of cellular proteins are targeted by other signals. The identity of the native cellular substrates of the system is another important, yet unresolved, problem: only few proteins have been recognized so far as substrates of the system in vivo. The scope of this review is to discuss the mechanisms involved in ubiquitin activation, selection of substrates for conjugation, and degradation of ubiquitin-conjugated proteins in the cell-free system. In addition, we shall summarize what is currently known of the physiological roles of ubiquitin-mediated proteolysis in vivo.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; CHILDRENS HOSP,DEPT PEDIAT,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; CHILDRENS HOSP,DEPT PHARMACOL,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; St. Louis Children's Hospital; St. Louis Children's Hospital; Washington University (WUSTL)	CIECHANOVER, A (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,DEPT BIOCHEM,POB 9649,IL-31096 HAIFA,ISRAEL.		Ciechanover, Aaron J/C-9166-2017					BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BROWN GM, 1993, J IMMUNOL, V151, P1193; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIN DT, 1986, J BIOL CHEM, V261, P3883; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DAHLMANN B, 1991, BIOMED BIOCHIM ACTA, V50, P465; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P29299; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLAUMANN H, 1987, LYSOSOMES THEIR ROLE; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GONEN H, 1991, J BIOL CHEM, V266, P19221; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSHKO A, 1984, P NATL ACAD SCI USA, V81, P7201; HERSHKO A, 1991, J BIOL CHEM, V266, P376; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KONG SK, 1992, J BIOL CHEM, V267, P14189; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORI S, 1992, J BIOL CHEM, V267, P6429; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PICKART CM, 1985, J BIOL CHEM, V260, P1573; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SOFFER RL, 1973, MOL CELL BIOCHEM, V2, P3, DOI 10.1007/BF01738673; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	68	185	188	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					182	191		10.1096/fasebj.8.2.8119489	http://dx.doi.org/10.1096/fasebj.8.2.8119489			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119489				2022-12-28	WOS:A1994MY29900024
J	DOCHERTY, K; CLARK, AR				DOCHERTY, K; CLARK, AR			NUTRIENT REGULATION OF INSULIN GENE-EXPRESSION	FASEB JOURNAL			English	Review						TRANSCRIPTION; ISLETS OF LANGERHANS	PANCREATIC BETA-CELLS; PREPROINSULIN MESSENGER-RNA; ENHANCER-BINDING PROTEINS; RIBONUCLEIC-ACID; SODIUM-BUTYRATE; RIN-5F CELLS; CYCLIC-AMP; B-CELLS; I GENE; GLUCOSE	The beta cell of the islets of Langerhans contributes along with other factors to glucose homeostasis by sensing changes in the plasma glucose concentrations and adjusting the rate of insulin production and release. Over short periods of time, insulin production is controlled principally through translation of pre-existing mRNA. Over longer periods, insulin mRNA levels are modulated through effects on the rate of transcription of the insulin gene, and also through changes in the rate of decay of insulin mRNA. These long-term effects may be important in allowing the beta cell to adapt to changes in diet or periods of fasting. Several mechanisms involved in the control of the rate of translation of insulin mRNA have been described. Effects of glucose metabolism on the turnover of insulin mRNA have yet to be characterized in detail. At the level of transcription, cis-acting DNA elements and trans-acting factors involved in the transient response of the insulin gene to changes in intracellular cAMP levels, or to signals generated as a result of glucose metabolism, have been identified.			DOCHERTY, K (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Clark, Andrew/AAN-4043-2021	Docherty, Kevin/0000-0001-6765-2060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; CHARLES MA, 1975, J BIOL CHEM, V250, P6134; CLARK AR, 1993, FEBS LETT, V329, P139, DOI 10.1016/0014-5793(93)80210-L; CLARK AR, 1993, BIOCHEM SOC T, V21, P154, DOI 10.1042/bst0210154; CLARK AR, 1992, INSULIN MOL BIOL PAT, P37; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V18, P4925; EFRAT S, 1991, J BIOL CHEM, V266, P11141; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P2890, DOI 10.1210/en.130.5.2890; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Giddings S J, 1985, Diabetes Res, V2, P71; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; GIDDINGS SJ, 1981, J CLIN INVEST, V67, P952, DOI 10.1172/JCI110145; GIDDINGS SJ, 1985, DIABETES, V34, P235, DOI 10.2337/diabetes.34.3.235; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GUEST PC, 1992, NUTR REGULATION INSU, P59; GUEST PC, 1991, BIOCHEM J, V274, P431; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HAMMONDS P, 1987, FEBS LETT, V223, P131, DOI 10.1016/0014-5793(87)80523-9; HOLST JJ, 1992, NUTRIENT REGULATION, P23; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HUGHES SJ, 1992, NUTRIENT REGULATION, P271; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARLSEN AE, 1991, J BIOL CHEM, V266, P7542; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNIGHT SW, 1992, J MOL ENDOCRINOL, V8, P225, DOI 10.1677/jme.0.0080225; KOH G, 1989, ENDOCRINOLOGY, V124, P707, DOI 10.1210/endo-124-2-707; KORANYI L, 1992, J CLIN INVEST, V89, P432, DOI 10.1172/JCI115602; KORYANI L, 1992, DIABETOLOGIA, V35, P1125; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MACDONALD MJ, 1990, DIABETES, V39, P141; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MUSCHEL R, 1986, MOL CELL BIOL, V6, P337, DOI 10.1128/MCB.6.1.337; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; OLSON KL, 1993, J CLIN INVEST, V92, P514; ORLAND MJ, 1985, J CLIN INVEST, V75, P2047, DOI 10.1172/JCI111924; PARK CW, 1992, J BIOL CHEM, V267, P15642; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1993, DIABETES, V42, P244, DOI 10.2337/diabetes.42.2.244; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; PHILIPPE J, 1992, J CLIN INVEST, V90, P2228, DOI 10.1172/JCI116108; POWERS AC, 1988, DIABETES, V37, P1405, DOI 10.2337/diabetes.37.10.1405; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SCOTT V, 1991, FEBS LETT, V290, P27, DOI 10.1016/0014-5793(91)81217-V; STEINERE DF, 1990, HDB EXPT PHARM, V92, P68; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WANG SY, 1989, ENDOCRINOLOGY, V124, P1980, DOI 10.1210/endo-124-4-1980; WELSH M, 1986, J BIOL CHEM, V261, P2915; WELSH M, 1985, J BIOL CHEM, V260, P3590; WELSH M, 1986, BIOCHEM J, V235, P13590; WELSH N, 1990, BIOCHEM J, V271, P393, DOI 10.1042/bj2710393; WELSH N, 1987, BIOCHEM J, V246, P245, DOI 10.1042/bj2460245; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x	70	116	136	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					20	27		10.1096/fasebj.8.1.8299887	http://dx.doi.org/10.1096/fasebj.8.1.8299887			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299887				2022-12-28	WOS:A1994MV28200005
J	LEFRANCOISMARTINEZ, AM; DIAZGUERRA, MJM; VALLET, V; KAHN, A; ANTOINE, B				LEFRANCOISMARTINEZ, AM; DIAZGUERRA, MJM; VALLET, V; KAHN, A; ANTOINE, B			GLUCOSE-DEPENDENT REGULATION OF THE L-PYRUVATE KINASE GENE IN A HEPATOMA-CELL LINE IS INDEPENDENT OF INSULIN AND CYCLIC-AMP	FASEB JOURNAL			English	Note						GLUCOSE SIGNALING PATHWAY; TRANSCRIPTION; HIGH GLUCOSE DIET; HEPATOCYTE-LIKE CELL LINES; GLYCOLYTIC ENZYME	POST-TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; RAT-LIVER; GLUCOKINASE GENE; EXPRESSION; TISSUE; HEPATOCYTES; ELEMENTS; PROMOTER; FRUCTOSE	Hepatocyte-like mhAT3F cells have been derived from the hepatoma of a transgenic mouse expressing the SV40 large T antigen under the control of the antithrombin III gene regulatory region (Antoine, B., Levrat, F., Vallet, V., Berbar, T., Cartier, N., Dubois, N., Briand, P., and Kahn, A. (1992) Gene expression in hepatocyte-like lines established by targeted carcinogenesis in transgenic mice. Exp. Cell. Res. 200, 175-185; F. Levrat et al., unpublished results). In these cells, the L-PK gene is transcriptionally activated by glucose, as it is in vivo and in cultured hepatocytes. However, in contrast to the L-PK gene regulation in the liver and isolated hepatocytes, the glucose responsiveness does not require insulin and is not blocked by cyclic AMP. In mhAT3F cells, the insensitivity to insulin might be due to the replacement of insulin-dependent glucokinase by insulin-independent hexokinases able to phosphorylate glucose in the absence of the hormone. The glucose-dependent activation of the L-PK gene is delayed, requires ongoing protein synthesis, and is mediated by the same glucose response element as in vivo and in isolated hepatocytes. These results suggest that the glucose-dependent signaling pathway responsible for the transcriptional activation of glycolytic and lipogenic genes requires glucose phosphorylation, a phenomenon that is insulin-dependent in the liver but insulin-independent in cultured hepatoma cells. Nevertheless, the action of glucose 6-phosphate is most likely indirect.			LEFRANCOISMARTINEZ, AM (corresponding author), INSERM,U129,INST COCHIN GENET MOLEC,RECH GENET & PATHOL MOLEC LAB,F-75014 PARIS,FRANCE.		Díaz-Guerra, María José M/M-2855-2014	Díaz-Guerra, María José M/0000-0003-3843-3912				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; HAYZER DJ, 1990, BIOCHEM J, V270, P261, DOI 10.1042/bj2700261; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JENKINS AB, 1986, INT J BIOCHEM, V18, P311, DOI 10.1016/0020-711X(86)90036-4; LEVRAT F, 1993, IN PRESS EXP CELL RE; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MARIE S, 1993, IN PRESS J BIOL CHEM; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; Schapira F, 1973, Adv Cancer Res, V18, P77, DOI 10.1016/S0065-230X(08)60751-4; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P178; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; YAMADA K, 1990, J BIOL CHEM, V265, P19885	28	70	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					89	96		10.1096/fasebj.8.1.8299894	http://dx.doi.org/10.1096/fasebj.8.1.8299894			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299894				2022-12-28	WOS:A1994MV28200013
J	ALLEN, RH; STABLER, SP; SAVAGE, DG; LINDENBAUM, J				ALLEN, RH; STABLER, SP; SAVAGE, DG; LINDENBAUM, J			METABOLIC ABNORMALITIES IN COBALAMIN (VITAMIN-B(12) AND FOLATE-DEFICIENCY	FASEB JOURNAL			English	Review						COBALAMIN; VITAMIN-B(12); FOLIC ACID; METHYLMALONIC ACID; HOMOCYSTEINE; NEUROPSYCHIATRIC ABNORMALITIES	CHROMATOGRAPHY MASS-SPECTROMETRY; METHYLMALONIC ACID; TOTAL HOMOCYSTEINE; NITROUS-OXIDE; NORMAL SERUM; PATHOGENESIS; METHIONINE; VALINE; QUANTITATION; VITAMIN-B12	Mammalian cells contain two Cbl-dependent enzymes, L-methylmalonyl-CoA mutase and methionine synthase. The former requires adenosyl-Cbl and catalyzes the conversion of L-methylmalonyl-CoA to succinyl-CoA. The latter requires CH3-Cbl and catalyzes the conversion of 5-CH3-tetrahydrofolate and homocysteine to tetrahydrofolate and methionine, respectively. Biochemical abnormalities related to a decrease in the activity of methionine synthase are thought to be responsible for the indistinguishable hematologic abnormalities seen in both Cbl and folate deficiency. The biochemical basis for the neuropsychiatric abnormalities seen in Cbl deficiency, but not in folate deficiency, is not known although hypotheses have been proposed that implicate one or the other of the two Cbl-dependent enzymes. Recent studies have shown that levels of serum methylmalonic acid, 2-methylcitric acids I and II, total homocysteine, and cystathionine are elevated in most patients with Cbl deficiency and that total homocysteine, cystathionine, N,N-dimethylglycine, and N-methylglycine are elevated in most patients with folate deficiency. Analysis of these metabolic abnormalities in various patient groups fails to support hypotheses that either L-methylmalonyl-CoA mutase or methionine synthase alone are responsible for the neuropsychiatric abnormalities. We suggest that they may result from a third, unknown mammalian Cbl-dependent enzyme or from a combined deficiency of both Cbl-dependent enzymes together with an unknown genetic or environmental factor.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; COLUMBIA PRESBYTERIAN HOSP CTR,DEPT MED,NEW YORK,NY 10032; HARLEM HOSP MED CTR,NEW YORK,NY 10032	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Columbia University; Columbia University; NewYork-Presbyterian Hospital	ALLEN, RH (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV HEMATOL,4200 E 9TH AVE,CAMPUS BOX B170,DENVER,CO 80262, USA.				NIA NIH HHS [AG-09834] Funding Source: Medline; NIDDK NIH HHS [DK-21365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009834] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ALLEN RH, 1993, IN PRESS METABOLISM; ALLEN RH, 1991, CECIL TXB MED, P846; BARETZ BH, 1978, J BIOL CHEM, V253, P4203; Beck W S, 1991, Adv Intern Med, V36, P33; CARDINALE GJ, 1970, J BIOL CHEM, V245, P3771; DEACON R, 1978, LANCET, V2, P1023, DOI 10.1016/S0140-6736(78)92341-3; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FRENKEL EP, 1973, J CLIN INVEST, V52, P1237, DOI 10.1172/JCI107291; FRONTIERA MS, 1993, IN PRESS J NUTR BIOC; HAWORTH JC, 1993, AM J MED GENET, V45, P572, DOI 10.1002/ajmg.1320450510; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KONDO H, 1981, J CLIN INVEST, V67, P1270, DOI 10.1172/JCI110155; KOVACHY RJ, 1983, J BIOL CHEM, V258, P1415; LAYZER RB, 1978, LANCET, V2, P1227; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MARCELL PD, 1985, ANAL BIOCHEM, V150, P58, DOI 10.1016/0003-2697(85)90440-3; MATHEWS CK, 1990, BIOCHEMISTRY-US, P590; METZ J, 1992, ANNU REV NUTR, V12, P59, DOI 10.1146/annurev.nu.12.070192.000423; METZ J, 1993, NUTR REV, V51, P12, DOI 10.1111/j.1753-4887.1993.tb03046.x; MOELBY L, 1990, J INTERN MED, V228, P373, DOI 10.1111/j.1365-2796.1990.tb00248.x; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; ROSENBERG LE, 1989, METABOLIC BASIS INHE, P821; ROSENBLATT DS, 1989, METABOLIC BASIS INHE, P2049; SAVAGE DG, 1993, IN PRESS AM J MED; SCOTT JM, 1981, LANCET, V2, P334; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SHANE B, 1985, ANNU REV NUTR, V5, P115, DOI 10.1146/annurev.nu.05.070185.000555; STABLER SP, 1988, J BIOL CHEM, V263, P5581; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STABLER SP, 1993, BLOOD, V81, P3404; STABLER SP, 1990, BLOOD, V76, P871; STABLER SP, 1986, J CLIN INVEST, V77, P1606, DOI 10.1172/JCI112476; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; STABLER SP, 1991, NEUROLOGY, V41, P1627, DOI 10.1212/WNL.41.10.1627; STABLER SP, 1985, BLOOD S, V66, pA50; STRYER L, 1975, BIOCHEMISTRY-US, P549; TANAKA K, 1975, P NATL ACAD SCI USA, V72, P3692, DOI 10.1073/pnas.72.9.3692; VANDERWESTHUYZEN J, 1982, LIFE SCI, V31, P2001, DOI 10.1016/0024-3205(82)90039-X; VIEIRAMAKINGS E, 1991, BIOCHEM J, V275, P585, DOI 10.1042/bj2750585; VIEIRAMAKINGS E, 1990, INT J VITAM NUTR RES, V60, P41; WAGNER C, 1986, FOLATES PTERINS, V3, P251; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x	45	278	282	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1344	1353		10.1096/fasebj.7.14.7901104	http://dx.doi.org/10.1096/fasebj.7.14.7901104			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7901104				2022-12-28	WOS:A1993MH00800006
J	SAGER, R; ANISOWICZ, A; NEVEU, M; LIANG, P; SOTIROPOULOU, G				SAGER, R; ANISOWICZ, A; NEVEU, M; LIANG, P; SOTIROPOULOU, G			IDENTIFICATION BY DIFFERENTIAL DISPLAY OF ALPHA-6 INTEGRIN AS A CANDIDATE TUMOR-SUPPRESSOR GENE	FASEB JOURNAL			English	Note						ALPHA-6 INTEGRIN; DIFFERENTIAL DISPLAY; POSITIVE SELECTION; TUMOR SUPPRESSOR GENES	MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; NEOPLASTIC BREAST; DOWN-REGULATION; EXPRESSION; ADHESION; CLONING; SUBUNIT; KERATINOCYTES; RECEPTORS	A new method of differential expression cloning called differential display (DD) has been used to screen for novel tumor suppressor genes involved in breast cancer. The screen is based on positive selection at the mRNA level for genes expressed in normal mammary epithelial cells but decreased or lost in corresponding tumor cells. A candidate tumor suppressor gene recovered by DD is integrin alpha-6 (alpha6), a component of the heterodimeric integrin receptors alpha6beta1 and alpha6beta4. Loss of alpha6 expression was confirmed in total RNAs by Northern blot analysis and by immunostaining with alpha6 antibodies. Consistent with these cell culture findings, previous immunostaining of mammary tissue sections has identified decreased alpha6 protein expression during breast tumor progression. Southern blot analysis demonstrated that alpha6 gene is present in tumor cell lines, suggesting that re-expression may be inducible by pharmacological intervention. The likelihood that alpha6 may have tumor suppressing activity is supported by growing evidence of a central role for integrins in transducing growth control and differentiation signals from growth factors and the extracellular matrix (ECM).			SAGER, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC GENET, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [R35 CA3981407, P01 CA22427-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039814, P01CA022427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; FREINBERG AP, 1983, ANAL BIOCHEM, V132, P6; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GOULD VE, 1990, CELL DIFFER DEV, V32, P409, DOI 10.1016/0922-3371(90)90057-4; HAYASHI Y, 1991, CELL STRUCT FUNCT, V16, P241, DOI 10.1247/csf.16.241; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; KLEIN G, 1990, TUMOR SUPPRESSOR GEN, P1; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; NODA M, 1990, MOL CARCINOGEN, V3, P251, DOI 10.1002/mc.2940030502; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RUDLAND PS, 1989, J HISTOCHEM CYTOCHEM, V37, P1087, DOI 10.1177/37.7.2471725; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; YAMADA K, 1992, CURR OPIN CELL BIOL, V4; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	33	163	177	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					964	970		10.1096/fasebj.7.10.8344495	http://dx.doi.org/10.1096/fasebj.7.10.8344495			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344495				2022-12-28	WOS:A1993LQ33700022
J	COCQUERELLE, C; MASCREZ, B; HETUIN, D; BAILLEUL, B				COCQUERELLE, C; MASCREZ, B; HETUIN, D; BAILLEUL, B			MISSPLICING YIELDS CIRCULAR RNA MOLECULES	FASEB JOURNAL			English	Article						CIRCULAR RNA; C-ETS-1; MISSPLICING; PROTOONCOGENE	GENE; EXPRESSION; INTRON	We previously identified novel human ets-1 transcripts in which the normal order of exons is inverted, and demonstrated that although the order of exons is different than in the genomic DNA, splicing of these exons out of order occurs in pairs using genuine splice sites (1). Here we determine the structure of these novel transcripts, showing that they correspond to circular RNA molecules containing only exons in genomic order. These transcripts are stable molecules, localized in the cytoplasmic component of the cells. To our knowledge, this is the first case of circular transcripts being processed from nuclear pre-mRNA in eukaryotes. This new type of transcript might represent a novel aspect of gene expression and hold some interesting clues about the splicing mechanism.	INST RECH CANC, INSERM, U124, PL VERDUN, F-59045 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille								AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BERGER SL, 1989, METHOD ENZYMOL, V180, P3; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BISHOP JM, 1990, BIOSCIENCE REP, V10, P473, DOI 10.1007/BF01116609; BOVENBERG RAL, 1986, NUCLEIC ACIDS RES, V14, P8785, DOI 10.1093/nar/14.22.8785; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GATTONI R, 1986, J MOL BIOL, V187, P379, DOI 10.1016/0022-2836(86)90440-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; JORCYK CL, 1991, ONCOGENE, V6, P523; KERCKAERT JP, 1990, LEUKEMIA, V4, P16; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; REDDY ESP, 1988, ONCOGENE RES, V3, P239	20	780	866	5	76	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					155	160		10.1096/fasebj.7.1.7678559	http://dx.doi.org/10.1096/fasebj.7.1.7678559			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678559				2022-12-28	WOS:A1993KH88000023
J	MARTIN, A; SHULMAN, MJ; TSUI, FWL				MARTIN, A; SHULMAN, MJ; TSUI, FWL			EPITOPE STUDIES INDICATE THAT HISTIDYL-TRANSFER-RNA SYNTHETASE IS A STIMULATING ANTIGEN IN IDIOPATHIC MYOSITIS	FASEB JOURNAL			English	Article						AUTOANTIBODIES; POLYMYOSITIS; ANTI-JO-1; HISTIDYL-TRANSFER-RNA SYNTHETASE; AUTOANTIBODIES	TRANSFER RNA-SYNTHETASE; MESSENGER-RNA; AUTOANTIBODY; DERMATOMYOSITIS; POLYMYOSITIS; AUTOIMMUNITY; EXPRESSION; POLYMERASE; INHIBITION; GENES	The most frequently found myositis-specific antibody, the anti-Jo-1 antibody (anti-HRS), binds to histidyl-tRNA synthetase (HRS). Although this antibody reacts with HRS, it is unclear whether HRS is the stimulating antigen or is merely a protein that cross-reacts with a yet undefined antigen. Because antibody directed against an unrelated antigen would not be expected to cross-react with HRS at multiple sites, we mapped the epitopes on HRS to resolve this issue. We found by Western blot analyses that immunoglobulins G (IgG) from 18 of 19 anti-HRS positive patient sera react with amino acids 2-44 and 286-509 of HRS. Patient IgG specific for these two epitopes were found not to inhibit HRS enzyme activity. Instead, the inhibitory property of anti-HRS was found to be associated with antibodies that do not react to HRS in immunoblots, indicating the presence of other epitopes. In addition, antibodies that react in immunoblots were found to represent only a small fraction of total anti-HRS antibody. Our finding that patient IgG recognized at least three distinct epitopes on HRS strongly suggests that the immunological response at some point in the disease is directed against HRS and not against a cross-reactive antigen.	UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto	MARTIN, A (corresponding author), TORONTO HOSP,WESTERN DIV,RES INST,CTR ARTHRIT,RES UNIT,MC 14-117,399 BATHHURST ST,TORONTO,ON M5T 2S8,CANADA.			Martin, Alberto/0000-0002-0795-0418				BENNE R, 1988, TRENDS GENET, V4, P181, DOI 10.1016/0168-9525(88)90072-8; BLANQUET S, 1983, MOL CELL BIOCHEM, V52, P3; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; DANG CV, 1988, FASEB J, V2, P2376, DOI 10.1096/fasebj.2.8.2452112; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; JAMES JA, 1995, J EXP MED, V181, P453, DOI 10.1084/jem.181.2.453; LINDLEY IG, 1977, J GEN VIROL, V34, P17; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MILLER F W, 1990, Arthritis and Rheumatism, V33, pS23; MILLER FW, 1990, J CLIN INVEST, V85, P468, DOI 10.1172/JCI114461; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RABEN N, 1994, J BIOL CHEM, V269, P24277; RAMSDEN DA, 1989, J IMMUNOL, V143, P2267; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; SALOMON R, 1974, NATURE, V249, P32, DOI 10.1038/249032a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAMUELS DS, 1986, FEBS LETT, V209, P231; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARGOFF IN, 1993, J INVEST DERMATOL, V100, pS116, DOI 10.1111/1523-1747.ep12356607; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TOPFER F, 1995, P NATL ACAD SCI USA, V92, P875, DOI 10.1073/pnas.92.3.875; TSUI F W, 1991, International Reviews of Immunology, V7, P225, DOI 10.3109/08830189109061776; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; UIBO R, 1990, CLIN EXP IMMUNOL, V80, P19	29	32	44	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1226	1233		10.1096/fasebj.9.12.7672516	http://dx.doi.org/10.1096/fasebj.9.12.7672516			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672516				2022-12-28	WOS:A1995RU81600013
J	MERRILL, JE; JONAKAIT, GM				MERRILL, JE; JONAKAIT, GM			INTERACTIONS OF THE NERVOUS AND IMMUNE-SYSTEMS IN DEVELOPMENT, NORMAL BRAIN HOMEOSTASIS, AND DISEASE	FASEB JOURNAL			English	Article						CYTOKINES; GLIA IMMUNE CELLS; LIGANDS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEURONS; TIDES; NEUROTRANSMITTERS; NEUROTROPHINS; RECEPTORS	SUBSTANCE-P; NEURONAL CELLS; GROWTH-FACTOR; NITRIC-OXIDE; GLIAL-CELLS; RECEPTOR; INTERLEUKIN-1; CYTOKINES; INDUCTION; ASTROCYTES	Neurotransmitters, neuropeptides, neurotrophins, and neuroendocrine hormones have traditionally been assigned functions in normal development and homeostasis of neuronal networks; cytokines and adhesion molecules have been assigned functions within the peripheral immune system. Molecular dissection of the presence and function of these receptors and ligands during development of the immune and nervous systems, in normal healthy adult central and peripheral nervous tissue, and in the pathological response of immune elements in the brain and neuroelements in the immune system has forced us to alter these long-held concepts. Examples of how glia and neurons function in relationship to these paracrine and autocrine stimuli in health and disease are provided in this short review.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Rutgers State University Newark; Rutgers State University New Brunswick					NINDS NIH HHS [R0-1 NS30768] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030768] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANATI RB, IN PRESS DEV NEUROSC; BANNER LR, 1994, IN PRESS P NATL ACAD; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BHARUCHA VA, 1994, NEURON, V12, P627, DOI 10.1016/0896-6273(94)90218-6; BREDESEN DE, 1994, APOPTOSIS, V2, P397; BRENNEMAN D, 1994, SOC NEUR ABSTR, V20; BROSNAN CF, 1994, IN PRESS DEV NEUROSC; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DAWSON MT, 1994, IN PRESS NEUROSCIENT; DAWSON TM, 1994, IN PRESS ADV NEUROIM; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; FANSLOW WC, 1990, SCIENCE, V248, P793; FILBIN MT, 1994, IN PRESS DEV NEUROSC; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GRAU GE, 1993, EUR CYTOKINE NETW, V4, P415; HART RP, 1993, J NEUROIMMUNOL, V49, P56; HILL JM, 1993, BRAIN RES, V605, P222; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JONAKAIT GM, 1994, TINS, V16, P419; KALARIA RN, 1993, CLIN NEUROSCI, V1, P204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LIPTON SA, 1994, IN PRESS DEV NEUROSC; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; MARTIN FC, 1992, BRAIN RES, V599, P13, DOI 10.1016/0006-8993(92)90846-2; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MEHLER MF, 1994, IN PRESS DEV NEUROSC; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; MITROVIC B, 1994, IN PRESS NEUROSCIENC; MITSUO K, 1993, J MOL NEUROSCI, V4, P21, DOI 10.1007/BF02736687; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NOGUCHI M, 1993, SCIENCE, V262, P1977; OEHM A, 1992, J BIOL CHEM, V267; OLSSON T, 1994, EUR J IMMUNOL, V24, P308, DOI 10.1002/eji.1830240205; OTERO GC, 1994, GLIA, V11, P117, DOI 10.1002/glia.440110207; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAMESHWAR P, 1993, BLOOD, V81, P391; RAMESHWAR P, 1994, J IMMUNOL, V152, P4044; RELTON JK, 1992, BRAIN RES B, V585, P135; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SHADIACK AM, 1993, J NEUROSCI, V13, P2601, DOI 10.1523/JNEUROSCI.13-06-02601.1993; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SMITHSEINTOSKY VL, 1994, IN PRESS J NEUROCHEM; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; SUN Y, 1993, J NEUROBIOL, V25, P415; SUNDAR SK, 1991, P NATL ACAD SCI USA, V88, P11246, DOI 10.1073/pnas.88.24.11246; Togni PD, 1994, SCIENCE, V264, P703; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WELLER M, 1994, IN PRESS J CLIN INVE, V94; WONG MH, 1994, IN PRESS J CELL BIOL, V126	62	106	111	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					611	618		10.1096/fasebj.9.8.7768352	http://dx.doi.org/10.1096/fasebj.9.8.7768352			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768352				2022-12-28	WOS:A1995RC10600006
J	KABSCH, W; HOLMES, KC				KABSCH, W; HOLMES, KC			PROTEIN MOTIFS .2. THE ACTIN FOLD	FASEB JOURNAL			English	Review						HEAT-SHOCK PROTEINS; HEXOKINASE; GLYCEROL KINASE; ATP	X-RAY CRYSTALLOGRAPHY; YEAST HEXOKINASE-B; SHOCK COGNATE PROTEIN; BETA-HEAVY CHAIN; 3-DIMENSIONAL STRUCTURE; BINDING-PROTEINS; ESCHERICHIA-COLI; ATPASE FRAGMENT; ATOMIC MODEL; COMPLEX	X-ray structure analysis of actin and of the NH2-terminal domain of the heat-shock cognate protein Hsc70 has revealed an unexpected extensive structural similarity between these two molecules. Despite the absence of significant similarity of their amino acid sequences, both proteins share the same core architecture and a common nucleotide binding site resembling the structure of hexokinase. All three are ATPases or kinases and bind ATP in association with Mg2+ or Ca2+. The common fold consists of two alpha/beta domains, which are connected by a putative hinge with an ATP-binding site situated between the domains. Each domain contains a five-stranded beta-sheet of identical topology, which suggests that the molecules may have evolved by gene duplication. From a comparison of the three aligned structures, a fingerprint sequence of the adenine nucleotide binding pocket was derived, which predicted that members of the glycerol kinase family should also have a similar fold of their nucleotide binding domain. This was later confirmed when the X-ray structure was published. Data base search with a refined consensus sequence has retrieved other sugar kinases, as well as the prokaryotic cell cycle proteins FtsA, MreB, and StbA, and two Escherichia coli phosphatases. These proteins are predicted to possess a structure similar to actin in the common core region. As exemplified for actin, Hsc70, and glycerol kinase, the diversity of biological function is provided by the polymorphism of the loops joining the beta-strands and helices in the core region and by inserted domains that show high variability.			KABSCH, W (corresponding author), MAX PLANCK INST MED RES,BIOPHYS ABT,JAHNSTR 29,D-69028 HEIDELBERG,GERMANY.			Holmes, Kenneth/0000-0001-8894-9453				ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CARLIER MF, 1991, J BIOL CHEM, V266, P1; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILNERWHITE EJ, 1991, J MOL BIOL, V221, P751; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REIZER J, 1993, TRENDS BIOCHEM SCI, V18, P247, DOI 10.1016/0968-0004(93)90172-J; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROZYCKI MD, 1994, CURR OPIN CELL BIOL, V6, P87, DOI 10.1016/0955-0674(94)90121-X; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; Straub F.B., 1942, STUDIES I MED CHEM U, P3; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WALKER JE, 1982, EMBO J, V8, P945; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	53	152	153	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					167	174		10.1096/fasebj.9.2.7781919	http://dx.doi.org/10.1096/fasebj.9.2.7781919			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781919				2022-12-28	WOS:A1995QJ24900004
J	KEYS, A				KEYS, A			1944 SYMPOSIUM ON CONVALESCENCE AND REHABILITATION	FASEB JOURNAL			English	Editorial Material											KEYS, A (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454, USA.							KEYS A, 1949, FED PROC, V3, P188	1	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1201	1202		10.1096/fasebj.8.14.7958628	http://dx.doi.org/10.1096/fasebj.8.14.7958628			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958628				2022-12-28	WOS:A1994PT12800017
J	LOETSCHER, P; SEITZ, M; CLARKLEWIS, I; BAGGIOLINI, M; MOSER, B				LOETSCHER, P; SEITZ, M; CLARKLEWIS, I; BAGGIOLINI, M; MOSER, B			MONOCYTE CHEMOTACTIC PROTEINS MCP-1, MCP-2, AND MCP-3 ARE MAJOR ATTRACTANTS FOR HUMAN CD4(+) AND CD8(+) T-LYMPHOCYTES	FASEB JOURNAL			English	Article						CHEMOKINES; MONOCYTE CHEMOTACTIC PROTEINS; CHEMOTAXIS; CA2+ MOBILIZATION	NEUTROPHIL-ACTIVATING PEPTIDE-2; CELL ADHESION; GRO-ALPHA; MIGRATION; INTERLEUKIN-8; RECEPTORS; CYTOKINE; RANTES; MIP-1-BETA; CHEMOATTRACTANT	The responses of lymphocytes to six CC chemokines-MCP-1, MCP-2, MCP-3, MIP-1 alpha, MIP-1 beta, and RANTES-were studied using cloned human CD4(+) and CD8(+) T cells. All CC chemokines tested induced migration of both types of lymphocytes, whereas two CXC chemokines used as controls, IL-8 and IP-10, were inactive. The monocyte chemotactic proteins (MCP-1, MCP-2, and MCP-3) showed a typically bimodal concentration dependence, and were considerably more effective than MIP-1 alpha, MIP-1 beta, or RANTES. All CC chemokines also induced a rapid and transient rise in cytosolic free Ca2+ in either type of T cell. The rise was prevented by Bordetella pertussis toxin treatment, indicating that G-protein-coupled receptors are involved in signaling. It was most pronounced with MCP-1 and MCP-3, which is in agreement with the efficacy of these chemokines as chemoattractants. The responses to MCP-2, MIP-1 alpha, MIP-1 beta, and RANTES were weaker, and no changes were obtained on stimulation with IL-8 or IP-10. Freshly isolated human blood lymphocytes were also tested, but neither migration nor Ca2+ changes were observed. Low numbers of high-affinity receptors for MCP-1 were found on CD4(+) and CD8(+) cells (< 900 per cell, K-d <1 nM), and desensitization experiments showed that MCP-1, MCP-2, and MCP-3 share receptors. Owing to their superior effectiveness on CD4(+) and CD8(+) T cells, the monocyte chemotactic proteins could play a major role in the recruitment of activated T lymphocytes.	UNIV HOSP BERN,DIV RHEUMATOL,CH-3010 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of Bern; University Hospital of Bern; University of British Columbia; University of British Columbia	LOETSCHER, P (corresponding author), UNIV BERN,THEODOR KOCHER INST,PO BOX,FREIESTR 1,CH-3000 BERN 9,SWITZERLAND.			Moser, Bernhard/0000-0002-4354-4572				BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COLOTTA F, 1984, J IMMUNOL, V132, P936; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GEISER T, 1993, J BIOL CHEM, V268, P15419; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MOSER B, 1991, J BIOL CHEM, V266, P10666; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHNITZEL W, 1991, BIOCHEM BIOPH RES CO, V180, P301, DOI 10.1016/S0006-291X(05)81292-6; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	29	298	310	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1055	1060		10.1096/fasebj.8.13.7926371	http://dx.doi.org/10.1096/fasebj.8.13.7926371			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926371				2022-12-28	WOS:A1994PN06900010
J	OJCIUS, DM; GAPIN, L; KANELLOPOULOS, JM; KOURILSKY, P				OJCIUS, DM; GAPIN, L; KANELLOPOULOS, JM; KOURILSKY, P			IS ANTIGEN-PROCESSING GUIDED BY MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES	FASEB JOURNAL			English	Article						ANTIGEN PRESENTATION; IMMUNODOMINANCE; T LYMPHOCYTES; PROTEASES; PEPTIDES; MHC LOADING	T-CELL RECOGNITION; CLASS-I MOLECULES; PEPTIDE BINDING-PROTEIN; IMMUNOGENIC PEPTIDES; DISULFIDE BONDS; SELF-PEPTIDES; MHC MOLECULES; RMA-S; DETERMINANT; TRANSPORTER	Major histocompatibility complex class I (MHC-1) molecules bind peptide fragments derived from cytosolic antigens, and class II (MHC-2) molecules bind fragments of proteins that enter the endocytic pathway. How peptides of the right affinity and size are generated in vivo is still the focus of intense research. Current data are consistent with the view that precursor peptides of varying length are produced in the cytosol and transported into the endoplasmic reticulum lumen where nascent MHC-1 could sample the peptides for their affinity. High-affinity peptides would form stable complexes with MHC-1, which are resistant to proteolysis by luminal enzymes; peptides unable to bind to MHC-1 presumably undergo proteolysis in the lumen. On the other hand, multiple mechanisms are probably used to load MHC-2. Some proteins denatured in the acidic and reducing environment of the endosomes most likely bind to MHC-2 through the antigen's immunodominant region, and the exposed portions of the antigen are degraded by endosomal proteases. Other antigens must first be proteolysed into peptide fragments, which compete among themselves for binding to MHC-2, whereas heat shock proteins could also contribute peptides for MHC-2 loading. Because of their respective loading modes, there is a partial correlation between the MHC-2 binding affinity of the protein fragments and their in vivo immunodominance, which may not necessarily be the case for MHC-1.			OJCIUS, DM (corresponding author), INST PASTEUR, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; COGSWELL JP, 1988, ANTIGEN PRESENTING C, P115; COLLINS DS, 1991, J IMMUNOL, V147, P4054; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARDING CV, 1993, J IMMUNOL, V151, P3988; HOWARD JC, 1993, NATURE, V365, P211, DOI 10.1038/365211a0; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; JENSEN PE, 1993, J IMMUNOL, V150, P3347; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LAKEY EK, 1987, P NATL ACAD SCI USA, V84, P1659, DOI 10.1073/pnas.84.6.1659; LAMB JR, 1987, EMBO J, V6, P1245, DOI 10.1002/j.1460-2075.1987.tb02360.x; LEE P, 1988, J IMMUNOL, V140, P1063; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OJCIUS DM, 1994, J IMMUNOL, V152, P2798; OJCIUS DM, 1993, J IMMUNOL, V151, P6020; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; ROTZSCHKE O, 1994, CURR OPIN IMMUNOL, V6, P45, DOI 10.1016/0952-7915(94)90032-9; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; ROUAS N, 1992, MOL IMMUNOL, V29, P883, DOI 10.1016/0161-5890(92)90126-I; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1992, J IMMUNOL, V148, P844; SHASTRI N, 1986, J IMMUNOL, V137, P911; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; VANNOORT JM, 1991, EUR J IMMUNOL, V21, P1989, DOI 10.1002/eji.1830210904; WALLNY HJ, 1992, EUR J IMMUNOL, V22, P655, DOI 10.1002/eji.1830220307; WRAITH DC, 1992, J AUTOIMMUN, V5, P103, DOI 10.1016/0896-8411(92)90025-L; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; ZHUORU L, 1991, J IMMUNOL, V146, P438; ZISMAN E, 1991, P NATL ACAD SCI USA, V88, P9738, DOI 10.1073/pnas.88.21.9738	61	8	9	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					974	978		10.1096/fasebj.8.12.8088463	http://dx.doi.org/10.1096/fasebj.8.12.8088463			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088463				2022-12-28	WOS:A1994PG29300010
J	MARTEN, NW; BURKE, EJ; HAYDEN, JM; STRAUS, DS				MARTEN, NW; BURKE, EJ; HAYDEN, JM; STRAUS, DS			EFFECT OF AMINO-ACID LIMITATION ON THE EXPRESSION OF 19 GENES IN RAT HEPATOMA-CELLS	FASEB JOURNAL			English	Article						AMINO ACIDS; SERUM ALBUMIN; HEPATOMA CELLS	TRANSCRIPTIONAL ACTIVATOR PROTEIN; ALBUMIN MESSENGER-RNA; ALPHA-1-ACID GLYCOPROTEIN; REGULATED EXPRESSION; C-FOS; LIVER; C/EBP; PROMOTER; LAP; DEPRIVATION	We showed previously that the abundance of serum albumin mRNA is decreased in H4-II-E rat hepatoma cells limited for a single essential amino acid (phenylalanine, methionine, leucine, or tryptophan). To define the specificity of this phenomenon, we examined the effect of amino acid limitation on the abundance of mRNAs for 19 genes in the H4-II-E cells. These genes included six genes whose expression is either completely liver-specific or highly enriched in the liver compared with other tissues [albumin, transthyretin (TTR), transferrin, carbamyl phosphate synthetase-I, urate oxidase, class I alcohol dehydrogenase], as well as a number of ubiquitously expressed ''housekeeping'' genes. The results indicated that the 19 genes could be divided into three classes based on their response to amino acid limitation. Class I genes (the six liver-specific genes and alpha-tubulin) exhibit decreased expression in response to amino acid limitation. The expression of class II genes [beta(2)- microglobulin, hypoxanthine-guanine phosphoribosyl transferase (HPRT), H-ferritin, ubiquitin (UbB), insulin-like growth factor binding protein-4, HNF-1 alpha] is not significantly affected by amino acid limitation. Class III genes [gadd153, beta-actin, ubiquitin (UbC), phosphoglycerate kinase-1, C/EBP alpha, C/EBP beta] exhibit increased expression in response to amino acid limitation. Thus, specific inductive as well as repressive effects on gene expression are quite common in amino acid-limited cells. The observation that all six genes whose expression is liver-specific exhibited decreased expression in amino acid-limited cells suggests a common mode of regulation of these genes by amino acid availability. The strong induction by amino acid limitation of the C/EBP inhibitor gadd153 is of interest in this regard, as increased levels of gadd153 could interfere with C/EBP, which is required for high expression of most liver-specific genes. To investigate further the molecular mechanism for the decrease in albumin mRNA abundance, albumin nuclear transcript levels were quantified in control and tryptophan-limited cells. Tryptophan limitation caused a decrease in albumin nuclear transcript abundance, and this decrease preceded the decrease in albumin mRNA, suggesting that the decrease in albumin mRNA was caused at least partly by a decrease in albumin gene transcription. Additional experiments with actinomycin D indicated that albumin mRNA was also destabilized in the tryptophan-limited cells. Thus, the overall results indicate that the decrease in albumin mRNA in the tryptophan-limited cells is caused by a specific decrease in albumin nuclear transcript abundance and destabilization of albumin mRNA.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039739] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK39739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHENCYA, 1992, MOL CELL BIOL, V12, P5748; COWARD WA, 1981, BRIT MED BULL, V37, P19, DOI 10.1093/oxfordjournals.bmb.a071670; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, THESIS STANFORD U ST; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAINE RO, 1991, J BIOL CHEM, V266, P16969; MENDELZON D, 1990, NUCLEIC ACIDS RES, V18, P5717, DOI 10.1093/nar/18.19.5717; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTHSCHILD MA, 1969, J NUTR, V98, P395, DOI 10.1093/jn/98.4.395; SAKUMA K, 1987, J NUTR, V117, P1141, DOI 10.1093/jn/117.6.1141; SIDRANSKY H, 1968, J BIOL CHEM, V243, P1123; STRAUS DS, 1991, J NUTR, V121, P1279, DOI 10.1093/jn/121.8.1279; STRAUS DS, 1988, BIOCHIM BIOPHYS ACTA, V972, P33; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241	31	118	120	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					538	544		10.1096/fasebj.8.8.8181673	http://dx.doi.org/10.1096/fasebj.8.8.8181673			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181673				2022-12-28	WOS:A1994NM36400012
J	LOMAKO, J; LOMAKO, WM; WHELAN, WJ; DOMBRO, RS; NEARY, JT; NORENBERG, MD				LOMAKO, J; LOMAKO, WM; WHELAN, WJ; DOMBRO, RS; NEARY, JT; NORENBERG, MD			GLYCOGEN-SYNTHESIS IN THE ASTROCYTE - FROM GLYCOGENIN TO PROGLYCOGEN TO GLYCOGEN	FASEB JOURNAL			English	Note						ASTROCYTE; GLYCOGEN; GLYCOGENIN; PROGLYCOGEN; MACROGLYCOGEN; GLYCOGEN BIOGENESIS; GLYCOGEN SYNTHASE	RABBIT-MUSCLE GLYCOGEN; SKELETAL-MUSCLE; PROTEIN; BIOGENESIS; PRIMER; BIOSYNTHESIS; INITIATION; LINKAGE	The astrocyte of the newborn rat brain has proven to be a versatile system in which to study glycogen biogenesis. We have taken advantage of the rapid stimulation of glycogen synthesis that occurs when glucose is fed to astrocytes, and the marked limitation on this synthesis that occurs in astrocytes previously exposed to ammonium ions. These observations have been related to our earlier reports of the initiation of glycogen synthesis on a protein primer, glycogenin, and the discovery of a low-molecular-weight form of glycogen, proglycogen. The following conclusions have been drawn: 1) In the ammonia-treated astrocytes starved of glucose, free glycogenin is present. 2) When these astrocytes are fed with glucose, proglycogen is synthesized from the glycogenin primer by a glycogen-synthase-like UDPglucose transglucosylase activity (proglycogen synthase) distinct from the well-recognized glycogen synthase, and synthesis stops at this point. 3) Proglycogen is the precursor of macromolecular glycogen, which is synthesized from proglycogen by glycogen synthase when glucose is fed to untreated astrocytes, accounting for the much greater accumulation of total glycogen. 4) The stimulus to proglycogen and macroglycogen synthesis that occurs on feeding glucose to untreated or ammonia-treated astrocytes is the result of the activation of proglycogen synthase, not of glycogen synthase. 5) Therefore, in the synthesis of macromolecular glycogen from glycogenin via proglycogen, the step between glycogenin and proglycogen is rate-limiting. 6) The discovery of additional potential control points in glycogen synthesis, now emerging, may assist the identification of so-far-unexplained aberrations of glycogen metabolism.	UNIV MIAMI,SCH MED,DEPT BIOCHEM,1011 NW 15TH ST,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT SURG,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT PATHOL,MIAMI,FL 33101; VET ADM MED CTR,MIAMI,FL 33125	University of Miami; University of Miami; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK 38153, DK 37500] Funding Source: Medline; NINDS NIH HHS [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037500, R01DK038153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS030291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADROUNY GA, 1956, ENDOCRINOLOGY, V59, P241, DOI 10.1210/endo-59-2-241; BAILEY JM, 1993, BIOCHEM SOC T, V21, P124; BARTLEY W, 1968, ANAL BIOCHEM, V25, P99, DOI 10.1016/0003-2697(68)90084-5; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BUTLER NA, 1977, CARBOHYD RES, V55, P73, DOI 10.1016/S0008-6215(00)84444-4; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; DOMBRO RS, 1993, MOL CHEM NEUROPATHOL, V19, P259, DOI 10.1007/BF03160004; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P397, DOI 10.1097/00005072-198507000-00003; JUDD C, 1992, FASEB J, V6, pA1520; KAY MJ, 1987, FASEB J, V46, P2151; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAST WD, 1975, ANAL BIOCHEM, V68, P328; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1988, Biofactors, V1, P261; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1991, FASEB J, pA1014; LOMAKO J, 1988, 14TH INT C BIOCH PRA, P198; PASSONNEAU JV, 1976, J BIOL CHEM, P2015; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; ROE JH, 1961, J BIOL CHEM, V236, P1244; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STETTEN D, 1960, PHYSIOL REV, V40, P505, DOI 10.1152/physrev.1960.40.3.505; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	31	84	85	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1386	1393		10.1096/fasebj.7.14.8224611	http://dx.doi.org/10.1096/fasebj.7.14.8224611			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224611				2022-12-28	WOS:A1993MH00800012
J	KNUDSON, CB; KNUDSON, W				KNUDSON, CB; KNUDSON, W			HYALURONAN-BINDING PROTEINS IN DEVELOPMENT, TISSUE HOMEOSTASIS, AND DISEASE	FASEB JOURNAL			English	Review						HYALURONAN; HYALADHERINS; HYALURONAN RECEPTORS; CD44; RHAMM	LIVER ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODY; PERICELLULAR MATRIX; CARCINOMA-CELLS; RECEPTOR CD44; SURFACE; DEGRADATION; ACID; DIFFERENTIATION; IDENTIFICATION	The high molecular weight glycosaminoglycan hyaluronan plays an important role in tissue remodeling during development, normal tissue homeostasis, and disease. The interaction of hyaluronan with matrix hyaluronan-binding proteins and cell-surface hyaluronan receptors regulates many aspects of cell behavior such as cell migration, cell-cell adhesion, and cell differentiation. Hyaluronan-binding proteins have been grouped together as a family termed hyaladherins-further subdivided in matrix and cell-surface hyaladherins (receptors). Specific hyaluronan-hyaladherin interactions that affect cell behavior are the focus of this review. Both clearance and turnover of hyaluronan involve hyaluronan receptor-mediated endocytosis. Pericellular matrix assembly and retention on many cells, especially chondrocytes, are mediated by hyaluronan receptors, in coordination with other matrix hyaladherins. Hyaluronan can also have an independent, direct effect on cell-to-cell adhesion as well as migration, again mediated by specific cell-surface hyaluronan receptors. This is especially apparent in tumor cells, where metastatic potential is correlated with hyaluronan receptor expression. As migrating cells encounter new environments enriched in matrix hyaladherins, the capacity for matrix assembly may terminate cell migration. Thus, the temporal/spatial deposition of particular matrix hyaladherins also serves as signals or matrix cues to alter cell behavior.	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PATHOL, CHICAGO, IL 60612 USA	Rush University	KNUDSON, CB (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039507, P50AR039239, R01AR039507] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39239, R01 AR039507, AR39507] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BANERJEE SD, 1991, DEV BIOL, V146, P186, DOI 10.1016/0012-1606(91)90459-G; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BERNANKE DH, 1984, DEV BIOL, V106, P360, DOI 10.1016/0012-1606(84)90234-3; BERTRAND P, 1992, INT J CANCER, V52, P1, DOI 10.1002/ijc.2910520102; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DELPECH A, 1982, BRIT J DERMATOL, V106, P561, DOI 10.1111/j.1365-2133.1982.tb04559.x; DELPECH B, 1989, CIBA F SYMP, V143, P208; DELPECH B, 1993, EUR J CANCER, V29A, P1012, DOI 10.1016/S0959-8049(05)80214-X; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HUA Q, 1993, ORTHOP T, V18, P70; HUA Q, 1993, IN PRESS J CELL SCI; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KNUDSON C B, 1991, Journal of Cell Biology, V115, p297A; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KNUDSON W, 1991, J CELL SCI, V99, P227; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, CIBA F SYMP, V124, P9; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; MALESKI MP, 1992, ORTHOP T, V17, P105; MASON RM, 1989, CIBA F SYMP, V143, P107; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NEMEC RE, 1987, BIOCHEM BIOPH RES CO, V149, P249, DOI 10.1016/0006-291X(87)91632-9; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PREHM P, 1989, CIBA F SYMP, V143, P21; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHINOMURA T, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P35; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Toole BP, 1989, CIBA F SYMP, V143, P138; TURLEY EA, 1989, CIBA F SYMP, V143, P121; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; UNDERHILL C, 1992, J CELL SCI, V103, P293; UNDERHILL CB, 1989, CIBA F SYMP, V143, P87; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1989, CIBA F SYMP, V143, P187; YANG BH, 1993, J BIOL CHEM, V268, P8617; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	57	600	637	0	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1993	7	13					1233	1241		10.1096/fasebj.7.13.7691670	http://dx.doi.org/10.1096/fasebj.7.13.7691670			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	7691670				2022-12-28	WOS:A1993MB37600006
J	MONONEN, I; FISHER, KJ; KAARTINEN, V; ARONSON, NN				MONONEN, I; FISHER, KJ; KAARTINEN, V; ARONSON, NN			ASPARTYLGLYCOSAMINURIA - PROTEIN CHEMISTRY AND MOLECULAR-BIOLOGY OF THE MOST COMMON LYSOSOMAL STORAGE DISORDER OF GLYCOPROTEIN DEGRADATION	FASEB JOURNAL			English	Review						ASPARTYLGLYCOSAMINURIA; ASPARTYLGLUCOSAMINIDASE; ASPARTYLGLUCOSAMINURIA; GLYCOSYLASPARAGINASE; ASPARAGINASE; MECHANISM OF ACTION; GLYCOPROTEIN DEGRADATION; MOLECULAR BIOLOGY; DNA DIAGNOSTICS; LYSOSOMES; GENETICS	AMINO-ACID SEQUENCE; L-ASPARAGINASE; GLYCOASPARAGINASE GENE; RAT-LIVER; HUMAN ASPARTYLGLUCOSAMINIDASE; GLUTAMINASE-ASPARAGINASE; LINKED GLYCOPROTEINS; ERWINIA-CHRYSANTHEMI; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI	Aspartylglycosaminuria (AGU) (McKusick 20840) is the most common disorder of glycoprotein degradation caused by the failure of lysosomes to digest the protein-to-carbohydrate linkage of Asn-linked glycoproteins. During the past few years there has been significant progress in our understanding of both the protein chemistry and molecular biology of glycosylasparaginase (EC 3.5.1.26) as well as the molecular changes underlying the storage disease AGU that results from deficiency of this lysosomal hydrolase. Modern clinical assays have been developed for the diagnosis and carrier detection of this disease. Detailed structure, substrate specificity, mechanism of action, and a part of the active site of glycosylasparaginase have been defined. Molecular biology of glycosylasparaginase has progressed rapidly and already some mutations in the glycosylasparaginase gene resulting in AGU have been identified. Evolutionary aspects based on sequence data indicate a mechanistic relationship between mammalian glycosylasparaginases and bacterial/plant asparaginases.	UNIV KUOPIO,DEPT CLIN CHEM,SF-70210 KUOPIO,FINLAND; AI VIRTANEN INST,CTR DIAGNOST BIOTECHNOL,SF-70210 KUOPIO,FINLAND; WISTAR INST ANAT & BIOL,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; CHILDRENS HOSP LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90054; UNIV SO ALABAMA,DEPT BIOCHEM,MOBILE,AL 36688	University of Eastern Finland; The Wistar Institute; Children's Hospital Los Angeles; University of South Alabama			Kaartinen, Vesa/AAU-5396-2021	Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033314] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33314] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; AULA P, 1984, AM J MED GENET, V19, P359, DOI 10.1002/ajmg.1320190218; AULA P, 1976, PEDIATR RES, V10, P625, DOI 10.1203/00006450-197606000-00012; AULA P, 1982, GENETIC ERRORS GLYCO, P123; Autio S, 1972, J Ment Defic Res, V1, P1; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BAUMANN M, 1989, BIOCHEM J, V262, P189, DOI 10.1042/bj2620189; BEAUDET AL, 1989, METABOLIC BASIS INHE, P1603; BONNAUREMALLET M, 1991, J ORAL PATHOL MED, V20, P237, DOI 10.1111/j.1600-0714.1991.tb00426.x; BONTHRON DT, 1990, GENE, V91, P101, DOI 10.1016/0378-1119(90)90168-Q; CANTZ M, 1990, J INHERIT METAB DIS, V13, P523, DOI 10.1007/BF01799510; CHITAYAT D, 1988, AM J MED GENET, V31, P527, DOI 10.1002/ajmg.1320310307; CONCHIE J, 1969, BIOCHEM J, V115, P709, DOI 10.1042/bj1150709; CONZELMANN E, 1987, ADV ENZYMOL RAMB, V60, P89; DEGASPERI R, 1989, J BIOL CHEM, V264, P9329; DUGAL B, 1977, BIOCHEM J, V165, P497, DOI 10.1042/bj1650497; ENOMAA N, 1992, BIOCHEM J, V286, P613, DOI 10.1042/bj2860613; FILPULA D, 1988, NUCLEIC ACIDS RES, V16, P10385, DOI 10.1093/nar/16.21.10385; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; FISHER KJ, 1991, J BIOL CHEM, V266, P12105; FISHER KJ, 1991, FEBS LETT, V288, P173, DOI 10.1016/0014-5793(91)81028-7; GEHLER J, 1981, HELV PAEDIATR ACTA, V36, P179; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; HANDSCHUMACHER RE, 1968, SCIENCE, V161, P62, DOI 10.1126/science.161.3836.62; HAWORTH JC, 1992, J INHERIT METAB DIS, V15, P933, DOI 10.1007/BF01800237; HOLCENBERG JS, 1978, BIOCHEMISTRY-US, V17, P411, DOI 10.1021/bi00596a005; HREIDARSSON S, 1983, CLIN GENET, V23, P427; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1992, J BIOL CHEM, V267, P8715; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; IKONEN E, 1991, P NATL ACAD SCI USA, V88, P11222, DOI 10.1073/pnas.88.24.11222; ISENBERG JN, 1975, J PEDIATR-US, V86, P713, DOI 10.1016/S0022-3476(75)80355-6; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KAARTINEN V, 1990, CLIN CHIM ACTA, V191, P15, DOI 10.1016/0009-8981(90)90053-U; KAARTINEN V, 1991, BIOCHIM BIOPHYS ACTA, V1097, P28, DOI 10.1016/0925-4439(91)90019-6; KIM KW, 1988, J BIOL CHEM, V263, P11948; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAWCZAK M, 1991, HUM GENET, V86, P425; KURANDA MJ, 1986, J BIOL CHEM, V261, P5803; LOUGH TJ, 1992, PLANT MOL BIOL, V19, P391, DOI 10.1007/BF00023386; LUNDBLAD A, 1976, EUR J BIOCHEM, V67, P209, DOI 10.1111/j.1432-1033.1976.tb10651.x; MAHADEVA.S, 1967, J BIOL CHEM, V242, P4568; MAITA T, 1974, J BIOCHEM-TOKYO, V76, P1351, DOI 10.1093/oxfordjournals.jbchem.a130690; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MAURY CPJ, 1982, J INHERIT METAB DIS, V5, P192, DOI 10.1007/BF02179139; MCGOVERN MM, 1983, J BIOL CHEM, V258, P743; MINTON NP, 1986, GENE, V46, P25, DOI 10.1016/0378-1119(86)90163-0; MONONEN I, 1988, J INHERIT METAB DIS, V11, P194, DOI 10.1007/BF01799872; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; MONONEN I, 1988, SCAND J CLIN LAB INV, V48, P7; MONONEN I, 1992, J BIOL CHEM, V267, P3196; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; MONONEN T, 1986, CLIN CHEM, V32, P501; MONONEN T, 1991, HUM GENET, V87, P266; MONONEN TK, 1989, CLIN CHIM ACTA, V180, P99, DOI 10.1016/0009-8981(89)90302-1; MORRIS C, 1992, HUM GENET, V88, P295; MURAKAMI M, 1965, J BIOL CHEM, V240, P556; MUSUMECI S, 1984, AM J MED GENET, V19, P643, DOI 10.1002/ajmg.1320190403; Neuberger A, 1972, GLYCOPROTEINS THEIR, P450; OHGUSHI T, 1968, BIOCHIM BIOPHYS ACTA, V156, P417, DOI 10.1016/0304-4165(68)90276-6; PALO J, 1967, ACTA NEUROL SCAND, V43, P573, DOI 10.1111/j.1600-0404.1967.tb05552.x; PALO J, 1973, CLIN CHIM ACTA, V47, P69, DOI 10.1016/0009-8981(73)90061-2; PALO J, 1970, J MENT DEFIC RES, V14, P168; PARK H, 1993, BIOCHEM J, V290, P735, DOI 10.1042/bj2900735; PARK H, 1991, FEBS LETT, V288, P168, DOI 10.1016/0014-5793(91)81027-6; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; POLLITT RJ, 1968, LANCET, V2, P253; POLLITT RJ, 1974, BIOCHEM J, V141, P141, DOI 10.1042/bj1410141; RIP JW, 1992, BIOCHEM J, V288, P1005, DOI 10.1042/bj2881005; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SALASPURO M, 1990, LIFE SCI, V47, P627, DOI 10.1016/0024-3205(90)90574-B; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; SUGAHARA K, 1975, J BIOCHEM-TOKYO, V78, P673, DOI 10.1093/oxfordjournals.jbchem.a130954; SUN DX, 1991, J BACTERIOL, V173, P3831, DOI 10.1128/JB.173.12.3831-3845.1991; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X; TABAS I, 1978, J BIOL CHEM, V253, P7779; TANAKA M, 1973, J BIOCHEM-TOKYO, V73, P1285, DOI 10.1093/oxfordjournals.jbchem.a130202; TANAKA S, 1988, J BIOL CHEM, V263, P8583; TARENTINO AL, 1975, BIOCHEMISTRY-US, V14, P5516, DOI 10.1021/bi00696a021; TARENTINO AL, 1969, ARCH BIOCHEM BIOPHYS, V130, P295, DOI 10.1016/0003-9861(69)90036-8; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; TOLLERSRUD OK, 1988, BIOCHIM BIOPHYS ACTA, V953, P353, DOI 10.1016/0167-4838(88)90044-1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMASHINA I, 1972, GLYCOPROTEINS, P1187; YOSHIDA K, 1991, CLIN GENET, V40, P318; YOSHIDA K, 1992, HUM GENET, V90, P179	95	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1247	1256		10.1096/fasebj.7.13.8405810	http://dx.doi.org/10.1096/fasebj.7.13.8405810			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405810				2022-12-28	WOS:A1993MB37600008
J	ANDERSON, MJ; STANBRIDGE, EJ				ANDERSON, MJ; STANBRIDGE, EJ			TUMOR-SUPPRESSOR GENES STUDIED BY CELL HYBRIDIZATION AND CHROMOSOME TRANSFER	FASEB JOURNAL			English	Review						SOMATIC CELL HYBRIDIZATION; TUMOR SUPPRESSION; MICROCELL FUSION; CHROMOSOME TRANSFER	WILMS-TUMOR; TUMORIGENIC EXPRESSION; MICROCELL TRANSFER; CARCINOMA-CELLS; DIPLOID CELLS; HYBRIDS; MALIGNANCY; CANCER; LINE; IDENTIFICATION	Although the cloning of tumor suppressor genes has proved to be an arduous task, often involving several years of labor intensive cloning strategies, a greater understanding of neoplastic progression will be made once the function and role of these genes have been sorted out. To fully appreciate the state at which this field of research currently is, however, one must understand that the road to tumor suppression was paved by both somatic cell hybridization and chromosome transfer studies. Although regarded by many as laboratory artifact, somatic cell hybridization has provided strong circumstantial evidence, if not formal proof, for the existence of tumor suppressor genes. In further reducing the complexity associated with whole genome transfer, single chromosome transfer was subsequently developed as a refinement to this technique so that one could unequivocally correlate suppression with a particular chromosome. We have learned from these studies that single chromosomes harbor the genetic information necessary to reverse the malignant phenotype associated with cancer cells. Furthermore, multiple tumor suppressor loci are now known to exist, with one to several different loci associated with a given tumor type. In this review, we present evidence for tumor suppressor genes and discuss the early studies that led to their discovery.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANERJEE A, 1992, CANCER RES, V52, P6297; BARSKI G, 1962, J NATL CANCER I, V28, P801; BENEDICT WF, 1984, CANCER RES, V44, P3471; BRODEUR GM, 1990, CANCER SURV, V9, P673; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JONASSON J, 1977, J CELL SCI, V24, P217; KAELBLING M, 1986, CYTOGENET CELL GENET, V41, P65, DOI 10.1159/000132206; KAO FT, 1977, JNCI-J NATL CANCER I, V59, P409, DOI 10.1093/jnci/59.2.409; KLEIN G, 1971, J CELL SCI, V8, P659; KLINGER HP, 1986, CYTOGENET CELL GENET, V42, P225, DOI 10.1159/000132283; KLINGER HP, 1982, CYTOGENET CELL GENET, V32, P68, DOI 10.1159/000131688; KLINGER HP, 1980, CYTOGENET CELL GENET, V27, P254, DOI 10.1159/000131494; KUGOH HM, 1990, ONCOGENE, V5, P1637; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; MCBRIDE OW, 1973, P NATL ACAD SCI USA, V70, P1258, DOI 10.1073/pnas.70.4.1258; MILLER DA, 1983, ADV CANCER RES, V39, P153, DOI 10.1016/S0065-230X(08)61035-0; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MISRA BC, 1989, AM J HUM GENET, V45, P565; NEGRINI M, 1992, ONCOGENE, V7, P2013; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; OSHIMURA M, 1989, P AM ASSOC CANC RES, V30, P786; PEEHL DM, 1982, INT J CANCER, V30, P113, DOI 10.1002/ijc.2910300119; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; SAGER R, 1978, SOMAT CELL GENET, V4, P375, DOI 10.1007/BF01542849; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCALETTA LJ, 1965, NATURE, V205, P1169, DOI 10.1038/2051169a0; SHIMIZU M, 1990, ONCOGENE, V5, P185; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TUNNACLIFFE A, 1983, EMBO J, V2, P1577, DOI 10.1002/j.1460-2075.1983.tb01627.x; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WIENER F, 1974, J CELL SCI, V15, P177; XU HJ, 1991, CANCER RES, V51, P4481; YAMADA H, 1990, ONCOGENE, V5, P1141	61	48	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					826	833		10.1096/fasebj.7.10.8344482	http://dx.doi.org/10.1096/fasebj.7.10.8344482			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344482				2022-12-28	WOS:A1993LQ33700003
J	SUN, Y; DONG, ZG; NAKAMURA, K; COLBURN, NH				SUN, Y; DONG, ZG; NAKAMURA, K; COLBURN, NH			DOSAGE-DEPENDENT DOMINANCE OVER WILD-TYPE P53 OF A MUTANT P53 ISOLATED FROM NASOPHARYNGEAL CARCINOMA	FASEB JOURNAL			English	Note						P53; TUMOR SUPPRESSOR GENE; NASOPHARYNGEAL CARCINOMA; HETEROZYGOUS MUTATION; DOMINANT NEGATIVE	TUMOR SUPPRESSOR GENE; TATA-BINDING PROTEIN; CANCER CELLS; SV40-TRANSFORMED CELLS; LUNG-CANCER; MUTATIONS; ANTIGEN; TRANSFORMATION; GROWTH; EXPRESSION	Mutational inactivation of p53, a tumor suppressor gene, is the most common genetic alteration found in human cancer. Most mutated p53s either lose tumor suppressor function or gain oncogenic activity. We recently reported the detection of a heterozygous point mutation of p53 at codon 280 in nasopharyngeal carcinoma (NPC) (1), a high-incidence malignancy in southern China and southeast Asia. Given its heterozygous state, in which both wild-type and mutated p53 gene were expressed, p53-thr280 should function dominantly in the presence of the wild-type form if it is to play a role in nasopharynx carcinogenesis. We tested this dominance hypothesis in the cells of two model systems: 1) human Saos-2 cells lacking endogenous p53, and 2) mouse JB6 tumor promotion-resistant cells (P-) expressing endogenous wild-type p53. The results showed dosage-dependent dominance of p53-thr280 in controlling WT p53-driven transcriptional activity; in governing cell growth; and in progressing P- phenotype to tumor promotion-sensitive (P+) phenotype. This dominant negative effect was seen at a 1:1 (WT:MU) ratio and was more striking at a ratio of 1:3. A model is proposed to explain the dominant negative effect of mutant p53. We conclude from this study that p53-thr280 is likely to be dominant in the heterozygous state found in NPC and that this dominant-negative mutated p53 may contribute to the genesis of NPC or of other carcinomas in which both mutant and wild-type p53 are expressed.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BCDP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SUN, Y (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,CELL BIOL SECT,FREDERICK,MD 21702, USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7712; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HEINTZ N, 1991, HORMONAL CONTROL REG, P3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP, P87; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAZARS R, 1991, ONCOGENE, V6, P1685; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, IN PRESS MOL CARCINO; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1993, IN PRESS ONCOGENE	54	58	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					944	950		10.1096/fasebj.7.10.8344492	http://dx.doi.org/10.1096/fasebj.7.10.8344492			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344492				2022-12-28	WOS:A1993LQ33700019
J	ZAMBETTI, GP; LEVINE, AJ				ZAMBETTI, GP; LEVINE, AJ			A COMPARISON OF THE BIOLOGICAL-ACTIVITIES OF WILD-TYPE AND MUTANT-P53	FASEB JOURNAL			English	Review						TUMOR SUPPRESSION; TRANSFORMATION; TRANSACTIVATION	CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR GENE; LI-FRAUMENI SYNDROME; CANCER-PRONE FAMILY; HUMAN P53 GENE; TRANSFORMED-CELLS; MONOCLONAL-ANTIBODY; BREAST-CANCER; PROTEINS BIND; GERM-LINE	Tumorigenesis is characterized by a series of genetic alterations in both dominant oncogenes and tumor suppressor genes. A hallmark of tumor suppressor genes is that both alleles are generally altered during transformation, which usually represents a loss of function phenotype. The p53 tumor suppressor gene is the most frequently affected gene detected in human cancer. There is now growing evidence suggesting that mutation of p53 may involve not only a loss of function of wild-type p53 activity but also a gain of function phenotype contributed by the mutant p53 protein. The study of the biological properties and functions of both wild-type and mutant p53 is central to our understanding of human cancer. These properties and functions of wild-type and mutant p53 will be compared and contrasted here and elsewhere within this thematic issue. In addition, the mechanisms of inactivation of p53 function, which include: 1) mutation, 2) inhibition by viral oncogene products, 3) inhibition by cellular regulators, and 4) alteration in subcellular localization, will be discussed.			ZAMBETTI, GP (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, IN PRESS GENES DEV; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P44; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FINLAY M, 1993, IN PRESS NATURE GEN, P53; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	100	461	471	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					855	865		10.1096/fasebj.7.10.8344485	http://dx.doi.org/10.1096/fasebj.7.10.8344485			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344485				2022-12-28	WOS:A1993LQ33700007
J	ABDULKADIR, SA; ONO, SJ				ABDULKADIR, SA; ONO, SJ			HOW ARE CLASS-II MHC GENES TURNED ON AND OFF	FASEB JOURNAL			English	Review						MAJOR HISTOCOMPATIBILITY COMPLEX GENES; TRANSCRIPTION FACTORS; BARE LYMPHOCYTE SYNDROME; AUTOIMMUNE DISEASE; GENE REGULATION; PROTEIN PROTEIN INTERACTIONS	X-BOX-BINDING; HLA-DRA GENE; HISTOCOMPATIBILITY COMPLEX GENE; BARE LYMPHOCYTE SYNDROME; MACROPHAGE CELL-LINE; NF-KAPPA-B; INTERFERON-GAMMA; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; T-CELLS	Fragments of foreign antigen are detected by CD4(+) helper T cells via the T cell receptor for antigen in the context of major histocompatibility complex (MHC) class II molecules, Very few cells normally express class II MHC molecules, and these cells play critical roles in antigen presentation and in the thymic selection of T lymphocytes before their exit into the periphery, Because of the central role the class II MHC molecules play in immune system function, it is not surprising that the lack of expression of these molecules results in a severe combined immunodeficiency disorder (called bare lymphocyte syndrome) and that the aberrant expression of the molecules is frequently observed in the target organs of various autoimmune disorders (e.g., multiple sclerosis and rheumatoid arthritis), Because both classes of disease could conceivably be treated by molecular approaches targeted at either restoring or inhibiting expression of class II MHC genes, there has been an intense effort during the past decade to elucidate the regulatory mechanisms of class II MHC genes, An analysis of recent advances in this effort is provided in this review article.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,GRAD PROGRAM IMMUNOL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; AMALDI I, 1989, J IMMUNOL, V142, P999; ANDERSEN LC, 1991, J EXP MED, V173, P181, DOI 10.1084/jem.173.1.181; ARAGNOL D, 1986, J IMMUNOL, V137, P3347; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P861; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOTTGER EC, 1988, IMMUNOGENETICS, V28, P215, DOI 10.1007/BF00345497; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHANG CH, 1992, J EXP MED, V176, P1465, DOI 10.1084/jem.176.5.1465; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; COGSWELL JP, 1990, P NATL ACAD SCI USA, V87, P7703, DOI 10.1073/pnas.87.19.7703; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DENNIS GJ, 1986, J IMMUNOL, V136, P1600; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; DIDIER DK, 1992, P NATL ACAD SCI USA, V85, P7322; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; GAUR LK, 1992, IMMUNOGENETICS, V35, P136; GERMAIN RH, 1994, CELL, V7, P287; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KING DP, 1983, J IMMUNOL, V131, P315; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MOND JJ, 1981, J IMMUNOL, V127, P881; MONROE JG, 1984, J IMMUNOL, V132, P1472; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; ONO SJ, 1989, DIABETES, V38, P911, DOI 10.2337/diabetes.38.7.911; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; ONO SJ, 1995, J BIOL CHEM, V27, P6396; POLLA BS, 1988, J MOL CELL IMMUNOL, V3, P363; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; RILEY JL, 1993, J IMMUNOL, V151, P6942; SCHWIEBERT LM, 1995, IN PRESS CELL IMMUNO; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4245; SHEWEY LM, 1992, J IMMUNOL, V148, P1265; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; SONG ZM, 1994, J EXP MED, V180, P1763, DOI 10.1084/jem.180.5.1763; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P107; STIMAC E, 1988, MOL CELL BIOL, V8, P3734, DOI 10.1128/MCB.8.9.3734; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TING JP, 1993, IMMUNOL RES, V12, P65, DOI 10.1007/BF02918369; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TSANG SY, 1990, MOL CELL BIOL, V10, P1361; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; ZIER K, 1989, AUTOIMMUNITY, V5, P59, DOI 10.3109/08916938909029143	67	46	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1429	1435		10.1096/fasebj.9.14.7589984	http://dx.doi.org/10.1096/fasebj.9.14.7589984			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589984				2022-12-28	WOS:A1995TF67800007
J	LYNN, WS; WONG, PKY				LYNN, WS; WONG, PKY			NEUROIMMUNODEGENERATION - DO NEURONS AND T-CELLS USE COMMON PATHWAYS FOR CELL-DEATH	FASEB JOURNAL			English	Review						ACCESSORY CELL FUNCTION; CYTOKINE AND REDOX MODULATION; ATAXIA TELANGIETASIA; RETROVIRUS INFECTION	HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; KAPPA-B; ATAXIA-TELANGIECTASIA; ALZHEIMERS-DISEASE; INTERFERON-GAMMA; TRANSGENIC MICE; INTERLEUKIN-6; APOPTOSIS	In syndromes of pediatric neuroimmunodegeneration (NID), certain neurons and T cells degenerate and disappear during early development at an accelerated rate without alerting the peripheral immune cells. Current studies of some of these NID syndromes suggest that the primary cause of neuronal and T cell death is an imbalanced cytokine signaling system with a dysfunctional redox status, and that the loss of T cells and neurons may he secondary to impaired functions of their accessory supportive cells. These dysfunctions include inappropriate production of developmental cytokines, inadequate secretion of reductants, and disregulation of excitotoxic amino acid metabolism. Two examples of pediatric NID in humans are ataxia telangiectasia and pediatric human immunodeficiency virus infection, An animal model is retrovirus-induced T and neuronal cell loss in neonatal mice infected with a neuroimmunopathogenic mutant, ts 1, of the Moloney murine leukemia virus. Because both thymic and neuronal components share many growth factors and developmental signals, it is likely that disregulation of these signals would lead to concomitant dysfunction of neuronal and thymic cells. In this review, we focus on the pathogenic mechanisms involved in these developmental NID syndromes with the objective of identifying common pathogenic factors and pathways responsible for the concurrent losses of both neurons and T cells.	UNIV TEXAS, MD ANDERSON CANC CTR, DIV SCI PK RES, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA 45124] Funding Source: Medline; NIAID NIH HHS [AI28283] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028283, R21AI028283] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AMMANN AJ, 1994, PEDIATRICS, V93, P930; AMMANN AJ, 1993, ANN NY ACAD SCI, V693, P178, DOI 10.1111/j.1749-6632.1993.tb26266.x; BECKER Y, 1992, ISRAEL J MED SCI, V28, P837; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; BREDESEN DE, 1994, APOPTOSIS, V2, P397; BUTTKE TM, 1994, P NATL ACAD SCI USA, V90, P10061; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONZALESSCARANO F, 1995, RETROVIDRIDAE, V4, P409; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CUNNINGHAMRUNDLES C, 1994, NEW ENGL J MED, V331, P918, DOI 10.1056/NEJM199410063311405; DANESCU M, 1992, J EXP MED, V176, P1319; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DICKSON DW, 1993, ANN NY ACAD SCI, V693, P93, DOI 10.1111/j.1749-6632.1993.tb26259.x; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DROGE W, 1994, FASEB J, V8, P1131; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FAUSCI AS, 1993, SCIENCE, V262, P250; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GATTI RA, 1993, NEW CONCEPTS IMMUNOD, P202; GELEZIUNAS R, 1994, FASEB J, V8, P593, DOI 10.1096/fasebj.8.9.8005387; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1988, J NEUROSCI, V8, P709; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANSARI N, 1985, J NEUROIMMUNOL, V7, P279; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KORNBLUTH RS, 1994, J LEUKOCYTE BIOL, V56, P247, DOI 10.1002/jlb.56.3.247; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARTIN JB, 1993, SCIENCE, V262, P674, DOI 10.1126/science.8235586; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MENTIS GZ, 1993, NEUROSCIENCE, V54, P283, DOI 10.1016/0306-4522(93)90253-C; MEYERS A, 1992, PEDIATRICS, V90, P99; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; MOUSTACCHI E, 1994, 85TH P ANN M AM ASS; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PATTERSON PH, 1993, NEURON S, V10, P123; PIANI D, 1994, J IMMUNOL, V152, P3578; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; RAZAN J, 1992, NEURON, V7, P197; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; SAHA K, 1994, J VIROL, V68, P2735, DOI 10.1128/JVI.68.4.2735-2740.1994; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCREPANTI I, 1992, P NATL ACAD SCI USA, V89, P3209, DOI 10.1073/pnas.89.8.3209; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIVE W, 1988, ANNU REV NUTR, V8, P81, DOI 10.1146/annurev.nu.08.070188.000501; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STOICA G, 1992, LAB INVEST, V66, P427; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWIFT M, 1993, ADV NEUROL, V61, P115; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WILFERT CM, 1994, J INFECT DIS, V170, P286, DOI 10.1093/infdis/170.2.286; WONG PKY, 1992, MOL NEUROVIROLOGY PA, P161; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	99	25	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1995	9	12					1147	1156		10.1096/fasebj.9.12.7672507	http://dx.doi.org/10.1096/fasebj.9.12.7672507			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672507				2022-12-28	WOS:A1995RU81600004
J	KLOTH, S; EBENBECK, C; KUBITZA, M; SCHMIDBAUER, A; ROCKL, W; MINUTH, WW				KLOTH, S; EBENBECK, C; KUBITZA, M; SCHMIDBAUER, A; ROCKL, W; MINUTH, WW			STIMULATION OF RENAL MICROVASCULAR DEVELOPMENT UNDER ORGANOTYPIC CULTURE CONDITIONS	FASEB JOURNAL			English	Article						KIDNEY; VASCULAR DEVELOPMENT; PERFUSION CELL CULTURE; ENDOTHELIUM; GROWTH FACTORS	ENDOTHELIAL GROWTH-FACTOR; DEVELOPING KIDNEY; RABBIT KIDNEY; CELLS; DIFFERENTIATION; ANGIOGENESIS; RECEPTORS; NEPHRON; SPECIFICITY; EXPRESSION	The development of the renal vascular system requires the coordinated action of soluble morphogenic factors and specific extracellular matrix components, Despite intensive research it remains unknown whether the humoral or the environmental component is more important in the development of renal microvessels, The prolonged serum-free culture of embryonic kidney cortex explants was achieved by means of a newly developed perfusion culture system, This system made the investigation of renal vascular development under defined organotypic conditions possible, Thus, growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hormones (aldosterone, vitamin D-3) could be applied without the interference with serum components. Medium supplementation with VEGF or aldosterone in combination with vitamin D-3 resulted in the coordinated proliferation of endothelial cells in the explant, A well-developed collecting duct epithelium and numerous tubular structures were always observed, In contrast, only a uniform cell layer was found between fibrous organ capsule and the collecting duct epithelium after bFGF application, but neither tubular structures nor endothelial cells. Thus, the experiments indicate that bFGF alone has no stimulating effect on the growth of the renal microvasculature under perfusion culture conditions.	GESELL BIOTECHNOL FORSCH MBH,DEPT GENEXPRESS,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH	KLOTH, S (corresponding author), UNIV REGENSBURG,INST ANAT,UNIV STR 31,D-93053 REGENSBURG,GERMANY.							ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BARD JBL, 1991, DEVELOPMENT, V113, P193; BREIER G, 1992, DEVELOPMENT, V114, P521; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; EMURA M, 1972, DEV GROWTH DIFFER, V14, P237; FARMAN N, 1992, SEMIN NEPHROL, V12, P12; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; IIJIMA K, 1993, KIDNEY INT, V44, P959, DOI 10.1038/ki.1993.337; KAZIMIERCZAK J, 1971, ACTA PATHOL MICROB A, V218, P9; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KLOTH S, 1992, DIFFERENTIATION, V52, P79, DOI 10.1111/j.1432-0436.1992.tb00502.x; KLOTH S, 1994, CELL TISSUE RES, V277, P247, DOI 10.1007/s004410050152; KLOTH S, 1993, EUR J CELL BIOL, V63, P84; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KUMAR R, 1994, AM J PHYSIOL, V266, pF477, DOI 10.1152/ajprenal.1994.266.3.F477; Ledoux D, 1991, Growth Factors, V5, P221, DOI 10.3109/08977199109000286; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINUTH WW, 1987, DIFFERENTIATION, V36, P12, DOI 10.1111/j.1432-0436.1987.tb00177.x; MINUTH WW, 1992, EUR J CELL BIOL, V57, P132; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; POTTER EL, 1965, ARCH PATHOL, V80, P241; RAJI L, 1991, J AM SOC NEPHROL, V2, pS2; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SARIOLA H, 1983, DEV BIOL, V96, P427, DOI 10.1016/0012-1606(83)90180-X; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; UCHIDA K, 1994, AM J PHYSIOL, V266, pF81, DOI 10.1152/ajprenal.1994.266.1.F81; VAISMAN N, 1990, J BIOL CHEM, V265, P19461	35	30	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					963	967		10.1096/fasebj.9.10.7615165	http://dx.doi.org/10.1096/fasebj.9.10.7615165			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615165				2022-12-28	WOS:A1995RK89900019
J	VANHOOF, G; GOOSSENS, F; DEMEESTER, I; HENDRIKS, D; SCHARPE, S				VANHOOF, G; GOOSSENS, F; DEMEESTER, I; HENDRIKS, D; SCHARPE, S			PROLINE MOTIFS IN PEPTIDES AND THEIR BIOLOGICAL PROCESSING	FASEB JOURNAL			English	Review						CYTOKINES; DIPEPTIDYL PEPTIDASE IV; PROLYL OLIGOPEPTIDASE; CIS-TRANS ISOMERIZATION; SUBSTANCE P; IGA PROTEASES	CELL ACTIVATION ANTIGEN; AMINOPEPTIDASE-P; ANTIMICROBIAL PEPTIDES; TRANSMEMBRANE HELICES; CONVERTING ENZYME; HUMAN-LYMPHOCYTES; HUMAN-LEUKOCYTES; ALPHA-CHAIN; RAT-BRAIN; IV CD26	Many biologically important peptide sequences contain proline. It confers unique conformational constraints on the peptide chain in that the side-chain is cyclized back onto the backbone amide position. Inside an alpha-helix the possibility of making hydrogen bonds to the preceding turn is lost and a kink will be introduced. The conformational restrictions imposed by proline motifs in a peptide chain appear to imply important structural or biological functions as can be deduced from their often remarkably high degree of conservation as found in many proteins and peptides, especially cytokines, growth factors, G-protein-coupled receptors, V3 loops of the HIV envelope glycoprotein gp120, and neuro- and vasoactive peptides. Only a limited number of peptidases are known to be able to hydrolyze proline adjacent bonds. Their activity is influenced by the isomeric state (cis-trans) as well as the position of proline in the peptide chain. The three proline specific metallo-peptidases (aminopeptidase P, carboxypeptidase P and prolidase) are activated by Mn2+, whereas the three serine type peptidases cleaving a post proline bond (prolyl oligopeptidase, dipeptidyl peptidase IV, and prolylcarboxypeptidase) share the sequential order of the catalytic Ser-Asp-His triade, which differentiates them from the chymotrypsin (His-Asp-Ser) and subtilisin (Asp-His-Ser) families. An endo or C terminal Pro-Pro bond and an endo pre-Pro peptide bond possess a high degree of resistance to any mammalian proteolytic enzyme.	UNIV INSTELLING ANTWERP,DEPT CLIN BIOCHEM,B-2610 WILRIJK,BELGIUM	University of Antwerp			De Meester, Ingrid/A-6881-2017; Hendriks, Dirk/E-3797-2017	De Meester, Ingrid/0000-0002-3421-0124; 				BARELLI H, 1993, EUR J BIOCHEM, V211, P79, DOI 10.1111/j.1432-1033.1993.tb19872.x; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BAUVOIS B, 1992, EUR J IMMUNOL, V22, P923, DOI 10.1002/eji.1830220407; BIRKEN S, 1978, BIOCHEM BIOPH RES CO, V85, P1247, DOI 10.1016/0006-291X(78)91137-3; BLASQUEZ MV, 1992, J IMMUNOL, V149, P3073; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURTON PM, 1987, INT J IMMUNOPHARMACO, V9, P297, DOI 10.1016/0192-0561(87)90054-3; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; COWAN PM, 1955, NATURE, V176, P501, DOI 10.1038/176501a0; DEMEESTER I, 1992, CLIN CHIM ACTA, V210, P23, DOI 10.1016/0009-8981(92)90042-O; DEMEESTER I, 1994, EUR J IMMUNOL, V24, P566, DOI 10.1002/eji.1830240311; Fauve R.M., 1987, IMMUNOSTIMULANTS NOW, P225; FISCHER G, 1983, BIOCHIM BIOPHYS ACTA, V742, P452, DOI 10.1016/0167-4838(83)90261-3; FRANK RW, 1990, J BIOL CHEM, V265, P18871; FRIDKIN M, 1989, CRIT REV BIOCHEM MOL, V24, P1, DOI 10.3109/10409238909082550; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HEDEAGERSORENSE.S, 1985, BIOCHEM J, V229, P251; HENDRIKS D, 1991, CLIN CHIM ACTA, V196, P87, DOI 10.1016/0009-8981(91)90061-G; HOBBS MV, 1987, J IMMUNOL, V138, P2581; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; JANUSZ M, 1987, MOL IMMUNOL, V24, P1029, DOI 10.1016/0161-5890(87)90069-1; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; JU G, 1987, J BIOL CHEM, V262, P5723; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; Keil B, 1992, SPECIFICITY PROTEOLY, P206; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; LABSCH B, 1981, PHARMAZIE, V36, P161; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARINCHENKO GV, 1991, BIOCHEMISTRY-MOSCOW+, V56, P521; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MORIHARA K, 1984, J BIOCHEM, V95, P795, DOI 10.1093/oxfordjournals.jbchem.a134671; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; NAKATA Y, 1981, J NEUROCHEM, V37, P1529, DOI 10.1111/j.1471-4159.1981.tb06323.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; RUSU I, 1992, EUR J BIOCHEM, V210, P93, DOI 10.1111/j.1432-1033.1992.tb17395.x; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; SCHOONMAKER JN, 1991, AM J OBSTET GYNECOL, V165, P737, DOI 10.1016/0002-9378(91)90320-Q; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; STGEORGIEV V, 1990, TRENDS PHARMACOL SCI, V11, P373, DOI 10.1016/0165-6147(90)90183-9; TAN FL, 1993, J BIOL CHEM, V268, P16631; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1994, P NATL ACAD SCI USA, V61, P3082; TURZYNSKI A, 1990, EUR J BIOCHEM, V190, P509, DOI 10.1111/j.1432-1033.1990.tb15603.x; VANHAM G, 1992, J ACQ IMMUN DEF SYND, V6, P749; VANHOOF G, 1992, BIOCHEM PHARMACOL, V44, P479, DOI 10.1016/0006-2952(92)90439-P; Vanhoof G, 1992, Agents Actions Suppl, V38 ( Pt 2), P120; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WANG W, 1994, J BIOL CHEM, V269, P15937; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; ZOLFAGHARI R, 1986, ENZYME, V36, P165, DOI 10.1159/000469289	68	382	400	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					736	744		10.1096/fasebj.9.9.7601338	http://dx.doi.org/10.1096/fasebj.9.9.7601338			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601338				2022-12-28	WOS:A1995RH98200007
J	BAN, N; ESCOBAR, C; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A				BAN, N; ESCOBAR, C; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A			STRUCTURE OF AN ANTIIDIOTYPIC FAB AGAINST FELINE PERITONITIS VIRUS-NEUTRALIZING ANTIBODY AND A COMPARISON WITH THE COMPLEXED FAB	FASEB JOURNAL			English	Article						CRYSTAL STRUCTURE; INTERNAL IMAGE; CONFORMATIONAL CHANGE; INDUCED FIT	3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; HYPERVARIABLE REGIONS; CRYSTAL-STRUCTURES; AREA DETECTOR; BINDING; REFINEMENT; ALGORITHM; FRAGMENT; IMMUNOGLOBULINS	The crystal structure of anti-idiotopic Fab 409.5.3, made against an E2 specific feline infectious peritonitis virus-neutralizing antibody 730.1.4, has been determined in its free form, at 2.9 Angstrom resolution by molecular replacement. This antibody, used as an immunogen, elicits the production of anti-anti-idiotypic antibodies that in turn neutralize the virus. The structure of the uncomplexed Fab was refined using constrained-restrained least squares minimization and simulated annealing in combination with conjugate gradient techniques to a crystallographic R of 0.22 based on 16,482 unique reflections between 20.0 and 2.9 Angstrom. The free antiidiotypic Fab shows, when compared to its complexed form, a 5 degrees rotation of its variable light with respect to its variable heavy domain and rearrangement of complementarity determining region loops, which permits optimization of the stereocomplementarity between interacting molecules. This finding supports the induced fit hypothesis for antibody antigen interaction.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; IMMUNOPHARMACEUT INC,SAN DIEGO,CA 92127	University of California System; University of California Riverside			Greenwood, Alex/GWU-8292-2022		NIGMS NIH HHS [GM40706-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040706] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BAN N, 1991, J MOL BIOL, V222, P445, DOI 10.1016/0022-2836(91)90484-N; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DAVIE JM, 1986, ANNU REV IMMUNOL, V4, P147, DOI 10.1146/annurev.immunol.4.1.147; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; EDMUNDSON AB, 1994, RES IMMUNOL, V145, P56, DOI 10.1016/S0923-2494(94)80045-6; ESCOBAR JC, 1992, VIRAL IMMUNOL, V1, P71; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GELIN BR, 1979, BIOCHEMISTRY-US, V8, P1256; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1990, O MANUAL; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, SEQUENCES PROTEINS I; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATTMAN EE, 1972, ACTA CRYSTALLOGR B, V26, P1854; LOVE RA, 1993, BIOCHEMISTRY-US, V32, P10950, DOI 10.1021/bi00092a004; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1992, METHOD ENZYMOL, V203, P3; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TORMO J, 1992, PROTEIN SCI, V1, P1154, DOI 10.1002/pro.5560010909; WALLS PH, 1992, J MOL BIOL, V228, P277, DOI 10.1016/0022-2836(92)90506-F; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; [No title captured]	58	15	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					107	114		10.1096/fasebj.9.1.7821749	http://dx.doi.org/10.1096/fasebj.9.1.7821749			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821749				2022-12-28	WOS:A1995QD20200017
J	DELPRETE, G; DECARLI, M; ALMERIGOGNA, F; DANIEL, CK; DELIOS, MM; ZANCUOGHI, G; VINANTE, F; PIZZOLO, G; ROMAGNANI, S				DELPRETE, G; DECARLI, M; ALMERIGOGNA, F; DANIEL, CK; DELIOS, MM; ZANCUOGHI, G; VINANTE, F; PIZZOLO, G; ROMAGNANI, S			PREFERENTIAL EXPRESSION OF CD30 BY HUMAN CD4(+) T-CELLS PRODUCING TH2-TYPE CYTOKINES	FASEB JOURNAL			English	Article						MEMBRANE CD30; SOLUBLE CD30; HUMAN TH1 TH2; CELLS	HODGKINS-DISEASE; FUNCTIONAL SUBSETS; LYMPHOID-CELLS; HELPER; RECEPTOR; RESPONSES; CLONES; TH1; DEFINES; FAMILY	A large panel of human CD4(+) T helper (Th) cell clones with established Th1, Th2, or Th0 profiles of cytokine secretion were examined for the expression of CD30, a member of the tumor necrosis factor receptor superfamily. Th1 clones expressed poor or no CD30 mRNA, and showed low or undetectable expression of both membrane and soluble CD30 (sCD30) protein, whereas Th2 clones showed both CD30 mRNA and membrane CD30 and released substantial amounts of sCD30. Th0 clones exhibited an intermediate pattern of CD30 expression and release. When T cells from the same donor were stimulated with three different antigens (purified protein derivative, PPD; Toxocara canis excretory/secretory antigen, TES; Lolium perenne group I, Lo1 p I), production of high concentrations of IFN-gamma, but not expression of CD30 or production of IL-4 and IL-5, were observed at any time after stimulation with PPD. In contrast, both CD30 expression and production of IL-4 and IL-5, but not of IFN-gamma, were concomitantly detectable in TES- and Lo1 p I-reactive T cells, suggesting a temporal relationship between CD30 expression and beginning of Th2-type cytokine production. Finally, CD4(+)CD30(+) T cells specific for Lo1 p I and inducible to production of Th2-type cytokines were sorted out from the circulation of grass-sensitive patients in concomitance with the onset of allergic symptoms during the seasonal exposure to grass pollen. Thus, CD30 expression appears to be associated with the differentiation/activation pathway of human T cells producing Th2-type cytokines.	UNIV FLORENCE, IST CLIN MED 3, DIV CLIN IMMUNOL & ALLERGY, I-50134 FLORENCE, ITALY; UNIV PISA, POLICLIN SANTA CHIARA, IST CLIN MED 1, I-56100 PISA, ITALY; UNIV VERONA, POLICLIN BORGO ROMA, DEPT HEMATOL, I-37134 VERONA, ITALY	University of Florence; University of Pisa; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona			Almerigogna, Fabio/AAL-4583-2020; D'Elios, Mario Milco/Y-9573-2019; Almerigogna, Fabio/A-4636-2012	D'Elios, Mario Milco/0000-0001-9160-0930; Vinante, Fabrizio/0000-0002-3855-6747				ALZONA M, 1994, J IMMUNOL, V153, P2861; ANDREESEN R, 1984, BLOOD, V63, P1299; BOWEN MA, 1993, J IMMUNOL, V151, P5896; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; MAGGI E, 1992, J IMMUNOL, V148, P2142; MAGILAVY DB, 1989, J EXP MED, V170, P985, DOI 10.1084/jem.170.3.985; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MANETTI R, 1995, IN PRESS J EXP MED; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; REINER SL, 1993, PARASITOL TODAY, V9, P258, DOI 10.1016/0169-4758(93)90071-M; ROMAGNANI S, 1985, SEMIN HEMATOL, V22, P41; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STEIN H, 1985, BLOOD, V66, P848; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WILLIAMS IR, 1990, J IMMUNOL, V145, P85	33	370	377	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					81	86		10.1096/fasebj.9.1.7821763	http://dx.doi.org/10.1096/fasebj.9.1.7821763			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821763				2022-12-28	WOS:A1995QD20200013
J	SHOENFELD, Y				SHOENFELD, Y			IDIOTYPIC INDUCTION OF AUTOIMMUNITY - A NEW ASPECT OF THE IDIOTYPIC NETWORK	FASEB JOURNAL			English	Review						AUTOIMMUNE DISEASE; IDIOTYPE; INFECTION	ANTI-DNA IDIOTYPE; SYSTEMIC LUPUS-ERYTHEMATOSUS; EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME; RNA POLYMERASE-I; NAIVE MICE; EXPERIMENTAL SLE; 16/6 IDIOTYPE; AUTOANTIBODIES; IMMUNIZATION; ANTIBODIES	Three different experimental models of autoimmune diseases were induced in naive mice after idiotypic immunization. 1) systemic lupus erythematosus (SLE) after injection of anti-DNA antibodies carrying the pathogenic Id-16/6; 2) anti-phospholipid syndrome (APLS) after immunization with anti-cardiolipin antibodies (having the pathogenic H-3 and MIV-7 Ids); and 3) Wegener's granulomatosis (WG) induced with anti-neutrophile cytoplasmic antibodies (ANCA). In all three experiments the mice developed the respective anti-Id antibodies (Ab(2)), and, after a follow-up period of 4-8 months anti-anti-Id (Ab(3)) were generated by the immunized mice. The latter antibodies (Ab(3)) had the binding characteristics of the respective autoantibodies (Ab(1)) used in the first immunization. The appearance of autoantibodies in the sera of the mice was associated with emergence of all the typical clinical and laboratory findings seen in patients with SLE, APLS, and WG, respectively. We suggest that in some autoimmune diseases, especially in those in which the presumed autoantigen is not immunogenic (e.g., DNA, cardiolipin), the disease may follow a common infection: The antibodies against the infecting agent may carry a pathogenic idiotype of a specific autoantibody. In a subject prone to autoimmunity (genetic, hormonal, immunologic factors), the pathogenic idiotype will progress in dysregulating the immune system to evolve into a clinical overt autoimmune disease.-Shoenfeld, Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network.			SHOENFELD, Y (corresponding author), CHAIM SHEBA MED CTR,DEPT MED B,AUTOIMMUNE DIS RES UNIT,IL-52621 TEL HASHOMER,ISRAEL.							AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BAKIMER R, 1992, J CLIN INVEST, V89, P1558, DOI 10.1172/JCI115749; BLANK M, 1991, CELL IMMUNOL, V137, P474, DOI 10.1016/0008-8749(91)90095-S; BLANK M, 1991, CLIN IMMUNOL IMMUNOP, V60, P471, DOI 10.1016/0090-1229(91)90102-G; BLANK M, 1990, SCAND J IMMUNOL, V31, P45, DOI 10.1111/j.1365-3083.1990.tb02741.x; BLANK M, 1994, J RHEUMATOL, V21, P100; BLANK M, 1992, J AUTOIMMUN, V5, P495, DOI 10.1016/0896-8411(92)90008-E; BONA CA, 1987, MODERN CONCEPTS IMMU, V2, P1; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Buskila D, 1992, Concepts Immunopathol, V8, P114; CARSON DA, 1990, IDIOTYPES BIOL MED, P1; CAZENAVE PA, 1991, PROGR VACCINOLOGY, P1; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; COHEN J, 1994, CLIN EXP IMMUNOL, V97, P181; DANG H, 1993, J IMMUNOL, V151, P7260; EDBERG JC, 1989, CLIN IMMUNOL IMMUNOP, V51, P118, DOI 10.1016/0090-1229(89)90212-2; ELROIEY A, 1987, CLIN EXP IMMUNOL, V67, P507; FISHMAN P, 1993, J CLIN INVEST, V91, P1834, DOI 10.1172/JCI116396; FRICKE H, 1989, INT IMMUNOL, V2, P225; FRIEDMAN SM, 1993, RHEUM DIS CLIN N AM, V19, P207; GROSS WL, 1991, KLIN WOCHENSCHR, V69, P558, DOI 10.1007/BF01649318; ISENBERG DA, 1991, J IMMUNOL, V147, P4172; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KALLENBERG CGM, 1992, AM J MED, V93, P675, DOI 10.1016/0002-9343(92)90202-M; KRAMS SM, 1989, HEPATOLOGY, V9, P411, DOI 10.1002/hep.1840090311; KUNKEL HG, 1963, SCIENCE, V140, P1218, DOI 10.1126/science.140.3572.1218; MADAIO MP, 1984, J IMMUNOL, V132, P872; MENDLOVIC S, 1990, IMMUNOLOGY, V69, P228; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; NAPARSTEK Y, 1985, J EXP MED, V16, P1525; ORBEA HA, 1993, ANN RHEUM DIS, V52, pS6; OUDIN J, 1963, CR HEBD ACAD SCI, V257, P805; ROMBACH E, 1993, CLIN EXP IMMUNOL, V94, P466; ROMBACH E, 1992, AUTOIMMUNITY, V13, P291, DOI 10.3109/08916939209112338; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; SAEKI Y, 1992, P NATL ACAD SCI USA, V89, P6157, DOI 10.1073/pnas.89.13.6157; SELA O, 1987, ARTHRITIS RHEUM-US, V30, P50, DOI 10.1002/art.1780300107; SHOENFELD Y, 1990, FASEB J, V4, P2646, DOI 10.1096/fasebj.4.9.2140806; SHOENFELD Y, 1993, IMMUNOL LETT, V36, P109, DOI 10.1016/0165-2478(93)90041-Y; SHOENFELD Y, 1987, ANTIGENS, P307; SHOENFELD Y, 1988, MOSAIC AUTOIMMUNITY, P1; SMORDINSKY NI, 1989, EUR J IMMUNOL, V18, P1713; SUKENIK S, 1986, ACTA HAEMATOL-BASEL, V76, P86, DOI 10.1159/000206027; TINCANI A, 1993, CLIN EXP RHEUMATOL, V11, P129	47	127	131	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1296	1301		10.1096/fasebj.8.15.8001742	http://dx.doi.org/10.1096/fasebj.8.15.8001742			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001742				2022-12-28	WOS:A1994PY20900013
J	MCCARTY, M				MCCARTY, M			A RETROSPECTIVE LOOK AT THE DISCOVERY OF THE GENETIC ROLE OF DNA	FASEB JOURNAL			English	Editorial Material											MCCARTY, M (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							Alloway JL, 1933, J EXP MED, V57, P265, DOI 10.1084/jem.57.2.265; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; CHARGAFF E, 1963, ESSAYS NUCLEIC ACIDS; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; HOTCHKISS RD, 1951, COLD SPRING HARB SYM, V16, P457, DOI 10.1101/SQB.1951.016.01.032; HOTCHKISSRD, 1979, ANN NY ACAD SCI, V325, P321; MCCARTY M, 1946, J GEN PHYSIOL, V29, P123, DOI 10.1085/jgp.29.3.123; MCCARTY M, 1946, J EXP MED, V83, P89, DOI 10.1084/jem.83.2.89; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	10	1	1	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					889	890		10.1096/fasebj.8.11.8070640	http://dx.doi.org/10.1096/fasebj.8.11.8070640			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070640				2022-12-28	WOS:A1994PC88500014
J	MURPHY, RA				MURPHY, RA			WHAT IS SPECIAL ABOUT SMOOTH-MUSCLE - THE SIGNIFICANCE OF COVALENT CROSSBRIDGE REGULATION	FASEB JOURNAL			English	Review						CALCIUM, CONTRACTION; PHOSPHORYLATION; ENERGETICS; MECHANICS	CROSS-BRIDGE PHOSPHORYLATION; LIGHT CHAIN PHOSPHORYLATION; PROTEIN-KINASE-C; MYOSIN PHOSPHORYLATION; SHORTENING VELOCITY; CONTRACTION-RELAXATION; STRESS; ACTIN; DEPHOSPHORYLATION; DEPENDENCE	Knowledge of the molecular mechanisms involved in chemomechanical transduction and the regulatory elements determining contraction and relaxation are largely derived from cross-striated muscle. However, it has become clear that vertebrate smooth muscles have features lacking in striated muscle. These derive from regulated crossbridge cycling rates observed as variable shortening velocities and ATP consumption rates. The special properties of smooth muscle are associated with differences in the physiological roles of muscle in the walls of hollow organs and reflect a common molecular motor governed by different regulatory mechanisms. A remarkably simple scheme involving Ca2+-dependent phosphorylation of crossbridges in smooth muscle can predict much of the mechanical and energetics behavior characterizing the muscle of hollow organs. Nevertheless, many unresolved issues are identified that are the focus of current research efforts.			MURPHY, RA (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,BOX 449,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NHLBI NIH HHS [5PO1 HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANY M, 1992, ARCH BIOCHEM BIOPHYS, V294, P571, DOI 10.1016/0003-9861(92)90727-E; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; CHATTERJEE M, 1983, SCIENCE, V221, P464, DOI 10.1126/science.6867722; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DIBLASI P, 1992, AM J PHYSIOL, V262, pC1388, DOI 10.1152/ajpcell.1992.262.6.C1388; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; DRISKA SP, 1989, AM J PHYSIOL, V256, pC315, DOI 10.1152/ajpcell.1989.256.2.C315; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GONG MC, 1992, J BIOL CHEM, V267, P21492; HAI CM, 1989, AM J PHYSIOL, V256, pC282, DOI 10.1152/ajpcell.1989.256.2.C282; HAI CM, 1988, AM J PHYSIOL, V254, pC99, DOI 10.1152/ajpcell.1988.254.1.C99; HAI CM, 1988, AM J PHYSIOL, V255, pC86, DOI 10.1152/ajpcell.1988.255.1.C86; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HAI CM, 1991, ADV EXP MED BIOL, V304, P159; HAI CM, 1992, BIOPHYS J, V61, P530, DOI 10.1016/S0006-3495(92)81857-X; HARDIN CD, 1992, BIOCHIM BIOPHYS ACTA, V1133, P133, DOI 10.1016/0167-4889(92)90060-O; HARTSHORNE DJ, 1992, NEWS PHYSIOL SCI, V7, P59; HIROSE K, 1993, BIOPHYS J, V65, P397, DOI 10.1016/S0006-3495(93)81061-0; HORI M, 1992, J PHARMACOL EXP THER, V261, P506; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; JOSEPHSON RK, 1993, ANNU REV PHYSIOL, V55, P527, DOI 10.1146/annurev.ph.55.030193.002523; KAMM KE, 1985, AM J PHYSIOL, V249, pC238, DOI 10.1152/ajpcell.1985.249.3.C238; KAMM KE, 1989, J BIOL CHEM, V264, P21223; KARGACIN GJ, 1990, AM J PHYSIOL, V259, pC315, DOI 10.1152/ajpcell.1990.259.2.C315; KHALIL RA, 1992, NEWS PHYSIOL SCI, V7, P10; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LIGHTMAN A, 1992, SCIENCE, V255, P690, DOI 10.1126/science.255.5045.690; MARSTON S, 1988, CALCIUM CALCIUM BIND, P69; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MILLERHANCE WC, 1991, CIRC RES, V69, P1207, DOI 10.1161/01.RES.69.5.1207; MORGAN JP, 1991, AM HEART J, V121, P961, DOI 10.1016/0002-8703(91)90227-9; MURPHY RA, 1984, ANN BIOMED ENG, V12, P451, DOI 10.1007/BF02363916; MURPHY RA, 1983, FED PROC, V42, P51; MURPHY RA, 1980, HDB PHYSL 2, V2, P325; NGAI PK, 1987, J BIOL CHEM, V262, P5352; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PAUL RJ, 1990, AM J PHYSIOL, V258, pC369, DOI 10.1152/ajpcell.1990.258.2.C369; PAUL RJ, 1980, HDB PHYSL          2, V2, P201; PAUL RJ, 1987, PHYSL GASTROINTESTIN, P483; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; RATZ PH, 1989, AM J PHYSIOL, V256, pC96, DOI 10.1152/ajpcell.1989.256.1.C96; REISER PJ, 1985, J BIOL CHEM, V260, P9077; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1993, J MUSCLE RES CELL M, V14, P325, DOI 10.1007/BF00123097; REMBOLD CM, 1990, AM J PHYSIOL, V259, pC251, DOI 10.1152/ajpcell.1990.259.2.C251; REMBOLD CM, 1992, HYPERTENSION, V20, P129, DOI 10.1161/01.HYP.20.2.129; SEOW CY, 1991, J GEN PHYSIOL, V97, P541, DOI 10.1085/jgp.97.3.541; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SINGER HA, 1986, AM J PHYSIOL, V251, pC465, DOI 10.1152/ajpcell.1986.251.3.C465; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOMLYO AP, 1992, HEART CARDIOVASCULAR, P1295; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; TANG DC, 1992, J BIOL CHEM, V267, P11839; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WARSHAW DM, 1991, J BIOL CHEM, V266, P24339; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WOLEDGE RC, 1990, ENERGY TRANSFORMATIO, P36	63	126	130	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					311	318		10.1096/fasebj.8.3.8143937	http://dx.doi.org/10.1096/fasebj.8.3.8143937			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143937				2022-12-28	WOS:A1994NB62300005
J	WEIGLE, DS				WEIGLE, DS			APPETITE AND THE REGULATION OF BODY-COMPOSITION	FASEB JOURNAL			English	Review						OBESITY; BODY WEIGHT REGULATION; FOOD INTAKE; ENERGY BALANCE; ADIPOSE TISSUE; PARABIOSIS	MATURE FEMALE RATS; OVERFED OBESE RATS; ADIPOSE-TISSUE; FOOD-INTAKE; ENERGY-EXPENDITURE; PARABIOTIC RATS; METABOLIC RESPONSE; FEEDING-BEHAVIOR; WEIGHT-LOSS; FAT	Stability of body composition requires that energy intake equals energy expenditure when integrated over prolonged periods. As recent human studies have failed to demonstrate active changes in energy expenditure with changes in body composition, it is likely that energy intake is continually adjusted to preserve a constant total adipose tissue mass. If adipose tissue mass is regulated directly, then there must be some input reflecting this quantity to the central nervous system for the purpose of making corrective changes in appetite when total body fat content fluctuates. The nature of this input has been examined in a variety of animal experiments involving induced weight change, lipectomy, plasma transfer from obese or satiated animals to hungry animals, and parabiosis between obese and lean animals. The bulk of evidence suggests that the plasma level of one or more currently unidentified stable circulating molecules increases in proportion to total body fat content and augments the effect of meal-related satiety signals in the central nervous system. The implications of this adipose tissue-related satiety factor for the pathogenesis of obesity, and the possible nature of the factor are discussed.			WEIGLE, DS (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,ZA-24,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline; NIDDK NIH HHS [DK-17047, DK-35816] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CASSIDY SB, 1989, NEUROL CLIN, V7, P37, DOI 10.1016/S0733-8619(18)30827-2; CHLOUVERAKIS C, 1972, HORM METAB RES, V4, P143, DOI 10.1055/s-0028-1094088; CHLOUVERAKIS C, 1974, METABOLISM, V23, P133, DOI 10.1016/0026-0495(74)90110-3; COHN C, 1962, YALE J BIOL MED, V34, P598; COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; DARK J, 1985, AM J PHYSIOL, V249, pR73, DOI 10.1152/ajpregu.1985.249.1.R73; DAVIS JD, 1967, SCIENCE, V156, P1247, DOI 10.1126/science.156.3779.1247; DAVIS JD, 1971, J COMP PHYSIOL PSYCH, V75, P476, DOI 10.1037/h0030933; DAVIS JD, 1969, J COMP PHYSIOL PSYCH, V67, P407, DOI 10.1037/h0027298; DIAZ EO, 1992, AM J CLIN NUTR, V56, P641, DOI 10.1093/ajcn/56.4.641; DREWRY MM, 1989, PHYSIOL BEHAV, V45, P381, DOI 10.1016/0031-9384(89)90144-3; FAUST IM, 1984, METABOLISM, V33, P596, DOI 10.1016/0026-0495(84)90055-6; FAUST IM, 1977, SCIENCE, V197, P393, DOI 10.1126/science.877564; FAUST IM, 1977, SCIENCE, V197, P391, DOI 10.1126/science.877563; FLEMING DG, 1969, ANN NY ACAD SCI, V157, P985, DOI 10.1111/j.1749-6632.1969.tb12932.x; FORGER NG, 1988, METABOLISM, V37, P782, DOI 10.1016/0026-0495(88)90015-7; FOX FW, 1973, LANCET, V2, P1487; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; Gibbs J, 1992, OBESITY, P399; HAESSLER HA, 1965, ANN NY ACAD SCI, V131, P476, DOI 10.1111/j.1749-6632.1965.tb34813.x; HAMILTON JM, 1988, PHYSIOL BEHAV, V43, P85, DOI 10.1016/0031-9384(88)90102-3; HAN PW, 1963, AM J PHYSIOL, V205, P1139, DOI 10.1152/ajplegacy.1963.205.6.1139; Hansen B W, 1977, JPEN J Parenter Enteral Nutr, V1, P83, DOI 10.1177/014860717700100283; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HARRIS RBS, 1989, AM J PHYSIOL, V257, pR326, DOI 10.1152/ajpregu.1989.257.2.R326; HARRIS RBS, 1986, AM J PHYSIOL, V250, pR276, DOI 10.1152/ajpregu.1986.250.2.R276; HARRIS RBS, 1989, P SOC EXP BIOL MED, V191, P82; HARRIS RBS, 1990, AM J PHYSIOL, V259, pR45, DOI 10.1152/ajpregu.1990.259.1.R45; HARRIS RBS, 1984, AM J PHYSIOL, V247, pR380, DOI 10.1152/ajpregu.1984.247.2.R380; HARRIS RBS, 1987, INT J OBESITY, V11, P275; HARRIS RBS, 1986, J NUTR, V116, P2536, DOI 10.1093/jn/116.12.2536; HAUSBERGER FX, 1958, ANAT REC, V130, P313; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HUFF RL, 1950, AM J PHYSIOL, V161, P56, DOI 10.1152/ajplegacy.1950.161.1.56; HULSEY MG, 1992, PHYSIOL BEHAV, V52, P1141, DOI 10.1016/0031-9384(92)90473-F; HUTSON AM, 1992, CLIN RES, V40, pA60; JEQUIER E, 1984, CLIN ENDOCRINOL META, V13, P563, DOI 10.1016/S0300-595X(84)80038-9; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; Keys A, 1950, BIOL HUMAN STARVATIO; KING KR, 1976, PHYSIOL PSYCHOL, V4, P405; LAMARCHE B, 1993, INT J OBESITY, V17, P255; LARSON KA, 1978, GROWTH, V42, P469; LIEBELT RA, 1965, ANN NY ACAD SCI, V131, P559, DOI 10.1111/j.1749-6632.1965.tb34820.x; NISHIZAWA Y, 1980, AM J PHYSIOL, V239, pR344, DOI 10.1152/ajpregu.1980.239.3.R344; PARAMESWARAN SV, 1977, AM J PHYSIOL, V232, pR150, DOI 10.1152/ajpregu.1977.232.5.R150; PORTE D, 1981, DIABETOLOGIA, V20, P274, DOI 10.1007/BF00254493; PRICE RA, 1989, HUM HERED, V39, P121; RIESTRA JL, 1977, P SOC EXP BIOL MED, V156, P236, DOI 10.3181/00379727-156-39913; ROBERTS SB, 1990, AM J PHYSIOL, V259, pR461, DOI 10.1152/ajpregu.1990.259.3.R461; SCHEMMEL R, 1971, P SOC EXP BIOL MED, V136, P1269, DOI 10.3181/00379727-136-35473; SCHMIDT P, 1969, ACTA PHYSIOL HUNG, V36, P293; Sims E A, 1973, Recent Prog Horm Res, V29, P457; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; VANDERWEELE DA, 1983, PHYSIOL BEHAV, V31, P533, DOI 10.1016/0031-9384(83)90078-1; WEIGLE DS, 1988, METABOLISM, V37, P930, DOI 10.1016/0026-0495(88)90149-7; WEIGLE DS, 1988, INT J OBESITY, V12, P567; WEIGLE DS, 1991, ENDOCRINOLOGIST, V1, P385; WEITZE M, 1940, HEREDITARY ADIPOSITY, P1; WILSON BE, 1990, AM J PHYSIOL, V259, pR1148, DOI 10.1152/ajpregu.1990.259.6.R1148; WOLFF GL, 1963, GENETICS, V48, P1041	61	145	152	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					302	310		10.1096/fasebj.8.3.8143936	http://dx.doi.org/10.1096/fasebj.8.3.8143936			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143936	Bronze			2022-12-28	WOS:A1994NB62300004
J	CHIEN, S; SILVERSTEIN, SC				CHIEN, S; SILVERSTEIN, SC			ECONOMIC-IMPACT OF APPLICATIONS OF MONOCLONAL-ANTIBODIES TO MEDICINE AND BIOLOGY	FASEB JOURNAL			English	Article							COSTS; CLONE; MICE		UNIV CALIF SAN DIEGO,DEPT AMES BIOENGN,LA JOLLA,CA 92093; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; Columbia University; University of California System; University of California San Diego	CHIEN, S (corresponding author), UNIV CALIF SAN DIEGO,INST BIOMED ENGN,LA JOLLA,CA 92093, USA.							ASKONAS BA, 1970, P NATL ACAD SCI USA, V67, P1398, DOI 10.1073/pnas.67.3.1398; Berman SM., 1993, CAN IMPACT BASIC BIO; BURKE DS, 1989, CLIN LAB MED, V9, P369, DOI 10.1016/S0272-2712(18)30609-7; BURNET FM, 1959, CLONAL SELECTION THE; EDELMAN GM, 1962, J EXP MED, V116, P207; ERLICH P, 1900, P ROY SOC LOND B BIO, V66, P424; FUDENBURG HH, 1983, BIOMEDICAL I BIOMEDI, P11; Gutman AB, 1941, J CLIN INVEST, V20, P765, DOI 10.1172/JCI101269; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; Kabat EA, 1939, J EXP MED, V69, P103, DOI 10.1084/jem.69.1.103; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSTOFF RN, 1992, 3RD INT C MAN TECHN; LANDSTEINER K, 1947, SPECIFICITY SEROLOGI; LANDSTEINER KARL, 1940, PROC SOC EXP BIOL AND MED, V43, P223; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MANSFIELD E, 1991, RES POLICY, V20, P1, DOI 10.1016/0048-7333(91)90080-A; MILSTEIN C, 1980, SCI AM, V243, P66, DOI 10.1038/scientificamerican1080-66; MILSTEIN C, 1984, BIOSCIENCE REP, V4, P275; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; POTTER M, 1972, PHYSIOL REV, V52, P631, DOI 10.1152/physrev.1972.52.3.631; RAFF MC, 1973, J EXP MED, V137, P1024, DOI 10.1084/jem.137.4.1024; SCHWABER J, 1973, NATURE, V244, P444, DOI 10.1038/244444a0; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; Selma J.Mushkin, 1979, BIOMEDICAL RES COSTS; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SILVERSTEIN AM, 1989, HIST IMMUNOLOGY, P327; TALMAGE DW, 1986, ANNU REV IMMUNOL, V4, P1; Tiselius A, 1939, J EXP MED, V69, P119, DOI 10.1084/jem.69.1.119; Von Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [DOI 10.1055/S-0029-1207589, 10.1055/s-0029-1207589]; WEISBROD BA, 1971, J POLIT ECON, V79, P527, DOI 10.1086/259766; YELTON DE, 1981, ANNU REV BIOCHEM, V50, P657, DOI 10.1146/annurev.bi.50.070181.003301; 1989, UNPUB HLTH CARE COST; 1990, NIH903109 PUBL; 1968, TECHNOLOGY RETROSPEC; 1992, BIOTECHNOLOGY DIRECT; 1991, JOB RELATED IMPACTS; 1986, RES FUNDING INVESTME; UNPUB REGIONAL INPUT; 1973, INTERACTIONS SCI TEC; 1992, MONOCLONAL ANTIBODIE; 1969, AD495905	43	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1426	1431		10.1096/fasebj.7.15.8262326	http://dx.doi.org/10.1096/fasebj.7.15.8262326			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262326				2022-12-28	WOS:A1993ML74000002
J	KUPPER, TS; FERGUSON, TA				KUPPER, TS; FERGUSON, TA			A POTENTIAL PATHOPHYSIOLOGIC ROLE FOR ALPHA(2)BETA(1)-INTEGRIN IN HUMAN EYE DISEASES INVOLVING VITREORETINAL TRACTION	FASEB JOURNAL			English	Note						VITREOUS; INTEGRIN; RETINOPATHY; COLLAGEN; DIABETES-MELLITUS	HUMAN-SKIN FIBROBLASTS; CELL-ADHESION; COLLAGEN LATTICES; TISSUE-CULTURE; CONTRACTION; REORGANIZATION; FIBRONECTIN; DETACHMENT; IDENTIFICATION; PATHOGENESIS	Cell-mediated contraction of tissues containing fibrillar collagens can lead to organ compromise and loss of function. The same process that is biologically advantageous during the contraction phase of wound healing can be subverted in diseases such as hepatic cirrhosis, pulmonary fibrosis, and scleroderma, although the cellular and molecular mechanism of matrix tissue contraction is difficult to study in such chronic diseases. However, certain human eye diseases that result in tractional detachment of the retina and loss of vision are characterized by acute cell-mediated contraction of collagenous tissue in the vitreous cavity. In this study, we demonstrate that human cells can contract vitreous, a complex biological gel containing type II collagen, in vitro. This cell-mediated contraction can be blocked by antibodies and peptides that antagonize the function of alpha2beta1 integrin, and the potential for contraction can be conferred upon noncontracting cells by stable transfection of cells with alpha2 cDNA. We also show that this contractile process, if focally resisted, can result in remodeling vitreous from a gel to a structure that resembles a planar membrane, and that substantial isometric forces can be measured across this tissue. We propose that in diseases such as proliferative diabetic retinopathy and proliferative vitreoretinopathy, alpha2beta1 integrin-mediated contraction of the vitreous and tension at the site of vitreoretinal attachments contribute to the terminal event of tractional retinal detachment. By extension, we propose that alpha2beta1 integrin is a centrally important molecule in human diseases characterized by remodeling and contraction of collagenous tissue (i.e., fibrocontractive diseases).	WASHINGTON UNIV,DEPT OPHTHALMOL,ST LOUIS,MO 63110	Washington University (WUSTL)	KUPPER, TS (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV DERMATOL,75 FRANCIS ST,BOSTON,MA 02215, USA.		Kupper, Thomas/O-4962-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025082, R01AI025082, R37AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124] Funding Source: NIH RePORTER; NEI NIH HHS [EY06765] Funding Source: Medline; NIAID NIH HHS [AI25082] Funding Source: Medline; NIAMS NIH HHS [AR40124] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIYAN S, 1978, ARCH SURG-CHICAGO, V113, P1034; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BISSELL DM, 1990, HEPATOLOGY, V11, P488, DOI 10.1002/hep.1840110322; CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1403; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLEARY PE, 1979, AM J OPHTHALMOL, V88, P221, DOI 10.1016/0002-9394(79)90469-0; CONSTABLE IJ, 1972, ARCH OPHTHALMOL-CHIC, V88, P544, DOI 10.1001/archopht.1972.01000030546016; CONSTABLE IJ, 1974, RETINA C, P245; CROUCH E, 1990, AM J PHYSIOL, V259, P159; DAVIS MD, 1965, ARCH OPHTHALMOL-CHIC, V74, P741; EBERHARDKLEIN CE, 1991, J CELL BIOL, V115, P127; EHRLICH HP, 1988, EYE, V2, P149, DOI 10.1038/eye.1988.28; FAULBORN J, 1978, A GRAEF ARCH KLIN EX, V205, P157, DOI 10.1007/BF00414395; FERGUSON T, 1992, CLIN RES, V40, pA251; FOOS RY, 1985, OPHTHALMOLOGY, V92, P563; FORRESTER JV, 1986, INVEST OPHTH VIS SCI, V27, P1085; GLOOR BP, 1981, ADLERS PHYSL EYE CLI; GRINNELL F, 1984, J CELL SCI, V66, P51; GUIDRY C, 1985, J CELL SCI, V79, P67; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kirchhof B, 1989, Dev Ophthalmol, V16, P1; KISHI S, 1986, INT OPHTHALMOL, V9, P253, DOI 10.1007/BF00137539; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; MACHEMER R, 1988, INVEST OPHTH VIS SCI, V29, P1771; MACHEMER R, 1988, AM J OPHTHALMOL, V105, P170, DOI 10.1016/0002-9394(88)90182-1; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PRATT RM, 1972, DEV BIOL, V27, P322, DOI 10.1016/0012-1606(72)90171-6; SCHEIFFARTH OF, 1988, GRAEF ARCH CLIN EXP, V226, P357, DOI 10.1007/BF02172967; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SEBAG J, 1985, T OPHTHAL SOC UK, V104, P123; SEBAG J, 1989, VITREOUS, P3; SPENCER WH, 1985, OPHTHALMIC PATHOLOGY, P548; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; USSMANN JH, 1981, ARCH OPHTHALMOL-CHIC, V99, P869, DOI 10.1001/archopht.1981.03930010869016; van Nouhuys C E, 1989, Fortschr Ophthalmol, V86, P221; WALLOW IHL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1370; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133	42	30	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1401	1406		10.1096/fasebj.7.14.8224612	http://dx.doi.org/10.1096/fasebj.7.14.8224612			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224612				2022-12-28	WOS:A1993MH00800014
J	KLOTZ, IM				KLOTZ, IM			BIOGENESIS - NUMBER MYSTICISM IN PROTEIN THINKING	FASEB JOURNAL			English	Review						MYSTICAL INTEGERS; PROTEIN SEQUENCES; CYCLOL; PROTEIN HELIX; LIGAND-RECEPTOR AFFINITIES; BINDING CONSTANTS	BINDING	Historically, great minds have been tantalized by the idea that integers contain hidden, subtle meanings that could give us deep insights into natural (and supernatural) phenomena. Numerological analysis has been used in religion, mythology, and the sciences. In the field of proteins, integers played a stimulating role during early struggles to unravel structure, but they ultimately proved constrictive and misleading. In contrast, the introduction of imaginary (or complex) numbers into the algebra and numerical analysis of ligand-protein affinities can open new perspectives into such interactions.			KLOTZ, IM (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208, USA.							BECKMANN P, 1972, HIST PI; Bergmann M, 1936, J BIOL CHEM, V115, P77; BOHR C, 1903, ZENTRALBL PHYSL, V17, P682; BRODERSEN R, 1988, TRENDS PHARMACOL SCI, V9, P252, DOI 10.1016/0165-6147(88)90155-1; Bull HB, 1941, ADV ENZYMOL REL S BI, V1, P1; CHANDRASEKHAR S, 1984, EDDINGTON MOST DISTI; DANTZIG T, 1954, NUMBER; Davis P., 1981, MATH EXPERIENCE; FELDMAN HA, 1983, J BIOL CHEM, V258, P2865; FORSEN S, 1993, ACCOUNTS CHEM RES, V26, P7, DOI 10.1021/ar00025a002; HARRIS WR, 1985, BIOCHEMISTRY-US, V24, P7412, DOI 10.1021/bi00346a057; HUFNER G, 1901, ARCH ANAT ABT, V5, P187; Huggins ML, 1943, CHEM REV, V32, P195, DOI 10.1021/cr60102a002; Klotz I.M, 1986, INTRO BIOMOLECULAR E; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; KLOTZ IM, 1970, ANNU REV BIOCHEM, V39, P25, DOI 10.1146/annurev.bi.39.070170.000325; Latimer WM, 1920, J AM CHEM SOC, V42, P1419, DOI 10.1021/ja01452a015; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; MIURA S, 1987, BIOCHEMISTRY-US, V26, P2149, DOI 10.1021/bi00382a013; OSTWALD W, 1908, KOLLOIDZEITSCHRIFT, V2, P294; PAULING L, 1951, P NATL ACAD SCI USA, V37, P235, DOI 10.1073/pnas.37.5.235; ROUGHTON FJW, 1955, PROC R SOC SER B-BIO, V144, P29, DOI 10.1098/rspb.1955.0032; SUTER P, 1976, J BIOL CHEM, V251, P5986; Svedberg T, 1940, THE ULTRACENTRIFUGE; WRINCH DM, 1938, COLD SPRING HARB SYM, V6, P122	25	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1219	1225		10.1096/fasebj.7.13.8405807	http://dx.doi.org/10.1096/fasebj.7.13.8405807			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405807				2022-12-28	WOS:A1993MB37600004
J	DAVID, G				DAVID, G			INTEGRAL MEMBRANE HEPARAN-SULFATE PROTEOGLYCANS	FASEB JOURNAL			English	Review						SYNDECAN; GLYPICAN; GROWTH FACTORS; PROTEINASE INHIBITORS; EXTRACELLULAR MATRIX	FIBROBLAST GROWTH-FACTOR; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; MOLECULAR-CLONING; EPITHELIAL-CELLS; FACTOR BINDING; CORE PROTEINS; SYNDECAN; EXPRESSION; RECEPTOR	Heparan sulfate is a regulatory polysaccharide. It modulates specific growth factor-receptor interactions, accelerates the formation of specific proteinase-proteinase inhibitor complexes, and mediates interactions of the cell surface with several enzymes and structural proteins. It abounds on the surfaces of embryonic cells, respecting or outlining morphogenetic rather than histological boundaries. This cell surface-associated heparan sulfate is implanted on specific integral membrane proteins, which together constitute two novel molecular families. The first family includes four syndecan-like integral membrane proteoglycans (SLIPS), with core proteins that span the membrane and shared sequence motifs in highly conserved cytoplasmic domains. The second is made up by two or more glypican-related integral membrane proteoglycans (GRIPS) that are linked to the cell surface via glycosyl phosphatidylinositol. These proteoglycans show differential expression and turnover patterns, prevailing in distinct cell types, membrane domains, and endocytotic machineries, and are subject to strict developmental controls. This suggests that each of these cell surface proteoglycans functions in a specific context, and that these functions pertain to the transduction of signals that emanate from the continuous interplay between matrix components, growth factors, and proteinases. Caution: beware of loose GRIPS and SLIPS on unsteady cell surfaces.			DAVID, G (corresponding author), CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM.			NOIRI, Eisei/0000-0002-9515-7582				ANDRES JL, 1992, J BIOL CHEM, V267, P5927; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; BSHKIN P, 1992, J CELL PHYSL, V151, P126; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; GALLO RL, 1992, MOL BIOL CELL, V3, pA188; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LORIES V, 1992, J BIOL CHEM, V267, P1116; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PIERCE A, 1992, J BIOL CHEM, V267, P1; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SCHMIDTCHEN A, 1992, EUR J BIOCHEM, V208, P537, DOI 10.1111/j.1432-1033.1992.tb17218.x; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STIPP CS, 1992, MOL BIOL CELL, V3, pA65; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WOODS A, 1992, J CELL SCI, V313, P87; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEAMAN C, 1992, MOL BIOL CELL, V3, pA64	49	391	399	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1023	1030		10.1096/fasebj.7.11.8370471	http://dx.doi.org/10.1096/fasebj.7.11.8370471			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370471				2022-12-28	WOS:A1993LT83900007
J	HAMEL, PA; PHILLIPS, RA; MUNCASTER, M; GALLIE, BL				HAMEL, PA; PHILLIPS, RA; MUNCASTER, M; GALLIE, BL			SPECULATIONS ON THE ROLES OF RB1 IN TISSUE-SPECIFIC DIFFERENTIATION, TUMOR INITIATION, AND TUMOR PROGRESSION	FASEB JOURNAL			English	Review						RETINOBLASTOMA; RETINOMA; RB1; DIFFERENTIATION; TUMOR SUPPRESSOR GENE	RETINOBLASTOMA GENE-PRODUCT; LARGE-T-ANTIGEN; SV40 LARGE-T; E2F TRANSCRIPTION FACTOR; CELL LUNG-CANCER; SUSCEPTIBILITY GENE; C-MYC; PROTEIN EXPRESSION; ALTERED EXPRESSION; HUMAN SARCOMAS	Studies of retinoblastoma clearly identify mutation of the RB1 gene on chromosome 13 as the primary cause of this cancer. However, all retinoblastoma tumors have an abnormal karyotype (1, 2) indicating the presence of additional mutations and suggesting that mutation of both RB1 alleles is insufficient for development of retinoblastoma. In addition, analysis of RB1 expression and of RB1 mutations in different tumors leads to the following dilemma: while the RB1 gene product, p110RB1, is expressed in most dividing cells, germline mutations inactivating the function of p110RB1 predispose primarily to retinoblastoma and to a lesser extent to osteosarcoma, but do not predispose to cancer in general. However, many tumors contain somatic mutations that disrupt RB1 function. Thus, we are faced with the unusual situation in which germline mutations in the RB1 gene predispose to a very limited set of cancers, but somatic mutations in RB1 appear to contribute to malignancy in many tissues. We propose that the role of the RB1 gene is to maintain the cells in a stable, quiescent state required for terminal differentiation and that the effect of RB1 mutations in different tissues depends on the pattern of differentiation in that tissue. In tissues where differentiation follows a linear process from undifferentiated precursors to fully differentiated cells, loss of RB1 function during early stages of differentiation may lead to uncontrolled growth and the development of cancer. On the other hand, in cell renewal systems where cell number is usually maintained by a process of programmed cell death (PCD) or apoptosis, loss of RB1 function may lead to cell death.	UNIV TORONTO,DEPT PATHOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT OPHTHALMOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto	HAMEL, PA (corresponding author), HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,555 UNIV AVE,LONDON WC1N 3JH,ENGLAND.			Gallie, Brenda/0000-0002-9697-9211				AHUJA HG, 1991, BLOOD, V78, P3259; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BONAITIPELLIE C, 1981, HUM GENET, V57, P411, DOI 10.1007/BF00281695; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN HSL, 1991, OPHTHALMOLOGY, V98, P1425; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICAPRIO L, 1976, GENETICS, V84, P697; Doll R, 1981, THE CAUSES OF CANCER; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EAGLE RC, 1989, OPHTHALMOLOGY, V96, P1389; EGAN C, 1989, ONCOGENE, V4, P383; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1982, OPHTHALMOLOGY, V89, P1393; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; GINSBERG AM, 1991, BLOOD, V77, P833; GODBOUT R, 1993, GENE, V123, P195, DOI 10.1016/0378-1119(93)90124-L; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HILLION J, 1991, CANCER GENET CYTOGEN, V54, P197, DOI 10.1016/0165-4608(91)90207-B; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HORSTHEMKE B, 1989, CANCER GENET CYTOGEN, V37, P95, DOI 10.1016/0165-4608(89)90079-4; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSNETSOVA LE, 1982, HUM GENET, V61, P201, DOI 10.1007/BF00296442; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MADREPERLA SA, 1991, CANCER RES, V51, P6381; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUKAI N, 1975, J NEUROPATH EXP NEUR, V34, P28, DOI 10.1097/00005072-197501000-00003; MUKAI N, 1980, SCIENCE, V210, P1023, DOI 10.1126/science.7434012; MUKAI N, 1977, ACTA NEUROPATHOL, V39, P147, DOI 10.1007/BF00703321; MUNCASTER MM, 1992, CANCER RES, V52, P654; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; PHILLIPS RA, 1992, WHY DONT GERMLINE MU; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1989, ONCOGENE, V4, P839; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; RYGAARD K, 1990, CANCER RES, V50, P5312; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SCHOTTENFELD D, 1982, CANCER EPIDEMIOLOGY; SLACK R, 1993, IN PRESS ONCOGENE; SQUIRE J, 1986, NATURE, V322, P555, DOI 10.1038/322555a0; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; WUNDER JS, 1991, J NATL CANCER I, V83, P194, DOI 10.1093/jnci/83.3.194; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, CANCER RES, V51, P4481; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YATSUNAMI J, 1993, CANCER RES, V53, P239; YEN A, 1992, EUR J CELL BIOL, V57, P210; YOKOTA J, 1988, ONCOGENE, V3, P471; ZACKSENHAUS E, 1993, IN PRESS ONCOGENE	108	102	103	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					846	854		10.1096/fasebj.7.10.8344484	http://dx.doi.org/10.1096/fasebj.7.10.8344484			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344484				2022-12-28	WOS:A1993LQ33700006
J	WALLACE, CJA				WALLACE, CJA			UNDERSTANDING CYTOCHROME-C FUNCTION - ENGINEERING PROTEIN-STRUCTURE BY SEMISYNTHESIS	FASEB JOURNAL			English	Review						CYTOCHROME-C; PROTEIN ENGINEERING; SEMISYNTHESIS; STRUCTURE FUNCTION RELATIONSHIPS	ANALOGS; FRAGMENTS; SUBSTITUTIONS; CONFORMATION; CONSEQUENCES; MUTAGENESIS; RESYNTHESIS; RESIDUE-38; COMPLEX	Semisynthesis is a method of protein engineering that relies primarily on chemical manipulations of peptide fragments derived from natural proteins to produce intermediates for reassembly into defined analogs. In this respect it differs fundamentally from total chemical synthesis, but like it, it has unique capabilities for introducing noncoded amino acids or site-specific labels into the protein product. A favorite subject for semisynthesis is the redox protein cytochrome c: a vital link in the respiratory chain. The tactics that have evolved in the half dozen laboratories so engaged are briefly described. More than 100 semisynthetic analogs of this protein have resulted from this effort and have contributed to our understanding of the way in which the function of cytochrome c is determined by its three-dimensional structure. Questions concerning the folding and stability of the protein, the setting of heme redox potential, control and specificity of interaction with potential redox partners, and the mechanism of electron transfer are considered. A growing synergy between this approach and genetic methods will ensure that protein engineering by semisynthesis continues to increase our knowledge of this and other proteins.			WALLACE, CJA (corresponding author), DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA.							BAIN JD, 1992, NATURE, V356, P537, DOI 10.1038/356537a0; BOON PJ, 1979, FEBS LETT, V108, P131, DOI 10.1016/0014-5793(79)81194-1; BOOTS HA, 1987, PEPTIDES 1986, P211; BOOTS HA, 1986, THESIS CATHOLIC U NI; Brautigan D L, 1978, Methods Enzymol, V53, P128; BURTON J, 1970, J AM CHEM SOC, V92, P3746, DOI 10.1021/ja00715a035; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; CORRADIN G, 1971, P NATL ACAD SCI USA, V68, P3036, DOI 10.1073/pnas.68.12.3036; CORRADIN G, 1974, BIOCHEM BIOPH RES CO, V61, P4100; DIBELLO C, 1990, INT J PEPT PROT RES, V35, P336; Dickerson R., 1975, ENZYMES, V11, P397; DICKERSON RE, 1972, SCI AM, V226, P58, DOI 10.1038/scientificamerican0472-58; DIXON HBF, 1962, BIOCHEM J, V84, P462, DOI 10.1042/bj0840462; FRAUENHOFF MM, 1992, PROTEINS, V13, P202; HOMANDBERG GA, 1979, BIOCHEMISTRY-US, V18, P586, DOI 10.1021/bi00571a006; JUILLERAT MA, 1986, J BIOL CHEM, V261, P2697; KATSOYAN.PG, 1967, BIOCHEMISTRY-US, V6, P2656, DOI 10.1021/bi00861a003; MOORE GR, 1990, CYTOCHROMES EVOLUTIO; MORODER L, 1973, BIOPOLYMERS, V12, P477, DOI 10.1002/bip.1973.360120303; OFFORD RE, 1969, NATURE, V221, P37, DOI 10.1038/221037a0; OFFORD RE, 1987, PROTEIN ENG, V1, P151, DOI 10.1093/protein/1.3.151; OFFORD RE, 1980, SEMISYNTHETIC PROTEI; OFFORD RE, 1990, PROTEIN DESIGN DEV N, P253; PARR GR, 1978, J BIOL CHEM, V253, P5381; PETTIGREW GW, 1987, CYTOCHROMES BIOL ASP; PROUDFOOT AEI, 1984, BIOCHEM J, V221, P325, DOI 10.1042/bj2210325; PROUDFOOT AEI, 1987, BIOCHEM J, V248, P965, DOI 10.1042/bj2480965; PROUDFOOT AEI, 1989, J BIOL CHEM, V264, P8764; PROUDFOOT AEI, 1986, BIOCHEM J, V239, P333, DOI 10.1042/bj2390333; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RAPHAEL AL, 1989, PROTEINS, V6, P338, DOI 10.1002/prot.340060316; ROSE K, 1988, BIOCHEM J, V249, P83, DOI 10.1042/bj2490083; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; SANO S, 1972, STRUCTURE FUNCTION O, P69; SCOFFONE E., 1967, P280; SEALOCK RW, 1969, BIOCHEMISTRY-US, V8, P3703, DOI 10.1021/bi00837a032; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; TENKORTENAAR PBW, 1985, P NATL ACAD SCI USA, V82, P8279; WALLACE CJA, 1989, J BIOL CHEM, V264, P15199; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WALLACE CJA, 1987, J BIOL CHEM, V262, P16767; WALLACE CJA, 1979, BIOCHEM J, V179, P169, DOI 10.1042/bj1790169; WALLACE CJA, 1983, BIOCHEM J, V215, P651, DOI 10.1042/bj2150651; WALLACE CJA, 1991, J BIOL CHEM, V266, P21355; WALLACE CJA, 1984, BIOCHEM J, V217, P595, DOI 10.1042/bj2170595; WALLACE CJA, 1987, BIOCHEM J, V245, P773, DOI 10.1042/bj2450773; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23; WALLACE CJA, 1991, PEPTIDES 1990, P260; WALLACE CJA, 1990, PEPTIDES CHEM STRUCT, P1043; WALLACE CJA, 1986, 1ST P FOR PEPT, V6, P434; WALLACE CJA, 1980, PEPTIDE STRUCTURE BI, P609; WALLACE CJA, 1976, THESIS U OXFORD ANN; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; WESTERHUIS LW, 1982, INT J PEPT PROT RES, V19, P290	55	31	73	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					505	515		10.1096/fasebj.7.6.8386119	http://dx.doi.org/10.1096/fasebj.7.6.8386119			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8386119				2022-12-28	WOS:A1993KY00900003
J	LIN, LH; CHEN, LTL; HARRIS, RA				LIN, LH; CHEN, LTL; HARRIS, RA			ENFLURANE INHIBITS NMDA, AMPA, AND KAINATE-INDUCED CURRENTS IN XENOPUS OOCYTES EXPRESSING MOUSE AND HUMAN BRAIN MESSENGER-RNA	FASEB JOURNAL			English	Article						ENFLURANE; INHALATIONAL ANESTHETIC; NMDA; AMPA; KAINATE; XENOPUS OOCYTES; MOUSE CORTICAL MESSENGER RNA; HUMAN CORTICAL MESSENGER RNA	METHYL-D-ASPARTATE; VOLTAGE-OPERATED CHANNELS; RAT-BRAIN; AMINO-ACIDS; RECEPTORS; ANTAGONISTS; ETHANOL; CALCIUM; SUBUNIT; PHENCYCLIDINE	Effects of enflurane, an inhalational anesthetic, on NMDA, AMPA, and kainate-gated currents were examined in Xenopus laevis oocytes expressing mouse or human brain mRNA. In oocytes expressing mouse mRNA, enflurane at an anesthetic concentration (1.8 mM) inhibited the NMDA-, AMPA-, and kainate-induced currents by 29-40%, 30-33%, and 20-27%, respectively, suggesting that all three glutamate ionotropic receptors are susceptible to suppression by inhalational anesthetics. Furthermore, inhibition by enflurane was independent of the concentrations of the agonists (NMDA, AMPA, and kainate) or the NMDA-coagonist (glycine). This suggests that enflurane inhibition does not result from a competitive interaction at glutamate or glycine binding sites. Enflurane also suppressed the oscillation and apparent desensitization of NMDA currents, suggesting an inhibition of Ca2+ influx through the NMDA channel. In oocytes expressing human brain mRNA, only kainate produced observable currents. Kainate currents of human channels were smaller in size than those of the mouse; however, the kainate concentration-response curve and percent inhibition (27-29%) by enflurane were similar for mice and humans. The results suggest that human and mouse kainate receptors have similar pharmacological characteristics.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,BOX C-236,4200 E 9TH AVE,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06399] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLOTT PR, 1973, BRIT J ANAESTH, V45, P294, DOI 10.1093/bja/45.3.294; BALSTER R L, 1978, National Institute on Drug Abuse Research Monograph, P53; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINS GGS, 1987, NEUROPHARMACOLOGY, V26, P167, DOI 10.1016/0028-3908(87)90205-X; DANIELL LC, 1991, PHARMACOL BIOCHEM BE, V40, P767, DOI 10.1016/0091-3057(91)90083-E; DANIELL LC, 1990, PHARMACOL BIOCHEM BE, V36, P111, DOI 10.1016/0091-3057(90)90134-4; DILDYMAYFIELD JE, 1992, J PHARMACOL EXP THER, V262, P487; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GUNDERSEN CB, 1984, NATURE, V308, P421, DOI 10.1038/308421a0; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOEK W, 1988, SIGMA PHENCYCLIDINE, P493; KUSHNER L, 1988, P NATL ACAD SCI USA, V85, P3250, DOI 10.1073/pnas.85.9.3250; LEONARD JP, 1990, NEURON, V2, P53; LEONARD S, 1991, SOC NEUR ABSTR, V21, P798; LIN LH, 1992, IN PRESS J PHARM EXP; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MARSHALL BE, 1990, PHARMACOL BASIS THER, P285; MARTIN D, 1985, NEUROPHARMACOLOGY, V24, P999, DOI 10.1016/0028-3908(85)90128-5; MAZZE RI, 1985, ANESTHESIOLOGY, V62, P339, DOI 10.1097/00000542-198503000-00021; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; PUIL E, 1990, BRIT J PHARMACOL, V101, P61, DOI 10.1111/j.1476-5381.1990.tb12089.x; PUIL E, 1986, MOL CELLULAR MECHANI, P82; RAGSDALE DS, 1991, P NATL ACAD SCI USA, V88, P1854, DOI 10.1073/pnas.88.5.1854; RENZI R, 1977, ANESTHESIOLOGY, V47, P62; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; UMBACH JA, 1989, MOL PHARMACOL, V36, P582; VERDOORN TA, 1987, SCIENCE, V238, P1114, DOI 10.1126/science.2825347; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8	35	41	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					479	485		10.1096/fasebj.7.5.7681790	http://dx.doi.org/10.1096/fasebj.7.5.7681790			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	7681790				2022-12-28	WOS:A1993KV35100013
J	HARRIS, RA; MIHIC, SJ; DILDYMAYFIELD, JE; MACHU, TK				HARRIS, RA; MIHIC, SJ; DILDYMAYFIELD, JE; MACHU, TK			ACTIONS OF ANESTHETICS ON LIGAND-GATED ION CHANNELS - ROLE OF RECEPTOR SUBUNIT COMPOSITION	FASEB JOURNAL			English	Review						GABA; NMDA; GLUTAMATE RECEPTOR; ALCOHOL; PENTOBARBITAL	GABA-A-RECEPTOR; GLYCINE RECEPTORS; XENOPUS OOCYTES; ACID RESPONSES; BENZODIAZEPINE; ETHANOL; MODULATION; POTENTIATION; SENSITIVITY; ISOFLURANE	Molecular cloning of cDNAs coding for Ligand-gated ion channel subunits makes it possible to study the pharmacology of recombinant receptors with defined subunit compositions, Many laboratories have used these techniques recently to study actions of agents that produce general anesthesia, We review the effects of volatile and intravenous anesthetics on recombinant GABA(A), glycine, AMPA, kainate, NMDA, and 5HT(3) receptors, Evidence for and against specific ligand-gated ion channel subunits as targets responsible for anesthesia or the side effects of anesthetic agents is discussed for each type of receptor, Subunit specific actions of some of the agents suggest that construction and testing of certain chimeric receptor subunits may be useful for defining the amino acid sequences responsible for anesthetic actions.	VET AFFAIRS MED CTR,DENVER,CO 80262	US Department of Veterans Affairs; Veterans Health Administration (VHA)	HARRIS, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.				NIAAA NIH HHS [AA06399, AA10561] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399, R29AA010561] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; BOWERY NG, 1978, BRIT J PHARMACOL, V63, P179; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BUCK KJ, 1989, EUR J PHARMACOL, V160, P359, DOI 10.1016/0014-2999(89)90091-5; CHEN RT, 1994, P NATL ACAD SCI USA, V91, P6069, DOI 10.1073/pnas.91.13.6069; CURTIS DR, 1977, NATURE, V270, P543, DOI 10.1038/270543c0; DEITRICH RA, 1989, PHARMACOL REV, V41, P491; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; Dunn Susan M. J., 1994, V36, P51; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GREEN G, 1993, ACTA ANAESTH SCAND, V37, P742, DOI 10.1111/j.1399-6576.1993.tb03801.x; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRIS RA, 1995, ALCOHOL CLIN EXP RES, V19, P226, DOI 10.1111/j.1530-0277.1995.tb01496.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; HORNE AL, 1993, BRIT J PHARMACOL, V108, P711; KENDIG JJ, 1993, ANESTHESIOLOGY, V79, P1161; KENDIG JJ, 1994, EUR J PHARMACOL, V264, P427, DOI 10.1016/0014-2999(94)00499-4; KNOFLACH F, 1991, FEBS LETT, V293, P191, DOI 10.1016/0014-5793(91)81184-A; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; KOLTCHINE V, 1993, NEUROSCI LETT, V152, P13, DOI 10.1016/0304-3940(93)90471-V; KUNER T, 1993, NEUROREPORT, V5, P297, DOI 10.1097/00001756-199312000-00029; KURATA Y, 1993, BRAIN RES, V631, P143, DOI 10.1016/0006-8993(93)91200-C; LEIDENHEIMER NJ, 1993, J NEUROCHEM, V60, P1972, DOI 10.1111/j.1471-4159.1993.tb13432.x; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; LIU Y, 1994, MOL PHARMACOL, V45, P1235; LOVINGER DM, 1993, ALCOHOL, CELL MEMBRANES, AND SIGNAL TRANSDUCTION IN BRAIN, P157; LOVINGER DM, 1993, NEUROSCI LETT, V159, P83, DOI 10.1016/0304-3940(93)90804-T; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACHU TK, 1991, J PHARMACOL EXP THER, V271, P898; MARSZALEC W, 1994, J PHARMACOL EXP THER, V269, P157; MASOOD K, 1994, MOL PHARMACOL, V45, P324; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; MIHIC SJ, IN PRESS PHARM EFFEC; Overton E., 1901, STUDIEN NARKOSE; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; RAINES DE, 1994, ANESTH ANALG, V79, P1031; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RICHARDS CD, 1978, NATURE, V276, P775, DOI 10.1038/276775a0; Roth S, 1986, MOL CELLULAR MECHANI, P455; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; Sanna E, 1993, Recent Dev Alcohol, V11, P169; SANNA E, 1995, MOL PHARMACOL, V47, P213; SAXENA NC, 1994, J NEUROSCI, V14, P7077; SCHOEPFER R, 1991, PROG NEUROBIOL, V42, P353; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHINGAI R, 1991, EUR J PHARM-MOLEC PH, V206, P77, DOI 10.1016/0922-4106(91)90149-C; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1993, FEBS LETT, V324, P140, DOI 10.1016/0014-5793(93)81380-I; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; WANG TL, 1994, J NEUROSCI, V14, P6524; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x	59	177	180	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1454	1462		10.1096/fasebj.9.14.7589987	http://dx.doi.org/10.1096/fasebj.9.14.7589987			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589987				2022-12-28	WOS:A1995TF67800010
J	JAVITT, NB				JAVITT, NB			CHOLESTEROL HOMEOSTASIS - ROLE OF THE LDL RECEPTOR	FASEB JOURNAL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; REDUCTASE-ACTIVITY; HUMAN FIBROBLASTS; METABOLISM; TRANSCRIPTION; CLONING				JAVITT, NB (corresponding author), NYU, MED CTR, DIV HEPAT DIS, NEW YORK, NY 10016 USA.			Javitt, Norman B/0000-0001-9265-3508	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1983, J CELL SCI, V63, P1; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; [Anonymous], 1994, CIRCULATION, V89, P1329; [Anonymous], 1993, CHOLESTEROL MEMBRANE; BAILEY JM, 1964, P SOC EXP BIOL MED, V115, P747; BAILEY JM, 1966, BIOCHIM BIOPHYS ACTA, V125, P226; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Brown M S, 1975, Adv Intern Med, V20, P273; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; DUGAN RE, 1972, ARCH BIOCHEM BIOPHYS, V152, P21, DOI 10.1016/0003-9861(72)90188-9; ESTERMAN AL, 1985, J LIPID RES, V26, P950; GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804; HOEG JM, 1985, J SURG RES, V39, P369, DOI 10.1016/0022-4804(85)90090-3; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JESKE DJ, 1980, J LIPID RES, V21, P364; MCNAMARA DJ, 1983, P NATL ACAD SCI-BIOL, V80, P564, DOI 10.1073/pnas.80.2.564; MIAO E, 1988, BIOCHEM J, V255, P1049, DOI 10.1042/bj2551049; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; REISS AB, 1994, J LIPID RES, V35, P1026; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG Z, 1995, J BIOL CHEM, V92, P935; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; Tanford C., 1973, HYDROPHOBIC EFFECT; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1995	9	13					1378	1381		10.1096/fasebj.9.13.7557029	http://dx.doi.org/10.1096/fasebj.9.13.7557029			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557029				2022-12-28	WOS:A1995TA37000018
J	ALONSO, MD; LOMAKO, J; LOMAKO, WM; WHELAN, WJ				ALONSO, MD; LOMAKO, J; LOMAKO, WM; WHELAN, WJ			A NEW LOOK AT THE BIOGENESIS OF GLYCOGEN	FASEB JOURNAL			English	Article						GLYCOGENIN; PROGLYCOGEN; MACROGLYCOGEN; PROGLYCOGEN SYNTHASE; MACROGLYCOGEN SYNTHASE; GLYCOGEN BIOGENESIS	RABBIT SKELETAL-MUSCLE; SUBSTRATE-SPECIFICITY; AUTOCATALYTIC PROTEIN; SYNTHASE; INSULIN; PRIMER; BIOSYNTHESIS; PROGLYCOGEN; INITIATION; EXERCISE	The discovery of glycogenin as a self-glucosylating protein that primes glycogen synthesis has significantly increased our understanding of the structure and metabolism of this storage polysaccharide. The amount of glycogenin will influence how much glycogen the cell can store. Therefore, the production of active glycogenin primer in the cell has the potential to be the overall rate-limiting process in glycogen formation, capable of overriding the better understood hormonally controlled mechanisms of protein phosphorylation/dephosphorylation that regulate the activities of glycogen synthase and phosphorylase. There are indications that a similar covalent modification control is also being exerted on glycogenin. Glycogenin has the ability to glucosylate molecules other than itself and to hydrolyze UDP glucose. These are independent of self-glucosylation, so that glycogenin, even when it has completed its priming role and become part of the glycogen molecule, retains its catalytic potential. Another new component of glycogen metabolism has been discovered that may have even greater influence on total glycogen stores than does glycogenin. This is proglycogen, a low molecular mass (similar to 400 kDa) form of glycogen that serves as a stable intermediate on the pathways to and from depot glycogen (macroglycogen, mass 10(7) Da, in muscle). It is suggested that glycogen oscillates, according to glucose supply and energy demand, between the macroglycogen and proglycogen, but not usually the glycogenin, forms. The proportion of proglycogen to macroglycogen varies widely between Liver, skeletal muscle, and heart, from 3 to 15% to 50% by weight, respectively. On a molar basis, proglycogen is greatly in excess over macroglycogen hi muscle and heart, meaning that if the proglycogen in these tissues could be converted into macroglycogen, they could store much more total glycogen. Discovering the factors that regulate the balance between glycogenin, proglycogen, and macroglycogen may have important implications for the understanding and management of noninsulin-dependent diabetes and for exercise physiology.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037500] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37500] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADROUNY GA, 1956, ENDOCRINOLOGY, V59, P241, DOI 10.1210/endo-59-2-241; ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1995, FEBS LETT, V359, P110, DOI 10.1016/0014-5793(95)00018-5; ALONSO MD, 1995, J BIOL CHEM, V270, P15315, DOI 10.1074/jbc.270.25.15315; ALONSO MD, 1994, FEBS LETT, V353, P222; BARTLEY W, 1968, ANAL BIOCHEM, V425, P99; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; BLOCH G, 1994, AM J PHYSIOL, V266, pE85, DOI 10.1152/ajpendo.1994.266.1.E85; BRAMMER GL, 1972, CARBOHYD RES, V24, P343, DOI 10.1016/S0008-6215(00)85068-5; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAO Y, 1994, FASEB J, V8, pA1362; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CAO YJ, 1993, J BIOL CHEM, V268, P21717; DHUGGA KS, 1991, J BIOL CHEM, V226, P21964; ERCAN N, 1994, J BIOL CHEM, V269, P22328; FARKAS I, 1991, J BIOL CHEM, V266, P15602; GAESSER GA, 1980, J APPL PHYSIOL, V49, P722, DOI 10.1152/jappl.1980.49.4.722; GHOSH P, 1989, COMP BIOCHEM PHYS B, V94, P715, DOI 10.1016/0305-0491(89)90155-7; GOLDRAIJ A, 1993, BIOCHEM MOL BIOL INT, V30, P453; IVY JL, 1991, SPORTS MED, V11, P6, DOI 10.2165/00007256-199111010-00002; JUDD C, 1992, FASEB J, V6, pA1520; KOCHAN RG, 1979, AM J PHYSIOL, V236, pE660, DOI 10.1152/ajpendo.1979.236.6.E660; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAUGHLIN MR, 1991, DIABETES, V40, P385, DOI 10.2337/diabetes.40.3.385; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, Biofactors, V1, P261; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1993, FASEB J, V7, P1386, DOI 10.1096/fasebj.7.14.8224611; LOMAKO J, 1990, Biofactors, V2, P251; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; LOMAKO J, 1994, UNPUB EUR J BIOCH; LOMAKO J, 1988, 14 IUB C PRAG; MANZELLA SM, 1995, GLYCOBIOLOGY, V5, P263, DOI 10.1093/glycob/5.2.263; MANZELLA SM, 1994, ANAL BIOCHEM, V216, P383, DOI 10.1006/abio.1994.1056; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; QUENTMEIER H, 1987, PLANTA, V171, P483, DOI 10.1007/BF00392295; RAMACHANDRAN C, 1983, J BIOL CHEM, V258, P3377; RICHTER EA, 1988, AM J PHYSIOL, V255, pE621, DOI 10.1152/ajpendo.1988.255.5.E621; RODEN L, 1994, J BIOL CHEM, V269, P11509; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; ROTHSCHILD A, 1994, PLANT SCI, V97, P119, DOI 10.1016/0168-9452(94)90048-5; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SINGH DG, 1988, FASEB J, V2, pA557; SINGH DG, 1994, THESIS U MIAMI FLORI; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1976, TRENDS BIOCHEM SCI, V1, P13, DOI 10.1016/0968-0004(76)90257-7; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	58	188	193	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1126	1137		10.1096/fasebj.9.12.7672505	http://dx.doi.org/10.1096/fasebj.9.12.7672505			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672505				2022-12-28	WOS:A1995RU81600002
J	ALLENDE, JE; ALLENDE, CC				ALLENDE, JE; ALLENDE, CC			PROTEIN KINASES .4. PROTEIN-KINASE CK2 - AN ENZYME WITH MULTIPLE SUBSTRATES AND A PUZZLING REGULATION	FASEB JOURNAL			English	Review						PROTEIN SUBSTRATE; CONSERVED REGION; AUTOPHOSPHORYLATION; ZINC FINGER; DESTRUCTION BOX	EPIDERMAL GROWTH-FACTOR; CASEIN KINASE; BETA-SUBUNIT; XENOPUS-LAEVIS; ALPHA-SUBUNIT; II ACTIVITY; DNA-BINDING; CELLULAR-REGULATION; TOPOISOMERASE-II; ESCHERICHIA-COLI	Protein kinase CK2 (also known as casein kinase II) is a ubiquitous eukaryotic ser/thr protein kinase present in the nucleus and cytoplasm. CK2 is known to phosphorylate more than 100 substrates, many of which are involved in the control of cell division and in signal transduction. The review centers on the structure and function of CK2 alpha and beta subunits and on the regulation of its activity, a topic that remains to be elucidated. An analogy is drawn between CK2 and the cyclin-dependent kinases (cdks); both types of protein kinases share many substrates and are activated by regulatory subunits.	UNIV CHILE, FAC CIENCIAS, DEPT BIOL, SANTIAGO 7, CHILE	Universidad de Chile	ALLENDE, JE (corresponding author), UNIV CHILE, FAC MED, DEPT BIOQUIM, CASILLA 70086, SANTIAGO 7, CHILE.							ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIDWAI AP, 1994, ARCH BIOCHEM BIOPHYS, V309, P348, DOI 10.1006/abbi.1994.1123; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BOSSER R, 1993, J BIOL CHEM, V268, P15477; BURNETT G, 1954, J BIOL CHEM, V211, P969; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COCHET C, 1980, ENDOCRINOLOGY, V106, P750, DOI 10.1210/endo-106-3-750; COCHET C, 1983, J BIOL CHEM, V258, P1403; COLLINGE MA, 1994, IN PRESS PLANT MOL B; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Dhokakia JN, 1988, P NATL ACAD SCI USA, V85, P51; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P221, DOI 10.1016/0167-4838(91)90005-K; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; GATICA M, 1993, FEBS LETT, V315, P173, DOI 10.1016/0014-5793(93)81157-U; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; GATICA M, 1994, FEBS LETT, V339, P93, DOI 10.1016/0014-5793(94)80392-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONZATTIHACES MI, 1982, J BIOL CHEM, V257, P6642; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HU E, 1990, J BIOL CHEM, V265, P20609; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; JEDLICKI A, 1992, FEBS LETT, V297, P280, DOI 10.1016/0014-5793(92)80556-V; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MESTRES P, 1994, ACTA ANAT, V149, P13; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; Murray A, 1993, CELL CYCLE INTRO; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OSPINA B, 1992, MOL CELL BIOCHEM, V118, P49, DOI 10.1007/BF00249694; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINNA LA, 1994, BIOCH CELL MEMBRANES; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RIHIS HP, 1991, EMBO J, V10, P633; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SERRANO L, 1986, J BIOL CHEM, V261, P7076; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; TAYLOR A, 1987, FEBS LETT, V226, P109, DOI 10.1016/0014-5793(87)80561-6; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TELLEZ R, 1990, FEBS LETT, V265, P113, DOI 10.1016/0014-5793(90)80897-R; TELLEZ R, 1992, FEBS LETT, V308, P113, DOI 10.1016/0014-5793(92)81255-K; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	86	575	585	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					313	323		10.1096/fasebj.9.5.7896000	http://dx.doi.org/10.1096/fasebj.9.5.7896000			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896000				2022-12-28	WOS:A1995QP45100002
J	PAPPAS, TC; GAMETCHU, B; WATSON, CS				PAPPAS, TC; GAMETCHU, B; WATSON, CS			MEMBRANE ESTROGEN-RECEPTORS IDENTIFIED BY MULTIPLE ANTIBODY LABELING AND IMPEDED-LIGAND BINDING	FASEB JOURNAL			English	Article						GH(3)/B6; CONFOCAL MICROSCOPY; MONOCLONAL ANTIBODY; E(2)	S-49 LYMPHOMA-CELLS; PLASMA-MEMBRANE; GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; STEROID-BINDING; PROTEIN-KINASE; RAT-BRAIN; OOCYTES; MYRISTYLATION	GH(3)/B6 rat pituitary tumor cells exhibit rapid prolactin release (within 5 min) when treated with nanomolar amounts of estrogen. However, the putative protein mediator of this nongenomic action has not been described, Using antibodies directed against a peptide representing the hinge region of the intracellular estrogen receptor (iER), we have demonstrated that these cells contain a membrane ER (mER). We now report that confocal scanning laser microscopy of cells labeled live with the anti-peptide antibody further supports a membrane localization of ER. The monoclonal antibodies H226 and H222 and a polyclonal antibody, ER21, each recognizing a unique epitope on iER (NH2 terminal to the DNA-binding region, within the steroid binding region, and the NH2-terminal end, respectively), also immunohistochemically label membrane proteins of immune-selected GH(3)/B6 cells. These cells also specifically bind a fluorescent estrogen-BSA conjugate. Coincubation of cells with anti-ER antibody and the fluorescent estrogen-BSA conjugate reveals that these labels colocalize on cells. These results suggest that mER may be structurally similar to iER.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226	University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin								BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; BLAUSTEIN JD, 1992, ENDOCRINOLOGY, V131, P1336, DOI 10.1210/en.131.3.1336; BLAUSTEIN JD, 1993, ENDOCRINOLOGY, V132, P1218, DOI 10.1210/en.132.3.1218; BLONDEAU JP, 1984, BIOCHEM J, V219, P785, DOI 10.1042/bj2190785; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; CHEN SSL, 1991, INTERVIROLOGY, V32, P193, DOI 10.1159/000150199; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALETTO DL, 1992, ONCOGENE, V7, P1149; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115, DOI 10.1073/pnas.77.9.5115; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAYASHI I, 1976, NATURE, V259, P132, DOI 10.1038/259132a0; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HOFFMAN M, 1991, SCIENCE, V254, P650, DOI 10.1126/science.1948044; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MEIZEL S, 1990, Journal of Cell Biology, V111, p89A; NENCI I, 1980, PERSPECTIVES STEROID, P61; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PATINO R, 1990, GEN COMP ENDOCR, V78, P204, DOI 10.1016/0016-6480(90)90007-9; PIETRAS RJ, 1979, J CELL PHYSIOL, V98, P145, DOI 10.1002/jcp.1040980116; SADLER SE, 1985, J STEROID BIOCHEM, V22, P419, DOI 10.1016/0022-4731(85)90448-0; SADLER SE, 1982, P NATL ACAD SCI USA, V77, P1534; Scheffe H, 1959, ANAL VARIANCE; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH SS, 1989, BRAIN RES, V476, P307, DOI 10.1016/0006-8993(89)91251-1; SZEGO CM, 1985, NATURE, V317, P88, DOI 10.1038/317088a0; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; WATSON CS, 1995, IN PRESS ENV HLTH PE; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WELSHONS WV, 1985, ENDOCRINOLOGY, V117, P2140, DOI 10.1210/endo-117-5-2140	41	442	457	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					404	410		10.1096/fasebj.9.5.7896011	http://dx.doi.org/10.1096/fasebj.9.5.7896011			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896011				2022-12-28	WOS:A1995QP45100014
J	WALSH, DA; VANPATTEN, SM				WALSH, DA; VANPATTEN, SM			MULTIPLE PATHWAY SIGNAL-TRANSDUCTION BY THE CAMP-DEPENDENT PROTEIN-KINASE	FASEB JOURNAL			English	Review						SUBSTRATE PREFERENCE; PROTEIN PHOSPHORYLATION; 2ND MESSENGERS; RESPONSE COORDINATION	LIVER PYRUVATE-KINASE; AMINO-ACID SEQUENCE; PERFUSED RAT-HEART; CATALYTIC SUBUNIT; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; PHOSPHORYLASE-KINASE; BASIC RESIDUES; C-GAMMA	Since its discovery a quarter century ago, the cAMP-dependent protein kinase has been a central model for study of the mode of transduction of second messenger signals; more than 300 protein kinases are now known to play keys roles in cellular control. Multiple cellular events are initiated by the activation of the cAMP-dependent protein kinase and correlated with these events has been the identification of a broad spectrum of protein substrates. From model substrates and inhibitors an excellent understanding has been obtained of the ''optimum'' sequence for protein phosphorylation by the cAMP-dependent protein kinases, and now, from pioneering crystal structure studies, we are beginning to understand exactly how an optimum substrate can interact with and be efficiently phosphorylated by the kinase. The next important step is for us to understand the full sequence of events that occurs within the cell upon activation of the protein kinase, and it is abundantly evident that this is indeed a complex process. It is not sufficient to simply know which proteins are phosphorylated but it is critical that we understand the dynamics of the events surrounding the phosphorylation of multiple proteins, what factors dictate those dynamics, and what might happen when the sequence of events is perturbed. This review focuses on the first simple question that must be addressed, namely, how might proteins vary as substrates for the cAMP-dependent protein kinase and what ramifications might such variations have for the consequential events within the cell?-Walsh, D. A., Van Patten, S. M. Multiple pathway signal transduction by the cAMP-dependent protein kinase.			WALSH, DA (corresponding author), UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA.							ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ADAMS JA, 1993, J BIOL CHEM, V268, P7747; ANGELOS KL, 1987, J BIOL CHEM, V262, P3219; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHENG HC, 1986, J BIOL CHEM, V261, P989; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; EDLUND B, 1975, BIOCHEM BIOPH RES CO, V67, P1516, DOI 10.1016/0006-291X(75)90198-9; ENGLAND PJ, 1975, FEBS LETT, V50, P57, DOI 10.1016/0014-5793(75)81040-4; ENGLAND PJ, 1976, BIOCHEM J, V160, P295, DOI 10.1042/bj1600295; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HJELMQUIST G, 1974, BIOCHEM BIOPH RES CO, V61, P559, DOI 10.1016/0006-291X(74)90993-0; HUGGINS JP, 1983, FEBS LETT, V163, P297, DOI 10.1016/0014-5793(83)80839-4; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; PILKIS SJ, 1980, J BIOL CHEM, V255, P2770; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1979, BIOCHEMISTRY-US, V18, P871, DOI 10.1021/bi00572a021; WALSH DA, 1991, PHYSIOL REV, V71, P285, DOI 10.1152/physrev.1991.71.1.285; WALSH DA, 1979, BIOCH ACTIONS HORM, V6, P1; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	45	205	211	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1994	8	15					1227	1236		10.1096/fasebj.8.15.8001734	http://dx.doi.org/10.1096/fasebj.8.15.8001734			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001734				2022-12-28	WOS:A1994PY20900005
J	SCHWABE, C; BULLESBACH, EE				SCHWABE, C; BULLESBACH, EE			RELAXIN - STRUCTURES, FUNCTIONS, PROMISES, AND NONEVOLUTION	FASEB JOURNAL			English	Review						RECEPTOR-BINDING SITE; ALLOSTERIC EFFECT; CHEMICAL SYNTHESIS; SITE-SPECIFIC CROSS-LINKING; RELAXIN PHYLOGENY	RECEPTOR-BINDING SITE; PORCINE RELAXIN; RAT RELAXIN; SEQUENCE DETERMINATION; A-CHAIN; MONOCLONAL-ANTIBODIES; PASSIVE-IMMUNIZATION; TERTIARY STRUCTURE; MOUSE RELAXIN; INSULIN	During the last two decades synthetic chemistry and molecular biology have transformed the little-known parturition-mediating factor relaxin into a chemically defined entity. Relaxin is a disulfide bond analog of insulin that shows no cross-reactivity to the insulin receptors, causes widening of the birth canal in most mammals, and has additional or different functions in various species. The receptor interaction site in relaxin has been located quite precisely in the midregion of the B chain helix and is now known to involve two arginine residues that project from the alpha helix in an n, n + 4 configuration. The A chain of relaxin which appears to be uninvolved in receptor binding, is nonetheless essential. In fact, a major structural determinant in relaxin and insulin responsible for achieving either an insulin-like or a relaxin-like conformation is located in the penultimate position in the intrachain loop of the A chains.			SCHWABE, C (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							BAGNA B, 1991, J REPROD FERTIL, V91, P605, DOI 10.1530/jrf.0.0910605; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BEDARKAR S, 1982, ANN NY ACAD SCI, V380, P22, DOI 10.1111/j.1749-6632.1982.tb18025.x; BRYANTGREENWOOD GD, 1994, ENDOCR REV, V15, P5, DOI 10.1210/er.15.1.5; BULLESBACH EE, 1985, BIOCHEMISTRY-US, V24, P7722, DOI 10.1021/bi00347a033; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; BULLESBACH EE, 1987, J BIOL CHEM, V262, P12496; BULLESBACH EE, 1985, BIOCHEMISTRY-US, V24, P7717, DOI 10.1021/bi00347a032; BULLESBACH EE, 1993, BIOCHEM BIOPH RES CO, V196, P311, DOI 10.1006/bbrc.1993.2250; BULLESBACH EE, 1986, BIOCHEMISTRY-US, V25, P5998; BULLESBACH EE, 1994, J BIOL CHEM, V269, P13124; BULLESBACH EE, 1987, BIOCHEM BIOPH RES CO, V143, P273; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; BULLESBACH EE, 1986, EUR J BIOCHEM, V161, P335, DOI 10.1111/j.1432-1033.1986.tb10452.x; BULLESBACH EE, 1994, IN PRESS ENDOCR J; CANOVADAVIS E, 1990, J CHROMATOGR, V508, P81, DOI 10.1016/S0021-9673(00)91242-1; CASTEN GG, 1958, JAMA-J AM MED ASSOC, V166, P319, DOI 10.1001/jama.1958.02990040005002; CASTEN GUS G., 1960, ANGIOLOGY, V11, P408, DOI 10.1177/000331976001100506; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; DODSON GG, 1982, INT J BIOL MACROMOL, V4, P399, DOI 10.1016/0141-8130(82)90083-6; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; ESSIG M, 1982, ANN NY ACAD SCI, V380, P224, DOI 10.1111/j.1749-6632.1982.tb18045.x; EVANS BA, 1994, J ENDOCRINOL, V140, P385, DOI 10.1677/joe.0.1400385; EVANS BA, 1993, J MOL ENDOCRINOL, V10, P15, DOI 10.1677/jme.0.0100015; EVANS BA, 1994, IN PRESS ENDOCR J; EVANS JA, 1959, ARCH DERMATOL, V79, P150, DOI 10.1001/archderm.1959.01560140012003; GOWAN LK, 1981, FEBS LETT, V129, P80, DOI 10.1016/0014-5793(81)80760-0; HANSELL DJ, 1991, J CLIN ENDOCR METAB, V72, P899, DOI 10.1210/jcem-72-4-899; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; HWANG JJ, 1988, ENDOCRINOLOGY, V123, P2486, DOI 10.1210/endo-123-5-2486; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; ISAACS N, 1981, RELAXIN, P101; JAMES R, 1977, NATURE, V267, P544, DOI 10.1038/267544a0; JHOTI H, 1987, FEBS LETT, V219, P419, DOI 10.1016/0014-5793(87)80264-8; JOHN MJ, 1981, ENDOCRINOLOGY, V108, P726, DOI 10.1210/endo-108-2-726; KAKOURIS H, 1993, TRENDS PHARMACOL SCI, V14, P4, DOI 10.1016/0165-6147(93)90105-S; KAKOURIS H, 1992, LANCET, V339, P1076, DOI 10.1016/0140-6736(92)90665-P; KATSOYAN.PG, 1966, P NATL ACAD SCI USA, V55, P1554, DOI 10.1073/pnas.55.6.1554; KEMP BE, 1984, VITAM HORM, V41, P79; KUENZI MJ, 1992, ENDOCRINOLOGY, V131, P1841, DOI 10.1210/en.131.4.1841; LEE YA, 1992, ENDOCRINOLOGY, V130, P1165, DOI 10.1210/en.130.3.1165; MacLennan A H, 1983, Clin Reprod Fertil, V2, P77; MCMURTRY JP, 1980, J REPROD FERTIL, V58, P43; MUGGEO M, 1979, ENDOCRINOLOGY, V104, P1393, DOI 10.1210/endo-104-5-1393; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; POTTS JT, 1976, PEPTIDE HORMONES, P119; SAKBUN V, 1990, J CLIN ENDOCR METAB, V70, P508, DOI 10.1210/jcem-70-2-508; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1976, BIOCHEM BIOPH RES CO, V70, P397, DOI 10.1016/0006-291X(76)91059-7; SCHWABE C, 1977, SCIENCE, V197, P914, DOI 10.1126/science.887933; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1976, BIOCHEM BIOPH RES CO, V68, P1126, DOI 10.1016/0006-291X(76)90313-2; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V74, P1501, DOI 10.1016/0006-291X(77)90612-X; SCHWABE C, 1994, COMP BIOCHEM PHYS B, V107, P167, DOI 10.1016/0305-0491(94)90036-1; SHERWOOD OD, 1979, ENDOCRINOLOGY, V104, P886, DOI 10.1210/endo-104-4-886; SHERWOOD OD, 1974, ARCH BIOCHEM BIOPHYS, V60, P185; SHERWOOD OD, 1994, PHYSL REPRODUCTION, pA861; SMITH LF, 1972, DIABETES, V21, P457, DOI 10.2337/diab.21.2.S457; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEINETZ BG, 1969, METHOD HORMONE RES, P481; STEINETZ BG, 1982, RELAXIN, P79; STEWART DR, 1991, ENDOCRINOLOGY, V129, P375, DOI 10.1210/endo-129-1-375; STEWART DR, 1992, J PROTEIN CHEM, V11, P247, DOI 10.1007/BF01024863; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; WARD DG, 1992, BIOCHEM BIOPH RES CO, V186, P999, DOI 10.1016/0006-291X(92)90845-C; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197; WINSLOW JW, 1992, ENDOCRINOLOGY, V130, P2660, DOI 10.1210/en.130.5.2660; WOODS AS, 1991, INT J MASS SPECTROM, V111, P77, DOI 10.1016/0168-1176(91)85049-R; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	77	55	64	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1152	1160		10.1096/fasebj.8.14.7958621	http://dx.doi.org/10.1096/fasebj.8.14.7958621			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958621				2022-12-28	WOS:A1994PT12800010
J	LEE, WY; LOCKNISKAR, MF; FISCHER, SM				LEE, WY; LOCKNISKAR, MF; FISCHER, SM			INTERLEUKIN-1-ALPHA MEDIATES PHORBOL ESTER-INDUCED INFLAMMATION AND EPIDERMAL HYPERPLASIA	FASEB JOURNAL			English	Article						TPA; MURINE SKIN; CYTOKINE; VASCULAR PERMEABILITY; KERATINOCYTE	MESSENGER-RNA EXPRESSION; HUMAN KERATINOCYTES; ORNITHINE DECARBOXYLASE; VASCULAR-PERMEABILITY; CYTOKINE MODULATION; ADHESION MOLECULES; DERMAL FIBROBLASTS; ACTIVATING FACTOR; TUMOR PROMOTION; SKIN DISEASES	The topical application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to murine skin produces acute inflammatory and hyperplastic responses that have been associated with the promotion stage of skin carcinogenesis. It has been shown in a previous study that TPA induces the expression of the highly inflammatory cytokine, interleukin (IL) -1 alpha, in the epidermis of SENCAR mice. The goal of this study induced responses in skin. Topical application of TPA (1 mu g) enhanced the production of immunoreactive IL-1 alpha protein, primarily associated with the suprabasal keratinocytes. IL-1 alpha intradermally injected in the dorsal surface significantly increased (P < 0.001) vascular permeability at low concentrations (1-1000 mu U) and increased (P < 0.001) inflammatory cell infiltration and epidermal hyperplasia at higher concentrations (10(3) U). TPA produced fourfold increases in vascular permeability as measured by Evans blue dye leakage; this effect was prevented by intradermal injection of anti-IL-1 alpha antibody (25-75 mu g). Furthermore, injected anti-IL-1 alpha antibody significantly reduced (P < 0.001) TPA-induced inflammatory cell infiltration and epidermal hyperplasia. This study suggests that IL-1 alpha directly or indirectly mediates the inflammatory and hyperplastic responses elicited by topical treatment with TPA.	UNIV TEXAS, MD ANDERSON CANC CTR, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; UNIV TEXAS, COLL PHARM, DIV PHARMACOL TOXICOL, AUSTIN, TX 78712 USA; UNIV TEXAS, DIV NUTR SCI, AUSTIN, TX 78712 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NCI NIH HHS [CA 42211, CA 34443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034443, R01CA042211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1985, CANCER RES, V45, P2753; ANSEL J, 1990, J INVEST DERMATOL, V94, pS101, DOI 10.1111/1523-1747.ep12876053; ANSEL JC, 1988, J IMMUNOL, V140, P2274; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; CAMP R, 1990, J INVEST DERMATOL, V94, P735, DOI 10.1111/1523-1747.ep12874591; DEYOUNG LM, 1987, AGENTS ACTIONS, V21, P325; DIDIERJEAN L, 1989, J INVEST DERMATOL, V92, P809, DOI 10.1111/1523-1747.ep12696825; DINARELLO CA, 1991, BLOOD, V77, P1627; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; GROVES RW, 1992, J INVEST DERMATOL, V98, P384, DOI 10.1111/1523-1747.ep12499816; HECKMANN M, 1993, J INVEST DERMATOL, V100, P780, DOI 10.1111/1523-1747.ep12476479; KUPPER TS, 1989, ARCH DERMATOL, V125, P1406, DOI 10.1001/archderm.125.10.1406; KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LEE WY, 1993, MOL CARCINOGEN, V7, P26, DOI 10.1002/mc.2940070106; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MARTIN S, 1988, IMMUNOLOGY, V64, P301; MCGUIRE J, 1988, ANN NY ACAD SCI, V548, P283, DOI 10.1111/j.1749-6632.1988.tb18816.x; MORHENN VB, 1988, IMMUNOL TODAY, V9, P104, DOI 10.1016/0167-5699(88)91278-9; NAKADATE T, 1982, CANCER RES, V42, P2841; NORRIS DA, 1990, J INVEST DERMATOL, V95, pS111, DOI 10.1111/1523-1747.ep12874977; OBERYSZYN TM, 1993, MOL CARCINOGEN, V7, P238, DOI 10.1002/mc.2940070406; RISTOW HJ, 1987, P NATL ACAD SCI USA, V84, P1940, DOI 10.1073/pnas.84.7.1940; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SCHMITT A, 1986, LYMPHOKINE RES, V5, P105; Slaga T. J., 1984, MECH TUMOR PROMOTION, P1; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, P189; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	36	55	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1081	1087		10.1096/fasebj.8.13.7926375	http://dx.doi.org/10.1096/fasebj.8.13.7926375			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926375				2022-12-28	WOS:A1994PN06900014
J	MAHER, F; VANNUCCI, SJ; SIMPSON, IA				MAHER, F; VANNUCCI, SJ; SIMPSON, IA			GLUCOSE-TRANSPORTER PROTEINS IN BRAIN	FASEB JOURNAL			English	Review						GLUCOSE TRANSPORT; CEREBRAL GLUCOSE UTILIZATION; NEURONS; GLIA	RAT-BRAIN; GENE-EXPRESSION; INSITU HYBRIDIZATION; PRIMARY CULTURES; XENOPUS OOCYTES; SMALL-INTESTINE; GROWTH-FACTOR; GLIAL-CELLS; BARRIER; GLUT3	Glucose is the principal energy source for the mammalian brain. The presence of glucose transport proteins is essential to supply glucose to the neurons and glia within the brain. At least three glucose transporter isoforms have now been identified, and are thought to play a significant role, in the brain. This review describes our current understanding of cell-specific glucose transporter expression in brain, which includes GLUT1 (55-kDa form) present at a high concentration at the blood-brain barrier as well as in parenchymal cells (45-kDa form), most likely in astrocytes, GLUT3 expressed in neurons, and GLUT5 in microglia. We discuss some potential implications of this glucose transporter heterogeneity for cerebral metabolic activity.	NIDDKD, BETHESDA, MD 20892 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PEDIAT, HERSHEY, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								APPEL NM, 1992, J PHARMACOL EXP THER, V263, P1415; ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BELL GI, 1993, J BIOL CHEM, V268, P19161; BELL JE, 1993, NEUROPATH APPL NEURO, V19, P429, DOI 10.1111/j.1365-2990.1993.tb00465.x; BHATTACHARYYA MV, 1988, BIOCHEM BIOPH RES CO, V155, P685, DOI 10.1016/S0006-291X(88)80549-7; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BONDY CA, 1992, MOL CELL NEUROSCI, V3, P305, DOI 10.1016/1044-7431(92)90027-Y; BRANT AM, 1993, BIOCHEM BIOPH RES CO, V192, P1297, DOI 10.1006/bbrc.1993.1557; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CORNFORD EM, 1993, J CEREBR BLOOD F MET, V13, P841, DOI 10.1038/jcbfm.1993.106; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; DEVASKAR S, 1991, ENDOCRINOLOGY, V129, P1530, DOI 10.1210/endo-129-3-1530; DICK APK, 1984, P NATL ACAD SCI-BIOL, V81, P7233, DOI 10.1073/pnas.81.22.7233; DIENEL GA, 1991, J CEREBR BLOOD F MET, V11, P25, DOI 10.1038/jcbfm.1991.3; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FARRELL CL, 1992, J HISTOCHEM CYTOCHEM, V40, P193, DOI 10.1177/40.2.1552163; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GLIEMANN J, 1983, CURR TOP MEMBR TRANS, V18, P339; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GREUTTER R, 1992, P NATL ACAD SCI USA, V89, P1109; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; KALARIA RN, 1989, J NEUROCHEM, V53, P1083, DOI 10.1111/j.1471-4159.1989.tb07399.x; KASANICKI MA, 1987, BIOCHEM J, V247, P101, DOI 10.1042/bj2470101; KASANICKI MA, 1989, HISTOCHEM J, V21, P47, DOI 10.1007/BF01002471; Laterra John, 1993, P1; Lawrence M. S., 1993, Society for Neuroscience Abstracts, V19, P1030; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; LELOUP C, 1994, BRAIN RES, V638, P221, DOI 10.1016/0006-8993(94)90653-X; MAHER F, 1993, ADV EXP MED BIOL, V331, P9; MAHER F, 1993, J CEREBR BLOOD F MET, V13, P342, DOI 10.1038/jcbfm.1993.43; MAHER F, 1994, MOL CELL NEUROSCI, V5, P369, DOI 10.1006/mcne.1994.1044; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; MAHER F, 1991, Molecular and Cellular Neuroscience, V2, P351, DOI 10.1016/1044-7431(91)90066-W; MAHER F, 1994, BIOCHEM J, V301, P379, DOI 10.1042/bj3010379; Maher F., 1993, Society for Neuroscience Abstracts, V19, P898; MANTYCH GJ, 1992, ENDOCRINOLOGY, V131, P1270, DOI 10.1210/en.131.3.1270; MANTYCH GJ, 1993, ENDOCRINOLOGY, V132, P35, DOI 10.1210/en.132.1.35; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MCCALL AL, 1992, DIABETES, V41, P557, DOI 10.2337/diabetes.41.5.557; MCCALL AL, 1992, DIABETES, V41, pA153; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NAGAMATSU S, 1993, FEBS LETT, V334, P289, DOI 10.1016/0014-5793(93)80697-S; NISHIOKA T, 1992, CANCER RES, V52, P3972; Pardridge William M., 1993, P395; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Payne J., 1993, Society for Neuroscience Abstracts, V19, P1042; SHEPHERD PR, 1992, DIABETES, V41, P1360, DOI 10.2337/diabetes.41.10.1360; SHEPHERD PR, 1992, BIOCHEM BIOPH RES CO, V188, P149, DOI 10.1016/0006-291X(92)92362-2; Siesjo B.K., 1978, BRAIN ENERGY METABOL; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; THOMAS HM, 1993, BIOCHEM J, V290, P707, DOI 10.1042/bj2900707; VANBUEREN AM, 1993, BIOCHEM BIOPH RES CO, V197, P1492, DOI 10.1006/bbrc.1993.2645; VANNUCCI SJ, 1994, J NEUROCHEM, V62, P240; VANNUCCI SJ, 1994, IN PRESS AM J PHYSL; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; WHITE MK, 1991, MOL CELL BIOL, V11, P4448, DOI 10.1128/MCB.11.9.4448; YAMAMOTO T, 1990, BIOCHEM BIOPH RES CO, V170, P223, DOI 10.1016/0006-291X(90)91263-R; YANO H, 1991, BIOCHEM BIOPH RES CO, V174, P470, DOI 10.1016/0006-291X(91)91440-N	65	394	401	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1003	1011		10.1096/fasebj.8.13.7926364	http://dx.doi.org/10.1096/fasebj.8.13.7926364			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926364				2022-12-28	WOS:A1994PN06900003
J	ANDERSON, DJ				ANDERSON, DJ			STEM-CELLS AND TRANSCRIPTION FACTORS THE MAMMALIAN NEURAL CREST	FASEB JOURNAL			English	Review						MASH1; GLIAL GROWTH FACTOR; NEUROGENESIS; BHLH; PROTEINS; GLIOGENESIS	ACHAETE-SCUTE HOMOLOG-1; INVITRO CLONAL ANALYSIS; CENTRAL-NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; LINEAGE DIVERSIFICATION; MELANOCYTE PRECURSORS; SYMPATHETIC-GANGLIA; GROWTH-FACTORS; MOUSE EMBRYO; DORSAL-ROOT	The neural crest is a migratory population of multipotent embryonic cells that generates the neurons and glia of the peripheral nervous system, as well as a variety of non-neural mesectodermal and endocrine cell types. The study of neural crest cell and molecular biology provides a system to investigate how such multipotent cells choose their fates, and whether the repertoire of fates becomes progressively restricted with time. The study of mammalian neural crest development has lagged behind studies of avian crest development due to the relative inaccessibility of mammalian embryos. The development of reverse genetic methods in mice, however, has made the analysis of mammalian neural crest development both more attractive and more tractable. Rodent neural crest cells have been isolated and grown in clonogenic cultures, where they behave as multipotent stem cells. This system provides an assay for factors that influence the differentiation of these multipotent cells. Transcription factors provide valuable early markers for neural crest cells as well as molecular handles on the lineage segregation process. One such factor is Mash1, a homolog of the Drosophila proneural genes, achaete-scute. Mash1 marks autonomic progenitor cells and is essential for their development in vivo, as shown by gene knockout experiments.			ANDERSON, DJ (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, 391 S HOLLISTON AVE, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; ANDERSON DJ, 1993, CR ACAD SCI III-VIE, V316, P1090; ARTINGER KB, 1992, DEV BIOL, V149, P149, DOI 10.1016/0012-1606(92)90271-H; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOISSEAU S, 1989, DEVELOPMENT, V106, P665; BRONNERFRASER M, 1991, DEVELOPMENT, P17; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARNAHAN JF, 1991, J NEUROSCI, V11, P3493; CIMENT G, 1990, COMMENTS DEV NEUROBI, V1, P207; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FRANK E, 1991, DEVELOPMENT, V111, P895; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; ITO K, 1993, DEV BIOL, V157, P517, DOI 10.1006/dbio.1993.1154; ITO K, 1984, J EMBRYOL EXP MORPH, V84, P49; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEMKE GE, 1984, J NEUROSCI, V4, P75; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LO L, 1994, IN PRESS PERSPECT DE; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LORING J, 1982, DEV BIOL, V90, P165, DOI 10.1016/0012-1606(82)90222-6; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Marusich MF, 1991, CURR OPIN GENET DEV, V1, P221, DOI 10.1016/S0959-437X(05)80074-7; MAXWELL GD, 1987, DEVELOPMENT, V101, P767; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MORRISONGRAHAM K, 1993, DEV BIOL, V159, P346, DOI 10.1006/dbio.1993.1246; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RAIBLE DW, 1994, DEVELOPMENT, V120, P495; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROGERS SL, 1990, DEV BIOL, V141, P173, DOI 10.1016/0012-1606(90)90112-V; ROHRER H, 1990, EUR J NEUROSCI, V2, P1005, DOI 10.1111/j.1460-9568.1990.tb00013.x; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHANKLAND M, 1992, DETERMINANTS NEURONA; Sieber-Blum M., 1990, Comments on Developmental Neurobiology, V1, P225; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1991, NEUROSCI LETT, V124, P57, DOI 10.1016/0304-3940(91)90821-A; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOGEL KS, 1988, NEURON, V1, P569, DOI 10.1016/0896-6273(88)90106-7; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WESTON JA, 1991, CURR TOP DEV BIOL, V25, P133	64	43	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1994	8	10					707	713		10.1096/fasebj.8.10.8050669	http://dx.doi.org/10.1096/fasebj.8.10.8050669			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050669				2022-12-28	WOS:A1994NY35000007
J	BOROVSKY, D; POWELL, CA; NAYAR, JK; BLALOCK, JE; HAYES, TK				BOROVSKY, D; POWELL, CA; NAYAR, JK; BLALOCK, JE; HAYES, TK			CHARACTERIZATION AND LOCALIZATION OF MOSQUITO-GUT RECEPTORS FOR TRYPSIN MODULATING OOSTATIC FACTOR USING A COMPLEMENTARY PEPTIDE AND IMMUNOCYTOCHEMISTRY	FASEB JOURNAL			English	Note						IMMUNOCYTOCHEMISTRY; RECEPTOR; BINDING; ELISA; PEPTIDE HORMONE	JUVENILE-HORMONE; MIDGUT	The gut receptor of trypsin-modulating oostatic factor (TMOF), a decapeptide hormone that regulates trypsin biosynthesis in the mosquito gut, has been characterized. The binding of TMOF to mosquito gut membranes reached maximum at pH 7.4 and 24 degrees C. No binding was observed at pH 2.5 and the binding to the membranes declined rapidly at pH 8.0. At equilibrium, maximum binding to the receptor was observed at 60 min and 24 degrees C. A synthetic complementary decapeptide NH2-Ile-Leu-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Gly-COOH (FOMT) for TMOF successfully competed with the gut receptor, and specifically bound TMOF (K-d = 4: mu M and K-assoc = 2.5 x 10(5) M(-1)). TMOF binding to gut membranes was characterized with FOMT and a specific ELISA to the hormone at 24 and 72 h after blood feeding. Two classes of binding sites were found on the gut membrane; high affinity (K-d1 = 4.6 +/- 0.7 x 10(-7) M; K-assoc = 2.2 x 10(6) M(-1) B-max = 0.1 pmol/gut) and low affinity (K-d2 = 4.43 +/- 1 x 10(-6) M; K-assoc = 2.3 x 10(5) M(-1); B-max = 0.2 pmol/gut). The total binding sites for high and low affinity classes of TMOF per put were estimated as 6.3 x 10(10) and 1.1 x 10(11) sites, respectively. Specific binding sites on the put increased after the blood meal and were visualized by immunocytochemical staining. These results suggest that TMOF regulates trypsin biosynthesis by binding to specific receptor sites that are located on the mosquito gut, and that this receptor can be studied using a complementary peptide approach.	UNIV FLORIDA,INST FOOD & AGR SCI,CTR AGR RES & EDUC,FT PIERCE,FL 34954; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; TEXAS A&M UNIV,DEPT ENTOMOL,COLL STN,TX 77843	State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; Texas A&M University System; Texas A&M University College Station	BOROVSKY, D (corresponding author), UNIV FLORIDA,INST FOOD & AGR SCI,FLORIDA MED ENTOMOL LAB,VERO BEACH,FL 32962, USA.			Blalock, J. Edwin/0000-0001-5303-8123	NIDDK NIH HHS [DK 38024] Funding Source: Medline; NINDS NIH HHS [NS 29719] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOROVSKY D, 1993, INSECT BIOCHEM MOLEC, V23, P703, DOI 10.1016/0965-1748(93)90044-S; BOROVSKY D, 1990, FASEB J, V4, P3015, DOI 10.1096/fasebj.4.12.2394318; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P333, DOI 10.1002/arch.940020402; BOROVSKY D, 1992, ARCH INSECT BIOCHEM, V21, P13, DOI 10.1002/arch.940210103; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P75, DOI 10.1002/arch.940020108; BOROVSKY D, 1988, ARCH INSECT BIOCHEM, V8, P249, DOI 10.1002/arch.940080406; BOROVSKY D, 1993, IN PRESS ARCH INSECT; Borovsky Dov, 1993, P36; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRIEGEL H, 1975, J INSECT PHYSIOL, V21, P1597, DOI 10.1016/0022-1910(75)90197-3; Clements AN., 1992, BIOL MOSQUITOES DEV; CURTO EV, 1993, BIOCHEM BIOPH RES CO, V193, P688, DOI 10.1006/bbrc.1993.1679; ENGELMANN F, 1987, INSECT BIOCHEM, V17, P1045, DOI 10.1016/0020-1790(87)90118-1; GOODING RH, 1966, COMP BIOCHEM PHYSIOL, V17, P115, DOI 10.1016/0010-406X(66)90013-2; HANDLER AM, 1989, MOL CELL ENDOCRINOL, V63, P103, DOI 10.1016/0303-7207(89)90086-5; JARPE MA, 1993, IN PRESS PEPTIDES DE; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; VANDESANDE P, 1983, IMMUNOCYTOCHEMISTRY, P257	21	49	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					350	355		10.1096/fasebj.8.3.7908271	http://dx.doi.org/10.1096/fasebj.8.3.7908271			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	7908271				2022-12-28	WOS:A1994NB62300010
J	VENER, KJ; FEUER, EJ; GORELIC, L				VENER, KJ; FEUER, EJ; GORELIC, L			A STATISTICAL-MODEL VALIDATING TRIAGE FOR THE PEER-REVIEW PROCESS - KEEPING THE COMPETITIVE APPLICATIONS IN THE REVIEW PIPELINE	FASEB JOURNAL			English	Article						GRANT REVIEW; NATIONAL INSTITUTES OF HEALTH; STATISTICAL MODEL; APPLICATION TRIAGE		Triage of grant application at the National Institutes of Health (NIH) is a process whereby an initial screening of applications by a scientific peer review group eliminates applications that are not competitive for awards. The process of application triage has been limited to those applications submitted to the NIH in response to an RFA (Request for Applications). A hypergeometric model was developed to determine the extent to which five, six, seven, or eight member triage teams or subsets of 12-to-20 member full committees could provide a statistically defensible triage decision. Although the intent of triage is to remove from review those applications that are noncompetitive, the model was weighted in favor of the applicant to minimize the likelihood that highly competitive applications would be eliminated. Within the assumptions and rules developed, it was determined that there was little likelihood that the latter would occur. For example, in the worst case scenario, the greatest probability that a highly competitive application would be knocked out of competition is P less-than-or-equal-to 0.014 in the case of a five-member triage subset of a 20-member committee. Using the latter case, the model was tested on a set of 73 applications that were submitted to the National Cancer Institute for action at the February 1993 National Cancer Advisory Board. The model selected for triage required that each application be assigned to five reviewers, that each reviewer be blinded to the review assignments of the other reviewers, and that four noncompetitive votes be registered to triage out an application. Each of 19 applications received four to five noncompetitive votes, and were triaged out of the review process. The remaining 54 applications were then reviewed according to the usual NIH review process. Four of the applications received three noncompetitive triage votes each and were either rated as not recommended for further consideration (NRF, n=2)) or received priority scores greater-than-or-equal-to 250 (n=2) (The smaller the priority score the better the technical merit). Thirteen of the 53 applications received two noncompetitive votes. Of the latter, two were not recommended for further consideration and the remaining 11 received priority scores between in excess of 200. The distribution of competitive applications was such that funding was limited to those applications with priority scores of less than 190. Thus, the data suggest that the conservative model is valid such that the likelihood of eliminating a highly competitive application from consideration for funding is remotely small. With this model, the process of triage is fair to applicants on the one hand and is also effective in reducing consultant workloads on the other. The model could be applied to many different types of review situations (private sponsors as well as federal), especially when few awards are to be issued relative to the number of competing applications.	NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	VENER, KJ (corresponding author), NCI,PREVENT EPIDEMIOL & CONTROL REVIEW SECT,BETHESDA,MD 20892, USA.							1985, SAS USERS GUIDE; 1988, OER885 INSTR INF MEM	3	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1312	1319		10.1096/fasebj.7.14.8224604	http://dx.doi.org/10.1096/fasebj.7.14.8224604			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224604				2022-12-28	WOS:A1993MH00800002
J	BERNI, R; CLERICI, M; MALPELI, G; CLERIS, L; FORMELLI, F				BERNI, R; CLERICI, M; MALPELI, G; CLERIS, L; FORMELLI, F			RETINOIDS - IN-VITRO INTERACTION WITH RETINOL-BINDING PROTEIN AND INFLUENCE ON PLASMA RETINOL	FASEB JOURNAL			English	Article						RETINOL-BINDING PROTEIN; PLASMA RETINOL; FENRETINIDE; RETINOIC ACID; TRANSTHYRETIN	VITAMIN-A; METABOLISM; TRANSPORT; FENRETINIDE; SECRETION; RATS; ACID	Studies have been conducted to investigate the structure-function relationships of retinoids in their in vitro interaction with plasma retinol-binding protein (RBP) and in their influence on plasma retinol concentration. Two classes of retinoids, one bearing modifications in the area of the retinol hydroxyl end group (fenretinide, N-(ethyl) retinamide, all-trans, and 13-cis retinoic acid) and the other one also bearing modifications in the area of the cyclohexene ring (etretinate, acitretin, and arotinoid Ro 13-7410), were investigated. Whereas substantial modifications of the retinol hydroxyl group do not prevent the binding to RBP, an intact trimethylcyclohexenyl group seems to be crucial for binding. Both classes of retinoids, administered orally at equimolar doses, reduce plasma retinol concentration in rats but with different kinetics. A marked lowering of plasma retinol occurs early (within 5 h) after administration of retinoids that interact with RBP in vitro, whereas it occurs at later times (24 h) after retinoids that do not interact with RBP. The concentrations of both classes of retinoids found in plasma do not account for the temporal difference in this effect. The early reduction of plasma retinol might be the consequence of in vivo specific binding of retinoids to RBP, as suggested by the in vitro results. The late reduction observed for retinoids lacking in vitro affinity for RBP is due to other mechanisms or to metabolism to retinoids binding to RBP.	NATL CANC INST,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	BERNI, R (corresponding author), UNIV PARMA,INST BIOCHEM SCI,VIA SCI,I-43100 PARMA,ITALY.		Cleris, Loredana/T-3144-2018	Cleris, Loredana/0000-0001-8778-7931; Berni, Rodolfo/0000-0002-1839-0479; Malpeli, Giorgio/0000-0002-2996-2903				[Anonymous], 1989, MERCK INDEX; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1985, ANAL BIOCHEM, V150, P273, DOI 10.1016/0003-2697(85)90510-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOYD AS, 1989, AM J MED, V86, P568, DOI 10.1016/0002-9343(89)90386-0; CHYTIL F, 1984, RETINOIDS, V2, P89; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; FORMELLI F, 1989, CANCER RES, V49, P6149; FRELREICH EJ, 1966, CANCER CHEMOTH REP, V50, P219; Ganguly J., 1989, BIOCH VITAMIN A, P63; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; HASE J, 1976, J BIOCHEM-TOKYO, V79, P373, DOI 10.1093/oxfordjournals.jbchem.a131080; HORWITZ J, 1973, J BIOL CHEM, V248, P6317; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARINARI L, 1987, J LIPID RES, V28, P941; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SMITH JE, 1973, BIOCHEM J, V132, P821, DOI 10.1042/bj1320821; SMITH JE, 1985, ARCH BIOCHEM BIOPHYS, V238, P1, DOI 10.1016/0003-9861(85)90134-1; SMITH JE, 1992, J NUTR, V122, P1999, DOI 10.1093/jn/122.10.1999; SMITH JE, 1979, FED PROC, V38, P2504; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VAHLQUIST A, 1990, METHOD ENZYMOL, V190, P163; VAHLQUIST A, 1991, RETINOIDS 10 YEARS; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	34	56	57	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1179	1184		10.1096/fasebj.7.12.8375617	http://dx.doi.org/10.1096/fasebj.7.12.8375617			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375617				2022-12-28	WOS:A1993LW81700013
J	KAUFMANN, WK; KAUFMAN, DG				KAUFMANN, WK; KAUFMAN, DG			CELL-CYCLE CONTROL, DNA-REPAIR AND INITIATION OF CARCINOGENESIS	FASEB JOURNAL			English	Article						CELL CYCLE; CARCINOGENESIS; DNA REPAIR	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; CHEMICAL CARCINOGENESIS; GENE AMPLIFICATION; DAMAGE; PROGRESSION; FIBROBLASTS; HEPATOCYTES; INHIBITION; RADIATION	We hypothesize that degradation of controls that normally act to inhibit cell proliferation is an early step in carcinogenesis. This alteration gives rise to initiated clones that display a selective growth advantage over normal cells when subjected to appropriate growth-promoting influences. In cell culture, such initiated cells also may display a selective growth advantage that lets them proliferate under conditions in which normal cell growth ceases. Cells with these properties have been designated enhanced-growth variants (EGVs)2 (1) or extended life span variants (ELVs) (2). We propose that the EGV/ELV phenotypes in vitro and initiation of carcinogenesis in vivo are consequences of genetic changes in pathways that regulate the passage of cells through the cell cycle. These regulatory pathways normally delay or arrest cell cycle progression in response to homeostatic regulators and DNA damage. DNA damage induced by a variety of genotoxic agents triggers delays in cycle progression at three steps of the cell cycle. Two of these involve delays in progression from G1 into S phase and G2 into mitosis. The third occurs within S phase cells and involves reduction in the rate of initiation of DNA synthesis in replicon clusters. If these cycle delay responses fail, damaged DNA may be replicated before it is adequately repaired. This would enhance production of additional genetic alterations. Thus, mutations in genes that normally exert a negative control over cell cycle progression may give cells a growth advantage and make the cells more genetically unstable.	UNIV N CAROLINA, DEPT PATHOL,CB 7525,RM 515,BRINKHOUS BULLITT BLDG, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [P01CA042765] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA M, 1987, CANCER RES, V47, P573; BARRETT JC, 1987, CRITICAL MOL DETERMI, V39, P45; BENDER MA, 1974, MUTAT RES, V23, P197, DOI 10.1016/0027-5107(74)90140-7; BOONE CW, 1992, CANCER RES, V52, P1651; CLEAVER JE, 1983, BIOCHIM BIOPHYS ACTA, V739, P207, DOI 10.1016/0167-4781(83)90031-3; COHEN MM, 1989, ADV HUM GENET, V18, P43; DAY RS, 1980, CARCINOGENESIS, V1, P21, DOI 10.1093/carcin/1.1.21; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ELMORE E, 1983, CANCER RES, V43, P1650; FARBER E, 1986, PATHOL IMMUNOPATH R, V5, P1, DOI 10.1159/000157000; FREIDBERG EC, 1986, DNA REPAIR; GRISHAM JW, 1983, SURV SYN PATHOL RES, V1, P49; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMAN DG, 1988, TUMOR PROMOTERS BIOL, P289; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; KRAEMER KH, 1987, DERMATOLOGY GENERAL; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; NETTESHEIM P, 1984, CRC CR REV TOXICOL, V12, P215, DOI 10.3109/10408448409021603; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; RILEY PA, 1982, MED HYPOTHESES, V9, P163, DOI 10.1016/0306-9877(82)90132-3; SANFORD KK, 1991, EXP BIOL M, P15; SARGENT L, 1989, CARCINOGENESIS, V10, P387, DOI 10.1093/carcin/10.2.387; SMITH ML, 1991, CARCINOGENESIS, V12, P1137, DOI 10.1093/carcin/12.6.1137; SUN Q, 1992, CANCER RES, V52, P4254; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	35	72	75	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1188	1191		10.1096/fasebj.7.12.8375618	http://dx.doi.org/10.1096/fasebj.7.12.8375618			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375618				2022-12-28	WOS:A1993LW81700015
J	HAYRY, P; RAISANEN, A; USTINOV, J; MENNANDER, A; PAAVONEN, T				HAYRY, P; RAISANEN, A; USTINOV, J; MENNANDER, A; PAAVONEN, T			SOMATOSTATIN ANALOG LANREOTIDE INHIBITS MYOCYTE REPLICATION AND SEVERAL GROWTH-FACTORS IN ALLOGRAFT ARTERIOSCLEROSIS	FASEB JOURNAL			English	Article						ALLOGRAFT ARTERIOSCLEROSIS; CHRONIC REJECTION; SMOOTH MUSCLE CELL; GROWTH FACTORS	CHRONIC REJECTION; ANGIOPEPTIN; HORMONE; CELLS; ATHEROSCLEROSIS; PROLIFERATION; PHOSPHATASE; OCTREOTIDE; ARTERY	Chronic rejection is the most common reason for late loss of a transplant. The molecular mechanism of chronic rejection is not known and there is no treatment for this disorder. The characteristic histological feature in chronic rejection is increased smooth muscle cell replication in the vascular wall, leading to allograft arteriosclerosis. In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantitites of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors. Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo. It has no inhibitory effect on the proliferation of smooth muscle cells in vitro. Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced. The results suggest that growth factors are the main effector molecules leading to myocyte proliferation in allograft arteriosclerosis and that allograft arteriosclerosis (chronic rejection) may be specifically inhibited by lanreotide administration.			HAYRY, P (corresponding author), UNIV HELSINKI,TRANSPLANTAT LAB,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.			Raisanen-Sokolowski, Anne/0000-0002-2154-7377				BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHATEAUNEUF C, 1989, DIABETES METAB, V15, P18; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; CONTE JV, 1989, TRANSPLANT P, V21, P3686; DEMETRIS AJ, 1989, TRANSPLANT P, V21, P3667; EZZAT S, 1991, J CLIN ENDOCR METAB, V73, P441, DOI 10.1210/jcem-73-2-441; FASSLER JE, 1988, CLIN RES, V36, P869; FELLSTROM B, 1991, TRANSPLANT P, V23, P525; FOEGH ML, 1990, TRANSPL P, V22, P119; FOEGH ML, 1989, ATHEROSCLEROSIS, V78, P229, DOI 10.1016/0021-9150(89)90228-1; LEMBCKE B, 1987, DIGESTION, V36, P108, DOI 10.1159/000199408; LUNDERGAN C, 1989, ATHEROSCLEROSIS, V80, P49, DOI 10.1016/0021-9150(89)90067-1; MENNANDER A, 1991, ARTERIOSCLER THROMB, V11, P671, DOI 10.1161/01.ATV.11.3.671; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; REUBI JC, 1990, INT J CANCER, V46, P416, DOI 10.1002/ijc.2910460315; SCHALLY AV, 1988, CANCER RES, V48, P6977; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; 1990, LANCET, V336, P909	20	64	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1055	1060		10.1096/fasebj.7.11.8370476	http://dx.doi.org/10.1096/fasebj.7.11.8370476			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370476				2022-12-28	WOS:A1993LT83900012
J	HARRIS, H				HARRIS, H			HOW TUMOR-SUPPRESSOR GENES WERE DISCOVERED	FASEB JOURNAL			English	Editorial Material							CELL-FUSION; MALIGNANCY				HARRIS, H (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, S PARKS RD, OXFORD OX1 3RE, ENGLAND.							BARSKI G, 1962, J NATL CANCER I, V28, P801; EPHRUSSI B, 1969, NATURE, V224, P1314, DOI 10.1038/2241314a0; EVANS EP, 1982, J CELL SCI, V56, P113; HARRIS H, 1971, PROC R SOC SER B-BIO, V179, P1, DOI 10.1098/rspb.1971.0078; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HARRIS H, 1965, NATURE, V205, P640, DOI 10.1038/205640a0; JONASSON J, 1977, J CELL SCI, V24, P217	7	10	10	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					978	979		10.1096/fasebj.7.10.8344496	http://dx.doi.org/10.1096/fasebj.7.10.8344496			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344496				2022-12-28	WOS:A1993LQ33700024
J	VOELKEL, NF; LOBEL, K; WESTCOTT, JY; BURKE, TJ				VOELKEL, NF; LOBEL, K; WESTCOTT, JY; BURKE, TJ			NITRIC OXIDE-RELATED VASOCONSTRICTION IN LUNGS PERFUSED WITH RED-CELL LYSATE	FASEB JOURNAL			English	Article						PULMONARY VASOCONSTRICTION; HEMOSYLATE; MITOCHONDRIAL ELECTRON TRANSPORT; KCL	VASCULAR SMOOTH-MUSCLE; PULMONARY-HYPERTENSION; RELAXING FACTOR; INHIBITION; RELAXATION; MACROPHAGE; MECHANISM; ARTERY	The present study in isolated rat lungs demonstrates that nitric oxide gas (. NO, 70 nM) added to the perfusate containing a small amount of hemolysate [175 mu l of lysed red blood cells (RBC) per 50 ml of Earle's balanced salt solution (EBSS)] triggered profound and sustained vasoconstriction, Vasoconstriction was not observed when . NO was added to lungs perfused with washed intact rat or human RBC or with oxyhemoglobin (Hgb 20 mu M). The presence of hemolysate in the perfusate also caused vasoconstriction in response to n-acetylcysteine (50 mu M), glutathione (10(-4) M), or ascorbic acid (10(-4) M) and potentiated greatly the vasoconstrictor response to 5 mM KCl. Not only . NO, but also nitroprusside (SNP) or L-arginine and paradoxically three . NO synthesis inhibitors, including N-monomethyl L-arginine, L-NAME, and nitroblue tetrazolium, which have different mechanisms of action, each caused in the presence of hemolysate large vasoconstrictive responses. Hemolysate itself enhanced O-2 consumption by slices of lung; no effects of this dose of . NO on lung slice respiration were seen in the absence of hemolysate. Both Hgb and hemolysate lowered perfusate cGMP levels to the same degree suggesting that the vasoconstrictive response was not due to unique effects of hemolysate on guanylyl cyclase, Addition of superoxide dismutase (SOD) and catalase (CAT) to the hemolysate containing perfusate, or addition of a cyclooxygenase or 5-lipoxygenase inhibitor, virtually abolished the . NO induced vasoconstriction. The latter data are consistent with the concept that exposure of the vasculature to hemolysate may result in the formation of peroxynitrite. However, SOD and CAT did not abolish the pulmonary vasoconstriction induced by L-arginine or by NAG. Our data indicate that hemolysate has profound effects on lung vessel tone regulation and on lung tissue mitochondrial function, yet the precise molecular mechanisms responsible for the action of hemolysate are likely to be very complex.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	VOELKEL, NF (corresponding author), UNIV COLORADO,HLTH SCI CTR,CTR PULM HYPERTENS,DENVER,CO 80262, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043180] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL43180] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1992, BIOCHEM BIOPH RES CO, V188, P590, DOI 10.1016/0006-291X(92)91097-A; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CHANG SW, 1989, J APPL PHYSIOL, V66, P2407, DOI 10.1152/jappl.1989.66.5.2407; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; HAYNES F, 1994, SICKLE CELL DISEASE, P623; HAYNES J, 1993, AM J PHYSIOL, V264, pH484, DOI 10.1152/ajpheart.1993.264.2.H484; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOSCALZO J, 1985, J CLIN INVEST, V76, P703, DOI 10.1172/JCI112024; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEHRKE G, 1990, J PHYSIOL-LONDON, V430, P251, DOI 10.1113/jphysiol.1990.sp018290; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONTGOMERY MR, 1982, TOXICOL APPL PHARM, V65, P63, DOI 10.1016/0041-008X(82)90362-3; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V187, P324; OKABE K, 1987, PFLUG ARCH EUR J PHY, V409, P561, DOI 10.1007/BF00584654; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARENT RA, 1992, COMP BIOL NORMAL LUN, V1, P587; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; RIMAR S, 1993, CIRCULATION, V88, P2884, DOI 10.1161/01.CIR.88.6.2884; ROUNDS S, 1981, CIRC RES, V48, P393, DOI 10.1161/01.RES.48.3.393; SCHMIDT HHHW, 1992, LANCET, V339, P986, DOI 10.1016/0140-6736(92)91556-N; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; SNYDER SH, 1993, NATURE, V364, P577, DOI 10.1038/364577a0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOELKEL NF, 1994, FASEB J, V8, P4613; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; YU L, 1994, P NATL ACAD SCI USA, V65, P1691; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116	41	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					379	386		10.1096/fasebj.9.5.7896007	http://dx.doi.org/10.1096/fasebj.9.5.7896007			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896007				2022-12-28	WOS:A1995QP45100010
J	MACDONALD, MJ; COOK, JD; EPSTEIN, ML; FLOWERS, CH				MACDONALD, MJ; COOK, JD; EPSTEIN, ML; FLOWERS, CH			LARGE AMOUNT OF (APO)FERRITIN IN THE PANCREATIC INSULIN CELL AND ITS STIMULATION BY GLUCOSE	FASEB JOURNAL			English	Article						FERRITIN; GLUCOSE; PANCREATIC ISLET; BETA CELL	FREE-RADICAL SCAVENGERS; DEFEROXAMINE THERAPY; LIPID-PEROXIDATION; GENE-REGULATION; IRON TRANSPORT; SERUM FERRITIN; MESSENGER-RNA; METAL-IONS; RAT; ISLETS	In screening a rat pancreatic islet cDNA library by differential hybridization for transcripts increased by glucose, the H chain of ferritin, an iron storage protein, was identified. An ELISA for rat ferritin showed that the insulin cell contains a surprisingly high amount of ferritin comparable to that of iron storage tissues. Most of the ferritin was located in the beta cell, as judged from colocalization of ferritin and insulin by immunohistochemical staining of the pancreas. Islets maintained for 24 h in culture medium containing 20 mM glucose are capable of releasing insulin in response to stimulation with glucose, but islets maintained at 1 mM glucose are incapacitated in response to glucose (see ref 1). Immunoassayable ferritin was threefold higher in 20 mM glucose islets than in 1 mM glucose islets and the glucose-stimulated increase in H ferritin mRNA was confirmed by probing Northern blots of islet RNA with authentic H and L chain cDNAs. This showed that H ferritin mRNA was four- to eightfold higher in 20 mM-glucose islets than in 1 mM glucose islets, whereas L ferritin mRNA was decreased 75-90% in 20 mM glucose islets relative to 1 mM glucose islets. The physiological reason for the abundance of(apo)ferritin in the beta cell is not readily apparent because the islet contains very little iron. Whether or not ferritin is used to handle another metal such as zinc, which is plentiful in the beta cell, is unknown. Another potential reason for ferritin in the beta cell is that ferritin has antioxidant properties and the beta cell is particularly sensitive to oxygen radicals. Regardless of its physiologic purpose, the high amount of ferritin can explain why iron is preferentially retained in the insulin cell and causes diabetes in diseases of iron overloading.	UNIV WISCONSIN, SCH MED, DEPT ANAT, MADISON, WI 53706 USA; UNIV KANSAS, MED CTR, DEPT MED, KANSAS CITY, KS 66103 USA	University of Wisconsin System; University of Wisconsin Madison; University of Kansas; University of Kansas Medical Center	MACDONALD, MJ (corresponding author), UNIV WISCONSIN, SCH MED, CTR CHILDRENS DIABET, ROOM 3459, 1300 UNIV AVE, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK042176, R01DK028348] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28348, DK42176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSSON T, 1980, HORM METAB RES, V12, P275, DOI 10.1055/s-2007-996266; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BALLA G, 1992, J BIOL CHEM, V267, P18148; BOMFORD A, 1981, J BIOL CHEM, V256, P948; BOYD D, 1985, J BIOL CHEM, V260, P1755; CLEGG GA, 1980, PROG BIOPHYS MOL BIO, V36, P53; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; CUTLER P, 1989, DIABETES, V38, P1207, DOI 10.2337/diabetes.38.10.1207; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; DORNER MH, 1985, P NATL ACAD SCI USA, V82, P3139, DOI 10.1073/pnas.82.10.3139; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; EBADI M, 1991, METHOD ENZYMOL, V205, P363; EPSTEIN ML, 1992, J COMP NEUROL, V321, P83, DOI 10.1002/cne.903210108; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FIGLEWICZ DP, 1980, DIABETES, V29, P767, DOI 10.2337/diacare.20.10.767; FLOWERS CA, 1986, AM J HEMATOL, V23, P141, DOI 10.1002/ajh.2830230209; HARRISON PM, 1980, IRON BIOCH MED, V2, P131; IANCU TC, 1990, J PEDIATR GASTR NUTR, V10, P95, DOI 10.1097/00005176-199001000-00018; JACOBS A, 1984, FERRITIN ISOFERRITIN; JIANG WP, 1986, EXP MYCOL, V10, P289, DOI 10.1016/0147-5975(86)90014-9; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOHGO Y, 1980, J BIOL CHEM, V255, P5195; LINDER MC, 1972, ANAL BIOCHEM, V48, P266, DOI 10.1016/0003-2697(72)90189-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU JP, 1991, ACTA PATHOL JAPON, V41, P647; LUDVIGSEN C, 1979, DIABETES, V28, P570, DOI 10.2337/diab.28.6.570; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACDONALD MJ, 1991, AMJ PHYSL, V259, pE548; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MANDRUPPOULSEN T, 1993, DIABETOLOGIA, V36, P470, DOI 10.1007/BF00402286; MASKE H, 1957, DIABETES, V6, P335, DOI 10.2337/diab.6.4.335; MENDOLA J, 1989, DIABETES, V38, P379, DOI 10.2337/diabetes.38.3.379; NIEDERER W, 1970, EXPERIENTIA, V26, P218, DOI 10.1007/BF01895596; NOMIKOS IN, 1986, DIABETES, V35, P1302, DOI 10.2337/diabetes.35.11.1302; NOMIKOS IN, 1989, IMMUNOL CELL BIOL, V67, P85, DOI 10.1038/icb.1989.12; PRICE D, 1982, P NATL ACAD SCI-BIOL, V79, P3116, DOI 10.1073/pnas.79.10.3116; PRICE DJ, 1983, J BIOL CHEM, V258, P873; RABINOVITCH A, 1992, J LAB CLIN MED, V119, P455; RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435; RAHIER J, 1987, DIABETOLOGIA, V30, P5, DOI 10.1007/BF01788899; REDMON JB, 1993, DIABETES, V42, P544, DOI 10.2337/diabetes.42.4.544; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; SAVIN MA, 1980, BLOOD, V56, P1029; SUMOSKI W, 1989, DIABETOLOGIA, V32, P792; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1983, IRON BINDING PROTEIN, P1; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; ZAMAN Z, 1981, BIOCHIM BIOPHYS ACTA, V675, P77, DOI 10.1016/0304-4165(81)90071-4	50	35	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1994	8	10					777	781		10.1096/fasebj.8.10.8050678	http://dx.doi.org/10.1096/fasebj.8.10.8050678			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050678				2022-12-28	WOS:A1994NY35000017
J	LASALLE, JM; HAFLER, DA				LASALLE, JM; HAFLER, DA			T-CELL ANERGY	FASEB JOURNAL			English	Review						T LYMPHOCYTE; TOLERANCE; AUTOIMMUNITY; ANERGY; ANTIGEN PRESENTATION	ANTIGEN-PRESENTING CELLS; MHC CLASS-II; MYELIN BASIC-PROTEIN; HUMAN LYMPHOCYTES-T; DEPENDENT DIABETES-MELLITUS; CLONAL ANERGY; TRANSGENIC MICE; HISTOCOMPATIBILITY ANTIGENS; MONOCLONAL-ANTIBODY; RECEPTOR OCCUPANCY	T cell clonal anergy is a proposed mechanism of immunologic self tolerance in which T cells become functionally inactivated after previous stimulation. MHC class II-restricted antigen presentation by different cell types has been speculated to have a role in determining activation vs. anergy in responding T cells. Human T cells express MHC class II after activation and have been shown to present high concentrations of degraded peptide antigen to autologous T cells resulting in clonal anergy. In contrast to low antigen dose T cell clonal anergy, which occurs in the absence of costimulation, T cell anergy induced by human T cell presentation of antigen results in both primary proliferation and secondary unresponsiveness to high-dose antigenic stimulation. Although clonal anergy was previously thought to prevent autoreactive T cells from ever responding to self antigen presented without costimulation, we postulate that T cell presentation of antigen represents a ''fail-safe'' mechanism of immunologic self tolerance that would anergize clonally expanded autoreactive T cells when they are surrounded by a high extracellular concentration of degraded self antigen.	BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, MOLEC IMMUNOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			LaSalle, Janine/A-4643-2008	LaSalle, Janine/0000-0002-3480-2031				ASHWELL JD, 1988, J IMMUNOL, V140, P3697; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BENNUN A, 1985, IMMUNOGENETICS, V22, P123, DOI 10.1007/BF00563509; BERLET HH, 1985, FEBS LETT, V179, P299, DOI 10.1016/0014-5793(85)80538-X; BERLET HH, 1987, NEUROSCI LETT, V73, P266, DOI 10.1016/0304-3940(87)90256-4; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DESILVA DR, 1991, J IMMUNOL, V147, P3261; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FRANCO A, 1992, J EXP MED, V175, P1195, DOI 10.1084/jem.175.5.1195; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; GERRARD TL, 1986, HUM IMMUNOL, V17, P416, DOI 10.1016/0198-8859(86)90301-0; GERRARD TL, 1988, J IMMUNOL, V140, P3450; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GO C, 1992, J EXP MED, V175, P1327, DOI 10.1084/jem.175.5.1327; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GRAF L, 1985, MOL IMMUNOL, V22, P1371, DOI 10.1016/0161-5890(85)90059-8; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HEWITT CRA, 1989, J IMMUNOL, V142, P1429; JENKINS MK, 1987, IMMUNOL REV, V95, P113, DOI 10.1111/j.1600-065X.1987.tb00502.x; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1992, IMMUNOL TODAY, V13, P69, DOI 10.1016/0167-5699(92)90137-V; JENKINS MK, 1990, J IMMUNOL, V144, P16; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KONING F, 1992, J IMMUNOL, V149, P317; LAMB JR, 1984, NATURE, V308, P72, DOI 10.1038/308072a0; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LASALLE JM, 1991, J IMMUNOL, V147, P774; LASALLE JM, 1992, J EXP MED, V176, P177, DOI 10.1084/jem.176.1.177; LASALLE JM, 1993, J IMMUNOL, V151, P649; LASALLE JM, 1991, CELL IMMUNOL, V138, P197, DOI 10.1016/0008-8749(91)90144-Z; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LORBER MI, 1982, J IMMUNOL, V128, P2798; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATSUI Y, 1986, EUR J IMMUNOL, V16, P248, DOI 10.1002/eji.1830160307; MILLER A, 1991, FASEB J, V5, P2560, DOI 10.1096/fasebj.5.11.1868980; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MORAHAN G, 1991, P NATL ACAD SCI USA, V88, P11421, DOI 10.1073/pnas.88.24.11421; MOSS DJ, 1991, J EXP MED, V173, P681, DOI 10.1084/jem.173.3.681; MOURAD W, 1990, J EXP MED, V172, P1513, DOI 10.1084/jem.172.5.1513; MUELLER DL, 1991, J IMMUNOL, V147, P4118; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURALIDHAR G, 1992, J EXP MED, V175, P1589, DOI 10.1084/jem.175.6.1589; NISINI R, 1992, EUR J IMMUNOL, V22, P2033, DOI 10.1002/eji.1830220812; OETTINGER HF, 1993, J NEUROIMMUNOL, V44, P157, DOI 10.1016/0165-5728(93)90037-Y; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OSHIMA S, 1990, HUM IMMUNOL, V27, P208, DOI 10.1016/0198-8859(90)90051-P; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; OTTENHOFF THM, 1990, J EXP MED, V171, P2011, DOI 10.1084/jem.171.6.2011; PARKER DC, 1991, FASEB J, V5, P2777, DOI 10.1096/fasebj.5.13.1916102; QUILL H, 1987, J IMMUNOL, V138, P3704; QUILL H, 1992, J IMMUNOL, V149, P2887; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; RESKE K, 1987, EUR J IMMUNOL, V17, P909, DOI 10.1002/eji.1830170703; RESKEKUNZ AB, 1986, J IMMUNOL, V136, P2033; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHURMANS S, 1991, J IMMUNOL, V146, P2152; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIDHU S, 1992, J EXP MED, V176, P875, DOI 10.1084/jem.176.3.875; SPERTINI F, 1992, J IMMUNOL, V149, P65; SU MWC, 1993, J IMMUNOL, V151, P658; SUZUKI G, 1988, J IMMUNOL, V140, P1359; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TARYLEHMANN M, 1992, J EXP MED, V175, P503, DOI 10.1084/jem.175.2.503; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TREDE NS, 1991, J IMMUNOL, V146, P2310; TRENN G, 1992, J IMMUNOL, V148, P1338; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WILLIAMS IR, 1990, J IMMUNOL, V145, P85; WILLIAMS ME, 1990, J IMMUNOL, V144, P1208; WILLIAMS ME, 1992, J IMMUNOL, V149, P1921; YU DTY, 1980, J EXP MED, V151, P91, DOI 10.1084/jem.151.1.91	92	60	63	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					601	608		10.1096/fasebj.8.9.8005388	http://dx.doi.org/10.1096/fasebj.8.9.8005388			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005388				2022-12-28	WOS:A1994NR90600007
J	KOCHAKIAN, CD				KOCHAKIAN, CD			ROLE OF THE MOUSE IN THE DELINEATION OF THE ANABOLIC-ANDROGENIC ACTION OF STEROIDS	FASEB JOURNAL			English	Editorial Material									UNIV ALABAMA, EXPTL ENDOCRINOL LAB, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham								DEANESLY R., 1941, Journal of Endocrinology, V2, P487, DOI 10.1677/joe.0.0020487; Fox R. P., 1944, ENDOCRINOLOGY, V35, P210; FOX RP, 1943, FED PROC, V3, P11; Kochakian C D, 1977, Adv Steroid Biochem Pharmacol, V6, P1; Kochakian C.D., 1993, ANABOLIC STEROIDS SP, P3; KOCHAKIAN CD, 1946, VITAM HORM, V4, P255, DOI 10.1016/S0083-6729(08)61085-7; Kochakian CD, 1941, ENDOCRINOLOGY, V28, P478, DOI 10.1210/endo-28-3-478; KOCHAKIAN CD, 1980, ALA J MED SCI, V17, P215; KOCHAKIAN CD, 1989, J BIOTECHNOL, V10, P209, DOI 10.1016/0168-1656(89)90066-7; KOCHAKIAN CD, 1990, ANABOLIC STEROID ABU, P29; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC, P247; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC, P1; KOPERA H, 1993, ANABOLIC ANDROGENIC; PFEIFFER CARROLL A., 1940, YALE JOUR BIOL AND MED, V12, P493; Selye H, 1939, J UROLOGY, V42, P637, DOI 10.1016/S0022-5347(17)71560-1; YESALIS C, 1993, ANABOLIC STEROIDS SP; [No title captured]	17	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1994	8	3					356	357		10.1096/fasebj.8.3.8143941	http://dx.doi.org/10.1096/fasebj.8.3.8143941			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143941				2022-12-28	WOS:A1994NB62300012
J	LANE, BG				LANE, BG			OXALATE, GERMIN, AND THE EXTRACELLULAR-MATRIX OF HIGHER-PLANTS	FASEB JOURNAL			English	Review						PLANT DEVELOPMENT; CELL WALLS; GERMINATION; EMBRYOGENESIS	GLEDITSIA-TRIACANTHOS L; CELL-WALLS; HYDROGEN-PEROXIDE; ISOLATED LEAFLETS; WHEAT EMBRYOS; MESSENGER-RNA; PROTEIN; PURIFICATION; CRYSTALS; COMPARTMENTATION	In forthcoming issues of The FASEB Journal, there will be a series of articles, each dealing with a selected aspect of the extracellular matrix in higher plants. This is the initial article in the series and it alludes only briefly to differences and similarities between the extracellular matrices of higher plants and animals. For more detailed information, the reader is referred to two recent surveys (1, 2) that provide expert and comprehensive coverage of recent advances, and summarize our current understanding of the extracellular matrix in higher plants. Oxalate, in the form of its water-insoluble calcium salt, is a familiar source of pathology in the 'stone' diseases of animals (3) and is important in regulating the levels of tissue calcium in at least some higher plants (4-6). Only recently, the significance of oxalate as a possible source of the H2O2 that is needed to fuel peroxidase reactions and cross-link polymers in the extracellular matrix of higher plants has become apparent, and this will be the principal subject of the article.			LANE, BG (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA.							ANDREWS JC, 1951, FOOD RES, V16, P306; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; Arnott H.J., 1970, BIOLOGICAL CALCIFICA, P375, DOI [10.1007/978-1-4684-8485-4_8, DOI 10.1007/978-1-4684-8485-4_8]; BEARD ME, 1985, J HISTOCHEM CYTOCHEM, V33, P460, DOI 10.1177/33.5.3921604; BERNIER F, 1992, 4TH INT M SEEDS ANG; BIZE I, 1991, BIOL REPROD, V44, P398, DOI 10.1095/biolreprod44.3.398; BORCHERT R, 1986, PLANTA, V168, P571, DOI 10.1007/BF00392278; BORCHERT R, 1985, PLANTA, V165, P301, DOI 10.1007/BF00392226; CAMPBELL AK, 1983, INTRACELLULAR CALCIU, P85; Carpita N. C., 1988, Current Topics in Plant Biochemistry and Physiology, V7, P112; Carpita N. C., 1987, PHYSL CELL EXPANSION, P28; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CLELAND R, 1976, S SOC EXP BIOL, V31, P101; DARVILL JE, 1980, PLANT PHYSIOL, V66, P1135, DOI 10.1104/pp.66.6.1135; DRATEWKAKOS E, 1989, J BIOL CHEM, V264, P4896; DUMAS B, 1993, MECHANISMS PLANT DEF, P451; EARNEST DL, 1979, ADV INTERNAL MED, P407; ELSTNER EF, 1976, PLANTA, V130, P175, DOI 10.1007/BF00384416; FAHN A, 1990, PLANT ANATOMY, P211; FRANCESCHI VR, 1980, BOT REV, V46, P361, DOI 10.1007/BF02860532; FRANCESCHI VR, 1989, PROTOPLASMA, V148, P130, DOI 10.1007/BF02079332; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; FSSETT DW, 1973, TOXICANTS OCCURRING, P346; GAMBLES RL, 1974, CAN J BOT, V52, P1049, DOI 10.1139/b74-134; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; GIBSON DM, 1988, ARCH BIOCHEM BIOPHYS, V260, P503, DOI 10.1016/0003-9861(88)90475-4; GREPPIN H, 1986, MOL PHYSL ASPECTS PL; GRZELCZAK ZF, 1985, CAN J BIOCHEM CELL B, V63, P1003, DOI 10.1139/o85-125; GRZELCZAK ZF, 1984, CAN J BIOCHEM CELL B, V62, P1351, DOI 10.1139/o84-172; HALLIWELL B, 1978, PLANTA, V140, P81, DOI 10.1007/BF00389384; HANGER BC, 1974, MECHANISMS REGULATIO, P619; HILLMAN RE, 1989, METABOLIC BASIS INHE, P933; HODGKINSON A, 1977, OXALIC ACID BIOL MED, P168; HURKMAN WJ, 1991, PLANT PHYSIOL, V97, P366, DOI 10.1104/pp.97.1.366; JACOBSON L, 1954, PLANT PHYSIOL, V29, P70, DOI 10.1104/pp.29.1.70; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; KARIMI SH, 1986, BOT GAZ, V147, P65, DOI 10.1086/337569; KAWASHIMA I, 1992, EUR J BIOCHEM, V209, P971, DOI 10.1111/j.1432-1033.1992.tb17370.x; KOHL FG, 1889, OXALIC ACID BIOL MED, P142; LACHMANN PJ, 1986, NATURE, V321, P560, DOI 10.1038/321560a0; LAMPORT DTA, 1981, ENCY PLANT PHYSL B, V13, P133; LANE B, 1987, BIOCHEM CELL BIOL, V65, P354, DOI 10.1139/o87-045; LANE BG, 1986, BIOCHEM CELL BIOL, V64, P1025, DOI 10.1139/o86-136; LANE BG, 1992, EUR J BIOCHEM, V209, P961, DOI 10.1111/j.1432-1033.1992.tb17369.x; LANE BG, 1988, ROOTS OF MODERN BIOCHEMISTRY, P457; LANE BG, 1993, J BIOL CHEM, V268, P12239; LANE BG, 1991, J BIOL CHEM, V266, P10461; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LIBERT B, 1987, J AGR FOOD CHEM, V35, P926, DOI 10.1021/jf00078a019; LIECESTER HM, 1974, DEV BIOCH CONCEPTS A, P118; Lott J. N. A., 1980, The biochemistry of plants. A comprehensive treatise. Volume 1. The plant cell., P589; MICHALOWSKI CB, 1992, PLANT PHYSIOL, V100, P537, DOI 10.1104/pp.100.1.537; Nelson EK, 1931, J AM CHEM SOC, V53, P3046, DOI 10.1021/ja01354a031; NELSON EK, 1931, J AM CHEM SOC, V53, P1040; NUSS RF, 1978, PLANT PHYSIOL, V61, P590, DOI 10.1104/pp.61.4.590; Oberleas D., 1973, TOXICANTS OCCURRING, P363; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; OSMOND B, 1963, NATURE, V198, P503, DOI 10.1038/198503a0; Pepkowitz LP, 1944, SOIL SCI, V58, P295, DOI 10.1097/00010694-194410000-00006; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PRINCE RC, 1987, TRENDS BIOCHEM SCI, V12, P86, DOI 10.1016/0968-0004(87)90041-7; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P35, DOI 10.1016/0968-0004(93)90047-Q; PUNDIR S, 1993, BIOCHIM BIOPHYS ACTA, V1161, P1; RATH M, 1991, J ORTHOMOL MED, V6, P125; ROBERTS K, 1983, MOL BIOL CELL, P1099; ROSENBLOOM J, 1968, REPAIR REGENERATION, P117; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SADAVA D, 1971, BIOCHIM BIOPHYS ACTA, V227, P278, DOI 10.1016/0005-2744(71)90060-X; SCALBERT A, 1985, PHYTOCHEMISTRY, V24, P1359, DOI 10.1016/S0031-9422(00)81133-4; SCHMITT M R, 1991, Plant Physiology (Rockville), V96, P85; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SMITH FW, 1972, AUST J AGR RES, V23, P969, DOI 10.1071/AR9720969; STENGE A, 1981, UROLITHIASIS, P789; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; THOMPSON EW, 1980, J BIOL CHEM, V255, P5965; TILTON VR, 1980, ANN BOT-LONDON, V46, P533, DOI 10.1093/oxfordjournals.aob.a085951; VAISEY EB, 1961, ARCH BIOCHEM BIOPHYS, V95, P66, DOI 10.1016/0003-9861(61)90109-6; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; VARNER JE, 1993, J CELL BIOCH S, V17, P2; Wadleigh CH, 1939, AM J BOT, V26, P244, DOI 10.2307/2436497; WAGNER GJ, 1981, PLANT PHYSIOL, V67, P591, DOI 10.1104/pp.67.3.591; WHEELER H, 1968, ANNU REV PHYTOPATHOL, V6, P331, DOI 10.1146/annurev.py.06.090168.001555; WOESSNER FJ, 1993, FASEB J, V7, P735; Zaleski W, 1911, BIOCHEM Z, V33, P449	87	173	188	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					294	301		10.1096/fasebj.8.3.8143935	http://dx.doi.org/10.1096/fasebj.8.3.8143935			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143935				2022-12-28	WOS:A1994NB62300003
J	COX, TM				COX, TM			ALDOLASE-B AND FRUCTOSE INTOLERANCE	FASEB JOURNAL			English	Review						DIETARY FRUCTOSE; HEREDITARY FRUCTOSE INTOLERANCE; HUMAN ALDOLASE-B; NUTRITIONAL ENVIRONMENT; MUTATION	AMINO-ACID-SEQUENCE; MOLECULAR ANALYSIS; LIVER ALDOLASE; GENE; DIAGNOSIS; MUTATION; IDENTIFICATION; DEFICIENCY; CHILDHOOD; CHILDREN	Hereditary fructose intolerance is an autosomal recessive disorder that illustrates vividly the interplay between heredity and environment in the genesis of human nutritional disease. Genetically determined defects of an isozyme of fructose bisphosphate aldolase (aldolase B, which is specialized for the metabolic assimilation of dietary sugars) predispose to this widely distributed condition. Ingestion of fructose, sorbitol, or sucrose induces abdominal pain, vomiting, and metabolic disturbances - including low concentrations of blood glucose-that may prove fatal. The response to dietary exclusion is rapid and, when so treated, the disease is compatible with a normal life span. A noteworthy feature of the condition in individuals who survive the stormy period of weaning is the development of powerful aversions to fruit, nuts, and sweet-tasting foods and drinks. The incidence of dental caries is consequently much reduced.			COX, TM (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QQ, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI M, 1993, Q J MED, V86, P25; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAERLOCHER K, 1978, HELV PAEDIATR ACTA, V33, P465; BISMUT H, 1993, EUR J BIOCHEM, V213, P721, DOI 10.1111/j.1432-1033.1993.tb17812.x; BROOKS CC, 1991, AM J HUM GENET, V49, P1075; BROOKS CC, 1993, AM J HUM GENET, V52, P835; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CERTA U, 1988, SCIENCE, V240, P1036, DOI 10.1126/science.3285469; CHAMBERS RA, 1956, LANCET, V271, P340; CORI GT, 1951, BIOCHIM BIOPHYS ACTA, V7, P304, DOI 10.1016/0006-3002(51)90032-7; Cox T M, 1983, Mol Biol Med, V1, P393; COX TM, 1988, Q J MED, V68, P585; COX TM, 1993, ARCH DIS CHILD, V69, P413, DOI 10.1136/adc.69.4.413; COX TM, 1982, NEW ENGL J MED, V307, P537, DOI 10.1056/NEJM198208263070906; COX TM, 1983, J CLIN INVEST, V72, P201, DOI 10.1172/JCI110958; COX TM, 1990, GENETICS AND HUMAN NUTRITION, P81; COX TM, 1991, AM J HUM GENET, V49, P184; CROSS NCP, 1990, AM J HUM GENET, V47, P101; CROSS NCP, 1990, LANCET, V335, P306, DOI 10.1016/0140-6736(90)90603-3; CROSS NCP, 1990, NUCLEIC ACIDS RES, V18, P1925, DOI 10.1093/nar/18.7.1925; CROSS NCP, 1988, CELL, V53, P881, DOI 10.1016/S0092-8674(88)90349-2; CROSS NCP, 1989, Q J MED, V73, P1015; DAZZO C, 1990, AM J HUM GENET, V46, P1194; Deerr N., 1950, HIST SUGAR, V2; Deerr N., 1949, HIST SUGAR, V1; FROESCH ER, 1963, AM J MED, V34, P151, DOI 10.1016/0002-9343(63)90050-0; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; Gitzelmann R, 1989, METABOLIC BASIS INHE, P399; Gitzelmann R, 1973, PADIATR FORTBILDK PR, V37, P40; GOPHER A, 1990, P NATL ACAD SCI USA, V87, P5449, DOI 10.1073/pnas.87.14.5449; GREGORI C, 1982, ANN HUM GENET, V46, P281, DOI 10.1111/j.1469-1809.1982.tb01579.x; Heine W, 1969, Dtsch Gesundheitsw, V24, P2325; Hers, 1957, METABOLISME FRUCTOSE; HERS H. G., 1961, ENZYMOL BIOL ET CLIN, V1, P4; HERS HG, 1952, BIOCHIM BIOPHYS ACTA, V8, P416, DOI 10.1016/0006-3002(52)90067-X; HERS HG, 1953, BIOCHIM BIOPHYS ACTA, V11, P427, DOI 10.1016/0006-3002(53)90062-6; Holland B., 1991, COMPOSITION FOODS; HUE L, 1972, EUR J BIOCHEM, V29, P268, DOI 10.1111/j.1432-1033.1972.tb01984.x; HUPE DJ, 1984, CHEM ENZYME ACTIONS, V6, P274; KAJIHARA S, 1990, AM J HUM GENET, V47, P562; KAUFMANN U, 1973, EUR J CLIN INVEST, V3, P407, DOI 10.1111/j.1365-2362.1973.tb02208.x; KELLEY PM, 1986, PLANT PHYSIOL, V82, P1076, DOI 10.1104/pp.82.4.1076; KORESCH ER, 1957, SCHWEIZ MED WOCHENSC, V87, P1168; LANDAU BR, 1971, J LAB CLIN MED, V78, P608; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LITTLECHILD JA, 1993, TRENDS BIOCHEM SCI, V18, P36, DOI 10.1016/0968-0004(93)90048-R; MOCK DM, 1983, NEW ENGL J MED, V309, P764, DOI 10.1056/NEJM198309293091305; MORRIS RC, 1968, J CLIN INVEST, V47, P1648, DOI 10.1172/JCI105856; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; NEWBRUN E, 1980, J AM DENT ASSOC, V101, P619, DOI 10.14219/jada.archive.1980.0383; NORDMANN Y, 1968, BIOCHEM BIOPH RES CO, V31, P884, DOI 10.1016/0006-291X(68)90534-2; OBERHAENSLI RD, 1987, LANCET, V2, P931; ODIEVRE M, 1978, AM J DIS CHILD, V132, P605, DOI 10.1001/archpedi.1978.02120310069014; ODIEVRE M, 1969, ARCH FR PEDIATR, V26, P433; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PERHEENT.J, 1967, LANCET, V2, P528; PHILLIPS MJ, 1968, AM J MED, V44, P910, DOI 10.1016/0002-9343(68)90091-0; ROTTMANN WH, 1984, P NATL ACAD SCI-BIOL, V81, P2738, DOI 10.1073/pnas.81.9.2738; RUTTER WJ, 1964, FED PROC, V23, P1248; SHAWLEE R, 1992, J BIOL CHEM, V267, P3959; SIBLEY JA, 1949, J BIOL CHEM, V177, P859; STEINMANN B, 1981, HELV PAEDIATR ACTA, V36, P297; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAKASAKI Y, 1992, PROTEIN ENG, V5, P101, DOI 10.1093/protein/5.1.101; TOLAN DR, 1987, AM J HUM GENET, V41, P907; TOLAN DR, 1986, MOL BIOL MED, V3, P245; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	67	53	54	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1994	8	1					62	71		10.1096/fasebj.8.1.8299892	http://dx.doi.org/10.1096/fasebj.8.1.8299892			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299892				2022-12-28	WOS:A1994MV28200010
J	BONEN, L				BONEN, L			TRANSSPLICING OF PREMESSENGER RNA IN PLANTS, ANIMALS, AND PROTISTS	FASEB JOURNAL			English	Article						TRANSSPLICING; RNA SPLICING; INTRONS	GROUP-II INTRON; CHLAMYDOMONAS-REINHARDTII; RIBOSOMAL PROTEIN-S12; MARCHANTIA-POLYMORPHA; LEADER RNA; 5' END; GENE; SEQUENCES; TRYPANOSOMES; CHLOROPLASTS	Messenger RNA maturation in eukaryotes typically involves the removal of introns from long precursor molecules. An unusual form of RNA splicing in which separate precursor transcripts contribute sequences to the mature mRNA through intermolecular reactions has now been documented in a number of diverse organisms. In this review, the phenomenon of pre-mRNA trans-splicing has been divided into two categories. The ''spliced leader'' type, found in protozoans such as trypanosomes and lower invertebrates such as nematodes, results in the addition of a short, capped 5' noncoding sequence to the mRNA. The ''discontinuous group II intron'' form of trans-splicing, found in plant/algal chloroplasts and plant mitochondria, involves the joining of independently transcribed coding sequences, presumably through interactions between ''intronic'' RNA pieces. Both categories of trans-splicing are mechanistically similar to conventional nuclear pre-mRNA cis-splicing; potential evolutionary relationships are discussed.			BONEN, L (corresponding author), UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BINDER S, 1992, J BIOL CHEM, V267, P7615; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BUTOW R A, 1991, Current Biology, V1, P331, DOI 10.1016/0960-9822(91)90103-4; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CONKLIN PL, 1991, GENE DEV, V5, P1407, DOI 10.1101/gad.5.8.1407; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; COPERTINO DW, 1991, NUCLEIC ACIDS RES, V19, P6491, DOI 10.1093/nar/19.23.6491; DANDEKAR T, 1990, NUCLEIC ACIDS RES, V18, P4719, DOI 10.1093/nar/18.16.4719; DESOUZA AP, 1991, PLANT CELL, V3, P1363, DOI 10.1105/tpc.3.12.1363; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GUNZL A, 1992, MOL CELL BIOL, V12, P468; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KELLER M, 1992, NUCLEIC ACIDS RES, V20, P1711, DOI 10.1093/nar/20.7.1711; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P10025, DOI 10.1093/nar/16.21.10025; KOLLER B, 1987, CELL, V48, P111, DOI 10.1016/0092-8674(87)90361-8; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; PARK YS, 1990, J MOL BIOL, V211, P395, DOI 10.1016/0022-2836(90)90360-X; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUCHY M, 1991, J MOL BIOL, V222, P179, DOI 10.1016/0022-2836(91)90204-J; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; WISSINGER B, 1992, TRENDS GENET, V8, P322, DOI 10.1016/0168-9525(92)90265-6; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1; ZWIERZYNSKI TA, 1991, P NATL ACAD SCI USA, V88, P5626, DOI 10.1073/pnas.88.13.5626	53	151	161	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					40	46		10.1096/fasebj.7.1.8422973	http://dx.doi.org/10.1096/fasebj.7.1.8422973			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422973				2022-12-28	WOS:A1993KH88000007
J	REUVEN, NB; DEUTSCHER, MP				REUVEN, NB; DEUTSCHER, MP			MULTIPLE EXORIBONUCLEASES ARE REQUIRED FOR THE 3' PROCESSING OF ESCHERICHIA-COLI TRANSFER-RNA PRECURSORS INVIVO	FASEB JOURNAL			English	Article						TRANSFER RNA MATURATION; SUPPRESSION	POLYNUCLEOTIDE PHOSPHORYLASE; TURNOVER; INVITRO; BN	Our knowledge of the 3' processing of tRNA precursors is severely limited. Although six exoribonucleases able to act on Escherichia coli tRNA precursors in vitro have been identified, their involvement in tRNA maturation in vivo has not been demonstrated. Here we show, using a wide range of multiple RNase-deficient strains and a quantitative suppression assay, that at least five of these enzymes-RNase II, RNase D, RNase BN, RNase T, and RNase PH - can participate in the synthesis of functional tRNA(Tyr)su+3 in vivo. Moreover, any one of the five RNases is sufficient to allow tRNA processing to proceed although with varying effectiveness. Examination of the level of aminoacylation of tRNA isolated from RNase-deficient strains suggested that tRNA precursors accumulate in the most defective cells. These data indicate that exoribonucleases are required for tRNA maturation in vivo and that there is a high degree of functional overlap among the enzymes. These studies contribute to the identification of all the enzymes necessary for defining the complete processing pathway for E. coli tRNA precursors.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut			Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CRAVEN MG, 1992, J BACTERIOL, V174, P41727; CUDNY H, 1988, J BIOL CHEM, V263, P1518; CUDNY H, 1980, P NATL ACAD SCI USA, V77, P834; DEUTSCHER MP, 1977, J MOL BIOL, V109, P593, DOI 10.1016/S0022-2836(77)80093-4; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DEUTSCHER MP, 1974, J BACTERIOL, V118, P628; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KELLY KO, 1992, IN PRESS J BACTERIOL; KING TC, 1987, ESCHERICHIA COLI SAL, P703; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; MCCLAIN WH, 1977, ACCOUNTS CHEM RES, V10, P418, DOI 10.1021/ar50119a006; MICHELSEN U, 1989, J BACTERIOL, V171, P5987, DOI 10.1128/jb.171.11.5987-5994.1989; Miller J. H, 1972, EXPT MOL GENETICS; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; REILLY RM, 1986, J BIOL CHEM, V261, P2928; SAKANO H, 1978, J MOL BIOL, V123, P287, DOI 10.1016/0022-2836(78)90082-7; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651	28	62	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					143	148		10.1096/fasebj.7.1.8422961	http://dx.doi.org/10.1096/fasebj.7.1.8422961			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422961				2022-12-28	WOS:A1993KH88000021
J	DANIEL, H; ADIBI, SA				DANIEL, H; ADIBI, SA			SELECTIVE EFFECT OF ZINC ON UPHILL TRANSPORT OF OLIGOPEPTIDES INTO KIDNEY BRUSH-BORDER MEMBRANE-VESICLES	FASEB JOURNAL			English	Article						BETA-LACTAM ANTIBIOTICS; RENAL TRANSPORT; TRANSITION-STATE METALS	INTRAVENOUSLY ADMINISTERED DIPEPTIDES; LEUCINE AMINOPEPTIDASE; PROTEINS; ENZYMES; AFFINITY; ROLES; RATS	Based on the involvement of zinc in hydrolysis of peptides, we hypothesized that Zn2+ may also play a role in peptide transport. To investigate this hypothesis, kidney brush border membrane vesicles (BBMV) were incubated for 30 min with different concentrations of ZnSO4 before use in uptake studies. This incubation increased by twofold the overshoot uptake of H-3-Gly-L-Gln, D-Leu-I-125-Tyr and H-3-cephalexin (all high-affinity substrates for the oligopeptide/H+ symporter) without affecting passive and/or facilitated diffusion of these substrates. Zinc had no effect on the uptake of either glutamine or glucose by kidney BBMV. Among a group of metal ions (cobalt, iron, copper, cadmium, and manganese), only manganese and copper substantially stimulated the activity of the oligopeptide/H+ symporter. DTPA (a complexing agent) inhibited dipeptide uptake, which was reversed by the addition of zinc to the BBMV. Zinc treatment of BBMV reduced the EC(50) value of inhibition of H-3-Gly-L-Gln uptake by unlabeled Gly-L-Gln by twofold (90 +/- 8 vs. 45 +/- 4 mu M). Similarly, zinc treatment of BBMV reduced the EC(50) value for inhibition of D-Leu-I-125-Tyr uptake by bestatin from 80 +/- 4 to 40 +/- 3 mM. In conclusion, the data show that zinc has a selective effect on transport of nutrients into kidney BBMV. It stimulates uphill transport of oligopeptides by a modification of their affinity for the binding site of the membrane transporter.	UNIV PITTSBURGH,SCH MED,DEPT MED,CLIN NUTR RES UNIT,PITTSBURGH,PA 15213; UNIV GIESSEN,INST NUTR SCI,D-35392 GIESSEN,GERMANY	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Justus Liebig University Giessen			Daniel, Hannelore/B-8982-2009					ADIBI SA, 1977, CLIN SCI MOL MED, V52, P193, DOI 10.1042/cs0520193; ADIBI SA, 1977, CLIN SCI MOL MED, V52, P205, DOI 10.1042/cs0520205; ALLEN MP, 1983, BIOCHEMISTRY-US, V22, P3778, DOI 10.1021/bi00285a010; BETTGER WJ, 1993, J NUTR BIOCHEM, V4, P194, DOI 10.1016/0955-2863(93)90052-X; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DANIEL H, 1991, J BIOL CHEM, V266, P19917; DANIEL H, 1992, J BIOL CHEM, V267, P9565; DANIEL H, 1994, FASEB J, V8, P759; DANIEL H, 1993, J CLIN INVEST, V92, P221; Delange R. J., 1971, ENZYMES, VIII, P81; GANAPATHY V, 1987, CONTRIB INFUSION THE, V17, P54; GEE NS, 1987, BIOCHEM J, V246, P97, DOI 10.1042/bj2460097; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; MIYAMOTO Y, 1988, AM J PHYSIOL, V255, pF177; ODELL BL, 1992, NUTR REV, V50, P48, DOI 10.1111/j.1753-4887.1992.tb02513.x; Penate M A, 1990, J Hyg Epidemiol Microbiol Immunol, V34, P267; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; VANWART HE, 1981, BIOCHEMISTRY-US, V20, P5682, DOI 10.1021/bi00523a007	21	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1112	1117		10.1096/fasebj.9.11.7649411	http://dx.doi.org/10.1096/fasebj.9.11.7649411			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649411				2022-12-28	WOS:A1995RP99600017
J	NAEGELI, H				NAEGELI, H			MECHANISMS OF DNA-DAMAGE RECOGNITION IN MAMMALIAN NUCLEOTIDE EXCISION-REPAIR	FASEB JOURNAL			English	Review						MOLECULAR RECOGNITION; XERODERMA PIGMENTOSUM; MUTAGENESIS	CYCLOBUTANE PYRIMIDINE DIMERS; A COMPLEMENTING PROTEIN; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; 6-4 PHOTOPRODUCTS; BINDING-PROTEIN; HELICASE ACTIVITY; CRYSTAL-STRUCTURE	The ability of nucleotide excision repair (NER) to process multiple forms of DNA damage is highly dependent on the precision by which DNA modifications are located in the genome. Studies of mammalian NER have shown that this system eliminates a nide range of chemically and structurally distinct DNA lesions whereby some types of damage are repaired at higher rates than others. Although the biochemical basis for this broad but heterogeneous response to DNA damage is poorly understood, recent discoveries in closely related areas of DNA metabolism indicate that selectivity for specific sites is achieved through the assembly of nucleoprotein complexes, in which DNA is frequently bent and unwound. In many cases, selectivity may be further enhanced by the action of specialized DNA helicases. These principles in protein-DNA recognition suggest a hypothetical mechanism of damage recognition that accounts for the wide substrate range of mammalian NER and also accommodates its preference for specific DNA lesions.			NAEGELI, H (corresponding author), UNIV ZURICH,TIERSPITAL,INST PHARMACOL & TOXICOL,WINTERTHURERSTR 260,CH-8057 ZURICH,SWITZERLAND.							[Anonymous], 1985, DNA REPAIR; ARAI K, 1981, J BIOL CHEM, V256, P5273; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DRAPER DE, 1993, P NATL ACAD SCI USA, V90, P7429, DOI 10.1073/pnas.90.16.7429; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FELDBERG RS, 1982, J BIOL CHEM, V257, P6394; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; FRIEDBERG EC, 1991, MOL MICROBIOL, V5, P2303, DOI 10.1111/j.1365-2958.1991.tb02074.x; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1994, J BIOL CHEM, V269, P19034; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LINK CJ, 1992, CARCINOGENESIS, V13, P1975, DOI 10.1093/carcin/13.11.1975; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; REARDON JT, 1993, J BIOL CHEM, V268, P21301; ROSENBERG M, 1990, J BIOL CHEM, V265, P20641; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1994, J BIOL CHEM, V269, P8303; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENEMA J, 1992, J BIOL CHEM, V267, P8852; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4	75	33	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1043	1050		10.1096/fasebj.9.11.7649403	http://dx.doi.org/10.1096/fasebj.9.11.7649403			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649403				2022-12-28	WOS:A1995RP99600008
J	JAMES, NL; HARRISON, DG; NEREM, RM				JAMES, NL; HARRISON, DG; NEREM, RM			EFFECTS OF SHEAR ON ENDOTHELIAL-CELL CALCIUM IN THE PRESENCE AND ABSENCE OF ATP	FASEB JOURNAL			English	Article						CALCIUM; ENDOTHELIAL CELLS; FLOW; CONFOCAL; FLUO-3	PROSTACYCLIN PRODUCTION; STRESS; FLOW; SECRETION; CA2+	The purpose of this study was to characterize the effect of various shear conditions on endothelial cell intracellular calcium ([Ca2+](i)). Bovine aortic endothelial cells (BAEC) were loaded with Fluo-3 and exposed to flow in a paralled plate flow chamber designed for confocal microscopy. The flow medium was medium 199 (M-199), which was prepared with and without adenosine triphosphate (ATP). In the presence of ATP, initiation of flow at a shear stress of 2.5 dyn/cm(2) evoked a strong, sustained elevation of [Ca2+](i) that gradually returned to baseline levels over 10 to 15 min. By contrast, in the absence of ATP, initiation of flow at 2.5 dyn/cm(2) produced only transient increases in [Ca2+](i) in a small proportion of the cells, As shear rate was increased from 2.5 to 15 dyn/cm(2) in this medium, both the relative fluorescence of the monolayer and the proportion of cells across the monolayer that displayed calcium transients increased in a dose-dependent fashion, In conclusion, the response of an endothelial cell monolayer to increasing levels of shear is not only to increase [Ca2+](i) within individual cells, but to increase the duration of response and the number of cells responding at the onset of shear, This recruitment of larger numbers of cells at higher levels of shear may represent a novel signaling mechanism within the endothelium.	EMORY UNIV,VET ADM MED CTR,SCH MED,DEPT INTERNAL MED,ATLANTA,GA; GEORGIA INST TECHNOL,SCH MECH ENGN,ATLANTA,GA 30322	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University System of Georgia; Georgia Institute of Technology					NHLBI NIH HHS [HL32717, HL39006] Funding Source: Medline; NIDDK NIH HHS [DK 45215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032717, R01HL039006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO J, 1993, BIOCHEM BIOPH RES CO, V190, P716, DOI 10.1006/bbrc.1993.1108; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; HADJIAGAPIOU C, 1986, BIOCHIM BIOPHYS ACTA, V875, P369, DOI 10.1016/0005-2760(86)90188-8; HELMLINGER G, 1994, THESIS GEORGIA I TEC; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; LEVESQUE MJ, 1989, BIOTECHNOL PROGR, V5, P1, DOI 10.1002/btpr.5420050105; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Savino J. M., 1964, INT J HEAT MASS TRAN, V7, P733; SCHILLING WP, 1992, EXP CELL RES, V198, P31, DOI 10.1016/0014-4827(92)90145-X; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SHEN J, 1993, BIOPHYS J, V64, P1323, DOI 10.1016/S0006-3495(93)81498-X; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1	21	51	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					968	973		10.1096/fasebj.9.10.7615166	http://dx.doi.org/10.1096/fasebj.9.10.7615166			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615166				2022-12-28	WOS:A1995RK89900020
J	FELDER, CC				FELDER, CC			MUSCARINIC ACETYLCHOLINE-RECEPTORS - SIGNAL-TRANSDUCTION THROUGH MULTIPLE EFFECTORS	FASEB JOURNAL			English	Review						ADENYLATE CYCLASE; CALCIUM; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; G-PROTEIN	PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; SITE-DIRECTED MUTAGENESIS; PHOSPHOLIPASE-D ACTIVITY; PHOSPHOINOSITIDE TURNOVER; ADENYLATE-CYCLASE; INTRACELLULAR CALCIUM; PAROTID-GLAND; CA2+ INFLUX; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE	Muscarinic receptors regulate a number of important basic physiologic functions including heart rate and motor and sensory control as well as more complex behaviors including arousal, memory, and learning, Loss of muscarinic receptor number or function has been implicated in the etiology of several neurological disorders including Alzheimer's dementia, Down's syndrone, and Parkinson's disease. Muscarinic receptors transduce their signals by coupling with G-proteins, which then modulate the activity of a number of effector enzymes and ion channels, Five subtypes of muscarinic receptors (m1-m5) have been identified by molecular cloning and much has been learned about their distribution, pharmacology, and structure, Less is known about the molecular mechanisms of receptor-effector coupling and the biological role of each receptor subtype, The ectopic expression of genes encoding a single muscarinic receptor subtype in mammalian cell lines has provided an important model system in which to investigate receptor subtype-specific pharmacology and signal transduction. Expression models have revealed that single muscarinic receptor m1, m3, or m5 subtypes can activate multiple signaling effecters simultaneously including phospholipases A2, C, and D, as well as tyrosine kinase and a novel class of voltage-insensitive calcium channels, The m2 or m4 receptors have been shown to augment phospholipase A2 in addition to their established role as inhibitory receptors acting through the attenuation of adenylate cyclase, In addition to allowing investigations of the regulatory mechanisms of muscarinic receptors, expression models provide an excellent tool to investigate receptor-subtype specific physiology and pharmacology.			FELDER, CC (corresponding author), NIMH, CELL BIOL LAB, BLDG 36, RM 3A-15, BETHESDA, MD 20892 USA.			Felder, Christian/0000-0003-1134-8881				ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ALLING C, 1984, BIOCHIM BIOPHYS ACTA, V793, P119, DOI 10.1016/0005-2760(84)90060-2; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BAUMGOLD J, 1992, LIFE SCI, V50, P1755, DOI 10.1016/0024-3205(92)90058-W; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BRANDI ML, 1987, J ENDOCRINOL INVEST, V10, P451, DOI 10.1007/BF03348169; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BUCKLEY NJ, 1990, INTRACELLULAR MESSEN, P11; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASTOLDI AF, 1993, BRAIN RES, V610, P57, DOI 10.1016/0006-8993(93)91216-F; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARO E, 1989, J BIOL CHEM, V264, P18288; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUBOIS B, 1983, BRAIN RES, V288, P213; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1994, IN PRESS BIOCH PHARM; FERRARIDILEO G, 1993, LIFE SCI, V53, pPL439, DOI 10.1016/0024-3205(93)90037-4; GUILLEMAIN I, 1992, FEBS LETT, V314, P489, DOI 10.1016/0014-5793(92)81533-R; GURWITZ D, 1994, EUR J PHARM-MOLEC PH, V267, P21, DOI 10.1016/0922-4106(94)90220-8; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HILDEBRANDT JP, 1993, J MEMBRANE BIOL, V133, P183; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; HOKIN MR, 1954, J BIOL CHEM, V209, P549; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HU JG, 1993, J NEUROCHEM, V61, P578; HUNG AY, 1993, J BIOL CHEM, V268, P22959; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JANSSON CC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P255, DOI 10.1016/0167-4889(91)90108-A; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAMBERT DG, 1992, BIOCHEM SOC T, V20, P130, DOI 10.1042/bst0200130; LAMBERT DG, 1992, PROG NEURO-PSYCHOPH, V16, P253, DOI 10.1016/0278-5846(92)90078-S; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MATHES C, 1994, J GEN PHYSIOL, V104, P107, DOI 10.1085/jgp.104.1.107; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MCKINNEY M, 1991, MAYO CLIN PROC, V66, P1225, DOI 10.1016/S0025-6196(12)62474-4; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NAKAGAWAYAGI Y, 1992, BIOCHEM BIOPH RES CO, V182, P45, DOI 10.1016/S0006-291X(05)80110-X; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OETTLING G, 1992, J DEV PHYSIOL, V17, P147; OHARA K, 1990, EUR J PHARM-MOLEC PH, V189, P341, DOI 10.1016/0922-4106(90)90030-2; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OLIANAS MC, 1992, J NEUROCHEM, V58, P1723, DOI 10.1111/j.1471-4159.1992.tb10046.x; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEPITONI S, 1991, BIOCHEM BIOPH RES CO, V176, P453, DOI 10.1016/0006-291X(91)90945-4; PINKASKRAMARSKI R, 1992, J NEUROCHEM, V59, P2158; QIAN Z, 1989, J BIOL CHEM, V264, P21720; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REGUNATHAN S, 1990, LIFE SCI, V47, P2127, DOI 10.1016/0024-3205(90)90312-F; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROCHE S, 1993, BIOCHEM J, V289, P117, DOI 10.1042/bj2890117; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SANDMANN J, 1991, J NEUROCHEM, V56, P1312, DOI 10.1111/j.1471-4159.1991.tb11427.x; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SAWAKI K, 1993, ARCH BIOCHEM BIOPHYS, V305, P546, DOI 10.1006/abbi.1993.1459; SCHWARZ RD, 1993, LIFE SCI, V52, P465, DOI 10.1016/0024-3205(93)90303-K; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; SUIDAN HS, 1991, CELL REGUL, V2, P13, DOI 10.1091/mbc.2.1.13; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; WANG XB, 1993, BIOCHEM BIOPH RES CO, V193, P483, DOI 10.1006/bbrc.1993.1649; WATSON EL, 1990, MOL PHARMACOL, V38, P547; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YATES CM, 1980, LANCET, V2, P979; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	97	434	455	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					619	625		10.1096/fasebj.9.8.7768353	http://dx.doi.org/10.1096/fasebj.9.8.7768353			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768353				2022-12-28	WOS:A1995RC10600007
J	LUND, J; TAKAHASHI, N; POUND, JD; GOODALL, M; NAKAGAWA, H; JEFFERIS, R				LUND, J; TAKAHASHI, N; POUND, JD; GOODALL, M; NAKAGAWA, H; JEFFERIS, R			OLIGOSACCHARIDE PROTEIN INTERACTIONS IN IGG CAN MODULATE RECOGNITION BY FC-GAMMA RECEPTORS	FASEB JOURNAL			English	Article						GLYCOSYLATION; HUMAN IGG	EFFECTOR FUNCTIONS; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN-G; BINDING-SITE; CARBOHYDRATE; FRAGMENT; REGION; MOUSE; CELLS	X-ray crystal structures of IgG-Fc provide evidence of extensive noncovalent interactions between the protein and carbohydrate moieties, and glycosylation, at Asn-297 within the Fc, has been shown to be important for effector functions mediated through Fc gamma receptors expressed on leukocytes. We have applied protein engineering in an attempt to define protein/carbohydrate interactions essential to wild-type biological activity. We demonstrate that replacement of Lys-246, Asp-249, and Glu-258, which make contacts with GlcNac and Gal on the outer alpha[1-->6] arm, do not affect recognition of human chimeric IgG3 by human Fc gamma RI and Fc gamma RII. However, replacement of Asp-265, which make contacts with the primary GlcNac sugar residue and is covalently attached to Asn-297, resulted in loss of recognition of both Fc gamma RI and Fc gamma RII. Similarly, replacement of Asp-265 in mouse IgG2b resulted in loss of recognition by mouse Fc gamma RII. These results suggest that noncovalent contacts of Asp-265 with the primary GlcNac residue are important for maintenance of recognition of IgG by Fc gamma receptors whereas contacts with GlcNac and Gal on the alpha[1-->6] arm do not have a measurable effect. This conclusion was supported by experiments in which galactose-deficient and fully galactosylated forms of a human IgG4-Fc fragment were shown to be equivalent in their ability to inhibit superoxide generation by IgG4 stimulated U937 cells.	NAKANO VINEGAR CO LTD,GLYCOLAB,HANDA,AICHI 475,JAPAN		LUND, J (corresponding author), UNIV BIRMINGHAM SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; GILHESPIEMUSKET.A, 1994, J GLYCOBIOL, V4, P485; HINDLEY SA, 1993, BIOCH SOC T, V21; HORWITZ AH, 1988, P NATL ACAD SCI USA, V85, P8678, DOI 10.1073/pnas.85.22.8678; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; JEFFERIS R, 1993, PROTEIN ENG ANTIBODY, P115; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LUND J, 1993, MOL IMMUNOL, V30, P741, DOI 10.1016/0161-5890(93)90145-2; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; LUND J, 1992, MOL IMMUNOL, V29, P633; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PADLAN E, 1991, FC RECEPTORS ACTION; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAO MH, 1989, J IMMUNOL, V143, P2595; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347	26	63	189	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					115	119		10.1096/fasebj.9.1.7821750	http://dx.doi.org/10.1096/fasebj.9.1.7821750			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821750				2022-12-28	WOS:A1995QD20200018
J	HARKIN, T				HARKIN, T			MEDICAL-RESEARCH AND HEALTH-CARE REFORM	FASEB JOURNAL			English	Editorial Material											HARKIN, T (corresponding author), US SENATE,WASHINGTON,DC 20510, USA.								0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1215	1216		10.1096/fasebj.8.15.8001732	http://dx.doi.org/10.1096/fasebj.8.15.8001732			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001732				2022-12-28	WOS:A1994PY20900003
J	PREEDY, VR; PETERS, TJ; PATEL, VB; MIELL, JP				PREEDY, VR; PETERS, TJ; PATEL, VB; MIELL, JP			CHRONIC-ALCOHOLIC MYOPATHY - TRANSCRIPTION AND TRANSLATIONAL ALTERATIONS	FASEB JOURNAL			English	Review						ALCOHOLISM; IGF-I; IN VIVO; PROTEIN SYNTHESIS; PROTEIN TURNOVER; SKELETAL MUSCLE	SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; LIPID-PEROXIDATION; ETHANOL; RAT; ACETALDEHYDE; METABOLISM; ASSOCIATION; RIBOSOMES; ENZYMES	Alcoholic myopathy is characterized by selective atrophy of type II fibers and affected subjects lose up to 20% of the entire musculature. Between one and two-thirds of all alcohol abusers are affected. In acute studies, defective rates of translation occur and type II fiber-predominant muscles are more adversely affected than type I fiber-predominant muscles. Furthermore, acetaldehyde is also a potent modulator of translation, and contractile and noncontractile proteins are affected equally. In chronic ethanol feeding there is rapid and sustained loss of ribosomal RNA. Recent attention has focused on the observation that total messenger RNA (mRNA) falls after ethanol consumption, but mRNA for specific myofibrillary contractile proteins are unaffected, implicating a role for translational modifications in the initial stages of the myopathy. Clinical studies have also shown that chronic alcohol abusers have defective rates of muscle protein synthesis and whole-body protein metabolism. The modulations in transcription and translation are not mediated by availability of amino acids, the effects of endocrine dysfunction (cortisol and growth hormone), liver impairment, or malnutrition. Free radicals, however, may be contributory mediators. Receptor-mediated events and the putative roles of growth factors are generally unexplored, though a distinguishing feature of acute ethanol administration is a reduction in circulating IGF-I. Thus, ethanol may act directly on muscle, although other concordant processes may coexist.	UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT MED, LONDON SE5 9PJ, ENGLAND	University of London; King's College London	PREEDY, VR (corresponding author), UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT CLIN BIOCHEM, BESSEMER RD, LONDON SE5 9PJ, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLER AJ, 1985, AM J PHYSIOL, V249, pE584, DOI 10.1152/ajpendo.1985.249.6.E584; ASAYAMA K, 1987, ENDOCRINOLOGY, V121, P2112, DOI 10.1210/endo-121-6-2112; BOADA J, 1991, J STUD ALCOHOL, V52, P613, DOI 10.15288/jsa.1991.52.613; BUNOUT D, 1987, METABOLISM, V36, P651, DOI 10.1016/0026-0495(87)90148-X; CHICK J, 1994, BRIT MED BULL, V50, P200, DOI 10.1093/oxfordjournals.bmb.a072878; CONDE A, 1992, ALCOHOL ALCOHOLISM, V27, P159; COOK EB, 1994, BIOCHEM SOC T, V22, pS172, DOI 10.1042/bst022172s; COX S, 1988, BIOCHEM PHARMACOL, V37, P2045, DOI 10.1016/0006-2952(88)90555-2; CUSSO R, 1989, ALCOHOL ALCOHOLISM, V24, P291, DOI 10.1093/oxfordjournals.alcalc.a044915; DIANZANI MU, 1991, NATO ADV SCI I A-LIF, V206, P35; DOUGLAS RM, 1966, AUSTRALAS ANN MED, V15, P251; Faris A A, 1967, Trans Am Neurol Assoc, V92, P102; FERGUSON ER, 1984, AM J PHYSIOL, V246, pF700, DOI 10.1152/ajprenal.1984.246.5.F700; GARCIABUNUEL L, 1984, MED HYPOTHESES, V13, P217, DOI 10.1016/0306-9877(84)90034-3; HALSTED CH, 1990, EUR J GASTROEN HEPAT, V2, P399; HARBITZ I, 1984, BIOCHEM PHARMACOL, V33, P3465, DOI 10.1016/0006-2952(84)90121-7; HELD IR, 1991, ALCOHOL, V8, P173, DOI 10.1016/0741-8329(91)90742-F; HELD IR, 1991, ALCOHOL, V9, P79; HICKISH T, 1989, CLIN SCI, V77, P171, DOI 10.1042/cs0770171; HORNE Z, 1990, BIOCHEM J, V268, P231, DOI 10.1042/bj2680231; HORNE Z, 1990, BIOCHEM J, V272, P831, DOI 10.1042/bj2720831; LANGFORD KS, 1993, EUR J CLIN INVEST, V23, P503, DOI 10.1111/j.1365-2362.1993.tb00958.x; LAUGHLIN MH, 1990, J APPL PHYSIOL, V68, P2337, DOI 10.1152/jappl.1990.68.6.2337; MARTIN F, 1985, Q J MED, V55, P233; MARWAY JS, 1994, BIOCHEM SOC T, V22, pS429, DOI 10.1042/bst022429s; MARWAY JS, 1993, THESIS U LONDON LOND; MAY C, 1992, ALCOHOL ALCOHOLISM, V27, P109; NEGRO AD, 1984, ACTA NEUROL SCAND, V70, P185; OHNISHI ST, 1984, ARCH BIOCHEM BIOPHYS, V233, P588, DOI 10.1016/0003-9861(84)90483-1; ORNDAHL G, 1986, ACTA MED SCAND, V219, P407; PATEL VB, 1994, BIOCHEM SOC T, V22, pS446, DOI 10.1042/bst022446s; PREEDY VR, 1992, ALCOHOL ALCOHOLISM, V27, P241; PREEDY VR, 1991, NATO ADV SCI I A-LIF, V206, P253; PREEDY VR, 1992, NUTR ALCOHOL, P143; RENNIE MJ, 1993, BR J INTENSIVE CARE, V3, P139; ROSS J, 1988, MOL BIOL MED, V5, P1; SHAW S, 1982, BIOCHEM MED METAB B, V28, P210, DOI 10.1016/0006-2944(82)90072-2; SHOREY RL, 1982, BIOCHEM PHARMACOL, V31, P2447, DOI 10.1016/0006-2952(82)90052-1; TIERNAN JM, 1986, ALCOHOL ALCOHOLISM, V21, P171; TOMAS FM, 1993, PORTL PR P, P141; TROUNCE I, 1987, AUST NZ J MED, V17, P413, DOI 10.1111/j.1445-5994.1987.tb00078.x; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; WARD RJ, 1992, ALCOHOL ALCOHOLISM, V27, P359; WASSIF WS, 1993, ALCOHOL ALCOHOLISM, V28, P325; WICKRAMASINGHE SN, 1989, J CLIN PATHOL, V42, P295, DOI 10.1136/jcp.42.3.295; WORDEN RE, 1976, ANN NY ACAD SCI, V273, P351, DOI 10.1111/j.1749-6632.1976.tb52899.x	46	51	53	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1146	1151		10.1096/fasebj.8.14.7958620	http://dx.doi.org/10.1096/fasebj.8.14.7958620			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958620				2022-12-28	WOS:A1994PT12800009
J	EDSALL, JT				EDSALL, JT			HYDRODYNAMICS AND THE DIMENSIONS OF PROTEIN MOLECULES - 1944	FASEB JOURNAL			English	Editorial Material							WILSON DISEASE GENE				EDSALL, JT (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Cohn EJ., 1948, ADV MILITARY MED; EDSALL JT, 1947, J AM CHEM SOC, V69, P2731, DOI 10.1021/ja01203a048; EDSALL JT, 1947, ADV PROTEIN CHEM, V3, P383, DOI 10.1016/S0065-3233(08)60084-4; Edsall JT, 1944, REV SCI INSTRUM, V15, P243, DOI 10.1063/1.1770203; FOSTER JF, 1945, J AM CHEM SOC, V67, P617, DOI 10.1021/ja01220a034; FOSTER JF, 1944, FED PROC, V3, P57; KOENIG SH, 1975, BIOPOLYMERS, V14, P2421, DOI 10.1002/bip.1975.360141115; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; SCHEINBERG IH, 1984, WILSONS DISEASE, V23; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344	13	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1088	1089		10.1096/fasebj.8.13.7926376	http://dx.doi.org/10.1096/fasebj.8.13.7926376			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926376				2022-12-28	WOS:A1994PN06900015
J	SARKADI, B; MULLER, M; HOMOLYA, L; HOLLO, Z; SEPRODI, J; GERMANN, UA; GOTTESMAN, MM; PRICE, EM; BOUCHER, RC				SARKADI, B; MULLER, M; HOMOLYA, L; HOLLO, Z; SEPRODI, J; GERMANN, UA; GOTTESMAN, MM; PRICE, EM; BOUCHER, RC			INTERACTION OF BIOACTIVE HYDROPHOBIC PEPTIDES WITH THE HUMAN MULTIDRUG TRANSPORTER	FASEB JOURNAL			English	Article						MDR1; P-GLYCOPROTEIN; PEPTIDES; MULTIDRUG TRANSPORTER; ATPASE ACTIVITY; FLUORESCENT DYE EXTRUSION	P-GLYCOPROTEIN; RESISTANCE PUMP; INSECT CELLS; GENE; VINCRISTINE; EXPRESSION; INVITRO	In this report we demonstrate that various biologically active hydrophobic peptide derivatives, e.g., proteinase inhibitors, chemoattractants, ionophores, enkephalins, and immunosuppressants, stimulate a membrane ATPase activity associated with the human multidrug transporter (MDR1). The stimulation of the MDR1-ATPase by these agents does not correlate with their known biochemical or pharmacological activities but rather with their hydrophobicity. The peptides that show high-affinity interaction with the MDR1-ATPase also interfere strongly with fluorescent dye extrusion catalyzed by the multidrug transporter in intact cells and some have been shown to reverse drug resistance in cultured cells. These data suggest that several hydrophobic peptides behave as substrates of the multidrug transporter and may be used to modulate the chemotherapy resistance of tumor cells.	SEMMELWEIS UNIV MED, INST BIOCHEM 1, BUDAPEST, HUNGARY; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27599 USA	Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill	SARKADI, B (corresponding author), NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL, DAROCZI 24, H-1113 BUDAPEST, HUNGARY.		Sarkadi, Balazs/I-5024-2013; Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DAOUD SS, 1989, CANCER RES, V49, P2661; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLO Z, 1993, IN PRESS BIOCH BIOPH; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MINTENIG GM, 1993, RECEPTOR CHANNEL, V1, P305; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SLOVAK ML, 1988, CANCER RES, V48, P2793; TARNAI I, 1990, J BIOL CHEM, V265, P16509; TSURUO T, 1983, CANCER RES, V43, P2905; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165	25	89	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1994	8	10					766	770		10.1096/fasebj.8.10.7914178	http://dx.doi.org/10.1096/fasebj.8.10.7914178			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	7914178				2022-12-28	WOS:A1994NY35000015
J	HENRY, Y; LEPOIVRE, M; DRAPIER, JC; DUCROCQ, C; BOUCHER, JL; GUISSANI, A				HENRY, Y; LEPOIVRE, M; DRAPIER, JC; DUCROCQ, C; BOUCHER, JL; GUISSANI, A			EPR CHARACTERIZATION OF MOLECULAR TARGETS FOR NO IN MAMMALIAN-CELLS AND ORGANELLES	FASEB JOURNAL			English	Review						NITRIC OXIDE; ELECTRON PARAMAGNETIC RESONANCE; METALLOPROTEINS	ELECTRON-PARAMAGNETIC RESONANCE; NITRIC-OXIDE SYNTHASE; SPIN TRAPPING TECHNIQUES; HYDROXY-L-ARGININE; NON-HEME IRON; RIBONUCLEOTIDE REDUCTASE; ACTIVATED MACROPHAGES; PHANEROCHAETE-CHRYSOSPORIUM; ADENOCARCINOMA CELLS; CARBON-MONOXIDE	Nitric oxide is synthesized in mammalian cells from L-arginine or from pharmaceutical drugs. It forms paramagnetic complexes with some metalloproteins, inhibiting key enzymes in DNA synthesis, mitochondrial respiration, iron metabolism, etc. This article reviews how electron paramagnetic resonance spectroscopy helps to detect unambiguously such specific molecular targets for NO in mammalian whole cells and organelles. EPR has also been used for the detection of spin adducts of free NO by spin-trapping methods.	INST BIOCHIM, CNRS, URA 1116, F-91405 ORSAY, FRANCE; INST CURIE, INSERM, U196, F-75005 PARIS, FRANCE; INST CHIM SUBST NAT, CNRS, F-91198 GIF SUR YVETTE, FRANCE; UNIV PARIS 05, CNRS, URA 400, F-75270 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	HENRY, Y (corresponding author), CTR UNIV ORSAY, INST CURIE,INSERM,U350,BIOL SECT, BATIMENT 112, F-91405 ORSAY, FRANCE.		Lepoivre, Michel/J-8578-2013					ANDRONIKLION V, 1992, BIOCHEM BIOPH RES CO, V185, P452, DOI 10.1016/S0006-291X(05)81006-X; ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; ARROYO CM, 1991, FREE RADICAL RES COM, V14, P145, DOI 10.3109/10715769109094127; ARROYO CM, 1990, BIOCHEM BIOPH RES CO, V170, P1177, DOI 10.1016/0006-291X(90)90517-Q; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V184, P1158, DOI 10.1016/S0006-291X(05)80004-X; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V187, P880, DOI 10.1016/0006-291X(92)91279-Y; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BUTLER AR, 1990, POLYHEDRON, V9, P913, DOI 10.1016/S0277-5387(00)84291-6; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; Dal Nogare A R, 1991, Am J Med Sci, V302, P50; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1992, PORTL PR P, V1, P72; FEELISCH M, 1987, EUR J PHARMACOL, V142, P465, DOI 10.1016/0014-2999(87)90090-2; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GREENBERG SS, 1990, CIRC RES, V67, P1446, DOI 10.1161/01.RES.67.6.1446; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KORTH HG, 1992, ANGEW CHEM INT EDIT, V31, P891, DOI 10.1002/anie.199208911; KOSAKA H, 1992, BIOCHEM BIOPH RES CO, V189, P392, DOI 10.1016/0006-291X(92)91571-7; KOSAKA H, 1992, BIOCHEM BIOPH RES CO, V184, P1119, DOI 10.1016/0006-291X(92)90708-S; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1989, CANCER RES, V49, P1970; LUCKEY TD, 1972, AM J CLIN NUTR, V25, P1292; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PRONAI L, 1991, EUR J BIOCHEM, V202, P923, DOI 10.1111/j.1432-1033.1991.tb16452.x; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; SERVENT D, 1992, BIOTECHNOL APPL BIOC, V15, P257; SERVENT D, 1991, BIOCHIM BIOPHYS ACTA, V1074, P320, DOI 10.1016/0304-4165(91)90170-L; SHONGWE MS, 1992, BIOCHEMISTRY-US, V31, P4451, DOI 10.1021/bi00133a010; Snyder S H, 1992, Curr Opin Neurobiol, V2, P323, DOI 10.1016/0959-4388(92)90123-3; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WAJNBERG E, 1992, EUR BIOPHYS J BIOPHY, V21, P57, DOI 10.1007/BF00195444; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P507, DOI 10.1111/j.1476-5381.1992.tb14365.x; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; WHARTON M, 1988, J IMMUNOL, V141, P1311; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; 1991, RES IMMUNOL, V142, P553	71	350	355	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1124	1134		10.1096/fasebj.7.12.8397130	http://dx.doi.org/10.1096/fasebj.7.12.8397130			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8397130				2022-12-28	WOS:A1993LW81700004
J	BHATIA, K; GOLDSCHMIDTS, W; GUTIERREZ, M; GAIDANO, G; DALLAFAVERA, R; MAGRATH, I				BHATIA, K; GOLDSCHMIDTS, W; GUTIERREZ, M; GAIDANO, G; DALLAFAVERA, R; MAGRATH, I			HEMIZYGOSITY OR HOMOZYGOSITY - A REQUIREMENT FOR SOME BUT NOT OTHER P53 MUTANT PROTEINS TO ACCUMULATE AND EXERT A PATHOGENETIC EFFECT	FASEB JOURNAL			English	Note						BURKITT LYMPHOMA; P53; HETEROZYGOSITY	WILD-TYPE; BURKITTS-LYMPHOMA; MUTATIONS; CANCER; MALIGNANCIES; ASSOCIATION; EXPRESSION; RELEVANCE; CELLS; GENE	Activating mutations within the p53 gene cause stabilization and therefore increased steady-state levels of the p53 protein; some, but not all, also result in the generation of an epitope recognized by the antibody pAB240. We have shown here that in 70% of Burkitt lymphoma cell lines, but not in normal EBV transformed B cell lines, p53 protein is readily detectable by Western blot analysis using either an antibody directed against the 240 epitope or an antibody against wild-type p53. Genomic analysis of these BL cell lines demonstrated the presence of mutations within the p53 gene in all cell lines with detectable p53 protein. We have also shown that in the cell lines ST486, Raji, and TE 110, which are heterozygous for a neutral sequence codon polymorphism (Arg/Pro) that causes altered migration of an otherwise normal protein and also contain a heterozygous mutation, only the protein derived from the mutated allele is stabilized. Thus the dominant effect of the mutations present in these cell lines apparently does not result from sequestering of the normal protein by the abnormal protein, and therefore presumably is a consequence of a gain-of-function resulting from the mutation. Although all cell lines with stabilized p53 also contained p53 mutations, three lymphoid tumors (two cell lines and one fresh B-CLL) with a heterozygous mutation at codon 248 did not express elevated levels of p53. In contrast, p53 was readily detectable in Western blot analysis from cell lines KK124, Namalwa, and CA46, which had homo- or hemizygous mutations at codon 248, and from PP1084, a cell line with a codon 273 mutation and a carboxyl-terminal truncation in the other allele. These results suggest that mutations at codon 248, unlike those in cell lines ST486 and TE110, are stabilizing only in the absence of the wild-type p53. Heterozygous mutations at codons 248 have been described in the germline of individuals belonging to cancer-prone families described by Li and Fraumeni (see ref 18), but tumors detected in such individuals are homozygous, i.e., contain only mutated p53. This is consistent with the possibility that such mutations exert a pathogenetic effect only in the absence of the wild-type protein, and are coupled to our findings that stabilization of p53 is a necessary component of the oncogenic pathways relevant to p53. However, whereas some mutations are stabilizing in the presence of the normal p53 protein, others are stabilizing only in the homozygous state.	COLUMBIA UNIV,DEPT PATHOL,NEW YORK,NY 10032	Columbia University	BHATIA, K (corresponding author), NCI,PEDIAT BRANCH,LYMPHOMA BIOL SECT,BLDG 10,ROOM 13C206,BETHESDA,MD 20892, USA.		Gaidano, Gianluca/AAW-2773-2021	Gaidano, Gianluca/0000-0002-4681-0151				BARTEK J, 1991, ONCOGENE, V6, P1699; BHATIA KG, 1992, CANCER RES, V52, P4273; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KOPELOVICH L, 1986, J NATL CANCER I, V77, P1241; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	20	38	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					951	956		10.1096/fasebj.7.10.8344493	http://dx.doi.org/10.1096/fasebj.7.10.8344493			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344493				2022-12-28	WOS:A1993LQ33700020
J	CONRAD, KP; JOFFE, GM; KRUSZYNA, H; KRUSZYNA, R; ROCHELLE, LG; SMITH, RP; CHAVEZ, JE; MOSHER, MD				CONRAD, KP; JOFFE, GM; KRUSZYNA, H; KRUSZYNA, R; ROCHELLE, LG; SMITH, RP; CHAVEZ, JE; MOSHER, MD			IDENTIFICATION OF INCREASED NITRIC-OXIDE BIOSYNTHESIS DURING PREGNANCY IN RATS	FASEB JOURNAL			English	Note						PSEUDOPREGNANCY; NITRATE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE; NITRIC OXIDE HEMOGLOBIN; ELECTRON PARAMAGNETIC RESONANCE SPECTROSCOPY	CYCLIC GUANOSINE-MONOPHOSPHATE; L-ARGININE; URINARY-EXCRETION; NITRATE BIOSYNTHESIS; BIOLOGICAL-ACTIVITY; CONSCIOUS RATS; PLASMA; CELLS; HYPERTENSION; MACROPHAGES	We reported previously that plasma levels. urinary excretion, and metabolic production of cyclic guanosine 3',5'-monophosphate (cGMP) are increased in gravid rats, and postulated that endogenous nitric oxide (NO), a potent vasodilator and immune modulator, may mediate this change. Four lines of evidence are now presented demonstrating increased biosynthesis of NO during pregnancy in rats: 1) Urinary excretion and plasma levels of the stable NO metabolite, nitrate, are elevated in pregnant rats; urinary excretion of nitrate is increased in pseudopregnant rats. 2) The urinary excretion of cGMP also increases during pregnancy and pseudopregnancy, paralleling the rise in urinary nitrate excretion. 3) Chronic treatment with the NO synthase inhibitor, N(G)-nitroarginine methyl ester (NAME), inhibits the increase in urinary nitrate excretion. 4) Nitric oxide hemoglobin is detected by electron paramagnetic resonance spectroscopy in the blood of pregnant, but not in nonpregnant, rats. The results show endogenous NO production is increased in gravid rats. This finding raises the possibility that NO may contribute to maternal vasodilation and uterine immune suppression of normal pregnancy.	UNIV NEW MEXICO,SCH MED,DEPT PHYSIOL & OBSTET & GYNECOL,ALBUQUERQUE,NM 87131; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756	University of New Mexico; Dartmouth College					NHLBI NIH HHS [HL14127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINA JE, 1991, J IMMUNOL, V147, P144; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; ATHERTON JC, 1982, J PHYSIOL-LONDON, V330, P81, DOI 10.1113/jphysiol.1982.sp014330; BAYLIS C, 1987, AM J PHYSIOL, V253, pF158, DOI 10.1152/ajprenal.1987.253.1.F158; BAYLIS C, 1982, AM J PHYSIOL, V234, pF300; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CHESLEY LC, 1971, OBSTET GYNECOL, V38, P1; CONRAD KP, 1987, AM J PHYSIOL, V253, pF1197, DOI 10.1152/ajprenal.1987.253.6.F1197; CONRAD KP, 1984, KIDNEY INT, V26, P24, DOI 10.1038/ki.1984.129; CONRAD KP, 1989, AM J PHYSIOL, V257, pR847, DOI 10.1152/ajpregu.1989.257.4.R847; CONRAD KP, 1991, J CLIN INVEST, V87, P1700, DOI 10.1172/JCI115187; CONRAD KP, 1986, J CLIN INVEST, V77, P236, DOI 10.1172/JCI112282; CONRAD KP, 1992, UROL ANN, V6, P313; DAVIDGE ST, 1992, AM J OBSTET GYNECOL, V167, P1691, DOI 10.1016/0002-9378(92)91763-Z; FEINBERG BB, 1991, CLIN OBSTET GYNECOL, V34, P3, DOI 10.1097/00003081-199103000-00005; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GARNER GB, 1956, ANAL CHEM, V28, P1589, DOI 10.1021/ac60118a026; GERBER JG, 1981, J CLIN INVEST, V67, P632, DOI 10.1172/JCI110077; GERZER R, 1985, J CLIN ENDOCR METAB, V61, P1217, DOI 10.1210/jcem-61-6-1217; GILSON GJ, 1992, AM J PHYSIOL, V263, pH1911, DOI 10.1152/ajpheart.1992.263.6.H1911; GOODMAN RP, 1982, AM J OBSTET GYNECOL, V142, P817, DOI 10.1016/S0002-9378(16)32525-X; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; GROENENDIJK R, 1984, AM J OBSTET GYNECOL, V150, P232, DOI 10.1016/S0002-9378(84)90357-0; HARRISON GL, 1989, AM J OBSTET GYNECOL, V160, P258, DOI 10.1016/0002-9378(89)90132-4; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HUNT JS, 1992, IMMUNOLOGICAL OBSTET, P73; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JANSAKUL C, 1989, J ENDOCRINOL, V120, P113, DOI 10.1677/joe.0.1200113; KOPP L, 1977, J CLIN ENDOCR METAB, V44, P590, DOI 10.1210/jcem-44-3-590; KRUSZYNA H, 1987, TOXICOL APPL PHARM, V91, P429, DOI 10.1016/0041-008X(87)90064-0; LEAF CD, 1989, BIOCHEM BIOPH RES CO, V163, P1032, DOI 10.1016/0006-291X(89)92325-5; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MILLS CD, 1991, J IMMUNOL, V146, P2719; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NADEN RP, 1985, AM J OBSTET GYNECOL, V151, P484, DOI 10.1016/0002-9378(85)90275-3; NISELL H, 1985, CLIN PHYSIOL, V5, P479, DOI 10.1111/j.1475-097X.1985.tb00779.x; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REDMAN CWG, 1990, FETAL MED REV, V2, P21; ROBSON SC, 1989, AM J PHYSIOL, V256, pH1060, DOI 10.1152/ajpheart.1989.256.4.H1060; SABAI BM, 1991, CLIN OBSTET GYNECOL, V34, P27; WAGNER DA, 1983, CANCER RES, V43, P1921; WILCOX DE, 1990, CHEM RES TOXICOL, V3, P71, DOI 10.1021/tx00013a012	50	400	416	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					566	571		10.1096/fasebj.7.6.7682524	http://dx.doi.org/10.1096/fasebj.7.6.7682524			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	7682524				2022-12-28	WOS:A1993KY00900010
J	GOMMERSAMPT, JH; BORST, P				GOMMERSAMPT, JH; BORST, P			HYPERMODIFIED BASES IN DNA	FASEB JOURNAL			English	Review						MODIFIED NUCLEOTIDES; BACTERIOPHAGE DNA; EUKARYOTES	TRYPANOSOMA-BRUCEI; RESTRICTION ENDONUCLEASES; ESCHERICHIA-COLI; 5-HYDROXYMETHYLURACIL-DNA GLYCOSYLASE; NEUROSPORA-CRASSA; METHYLATION; PHAGE; HYDROXYMETHYLURACIL; CLEAVAGE; ADENINE	Modified DNA bases are widespread in nature. They can be found in eukaryotes, prokaryotes, and bacteriophages. They may completely replace the standard base or replace only a small fraction. Their substituents vary from simple methyl or hydroxy groups to large moieties like amino acids and multiply hexosylated side chains. This review gives an overview of the modified DNA bases identified thus far, with emphasis on the ''very unusual'' or hypermodified DNA bases. Although these have been detected mainly in bacteriophages, recent work has shown the presence of a novel hypermodified DNA base in the eukaryote Trypanosoma brucei. We speculate on the biosynthesis and function of this novel base beta-D-glucosyl-hydroxymethyluracil.	NETHERLANDS CANC INST, DIV MOLEC BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ALEGRIA ALVARO H., 1968, BIOCHEMISTRY, V7, P1132, DOI 10.1021/bi00843a034; BANKEL L, 1977, BIOCHIM BIOPHYS ACTA, V481, P431, DOI 10.1016/0005-2744(77)90276-5; BERKNER KL, 1979, J BIOL CHEM, V254, P2551; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; BOORSTEIN RJ, 1987, MUTAT RES, V183, P257, DOI 10.1016/0167-8817(87)90008-3; BORST P, 1993, COLD SPRING HARB SYM, V58, P105, DOI 10.1101/SQB.1993.058.01.014; BRANDON C, 1972, NATURE-NEW BIOL, V239, P70, DOI 10.1038/newbio239070a0; BRON S, 1983, J VIROL, V46, P703, DOI 10.1128/JVI.46.3.703-708.1983; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHOLLET A, 1988, NUCLEIC ACIDS RES, V16, P305, DOI 10.1093/nar/16.1.305; COMMERSAMPT JH, 1993, NUCLEIC ACIDS RES, V9, P2039; CROZATIER M, 1988, MOL BIOCHEM PARASIT, V31, P127, DOI 10.1016/0166-6851(88)90163-6; DUNHAM LT, 1974, J VIROL, V14, P709, DOI 10.1128/JVI.14.3.709-712.1974; EHRLICH M, 1985, NUCLEIC ACIDS RES, V13, P1399, DOI 10.1093/nar/13.4.1399; EHRLICH M, 1981, J BIOL CHEM, V256, P9966; ERIKSON RL, 1964, VIROLOGY, V22, P111, DOI 10.1016/0042-6822(64)90053-4; GEFTER M, 1966, J BIOL CHEM, V241, P1995; GERHARD B, 1982, BIOCHEMISTRY-US, V21, P5458, DOI 10.1021/bi00265a012; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOMMERSAMPT JH, 1994, THESIS U AMSTERDAM; GOROVSKY MA, 1973, J CELL BIOL, V56, P697, DOI 10.1083/jcb.56.3.697; HALL RH, 1971, MODIFIED NUCLEOSIDES, P282; HATTMAN S, 1980, J VIROL, V34, P277, DOI 10.1128/JVI.34.1.277-279.1980; HEMPHILL HE, 1975, BACTERIOL REV, V39, P257, DOI 10.1128/MMBR.39.3.257-315.1975; HOET PP, 1992, ANNU REV MICROBIOL, V46, P95, DOI 10.1146/annurev.mi.46.100192.000523; HOLLSTEIN MC, 1984, P NATL ACAD SCI-BIOL, V81, P4003, DOI 10.1073/pnas.81.13.4003; HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315; HSU FF, 1989, ADV MASS SPECTROM B, V11, P1450; HUANG LH, 1982, NUCLEIC ACIDS RES, V10, P1579, DOI 10.1093/nar/10.5.1579; JANULAITIS A, 1983, FEBS LETT, V161, P131, DOI 10.1016/0014-5793(83)80745-5; KALLEN RG, 1962, J MOL BIOL, V5, P248, DOI 10.1016/S0022-2836(62)80087-4; KIRNOS MD, 1977, NATURE, V270, P369, DOI 10.1038/270369a0; KOOTER JM, 1988, THESIS U AMSTERDAM; Kornberg A., 1992, DNA REPLICATION, P637; KORNBERG A, 1992, DNA REPLCATION; KORNBERG S, 1961, J BIOL CHEM, V236, P1487; KOTHARI RM, 1976, J MOL EVOL, V7, P325, DOI 10.1007/BF01743628; KROPINSKI AM, 1973, BIOCHEMISTRY-US, V12, P151, DOI 10.1021/bi00725a025; KUO TT, 1968, J MOL BIOL, V34, P373, DOI 10.1016/0022-2836(68)90263-5; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; LEWIS HA, 1975, J VIROL, V16, P1375, DOI 10.1128/JVI.16.6.1375-1379.1975; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; MALTMAN KL, 1981, BIOCHEMISTRY-US, V20, P3586, DOI 10.1021/bi00515a043; MARMUR J, 1972, NATURE-NEW BIOL, V239, P68, DOI 10.1038/newbio239068a0; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MILLER PB, 1985, NUCLEIC ACIDS RES, V13, P2559, DOI 10.1093/nar/13.7.2559; MOSIG G, 1988, BACTERIOPHAGES, V2, P521; NEUHARD J, 1980, J VIROL, V34, P347, DOI 10.1128/JVI.34.2.347-353.1980; NIKOLSKAYA II, 1976, BIOCHIM BIOPHYS ACTA, V435, P206, DOI 10.1016/0005-2787(76)90251-3; NOIYERWEIDNER M, 1993, DNA METHYLATION MOL, P39; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PENN NW, 1972, BIOCHEM J, V126, P781, DOI 10.1042/bj1260781; PROFFITT JH, 1984, MOL CELL BIOL, V4, P985, DOI 10.1128/MCB.4.5.985; RAE PMM, 1973, P NATL ACAD SCI USA, V70, P1141, DOI 10.1073/pnas.70.4.1141; RAE PMM, 1978, BIOSYSTEMS, V10, P37, DOI 10.1016/0303-2647(78)90027-8; RAE PMM, 1976, SCIENCE, V194, P1062, DOI 10.1126/science.988637; RAIBAUD A, 1983, P NATL ACAD SCI-BIOL, V80, P4306, DOI 10.1073/pnas.80.14.4306; RALEIGH EA, 1989, GENETICS, V122, P279; RAZIN A, 1970, J MOL BIOL, V53, P251, DOI 10.1016/0022-2836(70)90298-6; REDDY MV, 1981, ANAL BIOCHEM, V117, P271, DOI 10.1016/0003-2697(81)90722-3; REVEL HR, 1970, ANNU REV GENET, V4, P177, DOI 10.1146/annurev.ge.04.120170.001141; ROSCOE DH, 1969, J VIROL, V38, P527; ROSENBERG E, 1965, BIOCHEMISTRY-US, V53, P836; SCRABA DG, 1983, VIROLOGY, V124, P152, DOI 10.1016/0042-6822(83)90298-2; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1987, CELL, V51, P741, DOI 10.1016/0092-8674(87)90097-3; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SELKER EU, 1993, DNA METHYLATION MOL, P212; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P8070, DOI 10.1073/pnas.87.20.8070; SWINTON D, 1983, P NATL ACAD SCI-BIOL, V80, P7400, DOI 10.1073/pnas.80.24.7400; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TOMASCHEWSKI J, 1985, NUCLEIC ACIDS RES, V13, P7551, DOI 10.1093/nar/13.21.7551; TOUSSAINT A, 1976, VIROLOGY, V70, P17, DOI 10.1016/0042-6822(76)90232-4; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; WALKER MS, 1978, J VIROL, V25, P500, DOI 10.1128/JVI.25.2.500-509.1978; WARREN RAJ, 1980, ANNU REV MICROBIOL, V34, P137, DOI 10.1146/annurev.mi.34.100180.001033; WASCHKE S, 1975, NATURE, V255, P629, DOI 10.1038/255629a0; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WILSON GG, 1988, TRENDS GENET, V4, P314, DOI 10.1016/0168-9525(88)90109-6; WINKLER M, 1993, NUCLEIC ACIDS RES, V21, P1500, DOI 10.1093/nar/21.6.1500; WONDRACK LM, 1978, J BIOL CHEM, V253, P6511; WYATT GR, 1953, BIOCHEM J, V55, P774, DOI 10.1042/bj0550774	87	87	101	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1034	1042		10.1096/fasebj.9.11.7649402	http://dx.doi.org/10.1096/fasebj.9.11.7649402			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649402				2022-12-28	WOS:A1995RP99600007
J	MACKMAN, N				MACKMAN, N			REGULATION OF THE TISSUE FACTOR GENE	FASEB JOURNAL			English	Review						TISSUE FACTOR; BLOOD COAGULATION; GENE REGULATION; TRANSCRIPTION FACTORS	FACTOR MESSENGER-RNA; HUMAN-ENDOTHELIAL-CELLS; THP-1 MONOCYTIC CELLS; NF-KAPPA-B; FACTOR EXPRESSION; SMOOTH-MUSCLE; BINDING-SITES; ACTIVATION; ENDOTOXIN; LIPOPOLYSACCHARIDE	The tissue factor (TF) gene is expressed in a cell type-specific manner in vivo. It is constitutively expressed by several extravascular cell types and inducibly expressed within the vasculature by monocytes and endothelial cells, TF expression initiates thrombotic episodes associated with various diseases, including atherosclerosis, septic shock, and cancer, Regulatory elements within the human TF promoter have been identified by functional analysis Of TF promoter-luciferase gene plasmids transiently transfected into various cell types, Transcription factors that control expression of the TF gene were identified using gel shift mobility assays. Induction of the TF gene in human monocytic cells and endothelial cells exposed to bacterial lipopolysaccharide or cytokines is mediated by a distal enhancer (-227 to -172 bp) containing two AP-1 sites and a kappa B site, Functional interactions between Fos-Jun heterodimers and c-Rel-p65 heterodimers are required for transcriptional activation of the TF gene, In contrast, serum and phorbol ester induction of the TF gene in human epithelial cells is controlled by a proximal enhancer (-111 to +14 bp) containing three overlapping Egr-1/Sp1 binding sites, Sp1 is constitutively expressed whereas Egr-1 expression is induced by serum or phorbol ester stimulation, Sp1 also mediates basal promoter activity. Thus, TF gene expression is complex and is regulated by a number of transcription factors that bind to distinct regions of the TF promoter.	SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	MACKMAN, N (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM-17, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16411, HL-48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abate C, 1990, Semin Cancer Biol, V1, P19; AHERN SM, 1993, J BIOL CHEM, V268, P2154; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIERHAUS A, 1995, THROMB HAEMOSTASIS, V73, P39; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DRAKE TA, 1983, AM J PATHOL, V142, P1; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FAULK WP, 1990, BLOOD, V76, P86; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; FLECK RA, 1990, THROMB RES, V57, P765, DOI 10.1016/0049-3848(90)90034-A; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Grilli Mariagrazia, 1993, V143, P1; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIRCHHOFER D, 1994, J CLIN INVEST, V93, P2073, DOI 10.1172/JCI117202; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LOCKWOOD CJ, 1993, J CLIN ENDOCR METAB, V76, P231, DOI 10.1210/jc.76.1.231; MACKMAN N, 1994, J BIOL CHEM, V269, P26363; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1993, AM J PATHOL, V143, P76; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MESZAROS K, 1994, BLOOD, V83, P2516; Morrissey JH, 1993, PATHOPHYSIOLOGY SHOC, P564; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OLLIVIER V, 1993, BLOOD, V81, P973; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; QUIRK SM, 1995, ENDOCRINE, V3, P177, DOI 10.1007/BF02990070; RAO LVM, 1992, CANCER METAST REV, V11, P249; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SOIFER SJ, 1994, AM J PATHOL, V144, P60; Solberg S, 1990, Blood Coagul Fibrinolysis, V1, P595; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEINEMANN S, 1994, ARTERIOSCLER THROMB, V14, P1202, DOI 10.1161/01.ATV.14.7.1202; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; WARR TA, 1990, BLOOD, V75, P1481; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILCOX JN, 1989, THROMB HAEMOSTASIS, V62, P348	54	247	251	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1995	9	10					883	889		10.1096/fasebj.9.10.7615158	http://dx.doi.org/10.1096/fasebj.9.10.7615158			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615158				2022-12-28	WOS:A1995RK89900009
J	INAGAKI, N; KUROMI, H; GONOI, T; OKAMOTO, Y; ISHIDA, H; SEINO, Y; KANEKO, T; IWANAGA, T; SEINO, S				INAGAKI, N; KUROMI, H; GONOI, T; OKAMOTO, Y; ISHIDA, H; SEINO, Y; KANEKO, T; IWANAGA, T; SEINO, S			EXPRESSION AND ROLE OF IONOTROPIC GLUTAMATE RECEPTORS IN PANCREATIC-ISLET CELLS	FASEB JOURNAL			English	Article						GABA; INSULIN; GLUCAGON; PARACRINE; NEUROTRANSMITTERS	GAMMA-AMINOBUTYRIC-ACID; SYNAPTIC-LIKE MICROVESICLES; BETA-CELLS; MOLECULAR DIVERSITY; GLUCAGON-SECRETION; INSULIN RELEASE; AMPA SUBTYPE; GABA; CHANNELS; GLUCOSE	Although the excitatory amino acid glutamate and its receptors play crucial roles in many functions of the central nervous system (CNS), their presence in the peripheral tissues has remained unclear. In the present study, we have identified kainate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and N-methyl-D-aspartate (NMDA) receptor subtype mRNAs in pancreatic islets, using reverse transcriptase polymerase chain reaction (RT-PCR). Intracellular calcium ([Ca2+](i)) measurements and electrophysiological recordings indicate that kainate, AMPA, and NMDA. all elicit increases of [Ca2+](i) in single pancreatic beta-cells and depolarize them. In addition, kainate and AMPA stimulate insulin secretion from isolated pancreatic islets, whereas NMDA does not. Also, immunocytochemical study shows the presence of intense glutaminase immunoreactivity in pancreatic alpha-cells and intrapancreatic ganglia, a finding compatible with the possibility that glutamate is released from alpha-cells as well as from neurons. Because the inhibitory amino acid gamma-amino butyric acid (GABA) is present in beta-cells as well as in neurons and inhibits glucagon secretion from alpha-cells, the present study suggests that glutamate and GABA are coordinated in the regulation of hormone secretion in pancreatic islets.	CHIBA UNIV, SCH MED, CTR BIOMED SCI, DIV MOLEC MED, CHUO KU, CHIBA 260, JAPAN; CHIBA UNIV, PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR, CHUO KU, CHIBA 260, JAPAN; KYOTO UNIV, FAC MED, DEPT METAB & CLIN NUTR, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MORPHOL BRAIN SCI, SAKYO KU, KYOTO 606, JAPAN; NIIGATA UNIV, SCH MED, DEPT ANAT, NIIGATA 951, JAPAN	Chiba University; Chiba University; Kyoto University; Kyoto University; Niigata University			, gonoi/GRS-0648-2022; gonoi, tohru/AAC-5181-2021	, gonoi/0000-0003-3655-7911; gonoi, tohru/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593				AKIYAMA H, 1990, J COMP NEUROL, V297, P239, DOI 10.1002/cne.902970207; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Gasic G P, 1991, Curr Opin Neurobiol, V1, P20, DOI 10.1016/0959-4388(91)90006-S; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GILON P, 1991, ENDOCRINOLOGY, V129, P2521, DOI 10.1210/endo-129-5-2521; GONOI T, 1994, J BIOL CHEM, V269, P16989; GONOI T, 1988, J PHYSIOL-LONDON, V401, P617, DOI 10.1113/jphysiol.1988.sp017183; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KATAOKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3218, DOI 10.1073/pnas.81.10.3218; KITAYAMA S, 1984, N-S ARCH PHARMACOL, V326, P106, DOI 10.1007/BF00517305; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LINDSTROM P, 1992, ENDOCRINOLOGY, V131, P1903, DOI 10.1210/en.131.4.1903; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; RACAGNI G, 1979, NATURE, V281, P575, DOI 10.1038/281575a0; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOMIKO SA, 1983, NATURE, V301, P706, DOI 10.1038/301706a0; UNGER RH, 1978, ANNU REV PHYSIOL, V40, P307, DOI 10.1146/annurev.ph.40.030178.001515; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6; YONEDA Y, 1986, Neuroscience Research, V3, P430, DOI 10.1016/0168-0102(86)90034-9	35	166	176	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					686	691		10.1096/fasebj.9.8.7768362	http://dx.doi.org/10.1096/fasebj.9.8.7768362			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768362				2022-12-28	WOS:A1995RC10600016
J	SMALLEY, DL; SHANKLIN, DR; HALL, MF; STEVENS, MV; HANISSIAN, A				SMALLEY, DL; SHANKLIN, DR; HALL, MF; STEVENS, MV; HANISSIAN, A			IMMUNOLOGICAL STIMULATION OF T-LYMPHOCYTES BY SILICA AFTER USE OF SILICONE MAMMARY IMPLANTS	FASEB JOURNAL			English	Article						LYMPHOCYTE STIMULATION; SILICON DIOXIDE; SILICONE BREAST IMPLANTS; SILICONES	BREAST IMPLANTS; TISSUE; DISEASE	Difficulties in showing the biologic activity of silicones in vitro have contributed to the controversy over effects of silicone mammary implants in vivo. We adapted a standard lymphocyte stimulation test to detect evidence of cellular immunity in patients with silicone gel implants. Initially, lymphocytes were harvested from 70 implant patients, 76 normal controls without implants or symptoms, and 18 patients with classic rheumatic disorders and without a history of silicone implants. The harvested lymphocytes were stimulated with PWM, PHA, Con A, and pharmaceutical grade colloidal silicon dioxide (silica). Implant patients showed increased SI compared to controls and those with rheumatic disorders. The mean SI of implant patients was 195.0 +/- 19.3, 18-fold that of normal controls (< 0.0001). Patients with rheumatic disease showed the same SI as controls (P = 0.3577). A follow-up study included 220 normal controls without implants, 942 silicone gel implant patients with demonstrable rheumatic symptoms, and 34 implant patients without symptoms at the time of the study. The average SI for the 220 normal controls was 10.0 +/- 0.41. Among the symptomatic implant women, 860 (91.3%) had SI significantly above those of the normal controls. Of these, 171 (18.2%) had SI between 25 and 50, 316 (33.5%) had SI between 50 and 100, and 373 (39.6%) had SI over 100. The data presented confirms that silicone implant patients respond immunologically to the silicon dioxide contained in mammary prostheses.	BAPTIST MEM HLTH CARE SYST, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, DEPT OBSTET & GYNECOL, MEMPHIS, TN 38163 USA; BAPTIST MEM HOSP, DEPT MED, MEMPHIS, TN 38120 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Baptist Memorial Hospital Memphis; University of Tennessee System; University of Tennessee Health Science Center								BAKER JL, 1982, PLAST RECONSTR SURG, V69, P56, DOI 10.1097/00006534-198269010-00008; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; CHILSON OP, 1989, EUR J IMMUNOL, V19, P389, DOI 10.1002/eji.1830190225; GARRIDO L, 1993, MAGNET RESON MED, V29, P839, DOI 10.1002/mrm.1910290620; GEHA RS, 1974, EUR J IMMUNOL, V4, P193, DOI 10.1002/eji.1830040308; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; OJOMAIZE EA, 1994, CLIN DIAGN LAB IMMUN, V1, P689, DOI 10.1128/CDLI.1.6.689-695.1994; PICHA GJ, 1991, PLAST RECONSTR SURG, V87, P490, DOI 10.1097/00006534-199103000-00017; RUDOLPH R, 1978, PLAST RECONSTR SURG, V62, P185, DOI 10.1097/00006534-197808000-00006; SCHMITERLOW CG, 1975, ACTA PHARMACOL TOX, V36, P131; SHANKLIN DR, 1991, SILICONE MED DEVICES, P103; SHANKLIN DR, 1993, SOUTH MED J, V86, pS104; SHONS AR, 1992, ANN PLAS SURG, V28, P491, DOI 10.1097/00000637-199205000-00017; SILVER RM, 1993, ARCH DERMATOL, V129, P63, DOI 10.1001/archderm.129.1.63; SMALLEY DL, 1995, IN PRESS J OCCUPAT M; SPIERA H, 1993, J RHEUMATOL, V20, P958; THOMSEN JL, 1990, PLAST RECONSTR SURG, V85, P38, DOI 10.1097/00006534-199001000-00007; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WOLF LE, 1993, FASEB J, V7, P1265, DOI 10.1096/fasebj.7.13.8405812; 1993, SIL BREAST IMPL TEAM	20	40	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					424	427		10.1096/fasebj.9.5.7896014	http://dx.doi.org/10.1096/fasebj.9.5.7896014			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896014				2022-12-28	WOS:A1995QP45100017
J	TRUMP, BF; BEREZESKY, IK				TRUMP, BF; BEREZESKY, IK			CALCIUM-MEDIATED CELL INJURY AND CELL-DEATH	FASEB JOURNAL			English	Review						ACCIDENTAL AND PROGRAMMED CELL DEATH; NECROSIS; APOPTOSIS; GENE SIGNALING; IMMEDIATE-EARLY GENES	CYTOSOLIC IONIZED CALCIUM; PROXIMAL TUBULE CELLS; SIGNAL TRANSDUCTION; INDUCED APOPTOSIS; PLASMA-MEMBRANE; RAT HEPATOCYTES; GENE CED-3; C-FOS; PROTEIN; CA2+	The effect of intracellular ion deregulation, particularly of [Ca2+], on the events following acute cell injury and the progression of change from initiation (reversible) to maintenance (reversible-irreversible) phases and finally to cell death has been the major thrust of experimentation in our laboratory for over 20 years. Cell death, which plays an important role in both normal and pathological phenomena, has been classified into two principal types, accidental and programmed. Recent exploration of programmed cell death (or apoptosis) has revealed extensive data showing it is an important mechanism for the normal maintenance and also differentiation of a variety of cell types and organs. From the results from our laboratory and those of others, we continue to expand and refine our working hypothesis: deregulation of [Ca2+] results in a number of phenomena from activation of signaling mechanisms and alterations in cellular structure to alterations in gene expression, all of which contribute to or play a critical role in cellular toxicity, including carcinogenesis and cell death. Therefore, although much more experimentation is needed to clarify some of these phenomena, the implications of such data for understanding the mechanisms and processes involved in carcinogenesis and the chemotherapeutic killing of cancer cells are extremely exciting. These relationships between [Ca2+], cell injury, and cell death are briefly reviewed here within the framework of our hypothesis.	MARYLAND INST EMERGENCY MED SERV SYST, BALTIMORE, MD 21201 USA		TRUMP, BF (corresponding author), UNIV MARYLAND, SCH MED, DEPT PATHOL, 10 S PINE ST, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015440] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15440] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBUDKAR IS, 1988, TOXICOL IND HEALTH, V4, P107, DOI 10.1177/074823378800400108; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARRY MA, 1993, CANCER RES, V53, P2349; BENNET J, 1993, BR MED B, V42, P385; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONVENTRE JV, 1990, ENVIRON HEALTH PERSP, V84, P155, DOI 10.2307/3430717; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; DAVIS MA, 1994, TOXICOL PATHOL, V22, P595, DOI 10.1177/019262339402200604; ELDEIRY WS, 1994, CANCER RES, V56, P1; ELLIGET KA, 1991, CELL BIOL TOXICOL, V7, P263; EVANS VG, 1993, CELL BIOL INT, V17, P461, DOI 10.1006/cbir.1993.1087; FAWTHROP DJ, 1991, TOXICOLOGY, V55, P437; GANAPATHY V, 1991, KIDNEY INT, V40, pS4; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAYASHI H, 1992, AM J PHYSIOL, V262, pC628, DOI 10.1152/ajpcell.1992.262.3.C628; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIMPENS B, 1994, FASEB J, V8, P879, DOI 10.1096/fasebj.8.11.8070638; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JAIN PT, 1993, TOXICOL PATHOL, V21, P572, DOI 10.1177/019262339302100608; JAIN PT, 1994, MOL CARCINOGEN, V11, P164, DOI 10.1002/mc.2940110307; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KUBOHARA Y, 1994, FASEB J, V8, P869, DOI 10.1096/fasebj.8.11.8070636; LAPETINA EG, 1989, ANN NY ACAD SCI, V559, P153; LAVIN M, 1993, PROGRAMMED CELL DEAT; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICOTERA P, 1986, FEBS LETT, V209, P139, DOI 10.1016/0014-5793(86)81099-7; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; PAPADIMITRIOU JC, 1994, CELL CALCIUM, V15, P217, DOI 10.1016/0143-4160(94)90061-2; PENTTILA A, 1975, LAB INVEST, V32, P690; PHELPS PC, 1989, LAB INVEST, V60, P630; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; SHELANSKI ML, 1989, ANN NY ACAD SCI, V568, P121; SINGH N, 1994, IN PRESS CYTOKINE; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MW, 1987, BIOCHIM BIOPHYS ACTA, V931, P130, DOI 10.1016/0167-4889(87)90199-6; SMITH MW, 1991, P NATL ACAD SCI USA, V88, P4926, DOI 10.1073/pnas.88.11.4926; SMITH MW, 1992, AM J PHYSIOL, V262, pF647, DOI 10.1152/ajprenal.1992.262.4.F647; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P4998; SWANN JD, 1991, TOXICOL PATHOL, V19, P128, DOI 10.1177/019262339101900207; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOMEI LD, 1994, APOPTOSIS 2 MOL BASI; TREVES S, 1994, EXP CELL RES, V211, P339, DOI 10.1006/excr.1994.1096; TROYER DA, 1986, KIDNEY INT, V29, P530, DOI 10.1038/ki.1986.31; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; Trump B.F, 1969, METHODS ACHIEVEMENTS, VIV, P1; Trump B. F., 1971, PRINCIPLES PATHOBIOL, p9e95; TRUMP BF, 1962, LAB INVEST, V11, P986; TRUMP BF, 1984, DRUG METABOLISM DRUG, P261; TRUMP BF, 1992, CARDIOVASCULAR TOXIC, P75; TRUMP BF, 1971, CELL MEMBRANES BIOL, P84; TRUMP BF, 1982, PATHOPHYSIOLOGY SHOC, P6; TRUMP BF, 1994, METH TOXICOL, V1, P1; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER ACC, 1994, AM J PHYSIOL, V266, pG1, DOI 10.1152/ajpgi.1994.266.1.G1; WEINBERG JM, 1991, J CLIN INVEST, V87, P581, DOI 10.1172/JCI115033; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; YAMAMOTO N, 1993, RENAL FAILURE, V15, P163, DOI 10.3109/08860229309046148; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	91	553	571	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					219	228		10.1096/fasebj.9.2.7781924	http://dx.doi.org/10.1096/fasebj.9.2.7781924			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781924				2022-12-28	WOS:A1995QJ24900010
J	DAVIES, DR; WLODAWER, A				DAVIES, DR; WLODAWER, A			CYTOKINES AND THEIR RECEPTOR COMPLEXES	FASEB JOURNAL			English	Review						GROWTH FACTORS; 3-DIMENSIONAL STRUCTURES; SUPER-FAMILIES; SIGNAL TRANSDUCTION	COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; NERVE GROWTH-FACTOR; HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2; REFINED CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; INTERLEUKIN 1-ALPHA; 2.6-A RESOLUTION; 2.7-A RESOLUTION	The 3-dimensional structures resulted from X-ray diffraction and nuclear magnetic resonance analyses of a variety of cytokines are reviewed. These proteins form distinct, well-defined superfamilies based on the structures of their monomers, even in the absence of significant sequence homology. However, in several cases, where the active form of a cytokine is a dimer or higher oligomer, these similar monomers adopt very different modes of dimerization. Two examples of complexes of cytokines with receptor molecules are described and the implications for signal transduction are discussed.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MACROMOLEC STRUCT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	DAVIES, DR (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BAMBOROUGH P, 1994, PROTEIN-STRUCT FUNCT, V17, P11; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHELVANAYAGAM G, 1992, J MOL BIOL, V228, P220, DOI 10.1016/0022-2836(92)90502-B; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAOPIN S, 1992, SCIENCE, V258, P1161, DOI 10.1126/science.258.5085.1161; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P257; DEVOS AM, 1992, CURR OPIN STRUC BIOL, V2, P852; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KILIAN PL, 1986, J IMMUNOL, V136, P4509; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LENGUYEN D, 1990, BIOCHIMIE, V72, P431, DOI 10.1016/0300-9084(90)90067-Q; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURRAYRUST J, 1993, CURR BIOL, V1, P153; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NISHIUCHI Y, 1986, BIOPOLYMERS, V25, P561; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V80, P9667; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; SMITH LJ, 1994, NAT STRUCT BIOL, V1, P301, DOI 10.1038/nsb0594-301; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; SWINDELLS MB, 1992, SCIENCE, V258, P1160, DOI 10.1126/science.1439827; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WLODAWER A, 1993, PROTEIN SCI, V2, P1375; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	61	45	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					50	56		10.1096/fasebj.9.1.7821759	http://dx.doi.org/10.1096/fasebj.9.1.7821759			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821759				2022-12-28	WOS:A1995QD20200009
J	BACMAN, S; STERINBORDA, L; CAMUSSO, JJ; HUBSCHER, O; ARANA, R; BORDA, ES				BACMAN, S; STERINBORDA, L; CAMUSSO, JJ; HUBSCHER, O; ARANA, R; BORDA, ES			CIRCULATING ANTIBODIES AGAINST NEUROTRANSMITTER RECEPTOR ACTIVITIES IN CHILDREN WITH CONGENITAL HEART-BLOCK AND THEIR MOTHERS	FASEB JOURNAL			English	Article						BETA-ADRENERGIC ANTIBODIES; MUSCARINIC CHOLINERGIC ANTIBODIES; CAMP; ATRIA CONTRACTILITY; BINDING ASSAY	SYSTEMIC LUPUS-ERYTHEMATOSUS; SS-A ANTIGEN; CHAGASIC IGG; BETA-ADRENOCEPTORS; SJOGRENS SYNDROME; AUTOANTIBODIES; DISEASE; BINDING; A/RO; MONOPHOSPHATE	In this work we demonstrated that IgG present in the sera of patients with congenital heart block (CHB) and their mothers could bind and activate beta adrenoceptors and muscarinic cholinergic receptors of neonatal heart. These antibodies were able to inhibit in a noncompetitive manner the binding of [H-3]QNB and [H-3]CGP to muscarinic cholinergic and beta adrenoceptors of purified neonatal rat myocardial membranes, respectively. Moreover, IgG from children with CHB and their mothers could modify biological effects mediated by these neurotransmitter receptors, i.e., heart contractility and cAMP production. Neither binding nor biological effects were obtained using adult instead of neonatal rat atria. Both reactivities (adrenergic and cholinergic) were independent of Ro/SS-A and La/SS-B antibodies and were absent in the sera of normal women of childbearing age and of normal children. It could be concluded that antibodies against cardiac neurotransmitter receptors may be another serum factor (or factors) to be considered in the pathophysiology of the development of CHB.	CEMIC,RA-1414 BUENOS AIRES,DF,ARGENTINA	Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)	BACMAN, S (corresponding author), CONSEJO NACL INVEST CIENT & TECN,CEFYBO,SERRANO 669,RA-1414 BUENOS AIRES,DF,ARGENTINA.							AHEARN JM, 1982, ARTHRITIS RHEUM-US, V25, P1031, DOI 10.1002/art.1780250901; ALEXANDER E, 1992, ARTHRITIS RHEUM-US, V35, P176, DOI 10.1002/art.1780350209; ALEXANDER EL, 1989, J INVEST DERMATOL, V93, P751, DOI 10.1111/1523-1747.ep12284404; ALEXANDER EL, 1982, J RHEUMATOL, V9, P239; ALMON RR, 1974, SCIENCE, V186, P55, DOI 10.1126/science.186.4158.55; BEHAN WMH, 1989, BRIT HEART J, V62, P320; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CREMASCHI GA, 1991, IMMUNOPHARMACOLOGY, V22, P195, DOI 10.1016/0162-3109(91)90044-Y; DENG JS, 1987, ARTHRITIS RHEUM, V30, P1232, DOI 10.1002/art.1780301105; DENG JS, 1985, J INVEST DERMATOL, V85, P412, DOI 10.1111/1523-1747.ep12277079; FLEMING JW, 1992, CIRCULATION, V85, P420, DOI 10.1161/01.CIR.85.2.420; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; FLIER JS, 1976, J CLIN INVEST, V58, P1442, DOI 10.1172/JCI108600; HARBON S, 1971, BIOCHEM BIOPH RES CO, V44, P1496, DOI 10.1016/S0006-291X(71)80255-3; HUNTER F A, 1991, Arthritis and Rheumatism, V34, pS75; IOSA D, 1990, J AUTONOM NERV SYST, V30, P583; KURATA N, 1976, ARTHRITIS RHEUM, V19, P574, DOI 10.1002/art.1780190309; LEE LA, 1985, J INVEST DERMATOL, V85, P143, DOI 10.1111/1523-1747.ep12276566; LEE LA, 1989, J INVEST DERMATOL, V86, P488; LEIROS CP, 1990, P SOC EXP BIOL MED, V195, P356; LIEU T S, 1991, Arthritis and Rheumatism, V34, pS102; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MEVORACH D, 1993, ARTHRITIS RHEUM, V36, P259, DOI 10.1002/art.1780360219; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; PASCUAL J, 1987, LIFE SCI, V19, P574; PROVOST TT, 1988, ARCH DERMATOL, V124, P63, DOI 10.1001/archderm.124.1.63; REED BR, 1983, J PEDIATR-US, V103, P889, DOI 10.1016/S0022-3476(83)80707-0; REESSMITH B, 1974, LANCET, V2, P427; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JS, 1983, NEW ENGL J MED, V309, P209, DOI 10.1056/NEJM198307283090403; SONTHEIMER RD, 1982, ANN INTERN MED, V97, P664, DOI 10.7326/0003-4819-97-5-664; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9; STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAYLOR PV, 1986, NEW ENGL J MED, V315, P667, DOI 10.1056/NEJM198609113151103; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; WATSON RM, 1984, MEDICINE, V63, P362, DOI 10.1097/00005792-198411000-00003; ZAKARIJA M, 1980, ANN INTERN MED, V93, P28, DOI 10.7326/0003-4819-93-1-28	42	24	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1170	1176		10.1096/fasebj.8.14.7958624	http://dx.doi.org/10.1096/fasebj.8.14.7958624			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958624				2022-12-28	WOS:A1994PT12800013
J	PAWSON, T				PAWSON, T			INTRODUCTION - PROTEIN-KINASES	FASEB JOURNAL			English	Review							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; DOMAINS				PAWSON, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Pawson, Tony J/E-4578-2013					BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUGHES DA, 1994, NATURE, V369, P187, DOI 10.1038/369187a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	24	21	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1994	8	14					1112	1113		10.1096/fasebj.8.14.7958615	http://dx.doi.org/10.1096/fasebj.8.14.7958615			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958615				2022-12-28	WOS:A1994PT12800004
J	SKEATH, JB; CARROLL, SB				SKEATH, JB; CARROLL, SB			THE ACHAETE-SCUTE COMPLEX - GENERATION OF CELLULAR-PATTERN AND FATE WITHIN THE DROSOPHILA NERVOUS-SYSTEM	FASEB JOURNAL			English	Review						PRONEURAL GENES; NEUROBLAST; SEGMENTATION; POSITIONAL INFORMATION; LATERAL INHIBITION	DROSOPHILA-MELANOGASTER; NEUROBLAST SEGREGATION; PRONEURAL ACHAETE; HOMOLOGOUS GENES; MYOGENIN GENE; EXPRESSION; NOTCH; SPECIFICATION; NEUROGENESIS; DOMAINS	In developing embryos, cells receive and interpret positional information as they become organized into discrete patterns and structures. One excellent model for understanding the genetic regulatory mechanisms that pattern cellular fields is the regulation and function of the achaete-scute complex (AS-C) in the developing nervous system of the fruit fly, Drosophila melanogaster. Three structurally homologous proneural genes - achaete (ac), scute (sc), and lethal of scute (l'sc) - are required for neural stem cell formation. In Drosophila, the AS-C genes are initially expressed in patterns of cell clusters at reproducible anteroposterior (AP) and dorsoventral (DV) coordinates that foreshadow where neural precursors arise. In the embryonic central nervous system (CNS), the gene products of AP and DV axis-patterning genes act combinatorially via a large array of cis-regulatory regions scattered throughout the AS-C to generate a segmentally repeated pattern of proneural clusters. Within each cluster (an equivalence group), one cell then retains proneural gene expression and is singled out as the neural stem cell (neuroblast). The neuroblast inhibits the surrounding cells from adopting neural fates (lateral inhibition) through a signaling pathway that is mediated via the action of the proneural and neurogenic genes. The proneural genes therefore represent a nodal point in the patterning of the nervous system. They receive global positional information, transduce it to discrete sets of cells, and trigger local cell interactions that mediate cell fate decisions.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign								ALBERGA A, 1991, DEVELOPMENT, V111, P983; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DOE CQ, 1992, DEVELOPMENT, V116, P855; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERREIRO B, 1992, MECH DEVELOP, V40, P25; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JARMAN AP, 1993, DEVELOPMENT, V119, P19; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1993, CURR OPIN GENET DEV, V3, P626, DOI 10.1016/0959-437X(93)90099-B; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KNUST E, 1992, GENETICS, V132, P505; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Lawrence P., 1992, MAKING FLY GENETICS; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; MARTINBERMUDO MD, 1993, DEVELOPMENT, V118, P1003; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; ORENIC TV, 1993, DEVELOPMENT, V118, P9; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; SIMPSON P, 1989, DEVELOPMENT, V106, P57; SKEATH JB, 1992, DEVELOPMENT, V114, P939; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SKEATH JB, 1994, IN PRESS DEVELOPMENT; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STERN CURT, 1954, AMER SCI, V42, P213; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	53	86	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					714	721		10.1096/fasebj.8.10.8050670	http://dx.doi.org/10.1096/fasebj.8.10.8050670			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050670				2022-12-28	WOS:A1994NY35000008
J	FRAENKELCONRAT, H				FRAENKELCONRAT, H			EARLY DAYS OF PROTEIN CHEMISTRY	FASEB JOURNAL			English	Article											FRAENKELCONRAT, H (corresponding author), UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720, USA.							ANDERER FA, 1960, NATURE, V186, P922, DOI 10.1038/186922a0; ANDERER FA, 1959, Z NATURFORSCH PT B, V14, P642; Bergmann M, 1937, J BIOL CHEM, V119, P707; Bergmann M, 1938, J BIOL CHEM, V124, P1; FRAENKEL-CONRAT H., 1943, Annual Review of Biochemistry, V12, P273, DOI 10.1146/annurev.bi.12.070143.001421; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; FRAENKELCONRAT H, 1957, VIROLOGY, V4, P1, DOI 10.1016/0042-6822(57)90038-7; FRAENKELCONRAT H, 1956, ANNU REV BIOCHEM, V25, P291, DOI 10.1146/annurev.bi.25.070156.001451; FRAENKELCONRAT H, 1955, J BIOL CHEM, V217, P373; FRAENKELCONRAT H, 1954, J AM CHEM SOC, V76, P3606, DOI 10.1021/ja01642a085; FRAENKELCONRAT H, 1955, P NATL ACAD SCI USA, V41, P690, DOI 10.1073/pnas.41.10.690; FRAENKELCONRAT H, 1957, BIOCHIM BIOPHYS ACTA, V24, P540, DOI 10.1016/0006-3002(57)90244-5; GLENDENING MB, 1947, J BIOL CHEM, V167, P125; HENDON RA, 1971, P NATL ACAD SCI USA, V68, P1560, DOI 10.1073/pnas.68.7.1560; Li CH, 1942, J AM CHEM SOC, V64, P1586, DOI 10.1021/ja01259a028; NARITA K, 1958, BIOCHIM BIOPHYS ACTA, V28, P184, DOI 10.1016/0006-3002(58)90445-1; NIU CI, 1955, J AM CHEM SOC, V77, P5882, DOI 10.1021/ja01627a031; Slotta KH, 1938, BER DTSCH CHEM GES, V71, P1076, DOI 10.1002/cber.19380710527; TSUGITA A, 1960, P NATL ACAD SCI USA, V46, P1463, DOI 10.1073/pnas.46.11.1463	19	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					452	453		10.1096/fasebj.8.6.8168696	http://dx.doi.org/10.1096/fasebj.8.6.8168696			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168696				2022-12-28	WOS:A1994NH25000014
J	LOWRY, OH				LOWRY, OH			THE EVOLUTION OF ANALYTICAL BIOCHEMISTRY (1933-1983) - A BIASED 50-YEAR REVIEW .34.	FASEB JOURNAL			English	Editorial Material											LOWRY, OH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NINDS NIH HHS [R01-NSO8862] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008862] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Passonneau J.V., 1993, ENZYMATIC ANAL PRACT	1	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					262	264		10.1096/fasebj.8.2.8119497	http://dx.doi.org/10.1096/fasebj.8.2.8119497			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119497				2022-12-28	WOS:A1994MY29900035
J	KILBERG, MS; HUTSON, RG; LAINE, RO				KILBERG, MS; HUTSON, RG; LAINE, RO			AMINO ACID-REGULATED GENE-EXPRESSION IN EUKARYOTIC CELLS	FASEB JOURNAL			English	Review						AMINO ACIDS; NUTRIENT CONTROL; TRANSCRIPTIONAL REGULATION; TRANSPORT; ASPARAGINE SYNTHETASE; RIBOSOMAL PROTEINS	HAMSTER OVARY CELLS; TRANSFER-RNA-SYNTHETASES; HISTIDYL-TRANSFER RNA; TRANSPORT SYSTEM-A; ASPARAGINE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSLATIONAL CONTROL; MAMMALIAN-CELLS; PROTEIN-KINASE	Given the central role of protein synthesis in cellular function, it is likely that intricate mechanisms exist to detect and respond to amino acid deprivation. However, the current understanding of amino acid-dependent control of gene expression in mammalian cells is limited. A few examples of enzymes, transporters, and unidentified mRNA species subject to amino acid availability have been reported and some examples are summarized here. Each example chosen - asparagine synthetase, system A transport activity, and ribosomal protein L17-are associated with different aspects of amino acid metabolism, and therefore reflect the spectrum of metabolic pathways influenced by substrate control. Most of the data accumulated thus far suggest that a general control response exists such that these various activities are induced when any one of several amino acids becomes limiting: Consistent with observations in yeast, it appears that the degree of tRNA acylation and its resultant effect on protein synthesis may play an important role in initiating the starvation signal. De novo protein synthesis is required for starvation-dependent increases in several mRNA species, which suggests that the amino acid signaling pathway is composed of a series of intermediate steps before activation of specific structural genes.			KILBERG, MS (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,BOX 100245,1600 SW ARCHER RD,GAINESVILLE,FL 32610, USA.				NIDDK NIH HHS [DK-31580] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031580] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; ANDRULIS IL, 1979, J BIOL CHEM, V254, P629; BOERNER P, 1985, J CELL PHYSIOL, V122, P308, DOI 10.1002/jcp.1041220221; BRACY DS, 1986, J BIOL CHEM, V261, P1514; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CHAKRABARTI R, 1993, J BIOL CHEM, V268, P1298; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; CHEREST H, 1971, Journal of Bacteriology, V106, P758; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CRAWFORD IP, 1980, ANNU REV BIOCHEM, V49, P163, DOI 10.1146/annurev.bi.49.070180.001115; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ENGLESBERG E, 1986, J MEMBRANE BIOL, V91, P199, DOI 10.1007/BF01868814; FONG AD, 1989, BIOCHIM BIOPHYS ACTA, V1022, P325; GAZZOLA GC, 1972, BIOCHIM BIOPHYS ACTA, V266, P407, DOI 10.1016/0005-2736(72)90097-1; GAZZOLA GC, 1986, J BIOL CHEM, V256, P3191; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GONG SS, 1990, NUCLEIC ACIDS RES, V18, P3509, DOI 10.1093/nar/18.12.3509; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HANDLOGTEN ME, 1982, J BIOL CHEM, V257, P345; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; HATAKEYAMA T, 1988, FEBS LETT, V240, P21, DOI 10.1016/0014-5793(88)80333-8; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KILBERG MS, 1985, J CELL PHYSIOL, V122, P290, DOI 10.1002/jcp.1041220219; KILBERG MS, 1986, FED PROC, V45, P2438; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LAINE RO, 1991, J BIOL CHEM, V266, P16969; MANKIN AS, 1989, FEBS LETT, V246, P13, DOI 10.1016/0014-5793(89)80243-1; MESSENGUY F, 1976, EUR J BIOCHEM, V67, P335, DOI 10.1111/j.1432-1033.1976.tb10696.x; MOFFETT J, 1986, J CELL PHYSIOL, V126, P421, DOI 10.1002/jcp.1041260313; MOORE PA, 1977, J BIOL CHEM, V252, P7427; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RIGGS TR, 1972, BIOCHEM J, V128, P19, DOI 10.1042/bj1280019; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCORNIK OA, 1980, J BIOL CHEM, V255, P6322; SHAY NF, 1990, J BIOL CHEM, V265, P17844; SHOTWELL MA, 1982, J BIOL CHEM, V257, P2974; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SUZUKI K, 1991, BIOCHEM BIOPH RES CO, V178, P322, DOI 10.1016/0006-291X(91)91817-V; TERNS MP, 1989, MOL CELL BIOL, V9, P1435, DOI 10.1128/MCB.9.4.1435; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WHITE MF, 1983, J BIOL CHEM, V258, P8028; WITTMANNLIEBOLD B, 1980, FEBS LETT, V121, P105; WOOL IG, 1990, STRUCTURE FUNCTION E, P203	53	89	90	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					13	19		10.1096/fasebj.8.1.8299885	http://dx.doi.org/10.1096/fasebj.8.1.8299885			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299885				2022-12-28	WOS:A1994MV28200004
J	STRAUS, DS				STRAUS, DS			NUTRITIONAL REGULATION OF HORMONES AND GROWTH-FACTORS THAT CONTROL MAMMALIAN GROWTH	FASEB JOURNAL			English	Review						PITUITARY GROWTH HORMONE; IGF-I SYNTHESIS; IGF RECEPTORS; IGF BINDING PROTEINS	FACTOR-II GENE; MESSENGER-RIBONUCLEIC-ACID; CULTURED RAT HEPATOCYTES; IGF-I; SERUM CONCENTRATIONS; BINDING PROTEIN-2; RESTRICTED RATS; RNA LEVELS; INSULIN; EXPRESSION	Juvenile animals stop growing if they are fed a diet containing an inadequate amount of energy or protein. The molecular basis for this growth arrest is not completely understood. The cessation of growth that occurs in nutritionally restricted animals is not generally explained by a decrease in circulating growth hormone (GH). In most species, plasma GH is increased rather than decreased under conditions of nutritional restriction. Current evidence suggests that the biosynthesis of insulin-like growth factor-I (IGF-I) is a key control point for nutritional regulation of growth. Plasma IGF-I peptide levels and hepatic IGF-I mRNA abundance are correlated with growth velocity and are consistently decreased when growth is arrested by nutritional deprivation. The decreased IGF-I mRNA abundance observed in the fasting rat appears to be caused primarily by a decrease in IGF-I gene transcription. In tissues and plasma, the insulin-like growth factors are complexed with high-affinity binding proteins, which are thought to modulate the tissue access and action of the IGFs. The hepatic mRNA abundance of two of the binding proteins (IGFBP-1 and -2) is increased in nutritionally restricted animals. This increase in mRNA abundance is caused primarily by an increase in transcription of the IGFBP-1 and IGFBP-2 genes. Current research is focused on molecular mechanisms for regulation of IGF-I and IGF-binding protein gene expression.	UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	STRAUS, DS (corresponding author), UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039739] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK39739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1993, ENDOCRINOLOGY, V132, P935, DOI 10.1210/en.132.2.935; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BOISCLAIR YR, 1993, IN PRESS J BIOL CHEM; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVENPORT ML, 1988, J CLIN ENDOCR METAB, V67, P1231, DOI 10.1210/jcem-67-6-1231; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DONOVAN SM, 1991, ENDOCRINOLOGY, V129, P149, DOI 10.1210/endo-129-1-149; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAYDEN JM, 1994, IN PRESS ENDOCRINOLO; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JOHNSON TR, 1989, MOL ENDOCRINOL, V3, P580, DOI 10.1210/mend-3-3-580; LEWITT MS, 1991, MOL CELL ENDOCRINOL, V77, P149, DOI 10.1016/0303-7207(91)90069-5; LOWE WL, 1989, J CLIN INVEST, V84, P619, DOI 10.1172/JCI114207; MIURA Y, 1992, BRIT J NUTR, V67, P257, DOI 10.1079/BJN19920029; MIURA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P358, DOI 10.1271/bbb.57.358; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; PAO CI, 1992, MOL ENDOCRINOL, V6, P969, DOI 10.1210/me.6.6.969; PELL JM, 1993, ENDOCRINOLOGY, V132, P1797, DOI 10.1210/en.132.4.1797; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; PILISTINE SJ, 1984, P NATL ACAD SCI-BIOL, V81, P5853, DOI 10.1073/pnas.81.18.5853; POWELL DR, 1993, DNA CELL BIOL, V12, P283, DOI 10.1089/dna.1993.12.283; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SOLIMAN AT, 1986, PEDIATR RES, V20, P1122, DOI 10.1203/00006450-198611000-00012; STRAUS DS, 1990, MOL ENDOCRINOL, V4, P91, DOI 10.1210/mend-4-1-91; STRAUS DS, 1991, J NUTR, V121, P1279, DOI 10.1093/jn/121.8.1279; STRAUS DS, 1991, ENDOCRINOLOGY, V128, P518, DOI 10.1210/endo-128-1-518; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; STRAUS DS, 1993, 75TH ANN M END SOC, P6; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THISSEN JP, 1992, AM J PHYSIOL, V262, pE406, DOI 10.1152/ajpendo.1992.262.4.E406; THISSEN JP, 1991, ENDOCRINOLOGY, V129, P429, DOI 10.1210/endo-129-1-429; TSENG LYH, 1992, MOL ENDOCRINOL, V6, P1195, DOI 10.1210/me.6.8.1195; VANCE ML, 1992, HORM RES, V38, P85, DOI 10.1159/000182577; VANDEHAAR MJ, 1991, J ENDOCRINOL, V130, P305, DOI 10.1677/joe.0.1300305; VANDIJK MA, 1992, NUCLEIC ACIDS RES, V20, P3099, DOI 10.1093/nar/20.12.3099; YOON JB, 1990, J BIOL CHEM, V265, P19947	42	141	144	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1994	8	1					6	12		10.1096/fasebj.8.1.8299891	http://dx.doi.org/10.1096/fasebj.8.1.8299891			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299891				2022-12-28	WOS:A1994MV28200003
J	KANAI, Y; SMITH, CP; HEDIGER, MA				KANAI, Y; SMITH, CP; HEDIGER, MA			A NEW FAMILY OF NEUROTRANSMITTER TRANSPORTERS - THE HIGH-AFFINITY GLUTAMATE TRANSPORTERS	FASEB JOURNAL			English	Review						TRANSPORTER STRUCTURE; EXCITATORY AMINO ACIDS; SYNAPTIC TRANSMISSION; TRANSMITTER CLEARANCE; NEURODEGENERATIVE DISEASES	BORDER MEMBRANE-VESICLES; EXCITATORY AMINO-ACIDS; LONG-TERM POTENTIATION; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT-BRAIN SYNAPTOSOMES; METHYL-D-ASPARTATE; GLIAL-CELLS; SYNAPTIC TRANSMISSION; GLUCOSE COTRANSPORTER; SEROTONIN TRANSPORTER	An essential component of the transmission process at glutamatergic synapses is the removal of glutamate from the synaptic cleft. This is achieved by powerful transport systems which have a high affinity for glutamate and exhibit a novel coupling to inorganic ions. Transporters situated on presynaptic termini sequester glutamate directly from the synaptic cleft. In concert, transporters situated on glial cells maintain a low extracellular glutamate concentration, thereby establishing a diffusion gradient favoring movement of glutamate out of the synaptic cleft. Maintenance of a low extracellular glutamate concentration also serves to protect neurons from the excitotoxic action of glutamate. Despite the physiological importance of the glutamate transporters, little information has been available on their molecular structures. This gap, however, has begun to be bridged with the recent cloning of three species of eukaryotic glutamate transporters. The purpose of this review is to summarize the results of these three cloning successes, to compare and contrast the three novel transporters, and to reinterpret, in the light of these recent breakthroughs, information from previous studies.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BREW H, 1987, NATURE, V328, P742, DOI 10.1038/328742c0; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CHOI DW, 1987, J NEUROSCI, V7, P357; CHRISTENSEN HN, 1983, LIFE SCI, V33, P2255, DOI 10.1016/0024-3205(83)90258-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORCELLI A, 1982, BIOCHIM BIOPHYS ACTA, V689, P97, DOI 10.1016/0005-2736(82)90193-6; CROSS AJ, 1986, NEUROSCI LETT, V63, P121, DOI 10.1016/0304-3940(86)90047-9; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DEVRIJ W, 1989, J BACTERIOL, V171, P1118, DOI 10.1128/jb.171.2.1118-1125.1989; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; EUBANKS JH, 1993, P NATL ACAD SCI USA, V90, P178, DOI 10.1073/pnas.90.1.178; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FUKUHARA Y, 1985, AM J PHYSIOL, V248, pF869, DOI 10.1152/ajprenal.1985.248.6.F869; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HOLLMANN M, 1988, FEBS LETT, V228, P74, DOI 10.1016/0014-5793(88)80588-X; HOLLMANN M, 1989, J NEUROCHEM, V53, P716, DOI 10.1111/j.1471-4159.1989.tb11763.x; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1994, IN PRESS J CLIN INVE; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KONG CT, 1993, J BIOL CHEM, V268, P1509; KWON HM, 1992, J BIOL CHEM, V267, P6297; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; NAITO S, 1983, J BIOL CHEM, V258, P696; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PALMER AM, 1986, NEUROSCI LETT, V66, P199, DOI 10.1016/0304-3940(86)90190-4; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PENG L, 1991, NEUROCHEM RES, V16, P29, DOI 10.1007/BF00965824; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PIN JP, 1984, FEBS LETT, V175, P31, DOI 10.1016/0014-5793(84)80563-3; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PLAITAKIS A, 1988, ANN NEUROL, V24, P446, DOI 10.1002/ana.410240314; POMARA N, 1992, AM J PSYCHIAT, V149, P251; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHANK RP, 1989, NEUROCHEM RES, V14, P371, DOI 10.1007/BF01000041; Shank RP, 1988, GLUTAMINE GLUTAMATE, VII, P3; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SILBERNAGL S, 1979, KLIN WOCHENSCHR, V57, P1009, DOI 10.1007/BF01479986; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TAYLOR R, 1993, J NIH RES, V5, P55; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WANG CD, 1991, MOL PHARMACOL, V40, P168; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WINGROVE TG, 1988, AM J PHYSIOL, V255, pC737, DOI 10.1152/ajpcell.1988.255.6.C737; ZACZEK R, 1987, J NEUROSCI RES, V18, P425, DOI 10.1002/jnr.490180307	90	139	145	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1993	7	15					1450	1459		10.1096/fasebj.7.15.7903261	http://dx.doi.org/10.1096/fasebj.7.15.7903261			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	7903261				2022-12-28	WOS:A1993ML74000007
J	BALASUBRAMANIAN, AS; BHANUMATHY, CD				BALASUBRAMANIAN, AS; BHANUMATHY, CD			NONCHOLINERGIC FUNCTIONS OF CHOLINESTERASES	FASEB JOURNAL			English	Review						ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; ARYL ACYLAMIDASE; METALLOCARBOXYPEPTIDASE; NEURAL CELL DIFFERENTIATION	HUMAN-SERUM PSEUDOCHOLINESTERASE; ALPHA-CHYMOTRYPSIN DIGESTION; ARYL ACYLAMIDASE ACTIVITIES; SERINE CARBOXYPEPTIDASE-II; TRYPSIN-LIKE; CHEMICAL MODIFICATION; TORPEDO-CALIFORNICA; PEPTIDASE ACTIVITY; BASAL GANGLIA; SUBSTANCE-P	Cholinesterases (acetylcholinesterase and butyrylcholinesterase) exhibit additional catalytic activities apart from their well-known action in hydrolyzing choline esters. An amine-sensitive aryl acylamidase activity is exhibited by both acetyl- and butyrylcholinesterases. A metallocarboxypeptidase-like activity is found associated with both acetyl- and butyrylcholinesterases. The peptidase activity exhibited by butyrylcholinesterase was located in a 50-kDa COOH-terminal fragment. Acetylcholinesterase is implicated in noncholinergic functions in the substantia nigra. A relationship between tumorigenesis, cell differentiation, and cholinesterases has been speculated. The sequence similarities between different esterases, lipases, thyroglobulin, cell adhesion proteins, and cholinesterases would make it appear that cholinesterases are capable of exhibiting more than one biological activity and their functions are wider than what is hitherto known.			BALASUBRAMANIAN, AS (corresponding author), CHRISTIAN MED COLL & HOSP,DEPT NEUROL SCI,NEUROCHEM LAB,VELLORE 632004,INDIA.							AIRLES FX, 1993, EUR J BIOCHEM, V211, P381; APPLEYARD M, 1992, NEUROSCIENCE, V47, P291, DOI 10.1016/0306-4522(92)90245-W; APPLEYARD ME, 1992, TRENDS NEUROSCI, V15, P485, DOI 10.1016/0166-2236(92)90100-M; ARPAGAUS M, 1991, J BIOL CHEM, V266, P6966; BALASUBRAMANIAN AS, 1984, TRENDS NEUROSCI, V7, P467, DOI 10.1016/S0166-2236(84)80256-8; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BOOPATHY R, 1985, EUR J BIOCHEM, V151, P351, DOI 10.1111/j.1432-1033.1985.tb09108.x; BOOPATHY R, 1987, EUR J BIOCHEM, V162, P191, DOI 10.1111/j.1432-1033.1987.tb10560.x; CARROLL RT, 1991, BIOCHEM BIOPH RES CO, V181, P858, DOI 10.1016/0006-291X(91)91269-I; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; CHECLER F, 1989, J NEUROCHEM, V53, P924, DOI 10.1111/j.1471-4159.1989.tb11793.x; CHECLER F, 1990, J NEUROCHEM, V55, P750, DOI 10.1111/j.1471-4159.1990.tb04555.x; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Drews U, 1975, Prog Histochem Cytochem, V7, P1; GATLEY SJ, 1991, BIOCHEM PHARMACOL, V41, P1249, DOI 10.1016/0006-2952(91)90665-R; GATLEY SJ, 1990, J NEUROCHEM, V54, P720, DOI 10.1111/j.1471-4159.1990.tb01933.x; GEORGE ST, 1980, EUR J BIOCHEM, V111, P511, DOI 10.1111/j.1432-1033.1980.tb04967.x; GEORGE ST, 1981, EUR J BIOCHEM, V121, P177, DOI 10.1111/j.1432-1033.1981.tb06447.x; GEORGE ST, 1983, INDIAN J BIOCHEM BIO, V20, P331; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GOEBEL DJ, 1992, NEUROPEPTIDES, V21, P35, DOI 10.1016/0143-4179(92)90150-U; GREENFIELD S, 1984, TRENDS NEUROSCI, V7, P364, DOI 10.1016/S0166-2236(84)80055-7; GREENFIELD SA, 1991, CELL MOL NEUROBIOL, V11, P55, DOI 10.1007/BF00712800; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; JAYANTHI LD, 1992, CLIN CHIM ACTA, V205, P157, DOI 10.1016/0009-8981(92)90056-V; KORZA G, 1988, J BIOL CHEM, V263, P3486; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LAYER PG, 1992, CELL TISSUE RES, V268, P409, DOI 10.1007/BF00319147; LAYER PG, 1990, BIOESSAYS, V12, P415, DOI 10.1002/bies.950120904; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MAJUMDAR R, 1984, BIOCHEMISTRY-US, V23, P4088, DOI 10.1021/bi00313a012; MAJUMDAR R, 1982, BIOCHEM PHARMACOL, V31, P2319, DOI 10.1016/0006-2952(82)90524-X; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MESSING RB, 1977, PAIN, V4, P1, DOI 10.1016/0304-3959(77)90083-5; NAUSCH I, 1985, J NEUROCHEM, V44, P1354, DOI 10.1111/j.1471-4159.1985.tb08769.x; OAKESHOTT JG, 1987, P NATL ACAD SCI USA, V84, P3359, DOI 10.1073/pnas.84.10.3359; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; OOMMEN A, 1979, EUR J BIOCHEM, V94, P135, DOI 10.1111/j.1432-1033.1979.tb12880.x; OOMMEN A, 1980, LIFE SCI, V26, P2129, DOI 10.1016/0024-3205(80)90599-8; RAO RV, 1989, EUR J BIOCHEM, V179, P639, DOI 10.1111/j.1432-1033.1989.tb14595.x; RAO RV, 1989, CLIN CHIM ACTA, V183, P135, DOI 10.1016/0009-8981(89)90329-X; RAO RV, 1990, EUR J BIOCHEM, V188, P637, DOI 10.1111/j.1432-1033.1990.tb15445.x; RAO RV, 1993, J PROTEIN CHEM, V12, P103, DOI 10.1007/BF01024921; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SMALL DH, 1987, NEUROSCIENCE, V21, P991, DOI 10.1016/0306-4522(87)90053-4; SMALL DH, 1988, NEUROSCI LETT, V95, P307, DOI 10.1016/0304-3940(88)90676-3; SMALL DH, 1991, BIOCHEMISTRY-US, V30, P10795, DOI 10.1021/bi00108a027; SMITH I, 1971, NATURE, V230, P246, DOI 10.1038/230246a0; SOREQ H, 1991, CANCER CELL-MON REV, V3, P511; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TSUJITA T, 1983, EUR J BIOCHEM, V133, P215, DOI 10.1111/j.1432-1033.1983.tb07450.x; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEBB CP, 1992, EXP BRAIN RES, V89, P49; WILLBOLD E, 1992, EUR J NEUROSCI, V4, P210, DOI 10.1111/j.1460-9568.1992.tb00869.x; WRIGHT CI, 1993, P NATL ACAD SCI USA, V90, P683, DOI 10.1073/pnas.90.2.683	61	73	75	3	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1354	1358		10.1096/fasebj.7.14.8224608	http://dx.doi.org/10.1096/fasebj.7.14.8224608			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224608				2022-12-28	WOS:A1993MH00800007
J	BAGGIOLINI, M; BOULAY, F; BADWEY, JA; CURNUTTE, JT				BAGGIOLINI, M; BOULAY, F; BADWEY, JA; CURNUTTE, JT			ACTIVATION OF NEUTROPHIL LEUKOCYTES - CHEMOATTRACTANT RECEPTORS AND RESPIRATORY BURST	FASEB JOURNAL			English	Review						NEUTROPHIL LEUKOCYTES; CHEMOTAXIS; ACTIVATION; RESPIRATORY BURST; NADPH OXIDASE; MECHANISM	CELL-FREE SYSTEM; FORMYL PEPTIDE RECEPTOR; GTP-BINDING PROTEIN; HUMAN INTERLEUKIN-8 RECEPTOR; XENOPUS OOCYTES REQUIRES; NADPH OXIDASE; FUNCTIONAL EXPRESSION; SUPEROXIDE PRODUCTION; BETA-2-ADRENERGIC RECEPTOR; PHOSPHATIDIC-ACID	The human organism survives the constant attack by bacteria and other pathogens thanks to the surveillance function of the neutrophil leukocytes. At sites of infection, several messenger molecules are generated that attract neutrophils from the blood and direct their migration toward the microbes, a process termed chemotaxis. Neutrophils sense , chemotactic agonists through a group of closely related, GTP-binding protein-coupled receptors. Several of these have been recently cloned and shown to belong to the superfamily of rhodopsin-like, seven transmembrane-domain receptors. At the site of infection, the neutrophils engulf and kill the invading microbes. This critical function depends on the production of superoxide and related radicals by a tightly regulated, membrane-bound NADPH oxidase that is activated by chemotactic agonists and other inflammatory stimuli. The characteristics of the receptors as well as new insights into the mechanism of activation of the superoxide-forming oxidase as presented at a recent FASEB meeting symposium are reviewed.	CEN, DEPT RECH FONDAMENTALE,BIOCHIM LAB,CNRS,URA 1130, F-38041 GRENOBLE, FRANCE; BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA USA	Centre National de la Recherche Scientifique (CNRS); Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Scripps Research Institute	BAGGIOLINI, M (corresponding author), UNIV BERN, THEODOR KOCHER INST, CH-3000 BERN 9, SWITZERLAND.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023323, R01AI028342, R01AI024838] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28342, AI-24838, AI23323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; Baggiolini M, 1992, Cytokines, V4, P1; Baggiolini Marco, 1992, News in Physiological Sciences, V7, P215; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DING JB, 1992, J BIOL CHEM, V267, P6442; DING JB, 1992, BIOCHIM BIOPHYS ACTA, V1133, P235, DOI 10.1016/0167-4889(92)90074-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KROLL B, 1991, FEBS LETT, V291, P208, DOI 10.1016/0014-5793(91)81285-G; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; LU DJ, 1990, J BIOL CHEM, V265, P13721; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURPHY PM, 1991, J BIOL CHEM, V266, P12560; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; PEVERI P, 1990, BLOOD S, V76, pA190; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; WYMANN MP, 1990, J BIOL CHEM, V265, P619	67	160	164	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1993	7	11					1004	1010		10.1096/fasebj.7.11.8396540	http://dx.doi.org/10.1096/fasebj.7.11.8396540			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8396540				2022-12-28	WOS:A1993LT83900004
J	BRAUTIGAN, DL				BRAUTIGAN, DL			PASSING OR FAILING - IS BIOMEDICAL SCIENCE MEETING NATIONAL NEEDS	FASEB JOURNAL			English	Article											BRAUTIGAN, DL (corresponding author), BROWN UNIV,BIOCHEM SECT,PROVIDENCE,RI 02912, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					730	732		10.1096/fasebj.7.9.8330678	http://dx.doi.org/10.1096/fasebj.7.9.8330678			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330678				2022-12-28	WOS:A1993LK43000002
J	SCHMITT, ME; BENNETT, JL; DAIRAGHI, DJ; CLAYTON, DA				SCHMITT, ME; BENNETT, JL; DAIRAGHI, DJ; CLAYTON, DA			SECONDARY STRUCTURE OF RNASE MRP RNA AS PREDICTED BY PHYLOGENETIC COMPARISON	FASEB JOURNAL			English	Article						ENDORIBONUCLEASE; RNA PROCESSING; RNASE MRP; RNASE-P	NUCLEAR GENE; MITOCHONDRIAL; RIBONUCLEOPROTEIN; ENDORIBONUCLEASE; CONTAINS; ENZYME	RNase MRP is a ribonucleoprotein endoribonuclease that has been shown to cleave mitochondrial primer RNA sequences from a variety of sources. The bulk of RNase MRP activity is found in the nucleus where its function remains unknown. Two different approaches have resulted in predictions of distinct secondary structures for RNase MRP RNA. In order to analyze more definitively the higher-order structure of RNase MRP RNA, we have conducted a phylogenetic comparison of the available RNase MRP RNA sequences from human, mouse, rat, cow, toad, and yeast. The resulting secondary structure shares features in common with previously described structures for prokaryotic and eukaryotic RNase P RNAs (1) and RNase MRP RNAs (2, 3). In addition, the phylogenetic structure is consistent with available chemical modification data on RNase MRP RNA and with the detailed analysis of the To antigen binding domain located near the 5' end of the RNase MRP RNA. The structure is not limited to RNase MRP RNAs, but can be expanded to cover both eukaryotic RNase P RNAs and RNase P/MRP RNAs from plants.			SCHMITT, ME (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365, T32GM008294, R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365-15, GM33088-22, GM08294-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BENNETT JL, 1992, J BIOL CHEM, V267, P21765; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; DAIRAGHI DJ, 1993, IN PRESS J MOL EVOL; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; JAMES BD, 1989, METHOD ENZYMOL, V180, P227; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KISS T, 1992, EMBO J, V11, P3737, DOI 10.1002/j.1460-2075.1992.tb05459.x; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHMITT ME, 1992, GENE DEV, V6, P1975, DOI 10.1101/gad.6.10.1975; STOHL LL, 1992, MOL CELL BIOL, V12, P2561, DOI 10.1128/MCB.12.6.2561; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1990, J BIOL CHEM, V265, P13254; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	20	92	92	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					208	213		10.1096/fasebj.7.1.7678563	http://dx.doi.org/10.1096/fasebj.7.1.7678563			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678563				2022-12-28	WOS:A1993KH88000032
J	MARTIN, DMA; BOYS, CWG; RUF, W				MARTIN, DMA; BOYS, CWG; RUF, W			TISSUE FACTOR - MOLECULAR RECOGNITION AND COFACTOR FUNCTION	FASEB JOURNAL			English	Review						RECEPTOR STRUCTURE; LIGAND BINDING; MACROMOLECULAR COFACTOR; COAGULATION PATHWAYS; THROMBOSIS	HUMAN FACTOR-VIIA; FACTOR EXTRACELLULAR DOMAIN; GROWTH-FACTOR DOMAIN; COAGULATION FACTOR-X; COMPLEX; BINDING; SURFACE; ACTIVATION; CRYSTALLIZATION; AUTOACTIVATION	One aspect of the inflammatory response is the activation of the coagulation protease cascade resulting from the expression of tissue factor (TF) on vascular cells, TF is the cell-surface receptor for the coagulation serine protease factor VIIa, providing cofactor function by ''switching on'' the catalytic site of the bound enzyme and by contributing to the assembly with macromolecular substrate, The recently determined crystal structure of the TF extracellular domain shows two beta-strand modules of C2 immunoglobulin-like topology that align at a 125 degrees angle with an extensive intermodule interface, Mutagenesis studies have identified residues in both modules that are important for the binding of ligand, The deduced ligand interface extends from the convex side of the molecule into the concave side of the elbow angle, Specific binding residues control the catalytic activity of the bound protease. At the lower end of the carboxyl-terminal module, basic residues form part of a region that is important for both recognition and activation of macromolecular substrate and, potentially, for modulation of proteolytic function, After combining the biochemical data with the crystal structure, a model of TF function can be proposed in which the catalytic activity of the active site of the protease and the extended recognition of macromolecular substrates are separately controlled by distinct structural sites of the cofactor.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, HAEMOSTASIS RES GRP, LONDON, ENGLAND; UNIV EDINBURGH, DEPT BIOCHEM, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND	Scripps Research Institute; Scripps Research Institute; Imperial College London; University of Edinburgh			Martin, David/C-2984-2009	Martin, David/0000-0002-8732-204X	NHLBI NIH HHS [HL-48752, HL-16411] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BOYS CWG, 1993, J MOL BIOL, V234, P1263, DOI 10.1006/jmbi.1993.1678; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; FAIR DS, 1987, J BIOL CHEM, V262, P11692; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LE DT, 1992, J BIOL CHEM, V267, P15447; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1991, BLOOD, V78, P132; OBRIEN DP, 1993, BIOCHEM J, V292, P7, DOI 10.1042/bj2920007; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO LVM, 1994, CIRCULATION, V90, P617; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; RUF W, 1992, J CRYST GROWTH, V122, P253, DOI 10.1016/0022-0248(92)90254-G; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; RUF W, 1995, IN PRESS BIOCHEMISTR; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPEIDEL CM, 1994, CIRCULATION, V90, P344; SRIDHARA S, 1993, BLOOD COAGUL FIBRIN, V4, P505, DOI 10.1097/00001721-199306000-00019; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WATZKE HH, 1990, J BIOL CHEM, V265, P11982; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	54	91	102	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					852	859		10.1096/fasebj.9.10.7615155	http://dx.doi.org/10.1096/fasebj.9.10.7615155			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615155				2022-12-28	WOS:A1995RK89900005
J	STRICKLAND, DK; KOUNNAS, MZ; ARGRAVES, WS				STRICKLAND, DK; KOUNNAS, MZ; ARGRAVES, WS			LDL RECEPTOR-RELATED PROTEIN - A MULTILIGAND RECEPTOR FOR LIPOPROTEIN AND PROTEINASE CATABOLISM	FASEB JOURNAL			English	Review						PLASMINOGEN ACTIVATIONS; THROMBOSPONDIN; LIPOPROTEIN LIPASE; RAP; CHYLOMICRON REMNANTS	LOW-DENSITY-LIPOPROTEIN; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; HIGH-AFFINITY; BINDING; COMPLEXES; DEGRADATION	The accumulation of excessive cholesterol-rich lipoproteins within vascular cells, the proliferation of vascular cells, and fibrin deposition are hallmark features of atherosclerosis. Evidence accumulated over the past few years supports the hypothesis that one member of the LDL receptor family, the low density lipoprotein receptor-related protein (LRP), affects the dynamics of each of these processes, LRP is expressed in several vascular cell types, including smooth muscle cells, and in macrophages, and is also expressed in these cells in atherosclerotic lesions, This receptor is a large endocytotic receptor that mediates the catabolism of a number of molecules known to be important in vascular biology, including apolipoprotein E- and lipoprotein lipase-enriched lipoproteins, thrombospondin, and plasminogen activators, The capacity of LRP to mediate Lipoprotein catabolism may be a factor in the development of the lesion by contributing to the formation of foam cells, LRP has recently been shown to mediate the catabolism of thrombospondin, a molecule that has potent biological effects on cells of the vasculature, The regulation of its extracellular accumulation by LRP might modulate the dynamic: processes of tissue remodeling associated with the response to vascular injury, In addition, LRP regulates the expression of plasmin activity by directly binding and mediating the cellular internalization of urokinase- and tissue-type plasminogen activators, The cellular removal of these two enzymes decreases the local profibrinolytic potential, possibly leading to a thrombotic state at lesion sites.			STRICKLAND, DK (corresponding author), AMER RED CROSS,DEPT BIOCHEM,HOLLAND LAB,15601 CRABBS BRACH WAY,ROCKVILLE,MD 20855, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1994, BLOOD, V83, P3427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHU CT, 1994, LAB INVEST, V71, P792; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DAUGHERTY A, 1994, ARTERIOSCLER THROMB, V14, P2017, DOI 10.1161/01.ATV.14.12.2017; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; JI ZS, 1994, J BIOL CHEM, V269, P2764; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P28162; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; ORTH K, 1994, J BIOL CHEM, V269, P21117; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572	52	249	258	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					890	898		10.1096/fasebj.9.10.7615159	http://dx.doi.org/10.1096/fasebj.9.10.7615159			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615159				2022-12-28	WOS:A1995RK89900010
J	KNAPP, RJ; MALATYNSKA, E; COLLINS, N; FANG, L; WANG, JY; HRUBY, VJ; ROESKE, WR; YAMAMURA, HI				KNAPP, RJ; MALATYNSKA, E; COLLINS, N; FANG, L; WANG, JY; HRUBY, VJ; ROESKE, WR; YAMAMURA, HI			MOLECULAR-BIOLOGY AND PHARMACOLOGY OF CLONED OPIOID RECEPTORS	FASEB JOURNAL			English	Article						ENDORPHIN RECEPTORS; G-PROTEIN; ADENYLYL CYCLASE; CAMP FORMATION; CDNA; CLONING; EXPRESSION; ANTISENSE OLIGONUCLEOTIDES; SITE-DIRECTED MUTAGENESIS; MOLECULAR MODELING	NALORPHINE-LIKE DRUGS; CHRONIC SPINAL DOG; RAT-BRAIN; MU-OPIATE; FUNCTIONAL EXPRESSION; AGONIST BINDING; MORPHINE-LIKE; MOUSE-BRAIN; CLONING; SPECIFICITY	The cloning and expression of DNA for the three major opioid receptor types (mu, delta, and kappa) present new research opportunities for the characterization of opioid drugs and their interactions with these receptors. Genomic and cDNA clones for opioid receptors exist for several animal species including mouse, rat, guinea pig, and human. These include clones for all three human opioid receptor types. The receptor proteins consist of about 400 amino acids and have the characteristic seven transmembrane domain structure of G-protein-coupled receptors. There is about 60% amino acid identity between opioid receptor types and about 90% identity between a receptor type cloned from different animal species. Ah opioid receptor types mediate the inhibition of adenylyl cyclase in response to agonist binding. Radioligand binding and functional studies using the cloned receptors tend to support current conclusions on opioid drug receptor selectivity and activity. Investigations of opioid receptor chimeras and single amino acid mutants are providing information on the ligand recognition sites of these receptors and essential support for the development of computational opioid receptor models. A molecular model of the human delta opioid receptor is included in this review.	UNIV ARIZONA,COLL MED,DEPT PHARMACOL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT MED,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PSYCHIAT,TUCSON,AZ 85724; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85724; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85724; UNIV ARIZONA,PROGRAM NEUROSCI,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004248, P01DA006284, P01DA008657] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06284, DA-04248, DA-08657] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BILSKY EJ, 1994, LIFE SCI, V55, pPL37, DOI 10.1016/0024-3205(94)90110-4; BOWEN JP, 1993, J CLIN PHARMACOL, V33, P1149, DOI 10.1002/j.1552-4604.1993.tb03915.x; CHANG KJ, 1984, OPIOID RECEPTORS MUL, P1; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FANG L, 1994, J PHARMACOL EXP THER, V268, P836; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GILBERT PE, 1976, J PHARMACOL EXP THER, V198, P66; GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOFLACK J, 1994, TRENDS PHARMACOL SCI, V15, P7, DOI 10.1016/0165-6147(94)90119-8; HUMBLET C, 1992, ANNU REP MED CHEM, V27, P291; KENAKIN T, 1993, PHARM ANAL DRUG RECE, P392; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KIEFFER GL, 1994, P NATL ACAD SCI USA, V91, P1193; KNAPP PJ, 1994, LIFE SCI, V54, pPL463; KNAPP RJ, 1989, DRUG TREATMENT CANCE, P247; KNAPP RJ, 1993, IMAGING DRUG ACTION, P119; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; KONG HY, 1993, MOL PHARMACOL, V44, P380; LAI J, 1994, NEUROREPORT, V5, P1049, DOI 10.1097/00001756-199405000-00008; LESLIE FM, 1987, PHARMACOL REV, V39, P197; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LOMIZE AL, 1994, J AM CHEM SOC, V116, P429, DOI 10.1021/ja00081a001; LORD JA, 1977, NATURE, V167, P49; MALATYNSKA E, 1994, REGUL PEPTIDES, V54, P73; MANSSON E, 1994, BIOCHEM BIOPH RES CO, V202, P1431, DOI 10.1006/bbrc.1994.2091; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; MOSBERG HI, 1988, LIFE SCI, V43, P1013, DOI 10.1016/0024-3205(88)90547-4; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; NOCK B, 1993, J PHARMACOL EXP THER, V264, P349; PASTERNAK GW, 1986, LIFE SCI, V38, P1889, DOI 10.1016/0024-3205(86)90217-1; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PORTOGHESE P S, 1992, Journal of Medicinal Chemistry, V35, P1927, DOI 10.1021/jm00089a001; QUIRION R, 1987, TRENDS NEUROSCI, V10, P444, DOI 10.1016/0166-2236(87)90094-4; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1994, REGUL PEPTIDES, pS5; REISINE T, 1993, TRENDS NEUROSCI, V16, P503; Rossi Grace, 1994, Life Sciences, V54, P375; SHOOK JE, 1988, J PHARMACOL EXP THER, V246, P1018; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; STADER CD, 1988, J BIOL CHEM, V263, P10267; STANDIFER KM, 1994, NEURON, V12, P805, DOI 10.1016/0896-6273(94)90333-6; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; TRUMPPKALLMEYER S, 1994, TACHYKININ RECEPTORS, P237; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOLLEMANN M, 1993, LIFE SCI, V52, P599, DOI 10.1016/0024-3205(93)90451-8; WOLLEMANN M, 1990, J NEUROCHEM, V54, P1095, DOI 10.1111/j.1471-4159.1990.tb01934.x; WUSTER M, 1979, NEUROSCI LETT, V15, P193, DOI 10.1016/0304-3940(79)96112-3; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	65	204	219	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					516	525		10.1096/fasebj.9.7.7737460	http://dx.doi.org/10.1096/fasebj.9.7.7737460			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737460				2022-12-28	WOS:A1995QX14800009
J	WRIGHT, PS; CROSSDOERSEN, DE; CHMIELEWSKI, PA; BUSH, TL; BITONTI, AJ; MILLER, JA				WRIGHT, PS; CROSSDOERSEN, DE; CHMIELEWSKI, PA; BUSH, TL; BITONTI, AJ; MILLER, JA			MEASUREMENT OF MESSENGER-RNA LEVELS IN TUMOR XENOGRAFTS WITH QUANTITATIVE AUTORADIOGRAPHY AND IN-SITU HYBRIDIZATION	FASEB JOURNAL			English	Article						ESTROGEN RECEPTOR; TAMOXIFEN	HUMAN-BREAST-CANCER; RECEPTOR MESSENGER-RNA; ESTROGEN-RECEPTOR; GROWTH-FACTORS; TAMOXIFEN; BRAIN; CALIBRATION; CELLS; GENE; RAT	In situ methodologies allow qualitative and semi-quantitative analysis of spatial gene expression in whole organisms or tissues. We have applied quantitative autoradiography to in situ hybridizations of sections from human breast tumor xenografts to measure mRNA levels for ornithine decarboxylase, estrogen receptor, transforming growth factor alpha, and glyceraldehyde-3-phosphate dehydrogenase. Comparisons of control and tamoxifen-treated animals show significant decreases in MCF-7 tumor estrogen receptor mRNA levels in the drug-treated animals. Combining quantitative autoradiography with in situ hybridization allows measurement of absolute rather than relative mRNA levels for genes of interest, and to monitor effector-induced changes in these mRNAs in vivo.	FISONS PHARMACEUT,DEPT BIOL,ROCHESTER,NY 14623		WRIGHT, PS (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CULLEN KJ, 1991, CANCER RES, V51, P4978; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HENRY JA, 1988, BRIT J CANCER, V58, P600, DOI 10.1038/bjc.1988.267; LEROY X, 1991, ONCOGENE, V6, P431; MILLER JA, 1988, J NEUROSCI METH, V22, P233, DOI 10.1016/0165-0270(88)90044-1; MILLER JA, 1988, NEUROBIOL AGING, V9, P267, DOI 10.1016/S0197-4580(88)80064-2; MILLER JA, 1991, NEUROSCI LETT, V121, P211, DOI 10.1016/0304-3940(91)90687-O; NOGUCHI S, 1993, CANCER, V72, P131, DOI 10.1002/1097-0142(19930701)72:1<131::AID-CNCR2820720125>3.0.CO;2-Z; NOGUCHI S, 1993, CANCER, V71, P1266, DOI 10.1002/1097-0142(19930215)71:4<1266::AID-CNCR2820710416>3.0.CO;2-K; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UNNERSTALL JR, 1982, J NEUROSCI METH, V6, P59, DOI 10.1016/0165-0270(82)90016-4; WOLF DM, 1994, BREAST CANCER RES TR, V31, P117, DOI 10.1007/BF00689682	18	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					279	283		10.1096/fasebj.9.2.7781931	http://dx.doi.org/10.1096/fasebj.9.2.7781931			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781931				2022-12-28	WOS:A1995QJ24900018
J	LEAHY, DJ				LEAHY, DJ			A STRUCTURAL VIEW OF CD4 AND CD8	FASEB JOURNAL			English	Review						STRUCTURE; T CELL; GLYCOPROTEIN; CORECEPTOR	T-CELL RECEPTOR; MHC CLASS-II; HLA CLASS-I; CRYSTAL-STRUCTURE; BINDING-SITE; LOW-AFFINITY; IMMUNOGLOBULIN SUPERFAMILY; HISTOCOMPATIBILITY ANTIGEN; DIFFERENTIATION ANTIGEN; 3-DIMENSIONAL STRUCTURE	CD4 and CD8 are cell-surface glycoproteins that participate in molecular complexes involved in both T cell development and antigen recognition by T cells. CD4 and CD8 interact with nonpolymorphic regions of class II and class I major histocompatibility complex (MHC) molecules, respectively, and these interactions result in increased intercellular adhesion and enhanced stimulation of T cells. A src-like tyrosine kinase, p56(lck), is associated with the cytoplasmic domain of both CD4 and CD8 and may be involved in transmembrane signaling. Crystal structures of extracellular regions of CD4 and CD8 have been determined and have provided a basis for understanding and probing CD4 and CD8 function. The structures of CD4 and CD8 are reviewed here, along with the implications of these structures for CD4 and CD8 function.			LEAHY, DJ (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, 725 WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051202] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51202-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernard A., 1984, LEUCOCYTE TYPING; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOURSIER JP, 1993, J BIOL CHEM, V268, P2013; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CASABO LG, 1994, J IMMUNOL, V152, P397; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; HARRISON SC, 1992, COLD SPRING HARB SYM, V57, P541, DOI 10.1101/SQB.1992.057.01.059; HENDRICKSON W A, 1992, Current Biology, V2, P57, DOI 10.1016/0960-9822(92)90188-G; HENDRICKSON WA, 1992, COLD SPRING HARB SYM, V57, P549, DOI 10.1101/SQB.1992.057.01.060; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JOHNSON P, 1987, IMMUNOGENETICS, V26, P174, DOI 10.1007/BF00365908; JULIUS M, 1993, IMMUNOL TODAY, V14, P177; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LANGE G, 1994, STRUCTURE, V2, P469, DOI 10.1016/S0969-2126(00)00048-4; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALLACE VA, 1993, CURR OPIN IMMUNOL, V5, P235, DOI 10.1016/0952-7915(93)90010-P; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WEBER S, 1993, INT IMMUNOL, V5, P695, DOI 10.1093/intimm/5.6.695; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637	74	55	68	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					17	25		10.1096/fasebj.9.1.7821755	http://dx.doi.org/10.1096/fasebj.9.1.7821755			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821755				2022-12-28	WOS:A1995QD20200005
J	DROGE, W; SCHULZEOSTHOFF, K; MIHM, S; GALTER, D; SCHENK, H; ECK, HP; ROTH, S; GMUNDER, H				DROGE, W; SCHULZEOSTHOFF, K; MIHM, S; GALTER, D; SCHENK, H; ECK, HP; ROTH, S; GMUNDER, H			FUNCTIONS OF GLUTATHIONE AND GLUTATHIONE DISULFIDE IMMUNOLOGY AND IMMUNOPATHOLOGY	FASEB JOURNAL			English	Review						TRANSCRIPTION FACTORS; REDOX REGULATION; GSSG REGULATION; NF-KAPPA-B	NF-KAPPA-B; PROTEIN-TYROSINE KINASE; HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA EXPRESSION; TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; HUMAN LYMPHOCYTES-T; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; OXIDATION-REDUCTION	Even a moderate increase in the cellular cysteine supply elevates the intracellular glutathione (GSH) and glutathione disulfide (GSSG) levels and potentiates immunological functions of lymphocytes in vitro. At low GSSG levels, T cells cannot optimally activate the immunologically important transcription factor NF kappa B, whereas high GSSG levels inhibit the DNA binding activity of NF kappa B. The effects of GSSG are antagonized by reduced thioredoxin (TRX). As the protein tyrosine kinase activities p56(lck) and p59(fyn) are activated in intact cells by hydrogen peroxide, they are likely targets for GSSG action. These redox-regulated enzymes trigger signal cascades for NF kappa B activation and transduce signals from the T cell antigen receptor, from CD4 and CD8 molecules, and from the IL-2 receptor beta-chain. The effector phase of cytotoxic T cell responses and IL-2-dependent functions are inhibited even by a partial depletion of the intracellular GSH pool. As signal transduction is facilitated by prooxidant conditions, we propose that the well-known immunological consequences of GSH depletion ultimately may be results of the accompanying GSSG deficiency. As HIV-infected patients and SIV-infected rhesus macaques have, on the average, significantly decreased plasma cyst(e)ine and intracellular GSH levels, we also hypothesize that AIDS may be the consequence of a GSSG deficiency as well.			DROGE, W (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT IMMUNOCHEM, D-69120 HEIDELBERG, GERMANY.		Galter, Dagmar/C-4826-2011; Schulze-Osthoff, Klaus/N-9025-2013	Galter, Dagmar/0000-0001-6485-6244; Schulze-Osthoff, Klaus/0000-0003-1443-2720				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1991, MOL ASPECTS CELLULAR, P423; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Donnell-Tormey J. O., 1987, J EXP MED, V165, P500; DROGE W, 1986, IMMUNOBIOLOGY, V172, P151; DROGE W, 1993, AIDS RES HUM RETROV, V9, P807, DOI 10.1089/aid.1993.9.807; DROGE W, 1994, METHOD ENZYMOL, V234, P135; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DROGE W, 1984, J IMMUNOL, V132, P2749; DROGE W, 1989, PROJECT NEWS, V2, P4; DROGE W, 1994, IN PRESS METHODS ENZ; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ECK HP, 1992, INT IMMUNOL, V4, P7, DOI 10.1093/intimm/4.1.7; FANGER MW, 1970, J IMMUNOL, V105, P1043; FIDELUS RK, 1988, CELL IMMUNOL, V113, P175, DOI 10.1016/0008-8749(88)90015-9; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GMUNDER H, 1991, EUR J BIOCHEM, V201, P113, DOI 10.1111/j.1432-1033.1991.tb16263.x; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GMUNDER H, 1991, CELL IMMUNOL, V138, P229, DOI 10.1016/0008-8749(91)90147-4; GMUNDER H, 1990, CELL IMMUNOL, V130, P520, DOI 10.1016/0008-8749(90)90292-Y; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HARGROVE ME, 1993, CELL IMMUNOL, V149, P433, DOI 10.1006/cimm.1993.1168; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOFFELD JT, 1981, LYMPHOKINES, V2, P63; ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217; ISRAEL N, 1992, J IMMUNOL, V149, P3386; IVANOV V, 1993, J IMMUNOL, V151, P4694; KEISARI Y, 1983, IMMUNOBIOLOGY, V165, P78, DOI 10.1016/S0171-2985(83)80048-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LIANG CM, 1989, J BIOL CHEM, V264, P13519; LIANG SM, 1992, CELL IMMUNOL, V144, P131, DOI 10.1016/0008-8749(92)90231-D; LIM JS, 1992, CELL IMMUNOL, V140, P345, DOI 10.1016/0008-8749(92)90201-Y; MACDERMOTT RP, 1986, IMMUNOLOGY, V57, P521; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MESSINA JP, 1989, J IMMUNOL, V143, P1974; METZGER Z, 1980, J IMMUNOL, V124, P983; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; ROTH S, 1987, CELL IMMUNOL, V108, P417, DOI 10.1016/0008-8749(87)90224-3; ROTH S, 1991, EUR J IMMUNOL, V21, P1933, DOI 10.1002/eji.1830210823; ROTH S, 1994, CELL IMMUNOL, V155, P183, DOI 10.1006/cimm.1994.1111; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sies H, 1980, Adv Enzyme Regul, V18, P303, DOI 10.1016/0065-2571(80)90022-9; SMYTH MJ, 1991, J IMMUNOL, V146, P1921; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEVENS JL, 1989, COENZYMES COFACTOR B, V3, P45; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; SUZUKI YJ, 1993, BIOCHEM BIOPH RES CO, V193, P277, DOI 10.1006/bbrc.1993.1620; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; YAMAUCHI A, 1993, J IMMUNOL, V151, P5535; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	79	399	412	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1994	8	14					1131	1138						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958618				2022-12-28	WOS:A1994PT12800007
J	SAIDO, TC; SORIMACHI, H; SUZUKI, K				SAIDO, TC; SORIMACHI, H; SUZUKI, K			CALPAIN - NEW PERSPECTIVES IN MOLECULAR DIVERSITY AND PHYSIOLOGICAL-PATHOLOGICAL INVOLVEMENT	FASEB JOURNAL			English	Review						CALCIUM; CALPASTATIN; ISCHEMIA	ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; LONG-TERM POTENTIATION; SKELETAL-MUSCLE; MU-CALPAIN; KINASE-C; PROTEINASE CALPAIN; GERBIL HIPPOCAMPUS; HUMAN-PLATELETS; PROTEOLYSIS	Calpain, calcium-activated neutral protease, stands as a unique receptor for calcium signals in biological systems; its activation leads to irreversible proteolytic processing of substrate proteins, modifying cellular situations in a manner distinct from that of reversible processes including the phosphorylation-dephosphorylation reactions. Because the enzyme participates not only in normal intracellular signal transduction cascades but also in various pathological states including ischemia, calpain research has attracted tremendous interest in wide areas of life sciences in both basic and clinical terms. This review will address the new perspectives evoked by recent discoveries since 1990. Molecular biological studies have established that calpain in fact constitutes a large family of distinct isozymes differing in structure and distribution, whereas an increasing; number of reports describe physiological-pathological involvement of calpain. Another major accomplishment is the technical breakthrough allowing spatial resolution of calpain action presenting a clearer in vivo picture of how calpain acts in cells and tissues.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Medical Science			Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Sorimachi, Hiroyuki/C-6448-2009	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727				ADACHI E, 1990, ARCH HISTOL CYTOL, V53, P413, DOI 10.1679/aohc.53.413; ADACHI Y, 1992, J BIOL CHEM, V267, P19373; BHATTACHARYYA J, 1991, CIRC SHOCK, V35, P117; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; CONG JY, 1993, J BIOL CHEM, V268, P25740; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; COVAULT J, 1991, MOL BRAIN RES, V11, P11, DOI 10.1016/0169-328X(91)90015-P; Crawford C., 1990, INTRACELLULAR CALCIU, P75; DAVID LL, 1993, J BIOL CHEM, V268, P1937; DELCERRO S, 1990, BRAIN RES, V530, P91; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Goll DE, 1990, INTRACELLULAR CALCIU, P3; HATA A, 1992, FEBS LETT, V304, P241, DOI 10.1016/0014-5793(92)80628-T; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IIZUKA K, 1991, BIOCHEM MED METAB B, V46, P427, DOI 10.1016/0885-4505(91)90091-X; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P433, DOI 10.1016/0006-291X(89)92451-0; JOHNSON P, 1993, COMP BIOCHEM PHYS B, V104, P63, DOI 10.1016/0305-0491(93)90338-6; KAMBAYASHI J, 1989, METHOD ENZYMOL, V169, P442; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KWAK KB, 1993, FEBS LETT, V323, P151, DOI 10.1016/0014-5793(93)81468-F; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEE WJ, 1992, J BIOL CHEM, V267, P8437; Maki M., 1990, INTRACELLULAR CALCIU, P37; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; NAKAMURA M, 1992, THROMB RES, V66, P757, DOI 10.1016/0049-3848(92)90051-B; NAKAMURA M, 1992, EXP CELL RES, V200, P513, DOI 10.1016/0014-4827(92)90203-K; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OKITA JR, 1989, BLOOD, V74, P715; OLAYA P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P217, DOI 10.1016/0925-4439(91)90008-W; REMOLDODONNELL E, 1992, BLOOD, V79, P1754; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SASAKI M, 1991, BIOMED BIOCHIM ACTA, V50, P499; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIDDIQUI AA, 1993, BIOCHIM BIOPHYS ACTA, V1181, P37, DOI 10.1016/0925-4439(93)90087-H; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; SUZUKI T, 1992, BIOCHEM BIOPH RES CO, V189, P1515, DOI 10.1016/0006-291X(92)90247-I; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YAMAMOTO S, 1992, ARTHRITIS RHEUM-US, V35, P1309, DOI 10.1002/art.1780351111; YAMAURA I, 1993, J NEUROSURG, V79, P537, DOI 10.3171/jns.1993.79.4.0537; YOKOTA M, 1992, BRAIN RES, V587, P123, DOI 10.1016/0006-8993(92)91436-I	62	613	632	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					814	822		10.1096/fasebj.8.11.8070630	http://dx.doi.org/10.1096/fasebj.8.11.8070630			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070630				2022-12-28	WOS:A1994PC88500003
J	RUF, W; EDGINGTON, TS				RUF, W; EDGINGTON, TS			STRUCTURAL BIOLOGY OF TISSUE, FACTOR, THE INITIATOR OF THROMBOGENESIS IN-VIVO	FASEB JOURNAL			English	Article						THROMBOSIS; COAGULATION PATHWAYS; DISSEMINATE INTRAVASCULAR; COAGULATION	COAGULATION FACTOR-VII; FACTOR-DEPENDENT AUTOACTIVATION; INFECTED ENDOTHELIAL-CELLS; BLOOD-COAGULATION; FACTOR-X; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; EXTRINSIC PATHWAY; FACTOR EXPRESSION; COFACTOR FUNCTION	Thromboembolic disorders are commonly associated with cardiovascular, infectious, and neoplastic disease. A major link in the pathophysiology of thrombosis is the excessive triggering of the coagulation pathways by the initiating cofactor molecule termed tissue factor, an integral membrane glycoprotein. The tissue factor extracellular ligand binding domain is predicted to fold in an architecture similar to the cytokine receptor homology module. Functional sites in tissue factor have been defined by a combination of antibody, chemical crosslinking, and mutational analyses providing a model for cofactor function that involves discrete interactions with both enzyme and substrate. The understanding of the structural basis of tissue factor function promises to facilitate rational design of inhibitor molecules for defined functional sites, eventually leading to effective in vivo therapeutics.	SCRIPPS RES INST, DEPT IMMUNOL, IMM17, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BAUER KA, 1990, BLOOD, V76, P731; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1993, AM J PATHOL, V142, P1458; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; EDGINGTON TS, 1992, NOUV REV FR HEMATOL, V34, pS15; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; FIORE MM, 1992, BLOOD, V80, P3127; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LE DT, 1992, J BIOL CHEM, V267, P15447; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; OBRIEN DP, 1991, BLOOD, V78, P132; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PERNOD G, 1992, THROMB HAEMOSTASIS, V68, P111; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; RAO LVM, 1993, BLOOD, V81, P2600; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1992, CANCER METAST REV, V11, P249; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; REHEMTULLA A, 1992, BIOCHEM J, V282, P737, DOI 10.1042/bj2820737; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROY S, 1991, J BIOL CHEM, V266, P4665; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1992, J CRYST GROWTH, V122, P253, DOI 10.1016/0022-0248(92)90254-G; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; RUF W, 1994, IN PRESS BIOCHEMISTR; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SETO Y, 1992, J IMMUNOL, V148, P259; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1991, BLOOD, V78, P364; TENCATE H, 1993, J CLIN INVEST, V92, P1207, DOI 10.1172/JCI116691; TEYSSEIRE N, 1992, INFECT IMMUN, V60, P4388, DOI 10.1128/IAI.60.10.4388-4393.1992; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	60	217	233	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					385	390		10.1096/fasebj.8.6.8168689	http://dx.doi.org/10.1096/fasebj.8.6.8168689			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168689				2022-12-28	WOS:A1994NH25000004
J	KRAMER, JM				KRAMER, JM			STRUCTURES AND FUNCTIONS OF COLLAGENS IN CAENORHABDITIS-ELEGANS	FASEB JOURNAL			English	Review						EXTRACELLULAR MATRIX; BASEMENT MEMBRANE; MUTATIONS; GENETICS; MORPHOLOGY	C-ELEGANS; PHENOTYPIC CHARACTERIZATION; EMBRYONIC-DEVELOPMENT; CUTICLE COLLAGEN; ROLLER MUTANTS; BODY SHAPE; GENES; MUTATIONS; EXPRESSION; EMBRYOGENESIS	Two types of collagens have been identified in Caenorhabditis elegans corresponding to two types of extracellular matrix, the cuticle and basement membranes. Cuticle collagens are encoded by a developmentally regulated family of similar to 100 genes. Mutations in cuticle collagens can produce animals that are longer or shorter than normal and/or that are helically twisted. Mutations in different collagens can cause different morphological abnormalities, as can different mutations in the same collagen. Genetic interactions between collagen genes have been described and may identify collagens that interact to form the cuticle. Two basement membrane (type IV) collagen genes have been identified in C. elegans. They encode proteins similar in structure to vertebrate type IV collagen. One of the genes produces two alternatively spliced forms, one predominantly expressed in embryos and the other in larvae and adults, suggesting that embryonic basement membranes may have unique properties. Most mutations in the type IV genes cause embryonic lethality, indicating that normal basement membranes are required for embryogenesis. Temperature-sensitive mutations have been used to show that type IV collagen function is also required for larval development and adult fertility.			KRAMER, JM (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,WARD 7-334,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.							BIRD DM, 1992, GENE, V120, P261, DOI 10.1016/0378-1119(92)90102-U; BRENNER S, 1974, GENETICS, V77, P71; CASSADA R, 1981, DEV BIOL, V84, P193, DOI 10.1016/0012-1606(81)90383-3; COX GN, 1980, GENETICS, V95, P317; COX GN, 1992, J PARASITOL, V78, P1, DOI 10.2307/3283678; COX GN, 1984, MOL CELL BIOL, V4, P2389, DOI 10.1128/MCB.4.11.2389; COX GN, 1985, MOL CELL BIOL, V5, P363, DOI 10.1128/MCB.5.2.363; COX GN, 1981, DEV BIOL, V84, P277, DOI 10.1016/0012-1606(81)90395-X; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; COX GN, 1985, GENETICS, V109, P513; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; COX GN, 1989, GENE, V76, P331, DOI 10.1016/0378-1119(89)90173-X; FUJIMOTO D, 1981, BIOCHEM BIOPH RES CO, V99, P637, DOI 10.1016/0006-291X(81)91792-7; GUO X, 1989, J BIOL CHEM, V264, P17575; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HIGGINS BJ, 1977, MOL GEN GENET, V150, P63, DOI 10.1007/BF02425326; ISNENGHI E, 1983, DEV BIOL, V98, P465, DOI 10.1016/0012-1606(83)90376-7; JOHNSTONE IL, 1992, EMBO J, V11, P3857, DOI 10.1002/j.1460-2075.1992.tb05478.x; KRAMER JM, 1993, GENETICS, V135, P1035; KRAMER JM, 1985, J BIOL CHEM, V260, P1945; KRAMER JM, 1988, CELL, V55, P555, DOI 10.1016/0092-8674(88)90214-0; KRAMER JM, 1982, CELL, V30, P599, DOI 10.1016/0092-8674(82)90256-2; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KUSCH M, 1986, GENETICS, V113, P621; LEVY AD, 1993, MOL BIOL CELL, V4, P803, DOI 10.1091/mbc.4.8.803; LEVY AD, 1993, IN PRESS GENE; LIU ZC, 1991, NATURE, V350, P162, DOI 10.1038/350162a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENEELY PM, 1981, GENETICS, V97, P65; MENEELY PM, 1979, GENETICS, V92, P99; MIWA J, 1980, DEV BIOL, V76, P160, DOI 10.1016/0012-1606(80)90369-3; OUAZANA R, 1981, BIOCHIM BIOPHYS ACTA, V669, P236, DOI 10.1016/0005-2795(81)90246-4; PARK YS, 1990, J MOL BIOL, V211, P395, DOI 10.1016/0022-2836(90)90360-X; PETTITT J, 1991, J BIOL CHEM, V266, P16149; POLITZ JC, 1984, CELL, V37, P853, DOI 10.1016/0092-8674(84)90420-3; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; VONMENDE N, 1988, CELL, V55, P567, DOI 10.1016/0092-8674(88)90215-2; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5	40	86	107	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					329	336		10.1096/fasebj.8.3.8143939	http://dx.doi.org/10.1096/fasebj.8.3.8143939			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143939				2022-12-28	WOS:A1994NB62300007
J	ELBLING, L; BERGER, W; REHBERGER, A; WALDHOR, T; MICKSCHE, M				ELBLING, L; BERGER, W; REHBERGER, A; WALDHOR, T; MICKSCHE, M			P-GLYCOPROTEIN REGULATES CHEMOSENSITIVITY IN EARLY DEVELOPMENTAL STAGES OF THE MOUSE	FASEB JOURNAL			English	Note						OOCYTES; EARLY CLEAVAGE EMBRYOS; MDR-GENE PRODUCTS; DRUG RESISTANCE; IN-VITRO IN-VIVO	RESISTANT CELL-LINES; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; KB-CELL; EXPRESSION; METALLOTHIONEIN; POLARIZATION; BLASTOMERES; COMPACTION; PATTERNS	The multidrug resistance (MDR) P-glycoprotein (P-gp) is an active transporter associated with chemoresistance of tumor cells. A fundamental aspect not yet entirely clarified is the physiological role of MDR-P-gp in normal mammalian tissues. In this paper we report that multidrug (chemo)resistance is already present in mouse oocytes and early cleavage embryos. Expression of MDR-specific P-gp is detectable by antibody (C219) staining from the primary oocyte onward to the eight-cell embryo. MDR-mRNA is demonstrated in mature oocytes using an Mdr1-specific cDNA probe. Functional activity of P-gp is shown by the efficacy of MDR reversers (verapamil or quinidine) in enhancement of: 1) drug accumulation (daunomycin) in all stages investigated, 2) drug cytotoxicity (daunomycin or mitomycin C-induced developmental impairment) in two-cell embryos cultured for 24 h, and 3) drug cytokinesis-blocking activity (cytochalasin D; our recent findings demonstrate cytochalasins to be substrates for P-gp and to indicate the presence of MDR by their microfilament-disrupting action on cycling cells) in four- and eight-cell embryos cultured for 24 h. Furthermore, functional involvement of P-gp in vivo is demonstrated. Concurrent administration of verapamil increases doxorubicin-induced developmental impairment in the zygote stage during the first cleavage cycle in pregnant females. Results provide evidence that MDR-P-gp has an efficient protective function in early reproduction.			ELBLING, L (corresponding author), UNIV VIENNA,INST TUMOR BIOL CANC RES,A-1090 VIENNA,AUSTRIA.			Berger, Walter/0000-0003-0014-1658				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; ANDREWS GK, 1991, DEV BIOL, V145, P13, DOI 10.1016/0012-1606(91)90209-L; AUSTIN CR, 1973, NATURE, V244, P333, DOI 10.1038/244333a0; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BERGER W, 1992, ANN HEMATOL S, V65, P27; CARDONCARDO C, 1990, J BIOL CHEM, V38, P1277; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHAUDHARY PM, 1992, BLOOD, V80, P2735; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CURCI A, 1991, DEV BIOL, V144, P362, DOI 10.1016/0012-1606(91)90428-6; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FORD JM, 1990, PHARMACOL REV, V42, P155; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOTTESMAN MM, 1993, CANCER RES, V53, P747; Holden HE, 1982, J APPL TOXICOL, V2, P196, DOI 10.1002/jat.2550020405; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON MH, 1986, J EMBRYOL EXP MORPH, V93, P239; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KESSEL D, 1991, CANCER RES, V51, P4665; KIM S, 1972, CANCER RES, V34, P323; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PIKO L, 1982, DEV BIOL, V89, P362, DOI 10.1016/0012-1606(82)90325-6; PRATT HPM, 1981, CELL, V26, P279, DOI 10.1016/0092-8674(81)90310-X; SCHULTZ RM, 1979, DEV BIOL, V73, P120, DOI 10.1016/0012-1606(79)90142-8; SMITH CD, 1993, CANCER RES, V53, P1343; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TSURUO T, 1981, CANCER RES, V41, P1967; VANKALKEN CK, 1992, AM J PATHOL, V141, P1063; VOLM M, 1988, ANTICANCER RES, V8, P1169; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; YOSHIMURA A, 1989, BIOCHIM BIOPHYS ACTA, V992, P307, DOI 10.1016/0304-4165(89)90089-5; ZIOMEK CA, 1980, CELL, V21, P935, DOI 10.1016/0092-8674(80)90457-2; 1991, STATISTICAL SOFTWARE; 1984, TECHNICAL B PROMEGA, V1	44	28	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1499	1506		10.1096/fasebj.7.15.7903262	http://dx.doi.org/10.1096/fasebj.7.15.7903262			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	7903262				2022-12-28	WOS:A1993ML74000013
J	VENSTROM, KA; REICHARDT, LF				VENSTROM, KA; REICHARDT, LF			EXTRACELLULAR-MATRIX .2. ROLE OF EXTRACELLULAR-MATRIX MOLECULES AND THEIR RECEPTORS IN THE NERVOUS-SYSTEM	FASEB JOURNAL			English	Review						EXTRACELLULAR MATRIX; NERVOUS SYSTEM; INTEGRINS; LAMININ; PROTEOGLYCANS	HEPARAN-SULFATE PROTEOGLYCAN; NEURITE OUTGROWTH INVITRO; NEURAL CELL-ADHESION; GROWTH-FACTOR; BINDING DOMAIN; BASAL LAMINAE; S-LAMININ; FIBRONECTIN; EXPRESSION; TENASCIN	Extracellular matrix molecules help regulate many aspects of neural development, including survival, migration, axon growth, and synapse formation by neurons. These same molecules have been shown to modulate regeneration of neurons after injuries. They also regulate the development and differentiation of other neural cells, such as astroglia and Schwann cells. Significant progress has been made recently in characterizing both ECM constituents and their receptors in the nervous system. Extracellular matrix molecules promote cell adhesion, activate intracellular signaling pathways, and modulate the activities of several growth factors and proteins. Our current understanding of the extracellular matrix, its receptors, and its functions in the nervous system are discussed.	UCSF,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	VENSTROM, KA (corresponding author), UCSF,DEPT PHYSIOL,DIV NEUROSCI,SAN FRANCISCO,CA 94143, USA.							BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HAUGEN PK, 1992, J NEUROSCI, V12, P2597; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; HUNTER DD, 1991, J NEUROSCI, V11, P3960; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KLEIN G, 1990, DEVELOPMENT, V110, P823; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LEFCORT F, 1992, DEVELOPMENT, V116, P767; LILLIEN LE, 1990, J CELL BIOL, V111, P635, DOI 10.1083/jcb.111.2.635; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MATSUMOTO K, 1992, IMMUNOGENETICS, V36, P400; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; OOHIRA A, 1991, J NEUROSCI, V11, P822; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; RAUCH U, 1992, J BIOL CHEM, V267, P19536; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHEPPARD AM, 1991, J NEUROSCI, V11, P3928; SHIGA T, 1991, J COMP NEUROL, V310, P234, DOI 10.1002/cne.903100208; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TUCKER RP, 1993, DEVELOPMENT, V117, P347; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOS HL, 1992, J BIOL CHEM, V267, P12192; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEHRLE B, 1990, DEVELOPMENT, V110, P401; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	71	235	242	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					996	1003		10.1096/fasebj.7.11.8370483	http://dx.doi.org/10.1096/fasebj.7.11.8370483			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370483				2022-12-28	WOS:A1993LT83900003
J	PATEL, MS; HARRIS, RA				PATEL, MS; HARRIS, RA			MAMMALIAN ALPHA-KETO ACID DEHYDROGENASE COMPLEXES - GENE-REGULATION AND GENETIC-DEFECTS	FASEB JOURNAL			English	Article						PYRUVATE DEHYDROGENASE COMPLEX; BRANCHED-CHAIN ALPHA-KETO; ACID DEHYDROGENASE COMPLEX; GENE ORGANIZATION; GENETIC DEFECTS	SYRUP-URINE-DISEASE; E1-ALPHA SUBUNIT GENE; PYRUVATE-DEHYDROGENASE; STRUCTURAL ORGANIZATION; MULTIENZYME COMPLEX; LACTIC-ACIDOSIS; Y393N MUTATION; MESSENGER-RNA; 3T3-L1 CELLS; HIGH-SUCROSE	Recent application of the tools of molecular biology has provided insight with respect to the structure, regulation, and defects of the genes encoding the PDC and the BCKADC, cDNAs for the alpha-KGDC have only recently been cloned. Evidence for long-term regulation of the expression of the subunits of the PDC and the BCKADC has been obtained. Detailed analyses of the promoter-regulatory regions of the genes encoding the individual subunits of these complexes have provided leads as to molecular mechanisms involved. Evidence for coordinated regulation of expression of the subunits of the complexes has been obtained under some conditions but not others. Except for the PDC E1 alpha(X) promoter, the other promoters of the genes encoding PDC and BCKADC components are TATA-less with characteristics of housekeeping genes. Most cases of PDC deficiency, which produces lactic acidosis, are caused by defects in the coding region of the E1 alpha subunit. In contrast, gene defects that cause maple syrup urine disease are more heterogeneous, involving errors in any one of the subunits of the BCKADC, alpha-KGDC deficiency has been reported but specific mutations have not been identified. Future work is expected to include detailed studies of the genes encoding the protein kinases and phosphatases that specifically regulate the PDC and the BCKADC by covalent modification.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	PATEL, MS (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,140 FARBER HALL,3435 MAIN ST,BUFFALO,NY 14214, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259, R01DK020478, R01DK042885] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20478, DK42885, DK19259] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWATA H, 1994, J INHERIT METAB DIS, V17, P189, DOI 10.1007/BF00711616; BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; BONNEFONT JP, 1992, J PEDIATR-US, V121, P255, DOI 10.1016/S0022-3476(05)81199-0; BROWN RM, 1993, J MED GENET, V30, P177, DOI 10.1136/jmg.30.3.177; CHANG M, 1993, BIOCHEMISTRY-US, V32, P4263, DOI 10.1021/bi00067a014; CHICCO AG, 1994, J BIOL CHEM, V269, P19427; CHINSKY JM, 1994, FASEB J, V8, P114, DOI 10.1096/fasebj.8.1.7507870; CHUANG DT, 1991, MOL BIOL MED, V8, P49; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; CHUANG DT, 1995, J NUTR, V125, P17665; CHUANG JL, 1994, AM J HUM GENET, V55, P297; CHUANG JL, 1993, J BIOL CHEM, V268, P8309; CHUN K, 1993, HUM MOL GENET, V2, P449, DOI 10.1093/hmg/2.4.449; Dahl H.-H. M., 1992, Human Mutation, V1, P97, DOI 10.1002/humu.1380010203; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DASILVA LA, 1992, COMP BIOCHEM PHYS A, V103, P407, DOI 10.1016/0300-9629(92)90602-M; DASILVA LA, 1993, BIOCHIM BIOPHYS ACTA, V1169, P126, DOI 10.1016/0005-2760(93)90197-H; DEMEIRLEIR L, 1993, PEDIATR NEUROL, V9, P216, DOI 10.1016/0887-8994(93)90088-T; ELLERINE NP, 1993, BIOCHEM MED METAB B, V49, P363, DOI 10.1006/bmmb.1993.1037; ESPINAL J, 1985, BIOCHEM J, V225, P509, DOI 10.1042/bj2250509; FEIGENBAUM AS, 1993, GENOMICS, V17, P376, DOI 10.1006/geno.1993.1335; FEKETE G, 1989, CYTOGENET CELL GENET, V50, P236, DOI 10.1159/000132768; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CR, 1991, AM J HUM GENET, V49, P429; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; FUJII T, 1994, ANN NEUROL, V36, P83, DOI 10.1002/ana.410360116; HANSEN LL, 1993, HUM MOL GENET, V2, P805, DOI 10.1093/hmg/2.6.805; HANSEN LL, 1994, HUM MOL GENET, V3, P1021, DOI 10.1093/hmg/3.6.1021; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HAYASHIDA Y, 1994, BBA-MOL BASIS DIS, V1225, P317, DOI 10.1016/0925-4439(94)90013-2; HEMALATHA SG, 1995, HUM MOL GENET, V4, P315, DOI 10.1093/hmg/4.2.315; HERRING WJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P236, DOI 10.1016/0925-4439(92)90043-M; HU CWC, 1988, J BIOL CHEM, V263, P9007; HU CWC, 1983, J BIOL CHEM, V258, P2315; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; IANNELLO RC, 1992, BIOL REPROD, V47, P48, DOI 10.1095/biolreprod47.1.48; ITO M, 1992, CLIN CHIM ACTA, V209, P1, DOI 10.1016/0009-8981(92)90327-M; JOHANNING GL, 1992, P NATL ACAD SCI USA, V89, P10964, DOI 10.1073/pnas.89.22.10964; KEDISHVILI NY, 1994, ARCH BIOCHEM BIOPHYS, V315, P317, DOI 10.1006/abbi.1994.1506; KOIKE K, 1990, P NATL ACAD SCI USA, V87, P5594, DOI 10.1073/pnas.87.15.5594; KOIKE K, 1992, P NATL ACAD SCI USA, V89, P1963, DOI 10.1073/pnas.89.5.1963; KOYATA H, 1993, BIOCHEM J, V295, P635, DOI 10.1042/bj2950635; LAU KS, 1992, J BIOL CHEM, V267, P24090; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LIU TC, 1993, P NATL ACAD SCI USA, V90, P5186, DOI 10.1073/pnas.90.11.5186; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; MARAGOS C, 1989, J BIOL CHEM, V264, P12294; MARSAC C, 1993, J PEDIATR-US, V123, P915, DOI 10.1016/S0022-3476(05)80387-7; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MATTHEWS PM, 1994, BRAIN, V117, P435, DOI 10.1093/brain/117.3.435; MATTHEWS PM, 1993, NEUROLOGY, V43, P2025, DOI 10.1212/WNL.43.10.2025; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; MITSUBUCHI H, 1991, J CLIN INVEST, V87, P1207, DOI 10.1172/JCI115120; NAITO E, 1994, PEDIATR RES, V36, P340, DOI 10.1203/00006450-199409000-00013; NOBUKUNI Y, 1992, J INHERIT METAB DIS, V15, P827, DOI 10.1007/BF01800029; NOBUKUNI Y, 1993, BIOCHIM BIOPHYS ACTA, V1225, P64, DOI 10.1016/0925-4439(93)90123-I; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Patel MS, 1992, INT PEDIATR, V7, P16; PEINEMANN F, 1994, J INHERIT METAB DIS, V17, P3, DOI 10.1007/BF00735389; POPOV KM, 1995, ARCH BIOCHEM BIOPHYS, V316, P148, DOI 10.1006/abbi.1995.1022; REED LJ, 1990, J BIOL CHEM, V265, P8971; Robinson B.H., 1995, METABOLIC MOL BASES, P1479; ROBINSON BH, 1990, J CLIN INVEST, V85, P1821, DOI 10.1172/JCI114641; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P1; SUGDEN MC, 1994, FASEB J, V8, P54, DOI 10.1096/fasebj.8.1.8299890; TAKAKUBO F, 1993, HUM MOL GENET, V2, P473, DOI 10.1093/hmg/2.4.473; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHANG B, 1990, J BIOL CHEM, V265, P2425; ZHANG B, 1991, MOL BIOL MED, V8, P39; ZHANG B, 1989, J CLIN INVEST, V83, P1425, DOI 10.1172/JCI114033; ZHAO Y, 1994, ARCH BIOCHEM BIOPHYS, V308, P446, DOI 10.1006/abbi.1994.1063; ZHAO Y, 1993, BIOCHEM J, V290, P395, DOI 10.1042/bj2900395; ZNEIMER SM, 1991, GENOMICS, V10, P740, DOI 10.1016/0888-7543(91)90458-Q	75	69	74	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1164	1172		10.1096/fasebj.9.12.7672509	http://dx.doi.org/10.1096/fasebj.9.12.7672509			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672509				2022-12-28	WOS:A1995RU81600006
J	VALERA, A; PUJOL, A; GREGORI, X; RIU, E; VISA, J; BOSCHI, F				VALERA, A; PUJOL, A; GREGORI, X; RIU, E; VISA, J; BOSCHI, F			EVIDENCE FROM TRANSGENIC MICE THAT MYC REGULATES HEPATIC GLYCOLYSIS	FASEB JOURNAL			English	Article						C-MYC; P-ENOLPYRUVATE CARBOXYKINASE GENE PROMOTER; GLYCOLYSIS; TRANSGENIC MICE; LIVER	GROWTH-HORMONE GENE; GLUCOSE-TRANSPORTER PROTEIN; LOOP-HELIX PROTEIN; C-MYC; MAMMALIAN GLUCOKINASE; GLYCOGEN-SYNTHASE; RAT HEPATOCYTES; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION	The product of the c-myc proto-oncogene (c-Myc) is involved in the control of cell proliferation, differentiation, and apoptosis. It acts as a transcription factor that recognizes the CACGTG motif. This sequence has also been found in the glucose-responsive elements of genes involved in the control of liver glycolysis and lipogenesis. To determine whether c-Myc can regulate hepatic carbohydrate metabolism in vivo, transgenic mice that overexpress c-myc under control of the P-enolpyruvate carboxykinase (PEPCK) gene promoter have been generated. These mice showed a threefold increase in c-Myc protein in liver nuclei. Hepatocytes from transgenic mice were normal and did not acquire the fetal phenotype. However, transgenic mice showed higher levels (threefold) of L-type pyruvate kinase mRNA and enzyme activity than control mice. The increase in pyruvate kinase activity led to a three- to fivefold increase in liver lactate content and a fivefold induction of lactate production by hepatocytes in primary culture. The expression of the 6-phosphofructo-2-kinase gene was also increased in the liver of these transgenic mice. The induction of hepatic glycolysis was related with an increase in the expression (about fourfold) and activity (about threefold) of liver glucokinase, whereas no change was noted in hexokinase-I. This change in glucokinase activity led to an increase in both glucose 6-phosphate and glycogen contents in the liver of transgenic mice. The expression of the liver-specific glucose transporter GLUT2 was also increased in transgenic mice, whereas no change was noted in the mRNA concentration of GLUT1. Furthermore, the changes of liver glucose metabolism led to a marked reduction of blood glucose (25%) and insulin (40%) concentrations in starvation, whereas the fall in bath was only 10% in fed mice. Thus, liver glucose metabolism could determine the blood glucose and insulin set points in the transgenic mice. All these results indicated that the increase in c-Myc protein was able to induce liver glucose utilization and accumulation, and suggested that c-Myc transcription factor is involved in the control in vivo of liver carbohydrate metabolism.	UNIV AUTONOMA BARCELONA, SCH VET MED, DEPT BIOCHEM & MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona				BOSCH, FATIMA/0000-0002-7705-5515; Pujol, Anna/0000-0002-3484-598X; Riu, Efren/0000-0002-2574-3578; Gregori, Xavier/0000-0002-5889-5252				ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANCROFT JD, 1982, THEORY PRACTICE HIST, P122; BANSKOTA NK, 1989, DIABETES, V38, P123, DOI 10.2337/diabetes.38.1.123; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELL GI, 1993, J BIOL CHEM, V268, P19161; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROBHOLZ R, 1993, CANCER RES, V53, P4204; HOGAN B, 1986, MANIPULATING MOUSE E; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MESSINA JL, 1991, J BIOL CHEM, V266, P17995; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RONGNOPARUT P, 1991, J BIOL CHEM, V265, P19263; SANDGREN EP, 1989, ONCOGENE, V4, P715; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	59	73	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1067	1078		10.1096/fasebj.9.11.7649406	http://dx.doi.org/10.1096/fasebj.9.11.7649406			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649406				2022-12-28	WOS:A1995RP99600011
J	RESNICK, N; GIMBRONE, MA				RESNICK, N; GIMBRONE, MA			HEMODYNAMIC FORCES ARE COMPLEX REGULATORS OF ENDOTHELIAL GENE-EXPRESSION	FASEB JOURNAL			English	Review						ENDOTHELIUM; SHEAR STRESS; GENE EXPRESSION	FLUID SHEAR-STRESS; MESSENGER-RNA LEVELS; FACTOR-B CHAIN; GROWTH-FACTOR; PROSTACYCLIN PRODUCTION; VASCULAR ENDOTHELIUM; STEADY FLOW; BLOOD-FLOW; WALL SHEAR; C-FOS	Vascular endothelial cells, by virtue of their unique anatomical position, are constantly exposed to the fluid mechanical forces generated by flowing blood, In vitro studies with model flow systems have demonstrated that wall shear stresses can modulate various aspects of endothelial structure and function, Certain of these effects appear to result from the regulation of expression of endothelial genes at the transcriptional level, Recent molecular biological studies have defined a ''shear stress response element'' (SSRE) in the promoter of the human platelet derived growth factor (PDGF)-B chain gene that interacts with DNA binding proteins in the nuclei of shear-stressed endothelial cells to up-regulate transcriptional activity. Insertion of this element into reporter genes also renders them shear-inducible, Further characterization of this and other positive (and negative) shear-responsive genetic: regulatory elements, as well as their transactivating factors, should enhance our understanding of vascular endothelium as an integrator of humoral and biomechanical stimuli in health and disease.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051150] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL51150, P01-HL30628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO J, 1993, BIOCHEM BIOPH RES CO, V190, P716, DOI 10.1006/bbrc.1993.1108; ANDO J, 1994, AM J PHYSIOL, pC679; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; BUSSOLARI SR, 1982, REV SCI INSTRUM, V53, P1851, DOI 10.1063/1.1136909; CARO CG, 1971, PROC R SOC SER B-BIO, V177, P109, DOI 10.1098/rspb.1971.0019; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COOPER GM, 1990, ONCOGENES, P230; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; DAVIES PF, 1983, J CLIN INVEST, V73, P1121; DAVIES PF, 1995, IN PRESS PHYSL REV; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; DIAMOND SL, 1990, J CELL PHYSIOL, V143, P364, DOI 10.1002/jcp.1041430222; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; ESKIN SG, 1984, MICROVASC RES, V28, P87, DOI 10.1016/0026-2862(84)90031-1; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIMBRONE MA, 1995, IN PRESS MOL CARDIOV; GRABOWSKI EF, 1985, J LAB CLIN MED, V105, P36; HALNON NJ, 1994, CIRCULATION, V90, P468; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; KHACHIGIAN LM, 1995, IN PRESS J CLIN INVE; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; MALEK AM, 1994, CIRC RES, V74, P852, DOI 10.1161/01.RES.74.5.852; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MALEK AM, 1994, J HYPERTENS, V12, P989; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MILLS I, 1993, HEMODYNAMIC FORCES V, P66; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NEREM RM, 1981, J BIOMECH ENG-T ASME, V103, P172, DOI 10.1115/1.3138275; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; POHL U, 1986, HYPERTENSION, V7, P37; RANJAN V, 1993, BIOCHEM BIOPH RES CO, V196, P79, DOI 10.1006/bbrc.1993.2218; REMUZZI A, 1984, BIORHEOLOGY, V21, P617; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RESNICK N, 1994, IN PRESS 10TH P INT; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SDOUGOS HP, 1984, J FLUID MECH, V138, P379, DOI 10.1017/S0022112084000161; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; SUMPIO BE, 1994, J CELL PHYSIOL, V158, P133, DOI 10.1002/jcp.1041580117; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P2, DOI 10.1161/01.ATV.15.1.2; WHITE GE, 1983, J CELL BIOL, V97, P416, DOI 10.1083/jcb.97.2.416; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X	55	442	470	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					874	882		10.1096/fasebj.9.10.7615157	http://dx.doi.org/10.1096/fasebj.9.10.7615157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615157				2022-12-28	WOS:A1995RK89900008
J	STRADER, CD; FONG, TM; GRAZIANO, MP; TOTA, MR				STRADER, CD; FONG, TM; GRAZIANO, MP; TOTA, MR			THE FAMILY OF G-PROTEIN-COUPLED RECEPTORS	FASEB JOURNAL			English	Review						AMINO ACID SEQUENCES; PEPTIDE BINDING SITE; SIGNAL TRANSDUCTION; MUTAGENESIS; HELICES	BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; NEUROKININ-1 RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SUBTYPE SPECIFICITY; GLUTAMATE RECEPTORS; ANTAGONIST BINDING; EXPRESSION CLONING; MOLECULAR-CLONING	The family of G-protein-coupled receptors can be defined by their similar structural and functional characteristics. Although their primary sequences are quite diverse, these proteins share several common structural features that reflect their common mechanism of action. Mutagenesis and biophysical analysis of several of these receptors indicate that small molecule agonists and antagonists bind to a hydrophobic pocket buried in the transmembrane core of the receptor. In contrast, peptide ligands bind to both the extracellular and transmembrane domains. The mechanisms by which these peptide and small molecule agonists cause receptor activation are being explored by various approaches, but are not yet well defined. A deeper understanding of structural basis for the functional activity of this large family of receptors will have important implications for drug design in a variety of therapeutic areas.			STRADER, CD (corresponding author), MERCK RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,80M 213,BOX 2000,RAHWAY,NJ 07065, USA.							AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOYLE WR, 1994, NATURE, V368, P251; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DRYSDALE MJ, 1992, J MED CHEM, V35, P2573, DOI 10.1021/jm00092a007; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1994, J BIOL CHEM, V269, P14957; FONG TM, 1993, NATURE, V362, P350; FONG TM, 1994, MED RES REV, V14, P387, DOI 10.1002/med.2610140402; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FRIEDINGER RM, 1989, MED RES REV, V9, P271; GANTZ I, 1992, J BIOL CHEM, V267, P20840; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1994, J BIOL CHEM, V269, P23959; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JI H, 1994, J BIOL CHEM, V269, P16533; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12883; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIU LW, 1991, J BIOL CHEM, V266, P16977; MAIN BG, 1985, PROG MED CHEM, V22, P122; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEVE KA, 1991, MOL PHARMACOL, V39, P733; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REGOLI D, 1984, PHARMACOLOGY, V28, P301, DOI 10.1159/000137979; REMMERS AE, 1993, BIOCHEMISTRY-US, V32, P2409, DOI 10.1021/bi00060a036; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; THOMAS DD, 1982, J MOL BIOL, V154, P145, DOI 10.1016/0022-2836(82)90422-3; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; TOTA MR, 1990, J BIOL CHEM, V28, P16891; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; ZGOMBICK JM, 1991, MOL PHARMACOL, V40, P1038; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	72	319	331	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					745	754		10.1096/fasebj.9.9.7601339	http://dx.doi.org/10.1096/fasebj.9.9.7601339			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601339				2022-12-28	WOS:A1995RH98200008
J	PREMONT, RT; INGLESE, J; LEFKOWITZ, RJ				PREMONT, RT; INGLESE, J; LEFKOWITZ, RJ			PROTEIN-KINASES .3. PROTEIN-KINASES THAT PHOSPHORYLATE ACTIVATED G-PROTEIN COUPLED RECEPTORS	FASEB JOURNAL			English	Review						BETA-ADRENERGIC RECEPTOR KINASE; GRK4; GRK5; GRK6; HOMOLOGOUS DENSITIZATION; RHODOPSIN KINASE	BETA-GAMMA-SUBUNITS; RHODOPSIN KINASE; INDUCED DESENSITIZATION; PHOTOEXCITED RHODOPSIN; MULTIGENE FAMILY; IDENTIFICATION; EXPRESSION; MECHANISM; ARRESTIN; CLONING	G protein-coupled receptor kinases (GRKs) are a family of serine/threonine protein kinases that specifically recognize agonist-occupied, activated G protein-coupled receptor proteins as substrates. Phosphorylation of an activated receptor by a GRK terminates signaling by that receptor, by initiating the uncoupling of the receptor from heterotrimeric G proteins. Six distinct mammalian GRKs are known, which differ in tissue distribution and in regulatory properties. The intracellular localization of GRKs to membrane-bound receptor substrates is the most important known regulatory feature of these enzymes. Rhodopsin kinase (GRK1) requires a post-translationally added farnesyl isoprenoid to bind to light-activated rhodopsin. The beta-adrenergic receptor kinases (GRK2 and GRK3) associate with heterotrimeric G protein beta gamma-subunits, released upon receptor activation of G proteins, for membrane anchorage. The recently-described GRKs 4, 5, and 6 comprise a distinct subgroup of GRKs. These kinases utilize distinct mechanisms for membrane localization, which are just beginning to be defined. All GRKs appear to play the same general cellular role of desensitizing activated G protein-coupled receptors, but utilize distinctly individual means to the same end.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSE C, 1993, HUM MOL GENET, V1, P697; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1993, INT REV CYTOL B, V137, P49; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KIM CM, 1993, J BIOL CHEM, V268, P15412; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1988, J BIOL CHEM, V263, P16087; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SMITH WC, 1994, J BIOL CHEM, V267, P15407; STOFFEL RH, 1995, J BIOL CHEM, V269, P27791; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; Watson S., 1994, G PROTEIN LINKED REC; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	55	458	467	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					175	182		10.1096/fasebj.9.2.7781920	http://dx.doi.org/10.1096/fasebj.9.2.7781920			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781920				2022-12-28	WOS:A1995QJ24900005
J	KLEIN, R				KLEIN, R			ROLE OF NEUROTROPHINS IN MOUSE NEURONAL DEVELOPMENT	FASEB JOURNAL			English	Review						GENE TARGETING; TRK RECEPTOR FAMILY; P75; HOMOLOGOUS RECOMBINATION; TYROSINE PHOSPHORYLATION; NEURONAL SURVIVAL	NERVE GROWTH-FACTOR; ROOT GANGLION NEURONS; FACTOR PREVENTS; CELL-DEATH; RAT TRKC; DIFFERENTIAL RESPONSE; SENSORY NEURONS; MESSENGER-RNA; RECEPTORS; SYSTEM	During vertebrate development, naturally occurring neuronal cell death is regulated by target-derived peptide factors, called neurotrophins. A recent series of papers describe the phenotypes of germline-targeted mutant mice deficient in neurotrophins and their receptors. Histological analysis of these mice for the first time has provided knowledge about the specific neuron populations that are dependent on neurotrophin action for development. Mice deficient for nerve growth factor (NGF) and its high-affinity receptor, encoded by the trkA proto-oncogene, suffer from complete loss of sympathetic neurons and sensory neurons responsive to temperature and pain. Mice deficient for brain-derived neurotrophic factor (BDNF) and its receptor, encoded by the trkB gene, display loss of sensory neurons responsive to tactile stimuli. In addition, trkB mutant mice experience loss of motor neurons indicating a possible specific function of the second TrkB ligand, neurotrophin-4 (NT-4), in motor neuron development. Mice deficient for neurotrophin-3 (NT-3) and its receptor, encoded by the trkC gene, show abnormal movements caused by the loss of sensory proprioceptive neurons.			KLEIN, R (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,POB 102209,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163				AYERLELIEVRE C, 1988, P NATL ACAD SCI USA, V85, P2628, DOI 10.1073/pnas.85.8.2628; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BARBACID M, 1993, ONCOGENE, V8, P2033; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BECK KD, 1993, J NEUROSCI, V13, P4001; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LINDHOLM D, 1994, EUR J NEUROSCI, V6, P244, DOI 10.1111/j.1460-9568.1994.tb00267.x; LINDHOLM D, 1993, J CELL BIOL, V122, P443, DOI 10.1083/jcb.122.2.443; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	54	224	233	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					738	744		10.1096/fasebj.8.10.8050673	http://dx.doi.org/10.1096/fasebj.8.10.8050673			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050673				2022-12-28	WOS:A1994NY35000011
J	THOMASREETZ, AC; DECAMILLI, P				THOMASREETZ, AC; DECAMILLI, P			A ROLE FOR SYNAPTIC VESICLES IN NONNEURONAL CELLS - CLUES FROM PANCREATIC BETA-CELLS AND FROM CHROMAFFIN CELLS	FASEB JOURNAL			English	Review						GABA; GAD; INSULIN; ACETYLCHOLINE	INTEGRAL MEMBRANE-PROTEIN; ACID DECARBOXYLASE GAD; PHEOCHROMOCYTOMA CELLS; GLUCOSE TRANSPORTER; ENDOCRINE-CELLS; PLASMA-MEMBRANE; RAT; SYNAPTOPHYSIN; GABA; MICROVESICLES	Synaptic vesicles, vesicular carriers highly specialized for the secretion of fast nonpeptide neurotransmitters, until recently were considered neuronspecific organelles. The identification and characterization of several of the most abundant synaptic vesicle proteins have led to the identification in peptide-secreting endocrine cells of a class of microvesicles, referred to as synaptic-like microvesicles (SLMVs), which are similar to synaptic vesicles in membrane composition, biogenesis, and life cycle. Studies of pancreatic beta cells and of a chromaffin cell-derived cell line (PC12 cells) have suggested that SLMVs, like synaptic vesicles, store and secrete neurotransmitter-like substances that act as paracrine/endocrine signaling molecules. SLMVs of pancreatic beta cells store GABA; SLMVs of PC12 cells contain acetylcholine. Both synaptic vesicles and SLMVs are recycling organelles that represent a specialized subcompartment of the receptor-mediated recycling pathway of all cells. Recently, homologues of membrane proteins of synaptic vesicles and SLMVs have been identified in the endocytic/recycling compartment of non-neuronal, nonendocrine cells. Tracing the evolution of synaptic vesicles from vesicular carriers present in all cells will help to advance our understanding of neurotransmitter release as well as of molecular mechanisms of vesicular traffic.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								AHNERTHILGER G, 1992, FEBS LETT, V314, P41, DOI 10.1016/0014-5793(92)81457-W; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BONNERWEIR S, 1982, DIABETES, V31, P883, DOI 10.2337/diabetes.31.10.883; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; GARRY DJ, 1987, DIABETOLOGIA, V30, P115; GRATZL M, 1991, MARKERS NEURAL ENDOC, P1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; JAHN R, 1993, IN PRESS ANN REV NEU; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LINSTEDT AD, 1991, J NEUROCYTOL, V22, P92; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MCMAHON H, 1993, IN PRESS NATURE LOND; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PEARSE AGE, 1979, FED PROC, V38, P2288; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; SOLIMENA M, 1993, P NATL ACAD SCI USA, V90, P3073, DOI 10.1073/pnas.90.7.3073; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; Thureson-Klein A K, 1990, Int Rev Cytol, V121, P67, DOI 10.1016/S0074-7696(08)60659-2; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; USHARYOV YA, 1992, SCIENCE, V257, P50; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZHONG CZ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P235, DOI 10.1016/0167-4781(92)90495-L	61	164	166	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					209	216		10.1096/fasebj.8.2.7907072	http://dx.doi.org/10.1096/fasebj.8.2.7907072			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	7907072				2022-12-28	WOS:A1994MY29900027
J	GIRARD, J; PERDEREAU, D; FOUFELLE, F; PRIPBUUS, C; FERRE, P				GIRARD, J; PERDEREAU, D; FOUFELLE, F; PRIPBUUS, C; FERRE, P			REGULATION OF LIPOGENIC ENZYME GENE-EXPRESSION BY NUTRIENTS AND HORMONES	FASEB JOURNAL			English	Review						GLUCOSE; INSULIN; GLUCAGON; POLYUNSATURATED FATTY ACIDS; ACETYL-COA CARBOXYLASE; FATTY ACID SYNTHASE; LIVER; WHITE ADIPOSE TISSUE	FATTY-ACID SYNTHASE; SUCKLING-WEANING TRANSITION; ACETYL-COA CARBOXYLASE; PYRUVATE-KINASE GENE; MESSENGER-RNA ABUNDANCE; WHITE ADIPOSE-TISSUE; ATP-CITRATE-LYASE; RAT-LIVER; POSTTRANSCRIPTIONAL REGULATION; MEDIUM-CHAIN	In vivo and in vitro experiments strongly support the view that marked increases in the levels of mRNA and in the activities of lipogenic enzymes that occur in liver and white adipose tissue of the rat after weaning to a high-carbohydrate diet are dependent on an increase in plasma glucose and insulin concentrations. An increased glucose metabolism is necessary for the expression of insulin effects on fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) mRNA accumulation in white adipose tissue, as insulin is ineffective in vitro in the absence of glucose. It is suggested that intracellular glucose-6-phosphate could play an important role in the effect of insulin on lipogenic enzyme gene expression in white adipose tissue. Other hormones and substrates could also play a role in the surge of lipogenesis after weaning. The fall in plasma glucagon after weaning to a high-carbohydrate diet could reinforce the insulin-induced accumulation of FAS and ACC mRNA, as this hormone inhibits the accumulation of lipogenic enzyme mRNA in liver and white adipose tissue. The decrease in the dietary supply of fat after weaning to a high-carbohydrate diet could also potentiate the accumulation of FAS and ACC mRNA in liver because long-chain polyunsaturated fatty acids are potent inhibitors of the expression of the genes encoding liver lipogenic enzymes. A direct effect of fatty acids on a cis-acting element of the lipogenic enzyme genes could be involved, as the regulatory region of FAS gene contains a polyunsaturated fatty acid response element that shares some similarity with the peroxisome proliferator-activated receptor recently described.	HOP ST VINCENT DE PAUL, INSERM, U342, F-75674 PARIS 14, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	GIRARD, J (corresponding author), CTR RECH ENDOCRINOL MOLEC & DEV, CNRS, 9 RUE JULES HETZEL, F-92190 MEUDON, FRANCE.		Ferré, Pascal/K-1250-2013; PRIP-BUUS, Carina/P-9084-2017	Ferré, Pascal/0000-0003-0115-7045; Prip-Buus, Carina/0000-0002-2153-7857; FOUFELLE, Fabienne/0000-0002-0752-622X				ARMSTRONG MK, 1991, BIOCHEM BIOPH RES CO, V177, P1056, DOI 10.1016/0006-291X(91)90645-N; BALLARD FJ, 1967, BIOCHEM J, V102, P952, DOI 10.1042/bj1020952; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BRUN T, 1993, J BIOL CHEM, V268, P18905; CLARKE BA, 1982, J NUTR, V112, P1212, DOI 10.1093/jn/112.6.1212; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; CLARKE SD, 1993, NUTR GENE EXPRESSION, P227; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1992, EUR J BIOCHEM, V208, P381, DOI 10.1111/j.1432-1033.1992.tb17198.x; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; GANDEMER G, 1982, INT J BIOCHEM, V14, P797, DOI 10.1016/0020-711X(82)90100-8; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; HAHN P, 1970, PHYSIOL BOHEMOSLOV, V19, P369; HAHN P, 1982, BIOL NEONATE, V41, P1; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HENNING SJ, 1979, AM J PHYSIOL, V237, pR187, DOI 10.1152/ajpregu.1979.237.3.R187; HIREMAGALUR BK, 1992, J NUTR BIOCHEM, V3, P474, DOI 10.1016/0955-2863(92)90006-5; IRITANI N, 1993, J BIOCHEM, V113, P519, DOI 10.1093/oxfordjournals.jbchem.a124076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM KS, 1992, BIOCHEM BIOPH RES CO, V189, P264, DOI 10.1016/0006-291X(92)91553-3; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LOCKWOOD EA, 1970, BIOCHEM J, V118, P155, DOI 10.1042/bj1180155; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PERDEREAU D, 1990, ADV ENZYME REGUL, V30, P91; PERDEREAU D, 1992, P NUTR SOC, V51, P387, DOI 10.1079/PNS19920052; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE536, DOI 10.1152/ajpendo.1987.253.5.E536; PILLAY D, 1982, BIOCHIM BIOPHYS ACTA, V713, P663, DOI 10.1016/0005-2760(82)90327-7; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHILLABEER G, 1990, J LIPID RES, V31, P623; STOREY JM, 1978, ENZYME, V23, P382, DOI 10.1159/000458606; TAYLOR CB, 1967, BIOCHEM J, V105, P717, DOI 10.1042/bj1050717; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TSUJIKAWA M, 1980, J NUTR SCI VITAMINOL, V26, P367, DOI 10.3177/jnsv.26.367; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VERNON RG, 1968, BIOCHEM J, V106, P321, DOI 10.1042/bj1060321; VOLPE JJ, 1973, J BIOL CHEM, V248, P2502; VOLPE JJ, 1975, BIOCHIM BIOPHYS ACTA, V380, P454, DOI 10.1016/0005-2760(75)90113-7; WEBB JR, 1975, INT J BIOCHEM, V6, P807, DOI 10.1016/0020-711X(75)90096-8; WILSON MD, 1986, J NUTR, V116, P1511, DOI 10.1093/jn/116.8.1511	54	221	230	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1994	8	1					36	42		10.1096/fasebj.8.1.7905448	http://dx.doi.org/10.1096/fasebj.8.1.7905448			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	7905448				2022-12-28	WOS:A1994MV28200007
J	NISHIO, Y; AIELLO, LP; KING, GL				NISHIO, Y; AIELLO, LP; KING, GL			GLUCOSE-INDUCED GENES IN BOVINE AORTIC SMOOTH-MUSCLE CELLS IDENTIFIED BY MESSENGER-RNA DIFFERENTIAL DISPLAY	FASEB JOURNAL			English	Note						GENE REGULATION; ELONGATION FACTOR	PROTEIN-KINASE-C; ELONGATION FACTOR-II; HUMAN-BREAST-CANCER; GLYCEMIC CONTROL; DIABETIC RATS; CLONING; CDNA; EXPRESSION; MORTALITY; SEQUENCE	Hyperglycemia is postulated to cause chronic changes in the vasculature of diabetic patients, suggesting structural or genetic alterations. We have characterized the glucose induced alterations of gene expression in cultured bovine aortic smooth muscle cells using the recently developed mRNA differential display method. After five days of incubation with either 5.5 or 22 mM glucose, RNA preparations were isolated from confluent cells and probed with 10 candidate clones identified after screening up to 3000 mRNA species. Among these, three clones (2A, 2C, 3) showed significant changes in expression by Northern blot analysis. Elevated glucose levels decreased the mRNA expression of clones 2A and 3 to 51 +/- 7% (P < .01) and 59 +/- 10% (P < .05) (mean% of control +/- SEM), respectively. Expression of clone 2C was increased in 22 mM glucose condition to 221 +/- 23% (P < .05). Nucleotide sequence analysis showed that clone 3 had 77% homology to the 3'-noncoding region of human elongation factor 2, a member of the GTPase family which is essential for polypeptide synthesis. Clones 2A and 2C do show no homology to known nucleotide sequences. These results indicate that physiologically attainable high glucose conditions can significantly effect gene expression in aortic smooth muscle cells. Furthermore, mRNA differential display can be used in metabolic studies to identify new genes regulated by nutrients such as glucose.	HARVARD UNIV,SCH MED,JOSLIN DIABETES CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115; HARVARD UNIV,JOSLIN DIABET CTR,BEETHAM EYE INST,CAMBRIDGE,MA 02138; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NEI NIH HHS [EY05110] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1993, DIABETES, V42, pA88; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAGLIERO E, 1988, J CLIN INVEST, V82, P735, DOI 10.1172/JCI113655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DWORKIN MB, 1980, DEV BIOL, V76, P449, DOI 10.1016/0012-1606(80)90393-0; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GAWLER D, 1986, NATURE, V323, P182; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MNIATIS T, 1982, MOL CLONING, P197; MUONA P, 1991, DIABETES, V40, P605, DOI 10.2337/diabetes.40.5.605; NISHIO Y, 1988, DIABETES, V37, P1181, DOI 10.2337/diabetes.37.9.1181; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAPP G, 1988, BIOL CHEM H-S, V369, P247, DOI 10.1515/bchm3.1988.369.1.247; REYNET C, 1993, DIABETES, V42, pA94; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; WEISSBACH H, 1976, ANNU REV BIOCHEM, V45, P191, DOI 10.1146/annurev.bi.45.070176.001203; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; WILLIAMS JG, 1979, J MOL BIOL, V129, P19, DOI 10.1016/0022-2836(79)90056-1; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; ZIYADEH FN, 1990, AM J PHYSIOL, V259, pF704, DOI 10.1152/ajprenal.1990.259.4.F704	29	88	90	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					103	106		10.1096/fasebj.8.1.8299882	http://dx.doi.org/10.1096/fasebj.8.1.8299882			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299882				2022-12-28	WOS:A1994MV28200015
J	LORSCHEIDER, FL; VIMY, MJ				LORSCHEIDER, FL; VIMY, MJ			EVALUATION OF THE SAFETY ISSUE OF MERCURY RELEASE FROM DENTAL FILLINGS	FASEB JOURNAL			English	Editorial Material							AMALGAMS				LORSCHEIDER, FL (corresponding author), UNIV CALGARY,FAC MED,DEPT MED PHYSIOL,CALGARY T2N 4N1,AB,CANADA.							APOSHIAN HV, 1992, FASEB J, V6, P2472, DOI 10.1096/fasebj.6.7.1563599; BEGLEY S, 1990, NEWSWEEK        1015, V116, P80; BOYD ND, 1991, AM J PHYSIOL, V261, pR1010, DOI 10.1152/ajpregu.1991.261.4.R1010; GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I; GROSS MJ, 1989, J APPL ELECTROCHEM, V19, P301, DOI 10.1007/BF01015227; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; MITCHELL ED, 1984, NIDR ADA WORKSHOP BI, P416; SHEARER BG, 1993, ANTIMICROB AGENTS CH, V37, P1730, DOI 10.1128/AAC.37.8.1730; SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825; VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111; 1990, J AM DENT ASSOC, V120, P395; 1991, ENV HLTH CRITERIA, V118, P36	12	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1432	1433		10.1096/fasebj.7.15.8262327	http://dx.doi.org/10.1096/fasebj.7.15.8262327			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262327				2022-12-28	WOS:A1993ML74000003
J	STETLERSTEVENSON, WG; LIOTTA, LA; KLEINER, DE				STETLERSTEVENSON, WG; LIOTTA, LA; KLEINER, DE			EXTRACELLULAR MATRIX-6 - ROLE OF MATRIX METALLOPROTEINASES IN TUMOR INVASION AND METASTASIS	FASEB JOURNAL			English	Review						CELL INVASION; METASTASIS; MATRIX METALLOPROTEASES	BASEMENT-MEMBRANE MATRIGEL; CONSERVED PEPTIDE SEQUENCE; HUMAN-TISSUE INHIBITOR; C-TERMINAL DOMAIN; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; INTERSTITIAL COLLAGENASE; PROTEOLYTIC ACTIVITY; CANCER METASTASIS	Over the course of these Serial Reviews the reader has been made aware of the growing importance of the extracellular matrix in modern cell biology. The matrix not only has a mechanical role in maintaining the integrity of the tissues, but also controls the flow of nutrients and signals to the cells, and indeed, provides many of these signals. There are a number of pathological situations in which cells cause excessive degradation of their own matrix, e.g., osteoarthritis, periodontitis and decubitus ulcer. One of the most striking examples of unbridled attack upon the matrix is seen in the process of tumor invasion and metastasis. All barriers to cell movement through tissues and into vessels are obliterated, largely through the action of a battery-of extracellular metalloproteinases. The regulation of these proteinases in cancer is the subject of this review.			STETLERSTEVENSON, WG (corresponding author), NCI,DCBDC,PATHOL LAB,BLDG 10,ROOM 2A33,BETHESDA,MD 20892, USA.		Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, William/AAE-3501-2020; Kleiner, David E/N-2770-2013	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808; Kleiner, David E/0000-0003-3442-4453				ALBELDA SM, 1993, LAB INVEST, V68, P4; ATKINSON SJ, 1992, BIOCHEM J, V288, P605, DOI 10.1042/bj2880605; AZZAM HS, 1992, CANCER RES, V52, P4540; BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BONFIL RD, 1989, JNCI-J NATL CANCER I, V81, P587, DOI 10.1093/jnci/81.8.587; BONFIL RD, 1992, CLIN EXP METASTAS, V10, P211; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CAMPO E, 1992, HUM PATHOL, V23, P1395, DOI 10.1016/0046-8177(92)90060-G; CAMPO E, 1992, AM J SURG PATHOL, V16, P500, DOI 10.1097/00000478-199205000-00009; CLAVEL C, 1992, B CANCER, V79, P261; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; CURRY VA, 1992, BIOCHEM J, V285, P143, DOI 10.1042/bj2850143; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EMONARD HP, 1992, CANCER RES, V52, P5845; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KANEMOTO T, 1991, INVAS METAST, V11, P84; KATO Y, 1992, J BIOL CHEM, V267, P11424; KERBEL RS, 1992, AM J PATHOL, V141, P519; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MAREEL MM, 1990, CANCER METAST REV, V9, P45, DOI 10.1007/BF00047588; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MELCHIORI A, 1992, CANCER RES, V52, P2353; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1992, SEP P MATR MET C SAN; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NOMURA K, 1993, FEBS LETT, V321, P84, DOI 10.1016/0014-5793(93)80626-6; OGATA Y, 1992, EXP CELL RES, V201, P245, DOI 10.1016/0014-4827(92)90271-9; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; POULSOM R, 1992, AM J PATHOL, V141, P389; POWELL WC, 1993, CANCER RES, V53, P417; SALO T, 1982, INT J CANCER, V30, P669, DOI 10.1002/ijc.2910300520; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SREENATH T, 1992, CANCER RES, V52, P4942; STEARNS ME, 1993, CANCER RES, V53, P878; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1991, AM J MED SCI, V302, P163, DOI 10.1097/00000441-199109000-00009; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	78	541	560	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1434	1441		10.1096/fasebj.7.15.8262328	http://dx.doi.org/10.1096/fasebj.7.15.8262328			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262328				2022-12-28	WOS:A1993ML74000005
J	PAUL, IA; BASILE, AS; ROJAS, E; YOUDIM, MBH; DECOSTA, B; SKOLNICK, P; POLLARD, HB; KUIJPERS, GAJ				PAUL, IA; BASILE, AS; ROJAS, E; YOUDIM, MBH; DECOSTA, B; SKOLNICK, P; POLLARD, HB; KUIJPERS, GAJ			SIGMA-RECEPTORS MODULATE NICOTINIC RECEPTOR FUNCTION IN ADRENAL CHROMAFFIN CELLS	FASEB JOURNAL			English	Article						CHROMAFFIN CELLS; CALCIUM FLUORESCENCE; KINETIC DATA	CENTRAL NERVOUS-SYSTEM; GUINEA-PIG BRAIN; NEUROPEPTIDE-Y; BINDING-SITES; ACETYLCHOLINE-RECEPTOR; ANTIPSYCHOTIC-DRUGS; RAT-BRAIN; CATECHOLAMINE SECRETION; SELECTIVE LIGAND; IMMUNE-SYSTEMS	Neither the physiological function of sigma (sigma) receptors nor the cellular mechanism responsible for the pharmacological effects of sigma receptor ligands is known. We now report that sigma receptor ligands noncompetitively inhibit nicotine-stimulated catecholamine release from bovine adrenal chromaffin cells in a concentration-dependent and reversible manner. The rank order of potency of ligands to inhibit nicotine-stimulated catecholamine release is significantly correlated (P < 0.005) with that observed in radioligand binding assays selective for the sigma1 receptor subtype. This naltrexone-insensitive effect is paralleled by an inhibition of nicotine-stimulated increases in [Ca2+]i. Sigma ligands were without effect on catecholamine release or [Ca2+]i in the absence of nicotine. In addition, nicotine accelerated the association of the sigma receptor selective radioligand, [H-3](+)pentazocine, to adrenal medullary homogenates while having no effect on the rate of ligand dissociation, consistent with a sigma ligand binding site closely associated with and allosterically modulated by the nicotinic acetylcholine receptor. Thus, the actions of agonists at the nicotinic acetylcholine receptor in bovine chromaffin cells are modulated by sigma1 receptor selective ligands.	NIDDKD,NEUROSCI LAB,BETHESDA,MD 20892; NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892; NIDDKD,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ARONSTAM RS, 1981, J BIOL CHEM, V256, P2843; BASILE AS, 1992, MOL PHARMACOL, V42, P882; BOWEN WD, 1988, EUR J PHARMACOL, V149, P399, DOI 10.1016/0014-2999(88)90678-4; BOWEN WD, 1989, EUR J PHARMACOL, V163, P309, DOI 10.1016/0014-2999(89)90200-8; CULP SG, 1992, J PHARMACOL EXP THER, V263, P1175; DECOSTA BR, 1990, J MED CHEM, V33, P3100, DOI 10.1021/jm00173a030; DECOSTA BR, 1989, FEBS LETT, V251, P53, DOI 10.1016/0014-5793(89)81427-9; GREENBERG A, 1982, CELL TISSUE RES, V226, P655; GUNDLACH AL, 1986, J NEUROSCI, V6, P1757; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HIGUCHI H, 1988, J PHARMACOL EXP THER, V244, P468; JUNIEN JL, 1991, EUR J PHARMACOL, V200, P343, DOI 10.1016/0014-2999(91)90593-F; KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7; KILPATRICK DL, 1980, J NEUROCHEM, V35, P697; KING CT, 1983, EUR J PHARMACOL, V90, P419, DOI 10.1016/0014-2999(83)90564-2; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LARGENT BL, 1987, MOL PHARMACOL, V32, P772; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MARTIN WR, 1967, PHARMACOL REV, V19, P463; MCLEAN S, 1988, NEUROSCIENCE, V25, P259, DOI 10.1016/0306-4522(88)90024-3; NORENBERG W, 1991, PFLUG ARCH EUR J PHY, V418, P346, DOI 10.1007/BF00550872; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PAUL IA, 1990, EUR J PHARMACOL, V184, P203, DOI 10.1016/0014-2999(90)90685-Y; QUIRION R, 1992, TRENDS PHARMACOL SCI, V13, P85, DOI 10.1016/0165-6147(92)90030-A; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; ROGERS C, 1989, BIOCHEM PHARMACOL, V38, P2467, DOI 10.1016/0006-2952(89)90090-7; ROMAN FJ, 1990, J PHARM PHARMACOL, V42, P439, DOI 10.1111/j.2042-7158.1990.tb06588.x; ROMAN FJ, 1989, EUR J PHARMACOL, V174, P301, DOI 10.1016/0014-2999(89)90326-9; STEINFELS GF, 1988, NEUROPSYCHOPHARMACOL, V1, P321; SU TP, 1991, EUR J BIOCHEM, V200, P633, DOI 10.1111/j.1432-1033.1991.tb16226.x; SU TP, 1988, SCIENCE, V240, P219, DOI 10.1126/science.2832949; TAM SW, 1992, J PHARMACOL EXP THER, V263, P1167; TAM SW, 1983, P NATL ACAD SCI-BIOL, V80, P6703, DOI 10.1073/pnas.80.21.6703; TAM SW, 1984, P NATL ACAD SCI-BIOL, V81, P5618, DOI 10.1073/pnas.81.17.5618; TAM SW, 1991, EUR J PHARMACOL, V193, P121; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; WADA A, 1988, NEUROSCIENCE, V25, P687, DOI 10.1016/0306-4522(88)90269-2; WALKER JM, 1990, PHARMACOL REV, V42, P355; WALKER JM, 1988, NEUROLOGY, V38, P961, DOI 10.1212/WNL.38.6.961; WEBER E, 1986, P NATL ACAD SCI USA, V83, P8784, DOI 10.1073/pnas.83.22.8784	41	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1171	1178		10.1096/fasebj.7.12.8375616	http://dx.doi.org/10.1096/fasebj.7.12.8375616			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375616				2022-12-28	WOS:A1993LW81700012
J	WOESSNER, JF				WOESSNER, JF			INTRODUCTION TO SERIAL REVIEWS - THE EXTRACELLULAR-MATRIX	FASEB JOURNAL			English	Article											WOESSNER, JF (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101, USA.							BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	9	20	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					735	736		10.1096/fasebj.7.9.8330680	http://dx.doi.org/10.1096/fasebj.7.9.8330680			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330680				2022-12-28	WOS:A1993LK43000004
J	KUMAR, PKR; ELLINGTON, AD				KUMAR, PKR; ELLINGTON, AD			ARTIFICIAL EVOLUTION AND NATURAL RIBOZYMES	FASEB JOURNAL			English	Review						IN VITRO SELECTION; RNA WORLD; GROUP I; HAMMERHEAD; HAIRPIN; HDV	INVITRO SELECTION; HAIRPIN RIBOZYME; RNA ENZYME; CLEAVAGE; SEQUENCES; WORLD	In vitro selection techniques have been used to probe the sequence, structure, and function of natural ribozymes such as the viroid hammerheads and group I self-splicing introns. These artifical evolution experiments help to delimit the range of alternative structures and functions that are available to catalytic RNAs, and thus can provide insights into why particular sequences or mechanisms were fixed during the course of natural selection. Further, the wide variety of forms and functions that ribozymes have been found to assume in the laboratory provides inferential support for the hypothesis that much of modern metabolism may have been distantly derived from biochemistry centered on RNA rather than protein catalysts.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405; MINIST INT TRADE & IND,AIST CTR,NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN	Indiana University System; Indiana University Bloomington; National Institute of Advanced Industrial Science & Technology (AIST)			Penmetcha, Kumar/K-8834-2017	Penmetcha, Kumar/0000-0002-3512-704X	NIGMS NIH HHS [R01GM48175] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048175] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BENNER SA, 1993, RNA WORLD, P27; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; Castanotto Daniela, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P331; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DICHTL B, 1993, NUCLEIC ACIDS RES, V21, P531, DOI 10.1093/nar/21.3.531; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GREEN R, 1994, J MOL BIOL, V235, P14; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KAWAKAMI J, 1993, EUR J BIOCHEM, V217, P29, DOI 10.1111/j.1432-1033.1993.tb18214.x; LEHMAN N, 1993, CURR BIOL, V3, P723, DOI 10.1016/0960-9822(93)90019-K; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LONG DM, 1994, P NATL ACAD SCI USA, V91, P6977, DOI 10.1073/pnas.91.15.6977; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; NAKAMAYE KL, 1994, BIOCHEMISTRY-US, V33, P1271, DOI 10.1021/bi00171a030; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PAN T, 1994, BIOCHEMISTRY-US, V33, P9561, DOI 10.1021/bi00198a023; PRUDENT JR, 1994, SCIENCE, V264, P1924; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; WILLIAMS KP, 1994, NUCLEIC ACIDS RES, V22, P2003, DOI 10.1093/nar/22.11.2003; YUAN Y, 1994, SCIENCE, V263, P1269, DOI 10.1126/science.8122108	30	33	59	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1183	1195		10.1096/fasebj.9.12.7672511	http://dx.doi.org/10.1096/fasebj.9.12.7672511			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672511				2022-12-28	WOS:A1995RU81600008
J	ROSSENEU, M; LABEUR, C				ROSSENEU, M; LABEUR, C			PHYSIOLOGICAL SIGNIFICANCE OF APOLIPOPROTEIN MUTANTS	FASEB JOURNAL			English	Review						HYPERLIPOPROTEINEMIA; HIGH DENSITY LIPOPROTEIN; LCAT	FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100; HIGH-DENSITY-LIPOPROTEINS; A-I GENE; SPLICE SITE MUTATION; III HYPERLIPOPROTEINEMIA; C-II; PREMATURE ATHEROSCLEROSIS; MOLECULAR-CLONING; DEFICIENCY; VARIANT	The major plasma lipids, cholesterol, and triglycerides are transported in the blood by different classes of lipoprotein, which can be differentiated from each other by their apoprotein and lipid constituents. Defects in the genes coding for the apolipoprotein components, besides those coding for lipolytic enzymes and cellular receptors, can cause an imbalance in the plasma lipid homeostasis. The physiological significance on lipid metabolism of genetic defects, both rare inborn errors or common genetic variation at these gene loci, are the topics of this review.	AKAD ZIEKENHUIS ST JAN,DEPT CLIN CHEM,B-8000 BRUGGE,BELGIUM		ROSSENEU, M (corresponding author), FAC MED GENT,LIPOPROT CHEM LAB,HOSP ST 13,B-9000 GHENT,BELGIUM.							ASSMANN G, 1992, STRUCTURE FUNCTION A, P85; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; COLLINS DR, 1988, NUCLEIC ACIDS RES, V16, P8361, DOI 10.1093/nar/16.17.8361; CONNELLY PW, 1987, J CLIN INVEST, V80, P1597, DOI 10.1172/JCI113246; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COX DW, 1988, J MED GENET, V25, P649, DOI 10.1136/jmg.25.10.649; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEEB SS, 1991, J BIOL CHEM, V266, P13654; DEEB SS, 1990, AM J HUM GENET, V46, P822; FOJO SS, 1988, J CLIN INVEST, V82, P1489, DOI 10.1172/JCI113756; FOJO SS, 1989, J BIOL CHEM, V264, P20839; FUNKE H, 1991, J CLIN INVEST, V87, P375; Gabelli C, 1992, CURR OPIN LIPIDOL, V3, P208; GROENEWEGEN WA, 1993, J LIPID RES, V34, P971; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HORIE Y, 1992, J BIOL CHEM, V267, P1962; INNERARITY TL, 1990, J LIPID RES, V31, P1337; KARATHANASIS SK, 1987, P NATL ACAD SCI USA, V84, P7198, DOI 10.1073/pnas.84.20.7198; LACKNER KJ, 1993, J CLIN INVEST, V92, P2262, DOI 10.1172/JCI116830; LADIAS JAA, 1990, HUM GENET, V84, P439; LI WH, 1988, J LIPID RES, V29, P245; LINTON MF, 1992, P NATL ACAD SCI USA, V89, P11431, DOI 10.1073/pnas.89.23.11431; LOHSE P, 1992, J LIPID RES, V33, P1583; LOHSE P, 1990, J BIOL CHEM, V265, P10061; LOHSE P, 1992, J BIOL CHEM, V267, P13642; LOHSE P, 1991, J BIOL CHEM, V266, P13513; MAEDA H, 1987, J LIPID RES, V28, P1405; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAILLY F, 1991, J LIPID RES, V32, P613; MATSUNAGA T, 1991, P NATL ACAD SCI USA, V88, P2793, DOI 10.1073/pnas.88.7.2793; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; NG DS, 1994, J CLIN INVEST, V93, P223, DOI 10.1172/JCI116949; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; PARHOFER KG, 1990, J LIPID RES, V31, P2001; PULLINGER CR, 1993, HUM MOL GENET, V2, P69, DOI 10.1093/hmg/2.1.69; PULLINGER CR, 1992, J LIPID RES, V33, P699; RADER DJ, 1992, J LIPID RES, V33, P755; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; ROSS RS, 1988, J CLIN INVEST, V81, P590, DOI 10.1172/JCI113357; Santamarina-Fojo S., 1992, CURR OPIN LIPIDOL, V3, P186; SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105; SCHUSTER H, 1990, ARTERIOSCLEROSIS, V10, P577, DOI 10.1161/01.ATV.10.4.577; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; TAKADA Y, 1989, ARTERIOSCLEROSIS, V9, pA707; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALMUD P, 1992, STRUCTURE FUNCTION A, P123; TENKANEN H, 1991, ARTERIOSCLER THROMB, V11, P851, DOI 10.1161/01.ATV.11.4.851; VANDENMAAGDENBE.AM, 1993, AM J HUM GENET, V52, P937; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; VONECKARDSTEIN A, 1991, J CLIN INVEST, V87, P1724, DOI 10.1172/JCI115190; WALDEN CC, 1994, J CLIN ENDOCR METAB, V78, P699, DOI 10.1210/jc.78.3.699; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1980, J CLIN INVEST, V66, P901, DOI 10.1172/JCI109957; WETTERAU JR, 1993, SCIENCE, V258, P999; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	61	14	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					768	776		10.1096/fasebj.9.9.7601341	http://dx.doi.org/10.1096/fasebj.9.9.7601341			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601341				2022-12-28	WOS:A1995RH98200010
J	SINGER, TP; RAMSAY, RR				SINGER, TP; RAMSAY, RR			FLAVOPROTEIN STRUCTURE AND MECHANISM .2. MONOAMINE OXIDASES - OLD FRIENDS HOLD MANY SURPRISES	FASEB JOURNAL			English	Review						AGING; INHIBITORS; PARKINSONS DISEASE	SUICIDE INACTIVATION; OXIDATION; FLAVIN; BOVINE; ANALOGS; AMINE; MPTP; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; IDENTIFICATION	The two forms of monoamine oxidase (MAO), A and B, continue to be of major interest to biochemists, pharmacologists, neurologists, and gerontologists. Despite intensive study for more than half a century, unexpected and unique properties of these enzymes continue to come to light. Recent studies have centered on their kinetic mechanism, their unique predilection for substrates related to the neurotoxic tertiary amine MPTP, and their putative role in aging and in the etiology of neurodegenerative diseases. New and potent inhibitors of MAO A and MAO B continue to be developed because of their potential use in clinical medicine. Some are effective in the picomolar range but MAO B from different mammalian species shows remarkable differences in sensitivity to these agents.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV TOXICOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SINGER, TP (corresponding author), DEPT VET AFFAIRS MED CTR, DIV MOLEC BIOL, 151-S, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.		Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904				BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BENEDETTI MS, 1987, J NEURAL TRANSM, P103; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; EFANGE SMN, 1993, J MED CHEM, V36, P1278, DOI 10.1021/jm00061a020; ERWIN VG, 1967, J BIOL CHEM, V242, P4230; HOUSLAY MD, 1973, BIOCHEM J, V135, P173, DOI 10.1042/bj1350173; HUSAIN M, 1982, BIOCHEMISTRY-US, V21, P595, DOI 10.1021/bi00532a028; KNOLL J, 1992, PHARMACOL TOXICOL, V70, P317, DOI 10.1111/j.1600-0773.1992.tb00480.x; KNOLL J, 1993, J NEURAL TRANSM-GEN, P69; LANGSTON JW, 1984, SCIENCE, V225, P1480, DOI 10.1126/science.6332378; MANTLE TJ, 1975, BIOCHEM PHARMACOL, V24, P2031, DOI 10.1016/0006-2952(75)90099-4; MAZOUZ F, 1993, J MED CHEM, V36, P1157, DOI 10.1021/jm00061a006; NAGY J, 1981, ARCH BIOCHEM BIOPHYS, V208, P388, DOI 10.1016/0003-9861(81)90523-3; PAECH C, 1980, J BIOL CHEM, V255, P2700; RAMSAY RR, 1987, BIOCHEMISTRY-US, V26, P3045, DOI 10.1021/bi00385a015; Ramsay RR, 1994, FLAVINS AND FLAVOPROTEINS 1993, P99; RAMSAY RR, 1991, BIOCHEMISTRY-US, V30, P4624, DOI 10.1021/bi00232a038; SABLIN SO, 1994, J MED CHEM, V37, P151, DOI 10.1021/jm00027a019; SALACH JI, 1984, BIOCHEM BIOPH RES CO, V125, P831, DOI 10.1016/0006-291X(84)90614-4; SALACH JI, 1979, ARCH BIOCHEM BIOPHYS, V192, P128, DOI 10.1016/0003-9861(79)90078-X; SAYRE LM, 1989, TOXICOL LETT, V48, P121, DOI 10.1016/0378-4274(89)90168-9; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; Silverman R. B., 1992, ADV ELECTRON TRANSFE, P177; SILVERMAN RB, 1986, BIOCHEM BIOPH RES CO, V135, P154, DOI 10.1016/0006-291X(86)90955-1; SILVERMAN RB, 1987, J AM CHEM SOC, V109, P2219, DOI 10.1021/ja00241a070; Singer T. P, 1991, CHEM BIOCH FLAVOENZY, V2, P437; SINGER TP, IN PRESS PROG BRAIN; SZELENYI I, 1993, INHIBITION MONOAMINE; TAN AK, 1993, BIOCHEMISTRY-US, V32, P2137, DOI 10.1021/bi00060a003; TIPTON KF, 1968, BIOCHIM BIOPHYS ACTA, V159, P451, DOI 10.1016/0005-2744(68)90129-0; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; WALKER WH, 1971, EUR J BIOCHEM, V24, P328, DOI 10.1111/j.1432-1033.1971.tb19690.x; WEYLER W, 1985, J BIOL CHEM, V260, P3199; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WEYLER W, 1981, ARCH BIOCHEM BIOPHYS, V212, P147, DOI 10.1016/0003-9861(81)90353-2; WU HF, 1993, MOL PHARMACOL, V43, P888; YAGI K, 1982, BIOCHEM INT, V4, P457; YOUNGSTER SK, 1989, J NEUROCHEM, V53, P1837, DOI 10.1111/j.1471-4159.1989.tb09250.x; YUE KT, 1993, ARCH BIOCHEM BIOPHYS, V300, P178, DOI 10.1006/abbi.1993.1025	40	65	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					605	610		10.1096/fasebj.9.8.7768351	http://dx.doi.org/10.1096/fasebj.9.8.7768351			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768351				2022-12-28	WOS:A1995RC10600005
J	REARDON, D; FARBER, GK				REARDON, D; FARBER, GK			PROTEIN MOTIFS .4. THE STRUCTURE AND EVOLUTION OF ALPHA/BETA BARREL PROTEINS	FASEB JOURNAL			English	Review						TIM BARREL; MOLECULAR EVOLUTION	TRIOSE PHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; XYLOSE ISOMERASE; PYRUVATE-KINASE; RESOLUTION; MECHANISM; ENZYMES; INHIBITOR; MODEL	Roughly 10% of all known enzyme structures have an alpha/beta barrel domain. The members of this large family of proteins catalyze very different types of reactions. Such diversity of function has made this family a target for protein engineering. The evolutionary history of this family has been the subject of vigorous debate. In this paper, arguments are made to support the divergence of all members of this family from a common ancestor. Because of the lack of strong sequence homology, the ancestral molecule must be very old. A hypothesis concerning the relationship between chemical mechanism and evolutionary history is discussed. Evidence is presented to suggest that convergent molecular evolution occurs when there is only one energetically reasonable pathway for a chemical reaction.			REARDON, D (corresponding author), PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, 108 ALTHOUSE LAB, UNIVERSITY PK, PA 16802 USA.							ALLEN KN, 1994, BIOCHEMISTRY-US, V33, P1481, DOI 10.1021/bi00172a026; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARBER GK, 1989, BIOCHEMISTRY-US, V28, P7289, DOI 10.1021/bi00444a022; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; FOSX KM, 1994, AM CRYSTAL ASS ANN M, V22, P167; HENNIG M, 1992, FEBS LETT, V306, P80, DOI 10.1016/0014-5793(92)80842-5; HOIER H, 1994, ACTA CRYSTALLOGR D, V50, P75, DOI 10.1107/S090744499300900X; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; IZARD T, 1994, STRUCTURE, V2, P361, DOI 10.1016/S0969-2126(00)00038-1; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JAFRI E, 1994, AM CRYSTAL ASS ANN M, V22, P123; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KIZAKI H, 1993, J BIOCHEM-TOKYO, V113, P646, DOI 10.1093/oxfordjournals.jbchem.a124097; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MIKAMI B, 1992, J BIOCHEM-TOKYO, V112, P541, DOI 10.1093/oxfordjournals.jbchem.a123935; MOORE SA, 1993, EMBO J, V12, P1767, DOI 10.1002/j.1460-2075.1993.tb05824.x; MUIRHEAD H, 1983, TRENDS BIOCHEM SCI, V8, P326, DOI 10.1016/0968-0004(83)90103-2; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; POLGAR L, 1987, HYDROLYTIC ENZYMES, P159; ROEY PV, 1994, AM CRYSTAL ASSN ANN, V22, P112; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STEC B, 1990, J MOL BIOL, V211, P235, DOI 10.1016/0022-2836(90)90023-F; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; STEWART CB, 1993, METHOD ENZYMOL, V224, P591, DOI 10.1016/0076-6879(93)24044-U; TSUKAEDA H, 1985, J MOL BIOL, V1843, P703; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YATES K, 1978, ACCOUNTS CHEM RES, V11, P190, DOI 10.1021/ar50125a003; YENNAWAR NH, 1994, BIOCHEMISTRY-US, V33, P7236; ZHENG YJ, 1993, PROTEIN ENG, V6, P479, DOI 10.1093/protein/6.5.479	42	156	159	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1995	9	7					497	503		10.1096/fasebj.9.7.7737457	http://dx.doi.org/10.1096/fasebj.9.7.7737457			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737457				2022-12-28	WOS:A1995QX14800006
J	REITER, RJ				REITER, RJ			OXIDATIVE PROCESSES AND ANTIOXIDATIVE DEFENSE-MECHANISMS IN THE AGING BRAIN	FASEB JOURNAL			English	Article						ANTIOXIDANTS; FREE RADICALS; OXIDATIVE DAMAGE; VITAMIN-E; VITAMIN-C; MELATONIN; NEURODEGENERATIVE DISEASES	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; FREE-RADICALS; LIPID-PEROXIDATION; MAMMALIAN-TISSUES; PINEAL-GLAND; RAT-BRAIN; MELATONIN; SUPEROXIDE; DAMAGE	The debilitating consequences of age-related brain deterioration are widespread and extremely costly in terms of quality of life and longevity. One of the potential major causes of age-related destruction of neuronal tissue is toxic free radicals that are a natural result of aerobic metabolism. The brain is particularly susceptible to free radical attack because it generates more of these toxicants per gram of tissue than does any other organ. The major defense mechanisms the brain uses to combat reducing equivalents is via their enzymatic metabolism. The vitamin antioxidants, vitamin E (alpha-tocopherol in particular) and vitamin C (ascorbate), also aid in protecting the brain from oxidative stress by directly scavenging toxic radicals. A newly discovered, potentially highly important antioxidant in the brain is the indole melatonin. The pineal hormone melatonin is rapidly taken up by the brain. In vitro melatonin is more effective than glutathione in scavenging the highly toxic hydroxyl radical and also more efficient than vitamin E in neutralizing the peroxyl radical. Furthermore, it stimulates the main antioxidant enzyme of the brain, glutathione peroxidase. In vivo melatonin is a potent antioxidant and it lacks prooxidant actions.			REITER, RJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.							ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x; BARLOWWALDEN L, 1975, IN PRESS NEUROCHEM I; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Borg D. C., 1993, OXYGEN FREE RADICALS, P12; CHEESEMAN KH, 1993, TOXICOL IND HEALTH, V9, P39, DOI 10.1177/0748233793009001-205; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COCHRANE CG, 1991, MOL ASPECTS MED, V12, P137, DOI 10.1016/0098-2997(91)90009-B; Cohen G, 1988, OXYGEN RADICALS TISS, P130; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DUGAN LL, 1987, ANN NEUROL, V35, P517; FAHN S, 1992, ANN NEUROL, V32, pS128, DOI 10.1002/ana.410320722; FLOYD RA, 1993, TOXICOL IND HEALTH, V9, P197, DOI 10.1177/0748233793009001-214; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GUTTERIDGE JMC, 1984, BIOCHEM J, V218, P983, DOI 10.1042/bj2180983; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HARMAN D, 1969, J AM GERIATR SOC, V17, P721, DOI 10.1111/j.1532-5415.1969.tb02286.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x; IANAS O, 1991, ROM J ENDOCRINOL, V29, P147; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; KANNER J, 1987, CRC CR REV FOOD SCI, V25, P317, DOI 10.1080/10408398709527457; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KOPPENOL WH, 1990, FREE RADICAL BIO MED, V9, P225, DOI 10.1016/0891-5849(90)90032-E; LEJEUNE J, 1990, AM J MED GENET, P20; MARKLUND SL, 1983, DRUG ALCOHOL DEPEN, V12, P209, DOI 10.1016/0376-8716(83)90062-5; Matsuo M., 1993, FREE RADICALS AGING, P143; MCCORD JM, 1993, TOXICOL IND HEALTH, V9, P23, DOI 10.1177/0748233793009001-204; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MULLER DPR, 1990, CRIT REV NEUROBIOL, V5, P239; NAKAJIMA M, 1991, NEUROSCI LETT, V133, P49, DOI 10.1016/0304-3940(91)90054-W; NIKI E, 1993, BIOCHEM SOC T, V21, P313, DOI 10.1042/bst0210313; OLANOW CW, 1990, NEUROLOGY, V40, P32; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIERPAOLI W, 1994, P NATL ACAD SCI USA, V91, P787, DOI 10.1073/pnas.91.2.787; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V80, P211; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; RADI R, 1991, J BIOL CHEM, V266, P4244; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; REITER RJ, 1994, ACTA GERONTOL, V44, P92; REITER RJ, 1994, IN PRESS EXP GERONTO; REITER RJ, 1995, IN PRESS NEUROCHEM I; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; ROMERO FJ, 1990, METABOLISM PHYSL FUN, P29; ROSE MR, 1994, FASEB J, V8, P925, DOI 10.1096/fasebj.8.12.8088458; SADRZADEH SMH, 1988, J CLIN INVEST, V82, P1510, DOI 10.1172/JCI113759; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHIDA CS, 1994, J PINEAL RES, V16, P198, DOI 10.1111/j.1600-079X.1994.tb00102.x; SINET PM, 1980, J NEUROCHEM, V34, P1421, DOI 10.1111/j.1471-4159.1980.tb11222.x; Sokoloff L., 1960, HANDBOOK PHYSIOLOG 1, P1843; SPECTOR R, 1984, FED PROC, V43, P196; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STOKKAN KA, 1991, BRAIN RES, V545, P66, DOI 10.1016/0006-8993(91)91270-B; TAKIZAWA S, 1994, J NEUROL SCI, V122, P66, DOI 10.1016/0022-510X(94)90053-1; TAN DX, 1994, CARCINOGENESIS, V15, P215, DOI 10.1093/carcin/15.2.215; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; WILLS ED, 1969, BIOCHEM J, V113, P325, DOI 10.1042/bj1130325; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625	72	749	785	2	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1995	9	7					526	533		10.1096/fasebj.9.7.7737461	http://dx.doi.org/10.1096/fasebj.9.7.7737461			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737461				2022-12-28	WOS:A1995QX14800010
J	CHANDA, S; MEHENDALE, HM				CHANDA, S; MEHENDALE, HM			NUTRITIONAL IMPACT ON THE FINAL OUTCOME OF LIVER-INJURY INFLICTED BY MODEL HEPATOTOXICANTS - EFFECT OF GLUCOSE LOADING	FASEB JOURNAL			English	Article						THIOACETAMIDE; GLUCOSE LOADING; TISSUE REPAIR; H-3 THYMIDINE INCORPORATION; PROLIFERATING CELL NUCLEAR ANTIGEN	PARTIALLY HEPATECTOMIZED RATS; REGENERATION	Fifteen percent glucose in drinking water for 7 days increased lethality of four structurally and mechanistically different model centrilobular hepatotoxicants (acetaminophen, thioacetamide, chloroform, and carbon tetrachloride) in male Sprague-Dawley rats (n = 10/group). A nonlethal injection of thioacetamide was lethal in glucose loaded rats and therefore was chosen for further studies. Serum enzyme elevations and liver histopathology revealed that actual infliction of liver injury peaked between 36 to 48 h after thioacetamide injection; however, the liver injury progressed in rats receiving glucose, whereas it regressed in rats maintained on normal diet and drinking water without glucose supplement. Glucose loading did not increase the hepatic microsomal cytochrome P450. [H-3]thymidine incorporation studies along with proliferating cell nuclear antigen immunohistochemical analysis of liver sections revealed inhibition of S-phase stimulation and decelerated cell cycle progression. These findings suggest that glucose loading inhibits cellular regeneration and tissue repair resulting in accelerated progression of liver injury inflicted by thioacetamide culminating in increased death of animals receiving a moderately hepatotoxic dose of thioacetamide.	NE LOUISIANA UNIV, COLL PHARM & HLTH SCI, DIV PHARMACOL & TOXICOL, MONROE, LA 71209 USA	University of Louisiana System; University of Louisiana Monroe								BENGMARK S., 1965, Acta Chirurgica Scandinavica, V130, P216; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CARUANA JA, 1986, ENDOCR RES, V12, P147, DOI 10.1080/07435808609035434; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; CERAMI A, 1985, J AM GERIATR SOC, V33, P626, DOI 10.1111/j.1532-5415.1985.tb06319.x; CHANDA S, 1995, HEPATOLOGY, V21, P477, DOI 10.1002/hep.1840210232; CHANDA S, 1994, FASEB J, V8, P1061, DOI 10.1096/fasebj.8.13.7926372; CHANG LO, 1965, CANCER RES, V25, P1817; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HINKLE PC, 1988, LIVER BIOL PATHOBIOL, P269; HOLECEK M, 1991, J HEPATOL, V13, P14, DOI 10.1016/0168-8278(91)90857-8; HOLECEK M, 1988, EXP PATHOL-JENA, V33, P257; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KATZ N, 1976, H-S Z PHYSIOL CHEM, V357, P359, DOI 10.1515/bchm2.1976.357.1.359; KENDA JFN, 1984, EUR SURG RES, V16, P294; KOCH KS, 1976, METABOLISM, V25, P1419, DOI 10.1016/S0026-0495(76)80155-2; KODAVANTI PRS, 1992, TOXICOL PATHOL, V20, P556, DOI 10.1177/019262339202000402; LEDUC EH, 1949, AM J ANAT, V84, P397, DOI 10.1002/aja.1000840304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKATA R, 1985, BIOCHEM PHARMACOL, V34, P586, DOI 10.1016/0006-2952(85)90195-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; PRICE JB, 1982, ARCH SURG-CHICAGO, V117, P1139; SHORT J, 1973, BIOCHEM BIOPH RES CO, V50, P430, DOI 10.1016/0006-291X(73)90858-9; STRECKER W, 1980, HORM METAB RES, V12, P604, DOI 10.1055/s-2007-999210; WEINBREN K, 1972, BRIT J EXP PATHOL, V53, P78; ZIVNY P, 1989, PHYSIOL BOHEMOSLOV, V38, P251	27	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					240	245		10.1096/fasebj.9.2.7781926	http://dx.doi.org/10.1096/fasebj.9.2.7781926			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781926				2022-12-28	WOS:A1995QJ24900012
J	CHO, MR; THATTE, HS; LEE, RC; GOLAN, DE				CHO, MR; THATTE, HS; LEE, RC; GOLAN, DE			INDUCED REDISTRIBUTION OF CELL-SURFACE RECEPTORS BY ALTERNATING-CURRENT ELECTRIC-FIELDS	FASEB JOURNAL			English	Article						CELLULAR ANISOTROPY; TRANSFERRIN RECEPTORS; LOW DENSITY; LIPOPROTEIN RECEPTORS; AC ELECTRIC FIELD	LOW-DENSITY LIPOPROTEIN; EMBRYONIC MUSCLE-CELL; HUMAN-FIBROBLASTS; ELECTROPHORESIS; DIFFUSION; MEMBRANES; CONCANAVALIN; MOTION; SHAPE	The molecular mechanisms that underlie the biological effects of low frequency sinusoidal electric fields may involve induced changes in the physical state of charged cell surface receptors. We have used intensified fluorescence video microscopy to study the redistribution of cell surface receptors, including transferrin receptors (T(F)R) and low density lipoprotein receptors (LDL-R), in response to externally applied alternating current electric fields in the 3 to 23 V/cm range (peak to peak). Redistribution of both T(F)R and LDL-R was prominent at frequencies of 1 and 10 Hz but negligible at frequencies of 60 and 120 Hz. Application of a 1 Hz, 23 V/cm field for 15 min caused a twofold change in local T(F)R surface density, whereas application of a 60 Hz, 23 V/cm field resulted in no significant T(F)R redistribution. The extent of T(F)R redistribution induced by a 1 Hz field changed by only 20% over the field strength range from 3.5 to 23 V/cm. AC field-induced cell surface receptor migration did not consistently follow electric field lines, suggesting that mechanisms more complex than classical electrophoresis and electroosmosis mediate receptor redistribution. Joule heating and plasma membrane calcium channel activation were shown not to be involved in the mechanism of receptor redistribution. Applied external electric fields may reorganize cytoskeletal and plasma membrane structures, providing pathways for cell surface receptors to migrate anharmonically.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,DEPT ORGANISMAL BIOL,CHICAGO,IL 60637	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Chicago; University of Chicago				Lee, Raphael C./0000-0002-6628-1867; Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-32854, HL-15157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032854, R37HL032854, P60HL015157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P517, DOI 10.1073/pnas.83.2.517; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; JAFFE LF, 1977, NATURE, V265, P600, DOI 10.1038/265600a0; JAFFE LF, 1979, J EXP ZOOL, V209, P115, DOI 10.1002/jez.1402090114; LEE RC, 1982, AM SURGEON, V48, P567; LEE RC, 1993, BIOPHYS J, V64, P44, DOI 10.1016/S0006-3495(93)81339-0; MCCLOSKEY M, 1984, INT REV CYTOL, V87, P19, DOI 10.1016/S0074-7696(08)62439-0; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; MCLEOD KJ, 1987, SCIENCE, V236, P1465, DOI 10.1126/science.3589667; OTTEWILL RH, 1987, NATURE, V325, P232, DOI 10.1038/325232a0; PATEL N, 1982, J NEUROSCI, V2, P483; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; POO MM, 1978, J CELL BIOL, V76, P483, DOI 10.1083/jcb.76.2.483; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; RODAN GA, 1978, SCIENCE, V199, P690, DOI 10.1126/science.625660; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; SISKEN BF, 1975, J EMBRYOL EXP MORPH, V33, P29; SMITH BA, 1979, P NATL ACAD SCI USA, V76, P5641, DOI 10.1073/pnas.76.11.5641; STOLPEN AH, 1988, P NATL ACAD SCI USA, V85, P1844, DOI 10.1073/pnas.85.6.1844; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; THATTE HS, 1994, IN PRESS J CELL PHYS; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; YECHIEL E, 1987, J CELL BIOL, V105, P755, DOI 10.1083/jcb.105.2.755	25	47	47	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					771	776		10.1096/fasebj.8.10.8050677	http://dx.doi.org/10.1096/fasebj.8.10.8050677			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050677				2022-12-28	WOS:A1994NY35000016
J	DANIEL, H; ADIBI, SA				DANIEL, H; ADIBI, SA			FUNCTIONAL SEPARATION OF DIPEPTIDE TRANSPORT AND HYDROLYSIS KIDNEY BRUSH-BORDER MEMBRANE-VESICLES	FASEB JOURNAL			English	Article						PEPTIDE TRANSPORT; PEPTIDE HYDROLYSIS; AMINOPEPTIDASES; BRUSH BORDER MEMBRANE VESICLES	AMINOPEPTIDASE-M; INTESTINE; LEUHISTIN; INHIBITOR; AFFINITY	Dipeptides serve as substrates for both transport and hydrolytic processes. This has caused uncertainty as to whether different systems mediate both processes, and if so, whether they can be functionally separated. To investigate these problems, we determined the effects of a series of compounds previously characterized as aminopeptidase (AP) inhibitors on transport and hydrolytic activities of the kidney brush border membrane. The substrate used for assaying transport activity was Gly-Gln whereas Leu-, Arg-, and Glu-nitroanilides, as well as Gly-Tyr and Ala-Tyr, were used in assaying hydrolytic activity. The AP inhibitors, arphamenines A and B and bestatin, strongly inhibited transport by the oligopeptide/H+ symporter (EC(50) values of 15 to 67 mu M). The mechanism of inhibition appeared to be competition for the binding site of the symporter. In contrast, leucinethiol, leuhistin, and amastatin had little or no effect on dipeptide transport (EC(50) values of 4 to more than 50 mM). Arphamenine and leucinethiol, in concentrations as high as 100 mu M, were found to be either ineffective or weak inhibitors of membrane-associated hydrolysis. In contrast, amastatin and leuhistin, in concentrations as low as 20 mu M, almost completely inhibited dipeptide hydrolysis. These results show that dipeptide hydrolysis can be selectively suppressed by either amastatin or leuhistin and dipeptide transport by arphamenine. Furthermore, the results provide new insight into the structural features of substrates that are recognized at the binding site of the oligopeptide/H+ symporter.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Daniel, Hannelore/B-8982-2009		NIDDK NIH HHS [DK-15861] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015861] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL W, 1974, METHOD ENZYMAT AN, V2, P950; BERTELOOT A, 1982, BIOCHIM BIOPHYS ACTA, V686, P47, DOI 10.1016/0005-2736(82)90150-X; DANIEL H, 1991, J BIOL CHEM, V266, P19917; DANIEL H, 1992, J BIOL CHEM, V267, P9565; GANAPATHY V, 1981, LIFE SCI, V29, P2451, DOI 10.1016/0024-3205(81)90699-8; HARBESON SL, 1988, BIOCHEMISTRY-US, V27, P7301, DOI 10.1021/bi00419a019; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; MIYAMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V978, P25, DOI 10.1016/0005-2736(89)90493-8; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; SKOPICKI HA, 1991, AM J PHYSIOL, V261, pF670, DOI 10.1152/ajprenal.1991.261.4.F670; YOSHIDA S, 1991, J ANTIBIOT, V44, P579, DOI 10.7164/antibiotics.44.579; YOSHIDA S, 1991, J ANTIBIOT, V44, P683, DOI 10.7164/antibiotics.44.683	12	33	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					753	759		10.1096/fasebj.8.10.8050675	http://dx.doi.org/10.1096/fasebj.8.10.8050675			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050675				2022-12-28	WOS:A1994NY35000013
J	DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P				DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P			FUNCTIONAL AND IMMUNOLOGICAL RELEVANCE OF THE COOH-TERMINAL EXTENSION OF HUMAN CHORIONIC GONADOTROPIN-BETA - IMPLICATIONS FOR THE WHO BIRTH-CONTROL VACCINE	FASEB JOURNAL			English	Note						WHO; BIRTH CONTROL VACCINE; HCG; HCG-BETA-CTP	MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; HUMAN CHORIOGONADOTROPIN; ANTIFERTILITY VACCINES; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; SUBUNIT; HCG	The World Health Organisation (WHO) Task Force on Birth Control Vaccines has selected the pregnancy hormone human chorionic gonadotropin (hCG) as a target molecule for a contraceptive vaccine. A synthetic peptide antigen corresponding to the amino acid sequence 109-145 of the carboxyl-terminal portion of the hCGbeta-subunit (hCGbetaCTP), which is supposed to elicit hCG-immunoneutralizing antibodies, has been submitted to clinical trails. Recent findings suggest that hCGbetaCTP does not play a role in the biological activity of hCG. This raises the question concerning the assumed mechanism of action of the hCGbetaCTP-based birth control vaccine. We therefore investigated the immunoneutralizing capacity of antibodies directed against hCGbetaCTP. Although it is possible to generate specific monoclonal and polyclonal antibodies for hCG by using hCGbetaCTP as an immunogen, it appeared that the biological response to hCG was not affected by such antibodies. The reason for this is that the hCG-antibody-complex is still able to bind to target cell receptors and therefore the intended contraceptive effect should not occur. In addition there is a risk of hazardous possible side effects such as an autoimmune reaction against the ovary because we found that at least one epitope is still accessible for antibody binding on receptor-bound hCG. We conclude from our results that both the efficacy and safety of the WHO vaccine are not yet ensured.	AUSTRIAN ACAD SCI, INST BIOMED AGING RES, RENNWEG 10, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK HOSP, DEPT OBSTET & GYNECOL, INNSBRUCK, AUSTRIA; ORGANON INT BV, DEPT ENDOCRINOL, OSS, NETHERLANDS; INST GUSTAVE ROUSSY, DEPT CLIN BIOL, F-94805 VILLEJUIF, FRANCE; UNIV HEIDELBERG, INST BIOCHEM 2, W-6900 HEIDELBERG, GERMANY; UNIV INNSBRUCK, INST GEN & EXPTL PATHOL, A-6020 INNSBRUCK, AUSTRIA	Austrian Academy of Sciences; Medical University of Innsbruck; UNICANCER; Gustave Roussy; Ruprecht Karls University Heidelberg; University of Innsbruck								BERGER P, 1987, NATURE, V326, P648, DOI 10.1038/326648a0; BERGER P, 1988, ENDOCRINOLOGY, V123, P2351, DOI 10.1210/endo-123-5-2351; BERGER P, 1990, J ENDOCRINOL, V125, P301, DOI 10.1677/joe.0.1250301; BERGER P, 1984, AM J REPROD IMMUNOL, V5, P157, DOI 10.1111/j.1600-0897.1984.tb00188.x; BERGER P, 1992, FOLLICLE STIMULATING, P319; BIDART JM, 1987, MOL IMMUNOL, V24, P339, DOI 10.1016/0161-5890(87)90175-1; BIRKEN S, 1982, ENDOCRINOLOGY, V110, P1555, DOI 10.1210/endo-110-5-1555; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN W, 1991, J BIOL CHEM, V266, P6264; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRIFFIN PD, 1991, STAT MED, V10, P177, DOI 10.1002/sim.4780100204; JONES WR, 1988, LANCET, V1, P1295; KOFLER R, 1982, AM J REPROD IMMUNOL, V2, P212, DOI 10.1111/j.1600-0897.1982.tb00168.x; KOFLER R, 1981, IMMUNOBIOLOGY, V160, P196, DOI 10.1016/S0171-2985(81)80047-2; MANNAERTS BMJ, 1987, NEUROENDOCRINOLOGY R, P49; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; ROSE NR, 1991, VACCINES FERTILITY R, P121; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHWARZ S, 1986, ENDOCRINOLOGY, V118, P189, DOI 10.1210/endo-118-1-189; SCHWARZ S, 1988, J RECEPTOR RES, V8, P437, DOI 10.3109/10799898809049003; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; STEVENS VC, 1986, IMMUNOL TODAY, V7, P369, DOI 10.1016/0167-5699(86)90029-0; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; YAMAMOTO Y, 1984, AM J REPROD IMMUNOL, V5, P164, DOI 10.1111/j.1600-0897.1984.tb00190.x	25	39	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1381	1385		10.1096/fasebj.7.14.7693535	http://dx.doi.org/10.1096/fasebj.7.14.7693535			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693535				2022-12-28	WOS:A1993MH00800011
J	KARCZMAR, AG				KARCZMAR, AG			RAUHSCHE NASE - THEN AND NOW	FASEB JOURNAL			English	Article							SKELETAL-MUSCLE FIBERS; CONTRACTION; TENSION; FROG				KARCZMAR, AG (corresponding author), EDWARD HINES JR VET ADM HOSP,RES SERV,HINES,IL 60141, USA.							AIDLEY DJ, 1987, PHYSL EXCITABLE CELL; BARTELS EM, 1979, ACTA PHYSIOL SCAND, V106, P129, DOI 10.1111/j.1748-1716.1979.tb06381.x; Berne R. M., 1993, PHYSIOLOGY, V3; CLAFLIN DR, 1990, BIOPHYS J, V57, P425, DOI 10.1016/S0006-3495(90)82559-5; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; Engelhardt WA, 1941, CR ACAD SCI URSS, V30, P644; Engelhardt WA, 1939, NATURE, V144, P668, DOI 10.1038/144668b0; Fischer E, 1926, PFLUG ARCH GES PHYS, V213, P352, DOI 10.1007/BF01733556; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GARTEN S, 1922, Z BIOL, V76, P43; Gopfert H, 1941, PFLUG ARCH GES PHYS, V245, P60; HAUGEN P, 1982, ACTA PHYSIOL SCAND, V114, P187, DOI 10.1111/j.1748-1716.1982.tb06971.x; HAUGEN P, 1976, J GEN PHYSIOL, V68, P247, DOI 10.1085/jgp.68.3.247; HAUGEN P, 1981, ACTA PHYSIOL SCAND, V112, P121, DOI 10.1111/j.1748-1716.1981.tb06794.x; HERBST M, 1974, BIOCHEM BIOPH RES CO, V57, P120, DOI 10.1016/S0006-291X(74)80365-7; HILL DK, 1968, J PHYSIOL-LONDON, V199, P637, DOI 10.1113/jphysiol.1968.sp008672; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, J PHYSIOL, V218, P59; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; KARCZMAR AG, 1967, PHYSIOL PHARMACOL, V3, P163; Kleinknecht F, 1924, Z BIOL-MUNICH, V81, P5; MORGAN DL, 1991, J PHYSIOL-LONDON, V441, P719, DOI 10.1113/jphysiol.1991.sp018775; MORGAN DL, 1990, BIOPHYS J, V57, P1001, DOI 10.1016/S0006-3495(90)82619-9; MULIERI LA, 1972, J PHYSIOL-LONDON, V233, P333; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; Rauh F, 1922, Z BIOL-MUNICH, V76, P25; ROOS J., 1931, PFLUGER S ARCH GES PHYSIOL, V229, P15; Sandow A, 1970, Annu Rev Physiol, V32, P87, DOI 10.1146/annurev.ph.32.030170.000511; Sandow A, 1944, J CELL COMPAR PHYSL, V24, P221, DOI 10.1002/jcp.1030240306; SANDOW A, 1966, MED COLL VA QUART, V2, P82; SANDOW A, 1964, FED PROC, V23, P366; SANDOW A, 1949, ANNU REV PHYSIOL, V11, P297, DOI 10.1146/annurev.ph.11.030149.001501; SANDOW A, 1952, AM J PHYSIOL, V169, P649, DOI 10.1152/ajplegacy.1952.169.3.649; SANDOW A, 1950, AM J PHYSIOL, V163, P247, DOI 10.1152/ajplegacy.1950.163.2.247; SANDOW A, 1943, YB AM PHIL SOC, P195; SANDOW A, 1943, FED PROC, V2, P43; Schaefer H, 1937, PFLUG ARCH GES PHYS, V238, P684, DOI 10.1007/BF01767676; SCHOEPFLE GM, 1945, J CELL COMPAR PHYSL, V26, P119, DOI 10.1002/jcp.1030260206; SZENTGYO.A, 1974, P NATL ACAD SCI USA, V71, P3343, DOI 10.1073/pnas.71.9.3343	39	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1414	1416		10.1096/fasebj.7.14.8224614	http://dx.doi.org/10.1096/fasebj.7.14.8224614			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224614				2022-12-28	WOS:A1993MH00800016
J	MUCKE, L; EDDLESTON, M				MUCKE, L; EDDLESTON, M			ASTROCYTES IN INFECTIOUS AND IMMUNE-MEDIATED DISEASES OF THE CENTRAL-NERVOUS-SYSTEM	FASEB JOURNAL			English	Review						ASTROCYTES; INFECTION; VIRAL; IMMUNE; MICROGLIA	TUMOR-NECROSIS-FACTOR; MYELIN BASIC-PROTEIN; INSITU HYBRIDIZATION; QUINOLINIC ACID; MHC ANTIGENS; BRAIN-CELLS; RAT-BRAIN; MICROGLIA; EXPRESSION; MOUSE	The central nervous system (CNS) can be invaded and damaged by a variety of microbes. The host response to such injury involves CNS cells, and in many cases hematogenous cells also. Recent experiments indicate that astrocytes, macroglial resident cells of the CNS, play key roles in this process. The astroglial production of trophic factors and elimination of neurotoxins are likely to fulfill important protective and reparative functions during CNS infection. In addition, astrocytes could, in concert with microglial cells, regulate the recruitment and activity of infiltrating hematogenous cells through their expression of cytokines, proteases, protease inhibitors, adhesion molecules, and extracellular matrix components. Although previous experiments suggested that astrocytes might initiate inflammatory demyelinating disease by presenting CNS antigens to autoreactive immune cells, current evidence points against such a detrimental activity. In view of the generally beneficial role of astrocytes, impairments of astroglial function by microbes or host-derived factors have the potential to contribute to neurologic disease. Diseases in which this pathogenetic process may be relevant include HIV-1-associated cognitive/motor complex and spongiform encephalopathies.			MUCKE, L (corresponding author), SCRIPPS RES INST, DEPT NEUROPHARMACOL, DIV VIROL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Mucke, Lennart/0000-0001-6256-9559	NIMH NIH HHS [MH47680] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM CR, 1993, IN PRESS BRAIN RES; Adams J. H., 1992, GREENFIELDS NEUROPAT; AKSAMIT AJ, 1986, NEUROLOGY, V36, P499, DOI 10.1212/WNL.36.4.499; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; AUBERT C, 1987, MICROB PATHOGENESIS, V3, P319, DOI 10.1016/0882-4010(87)90002-7; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1991, J NEUROSCI, V11, P3685; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CARBONE KM, 1991, J NEUROPATH EXP NEUR, V50, P205, DOI 10.1097/00005072-199105000-00003; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CHOI BH, 1990, AM J PATHOL, V137, P741; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COTMAN CW, 1989, BASIC NEUROCHEMISTRY, P507; DELAMONTE SM, 1987, NEUROLOGY, V37, P562, DOI 10.1212/WNL.37.4.562; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FEDOROFF S, 1986, ASTROCYTES, V2; FEDOROFF S, 1986, ASTROCYTES, V3; FEDOROFF S, 1986, ASTROCYTES, V1; FIERZ W, 1986, ASTROCYTES CELL BIOL, P203; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; GARLAND JM, 1991, CYTOKINE HDB, P269; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GRAEBER MB, 1993, GLIA, P7; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAYASHI T, 1988, ANN NEUROL, V24, P523, DOI 10.1002/ana.410240408; HERTZ L, 1990, IMMUNOL TODAY, V11, P265, DOI 10.1016/0167-5699(90)90106-J; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HOFFMANN MC, 1992, NEUROSCIENCE, V49, P397, DOI 10.1016/0306-4522(92)90105-B; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOSLI E, 1986, ASTROCYTES BIOCH PHY, P133; ITOYAMA Y, 1991, ANN NEUROL, V29, P285, DOI 10.1002/ana.410290310; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KOHLER C, 1988, NEUROSCIENCE, V27, P49, DOI 10.1016/0306-4522(88)90219-9; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; LAWRENCE JM, 1990, NEUROSCIENCE, V37, P431, DOI 10.1016/0306-4522(90)90413-X; LEE SC, 1993, J IMMUNOL, V150, P594; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIU Y, 1989, J NEUROIMMUNOL, V21, P157, DOI 10.1016/0165-5728(89)90171-9; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LYNCH WP, 1991, NEURON, V7, P365, DOI 10.1016/0896-6273(91)90289-C; MATSUMOTO Y, 1992, IMMUNOLOGY, V76, P209; MUCKE L, 1993, J NEUROPATH EXP NEUR, V52, P314, DOI 10.1097/00005072-199305000-00217; MUCKE L, 1993, TRANSGENE, V1, P3; Norenberg M. D., 1986, ASTROCYTES, V3, P425; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; PULLIAM L, 1993, AIDS RES HUM RETROV, V9, P439, DOI 10.1089/aid.1993.9.439; RINAMAN L, 1993, J NEUROSCI, V13, P685; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; SCHELD WM, 1991, INFECTIONS CENTRAL N; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHORE VG, 1987, J LIPID RES, V28, P119; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STEINIGER B, 1988, J NEUROIMMUNOL, V19, P111, DOI 10.1016/0165-5728(88)90040-9; STOWRING L, 1985, VIROLOGY, V141, P311, DOI 10.1016/0042-6822(85)90264-8; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; SUN D, 1986, NATURE, V320, P70, DOI 10.1038/320070a0; TORNATORE CB, 1993, IN PRESS PEDIATRIC A; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1990, J NEUROPATH EXP NEUR, V49, P21, DOI 10.1097/00005072-199001000-00003; VASS K, 1990, AM J PATHOL, V137, P789; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WILLIAMS K, 1992, J NEUROPATH EXP NEUR, V51, P538, DOI 10.1097/00005072-199209000-00009; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; ZLOTNIK I, 1968, BRIT J EXP PATHOL, V49, P555	78	201	203	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1226	1232		10.1096/fasebj.7.13.8405808	http://dx.doi.org/10.1096/fasebj.7.13.8405808			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405808				2022-12-28	WOS:A1993MB37600005
J	BRENGELMANN, GL				BRENGELMANN, GL			SPECIALIZED BRAIN COOLING IN HUMANS	FASEB JOURNAL			English	Article						BRAIN TEMPERATURE; TYMPANIC TEMPERATURE; FACE COOLING	CEREBRAL BLOOD-FLOW; TYMPANIC TEMPERATURES; HUMAN HEAD; HYPERTHERMIA; RESPONSES; EXERCISE	Humans, compared to other species, have exceptional capability for dissipation of heat from the entire skin surface. We can secrete more than two liters per hour of sweat, indefinitely. The corresponding potential for evaporative cooling is near a thousand watts, sufficient to compensate for the extreme high levels of heat production during exercise. Also, the blood vessels of our skin have exceptional capability to dilate and deliver heat to the body surface. These are our special adaptations for thermal stress. They allow prolonged heavy exercise with modest elevations in the temperature of the fluid that cools all the internal organs, not just the brain-arterial blood. The vascular architecture of the human head is radically different from that of animals that exhibit SBC. These species have special adaptations that reflect their dependence on respiratory evaporation, particularly the limitation imposed on capability to dispose of heat produced during exercise. The increase in blood temperature in an intense sprint would heat the well-perfused brain rapidly. But the heat exchange over the large surface area of contact between a venous plexus cooled by respiratory evaporation and the meshwork of arterial vessels in the carotid rete precools blood bound for the brain. Specialized cooling of the brain (SBC) has not been demonstrated by direct measurements in humans. Changes in tympanic temperature (T(ty)) are taken as evidence for SBC. This continues an unfortunate tradition of exaggeration of the significance of T(ty). In the only direct measurements available, brain temperature was unaffected by fanning the face although T(ty) did fall. What may appear to be a remnant of the carotid rete heat exchanger in humans is the intimate association between a short segment of the internal carotid artery and the plexus of veins in the cavernous sinus. Fortunately, the brain need not rely for its cooling on countercurrent heat exchange across this small surface area of contact. In humans, SBC stands for skin: the body cooler-we use our entire skin surface for heat dissipation.			BRENGELMANN, GL (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							AFONSO S, 1962, J APPL PHYSIOL, V17, P706, DOI 10.1152/jappl.1962.17.4.706; Anson BJ, 1973, SURG ANATOMY TEMPORA, P1; BENZINGER TH, 1969, J AMER MED ASSOC, V209, P1200, DOI 10.1001/jama.209.8.1200; BENZINGER TH, 1961, SCI AM, V204, P134, DOI 10.1038/scientificamerican0161-134; Boyd GI, 1930, J ANAT, V65, P108; BRENGELMANN GL, 1989, SCI F SPORTS MED, P77; BRENGELMANN GL, 1983, MAN STRESSFUL ENV TH, P5; BURGER FJ, 1964, AM J PHYSIOL, V206, P1057, DOI 10.1152/ajplegacy.1964.206.5.1057; CABANAC M, 1985, EUR J APPL PHYSIOL O, V54, P172, DOI 10.1007/BF02335925; CABANAC M, 1987, EUR J APPL PHYSIOL O, V56, P534, DOI 10.1007/BF00635366; CABANAC M, 1986, NEWS PHYSIOL SCI, V1, P41; COOPER T, 1959, J APPL PHYSIOL, V14, P207, DOI 10.1152/jappl.1959.14.2.207; CREZEE J, 1992, PHYS MED BIOL, V37, P1321, DOI 10.1088/0031-9155/37/6/009; DUCHARME MB, 1991, J APPL PHYSIOL, V71, P1973, DOI 10.1152/jappl.1991.71.5.1973; Edvinsson L, 1993, CEREBRAL BLOOD FLOW, V1185, P1; FROESE G, 1957, J APPL PHYSIOL, V10, P235, DOI 10.1152/jappl.1957.10.2.235; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRAF W, 1959, ACTA PHYSL SCAND S, V46, P5; GRAF W, 1959, ACTA PHYSL SCAND S, V46, P160; HAYWARD JN, 1968, AM J PHYSIOL, V215, P389, DOI 10.1152/ajplegacy.1968.215.2.389; JANSSEN S, 1957, ARCH EXP PATHOL PH, V230, P245; JESSEN C, 1992, J APPL PHYSIOL, V72, P664, DOI 10.1152/jappl.1992.72.2.664; KISSEN AT, 1971, AEROSPACE MED, V42, P882; KOHSHI K, 1990, J APPL PHYSIOL, V69, P1419, DOI 10.1152/jappl.1990.69.4.1419; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; LEMONS DE, 1987, AM J PHYSIOL, V253, pR128, DOI 10.1152/ajpregu.1987.253.1.R128; MCCAFFREY TV, 1975, J APPL PHYSIOL, V39, P114, DOI 10.1152/jappl.1975.39.1.114; MCHEDLISHVILI G, 1986, ARTERIAL BEHAVIOR BL, P1; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; NIELSEN B, 1965, ACTA PHYSIOL SCAND, V64, P314, DOI 10.1111/j.1748-1716.1965.tb04185.x; NIELSEN B, 1992, PFLUG ARCH EUR J PHY, V422, P168, DOI 10.1007/BF00370416; RASCH W, 1991, J APPL PHYSIOL, V71, P590, DOI 10.1152/jappl.1991.71.2.590; ROGERS HB, 1990, J APPL PHYSIOL, V68, P2358, DOI 10.1152/jappl.1990.68.6.2358; ROWELL LB, 1986, HUMAN CIRCULATION RE, P1; RUBENSTEIN E, 1960, J APPL PHYSIOL, V15, P603, DOI 10.1152/jappl.1960.15.4.603; SALTIN B, 1968, J APPL PHYSIOL, V25, P679, DOI 10.1152/jappl.1968.25.6.679; SHIRAKI K, 1986, J APPL PHYSIOL, V61, P98, DOI 10.1152/jappl.1986.61.1.98; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482, DOI 10.1152/jappl.1988.65.1.482; TABOR MW, 1981, ORAL SURG ORAL MED O, V51, P581, DOI 10.1016/S0030-4220(81)80003-5; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744, DOI 10.1152/jappl.1989.67.2.744; TOGAWA T, 1985, CLIN PHYS PHYSIOL M, V6, P83, DOI 10.1088/0143-0815/6/2/001; TONNESEN AS, 1987, J APPL PHYSIOL, V62, P1596, DOI 10.1152/jappl.1987.62.4.1596; WALLACE CT, 1974, ANESTHESIOLOGY, V41, P290, DOI 10.1097/00000542-197409000-00015; WENGER CB, 1987, NEWS PHYSIOL SCI, V2, P150; 1973, GRAYS ANATOMY	45	82	93	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1148	1152		10.1096/fasebj.7.12.8375613	http://dx.doi.org/10.1096/fasebj.7.12.8375613			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375613				2022-12-28	WOS:A1993LW81700008
J	COPPES, MJ; CAMPBELL, CE; WILLIAMS, BRG				COPPES, MJ; CAMPBELL, CE; WILLIAMS, BRG			THE ROLE OF WT1 IN WILMS TUMORIGENESIS	FASEB JOURNAL			English	Review						CLONING; WT1 MUTATIONS	DENYS-DRASH SYNDROME; ZINC-FINGER GENE; FACTOR-II GENE; TUMOR LOCUS; EPIDEMIOLOGICAL FEATURES; FAMILIAL PREDISPOSITION; UROGENITAL DEVELOPMENT; DNA RECOGNITION; H19 GENE; EXPRESSION	Genetic alterations in tumor suppressor genes are believed to play an important role in the initiation of childhood and adult malignancies. Tumor-specific loss of heterozygosity for particular chromosomal regions has provided the starting point for the cloning of different tumor suppressor genes, including the Wilms tumor predisposing gene, WT1, at chromosome 11p13. This article reviews the pathology and genetics of Wilms tumor, the cloning of WT1, and the WT1 mutations reported thus far in 15 hereditary and nonhereditary Wilms tumors. The presence of constitutional WT1 mutations in 35 patients with the Denys-Drash syndrome (a syndrome consisting of nephropathy, intersex disorders, and Wilms tumor) is also described. To date, mutations in the WT1 gene have been found in less than 10% of Wilms tumors specimens examined and in greater than 95% of Denys-Drash patients. The possible significance of this observation with regard to both the cellular function of the WT1 protein and the involvement of alternative loci in the development of Wilms tumor is discussed.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL NN106,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRESLOW N, 1988, CANCER RES, V48, P1653; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1989, J CLIN ONCOL, V7, P310, DOI 10.1200/JCO.1989.7.3.310; COPPES MJ, 1993, J PEDIATRICS; COWELL JK, 1991, ONCOGENE, V6, P595; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HALL JG, 1990, AM J HUM GENET, V46, P857; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUFF V, 1991, AM J HUM GENET, V49, P44; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LEMERLE J, 1983, J CLIN ONCOL, V1, P604, DOI 10.1200/JCO.1983.1.10.604; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; LITTLE MH, 1992, ONCOGENE, V7, P635; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANNENS M, 1990, CANCER RES, V50, P3279; MAW MA, 1992, CANCER RES, V52, P3094; OGAWA O, 1993, INPRESS NATURE LONDO; OGAWA O, 1993, IN PRESS HUM MOL GEN; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WILKINS RJ, 1988, LANCET, V1, P329; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	57	151	155	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					886	895		10.1096/fasebj.7.10.8393819	http://dx.doi.org/10.1096/fasebj.7.10.8393819			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393819				2022-12-28	WOS:A1993LQ33700011
J	LI, B; FIELDS, S				LI, B; FIELDS, S			IDENTIFICATION OF MUTATIONS IN P53 THAT AFFECT ITS BINDING TO SV40 LARGE T-ANTIGEN BY USING THE YEAST 2-HYBRID SYSTEM	FASEB JOURNAL			English	Note						P53 PROTEIN; T-ANTIGEN; 2-HYBRID ASSAY	DNA-BINDING; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; PROTEINS BIND; WILD-TYPE; REPLICATION; SEQUENCE; DOMAIN; TRANSCRIPTION; COMPLEXES	The tumor suppressor p53 protein binds to the products of several viral oncogenes, including SV40 large T antigen. We reconstructed the p53-T antigen interaction in the yeast two-hybrid system, a genetic assay that uses the reconstitution of the activity of a transcriptional activator to detect protein-protein interactions. Using mutants of T antigen known to be defective in binding to p53, we demonstrate that the two-hybrid system is more sensitive than immunoprecipitation in the detection of weak interactions. We mutagenized the murine p53 gene and screened in the yeast assay for decreased reporter gene expression indicative of the failure of p53 to bind T antigen. This screen identified 34 p53 mutants, almost all of which contain at least one mutation in the conserved domains frequently found mutated in human cancers. These results support the idea that the function of the wild-type p53 protein requires residues involved in binding to T antigen, and indicate that this approach may be generally applicable in the analysis of protein-protein interactions.	SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	LI, B (corresponding author), SUNY,GRAD PROGRAM MOLEC & CELLULAR BIOL,STONY BROOK,NY 11794, USA.				NATIONAL CANCER INSTITUTE [R01CA054699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE A, 1987, NATURE, V329, P456; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1993, IN PRESS ONCOGENE; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leung DW, 1989, TECHNIQUE, V1, P11; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Miller J.H., 1972, EXPT MOL GENETICS; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	29	196	215	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					957	963		10.1096/fasebj.7.10.8344494	http://dx.doi.org/10.1096/fasebj.7.10.8344494			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344494				2022-12-28	WOS:A1993LQ33700021
J	YOKOTA, J; SUGIMURA, T				YOKOTA, J; SUGIMURA, T			MULTIPLE STEPS IN CARCINOGENESIS INVOLVING ALTERATIONS OF MULTIPLE TUMOR-SUPPRESSOR GENES	FASEB JOURNAL			English	Review						TUMOR SUPPRESSOR GENE; MULTISTAGE CARCINOGENESIS; RB; P53; LOSS OF HETEROZYGOSITY	PRIMARY BREAST-CANCER; SMALL-CELL CARCINOMA; WILD-TYPE P53; RETINOBLASTOMA GENE; HUMAN SARCOMAS; LUNG-CANCER; C-MYC; MULTISTEP CARCINOGENESIS; COLORECTAL TUMORIGENESIS; HEPATOCELLULAR-CARCINOMA	Recent advances in molecular genetics have made it possible to understand the molecular mechanisms of human cancer progression. The results indicate that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration occurs during tumor progression. It is widely accepted that tumor suppressor genes play a central role in the genesis and progression of human cancers, as frequent alterations of tumor suppressor genes have been found in a variety of human cancers. Molecular analyses of various stages of human cancers, from precancerous lesions to advanced or metastatic tumors, indicate that sequential accumulation of genetic alterations correlates with more malignant phenotypes of tumor cells. Furthermore, biological studies of tumor suppressor genes have revealed that a single gene defect is not sufficient for the cells to gain growth advantage and start clonal expansion in vivo. These results are consistent with the concept of human multistage carcinogenesis, indicated by experimental animal models and epidemiological studies. Although it is supposed that there are more than 20 tumor suppressor genes in the human genome, only a few tumor suppressor genes have been identified to date. Thus, further studies should focus on the identification and characterization of novel tumor suppressor genes, and molecular analysis of those genes in human cancer would be of great help in clarifying the multiple steps in the process of human carcinogenesis.			YOKOTA, J (corresponding author), NATL CANC CTR, RES INST, DIV BIOL, 1-1 TSUKIJI 5 CHOME, CHUO KU, TOKYO 104, JAPAN.							BAKER SJ, 1990, CANCER RES, V50, P7717; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, PRINCESS TAKAMATSU S, V22, P37; FEY MF, 1989, BRIT J CANCER, V59, P750, DOI 10.1038/bjc.1989.157; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIROHASHI S, 1992, PRINCESS TAKAMATSU S, V22, P87; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAMES CD, 1988, CANCER RES, V48, P5546; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; ODA T, 1992, CANCER RES, V52, P6358; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; OOKAWA K, 1993, IN PRESS ONCOGENE; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PITOT HC, 1992, PRINCESS TAKAMATSU S, V22, P21; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1990, CANCER RES, V50, P7184; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOZZI G, 1992, CANCER RES, V52, P6079; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607; YOKOTA J, 1990, GENETIC BASIS FOR CARCINOGENESIS, P43; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	56	120	123	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					920	925		10.1096/fasebj.7.10.8344488	http://dx.doi.org/10.1096/fasebj.7.10.8344488			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344488				2022-12-28	WOS:A1993LQ33700015
J	KRAUTHSIEGEL, RL; SCHONECK, R				KRAUTHSIEGEL, RL; SCHONECK, R			FLAVOPROTEIN STRUCTURE AND MECHANISM .5. TRYPANOTHIONE REDUCTASE AND LIPOAMIDE DEHYDROGENASE AS TARGETS FOR A STRUCTURE-BASED DRUG DESIGN	FASEB JOURNAL			English	Review						TRYPANOTHIONE REDUCTASE; LIPOAMIDE DEHYDROGENASE; DRUG DESIGN; CHAGAS DISEASE; FLAVOPROTEIN STRUCTURES	GLUTATHIONE-REDUCTASE; TRYPANOSOMA-CRUZI; CRITHIDIA-FASCICULATA; ESCHERICHIA-COLI; DIHYDROLIPOAMIDE DEHYDROGENASE; DISULFIDE OXIDOREDUCTASES; SUBSTRATE-SPECIFICITY; ARSENICAL-RESISTANT; SUPEROXIDE ANION; ENZYME	Trypanothione reductase (TR) is a flavoenzyme that has been found only in parasitic protozoa of the order Kinetoplastida. The enzyme catalyzes the NADPH-dependent reduction of glutathionylspermidine conjugates and is a key enzyme of the parasite's thiol metabolism, Consequently, TR is an attractive target molecule for a structure-based drug development against Chagas' disease, African sleeping sickness, and other diseases caused by trypanosomes and leishmanias. The three-dimensional structures of TR and of three enzyme substrate complexes have been solved, Several classes of compounds are discussed as guide structures for the design of specific inhibitors. Among them are tricyclic compounds such as acridines and phenothiazines, which competitively inhibit TR but not the related host enzyme glutathione reductase, as well as oxidase activity-inducing quinones and nitrofurans. Lipoamide dehydrogenase (LipDH) is another flavoprotein discussed as a target molecule for an antitrypanosomal therapy. In Trypnnosoma cruzi, an organism that is highly susceptible to oxidative stress, LipDH participates in the redox cycling of nifurtimox, one of the most effective anti-Chagas agents. In conclusion, the structurally related enzymes TR and LipDH exhibit an unusually high one-electron-reducing capacity. Consequently, turncoat inhibitors and other compounds inducing an oxidase activity in both enzymes are promising drug candidates against Chagas' disease.			KRAUTHSIEGEL, RL (corresponding author), UNIV HEIDELBERG, INST BIOCHEM 2, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.							ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; BAILEY S, 1993, EUR J BIOCHEM, V213, P67, DOI 10.1111/j.1432-1033.1993.tb17734.x; BAILEY S, 1994, ACTA CRYSTALLOGR B, V50, P193; BENSON TJ, 1992, BIOCHEM J, V286, P9, DOI 10.1042/bj2860009; BRADLEY M, 1991, BIOCHEMISTRY-US, V30, P6124, DOI 10.1021/bi00239a006; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CENAS N, 1994, BIOCHEM BIOPH RES CO, V204, P221; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CUNNINGHAM ML, 1994, EUR J BIOCHEM, V221, P285, DOI 10.1111/j.1432-1033.1994.tb18740.x; DOCAMPO R, 1979, ARCH BIOCHEM BIOPHYS, V197, P317, DOI 10.1016/0003-9861(79)90251-0; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; ELSE AJ, 1993, EUR J BIOCHEM, V212, P423, DOI 10.1111/j.1432-1033.1993.tb17678.x; EVANS AT, 1994, BIOCHEM PHARMACOL, V48, P613, DOI 10.1016/0006-2952(94)90293-3; FAIRLAMB AH, 1989, PARASITOLOGY, V99, pS93, DOI 10.1017/S003118200008344X; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P223, DOI 10.1016/0166-6851(92)90024-E; FIELD H, 1992, MOL BIOCHEM PARASIT, V50, P47, DOI 10.1016/0166-6851(92)90243-D; FROST SC, 1985, J BIOL CHEM, V260, P2646; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; GRINBLAT L, 1991, BIOCHEM INT, V23, P83; HENDERSON GB, 1991, P NATL ACAD SCI USA, V88, P8769, DOI 10.1073/pnas.88.19.8769; HENDERSON GB, 1988, P NATL ACAD SCI USA, V85, P5374, DOI 10.1073/pnas.85.15.5374; HUNTER WN, 1992, J MOL BIOL, V227, P322, DOI 10.1016/0022-2836(92)90701-K; JOCKERSSCHERUBL MC, 1989, EUR J BIOCHEM, V180, P267, DOI 10.1111/j.1432-1033.1989.tb14643.x; KAGAN VE, 1992, BIOCHEM PHARMACOL, V44, P1637, DOI 10.1016/0006-2952(92)90482-X; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; Krauth-Siegel R.L., 1991, P493; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; KRAUTHSIEGEL RL, 1987, EUR J BIOCHEM, V164, P123, DOI 10.1111/j.1432-1033.1987.tb11002.x; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; KUWAHARA T, 1985, ARCH BIOCHEM BIOPHYS, V241, P45, DOI 10.1016/0003-9861(85)90359-5; LANTWIN CB, 1994, PROTEINS, V18, P161, DOI 10.1002/prot.340180208; LOHRER H, 1990, EUR J BIOCHEM, V194, P863, DOI 10.1111/j.1432-1033.1990.tb19480.x; MASLOV DA, 1995, PARASITOL TODAY, V11, P1; RICHARME G, 1986, EUR J BIOCHEM, V156, P399, DOI 10.1111/j.1432-1033.1986.tb09596.x; Schirmer R. H., 1989, GLUTATHIONE CHEM B A, P553; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; SREIDER CM, 1992, BIOCHEM INT, V28, P323; SULLIVAN FX, 1991, BIOCHEMISTRY-US, V30, P2761, DOI 10.1021/bi00225a004; SULLIVAN FX, 1989, BIOCHEMISTRY-US, V28, P4986, DOI 10.1021/bi00438a013; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TAYLOR MC, 1994, MOL BIOCHEM PARASIT, V64, P293, DOI 10.1016/0166-6851(94)00034-4; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TROMELIN A, 1993, BIOORG MED CHEM LETT, V3, P1971, DOI 10.1016/S0960-894X(01)80997-5; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	49	69	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1138	1146		10.1096/fasebj.9.12.7672506	http://dx.doi.org/10.1096/fasebj.9.12.7672506			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672506				2022-12-28	WOS:A1995RU81600003
J	FETROW, JS				FETROW, JS			PROTEIN MOTIFS .6. OMEGA-LOOPS - NONREGULAR SECONDARY STRUCTURES SIGNIFICANT IN PROTEIN FUNCTION AND STABILITY	FASEB JOURNAL			English	Review						OMEGA LOOPS; PROTEIN SECONDARY STRUCTURE; NONREGULAR SECONDARY STRUCTURE; PROTEIN STRUCTURE CLASSIFICATION	COLI DIHYDROFOLATE-REDUCTASE; C-TERMINAL DOMAIN; CONFORMATIONAL CHANGE; FLEXIBLE LOOP; SURFACE LOOP; TRIOSEPHOSPHATE ISOMERASE; STAPHYLOCOCCAL NUCLEASE; TRYPTOPHAN SYNTHASE; GLOBULAR-PROTEINS; ALPHA-SUBUNIT	Omega (Omega-) loops, a nonregular secondary structure found in globular proteins, are characterized by a polypeptide chain that follows a loop-shaped course in three-dimensional space, They do not contain repeating backbone dihedral angles or regular patterns of hydrogen bonding; however, many Omega-loops contain a large number of hydrogen bonds, therefore it is not correct to think of Omega-loops as structures lacking in hydrogen bonds, Omega-Loops are found almost exclusively at the protein surface and exhibit amino acid preferences consistent with this observation, Since the first description of Omega-loops in 1986, experiments have been conducted to probe the role of these structures in protein function, stability, and folding, It has become clear that Omega-loops are often involved in protein function and molecular recognition, One motif, an Omega-loop lid, that is flexible and mobile until substrate or inhibitor is bound and which probably plays a role in one or more steps of enzymatic catalysis, has been described in a variety of enzymes, Because they lack the periodic hydrogen bonding patterns of the regular secondary structures, some Omega-loops are well suited for such functional roles in proteins, However, loops with a higher-than-average number of hydrogen bonds or hydrophobic contacts may play roles in protein stability or folding, Rather than determining further geometric definitions of loops, it may be instructional to group them according to their roles in protein structure, i.e., as categories of functional Omega-loops, stability Omega-loops, and folding Omega-loops.			FETROW, JS (corresponding author), SUNY ALBANY,CTR MOLEC GENET,DEPT BIOL SCI,1400 WASHINGTON AVE,ALBANY,NY 12222, USA.			Fetrow, Jacquelyn/0000-0002-0528-2049	NIGMS NIH HHS [GM44829] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044829] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, J BIOL CHEM, V263, P14925; BALDISSERI DM, 1991, BIOCHEMISTRY-US, V30, P3628, DOI 10.1021/bi00229a006; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHRUNYK BA, 1993, PROTEIN ENG, V6, P733, DOI 10.1093/protein/6.7.733; COLLOCH N, 1991, J MOL BIOL, V221, P603, DOI 10.1016/0022-2836(91)80075-6; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; EDWARDS MS, 1987, PROTEIN ENG, V1, P173, DOI 10.1093/protein/1.3.173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FETROW JS, 1989, PROTEINS, V6, P372, DOI 10.1002/prot.340060404; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13658, DOI 10.1021/bi00212a034; GEKKO K, 1993, J BIOCHEM-TOKYO, V113, P74, DOI 10.1093/oxfordjournals.jbchem.a124007; GOOLEY PR, 1988, BIOCHEMISTRY-US, V27, P802, DOI 10.1021/bi00402a047; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOEDEMAEKER FJ, 1993, PLANT MOL BIOL, V22, P1039, DOI 10.1007/BF00028976; JAPPELLI R, 1992, J MOL BIOL, V227, P532, DOI 10.1016/0022-2836(92)90905-Y; JIMENEZ MA, 1993, EUR J BIOCHEM, V211, P569, DOI 10.1111/j.1432-1033.1993.tb17584.x; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KUIPERS OP, 1989, SCIENCE, V244, P82, DOI 10.1126/science.2704992; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MATOUSCHEK A, 1990, NATURE, V346, P400; MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3; MURPHY MEP, 1993, PROTEIN SCI, V2, P1429, DOI 10.1002/pro.5560020907; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PAULING L, 1951, P NATL ACAD SCI USA, V37, P729, DOI 10.1073/pnas.37.11.729; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; PAVONE V, 1988, INT J BIOL MACROMOL, V10, P238, DOI 10.1016/0141-8130(88)90054-2; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; POOLE LB, 1991, BIOCHEMISTRY-US, V30, P3621, DOI 10.1021/bi00229a005; RICE PA, 1990, PROTEINS, V8, P334, DOI 10.1002/prot.340080407; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RING CS, 1992, J MOL BIOL, V224, P685, DOI 10.1016/0022-2836(92)90553-V; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SARABU R, 1993, TETRAHEDRON, V49, P3629, DOI 10.1016/S0040-4020(01)90219-4; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; VENKATACHALAM CM, 1968, BIOPOLYMERS, V6, P1425, DOI 10.1002/bip.1968.360061006; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YAMAGUCHI H, 1993, J MOL BIOL, V234, P1083; ZEHFUS MH, 1986, BIOCHEMISTRY-US, V25, P5759, DOI 10.1021/bi00367a062	57	158	159	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					708	717		10.1096/fasebj.9.9.7601335	http://dx.doi.org/10.1096/fasebj.9.9.7601335			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601335				2022-12-28	WOS:A1995RH98200004
J	BLACKMAN, CF; BLANCHARD, JP; BENANE, SG; HOUSE, DE				BLACKMAN, CF; BLANCHARD, JP; BENANE, SG; HOUSE, DE			THE ION PARAMETRIC RESONANCE MODEL PREDICTS MAGNETIC-FIELD PARAMETERS THAT AFFECT NERVE-CELLS	FASEB JOURNAL			English	Article						PC-12 CELLS; NERVE GROWTH FACTOR; NGF, MAGNETIC FIELDS; IPR MODEL	GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; QUANTITATIVE BIOASSAY; NEURITE OUTGROWTH; PC12 CELLS; PROTEIN-2; KINASE; LINE	An ion parametric resonance (IPR) model recently developed by Blanchard and Blackman predicts distinct magnetic field interactions with biological systems based on a selective relation among four factors: the flux density of the static magnetic field, the frequency and flux density (B-ac) of the parallel ac magnetic field, and the charge to-mass ratio of ions of biological relevance, To test this model, PC-12 cells stimulated by nerve growth factor to produce neurites were exposed for 23 h in a 5% CO2 incubator using a multiple coil exposure system to produce 45 Hz ac and de (366 mG parallel to ac; less than 2 mG perpendicular to ac) magnetic fields, Our earlier work showed a cycle of inhibition/no inhibition of neurite outgrowth consistent with the IPR model predictions for B-ac exposures between 0 and 468 mG rms, The work described here tests neurite outgrowth over a broader range of B-ac (233-1416 mG rms), The experimental results remain consistent with earlier results, and with IPR model predictions of a second cycle of inhibition, return to control values, followed by a third cycle of inhibition of neurite outgrowth, These responses support the fundamental relationships predicted by the IPR model, The results have broad significance for biology.	BECHTEL CORP,RES & DEV,SAN FRANCISCO,CA 94119		BLACKMAN, CF (corresponding author), US EPA,HLTH EFFECTS RES LAB,MD-68,RES TRIANGLE PK,NC 27711, USA.		Blackman, Carl/O-1951-2016	Blackman, Carl/0000-0003-3267-5224				BLACKMAN CF, 1994, BIOELECTROMAGNETICS, V15, P239, DOI 10.1002/bem.2250150307; BLACKMAN CF, 1993, FASEB J, V7, P801, DOI 10.1096/fasebj.7.9.8330687; BLACKMAN CF, 1993, BIOELECTROMAGNETICS, V14, P273, DOI 10.1002/bem.2250140310; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; BLANCHARD JP, 1994, IN PRESS BIOELECTROM; BLANCHARD JP, 1994, NATURE ELECTROMAGNET, P43; CARPENTER DO, 1994, BIOL EFFECTS ELECTRI, V2; CARPENTER DO, 1994, BIOL EFFECTS ELECTRI, V1; FREY AH, 1994, NATURE ELECTROMAGNET; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; KOBAYASHI AK, 1995, NATURE, V374, P123, DOI 10.1038/374123a0; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; RUKENSTEIN A, 1983, BRAIN RES, V263, P177, DOI 10.1016/0006-8993(83)91218-0; SANO M, 1992, J NEUROCHEM, V59, P1263, DOI 10.1111/j.1471-4159.1992.tb08436.x; SMITH RF, 1988, BIOELECTROMAGNETICS, V9, P387, DOI 10.1002/bem.2250090409; TRILLO A, 1994, 16TH ANN M BIOEL SOC	17	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					547	551		10.1096/fasebj.9.7.7737464	http://dx.doi.org/10.1096/fasebj.9.7.7737464			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737464				2022-12-28	WOS:A1995QX14800013
J	STUMPF, PK				STUMPF, PK			THEN	FASEB JOURNAL			English	Editorial Material											STUMPF, PK (corresponding author), UNIV CALIF DAVIS,MOLEC & CELULAR BIOL SECT,DAVIS,CA 95616, USA.							STUMPF PK, 1945, FED PROC, V4, P106	1	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					458	459		10.1096/fasebj.9.5.7896020	http://dx.doi.org/10.1096/fasebj.9.5.7896020			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896020				2022-12-28	WOS:A1995QP45100023
J	MEHENDALE, HM; ROTH, RA; GANDOLFI, AJ; KLAUNIG, JE; LEMASTERS, JJ; CURTIS, LR				MEHENDALE, HM; ROTH, RA; GANDOLFI, AJ; KLAUNIG, JE; LEMASTERS, JJ; CURTIS, LR			NOVEL MECHANISMS IN CHEMICALLY-INDUCED HEPATOTOXICITY	FASEB JOURNAL			English	Review						ALPHA-NAPHTHYLISOTHIOCYANATE; AUTOPROTECTION; CARBON TETRACHLORIDE; GAP JUNCTION; GLUTATHIONE; HALOTHANE; HEPATITIS; HYPOXIA; INTRACELLULAR PH; NEUTROPHIL; TISSUE REPAIR	INDUCED LIVER-INJURY; NONPROTEIN SULFHYDRYL CONTENT; INTER-CELLULAR COMMUNICATION; ALPHA-NAPHTHYLISOTHIOCYANATE; RAT HEPATOCYTES; LETHAL INJURY; INTERCELLULAR COMMUNICATION; CARBON-TETRACHLORIDE; CCL4 AUTOPROTECTION; OXIDANT CHEMICALS	This review focuses on cellular events that modulate hepatotoxicity subsequent to initial liver insult. Cellular events that determine the nature and extent of hepatotoxic injury and the ultimate outcome of that injury are also discussed. The roles of cell types other than hepatocytes, hepatocyte organelle-specific processes, and regeneration in progression or recovery from liver injury are emphasized. Leukocyte activities are key events in two distinct hepatotoxicities. Neutrophil-mediated, periportal inflammation appears to play a primary role in progression of alpha-naphthylisothiocyanate-induced cholangiolitic hepatitis. However, a humorally mediated autoimmune response to protein adducts that occurs after anesthesia is critical in onset of halothane-induced hepatitis. New insights into specific events at the hepatocyte level are also emerging. Although reducing gap junctional communication between hepatocytes can protect against progression of liver injury, down-regulation of the subunit proteins (connexins) can isolate neoplastic cells from growth regulation. Acidic intracellular pH characteristic of hypoxia is protective against both hypoxic and toxicant-induced cell injury. In oxidative injury, a pH-mediated mitochondrial permeability transition causes mitochondrial uncoupling and ATP loss and leads to cell death. The ultimate outcome of hepatotoxic injury depends on the extent of tissue repair. Stimulation of tissue repair after a sublethal dose of CCl4 appears to be the central mechanism in protection against death from a subsequent large dose. Taken together, these examples illustrate the importance of events subsequent to initial liver injury as determinants of extent of liver damage.-Mehendale, H. M., Roth, R. A., Gandolfi, A. J., Klaunig, J. E., Lemasters, J. J., Curtis, L. R. Novel mechanisms in chemically induced hepatotoxicity.	MICHIGAN STATE UNIV,DEPT PHARMACOL & TOXICOL,E LANSING,MI 48824; UNIV ARIZONA,DEPT ANESTHESIOL,TUCSON,AZ 85724; INDIANA UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,INDIANAPOLIS,IN 46202; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; OREGON STATE UNIV,DEPT FISHERIES & WILDLIFE,CORVALLIS,OR 97331	Michigan State University; University of Arizona; Indiana University System; Indiana University-Purdue University Indianapolis; University of North Carolina; University of North Carolina Chapel Hill; Oregon State University	MEHENDALE, HM (corresponding author), NE LOUISIANA UNIV,COLL PHARM & HLTH SCI,SCH PHARM,DIV PHARMACOL,MONROE,LA 71209, USA.			Klaunig, James/0000-0002-4736-2223	NIA NIH HHS [AG07218] Funding Source: Medline; NIDDK NIH HHS [DK37034] Funding Source: Medline; NIEHS NIH HHS [ES04139] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037034, R01DK037034, R37DK037034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007218, R37AG007218] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERS MW, 1988, CRC CR REV TOXICOL, V18, P311, DOI 10.3109/10408448809037470; ANUNDI I, 1987, AM J PHYSIOL, V253, pG390, DOI 10.1152/ajpgi.1987.253.3.G390; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOND JM, 1993, AM J PHYSIOL, V265, pC129, DOI 10.1152/ajpcell.1993.265.1.C129; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; BROWN BR, 1987, BRIT J ANAESTH, V59, P14, DOI 10.1093/bja/59.1.14; BRUGGEMAN IM, 1986, TOXICOL APPL PHARM, V83, P349, DOI 10.1016/0041-008X(86)90312-1; CALABRESE EJ, 1993, TOXICOL APPL PHARM, V121, P1, DOI 10.1006/taap.1993.1121; CALCAMUGGI G, 1992, ARCH TOXICOL, V66, P126, DOI 10.1007/BF02342506; CARPENTERDEYO L, 1991, BIOCHEM PHARMACOL, V42, P2171, DOI 10.1016/0006-2952(91)90353-7; CHANDA S, 1995, IN PRESS HEPATOLOGY; CLARKE JB, 1992, ADV ANESTHESIA, V10, P219; CLARKE JB, 1993, TOXICOLOGIST, V13, P359; CONNOLLY AK, 1988, TOXICOL APPL PHARM, V93, P208, DOI 10.1016/0041-008X(88)90121-4; CORCORAN GB, 1992, TOXICOL APPL PHARM, V113, P167, DOI 10.1016/0041-008X(92)90112-6; DAHM LJ, 1991, BIOCHEM PHARMACOL, V42, P1181, DOI 10.1016/0006-2952(91)90252-Z; DAHM LJ, 1991, BIOCHEM PHARMACOL, V42, P1189, DOI 10.1016/0006-2952(91)90253-2; DAHM LJ, 1991, J PHARMACOL EXP THER, V256, P412; DIMONTE D, 1988, BIOCHEM BIOPH RES CO, V153, P734, DOI 10.1016/S0006-291X(88)81156-2; FLORSCHEIM GL, 1966, BIOCHEM PHARMACOL, V13, P1589; GANEY PE, 1994, LAB INVEST, V70, P53; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GUIGUI B, 1988, LAB INVEST, V59, P831; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GUT J, 1993, PHARMACOL THERAPEUT, V58, P133, DOI 10.1016/0163-7258(93)90047-H; HARMAN AW, 1992, MOL PHARMACOL, V41, P665; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; HEWETT JA, 1992, LAB INVEST, V66, P347; HUBBARD AK, 1989, CLIN EXP IMMUNOL, V76, P422; HUBBARD AK, 1991, POTENTIAL ROLE IMMUN, P647; HUWYLER J, 1992, BIOCHEM BIOPH RES CO, V184, P1344, DOI 10.1016/S0006-291X(05)80030-0; IMBERTI R, 1992, RES COMMUN CHEM PATH, V78, P27; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JEAN PA, 1994, TOXICOLOGIST, V14, P1476; KLAUNIG JE, 1990, LAB INVEST, V62, P135; KLAUNIG JE, 1991, P SOC EXP BIOL MED, V198, P688; KLAUNIG JE, 1989, 5TH P ICEM INT C ENV; KRELL H, 1982, GASTROENTEROLOGY, V82, P507; LEMASTERS JJ, 1993, SURVIVING HYPOXIA ME, P495; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LUNAM CA, 1985, J PHARMACOL EXP THER, V232, P802; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MANGIPUDY RS, 1993, FASEB J, V7, pA40; Mehendale Harihara M., 1994, P299; MEHENDALE HM, 1994, J BIOCHEM TOXICOL, V9, P131, DOI 10.1002/jbt.2570090304; MEYER DJ, 1981, J CELL BIOL, V91, P505, DOI 10.1083/jcb.91.2.505; MURATA M, 1994, HEPATOLOGY, V19, P1223, DOI 10.1016/0270-9139(94)90870-2; NICHOLSON BJ, 1981, P NATL ACAD SCI USA, V78, P759; NIEMINEN AL, 1990, J BIOL CHEM, V265, P2399; NIEMINEN AL, 1994, AM J PHYSIOL, V267, pC67, DOI 10.1152/ajpcell.1994.267.1.C67; NIEMINEN AL, 1990, BIOCHEM BIOPH RES CO, V167, P600, DOI 10.1016/0006-291X(90)92067-A; NIEMINEN AL, 1993, HEPATOLOGY, V18, pA153, DOI 10.1016/0270-9139(93)92139-Q; PEARSON JM, 1994, TOXICOLOGIST, V14, P682; POUND AW, 1975, BRIT J EXP PATHOL, V56, P271; RAO VC, 1993, ARCH TOXICOL, V67, P392, DOI 10.1007/BF01977400; RAO VC, 1991, TOXICOL PATHOL, V19, P597, DOI 10.1177/019262339101900405; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; ROTH RA, 1990, LAB INVEST, V62, P736; ROTH RA, 1994, TOXICOLOGIST, V14, P1437; SIVARAO DV, 1993, FASEB J, V7, pA803; SNYDER JW, 1993, AM J PHYSIOL, V264, pC709, DOI 10.1152/ajpcell.1993.264.3.C709; SOBIECH KA, 1980, ACTA HISTOCHEMICA JE, V66, P152; THAKORE KN, 1991, TOXICOL PATHOL, V19, P47, DOI 10.1177/019262339101900106; VERGANI D, 1980, NEW ENGL J MED, V303, P66, DOI 10.1056/NEJM198007103030202; [No title captured]	67	93	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1285	1295		10.1096/fasebj.8.15.8001741	http://dx.doi.org/10.1096/fasebj.8.15.8001741			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001741				2022-12-28	WOS:A1994PY20900012
J	MOSSINGHOFF, GJ				MOSSINGHOFF, GJ			BIOMEDICAL-RESEARCH - THE PRIVATE-SECTOR	FASEB JOURNAL			English	Editorial Material											MOSSINGHOFF, GJ (corresponding author), PHARMACEUT RES & MANUFACTURERS AMER,1100 15TH ST NW,SUITE 900,WASHINGTON,DC 20005, USA.							DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; Halliday RG, 1992, J PHARM MED, V2, P139; HANSEN RW, 1979, ISSUES PHARM EC, P151; KAITIN KI, 1993, J CLIN PHARMACOL, V33, P412, DOI 10.1002/j.1552-4604.1993.tb04680.x; MOSSINGHOFF GJ, 1994, PHARM REPRESENTA APR; SCHWARTZ H, 1994, SCRIP           0819; WIGGINS SN, 1987, COST DEV NEW DRUG; 1993, TRENDS US PHARMACEUT; 1994, ANN SURVEY; 1993, OTAH522 US C OFF TEC	10	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1214	1215		10.1096/fasebj.8.15.8001731	http://dx.doi.org/10.1096/fasebj.8.15.8001731			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001731				2022-12-28	WOS:A1994PY20900002
J	DOREE, M; GALAS, S				DOREE, M; GALAS, S			THE CYCLIN-DEPENDENT PROTEIN-KINASES AND THE CONTROL OF CELL-DIVISION .1.	FASEB JOURNAL			English	Review						CDC2; OOCYTE; CELL CYCLE; M-PHASE PROMOTING FACTOR; METAPHASE	MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; AMPHIBIAN EGGS; XENOPUS EGGS; M-PHASE; MAMMALIAN FIBROBLASTS; INTERPHASE EXTRACTS; STARFISH OOCYTES; DNA-REPLICATION; DISTINCT ROLES	A few years after the identification of cyclin B-cdc2 kinase as the universal factor that controls onset of M-phase in eukaryotic cells, MPF (M-phase promoting factor), it became evident that all transitions of the cell cycle are controlled through phosphorylation of specific targets due to changes in the activity of a variety of cyclin-dependent kinase (cdks). These transitions include conversion of quiescent cells to a state of active proliferation, commitment to DNA replication, initiation of DNA replication, and entry into and exit from mitosis. Changes in the activity of cdks along the cell cycle depend not only on their association with a variety of cyclins (including G1/S and G2/M cyclins) and on posttranslational modifications by phosphorylation-dephosphorylation reactions, but also on specific protein inhibitors and on protein degradation.-Doree, M., Galas, S. The cyclin-dependent protein kinases and the control of cell division.	INSERM, F-34033 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	DOREE, M (corresponding author), CNRS, BP 5051, ROUTE MENDE, F-34033 MONTPELLIER, FRANCE.							BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG F, 1993, J CELL SCI, V106, P983; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GALAS S, 1993, MOL BIOL CELL, V4, P1295, DOI 10.1091/mbc.4.12.1295; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1986, J CELL SCI, P155; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hunt T, 1991, Semin Cell Biol, V2, P213; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUANG J, 1991, P NATL ACAD SCI USA, V88, P11530, DOI 10.1073/pnas.88.24.11530; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MASUI Y, 1992, BIOCHEM CELL BIOL, V70, P920, DOI 10.1139/o92-138; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEILL SA, 1993, MOL GEN GENET, V236, P415; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; OHTA K, 1993, J CELL SCI, V104, P125; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PICARD A, 1985, DEV BIOL, V109, P311, DOI 10.1016/0012-1606(85)90458-0; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roberts JM, 1993, CURR OPIN CELL BIOL, V5, P201, DOI 10.1016/0955-0674(93)90103-W; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	81	170	172	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1994	8	14					1114	1121		10.1096/fasebj.8.14.7958616	http://dx.doi.org/10.1096/fasebj.8.14.7958616			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958616				2022-12-28	WOS:A1994PT12800005
J	CHANDA, S; MEHENDALE, HM				CHANDA, S; MEHENDALE, HM			ROLE OF NUTRITIONAL FATTY-ACID AND L-CARNITINE IN THE FINAL OUTCOME OF THIOACETAMIDE HEPATOTOXICITY	FASEB JOURNAL			English	Article						TISSUE REPAIR; PALMITIC ACID; PROLIFERATING CELL NUCLEAR ANTIGEN; CYTOCHROME P-450	CARBON-TETRACHLORIDE; LIVER-REGENERATION; RAT; HEPATECTOMY; TISSUES; GLUCOSE; PLASMA	Male Sprague-Dawley rats (n = 10/group) were fully protected from a lethal dose (600 mg/kg, i.p.) of thioacetamide by adding 8% (w/w) palmitic acid to the diet and L-carnitine (2 mg/ml) to drinking water for the previous 7 days. Supplements of palmitic acid or L-carnitine alone did not confer protection. Liver injury induced by thioacetamide peaked between 36 and 48 h in both control and supplemented rats. Liver damage regressed thereafter in supplemented rats but progressed in control rats. Immunohistochemical and histopathological observations confirmed biochemical indicators of liver damage. Thus, hepatic tissue repair after thioacetamide-induced tissue injury seems to be stimulated by supplements of fatty acids together with L-carnitine, a mitochondrial transfer agent. The extent to which nutritional supplements may aid in inducing the recovery of liver from injury caused by other hepatotoxic agents remains to be explored.	NE LOUISIANA UNIV, COLL PHARM & HLTH SCI, DIV PHARMACOL & TOXICOL, MONROE, LA USA	University of Louisiana System; University of Louisiana Monroe								ANNINOJS, 1966, AM J CLIN PATHOL, V46, P397; BERGMEYER HU, 1978, CLIN CHEM, V24, P58; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CALABRESE EJ, 1993, TOXICOL APPL PHARM, V121, P1, DOI 10.1006/taap.1993.1121; CHANG LO, 1965, CANCER RES, V25, P1817; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; DEMACKER PNM, 1982, CLIN CHEM, V28, P1765; DIAZGIL JJ, 1987, BRIT J CANCER, V55, P599, DOI 10.1038/bjc.1987.122; FITZHUGH OG, 1948, SCIENCE, V108, P626, DOI 10.1126/science.108.2814.626; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HOLECEK M, 1991, J HEPATOL, V13, P14, DOI 10.1016/0168-8278(91)90857-8; HUNTER AL, 1977, J PHARMACOL EXP THER, V200, P439; IRIE R, 1983, J LAB CLIN MED, V101, P692; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KODAVANTI PRS, 1989, ARCH TOXICOL, V63, P367, DOI 10.1007/BF00303125; KODAVANTI PRS, 1989, TOXICOL PATHOL, V17, P494, DOI 10.1177/019262338901700304; LAKE BG, 1987, BIOCH TOXICOLOGY PRA, P184; LEDUC EH, 1949, AM J ANAT, V84, P397, DOI 10.1002/aja.1000840304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANO C, 1989, EARLY HUM DEV, V19, P21, DOI 10.1016/0378-3782(89)90101-1; NAKATA R, 1985, BIOCHEM PHARMACOL, V34, P586, DOI 10.1016/0006-2952(85)90195-9; NAKATANI T, 1981, J LAB CLIN MED, V97, P887; OMURA T, 1964, J BIOL CHEM, V239, P2370; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; SECCHI GC, 1971, ENZYME, V12, P63, DOI 10.1159/000459515; SHORT J, 1973, BIOCHEM BIOPH RES CO, V50, P430, DOI 10.1016/0006-291X(73)90858-9; SIMEK J, 1966, PHYSIOL BOHEMOSLOV, V15, P362	27	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1061	1068		10.1096/fasebj.8.13.7926372	http://dx.doi.org/10.1096/fasebj.8.13.7926372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926372				2022-12-28	WOS:A1994PN06900011
J	ESCARGUEILBLANC, I; SALVAYRE, R; NEGRESALVAYRE, A				ESCARGUEILBLANC, I; SALVAYRE, R; NEGRESALVAYRE, A			NECROSIS AND APOPTOSIS INDUCED BY OXIDIZED LOW-DENSITY LIPOPROTEINS OCCUR THROUGH 2 CALCIUM-DEPENDENT PATHWAYS IN LYMPHOBLASTOID-CELLS	FASEB JOURNAL			English	Article						ENDONUCLEASE; PROTEASE; CYTOSOLIC CALCIUM; LDL OXIDATION; ENDOGENOUS PROTEOLYSIS; LDL ISOLATION; NDA FRAGMENTATION	KILLS IMMATURE THYMOCYTES; ENDONUCLEASE ACTIVATION; ENDOTHELIAL-CELLS; LIPID PEROXIDES; TREATED LIPOPROTEINS; DNA FRAGMENTATION; CULTURED-CELLS; MODEL SYSTEM; LDL; CYTOTOXICITY	Oxidized low density lipoproteins (LDL) elicit in cultured lymphoblastoid cell lines a delayed and sustained calcium rise followed by a progressive rise of DNA fragmentation, endogenous proteolysis, and morphological features of necrosis and apoptosis. All these events were blocked by chelating the calcium of the culture medium by EGTA, thus suggesting that the two types of cell death induced by oxidized LDL (necrosis and apoptosis) were subsequent to the rise in calcium. The protease inhibitors leupeptin and antipain were able to block (at least in part) the endogenous proteolysis and the necrotic process, but exhibited no effect on apoptosis and DNA fragmentation. At the opposite, aurintricarboxylic acid and spermine (inhibitors of DNA degradation by endonucleases) inhibit DNA fragmentation and morphological apoptosis, but not endogenous proteolysis and necrosis. These data suggest that cell death induced by oxidized LDL occurs through two calcium-dependent processes triggering 1) on one hand, proteolysis and subsequently necrosis characterized by the loss of cell membrane integrity; and 2) on the other hand, internucleosomal DNA cleavage and subsequently morphological apoptosis. The RNA or protein synthesis inhibitors, actinomycin D and cycloheximide, were completely ineffective in preventing endogenous proteolysis, DNA fragmentation, necrosis, and apoptosis induced by oxidized LDL. The subclassification of the type of apoptosis elicited by oxidized LDL is discussed.	UNIV TOULOUSE 3,FAC MED,DEPT BIOCHEM,METAB DIS SECT,TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Negre-Salvayre, Anne/0000-0003-2136-5706				ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; CATHCART MK, 1989, J IMMUNOL, V142, P1963; ESCARGUEIL I, 1992, FEBS LETT, V305, P155, DOI 10.1016/0014-5793(92)80885-K; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GREGORY CD, 1991, NATURE, V349, P621; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLONI E, 1992, BIOCHIMIE, V74, P217, DOI 10.1016/0300-9084(92)90120-4; MIRABELLI F, 1989, ARCH BIOCHEM BIOPHYS, V270, P478, DOI 10.1016/0003-9861(89)90529-8; MURACHI T, 1989, BIOCHEM INT, V18, P263; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; NEGRESALVAYRE A, 1992, BRIT J PHARMACOL, V107, P738, DOI 10.1111/j.1476-5381.1992.tb14516.x; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; NICOTERA P, 1986, FEBS LETT, V209, P139, DOI 10.1016/0014-5793(86)81099-7; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V138, P1370, DOI 10.1016/S0006-291X(86)80434-X; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SALVAYRE R, 1981, BIOCHIM BIOPHYS ACTA, V659, P445, DOI 10.1016/0005-2744(81)90070-X; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	43	123	123	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1075	1080		10.1096/fasebj.8.13.7926374	http://dx.doi.org/10.1096/fasebj.8.13.7926374			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926374				2022-12-28	WOS:A1994PN06900013
J	STADNYK, AW				STADNYK, AW			CYTOKINE PRODUCTION BY EPITHELIAL-CELLS	FASEB JOURNAL			English	Article						EPITHELIUM; INTERLEUKIN; TUMOR NECROSIS FACTOR; CHEMOKINE	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-ALPHA; INTERLEUKIN-8 GENE-EXPRESSION; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; TNF-ALPHA; PANETH CELLS; IN-VITRO; GM-CSF; IL-6	The epithelium has long been regarded as a passive barrier intended to protect the underlying tissues. Many regulatory signals, including cytokines, that control epithelial cell proliferation and differentiation and cell function during inflammation were thought to be nonepithelial-derived. Now there is a growing appreciation that epithelial cells provide some of the impetus for their own growth and differentiation, and may also regulate the function of other cells through the elaboration of certain cytokines. Moreover, because epithelial cells serve as the interface between the organism and environment, they are in a position to signal changes in the environment. It is now clear that epithelial cells respond to injury or infection with cytokine secretion. Various approaches to detecting cytokines in normal and diseased tissue have been undertaken during the past few years to establish cytokine synthesis by different epithelia. This review will examine these recent investigations in various general contexts of epithelial cell function.	DALHOUSIE UNIV, DEPT PEDIAT, HALIFAX, NS, CANADA; DALHOUSIE UNIV, DEPT MICROBIOL & IMMUNOL, HALIFAX, NS, CANADA	Dalhousie University; Dalhousie University								AGACE W, 1993, INFECT IMMUN, V61, P602, DOI 10.1128/IAI.61.2.602-609.1993; AGGARWAL BB, 1992, ARCH BIOCHEM BIOPHYS, V292, P335, DOI 10.1016/0003-9861(92)90002-E; ALISON MR, 1993, CELL PROLIFERAT, V26, P449, DOI 10.1111/j.1365-2184.1993.tb00132.x; BARKER JNWN, 1991, AM J PATHOL, V139, P869; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BLAU H, 1994, AM J PHYSIOL, V266, pL148, DOI 10.1152/ajplung.1994.266.2.L148; CAMPOCHIARO PA, 1993, INT REV CYTOL, V146, P75, DOI 10.1016/S0074-7696(08)60380-0; CANNON JG, 1993, J APPL PHYSIOL, V75, P1897, DOI 10.1152/jappl.1993.75.4.1897; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; COHENKAMINSKY S, 1991, CELL IMMUNOL, V138, P79, DOI 10.1016/0008-8749(91)90134-W; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; DALLOUL AH, 1991, BLOOD, V77, P69; DINARELLO CA, 1991, BLOOD, V77, P1627; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ELNER SG, 1991, LAB INVEST, V64, P819; ENK AH, 1992, J IMMUNOL, V149, P92; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRANK J, 1993, EXP NEPHROL, V1, P26; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAYASHI O, 1994, J UROLOGY, V151, P750, DOI 10.1016/S0022-5347(17)35080-2; HEISS LN, 1993, INFECT IMMUN, V61, P3123, DOI 10.1128/IAI.61.8.3123-3128.1993; ITO R, 1993, CANCER RES, V53, P4102; JAFFE GJ, 1993, INVEST OPHTH VIS SCI, V34, P2776; JONES SC, 1993, J CLIN PATHOL, V46, P1097, DOI 10.1136/jcp.46.12.1097; KESHAV S, 1990, J EXP MED, V171, P327, DOI 10.1084/jem.171.1.327; KOMMINOTH P, 1993, VIRCHOWS ARCH B, V64, P67, DOI 10.1007/BF02915097; KROEMER G, 1993, CRIT REV IMMUNOL, V13, P163; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; KUTSCH CL, 1993, J INVEST DERMATOL, V101, P79, DOI 10.1111/1523-1747.ep12360119; LE PT, 1990, J IMMUNOL, V145, P3310; LE PT, 1991, J EXP MED, V174, P1147, DOI 10.1084/jem.174.5.1147; LEVINE SJ, 1993, AM J PHYSIOL, V265, pL360, DOI 10.1152/ajplung.1993.265.4.L360; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUGER TA, 1988, ANN NY ACAD SCI, V548, P253, DOI 10.1111/j.1749-6632.1988.tb18813.x; LUGER TA, 1981, J IMMUNOL, V127, P1493; LUGER TA, 1990, CURR PROBL DERMATOL, V19, P35; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUE H, 1993, J INVEST DERMATOL, V101, P543, DOI 10.1111/1523-1747.ep12365938; MATTNER F, 1993, EUR J IMMUNOL, V23, P2202, DOI 10.1002/eji.1830230923; MATTOLI S, 1991, J CELL PHYSIOL, V149, P260, DOI 10.1002/jcp.1041490212; MCGEE DW, 1993, J IMMUNOL, V151, P970; MIZUNO K, 1994, JPN J CANCER RES, V85, P179, DOI 10.1111/j.1349-7006.1994.tb02080.x; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; NICOD LP, 1993, THORAX, V48, P660, DOI 10.1136/thx.48.6.660; OCHIAI H, 1993, J VIROL, V67, P6811, DOI 10.1128/JVI.67.11.6811-6814.1993; OGARRA A, 1992, CURR OPIN IMMUNOL, V4, P211, DOI 10.1016/0952-7915(92)90016-8; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PAINE R, 1993, J IMMUNOL, V150, P4561; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; RADEMA SA, 1991, GASTROENTEROLOGY, V100, P1180; Ross M.H., 1989, HISTOLOGY TEXT ATLAS, P51; SCHMOUDER RL, 1992, KIDNEY INT, V41, P191, DOI 10.1038/ki.1992.26; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; SECKINGER P, 1990, P NATL ACAD SCI USA, V87, P5188, DOI 10.1073/pnas.87.13.5188; SHEN MM, 1994, EMBO J, V13, P1375, DOI 10.1002/j.1460-2075.1994.tb06391.x; SHIROTA K, 1990, VIRCHOWS ARCH B, V58, P303; STADNYK AW, 1994, UNPUB INFECT IMMUN; STADNYK AW, 1994, UNPUB BIOCH BIOPHYS; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAKIZAWA H, 1992, BIOCHEM BIOPH RES CO, V187, P596, DOI 10.1016/0006-291X(92)91236-J; TAN XD, 1993, AM J PATHOL, V142, P1858; TSUKUI T, 1994, EXP CELL RES, V210, P172, DOI 10.1006/excr.1994.1026; WHICHER JT, 1990, CLIN CHEM, V36, P1269; Wright N. A., 1984, BIOL EPITHELIAL CELL, V1; WUTHRICH RP, 1990, KIDNEY INT, V37, P783, DOI 10.1038/ki.1990.46; YARD BA, 1992, KIDNEY INT, V42, P383, DOI 10.1038/ki.1992.299	76	234	243	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1041	1047		10.1096/fasebj.8.13.7926369	http://dx.doi.org/10.1096/fasebj.8.13.7926369			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926369				2022-12-28	WOS:A1994PN06900008
J	COLLINS, JF; GHISHAN, FK				COLLINS, JF; GHISHAN, FK			MOLECULAR-CLONING, FUNCTIONAL EXPRESSION, TISSUE DISTRIBUTION, AND IN-SITU HYBRIDIZATION OF THE RENAL SODIUM-PHOSPHATE (NA+/P-I) TRANSPORTER IN THE CONTROL AND HYPOPHOSPHATEMIC MOUSE	FASEB JOURNAL			English	Article						NA+/P-I TRANSPORTER; HYPOPHOSPHATEMIC; VITAMIN D-RESISTANT RICKETS; (HYP) MOUSE MODEL; REVERSE TRANSCRIPTASE PCR; XENOPUS LAEVIS MICROINJECTION	X-LINKED HYPOPHOSPHATEMIA; HYP MICE; DEFECT; COTRANSPORT; MEMBRANE; RICKETS; PROTEIN	The current studies were designed to isolate a cDNA encoding the control mouse renal sodium phosphate (Na+/P-i) transporter and to determine mRNA levels encoding this transporter in control and (Hyp) mice. A 2.4 kb cDNA was isolated from a control mouse kidney cDNA library using a PCR-amplified 850 base pair (bp) fragment of rat cDNA. The cDNA encoding the mouse renal Na+/P-i transporter shows sequence similarity to the rat and human Na+/P-i transporters. The predicted protein exhibits 98% and 91% amino acid sequence identity with the rat and human proteins, respectively. A cRNA was synthesized from the cDNA and showed an expression of sodium-dependent phosphate transport in Xenopus laevis oocytes. Northern blot analysis of renal poly(A)(+) RNA from (Hyp) and control mice showed a threefold decrease in mRNA level in the (Hyp) mice compared with control mice. In situ hybridization analysis localizes the Na+/P-i transporter message to the renal proximal tubule, with message levels distinctly lower in the (Hyp) mouse. Also, genomic Southern blotting suggests that the gene encoding the sodium phosphate transporter in structurally identical in the control and (Hyp) mice. These studies suggest that we have cloned the cDNA encoding the renal Na+/P-i transporter in the control [C57BL/6J+/ymale] mouse, localized the message to the renal proximal tubule, and shown that the mRNA level encoding the renal Na+/P-i transporter is decreased in the hypophosphatemic mouse.	VANDERBILT UNIV, SCH MED, DEPT PEDIAT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK26657, DK33209] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033209, R01DK033209, P30DK026657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL CL, 1988, AM J HUM GENET, V43, P293; COWGILL LD, 1979, J CLIN INVEST, V63, P1203, DOI 10.1172/JCI109415; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EICHER EM, 1976, P NATL ACAD SCI USA, V73, P4667, DOI 10.1073/pnas.73.12.4667; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Ghishan Fayez K., 1994, Pediatric Research, V35, P510, DOI 10.1203/00006450-199404000-00026; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MEYER RA, 1989, J BONE MINER RES, V4, P493; NAKAGAWA N, 1991, J BIOL CHEM, V266, P13616; NAKAGAWA N, 1992, P SOC EXP BIOL MED, V203, P328; NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735; Rasmussen H., 1983, METABOLIC BASIS INHE, V5th, P1743; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TENENHOUSE HS, 1978, KIDNEY INT, V14, P236, DOI 10.1038/ki.1978.115; TENENHOUSE HS, 1979, CAN J BIOCHEM CELL B, V57, P938, DOI 10.1139/o79-114; TENENHOUSE HS, 1993, J BONE MINER RES, V8, pS139; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9808	19	86	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					862	868		10.1096/fasebj.8.11.8070635	http://dx.doi.org/10.1096/fasebj.8.11.8070635			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070635				2022-12-28	WOS:A1994PC88500009
J	HARDY, SP; VALVERDE, MA				HARDY, SP; VALVERDE, MA			NOVEL PLASMA-MEMBRANE ACTION OF ESTROGEN AND ANTIESTROGENS REVEALED BY THEIR REGULATION OF A LARGE-CONDUCTANCE CHLORIDE CHANNEL	FASEB JOURNAL			English	Article						COLCHICINE; TAMOXIFEN; TOREMIFENE; NIH3T3; FIBROBLAST	BINDING-SITES; CELLS; RAT; RECEPTOR; CALCIUM; COLCHICINE; MUSCLE; EXPRESSION; DISTINCT	Antiestrogens antagonize many genomic effects of estrogen through binding to the nuclear estrogen receptor. We report here that NIH3T3 fibroblasts grown in the presence of colchicine acquire the activation of a large conductance chloride channel upon exposure to extracellular but not intracellular antiestrogens. This effect can be prevented by extracellular 17 beta-estradiol, but not intracellular l7 beta-estradiol or extracellular 17 alpha-estradiol. This is the first demonstration of a regulatory role for antiestrogens and estrogens in the regulation of ionic channels occurring through an interaction of these compounds with a plasma membrane binding site distinct from the classical estrogen receptor and subsequent activation of intracellular second messenger pathway (or pathways).	AFRC,BABRAHAM INST,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute				Valverde, Miguel A./0000-0002-6961-3361				BATRA S, 1986, EUR J PHARMACOL, V127, P37, DOI 10.1016/0014-2999(86)90203-7; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBARUCH G, 1981, MOL PHARMACOL, V21, P287; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BLAUSTEIN JD, 1993, J NEUROENDOCRINOL, V5, P63, DOI 10.1111/j.1365-2826.1993.tb00364.x; BRANDES LJ, 1986, BIOCHEM BIOPH RES CO, V126, P905; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; BROWN PD, 1993, PLACENTA, V14, P103, DOI 10.1016/S0143-4004(05)80253-X; CECCATELLI S, 1991, MOL BRAIN RES, V9, P57, DOI 10.1016/0169-328X(91)90130-P; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; DIXON DM, 1993, J MEMBRANE BIOL, V131, P143, DOI 10.1007/BF02791323; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; FERNANDEZ A, 1993, GEN PHARMACOL-VASC S, V24, P391, DOI 10.1016/0306-3623(93)90322-O; FRIZZELL RA, 1990, CURRENT TOPICS MEMBR, V37, P247; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; JORDAN VC, 1984, PHARMACOL REV, V36, P245; KANGAS L, 1990, CANCER CHEMOTH PHARM, V27, P8, DOI 10.1007/BF00689269; KLINGE CM, 1992, ONCOL RES, V4, P145; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MCGILL JM, 1993, J MEMBRANE BIOL, V133, P253; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; NOBILE M, 1988, BIOCHEM BIOPH RES CO, V154, P719, DOI 10.1016/0006-291X(88)90199-4; PARKER MG, 1993, J NEUROENDOCRINOL, V5, P223, DOI 10.1111/j.1365-2826.1993.tb00476.x; PASQUALINI JR, 1988, J STEROID BIOCHEM, V31, P613, DOI 10.1016/0022-4731(88)90013-1; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHLICHTER LC, 1990, PFLUG ARCH EUR J PHY, V416, P413, DOI 10.1007/BF00370748; SCHNEIDER GT, 1985, PFLUG ARCH EUR J PHY, V404, P354, DOI 10.1007/BF00585348; SUDO K, 1983, ENDOCRINOLOGY, V112, P425, DOI 10.1210/endo-112-2-425; SUTHERLAND RL, 1980, NATURE, V288, P273, DOI 10.1038/288273a0; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; VONDERHAAR BK, 1991, MOL CELL ENDOCRINOL, V79, pC159, DOI 10.1016/0303-7207(91)90088-A; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WANGOO A, 1992, MOL PHARMACOL, V42, P584; WONG M, 1991, BRAIN RES, V543, P148, DOI 10.1016/0006-8993(91)91057-8	38	57	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					760	765		10.1096/fasebj.8.10.8050676	http://dx.doi.org/10.1096/fasebj.8.10.8050676			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050676				2022-12-28	WOS:A1994NY35000014
J	JOHNSON, MA; FISCHER, JG; BOWMAN, BA; GUNTER, EW				JOHNSON, MA; FISCHER, JG; BOWMAN, BA; GUNTER, EW			IRON NUTRITURE IN ELDERLY INDIVIDUALS	FASEB JOURNAL			English	Review						IRON DEFICIENCY; IRON OVERLOAD; CALCIUM; ASCORBIC ACID; ANEMIA; HEART DISEASE; CANCER; IMMUNITY; ALZHEIMERS DISEASE	ISCHEMIC-HEART-DISEASE; NUTRITIONAL-STATUS; ASCORBIC-ACID; IDIOPATHIC HEMOCHROMATOSIS; BIOCHEMICAL INDICATORS; MYOCARDIAL-INFARCTION; TRANSFERRIN RECEPTOR; POSTMENOPAUSAL WOMEN; SURVEILLANCE SYSTEM; DEFICIENCY ANEMIA	The purpose of this review is to examine current research on the iron status of the elderly and factors that influence the body burden of iron. Studies of noninstitutionalized elderly individuals report mean iron intakes that meet current Recommended Dietary Allowances for iron. Dietary practices that may decrease iron bioavailability, and hence iron stores in the body, include low intakes of ascorbic acid or high intakes of calcium, and decreased consumption of highly available iron from meat, fish, and poultry. Although not well documented, the effect of age on iron absorption and iron excretion appears to be small, and body stores of iron increase with age. It is difficult to estimate the prevalence of iron deficiency in elderly persons, because impaired iron status can be the result of iron deficiency or chronic disease. Further study is necessary to determine whether red blood cell ferritin and serum transferrin receptors may be useful biochemical markers to differentiate the anemia of chronic disease from iron deficiency anemia. Hereditary hemochromatosis is a genetic disease that greatly increases the body burden of iron and the risk of hepatic disease among homozygotes. Because iron deficiency or iron excess may impair health, the role of icon in diseases associated with aging such as depressed immune response, neurological dysfunction, cancer, and heart disease is discussed.	CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA	JOHNSON, MA (corresponding author), UNIV GEORGIA, DEPT FOODS & NUTR, DAWSON HALL, ATHENS, GA 30602 USA.							ADRIAN GS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P168, DOI 10.1016/0167-4781(92)90008-N; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; BEARD JL, 1993, NUTR REV, V51, P112; BENDICH A, 1990, TOXICOL LETT, V51, P189, DOI 10.1016/0378-4274(90)90210-D; BOREL MJ, 1991, AM J CLIN NUTR, V54, P729, DOI 10.1093/ajcn/54.4.729; BOTHWELL TH, 1989, METABOLIC BASIS INHE, V1, P1433; BOWMAN BH, 1988, ADV GENET, V25, P1; BRANTS HAM, 1990, J AM COLL NUTR, V9, P292; CECCHETTI G, 1991, EUR HEART J, V12, P224, DOI 10.1093/oxfordjournals.eurheartj.a059873; Champagne E T, 1989, Adv Exp Med Biol, V249, P173; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHANDRA RK, 1992, NUTR REV, V50, P367, DOI 10.1111/j.1753-4887.1992.tb02482.x; CHANDRA RK, 1992, J NUTR, V122, P754, DOI 10.1093/jn/122.suppl_3.754; CHEN LH, 1989, INT J VITAM NUTR RES, V59, P207; CONNOR JR, 1990, J NEUROSCI RES, V27, P595, DOI 10.1002/jnr.490270421; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; CONRAD ME, 1993, J AM COLL NUTR, V12, P720; COOK JD, 1991, AM J CLIN NUTR, V54, P717, DOI 10.1093/ajcn/54.4.717; COOK JD, 1984, BLOOD, V64, P721; COOPER RS, 1993, CIRCULATION, V87, P686; DALLMAN PR, 1984, AM J CLIN NUTR, V39, P937, DOI 10.1093/ajcn/39.6.937; DAWSONHUGHES B, 1986, AM J CLIN NUTR, V44, P83, DOI 10.1093/ajcn/44.1.83; DEEHR MS, 1990, AM J CLIN NUTR, V51, P95, DOI 10.1093/ajcn/51.1.95; DWYER JT, 1991, SCREENING OLDER AM N, P51; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; Fairbanks VF, 1994, MODERN NUTR HLTH DIS, P185; FARTHING MJG, 1989, ACTA PAEDIATR SCAND, P44; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; FREELANDGRAVES JH, 1989, MINERAL HOMEOSTASIS, P141; GALAN P, 1990, CLIN CHIM ACTA, V189, P159, DOI 10.1016/0009-8981(90)90087-9; GALAN P, 1992, BIOL TRACE ELEM RES, V32, P421, DOI 10.1007/BF02784628; GARRY PJ, 1983, J AM GERIATR SOC, V31, P389, DOI 10.1111/j.1532-5415.1983.tb03712.x; GARRY PJ, 1992, AM J CLIN NUTR, V56, P691, DOI 10.1093/ajcn/56.4.691; GOODWIN JS, 1988, J GERONTOL, V43, pM46, DOI 10.1093/geronj/43.2.M46; GORDEUK VR, 1987, ANNU REV NUTR, V7, P485, DOI 10.1146/annurev.nu.07.070187.002413; GUYATT GH, 1990, AM J MED, V88, P205, DOI 10.1016/0002-9343(90)90143-2; HALLBERG L, 1991, AM J CLIN NUTR, V54, P1047, DOI 10.1093/ajcn/54.6.1047; HALLBERG L, 1992, EUR J CLIN NUTR, V46, P317; HORNIG DH, 1988, MODERN NUTRITION HLT, P417; HUNT JR, 1990, AM J CLIN NUTR, V51, P649, DOI 10.1093/ajcn/51.4.649; INSEL PA, 1990, PHARMACOL BASIS THER, P638; JACKSON LS, 1992, CRIT REV FOOD SCI, V31, P259, DOI 10.1080/10408399209527573; JACOBS AM, 1969, J GERONTOL, V24, P95, DOI 10.1093/geronj/24.1.95; JACOBS P, 1964, J APPL PHYSIOL, V19, P187, DOI 10.1152/jappl.1964.19.2.187; JOHNSON MA, 1990, J NUTR, V120, P1486, DOI 10.1093/jn/120.suppl_11.1486; JOHNSTON DL, 1989, AM J MED, V87, P40; JOOSTEN E, 1992, GERONTOLOGY, V38, P111, DOI 10.1159/000213315; KASSARJIAN Z, 1989, ANNU REV NUTR, V9, P271, DOI 10.1146/annurev.nu.09.070189.001415; KEMP JD, 1992, PATHOBIOLOGY, V60, P27, DOI 10.1159/000163693; KIRKEBY O J, 1991, Scandinavian Journal of Primary Health Care, V9, P167, DOI 10.3109/02813439109018513; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; KOEHLER KM, 1992, J AM DIET ASSOC, V92, P325; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; LABBE RF, 1989, SEMIN HEMATOL, V26, P40; LAUFFER RB, 1991, MED HYPOTHESES, V35, P103, DOI 10.1016/0306-9877(91)90031-S; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LIPSCHITZ DA, 1991, GERIATRIC NUTR HLTH, P271; LOOKER AC, 1990, AM J CLIN NUTR, V52, P541, DOI 10.1093/ajcn/52.3.541; LOOKER AC, 1991, VITAL HLTH STAT, V2, P1; LOWIK MRH, 1990, J AM COLL NUTR, V9, P600; LYNCH SR, 1982, AM J CLIN NUTR, V36, P1032, DOI 10.1093/ajcn/36.5.1032; MARKUS HS, 1989, BRIT J CLIN PRACT, V43, P451; MARX JJM, 1979, BLOOD, V53, P204; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MILDER MS, 1980, MEDICINE, V59, P34, DOI 10.1097/00005792-198001000-00002; NOMURA A, 1992, CANCER EPIDEM BIOMAR, V1, P547; OLSON LJ, 1989, J AM COLL CARDIOL, V13, P116, DOI 10.1016/0735-1097(89)90558-5; OSTER O, 1989, CLIN CHEM, V35, P851; PALOSUO T, 1986, ACTA MED SCAND, V220, P175; PAYETTE H, 1991, AM J CLIN NUTR, V54, P478, DOI 10.1093/ajcn/54.3.478; PERRY GS, 1992, J NUTR, V122, P1417, DOI 10.1093/jn/122.7.1417; PETERS SW, 1983, BRIT J HAEMATOL, V53, P211, DOI 10.1111/j.1365-2141.1983.tb02013.x; REILLY IAG, 1988, DRUGS, V35, P154, DOI 10.2165/00003495-198835020-00005; REIZENSTEIN P, 1991, MED ONCOL TUMOR PHAR, V8, P229; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIEMERSMA RA, 1991, LANCET, V337, P677, DOI 10.1016/0140-6736(91)92496-O; RIMM EB, 1993, CIRCULATION, V87, P692; ROSENQVIST M, 1989, EUR HEART J, V10, P473, DOI 10.1093/oxfordjournals.eurheartj.a059512; SAHYOUN NR, 1988, AM J CLIN NUTR, V47, P524, DOI 10.1093/ajcn/47.3.524; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SEARS DA, 1992, MED CLIN N AM, V76, P567, DOI 10.1016/S0025-7125(16)30340-6; SHERMAN AR, 1990, ANN NY ACAD SCI, V587, P140, DOI 10.1111/j.1749-6632.1990.tb00141.x; SHERMAN AR, 1992, J NUTR, V122, P604, DOI 10.1093/jn/122.suppl_3.604; SKIKNE BS, 1990, BLOOD, V75, P1870; SNEDEKER SM, 1982, J NUTR, V112, P136, DOI 10.1093/jn/112.1.136; SOLOMONS NW, 1989, MINERAL HOMEOSTASIS, P35; SPALLHOLZ JE, 1989, BIOL TRACE ELEM RES, V19, P129, DOI 10.1007/BF02924291; SPENCER G, 1989, CURRENT POPULATI P25, V1018, P3; STAMPFER MJ, 1993, CIRCULATION, V87, P688; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; SULLIVAN JL, 1992, CIRCULATION, V86, P1036, DOI 10.1161/01.CIR.86.3.1036; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SUSSMAN HH, 1992, PATHOBIOLOGY, V60, P2, DOI 10.1159/000163690; THOMAS AJ, 1989, Q J MED, V70, P175; TORRE M, 1991, CRIT REV FOOD SCI, V30, P1, DOI 10.1080/10408399109527539; TUCKER DM, 1990, AM J CLIN NUTR, V52, P93, DOI 10.1093/ajcn/52.1.93; TURNLUND JR, 1990, AM J CLIN NUTR, V52, P373, DOI 10.1093/ajcn/52.2.373; TURNLUND JR, 1988, NUTR RES, V8, P333, DOI 10.1016/S0271-5317(88)80028-9; VALBERG LS, 1985, ANNU REV MED, V36, P27; WEINBERG ED, 1992, BIOL TRACE ELEM RES, V34, P123, DOI 10.1007/BF02785242; WILLIAMS RE, 1991, CIRCULATION, V83, P1006, DOI 10.1161/01.CIR.83.3.1006; WORTHINGTONROBERTS BS, 1988, AM J CLIN NUTR, V47, P275, DOI 10.1093/ajcn/47.2.275; WOTEKI CE, 1988, AM J CLIN NUTR, V47, P320, DOI 10.1093/ajcn/47.2.320; YIP R, 1984, AM J CLIN NUTR, V39, P427, DOI 10.1093/ajcn/39.3.427; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; YIP R, 1989, NEW ENGL J MED, V320, P1012; YIP R, 1991, AM J EPIDEMIOL, V134, P117; 1991, DHHS FCOA9128001 PUB, P10; 1984, PUBL NATIONAL I ARTH, V421, P4652; 1989, DIET HLTH IMPLICATIO, P368; 1989, NUTR REV, V47, P176; 1989, RECOMMENDED DIETARY; 1989, DHHS PHS891255 USDA, P129	117	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					609	621		10.1096/fasebj.8.9.8005389	http://dx.doi.org/10.1096/fasebj.8.9.8005389			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005389	Bronze			2022-12-28	WOS:A1994NR90600008
J	KWON, NS; LEE, SH; CHOI, CS; LEE, HS; KHO, T				KWON, NS; LEE, SH; CHOI, CS; LEE, HS; KHO, T			NITRIC-OXIDE GENERATION FROM STREPTOZOTOCIN	FASEB JOURNAL			English	Article						AORTIC STRIPS; HEMOGLOBIN; NITRITE; NITRATE; LIGHT; DIABETES MELLITUS	INDUCED PANCREATIC INSULITIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RIBONUCLEOTIDE REDUCTASE; BIOLOGICAL-FLUIDS; ADP-RIBOSYLATION; RELAXING FACTOR; CELLS; INHIBITION; ISLETS; DNA	Streptozotocin (STZ), a diabetogenic agent, is thought to damage pancreatic beta-cells by activating immune mechanisms and by alkylating DNA. In the present study, we demonstrated that STZ can produce nitric oxide (NO), a bioregulatory and cytotoxic molecule. When STZ was dissolved in a sodium phosphate buffer (50 mM, pH 7.4) and irradiated with a 22 W circular fluorescent light, nitrite and nitrate, stable oxidation products of NO, were produced. The wavelengths of light most responsible for the photo-decomposition were 300-310 nm and 410-420 nm. When a mixture of reduced hemoglobin and STZ was irradiated with UV light (280-320 nm), hemoglobin underwent characteristic NO-dependent spectral changes. STZ relaxed deendothelialized aortic strips only in the presence of light. STZ/light-dependent relaxation was attenuated by reduced hemoglobin. These results indicated photoinduced NO production from STZ. NO generation depended on the concentration of STZ, the duration of irradiation, and the distance between sample and light source. In acidic conditions, NO production from STZ was spontaneous even in the dark. Light-independent NO generation was augmented by increasing acidity, and markedly diminished in a D2O-based buffer, indicating the involvement of protons in the mechanism of STZ decomposition in acid. These results imply the usefulness of STZ as an NO-generating reagent, and indicate that direct NO-generation may be a mechanism of STZ toxicity in diabetogenesis.			KWON, NS (corresponding author), CHUNG ANG UNIV,COLL MED,DEPT BIOCHEM,221 HEUCKSUK DONG,SEOUL 156756,SOUTH KOREA.							ANDRADE J, 1993, FEBS LETT, V327, P32, DOI 10.1016/0014-5793(93)81033-V; APPEL KE, 1982, CARCINOGENESIS, V3, P293, DOI 10.1093/carcin/3.3.293; ARMSTRONG D, 1991, FREE RADICAL BIO MED, V11, P433, DOI 10.1016/0891-5849(91)90161-U; ARNOLD WP, 1984, ANESTHESIOLOGY, V61, P254, DOI 10.1097/00000542-198409000-00004; BENNETT RA, 1981, CANCER RES, V41, P2786; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BUGA GM, 1992, FASEB J, V6, pA1733; CHANG KC, 1993, BIOCHEM BIOPH RES CO, V191, P509, DOI 10.1006/bbrc.1993.1247; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; DIMMELER S, 1993, J IMMUNOL, V150, P2964; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FURCHGOTT R, 1961, J GEN PHYSIOL, V44, P499, DOI 10.1085/jgp.44.3.499; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GARTHWAITE G, 1991, TRENDS NEUROSCI, V2, P60; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROVER TA, 1987, FREE RADICAL BIO MED, V3, P27, DOI 10.1016/0891-5849(87)90036-0; HERR RR, 1967, J AM CHEM SOC, V89, P4808, DOI 10.1021/ja00994a053; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IVANOVA K, 1993, EUR J PHARM-MOLEC PH, V244, P37, DOI 10.1016/0922-4106(93)90057-G; JOHANSSON EB, 1978, ACTA ENDOCRINOL-COP, V89, P339, DOI 10.1530/acta.0.0890339; JOHNSON DD, 1986, CURR EYE RES, V5, P1, DOI 10.3109/02713688608995159; Kolb H, 1993, DIABETES REV, V1, P116; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; LIKE AA, 1978, LAB INVEST, V38, P470; MARCH J, 1985, ADV ORG CHEM, P1106; MUSSON DG, 1979, J PHARM SCI, V68, P1159, DOI 10.1002/jps.2600680927; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ONEILL SK, 1993, J PHARMACOL TOXICOL, V29, P217, DOI 10.1016/1056-8719(93)90028-D; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POTTER DW, 1982, ARCH BIOCHEM BIOPHYS, V216, P158, DOI 10.1016/0003-9861(82)90200-4; POTTER DW, 1983, J BIOL CHEM, V258, P6906; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHUKER DEG, 1983, ANAL CHEM, V55, P2152, DOI 10.1021/ac00263a034; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; THOMAS G, 1989, EUR J PHARMACOL, V161, P279, DOI 10.1016/0014-2999(89)90860-1; VESELY DL, 1977, CANCER RES, V37, P28; WELSH N, 1992, BIOCHEM BIOPH RES CO, V182, P333, DOI 10.1016/S0006-291X(05)80149-4; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	49	115	118	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					529	533		10.1096/fasebj.8.8.8181671	http://dx.doi.org/10.1096/fasebj.8.8.8181671			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181671				2022-12-28	WOS:A1994NM36400010
J	LEE, AT; DESIMONE, C; CERAMI, A; BUCALA, R				LEE, AT; DESIMONE, C; CERAMI, A; BUCALA, R			COMPARATIVE-ANALYSIS OF DNA MUTATIONS IN LACI TRANSGENIC MICE WITH AGE	FASEB JOURNAL			English	Article						DNA MUTATIONS; AGING; TRANSGENIC MICE	SOMATIC MUTATION; LAMBDA-ZAP; INVIVO; LYMPHOCYTES; FREQUENCY; CELLS; INSTABILITY; SPECTRUM; VECTOR; GENE	Transgenic mice have been developed recently that contain copies of the well-defined mutagenesis reporter gene, lacI, in an integrated bacteriophage-based shuttle vector. The lacI gene, which is present in all cells of the mouse, can be excised specifically from isolated genomic DNA and efficiently packaged into bacteriophage particles after the addition of packaging extracts. Mutations df the lacI gene are easily detected by the derepression of beta-galactosidase resulting in blue plaques in the presence of X-gal. Originally developed as a shortterm in vivo mutagenesis assay to screen genotoxic agents, we have used this system to measure naturally occurring DNA mutations as a function of chronological age. There was a linear increase in the presence of phenotypic lacI mutants from birth to 24 months (r = 0.731, P < 0.001), such that 24-month-old mice have accumulated approximately fourfold more mutants than newborn pups. Molecular analysis of these spontaneously arising DNA mutations showed them to result predominantly from base substitutions (80.6-98.5%) that were equally distributed between transitions and transversions. However, lad mutations in animals > 3 months of age demonstrated a higher percentage of mutations (12-19.4% vs. 1.2%) resulting from discriminable size changes (> 20 bp) than was observed for mice 1-2 months old. Sequence analysis of mutations resulting from a > 20 bp size change revealed them to be due to a duplication of adjacent lad sequence. These results indicate that there is a gradual accumulation of DNA mutations with age and that the types of mutations also are influenced by the age of the animal.			LEE, AT (corresponding author), PICOWER INST MED RES,350 COMMUNITY DR,MANHASSET,NY 11030, USA.							ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BOJANOVI.JJ, 1970, GERONTOLOGY, V16, P304, DOI 10.1159/000211792; CALOS MP, 1980, CELL, V20, P579, DOI 10.1016/0092-8674(80)90305-0; CARRANO AV, 1989, GENOME, V31, P458, DOI 10.1139/g89-079; COLLINS JM, 1985, J CELL PHYSIOL, V124, P165, DOI 10.1002/jcp.1041240126; DAVIES MJ, 1992, MUTAT RES, V265, P165, DOI 10.1016/0027-5107(92)90045-4; DUTKOWSKI RT, 1985, MUTAT RES, V149, P505, DOI 10.1016/0027-5107(85)90169-1; EBBESEN P, 1984, MECH AGEING DEV, V25, P269, DOI 10.1016/0047-6374(84)90001-0; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; GRIST SA, 1992, MUTAT RES, V266, P189, DOI 10.1016/0027-5107(92)90186-6; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; INAMIZU T, 1986, P NATL ACAD SCI USA, V83, P2488, DOI 10.1073/pnas.83.8.2488; KIRKWOOD TBL, 1989, MUTAT RES, V219, P1, DOI 10.1016/0921-8734(89)90035-0; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; MARLHENS F, 1986, HUM GENET, V73, P290, DOI 10.1007/BF00279088; MARTIN GM, 1985, ISRAEL J MED SCI, V21, P296; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MULLAART E, 1990, MUTAT RES, V237, P9, DOI 10.1016/0921-8734(90)90027-O; PRIEUR M, 1988, HUM GENET, V79, P147, DOI 10.1007/BF00280554; PROVOST GS, 1993, MUTAT RES, V288, P133; RANDERATH K, 1993, MUTAT RES, V295, P11, DOI 10.1016/0921-8734(93)90007-P; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; Vijg J, 1990, Aging (Milano), V2, P105; VIZIRI H, 1993, AM J HUM GENET, V52, P661	29	71	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					545	550		10.1096/fasebj.8.8.8181674	http://dx.doi.org/10.1096/fasebj.8.8.8181674			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181674				2022-12-28	WOS:A1994NM36400013
J	LANOUE, KF; BERDANIER, CD				LANOUE, KF; BERDANIER, CD			50 YEARS AGO .33. THE CASE OF THE DISAPPEARING SILVER	FASEB JOURNAL			English	Editorial Material											LANOUE, KF (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033, USA.							BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; Brobeck J R, 1943, Yale J Biol Med, V15, P831; Hetherington AW, 1940, ANAT REC, V78, P149, DOI 10.1002/ar.1090780203; LANOUE KF, 1992, FASEB J, V8, P72; Salcedo J, 1943, J BIOL CHEM, V151, P413; SCHOENHEIMER R, 1936, J BIOL CHEM, V114, P391; TEPPERMAN J, 1992, FASEB J, V6, P2614, DOI 10.1096/fasebj.6.8.1592212; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093	8	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					132	133		10.1096/fasebj.8.1.8299886	http://dx.doi.org/10.1096/fasebj.8.1.8299886			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299886				2022-12-28	WOS:A1994MV28200020
J	DAMSKY, C; SUTHERLAND, A; FISHER, S				DAMSKY, C; SUTHERLAND, A; FISHER, S			EXTRACELLULAR MATRIX-5 - ADHESIVE INTERACTIONS IN EARLY MAMMALIAN EMBRYOGENESIS, IMPLANTATION, AND PLACENTATION	FASEB JOURNAL			English	Review						INTEGRINS; CADHERINS; EXTRACELLULAR MATRIX; INVASION; MOUSE; DIFFERENTIATION	UTERINE EPITHELIAL-CELLS; BASEMENT-MEMBRANE; MOUSE BLASTOCYST; IV COLLAGENASE; MESSENGER-RNA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MALIGNANT-CELLS; LAMININ; INTEGRIN	Normal morphogenesis and differentiation depend heavily on the coordination of cell-cell and cell-extracellular matrix interactions. During early mammalian development, the first cell lineages to be established are extraembryonic (trophoblast and extraembryonic endoderm), which are essential for satisfying the nutritional requirements of the developing embryo. This review emphasizes the importance of the cadherin family of cell-cell adhesion molecules and the integrin family of extracellular matrix receptors in mediating interactions between cells and their environment during early development. The review first discusses the critical role of cell-cell interactions in fertilization and early lineage decisions that occur during pre- and peri-implantation development in the mouse, using the calcium-dependent cell adhesion molecule E-cadherin as the primary example. The remainder of the review discusses the importance of cell-ECM interactions in the further morphogenesis and differentiation of the newly segregated lineages. The critical roles of integrins in differentiation, migration, and invasion of trophoblast in both mouse and human are emphasized.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD ENDOCRINOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	DAMSKY, C (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, HSW-604, SAN FRANCISCO, CA 94143 USA.			Sutherland, Ann/0000-0003-1925-2825				Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; APLIN JD, 1991, J CELL SCI, V99, P681; ARMANT DR, 1991, BIOL REPROD, V45, P664, DOI 10.1095/biolreprod45.5.664; BASS KE, 1993, IN PRESS NONHUMAN PR; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BURDSAL C, 1993, IN PRESS DEVELOPMENT; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; DAMJANOV I, 1986, DEV BIOL, V116, P194, DOI 10.1016/0012-1606(86)90056-4; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FUSI FM, 1992, MOL REPROD DEV, V31, P215, DOI 10.1002/mrd.1080310309; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kemler R, 1992, Semin Cell Biol, V3, P149; KIMBER SJ, 1990, J REPROD FERTIL, V89, P13, DOI 10.1530/jrf.0.0890013; KIMBER SJ, 1990, INT REV CYTOL, V120, P53; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; LEVIO I, 1989, INT J DEV BIOL, V33, P81; LIBRACH C, 1991, Journal of Cell Biology, V115, p6A; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1993, J CELL BIOCH B, V17, P267; NORMURA S, 1989, DEVELOPMENT, V105, P575; RICHA J, 1985, DEV BIOL, V108, P513, DOI 10.1016/0012-1606(85)90054-5; ROSSANT J, 1985, J EMBRYOL EXP MORPH, V86, P177; SANG QX, 1991, BIOL REPROD, V45, P387, DOI 10.1095/biolreprod45.3.387; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SEFTON M, 1992, DEVELOPMENT, V115, P313; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; STARKEY PM, 1988, IMMUNOLOGY, V65, P129; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; SUTHERLAND AE, 1993, IN PRESS DEVELOPMENT; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TARONE G, 1993, DEVELOPMENT, V117, P1369; Thiery Jean Paul, 1992, Current Opinion in Cell Biology, V4, P782, DOI 10.1016/0955-0674(92)90101-H; THORSTEINSDOTTIR S, 1992, ANAT RECORD, V232, P141, DOI 10.1002/ar.1092320116; TURPEENNIEMIHUJANEN T, 1992, FERTIL STERIL, V58, P105; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; VALDIZAN MC, 1992, J CELL PHYSIOL, V151, P451, DOI 10.1002/jcp.1041510304; WASSARMAN PM, 1992, BIOL REPROD, V46, P186, DOI 10.1095/biolreprod46.2.186; WEGMANN TG, 1992, DEV COMP IMMUNOL, V16, P425, DOI 10.1016/0145-305X(92)90026-9; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WEWER UM, 1986, DIFFERENTIATION, V32, P49, DOI 10.1111/j.1432-0436.1986.tb00555.x; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WINKEL GK, 1990, DEV BIOL, V138, P1, DOI 10.1016/0012-1606(90)90171-E; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	71	188	189	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1993	7	14					1320	1329		10.1096/fasebj.7.14.8224605	http://dx.doi.org/10.1096/fasebj.7.14.8224605			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224605				2022-12-28	WOS:A1993MH00800003
J	BELYI, YF				BELYI, YF			INTRACELLULAR PARASITISM OF LEGIONELLA AND SIGNALING IN EUKARYOTIC CELLS	FASEB JOURNAL			English	Review						LEGIONELLA; PHAGOCYTOSIS; BACTERICIDAL ACTIVITY; REGULATION OF FUNCTIONS	AERUGINOSA EXOENZYME-S; PERTUSSIS ADENYLATE-CYCLASE; GTP-BINDING PROTEINS; BOTULINUM TYPE-C; PSEUDOMONAS-AERUGINOSA; ADP-RIBOSYLATION; HUMAN NEUTROPHIL; BORDETELLA-PERTUSSIS; LEGIONNAIRES-DISEASE; PNEUMOPHILA TOXIN	In this review the phenomenon of antibacterial activity of phagocytes and its relationship to the general system of signal transduction in eukaryotic cells is examined. Data are reviewed that support the hypothesis that interference in transduction of regulatory signals during microbial invasion could be caused by specific bacterial products and lead to an inadequate bactericidal response, and hence multiplication of the bacteria in a host. In this connection, information concerning virulence factors of the facultative intracellular parasite Legionella is discussed.			BELYI, YF (corresponding author), NF GAMALEI INST EPIDEMIOL & MICROBIOL, MOSCOW 123098, RUSSIA.		Belyi, Yury/AAU-8092-2020					AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; ALTHAUS FR, 1987, MOL BIOL BIOCH BIOPH, V37, P131; BACKLUND PS, 1985, P NATL ACAD SCI USA, V82, P2637, DOI 10.1073/pnas.82.9.2637; BAINE WB, 1979, J CLIN MICROBIOL, V9, P453; BAINE WB, 1985, J GEN MICROBIOL, V131, P1383; BAINE WB, 1988, J GEN MICROBIOL, V134, P489; BEAMAN L, 1984, ANNU REV MICROBIOL, V38, P27; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BELYI YF, 1985, MOL STRUKTURA BAKTER, P1; BELYI YF, 1988, ZH MIKROBIOL EPIDEMI, V2, P4; Belyi YuF, 1990, Biomed Sci, V1, P494; Belyi YuF, 1991, Biomed Sci, V2, P94; Belyi YuF, 1991, Biomed Sci, V2, P169; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLANK JA, 1990, TOXICOL APPL PHARM, V106, P278, DOI 10.1016/0041-008X(90)90247-R; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHEN GCC, 1985, CURR MICROBIOL, V12, P23, DOI 10.1007/BF01567748; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; CONLAN JW, 1986, J GEN MICROBIOL, V132, P1565; DENSEN P, 1980, REV INFECT DIS, V2, P817; DONOWITZ GR, 1990, INFECT IMMUN, V58, P3307, DOI 10.1128/IAI.58.10.3307-3311.1990; DOWLING JN, 1992, MICROBIOL REV, V56, P32, DOI 10.1128/MMBR.56.1.32-60.1992; DREYFUS LA, 1986, INFECT IMMUN, V51, P736, DOI 10.1128/IAI.51.3.736-743.1986; ELSBACH P, 1980, REV INFECT DIS, V2, P106; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; FOSTER JW, 1985, CRC CR REV MICROBIOL, V11, P273; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; FRIEDMAN RL, 1980, INFECT IMMUN, V29, P271, DOI 10.1128/IAI.29.1.271-274.1980; FRIEDMAN RL, 1982, J INFECT DIS, V146, P328, DOI 10.1093/infdis/146.3.328; GILL DM, 1988, METHOD ENZYMOL, V165, P235; HEDLUND KW, 1981, PHARMACOL THERAPEUT, V15, P123, DOI 10.1016/0163-7258(81)90021-8; HEWLETT E, 1976, J BACTERIOL, V127, P890, DOI 10.1128/JB.127.2.890-898.1976; HIEMSTRA PS, 1992, INFECT IMMUN, V60, P202, DOI 10.1128/IAI.60.1.202-205.1992; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JACOBS RF, 1984, J CLIN INVEST, V73, P1515, DOI 10.1172/JCI111357; JUST I, 1992, J BIOL CHEM, V267, P10274; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LOCHNER JE, 1985, J INFECT DIS, V151, P42, DOI 10.1093/infdis/151.1.42; McPhail L C, 1984, Contemp Top Immunobiol, V14, P247; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; MOSS J, 1978, J CLIN INVEST, V62, P281, DOI 10.1172/JCI109127; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; NICAS TI, 1985, J INFECT DIS, V152, P716, DOI 10.1093/infdis/152.4.716; NICAS TI, 1985, CAN J MICROBIOL, V31, P387, DOI 10.1139/m85-074; NOZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1082, P219, DOI 10.1016/0005-2760(91)90197-P; PEARSON RD, 1987, J IMMUNOL, V139, P2749; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; RECHNITZER C, 1992, MICROB PATHOGENESIS, V12, P115, DOI 10.1016/0882-4010(92)90114-4; SAHA AK, 1985, ARCH BIOCHEM BIOPHYS, V243, P150, DOI 10.1016/0003-9861(85)90783-0; SAHA AK, 1988, ARCH BIOCHEM BIOPHYS, V265, P94, DOI 10.1016/0003-9861(88)90375-X; SAHA AK, 1988, J GEN MICROBIOL, V134, P1275; SAHA AK, 1989, J BACTERIOL, V171, P5103, DOI 10.1128/jb.171.9.5103-5110.1989; SEVERIN ES, 1985, ROLE PHOSPHORYLATION, P167; SIMPSON LL, 1984, J PHARMACOL EXP THER, V230, P665; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; Spitznagel J K, 1984, Contemp Top Immunobiol, V14, P283; SUMMERSGILL JT, 1990, J LEUKOCYTE BIOL, V47, P31, DOI 10.1002/jlb.47.1.31; TARTAKOVSKII IS, 1989, ZH MIKROBIOL EPIDEMI, V12, P93; VANNESS BG, 1980, J BIOL CHEM, V255, P710	65	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1993	7	11					1011	1015		10.1096/fasebj.7.11.8370469	http://dx.doi.org/10.1096/fasebj.7.11.8370469			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370469				2022-12-28	WOS:A1993LT83900005
J	ENG, C; PONDER, BAJ				ENG, C; PONDER, BAJ			THE ROLE OF GENE-MUTATIONS IN THE GENESIS OF FAMILIAL CANCERS	FASEB JOURNAL			English	Review						INHERITED CANCER SYNDROMES; TUMOR SUPPRESSOR GENES; ONCOGENES	NEUROFIBROMATOSIS TYPE-1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; LI-FRAUMENI SYNDROME; NONPOLYPOSIS COLORECTAL-CARCINOMA; VONHIPPEL-LINDAU DISEASE; RENAL-CELL CARCINOMA; BREAST-CANCER; ADENOMATOUS POLYPOSIS; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; ATAXIA-TELANGIECTASIA	The simplest molecular mechanism of hereditary tumorigenesis is represented by retinoblastoma (RB). Knudson's model specifies that, in herediatry RB, the first mutation in an allele of the RB gene exists in the germline. A subsequent somatic mutation in the second normal RB allele releases RB formation in the eye. This mechanism of loss of function of both normal tumor suppressor gene copies applies to other hereditary cancer syndromes as well, including multiple endocrine neoplasia type 1, neurofibromatosis type 2, Li-Fraumeni syndrome, and probably familial breast/ovarian syndrome. In some syndromes, e.g. familial adenomatous polyposis and multiple endocrine neoplasia type 2, the mechanism may be slightly different. Loss of function of only one allele of the susceptibility locus appears to be sufficient to promote a proliferative advantage in target tissues. In many of these inherited cancer syndromes, variable expression and variable penetrance of phenotypes exist. Allelism, existence of a multigene complex, or modulation of expression by modifier genes may explain the phenomena.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND	University of Cambridge				Eng, Charis/0000-0002-3693-5145				Arnold A, 1992, Henry Ford Hosp Med J, V40, P177; BALE AE, 1991, CANCER RES, V51, P1154; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COLLINS FS, 1989, AM J HUM GENET, V44, P1; CROSSEY PA, 1993, HUM MOL GENET, V2, P279, DOI 10.1093/hmg/2.3.279; EASTON D, 1990, CANCER SURV, V9, P395; EASTON DF, 1993, IN PRESS AM J HUM GE; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDMANN T, 1992, CANCER, V70, P1810, DOI 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRIEND SH, 1992, TUMOR SUPPRESSOR GEN, P169; GARBER JE, 1991, CANCER RES, V51, P6094; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GO RCP, 1983, J NATL CANCER I, V71, P455; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; JORDAN DK, 1989, CANCER GENET CYTOGEN, V42, P227, DOI 10.1016/0165-4608(89)90091-5; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LYNCH HT, 1990, CANCER, V66, P909, DOI 10.1002/1097-0142(19900901)66:5<909::AID-CNCR2820660516>3.0.CO;2-H; LYNCH HT, 1988, DIS COLON RECTUM, V31, P439, DOI 10.1007/BF02552613; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATHEW CGP, 1989, AM J HUM GENET, V44, P38; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; McKusick VA, 1990, MENDELIAN INHERITANC; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MOCHIZUKI H, 1992, MOL CARCINOGEN, V6, P83, DOI 10.1002/mc.2940060203; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAGASE H, 1992, CANCER RES, V52, P4055; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OGAWA O, 1992, CANCER RES, V52, P1881; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1992, CANCER RES, V52, P4530; PONDER BAJ, 1987, EUR J SURG ONCOL, V13, P463; PONDER BAJ, 1992, TUMOR SUPPRESSOR GEN, P143; RADFORD DM, 1990, CANCER RES, V50, P6529; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SMITH SA, 1993, IN PRESS AM J HUM GE; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WARREN W, 1992, ONCOGENE, V7, P1043; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065; GENETICS CELL BIOL B, V29, P57; 1991, LANCET, V337, P329	79	48	48	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					910	919		10.1096/fasebj.7.10.8102106	http://dx.doi.org/10.1096/fasebj.7.10.8102106			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8102106				2022-12-28	WOS:A1993LQ33700014
J	MORAN, E				MORAN, E			INTERACTION OF ADENOVIRAL PROTEINS WITH PRB AND P53	FASEB JOURNAL			English	Review						P53 FUNCTION; ADENOVIRUS GENES; PRB BINDING SITE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; HUMAN CYCLIN-A; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; CELL-CYCLE; VIRAL ONCOPROTEINS; MOLECULAR-CLONING; BINDING PROTEIN; P107	The transforming gene products of the small DNA tumor viruses subvert host cell growth control mechanisms by binding to specific cell regulatory proteins. These include the retinoblastoma gene product (pRB) and p53. One indication of the pivotal roles played by these regulatory products is the observation that they are each targeted consistently by viruses of several groups, by adenoviruses, the human papillomaviruses, and the papovaviruses. In adenovirus, pRB and p53 are targeted by the E1A and E1B genes, respectively. The genetic probes made possible by manipulation of the virus genes in vitro have helped to illuminate the pathways in which pRB and p53 function. E1A studies have contributed to our current understanding that the retinoblastoma product is one of a family of related proteins, which with associated cyclins and kinases can modulate the activity of the cellular E2F transcription factor. E1B studies have helped explore models of p53 function, including the suggestion that p53, probably through aspects of its transcription regulating activity, can initiate a pathway in which programmed cell death can be invoked to stop unrestricted cell proliferation.			MORAN, E (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				NATIONAL CANCER INSTITUTE [R01CA055330, R01CA053592] Funding Source: NIH RePORTER; NCI NIH HHS [CA55330, CA53592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEBBAS M, 1993, GENE DEV, V7, P346; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1992, CANCER SURV, V12, P161; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIORDANO A, 1991, ONCOGENE, V6, P481; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HEIBERT SW, 1993, MOL CELL BIOL, V13, P3384; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAMAND J, 1992, CELL, V69, P1237; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; ULLIRCH SJ, 1992, ONCOGENE, V7, P1635; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHIE E, 1992, MOL CELL BIOL, V12, P2570; WHITE E, 1993, IN PRESS P SOC EXP S; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	56	136	145	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					880	885		10.1096/fasebj.7.10.8344487	http://dx.doi.org/10.1096/fasebj.7.10.8344487			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344487				2022-12-28	WOS:A1993LQ33700010
J	MUSIERFORSYTH, K; SCHIMMEL, P				MUSIERFORSYTH, K; SCHIMMEL, P			AMINOACYLATION OF RNA OLIGONUCLEOTIDES - MINIMALIST STRUCTURES AND ORIGIN OF SPECIFICITY	FASEB JOURNAL			English	Review							ESCHERICHIA-COLI; ENZYMATIC AMINOACYLATION; MOLECULAR RECOGNITION; MAJOR DETERMINANT; GROUP-I; SYNTHETASE; IDENTITY; SEQUENCE; PARAMETERS; RESOLUTION	Aminoacyl tRNA synthetases are divided into two unrelated classes of ten enzymes each. Members from each class specifically aminoacylate small RNA oligonucleotides lacking anticodon sequences. Duplex structures with only four base pairs stabilized by RNA tetraloop motifs are active. Atomic groups on bases and ribose 2'-hydroxyl groups in the RNA minor groove make functional contacts that are essential for aminoacylation and provide the high specificity. A system for specific aminoacylation of small RNA oligonucleotides that is based on sequences proximal to the amino acid attachment site may reflect the small sizes of early synthetases.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; CSANK C, 1992, J BIOL CHEM, V267, P4592; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCOIS M, 1990, J MOL BIOL, V216, P585; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; GUO QB, 1991, J BIOL CHEM, V266, P1809; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JASIN M, 1983, NATURE, V306, P441, DOI 10.1038/306441a0; JASIN M, 1984, CELL, V36, P1089, DOI 10.1016/0092-8674(84)90059-X; KIM SH, 1992, J BIOL CHEM, V267, P15563; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PARK SJ, 1988, J BIOL CHEM, V263, P16527; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; REGAN L, 1987, SCIENCE, V235, P1651, DOI 10.1126/science.2435005; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005	47	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					282	289		10.1096/fasebj.7.2.7680012	http://dx.doi.org/10.1096/fasebj.7.2.7680012			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	7680012				2022-12-28	WOS:A1993KN88500003
J	BRANDSCH, M; BRANDSCH, C; PRASAD, PD; GANAPATHY, V; HOPFER, U; LEIBACH, FH				BRANDSCH, M; BRANDSCH, C; PRASAD, PD; GANAPATHY, V; HOPFER, U; LEIBACH, FH			IDENTIFICATION OF A RENAL-CELL LINE THAT CONSTITUTIVELY EXPRESSES THE KIDNEY-SPECIFIC HIGH-AFFINITY H+/PEPTIDE COTRANSPORTER	FASEB JOURNAL			English	Article						H+ PEPTIDE COTRANSPORTER; PEPT 1; PEPT 2; SKPT-0193 RENAL CELL LINE; RAT KIDNEY	BORDER MEMBRANE-VESICLES; GLYCYL-L-PROLINE; CARRIER-MEDIATED TRANSPORT; DIPEPTIDE TRANSPORT; PROXIMAL TUBULE; PH GRADIENT; RABBIT; GLYCYLSARCOSINE; PEPTIDES; REABSORPTION	In this study we describe for the first time the identification of a renal cell line that expresses the kidney-specific high-affinity H+/peptide cotransport system, The kidney cell line SKPT-0193 Cl.2 was obtained by SV40 transformation of rat proximal tubular cells, The transport of the dipeptide glycylsarcosine (Gly-Sar) was studied in this cell line grown as a confluent monolayer on impermeable plastic supports, Uptake of the dipeptide was rapid and was stimulated sixfold by an inwardly directed H+ gradient, with optimal uptake occurring at an extracellular pH of 6.0. The uptake was markedly reduced by the protonophore carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone whether measured at pH 7.5 or 6.0. Intracellular acidification of the cells by NH4Cl prepulse also reduced the uptake of glycylsarcosine, The dipeptide uptake was found to be mediated by a high-affinity transport system with a Michaelis-Menten constant (K-t) of 67 +/- 2 mu M and a maximal transport velocity of 1.20 +/- 0.02 nmol . 10 min(-1). mg protein(-1). Studied over a concentration range of 5 mu M to 5 mM, there was no evidence for a second saturable transport component, Di- and tripeptides, but not glycine, were strong inhibitors of glycylsarcosine uptake, indicating that these peptides also interact with the transport system with high affinity, Northern blot analysis of poly(A)(+)RNA from these cells using cDNA probes specific for the human intestinal peptide transporter (PEPT 1) or the human kidney-specific peptide transporter (PEPT 2) revealed that the transport system expressed in these cells is PEPT 2, It is concluded that the SKPT-0193 Cl.2 cell line constitutively expresses the kidney-specific high-affinity H+/peptide cotransporter described in the proximal tubular epithelial cells of the normal kidney.	MED COLL GEORGIA, DEPT BIOCHEM & MOLEC BIOL, AUGUSTA, GA 30912 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	University System of Georgia; Augusta University; Case Western Reserve University			Hopfer, Ulrich/B-5463-2009	Hopfer, Ulrich/0000-0003-1357-0101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50173] Funding Source: Medline; NIDDK NIH HHS [DK-28389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1987, METABOLISM, V36, P1001, DOI 10.1016/0026-0495(87)90140-5; BARFUSS DW, 1988, AM J PHYSIOL, V255, pF177, DOI 10.1152/ajprenal.1988.255.1.F177; BARFUSS DW, 1981, AM J PHYSIOL, V241, pF322, DOI 10.1152/ajprenal.1981.241.3.F322; BRANDSCH M, 1995, AM J PHYSIOL-RENAL, V268, pF391, DOI 10.1152/ajprenal.1995.268.3.F391; BRANDSCH M, 1994, BIOCHEM J, V299, P253, DOI 10.1042/bj2990253; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIEL H, 1991, J BIOL CHEM, V266, P19917; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FURST P, 1990, P NUTR SOC, V49, P343, DOI 10.1079/PNS19900041; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GANAPATHY V, 1987, ADV BIOSCI, V65, P91; Ganapathy Vadivel, 1994, P1773; GRIMBLE GK, 1994, ANNU REV NUTR, V14, P419, DOI 10.1146/annurev.nu.14.070194.002223; INUI KI, 1984, BIOCHIM BIOPHYS ACTA, V769, P449, DOI 10.1016/0005-2736(84)90329-8; KRAMER W, 1988, BIOCHIM BIOPHYS ACTA, V939, P167, DOI 10.1016/0005-2736(88)90059-4; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Matthews DM, 1991, PROTEIN ABSORPTION D; MIYAMOTO Y, 1985, BIOCHEM BIOPH RES CO, V132, P946, DOI 10.1016/0006-291X(85)91899-6; MIYAMOTO Y, 1988, BIOCHEM J, V249, P247, DOI 10.1042/bj2490247; RAMAMOORTHY S, 1991, BIOCHEM J, V280, P317, DOI 10.1042/bj2800317; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RAMAMOORTHY S, 1995, IN PRESS BIOCH BIOPH; ROMERO MF, 1992, KIDNEY INT, V42, P1130, DOI 10.1038/ki.1992.397; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SEAL CJ, 1991, COMP BIOCHEM PHYS B, V99, P679, DOI 10.1016/0305-0491(91)90354-G; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; SKOPICKI HA, 1991, AM J PHYSIOL, V261, pF670, DOI 10.1152/ajprenal.1991.261.4.F670; TAKUWA N, 1985, BIOCHIM BIOPHYS ACTA, V814, P186, DOI 10.1016/0005-2736(85)90435-3; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P2048; WOOST PG, 1994, FASEB J, V8, pA529	37	63	63	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1995	9	14					1489	1496		10.1096/fasebj.9.14.7589991	http://dx.doi.org/10.1096/fasebj.9.14.7589991			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589991				2022-12-28	WOS:A1995TF67800014
J	GOETZL, EJ; AN, SZ; SMITH, WL				GOETZL, EJ; AN, SZ; SMITH, WL			SPECIFICITY OF EXPRESSION AND EFFECTS OF EICOSANOID MEDIATORS IN NORMAL PHYSIOLOGY AND HUMAN-DISEASES	FASEB JOURNAL			English	Review						PROSTAGLANDIN; LEUKOTRIENE; ARACHIDONIC ACID; CYCLOOXYGENASE; LIPOXYGENASE; RECEPTOR; IMMUNITY	ARACHIDONIC-ACID; LYMPHOCYTES-B; PROSTAGLANDIN; LEUKOTRIENES; SYNTHASE; PROTEIN; CYCLOOXYGENASE; GENE; 5-LIPOXYGENASE; DEFICIENCY	The eicosanoids are a family of oxygenated arachidonic acid derivatives that potently mediate diverse physiological and pathophysiological processes. Recent research on eicosanoids has revealed novel pathways of synthesis, a family of related cell membrane receptors, and distinctive roles in cellular functions. There are two cyclooxygenases that convert arachidonic acid to thromboxane and prostaglandins, one of which is localized in the endoplasmic reticulum and the other in the nuclear envelope. The cyclooxygenases differ in their susceptibility to inhibition by nonsteroidal antiinflammatory drugs. The leukotriene-generating pathway consists of a cytosolic perinuclear 5-lipoxygenase, two integral nuclear envelope proteins, termed 5-lipoxygenase-activating protein and LTC4 synthase, and a cytosolic LTA4 hydrolase. Each protein of the leukotriene synthetic pathway is a target for specific pharmacological intervention. Cellular recognition and effects of eicosanoids are mediated by at least 12 different G protein-associated primary receptors, which differ in tissue distribution, signaling mechanisms, and cellular behavior, as well as binding specificity. Transient localized increases in tissue concentrations of eicosanoids and the concurrent upregulation of complementary receptors influence differentiation, migration, and specific activities of cells in immunity and other integrated physiological responses.	UNIV CALIF SAN FRANCISCO, MED CTR, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, MED CTR, DEPT IMMUNOL MICROBIOL, SAN FRANCISCO, CA 94143 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK042509, R01DK022042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31809] Funding Source: Medline; NIDDK NIH HHS [DK-42509, DK-22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; [Anonymous], 1987, PHOSPHOLIPASES; AWAD JA, 1994, J ALLERGY CLIN IMMUN, V93, P817, DOI 10.1016/0091-6749(94)90371-9; BETZ M, 1991, J IMMUNOL, V146, P108; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRESNAHAN BA, 1992, J CLIN INVEST, V90, P2304, DOI 10.1172/JCI116118; BROWN DM, 1992, CLIN IMMUNOL IMMUNOP, V63, P221, DOI 10.1016/0090-1229(92)90226-E; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1994, CELLULAR GENERATION; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GREALLY P, 1994, J ALLERGY CLIN IMMUN, V93, P100, DOI 10.1016/0091-6749(94)90238-0; HIRATA T, 1994, J CLIN INVEST, V94, P1662, DOI 10.1172/JCI117510; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KLICKSTEIN LB, 1980, J CLIN INVEST, V66, P1166, DOI 10.1172/JCI109947; KOO CH, 1989, ADV PROSTAG THROMB L, V19, P191; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LEPPERT D, 1995, FASEB J, V9, pA853; MARIJEVICALEKSI.N, 1994, BLOOD S, V84, pA320; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MAYATEPEK E, 1993, J CLIN INVEST, V91, P881, DOI 10.1172/JCI116309; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NUSING R, 1990, EICOSANOIDS, V3, P53; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OMING L, 1994, J BIOL CHEM, V269, P11269; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROLAPLESZCZYNSKI M, 1987, J IMMUNOL, V139, P513; ROPER RL, 1992, J IMMUNOL, V149, P2984; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHAFER AI, 1982, NEW ENGL J MED, V306, P381, DOI 10.1056/NEJM198202183060701; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WITTENBERG RH, 1993, ARTHRITIS RHEUM, V36, P1444, DOI 10.1002/art.1780361017; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996; Zeng L., 1994, Molecular Biology of the Cell, V5, p68A; ZHANG YY, 1993, J BIOL CHEM, V268, P2535	56	240	246	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1051	1058		10.1096/fasebj.9.11.7649404	http://dx.doi.org/10.1096/fasebj.9.11.7649404			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649404				2022-12-28	WOS:A1995RP99600009
J	COOKE, R				COOKE, R			THE ACTOMYOSIN ENGINE	FASEB JOURNAL			English	Review						FORCE; MYOSIN; ENERGETICS; ACTIN; STRUCTURE; MECHANICS	MYOSIN SUBFRAGMENT-1; MUSCLE-CONTRACTION; ROTATIONAL-DYNAMICS; ATOMIC MODEL; ACTIN; HEADS; MECHANISM; FILAMENT; COMPLEX; ANGLE	Two recent advances have extended our knowledge of the actomyosin interaction considerably. The first of these is the determination of the crystal structures of the actin monomer and of the myosin head. The structures of these proteins were fit into the quaternary protein complexes of the actin filament, and of the actin filament decorated by the myosin head, using data from fiber diffraction or electron microscopy as constraints. The atomic models of these protein complexes have led to new hypotheses concerning the large conformational changes that must occur in these proteins in order to generate force. The second advance has been the measurement of the forces and displacements of single motor proteins, in particular, of a single myosin molecule interacting with a single actin filament. These data lead to more unambiguous interpretations than did previous mechanical data, which were obtained using ensembles of motors that worked asynchronously on their filaments. This approach brings to the motor field the equivalent of what patch clamp techniques brought to the study of membrane channels: the ability to look at the function of a single molecule.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	COOKE, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030868, P01AR042895] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30868, AR42895] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN TS, 1994, BIOPHYS J, V66, pA234; ANDO T, 1982, BIOCHEM BIOPH RES CO, V109, P1, DOI 10.1016/0006-291X(82)91557-1; BERGER CL, 1993, BIOCHEMISTRY-US, V32, P3812, DOI 10.1021/bi00065a038; BURGHARDT TP, 1983, P NATL ACAD SCI-BIOL, V80, P7515, DOI 10.1073/pnas.80.24.7515; COOKE R, 1994, BIOPHYS J, V66, P778, DOI 10.1016/S0006-3495(94)80854-9; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COOKE R, 1982, NATURE, V30, P776; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; FAJER PG, 1990, P NATL ACAD SCI USA, V87, P5538, DOI 10.1073/pnas.87.14.5538; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FRANKSSKIBA K, 1994, BIOPHYS J, V66, pA347; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOLDMAN YE, 1987, ANN REV PHYSL, V49, P632; HAMBLY B, 1992, BIOPHYS J, V63, P306; HIGHSMITH S, 1990, BIOCHEMISTRY-US, V29, P4087, DOI 10.1021/bi00469a010; HIROSE K, 1993, BIOPHYS J, V65, P394; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KABSCH W, 1990, NATURE; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; LIANG Z, 1994, BIOPHYS J, V66, pA192; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NABER N, 1993, PROTEINS, V17, P347, DOI 10.1002/prot.340170403; PATE E, 1993, P NATL ACAD SCI USA, V90, P2451, DOI 10.1073/pnas.90.6.2451; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELLERS J R, 1991, Current Biology, V1, P347, DOI 10.1016/0960-9822(91)90188-3; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WALKER M, 1994, BIOPHYS J, V66, P1563, DOI 10.1016/S0006-3495(94)80948-8; YANAGIDA T, 1985, J MUSCLE RES CELL M, V6, P43, DOI 10.1007/BF00712310	37	27	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					636	642		10.1096/fasebj.9.8.7768355	http://dx.doi.org/10.1096/fasebj.9.8.7768355			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768355				2022-12-28	WOS:A1995RC10600009
J	SMITH, S				SMITH, S			THE ANIMAL FATTY-ACID SYNTHASE - ONE GENE, ONE POLYPEPTIDE, 7 ENZYMES	FASEB JOURNAL			English	Review						FAS DOMAIN; ACYL MOIETY; THIOESTERASE I; INTRON	ACYL CARRIER PROTEIN; RAT MAMMARY-GLAND; ESCHERICHIA-COLI; MOLECULAR-CLONING; LIMITED TRYPSINIZATION; MULTIFUNCTIONAL ENZYME; THIOESTERASE DOMAIN; ACTIVE SERINE; MULTIENZYME COMPLEX; HARDERIAN-GLAND	The animal fatty acid synthase comprises two multifunctional polypeptide chains, each containing seven discrete functional domains, juxtaposed head-to-tail such that two separate centers for fatty acid assembly are formed at the subunit interface. The kinetics and specificities of the component enzymes are well adapted to ensure that, at each of the two centers, the iterative condensation of an acetyl moiety with successive malonyl moieties and complete reduction of the beta-keto intermediates normally results in the formation of palmitic acid as the major product. Nevertheless, utilization of alternative substrates and alternative chain-terminating mechanisms can extend the range of products to include branched-chain, odd carbon-numbered, and shorter chain-length fatty acids. The potential of this multifunctional form of molecular architecture for the elaboration of more complex natural products has been further exploited in microorganisms that, by the use of different fatty acid synthase ''modules'' that perform variable beta-carbon processing at successive elongation steps, generate a structurally diverse family of polyketides retaining keto, hydroxyl, enoyl, or alkyl functions at specific positions in the carbon chain.-Smith, S. The fatty acid synthase: one gene, one polypeptide, seven enzymes.			SMITH, S (corresponding author), CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609, USA.				NIDDK NIH HHS [DK 16073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BUCKNER JS, 1978, ARCH BIOCHEM BIOPHYS, V186, P152, DOI 10.1016/0003-9861(78)90474-5; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; FOSTER RJ, 1985, J BIOL CHEM, V260, P2826; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; HANSEN JK, 1980, BIOCHEM J, V186, P287, DOI 10.1042/bj1860287; HARDIE DG, 1986, MULTIDOMAIN PROTEINS; HARDIE DG, 1986, MULTIDOMAIN PROTEINS, P229; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JAWORSKI JG, 1993, EUR J BIOCHEM, V213, P981, DOI 10.1111/j.1432-1033.1993.tb17843.x; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KITAMOTO T, 1988, J MOL BIOL, V203, P183, DOI 10.1016/0022-2836(88)90101-5; Knudsen J, 1981, Methods Enzymol, V71 Pt C, P200, DOI 10.1016/0076-6879(81)71028-0; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; LINN TC, 1980, J BIOL CHEM, V255, P1388; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MCCARTHY AD, 1983, FEBS LETT, V160, P296, DOI 10.1016/0014-5793(83)80986-7; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NICOLAIDES N, 1974, SCIENCE, V186, P19, DOI 10.1126/science.186.4158.19; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PAWAR S, 1981, J BIOL CHEM, V256, P3894; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; PETITHORY JR, 1993, BIOCHEM J, V292, P361, DOI 10.1042/bj2920361; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; RAIBAUD A, 1991, J BACTERIOL, V173, P4454, DOI 10.1128/JB.173.14.4454-4463.1991; RANGAN VS, 1991, J BIOL CHEM, V266, P19180; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; SCHWEIZER E, 1980, MULTIFUNCTIONAL PROT, P197; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SEYAMA Y, 1981, J BIOCHEM-TOKYO, V90, P789, DOI 10.1093/oxfordjournals.jbchem.a133535; SINGH N, 1984, J BIOL CHEM, V259, P3605; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; SMITH S, 1976, P NATL ACAD SCI USA, V73, P1184, DOI 10.1073/pnas.73.4.1184; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; STERN A, 1982, J BIOL CHEM, V257, P799; STOOPS JK, 1987, J BIOL CHEM, V262, P10246; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; TSAY JT, 1992, J BIOL CHEM, V267, P6807; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1961, J LIPID RES, V2, P1; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; YUAN Z, 1986, J BIOL CHEM, V261, P3643	59	488	518	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1248	1259		10.1096/fasebj.8.15.8001737	http://dx.doi.org/10.1096/fasebj.8.15.8001737			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001737				2022-12-28	WOS:A1994PY20900008
J	LUBEC, G; WENINGER, M; ANDERSON, SR				LUBEC, G; WENINGER, M; ANDERSON, SR			RACEMIZATION AND OXIDATION STUDIES OF HAIR PROTEIN IN THE HOMO-TIROLENSIS	FASEB JOURNAL			English	Article						O-TYROSINE; DI-TYROSINE; DATING; TEMPERATURE; RADIATION	ASPARTIC-ACID; AMINO-ACIDS	Amino acids contained in fossil materials show an increasing extent of racemization with age, postulating time and temperature as the two major variables. The recent discovery of the Home tirolensis made possible a comparison between racemization rates of the amino acids found in hair at identical ages (5200 years of age) but at different diagenetic temperatures (''Ginger,'' found in the hot, dry sand of Egypt; H. tirolensis, found on a glacier of the Otztaler Alps). The rate of racemization was higher in the H. tirolensis, which is surprising and in contrast to current concepts. Ortho-tyrosine and di-tyrosine, parameters for OH-radical attack, were also higher in the H. tirolensis, suggesting a role for free OH-radical involvement in the racemization process.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University	LUBEC, G (corresponding author), UNIV VIENNA, DEPT PEDIAT, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.			Lubec, Gert/0000-0002-6333-9461				BADA JL, 1982, INTERDISCIPL SCI REV, V7, P30, DOI 10.1179/030801882789801304; BADA JL, 1980, EARTH-SCI REV, V16, P21, DOI 10.1016/0012-8252(80)90003-3; BADA JL, 1975, NATURWISSENSCHAFTEN, V62, P71, DOI 10.1007/BF00592179; BARMAN TE, 1974, ENZYME HDB S, V1, P463; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGL KW, 1989, APPL RADIAT ISOTOPES, V40, P1203, DOI 10.1016/0883-2889(89)90064-6; Bonani G., 1992, MANN EIS, V187, P108; FUJII N, 1991, BIOMED RES-TOKYO, V12, P315, DOI 10.2220/biomedres.12.315; GETOFF N, 1992, Amino Acids (Vienna), V2, P195, DOI 10.1007/BF00805942; GOODFRIEND GA, 1992, NATURE, V357, P399, DOI 10.1038/357399a0; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; KAMPEL D, 1990, AMINO ACIDS CHEM BIO, P1164; LUBEC G, 1993, AMINO ACIDS, V4, P1, DOI 10.1007/BF00805796; LUBEC G, 1987, J ARCHAEOL SCI, V14, P113, DOI 10.1016/0305-4403(87)90001-X; MASTERS PM, 1979, J AGR FOOD CHEM, V27, P507, DOI 10.1021/jf60223a035; Meier W., 1988, Beta-gamma, V1, P34; TIEFENBRUNNER F, 1992, MANN EIS, V1, P100; WEINER S, 1980, NATURE, V287, P820, DOI 10.1038/287820a0	18	34	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1994	8	14					1166	1169		10.1096/fasebj.8.14.7958623	http://dx.doi.org/10.1096/fasebj.8.14.7958623			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958623				2022-12-28	WOS:A1994PT12800012
J	ROSE, MR; NUSBAUM, TJ				ROSE, MR; NUSBAUM, TJ			PROSPECTS FOR POSTPONING HUMAN AGING	FASEB JOURNAL			English	Review						GENETICS OF SENESCENCE; DROSOPHILA; NEMATODE; GENETIC ENGINEERING	CAENORHABDITIS-ELEGANS; LIFE-SPAN; DROSOPHILA-MELANOGASTER; REPRODUCTION; RESTRICTION; SENESCENCE	The postponement of human aging is a long-standing aspiration in many cultures, particularly non-Western ones. Renewed interest in this goal is now being shown within the biomedical research context. This interest has probably arisen because several different approaches have yielded dramatic increases in mean and maximum life span in laboratory organisms. Among the cases where aging has been postponed in animal models are the nematode, Caenorhabditis elegans, the common lab fruit fly, Drosophila melanogaster, and the dietarily restricted rodent, both Mus and Rattus. These successes raise the question of whether similar postponement of aging might be achieved in humans. Among the broad research strategies available, five can be delineated: 1) random testing of favorite interventions; 2) searching for genes that can postpone aging among all or most species; 3) study of in vitro mammalian cell cultures; 4) study of dietarily restricted mammals; and 5) selecting mammals for postponed aging. Although all these methods could conceivably lead to the postponement of human aging, they are very different from each other with respect to their degree of uncertainty, cost, and delay.			ROSE, MR (corresponding author), UNIV CALIF IRVINE,SCH BIOL SCI,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92717, USA.				NATIONAL INSTITUTE ON AGING [P01AG009970, R01AG006346] Funding Source: NIH RePORTER; NIA NIH HHS [AG06346, AG09970] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CLARKE JM, 1955, J GENET, V53, P72; Comfort A., 1979, BIOL SENESCENCE; FLEMING JE, 1993, GENETICA, V91, P183, DOI 10.1007/BF01435997; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRIEDMAN DB, 1988, GENETICS, V118, P75; GRAVES JL, 1993, GROWTH DEVELOP AGING, V57, P233; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAZWINSKI MS, 1993, GENETICA, V91, P35; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSON TE, 1993, GENETICA, V91, P65, DOI 10.1007/BF01435988; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3771; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; MASORO EJ, 1988, J GERONTOL, V43, pB59, DOI 10.1093/geronj/43.3.B59; McCAY CLIVE M., 1956, BULL NEW YORK ACAD MED, V32, P91; NUSBAUM TJ, 1994, IN PRESS COMP BIOCH; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; ROSE MR, 1990, GROWTH DEVELOP AGING, V54, P7; ROSE MR, 1989, BIOESSAYS, V11, P132, DOI 10.1002/bies.950110505; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; TYLER RH, 1993, GENETICA, V91, P143, DOI 10.1007/BF01435994; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0	28	8	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1994	8	12					925	928		10.1096/fasebj.8.12.8088458	http://dx.doi.org/10.1096/fasebj.8.12.8088458			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088458				2022-12-28	WOS:A1994PG29300004
J	HIMPENS, B; DESMEDT, H; BOLLEN, M				HIMPENS, B; DESMEDT, H; BOLLEN, M			MODULATION NUCLEOCYTOSOLIC [CA2+] GRADIENT IN SMOOTH-MUSCLE BY PROTEIN-PHOSPHORYLATION	FASEB JOURNAL			English	Article						CALCIUM; PROTEIN KINASE; PROTEIN PHOSPHATASE; NUCLEUS	NUCLEAR-PORE COMPLEX; CALCIUM GRADIENTS; CELL-NUCLEUS; KINASE-C; MOBILIZATION; HEPATOCYTES; VASOPRESSIN; MICROSCOPE; TRANSIENTS; INHIBITOR	In resting DDT(1)MF-2 smooth muscle cells, the cytosolic free Ca2+ concentration ([Ca2+](c)) was higher than the free Ca2+ concentration in the nucleus ([Ca2+](n)). However, this nucleocytosolic [Ca2+] gradient was reversed by Ca2+ agonists like ATP or, as is shown here, by the epidermal growth factor (EGF). The ATP-induced reversal of the nucleocytosolic [Ca2+] gradient was blocked by stimulation of protein kinase C with phorbol 12-myristate 13-acetate or with the diacylglycerol kinase inhibitor R59949, or by inhibition of the Ser/Thr-specific protein phosphatases-1 and -2A with okadaic acid or calyculin A. Moreover, the magnitude of the ATP-induced reversal of the [Ca2+] gradient diminished during prolonged culture of the cells. The EGF-induced [Ca2+] rise in the cytosol and nucleus was blocked by okadaic acid and by the tyrosine kinase inhibitors herbimycin A and psi-tectorigenin. Our data suggest that the nucleocytosolic [Ca2+] gradient is modulated by (de)phosphorylation processes catalyzed by tyrosine protein kinases, by protein kinase C, and by Ser/Thr protein phosphatases-1. and -2A.	KATHOLIEKE UNIV LEUVEN, FAC MED, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, FAC MED, BIOCHEM LAB, B-3000 LOUVAIN, BELGIUM	KU Leuven; KU Leuven								ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BOLLEN M, 1993, ADV PROTEIN PHOSPHAT, V7, P31; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V24, P69; BUSTAMANTE JO, 1993, BIOPHYS J, V64, P1735, DOI 10.1016/S0006-3495(93)81545-5; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHEN CS, 1993, J BIOL CHEM, V268, P15812; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DECOURCELLES DD, 1990, ADV SEC MESS PHOSPH, V24, P491; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1994, CELL CALCIUM, V15, P55, DOI 10.1016/0143-4160(94)90104-X; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KHALIL RA, 1992, NEWS PHYSIOL SCI, V7, P10; MEEK DW, 1992, BIOCHEM J, V287, P1; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NAKATO K, 1992, EUR J BIOCHEM, V209, P745, DOI 10.1111/j.1432-1033.1992.tb17343.x; OBERLEITHNER H, 1992, P NATL ACAD SCI USA, V89, P241, DOI 10.1073/pnas.89.1.241; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; STEHNOBITTEL L, 1994, BIOPHYS J, V66, pA119; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	31	20	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					879	883		10.1096/fasebj.8.11.8070638	http://dx.doi.org/10.1096/fasebj.8.11.8070638			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070638				2022-12-28	WOS:A1994PC88500012
J	RAGHOW, R				RAGHOW, R			THE ROLE OF EXTRACELLULAR-MATRIX IN POSTINFLAMMATORY WOUND-HEALING AND FIBROSIS	FASEB JOURNAL			English	Review						EXTRACELLULAR MATRIX; CYTOKINES; SIGNAL TRANSDUCTION; WOUND HEALING; FIBROSIS	PROTEIN-KINASE-C; FIBROBLAST GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-ADHESION; HEPARIN-BINDING; FACTOR-BETA; TGF-BETA; THROMBOSPONDIN; GENERATION	Massive cell migration, proliferation, phenotypic differentiation, and enhanced biosynthetic activities characterize the sites of wound healing and fibrosis. Regulation of cellular functions by extracellular matrix, which consists of a dynamic assemblage of a variety of interacting molecules capable of reorganization in response to endogenous and exogenous stimuli, represents a fundamental epigenetic mechanism regulating cellular behavior and phenotype. Interactions of the individual components of extracellular matrix with specific cell surface molecules, integrin receptors, and proteoglycans initiate a cascade of signal transduction leading to varied short-term or persistent cellular responses. Extracellular matrix also serves as an important reservoir of cytokines and growth factors, thus modulating the action of a host of potent biological response modifiers by their selective, local accumulation and release. Currently known mechanisms by which extracellular matrix modulates different facets of the process of tissue remodeling after injury, which culminate either in normal wound repair or fibrosis, are discussed.	VET AFFAIRS MED CTR, MEMPHIS, TN 38104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	RAGHOW, R (corresponding author), UNIV TENNESSEE, COLL MED, DEPT PHARMACOL, MEMPHIS, TN 38104 USA.							ARMENDARIZBORUNDA J, 1993, LAB INVEST, V69, P283; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; ETTINGER L, 1992, BIOL REV, V67, P459, DOI 10.1111/j.1469-185X.1992.tb01190.x; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOETINCK PF, 1991, CURR TOP DEV BIOL, V25, P111; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Howell John M., 1992, Emergency Medicine Clinics of North America, V10, P655; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KHALIL N, 1991, CIBA F SYMP, V157, P194; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LIMPER AH, 1992, CHEST, V101, P1663, DOI 10.1378/chest.101.6.1663; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MAST BA, 1992, SURG GYNECOL OBSTET, V174, P441; MCGOWAN SE, 1992, FASEB J, V6, P2895, DOI 10.1096/fasebj.6.11.1644255; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; ROBERTS K, 1991, J EXP MED, V173, P231, DOI 10.1084/jem.173.1.231; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1992, COLD SPRING HARB SYM, V57, P309, DOI 10.1101/SQB.1992.057.01.035; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; SEYER JM, 1992, WOUND HEALING BIOCH, P416; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TERKELTAUB RA, 1988, MOL CELLULAR BIOL WO; Thiery Jean Paul, 1992, Current Opinion in Cell Biology, V4, P782, DOI 10.1016/0955-0674(92)90101-H; TOTT A, 1991, WOUNDS LACERATIONS E; TRANQUILLO RT, 1992, J THEOR BIOL, V158, P135, DOI 10.1016/S0022-5193(05)80715-5; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; TURNER ML, 1992, BIOL REV, V67, P359, DOI 10.1111/j.1469-185X.1992.tb00729.x; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; VONDERMARK K, 1992, KIDNEY INT, V41, P632, DOI 10.1038/ki.1992.97; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; YAMADA A, 1991, J IMMUNOL, V146, P53; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; YANG JT, 1993, DEVELOPMENT, V119, P1093; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0	65	341	355	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					823	831		10.1096/fasebj.8.11.8070631	http://dx.doi.org/10.1096/fasebj.8.11.8070631			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070631				2022-12-28	WOS:A1994PC88500004
J	BEAN, AJ; ZHANG, X; HOKFELT, T				BEAN, AJ; ZHANG, X; HOKFELT, T			PEPTIDE SECRETION - WHAT DO WE KNOW	FASEB JOURNAL			English	Review						VESICLE TRANSPORT; G-PROTEIN; CHROMAFFIN GRANULE MEMBRANES; NEUROTRANSMISSION; SYNAPSE; RELEASE; SUBSTANCE P; CGRP; GALANIN; LARGE DENSE-CORE VESICLE	ADRENAL CHROMAFFIN CELLS; ROUGH ENDOPLASMIC-RETICULUM; SYNAPTIC VESICLE MEMBRANE; GTP-BINDING PROTEINS; GENE-RELATED PEPTIDE; DENSE-CORE VESICLES; NEUROTRANSMITTER RELEASE; INTRACELLULAR-TRANSPORT; SYNAPTOTAGMIN P65; DIFFERENTIAL RELEASE	Understanding factors that regulate peptide release became an issue when the presence and possible role of these compounds as transmitter/modulators in various systems were realized. Many studies measuring the levels of peptides in various tissues and fluids have been performed using radioimmunoassay. However, because these peptides are measured in postmortem tissues, or perfusates that are collected at time intervals that do not approach the time scale used for exocytosis, limited information can be derived from these data. Recently the quantitative use of Northern analysis, RNase protection assays, and in situ hybridization has led to a large literature reporting on changes in peptide mRNA levels as a consequence of a variety of treatments. The assumptions involved in using radioimmunoassay measurements of peptide levels and the various methods used to measure peptide mRNAs are different, but data obtained from experiments using both methods are nonetheless used as an indication of the regulation of peptidergic neurons, and ultimately of peptide release. The mechanisms dedicated to translating cellular input into alterations in secretion have begun to be appreciated at a molecular level. Herein we will discuss the cell biology of regulated secretion and consider some levels in this pathway at which peptide release may be controlled.	KAROLINSKA INST,DEPT HISTOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT NEUROBIOL,STOCKHOLM,SWEDEN; LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research								AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; AUNIS D, 1988, J EXP BIOL, V139, P253; Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BEAN AJ, 1991, J NEUROSCI, V11, P2694; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1994, IN PRESS ANN REV BIO; BLOOM SR, 1987, J PHYSIOL-LONDON, V393, P91, DOI 10.1113/jphysiol.1987.sp016812; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUTTON A, 1979, J PHYSIOL-LONDON, V290, P433, DOI 10.1113/jphysiol.1979.sp012781; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELYTE A, 1992, EMBO J, V11, P4795; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDING DW, 1991, BIOL CELL, V73, P157, DOI 10.1016/0248-4900(91)90098-8; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; GUILLEMIN R, 1978, HYPOTHALAMUS, P155; HATTORI T, 1991, J COMP NEUROL, V309, P391, DOI 10.1002/cne.903090308; HEKIMI S, 1991, J NEUROSCI, V11, P3246; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; IVERFELDT K, 1989, ACTA PHYSIOL SCAND, V137, P63, DOI 10.1111/j.1748-1716.1989.tb08721.x; JAN YN, 1983, PROG BRAIN RES, V58, P49, DOI 10.1016/S0079-6123(08)60006-0; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; LUNDBERG JM, 1990, ARCH INT PHARMACOD T, V303, P9; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MERIGHI A, 1988, CELL TISSUE RES, V254, P101; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NEMEROFF CB, 1987, PSYCHOPHARMACOLOGY 3, P887; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OBENDORF D, 1988, J NEUROCHEM, V51, P1573, DOI 10.1111/j.1471-4159.1988.tb01127.x; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PEREZVELAZQUEZ JL, 1993, NATURE, V361, P457, DOI 10.1038/361457a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Perry EK, 1987, PSYCHOPHARMACOLOGY 3, P887; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RICE ME, 1985, NEUROSCIENCE, V15, P891, DOI 10.1016/0306-4522(85)90087-9; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBIN RW, 1984, J CELL BIOL, V99, P356, DOI 10.1083/jcb.99.1.356; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHALLY AV, 1973, SCIENCE, V179, P341, DOI 10.1126/science.179.4071.341; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SEVERINO KA, 1989, CELL, V57, P11; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; STRAND FL, 1991, PHYSIOL REV, V71, P1017, DOI 10.1152/physrev.1991.71.4.1017; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TBUTANT M, 1987, FEBS LETT, V215, P339; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WHIM MD, 1989, P NATL ACAD SCI USA, V86, P9034, DOI 10.1073/pnas.86.22.9034; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; ZHANG X, 1993, NEUROSCIENCE, V57, P365, DOI 10.1016/0306-4522(93)90069-R; ZHU PC, 1986, NEUROSCIENCE, V19, P43, DOI 10.1016/0306-4522(86)90004-7	118	88	91	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1994	8	9					630	638		10.1096/fasebj.8.9.8005390	http://dx.doi.org/10.1096/fasebj.8.9.8005390			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005390				2022-12-28	WOS:A1994NR90600010
J	APERIA, A; HOLTBACK, U; SYREN, ML; SVENSSON, LB; FRYCKSTEDT, J; GREENGARD, P				APERIA, A; HOLTBACK, U; SYREN, ML; SVENSSON, LB; FRYCKSTEDT, J; GREENGARD, P			ACTIVATION/DEACTIVATION OF RENAL NA+,K+-ATPASE - A FINAL COMMON PATHWAY FOR REGULATION OF NATRIURESIS	FASEB JOURNAL			English	Article						SODIUM TRANSPORT SYSTEM; KIDNEY PERFUSION; ANGIOTENSIN; NATRIURETIC HORMONE	NA+-K+-ATPASE; TUBULAR SODIUM-REABSORPTION; ANGIOTENSIN-II; PROXIMAL TUBULE; CELLS; DOPAMINE; STIMULATION; INHIBITION; TRANSPORT; PHOSPHOPROTEIN	Renal sodium metabolism, a major determinant of blood pressure, is regulated with great precision by a variety of endocrine, autocrine, and neuronal factors. Although these factors are known to regulate sodium metabolism by affecting the rate of tubular sodium reabsorption, the molecular mechanisms by which they act are poorly understood. Na+,K+-ATPase plays a pivotal role for sodium reabsorption in all tubular segments. The activity of this enzyme can be dynamically regulated by phosphorylation and dephosphorylation. Here we summarize both old and new evidence that several major substances believed to be involved in the regulation of sodium metabolism and blood pressure, i.e., the antidiuretic agents angiotensin II and norepinephrine, and the diuretic agents dopamine and atrial natriuretic peptide (ANP), may achieve their effects through a common pathway that involves reversible activation/deactivation of renal tubular Na+,K+-ATPase. Regulation of Na+,K+-ATPase activity was studied using a preparation of single proximal tubule (PT) segments, dissected from rat kidneys. Na+,K+-ATPase activity was stimulated by angiotensin II and the alpha-adrenergic agonist, oxymetazoline, at physiological, nonsaturating Nai concentrations. These stimulatory effects were blocked by dopamine and ANP as well as by their respective second messengers, cAMP and cGMP. They were also blocked by the specific protein phosphatase 2B inhibitor FK506. These results indicate that regulation of sodium excretion by norepinephrine, angiotensin II, dopamine, and ANP can be accounted for by a bidirectionally regulated intracellular protein phosphorylation cascade that modulates the activity of renal tubular Na+,K+-ATPase.	ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT WOMEN & CHILD HLTH,PEDIAT UNIT,S-11281 STOCKHOLM,SWEDEN	Rockefeller University; Karolinska Institutet				Syren, Marie-Louise/0000-0003-0857-8432	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1991, P NATL ACAD SCI USA, V88, P2798, DOI 10.1073/pnas.88.7.2798; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAUSEN T, 1991, PHYSIOL REV, V71, P733, DOI 10.1152/physrev.1991.71.3.733; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DIBONA GF, 1985, FED PROC, V44, P2816; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; GARVIN JL, 1989, AM J PHYSIOL, V257, pF907, DOI 10.1152/ajprenal.1989.257.5.F907; GOLIGORSKY MS, 1986, J CELL PHYSIOL, V128, P466, DOI 10.1002/jcp.1041280316; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HARRIS PJ, 1987, NATURE, V326, P697, DOI 10.1038/326697a0; HARRIS PJ, 1977, PFLUG ARCH EUR J PHY, V367, P295, DOI 10.1007/BF00581370; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; IBARRA F, 1993, P NATL ACAD SCI USA, V90, P21, DOI 10.1073/pnas.90.1.21; JABS K, 1989, AM J PHYSIOL, V257, pF424, DOI 10.1152/ajprenal.1989.257.3.F424; KUCHEL OG, 1991, HYPERTENSION, V18, P709, DOI 10.1161/01.HYP.18.6.709; LANG CC, 1992, KIDNEY INT, V42, P433, DOI 10.1038/ki.1992.306; LARSSON S, 1986, AM J PHYSIOL, V251, pC455, DOI 10.1152/ajpcell.1986.251.3.C455; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYTTON J, 1985, J BIOL CHEM, V260, P75; NISHI A, 1993, HYPERTENSION, V21, P767, DOI 10.1161/01.HYP.21.6.767; POGGIOLI J, 1992, AM J PHYSIOL, V263, pC750, DOI 10.1152/ajpcell.1992.263.4.C750; RIBEIRO CP, 1992, AM J PHYSIOL, V262, pF209, DOI 10.1152/ajprenal.1992.262.2.F209; SCHUSTER VL, 1984, J CLIN INVEST, V73, P507, DOI 10.1172/JCI111237; SOWERS JR, 1988, HYPERTENSION, V12, P485, DOI 10.1161/01.HYP.12.5.485; WANG T, 1990, J PHARMACOL EXP THER, V252, P689; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101	30	225	227	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					436	439		10.1096/fasebj.8.6.8168694	http://dx.doi.org/10.1096/fasebj.8.6.8168694			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168694				2022-12-28	WOS:A1994NH25000011
J	CLAIBORNE, A; MILLER, H; PARSONAGE, D; ROSS, RP				CLAIBORNE, A; MILLER, H; PARSONAGE, D; ROSS, RP			PROTEIN-SULFENIC ACID STABILIZATION AND FUNCTION IN ENZYME CATALYSIS AND GENE-REGULATION	FASEB JOURNAL			English	Review						NADH PEROXIDASE; PROTEIN-SULFENIC ACID; OXIDATION-REDUCTION; FOS; JUN; TRANSCRIPTION FACTOR FUNCTION	STREPTOCOCCAL NADH PEROXIDASE; DNA-BINDING ACTIVITY; FLAVOPROTEIN DISULFIDE REDUCTASES; FLAVIN REDOX CENTER; GLUTATHIONE-REDUCTASE; OXIDATIVE STRESS; FAECALIS 10C1; ACTIVITY INVITRO; REACTIVITY; RESOLUTION	Sulfenic acids (R-SOH) result from the stoichiometric oxidations of thiols with mild oxidants such as H2O2; in solution, however, these derivatives accumulate only transiently due to rapid self-condensation reactions, further oxidations to the sulfinic and/or sulfonic acids, and reactions with nucleophiles such as R-SH. In contrast, oxidations of cysteinyl side chains in proteins, where disulfide bond formation can be prevented and where the reactivity of the nascent cysteine-sulfenic acid (Cys-SOH) can be controlled, have previously been shown to yield stable active-site Cys-SOH derivatives of papain and glyceraldehyde-3-phosphate dehydrogenase. More recently, however, functional Cys-SOH residues have been identified in the native oxidized forms of the FAD-containing NADH peroxidase and NADH oxidase from Streptococcus faecalis; these two proteins constitute a new class within the flavoprotein disulfide reductase family. In addition, Cys-SOH derivatives have been suggested to play important roles in redox regulation of the DNA-binding activities of transcription factors such as Fos and Jun, OxyR, and bovine papillomavirus type 1 E2 protein. Structural inferences for the stabilization of protein-sulfenic acids, drawn from the refined 2.16-angstrom structure of the streptococcal NADH peroxidase. provide a molecular basis for understanding the proposed redox functions of these novel cofactors in both enzyme catalysis; and transcriptional regulation.			CLAIBORNE, A (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,WINSTON SALEM,NC 27157, USA.		Miller, Holly/I-6942-2015; Ross, Paul/A-7584-2015	Miller, Holly/0000-0002-9076-5335; Ross, Paul/0000-0003-4876-8839	NIGMS NIH HHS [GM-35394] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035394] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AHMED SA, 1989, J BIOL CHEM, V264, P19856; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; CLAIBORNE A, 1992, TRENDS BIOCHEM SCI, V17, P183, DOI 10.1016/0968-0004(92)90263-9; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; HECKEL A, 1983, TETRAHEDRON LETT, V24, P5047, DOI 10.1016/S0040-4039(00)94037-1; Hogg D. R., 1990, CHEM SULPHENIC ACIDS, P361; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; LIU TY, 1977, PROTEINS, V3, P239; LO SS, 1984, J BIOL CHEM, V259, P1041; MASSEY V, 1965, J BIOL CHEM, V240, P4470; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MILLER H, 1991, J BIOL CHEM, V266, P19342; NAKAMURA N, 1983, J AM CHEM SOC, V105, P7172, DOI 10.1021/ja00362a026; OKUNO H, 1993, ONCOGENE, V8, P695; PAL BC, 1969, J AM CHEM SOC, V91, P3634, DOI 10.1021/ja01041a036; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POOLE LB, 1989, J BIOL CHEM, V264, P12322; POOLE LB, 1989, J BIOL CHEM, V264, P12330; POOLE LB, 1986, J BIOL CHEM, V261, P4525; POOLE LB, 1988, BIOCHEM BIOPH RES CO, V153, P261; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; ROSS RP, 1991, J MOL BIOL, V221, P857, DOI 10.1016/0022-2836(91)80180-3; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; VOET D, 1990, BIOCHEMISTRY-US, P538; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YOSHIMURA T, 1992, J CHEM SOC CHEM COMM, P1337, DOI 10.1039/c39920001337; YU J, 1993, J BIOL CHEM, V268, P4326	40	223	227	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1483	1490		10.1096/fasebj.7.15.8262333	http://dx.doi.org/10.1096/fasebj.7.15.8262333			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262333				2022-12-28	WOS:A1993ML74000011
J	DENHARDT, DT; GUO, XJ				DENHARDT, DT; GUO, XJ			OSTEOPONTIN - A PROTEIN WITH DIVERSE FUNCTIONS	FASEB JOURNAL			English	Review						CELL ADHESION; CALCIUM BINDING; PHOSPHOPROTEIN; BONE FORMATION; CELL SIGNALING; RGD	SECRETED PHOSPHOPROTEIN-1 SPP-1; RAT-KIDNEY CELLS; MESSENGER-RNA; BONE SIALOPROTEIN; INSITU HYBRIDIZATION; CDNA CLONING; TRANSCRIPTIONAL REGULATION; NEOPLASTIC TRANSFORMATION; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS	In this review most of the various known, suspected, or postulated functions of osteopontin, a secreted highly acidic phosphoprotein, are discussed in terms of what we currently know about the protein. These include 1) binding of OPN both to cells via a GRGDS cell adhesion sequence that recognizes the alpha(v)beta3 integrin and to extracellular matrix components via poorly characterized motifs, 2) regulation of the formation and remodeling of mineralized tissue, 3) recruiting and stimulating macrophages and lymphocytes as part of a nonspecific response to microbial infections, 4) multiple interactions with Ca2+ that likely influence OPN protein conformation and may be important in Ca2+-mediated of Ca2+-dependent processes, 5) inhibiting the growth of calcium oxalate crystals by disruption of the growing crystal lattice, 6) effects on gene expression, Ca2+ regulation, and nitric oxide production, and 7) involvement in cell migration. OPN production is frequently augmented when cell signaling pathways are activated by any of a variety of stimuli, for example in cancer cells.			DENHARDT, DT (corresponding author), RUTGERS UNIV, DEPT BIOL SCI, PISCATAWAY, NJ 08855 USA.							ALBELDA SM, 1990, CANCER RES, V50, P6757; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V194, P274, DOI 10.1006/bbrc.1993.1815; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BENINATI S, 1991, Journal of Cell Biology, V115, p135A; BOSKEY AL, 1993, IN PRESS BONE MINER; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BRUDER SP, 1991, CALCIFIED TISSUE INT, V48, P429, DOI 10.1007/BF02556457; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CARLSON CS, 1993, J BONE MINER RES, V8, P71; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHANG PL, 1991, CANCER RES, V51, P2144; CHANG PL, 1993, CANCER RES, V53, P2217; CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934-8832(11)80070-3; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; CRIVELLO JF, 1992, J BONE MINER RES, V7, P693; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FET V, 1989, GENOMICS, V5, P375, DOI 10.1016/0888-7543(89)90074-8; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GARDNER HAR, 1993, FASEB J, V7, pA371; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI C, 1993, IN PRESS J CLIN INVE; GIACHELLI CM, 1993, IN PRESS KIDNEY INT; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HWANG SM, 1993, IN PRESS J BIOL CHEM; JIN CH, 1990, MOL CELL ENDOCRINOL, V74, P221; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KERR JM, 1991, GENE, V108, P237, DOI 10.1016/0378-1119(91)90439-I; KUBOTA T, 1993, ARCH ORAL BIOL, V38, P23, DOI 10.1016/0003-9969(93)90150-K; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LAMPE MA, 1991, J IMMUNOL, V147, P2902; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LIAN JB, 1993, J CELL BIOCHEM, V52, P206, DOI 10.1002/jcb.240520212; LOPEZ CA, 1993, IN PRESS LAB INVEST; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1993, J BONE MINER RES, V8, P485; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; NAGATA T, 1991, BIOCHEM J, V274, P513, DOI 10.1042/bj2740513; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NODA M, 1988, J BIOL CHEM, V263, P13916; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, IN PRESS CRIT REV IM; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; RAFIDI K, 1993, IN PRESS GENE; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RITTER NM, 1992, J BONE MINER RES, V7, P877; ROBEY PG, 1992, DISORDERS BONE MINER, P241; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAUK JJ, 1990, BIOCHEM BIOPH RES CO, V172, P135, DOI 10.1016/S0006-291X(05)80183-4; SAUK JJ, 1990, EXP CELL RES, V188, P105, DOI 10.1016/0014-4827(90)90283-G; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1992, J BIOL CHEM, V267, P23847; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SODEK J, 1992, INT CONGR SER, V1002, P297; SOMERMAN MJ, 1989, MATRIX, V9, P49, DOI 10.1016/S0934-8832(89)80018-6; SWANSON GJ, 1989, HEARING RES, V41, P169, DOI 10.1016/0378-5955(89)90008-7; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; VANDIJK S, 1993, IN PRESS J BONE MINE; WATERHOUSE P, 1992, MOL REPROD DEV, V32, P315, DOI 10.1002/mrd.1080320403; WEINREB M, 1990, J BONE MINER RES, V5, P831; WORCESTER EM, 1992, J BONE MINER RES, V7, P1029; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZIMOLO Z, 1993, IN PRESS AM J PHYSL	87	967	1009	1	77	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1993	7	15					1475	1482		10.1096/fasebj.7.15.8262332	http://dx.doi.org/10.1096/fasebj.7.15.8262332			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262332				2022-12-28	WOS:A1993ML74000010
J	ERNSTER, L				ERNSTER, L			P/O RATIOS - THE 1ST 50 YEARS	FASEB JOURNAL			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; CYTOCHROME-C OXIDASE; MECHANISTIC STOICHIOMETRY; TRANSPORT; GRADIENT				ERNSTER, L (corresponding author), UNIV STOCKHOLM, ARRHENIUS LAB, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN.							ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; AZZONE GF, 1979, FERGUU, V254, P10206; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P233, DOI 10.1007/BF00762585; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BEINERT H, 1960, BIOCHEM BIOPH RES CO, V3, P41, DOI 10.1016/0006-291X(60)90100-5; Belitzer V., 1939, BIOKHIMIYA, V4, P516; BERRY EA, 1983, J BIOL CHEM, V258, P1474; BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BOYER PD, 1965, OXIDASES RELATED RED, P994; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANCE B, 1963, 1ST C JOHNS RES F PH; CRANE FL, 1957, BIOCHIM BIOPHYS ACTA, V25, P220, DOI 10.1016/0006-3002(57)90457-2; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; Engelhardt WA, 1930, BIOCHEM Z, V227, P16; ERNSTER L, 1990, BIOENERGETICS, P451; ERNSTER L, 1964, ANNU REV BIOCHEM, V33, P729, DOI 10.1146/annurev.bi.33.070164.003501; ERNSTER L, 1959, NATURE, V184, P1851, DOI 10.1038/1841851a0; ERNSTER L, 1963, EXP CELL RES, V32, P26, DOI 10.1016/0014-4827(63)90065-X; ERNSTER L, 1974, BBA LIBR, V13, P283; ERNSTER L, 1984, NEW COMPR BIOCH, V9; ERNSTER L, 1992, NEW COMPR BIOCH, V23; ERNSTER LARS, 1964, ADVAN METAB DISORDERS, V1, P95; GAEBLER OH, 1956, 1955 INT S EN UN BIO; Goodwin T. W., 1961, BIOL STRUCTURE FUNCT; GREEN DE, 1963, FED PROC, V22, P1460; HALTIA T, 1992, NEW COMPR BIOCH, V23, P217; HATEFI YOUSSEF, 1966, COMPR BIOCHEM, V14, P199; Hinkle P.C., 1981, CHEMIOSMOTIC PROTON, P49; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; HINKLE PC, 1979, J BIOL CHEM, V254, P2450; HOEK JB, 1992, NEW COMPR BIOCH, V23, P421; HOGEBOOM GH, 1946, J BIOL CHEM, V165, P615; HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619; HUNTER EF, 1951, PHOSPHORUS METAB, V1, P297; HUNTER FE, 1949, J BIOL CHEM, V181, P73; ICHIHARA K, 1958, 1957 P INT S EN CHEM; KALCKAR H, 1938, ENZYMOLOGIA, V5, P365; KALCKAR HERMAN, 1937, ENZYMOLOGIA [HAGUE], V2, P47; Kalckar HM, 1941, CHEM REV, V28, P71, DOI 10.1021/cr60089a002; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; KING TE, 1965, 1964 INT S OX REL RE; KLINGENBERG M, 1977, EUR J BIOCHEM, V73, P125, DOI 10.1111/j.1432-1033.1977.tb11298.x; KRAMER R, 1992, NEW COMPR BIOCH, V23, P359; LARDY HA, 1952, J BIOL CHEM, V195, P215; LARDY HA, 1958, ARCH BIOCHEM BIOPHYS, V78, P587, DOI 10.1016/0003-9861(58)90383-7; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEE CP, 1968, EUR J BIOCHEM, V3, P385, DOI 10.1111/j.1432-1033.1967.tb19541.x; LEE CP, 1964, NATURE, V201, P152, DOI 10.1038/201152a0; LEHININGER AL, 1957, ADV ENZYMOL, V29, P259; LEHNINGER AL, 1949, J BIOL CHEM, V181, P415; LEHNINGER AL, 1965, MITOCHONDRION, P38; Lindberg O., 1981, Mitochondria and microsomes, P93; LINDBERG O, 1954, CHEM PHYSL MITOCHOND; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; LIPMANN F., 1946, Currents in Biochemical Research, P137; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; Lohmann K, 1929, NATURWISSENSCHAFTEN, V17, P624; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; MOODY AJ, 1987, BIOCHIM BIOPHYS ACTA, V894, P209, DOI 10.1016/0005-2728(87)90191-5; NICHOLLS B, 1984, NEW COMPR BIOCH, V9, P29; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; Ochoa S, 1941, J BIOL CHEM, V138, P751; Ochoa S, 1943, J BIOL CHEM, V151, P493; OCHOA S, 1943, FED PROC, V2, P67; PAPA S, 1969, 1968 INT S EN LEV ME; POZZAN T, 1979, J BIOL CHEM, V254, P200; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; QUAGLIARIELLO E, 1967, 1966 INT S MIT STRUC; RACKER E, 1965, MECHANISMS BIGENERGE; RACKER E, 1979, MEMBRANE BIOENERGETI, P569; REYNAFARJE B, 1976, J BIOL CHEM, V251, P7442; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; RYDSTROM J, 1981, CHEMIOSMOTIC PROTON, P483; SANADI DR, 1952, SCIENCE, V116, P327, DOI 10.1126/science.116.3013.327; SKULACHEV VP, 1981, CHEMIOSMOTIC PROTON, P3; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; SLATER EC, 1952, COMP BIOCH, V116, P327; SLATER EC, 1963, 1961 P 5TH INT C BIO; SLATTER E. C., 1966, COM PR BIOCHEM, V14, P327; TAGER JM, 1970, 1969 INT S EL TRANSP; TAGER JM, 1966, BBA LIBRARY, V7; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VANDAM K, 1984, NEW COMPR BIOCH, V9, P1; VERCESI A, 1978, J BIOL CHEM, V253, P6379; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; WIKSTROM M, 1984, NEW COMPREHENSIVE BI, P49; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6; WILSON DF, 1974, BBA LIBRARY, V13, P221; WOLSTENHOLME GE, 1959, CIBA F S	95	13	13	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1993	7	15					1520	1524		10.1096/fasebj.7.15.8262336	http://dx.doi.org/10.1096/fasebj.7.15.8262336			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262336				2022-12-28	WOS:A1993ML74000016
J	WANG, CC; TSOU, CL				WANG, CC; TSOU, CL			PROTEIN DISULFIDE-ISOMERASE IS BOTH AN ENZYME AND A CHAPERONE	FASEB JOURNAL			English	Article						PROTEIN DISULFIDE ISOMERASE; CHAPERONE; THIOREDOXIN; FOLDING	ENDOPLASMIC-RETICULUM; MULTIFUNCTIONAL PROTEIN; THIOREDOXIN; SUBSTRATE; RESIDENT; BINDING; LUMEN; CHAIN	Protein disulfide isomerase (PDI) catalyzes the formation of native disulfides of peptide chains from either the reduced form or randomly joined disulfides. So that thiols situated at distant parts of the polypeptide chain can be joined together to form the native disulfides, the polypeptide chain has to be folded, at least to some extent, into the native conformation. It is suggested that PDI promotes folding of the chains as well as formation of the disulfides and plays a role similar to the chaperones in the folding process. PDI is known to bc a multifunctional protein and capable of nonspecific peptide binding. These properties are closely connected to its possible function as a chaperone. Thioredoxin, which has an active site sequence similar to that of PDI but lacks the property of peptide binding, is much less efficient as a disulfide isomerase.			WANG, CC (corresponding author), CHINESE ACAD SCI,INST BIOPHYS,NATL LAB BIOMACROMOLEC,BEIJING,PEOPLES R CHINA.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLIEGEL L, 1990, J BIOL CHEM, V265, P1496; FREEDMAN RB, 1992, AAAS, V4, P448; FREEDMAN RB, 1991, CONFORMATIONS FORCES, V16, P204; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GIVOL D, 1964, J BIOL CHEM, V239, P3114; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HEITMAN J, 1992, NEW BIOL, V4, P448; HU CH, 1991, FEBS LETT, V290, P87, DOI 10.1016/0014-5793(91)81232-W; JACOB U, 1993, J BIOL CHEM, V268, P1517; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1991, ANN MED, V23, P393, DOI 10.3109/07853899109148079; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; VURORI K, 1992, P NATL ACAD SCI USA, V89, P7467; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; YU XC, 1992, BIOCHEM INT, V28, P461; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	133	146	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1515	1517		10.1096/fasebj.7.15.7903263	http://dx.doi.org/10.1096/fasebj.7.15.7903263			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	7903263				2022-12-28	WOS:A1993ML74000015
J	SIMIONESCU, M; SIMIONESCU, N				SIMIONESCU, M; SIMIONESCU, N			PROATHEROSCLEROTIC EVENTS - PATHOBIOCHEMICAL CHANGES OCCURRING IN THE ARTERIAL-WALL BEFORE MONOCYTE MIGRATION	FASEB JOURNAL			English	Review						PRELESIONAL ATHEROGENESIS; BETA-LIPOPROTEINS; CHEMICALLY MODIFIED LIPOPROTEINS; LIPID DEPOSITS; ENDOTHELIAL DYSFUNCTIONS	LOW-DENSITY-LIPOPROTEIN; FATTY STREAK FORMATION; ATHEROSCLEROTIC LESIONS; HYPERLIPIDEMIC RABBIT; PRELESIONAL EVENTS; MACROPHAGE UPTAKE; NONHUMAN PRIMATE; ATHEROGENESIS; CHOLESTEROL; AORTA	The inception of experimentally induced atherogenesis is marked by subtle biochemical and ultrastructural changes of the arterial intima, modifications that precede the monocytes migration within the vessel wall. Long before any recognizable endothelial denudation, hypercholesterolemia induces a sequence of prelesional events that start with the enhanced transport of excess plasma lipoproteins especially by transcytosis, followed by intima accumulation of chemically (oxidatively) modified and reassembled lipoproteins (MRLp). Exposure of endothelial cells concomitantly to hypercholesterolemia on the luminal side, and to the MRLp cytotoxic effects on the abluminal side, generates endothelial dysfunctions with altered biosynthetic activities. The latter are manifested initially by the hyperplasia of basal lamina and its disjunction from endothelium, and by the proliferation and reorganization of a modified extracellular matrix that traps MRLp. The cytotoxic effects of MRLp contribute to the endothelial production of chemoattractants and adhesion molecules that are instrumental in monocyte recruitment and migration in the subendothelium, where activated and differentiated as macrophages, they avidly ingest MRLp and their complexes to form foam cells. The latter are the hallmark of fatty streaks that marks the transition from the prelesional to the lesional stage of atherogenesis. Understanding the earliest biochemical alterations of the artery wall is a prerequisite for designing more successful means of prevention and treatment of atherosclerosis.			SIMIONESCU, M (corresponding author), INST CELLULAR BIOL & PATHOL,8 BP HASDEU ST,R-79691 BUCHAREST,ROMANIA.		Simionescu, Maya/C-4794-2011					BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CAMEJO G, 1991, J LIPID RES, V32, P1983; CHAO FF, 1992, J BIOL CHEM, V267, P4992; CHAO FF, 1990, AM J PATHOL, V136, P136; CHUANG PT, 1990, ARTERIOSCLEROSIS, V10, P188, DOI 10.1161/01.ATV.10.2.188; Cotran R, 1988, ENDOTHELIAL CELL BIO, P335; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DOBRIAN A, 1993, BIOCHIM BIOPHYS ACTA, V1169, P12, DOI 10.1016/0005-2760(93)90076-L; FILIP DA, 1987, ATHEROSCLEROSIS, V67, P199, DOI 10.1016/0021-9150(87)90280-2; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FRANK JS, 1989, J LIPID RES, V30, P967; FRAUGI RM, 1993, BRIT HEART J, V69, P19; Gimbrone M A Jr, 1989, J Card Surg, V4, P180, DOI 10.1111/j.1540-8191.1989.tb00275.x; GUYTON JR, 1992, AM J PATHOL, V141, P925; GUYTON JR, 1991, J LIPID RES, V32, P953; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HEINECKE JW, 1991, ARTERIOSCLER THROMB, V11, P1643, DOI 10.1161/01.ATV.11.6.1643; HERMANN M, 1992, ARTERIOSCLER THROMB, V12, P1503, DOI 10.1161/01.ATV.12.12.1503; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; JIANG YL, 1992, J IMMUNOL, V148, P2423; JORIS I, 1983, AM J PATHOL, V113, P341; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1992, ARTERIOSCLER THROMB, V12, P1258, DOI 10.1161/01.ATV.12.11.1258; KRUTH HS, 1984, LAB INVEST, V50, P87; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LIBBY P, 1991, LAB INVEST, V64, P5; LIN SJ, 1989, ARTERIOSCLEROSIS, V9, P230, DOI 10.1161/01.ATV.9.2.230; MAJNO G, 1985, HUM PATHOL, V16, P3, DOI 10.1016/S0046-8177(85)80207-0; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; MORA R, 1990, J LIPID RES, V31, P1793; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; NEREM RM, 1987, HDB BIOENGINEERING; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; NISTOR A, 1987, ATHEROSCLEROSIS, V68, P159, DOI 10.1016/0021-9150(87)90106-7; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V1, P9; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1992, ENDOTHELIAL CELL DYS, P295; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P1, DOI 10.1002/clc.4960141302; SIMA A, 1990, J SUBMICR CYTOL PATH, V22, P1; Simionescu M., 1992, ENDOTHEL CELL DYSFUN, P3, DOI [10.1007/978-1-4899-0721-9_1., DOI 10.1007/978-1-4899-0721-9_1]; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Simionescu N, 1988, ENDOTHELIAL CELL BIO, P385; SIMIONESCU N, 1992, ENDOTHELIAL CELL DYS, P321; STARY HC, 1992, VIRCHOWS ARCH A, V421, P277, DOI 10.1007/BF01660974; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VASILE E, 1989, ATHEROSCLEROSIS, V75, P195, DOI 10.1016/0021-9150(89)90177-9; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; Wissler R W, 1978, Adv Exp Med Biol, V104, P77; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	55	64	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1359	1366		10.1096/fasebj.7.14.8224609	http://dx.doi.org/10.1096/fasebj.7.14.8224609			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224609	Bronze			2022-12-28	WOS:A1993MH00800008
J	IVANETICH, KM; NIECE, RL; ROHDE, M; FOWLER, E; HAYES, TK				IVANETICH, KM; NIECE, RL; ROHDE, M; FOWLER, E; HAYES, TK			BIOTECHNOLOGY CORE FACILITIES - TRENDS AND UPDATE	FASEB JOURNAL			English	Article						BIOTECHNOLOGY; CORE FACILITY; DNA; PROTEIN		A survey of 128 biotechnology core facilities has provided data on the finances, services, space requirements, and personnel. An average facility had four full-time personnel and 7.5 major instrument systems, and occupied 969 sq. ft. Average total income was $244,000/year, but annual user fee income was only $125,000. Typically, facilities required substantial institutional support or grants. Cost recovery (user fee income divided by total income) averaged 49%. During the last 5 years user fee income, total income, and cost recovery have increased. In-house charges for protein sequencing and peptide synthesis increased approximately 30%, while oligonucleotide synthesis charges decreased by 74%. The costs (charges corrected for subsidy from non-user fee income) for most services did not significantly change, except that oligonucleotide synthesis costs decreased by 25% in 1992. DNA synthesis had the highest throughput per month (116 samples), followed by amino acid analysis (86 samples) and DNA sequencing (67 samples). Other services averaged from 5 to 60 samples. DNA synthesis and purification were the services used by the greatest number of principal investigators. A number of services including DNA sequencing, mass spectrometry, capillary electrophoresis, RNA synthesis, electroblotting, and carbohydrate analysis have been introduced in the last 3 years. Although these services are characterized by high levels of methods development and non-user runs, they are offered by twice the percentage of facilities as in 1989, and are increasingly contributing to facility income.	UNIV WISCONSIN,CTR BIOTECHNOL,MADISON,WI 53705; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320; AUTOIMMUNE,LEXINGTON,MA 02174; TEXAS A&M UNIV SYST,TEXAS AGR EXPT STN,INST BIOSCI & TECHNOL,DEPT ENTOMOL,COLL STN,TX 77843	University of Wisconsin System; University of Wisconsin Madison; Amgen; Texas A&M University System; Texas A&M University College Station; Texas A&M AgriLife Research	IVANETICH, KM (corresponding author), UNIV CALIF SAN FRANCISCO,CTR BIOMOLEC RESOURCE,SAN FRANCISCO,CA 94143, USA.							NIECE RL, 1991, FASEB J, V5, P2756, DOI 10.1096/fasebj.5.13.1916100; NIECE RL, 1992, FASEB J, V6, P792; WILLIAMS KR, 1988, FASEB J, V2, P3124, DOI 10.1096/fasebj.2.15.3192042	3	16	16	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1109	1114		10.1096/fasebj.7.12.8375609	http://dx.doi.org/10.1096/fasebj.7.12.8375609			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375609				2022-12-28	WOS:A1993LW81700002
J	ALI, AA; MARCUS, JN; HARVEY, JP; ROLL, R; HODGSON, CP; WILDRICK, DM; CHAKRABORTY, A; BOMAN, BM				ALI, AA; MARCUS, JN; HARVEY, JP; ROLL, R; HODGSON, CP; WILDRICK, DM; CHAKRABORTY, A; BOMAN, BM			RB1 PROTEIN IN NORMAL AND MALIGNANT HUMAN COLORECTAL TISSUE AND COLON-CANCER CELL-LINES	FASEB JOURNAL			English	Note						RETINOBLASTOMA PROTEIN; IMMUNOSTAINING; COLORECTAL CANCER; CELL LINES; RB1 GENE	RETINOBLASTOMA SUSCEPTIBILITY GENE; CARCINOMA-CELLS; ALTERED EXPRESSION; TUMOR SUPPRESSOR; OSTEO-SARCOMA; C-MYC; PRODUCT; GROWTH; PHOSPHORYLATION; INACTIVATION	The pattern of human retinoblastoma (RB1) gene protein expression was directly examined in normal and malignant human colorectal tissues and in seven colorectal carcinoma cell lines by immunohistochemistry using the mouse monoclonal antibody (RB-MAb-1) directed against the retinoblastoma protein (RB). This is the first demonstration of RB immunostaining in adult human colonic epithelium and colorectal carcinomas. Specificity using RB-MAb-1 was confirmed by western blot analysis, which showed bands of 110-116 kDa corresponding to the sizes of unphosphorylated and phosphosrylated RB. RB staining of normal adult colonic epithelium was confined to the nucleus and was most intense in the transitional zone of the crypt, whereas lumenal cells (fully differentiated) were RB negative. Primary colorectal carcinomas and all the colon cancer cell lines stained positively for nuclear RB, but the expression was heterogeneous with varying fractions of RB negative cells present. Because we and others have previously shown that loss or inactivation of the RB1 gene is infrequent in colorectal carcinomas, reduced RB expression in such cells is probably due to a cellular regulatory mechanism. For example, RB negative cells may be those in early-G1 phase (known to have reduced RB levels) or growth-arrested cells that have differentiated. The ability to directly detect RB in primary colorectal carcinomas will permit assessment of whether heterogeneous expression of the RB1 gene product has prognostic significance for survival of patients with this cancer.	CREIGHTON UNIV, SCH MED, CREIGHTON CANC CTR, CALIF & 24TH STS, OMAHA, NE 68178 USA; CREIGHTON UNIV, SCH MED, DEPT PATHOL, OMAHA, NE 68178 USA; TRITON LABS, ALAMEDA, CA 94501 USA	Creighton University; Creighton University								ALI AA, 1992, INT CONGR SER, V990, P29; BOMAN BM, 1988, GENETIC EPIDEMIOLOGY, P343; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUSET M, 1987, IN VITRO CELL DEV B, V23, P403; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOPE R, 1990, HEREDITARY COLORECTA, P489; GOPE R, 1990, J NATL CANCER I, V82, P340; HAM AW, 1969, HISTOLOGY, P679; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1993, 1993 P AM ASS CANC R, P3; KORNBLAU SM, 1992, CANCER RES, V52, P4587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334; Moyer M. P., 1990, COLON CANCER CELLS, P85; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; Oi V.T., 1980, SELECTED METHODS CEL, P351; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; PASCAL RR, 1968, GASTROENTEROLOGY, V54, P835; PATTEN BM, 1968, HUMAN EMBRYOLOGY, P383; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SPARKS RL, 1990, CELL TISSUE KINET, V23, P71, DOI 10.1111/j.1365-2184.1990.tb01334.x; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YAN ZF, 1992, ONCOGENE, V7, P801; YOKOTA J, 1988, ONCOGENE, V3, P471	46	38	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					931	937		10.1096/fasebj.7.10.8344490	http://dx.doi.org/10.1096/fasebj.7.10.8344490			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344490				2022-12-28	WOS:A1993LQ33700017
J	UCHIMARU, T; UEBAYASI, M; TANABE, K; TAIRA, K				UCHIMARU, T; UEBAYASI, M; TANABE, K; TAIRA, K			THEORETICAL ANALYSES ON THE ROLE OF MG2+ IONS IN RIBOZYME REACTIONS	FASEB JOURNAL			English	Article						RIBOZYME; METALLOENZYMES; MOLECULAR ORBITAL CALCULATIONS; MAGNESIUM IONS; MECHANISM	MARGINALLY STABLE INTERMEDIATE; BASE-CATALYZED METHANOLYSIS; INTERVENING SEQUENCE; TETRAHYMENA RIBOZYME; RNA CLEAVAGE; HAMMERHEAD RIBOZYMES; MG-2+ BINDING; PHOSPHATE; PHOSPHOROTHIOATE; STEREOCHEMISTRY	To elucidate the role of the Mg2+ ion in ribozyme reactions, we carried out ab initio molecular orbital investigations on dianionic trimethoxyphosphorane A and its Mg2+ complex (overall a neutral molecule) as a model system for the reaction center of Tetrahymena-type ribozyme. Although dianionic oxyphosphorane A concentrates its negative charges on the equatorial phosphoryl oxygens, the coordination of the Mg2+ ion between these two oxygens is unlikely. Geometry optimizations of the complex and the electrostatic potential of A both suggest that Mg2+ coordination preferably occurs in the region between the axial oxygen and the equatorial phosphoryl oxygen. The considerations of electrostatic potential rationalize the geometries of carboxylate-metal and phosphate-metal interactions extracted from the Cambridge Structural Database as well. Consequently, the Mg2+ ion at the active site of Tetrahymena-type ribozyme most likely lies in the regions between the axial and equatorial oxygens. The axial-equatorial coordinations of Mg2+ ions conceivably increase the electronegativities of the axial oxygens and facilitate cleavage of the phosphodiester bond located at the junction of the intron and the exon. It is thus likely that the Mg2+ ions play the key role in the phosphodiester cleavage reactions mediated by ribozymes.	MINIST INT TRADE & IND, NATL INST BIOSCI & HUMAN TECHNOL, AGCY IND SCI & TECHNOL, TSUKUBA 305, JAPAN; NATL INST MAT & CHEM RES, TSUKUBA 305, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)								ALEXANDER RS, 1990, J AM CHEM SOC, V112, P933, DOI 10.1021/ja00159a004; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6365, DOI 10.1021/bi00369a004; CARPENTER JE, 1990, SPARTAN VERSION 1 0; CECH TR, 1990, ANGEW CHEM INT EDIT, V29, P759, DOI 10.1002/anie.199007591; CHRISTOPHER J, 1988, J AM CHEM SOC, V110, P8651; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FRISH MJ, 1988, GAUSSIAN PROGRAM 88; FRISH MJ, 1990, GAUSSIAN PROGRAM 90; GORENSTEIN DG, 1987, CHEM REV, V87, P1047, DOI 10.1021/cr00081a009; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Hehre W. J., 1986, AB INITIO MOL ORBITA; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; Kirby A. J., 1983, ANOMERIC EFFECT RELA; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; REED AE, 1988, CHEM REV, V88, P899, DOI 10.1016/0030-4018(75)90085-1; REED AE, 1988, INORG CHEM, V27, P3969, DOI 10.1021/ic00295a018; REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486; RICHARDS FM, 1971, ENZYMES, V4, P647; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STORER JW, 1991, J AM CHEM SOC, V113, P5216, DOI 10.1021/ja00014a012; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; Taira K., 1992, Gene regulation: biology of antisense RNA and DNA., P35; UCHIMARU T, 1991, J AM CHEM SOC, V113, P4351, DOI 10.1021/ja00011a060; UCHIMARU T, 1992, CHEM EXPRESS, V7, P501; UEBAYASI M, 1991, NUCLEIC ACIDS RES S, V25, P107; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	31	62	62	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					137	142		10.1096/fasebj.7.1.8422960	http://dx.doi.org/10.1096/fasebj.7.1.8422960			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422960				2022-12-28	WOS:A1993KH88000020
J	LEVY, E; MEHRAN, M; SEIDMAN, E				LEVY, E; MEHRAN, M; SEIDMAN, E			CACO-2 CELLS AS A MODEL FOR INTESTINAL LIPOPROTEIN SYNTHESIS AND SECRETION	FASEB JOURNAL			English	Review						APOLIPOPROTEIN; FREE FATTY ACIDS; LOW DENSITY LIPOPROTEIN	APOLIPOPROTEIN-A-I; LOW-DENSITY LIPOPROTEINS; ACID-BINDING PROTEIN; RAT SMALL-INTESTINE; LINE CACO-2; FATTY-ACID; CHOLESTEROL ACYLTRANSFERASE; ACYL-COA; INTRACELLULAR-TRANSPORT; MEMBRANE SPHINGOMYELIN	Caco-2 cells, an intestinal cell line derived from a human colorectal carcinoma that spontaneously differentiates under standard culture conditions, lends itself to the in vitro study of human gut in view of its efficient intestinal transport processes. Among its multiple biological functions are those related to the absorption, transport, and metabolism of lipids and lipoproteins. Despite their intestinal origin, confluent Caco-2 cell monolayers primarily express L-FABP for the uptake of apical dietary long chain fatty acids, incorporating them into triglycerides by the glycerol 3-phosphate pathway, and assembling very-low-density lipoprotein, high-density lipoprotein, and low-density lipoprotein. The monoacylglycerol pathway is inactive in Caco-2 cells. Furthermore, the secretion of newly synthesized triglyceride-rich lipoproteins is very restricted, despite abundant production of apolipoprotein (ape) B. The regulation of apoB synthesis and its mRNA editing at the enterocyte level has been intensively examined in Caco-2 cells. Luminal fatty acids, calcium ion, as well as vitamins and hormones are known to modulate the apoB-48/apoB-100 at the transcriptional and/or translational level. The regulation of 3-hydroxy-3-methylglutaryl-CoA reductase and acyl-CoA: (cholesterol acyltransferase), the key enzymes governing intracellular cholesterol handling, have also been extensively examined in Caco-2 cells. In many respects this cell line provides an excellent in vitro model for the investigation of intestinal lipoprotein metabolism; however, their limited secretion capacity remains a potential drawback to comparisons with the in vivo physiological state.	UNIV MONTREAL,DEPT NUTR,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PEDIAT,MONTREAL,PQ H3C 3J7,CANADA; HOP ST JUSTINE,CTR RECH,GASTROENTEROL NUTR RES UNIT,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal			Eckhardt, Erik/G-1567-2010					ALVAREZHERNANDEZ X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P205, DOI 10.1016/0005-2736(91)90165-5; ARTURSSON P, 1990, J PHARM SCI-US, V79, P476, DOI 10.1002/jps.2600790604; BEAULIEU JF, 1991, BIOCHEM J, V280, P598; BEG ZH, 1989, J BIOL CHEM, V264, P6913; BHAT SG, 1982, BIOCHEM BIOPH RES CO, V109, P486, DOI 10.1016/0006-291X(82)91747-8; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BORGSTROM B, 1980, GASTROENTEROLOGY, V78, P954; BRESLOW JL, 1975, ANN REV BIOCH, V54, P699; CHANTRET I, 1988, FEBS LETT, V235, P125, DOI 10.1016/0014-5793(88)81246-8; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; CHRISTENSEN NJ, 1983, J LIPID RES, V24, P1229; CLARK SB, 1984, J LIPID RES, V25, P148; COGBURN JN, 1991, PHARMACEUT RES, V8, P210, DOI 10.1023/A:1015844104539; DASHTI N, 1986, BIOCHEM BIOPH RES CO, V137, P493, DOI 10.1016/0006-291X(86)91237-4; DASHTI N, 1990, J LIPID RES, V31, P113; DAVIDSON NO, 1986, J LIPID RES, V27, P30; DAVIDSON NO, 1987, J LIPID RES, V28, P388; DAVIDSON NO, 1994, TXB GASTROENTEROLOGY, P353; DAVIS RA, 1984, J BIOL CHEM, V259, P3383; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; FAUST RA, 1988, J BIOL CHEM, V263, P8786; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FIELD FJ, 1991, J LIPID RES, V32, P1811; FIELD FJ, 1987, J LIPID RES, V28, P1057; FIELD FJ, 1984, J LIPID RES, V25, P103; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; GIANNONI F, 1994, J LIPID RES, V35, P340; GLICKMAN RM, 1976, GASTROENTEROLOGY, V70, P347; GO MF, 1988, J CLIN INVEST, V81, P1615, DOI 10.1172/JCI113496; GORDON JI, 1985, CHEM PHYS LIPIDS, V38, P137, DOI 10.1016/0009-3084(85)90063-5; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; GUPTA AK, 1991, J LIPID RES, V32, P125; HAUNG R, 1976, SCAND J GASTROENTERO, V11, P615; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P97, DOI 10.1016/0304-4165(90)90179-Z; HOEG JM, 1990, J LIPID RES, V31, P1761; HOWELL S, 1993, FEBS LETT, V317, P109, DOI 10.1016/0014-5793(93)81502-Q; HUANG Y, 1990, J LIPID RES, V31, P2029; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; HUGHES TE, 1988, J BIOL CHEM, V263, P3425; JIAO S, 1989, DIABETES, V38, P604, DOI 10.2337/diabetes.38.5.604; JIAO S, 1990, J LIPID RES, V31, P697; KAM NTP, 1990, BIOCHEM J, V272, P427, DOI 10.1042/bj2720427; KAM NTP, 1989, J LIPID RES, V30, P371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEE DM, 1988, BIOCHEM BIOPH RES CO, V156, P581, DOI 10.1016/S0006-291X(88)80882-9; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVY E, 1990, J LIPID RES, V31, P1937; LEVY E, 1992, P SOC EXP BIOL MED, V199, P128; LEVY E, 1987, GASTROENTEROLOGY, V93, P1129; MANSBACH CM, 1973, BIOCHIM BIOPHYS ACTA, V296, P386, DOI 10.1016/0005-2760(73)90097-0; MANSBACH CM, 1982, J LIPID RES, V23, P1009; MATHUR SN, 1993, BIOCHIM BIOPHYS ACTA, V1168, P130, DOI 10.1016/0005-2760(93)90117-R; MEHRAN M, 1994, GASTROENTEROLOGY, V106, pA1039; MEHRAN M, 1994, ATHEROSCLEROSIS, V109, P185; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MOHRMANN I, 1986, AM J PHYSIOL, V250, pG323, DOI 10.1152/ajpgi.1986.250.3.G323; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; NICKLIN PL, 1992, BIOCHIM BIOPHYS ACTA, V1104, P283, DOI 10.1016/0005-2736(92)90042-K; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; PINTO M, 1983, BIOL CELL, V47, P323; RACHMILEWITZ D, 1976, J CLIN INVEST, V57, P530, DOI 10.1172/JCI108307; RANHEIM T, 1992, J LIPID RES, V33, P1281; REAVEN EP, 1977, J CELL BIOL, V75, P559, DOI 10.1083/jcb.75.2.559; REIMANN FM, 1992, DIGESTION, V51, P10, DOI 10.1159/000200870; REISHER SR, 1993, P NATL ACAD SCI USA, V90, P5757, DOI 10.1073/pnas.90.12.5757; ROUSSET M, 1989, J CELL PHYSIOL, V141, P627, DOI 10.1002/jcp.1041410322; SABESIN SM, 1977, J LIPID RES, V18, P496; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCOW RO, 1967, J BIOL CHEM, V242, P4919; SEMENZA G, 1988, BRUSH BORDER MEMBRAN, P43; SHIAU YF, 1985, AM J PHYSIOL, V248, pG608, DOI 10.1152/ajpgi.1985.248.6.G608; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1991, J LIPID RES, V32, P293; TROTTER PJ, 1992, J BIOL CHEM, V268, P10017; TSO P, 1984, AM J PHYSIOL, V247, pG599, DOI 10.1152/ajpgi.1984.247.6.G599; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; WAGNER RD, 1992, AM J PHYSIOL, V263, pE374, DOI 10.1152/ajpendo.1992.263.2.E374; WINDMUELLER HG, 1968, J BIOL CHEM, V243, P4878	82	173	176	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					626	635		10.1096/fasebj.9.8.7768354	http://dx.doi.org/10.1096/fasebj.9.8.7768354			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768354				2022-12-28	WOS:A1995RC10600008
J	BELARDINELLI, L; SHRYOCK, JC; SONG, Y; WANG, D; SRINIVAS, M				BELARDINELLI, L; SHRYOCK, JC; SONG, Y; WANG, D; SRINIVAS, M			IONIC BASIS OF THE ELECTROPHYSIOLOGICAL ACTIONS OF ADENOSINE CARDIOMYOCYTES	FASEB JOURNAL			English	Review						CARDIAC ELECTROPHYSIOLOGY; ARRHYTHMIA; CATECHOLAMINES; I-KACH, ADO; A(1)-ADENOSINE RECEPTOR; I-KATP	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; MAMMALIAN VENTRICULAR MYOCYTES; SENSITIVE POTASSIUM CHANNELS; ACTION-POTENTIAL DURATION; GUINEA-PIG; ADENYLATE-CYCLASE; CALCIUM CURRENT; ATRIAL CELLS; K+ CHANNELS; ATRIOVENTRICULAR NODE	The purpose of this review is to examine the role of the extracellular A(1)-adenosine (Ado) receptor in modulating membrane potential and currents in cardiac cells. The cellular electrophysiological effects of adenosine are both cell type- and species-dependent, In supraventricular tissues (SA, AV node, and atrium) of all species studied, the ''direct'' cAMP-independent activation of the inwardly rectifying K+ current I-KAdo seems to be the most important action of adenosine. This current is activated bp both adenosine and acetylcholine and flows through K+ channels with unitary slope conductance of about 45 pS and an open time constant of 1.4 ms. The density of K+-ACh,Ado channels is much less in ventricular than in atrial myocytes, and thus adenosine has little or no effect on the ventricular action potential. In atrial myocytes adenosine has a small inhibitory effect on basal L-type calcium current (I-Ca,I-L), but no effect on T-type calcium current (I-Ca,I-T) In ventricular myocytes, adenosine does not inhibit I-Ca,I-L (except ferret), I-Ca,I-T, Or the sodium inward current I-Na. Adenosine has recently been shown to activate I-KATP in ventricular membrane patches, but the relevance of this finding remains to be defined. Irrespective of cell type and species, adenosine inhibits membrane currents that are stimulated by beta-adrenergic agonists and other agents known to stimulate the activity of the enzyme adenylyl cyclase. This indirect cAMP-dependent mechanism of action has been shown to be responsible for the inhibition by adenosine of isoproterenol-stimulated I-Ca,I-L, delayed rectifier K+ current (I-K), chloride current (I-Cl), the transient inward current I-Ti, and the pacemaker current I-F. The importance of the actions of adenosine on membrane currents in modulation of atrial, ventricular, sinoatrial, and atrioventricular nodal function are discussed. Likewise, the antiarrhythmic and proarrhythmic actions of adenosine are discussed and the clinical implications of these actions are noted.	UNIV FLORIDA, COLL MED, DEPT PHARMACOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	BELARDINELLI, L (corresponding author), UNIV FLORIDA, COLL MED, DEPT MED, POB 100277, GAINESVILLE, FL 32610 USA.				NHLBI NIH HHS [R01 HL-50488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050488] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELARDINELLI L, 1983, CIRC RES, V53, P287, DOI 10.1161/01.RES.53.3.287; BELARDINELLI L, 1988, J PHYSIOL-LONDON, V405, P615, DOI 10.1113/jphysiol.1988.sp017352; BELARDINELLI L, 1990, BRIT HEART J, V63, P3; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELARDINELLI L, 1987, TOPICS PERSPECTIVES, P344; BELARDINELLI L, 1989, ISOLATED ADULT CARDI, V2, P155; BENNDORF K, 1991, PFLUG ARCH EUR J PHY, V419, P108, DOI 10.1007/BF00373754; BOHM M, 1989, CIRC RES, V65, P1201, DOI 10.1161/01.RES.65.5.1201; BROWN LA, 1990, BRIT J PHARMACOL, V101, P484, DOI 10.1111/j.1476-5381.1990.tb12734.x; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CERBAI E, 1988, AM J PHYSIOL, V255, pH872, DOI 10.1152/ajpheart.1988.255.4.H872; CLEMO HF, 1986, CIRC RES, V59, P427, DOI 10.1161/01.RES.59.4.427; COLE WC, 1991, CIRC RES, V69, P571, DOI 10.1161/01.RES.69.3.571; DIMARCO JP, 1983, CIRCULATION, V68, P1254, DOI 10.1161/01.CIR.68.6.1254; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; DIMARCO JP, 1984, J AM COLL CARDIOL, V3, P1551, DOI 10.1016/S0735-1097(84)80295-8; DIMARCO JP, 1988, J AM COLL CARDIOL, V11, P210, DOI 10.1016/0735-1097(88)90193-3; DOBSON JG, 1978, CIRC RES, V43, P785, DOI 10.1161/01.RES.43.5.785; DOWNEY JM, 1993, CARDIOVASC RES, V27, P3, DOI 10.1093/cvr/27.1.3; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; ENDOH M, 1993, N-S ARCH PHARMACOL, V348, P282; ENGELSTEIN ED, 1994, CIRCULATION, V89, P2645, DOI 10.1161/01.CIR.89.6.2645; FENTON RA, 1991, AM J PHYSIOL, V261, pC1107, DOI 10.1152/ajpcell.1991.261.6.C1107; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; FROLDI G, 1990, CIRC RES, V67, P960, DOI 10.1161/01.RES.67.4.960; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HAZEKI O, 1981, J BIOL CHEM, V256, P2856; HESCHELER J, 1989, ISOLATED ADULT CARDI, V2; HOSEY MM, 1984, J MOL CELL CARDIOL, V16, P931, DOI 10.1016/S0022-2828(84)80029-2; IIJIMA T, 1985, J PHYSIOL-LONDON, V359, P485, DOI 10.1113/jphysiol.1985.sp015598; ISENBERG G, 1984, CIRC RES, V55, P309, DOI 10.1161/01.RES.55.3.309; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; ITO H, 1994, J PHYSIOL-LONDON, V478, P101, DOI 10.1113/jphysiol.1994.sp020233; JOCHEM G, 1983, AM J PHYSIOL, V244, pH734; JOHNSON EA, 1956, NATURE, V178, P1174, DOI 10.1038/1781174a0; KABELL G, 1994, CARDIOVASC RES, V28, P1385, DOI 10.1093/cvr/28.9.1385; KATO M, 1990, CIRC RES, V67, P1134, DOI 10.1161/01.RES.67.5.1134; KIRSCH GE, 1990, AM J PHYSIOL, V259, pH820, DOI 10.1152/ajpheart.1990.259.3.H820; KOUMI SI, 1994, AM J PHYSIOL, V266, pH1812, DOI 10.1152/ajpheart.1994.266.5.H1812; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LAMONICA DA, 1985, AM J PHYSIOL, V248, pH737, DOI 10.1152/ajpheart.1985.248.5.H737; LERMAN BB, 1986, CIRCULATION, V74, P270, DOI 10.1161/01.CIR.74.2.270; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; LI YW, 1993, CIRCULATION, V87, P1642, DOI 10.1161/01.CIR.87.5.1642; LIANG BT, 1989, J PHARMACOL EXP THER, V249, P775; LINDEN J, 1985, CIRC RES, V56, P728, DOI 10.1161/01.RES.56.5.728; LIU GS, 1994, CARDIOVASC RES, V28, P1057, DOI 10.1093/cvr/28.7.1057; MARTYNYUK A, 1994, DRUG DEVELOP RES, V31, P295; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NUNAIN SO, 1992, CARDIOVASC RES, V26, P939, DOI 10.1093/cvr/26.10.939; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; QU YS, 1993, J PHYSIOL-LONDON, V471, P295, DOI 10.1113/jphysiol.1993.sp019902; SAITO D, 1993, J AM COLL CARDIOL, V21, P1199, DOI 10.1016/0735-1097(93)90246-W; SCHOLZ H, 1993, DRUG DEVELOP RES, V28, P277, DOI 10.1002/ddr.430280315; SCHRADER J, 1977, PFLUG ARCH EUR J PHY, V372, P29, DOI 10.1007/BF00582203; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; SHRYOCK J, 1993, CIRC RES, V72, P194, DOI 10.1161/01.RES.72.1.194; SONG Y, 1995, ADENOSINE ADENINE NU; SONG Y, 1994, AM J COL CARDIOL, V23, pA467; SONG Y, 1994, DRUG DEVELOP RES, V31, P324; SONG YJ, 1992, CIRC RES, V70, P743, DOI 10.1161/01.RES.70.4.743; STEIN B, 1994, J MOL CELL CARDIOL, V26, P403, DOI 10.1006/jmcc.1994.1049; THORNTON JD, 1993, CIRC RES, V72, P44, DOI 10.1161/01.RES.72.1.44; TYTGAT J, 1990, PFLUG ARCH EUR J PHY, V417, P142, DOI 10.1007/BF00370691; VISENTIN S, 1990, AM J PHYSIOL, V258, pH1070, DOI 10.1152/ajpheart.1990.258.4.H1070; VISKIN S, 1993, ANN INTERN MED, V118, P279, DOI 10.7326/0003-4819-118-4-199302150-00006; WALSH RS, 1994, CARDIOVASC RES, V28, P1337, DOI 10.1093/cvr/28.9.1337; WANG D, 1994, FASEB J, V8, pA611; WANG DS, 1994, AM J PHYSIOL-HEART C, V267, pH2420, DOI 10.1152/ajpheart.1994.267.6.H2420; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5; WEST GA, 1985, PFLUG ARCH EUR J PHY, V403, P75, DOI 10.1007/BF00583285; WEST GA, 1985, PFLUG ARCH EUR J PHY, V403, P66, DOI 10.1007/BF00583284; WIT AL, 1986, HEART CARDIOVASCULAR, P1449; WU SN, 1989, THESIS U FLORIDA GAI; XU D, 1992, CIRC RES, V70, P56, DOI 10.1161/01.RES.70.1.56; XU J, 1994, CIRCULATION, V89, P1209, DOI 10.1161/01.CIR.89.3.1209; ZAZA A, 1994, J PHYSIOL-LONDON, V475P, pP84	77	226	234	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					359	365		10.1096/fasebj.9.5.7896004	http://dx.doi.org/10.1096/fasebj.9.5.7896004			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896004				2022-12-28	WOS:A1995QP45100007
J	OPDENAKKER, G; RUDD, PM; WORMALD, M; DWEK, RA; VANDAMME, J				OPDENAKKER, G; RUDD, PM; WORMALD, M; DWEK, RA; VANDAMME, J			CELLS REGULATE THE ACTIVITIES OF CYTOKINES BY GLYCOSYLATION	FASEB JOURNAL			English	Article						GLYCOBIOLOGY; GENE DUPLICATION; N-GLYCOSYLATION; INTERFERONS; INTERLEUKINS; CHEMOKINES	COLONY-STIMULATING FACTOR; HUMAN INTERFERON-GAMMA; TUMOR-NECROSIS-FACTOR; BIOLOGICAL-ACTIVITY; LINKED GLYCOSYLATION; HUMAN INTERLEUKIN-6; ENDOTHELIAL-CELLS; RECOMBINANT; HETEROGENEITY; PURIFICATION	Cytokines, including the interferons, interleukins, colony stimulating factors, and chemokines, are first-line, hormone-like defense molecules that orchestrate immune functions in a nonspecific, i.e., antigen-independent, way. The multiplicity of cytokines has a genetic basis, but oligomerization and especially glycosylation add to the heterogeneity and signaling functions of the cytokines. It is theorized that the cell uses glycosylation of cytokines to alter its functions. This is achieved by changing the specific biological activities, by altering diffusability, tissue distribution, and pharmacokinetics, and by targeting different populations of responsive cells. One interesting possibility is that multiple glycosylation forms compete for receptor binding resulting in a natural selection process or possibly antagonistic effects. Cytokines as ligands often are multimers and cytokine receptors are almost without exception heterodimers, which within receptor families share common subunits. Hence, carbohydrate-lectin interactions might contribute to ligand dimerization and receptor recognition through multivalent bindings.	UNIV OXFORD,INST GLYCOBIOL,OXFORD,ENGLAND	University of Oxford	OPDENAKKER, G (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST,MINDERBROEDERSSTR 10,B-3000 LOUVAIN,BELGIUM.		Wormald, Mark R/G-2785-2011; Opdenakker, Ghislain/Q-3130-2017; Opdenakker, Ghislain/V-8562-2019	Wormald, Mark R/0000-0002-4853-2773; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294				ADOLF GR, 1991, BIOCHEM J, V276, P511, DOI 10.1042/bj2760511; BIENKOWSKI MJ, 1990, J BIOL CHEM, V265, P14505; BROXMEYER HE, 1991, J IMMUNOL, V147, P2568; CEBON J, 1990, J BIOL CHEM, V265, P4483; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; DIJKMANS R, 1987, J BIOL CHEM, V262, P2528; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; FAHEY TJ, 1992, J IMMUNOL, V148, P2764; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; JAEKEN J, 1993, GLYCOBIOLOGY, V3, P423, DOI 10.1093/glycob/3.5.423; JI A, 1990, P NATL ACAD SCI USA, V87, P4396; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOFLER G, 1992, LYMPHOKINE CYTOK RES, V11, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNIMOTO DY, 1991, CYTOKINE, V3, P224, DOI 10.1016/1043-4666(91)90020-E; LIVI GP, 1991, J BIOL CHEM, V266, P15348; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; MARCHESE E, 1990, J CHROMATOGR, V504, P351, DOI 10.1016/S0021-9673(01)89538-8; MAY LT, 1991, CYTOKINE, V3, P204, DOI 10.1016/1043-4666(91)90018-9; MUTSAERS JHGM, 1986, EUR J BIOCHEM, V156, P651, DOI 10.1111/j.1432-1033.1986.tb09627.x; OHEDA M, 1990, J BIOL CHEM, V265, P11432; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAREKH RB, 1992, EUR J BIOCHEM, V203, P135, DOI 10.1111/j.1432-1033.1992.tb19838.x; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; RISKE FJ, 1991, LYMPHOKINE CYTOK RES, V10, P213; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SCHIEL X, 1990, EUR J IMMUNOL, V20, P883, DOI 10.1002/eji.1830200425; SHERRY B, 1990, BIOCHEM BIOPH RES CO, V173, P1072, DOI 10.1016/S0006-291X(05)80895-2; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TANNER J E, 1990, Cytokine, V2, P363, DOI 10.1016/1043-4666(90)90067-4; Thompson A, 1994, CYTOKINE HDB; THOMPSON A, 1991, CYTOKINE HDB; THOR G, 1992, IMMUNOLOGY, V75, P143; TOMINAGA A, 1990, J IMMUNOL, V144, P1345; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; WATANABE Y, 1983, J GEN VIROL, V64, P1391, DOI 10.1099/0022-1317-64-6-1391; ZILTENER HJ, 1993, CYTOKINE, V5, P291, DOI 10.1016/1043-4666(93)90059-E	41	68	73	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					453	457		10.1096/fasebj.9.5.7896019	http://dx.doi.org/10.1096/fasebj.9.5.7896019			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896019				2022-12-28	WOS:A1995QP45100022
J	AMZEL, LM; GAFFNEY, BJ				AMZEL, LM; GAFFNEY, BJ			STRUCTURAL IMMUNOLOGY - PROBLEMS IN MOLECULAR RECOGNITION	FASEB JOURNAL			English	Editorial Material									JOHNS HOPKINS UNIV,DEPT CHEM,BALTIMORE,MD 21218	Johns Hopkins University	AMZEL, LM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205, USA.		Gaffney, Betty J/C-9666-2015	Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM36232, GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036232, R01GM044692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; GOLINELLIPIMPAN.B, 1994, STRUCTURE, V0002; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; LEAHY DJ, 1995, FASEB J, V9, P17, DOI 10.1096/fasebj.9.1.7821755; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; PAN Y, 1995, FASEB J, V9, P43, DOI 10.1096/fasebj.9.1.7821758; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; WILSON TA, 1994, RES IMMUNOL, V145, P73; YOUNG ACM, 1995, FASEB J, V9, P26, DOI 10.1096/fasebj.9.1.7821756; ZHOU WA, 1994, SCIENCE, V265, P1059	16	5	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					7	8		10.1096/fasebj.9.1.7821761	http://dx.doi.org/10.1096/fasebj.9.1.7821761			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821761				2022-12-28	WOS:A1995QD20200003
J	LALONDE, JM; BERNLOHR, DA; BANASZAK, LJ				LALONDE, JM; BERNLOHR, DA; BANASZAK, LJ			THE UP-AND-DOWN BETA-BARREL PROTEINS	FASEB JOURNAL			English	Review						LIPID-BINDING PROTEIN; FATTY ACID; RETINOIC ACID; PROTEIN FAMILY; LIPID METABOLISM	RETINOL-BINDING-PROTEIN; MANDUCA-SEXTA L; FATTY-ACID; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; X-RAY; ANGSTROM RESOLUTION; REFINEMENT; CRYSTALLIZATION; LACTOGLOBULIN	The up-and-down beta-barrel is a common folding motif found frequently in proteins that bind and transport hydrophobic ligands. It is formed by an array of beta-strands arranged in an antiparallel manner with each strand hydrogen-bonded to neighboring strands nearly always adjacent in the amino acid sequence. The arrangement is completed by forming hydrogen bonds between the first and last strands. The barrel motif so formed produces interior and exterior components. Proteins belonging to this class of up-and-down beta-barrels are found typically to be lipid-binding proteins in which the interior surface forms a cavity or pit that serves as the ligand binding region. Two evolutionarily distinct but structurally related families of such carriers have been identified by comparing known crystal structures. One group found intracellularly uses a 10-stranded beta-structure and a second family of proteins typically found extracellularly utilizes an 8-stranded motif. The 10-stranded beta-barrels have a large, hydrophilic water-filled interior cavity that serves as the ligand-binding domain. Hydophobic lipids such as fatty acids and retinoids bind within the cavity, totally sequestered from the external milieu. The 8-stranded beta-barrel proteins have a hydrophobic pit, which serves as the ligand-binding domain for compounds such as bilins and retinoids. The up-and-down beta-barrel motif appears to be one of nature's primary choices for hydrophobic ligand transport proteins.-LaLonde, J. M., Bernlohr, D. A., Banaszak, L. J. The up-and-down beta-barrel proteins.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 13925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BENNING MM, 1992, J MOL BIOL, V228, P208; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; EADS J, 1993, J BIOL CHEM, V268, P26375; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; RICHARDSON JS, 1976, J MOL BIOL, V102, P221, DOI 10.1016/S0022-2836(76)80050-2; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SCAPIN G, 1993, MOL CELL BIOCHEM, V123, P3, DOI 10.1007/BF01076469; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	26	55	55	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1240	1247		10.1096/fasebj.8.15.8001736	http://dx.doi.org/10.1096/fasebj.8.15.8001736			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001736				2022-12-28	WOS:A1994PY20900007
J	IZQUIERDO, I				IZQUIERDO, I			PHARMACOLOGICAL EVIDENCE FOR A ROLE OF LONG-TERM POTENTIATION IN MEMORY	FASEB JOURNAL			English	Review						HIPPOCAMPUS; ENTORHINAL CORTEX; AMYGDALA	GLUTAMATE METABOTROPIC RECEPTORS; PROTEIN KINASE-II; ENTORHINAL CORTEX; RAT HIPPOCAMPUS; DENTATE GYRUS; MUTANT MICE; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; INHIBITORY AVOIDANCE; PIRIFORM CORTEX	Memory processes and long-term potentiation (LTP) are blocked at the time of their initiation by antagonists of glutamate NMDA or metabotropic receptors, by drugs that hinder the activity of carbon monoxide or the platelet-activating factor, and by GABA type A receptor agonists. In the next 2 h, memory and LTP are accompanied by an enhancement of the activity of calcium/calmodulin-dependent protein kinase II and of protein kinase C, and are blocked by inhibitors of these enzymes. At the time of expression, memory and LTP are blocked by antagonists of glutamate AMPA receptors. The effects of drugs on memory are seen upon their infusion into areas of the brain known to be responsible for the storage and retrieval of declarative memories (hippocampus, amygdala, medial septum, entorhinal cortex) and are both task- and structure-specific. When put together with other pharmacologic findings, with lesion and recording studies, and with data on transgenic animals showing deficits of both memory and LTP, the data reviewed here lend strong support to the hypothesis that LTP in these brain areas underlies memory processes.			IZQUIERDO, I (corresponding author), UNIV FED RIO GRANDE SUL,INST BIOCIENCIAS,DEPT BIOQUIM,CTR MEMORIA,BR-90046900 PORTO ALEGRE,RS,BRAZIL.							ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BERNABEU R, 1993, 8TH ANN M ARG SOC NE, P37; BIANCHIN M, 1993, BEHAV NEURAL BIOL, V59, P83, DOI 10.1016/0163-1047(93)90782-D; BIANCHIN M, 1994, BEHAV PHARMACOL, V5, P356, DOI 10.1097/00008877-199406000-00014; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIONI JD, 1993, DRUG DEVELOP RES, V28, P3, DOI 10.1002/ddr.430280103; BROWN RE, 1994, IN PRESS NEUROSCI LE; BURGARD EC, 1993, NEUROSCIENCE, V54, P377, DOI 10.1016/0306-4522(93)90259-I; BURGARD EC, 1991, J NEUROSCI, V11, P1198; CAMMAROTA M, 1993, 8TH P ANN M ARG SOC, P76; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DELCERRO S, 1992, NEUROSCIENCE, V49, P1, DOI 10.1016/0306-4522(92)90071-9; DUNN AJ, 1980, ANNU REV PSYCHOL, V31, P343, DOI 10.1146/annurev.ps.31.020180.002015; FERREIRA MBC, 1992, BEHAV PHARMACOL, V3, P387; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANGER R, 1993, SYNAPSE, V15, P326, DOI 10.1002/syn.890150409; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GROVER LM, 1992, NEUROSCIENCE, V49, P7, DOI 10.1016/0306-4522(92)90072-A; HARVEY J, 1992, NEUROSCI LETT, V139, P197, DOI 10.1016/0304-3940(92)90551-H; HUANG YY, 1990, NEUROSCIENCE, V4, P819; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; IZQUIERDO I, 1993, DRUG DEVELOP RES, V30, P1, DOI 10.1002/ddr.430300102; IZQUIERDO I, 1993, BEHAV BRAIN RES, V58, P91, DOI 10.1016/0166-4328(93)90093-6; IZQUIERDO I, 1989, BEHAV NEURAL BIOL, V51, P171, DOI 10.1016/S0163-1047(89)90812-1; IZQUIERDO I, 1993, BEHAV NEURAL BIOL, V59, P1, DOI 10.1016/0163-1047(93)91061-Q; IZQUIERDO I, 1993, BEHAV NEURAL BIOL, V60, P5, DOI 10.1016/0163-1047(93)90651-W; IZQUIERDO I, 1992, BEHAV NEURAL BIOL, V58, P16, DOI 10.1016/0163-1047(92)90847-W; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; JERUSALINSKY D, 1992, BEHAV NEURAL BIOL, V58, P76, DOI 10.1016/0163-1047(92)90982-A; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V61, P107, DOI 10.1016/S0163-1047(05)80063-9; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V61, P132; JERUSALINSKY D, 1994, COMMUN BIOL, V11, P179; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KIM M, 1992, BRAIN RES, V585, P35, DOI 10.1016/0006-8993(92)91188-K; LIN Y, 1991, BRAIN RES, V551, P342, DOI 10.1016/0006-8993(91)90955-U; MARKRAM H, 1992, J PHYSIOL-LONDON, V447, P513, DOI 10.1113/jphysiol.1992.sp019015; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MULLER D, 1992, HIPPOCAMPUS, V2, P29, DOI 10.1002/hipo.450020105; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; QUILLFELDT JA, 1994, PHARMACOL BIOCHEM BE, V48, P437, DOI 10.1016/0091-3057(94)90549-5; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; REYMANN KG, 1993, FUNCT NEUROL S5, V8, P7; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; ROMAN FS, 1993, BRAIN RES, V601, P265, DOI 10.1016/0006-8993(93)91719-9; SCHARENBERG AM, 1991, P NATL ACAD SCI USA, V88, P6637, DOI 10.1073/pnas.88.15.6637; SCHREIBER SS, 1991, MOL BRAIN RES, V11, P89, DOI 10.1016/0169-328X(91)90025-S; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SERGUEEVA OA, 1993, NEUROPHARMACOLOGY, V32, P933, DOI 10.1016/0028-3908(93)90150-2; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STAUBLI U, 1994, P NATL ACAD SCI USA, V91, P777, DOI 10.1073/pnas.91.2.777; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STEWART MG, 1992, EUR J NEUROSCI, V4, P936, DOI 10.1111/j.1460-9568.1992.tb00120.x; SUTHERLAND RJ, 1993, HIPPOCAMPUS, V3, P141, DOI 10.1002/hipo.450030206; TOCCO G, 1991, BRAIN RES, V559, P331, DOI 10.1016/0006-8993(91)90020-V; Walz Roger, 1992, Ciencia e Cultura (Sao Paulo), V44, P339; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOLFMAN C, 1994, BEHAV NEURAL BIOL, V61, P203, DOI 10.1016/S0163-1047(05)80001-9; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	65	88	89	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1139	1145		10.1096/fasebj.8.14.7958619	http://dx.doi.org/10.1096/fasebj.8.14.7958619			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958619				2022-12-28	WOS:A1994PT12800008
J	MILLS, JW; MANDEL, LJ				MILLS, JW; MANDEL, LJ			CYTOSKELETAL REGULATION OF MEMBRANE-TRANSPORT EVENTS	FASEB JOURNAL			English	Review							PATCH-CLAMPED MEMBRANES; RENAL EPITHELIAL-CELLS; BLADDER GRANULAR-CELL; F-ACTIN; SODIUM-CHANNEL; TUBULE CELLS; ANKYRIN; VASOPRESSIN; ACTIVATION; SPECTRIN	Recent advances in our understanding of the function of various components of the cytoskeleton indicate that, besides serving a structural role, the membrane skeleton may regulate the activity or number of transport proteins in the cell membrane. Abundant evidence indicates that individual proteins of the cytoskeletal system bind directly to transport proteins, resulting in the three-dimensional organization of a structure termed the membrane skeleton. This interaction between cytoskeleton and transporters can most readily be interpreted to serve a structural role, keeping the transporters in specific domains. However, because disruption or alteration of the cytoskeletal organization can lead to changes in transport, the interaction may play a key role in regulating transporter activity. Elements of the cytoskeleton also interact with components of second messenger systems. Thus, the cytoskeleton could play a regulatory role by altering the availability of signal transducers or by being an integral part of the signal transduction system.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DIV PHYSIOL & CELLULAR BIOPHYS,DURHAM,NC 27710	Duke University	MILLS, JW (corresponding author), CLARKSON UNIV,DEPT BIOL,POTSDAM,NY 13699, USA.							ARGANGELI A, 1993, J CELL BIOL, V122, P1131; BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CZEKAY RP, 1994, EUR J CELL BIOL, V63, P20; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V88, P6971; DOCTOR RB, 1994, IN PRESS J AM SOC NE; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; GAO Y, 1992, AM J PHYSIOL, V263, pC908, DOI 10.1152/ajpcell.1992.263.4.C908; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; HAYS RM, 1993, PEDIATR NEPHROL, V7, P672, DOI 10.1007/BF00852577; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; INGBER D, 1993, PHYSICAL FORCES MAMM; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; JESSEN F, 1992, BIOCHIM BIOPHYS ACTA, V1110, P199, DOI 10.1016/0005-2736(92)90359-T; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MILLS JW, 1986, AM J PHYSIOL, V250, pC319, DOI 10.1152/ajpcell.1986.250.2.C319; MILLS JW, 1993, CELLULAR MOL PHYSL C, P241; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MORGANS CW, 1993, J CELL SCI, V105, P1137; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PEARL M, 1985, BIOL CELL, V5, P163; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SCHWIEBERT EM, 1990, J BIOL CHEM, V265, P7725; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SIMON H, 1993, AM J PHYSIOL, V265, pC757, DOI 10.1152/ajpcell.1993.265.3.C757; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SOKABE M, 1990, J CELL BIOL, V111, P599, DOI 10.1083/jcb.111.2.599; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; STANTON BA, 1994, IN PRESS AM SOC NEPH; SUZUKI M, 1993, J MEMBRANE BIOL, V134, P31; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; ZHELEV DV, 1994, BIOPHYS J, V67, P696, DOI 10.1016/S0006-3495(94)80529-6	49	85	87	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1161	1165		10.1096/fasebj.8.14.7958622	http://dx.doi.org/10.1096/fasebj.8.14.7958622			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958622				2022-12-28	WOS:A1994PT12800011
J	SALTIEL, AR				SALTIEL, AR			THE PARADOXICAL REGULATION OF PROTEIN-PHOSPHORYLATION IN INSULIN ACTION	FASEB JOURNAL			English	Review						2ND-MESSENGER; SRC HOMOLOGY; PROTEIN PHOSPHATASE; SERINE KINASE	GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; HEPATIC PLASMA-MEMBRANES; SIGNAL TRANSDUCTION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; MAP KINASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; DEPENDENT PHOSPHORYLATION; DIFFERENTIAL REGULATION	Many cellular actions of insulin are mediated by changes in protein phosphorylation. The consequences of these phosphorylation events extend from a series of different short-term metabolic actions to longer-term effects of the hormone on cellular growth and differentiation. Although the insulin receptor itself is a tyrosine kinase that is activated upon hormone binding, the ensuing changes in phosphorylation occur predominantly on serine and threonine residues. Moreover, insulin can simultaneously stimulate the phosphorylation of some proteins and the dephosphorylation of others. These paradoxical effects of insulin suggest that separate signal transduction pathways may emanate from the receptor itself to produce the pleiotropic actions of the hormone.			SALTIEL, AR (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, 2800 PLYMOUTH RD, ANN ARBOR, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVRUCH J, 1982, FED PROC, V41, P2629; BOLLEN M, 1984, EUR J BIOCHEM, V144, P57, DOI 10.1111/j.1432-1033.1984.tb08430.x; BURANT CF, 1986, J CLIN INVEST, V77, P260, DOI 10.1172/JCI112285; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GAULTON GN, 1991, DIABETES, V40, P1297, DOI 10.2337/diabetes.40.10.1297; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; JHUN BH, 1994, IN PRESS MOL CELL BI; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLER SL, 1994, IN PRESS TRENDS CELL; KELLY KL, 1987, J BIOL CHEM, V262, P15285; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAZAR DF, 1994, IN PRESS P NATL ACAD; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, IN PRESS J BIOL CHEM; MISEK DE, 1992, J BIOL CHEM, V267, P16266; MISEK DE, 1994, IN PRESS ENDOCRINOLO; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; ORTMEYER HK, 1993, ENDOCRINOLOGY, V132, P640, DOI 10.1210/en.132.2.640; OSTLUND RE, 1993, P NATL ACAD SCI USA, V90, P9988, DOI 10.1073/pnas.90.21.9988; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PANG L, 1994, J BIOL CHEM, V269, P10604; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RICE KM, 1992, J BIOL CHEM, V267, P10163; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1987, BIOCHEM BIOPH RES CO, V149, P1084, DOI 10.1016/0006-291X(87)90519-5; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TOTH B, 1988, J BIOL CHEM, V263, P14061; TREADWAY JL, 1992, BIOCHEMISTRY-US, V31, P11801, DOI 10.1021/bi00162a018; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1994, IN PRESS P NATL ACAD; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	81	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1034	1040		10.1096/fasebj.8.13.7926368	http://dx.doi.org/10.1096/fasebj.8.13.7926368			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926368				2022-12-28	WOS:A1994PN06900007
J	MCINTIRE, WS				MCINTIRE, WS			QUINOPROTEINS	FASEB JOURNAL			English	Review						PYRROLOQUINOLINE QUINONE; TOPA QUINONE; TRYPTOPHAN TRYPTOPHYLQUINONE; AMINE OXIDASES; AMINE AND ALCOHOL DEHYDROGENASES	PYRROLOQUINOLINE QUINONE; METHYLAMINE DEHYDROGENASE; ACETOBACTER-POLYOXOGENES; ALDEHYDE DEHYDROGENASE; GALACTOSE-OXIDASE; COENZYME PQQ; METHOXATIN; COFACTOR; MODEL; GENE	As used today, the word quinoprotein defines three distinct groups of enzymes. Before 1979, the structures of the essential, quinonoid oxidation-reduction cofactors were a mystery for all these enzymes. The first proteins proven to harbor this type prosthetic group are those with noncovalently bound pyrroloquinoline quinone (PQQ). PQQ-containing enzymes can be described as alcohol dehydrogenases, with the exception of a single protein, which is an amine dehydrogenase. More recently, it was discovered that copper-containing amine oxidases contain 6-hydroxydopa quinone, also known as topa quinone (TQ), whereas certain bacterial amine dehydrogenases require 2',4-bitryptophan-6,7-dione (tryptophan tryptophylquinone, TTQ) for activity. These latter two quinones are formed, by unknown processes, from a specific tyrosyl residue for the amine oxidases, and from two widely separate tryptophyl residues in the polypeptide of the amine dehydrogenases.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MCINTIRE, WS (corresponding author), VET AFFAIRS MED CTR,DIV MOLEC BIOL 151S,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.		Vellieux, Frederic/J-4829-2019	Vellieux, Frederic/0000-0002-1922-5707	NHLBI NIH HHS [HL-16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTHONY C, 1992, INT J BIOCHEM, V24, P29, DOI 10.1016/0020-711X(92)90226-Q; ANTHONY C, 1993, PRINCIPLES APPL QUIN, P17; ANTHONY C, 1993, PRINCIPLES APPLICATI, P223; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; CHEN LY, 1993, PROTEIN SCI, V2, P147; CHISTOSERDOV AY, 1992, BIOCHEM BIOPH RES CO, V184, P1226; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; DAVIDSON VL, 1993, PRINCIPLES APPLICATI; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DOOLEY DM, 1993, PRINCIPLES APPLICATI, P275; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; FARAGGI M, 1986, BIOCHEM BIOPH RES CO, V139, P955, DOI 10.1016/S0006-291X(86)80270-4; GACHERU S, 1993, ARCH BIOCHEM BIOPHYS, V301, P325, DOI 10.1006/abbi.1993.1151; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HARRIS TK, 1993, BIOCHEMISTRY-US, V32, P4362, DOI 10.1021/bi00067a028; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HOMMEL R, 1990, J GEN MICROBIOL, V136, P1705, DOI 10.1099/00221287-136-9-1705; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITOH S, 1992, J AM CHEM SOC, V114, P7294, DOI 10.1021/ja00044a050; ITOH S, 1992, J ORG CHEM, V57, P2788, DOI 10.1021/jo00036a007; ITOH S, 1984, TETRAHEDRON LETT, V25, P4753, DOI 10.1016/S0040-4039(01)81510-0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; Jongejan J. A., 1989, PQQ QUINOPROTEINS; KAGAN HM, 1993, PRINCIPLES APPLICATI, P173; KANO K, 1993, BIOCHIM BIOPHYS ACTA, V1157, P324, DOI 10.1016/0304-4165(93)90117-Q; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; LAUFER K, 1993, PRINCIPLES APPLICATI, P193; LIDSTROM ME, 1990, METHODS ENZYMOLOGY, V188; MARISON IW, 1980, J GEN MICROBIOL, V117, P305; MARTIN P, 1993, HELV CHIM ACTA, V76, P988, DOI 10.1002/hlca.19930760221; MATHEWS FS, 1993, PRINCIPLES APPL QUIN, P245; MATSUSHITA K, 1993, BIOCHEMISTRY-US, V32, P5576, DOI 10.1021/bi00072a012; MATSUSHITA K, 1993, PRINCIPLES APPL QUIN, P47; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MCINTIRE WS, 1992, ESSAY BIOCH, P119; MCINTIRE WS, 1994, IN PRESS METHODS ENZ; MCPHERSON MJ, 1992, J BIOL CHEM, V267, P8146; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MUTZEL A, 1991, AGR BIOL CHEM TOKYO, V55, P1721, DOI 10.1080/00021369.1991.10870854; OHSHIRO Y, 1993, PRINCIPLES APPLICATI, P309; OLSON RE, 1985, ANN REV BIOCH, V54, P459; PEDERSEN JZ, 1993, FEBS LETT, V325, P53, DOI 10.1016/0014-5793(93)81412-S; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; RICHARDSON IW, 1992, BIOCHEM J, V287, P709, DOI 10.1042/bj2870709; RODRIGUEZ EJ, 1989, J AM CHEM SOC, V111, P7947, DOI 10.1021/ja00202a041; RUCKER RB, 1993, J NUTR, V123, P977; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; SLEATH PR, 1985, J AM CHEM SOC, V107, P3328, DOI 10.1021/ja00297a044; SMIDT CR, 1991, P SOC EXP BIOL MED, V197, P27; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V964, P175, DOI 10.1016/0304-4165(88)90164-X; TAMAKI T, 1989, J BIOCHEM-TOKYO, V106, P541, DOI 10.1093/oxfordjournals.jbchem.a122889; TAMAKI T, 1991, BIOCHIM BIOPHYS ACTA, V1088, P292, DOI 10.1016/0167-4781(91)90066-U; THOMAS RH, 1987, NATURALLY OCCURRING, V3; THOMAS RH, 1987, NATURALLY OCCURRING, V2; TUROWSKI PN, 1993, J BIOL CHEM, V268, P17680; UNKEFER CJ, 1993, PRINCIPLES APPLICATI, P343; URAKAMI T, 1992, APPL ENVIRON MICROB, V58, P3970, DOI 10.1128/AEM.58.12.3970-3976.1992; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VIGNEVICH V, 1993, J MOL BIOL, V229, P243, DOI 10.1006/jmbi.1993.1022; XIA Z, 1992, J BIOL CHEM, V27, P22289; YAMADA M, 1993, J BIOL CHEM, V268, P12812; ZHANG XP, 1993, J BACTERIOL, V175, P5617, DOI 10.1128/JB.175.17.5617-5627.1993	67	41	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					513	521		10.1096/fasebj.8.8.8181669	http://dx.doi.org/10.1096/fasebj.8.8.8181669			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181669				2022-12-28	WOS:A1994NM36400008
J	FOSTER, R; IZAWA, T; CHUA, NH				FOSTER, R; IZAWA, T; CHUA, NH			PLANT BZIP PROTEINS GATHER AT ACGT ELEMENTS	FASEB JOURNAL			English	Review						PROTEIN/DNA INTERACTIONS; TRANSCRIPTIONAL ACTIVATION; DNA BINDING SPECIFICITY; DIMERIZATION; POSTTRANSLATIONAL MODIFICATION; NUCLEAR LOCALIZATION	CHALCONE SYNTHASE PROMOTER; DNA-BINDING PROTEIN; INVITRO TRANSCRIPTION SYSTEM; LEUCINE ZIPPER PROTEINS; WHEAT HISTONE GENES; G-BOX; ABSCISIC-ACID; LIGHT RESPONSIVENESS; ARABIDOPSIS-THALIANA; OPAQUE-2 ENCODES	ACGT cis-acting DNA sequence elements have been identified in a multitude of plant genes regulated by diverse environmental, physiological, and environmental cues. In vivo transient and transgenic plant expression studies have shown that these ACGT elements are necessary for maximal transcriptional activation. Plants possess a conserved family of DNA-binding proteins specific for these DNA sequence motifs. Well-defined in terms of nucleotide sequence required for protein/DNA interactions and transcriptional activation, various ACGT elements have been used as molecular probes to clone sequence-specific DNA binding proteins. All plant DNA-binding proteins specific for ACGT elements belong to the bZIP classification. Most recombinant bZIP proteins can interact with ACGT elements derived from different plant genes, albeit with different affinity. Systematic protein/DNA binding studies have shown that sequences flanking the ACGT core affect bZIP protein binding specificity. These studies have provided the basis for a concise ACGT nomenclature and defined high-affinity A-box, C-box, and G-box elements. Plant bZIP factors can be classified according to their quantitative binding affinities for high-affinity ACGT elements. Potential molecular mechanisms that may control how plant bZIP proteins activate plant gene expression are discussed.	ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University				Izawa, Takeshi/0000-0001-5109-0024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHBACHER RA, 1991, PLANT J, V1, P303, DOI 10.1046/j.1365-313X.1991.t01-1-00999.x; ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; AUKERMAN MJ, 1991, GENE DEV, V5, P310, DOI 10.1101/gad.5.2.310; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BLOCK A, 1990, P NATL ACAD SCI USA, V87, P5387, DOI 10.1073/pnas.87.14.5387; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DELISLE AJ, 1990, PLANT CELL, V2, P547, DOI 10.1105/tpc.2.6.547; DEVETTEN NC, 1992, PLANT CELL, V4, P1295, DOI 10.1105/tpc.4.10.1295; DONALD RGK, 1990, EMBO J, V9, P1717, DOI 10.1002/j.1460-2075.1990.tb08295.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS JG, 1987, EMBO J, V6, P3203, DOI 10.1002/j.1460-2075.1987.tb02636.x; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FOLEY RC, 1993, PLANT J, V3, P669, DOI 10.1111/j.1365-313X.1993.00669.x; FOSTER R, 1992, ARABIDOPSIS RES, P378; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KAWATA T, 1992, NUCLEIC ACIDS RES, V20, P1141, DOI 10.1093/nar/20.5.1141; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; LAM E, 1991, J BIOL CHEM, V266, P17131; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1990, J BIOL CHEM, V265, P9909; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCKENDREE WL, 1992, PLANT MOL BIOL, V19, P859, DOI 10.1007/BF00027081; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MIKAMI K, 1989, FEBS LETT, V256, P67, DOI 10.1016/0014-5793(89)81719-3; MIKAMI K, 1987, FEBS LETT, V223, P273, DOI 10.1016/0014-5793(87)80303-4; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; NAKAYAMA T, 1989, PLANT CELL PHYSIOL, V30, P825, DOI 10.1093/oxfordjournals.pcp.a077812; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SCHULZE-LEFERT P, 1989, PLANT CELL, V1, P707, DOI 10.1105/tpc.1.7.707; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; STAIGER D, 1991, EUR J BIOCHEM, V199, P519, DOI 10.1111/j.1432-1033.1991.tb16150.x; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; UEDA T, 1992, PLANT CELL, V4, P701, DOI 10.1105/tpc.4.6.701; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	68	285	331	2	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					192	200		10.1096/fasebj.8.2.8119490	http://dx.doi.org/10.1096/fasebj.8.2.8119490			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119490				2022-12-28	WOS:A1994MY29900025
J	LOW, SY; RENNIE, MJ; TAYLOR, PM				LOW, SY; RENNIE, MJ; TAYLOR, PM			SODIUM-DEPENDENT GLUTAMATE TRANSPORT IN CULTURED RAT MYOTUBES INCREASES AFTER GLUTAMINE DEPRIVATION	FASEB JOURNAL			English	Note						AMINO ACID TRANSPORT; ADAPTIVE REGULATION; MUSCLE	AMINO-ACID-TRANSPORT; SKELETAL-MUSCLE CELLS; METABOLISM; LIVER	Glutamine produced and stored in skeletal muscle is an important source of nitrogen and energy for the whole body in health and disease and, unsurprisingly, glutamine turnover in muscle is subject to substantial metabolic control. L-Glutamate, a necessary substrate for glutamine synthetase, is transported into muscle cells by Na+-dependent and -independent transport systems. In primary cultures of rat skeletal muscle myotubes (a useful model system for studies of muscle metabolism and membrane transport), Na+-dependent glutamate transport (K(m) almost-equal-to 0.7 mM glutamate) shows adaptive up-regulation (65% increase in transport V(max) from 2.7 to 4.4 nmol . min-1 . mg protein-1) in cells within 24 h of glutamine depletion (t1/2 for increase of almost-equal-to 4 h), whereas Na+-independent glutamate uptake remains unaltered. Up-regulation of transport is suppressed by inhibitors of gene transcription (actinomycin-D) and translation (cycloheximide) and is reversed by glutamine supplementation. Increased glutamate transport capacity should provide extra substrate for glutamine synthesis in muscle cells. Thus, in concert with previously discovered increases in cell glutamine transport capacity and glutamine synthetase activity, it may represent part of a coordinated response to decreased glutamine availability (e.g., under circumstances of increased glutamine utilization by other tissues in vivo).			LOW, SY (corresponding author), UNIV DUNDEE,OLD MED SCH,DEPT ANAT & PHYSIOL,SMALLS WYND,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010					BANNAI S, 1980, J BIOL CHEM, V255, P2372; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BURGER HJ, 1989, HEPATOLOGY, V9, P22, DOI 10.1002/hep.1840090105; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DURSCHLAG RP, 1985, AM J PHYSIOL, V248, pC442, DOI 10.1152/ajpcell.1985.248.5.C442; FENG B, 1990, J CELL PHYSIOL, V145, P376, DOI 10.1002/jcp.1041450224; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HORN LW, 1989, AM J PHYSIOL, V257, pC442, DOI 10.1152/ajpcell.1989.257.3.C442; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KLIP A, 1982, J CELL PHYSIOL, V113, P56, DOI 10.1002/jcp.1041130111; LOW SY, 1992, BIOCHEM J, V284, P333, DOI 10.1042/bj2840333; RENNIE MJ, 1989, METABOLISM, V38, P47, DOI 10.1016/0026-0495(89)90140-6; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; TADROS LB, 1993, PROGR HEPATIC ENCEPH, V2; TADROS LB, 1993, IN PRESS AM J PHYSL; WATERLOW JC, 1978, PROTEIN TURNOVER MAM, P413	20	37	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					127	131		10.1096/fasebj.8.1.7905447	http://dx.doi.org/10.1096/fasebj.8.1.7905447			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	7905447				2022-12-28	WOS:A1994MV28200019
J	CHAKRABORTY, AK; ZINK, MA; BOMAN, BM; HODGSON, CP				CHAKRABORTY, AK; ZINK, MA; BOMAN, BM; HODGSON, CP			SYNTHETIC RETROTRANSPOSON VECTORS FOR GENE-THERAPY	FASEB JOURNAL			English	Note						GENE THERAPY; RETROVIRUS; VECTOR; RETROTRANSPOSON; VL30; PCR	CHROMOSOMAL POSITION; RETROVIRAL GENOMES; CELL-LINES; VIRUS; DNA; EXPRESSION; CONSTRUCTION; METHYLATION; SEQUENCE; PRIMATES	New gene therapy methods are rapidly being developed to permit the expression of tumor suppressor genes, cytotoxins, anticancer antigens, and immunoregulatory proteins in the treatment of cancer. Large-scale testing in humans has been delayed by questions concerning the safety and effectiveness of preferred retroviral vectors and helper cells. These vector systems are limited by their ability to undergo homologous recombination with endogenous retroviruses or helper-viral sequences, resulting in release of replication-competent retrovirus (RCR). In addition, transcriptional inactivation of the retroviral promoter often occurs, caused in part by methylation of CpG islands in the retroviral long terminal repeats (LTRs). We report the production of highly specific retrovectors using gene amplification together with oligonucleotide building blocks. The synthetic vectors were based on mouse VL30 retrotransposon NVL3, and lacked homology to retroviral helper gene sequences. Three of four constructs made by gene amplification yielded biologically active vectors. These constructs efficiently transmitted and stably inserted a neomycin resistance marker gene into the genome of recipient cells, expressing an abundant RNA species of the expected size in the absence of detectable replication competent retrovirus. The vectors and techniques described enable widely applicable expression modes using generic helper cells, and require only approximately 1.3 kb of cis-acting vector RNA sequences for faithful transfer and expression of genetic material.	CREIGHTON UNIV,SCH MED,CREIGHTON CANC CTR,2500 CALIF PLAZA,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT BIOMED SCI,OMAHA,NE 68178	Creighton University; Creighton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041314] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R29GM41314-4] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SE, 1988, MOL CELL BIOL, V8, P2989, DOI 10.1128/MCB.8.8.2989; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; ANDERSON WF, 1992, HUM GENE THER, V3, P617, DOI 10.1089/hum.1992.3.6-617; ANDESON WF, 1992, REPORT NIH RECOMBINA, P961; ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; Ausubel FM, 1988, MOL REPROD DEV; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CARTER AT, 1983, NUCLEIC ACIDS RES, V11, P6243, DOI 10.1093/nar/11.18.6243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK RF, 1991, BIO-TECHNOL, V9, P748, DOI 10.1038/nbt0891-748; COOK RF, 1993, J POULTRY SCI, V72, P554; CORNETTA K, 1991, HUM GENE THER, V2, P215, DOI 10.1089/hum.1991.2.3-215; CORNETTA K, 1990, HUM GENE THER, V1, P15, DOI 10.1089/hum.1990.1.1-15; DARNELL J, 1986, MOL CELL BIOL, P305; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; ECKERT AA, 1991, PCR METHODS APPLICAT, P17; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATZOGLOU M, 1990, HUM GENE THER, V1, P385, DOI 10.1089/hum.1990.1.4-385; HODGSON CP, 1993, CURR OPIN THER PAT, V3, P223; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCCLINTOCK B, 1956, COLD SPRING HARB SYM, V21, P197, DOI 10.1101/SQB.1956.021.01.017; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MUENCHAU DD, 1990, VIROLOGY, V176, P262, DOI 10.1016/0042-6822(90)90251-L; NORTON JD, 1988, DEV BIOL, V125, P226, DOI 10.1016/0012-1606(88)90076-0; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCADDEN DT, 1990, J VIROL, V64, P424, DOI 10.1128/JVI.64.1.424-427.1990	40	18	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					971	977		10.1096/fasebj.7.10.8393821	http://dx.doi.org/10.1096/fasebj.7.10.8393821			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393821				2022-12-28	WOS:A1993LQ33700023
J	GAUTHERET, D; CEDERGREN, R				GAUTHERET, D; CEDERGREN, R			MODELING THE 3-DIMENSIONAL STRUCTURE OF RNA	FASEB JOURNAL			English	Article						RNA MODELING; NUCLEOTIDES; DOUBLE-STRANDED RNA	16-S RIBOSOMAL-RNA; MOLECULAR-DYNAMICS SIMULATIONS; PHENYLALANINE TRANSFER-RNA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC REFINEMENT; ENERGY MINIMIZATION; DISTANCE GEOMETRY; TORSION ANGLES; NUCLEIC-ACIDS	The limited number of RNA structures determined by X-ray crystallography and NMR spectroscopy compels the use of experimental and theoretical methods that are less precise to obtain information on RNA conformation. RNA flexibility, a consequence of rotational freedom about seven intra- and internucleotide bonds, is unfortunately of such magnitude that these alternate techniques fall short of providing sufficient information to build robust tertiary structures. Various RNA modeling methods, described herein, permit the organization of this structural data to the form of three-dimensional structures. Interactive computer graphics techniques, for example, have generated several useful models. Also, conventional computer algorithms involving the minimization of empirical energy functions, previously limited to small molecules, are giving way to methods able to handle much larger molecules. Modified distance geometry and molecular mechanics algorithms, using simplified ''pseudoatom'' representations, can generate structures consistent with input data. A constraint satisfaction algorithm combined with discrete representations of nucleotide conformations systematically explores poorly defined regions of a molecule yielding all-atom representations, but requires enough structural constraints to avoid a computational explosion.			GAUTHERET, D (corresponding author), UNIV MONTREAL, DEPT BIOCHIM, CP 6128, SUCC A, MONTREAL H3C 3J7, QUEBEC, CANADA.			Gautheret, Daniel/0000-0002-1508-8469				ABAGYAN R, 1992, J MOL BIOL, V225, P519, DOI 10.1016/0022-2836(92)90936-E; ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035; BRAHMS S, 1992, J MOL BIOL, V223, P455, DOI 10.1016/0022-2836(92)90664-6; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNEL C, 1991, J MOL BIOL, V221, P293; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CHRISTIAN EL, 1992, IN PRESS J MOL BIOL; CRIPPEN GM, 1977, J COMPUT PHYS, V24, P96, DOI 10.1016/0021-9991(77)90112-7; DAGGETT V, 1991, BIOPOLYMERS, V31, P285, DOI 10.1002/bip.360310304; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; DONOHUE J, 1960, J MOL BIOL, V2, P363, DOI 10.1016/S0022-2836(60)80047-2; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAUTHERET D, IN PRESS J MOL BIOL; GLOTZ C, 1981, NUCLEIC ACIDS RES, V9, P3287, DOI 10.1093/nar/9.14.3287; GUTELL RR, 1992, IN PRESS RIBOSOMAL R; GUTELL RR, IN PRESS NUCLEIC ACI; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HADWIGER MA, 1991, J BIOMOL STRUCT DYN, V8, P759, DOI 10.1080/07391102.1991.10507843; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HINGERTY BE, 1989, BIOPOLYMERS, V28, P1195, DOI 10.1002/bip.360280703; HUBBARD JM, 1991, BIOCHEMISTRY-US, V30, P5458, DOI 10.1021/bi00236a019; HUBBARD JM, 1991, J MOL BIOL, V221, P889, DOI 10.1016/0022-2836(91)80182-T; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JONES TJ, 1978, COMPUTATIONAL CRYSTA, P303; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MALHOTRA A, 1990, P NATL ACAD SCI USA, V87, P1950, DOI 10.1073/pnas.87.5.1950; MANS RMW, 1992, J MOL BIOL, V223, P221, DOI 10.1016/0022-2836(92)90727-2; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON L, 1986, J COMPUT CHEM, V7, P591, DOI 10.1002/jcc.540070502; NILSSON L, 1986, J MOL BIOL, V188, P455, DOI 10.1016/0022-2836(86)90168-3; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PEARLMAN DA, 1986, J BIOMOL STRUCT DYN, V4, P49, DOI 10.1080/07391102.1986.10507646; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIGLEY GJ, 1975, NUCLEIC ACIDS RES, V2, P2329, DOI 10.1093/nar/2.12.2329; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SAENGER W, 1984, PRINCIPLES NUCL ACID, P15; SCHLICK T, 1990, THEORETICAL CHEM MOL, P39; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	65	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					97	105		10.1096/fasebj.7.1.7678567	http://dx.doi.org/10.1096/fasebj.7.1.7678567			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678567				2022-12-28	WOS:A1993KH88000015
J	YARUS, M				YARUS, M			HOW MANY CATALYTIC RNAS - IONS AND THE CHESHIRE CAT CONJECTURE	FASEB JOURNAL			English	Article						SELECTION AMPLIFICATION; EVOLUTION OF CATALYSIS; DIVALENT; IONS; RNA CATALYSIS	PHENYLALANINE TRANSFER-RNA; SELF-CLEAVAGE REACTION; DNA-POLYMERASE-I; CRYSTAL-STRUCTURE; ACTIVE-SITE; TETRAHYMENA RIBOZYME; ESCHERICHIA-COLI; RIBONUCLEASE-P; MULTISUBUNIT RIBOZYME; HAMMERHEAD RIBOZYMES	Three well-characterized RNA catalysts not only require Mg2+ for activity, but also bind a metal ion (or ions) within the active site, apparently in a catalytic rather than solely structural role. I suggest, in view of the general catalytic utility of bound ions, that catalytic RNAs be viewed as Cheshire cats, by dimming their complex three-dimensional ribonucleotide structure to leave only the sharp mineral parts in view. That is, catalytic RNAs may be viewed as metalloenzymes, with the burdens of catalysis frequently borne by specifically poised metal ions. Comparison to modern protein metalloenzymes predicts particular RNA metallocatalysts that may be possible presently, and in a hypothetical ancestral RNA world that did not encode peptide catalysts. In support of this view, known catalytic RNAs can be considered Cheshire catalysts; that is, they have apparent cognates among the protein metalloenzymes.			YARUS, M (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.		Yarus, Michael/Q-9813-2019		NIGMS NIH HHS [GM30881] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030881, R37GM030881] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; BARSHEVSKAYA T N, 1987, Molekulyarnaya Biologiya (Moscow), V21, P1235; BEAL RB, 1990, BIOCHEMISTRY-US, V29, P5994, DOI 10.1021/bi00477a017; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRIDSON PK, 1980, J MOL BIOL, V144, P567, DOI 10.1016/0022-2836(80)90337-X; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BUCKINGHAM DA, 1970, J AM CHEM SOC, V92, P5701, DOI 10.1021/ja00722a026; BUCKINGHAM DA, 1975, J AM CHEM SOC, V97, P5915, DOI 10.1021/ja00853a047; BUTZOW JJ, 1975, NATURE, V254, P358, DOI 10.1038/254358a0; BUTZOW JJ, 1965, BIOPOLYMERS, V3, P95, DOI 10.1002/bip.360030110; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; CARROLL L, 1865, ALICE WONDERLAND, P53; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CEDERGREN RJ, 1981, CRC CR REV BIOCH MOL, V11, P35, DOI 10.3109/10409238109108699; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1992, IN PRESS J MOL BIOL; CHRISTIAN EL, 1992, UNPUB BIOCHEMISTRY; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; COOPERMAN BS, 1976, METAL IONS BIOL SYST, V5; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; DAHM SC, 1992, MECHANISTIC ROLE MET; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; FARKAS WR, 1968, BIOCHIM BIOPHYS ACTA, V155, P401, DOI 10.1016/0005-2787(68)90184-6; Fersht A., 1985, ENZYME STRUCTURE MEC; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTHRIE C, 1989, AM ZOOL, V29, P557; HAN H, 1991, BIOCHEMISTRY-US, V30, P11104, DOI 10.1021/bi00110a012; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HAYDOCK K, 1985, PROGR CLIN BIOL RE A, V172; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7587, DOI 10.1021/ja00201a048; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; JENCKS WP, 1975, ADV ENZYMOLOGY RELAT, V43; JOYCE GF, 1991, NEW BIOL, V3, P399; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KLINMAN JP, 1981, CRC CR REV BIOCH MOL, V10, P39, DOI 10.3109/10409238109114635; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LINDAHL T, 1966, P NATL ACAD SCI USA, V55, P941, DOI 10.1073/pnas.55.4.941; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUIRHEAD H, 1987, BIOCHEM SOC T, V15, P996, DOI 10.1042/bst0150996; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PICCIRILLI JA, 1992, UNPUB NATURE LONDON; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RUBIN JR, 1983, BIOCHIM BIOPHYS ACTA, V256, P111; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SMITH D, 1992, J BIOL CHEM, V267, P2429; SMITH D, 1992, UNPUB BIOCHEMISTRY; STALLINGS WC, 1985, J BIOL CHEM, V260, P6424; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; SUNDARALINGAM M, 1984, INT J QUANTUM CHEM Q, V11, P355; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; TRUE AE, 1990, BIOCHEMISTRY-US, V29, P10847, DOI 10.1021/bi00500a019; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VALLEE BL, 1992, MATRIX METALLOPROTEI; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WALSH C, 1977, ENZYMATIC REACTION M, P214; WALSH CT, 1987, BIOCHEMISTRY-US, V26, P4901, DOI 10.1021/bi00390a001; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Williams R.J.P., 1991, BIOL CHEM ELEMENTS; WOOLLEY P, 1975, NATURE, V258, P677, DOI 10.1038/258677a0; YANAGAWA H, 1990, BIOCHEMISTRY-US, V29, P10585, DOI 10.1021/bi00499a002; YARUS M, 1992, J MOL BIOL, V225, P945, DOI 10.1016/0022-2836(92)90095-2; YARUS M, 1991, NEW BIOL, V3, P183; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354	96	157	163	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					31	39		10.1096/fasebj.7.1.8422972	http://dx.doi.org/10.1096/fasebj.7.1.8422972			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422972				2022-12-28	WOS:A1993KH88000006
J	LEBLOND, CP				LEBLOND, CP			THE TIME DIMENSION IN CELL BIOLOGY	FASEB JOURNAL			English	Editorial Material							EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; SMALL INTESTINE; COLUMNAR CELLS; MOUSE STOMACH; RAT INCISOR; PIT CELLS; MIGRATION; RENEWAL; AUTORADIOGRAPHY				LEBLOND, CP (corresponding author), MCGILL UNIV, DEPT ANAT & CELL BIOL, 3640 UNIV ST, MONTREAL, PQ H3A 2B2, CANADA.							ALTMANN GG, 1982, J CELL SCI, V56, P83; AMANO M, 1960, EXP CELL RES, V20, P250, DOI 10.1016/0014-4827(60)90252-4; AMANO M, 1965, EXP CELL RES, V38, P314, DOI 10.1016/0014-4827(65)90407-6; BELANGER LF, 1946, ENDOCRINOLOGY, V39, P8, DOI 10.1210/endo-39-1-8; BENNETT G, 1970, J CELL BIOL, V46, P409, DOI 10.1083/jcb.46.2.409; BENNETT G, 1974, J CELL BIOL, V60, P258, DOI 10.1083/jcb.60.1.258; BENNETT G, 1977, HISTOCHEM J, V9, P393, DOI 10.1007/BF01002973; BENNETT G, 1971, J CELL BIOL, V51, P875, DOI 10.1083/jcb.51.3.875; CARO LG, 1961, CR SOC BIOL, V155, P1750; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CLERMONT Y., 1959, ARCH ANAT MICROSC ET MORPHOL EXPTL, V48, P37; DOUGHERTY J, 1951, ENDOCRINOLOGY, V48, P700, DOI 10.1210/endo-48-6-700; DROZ B, 1963, J COMP NEUROL, V121, P325, DOI 10.1002/cne.901210304; ELALFY M, 1995, ANAT REC, V242, P433, DOI 10.1002/ar.1092420402; GIROUD A., 1935, Arch. Anat. Micros., V31, P111; GREULICH RC, 1953, ANAT REC, V115, P559, DOI 10.1002/ar.1091150308; GROSS J, 1951, ENDOCRINOLOGY, V48, P714, DOI 10.1210/endo-48-6-714; GROSS J, 1962, LANCET, V1, P439; HEYESY G, 1939, J CHEM SOC       JUL, P1213; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KOPRIWA BM, 1962, J HISTOCHEM CYTOCHEM, V10, P269, DOI 10.1177/10.3.269; LEBLOND C. P., 1964, NAT CANCER INST MONOGR, V14, P119; LEBLOND CP, 1957, AM J ANAT, V101, P225, DOI 10.1002/aja.1001010203; Leblond CP, 1943, J ANAT, V77, P149; LEBLOND CP, 1991, PROTOPLASMA, V160, P5, DOI 10.1007/BF01404003; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LEBLOND CP, 1958, ANAT REC, V132, P247, DOI 10.1002/ar.1091320303; LEBLOND CP, 1950, AM J ANAT, V86, P289, DOI 10.1002/aja.1000860205; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEBLOND CP, 1950, AM J ANAT, V86, P1, DOI 10.1002/aja.1000860102; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Leblond CP, 1944, ANAT REC, V88, P285, DOI 10.1002/ar.1090880306; Leblond CP, 1940, PEDAGOG SEMIN J GEN, V57, P327; Leblond CP, 1940, CR SOC BIOL, V133, P540; LEBLOND CP, 1989, AM J ANAT, V185, P367, DOI 10.1002/aja.1001850403; LEE ER, 1985, AM J ANAT, V172, P225, DOI 10.1002/aja.1001720305; MARCHI F, 1991, AM J ANAT, V190, P41, DOI 10.1002/aja.1001900106; MARCHI F, 1983, AM J ANAT, V168, P167, DOI 10.1002/aja.1001680206; MURRAY IC, 1988, J HISTOCHEM CYTOCHEM, V36, P763, DOI 10.1177/36.7.2968396; NADLER N J, 1955, Brookhaven Symp Biol, V7, P40; NADLER NJ, 1964, ENDOCRINOLOGY, V74, P333, DOI 10.1210/endo-74-3-333; NEUTRA M, 1966, J CELL BIOL, V30, P119, DOI 10.1083/jcb.30.1.119; RAMBOURG A, 1967, J CELL BIOL, V32, P27, DOI 10.1083/jcb.32.1.27; RAMBOURG A, 1966, ANAT REC, V154, P41, DOI 10.1002/ar.1091540105; REVEL JP, 1963, Z ZELLFORSCH MIK ANA, V61, P110, DOI 10.1007/BF00341524; Schoenheimer R, 1938, SCIENCE, V87, P221, DOI 10.1126/science.87.2254.221; WARSHAWSKY H, 1963, J CELL BIOL, V16, P1, DOI 10.1083/jcb.16.1.1; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92; WHUR P, 1969, J CELL BIOL, V43, P289, DOI 10.1083/jcb.43.2.289	51	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1995	9	12					1234	1238		10.1096/fasebj.9.12.7672517	http://dx.doi.org/10.1096/fasebj.9.12.7672517			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672517				2022-12-28	WOS:A1995RU81600014
J	KAPLAN, D; SMITH, D; HUANG, R; YILDIRIM, Z				KAPLAN, D; SMITH, D; HUANG, R; YILDIRIM, Z			SELF-ASSOCIATION OF INTERLEUKIN-2 BOUND TO ITS RECEPTOR	FASEB JOURNAL			English	Article						FLOW CYTOMETRY; UNSATURABLE BINDING; RADIOIODINATED IL-2; BIOTINYLATED IL-2; IL-2 CROSS-LINKING; COOPERATIVE BINDING	SOLID-PHASE INTERLEUKIN-2; AFFINITY IL-2 RECEPTOR; GROWTH-FACTOR; BINDING; CELLS; PROLIFERATION; INVIVO	Although radioiodinated interleukin 2 (IL-2) has been used to define the binding characteristics of the cytokine to the alpha chain of the receptor complex, we have found that unsubstituted IL-2 behaves differently. Whereas previous investigations with radioiodinated IL-2 have shown binding to the alpha chain with a K-d of 10 nM, we show that unsubstituted IL-2 binds to the alpha chain but does not reach saturation between 100 and 1000 nM. The explanation for the discrepancy between the analysis of radioiodinated and unsubstituted cytokine involves the propensity of unsubstituted IL-2 for self-association, a property that is abrogated by radioiodination. The functional relevance of our findings is indicated by the different capacities of unsubstituted and iodinated cytokine to induce prolonged proliferation of human T lymphocytes.			KAPLAN, D (corresponding author), CASE WESTERN RESERVE UNIV,DEPT PATHOL,2109 ADELBERT RD,BIOMED BLDG,ROOM 926,CLEVELAND,OH 44106, USA.				NCI NIH HHS [CA-43703] Funding Source: Medline; NIAID NIH HHS [AI-28923] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAKAWA T, 1986, BIOCHEMISTRY-US, V25, P8274, DOI 10.1021/bi00373a022; BERGMANN CA, 1991, MOL IMMUNOL, V28, P99, DOI 10.1016/0161-5890(91)90092-X; BERGMANN CA, 1992, CYTOKINE, V4, P192, DOI 10.1016/1043-4666(92)90055-V; CHURILLA AM, 1987, J IMMUNOL, V138, P1338; CRUM ED, 1991, CANCER RES, V51, P875; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FLEISCHMANN JD, 1988, BIOCHEM BIOPH RES CO, V152, P879, DOI 10.1016/S0006-291X(88)80121-9; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GILLIS S, 1978, J IMMUNOL, V120, P2027; GREENSPAN NS, 1993, SPRINGER SEMIN IMMUN, V15, P275; KAMIO M, 1990, INT IMMUNOL, V2, P521, DOI 10.1093/intimm/2.6.521; KAPLAN DR, 1991, MOL IMMUNOL, V28, P1255, DOI 10.1016/0161-5890(91)90012-9; KONDO S, 1986, P NATL ACAD SCI USA, V83, P9026, DOI 10.1073/pnas.83.23.9026; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MCKENZIE ANJ, 1991, MOL IMMUNOL, V28, P155, DOI 10.1016/0161-5890(91)90099-6; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; PTASHNE M, 1986, GENETIC SWITCH GENE, P83; ROBB RJ, 1985, J IMMUNOL METHODS, V81, P15, DOI 10.1016/0022-1759(85)90118-8; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SAITO Y, 1988, J EXP MED, V168, P1563, DOI 10.1084/jem.168.5.1563; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; TAKI S, 1989, J IMMUNOL METHODS, V122, P33, DOI 10.1016/0022-1759(89)90331-1; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055	26	13	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1096	1102		10.1096/fasebj.9.11.7649410	http://dx.doi.org/10.1096/fasebj.9.11.7649410			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649410				2022-12-28	WOS:A1995RP99600015
J	COHEN, GN				COHEN, GN			30 YEARS SINCE THE AWARD OF THE NOBEL-PRIZE TO LWOFF, MONOD, AND JACOB	FASEB JOURNAL			English	Editorial Material							ESCHERICHIA-COLI; MET REPRESSOR; BINDING; BIOSYNTHESIS				COHEN, GN (corresponding author), INST PASTEUR, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; COHEN G, 1959, CR HEBD ACAD SCI, V248, P3490; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GILBERT W, 1967, P NATL ACAD SCI USA, V58, P2415, DOI 10.1073/pnas.58.6.2415; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; LIM D, 1988, GENE EXPRESSION REGU, P55; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; Ptashne M., 1986, A GENETIC SWITCH; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAFFERTY JB, 1988, J MOL BIOL, V200, P217, DOI 10.1016/0022-2836(88)90348-8; SAINTGIRONS I, 1988, CRIT REV BIOCHEM MOL, V23, pS1, DOI 10.3109/10409238809083374; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOMERVILLE RL, 1965, J MOL BIOL, V11, P747, DOI 10.1016/S0022-2836(65)80032-8; ULLMANN A, 1965, J MOL BIOL, V12, P918, DOI 10.1016/S0022-2836(65)80338-2; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; 1961, COLD SPRING HARBOR S, V26	22	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1995	9	10					981	982		10.1096/fasebj.9.10.7615168	http://dx.doi.org/10.1096/fasebj.9.10.7615168			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615168				2022-12-28	WOS:A1995RK89900023
J	DEJANA, E; CORADA, M; LAMPUGNANI, MG				DEJANA, E; CORADA, M; LAMPUGNANI, MG			ENDOTHELIAL CELL-TO-CELL JUNCTIONS	FASEB JOURNAL			English	Review						ENDOTHELIUM; PERMEABILITY; LEUKOCYTE DIAPEDESIS	BLOOD-BRAIN-BARRIER; ADHESION; CADHERINS; PERMEABILITY; COMPONENTS; MODULATION; RECEPTORS; MOLECULES; MIGRATION; MEMBRANE	The endothelium forms the main barrier to the passage of macromolecules and circulating cells from blood to tissues, Endothelial permeability is in large part regulated by intercellular junctions, These are complex structures formed by transmembrane adhesive molecules linked to a network of cytoplasmic/cytoskeletal proteins. At least four different types of endothelial junctions have been described: tight junctions, gap junctions, adherence junctions and syndesmos. These organelles have some features and components in common with epithelial cells but there are also some that are specific for the endothelium, The mechanisms that regulate the opening and closing of endothelial junctions are still obscure, It is conceivable that inflammatory agents increase permeabilty by binding to specific: receptors generating intracellular signals, which in turn cause cytoskeletal reorganization and opening of interendothelial cell gaps. Endothelial junctions also control leukocyte extravasation, Once leukocytes have adhered to the endothelium, a coordinated opening of interendothelial cell junctions occurs, The mechanism by which this takes place is unknow, but it might present characteristics similar to that triggered by soluble mediators.	IST RIC FARMACOL MARIO NEGRI, VASC BIOL LAB, MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	DEJANA, E (corresponding author), CEN GRENOBLE, DEPT BIOL MOLEC & STRUCT,INSERM,U217,CEA, HEMATOL LAB, F-38054 GRENOBLE 9, FRANCE.			DEJANA, ELISABETTA/0000-0002-0007-0426; Lampugnani, Maria Grazia/0000-0002-4802-7064				Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; BAVISOTTO LM, 1990, J CELL PHYSIOL, V143, P39, DOI 10.1002/jcp.1041430106; BERMAN ME, 1995, J IMMUNOL, V154, P299; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BREVIARIO F, 1995, IN PRESS ATHER THROM; CARLOS TM, 1994, BLOOD, V84, P2068; CAVEDA L, 1994, ENDOTHELIUM, V2, P1; CONFORTI G, 1992, BLOOD, V80, P437; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DUFOUR S, 1994, J CELL BIOL, V127, P521, DOI 10.1083/jcb.127.2.521; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; HANGXIN L, 1990, J CELL SCI, V97, P231; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEIMARK RL, 1990, J CELL BIOL, V110, P1745, DOI 10.1083/jcb.110.5.1745; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HOEK JB, 1992, LAB INVEST, V67, P1; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; HUANG AJ, 1992, ENDOTHELIAL CELL DYS, P201; HUANG AL, 1992, LAB INVEST, V67, P201; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LAURI D, 1991, VASCULAR ENDOTHELIUM, P111; LEACH L, 1993, J CELL SCI, V104, P1073; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARTINPADURA I, 1995, J PATHOL, V175, P51, DOI 10.1002/path.1711750109; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MULLER WA, 1986, J CELL BIOL, V103, P2389, DOI 10.1083/jcb.103.6.2389; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PEPPER MS, 1989, J CELL BIOL, V109, P3027, DOI 10.1083/jcb.109.6.3027; POLACEK D, 1993, AM J PATHOL, V142, P593; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; SALOMON D, 1992, J CELL SCI, V102, P7; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; SCHULZE C, 1993, J CELL SCI, V104, P773; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SIMIONESCU M, 1991, CELL BIOL REV, V25, P5; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; [No title captured]	57	381	389	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1995	9	10					910	918		10.1096/fasebj.9.10.7615160	http://dx.doi.org/10.1096/fasebj.9.10.7615160			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615160				2022-12-28	WOS:A1995RK89900012
J	SEGER, R; KREBS, EG				SEGER, R; KREBS, EG			PROTEIN KINASES .7. THE MAPK SIGNALING CASCADE	FASEB JOURNAL			English	Review						MAP KINASE; SIGNALING; PROLIFERATION; ONCOGENESIS	EPIDERMAL GROWTH-FACTOR; RIBOSOMAL S6 KINASE; THREONINE RESIDUES; XENOPUS OOCYTES; RAF-1 KINASE; CELL-CYCLE; A431 CELLS; PC12 CELLS; 3T3 CELLS; V-RAF	The transmission of extracellular signals into their intracellular targets is mediated by a network of interacting proteins that regulate a large number of cellular processes. Cumulative efforts from many laboratories over the past decade have allowed the elucidation of one such signaling mechanism, which involves activations of several membranal signaling molecules followed by a sequential stimulation of several cytoplasmic protein kinases collectively known as mitogen-activated protein kinase (MAPK) signaling cascade. Up to six tiers in this cascade contribute to the amplification and specificity of the transmitted signals that eventually activate several regulatory molecules in the cytoplasm and in the nucleus to initiate cellular processes such as proliferation, differentiation, and development. Moreover, because many oncogenes have been shown to encode proteins that transmit mitogenic signals upstream of this cascade, the MAPK pathway provides a simple unifying explanation for the mechanism of action of most, if not all, nonnuclear oncogenes, The pattern of MAPK cascade is not restricted to growth factor signaling and it is now known that signaling pathways initiated by phorbol esters, ionophors, heat shock, and ligands for seven transmembrane receptors use distinct MAPK cascades with little or no cross-reactivity between them. In this review we emphasize primarily the first MAPK cascade to be discovered that uses the MEK and ERK isoforms and describe their involvement in different cellular processes.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	SEGER, R (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.				NIDDK NIH HHS [DK-42528] Funding Source: Medline; NIGMS NIH HHS [GM-42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMICK GD, 1992, ARCH BIOCHEM BIOPHYS, V297, P80, DOI 10.1016/0003-9861(92)90643-B; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELL JS, 1994, ADV 2ND MESSENGER PH; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; COBB MH, 1983, J BIOL CHEM, V258, P2472; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COLLER DE, 1994, AM J PHYSIOL, V266, P351; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DONELLADEANA A, 1993, BIOCHIM BIOPHYS ACTA, V1178, P189, DOI 10.1016/0167-4889(93)90008-D; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ETTEHADIEH E, 1994, SCIENCE, V265, P853; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1994, ONCOGENE, V9, P1891; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KATSURA I, 1993, GENETICA, V88, P137, DOI 10.1007/BF02424470; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MILTENBERGER RJ, 1993, J BIOL CHEM, V268, P15674; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAO VN, 1993, CANCER RES, V53, P3449; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; YAU M, 1994, NATURE, V372, P798; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	99	3045	3209	3	229	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1995	9	9					726	735		10.1096/fasebj.9.9.7601337	http://dx.doi.org/10.1096/fasebj.9.9.7601337			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601337				2022-12-28	WOS:A1995RH98200006
J	BOYER, PD				BOYER, PD			FROM HUMAN SERUM-ALBUMIN TO ROTATIONAL CATALYSIS BY ATP SYNTHASE	FASEB JOURNAL			English	Editorial Material							ACTIVE-TRANSPORT; ENERGIZATION											ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BALLOU GA, 1945, FED PROC, V4, P82; BIANCHET M, 1991, J BIOL CHEM, V266, P22197; Boyer P. D., 1979, MEMBRANE BIOENERGETI, P461; BOYER PD, 1946, J BIOL CHEM, V162, P199; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1975, FEBS LETT, V58, P1, DOI 10.1016/0014-5793(75)80212-2; CROSS RL, 1982, J BIOL CHEM, V257, P1201; DELUCA M, 1963, BIOCHEM Z, V338, P512; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Hackney D D, 1980, Methods Enzymol, V64, P60; KLEIN WL, 1972, J BIOL CHEM, V247, P7257; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MITCHELL P, 1974, FEBS LETT, V43, P189, DOI 10.1016/0014-5793(74)80997-X; MITCHELL P, 1975, FEBS LETT, V50, P95, DOI 10.1016/0014-5793(75)80465-0; ZHOU JM, 1993, J BIOL CHEM, V268, P1531	16	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					559	561		10.1096/fasebj.9.7.7737466	http://dx.doi.org/10.1096/fasebj.9.7.7737466			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737466				2022-12-28	WOS:A1995QX14800015
J	NISHIZUKA, Y				NISHIZUKA, Y			PROTEIN KINASES .5. PROTEIN-KINASE-C AND LIPID SIGNALING FOR SUSTAINED CELLULAR-RESPONSES	FASEB JOURNAL			English	Review						DIACYLGLYCEROL; FATTY ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASES	PHOSPHOLIPASE-D ACTIVATION; LYMPHOCYTE-T ACTIVATION; TUMOR-NECROSIS-FACTOR; UNSATURATED FATTY-ACIDS; EPIDERMAL GROWTH-FACTOR; LONG-TERM POTENTIATION; PHORBOL ESTER RECEPTOR; SMOOTH-MUSCLE CELLS; CANINE KIDNEY-CELLS; SWISS 3T3 CELLS	Since the second messenger role was proposed for the products of inositol phospholipid hydrolysis, considerable progress has been made in our understanding of the biochemical mechanism of the intracellular signaling network. It is now becoming evident that stimulation of a cell surface receptor initiates a degradation cascade of various membrane lipid constituents. Many of their metabolites have potentials to induce, intensify, and prolong the activation of protein kinase C that is needed for sustained cellular responses.	KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 657, JAPAN	Kobe University	NISHIZUKA, Y (corresponding author), KOBE UNIV, BIOSIGNAL RES CTR, NADA KU, 1-1 ROKKODAI CHO, KOBE 657, JAPAN.							ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; ARECES LB, 1994, J BIOL CHEM, V269, P19553; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; ASAOKA Y, 1991, P NATL ACAD SCI USA, V88, P8681, DOI 10.1073/pnas.88.19.8681; ASSAKI Y, 1993, FEBS LETT, V320, P47; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BAIER G, 1993, J BIOL CHEM, V268, P4997; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CHALIFOUR RJ, 1980, CAN J BIOCHEM CELL B, V58, P1189, DOI 10.1139/o80-159; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN SG, 1992, BIOCHEM J, V282, P33, DOI 10.1042/bj2820033; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COFFEY ET, 1994, J NEUROCHEM, V63, P1303; COLLINS DR, 1993, EUR J PHARMACOL, V240, P325, DOI 10.1016/0014-2999(93)90919-9; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CUADRADO A, 1993, ONCOGENE, V8, P2959; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DARNERO A, 1994, J CELL BIOL, V55, P1; DAWSON RMC, 1959, BIOCHIM BIOPHYS ACTA, V33, P68, DOI 10.1016/0006-3002(59)90499-8; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESSEV G, 1988, P NATL ACAD SCI USA, V85, P2994, DOI 10.1073/pnas.85.9.2994; DEVALCK D, 1993, EUR J BIOCHEM, V212, P491; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAROOQUI AA, 1989, ANN NY ACAD SCI, V559, P25; FAURE M, 1994, J BIOL CHEM, V269, P7851; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FORD DA, 1990, J BIOL CHEM, V265, P12280; GAUDRY M, 1993, FASEB J, V7, P687, DOI 10.1096/fasebj.7.8.7684713; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HAYASHI J, 1993, BIOCHEM MOL BIOL INT, V31, P143; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HERRERO I, 1992, J NEUROCHEM, V59, P1574, DOI 10.1111/j.1471-4159.1992.tb08478.x; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOLBROOK PG, 1992, J BIOL CHEM, V267, P16834; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HORWITZ J, 1993, BIOCHEM J, V295, P793, DOI 10.1042/bj2950793; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KONDO T, 1992, J BIOL CHEM, V267, P23609; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUO JF, 1994, PROTEIN KINASE C; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEE C, 1991, J BIOL CHEM, V266, P22837; LESTER DS, 1992, PROTEIN KINASE C CUR; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; LUO JH, 1993, J BIOL CHEM, V268, P3715; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MENAYA J, 1991, EXP CELL RES, V194, P260, DOI 10.1016/0014-4827(91)90363-Y; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NEWMAN RH, 1994, BIOCHEM J, V298, P391, DOI 10.1042/bj2980391; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OISHI K, 1988, J BIOL CHEM, V263, P6865; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1994, J BIOL CHEM, V269, P8383; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETROU S, 1993, TRENDS BIOCHEM SCI, V18, P41, DOI 10.1016/0968-0004(93)90050-W; PONZONI M, 1993, BIOCHEM J, V294, P893, DOI 10.1042/bj2940893; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V154, P20, DOI 10.1016/0006-291X(88)90643-2; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHEIKHNEJAD RG, 1986, J BIOL CHEM, V261, P7544; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STASEK JE, 1993, BIOCHEM BIOPH RES CO, V191, P134, DOI 10.1006/bbrc.1993.1194; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSUJISHITA Y, 1994, P NATL ACAD SCI USA, V91, P6274, DOI 10.1073/pnas.91.14.6274; UEKI K, 1994, J BIOL CHEM, V269, P15756; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; UNDROVINAS AI, 1992, CIRC RES, V71, P1231, DOI 10.1161/01.RES.71.5.1231; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZHANG H, 1990, J BIOL CHEM, V265, P21309	197	2344	2412	1	65	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1995	9	7					484	496		10.1096/fasebj.9.7.7737456	http://dx.doi.org/10.1096/fasebj.9.7.7737456			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737456				2022-12-28	WOS:A1995QX14800005
J	PILZ, RB; SUHASINI, M; IDRISS, S; MEINKOTH, JL; BOSS, GR				PILZ, RB; SUHASINI, M; IDRISS, S; MEINKOTH, JL; BOSS, GR			NITRIC-OXIDE AND CGMP ANALOGS ACTIVATE TRANSCRIPTION FROM AP-1-RESPONSIVE PROMOTERS IN MAMMALIAN-CELLS	FASEB JOURNAL			English	Article						GENE TRANSCRIPTION; CELL BIOLOGY; SIGNAL TRANSDUCTION PATHWAY; TRANSFECTED CELL LINES	C-JUN; PROTEIN-KINASE; FOS; GENE; SEQUENCES; CALCIUM	Nitric oxide (NO) increases cytosolic guanylate cyclase activity and thereby activates the cGMP signal transduction pathway, The cAMP and Ca2+-phospholipid signal transduction pathways activate transcription factors that bind to the cAMP response element (CRE) and phorbol ester response element (TRE), respectively, Little is known about transcriptional regulation of gene expression by NO/cGMP, In transient and stable transfection experiments and in microinjection studies we found that three different NO-releasing agents and two membrane-permeable cGMP analogs activated TRE-regulated but not CRE-regulated reporter genes in rodent fibroblast and epithelial cell lines, Activation of TRE regulated genes by NO-releasing agents and cGMP analogs appeared to be mediated by the AP-1 (Jun/Fos) transcription factor complex because we observed increased DNA binding of AP-1 and increased junB and c-fos mRNA in cells treated with these agents, The mechanism of gene activation by NO/cGMP was distinct from that used by phorbol esters and cAMP because it was not associated with c-jun mRNA induction and was not observed with CRE-containing promoters.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010	Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER; NCI NIH HHS [CA01538] Funding Source: Medline; NIDDK NIH HHS [DK45696] Funding Source: Medline; NIGMS NIH HHS [GM49360] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GARG UC, 1991, J BIOL CHEM, V266, P9; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HABY C, 1994, J NEUROCHEM, V62, P496; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOUSE C, 1987, J BIOL CHEM, V262, P772; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; MARGRINAT G, 1992, BLOOD, V88, P1880; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1992, J BIOL CHEM, V267, P16161; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Scholtholt J, 1985, CLIN PHARM ANTIANGIN, P365; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TAKASHIBA S, 1993, GENE, V131, P307, DOI 10.1016/0378-1119(93)90314-S	33	177	178	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1995	9	7					552	558		10.1096/fasebj.9.7.7737465	http://dx.doi.org/10.1096/fasebj.9.7.7737465			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737465				2022-12-28	WOS:A1995QX14800014
J	PATCHEV, VK; HAYASHI, S; ORIKASA, C; ALMEIDA, OFX				PATCHEV, VK; HAYASHI, S; ORIKASA, C; ALMEIDA, OFX			IMPLICATIONS OF ESTROGEN-DEPENDENT BRAIN ORGANIZATION FOR GENDER DIFFERENCES IN HYPOTHALAMO-PITUITARY-ADRENAL REGULATION	FASEB JOURNAL			English	Article						CORTICOTROPIN-RELEASING HORMONE; VASOPRESSIN; GLUCOCORTICOID RECEPTOR; CORTICOSTERONE	CORTICOTROPIN-RELEASING HORMONE; RECEPTOR MESSENGER-RNA; RAT-BRAIN; SEXUAL DIMORPHISM; INSITU HYBRIDIZATION; STRESS-RESPONSE; GENE-EXPRESSION; FEMALE RATS; VASOPRESSIN GENE; OXYTOCIN	Estrogens, derived from the aromatization of testosterone in the brain, account for sex-specific organization of neural circuits controlling gonadotropin release and sexual behavior. This study examines the possible organizing role of perinatal gonadal steroids in the manifestation of known, albeit unexplained, male-female differences in basal and stress-related adrenocortical secretion. We document here the existence of gender-specific differences in the gene expression of hypothalamic corticotropin-releasing hormone (CRH), and hippocampal and hypothalamic glucocorticoid receptors (GR), diurnal corticosterone secretion, as well as in the responsiveness of CRH and GR mRNA levels to exogenous estradiol, In addition, we report that neonatal estrogenization of female rats profoundly affects several regulatory substrates of the hypothalamo-pituitary-adrenal (HPA) axis, namely, the gene expression of CRH, arginine-vasopressin (AVP) and GR in the brain, and the responsiveness of these parameters to estrogen, The neonatal treatment appeared to ''defeminize'' a number of neuroendocrine mechanisms related to HPA function; these changes were reminiscent of those observed in earlier studies on sexual differentiation of reproductive behavior and hormonal secretion, The results indicate a pivotal role for estrogens during early development for the determination of gender-specific differences in HPA function in the mature animal and demonstrate for the first time that the brain-organizing actions of gonadal steroids may extend to nonreproductive neuroendocrine axes.	TOKYO METROPOLITAN INST NEUROSCI, DEPT ANAT & EMBRYOL, FUCHU, TOKYO 183, JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	PATCHEV, VK (corresponding author), MAX PLANCK INST PSYCHIAT, INST CLIN, DEPT NEUROENDOCRINOL, KRAEPELINSTR 2, D-80804 MUNICH, GERMANY.		Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				ADAN RAH, 1992, PROG BRAIN RES, V92, P127, DOI 10.1016/S0079-6123(08)61169-3; AHIMA RS, 1992, ENDOCRINOLOGY, V131, P1409, DOI 10.1210/en.131.3.1409; ALMEIDA OFX, 1993, CIBA F SYMP, V172, P151; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BINGAMAN EW, 1994, NEUROENDOCRINOLOGY, V59, P228, DOI 10.1159/000126663; BOHLER HCL, 1990, MOL BRAIN RES, V8, P259, DOI 10.1016/0169-328X(90)90025-9; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BURGESS LH, 1992, ENDOCRINOLOGY, V131, P1261, DOI 10.1210/en.131.3.1261; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; CROWLEY RS, 1993, ENDOCRINOLOGY, V133, P2711, DOI 10.1210/en.133.6.2711; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; DOrner G, 1976, HORMONES BRAIN DIFFE; GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0; GORSKI RA, 1963, AM J PHYSIOL, V205, P842, DOI 10.1152/ajplegacy.1963.205.5.842; GOY RW, 1978, SEXUAL DIFFERENTIATI; GREER ER, 1986, LIFE SCI, V38, P2311, DOI 10.1016/0024-3205(86)90638-7; HAAS DA, 1988, BRAIN RES BULL, V20, P361, DOI 10.1016/0361-9230(88)90065-2; HAYASHI S, 1991, NEUROSCI RES, V12, P366, DOI 10.1016/0168-0102(91)90004-I; HERBERT J, 1993, PROG NEUROBIOL, V41, P723, DOI 10.1016/0301-0082(93)90033-O; HOLSBOER F, 1992, PROG BRAIN RES, V93, P385; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JINGAMI H, 1985, FEBS LETT, V191, P63, DOI 10.1016/0014-5793(85)80994-7; KANT GJ, 1983, PSYCHONEUROENDOCRINO, V8, P421, DOI 10.1016/0306-4530(83)90021-5; KITAY JI, 1963, ENDOCRINOLOGY, V73, P253, DOI 10.1210/endo-73-2-253; LEHMAN MN, 1993, ENDOCRINOLOGY, V133, P876, DOI 10.1210/en.133.2.876; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; MCEWEN BS, 1991, J STEROID BIOCHEM, V39, P223, DOI 10.1016/0960-0760(91)90067-F; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER MA, 1989, PEPTIDES, V10, P615, DOI 10.1016/0196-9781(89)90152-6; PEIFFER A, 1991, ENDOCRINOLOGY, V129, P2166; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; RAINBOW TC, 1982, J NEUROSCI, V2, P1439; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SZOT P, 1993, DEV BRAIN RES, V73, P177, DOI 10.1016/0165-3806(93)90136-X; TURNER BB, 1985, BRAIN RES, V343, P16, DOI 10.1016/0006-8993(85)91153-9; VAMVAKOPOULOS NC, 1993, J CLIN INVEST, V92, P1896, DOI 10.1172/JCI116782; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; YOKOSUKA M, 1992, NEUROSCI RES, V15, P90, DOI 10.1016/0168-0102(92)90021-4	42	163	165	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					419	423		10.1096/fasebj.9.5.7896013	http://dx.doi.org/10.1096/fasebj.9.5.7896013			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896013				2022-12-28	WOS:A1995QP45100016
J	ROONEY, SA; YOUNG, SL; MENDELSON, CR				ROONEY, SA; YOUNG, SL; MENDELSON, CR			MOLECULAR AND CELLULAR PROCESSING OF LUNG SURFACTANT	FASEB JOURNAL			English	Review						PULMONARY SURFACTANT; PHOSPHATIDYLCHOLINE; GENE EXPRESSION; FETAL LUNG; LAMELLAR BODY; TYPE II PNEUMOCYTE; PHOSPHOLIPID BIOSYNTHESIS; PURINOCEPTOR	HUMAN-FETAL LUNG; PROTEIN SP-A; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; II EPITHELIAL-CELLS; B MESSENGER-RNA; PULMONARY SURFACTANT; RAT LUNG; FATTY-ACID; SP-C; RABBIT SURFACTANT	Pulmonary surfactant, a complex material that lines the alveolar surface of the lung, is synthesized in the type II pneumocyte. Surfactant consists largely of phospholipids, of which phosphatidylcholine is by far the most abundant component, and is mainly responsible for surface activity. Surfactant also contains four unique proteins, surfactant protein (SP)-A, SP-B, SP-C, and SP-D, which are synthesized in a lung-specific manner. SP-A and SP-D are glycoproteins (M(r) approximate to 30,000-40,000) whereas SP-B and SP-C are small (M(r) approximate to 5,000-18,000), extremely hydrophobic proteolipids released from large precursors by proteolysis. Synthesis of surfactant lipids and proteins is developmentally regulated in fetal lung and can be accelerated by glucocorticoids and other hormones. Developing fetal lung in vivo and in organ culture has been used extensively to study regulation of surfactant synthesis and gene expression. Glucocorticoids stimulate the fate of fetal lung phosphatidylcholine biosynthesis and the activity of the rate-regulatory enzyme, choline-phosphate cytidylyltransferase (CYT). The hormone, however, does not increase the amount of CYT; there is evidence that the increase in activity is mediated by increased fatty biosynthesis due to enhanced expression of the fatty acid synthase gene. Glucocorticoids also regulate expression of the SP-A, SP-B, and SP-C genes in the late gestation fetal lung. Hormone response elements and other cis-acting regulatory elements have been identified in the 5'-flanking regions of the SP-A, SP-B, and SP-C genes. Surfactant phospholipids are stored in lamellar bodies, secretory granules in the type II cell, and secreted by exocytosis. Lamellar bodies are also rich in SP-B and SP-C but there are conflicting data on the cellular distribution of SP-A. Secretion of SP-A may be constitutive and occur independently of lamellar bodies. Phosphatidylcholine secretion is a regulated process, and in isolated type II cells it can be stimulated by physiological and other agents that act via at least three signal-transduction mechanisms. After secretion, surfactant is transformed into tubular myelin, and the lipid and protein components are separated as the lipid is inserted into a monolayer at the air-liquid interface. The majority of surfactant is removed from the alveolar space by reuptake into the type II cell by mechanisms that may include receptor-mediated endocytosis. Some components of surfactant are directly recycled into new surfactant whereas other components are degraded.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; VET AFFAIRS MED CTR,DURHAM,NC 27710; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ROONEY, SA (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,DIV PERINATAL MED,POB 208064,NEW HAVEN,CT 06520, USA.			Mendelson, Carole Ruth/0000-0003-1696-9791	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043320, R01HL031175, P50HL046488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46488, HL-43320, HL-31175] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBRACCHIO MP, 1993, DRUG DEVELOP RES, V28, P207, DOI 10.1002/ddr.430280304; ACARREGUI MJ, 1990, ENDOCRINOLOGY, V127, P1105, DOI 10.1210/endo-127-3-1105; ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; ALCORN JL, 1993, AM J PHYSIOL, V264, pL27, DOI 10.1152/ajplung.1993.264.1.L27; BARITUSSIO A, 1992, AM J PHYSIOL, V263, pL607, DOI 10.1152/ajplung.1992.263.5.L607; BATENBURG JJ, 1992, FEBS LETT, V307, P164, DOI 10.1016/0014-5793(92)80759-A; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BOGGARAM V, 1992, AM J PHYSIOL, V263, pL634, DOI 10.1152/ajplung.1992.263.6.L634; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; BROWN LAS, 1990, AM J PHYSIOL, V258, pL301, DOI 10.1152/ajplung.1990.258.6.L301; BRUNS G, 1987, HUM GENET, V76, P58; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHANDER A, 1989, AM J PHYSIOL, V257, pL354, DOI 10.1152/ajplung.1989.257.6.L354; CHEN Q, 1992, AM J PHYSIOL, V262, pL662, DOI 10.1152/ajplung.1992.262.6.L662; CHEVALIER G, 1972, ANAT RECORD, V174, P289, DOI 10.1002/ar.1091740303; CHU AJ, 1985, BIOCHIM BIOPHYS ACTA, V834, P346, DOI 10.1016/0005-2760(85)90008-6; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; FISHER AB, 1991, AM J PHYSIOL, V261, pL334, DOI 10.1152/ajplung.1991.261.4.L334; FLOROS J, 1991, AM J RESP CELL MOL, V4, P449, DOI 10.1165/ajrcmb/4.5.449; FRASLON C, 1993, FEBS LETT, V325, P285, DOI 10.1016/0014-5793(93)81090-M; FROH D, 1993, AM J RESP CELL MOL, V8, P556, DOI 10.1165/ajrcmb/8.5.556; FROH D, 1990, BIOCHIM BIOPHYS ACTA, V1052, P78, DOI 10.1016/0167-4889(90)90060-Q; GAO E, 1993, J BIOL CHEM, V268, P19697; GLASSER SW, 1988, J BIOL CHEM, V263, P10326; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GOBRAN LI, 1994, IN PRESS AM J PHYSL; GONZALES LW, 1990, BIOCHIM BIOPHYS ACTA, V1042, P1, DOI 10.1016/0005-2760(90)90049-4; GONZALES LW, 1993, AM REV RESPIR DIS, V147, pA939; GRIESE M, 1991, AM J PHYSIOL, V260, pL586, DOI 10.1152/ajplung.1991.260.6.L586; GRIESE M, 1991, AM J PHYSIOL, V261, pL140, DOI 10.1152/ajplung.1991.261.2.L140; HALLMAN M, 1982, J CLIN INVEST, V70, P673, DOI 10.1172/JCI110662; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; IKEGAMI M, 1992, AM J PHYSIOL, V262, pL765, DOI 10.1152/ajplung.1992.262.6.L765; JOBE AH, 1993, NEW ENGL J MED, V328, P861; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6914; KORFHAGEN TR, 1991, AM J RESP CELL MOL, V4, P463, DOI 10.1165/ajrcmb/4.5.463; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; MALLAMPALLI RK, 1994, AM J RESP CELL MOL, V10, P48, DOI 10.1165/ajrcmb.10.1.8292380; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL367, DOI 10.1152/ajplung.1994.266.4.L367; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL354, DOI 10.1152/ajplung.1994.266.4.L354; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ODOM MJ, 1988, ENDOCRINOLOGY, V123, P1712; OGASAWARA Y, 1991, BIOCHIM BIOPHYS ACTA, V1083, P252, DOI 10.1016/0005-2760(91)90079-W; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; OREILLY MA, 1991, AM J PHYSIOL, V260, pLL7; PETTENAZZO A, 1989, AM REV RESPIR DIS, V139, P752, DOI 10.1164/ajrccm/139.3.752; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; RAMI J, 1994, IN PRESS AM J PHYSL; RICE WR, 1990, BIOCHEM J, V266, P407, DOI 10.1042/bj2660407; RICE WR, 1985, EXP LUNG RES, V9, P135, DOI 10.3109/01902148509061533; Rooney S A, 1992, FETAL NEONATAL PHYSL, P971; ROONEY SA, 1989, AM J PHYSIOL, V257, pL195, DOI 10.1152/ajplung.1989.257.4.L195; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROONEY SA, 1994, PROG R RES, V27, P84; ROONEY SA, 1993, AM J PHYSIOL, V265, pL586, DOI 10.1152/ajplung.1993.265.6.L586; ROONEY SA, 1993, AM J PHYSIOL, V264, pL133, DOI 10.1152/ajplung.1993.264.2.L133; ROONEY SA, 1992, COMP BIOL NORMAL LUN, P511; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SHARMA A, 1993, BIOCHIM BIOPHYS ACTA, V1170, P237, DOI 10.1016/0005-2760(93)90005-T; SHERMAN MP, 1992, ANNU REV PHYSIOL, V54, P331, DOI 10.1146/annurev.ph.54.030192.001555; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; SNYDER JM, 1987, BIOCHIM BIOPHYS ACTA, V920, P226, DOI 10.1016/0005-2760(87)90099-3; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VELETZA SV, 1992, AM J PHYSIOL, V262, pL684, DOI 10.1152/ajplung.1992.262.6.L684; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; VOYNOYASENETSKAYA TA, 1993, P NATL ACAD SCI USA, V90, P4256, DOI 10.1073/pnas.90.9.4256; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WHITSETT JA, 1985, EXP LUNG RES, V9, P191, DOI 10.3109/01902148509057523; WILLIAMS MC, 1984, P NATL ACAD SCI-BIOL, V81, P6383, DOI 10.1073/pnas.81.20.6383; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V6, P225, DOI 10.1165/ajrcmb/6.2.225; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Xu Z. X., 1993, Molecular Biology of the Cell, V4, p416A; XU ZX, 1993, AM J PHYSIOL, V265, pL140, DOI 10.1152/ajplung.1993.265.2.L140; XU ZX, 1990, BIOCHIM BIOPHYS ACTA, V1044, P70, DOI 10.1016/0005-2760(90)90220-R; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336; YOUNG SL, 1991, AM J PHYSIOL, V260, pL113, DOI 10.1152/ajplung.1991.260.2.L113; YOUNG SL, 1993, AM J PHYSIOL, V265, pL19, DOI 10.1152/ajplung.1993.265.1.L19; YOUNG SL, 1991, AM J PHYSIOL, V260, pL161, DOI 10.1152/ajplung.1991.260.2.L161	98	286	296	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1994	8	12					957	967		10.1096/fasebj.8.12.8088461	http://dx.doi.org/10.1096/fasebj.8.12.8088461			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088461				2022-12-28	WOS:A1994PG29300008
J	BRONNERFRASER, M				BRONNERFRASER, M			NEURAL CREST CELL-FORMATION AND MIGRATION IN THE DEVELOPING EMBRYO	FASEB JOURNAL			English	Review						DYE LABELING; CELL MOVEMENT; EXTRACELLULAR MATRIX; HINDBRAIN; LINEAGE	CHICK-EMBRYO; AVIAN EMBRYO; MOTOR AXONS; NERVOUS-SYSTEM; ROSTRAL HALF; FLOOR PLATE; HINDBRAIN; EXPRESSION; LAMININ; MORPHOGENESIS	Neural crest cells arise from the neural tube shortly after its closure and migrate extensively through prescribed regions of the embryos, where they differentiate into most of the peripheral nervous system as well as the facial skeleton and pigment cells. Along the embryonic axis, several distinct neural crest populations differ both in their migratory pathways and range of derivatives. Whereas those cells arising from the midbrain migrate as a uniform sheet of cells, neural crest cells emerging from the hindbrain and trunk regions migrate in a segmented manner. For example, trunk neural crest cells move preferentially through the rostral, but not caudal, half of each somite. Interactions with tissues encountered during migration strongly influence this segmental migratory pattern. For example, the mesodermal somites dictate the segmental migration of trunk neural crest cells and the otic placode appears to attract hindbrain neural crest cells. Although little is known about the molecular basis underlying migration, patterns of gene expression in the hindbrain are thought to contribute to the segmental arrangement of neural crest cells. Furthermore, neural crest cells possess integrin receptors that may be important for interacting with extracellular matrix molecules in their surroundings.			BRONNERFRASER, M (corresponding author), UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717, USA.			Bronner, Marianne/0000-0003-4274-1862	NICHD NIH HHS [HD-15527, HD-25138] Funding Source: Medline; NIDCR NIH HHS [DE10066] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025138, R01HD015527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010066] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKITAYA T, 1992, DEV DYNAM, V194, P12, DOI 10.1002/aja.1001940103; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; ARTINGER KB, 1993, NEURON, V11, P1147, DOI 10.1016/0896-6273(93)90227-I; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; BRONNERFRASER M, 1991, DEV BIOL, V143, P213, DOI 10.1016/0012-1606(91)90071-A; COULY G, 1990, DEVELOPMENT, V108, P543; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DUBAND JL, 1987, DEVELOPMENT, V101, P461; ERICKSON CA, 1993, DEV BIOL, V159, P60, DOI 10.1006/dbio.1993.1221; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GRAHAM A, 1993, DEVELOPMENT, V119, P233; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HENNING AK, 1991, J CELL BIOL, V115, pA731; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; JEFFREDO T, 1988, DEVELOPMENT, V103, P431; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KROTOSKI DM, 1986, J CELL BIOL, V103, P1061, DOI 10.1083/jcb.103.3.1061; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LALLIER T, 1991, DEVELOPMENT, V113, P1069; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; LAYER PG, 1988, DEVELOPMENT, V102, P387; Le Douarin N.M., 1982, NEURAL CREST; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARTINSGREEN M, 1987, DEVELOPMENT, V101, P517; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; NEWGREEN D, 1984, CELL TISSUE RES, V236, P265; NEWGREEN DF, 1986, CELL TISSUE RES, V244, P299; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; NORRIS WE, 1989, DEVELOPMENT, V105, P541; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; PERRIS R, 1991, DEVELOPMENT, V111, P583; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; PINTAR JE, 1978, DEV BIOL, V67, P444, DOI 10.1016/0012-1606(78)90211-7; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RICKMANN M, 1985, J EMBRYOL EXP MORPH, V90, P437; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; SCHOENWOLF GC, 1985, DEV BIOL, V109, P127, DOI 10.1016/0012-1606(85)90353-7; SCHOENWOLF GC, 1984, DEV BIOL, V105, P257, DOI 10.1016/0012-1606(84)90284-7; SCHRIST J, 1994, IN PRESS DEVELOPMENT; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SECHRIST J, 1994, IN PRESS DEVELOPMENT; SERBEDZIJA G, 1989, DEVELOPMENT, V106, P806; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SMITH G, 1989, FILM COMMENT, V25, P49; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STERN CD, 1989, DEVELOPMENT, V107, P309; STERN CD, 1991, DEVELOPMENT, V113, P207; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WESTON JA, 1963, DEV BIOL, V6, P279, DOI 10.1016/0012-1606(63)90016-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	60	156	162	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					699	706		10.1096/fasebj.8.10.8050668	http://dx.doi.org/10.1096/fasebj.8.10.8050668			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050668				2022-12-28	WOS:A1994NY35000006
J	FISHER, LJ; GAGE, FH				FISHER, LJ; GAGE, FH			INTRACEREBRAL TRANSPLANTATION - BASIC AND CLINICAL-APPLICATIONS TO THE NEOSTRIATUM	FASEB JOURNAL			English	Review						GRAFT; BRAIN; EXCITOTOXIC LESION; 6-HYDROXYDOPAMINE; DOPAMINE; GENETICALLY MODIFIED CELLS; NEURAL PRECURSORS	MESENCEPHALON SUSPENSION GRAFTS; ELECTRON-MICROSCOPIC ANALYSIS; INTRASTRIATAL NIGRAL GRAFTS; ACID-LESIONED STRIATUM; ADRENAL-MEDULLA GRAFTS; DOPAMINERGIC-NEURONS; RAT STRIATUM; HUNTINGTONS-CHOREA; MOTOR ASYMMETRY; HOST AFFERENTS	Many studies have used the intracerebral transplantation technique to study the neostriatum. Most of this work has been conducted in two well-characterized animal models of striatal dysfunction: the rat model of Huntington's disease (striatal damage) and the rat model of Parkinson's disease (damage of dopaminergic nigrostriatal afferents). In animals with striatal damage, fetal striatal tissue implanted into the neostriatum (homotypic transplants) displays a remarkable anatomical and functional incorporation into the host brain. These homotypic grafts also induce a wide range of behavioral improvements in experimental animals. In contrast, fetal substantia nigra neurons implanted into the dopamine-depleted neostriatum (heterotypic transplants) generally show a more restricted integration into the host brain and elicit fewer behavioral improvements. Nonetheless, the ability of grafted fetal neurons to survive, differentiate, and partially reconstruct an appropriate and functional neurocircuitry with host systems indicates that there are factors within the adult brain that promote neuronal development and regeneration. Such results have encouraged the clinical use of intracerebral grafts for the treatment of Parkinson's disease. Recent studies have emphasized the use of genetically modified cells and neural cell lines as alternative populations to study and repair the central nervous system.	UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NIA NIH HHS [AG08514, AG06088, AG10435] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010435, R37AG008514, R01AG008514, R01AG006088] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLSKOG JE, 1993, MAYO CLIN PROC, V68, P578, DOI 10.1016/S0025-6196(12)60373-5; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; CURRAN EJ, 1993, J NEUROSCI, V13, P3864; DECKEL AW, 1983, EUR J PHARMACOL, V93, P287; DOUCET G, 1989, EXP NEUROL, V106, P1, DOI 10.1016/0014-4886(89)90139-8; DOUCET G, 1990, EUR J NEUROSCI, V2, P279, DOI 10.1111/j.1460-9568.1990.tb00419.x; DUNNETT SB, 1988, NEUROSCIENCE, V24, P813, DOI 10.1016/0306-4522(88)90069-3; DUNNETT SB, 1987, BRAIN RES, V415, P63, DOI 10.1016/0006-8993(87)90269-1; FISHER LJ, 1990, PROG BRAIN RES, V82, P473; FISHER LJ, 1991, NEUROSCIENCE, V40, P109, DOI 10.1016/0306-4522(91)90178-Q; FISHERLJ, 1993, PHYSIOL REV, V73, P583; FREED WJ, 1990, EXP NEUROL, V110, P139, DOI 10.1016/0014-4886(90)90026-O; FREUND TF, 1985, J NEUROSCI, V5, P603; Gage F H, 1991, Curr Opin Neurobiol, V1, P414, DOI 10.1016/0959-4388(91)90063-D; GAGE FH, 1991, TRENDS NEUROSCI, V14, P328, DOI 10.1016/0166-2236(91)90156-O; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; HELM GA, 1990, NEUROSCIENCE, V37, P735, DOI 10.1016/0306-4522(90)90104-C; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; ISACSON O, 1984, NATURE, V311, P458, DOI 10.1038/311458a0; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; JAEGER CB, 1985, J COMP NEUROL, V231, P121, DOI 10.1002/cne.902310110; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; KEOWN J, 1993, J MED ETHICS, V19, P114, DOI 10.1136/jme.19.2.114; MAHALIK TJ, 1985, J COMP NEUROL, V240, P60, DOI 10.1002/cne.902400105; MANDEL RJ, 1990, EUR J NEUROSCI, V2, P888, DOI 10.1111/j.1460-9568.1990.tb00400.x; MAYER E, 1992, EUR J NEUROSCI, V4, P119, DOI 10.1111/j.1460-9568.1992.tb00858.x; MCALLISTER JP, 1985, DEV BRAIN RES, V23, P282, DOI 10.1016/0165-3806(85)90051-3; MCGEER EG, 1976, NATURE, V263, P517, DOI 10.1038/263517a0; MISGELD U, 1986, DEV BRAIN RES, V27, P59, DOI 10.1016/0165-3806(86)90232-4; NIKKAH G, 1993, IN PRESS BRAIN RES; NIKKHAH G, 1993, NEUROSCIENCE, V56, P33, DOI 10.1016/0306-4522(93)90559-X; PAKZEBAN P, 1993, IN PRESS EXP BRAIN R; PRITZEL M, 1986, EXP BRAIN RES, V65, P112; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Robbins T W, 1990, Rev Neurosci, V2, P181, DOI 10.1515/REVNEURO.1990.2.4.181; SCHMIDT RH, 1982, J NEUROCHEM, V38, P737, DOI 10.1111/j.1471-4159.1982.tb08693.x; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDERKELLER AM, 1989, NEUROSCIENCE, V30, P779, DOI 10.1016/0306-4522(89)90169-3; STRECKER RE, 1987, NEUROSCIENCE, V22, P169, DOI 10.1016/0306-4522(87)90207-7; SURMEIER DJ, 1992, NEUROSCIENCE, V48, P849, DOI 10.1016/0306-4522(92)90273-5; TAKASHIMA H, 1992, EXP NEUROL, V118, P24, DOI 10.1016/0014-4886(92)90019-M; TEPPER JM, 1993, PROG BRAIN RES, V99, P35; TEPPER JM, 1990, DEV BRAIN RES, V54, P21, DOI 10.1016/0165-3806(90)90061-3; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P69; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P49; UNGERSTEDT U, 1968, EUR J PHARMACOL, V5, P107, DOI 10.1016/0014-2999(68)90164-7; WICTORIN K, 1989, NEUROSCIENCE, V30, P297, DOI 10.1016/0306-4522(89)90255-8; WICTORIN K, 1989, NEUROSCIENCE, V30, P313, DOI 10.1016/0306-4522(89)90256-X; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; Wilson C. J., 1992, SINGLE NEURON COMPUT, P141, DOI [10.1016/B978-0-12-484815-3.50012-8, DOI 10.1016/B978-0-12-484815-3.50012-8]; WILSON CJ, 1990, SYNAPTIC ORG BRAIN, P279; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; XU ZC, 1991, J NEUROPHYSIOL, V65, P477, DOI 10.1152/jn.1991.65.3.477; XU ZC, 1991, J COMP NEUROL, V303, P22, DOI 10.1002/cne.903030104; XU ZC, 1989, NEUROSCIENCE, V29, P539, DOI 10.1016/0306-4522(89)90129-2; ZETTERSTROM T, 1986, BRAIN RES, V362, P344, DOI 10.1016/0006-8993(86)90460-9; ZHOU FC, 1989, NEUROSCIENCE, V30, P19, DOI 10.1016/0306-4522(89)90350-3	64	21	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1994	8	8					489	496		10.1096/fasebj.8.8.8181667	http://dx.doi.org/10.1096/fasebj.8.8.8181667			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181667				2022-12-28	WOS:A1994NM36400005
J	LOFT, S; ASTRUP, A; BUEMANN, B; POULSEN, HE				LOFT, S; ASTRUP, A; BUEMANN, B; POULSEN, HE			OXIDATIVE DNA-DAMAGE CORRELATES WITH OXYGEN-CONSUMPTION IN HUMANS	FASEB JOURNAL			English	Article						MITOCHONDRIAL RESPIRATION; 8-OXODG EXCRETION; SMOKING	COLI FPG PROTEIN; ENERGY-EXPENDITURE; 8-HYDROXYGUANINE; REPAIR; 8-HYDROXY-2'-DEOXYGUANOSINE; MITOCHONDRIAL; METABOLISM; NUCLEOTIDE; MUTATIONS; CODON-12	Generation of reactive oxygen species from mitochondrial respiration has been proposed as an important determinant of longevity and cumulative cancer risk. Interspecies correlations and animal calorie restriction studies of metabolic rate and oxidative DNA damage support this notion. In the present study we have demonstrated a close association between oxidative DNA damage as assessed by the urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and oxygen consumption in 33 healthy premenopausal women (r = 0.64; p = 0.00007). In the 12 women who smoked, 8-oxodG excretion was increased by 35%, although oxygen consumption increased only 10% compared with the 21 nonsmoking women. Apparently, the rate of oxidative DNA damage relates to mitochondrial respiration in humans and is aggravated by smoking.	ROYAL VET & AGR UNIV, HUMAN NUTR RES DEPT, DK-1870 FREDERIKSBERG, DENMARK	University of Copenhagen	LOFT, S (corresponding author), UNIV COPENHAGEN, PANUM INST, DEPT PHARMACOL, ROOM 18-5-32, BLEGDAMSVEJ 3, DK-2200 COPENHAGEN N, DENMARK.		Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996; Poulsen, Henrik Enghusen/0000-0003-4242-9924; Buemann, Benjamin/0000-0002-8657-419X; Loft, Steffen/0000-0001-9552-8518				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ASTRUP A, 1992, J CLIN ENDOCR METAB, V74, P279, DOI 10.1210/jc.74.2.279; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DORGAN JF, 1991, HEMATOL ONCOL CLIN N, V5, P43, DOI 10.1016/S0889-8588(18)30453-2; ELSE PL, 1985, AM J PHYSIOL, V248, pR415, DOI 10.1152/ajpregu.1985.248.4.R415; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GVOZDJAKOVA A, 1992, CARDIOLOGY, V81, P81, DOI 10.1159/000175780; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4747; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMIYA H, 1992, CANCER RES, V52, P3483; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KLEIN JC, 1992, NUCLEIC ACIDS RES, V20, P4437, DOI 10.1093/nar/20.17.4437; LEANDERSON P, 1992, CHEM-BIOL INTERACT, V81, P197, DOI 10.1016/0009-2797(92)90034-I; MALINS DC, 1991, CANCER RES, V51, P5430; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SIMIC MG, 1991, MUTAT RES, V250, P17, DOI 10.1016/0027-5107(91)90158-K; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; VAUGHAN L, 1991, AM J CLIN NUTR, V53, P821, DOI 10.1093/ajcn/53.4.821; VISTISEN K, 1992, CARCINOGENESIS, V13, P1561, DOI 10.1093/carcin/13.9.1561; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	31	156	156	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1994	8	8					534	537		10.1096/fasebj.8.8.8181672	http://dx.doi.org/10.1096/fasebj.8.8.8181672			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181672				2022-12-28	WOS:A1994NM36400011
J	STAMATOGLOU, SC; HUGHES, RC				STAMATOGLOU, SC; HUGHES, RC			CELL-ADHESION MOLECULES IN LIVER-FUNCTION AND PATTERN-FORMATION	FASEB JOURNAL			English	Review						HEPATIC BIOMATRIX; FIBRONECTIN; MATRIX SYNTHESIS; ADHESION RECEPTOR; CELL POLARITY	PLASMA-MEMBRANE DOMAINS; REGENERATING RAT-LIVER; SMOOTH-MUSCLE CELLS; PRIMARY CULTURE; PARTIAL-HEPATECTOMY; SUBSTRATE ADHESION; HEPATOCELLULAR CARCINOMAS; INTEGRIN ALPHA-5-BETA-1; FIBRONECTIN RECEPTORS; EXTRACELLULAR-MATRIX	In epithelia, adhesive interactions participate in specific histogenetic events and also instate a morphological polarization that is linked to the vectorial functioning of the epithelium. Cell polarity is a recurring event in differentiation, first observed in the preimplantation embryo and then during organogenesis, whereas in oncogenesis a breakdown of polarity may occur. We review here recent work on adhesive interactions in the liver parenchyma. We focus on the effect of cell-biomatrix interactions on hepatocyte function and polarization, on the integration of adhesive cell-cell and cell-matrix interactions, and on the correlation between structural differentiation and adhesion during hepatic development, regeneration, and oncogenesis. Although highlighting morphological differences between the liver and other epithelia, we stress that adhesion-mediated effects such as substratum regulation of differentiation, feedback control of matrix synthesis, and integration of intercellular and cell-matrix interactions, shown to transpire in the liver, most probably occur in other parenchymal tissues too.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research								ADAMSON ED, 1990, DEV BIOL, V138, P338, DOI 10.1016/0012-1606(90)90201-S; BAKER J, 1993, J CELL SCI, V104, P415; BARTLES JR, 1986, DEV BIOL, V118, P286, DOI 10.1016/0012-1606(86)90095-3; BEMENT WM, 1993, J CELL BIOL, V121, P565, DOI 10.1083/jcb.121.3.565; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BISSELL DM, 1986, EUR J CELL BIOL, V40, P72; BISSELL DM, 1984, HEPATOLOGY, V4, P1079; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; EDLUND M, 1993, EUR J BIOCHEM, V213, P1109, DOI 10.1111/j.1432-1033.1993.tb17860.x; ENRICH C, 1988, FEBS LETT, V228, P135, DOI 10.1016/0014-5793(88)80602-1; ETTENSOHN CA, 1985, Q REV BIOL, V60, P289, DOI 10.1086/414426; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FORSBERG E, 1990, J BIOL CHEM, V265, P6376; FRASLIN JM, 1985, EMBO J, V4, P2487, DOI 10.1002/j.1460-2075.1985.tb03960.x; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HIXSON DC, 1985, CANCER RES, V45, P3742; HOLDERBAUM D, 1986, J CELL PHYSIOL, V126, P216, DOI 10.1002/jcp.1041260210; HUGHES RC, 1987, J CELL SCI, P273; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JEFFERSON DM, 1984, MOL CELL BIOL, V4, P1929, DOI 10.1128/MCB.4.9.1929; JOHANSSON S, 1981, J CELL BIOL, V90, P260, DOI 10.1083/jcb.90.1.260; JOHANSSON S, 1984, J CELL BIOL, V98, P810, DOI 10.1083/jcb.98.3.810; JOHANSSON S, 1987, J BIOL CHEM, V262, P7819; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; MARTINEZPALOMO A, 1970, LAB INVEST, V22, P605; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAKAMURA T, 1983, P NATL ACAD SCI-BIOL, V80, P7229, DOI 10.1073/pnas.80.23.7229; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; ODENTHAL M, 1992, EXP CELL RES, V203, P289, DOI 10.1016/0014-4827(92)90001-O; ODIN P, 1988, EXP CELL RES, V179, P89, DOI 10.1016/0014-4827(88)90351-5; OGAWA K, 1979, BRIT J CANCER, V40, P782, DOI 10.1038/bjc.1979.261; OYAMA F, 1989, J BIOL CHEM, V264, P10331; PUJADES C, 1992, J CELL SCI, V102, P815; RABES HM, 1976, CELL TISSUE KINET, V9, P517; Rappaport A M, 1980, Int Rev Physiol, V21, P1; RESCAN PY, 1993, AM J PATHOL, V142, P199; ROJKIND M, 1980, J CELL BIOL, V87, P255, DOI 10.1083/jcb.87.1.255; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SELL S, 1982, J NATL CANCER I, V69, P1105; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STAMATOGLOU SC, 1987, J CELL BIOL, V105, P2417, DOI 10.1083/jcb.105.5.2417; STAMATOGLOU SC, 1990, J CELL BIOL, V111, P2117, DOI 10.1083/jcb.111.5.2117; STAMATOGLOU SC, 1990, J CELL SCI, V97, P595; STAMATOGLOU SC, 1992, J CELL BIOL, V116, P1507, DOI 10.1083/jcb.116.6.1507; STAMATOGLOU SC, 1991, FEBS LETT, V288, P241, DOI 10.1016/0014-5793(91)81044-9; STAMATOGLOU SC, 1992, EXP CELL RES, V198, P179, DOI 10.1016/0014-4827(92)90166-6; STAMM E, 1991, J ULTRAS MED, V10, P599; STREULI CH, 1990, J CELL BIOL, V110, P1405; SUDHAKARAN PR, 1986, EXP CELL RES, V167, P505, DOI 10.1016/0014-4827(86)90190-4; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TIMPL R, 1983, J BIOL CHEM, V258, P8922; TRAUB O, 1983, P NATL ACAD SCI-BIOL, V80, P755, DOI 10.1073/pnas.80.3.755; VOLPES R, 1993, AM J PATHOL, V142, P1483; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; WILLIAMS GM, 1980, BIOCHIM BIOPHYS ACTA, V605, P167, DOI 10.1016/0304-419X(80)90003-7; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; YEE AG, 1978, J CELL BIOL, V78, P554, DOI 10.1083/jcb.78.2.554	67	95	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					420	427		10.1096/fasebj.8.6.8168692	http://dx.doi.org/10.1096/fasebj.8.6.8168692			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168692				2022-12-28	WOS:A1994NH25000009
J	VARNER, JE; YE, ZH				VARNER, JE; YE, ZH			TISSUE PRINTING	FASEB JOURNAL			English	Review						TISSUE PRINTING; SUBSTRATE FILM PRINTING; TISSUE-SPECIFIC GENE EXPRESSION; IMMUNOCYTOCHEMISTRY	CELL-WALL PROTEINS; HISTOCHEMICAL-LOCALIZATION; NITROCELLULOSE; EXPRESSION; IMMUNOCYTOLOCALIZATION; COTYLEDONS; PLANTS; GENE; LEAF; HYBRIDIZATION	An image of the tissue distribution of specific mRNAs, proteins, enzymes, or antigens is conveniently obtained by ''printing'' the cut surface of a tissue section onto a suitable substrate film and developing the film with appropriate reagents. It is also possible to localize metabolites by tissue printing. Most plant tissues leave a physical print/impression with detailed anatomical information. Epidermal surfaces of growing organs can be printed without damaging the organ. We provide this review to encourage further use and further development of these convenient and helpful procedures.			VARNER, JE (corresponding author), WASHINGTON UNIV,DEPT BIOL,CAMPUS BOX 1137,1 BROOKINGS DR,ST LOUIS,MO 63130, USA.							ADAMS CW, 1961, J HISTOCHEM CYTOCHEM, V9, P469, DOI 10.1177/9.5.469; BAILEY BA, 1991, PLANT PHYSIOL, V97, P1181, DOI 10.1104/pp.97.3.1181; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; BEALS HL, 1957, AM BIOL TEACH, V19, P83; BICKAR D, 1992, ANAL BIOCHEM, V203, P109, DOI 10.1016/0003-2697(92)90049-D; BRONCHUD H, 1988, J HISTOCHEM CYTOCHEM, V36, P1191; CASSAB GI, 1987, J CELL BIOL, V105, P2581, DOI 10.1083/jcb.105.6.2581; CASSAB GI, 1988, PLANT PHYSIOL, V88, P522, DOI 10.1104/pp.88.3.522; DAOUST R, 1957, EXP CELL RES, V12, P203, DOI 10.1016/0014-4827(57)90134-9; DAOUST R., 1965, INT REV CYTOL, V18, P191, DOI 10.1016/S0074-7696(08)60554-9; DAOUST R, 1966, J HISTOCHEM CYTOCHEM, V14, P254, DOI 10.1177/14.3.254; DAOUST R, 1964, J HISTOCHEM CYTOCHEM, V12, P429, DOI 10.1177/12.6.429; DELCAMPILLO E, 1990, PLANT CELL, V2, P245, DOI 10.1105/tpc.2.3.245; DRIOUICH A, 1992, PLANT J, V2, P13, DOI 10.1111/j.1365-313X.1992.00013.x; EISNER T, 1987, J CHEM ECOL, V13, P943, DOI 10.1007/BF01020173; GADDUM P, 1970, SCIENCE, V170, P749, DOI 10.1126/science.170.3959.749; HARRIS N, 1975, PLANT PHYSIOL, V56, P292, DOI 10.1104/pp.56.2.292; HARRISON NA, 1988, PHYTOPATHOLOGY, V78, P722, DOI 10.1094/Phyto-78-722; HOLT CA, 1991, VIROLOGY, V181, P109, DOI 10.1016/0042-6822(91)90475-Q; HOOD KR, 1991, PLANT PHYSIOL, V96, P1214, DOI 10.1104/pp.96.4.1214; HOWLETT BJ, 1973, J CELL SCI, V13, P603; JACOBSEN JV, 1973, PLANTA, V112, P213, DOI 10.1007/BF00385325; JOY K. W., 1956, ANN BOT, V20, P635; JUNG JL, 1992, PLANT SCI, V82, P125, DOI 10.1016/0168-9452(92)90015-E; KAWAAN HC, 1967, LAB INVEST, V17, P140; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KELLER B, 1988, EMBO J, V7, P3625, DOI 10.1002/j.1460-2075.1988.tb03243.x; LIN NS, 1990, PHYTOPATHOLOGY, V80, P824, DOI 10.1094/Phyto-80-824; LIPKIN WI, 1989, CURR TOP MICROBIOL, V143, P33; Mansky L. M., 1990, Plant Molecular Biology Reporter, V8, P13, DOI 10.1007/BF02668876; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; MCCLURE BA, 1989, PLANT MOL BIOL, V12, P517, DOI 10.1007/BF00036966; MOORE BM, 1989, HISTOCHEMISTRY, V90, P379, DOI 10.1007/BF00508316; NOLAN MC, 1984, AM J BOT, V71, P137, DOI 10.2307/2443633; Pearse AGE, 1980, HISTOCHEMISTRY THEOR, P253; PEREIRA S, 1992, PROTOPLASMA, V167, P66, DOI 10.1007/BF01353582; POLSTON JE, 1991, ANAL BIOCHEM, V196, P267, DOI 10.1016/0003-2697(91)90464-5; PONTLEZICA RF, 1989, ANAL BIOCHEM, V182, P334, DOI 10.1016/0003-2697(89)90604-0; PONTLEZICA RF, 1991, J PLANT PHYSIOL, V137, P453, DOI 10.1016/S0176-1617(11)80316-0; REID PD, 1990, PLANT PHYSIOL, V93, P160, DOI 10.1104/pp.93.1.160; REID PD, 1992, TISSUE PRINTING TOOL; REINE BA, 1993, 51ST P ANN M MICR SO; RYSER U, 1992, PLANT CELL, V4, P773, DOI 10.1105/tpc.4.7.773; SAMPSON J, 1961, NATURE, V191, P932, DOI 10.1038/191932a0; SHEPHERD GMG, 1989, P NATL ACAD SCI USA, V86, P4973, DOI 10.1073/pnas.86.13.4973; SPRUCE J, 1987, PHYTOCHEMISTRY, V26, P2901, DOI 10.1016/S0031-9422(00)84559-8; TIEMAN DM, 1989, PLANT PHYSIOL, V90, P17, DOI 10.1104/pp.90.1.17; TIWARI SC, 1991, CAN J BOT, V69, P2302, DOI 10.1139/b91-291; VARNER JE, 1989, PLANT PHYSIOL, V91, P31, DOI 10.1104/pp.91.1.31; Varner JE, 1989, MOL BASIS PLANT DEV, P161; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879; YE ZH, 1991, PLANT J, V1, P175, DOI 10.1111/j.1365-313X.1991.00175.x; YE ZH, 1991, PLANT CELL, V3, P23, DOI 10.1105/tpc.3.1.23; YOMO H, 1973, PLANTA, V112, P35, DOI 10.1007/BF00386029	54	38	39	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					378	384		10.1096/fasebj.8.6.8168688	http://dx.doi.org/10.1096/fasebj.8.6.8168688			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168688				2022-12-28	WOS:A1994NH25000003
J	RUBBA, P; FACCENDA, F				RUBBA, P; FACCENDA, F			NONINVASIVE ULTRASOUND TECHNIQUES VERSUS ANGIOGRAPHY FOR MONITORING DRUG-INDUCED CHANGES OF THE ARTERIAL-WALLS	FASEB JOURNAL			English	Review						ATHEROSCLEROSIS; CHOLESTEROL; CORONARY ANGIOGRAPHY; ECHO-DOPPLER; B-MODE ULTRASOUND IMAGING	B-MODE ULTRASOUND; CORONARY HEART-DISEASE; LIPID-LOWERING THERAPY; COMMON CAROTID-ARTERY; FEMORAL ATHEROSCLEROSIS; INTRAVASCULAR ULTRASOUND; CLINICAL-TRIALS; FAMILIAL HYPERCHOLESTEROLEMIA; II HYPERLIPOPROTEINEMIA; MEASUREMENT VARIABILITY	Even though angiographic studies contribute to understanding the process of atherosclerosis progression/regression in humans, they have several important limitations. The number of participants in all the studies is small and those who accept the invasive vascular investigation are highly selected patients, in most instances in an advanced stage of cardiovascular disease. Furthermore, arteriography provides the image of the vessel lumen but no information on the vessel wall. Noninvasive methods can describe the characteristics of the arteries with regard to morphology (intima-media thickness, surface irregularities, areas of calcification) and the hemodynamic correlates of vascular lesions. No single methodology describes all aspects of the disease process. However, B-mode ultrasound imaging gives information on the vessel wall, whereas Doppler mainly describes the hemodynamic consequences of arterial disease. Before any noninvasive methodology can be adopted for a clinical trial, extensive validation data (preferably using pathology rather than angiography as a ''gold standard''), and accurate information on reproducibility and on inter-, intraobserver variability, should be available. Also, quantitative details on the natural history of the disease and on the potential of intervention, as evaluated by the specific methodology to be used, should be known.			RUBBA, P (corresponding author), UNIV FEDERICO II,SCH MED,INST INTERNAL MED & DIS METAB,VIA SERGIO PANSINI 5,I-80131 NAPLES,ITALY.							[Anonymous], 1991, J Neuroimaging, V1, P68; [Anonymous], 1989, AM J EPIDEMIOL, V129, P687; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BARTORELLI AL, 1992, EUR HEART J, V13, P102, DOI 10.1093/oxfordjournals.eurheartj.a060028; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P323; BOND MG, 1989, AM J MED, V86, P33; BOND MG, 1990, J CARDIOVASC PHAR S1, V13, pS30; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; COLLIER P, 1990, AM J SURG, V160, P171, DOI 10.1016/S0002-9610(05)80300-9; COMEROTA AJ, 1985, NONINVASIVE DIAGNOST, P384; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1986, STROKE, V17, P270, DOI 10.1161/01.STR.17.2.270; CROUSE JR, 1992, CONTROL CLIN TRIALS, V13, P495, DOI 10.1016/0197-2456(92)90206-F; DEFEYTER PJ, 1991, CIRCULATION, V84, P412, DOI 10.1161/01.CIR.84.1.412; DEFEYTER PJ, 1990, CURR OPIN LIPIDOL, V1, P346; DUFFIELD RGM, 1983, LANCET, V2, P639; FACCENDA F, 1989, ARTERY, V16, P189; FELL G, 1981, CIRCULATION, V64, P1191, DOI 10.1161/01.CIR.64.6.1191; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1989, AM J MED, V86, P37, DOI 10.1016/0002-9343(89)90188-5; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1986, ATHEROSCLEROSIS, V7, P95; Jager KA, 1985, NONINVASIVE DIAGNOST, P619; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KOHLER TR, 1987, CIRCULATION, V76, P1074, DOI 10.1161/01.CIR.76.5.1074; KOY KM, 1991, J AM COLL CARDIOL, V18, P1811; KUO PT, 1979, CIRCULATION, V59, P199, DOI 10.1161/01.CIR.59.2.199; LANGLOIS Y, 1983, ULTRASOUND MED BIOL, V9, P51, DOI 10.1016/0301-5629(83)90109-6; LIEBSON PR, 1992, AM HEART J, V123, P1643, DOI 10.1016/0002-8703(92)90819-H; MARGITIC SE, 1991, ARTERIOSCLER THROMB, V11, P443, DOI 10.1161/01.ATV.11.2.443; MERCURI M, 1992, DALM 11 FLORENCE, P40; MERCURI M, 1991, CIRCULATION S2, V84, P541; NASH DT, 1982, INT J CARDIOL, V2, P43, DOI 10.1016/0167-5273(82)90008-0; NICHOLLS SC, 1988, STROKE, V20, P175; NIKKILA EA, 1984, BMJ-BRIT MED J, V289, P220, DOI 10.1136/bmj.289.6439.220; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; OLEARY DH, 1987, STROKE, V18, P1011, DOI 10.1161/01.STR.18.6.1011; OLSSON AG, 1990, J INTERN MED, V227, P381, DOI 10.1111/j.1365-2796.1990.tb00176.x; OLSSON AG, 1991, CIRCULATION, V83, P698, DOI 10.1161/01.CIR.83.2.698; PHILLIPS DJ, 1983, ULTRASOUND MED BIOL, V9, P39, DOI 10.1016/0301-5629(83)90108-4; PHILLIPS DJ, 1985, NONINVASIVE DIAGNOST, P397; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLAK JF, 1989, RADIOLOGY, V173, P793, DOI 10.1148/radiology.173.3.2682776; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; RABBANI LE, 1991, CURR OPIN LIPIDOL, V2, P259; RICOTTA JJ, 1987, J VASC SURG, V6, P512, DOI 10.1067/mva.1987.avs0060512; RILEY WA, 1992, STROKE, V23, P1062, DOI 10.1161/01.STR.23.8.1062; RILEY WA, 1991, J NEUROIMAGING, V1, P168; ROEDERER GO, 1985, NONINVASIVE DIAGNOST, P465; ROSENFIELD K, 1989, AM J CARDIOL, V64, P247, DOI 10.1016/0002-9149(89)90472-4; RUBBA P, 1984, ARTERIOSCLEROSIS, V4, P625, DOI 10.1161/01.ATV.4.6.625; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SHEIKH KH, 1991, AM J CARDIOL, V67, P817, DOI 10.1016/0002-9149(91)90613-P; STRANDNESS DE, 1983, ARTERIOSCLEROSIS, V3, P103, DOI 10.1161/01.ATV.3.2.103; SUTTONTYRRELL K, 1992, STROKE, V23, P215, DOI 10.1161/01.STR.23.2.215; TABBARA M, 1991, J VASC SURG, V14, P496, DOI 10.1016/0741-5214(91)90243-N; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WENDELHAG I, 1992, ARTERIOSCLER THROMB, V12, P70, DOI 10.1161/01.ATV.12.1.70; WIKSTRAND J, 1992, ARTERIOSCLER THROMB, V12, P114, DOI 10.1161/01.ATV.12.1.114; ZARINS CK, 1988, J VASC SURG, V7, P386, DOI 10.1067/mva.1988.avs0070386; ZWIEBEL WJ, 1986, INTRO VASCULAR ULTRA, P139; 1984, JAMA-J AM MED ASSOC, V251, P365	68	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1491	1498		10.1096/fasebj.7.15.8262334	http://dx.doi.org/10.1096/fasebj.7.15.8262334			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262334				2022-12-28	WOS:A1993ML74000012
J	GURIANSHERMAN, D; LINDOW, SE				GURIANSHERMAN, D; LINDOW, SE			BACTERIAL ICE NUCLEATION - SIGNIFICANCE AND MOLECULAR-BASIS	FASEB JOURNAL			English	Review						ICE NUCLEATION PROTEIN; BACTERIAL ICE NUCLEI; AMINO ACID RESIDUES; WARM-TEMPERATURE NUCLEATION ACTIVITY	SYRINGAE PV-PHASEOLICOLA; PSEUDOMONAS-SYRINGAE; ACTIVE BACTERIA; FROST INJURY; ERWINIA-HERBICOLA; PLANTS; GENE; NUCLEI; PROTEIN; IDENTIFICATION	Several bacterial species are able to catalyze ice formation at temperatures as warm as -2-degrees-C. These microorganisms efficiently catalyze ice formation at temperatures much higher than most organic or inorganic substances. Because of their ubiquity on the surfaces of frost-sensitive plants, they are responsible for initiating ice formation, which results in frost injury. The high temperature of ice catalysis conferred by bacterial ice nuclei makes them useful in ice nucleation-limited processes such as artificial snow production, the freezing of some food products, and possibly in future weather modification schemes. The rarity of other ice nuclei active at high subfreezing temperature, and the ease and sensitivity with which ice nuclei can be quantified, have made the use of a promoterless bacterial ice nucleation gene valuable as a reporter of transcription. Target genes to which this promoter is fused can be used in cells in natural habitats. Warm-temperature ice nucleation sites have also been extensively studied at a molecular level. Nucleation sites active at high temperatures (above -5-degrees-C) are probably composed of bacterial ice nucleation protein molecules that form functionally aligned aggregates. Models of ice nucleation proteins predict that they form a planar array of hydrogen binding groups that closely complement that of an ice crystal face. Moreover, interdigitation of these molecules may produce a large contiguous template for ice formation.	UNIV CALIF BERKELEY,DEPT PLANT PATHOL,147 HILGARD HALL,BERKELEY,CA 94729	University of California System; University of California Berkeley								ABE K, 1989, FEBS LETT, V258, P297, DOI 10.1016/0014-5793(89)81678-3; ANDERSEN GL, 1991, PHYTOPATHOLOGY, V81, P648, DOI 10.1094/Phyto-81-648; ARAI S, 1986, AGR BIOL CHEM TOKYO, V50, P169, DOI 10.1080/00021369.1986.10867345; BAERTLEIN DA, 1992, PLANT PHYSIOL, V100, P1730, DOI 10.1104/pp.100.4.1730; BURKE MJ, 1976, ANNU REV PLANT PHYS, V27, P507, DOI 10.1146/annurev.pp.27.060176.002451; BURKE MJ, 1990, CRYOBIOLOGY, V27, P80, DOI 10.1016/0011-2240(90)90054-8; BURLAGE RS, 1990, J BACTERIOL, V172, P4749, DOI 10.1128/jb.172.9.4749-4757.1990; CARY JW, 1970, AGRON J, V62, P715, DOI 10.2134/agronj1970.00021962006200060009x; CONSTANTINIDOU HA, 1990, PHYTOPATHOLOGY, V80, P934, DOI 10.1094/Phyto-80-934; GOVINDARAJAN AG, 1988, P NATL ACAD SCI USA, V85, P1334, DOI 10.1073/pnas.85.5.1334; GOVINDARAJAN AG, 1988, J BIOL CHEM, V263, P9333; GREEN RL, 1988, MOL GEN GENET, V215, P165, DOI 10.1007/BF00331320; GREEN RL, 1985, NATURE, V317, P645, DOI 10.1038/317645a0; GROSS DC, 1983, APPL ENVIRON MICROB, V46, P1370, DOI 10.1128/AEM.46.6.1370-1379.1983; GURIAN-SHERMAN D, 1992, Current Opinion in Biotechnology, V3, P303, DOI 10.1016/0958-1669(92)90109-V; GURIANSHERMAN D, 1993, MOL MICROBIOL, V9, P383, DOI 10.1111/j.1365-2958.1993.tb01699.x; HIRANO SS, 1983, ANNU REV PHYTOPATHOL, V21, P243, DOI 10.1146/annurev.py.21.090183.001331; HIRANO SS, 1978, 4TH P INT C PLANT PA, V2, P717; HIRANO SS, 1986, MICROBIOLOGY PHYLLOS, P235; KAJAVA AV, 1993, IN PRESS J MOL BIOL; KOZLOFF LM, 1991, J BACTERIOL, V173, P2053, DOI 10.1128/jb.173.6.2053-2060.1991; LEVIN Z, 1987, J CLIM APPL METEOROL, V26, P1188, DOI 10.1175/1520-0450(1987)026<1188:PAOBCF>2.0.CO;2; LEVITT J, 1972, RESPONSES PLANTS ENV, P306; LIM HK, 1987, PLANT DIS, V71, P994; LINDGREN PB, 1989, EMBO J, V8, P1291, DOI 10.1002/j.1460-2075.1989.tb03508.x; Lindow S. E., 1978, Plant cold hardiness and freezing stress. Mechanisms and crop implications. [Li, P.H.; Sakai, A. (Editors)]., P249; Lindow S.E., 1985, BIOL CONTROL PHYLLOP, P83; Lindow S.E, 1990, METHODS PHYTOBACTERI, P428; LINDOW SE, 1984, J AM SOC HORTIC SCI, V109, P48; LINDOW SE, 1983, PLANT DIS, V67, P327, DOI 10.1094/PD-67-327; LINDOW SE, 1982, PLANT PHYSIOL, V70, P1084, DOI 10.1104/pp.70.4.1084; LINDOW SE, 1989, MOL PLANT MICROBE IN, V2, P262, DOI 10.1094/MPMI-2-262; LINDOW SE, 1983, ANNU REV PHYTOPATHOL, V21, P363, DOI 10.1146/annurev.py.21.090183.002051; LINDOW SE, 1978, PHYTOPATHOLOGY, V68, P523, DOI 10.1094/Phyto-68-523; LINDOW SE, 1983, PHYTOPATHOLOGY, V73, P1102, DOI 10.1094/Phyto-73-1102; LINDOW SE, 1983, PHYTOPATHOLOGY, V73, P809; LINDOW SE, 1978, APPL ENVIRON MICROB, V36, P831, DOI 10.1128/AEM.36.6.831-838.1978; LINDOW SE, 1987, APPL ENVIRON MICROB, V53, P2520, DOI 10.1128/AEM.53.10.2520-2527.1987; LINDOW SE, 1982, PLANT COLD HARDINESS, P395; LINDOW SE, 1985, MICROBIOLOGY PHYLLOS, P293; Loper J. E., 1991, Bulletin SROP, V14, P177; MAKI LR, 1978, J APPL METEOROL, V17, P1049, DOI 10.1175/1520-0450(1978)017<1049:BABSOF>2.0.CO;2; MAKI LR, 1974, APPL MICROBIOL, V28, P456, DOI 10.1128/AEM.28.3.456-459.1974; MARGARITIS A, 1991, CRIT REV BIOTECHNOL, V11, P277, DOI 10.3109/07388559109069185; MASON BJ, 1958, Q J ROY METEOR SOC, V84, P235, DOI 10.1002/qj.49708436104; MASON BJ, 1960, Q J R METEREOL SOC, V84, P553; MASON BJ, 1957, NATURE, V197, P357; MIZUNO H, 1989, PROTEINS, V5, P47, DOI 10.1002/prot.340050107; MUELLER GM, 1990, CRYOBIOLOGY, V27, P416, DOI 10.1016/0011-2240(90)90018-Y; PAULIN JP, 1978, 4TH P INT C PLANT PA, V2, P725; PHELPS P, 1986, J BACTERIOL, V167, P496, DOI 10.1128/jb.167.2.496-502.1986; POWER BA, 1962, NATURE, V194, P1170, DOI 10.1038/1941170a0; RAHME LG, 1991, J BACTERIOL, V173, P575, DOI 10.1128/jb.173.2.575-586.1991; RAJASHEKAR CB, 1983, PLANT PHYSIOL, V71, P749, DOI 10.1104/pp.71.4.749; ROGERS JS, 1987, CRYOBIOLOGY, V24, P270, DOI 10.1016/0011-2240(87)90030-7; ROSINSKI J, 1966, J APPL METEOR, V5, P119; SCHNELL RC, 1972, NATURE, V236, P163, DOI 10.1038/236163a0; SCHNELL RC, 1973, NATURE, V246, P212, DOI 10.1038/246212a0; SCHNELL RC, 1976, J ATMOS SCI, V33, P1554, DOI 10.1175/1520-0469(1976)033<1554:BINPIT>2.0.CO;2; SULE S, 1987, PHYTOPATHOLOGY, V77, P173, DOI 10.1094/Phyto-77-173; Sussman M., 1988, RELEASE GENETICALLY, P121; TURNER MA, 1991, J BACTERIOL, V173, P6515, DOI 10.1128/jb.173.20.6515-6527.1991; TURNER MA, 1990, J BACTERIOL, V172, P2521, DOI 10.1128/jb.172.5.2521-2526.1990; WARREN G, 1989, GENE, V85, P239, DOI 10.1016/0378-1119(89)90488-5; WARREN GJ, 1987, BIOTECHNOL GENET ENG, V5, P107, DOI 10.1080/02648725.1987.10647836; WELCH JF, 1989, CRYO-LETT, V10, P309; WOLBER P, 1989, TRENDS BIOCHEM SCI, V14, P179, DOI 10.1016/0968-0004(89)90270-3; WOLBER PK, 1986, P NATL ACAD SCI USA, V83, P7256, DOI 10.1073/pnas.83.19.7256; WOLBER PK, 1990, TRENDS BIOTECHNOL, V8, P276, DOI 10.1016/0167-7799(90)90195-4; Wolber PK, 1992, ADV MICROBIOL PHYSL, V34, P205	70	90	96	7	59	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1338	1343		10.1096/fasebj.7.14.8224607	http://dx.doi.org/10.1096/fasebj.7.14.8224607			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224607	Bronze			2022-12-28	WOS:A1993MH00800005
J	WARREN, JB; WILSON, AJ; LOI, RK; COUGHLAN, ML				WARREN, JB; WILSON, AJ; LOI, RK; COUGHLAN, ML			OPPOSING ROLES OF CYCLIC-AMP IN THE VASCULAR CONTROL OF EDEMA FORMATION	FASEB JOURNAL			English	Note						ENDOTHELIUM; ADENYLATE CYCLASE; EDEMA; PERMEABILITY; VASODILATION	CYCLASE-ACTIVATING POLYPEPTIDE; PLASMA-PROTEIN EXTRAVASATION; HAMSTER-CHEEK POUCH; ENDOTHELIAL PERMEABILITY; RABBIT SKIN; BLOOD-FLOW; GUINEA-PIG; MACROMOLECULAR LEAKAGE; DIBUTYRYL-CAMP; NITRIC-OXIDE	Eight agents that increase the intracellular concentration of cyclic AMP were tested for their effect on edema formation. The specificity of the agents for vascular smooth muscle or the endothelium was determined by measuring vasodilation with a laser Doppler flow probe and cAMP production by endothelial cells and vascular smooth muscle cells in culture. The agents were injected intradermally in anesthetized rabbit skin and the local accumulation of I-125-labeled albumin in response to intradermal bradykinin was measured. Iloprost, prostaglandin E1, prostaglandin E2, pituitary adenylate cyclase activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP) potentiated bradykinin-induced edema. These same agents also increased blood flow and vascular smooth muscle cAMP concentrations, but did not increase endothelial cell cAMP production. Albuterol suppressed edema formation, did not cause vasodilation, but did increase endothelial cell cAMP concentrations. The phosphodiesterase inhibitor rolipram did not cause vasodilation, but suppressed edema and potentiated the cAMP response to albuterol in cultured endothelial cells. L-Isoproterenol affected both cell types. At a lower concentration L-isoproterenol was a potent stimulus to endothelial cell cAMP production and inhibited edema formation; a higher dose had additional effects on vascular smooth muscle and significantly increased blood flow. These findings support the hypothesis that increasing intracellular cAMP concentrations in vascular smooth muscle promotes edema via increased blood flow. In contrast, increasing cAMP concentrations in endothelium may suppress edema by enhancing the permeability barrier.			WARREN, JB (corresponding author), NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.			Wilson, Amanda/0000-0001-5681-9611				ADVENIER C, 1992, BRIT J PHARMACOL, V105, P792, DOI 10.1111/j.1476-5381.1992.tb09059.x; ALEXANDER JS, 1988, MICROVASC RES, V35, P308, DOI 10.1016/0026-2862(88)90085-4; AMELANG E, 1981, CIRC RES, V49, P298, DOI 10.1161/01.RES.49.2.298; AXELROD L, 1983, LANCET, V1, P904; BARRY BW, 1978, J CLIN PHARMACY, V3, P43, DOI 10.1111/j.1365-2710.1978.tb00102.x; BEETS JL, 1980, BRIT J PHARMACOL, V70, P461, DOI 10.1111/j.1476-5381.1980.tb08724.x; CAMBRIDGE H, 1992, BRIT J PHARMACOL, V106, P746, DOI 10.1111/j.1476-5381.1992.tb14404.x; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; CHANG SW, 1989, AM REV RESPIR DIS, V140, P1814, DOI 10.1164/ajrccm/140.6.1814; DOUKAS J, 1989, MICROVASC RES, V37, P125, DOI 10.1016/0026-2862(89)90032-0; FARRUKH IS, 1987, J APPL PHYSIOL, V62, P47, DOI 10.1152/jappl.1987.62.1.47; GOLDMAN G, 1991, SURGERY, V109, P533; GREEN KL, 1972, BRIT J PHARMACOL, V223, P1165; GUDGEON JR, 1989, BRIT J PHARMACOL, V98, P1267, DOI 10.1111/j.1476-5381.1989.tb12673.x; JOYNER WL, 1979, MICROVASC RES, V18, P301, DOI 10.1016/0026-2862(79)90038-4; KATORI M, 1979, MICROVASC RES, V17, pS161; KAUFMAN RP, 1987, ANN SURG, V205, P195, DOI 10.1097/00000658-198702000-00015; KENNEDY TP, 1989, J APPL PHYSIOL, V67, P2542, DOI 10.1152/jappl.1989.67.6.2542; KLAUSNER JM, 1989, ANN SURG, V209, P219, DOI 10.1097/00000658-198902000-00013; KOPANIAK MM, 1978, MICROVASC RES, V15, P77, DOI 10.1016/0026-2862(78)90007-9; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MCEWAN JR, 1990, ENDOTHELIUM INTRO CU; MINNEAR FL, 1989, AM J PHYSIOL, V257, pH1613, DOI 10.1152/ajpheart.1989.257.5.H1613; MONCADA S, 1991, TRENDS PHARMACOL SCI, V12, P130, DOI 10.1016/0165-6147(91)90528-Z; MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0; PATTON WF, 1991, ANAL BIOCHEM, V196, P31, DOI 10.1016/0003-2697(91)90113-8; RAMPART M, 1986, AM J PATHOL, V124, P66; SEIBERT AF, 1992, J APPL PHYSIOL, V72, P389, DOI 10.1152/jappl.1992.72.1.389; SIMIONESCU N, 1978, MICROVASC RES, V15, P1, DOI 10.1016/0026-2862(78)90001-8; SVENSJO E, 1978, PROSTAG LEUKOTR ESS, V1, P397, DOI 10.1016/0161-4630(78)90126-X; UEDA S, 1990, CIRC RES, V66, P957, DOI 10.1161/01.RES.66.4.957; WARREN JB, 1988, CLIN ALLERGY, V18, P197, DOI 10.1111/j.1365-2222.1988.tb02859.x; WARREN JB, 1990, P ROY SOC B-BIOL SCI, V241, P127, DOI 10.1098/rspb.1990.0076; WARREN JB, 1991, NEW ENGL J MED, V325, P1658; WARREN JB, 1993, BRIT J PHARMACOL, V109, P802, DOI 10.1111/j.1476-5381.1993.tb13645.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P953, DOI 10.1111/j.1476-5381.1992.tb14441.x; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; WARREN JB, 1992, BRIT J PHARMACOL, V107, pP98; WARREN JB, 1989, BR J CLIN PHARM, V7, P173; WARREN JB, 1990, ENDOTHELIUM INTRO CU, P263; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WHELAN CJ, 1992, BRIT J PHARMACOL, V105, P831, DOI 10.1111/j.1476-5381.1992.tb09065.x; WILLIAMS TJ, 1982, BRIT J PHARMACOL, V77, P505, DOI 10.1111/j.1476-5381.1982.tb09324.x; WILLIAMS TJ, 1977, NATURE, V270, P530, DOI 10.1038/270530a0; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; WISSIG SL, 1979, ACTA PHYSL SCAND S, V463, P43; YAMADA Y, 1990, ARTERIOSCLEROSIS, V10, P410, DOI 10.1161/01.ATV.10.3.410	49	57	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1394	1400		10.1096/fasebj.7.14.7693536	http://dx.doi.org/10.1096/fasebj.7.14.7693536			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693536				2022-12-28	WOS:A1993MH00800013
J	BRADY, PS; RAMSAY, RR; BRADY, LJ				BRADY, PS; RAMSAY, RR; BRADY, LJ			REGULATION OF THE LONG-CHAIN CARNITINE ACYLTRANSFERASES	FASEB JOURNAL			English	Review						CARNITINE PALMITOYLTRANSFERASE; CARNITINE OCTANOYLTRANSFERASE	MALONYL-COA; PALMITOYLTRANSFERASE SYNTHESIS; MITOCHONDRIAL OUTER; RAT; LIVER; SENSITIVITY; INHIBITION; CLONING; GENE; ACID	Long-chain carnitine acyltransferases are a family of enzymes found in mitochondria, peroxisomes, and endoplasmic reticulum that catalyze the exchange of carnitine for coenzyme A in the fatty acyl-CoA. Conversion of the fatty acyl-CoA to fatty acylcarnitine renders the fatty acid more permeable to the various cellular membranes. The mitochondrial carnitine palmitoyltransferases are considered important in the regulation of mitochondrial beta-oxidation of long-chain fatty acids. However, palmitoylcarnitine produced by peroxisomal carnitine octanoyltransferase or by microsomal carnitine palmitoyltransferase is not different from that produced by the mitochondrial enzyme. Therefore, for there to be control of fatty acid oxidation by the long-chain carnitine acyltransferases, there would have to be some mechanism to coordinately regulate these varied enzymes. The first system of regulation involves inhibition by malonyl-CoA, an intermediate in the synthesis of fatty acids. Malonyl-CoA inhibits long-chain carnitine acyltransferase activity by all three enzymes at similar concentrations in the physiological range. In addition, the mitochondrial and peroxisomal enzymes are known to be regulated at the level of mRNA transcription by a number of shared factors. Although the microsomal enzyme is less well studied, there does, indeed, appear to be a pattern of coordinate regulation for this system.	VET ADM MED CTR,DIV MOLEC BIOL,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BRADY, PS (corresponding author), UNIV MINNESOTA,DEPT FOOD SCI & NUTR,ST PAUL,MN 55108, USA.		Ramsay, Rona R./A-6681-2008; Ramsay, Rona/A-4065-2009	Ramsay, Rona R./0000-0003-1535-4904; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39825, DK 41572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARDUINI A, 1992, J BIOL CHEM, V267, P12673; BARKE RA, 1992, SURGERY, V112, P412; BENITO M, 1978, BIOCHEM J, V176, P331, DOI 10.1042/bj1760331; BHAIRD NN, 1993, IN PRESS BIOCH J; BRADY LJ, 1989, DIABETES, V38, P65, DOI 10.2337/diabetes.38.1.65; BRADY LJ, 1991, J NUTR, V121, P525, DOI 10.1093/jn/121.4.525; BRADY LJ, 1987, BIOCHEM PHARMACOL, V36, P3419, DOI 10.1016/0006-2952(87)90320-0; BRADY PS, 1988, J NUTR, V118, P1128, DOI 10.1093/jn/118.9.1128; BRADY PS, 1986, BIOCHEM J, V238, P801, DOI 10.1042/bj2380801; BRADY PS, 1989, BIOCHEM J, V260, P93, DOI 10.1042/bj2600093; BRADY PS, 1987, BIOCHEM J, V246, P641, DOI 10.1042/bj2460641; BRADY PS, 1992, BIOCHEM J, V286, P779, DOI 10.1042/bj2860779; BRADY PS, 1993, NUTRITION GENE EXPRE, P319; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHUNG CD, 1992, J BIOL CHEM, V268, P4519; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; COOK GA, 1984, J BIOL CHEM, V259, P2030; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; ESSER V, 1993, J BIOL CHEM, V288, P5817; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; KOPEC B, 1971, CAN J BIOCHEM CELL B, V49, P941, DOI 10.1139/o71-136; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; LUND H, 1987, BIOCHIM BIOPHYS ACTA, V878, P243; MARKWELL MAK, 1976, ARCH BIOCHEM BIOPHYS, V172, P502, DOI 10.1016/0003-9861(76)90103-X; MCGARRY JD, 1991, BIOCHIMIE, V73, P77, DOI 10.1016/0300-9084(91)90078-F; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MOIR AMB, 1993, BIOCHEM J, V289, P49, DOI 10.1042/bj2890049; MURTHY MSR, 1987, BIOCHEM J, V248, P727, DOI 10.1042/bj2480727; OZASA H, 1983, J BIOCHEM-TOKYO, V94, P543, DOI 10.1093/oxfordjournals.jbchem.a134385; RAMSAY RR, 1993, IN PRESS LIFE SCI AD; ROBINSON IN, 1982, BIOCHEM J, V206, P177, DOI 10.1042/bj2060177; VALKNER K, 1982, ACTA, V689, P73; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; ZAMMIT VA, 1984, PROG LIPID RES, V23, P39, DOI 10.1016/0163-7827(84)90005-5	36	46	48	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1039	1044		10.1096/fasebj.7.11.8370473	http://dx.doi.org/10.1096/fasebj.7.11.8370473			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370473				2022-12-28	WOS:A1993LT83900009
J	RENSDOMIANO, S; HAMM, HE				RENSDOMIANO, S; HAMM, HE			STRUCTURAL AND FUNCTIONAL-RELATIONSHIPS OF HETEROTRIMERIC G-PROTEINS	FASEB JOURNAL			English	Review						SIGNAL TRANSDUCTION; GTPASE; RECEPTOR; EFFECTOR	BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; TRANSDUCIN ALPHA-SUBUNIT; PHOTORECEPTOR-G-PROTEIN; CGMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; COILED-COIL; PH DOMAIN; RHODOPSIN; SITE	Heterotrimeric GTP-binding proteins (G-proteins) are a critical component of signal transduction pathways that carry information received at the cell surface to the appropriate cellular effector system, ultimately achieving a specific cellular response. Heterotrimeric G-proteins consist of an alpha-subunit, which contains the guanine nucleotide binding site and intrinsic GTPase activity, and an inseparable beta gamma-subunit complex. G-proteins act to define the specificity by which a receptor regulates a particular intracellular signaling system, as well as to regulate the duration of the signal. A great deal of structural and functional insight into how G-protein-mediated signal transduction occurs has recently been achieved. This review will discuss the structural features of G-proteins, as well as detail the mechanism by which G-proteins interact with receptors and effectors.	UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014		NEI NIH HHS [EY10291, EY06062] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVIVO M, 1994, MOL CELL ENDOCRINOL, V100, P65, DOI 10.1016/0303-7207(94)90280-1; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1991, J BIOL CHEM, V266, P16226; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5815; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, J BIOL CHEM, V264, P15467; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1994, PROTEIN SCI, V3, P3; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; SPRING SR, 1994, SCIENCE, V265, P1405; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1; YI F, 1991, J BIOL CHEM, V266, P3900	62	140	142	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1059	1066		10.1096/fasebj.9.11.7649405	http://dx.doi.org/10.1096/fasebj.9.11.7649405			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649405				2022-12-28	WOS:A1995RP99600010
J	FARAH, CS; REINACH, FC				FARAH, CS; REINACH, FC			THE TROPONIN COMPLEX AND REGULATION OF MUSCLE-CONTRACTION	FASEB JOURNAL			English	Review						TROPONIN; TNI; TNC; CA2+; EF HAND; CA2+ BINDING; ACTOMYOSIN; REGULATION OF MUSCLE CONTRACTION	I INHIBITORY PEPTIDE; NUCLEAR-MAGNETIC-RESONANCE; CENTRAL HELIX MUTANTS; AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; T FRAGMENTS; CROSS-LINKING; CONFORMATIONAL TRANSITION; PROTEOLYTIC FRAGMENTS	In a wide variety of cellular settings, from organelle transport to muscle contraction, Ca2+ binding to members of the EF hand family of proteins controls the interaction between actin and different myosins that are responsible for generating movement. In vertebrate skeletal and cardiac muscle the Ca2+-binding protein troponin C (TnC) is one subunit of the ternary troponin complex which, through its association with actin and tropomyosin on the thin filament, inhibits the actomyosin interaction at sub2+ micromolar Ca2+ concentrations and stimulates the interaction at micromolar Ca2+ concentrations. Because TnC does not interact directly with actin or tropomyosin, the Ca2+-binding signal must be transmitted to the thin filament via the other two troponin subunits: troponin I (TnI), the inhibitory subunit, and troponin T (TnT), the tropomyosin-binding subunit. Thus, the troponin complex is a Ca2+-sensitive molecular switch and the structures of and interactions between its components have been of great interest for many years. Although the crystal structure of TnC has been known for almost a decade, the molecular structures of TnI and TnT are not known and therefore convincing models of the organization of the troponin complex and the Ca2+-induced changes in its structure have not been forthcoming. Recent advances on a wide variety of fronts including 1) the bacterial expression and characterization of mutants of TnC, TnI, and TnT; 2) cross-linking and fluorescence studies; and 3) the determination of the crystal and nuclear magnetic resonance structures of synthetic and recombinant troponin fragments and complexes between EF hand proteins and their target peptides have provided new insights into the nature of the interactions between troponin subunits. This review discusses these recent advances with the aim of critically assessing molecular models of the nature of the Ca2+-induced structural transition in troponin.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498970 SAO PAULO,BRAZIL	Universidade de Sao Paulo			Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302				BARTEGI A, 1990, EUR J BIOCHEM, V194, P845, DOI 10.1111/j.1432-1033.1990.tb19478.x; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOBROWOLSKI Z, 1991, BIOCHEMISTRY-US, V30, P7089, DOI 10.1021/bi00243a008; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; GREASER ML, 1971, J BIOL CHEM, V246, P4226; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HITCHCOCKDEGREG.SE, 1987, J BIOL CHEM, V262, P9730; HITCHCOCKDEGREG.SE, 1982, J BIOL CHEM, V257, P7372; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MALNIC B, 1994, EUR J BIOCHEM, V222, P49, DOI 10.1111/j.1432-1033.1994.tb18840.x; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; NGAI SM, 1994, J BIOL CHEM, V269, P2165; NGAI SM, 1992, J BIOL CHEM, V267, P15715; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P1800; PAN BS, 1992, J BIOL CHEM, V267, P23052; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SORENSON MM, 1995, IN PRESS J BIOL CHEM; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; TSUDA S, 1992, J BIOCHEM-TOKYO, V112, P665, DOI 10.1093/oxfordjournals.jbchem.a123956; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	91	456	481	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					755	767		10.1096/fasebj.9.9.7601340	http://dx.doi.org/10.1096/fasebj.9.9.7601340			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601340				2022-12-28	WOS:A1995RH98200009
J	SCHOBITZ, B; PEZESHKI, G; POHL, T; HEMMANN, U; HEINRICH, PC; HOLSBOER, F; REUL, JMHM				SCHOBITZ, B; PEZESHKI, G; POHL, T; HEMMANN, U; HEINRICH, PC; HOLSBOER, F; REUL, JMHM			SOLUBLE INTERLEUKIN-6 (IL-6) RECEPTOR AUGMENTS CENTRAL EFFECTS OF IL-6 IN-VIVO	FASEB JOURNAL			English	Article						BODY TEMPERATURE; CYTOKINES; RAT	SIGNAL TRANSDUCER; EXPRESSION; RAT; PURIFICATION; CLONING; TARGET; GP130	The pleiotropic cytokine interleukin-6 (IL-6) controls both the peripheral and central components of the acute-phase response. These activities are mediated via the IL-6 membrane receptor, but probably also via agonistic soluble IL-6 receptors (sIL-6Rs). In the present study we conducted dose-response experiments with rats that were intracerebroventricularly i.c.v.) injected with recombinant human IL-6 and sIL-6R and determined body temperature, locomotor activity, food intake, and water consumption using radiotelemetry and continuous recordings of feeding and drinking. IL-6 injected i.c.v. at 1, 10, and 100 ng increased body temperature and decreased locomotor activity and food intake, but it did not affect water consumption. When 10 ng sIL-6R, which lacked detectable biological activity, was injected i.c.v. 1 h before 1 ng IL-6, the central effects of IL-6 were enhanced and prolonged, and this was not due to endotoxin contamination of the recombinant proteins. Our data suggest that IL-6 plays an important role in the regulation of body temperature, general activity, and food intake in sick animals. Moreover, we have shown for the first time that it is possible to potentiate the effects of a mediator in vivo by administration of the corresponding receptor, which is a novel pharmacological tool for increasing receptor capacity.	MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,D-80804 MUNICH,GERMANY; RHEIN WESTFAL TH AACHEN,INST BIOCHEM,W-5100 AACHEN,GERMANY	Max Planck Society; RWTH Aachen University			Reul, Johannes/B-4132-2019	Reul, Johannes/0000-0002-8787-4012				AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DINARELLO CA, 1991, BLOOD, V77, P1627; GRADIENT RA, 1993, NEUROSCI LETT, V153, P13; HONDA M, 1992, J IMMUNOL, V148, P2175; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; KLIR JJ, 1994, AM J PHYSIOL, V266, pR185; LEMAY LG, 1990, AM J PHYSIOL, V258, pR798, DOI 10.1152/ajpregu.1990.258.3.R798; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAMAMI N, 1993, ENDOCRINOLOGY, V133, P2574, DOI 10.1210/en.133.6.2574; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; OPP M, 1989, PHYSIOL BEHAV, V45, P1069, DOI 10.1016/0031-9384(89)90239-4; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PLATASALAMAN CR, 1988, NEUROSCI RES COMMUN, V3, P159; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHOBITZ B, 1994, CRIT REV NEUROBIOL, V8, P263; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SCHOBITZ B, 1993, ENDOCRINOLOGY, V132, P1569, DOI 10.1210/en.132.4.1569; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	27	128	128	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					659	664		10.1096/fasebj.9.8.7768358	http://dx.doi.org/10.1096/fasebj.9.8.7768358			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768358				2022-12-28	WOS:A1995RC10600012
J	VALVERDE, MA; HARDY, SP; SEPULVEDA, FV				VALVERDE, MA; HARDY, SP; SEPULVEDA, FV			CHLORIDE CHANNELS - A STATE OF FLUX	FASEB JOURNAL			English	Review						CLASSIFICATION; REGULATION; PHARMACOLOGY; STRUCTURE	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; EPITHELIAL-CELLS; CL CHANNELS; PROTEIN-KINASE; ION CHANNELS; HT(29) CELLS; ACTIVATION; MEMBRANE; MUSCLE	Chloride channels play important functions in different aspects of cell physiology including volume regulation, transepithelial ion transport and stabilization of membrane potential. In recent years the molecular identity of the chloride channels defective in cystic fibrosis and myotonia congenita has been elucidated, highlighting the importance of anion-selective channels in cell and tissue function. Concurrently, several proteins have been identified as chloride channels along with proteins that possess channel regulatory behavior. Novel interactions with more potent pharmacological compounds have been reported with different chloride channels. This burgeoning field of interest is reviewed.	UNIV CHILE,FAC MED,DEPT EXPTL MED,SANTIAGO 7,CHILE; CTR ESTUDIOS CIENT SANTIAGO,SANTIAGO 7,CHILE	Universidad de Chile	VALVERDE, MA (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND.			Valverde, Miguel A./0000-0002-6961-3361; Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598				ACKERMAN M, 1993, J GEN PHYSIOL, V103, P153; ACKERMAN MJ, 1993, TRENDS CARDIOVAS MED, V3, P23, DOI 10.1016/1050-1738(93)90024-Z; ALTON EWF, 1991, J PHYS LONDON, V433, P137; ANDERSON MP, 1992, AM J PHYSIOL, V23, pL1; BECQ E, 1994, FEBS LETT, V327, P337; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CHUA M, 1991, BIOPHYS J, V59, P1251, DOI 10.1016/S0006-3495(91)82340-2; DEBIN JA, 1993, AM J PHYSIOL, V264, pC361, DOI 10.1152/ajpcell.1993.264.2.C361; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P711, DOI 10.1113/jphysiol.1991.sp018575; ELDEFRAWI AT, 1987, FASEB J, V1, P262, DOI 10.1096/fasebj.1.4.2443413; FINN AL, 1993, P NATL ACAD SCI USA, V90, P56910; FRIZZELL RA, CURRENT TOPCIS MEMBR, P247; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GEKLE M, 1993, PFLUG ARCH EUR J PHY, V425, P401, DOI 10.1007/BF00374865; GRAY MA, 1989, AM J PHYSIOL, V2570, pC240; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; HO MWY, 1994, BBA-BIOMEMBRANES, V1191, P151, DOI 10.1016/0005-2736(94)90243-7; HOFFMANN EK, 1993, ACEP SERIES, P187; Jentsch T J, 1993, Curr Opin Neurobiol, V3, P316, DOI 10.1016/0959-4388(93)90123-G; KOTERA T, 1993, J MEMBRANE BIOL, V134, P67; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; KUBITZ R, 1992, PFLUG ARCH EUR J PHY, V421, P447, DOI 10.1007/BF00370255; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MAYER ML, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P355; MCGILL JM, 1993, J MEMBRANE BIOL, V133, P253; MONAGHAN AS, 1995, J PHYSIOL-LONDON, V82, pP10; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; PUSCH M, 1994, BIOPHYS J, V66, P149, DOI 10.1016/S0006-3495(94)80753-2; RAN S, 1992, J BIOL CHEM, V267, P20630; RITCHIE JM, 1992, TRENDS NEUROSCI, V15, P345; SANCHEZVIVES MV, 1994, J PHYSIOL-LONDON, V475, P391, DOI 10.1113/jphysiol.1994.sp020080; SCHWIEBERT EM, 1992, J CLIN INVEST, V89, P834, DOI 10.1172/JCI115662; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SEPULVEDA FV, 1991, J PHYSIOL-LONDON, V434, P351, DOI 10.1113/jphysiol.1991.sp018474; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SIMS SM, 1991, PFLUG ARCH EUR J PHY, V419, P358, DOI 10.1007/BF00371118; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9; TILLY BC, 1991, J BIOL CHEM, V266, P2036; VALVERDE MA, 1994, J MEMBRANE BIOL, V137, P237; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; VANRENTERGHEM C, 1993, PFLUG ARCH EUR J PHY, V425, P156, DOI 10.1007/BF00374516; VENGLARIK CJ, 1993, J GEN PHYSIOL, V101, P545, DOI 10.1085/jgp.101.4.545; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WHITE MM, 1979, J BIOL CHEM, V254, P161; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514; ZHANG JJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1095, DOI 10.1152/ajpcell.1994.267.4.C1095	56	50	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					509	515		10.1096/fasebj.9.7.7737459	http://dx.doi.org/10.1096/fasebj.9.7.7737459			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737459	Bronze			2022-12-28	WOS:A1995QX14800008
J	MASON, PA; WALTERS, TJ; FANTON, JW; ERWIN, DN; GAO, JH; ROBY, JW; KANE, JL; LOTT, KA; LOTT, LE; BLYSTONE, RV				MASON, PA; WALTERS, TJ; FANTON, JW; ERWIN, DN; GAO, JH; ROBY, JW; KANE, JL; LOTT, KA; LOTT, LE; BLYSTONE, RV			DATABASE CREATED FROM MAGNETIC-RESONANCE IMAGES OF A SPRAGUE-DAWLEY RAT, RHESUS-MONKEY, AND PYGMY GOAT	FASEB JOURNAL			English	Article						ANATOMY; DOSIMETRY; IMAGING; MRI	BRAIN; RECONSTRUCTION; ALIGNMENT; DEXTRAN; MODEL; ATLAS; MRI	To obtain a database of accurate anatomical images onto which dosimetry data of electromagnetic fields could be mapped, a healthy Sprague-Dawley rat, rhesus monkey, and pigmy goat were scanned using magnetic resonance imaging (MRI). Axial sections throughout the length of the animals were collected. Sections were 3 mm thick for the rat and 5 mm thick for the monkey and goat. Sagittal sections (2 mm thick) of the rat head were also scanned. Images were recorded on magnetic tape and transferred to computer disk for image enhancement and network distribution. Images are available in 16 bit Big Endian signed or 8 bit TIFF formats. This is the first database of contiguous MRI axial scans of rat, monkey, and goat available for distribution via magnetic tape (4 mm DDS) or Internet file transfer protocol. Digital transfer of the data was selected to preserve the integrity of each image, circumventing the need for the user to scan the images back into a digital format for use with their software. These images should be useful to physiologists, neuroscientists, veterinarians, anatomists, and teachers. Reconstructing these 2-dimensional images into 3-dimensional structures is an effective media for conveying spatial anatomical information in a quick and comprehensive manner.	OPERAT TECHNOL CORP,SAN ANTONIO,TX 78229; SYST RES LABS,SAN ANTONIO,TX 78235; USAF,ARMSTRONG LAB,OERB,DIV RADIOFREQUENCY RADIAT,BROOKS AFB,TX 78235; UNIV TEXAS,HLTH SCI CTR,CTR RES IMAGING,SAN ANTONIO,TX 78284; TRINITY UNIV,DEPT BIOL,SAN ANTONIO,TX 78212	United States Department of Defense; United States Air Force; University of Texas System; University of Texas Health San Antonio; Trinity University				Walters, James/0000-0002-6980-4053				ALVAREZROYO P, 1991, J NEUROSCI METH, V38, P223, DOI 10.1016/0165-0270(91)90172-V; ANDREASEN A, 1992, J NEUROSCI METH, V45, P199, DOI 10.1016/0165-0270(92)90077-Q; Blystone R. V., 1993, Molecular Biology of the Cell, V4, p111A; BULTE JWM, 1992, MAGN RESON MED, V23, P215, DOI 10.1002/mrm.1910230203; DALRYMPLE GV, 1965, USAF TR6532 SCH AER; Emmers R, 1963, STEREOTAXIC ATLAS BR; GRANT G, 1994, BIOELECTROMAGNETICS, V15, P205, DOI 10.1002/bem.2250150305; HIBBARD LS, 1988, J NEUROSCI METH, V26, P55, DOI 10.1016/0165-0270(88)90129-X; HIBBARD LS, 1987, SCIENCE, V236, P1641, DOI 10.1126/science.3603004; KINNAMON JC, 1993, CELL PHYSIOL BIOCHEM, V3, P162, DOI 10.1159/000154681; Konig JFR, 1963, RAT BRAIN STEREOTAXI; Manocha S. L., 1968, STEREOTAXIC ATLAS BR; NISSANOV J, 1991, J CHEM NEUROANAT, V4, P329, DOI 10.1016/0891-0618(91)90041-A; OLDS RJ, 1988, COLOUR ATLAS RAT DIS; Palkovits M., 1988, MAPS GUIDE MICRODISS; Paxinos G., 2004, J CHEM INF MODEL, V5th; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Pellegrino L. J., 1979, STEREOTAXIC ATLAS RA; REBERT CS, 1991, J NEUROSCI METH, V39, P109, DOI 10.1016/0165-0270(91)90076-C; RUDIN M, 1988, MAGNET RESON MED, V7, P285, DOI 10.1002/mrm.1910070305; SANTORI EM, 1993, J NEUROSCI METH, V50, P187, DOI 10.1016/0165-0270(93)90007-E; SECRIST RD, 1989, MAGN RESON IMAGING, V7, P149, DOI 10.1016/0730-725X(89)90698-X; Snider RS, 1961, STEREOTAXIC ATLAS MO; TOGA AW, 1989, BRAIN RES BULL, V22, P323, DOI 10.1016/0361-9230(89)90060-9; TOGA AW, 1991, J CHEM NEUROANAT, V4, P313, DOI 10.1016/0891-0618(91)90039-F; TOGA AW, 1990, 3 DIMENSIONAL NEUROI, P189; Vanderwolf C.H., 1990, SHEEP BRAIN PHOTOGRA; WHITE DL, 1992, MAGNET RESON MED, V24, P14, DOI 10.1002/mrm.1910240103; WOLF RFE, 1992, LAB ANIM-UK, V26, P222, DOI 10.1258/002367792780740495	29	24	25	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					434	440		10.1096/fasebj.9.5.7896016	http://dx.doi.org/10.1096/fasebj.9.5.7896016			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896016				2022-12-28	WOS:A1995QP45100019
J	BAENZIGER, JU				BAENZIGER, JU			PROTEIN-SPECIFIC GLYCOSYLTRANSFERASES - HOW AND WHY THEY DO IT	FASEB JOURNAL			English	Review						OLIGOSACCHARIDE; GLYCOPROTEIN; THYROTROPIN; LUTROPIN; PROOPIOMELANCORTIN; UNIQUE	ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL-ENZYME PHOSPHORYLATION; N-ACETYLGALACTOSAMINE-TRANSFERASE; PITUITARY GLYCOPROTEIN HORMONES; INDIVIDUAL GLYCOSYLATION SITES; HUMAN CHORIONIC-GONADOTROPIN; SUGAR CHAINS; SIALYLATED OLIGOSACCHARIDES; BOVINE LUTROPIN; RECOGNITION DETERMINANTS	Glycosylation is a common and complex form of post-translational protein modification. Although a large and increasing number of unique structures is known to exist, most arise from a series of common synthetic intermediates and differ at their periphery. Glycosyltransferases, which recognize both the oligosaccharide acceptor and features of the underlying protein, may account for the synthesis of many unique oligosaccharides, particularly those associated with biologic functions dependent on specific oligosaccharide structures. UDP-Glc: glycoprotein glucosyltransferase, UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase and UDP-GalNAc:glycoprotein hormone N-acetylgalactosaminyltransferase are examples of glycosyltransferases that display peptide specificity. The features of peptide recognition are distinct for these three transferases and provide insights into the range of properties that can be expected for such transferases. Peptide-specific glycosyltransferases promise new insights into the regulation of glycosylation and its numerous biologic functions. They will also ultimately provide tools for engineering glycoproteins bearing specific oligosaccharide structures.	WASHINGTON UNIV,SCH MED,DEPT PATHOL CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [CA-21923] Funding Source: Medline; NIDDK NIH HHS [DK-41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923, R56CA021923, R01CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HERBERT E, 1983, J BIOL CHEM, V258, P257; HIYAMA J, 1992, GLYCOBIOLOGY, V2, P401, DOI 10.1093/glycob/2.5.401; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOBATA A, 1984, BIOL CARBOHYDRATES, V2, P88; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LANG L, 1984, J BIOL CHEM, V259, P4663; LANG L, 1985, J CLIN INVEST, V76, P2191, DOI 10.1172/JCI112227; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RENWICK AGC, 1987, J BIOCHEM-TOKYO, V101, P1209, DOI 10.1093/oxfordjournals.jbchem.a121985; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROSEN SD, 1993, RES IMMUNOL, V144, P699, DOI 10.1016/S0923-2494(93)80054-3; Rutishauser U., 1992, DEVELOPMENT S, V116, P99; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SMITH PL, 1991, THESIS WASHINGTON U; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WASSARMAN PM, 1992, BIOL REPROD, V46, P186, DOI 10.1095/biolreprod46.2.186; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x	54	61	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1019	1025		10.1096/fasebj.8.13.7926366	http://dx.doi.org/10.1096/fasebj.8.13.7926366			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926366				2022-12-28	WOS:A1994PN06900005
J	STERN, CD				STERN, CD			THE AVIAN EMBRYO - A POWERFUL MODEL SYSTEM FOR STUDYING NEURAL INDUCTION	FASEB JOURNAL			English	Review						EMBRYONIC AXIS; CHICK EMBRYO; PRIMITIVE STREAK; HENSENS NODE	EPITHELIAL SCATTER FACTOR; HOMEOBOX GENE; CHICK-EMBRYO; MESODERM FORMATION; XENOPUS-LAEVIS; HENSEN NODE; ORGANIZER; GASTRULATION; EXPRESSION; PROTEINS	Neural induction is the process during early embryonic development whereby the mesoderm of the embryo elicits a change of fate in cells of the overlying ectoderm, from epidermal to neural. Since its discovery in 1924 by Spemann and Mangold, who used newt embryos, most research on this developmental event has been conducted with urodelean and anuran amphibians. This is because of the ease with which they can be manipulated and because of the recent availability of cell type- and region-specific molecular markers. With the recent isolation and characterization of suitable markers in the chick embryo, and the equal ease with which it can be manipulated, the way is now open for amniote embryos to join amphibians as an experimental system for neural induction studies. Another advantage of the avian embryo is that it possesses a peripheral extraembryonic region, which although it does not contribute to embryonic tissues at all, is competent to respond to neural-inducing signals, thereby providing developmentally naive cells for in vivo and in vitro assays. Here, I review recent advances that make the chick embryo a system uniquely suited for the study of neural induction at both the cellular and the molecular level.			STERN, CD (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,701 W 168TH ST,NEW YORK,NY 10032, USA.		Stern, Claudio D/C-6265-2008; Stern, Claudio/AAZ-7381-2021	Stern, Claudio D/0000-0002-9907-889X; Stern, Claudio/0000-0002-9907-889X				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; DELARUE M, 1992, DEVELOPMENT, V114, P135; DEROBERTIS EM, 1989, CELL, V57, P189, DOI 10.1016/0092-8674(89)90954-9; GALLERA J, 1970, EXPERIENTIA, V26, P886, DOI 10.1007/BF02114239; GALLERA J, 1966, ACTA ANAT, V63, P388; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; HADORN E, 1970, EXPT ENTWICKLUNGSFOR; HARA K, 1961, THESIS U UTRECHT UTR; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; KELLER RA, 1988, DEVELOPMENT, V103, P190; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; ROBERTS C, 1991, DEVELOPMENT, V112, P959; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SOKOL SY, 1993, DEVELOPMENT, V118, P1335; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1985, J CELL SCI, V77, P209; STOREY KG, 1992, DEVELOPMENT, V114, P729; STREIT A, 1990, J NEUROCHEM, V55, P1494, DOI 10.1111/j.1471-4159.1990.tb04931.x; TSUNG SD, 1965, ACTA BIOL EXP SINICA, V10, P69; VAKAET L, 1965, CR SOC BIOL, V159, P232; Waddington CH, 1932, PHILOS T R SOC LON B, V221, P179, DOI 10.1098/rstb.1932.0003; Waddington CH, 1933, J EXP BIOL, V10, P38	36	13	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					687	691		10.1096/fasebj.8.10.8050666	http://dx.doi.org/10.1096/fasebj.8.10.8050666			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050666				2022-12-28	WOS:A1994NY35000004
J	DUNN, KW; MAYOR, S; MYERS, JN; MAXFIELD, FR				DUNN, KW; MAYOR, S; MYERS, JN; MAXFIELD, FR			APPLICATIONS OF RATIO FLUORESCENCE MICROSCOPY IN THE STUDY OF CELL PHYSIOLOGY	FASEB JOURNAL			English	Review						PH; CALCIUM; ENDOCYTOSIS; RESONANCE ENERGY TRANSFER; MEMBRANES	RESONANCE ENERGY-TRANSFER; GOLGI-APPARATUS; LIVING CELLS; ENDOSOMAL ACIDIFICATION; INSITU HYBRIDIZATION; CERAMIDE ANALOG; IMAGING-SYSTEM; ANIMAL-CELLS; MEMBRANE; OCCURS	Quantitative fluorescence microscopy is becoming an increasingly important tool in the study of cell biology. Fluorescence microscopy has long been used for qualitative characterizations of subcellular distributions of proteins, lipids, nucleic acids, and ions, but quantifying these distributions is complicated by a variety of optical, biological, and physical factors. Many factors that complicate quantification of fluorescence in cells can be circumvented by analyzing fluorescence ratios derived from pairs of fluorescence images. In this review we will discuss the factors that affect fluorescence quantification, the advantages of quantifying fluorescence as a ratio, and give examples of how fluorescence ratio microscopy is being applied in studies of cell biology.			DUNN, KW (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Maxfield, Frederick/0000-0003-4396-8866				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARENHOLZ Y, 1991, BIOPHYS J, V60, P110, DOI 10.1016/S0006-3495(91)82035-5; BENSON DM, 1985, J CELL BIOL, V100, P1309, DOI 10.1083/jcb.100.4.1309; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; CAIN C, 1986, J CELL BIOL, V106, P269; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; DIX JA, 1990, BIOCHEMISTRY-US, V29, P1949, DOI 10.1021/bi00459a041; DUNN K W, 1991, Biophysical Journal, V59, p345A; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; EISINGER J, 1986, BIOPHYS J, V49, P987, DOI 10.1016/S0006-3495(86)83727-4; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; Haugland R. P., HDB FLUORESCENT PROB; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; HERMAN BA, 1982, BIOCHEMISTRY-US, V21, P3275, DOI 10.1021/bi00257a005; HIRSCHFELD T, 1976, APPL OPTICS, V15, P3135, DOI 10.1364/AO.15.003135; HUANG ZJ, 1993, J HISTOCHEM CYTOCHEM, V41, P313, DOI 10.1177/41.2.8419466; Inouye S., 1986, VIDEO MICROSCOPY; JERICEVIC Z, 1989, METHOD CELL BIOL, V30, P47; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Jovin T.M, 1989, CELL STRUCT FUNCT, P99; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KELLER HE, 1989, HDB BIOL CONFOCAL MI, P69; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LUDWIG M, 1992, BIOPHYS J, V61, P845, DOI 10.1016/S0006-3495(92)81892-1; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MAXFIELD FR, 1989, METHOD ENZYMOL, V173, P745; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCNEIL JA, 1991, GENET ANAL-BIOMOL E, V8, P41, DOI 10.1016/1050-3862(91)90049-W; OHASHI M, 1992, EUR J CELL BIOL, V59, P116; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; POWNALL HJ, 1989, CHEM PHYS LIPIDS, V50, P191, DOI 10.1016/0009-3084(89)90050-9; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; REID T, 1992, P NATL ACAD SCI USA, V89, P1388; SIPE DM, 1991, J BIOL CHEM, V266, P3469; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; SZABO G, 1992, BIOPHYS J, V61, P661, DOI 10.1016/S0006-3495(92)81871-4; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; WELLS KS, 1989, HDB BIOL CONFOCAL MI, P23; WHITAKER J E, 1991, Biophysical Journal, V59, p358A; WU C, 1972, P NATL ACAD SCI USA, V69, P1104, DOI 10.1073/pnas.69.5.1104; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	49	99	105	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					573	582		10.1096/fasebj.8.9.8005385	http://dx.doi.org/10.1096/fasebj.8.9.8005385			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005385				2022-12-28	WOS:A1994NR90600004
J	INSCHO, EW; MITCHELL, KD; NAVAR, LG				INSCHO, EW; MITCHELL, KD; NAVAR, LG			EXTRACELLULAR ATP IN THE REGULATION OF RENAL MICROVASCULAR FUNCTION	FASEB JOURNAL			English	Review						PARACINE SYSTEM; ADENOSINE RECEPTOR; NUCLEOTIDE RELEASE; EXTRACELLULAR ATP	SMOOTH-MUSCLE CELLS; JUXTAMEDULLARY NEPHRONS; ADENOSINE RECEPTORS; ADENINE-NUCLEOTIDES; MACULA DENSA; POTASSIUM CHANNELS; ENDOTHELIAL-CELLS; MESANGIAL CELLS; NITRIC-OXIDE; RAT-KIDNEY	Considerable attention has been focused on the purine nucleoside, adenosine, in the control of renal blood flow, epithelial transport, and renin secretion; however, surprisingly little attention has been directed toward the renal effects of purine nucleotides such as adenosine triphosphate (ATP). Recent studies utilizing in vivo micropuncture and in vitro techniques have demonstrated that renal vascular, epithelial, and mesangial cells respond to extracellular ATP via mechanisms distinct from those elicited by adenosine. ATP vasoconstricts afferent but not efferent arterioles whereas adenosine vasoconstricts both vascular segments. Adenosine-mediated afferent arteriolar vasoconstriction is abolished by adenosine receptor antagonists, whereas the response to ATP is enhanced. ATP-mediated vasoconstriction reaches a maximum within seconds of exposure while the vasoconstriction induced by adenosine develops more slowly L-type calcium channel antagonists such as diltiazem or felodipine prevent the sustained afferent vasoconstriction produced by ATP. Data from micropuncture experiments indicate that peritubular capillary infusion of ATP reduces glomerular pressure and results in marked attenuation of the tubuloglomerular feedback mechanism, which transmits signals from the macula densa to the afferent arteriole. These data support the existence of ATP-sensitive P-2 purinoceptors in the preglomerular microvasculature that contribute to the control of renal vascular function via activation of calcium channels.			INSCHO, EW (corresponding author), TULANE UNIV, SCH MED, DEPT PHYSIOL, SL39, 1430 TULANE AVE, NEW ORLEANS, LA 70112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018426, R01HL018426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDSHORST WJ, 1993, DIS KIDNEY, V1, P65; BELL PD, 1992, RENAL PHYSIOL BIOCH, V15, P89; BENHAM CD, 1990, ANN NY ACAD SCI, V603, P275; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CARMINES PK, 1986, AM J PHYSIOL, V251, pF610, DOI 10.1152/ajprenal.1986.251.4.F610; CARMINES PK, 1990, FASEB J, V4, P3300, DOI 10.1096/fasebj.4.15.2147667; CARMINES PK, 1990, AM J PHYSIOL, V258, pF94, DOI 10.1152/ajprenal.1990.258.1.F94; CARMINES PK, 1994, IN PRESS HYPERTENSIO; CASELLAS D, 1984, AM J PHYSIOL, V246, pF349, DOI 10.1152/ajprenal.1984.246.3.F349; CHURCHILL PC, 1993, J PHARMACOL EXP THER, V265, P334; DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018; DEMEY JG, 1981, J PHYSIOL-LONDON, V316, P347, DOI 10.1113/jphysiol.1981.sp013792; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FLEETWOOD G, 1987, BRIT J PHARMACOL, V90, P219, DOI 10.1111/j.1476-5381.1987.tb16843.x; FORRESTER T, 1969, J PHYSIOL-LONDON, V204, P347, DOI 10.1113/jphysiol.1969.sp008917; FORRESTER T, 1972, J PHYSIOL-LONDON, V224, P611, DOI 10.1113/jphysiol.1972.sp009915; FRANCO M, 1989, AM J PHYSIOL, V257, pF231, DOI 10.1152/ajprenal.1989.257.2.F231; FRIEDRICH F, 1989, AM J PHYSIOL, V256, pC1016, DOI 10.1152/ajpcell.1989.256.5.C1016; GALLA HJ, 1993, ANGEW CHEM INT EDIT, V32, P378, DOI 10.1002/anie.199303781; GORDON EL, 1989, J BIOL CHEM, V264, P18986; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HALLAM TJ, 1986, FEBS LETT, V207, P95, DOI 10.1016/0014-5793(86)80019-9; HARVEY RB, 1964, CIRC RES, V15, P178; INSCHO EW, 1992, AM J PHYSIOL, V263, pF886, DOI 10.1152/ajprenal.1992.263.5.F886; INSCHO EW, 1991, HYPERTENSION, V17, P1033, DOI 10.1161/01.HYP.17.6.1033; INSCHO EW, 1993, FASEB J, V7, pA758; INSCHO EW, 1992, FASEB J, V6, pA1811; INSCHO EW, 1992, AM SOC NEPHROL, V3, P564; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIMBIRD LE, 1979, J BIOL CHEM, V254, P2677; Lindner F, 1931, PFLUG ARCH GES PHYS, V226, P697, DOI 10.1007/BF01751608; LORENZ JN, 1992, J CLIN INVEST, V90, P733, DOI 10.1172/JCI115945; MAJID DSA, 1992, AM J PHYSIOL, V262, pF40, DOI 10.1152/ajprenal.1992.262.1.F40; MARVER D, 1991, Journal of the American Society of Nephrology, V2, P458; MCLACHLAN EM, 1992, KIDNEY INT, V41, pS56; MIDDLETON JP, 1993, AM J PHYSIOL, V264, pF867, DOI 10.1152/ajprenal.1993.264.5.F867; MITCHELL KD, 1988, AM J PHYSIOL, V255, pF383, DOI 10.1152/ajprenal.1988.255.3.F383; MITCHELL KD, 1993, AM J PHYSIOL, V264, pF458, DOI 10.1152/ajprenal.1993.264.3.F458; MITCHELL KD, 1990, AM J PHYSIOL, V258, pF537, DOI 10.1152/ajprenal.1990.258.3.F537; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEEDLEMAN P, 1974, CIRC RES, V34, P455, DOI 10.1161/01.RES.34.4.455; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; OHISHI K, 1992, AM J PHYSIOL, V263, pF900, DOI 10.1152/ajprenal.1992.263.5.F900; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; OSSWALD H, 1982, KIDNEY INT S12, V22, pS136; PADDLE BM, 1974, BLOOD VESSELS, V11, P110; PAVENSTADT H, 1993, KIDNEY INT, V44, P241; PEARSON JD, 1983, BIOCHEM J, V214, P273, DOI 10.1042/bj2140273; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; RASCH R, 1991, APMIS, V99, P1069, DOI 10.1111/j.1699-0463.1991.tb01302.x; RIBEIRO JA, 1986, PROG NEUROBIOL, V26, P179, DOI 10.1016/0301-0082(86)90015-8; RUEGG UT, 1989, J CARDIOVASC PHARM, V14, pS49; SABOLIC I, 1992, AM J PHYSIOL, V262, pF217, DOI 10.1152/ajprenal.1992.262.2.F217; SAKAI K, 1979, JPN J PHARMACOL, V29, P235, DOI 10.1254/jjp.29.235; SATTIN A, 1970, MOL PHARMACOL, V6, P13; SCHNERMANN J, 1988, AM J PHYSIOL, V255, pF33, DOI 10.1152/ajprenal.1988.255.1.F33; SCHNERMANN J, 1986, PFLUG ARCH EUR J PHY, V407, P82, DOI 10.1007/BF00580725; SCHWARTZ DD, 1989, J PHARMACOL EXP THER, V250, P764; SPIELMAN WS, 1992, AM J PHYSIOL, V263, pC502, DOI 10.1152/ajpcell.1992.263.2.C502; SPIELMAN WS, 1991, HYPERTENSION, V17, P117, DOI 10.1161/01.HYP.17.2.117; STILES GL, 1990, CLIN RES, V38, P10; SUZUKI H, 1985, J PHYSIOL-LONDON, V359, P401, DOI 10.1113/jphysiol.1985.sp015592; TAGAWA H, 1970, CIRC RES, V26, P327, DOI 10.1161/01.RES.26.3.327; TRACHTE GJ, 1989, EUR J PHARMACOL, V164, P425, DOI 10.1016/0014-2999(89)90250-1; WEIHPRECHT H, 1992, AM J PHYSIOL, V263, pF1026, DOI 10.1152/ajprenal.1992.263.6.F1026; WEINBERG JM, 1989, AM J PHYSIOL, V256, pC967, DOI 10.1152/ajpcell.1989.256.5.C967; WESTFALL DP, 1990, ANN NY ACAD SCI, V603, P300; WHITE TD, 1990, ANN NY ACAD SCI, V603, P287	73	83	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1994	8	3					319	328		10.1096/fasebj.8.3.8143938	http://dx.doi.org/10.1096/fasebj.8.3.8143938			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143938				2022-12-28	WOS:A1994NB62300006
J	DUKE, RC; WITTER, RZ; NASH, PB; YOUNG, JDE; OJCIUS, DM				DUKE, RC; WITTER, RZ; NASH, PB; YOUNG, JDE; OJCIUS, DM			CYTOLYSIS MEDIATED BY IONOPHORES AND PORE-FORMING AGENTS - ROLE OF INTRACELLULAR CALCIUM IN APOPTOSIS	FASEB JOURNAL			English	Article						CELL DEATH; ENDONUCLEASE; IONOPHORES; TOXINS	PROGRAMMED CELL-DEATH; TOXIC LYMPHOCYTES-T; DNA FRAGMENTATION; IMMUNE-SYSTEM; TARGET-CELLS; GLUCOCORTICOIDS ACTIVATE; ENDONUCLEASE ACTIVATION; IMMATURE THYMOCYTES; SUICIDE PROCESS; LEUKEMIA-CELLS	Apoptosis is a term used to describe certain forms of physiological cell death that occur during embryogenesis, differentiation, and normal cell turnover. Previous reports concerning the effects of calcium ionophores on rodent thymocytes and the pore-forming proteins perforin and staphylococcal alpha-toxin on murine tumor cells led to the suggestion that simply raising intracellular calcium causes apoptotic cell death. This hypothesis was tested using two ionophores, A23187 and valinomycin, and two pore-forming agents, melittin and staphylococcal alpha-toxin, on four murine tumor cell lines. Although treatment with these agents could raise intracellular calcium, and in some instances cause DNA fragmentation, only valinomycin caused apoptosis. In contrast to previous reports, our results suggest that raising intracellular calcium and inducing internucleosomal DNA fragmentation is not sufficient to elicit apoptotic cell death in all cell types.	UNIV COLORADO, SCH MED, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80262 USA; ROCKEFELLER UNIV, MOLEC IMMUNOL & CELL BIOL LAB, NEW YORK, NY 10021 USA; INSERM, U277, UNITE BIOL MOLEC GENE, F-75724 PARIS 15, FRANCE	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Rockefeller University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	DUKE, RC (corresponding author), UNIV COLORADO, SCH MED,DEPT MED,DIV MED ONCOL,CAMPUS BOX B-171, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NCI NIH HHS [CA47307] Funding Source: Medline; NIAID NIH HHS [AI29953, AI07035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI029953, T32AI007035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLBRITTON NL, 1988, J EXP MED, V167, P514, DOI 10.1084/jem.167.2.514; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BELLOMO G, 1992, CANCER RES, V52, P1342; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CHOI OH, 1992, J PHARMACOL EXP THER, V260, P369; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1985, ADV EXP MED BIOL, V184, P493; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUKE RC, 1988, J IMMUNOL, V141, P2191; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUKE RC, 1992, CURRENT PROTOCOLS IM; DUKE RC, 1992, IN PRESS SEMIN IMMUN; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Green D R, 1992, Semin Immunol, V4, P355; GROMKOWSKI SH, 1988, J IMMUNOL, V141, P774; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; HEISLER S, 1989, CAN J PHYSIOL PHARM, V67, P411, DOI 10.1139/y89-065; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; ISEKI R, 1991, J IMMUNOL, V147, P4286; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KATSU T, 1989, BIOCHIM BIOPHYS ACTA, V983, P135, DOI 10.1016/0005-2736(89)90226-5; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LING YH, 1993, CANCER RES, V53, P1845; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; METZ SA, 1986, BIOCHEM PHARMACOL, V35, P3371, DOI 10.1016/0006-2952(86)90438-7; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; SHARMA SV, 1993, ONCOGENE, V8, P939; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; STARKE PE, 1986, J BIOL CHEM, V261, P3006; STORY MD, 1992, INT J RADIAT BIOL, V61, P243, DOI 10.1080/09553009214550871; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545	59	108	109	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					237	246		10.1096/fasebj.8.2.8119494	http://dx.doi.org/10.1096/fasebj.8.2.8119494			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119494				2022-12-28	WOS:A1994MY29900031
J	FITZGERALD, M; KEAST, D				FITZGERALD, M; KEAST, D			FAB FRAGMENTS FROM THE MONOCLONAL-ANTIBODY ML30 BIND TO TREATED HUMAN MYELOID-LEUKEMIA CELLS	FASEB JOURNAL			English	Article						ML30; SURFACE EXPRESSION; HSP60; MYELOID LEUKEMIA; GLUTAMINE ANALOGS	HEAT-SHOCK; EXPRESSION; HSP60	Traditionally, heat-shock proteins were believed to be located intracellularly; however, recent studies have demonstrated that under certain circumstances these proteins can be located at the cell surface. Murine ascites developed from the anti-mycobacterial hsp65 hybridoma ML30 have been shown to contain an antibody that binds to the surface of a range of stimulated myelomonocytic cell lines; however, as the purified ML30 monoclonal antibody produced in vitro did not bind to these cell lines, the results were not considered conclusive evidence of cell-surface expression of the hsp60 homologue of the mycobacterial hsp 65 on human cells. In an effort to clarify this situation, we have confirmed that the ascites derived from the ML30 hybridoma bound to the surface of human myeloid leukemia cell lines and myeloid blast cells purified from freshly diagnosed leukemic patients, but that the in vitro-derived ML30 antibody did not. In addition, we have isolated Fab fragments from the ascites derived from the ML30 hybridoma and demonstrated that these fragments bound to the surface of human myeloid leukemia cells after their treatment with the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) for various times up to four days. Evidence has been presented in the literature that the ML30 monoclonal antibody recognizes a molecule corresponding to the human hsp60 homologue of the mycobacterial hsp65; therefore our results from the binding of Fab fragment preparations from ascites imply that when human myeloid leukemic cells are treated with DON, they express a human hsp60 homologue on their surface.	UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT MICROBIOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia			Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179				CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; FERM MT, 1992, INT IMMUNOL, V4, P305, DOI 10.1093/intimm/4.3.305; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; JARJOUR W, 1989, Arthritis and Rheumatism, V32, pS44; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437	8	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					259	261		10.1096/fasebj.8.2.8119496	http://dx.doi.org/10.1096/fasebj.8.2.8119496			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119496				2022-12-28	WOS:A1994MY29900034
J	MEIGHEN, EA				MEIGHEN, EA			BACTERIAL BIOLUMINESCENCE - ORGANIZATION, REGULATION, AND APPLICATION OF THE LUX GENES	FASEB JOURNAL			English	Review						BACTERIAL BIOLUMINESCENCE; LUX GENES; AUTOINDUCTION; REPORTER GENES; LUCIFERASE	FISCHERI LUMINESCENCE SYSTEM; VIBRIO-FISCHERI; ESCHERICHIA-COLI; PHOTOBACTERIUM-LEIOGNATHI; NUCLEOTIDE-SEQUENCE; STRUCTURAL IDENTIFICATION; TRANSCRIPTIONAL ACTIVATOR; LUCIFERASE SUBUNITS; PROTEIN; HARVEYI	Significant advances have been made in the characterization of luciferases and other lux-specific proteins as well as the lux genes from a number of different species of marine and terrestrial luminescent bacteria. A common lux gene organization (luxCDAB..E) modulated by the presence of specific genes involved in regulation and flavin binding and metabolism (luxF-I,L,R,Y) has been found with the luciferase genes (luxAB) flanked by the genes involved in synthesis of its fatty aldehyde substrate (luxCDE). For many species, light intensity per cell is highly dependent on cellular growth resulting in a spectacular autoinduction of luminescence at high cell density. Consequently, the bacterial lux system is of particular interest as it can serve as an excellent model for more general signal transduction systems involved in developmental processes, intercellular communication, and even symbioses. Identification of the lux autoinducers and regulatory proteins of Vibrio harveyi and Vibrio fischeri has provided the biochemical and genetic basis for dissection of the luminescent system. Isolation of the lux genes and the ability to transfer these genes into prokaryotic and eukaryotic organisms have greatly expanded the scope and potential uses of bacterial bioluminescence as a safe, rapid, and sensitive sensor for a wide variety of compounds and metabolic processes.			MEIGHEN, EA (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ADAR YY, 1992, J BACTERIOL, V174, P7138, DOI 10.1128/jb.174.22.7138-7143.1992; AHMAD KA, 1991, J APPL BACTERIOL, V70, P113, DOI 10.1111/j.1365-2672.1991.tb04436.x; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BAINTON NJ, 1992, GENE, V116, P87, DOI 10.1016/0378-1119(92)90633-Z; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BOYLAN M, 1989, J BIOL CHEM, V264, P1915; BURLAGE RS, 1990, J BACTERIOL, V172, P4749, DOI 10.1128/jb.172.9.4749-4757.1990; BYERS DM, 1985, P NATL ACAD SCI USA, V82, P6085, DOI 10.1073/pnas.82.18.6085; CAO JG, 1989, J BIOL CHEM, V264, P21670; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; CONDEE CW, 1992, J BACTERIOL, V174, P8094, DOI 10.1128/JB.174.24.8094-8101.1992; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; DOLAN KM, 1992, J BACTERIOL, V174, P5132, DOI 10.1128/JB.174.15.5132-5135.1992; Dunlap P.V., 1991, MICROBIAL CELL CELL, P219; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ECKSTEIN JW, 1990, P NATL ACAD SCI USA, V87, P1466, DOI 10.1073/pnas.87.4.1466; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FERRI SR, 1991, J BIOL CHEM, V266, P12852; GREENBERG EP, 1979, ARCH MICROBIOL, V120, P87, DOI 10.1007/BF00409093; GUZZO A, 1991, APPL ENVIRON MICROB, V57, P2255, DOI 10.1128/AEM.57.8.2255-2259.1991; HASTINGS JW, 1985, ADV MICROB PHYSIOL, V26, P235, DOI 10.1016/S0065-2911(08)60398-7; KAPLAN HB, 1987, P NATL ACAD SCI USA, V84, P6639, DOI 10.1073/pnas.84.19.6639; KITA A, 1991, J BIOCHEM-TOKYO, V110, P748, DOI 10.1093/oxfordjournals.jbchem.a123652; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LEE CY, 1991, EUR J BIOCHEM, V201, P161, DOI 10.1111/j.1432-1033.1991.tb16269.x; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; MEGHEN EA, 1993, ADV MICROB PHYSL, V34, P1; MEIGHEN EA, 1992, J BACTERIOL, V174, P5371, DOI 10.1128/JB.174.16.5371-5381.1992; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MIYAMOTO CM, 1988, NUCLEIC ACIDS RES, V16, P1551, DOI 10.1093/nar/16.4.1551; MOORE SA, 1992, J MOL BIOL, V224, P523, DOI 10.1016/0022-2836(92)91015-H; OKAMOTO S, 1992, J BIOL CHEM, V267, P1093; OKANE DJ, 1992, MOL MICROBIOL, V6, P443, DOI 10.1111/j.1365-2958.1992.tb01488.x; OKANE DJ, 1988, PLANT MOL BIOL, V10, P387, DOI 10.1007/BF00014945; OLSSON O, 1989, GENE, V81, P335, DOI 10.1016/0378-1119(89)90194-7; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; RUBY EG, 1992, J BACTERIOL, V174, P4865, DOI 10.1128/JB.174.15.4865-4870.1992; SCHAUER A, 1988, SCIENCE, V240, P768, DOI 10.1126/science.3363358; SHADEL GS, 1992, J BIOL CHEM, V267, P7696; SHADEL GS, 1991, J BACTERIOL, V173, P568, DOI 10.1128/jb.173.2.568-574.1991; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHAW JJ, 1986, BIOTECHNOLOGY, V4, P60; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; Silverman M, 1989, GENETICS BACTERIAL D, P71; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; SOLY RR, 1991, J MOL BIOL, V219, P69, DOI 10.1016/0022-2836(91)90858-4; SOLY RR, 1988, BIOCHEM BIOPH RES CO, V155, P351, DOI 10.1016/S0006-291X(88)81092-1; STEWART GSAB, 1992, J GEN MICROBIOL, V138, P1289, DOI 10.1099/00221287-138-7-1289; SWARTZMAN E, 1992, J BACTERIOL, V174, P7490, DOI 10.1128/jb.174.22.7490-7493.1992; SWARTZMAN E, 1990, J BIOL CHEM, V265, P3513; SWENSON L, 1992, J MOL BIOL, V227, P572, DOI 10.1016/0022-2836(92)90909-4; ULTIZUR S, 1986, BIOLUMINESCENCE NEW, P463; WALL L, 1986, J BIOL CHEM, V261, P16018; WOLK CP, 1991, P NATL ACAD SCI USA, V88, P5355, DOI 10.1073/pnas.88.12.5355	59	218	245	5	86	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1016	1022		10.1096/fasebj.7.11.8370470	http://dx.doi.org/10.1096/fasebj.7.11.8370470			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370470				2022-12-28	WOS:A1993LT83900006
J	DAMM, K				DAMM, K			ERBA - TUMOR-SUPPRESSOR TURNED ONCOGENE	FASEB JOURNAL			English	Review						ERBA; THYROID HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; TUMOR SUPPRESSOR	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; V-ERBA; C-ERBA; RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; ERYTHROID-DIFFERENTIATION; T(15-17) TRANSLOCATION	Cancer has been commonly linked to aberrant proliferation and a failure of the transformed cells to differentiate. Activated proto-oncogenes are thought to provide continuous proliferation signals that enhance the growth of these cells. Conversely, cellular transformation may also be achieved by the inactivation of genes whose normal function is to constrain cell growth by either suppressing proliferation or inducing differentiation. Such an inactivation could result from dominant-negative mutations, leading to the expression of abnormal proteins that inhibit the function of their normal counterparts. A prototype example is the v-erbA oncogene of the avian erythroblastosis virus (AEV), which antagonizes the transcriptional regulatory function of the chicken c-ErbA/thyroid hormone receptors (c-ErbA/TR) and the structurally related retinoic acid receptors (RARs). The result of this inhibition is a loss of hormone responsiveness and hormone-induced differentiation. Here we have a parallel to the tumor suppressor gene where it is also a loss of function that induces the transformation process. In this way, the normal, hormone-activated c-ErbA/TRs and RARs act as growth suppressors because the resulting differentiated cells irreversibly lose proliferative potential. In this article, the properties of v-ErbA will be discussed in the context of c-ErbA/thyroid hormone and retinoic acid receptor function.			DAMM, K (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROENDOCRINOL,KRAEPELINSTR 10,W-8000 MUNICH 40,GERMANY.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BLACK DM, 1993, TRENDS GENET, V9, P22, DOI 10.1016/0168-9525(93)90068-S; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORREST D, 1990, ONCOGENE, V5, P309; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	22	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					904	909		10.1096/fasebj.7.10.8102105	http://dx.doi.org/10.1096/fasebj.7.10.8102105			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8102105				2022-12-28	WOS:A1993LQ33700013
J	HARVEY, M; MCARTHUR, MJ; MONTGOMERY, CA; BRADLEY, A; DONEHOWER, LA				HARVEY, M; MCARTHUR, MJ; MONTGOMERY, CA; BRADLEY, A; DONEHOWER, LA			GENETIC BACKGROUND ALTERS THE SPECTRUM OF TUMORS THAT DEVELOP IN P53-DEFICIENT MICE	FASEB JOURNAL			English	Note						P53; TUMOR SUPPRESSOR; P53-DEFICIENT MICE; GENE TARGETING; TUMORIGENESIS	WILD-TYPE P53; CELL-CYCLE CONTROL; ATAXIA-TELANGIECTASIA; SUPPRESSOR GENE; TRANSFORMATION; ONCOGENE; CANCER; MUTATIONS; PROTEIN; MODEL	Using gene targeting in embryonic stem cells, we have generated mice with one or two null p53 germ line alleles. Mice with both p53 alleles inactivated are developmentally normal but highly susceptible to the early development of spontaneous tumors. Initial studies were performed in mice with a mixed inbred genetic background (75% C57BL/6 and 25% 129/Sv) (Donehower et al., Nature (London) 356, 215-221, 1992). To study the effect of genetic background on tumorigenesis in p53-deficient mice, we have put the p53 null allele into a pure 129/Sv background and monitored tumor development. 129/Sv mice with two p53 null alleles developed tumors sooner than the mixed genetic background p53-deficient animals. The most frequently observed tumor in p53 null mice of both genetic backgrounds was a malignant lymphoma. Because the 129/Sv strain has a low incidence of lymphoma, the frequent occurrence of lymphomas in all p53 null mice suggests that this particular tumor type may be a direct result of p53 loss and not a result of a particular genetic background. In addition to malignant lymphomas, the 129/Sv p53-deficient mice showed an increased incidence of aggressive teratocarcinomas (8 of 18 tumor-bearing males), a tumor type rare in virtually all inbred mice except for 129 strains. Thus, it appears that loss of p53 may accelerate a prior tumor predisposition and that genetic background can play a role in mediating both the rate and spectrum of tumor development in these mice.	BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				ALTMAN PL, 1979, INBRED GENETICALLY D, P207; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunn T.B., 1958, PHYSIOPATHOLOGY CANC, P38; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FURMANSKI P, 1982, MOUSE BIOMEDICAL RES, V4, P352; GATTI RA, 1991, ADV CANCER RES, V56, P77; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; Stutman O, 1975, Adv Cancer Res, V22, P261; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	35	237	243	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					938	943		10.1096/fasebj.7.10.8344491	http://dx.doi.org/10.1096/fasebj.7.10.8344491			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344491				2022-12-28	WOS:A1993LQ33700018
J	CROOKE, ST				CROOKE, ST			PROGRESS TOWARD OLIGONUCLEOTIDE THERAPEUTICS - PHARMACODYNAMIC PROPERTIES	FASEB JOURNAL			English	Review						OLIGONUCLEOTIDE; RNA; MOLECULAR PHARMACOLOGY; PHARMACODYNAMICS	SEQUENCE-SELECTIVE RECOGNITION; THYMINE-SUBSTITUTED POLYAMIDE; MESSENGER-RNA; ANTISENSE OLIGONUCLEOTIDES; STRAND DISPLACEMENT; DUPLEX STABILITY; DNA; COMPLEMENTARY; INHIBITION; EXPRESSION	Although many issues remain to be resolved, recent progress suggests that oligonucleotides may have therapeutic potential. The first therapeutic oligonucleotide, ISIS 2105, an oligonucleotide designed to treat genital warts, has completed Phase I clinical trials and is undergoing Phase II testing. Conceptually, oligonucleotides may interact with nucleic acid or nonnucleic acid receptors; however, rational design of oligonucleotide drugs to interact with nucleic acid receptors is significantly simpler because the factors that determine affinity and selectivity are better understood. Recent progress demonstrates that this information can be coupled to rapid advances in the medicinal chemistry of oligonucleotides to create new generations of oligonucleotide drugs with dramatically improved properties. The purposes of this review are to place oligonucleotide therapeutics in the context of modern molecular drug discovery and to summarize progress in understanding the pharmacodynamic properties of oligonucleotides designed to bind to nucleic acid receptors. The pharmacokinetic and toxicologic properties of oligonucleotides have been reviewed recently (1-4). The activities of oligonucleotides that bind to nonnucleic acid receptors will be considered in future reviews.			CROOKE, ST (corresponding author), ISIS PHARMACEUT,CARLSBAD,CA 92008, USA.							BAKER B, 1992, IN PRESS J AM CHEM S; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURCH RM, 1991, J CLIN INVEST, V88, P1190, DOI 10.1172/JCI115421; CAZENAVE C, 1991, ANTISENSE NUCLEIC AC, P47; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COHEN JS, 1989, OLIGODEOXYNUCLEOTIDE; COOK PD, 1991, ANTI-CANCER DRUG DES, V6, P585; COOK PD, 1992, IN PRESS ANTISENSE R; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; CROOKE ST, 1992, IN PRESS ANTISENSE R; CROUCH RJ, NUCLEASES, P211; CRUM C, 1988, NUCLEIC ACIDS RES, V16, P4569, DOI 10.1093/nar/16.10.4569; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FREIER FM, 1992, IN PRESS ANTISENSE R; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Freier SM, 1992, GENE REGULATION BIOL, P95; GAGNOR C, 1989, NUCLEIC ACIDS RES, V17, P5107, DOI 10.1093/nar/17.13.5107; GASPARRO F, 1990, J INVEST DERMATOL, V94, P527; GASPARRO FP, 1989, CLIN RES, V37, pA30; GILES RV, 1992, ANTI-CANCER DRUG DES, V7, P37; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HELENE C, 1985, BIOCHIMIE, V67, P777, DOI 10.1016/S0300-9084(85)80167-X; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; Helene C., 1987, DNA LIGAND INTERACTI, P127; KAWASAKI AM, 1991, INT UNION BIOCH C NU, V71; KULKA M, 1989, P NATL ACAD SCI USA, V86, P6868, DOI 10.1073/pnas.86.18.6868; MANOHARAN M, 1992, IN PRESS ANTISENSE R; Miller P. S., 1989, OLIGODEOXYNUCLEOTIDE, P79; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MORVAN F, 1991, ANTI-CANCER DRUG DES, V6, P521; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; PERLAKY L, 1992, IN PRESS ANTICANCER; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; SANGHVI YS, 1992, NUCLEOSIDES NUCLEOTI; SANGHVI YS, 1992, IN PRESS ANTISENSE R; SIMONS RW, 1992, IN PRESS ANTISENSE R; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VASSEUR JJ, 1992, J AM CHEM SOC, V114, P4006, DOI 10.1021/ja00036a076; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WESTERMANN P, 1989, BIOMED BIOCHIM ACTA, V48, P85	45	120	145	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					533	539		10.1096/fasebj.7.6.7682523	http://dx.doi.org/10.1096/fasebj.7.6.7682523			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	7682523				2022-12-28	WOS:A1993KY00900006
J	KUMAR, PKR; SUH, YA; TAIRA, K; NISHIKAWA, S				KUMAR, PKR; SUH, YA; TAIRA, K; NISHIKAWA, S			POINT AND COMPENSATION MUTATIONS TO EVALUATE ESSENTIAL STEM STRUCTURES OF GENOMIC HDV RIBOZYME	FASEB JOURNAL			English	Article						RIBOZYME; HEPATITIS DELTA-VIRUS; STRUCTURE-FUNCTION RELATIONSHIP; MUTATIONS; SELF-CLEAVAGE ACTIVITY	HEPATITIS-DELTA-VIRUS; SELF-CLEAVAGE; ANTIGENOMIC RNA	In elucidating the part played by the essential stem structures (I, II, and III) in the self-cleavage activity of genomic HDV ribozyme; several point and compensation variants were constructed on pseudoknot-like structure by site-directed mutagenesis. The self-cleavage activities of these variants indicated that stems I and III were essential for the activity by forming Watson-Crick base pairs. On the other hand, disruption of A704:U767 had little influence on the cleavage activity, indicating that it is not essential in forming an active structure. Also, our V1 nuclease probing studies showed that the A704U and HDV88 variants have a sensitivity similar to the nuclease, and major cuts are visible in the stem I and stem II regions. Thus, stem I and stem II regions are maintained together with stem III regions in both molecules. These results and our earlier site-directed mutagenesis studies strongly support a pseudoknot-like structure for the genomic HDV ribozyme.	MINIST INT TRADE & IND, AGCY IND SCI & TECHNOL, FERMENTAT RES INST, DEPT CELLULAR & MOLEC BIOL, TSUKUBA, IBARAKI 305, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST)			Penmetcha, Kumar/K-8834-2017	Penmetcha, Kumar/0000-0002-3512-704X				BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; KUCHINO Y, 1989, METHOD ENZYMOL, V180, P154; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SUH YA, 1992, NUCLEIC ACIDS RES, V20, P747, DOI 10.1093/nar/20.4.747; Taira K., 1992, Gene regulation: biology of antisense RNA and DNA., P35; THILL G, 1991, NUCLEIC ACIDS RES, V19, P6519, DOI 10.1093/nar/19.23.6519; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; WU HN, 1990, MOL CELL BIOL, V10, P5575, DOI 10.1128/MCB.10.10.5575	16	29	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					124	129		10.1096/fasebj.7.1.8422958	http://dx.doi.org/10.1096/fasebj.7.1.8422958			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422958				2022-12-28	WOS:A1993KH88000018
J	ORGEL, LE; CRICK, FHC				ORGEL, LE; CRICK, FHC			ANTICIPATING AN RNA WORLD - SOME PAST SPECULATIONS ON THE ORIGIN OF LIFE - WHERE ARE THEY TODAY	FASEB JOURNAL			English	Editorial Material											ORGEL, LE (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,SAN DIEGO,CA 92138, USA.		crick, francis/B-7093-2009					BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CAIRNSSMITH AG, 1977, ENCY IGNORANCE; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CRICK FHC, 1967, NATURE, V213, P119, DOI 10.1038/213119d0; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; WOESE CR, 1967, GENETIC CODE; 1966, NATURE, V212, P1397	12	34	36	3	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					238	239		10.1096/fasebj.7.1.7678564	http://dx.doi.org/10.1096/fasebj.7.1.7678564			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678564				2022-12-28	WOS:A1993KH88000038
J	SHIMIZU, A; HONJO, T				SHIMIZU, A; HONJO, T			SYNTHESIS AND REGULATION OF TRANS-MESSENGER RNA ENCODING THE IMMUNOGLOBULIN-EPSILON HEAVY-CHAIN	FASEB JOURNAL			English	Article						POLYMERASE CHAIN REACTION; TRANSGENIC MU-CHAIN; TRANSCRIPTION	SWITCH CIRCULAR DNA; ISOTYPE EXPRESSION; MEMBRANE FORM; B-CELLS; REARRANGEMENT; RECOMBINATION; MOUSE; INTERLEUKIN-4; GENES; MU	We have detected an immunoglobulin heavy-chain trans-mRNA of the epsilon class in which the variable region of the human transgenic mu chain is correctly spliced to the first exon of the endogenous mouse epsilon constant region. Together with our previous observations, all the endogenous isotypes that are targets of class switching have proved to be expressed as trans-mRNA. This indicates that immunoglobulin trans-mRNA synthesis is a general mechanism to express a second heavy-chain isotype with the variable region of the transgenic mu chain. Synthesis of epsilon trans-mRNA is regulated in a way similar to the trans-mRNAs of the gamma subclasses or class switching to epsilon, i.e., interleukin-4 can induce the germline transcript of the epsilon constant region, but costimulation with lipopolysaccharide is necessary for epsilon trans-mRNA expression. The amount of epsilon trans-mRNA induced is similar to that of gamma1 and higher than expected as judged from the rate of class switching to epsilon. All these data are consistent with our previous hypothesis that trans-mRNA is synthesized by a trans-splicing mechanism and that this mechanism is involved in the simultaneous multiple-isotype expression of immunoglobulin in a single B lymphocyte.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University	SHIMIZU, A (corresponding author), KYOTO UNIV,CTR MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN.		Honjo, Tasuku/N-4470-2016					CHEN YW, 1986, J EXP MED, V164, P562, DOI 10.1084/jem.164.2.562; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FRIEDLANDER RM, 1990, NUCLEIC ACIDS RES, V18, P4278, DOI 10.1093/nar/18.14.4278; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; Guise J. W., 1989, Immunoglobulin genes., P275; HAN H, 1991, INT IMMUNOL, V3, P1197, DOI 10.1093/intimm/3.12.1197; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KINASHI T, 1987, GENE DEV, V1, P465, DOI 10.1101/gad.1.5.465; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MAKI R, 1981, CELL, V24, P353, DOI 10.1016/0092-8674(81)90325-1; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MOORE KW, 1981, P NATL ACAD SCI-BIOL, V78, P1800, DOI 10.1073/pnas.78.3.1800; NOLANWILLARD M, 1992, P NATL ACAD SCI USA, V89, P1234, DOI 10.1073/pnas.89.4.1234; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; PERLMUTTER AP, 1984, P NATL ACAD SCI-BIOL, V81, P7189, DOI 10.1073/pnas.81.22.7189; PERNIS B, 1976, COLD SPRING HARB SYM, V41, P175; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SHIMIZU A, 1991, J EXP MED, V173, P1385, DOI 10.1084/jem.173.6.1385; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; SHIMIZU A, 1989, COLD SPRING HARB SYM, V54, P175, DOI 10.1101/SQB.1989.054.01.022; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHINKAI Y, 1988, IMMUNOGENETICS, V27, P288, DOI 10.1007/BF00376124; Sideras P, 1989, Int Immunol, V1, P631, DOI 10.1093/intimm/1.6.631; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; VANHOVE B, 1991, MOL IMMUNOL, V29, P1; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; YAOITA Y, 1982, NATURE, V297, P697, DOI 10.1038/297697a0; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829	30	34	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					149	154		10.1096/fasebj.7.1.7916698	http://dx.doi.org/10.1096/fasebj.7.1.7916698			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7916698				2022-12-28	WOS:A1993KH88000022
J	LEPPERT, D; HAUSER, SL; KISHIYAMA, JL; AN, SZ; ZENG, L; GOETZL, EJ				LEPPERT, D; HAUSER, SL; KISHIYAMA, JL; AN, SZ; ZENG, L; GOETZL, EJ			STIMULATION OF MATRIX METALLOPROTEINASE-DEPENDENT MIGRATION OF T-CELLS BY EICOSANOIDS	FASEB JOURNAL			English	Article						ARACHIDONIC ACID; PROTEASE; CONNECTIVE TISSUE; IMMUNITY	ARACHIDONIC-ACID; LYMPHOCYTE MIGRATION; PROSTAGLANDIN-E2; EXPRESSION; RECEPTORS; 5-LIPOXYGENASE; LEUKOTRIENES; METABOLISM; ACTIVATION; INHIBITION	Prostaglandin E(2) (PGE(2)) and leukotriene B4 (LTB4), at nanomolar to micromolar concentrations, elicited migration of human blood T cells and cultured T lymphoblastoma cells of the Tsup-1 line through a layer of Matrigel basement membrane matrix, The density of Tsup-1 cell high-affinity receptors was low for PGE(2) and high for LTB4, resulting in respectively predominant chemokinetic and chemotactic: stimulation of migration, Migration-enhancing concentrations of PGE(2) and LTB4 also increased Tsup-1 cell content and secretion of matrix metalloproteinases (MMPs) 2, 3, and 9, which were quantified by Western blots and zymography, and augmented Tsup-1 cell-surface expression of the MMPs, as shown by flow cytometry, That a specific MMP inhibitor suppressed migration of blood T cells and Tsup-1 cells through Matrigel, but did not affect PGE(2)- and LTB4-initiated T cell migration through micropore filters without Matrigel, suggests dual requirements for MMP expression and enhanced motility in T cell passage through basement membranes.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT IMMUNOL & MED MICROBIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BALTER MS, 1989, J IMMUNOL, V142, P602; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BETZ M, 1991, J IMMUNOL, V146, P108; COETZL EJ, 1988, ANN NY ACAD SCI, V524, P345; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; FARRAR WL, 1985, J IMMUNOL, V135, P1153; FONTEH AN, 1993, J IMMUNOL, V150, P563; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FREITAS AA, 1979, IMMUNOLOGY, V36, P247; FUJIMOTO N, 1993, CLIN CHIM ACTA, V221, P91, DOI 10.1016/0009-8981(93)90024-X; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; GOETZL EJ, 1981, MED CLIN N AM, V65, P809, DOI 10.1016/S0025-7125(16)31499-7; GOETZL EJ, 1995, IN PRESS FASEB J; GOETZL EJ, 1994, CELLULAR GENERATION; GOLDMAN DW, 1991, J IMMUNOL, V146, P2671; HOPKINS J, 1981, IMMUNOLOGY, V42, P225; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; LEPPERT D, 1995, J IMMUNOL, V154, P4379; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MCCARTY J, 1979, CELL IMMUNOL, V43, P103, DOI 10.1016/0008-8749(79)90154-0; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OPPENHEIMERMARKS N, 1994, J IMMUNOL, V152, P5703; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; ROLAPLESZCZYNSK.M, 1987, J IMMUNOL, V139, P513; ROLAPLESZCZYNSK.M, 1982, BIOCHEM BIOPH RES CO, V108, P1531; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; VANEPPS DE, 1981, INFLAMMATION, V5, P81, DOI 10.1007/BF00910782; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	40	90	97	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1473	1481		10.1096/fasebj.9.14.7589989	http://dx.doi.org/10.1096/fasebj.9.14.7589989			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589989				2022-12-28	WOS:A1995TF67800012
J	ALTIERI, DC				ALTIERI, DC			XA RECEPTOR EPR-1	FASEB JOURNAL			English	Review						FACTOR XA; MONOCLONAL ANTIBODY; SIGNAL TRANSDUCTION; VASCULAR DISEASE	AORTIC ENDOTHELIAL-CELLS; COAGULATION FACTOR-X; FACTOR-V; FACTOR-VIII; PROTEIN; PROTHROMBINASE; ACTIVATION; DOMAINS; CDNA; INHIBITOR	Cellular inflammatory responses and early mechanisms of vascular injury are invariably associated with activation of blood coagulation and deposition of insoluble fibrin, This process occurs on vascular cell surfaces through the ability of the coagulation protease factor Xa to generate thrombin, However, experimental evidence accumulated during the past decade underscores how prothrombin activation is only one of the biological consequences of factor Xa assembly on vascular cells, Instead, binding of factor Xa to leukocytes, endothelium, and smooth muscle cells triggers complex pathways of intracellular signal transduction that participate, directly or indirectly, in the regulation of cellular growth, One of the cellular binding sites for factor Xa, designated effector cell protease receptor-1 (EPR-1); has recently emerged as a novel potential regulator of factor Xa-mediated mitogenic signaling, For its activation-dependent phenotype on leukocyte subsets, its ability to costimulate lymphocyte proliferation through release of intracellular second messengers, and its regulated cellular expression by alternative mRNA splicing, EPR-1 may influence vascular cell growth and aberrantly contribute to the earliest pathogenetic processes of vascular diseases.			ALTIERI, DC (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PATHOL,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.				NHLBI NIH HHS [HL-43773, HL-54131] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; ALTIERI DC, 1993, BLOOD, V81, P569; ANNAMALAI AE, 1987, BLOOD, V70, P139; ANNAMALAI AE, 1985, ARTERIOSCLEROSIS, V6, P196; CERVENY TJ, 1984, BLOOD, V63, P1467; COLVIN RB, 1979, J CLIN INVEST, V63, P1302, DOI 10.1172/JCI109425; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GITEL SN, 1984, J BIOL CHEM, V259, P6890; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; JACKSON CM, 1984, HAEMOSTASIS THROMB, V5, P55; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KAPPELMAYER J, 1993, THROMB HAEMOSTASIS, V70, P273; KAZAMA Y, 1993, BLOOD, V81, P676; LAROCCA D, 1991, CANCER RES, V51, P4994; MARUYAMA I, 1984, J CLIN INVEST, V74, P224, DOI 10.1172/JCI111405; MCGEE MP, 1986, J EXP MED, V164, P1902, DOI 10.1084/jem.164.6.1902; NAWROTH PP, 1985, J EXP MED, V162, P559, DOI 10.1084/jem.162.2.559; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NYKJAER A, 1994, J IMMUNOL, V152, P505; RAPOPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; RODGERS GM, 1985, BIOCHIM BIOPHYS ACTA, V844, P320, DOI 10.1016/0167-4889(85)90133-8; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SAKAI T, 1990, J BIOL CHEM, V265, P9105; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P349; STEINBERG S, 1985, THROMB HAEMOSTASIS, V54, P994; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WORFOLK LA, 1992, BLOOD, V80, P1989	40	74	80	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					860	865		10.1096/fasebj.9.10.7615156	http://dx.doi.org/10.1096/fasebj.9.10.7615156			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615156				2022-12-28	WOS:A1995RK89900006
J	FINKEL, T; EPSTEIN, SE				FINKEL, T; EPSTEIN, SE			GENE-THERAPY FOR VASCULAR-DISEASE	FASEB JOURNAL			English	Review						GENE TRANSFER; LIPOSOMES; RETROVIRUSES; ADENOVIRUSES	SMOOTH-MUSCLE CELLS; DNA LIPOSOME COMPLEXES; ENDOTHELIAL-CELLS; ARTERIAL-WALL; RECOMBINANT GENES; GROWTH-FACTOR; INTIMAL HYPERPLASIA; ADENOVIRUS VECTORS; EXPRESSION INVIVO; NUCLEAR ANTIGEN	Highly efficient methods that are now available allow for the genetic modification of cells that compose the vessel wall, The application of these gene transfer systems are already providing information that has enhanced our understanding of a variety of cellular processes relating to vascular biology, Recent experimental results using this technology also hold promise for more powerful therapeutic options in the treatment of vascular disease, This review discusses the most commonly used methods of gene transfer and details some current applications of these methodologies in animal-models of vascular disease.			FINKEL, T (corresponding author), NHLBI, CARDIOL BRANCH, BLDG 10, RM 7B15, 10 CTR DR MSC 1650, BETHESDA, MD 20892 USA.							ABE J, 1994, BIOCHEM BIOPH RES CO, V198, P16, DOI 10.1006/bbrc.1994.1003; ACSADI G, 1991, NEW BIOL, V3, P71; BALZARINI J, 1994, MOL PHARMACOL, V45, P1253; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN SJ, 1994, CIRCULATION, V89, P1922, DOI 10.1161/01.CIR.89.5.1922; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; FRENCH BA, 1994, CIRCULATION, V90, P2402, DOI 10.1161/01.CIR.90.5.2402; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; HILLWEST JL, 1994, P NATL ACAD SCI USA, V91, P5967, DOI 10.1073/pnas.91.13.5967; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302, DOI 10.1073/pnas.91.17.8302; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LINCOFF AM, 1994, CIRCULATION, V90, P2070, DOI 10.1161/01.CIR.90.4.2070; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; LYNCH CM, 1992, P NATL ACAD SCI USA, V89, P1138, DOI 10.1073/pnas.89.3.1138; MANN MJ, 1994, CIRCULATION, V90, P89; MESSINA LM, 1992, P NATL ACAD SCI USA, V89, P12018, DOI 10.1073/pnas.89.24.12018; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MORISHITA R, 1993, HYPERTENSION, V21, P894, DOI 10.1161/01.HYP.21.6.894; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; PLAUTZ G, 1991, NEW BIOL, V3, P709; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; RIESSEN R, 1993, HUM GENE THER, V4, P749, DOI 10.1089/hum.1993.4.6-749; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; SHI Y, 1993, CIRCULATION, V88, P1190, DOI 10.1161/01.CIR.88.3.1190; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPEIR E, 1992, CIRCULATION, V86, P538, DOI 10.1161/01.CIR.86.2.538; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; TAKESHITA S, 1993, CIRCULATION, V88, P476; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; VILLA AE, 1995, CIRC RES, V76, P505, DOI 10.1161/01.RES.76.4.505; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YLAHERTTULA S, 1994, CIRCULATION, V90, P135	68	40	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1995	9	10					843	851		10.1096/fasebj.9.10.7615154	http://dx.doi.org/10.1096/fasebj.9.10.7615154			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615154				2022-12-28	WOS:A1995RK89900004
J	KLUG, A; SCHWABE, JWR				KLUG, A; SCHWABE, JWR			PROTEIN MOTIFS .5. ZINC FINGERS	FASEB JOURNAL			English	Review						AUTONOMOUS FOLDING; DNA BINDING; TRANSCRIPTION FACTOR; MINIDOMAIN	DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR-IIIA; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; NUCLEOCAPSID PROTEIN; NMR STRUCTURE; COMPLEX	The term zinc finger was first used to describe a 30-residue, repeated sequence motif found in an unusually abundant Xenopus transcription factor, It was proposed that each motif is folded around a central zinc ion to form an independent minidomain and that adjacent zinc fingers are combined as modules to make up a DNA-binding domain with the modules ''gripping'' the DNA (hence the term finger), We now know that these proposals were correct and that these DNA-binding motifs are found in many eukaryotic DNA-binding proteins. More recently, crystal structures of three different complexes between zinc finger domains and their target DNA binding sites have revealed a remarkably simple mode of interaction with DNA. The simplicity of the zinc finger structure, and of its interaction with DNA, is a very striking feature of this protein domain, After the discovery of the zinc finger motif, patterns of potential zinc ligands have been found in several other proteins, some of which also bind to DNA. Structural studies of these domains have revealed how zinc can stabilize quite diverse protein architectures, In total, 10 such small zinc-binding domains have been studied structurally. These form a diverse collection, but each in turn has been termed a zinc finger motif-although clearly what they have in common is only their zinc-binding property, which stabilizes an apparently autonomously folded unit.			KLUG, A (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383				BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHOO Y, 1994, IN PRES P NATL ACAD; CHOO Y, 1994, IN PRESS NATURE; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FOURMY D, 1993, J MOL BIOL, V231, P1078, DOI 10.1006/jmbi.1993.1353; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KNEGTEL RM, 1993, J BIOMOL NMR, V1, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MERIC C, 1989, J VIROL, V63, P1558; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2	52	511	617	3	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					597	604		10.1096/fasebj.9.8.7768350	http://dx.doi.org/10.1096/fasebj.9.8.7768350			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768350				2022-12-28	WOS:A1995RC10600004
J	RICHIE, JP; LEUTZINGER, Y; PARTHASARATHY, S; MALLOY, V; ORENTREICH, N; ZIMMERMAN, JA				RICHIE, JP; LEUTZINGER, Y; PARTHASARATHY, S; MALLOY, V; ORENTREICH, N; ZIMMERMAN, JA			METHIONINE RESTRICTION INCREASES BLOOD GLUTATHIONE AND LONGEVITY IN F344 RATS	FASEB JOURNAL			English	Article						GLUTATHIONE METABOLISM; DIETARY RESTRICTION; AGING; ANTIOXIDATION; SULFUR AMINO ACID; OXIDATION-REDUCTION; CYSTEINE	LIFE-SPAN; HUMAN-ERYTHROCYTES; AGE; METABOLISM; CYSTEINE; MOUSE; MICE; ACETAMINOPHEN; ANTIOXIDANTS; CYST(E)INE	Little is known about the biochemical mechanisms responsible for the biological aging process. Our previous results and those of others suggest that one possible mechanism is based on the loss of glutathione (GSH), a multifunctional tripeptide present in high concentrations in nearly all living cells. The recent finding that life-long dietary restriction of the GSH precursor methionine (Met) resulted in increased longevity in rats led us to hypothesize that adaptive changes in Met and GSH metabolism had occurred, leading to enhanced GSH status. To test this, blood and tissue GSH levels were measured at different ages throughout the life span in E344 rats on control or Met-restricted diets. Met restriction resulted in a 42% increase in mean and 44% increase in maximum life span, and in 43% lower body weight compared to controls (P < 0.001). Increases in blood GSH levels of 81% and 164% were observed in mature and old Met-restricted animals, respectively (P < 0.001). Liver was apparently the source for this increase as hepatic GSH levels decreased to 40% of controls. Except for a 25% decrease in kidney, GSH was unchanged in other tissues. All changes in GSH occurred as early as 2 months after the start of the diet. Altogether, these results suggest that dramatic adaptations in sulfur amino acid metabolism occur as a result of chronic Met restriction, leading to increases in blood GSH levels and conservation of tissue GSH during aging.-Richie, J. P., Jr, Leutzinger, Y., Parthasarathy, S., Malloy, V., Orentreich, N., Zimmerman, J. A. Methionine restriction increases blood glutathione and longevity in F344 rats.	ORENTREICH FDN ADVANCEMENT SCI INC,COLD SPRING HARBOR,NY 10516; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Saint John's University	RICHIE, JP (corresponding author), AMER HLTH FDN,DIV NUTR CARCINOGENESIS,1 DANA RD,VALHALLA,NY 10595, USA.							ABRAHAM EC, 1978, BIOCHEM J, V174, P819, DOI 10.1042/bj1740819; ALTURK WA, 1987, J PHARM PHARMACOL, V39, P13, DOI 10.1111/j.2042-7158.1987.tb07154.x; CHEN TS, 1989, P SOC EXP BIOL MED, V190, P399; CHEN TS, 1990, DRUG METAB DISPOS, V18, P882; CHO ES, 1984, J NUTR, V114, P1853, DOI 10.1093/jn/114.10.1853; DAAS PD, 1992, CHIM BIOPHYS ACTA, V1156, P99; Fairbanks VF, 1987, FUNDAMENTALS CLIN CH, P789; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GLAZENBURG EJ, 1983, J NUTR, V113, P1363, DOI 10.1093/jn/113.7.1363; HARDING JJ, 1970, BIOCHEM J, V117, P957, DOI 10.1042/bj1170957; HAZELTON GA, 1984, P SOC EXP BIOL MED, V176, P249; HAZELTON GA, 1980, BIOCHEM J, V188, P25, DOI 10.1042/bj1880025; HORAKOVA M, 1988, MECH AGEING DEV, V45, P1, DOI 10.1016/0047-6374(88)90014-0; KABELIC T, 1991, P NATL ACAD SCI USA, V88, P986; KUBO C, 1984, J NUTR, V114, P1884, DOI 10.1093/jn/114.10.1884; LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5; Lang C A, 1989, Prog Clin Biol Res, V287, P241; LANG CA, 1992, J LAB CLIN MED, V120, P720; LAUTERBURG BH, 1984, HEPATOLOGY, V4, P586, DOI 10.1002/hep.1840040402; MACDONALD CM, 1977, BIOCHEM PHARMACOL, V26, P1529, DOI 10.1016/0006-2952(77)90428-2; MATSUBARA LS, 1991, BRAZ J MED BIOL RES, V24, P449; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MORTENSEN RA, 1953, J BIOL CHEM, V204, P239; MURAKAMI K, 1989, METABOLISM, V38, P753, DOI 10.1016/0026-0495(89)90061-9; ORENTREICH N, 1993, J NUTR, V123, P269; PYKE S, 1986, BIOCHEM BIOPH RES CO, V139, P926, DOI 10.1016/S0006-291X(86)80266-2; RATHBUN WB, 1991, EXP EYE RES, V53, P205, DOI 10.1016/0014-4835(91)90075-P; RICHIE JP, 1987, P SOC EXP BIOL MED, V184, P113; RICHIE JP, 1988, P SOC EXP BIOL MED, V187, P235; RICHIE JP, 1987, ANAL BIOCHEM, V163, P9, DOI 10.1016/0003-2697(87)90085-6; RICHIE JP, 1992, EXP GERONTOL, V27, P615, DOI 10.1016/0531-5565(92)90015-R; SENDELBACH LE, 1990, TOXICOL APPL PHARM, V102, P259, DOI 10.1016/0041-008X(90)90025-P; SMOLIN LA, 1989, ABSORPTION UTILIZATI, V1, P157; SOHAL RS, 1984, MECH AGEING DEV, V24, P185, DOI 10.1016/0047-6374(84)90070-8; STOHS SJ, 1980, AGE, V3, P11, DOI 10.1007/BF02435000; Tateishi N., 1983, GLUTATHIONE STORAGE, P13; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Vina J., 1990, GLUTATHIONE METABOLI; Weber H U, 1982, Arch Gerontol Geriatr, V1, P299, DOI 10.1016/0167-4943(82)90030-9; WEINDRUCH R, 1988, RETARDATION AGING DI; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657	44	251	260	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1302	1307		10.1096/fasebj.8.15.8001743	http://dx.doi.org/10.1096/fasebj.8.15.8001743			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001743				2022-12-28	WOS:A1994PY20900014
J	CHOI, AMK; TUCKER, RW; CARLSON, SG; WIEGAND, G; HOLBROOK, NJ				CHOI, AMK; TUCKER, RW; CARLSON, SG; WIEGAND, G; HOLBROOK, NJ			CALCIUM MEDIATES EXPRESSION OF STRESS-RESPONSE GENES IN PROSTAGLANDIN A(2)-INDUCED GROWTH ARREST	FASEB JOURNAL			English	Article						GADD153; GENE EXPRESSION; HEME OXYGENASE; HSP70; C-FOS; EGR-1	SHOCK TRANSCRIPTION FACTOR; CELL-CYCLE PROGRESSION; FOS PROTO-ONCOGENE; MESSENGER-RNA; C-FOS; CYCLOPENTENONE PROSTAGLANDINS; ELEVATED EXPRESSION; SKIN FIBROBLASTS; HEME OXYGENASE; DNA DAMAGE	We have explored the mechanisms involved in the induction of five stress-response genes (heme oxygenase [HO], c-fos, Egr-1; gadd153, and HSP70) in human diploid fibroblasts growth-arrested by treatment with the antiproliferative prostaglandin A(2) (PGA(2)). The kinetics of c-fos and Egr-1 induction were found to be rapid with maximum expression occurring within 60 min of treatment, whereas maximum expression of HO, gadd153, and HSP70 occurred between 4 and 8 h of treatment. Nuclear run-on assays and measurements of mRNA clearance in the presence of actinomycin D demonstrated that increases in both the rates of gene transcription and/or mRNA stability contribute to the genetic response to PGA(2). Although the mechanisms responsible for increasing the mRNA levels differ for the individual genes, additional experiments provided evidence that alterations in intracellular calcium ([Ca2+](i)) levels were important in initiating the genetic response to PGA(2). PGA(2) treatment resulted in a rapid increase in [Ca2+](i) with the dose-response relationship for Ca2+ mobilization consistent with that seen for the induction of all five genes. [Ca2+](i) chelators that attenuate Ca2+ mobilization by PGA(2) also blocked the mRNA induction by PGA(2) treatment. Density-inhibited confluent cells were less responsive than proliferating subconfluent cells with respect to Ca2+ mobilization after PGA(2) treatment. This was correlated with a lower level of gene induction. These studies support the hypothesis that increased Ca2+ mobilization is an early and central event in the signal transduction pathway (or pathways) mediating the activation of genes in response to PGA(2) treatment.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224; JOHNS HOPKINS MED INST,DIV PULM & CRIT CARE,BALTIMORE,MD; JOHNS HOPKINS MED INST,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NIA NIH HHS [K11AG00516] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K11AG000516] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BREGMAN MD, 1986, CANCER RES, V46, P2740; BUSCHER M, 1988, ONCOGENE, V3, P301; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P24; ISHIOKA C, 1988, CANCER RES, V48, P2813; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LINQUIST S, 1988, ANNU REV GENET, V22, P631; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARUI N, 1990, FEBS LETT, V270, P15, DOI 10.1016/0014-5793(90)81224-C; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; OHNO K, 1988, J PHARMACOL EXP THER, V245, P294; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; OHNO K, 1988, J BIOL CHEM, V263, P19764; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; PRESTON GM, 1990, MOL CELL BIOL, V10, P442, DOI 10.1128/MCB.10.2.442; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; SANTORO MG, 1986, CANCER RES, V46, P6073; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; WARE RE, 1992, INT IMMUNOL, V5, P179; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	41	48	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1048	1054		10.1096/fasebj.8.13.7926370	http://dx.doi.org/10.1096/fasebj.8.13.7926370			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926370				2022-12-28	WOS:A1994PN06900009
J	LOTAN, M; SCHWARTZ, M				LOTAN, M; SCHWARTZ, M			CROSS-TALK BETWEEN THE IMMUNE-SYSTEM AND THE NERVOUS-SYSTEM IN RESPONSE TO INJURY - IMPLICATIONS FOR REGENERATION	FASEB JOURNAL			English	Review						INFLAMMATION; NERVE INJURY; NERVE RECOVERY; NEUROIMMUNOLOGY	TUMOR-NECROSIS-FACTOR; FIBROBLAST GROWTH-FACTOR; COLONY-STIMULATING FACTOR; FISH OPTIC-NERVE; ACUTE INFLAMMATORY RESPONSE; FIBRILLARY ACIDIC PROTEIN; FACTOR GM-CSF; MESSENGER-RNA; FACTOR-I; GLIOBLASTOMA CELLS	The central nervous system has long been regarded as an immunologically privileged site. Accumulating evidence suggests, however, that the privilege is not total, and that certain immune functions involving immune components and resident glial cells can operate in the central nervous system. The nervous and immune systems interact during normal development, but in the mature brain their interaction is restricted mainly to cases of pathogenic infections and traumatic lesions. The focus of this review is on bidirectional interactions between immune and neuroglial components in response to nerve injury. The macrophage is the most ubiquitous of the immune-derived cell types associated with injury. Its role, as in any other organ, is tissue remodeling and promotion of healing. Macrophage activities include removal of dead tissue and debris by phagocytosis, lipid recycling, and secretion of a wide spectrum of cytokines possessing trophic, mitogenic, and chemotactic properties. These activities affect the behavior of resident cells in the vicinity of the wound. We discuss the possible association of these cytokines with the ability of injured nerves to regenerate. Finally, we consider the apparently conflicting effects of posttraumatic inflammation on the recovery of function.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ALOISI F, 1992, J IMMUNOL, V149, P2358; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; ANDERSSON PB, 1991, IMMUNOL LETT, V30, P177, DOI 10.1016/0165-2478(91)90022-3; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; BEDI KS, 1992, EUR J NEUROSCI, V4, P193, DOI 10.1111/j.1460-9568.1992.tb00867.x; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BEUCHE W, 1984, J NEUROCYTOL, V13, P767, DOI 10.1007/BF01148493; BLAUGRUND E, 1991, GLIA, V4, P393, DOI 10.1002/glia.440040407; BLAUGRUND E, 1992, EXP NEUROL, V118, P105, DOI 10.1016/0014-4886(92)90027-N; BRUCK W, 1992, J NEUROIMMUNOL, V38, P9, DOI 10.1016/0165-5728(92)90085-Y; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CAVAILLON JM, 1987, CELL IMMUNOL, V106, P293, DOI 10.1016/0008-8749(87)90173-0; CHERNAUSEK SD, 1993, J NEUROSCI RES, V34, P189, DOI 10.1002/jnr.490340206; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COHEN A, 1990, BRAIN RES, V537, P24, DOI 10.1016/0006-8993(90)90335-9; COHEN I, 1993, J COMP NEUROL, V334, P431, DOI 10.1002/cne.903340308; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DELRIO PH, 1927, B J HOPKINS HOSP, V31, P278; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; FABIAN RH, 1993, J NEUROIMMUNOL, V44, P95, DOI 10.1016/0165-5728(93)90272-Z; FARRAR WL, 1989, BLOOD, V73, P137; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FONTANA A, 1982, J IMMUNOL, V129, P2413; FREI K, 1986, J IMMUNOL, V137, P3521; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; FREI K, 1992, J IMMUNOL, V148, P3140; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1988, J NEUROSCI, V8, P4707; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAN VKM, 1987, J NEUROSCI, V7, P501; HAREL A, 1989, J NEUROCHEM, V52, P1218, DOI 10.1111/j.1471-4159.1989.tb01869.x; HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3; HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; HICKEY WF, 1985, CELL IMMUNOL, V91, P528, DOI 10.1016/0008-8749(85)90251-5; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HIRSCHBERG DL, 1994, IN PRESS J NEUROIMMU; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Legoux P, 1992, Eur Cytokine Netw, V3, P553; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LOTAN M, 1994, IN PRESS EXP NEUROL; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MCMORRIS FA, 1990, ANN NY ACAD SCI, V605, P101, DOI 10.1111/j.1749-6632.1990.tb42385.x; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; MILLER RH, 1986, J NEUROSCI, V6, P22; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; MUELLER HW, 1988, POSTLESION NEURAL PL, P85; MULLER HW, 1986, J CELL BIOL, V102, P393, DOI 10.1083/jcb.102.2.393; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; OHNO K, 1990, BIOCHEM BIOPH RES CO, V169, P719, DOI 10.1016/0006-291X(90)90390-9; PATERSON PY, 1981, IMMUNOL REV, V55, P89, DOI 10.1111/j.1600-065X.1981.tb00340.x; PATERSON PY, 1982, CLIN IMMUNOL REV, V1, P581; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Rapoport SI, 1976, BLOOD BRAIN BARRIER; RECIOPINTO E, 1984, BRAIN RES, V302, P323, DOI 10.1016/0006-8993(84)90246-4; RECIOPINTO E, 1988, NEUROCHEM INT, V12, P397, DOI 10.1016/0197-0186(88)90021-6; REIER PJ, 1983, SPINAL CORD RECONSTR, P163; RIOPELLE RJ, 1981, NEUROSCI LETT, V25, P311, DOI 10.1016/0304-3940(81)90410-9; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIVRON T, 1991, GLIA, V4, P591, DOI 10.1002/glia.440040606; SIVRON T, 1990, GLIA, V3, P267, DOI 10.1002/glia.440030406; SIVRON T, 1994, J COMP NEUROL, V341, P1; SIVRON T, 1994, IN PRESS TINS; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STOLL G, 1986, NEUROSCI LETT, V72, P233, DOI 10.1016/0304-3940(86)90519-7; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; TRAUGOTT U, 1985, SPRINGER SEMIN IMMUN, V8, P71; TWEARDY DJ, 1991, J NEUROIMMUNOL, V32, P269, DOI 10.1016/0165-5728(91)90197-F; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586	105	131	139	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1026	1033		10.1096/fasebj.8.13.7926367	http://dx.doi.org/10.1096/fasebj.8.13.7926367			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926367				2022-12-28	WOS:A1994PN06900006
J	WILLIAMS, RM; PISTON, DW; WEBB, WW				WILLIAMS, RM; PISTON, DW; WEBB, WW			2-PHOTON MOLECULAR-EXCITATION PROVIDES INTRINSIC 3-DIMENSIONAL RESOLUTION FOR LASER-BASED MICROSCOPY AND MICROPHOTOCHEMISTRY	FASEB JOURNAL			English	Review						2-PHOTON; LASER SCANNING; FLUORESCENCE EXCITATION; CONFOCAL; REVIEW	2-PHOTON EXCITATION; FLUORESCENCE MICROSCOPY; CORRELATION SPECTROSCOPY; SCANNING MICROSCOPY; CARDIAC MYOCYTES; SEA-URCHIN; CELLS	With the development of sensitive and specific fluorescent indicators, modern laser scanning microscopies enable visualization and measurement of submicron, dynamic processes inside living cells and tissues. Here we describe the working principles of new, nonlinear laser microscopies based on two-photon molecular excitation. In these techniques, a pulsed laser produces peak photon densities high enough that when focused into an appropriate medium, excitation by photon energy combinations can occur. For example, two red photons interacting simultaneously with a fluorescent molecule can excite within it a UV electronic transition, one corresponding to twice the energy of each single photon. Because the amount of two-photon excitation depends on the square of the local illumination intensity, this process exhibits a unique localization to the diffraction-limited spot of the beam focus. Elsewhere along the beam, excitation of background and photodamage is virtually nonexistent, Focal point localization of two-photon excitation lends to all visualization, measurement, and photopharmacology studies an intrinsic, three-dimensional resolution. We describe some preliminary biological applications, specifically, imaging of vital DNA stains in developing cells and embryos, imaging of cellular metabolic activity from NADH autofluorescence, spatially resolved measurements of cytoplasmic calcium ion activity, and optically induced micropharmacology using caged bioeffector molecules.	CORNELL UNIV,DEPT PHYS,ITHACA,NY 14853; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Cornell University; Vanderbilt University			Webb, Watt W./B-5905-2011	Williams, Rebecca/0000-0002-1391-5846	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-04224] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRAKENHOFF GJ, 1993, J MICROSC-OXFORD, V171, P17, DOI 10.1111/j.1365-2818.1993.tb03355.x; BREDIKHI.VI, 1970, FIZ TVERD TELA+, V11, P1871; CAUCHETEUXSILBERZAN I, 1993, BIOPHYS J, V64, pA109; CURLEY PF, 1992, OPT QUANT ELECTRON, V24, P851, DOI 10.1007/BF00620198; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk Winfried, 1993, Society for Neuroscience Abstracts, V19, P91; ELSON EL, 1975, ANNU REV BIOPHYS BIO, V4, P311, DOI 10.1146/annurev.bb.04.060175.001523; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; Goppert-Mayer M, 1931, ANN PHYS-BERLIN, V9, P273; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILD JB, 1993, BIOPHYS J, V64, pA110; Haugland R.P., 1992, HDB FLUORESCENT PROB; HELL S, 1992, OPT COMMUN, V93, P277, DOI 10.1016/0030-4018(92)90185-T; KOU LH, 1993, APPL OPTICS, V32, P3531, DOI 10.1364/AO.32.003531; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LUBYPHELPS K, 1988, CELL MOTIL CYTOSKEL, V10, P28, DOI 10.1002/cm.970100107; MALCOLM GPA, 1992, OPT QUANT ELECTRON, V24, P705, DOI 10.1007/BF00620151; PANG Y, 1993, OPT LETT, V18, P1168, DOI 10.1364/OL.18.001168; PELOUCH WS, 1992, OPT LETT, V17, P1070, DOI 10.1364/OL.17.001070; PISTON D W, 1992, Biophysical Journal, V61, pA34; PISTON DW, 1994, APPL OPTICS, V33, P662, DOI 10.1364/AO.33.000662; PISTON DW, 1992, P SOC PHOTO-OPT INS, V1640, P379, DOI 10.1117/12.58230; PISTON DW, 1993, BIOPHYS J, V64, pA110; RIDSDALE JA, 1993, BIOPHYS J, V64, pA109; SANDISON DR, 1994, IN PRESS APPL OPTICS; SHEPPARD CJR, 1987, J OPT SOC AM A, V4, P1354, DOI 10.1364/JOSAA.4.001354; SHEPPARD CJR, 1990, OPTIK, V86, P104; SO PTC, 1993, BIOPHYS J, V64, pA218; SUMMERS RG, 1993, DEV GROWTH DIFFER, V35, P41; SUMMERS RG, 1993, METHOD CELL BIOL, V38, P265; WILLIAMS RM, 1993, BIOPHYS J, V64, pA367; [No title captured]	32	161	175	0	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					804	813		10.1096/fasebj.8.11.8070629	http://dx.doi.org/10.1096/fasebj.8.11.8070629			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070629				2022-12-28	WOS:A1994PC88500002
J	PENNYPACKER, KR; HONG, JS; MCMILLIAN, MK				PENNYPACKER, KR; HONG, JS; MCMILLIAN, MK			PHARMACOLOGICAL REGULATION OF AP-1 TRANSCRIPTION FACTOR DNA-BINDING ACTIVITY	FASEB JOURNAL			English	Article						FOS-RELATED ANTIGEN; C-JUN; CNS; CAMP RESPONSIVE ELEMENT BINDING PROTEIN; ADRENAL GLAND; DOPAMINE; KAINATE; NICOTINE	TYROSINE-HYDROXYLASE GENE; C-FOS EXPRESSION; PROTEIN-KINASE-C; RAT STRIATUM; DIFFERENTIAL EXPRESSION; JUN; BRAIN; ACTIVATION; INDUCTION; SEIZURE	The AP-1 transcription factor family consists of two groups of proteins, fos-related antigens (fra) and jun proteins. These transcription factors are usually expressed at low basal levels but they can be dramatically induced in a variety of cell types by many different stimuli, in which the quantity of AP-1 transcription factor and the DNA binding activity also rise. The quantity and DNA binding activity of transcription factors are not always at low levels. For example, early in brain development a high basal expression of AP-1. DNA binding activity exists. Similarly, adult rat adrenal gland contains high levels of AP-1 DNA binding activity whose regulation appears to be through post-translational modification (i.e., phosphorylation). Thus, AP-1 DNA binding activity is modulated in a developmental and tissue-specific manner.			PENNYPACKER, KR (corresponding author), NIEHS,MOLEC & INTEGRAT NEUROSCI LAB,RES TRIANGLE PK,NC 27709, USA.		Pennypacker, Keith/I-5092-2012; Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401				ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COLE AJ, 1992, J NEUROCHEM, V58, P1420, DOI 10.1111/j.1471-4159.1992.tb11358.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DECRISTOFARO JD, 1990, NEUROSCIENCE, V35, P203, DOI 10.1016/0306-4522(90)90135-Q; DOUGLASS J, 1989, MOL ENDOCRINOL, V3, P2070, DOI 10.1210/mend-3-12-2070; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; DUGICHDJORDJEVIC MM, 1992, NEURON, V8, P1127, DOI 10.1016/0896-6273(92)90133-X; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GUBITS RM, 1993, MOL BRAIN RES, V18, P228, DOI 10.1016/0169-328X(93)90194-T; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P1022; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P431; NANKOVA B, 1993, J NEUROCHEM, V61, P776; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PELTOHUIKKO M, 1991, NEUROSCI LETT, V126, P163, DOI 10.1016/0304-3940(91)90544-4; PENNYPACKER KR, 1993, MOL BRAIN RES, V19, P349, DOI 10.1016/0169-328X(93)90138-F; PENNYPACKER KR, 1992, J BIOL CHEM, V267, P20148; PENNYPACKER KR, 1992, MOL BRAIN RES, V15, P151, DOI 10.1016/0169-328X(92)90163-6; PENNYPACKER KR, 1993, J NEUROCHEM, V62, P438; ROBERTSON GS, 1989, EUR J PHARMACOL, V159, P99, DOI 10.1016/0014-2999(89)90049-6; ROBERTSON GS, 1992, NEUROSCIENCE, V46, P315, DOI 10.1016/0306-4522(92)90054-6; SAKAURAIYAMASHI.Y, 1991, EUR J NEUROSCI, V3, P764; SCHREIBER SS, 1992, NEUROSCI LETT, V136, P31, DOI 10.1016/0304-3940(92)90640-S; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; VENDRELL M, 1993, NEUR ABSTR, V19, P262; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG WQ, 1992, BRAIN RES, V577, P312, DOI 10.1016/0006-8993(92)90289-L	43	65	67	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					475	478		10.1096/fasebj.8.8.8181665	http://dx.doi.org/10.1096/fasebj.8.8.8181665			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181665				2022-12-28	WOS:A1994NM36400003
J	YEN, TT; GILL, AM; FRIGERI, LG; BARSH, GS; WOLFF, GL				YEN, TT; GILL, AM; FRIGERI, LG; BARSH, GS; WOLFF, GL			OBESITY, DIABETES, AND NEOPLASIA IN YELLOW A(VY)/- MICE - ECTOPIC EXPRESSION OF THE AGOUTI GENE	FASEB JOURNAL			English	Review						OBESITY; DIABETES; NEOPLASIA; YELLOW MOUSE; AGOUTI LOCUS	VY F1-HYBRID MICE; BODY-WEIGHT; AVY/A MICE; GLUCOSE-TOLERANCE; ADIPOSE-TISSUE; COAT COLOR; INSULIN; MOUSE; THERMOGENESIS; CIGLITAZONE	The viable yellow A(vy) mutation results in a mottled yellow mouse that is obese, slightly larger than its nonyellow sibs, and more susceptible to tumor formation in those tissues sensitized by the strain genome. The mutation exhibits variable expressivity resulting in a continuum of coat color phenotypes, from clear yellow to pseudoagouti. The mouse agouti protein is a paracrine signaling molecule that induces hair follicle melanocytes to switch from the synthesis of black pigment to yellow pigment. Molecular cloning studies indicate that the obesity and growth effects of the A(vy) mutation result from ectopic expression of the normal agouti gene product. This review seeks to summarize the current state of knowledge regarding the obesity, stimulation of somatic growth, and enhancement of tumor formation caused by the A(vy) mutation, and to interpret these pleiotropic effects in terms of the normal function of the agouti protein.	US FDA, NATL CTR TOXICOL RES, DIV NUTR TOXICOL, JEFFERSON, AR 72079 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, INDIANAPOLIS, IN 46285 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; STANFORD UNIV, SCH MED, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM MOLEC BIOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, DEPT PHARMACOL TOXICOL, LITTLE ROCK, AR 72205 USA	US Food & Drug Administration (FDA); Eli Lilly; Scripps Research Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences								ANDERSON GH, 1984, BRAIN RES BULL, V12, P167, DOI 10.1016/0361-9230(84)90185-0; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BARSH GS, 1989, GENETICS, V121, P811; BRAY GA, 1988, OBESITY EUROPE 88, P259; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1974, DIABETOLOGIA, V10, P607, DOI 10.1007/BF01221993; CONKLIN BR, 1993, NATURE, V364, P110, DOI 10.1038/364110b0; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DICKIE MM, 1962, J HERED, V53, P4; FRIGERI LG, 1983, ENDOCRINOLOGY, V113, P2097, DOI 10.1210/endo-113-6-2097; FRIGERI LG, 1988, INT J OBESITY, V12, P305; FULLER RW, 1982, LIFE SCI, V31, P563, DOI 10.1016/0024-3205(82)90485-4; FURST AS, 1991, CARCINOGENESIS, V12, P1157, DOI 10.1093/carcin/12.7.1157; GALBRAITH DB, 1974, J HERED, V65, P137, DOI 10.1093/oxfordjournals.jhered.a108484; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P1165, DOI 10.1210/endo-79-6-1165; GILL AM, 1991, LIFE SCI, V48, P703, DOI 10.1016/0024-3205(91)90546-N; GILL AM, 1994, IN PRESS DIABETES; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HSIAO W L W, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P160; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JOHNSON PR, 1991, ANNU REV NUTR, V11, P325, DOI 10.1146/annurev.nu.11.070191.001545; JOHNSON PR, 1972, J LIPID RES, V13, P2; JOOSTEN HFP, 1974, METABOLISM, V23, P59, DOI 10.1016/0026-0495(74)90104-8; LAMOREAUX ML, 1973, THESIS U MAINE ORONO; LEITER EH, 1993, CRIT REV FOOD SCI, V33, P333, DOI 10.1080/10408399309527629; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MINTZ B, 1970, CONTROL MECHANISMS E, P15; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBERTS DW, 1984, P NATL ACAD SCI-BIOL, V81, P2152, DOI 10.1073/pnas.81.7.2152; SALANS LB, 1987, RECENT ADV OBESITY R, V5, P26; SALEM MAM, 1989, P SOC EXP BIOL MED, V191, P408; SHAW WN, 1981, LIFE SCI, V29, P2091; SHIMIZU H, 1989, AM J PHYSIOL, V256, pR494, DOI 10.1152/ajpregu.1989.256.2.R494; SHIMIZU H, 1989, LIFE SCI, V45, P543, DOI 10.1016/0024-3205(89)90105-7; SHUMAN CR, 1988, DIABETES MELLITUS, P2; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; STEINMET.J, 1969, DIABETOLOGIA, V5, P373, DOI 10.1007/BF00427974; TAMATE HB, 1984, SCIENCE, V224, P1241, DOI 10.1126/science.6328651; TURNER RC, 1992, INT J OBESITY, V16, pS43; VRIELING H, 1994, IN PRESS P NATL ACAD; WAJNGOT A, 1992, P NATL ACAD SCI USA, V89, P6035, DOI 10.1073/pnas.89.13.6035; WARBRITTON A, 1994, IN PRESS P SOC EXP B; WOLFF GL, 1973, GENETICS, V73, P109; WOLFF GL, 1986, CARCINOGENESIS, V7, P1895, DOI 10.1093/carcin/7.11.1895; WOLFF GL, 1991, PROG OBES R, P445; WOLFF GL, 1987, CARCINOGENESIS, V8, P1889, DOI 10.1093/carcin/8.12.1889; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOLFF GL, 1987, AM J CLIN NUTR, V45, P168, DOI 10.1093/ajcn/45.1.168; WOLFF GL, 1978, GENETICS, V88, P529; WOLFF GL, 1978, J HERED, V69, P295, DOI 10.1093/oxfordjournals.jhered.a108953; WOLFF GL, 1993, J EXP ANIM SCI, V35, P221; WOLFF GL, 1963, GENETICS, V48, P1041; YEN T, 1993, P EUR ASS STUDY DIAB, P698; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN T T T, 1970, Hormone and Metabolic Research, V2, P161; YEN TT, 1984, INT J OBESITY, V8, P65; YEN TT, 1976, BIOCHIM BIOPHYS ACTA, V441, P213, DOI 10.1016/0005-2760(76)90164-8; YEN TT, 1987, DRUG DEVELOP RES, V10, P37, DOI 10.1002/ddr.430100106; YEN TT, 1972, HORM METAB RES, V4, P331, DOI 10.1055/s-0028-1094027; YEN TT, 1976, HORM METAB RES, V8, P159, DOI 10.1055/s-0028-1093672; YEN TT, 1981, LIFE SCI, V28, P119, DOI 10.1016/0024-3205(81)90543-9; YEN TT, 1992, INT J OBESITY, V16, P923; YEN TT, 1984, INT J OBESITY, V8, P69; YEN TT, 1983, LIFE SCI, V32, P1515, DOI 10.1016/0024-3205(83)90918-9; YEN TT, 1988, INT J OBESITY, V12, P59; YEN TT, 1990, FRONTIERS DIABETES R, V3, P294	74	263	286	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					479	488		10.1096/fasebj.8.8.8181666	http://dx.doi.org/10.1096/fasebj.8.8.8181666			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181666				2022-12-28	WOS:A1994NM36400004
J	VALERA, A; FILLAT, C; COSTA, C; SABATER, J; VISA, J; PUJOL, A; BOSCH, F				VALERA, A; FILLAT, C; COSTA, C; SABATER, J; VISA, J; PUJOL, A; BOSCH, F			REGULATED EXPRESSION OF HUMAN INSULIN IN THE LIVER OF TRANSGENIC MICE CORRECTS DIABETIC ALTERATIONS	FASEB JOURNAL			English	Article						DIABETES; INSULIN; P-ENOLPYRUVATE CARBOXYKINASE; TRANSGENIC MICE; GENE THERAPY	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HEPATIC GLUCOSE-PRODUCTION; GROWTH-HORMONE GENE; MESSENGER-RNA; RAT-LIVER; DIETARY-REGULATION; GLYCOGEN-SYNTHASE; GLUCOKINASE GENE; CYCLIC-AMP; CELLS	Transgenic mice expressing the P-enolpyruvate carboxykinase (PEPCK)/human insulin chimeric gene have been obtained as a model to study the feasibility of gene therapy for diabetes. These transgenic animals were healthy and normoglycemic and expressed human insulin in a physiologically regulated manner, mainly in the liver. Streptozotocin-treated transgenic mice had high levels of human insulin immunoreactivity in serum and showed a significant decrease (up to 40%) in glycemia compared with streptozotocin-treated control mice. The expression of genes involved in liver glucose metabolism, such as glucokinase, pyruvate kinase, and PEPCK, which is markedly altered by diabetes, was significantly recovered in transgenic mice treated with streptozotocin. In addition, the activity of both glucokinase and glycogen synthase, and the content of glucose 6-phosphate and glycogen, were normal in the liver, even when transgenic animals were treated with diabetogenic doses of streptozotocin. These results constitute an indication in vivo that diabetes gene therapy is possible, by means of the production of insulin in extrapancreatic tissues.	AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT BIOCHEM & MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona			Pujol, Anna/J-7939-2017; Costa, Cristina/AAP-4005-2020; Fillat, Cristina/ABH-1674-2020	Pujol, Anna/0000-0002-3484-598X; Costa, Cristina/0000-0002-1837-4268; BOSCH, FATIMA/0000-0002-7705-5515; Fillat, Cristina/0000-0002-0801-3338				ANDREONE TL, 1989, J BIOL CHEM, V264, P363; BANCROFT JD, 1982, THEORY PRACTICE HIST, P122; BEALE EG, 1985, J BIOL CHEM, V260, P748; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BUCCHINI D, 1986, P NATL ACAD SCI USA, V83, P2511, DOI 10.1073/pnas.83.8.2511; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIL J, 1988, J BIOL CHEM, V263, P1868; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HOGAN B, 1986, MANIPULATING MOUSE E; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; KIOUSSIS D, 1978, J BIOL CHEM, V253, P4327; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MILLER TB, 1973, J BIOL CHEM, V248, P3483; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SELDEN RF, 1987, NEW ENGL J MED, V317, P1067; SELDEN RF, 1986, NATURE, V321, P525, DOI 10.1038/321525a0; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SIBROWSKI W, 1984, J BIOL CHEM, V259, P343; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Sokal R.R., 2011, BIOMETRY, V4th; TAYLOR R, 1988, BIOCHEM J, V250, P625, DOI 10.1042/bj2500625; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; UNGER R H, 1985, P1018; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1983, HDB EXPT PHARM, V2, P431; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895	63	68	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					440	447		10.1096/fasebj.8.6.8168695	http://dx.doi.org/10.1096/fasebj.8.6.8168695			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168695				2022-12-28	WOS:A1994NH25000012
J	VOUSDEN, K				VOUSDEN, K			INTERACTIONS OF HUMAN PAPILLOMAVIRUS TRANSFORMING PROTEINS WITH THE PRODUCTS OF TUMOR-SUPPRESSOR GENES	FASEB JOURNAL			English	Review						HUMAN TUMOR VIRUS; CELL CYCLE; ONCOPROTEIN	KINASE-II PHOSPHORYLATION; TYPE-16 E7 ONCOPROTEIN; LARGE T-ANTIGEN; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; PHYSICAL STATE; RETINOBLASTOMA PROTEIN; ADENOVIRUS E1A; E6 ONCOPROTEIN; WILD-TYPE	Human papillomaviruses (HPVs) contribute to the development of almost all cervical cancers, a common and often fatal human disease. The mechanisms by which the HPVs function in malignant progression appear to be related to the activity of the two viral oncoproteins, E6 and E7, which form complexes with several cell proteins normally involved in controlling cell growth. Of particular interest has been the association of E6 with p53 and E7 with Rb, both products of tumor suppressor genes. Expression of E6 and E7 is likely to overcome the regulation of cell proliferation normally mediated by proteins like p53 and Rb, allowing uncontrolled growth and providing the potential for malignant transformation. These activities of E6 and E7 support the importance of the tumor suppressor proteins in the maintenance of normal cell proliferation and provide novel approaches to understanding the mechanisms by which they function.			VOUSDEN, K (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DAS BC, 1992, J GEN VIROL, V73, P2327, DOI 10.1099/0022-1317-73-9-2327; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEHN H, 1988, J GEN VIROL, V69, P187, DOI 10.1099/0022-1317-69-1-187; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SPALHOLZ BA, 1989, ADV VIRAL ONCOL, V8, P27; STEELE C, 1992, CANCER RES, V52, P4706; TOMMASINO M, 1993, ONCOGENE, V8, P195; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCZYNSKI SP, 1988, VIROLOGY, V166, P624, DOI 10.1016/0042-6822(88)90539-9; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614	56	170	180	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					872	879		10.1096/fasebj.7.10.8393818	http://dx.doi.org/10.1096/fasebj.7.10.8393818			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393818				2022-12-28	WOS:A1993LQ33700009
J	BRUENGER, E; KOWALAK, JA; KUCHINO, Y; MCCLOSKEY, JA; MIZUSHIMA, H; STETTER, KO; CRAIN, PF				BRUENGER, E; KOWALAK, JA; KUCHINO, Y; MCCLOSKEY, JA; MIZUSHIMA, H; STETTER, KO; CRAIN, PF			5S RIBOSOMAL-RNA MODIFICATION IN THE HYPERTHERMOPHILIC ARCHAEA SULFOLOBUS-SOLFATARICUS AND PYRODICTIUM-OCCULTUM	FASEB JOURNAL			English	Article						PYRODICTIUM-OCCULTUM; SULFOLOBUS-SOLFATARICUS; 5S RIBOSOMAL-RNA ELECTROSPRAY MASS SPECTROMETRY; N4-ACETYL-2'-O-METHYLCYTIDINE	CHROMATOGRAPHY-MASS-SPECTROMETRY; TRANSFER-RNA; LIQUID-CHROMATOGRAPHY; STRUCTURAL CHARACTERIZATION; NUCLEOSIDES; ACIDOCALDARIUS; ARCHAEBACTERIA; RIBOSOMES	The 5S rRNAs from Sulfolobus solfataricus and Pyrodictium occultum were digested to nucleosides and analyzed using directly-combined HPLC/mass spectrometry. P. occultum 5S rRNA contains two modified nucleoside species, N4-acetylcytidine (ac4C) and N4-acetyl-2'-O-methylcytidine (ac4Cm). Oligonucleotides were generated from P. occultum 5S rRNA by RNase T1 hydrolysis, and their molecular weights were determined using electrospray mass spectrometry and compared with those predicted from the P. occultum 5S RNA gene sequence. Deviation in mass between expected and observed molecular weights permitted ac4Cm to be located at position 35, in the nonanucleotide CAA-CACC[ac4Cm]G, and the ac4C in one or both of two (C,U)G trinucleotides. 2'-O-Methylcytidine is unambiguously characterized in S. solfataricus 5S rRNA, confirming earlier tentative assignments at the analogous sequence position (Stahl, D. A., Luehrsen, K. R., Woese, C. R., and Pace, N. R. (1981) Nucleic Acids Res., Vol. 9, pp. 6129-6137; Dams, E., Londei, P.. Cammarano, P., Vandenberghe, A., and De Wachter, R. (1983) Nucleic Acids Res. Vol. 11, pp. 4667-4676). Potential effects of the presence of ac4C and ac4Cm on thermal stabilization of 5S rRNA in thermophiles are discussed.	UNIV UTAH,DEPT MED CHEM,311A SKAGGS HALL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,W-8400 REGENSBURG,GERMANY	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Cancer Center - Japan; University of Regensburg					NIGMS NIH HHS [GM 29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS PF, 1973, ARCH BIOCHEM BIOPHYS, V154, P277, DOI 10.1016/0003-9861(73)90058-1; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CRAIN PF, 1990, MASS SPECTROM REV, V9, P505, DOI 10.1002/mas.1280090504; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DAMS E, 1983, NUCLEIC ACIDS RES, V11, P4667, DOI 10.1093/nar/11.14.4667; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; EDMONDS CG, 1987, J CHEM SOC CHEM COMM, P909, DOI 10.1039/c39870000909; KAINE BP, 1989, SYST APPL MICROBIOL, V12, P8; KAWAI G, 1992, NUCLEOS NUCLEOT, V11, P759, DOI 10.1080/07328319208021740; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KOWALAK JA, 1992, 40TH P ANN C MASS SP, P1127; KOWALAK JA, 1993, IN PRESS J AM SOC MA; KUCHINO Y, 1987, P NATL ACAD SCI USA, V84, P2668, DOI 10.1073/pnas.84.9.2668; LONDEI P, 1986, EUR J BIOCHEM, V157, P455, DOI 10.1111/j.1432-1033.1986.tb09689.x; MCCLOSKEY JA, 1991, ACCOUNTS CHEM RES, V24, P81, DOI 10.1021/ar00003a004; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; STAHL DA, 1981, NUCLEIC ACIDS RES, V9, P6129, DOI 10.1093/nar/9.22.6129; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; TAKEDA N, 1991, J CHROMATOGR-BIOMED, V562, P225, DOI 10.1016/0378-4347(91)80580-6; THOMAS G, 1978, J BIOL CHEM, V253, P1101; WATANABE K, 1980, J BIOCHEM-TOKYO, V87, P1; WOLTERS J, 1988, NUCLEIC ACIDS RES, V16, pR1, DOI 10.1093/nar/16.suppl.r1	24	59	63	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					196	200		10.1096/fasebj.7.1.8422966	http://dx.doi.org/10.1096/fasebj.7.1.8422966			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422966				2022-12-28	WOS:A1993KH88000030
J	EDGINGTON, TS				EDGINGTON, TS			VASCULAR BIOLOGY - INTEGRATIVE MOLECULAR CELL BIOLOGY	FASEB JOURNAL			English	Article									Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	EDGINGTON, TS (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.								0	7	7	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					841	842		10.1096/fasebj.9.10.7615153	http://dx.doi.org/10.1096/fasebj.9.10.7615153			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615153				2022-12-28	WOS:A1995RK89900003
J	FORTE, LR; CURRIE, MG				FORTE, LR; CURRIE, MG			GUANYLIN - A PEPTIDE REGULATOR OF EPITHELIAL TRANSPORT	FASEB JOURNAL			English	Article						GUANYLATE CYCLASE; INTESTINE; KIDNEY; CL- SECRETION	HEAT-STABLE ENTEROTOXIN; CYSTIC-FIBROSIS GENE; RAT SMALL-INTESTINE; ESCHERICHIA-COLI; MESSENGER-RNA; CYCLASE-C; EXPRESSION; RECEPTOR; LOCALIZATION; BINDING	Regulation of intestinal salt and water transport is critical to the maintenance of fluid volume. Control of this life-sustaining activity is mediated by the concerted actions of hormones, neurotransmitters, and locally acting factors. The intestinal peptide guanylin is ideally suited to play a pivotal role in this regulation. Guanylin is produced by the epithelium and appears to be secreted mucosally to act locally on an apical receptor. The guanylin receptor is a member of the guanylate cyclase (GC-C) family of proteins. Elevation of intracellular cyclic GMP by guanylin mediates the stimulation of Cl- secretion, which results in the increased intestinal fluid secretion. Proguanylin is found in the circulation and GC-C occurs in other epithelia, suggesting that guanylin plays an endocrine role by regulating the function of tissues such as the kidney and liver. Uroguanylin is a structurally related peptide that is abundant in urine, has biological activity similar to guanylin, and appears to be made by the intestine. This peptide may link the intestine and kidney in an endocrine pathway for control of renal salt excretion. Overproduction of guanylin/uroguanylin would be expected to elicit secretory diarrhea similar to that caused by the bacteria that produce peptide analogs of these endogenous peptide hormones. This unique molecular mimicry has provided clues leading to the discovery of guanylin and insight into the mechanism of action of these intestinal peptides. The discoveries of guanylin and uroguanylin have provided exciting opportunities for further enhancing our understanding of epithelial transport and function.	TRUMAN VET AFFAIRS MED CTR, COLUMBIA, MO 65212 USA; SEARLE RES & DEV, ST LOUIS, MO 63167 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; Pfizer	FORTE, LR (corresponding author), UNIV MISSOURI, SCH MED, DEPT PHARMACOL, M515, MED SCI BLDG, COLUMBIA, MO 65212 USA.							ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; CETIN Y, 1994, P NATL ACAD SCI USA, V91, P2935, DOI 10.1073/pnas.91.8.2935; COHEN MB, 1992, BIOCHEM BIOPH RES CO, V186, P483, DOI 10.1016/S0006-291X(05)80833-2; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; CUTHBERT AW, 1994, BRIT J PHARMACOL, V112, P31, DOI 10.1111/j.1476-5381.1994.tb13024.x; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUFFIN KL, 1992, 40TH P ANN C MASS SP, P1525; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FIELD M, 1989, NEW ENGL J MED, V321, P800; FORTE LR, 1988, AM J PHYSIOL, V255, pF1040, DOI 10.1152/ajprenal.1988.255.5.F1040; FORTE LR, 1993, J CLIN INVEST, V91, P2423, DOI 10.1172/JCI116476; FORTE LR, 1989, AM J PHYSIOL, V257, pF874, DOI 10.1152/ajprenal.1989.257.5.F874; FREEMAN RH, 1994, FASEB J, V8, pA552; GARCIA KC, 1993, J BIOL CHEM, V268, P22397; GARRETT KL, 1992, J HISTOCHEM CYTOCHEM, V40, P1613, DOI 10.1177/40.10.1527380; GOLDSTEIN JL, 1994, GASTROENTEROLOGY, V107, P950, DOI 10.1016/0016-5085(94)90218-6; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HIRAYAMA T, 1993, MICROB PATHOGENESIS, V15, P283, DOI 10.1006/mpat.1993.1078; KATO J, ADV SEC MESS PHOSPH, P139; KITA T, 1994, AM J PHYSIOL, V266, pF342, DOI 10.1152/ajprenal.1994.266.2.F342; KRAUSE WJ, 1994, J ANAT, V184, P407; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; KUHN M, 1993, FEBS LETT, V318, P205, DOI 10.1016/0014-5793(93)80022-M; KUHN M, 1994, J PHYSIOL-LONDON, V479, P433, DOI 10.1113/jphysiol.1994.sp020307; KUHN M, 1994, FEBS LETT, V341, P218, DOI 10.1016/0014-5793(94)80460-5; LANEY DW, 1994, AM J PHYSIOL, V266, pG899, DOI 10.1152/ajpgi.1994.266.5.G899; LANEY DW, 1992, AM J PHYSIOL, V263, pG816, DOI 10.1152/ajpgi.1992.263.5.G816; LENNANE RJ, 1975, CLIN SCI MOL MED, V49, P433, DOI 10.1042/cs0490433; LEWIS LG, 1993, BIOCHEM BIOPH RES CO, V196, P553, DOI 10.1006/bbrc.1993.2285; LI ZP, 1993, AM J PHYSIOL, V265, pG394, DOI 10.1152/ajpgi.1993.265.2.G394; LIMA AAM, 1992, PHARMACOL TOXICOL, V70, P163, DOI 10.1111/j.1600-0773.1992.tb00449.x; MANN EA, 1993, AM J PHYSIOL, V264, pG172, DOI 10.1152/ajpgi.1993.264.1.G172; PARKINSON SJ, 1994, J BIOL CHEM, V269, P22683; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; TRANPATERSON R, 1992, AM J PHYSIOL, V263, pC55, DOI 10.1152/ajpcell.1992.263.1.C55; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; WIEGAND RC, 1992, FEBS LETT, V311, P150, DOI 10.1016/0014-5793(92)81387-2; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; YUEN PST, 1994, J BIOL CHEM, V269, P791	49	114	123	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					643	650		10.1096/fasebj.9.8.7768356	http://dx.doi.org/10.1096/fasebj.9.8.7768356			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768356				2022-12-28	WOS:A1995RC10600010
J	COSTANZO, JP; LEE, RE; DEVRIES, AL; WANG, TC; LAYNE, JR				COSTANZO, JP; LEE, RE; DEVRIES, AL; WANG, TC; LAYNE, JR			SURVIVAL MECHANISMS OF VERTEBRATE ECTOTHERMS AT SUBFREEZING TEMPERATURES - APPLICATIONS IN CRYOMEDICINE	FASEB JOURNAL			English	Review						HYPOTHERMIA; SUPERCOOLING; ANTIFREEZE; FREEZE TOLERANCE; CRYOPROTECTION; DEHYDRATION; CRYOPRESERVATION	MAMMALIAN CARDIAC EXPLANT; FROG RANA-SYLVATICA; NATURAL FREEZE TOLERANCE; WOOD FROG; ANTIFREEZE PROTEINS; CRYOPROTECTANT DISTRIBUTION; PHYSIOLOGICAL-RESPONSES; TERRAPENE-CAROLINA; ICE CONTENT; PRESERVATION	Various marine fishes, amphibians, and reptiles survive at temperatures several degrees below the freezing point of their body fluids by virtue of adaptive mechanisms that promote freeze avoidance or freeze tolerance. Freezing is avoided by a colligative depression of the blood freezing point, supercooling of the body fluids, or the biosynthesis of unique antifreeze proteins that inhibit the propagation of ice within body fluids. Conversely, freeze tolerance is an adaptation for the survival of tissue freezing under ecologically relevant thermal and temporal conditions that is conferred by the biosynthesis of permeating carbohydrate cryoprotectants and an extensive dehydration of tissues and organs. Such cryoprotective responses, invoked by the onset of freezing, mitigate the osmotic stress associated with freeze-concentration of cytoplasm, attendant metabolic perturbations, and physical damage. Cryomedical research has historically relied on mammalian models for experimentation even though endotherms do not naturally experience subfreezing temperatures. Some vertebrate ectotherms have ''solved'' not only the problem of freezing individual tissues and organs, but also that of simultaneously freezing all organ systems. An emerging paradigm in cryomedicine is the application of principles governing natural cold hardiness to the development of protocols for the cryopreservation of mammalian tissues and organs.	SLIPPERY ROCK UNIV, DEPT BIOL, SLIPPERY ROCK, PA 16057 USA; MIAMI UNIV, DEPT ZOOL, OXFORD, OH 45056 USA; UNIV ILLINOIS, DEPT PHYSIOL, URBANA, IL 61801 USA; UNIV ROCHESTER, DEPT SURG, ROCHESTER, NY 14642 USA	Pennsylvania State System of Higher Education (PASSHE); Slippery Rock University - Pennsylvania; University System of Ohio; Miami University; University of Illinois System; University of Illinois Urbana-Champaign; University of Rochester								AHLGREN JA, 1988, J EXP BIOL, V137, P549; BANKER MC, 1992, CRYOBIOLOGY, V29, P87, DOI 10.1016/0011-2240(92)90008-P; BARNES BM, 1989, SCIENCE, V244, P1593, DOI 10.1126/science.2740905; CANTY A, 1986, CRYO-LETT, V7, P81; CARPENTER JF, 1992, P NATL ACAD SCI USA, V89, P8953, DOI 10.1073/pnas.89.19.8953; CLAUSSEN DL, 1990, J THERM BIOL, V15, P223, DOI 10.1016/0306-4565(90)90006-4; COSTANZO JP, 1992, COPEIA, P565; COSTANZO JP, 1991, AM J PHYSIOL, V261, pR1549, DOI 10.1152/ajpregu.1991.261.6.R1549; COSTANZO JP, 1993, J EXP BIOL, V181, P245; COSTANZO JP, 1993, AM J PHYSIOL, V265, pR721, DOI 10.1152/ajpregu.1993.265.4.R721; COSTANZO JP, 1992, J EXP ZOOL, V261, P373, DOI 10.1002/jez.1402610403; COSTANZO JP, 1993, J HERPETOL, V27, P117, DOI 10.2307/1564923; COSTANZO JP, 1991, AM J PHYSIOL, V261, pR1346, DOI 10.1152/ajpregu.1991.261.6.R1346; COSTANZO JP, 1990, J EXP ZOOL, V254, P228, DOI 10.1002/jez.1402540215; COSTANZO JP, 1988, CRYO-LETT, V9, P380; COSTANZO JP, 1995, BIOL ICE NUCLEATION, pCH12; COSTANZO JP, 1995, IN PRESS ECOLOGY; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; FAHY GM, 1986, TRANSPLANTATION APPR; FISER PS, 1993, ANIM REPROD SCI, V30, P325, DOI 10.1016/0378-4320(93)90082-3; FRANKS F, 1990, PHILOS T ROY SOC B, V326, P517, DOI 10.1098/rstb.1990.0029; HERMESLIMA M, 1993, MOL CELL BIOCHEM, V124, P149, DOI 10.1007/BF00929207; HINCHA DK, 1993, BIOCHIM BIOPHYS ACTA, V1146, P258, DOI 10.1016/0005-2736(93)90364-6; KAROW AM, 1991, BIOSCIENCE, V41, P155, DOI 10.2307/1311455; KING PA, 1993, AM J PHYSIOL, V265, pR1036, DOI 10.1152/ajpregu.1993.265.5.R1036; KLING KB, 1994, IN PRESS J COMP PH B; KNIGHT CA, 1984, NATURE, V308, P295, DOI 10.1038/308295a0; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LAYNE JR, 1989, J EXP ZOOL, V249, P133, DOI 10.1002/jez.1402490203; LAYNE JR, 1991, AM J PHYSIOL, V261, pR134, DOI 10.1152/ajpregu.1991.261.1.R134; LAYNE JR, 1989, AM J PHYSIOL, V257, pR1046, DOI 10.1152/ajpregu.1989.257.5.R1046; LAYNE JR, 1992, J THERM BIOL, V17, P121, DOI 10.1016/0306-4565(92)90009-5; LAYNE JR, 1991, J HERPETOL, V25, P129, DOI 10.2307/1564816; LAYNE JR, 1995, IN PRESS J HERPETOL; Lee Marcia R., 1992, Cryobiology, V29, P759; LEE RE, 1992, J THERM BIOL, V17, P263, DOI 10.1016/0306-4565(92)90061-J; LEE RE, 1993, LIFE COLD, V3, P501; LEVINE RL, 1993, FASEB J, V7, P1242, DOI 10.1096/fasebj.7.13.8405809; MAZUR P, 1984, AM J PHYSIOL, V247, pC125, DOI 10.1152/ajpcell.1984.247.3.C125; PAYNE SR, 1994, CRYOBIOLOGY, V31, P180, DOI 10.1006/cryo.1994.1021; PEGG DE, 1988, LOW TEMPERATURE BIOT, V10, P3; PETZEL DH, 1979, CRYOBIOLOGY, V16, P585, DOI 10.1016/0011-2240(79)90087-7; RAYMOND JA, 1992, J EXP ZOOL, V262, P347, DOI 10.1002/jez.1402620316; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; RUBINSKY B, 1992, AM J PHYSIOL, V262, pR542, DOI 10.1152/ajpregu.1992.262.3.R542; RUBINSKY B, 1994, AM J PHYSIOL, V266, pR1771, DOI 10.1152/ajpregu.1994.266.6.R1771; SCHMID WD, 1982, SCIENCE, V215, P697, DOI 10.1126/science.7058335; SCHMID WD, 1965, ECOLOGY, V46, P261, DOI 10.2307/1936329; SOUTHARD JH, 1993, CLIN TRANSPLANT, V7, P134; STOREY KB, 1992, ANNU REV PHYSIOL, V54, P619, DOI 10.1146/annurev.physiol.54.1.619; STOREY KB, 1986, COMP BIOCHEM PHYS A, V83, P613, DOI 10.1016/0300-9629(86)90699-7; STOREY KB, 1992, AM J PHYSIOL, V263, pR185, DOI 10.1152/ajpregu.1992.263.1.R185; STOREY KB, 1988, P NATL ACAD SCI USA, V85, P8350, DOI 10.1073/pnas.85.21.8350; STOREY KB, 1994, AM J PHYSIOL, V266, pR1477, DOI 10.1152/ajpregu.1994.266.5.R1477; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; UMMINGER BL, 1969, J EXP ZOOL, V172, P409, DOI 10.1002/jez.1401720406; VALERIO PF, 1990, CAN J ZOOL, V68, P1065, DOI 10.1139/z90-156; VALERIO PF, 1992, CAN J FISH AQUAT SCI, V49, P2588, DOI 10.1139/f92-286; WANG TC, 1994, CRYOBIOLOGY, V31, P185, DOI 10.1006/cryo.1994.1022; WANG TC, 1991, CRYOBIOLOGY, V28, P171, DOI 10.1016/0011-2240(91)90019-K; WANG TC, 1992, CRYOBIOLOGY, V29, P470, DOI 10.1016/0011-2240(92)90049-8; YANG XP, 1993, CRYOBIOLOGY, V30, P366, DOI 10.1006/cryo.1993.1036; ZHU QY, 1992, CRYOBIOLOGY, V29, P478, DOI 10.1016/0011-2240(92)90050-C; [No title captured]	65	44	45	2	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					351	358		10.1096/fasebj.9.5.7896003	http://dx.doi.org/10.1096/fasebj.9.5.7896003			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896003				2022-12-28	WOS:A1995QP45100006
J	RICHARDSON, JS				RICHARDSON, JS			INTRODUCTION - PROTEIN MOTIFS	FASEB JOURNAL			English	Editorial Material											RICHARDSON, JS (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,211 NANALINE DUKE BLDG,BOX 3711,DURHAM,NC 27710, USA.							RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4	1	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1237	1239		10.1096/fasebj.8.15.8001735	http://dx.doi.org/10.1096/fasebj.8.15.8001735			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001735				2022-12-28	WOS:A1994PY20900006
J	THORBECKE, GJ; AMIN, AR; TSIAGBE, VK				THORBECKE, GJ; AMIN, AR; TSIAGBE, VK			BIOLOGY OF GERMINAL-CENTERS IN LYMPHOID-TISSUE	FASEB JOURNAL			English	Review						APOPTOSIS; SOMATIC MUTATION; MEMORY B CELLS; FOLLICULAR DENDRITIC CELLS; LYMPHOID FOLLICLES	FOLLICULAR DENDRITIC CELLS; CENTER B-CELLS; CLASS-II MOLECULES; PRIMARY IMMUNE-RESPONSE; T-CELLS; MONOCLONAL-ANTIBODIES; IMMUNOLOGICAL MEMORY; LYMPHOCYTES-B; EXPRESS CR-1; CD40 LIGAND	Germinal centers in lymphoid tissue are the sites of generation of memory B cells undergoing isotype switching and somatic mutation in their Ig genes. Their formation cannot be induced by stimuli other than immunogenic ones. It seems likely that in the function and possibly also in the formation of germinal centers, one important factor is the localization of immune complexes with fixed complement on the surface of follicular dendritic cells. CD4(+) T cells, located primarily in the ''apical light zones'' of the centers, are necessary for germinal center formation. However, their exact role in the process needs clarification, as both cell to cell contact and cytokine production could be involved at different stages of the germinal center generation. These T cells are usually specific for the antigen inducing the germinal center, but they may sometimes respond to other surface components on the B cell surface. In view of the possible stimulatory role of CD4(+) T cells in follicular center-derived lymphomas, the functional significance of these T cells in germinal center proliferation is important to unravel. The B cells in germinal centers proliferate extremely rapidly, especially those located in the ''dark zones.'' Many of them undergo apoptosis, particularly in the ''basal light zones.'' The microenvironment of these centers is well suited to the task of expanding and selecting memory B cells of high affinity for the inducing antigen. The interactions of the proliferating B cells with dendritic cells and T cells, unevenly distributed in the various zones of the germinal center, are thought to determine which cells deserve rescue from apoptosis and induction to differentiation into small resting memory B cells. The memory B cells that emerge from the germinal center bear sig, usually of ''switched'' isotype, and exhibit somatic mutations in the variable regions of their rearranged Ig genes.	NYU,SCH MED,COMPREHENS KAPLAN CANC CTR,NEW YORK,NY 10016; HOSP JOINT DIS & MED CTR,DEPT RHEUMATOL,NEW YORK,NY 10010	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	THORBECKE, GJ (corresponding author), NYU,MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016, USA.				NCI NIH HHS [CA-14462] Funding Source: Medline; NIA NIH HHS [AG-10303, AG-04980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010303, R01AG004980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAINE Y, 1981, EUR J IMMUNOL, V11, P990, DOI 10.1002/eji.1830111208; BAINE Y, 1982, J IMMUNOL, V128, P639; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BOGEN SA, 1993, J IMMUNOL, V150, P4197; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; BOWEN MB, 1991, HUM IMMUNOL, V31, P67, DOI 10.1016/0198-8859(91)90050-J; BUTCH AW, 1992, CELL IMMUNOL, V140, P331, DOI 10.1016/0008-8749(92)90200-9; BUTCH AW, 1993, J IMMUNOL, V150, P39; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CERNY A, 1988, CELL TISSUE RES, V254, P449; COICO RF, 1983, J IMMUNOL, V131, P2254; COICO RF, 1988, IMMUNOL REV, V105, P45, DOI 10.1111/j.1600-065X.1988.tb00765.x; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DEKRUYFF RH, 1976, EUR J IMMUNOL, V6, P462, DOI 10.1002/eji.1830060703; DONO M, 1993, EUR J IMMUNOL, V23, P873, DOI 10.1002/eji.1830230416; DUPASQUIER L, 1982, NATURE, V296, P311, DOI 10.1038/296311a0; EIKELENBOOM P, 1982, CELL TISSUE RES, V229, P83; FREEDMAN AA, 1990, SCIENCE, V24, P130; FULLER KA, 1993, J IMMUNOL, V151, P4505; FYFE G, 1987, J IMMUNOL, V139, P2187; GORDON J, 1989, IMMUNOL TODAY, V10, P153, DOI 10.1016/0167-5699(89)90171-0; GRAY D, 1984, EUR J IMMUNOL, V14, P47, DOI 10.1002/eji.1830140109; GREGORY CD, 1987, J IMMUNOL, V139, P313; HANNA MG, 1969, ADV EXP MED BIOL, V5, P149; HARDIE DL, 1993, EUR J IMMUNOL, V23, P997, DOI 10.1002/eji.1830230502; HEINEN E, 1986, EUR J IMMUNOL, V16, P167, DOI 10.1002/eji.1830160211; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLDER MJ, 1992, EUR J IMMUNOL, V22, P2725, DOI 10.1002/eji.1830221037; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOBSEN K, 1991, LYMPHATIC TISSUES AND IN VIVO IMMUNE RESPONSES, P343; JACOBSON EB, 1974, CELL IMMUNOL, V13, P416, DOI 10.1016/0008-8749(74)90261-5; JACOBSON EB, 1981, J EXP MED, V154, P318, DOI 10.1084/jem.154.2.318; Kapasi Zoher F., 1993, Aging Immunology and Infectious Disease, V4, P77; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KNOX KA, 1993, INT IMMUNOL, V5, P1085, DOI 10.1093/intimm/5.9.1085; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KOOPMAN G, 1994, LYMPHOID TISSUES GER; KOSCOVILBOIS MH, 1993, J EXP MED, V178, P2055, DOI 10.1084/jem.178.6.2055; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; KRAFT R, 1987, CLIN EXP IMMUNOL, V67, P447; KROESE FGM, 1990, CURR TOP PATHOL, V84, P119; LAGRESLE C, 1993, INT IMMUNOL, V5, P1259, DOI 10.1093/intimm/5.10.1259; LEANDERSON T, 1992, IMMUNOL REV, V126, P47, DOI 10.1111/j.1600-065X.1992.tb00630.x; LEBMAN DA, 1987, J EXP MED, V166, P1405, DOI 10.1084/jem.166.5.1405; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEVY NS, 1989, J EXP MED, V169, P2007, DOI 10.1084/jem.169.6.2007; Linton Phyllis-Jean, 1993, Aging Immunology and Infectious Disease, V4, P35; LINTON PJ, 1992, EUR J IMMUNOL, V22, P1293, DOI 10.1002/eji.1830220526; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MADASSERY J V, 1991, Journal of Immunology, V147, P823; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MANGENEY M, 1993, CANCER RES, V53, P5314; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NAHM MH, 1989, IMMUNOL LETT, V21, P201, DOI 10.1016/0165-2478(89)90105-3; NAHM MH, 1992, IMMUNOL TODAY, V13, P438, DOI 10.1016/0167-5699(92)90070-N; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; NIEUWENHUIS P, 1992, IMMUNOL REV, V126, P77, DOI 10.1111/j.1600-065X.1992.tb00632.x; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; NOSSAL GJV, 1968, J EXP MED, V127, P263, DOI 10.1084/jem.127.2.263; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; PANTALCO C, 1993, SCIENCE, V362, P355; POPPEMA S, 1987, AM J PATHOL, V127, P418; PRIETO J, 1989, EUR J IMMUNOL, V19, P1551, DOI 10.1002/eji.1830190906; RAZZECA KJ, 1986, EUR J IMMUNOL, V16, P393, DOI 10.1002/eji.1830160414; REYNES M, 1985, J IMMUNOL, V135, P2687; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; ROUSE RV, 1982, J IMMUNOL, V128, P2243; RYFFEL B, 1991, AM J PATHOL, V139, P7; SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SCHRATER AF, 1979, J EXP MED, V150, P808, DOI 10.1084/jem.150.4.808; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; STEDRA J, 1994, IN PRESS J IMMUNOL; SWENSON CD, 1994, FASEB J, V8, pA749; SZAKAL A K, 1988, Aging Immunology and Infectious Disease, V1, P7; SZAKAL AK, 1985, J IMMUNOL, V134, P1349; SZAKAL AK, 1988, J IMMUNOL, V140, P341; TEW JG, 1980, IMMUNOL REV, V53, P173; THORBECKE GJ, 1969, ADV EXPT MED BIOL, V5, P83; TOELLNER KM, LYMPHOID TISSUES GER; TSIAGBE VK, 1992, IMMUNOL REV, V126, P113, DOI 10.1111/j.1600-065X.1992.tb00634.x; TSIAGBE VK, 1993, SUPERANTIGENS PATHOG, P93; VANDENBERG TK, 1992, EUR J IMMUNOL, V22, P957, DOI 10.1002/eji.1830220412; VANDENEERTWEGH AJM, 1992, CRIT REV IMMUNOL, V11, P337; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; VELARDI A, 1986, J IMMUNOL, V137, P2808; VONDERHEIDE RH, 1990, IMMUNOLOGY, V69, P487; WANG DN, 1994, P NATL ACAD SCI USA, V91, P2502, DOI 10.1073/pnas.91.7.2502; WEINBERG DS, 1986, J IMMUNOL, V137, P1486	103	97	97	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					832	840		10.1096/fasebj.8.11.8070632	http://dx.doi.org/10.1096/fasebj.8.11.8070632			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070632	Bronze			2022-12-28	WOS:A1994PC88500005
J	KLETZIEN, RF; HARRIS, PKW; FOELLMI, LA				KLETZIEN, RF; HARRIS, PKW; FOELLMI, LA			GLUCOSE-6-PHOSPHATE-DEHYDROGENASE - A HOUSEKEEPING ENZYME SUBJECT TO TISSUE-SPECIFIC REGULATION BY HORMONES, NUTRIENTS, AND OXIDANT STRESS	FASEB JOURNAL			English	Review						GLUCOSE-6-PHOSPHATE DEHYDROGENASE; ADAPTIVE REGULATION; OXIDANT STRESS; GENE STRUCTURE	RED-CELL GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; MESSENGER-RNA LEVELS; ADIPOCYTE PRIMARY CULTURES; PENTOSE-PHOSPHATE PATHWAY; SEA-URCHIN EGGS; RAT HEPATOCYTES; NUTRITIONAL REGULATION; SOLUTION HYBRIDIZATION; LIPOGENIC ENZYMES; OXIDATIVE STRESS	The enzyme, glucose-6-phosphate dehydrogenase (G6PDH, EC1.1.1.49), has long been considered and studied as the archetypical X-linked ''housekeeping'' enzyme that is present in all cells, where it plays the key role in regulating carbon how through the pentose phosphate pathway. Specifically, the enzyme catalyzes the first reaction in the pathway leading to the production of pentose phosphates and reducing power in the form of NADPH for reductive biosynthesis and maintenance of the redox state of the cell. It was in this latter function that the crucial importance of the enzyme was first appreciated with the description of the human deficiency syndrome. While the gene can be considered to be a constitutively expressed ''housekeeping'' gene in many tissues, there are several other tissues (liver, adipose, lung, and proliferating cells) wherein modulation of cellular G6PDH activity represents an important component of the integrated response to external stimuli (hormones, growth factors, nutrients, and oxidant stress). In this regard, adaptive regulation of G6PDH has been found to be exerted at transcriptional and posttranscriptional levels. However, the regulation observed is tissue-specific, which elicits the central question of this review, ''How can the G6PDH gene be constitutively expressed in some tissues while displaying adaptive regulation in others when there exists a single transcription unit for the gene?'' Future studies utilizing cloned genomic fragments of the human and other mammalian G6PDH genes should provide answers to this question.			KLETZIEN, RF (corresponding author), UPJOHN CO, UPJOHN LABS, METAB DIS RES, 7250-126-327, KALAMAZOO, MI 49001 USA.							BAUTISTA AP, 1992, HEPATOLOGY, V15, P892, DOI 10.1002/hep.1840150523; BERDANIER CD, 1979, J NUTR, V109, P1766, DOI 10.1093/jn/109.10.1766; BERDANIER CD, 1989, FASEB J, V3, P2179, DOI 10.1096/fasebj.3.10.2666232; BEUTLER E, 1990, CELL, V62, P7, DOI 10.1016/0092-8674(90)90231-3; BEUTLER E, 1991, NEW ENGL J MED, V324, P169; BEUTLER E, 1992, ANNU REV MED, V43, P47, DOI 10.1146/annurev.me.43.020192.000403; BOUILLON DJ, 1980, J NUTR, V110, P286, DOI 10.1093/jn/110.2.286; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CLARKE SD, 1993, NUTR GENE EXPRESSION, P227; CRAMER CT, 1993, TOXICOLOGIST, V13, P20; FRITZ RS, 1986, BIOCHEM J, V237, P617, DOI 10.1042/bj2370617; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; HIRONO A, 1989, P NATL ACAD SCI USA, V86, P10015, DOI 10.1073/pnas.86.24.10015; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IRITANI N, 1992, EUR J BIOCHEM, V205, P433, DOI 10.1111/j.1432-1033.1992.tb16797.x; JEFFERY J, 1989, EUR J BIOCHEM, V186, P551, DOI 10.1111/j.1432-1033.1989.tb15242.x; JUMP DB, 1987, J BIOL CHEM, V262, P778; KANNO H, 1989, CELL, V58, P595, DOI 10.1016/0092-8674(89)90440-6; KATSURADA A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P104, DOI 10.1016/0005-2760(89)90329-9; KELLEY DS, 1984, BIOCHEM J, V217, P543, DOI 10.1042/bj2170543; KENNEDY KA, 1989, PEDIATR RES, V26, P400, DOI 10.1203/00006450-198911000-00002; KIM MH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P177, DOI 10.1016/0167-4781(90)90038-4; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLETZIEN RF, 1985, J BIOL CHEM, V260, P5621; KLETZIEN RF, 1993, NUTR GENE EXPRESSION, P187; KURTZ JW, 1981, J BIOL CHEM, V256, P870; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI Y, 1992, J BIOL CHEM, V267, P15097; LIANG HCL, 1992, BIOCHEM BIOPH RES CO, V182, P1160, DOI 10.1016/0006-291X(92)91853-I; LOUIE P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P25, DOI 10.1016/0167-4781(90)90116-J; LUZZATTO L, 1987, CELL BIOCHEM FUNCT, V5, P101, DOI 10.1002/cbf.290050204; MANOS P, 1991, BIOCHEM J, V276, P245, DOI 10.1042/bj2760245; MASON PJ, 1990, CELL, V62, P9, DOI 10.1016/0092-8674(90)90232-4; MOHSENIN V, 1990, J APPL PHYSIOL, V68, P2384, DOI 10.1152/jappl.1990.68.6.2384; NASR LB, 1989, AM J PHYSIOL, V193, pG760; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSA LFB, 1992, ENDOCRINOLOGY, V135, P213; SALATI LM, 1988, LIPIDS, V23, P36, DOI 10.1007/BF02535302; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SMITH ER, 1974, J BIOL CHEM, V249, P6541; STANTON RC, 1991, J BIOL CHEM, V266, P12442; STUMPO DJ, 1985, BIOCHEM J, V226, P123, DOI 10.1042/bj2260123; STUMPO DJ, 1984, EUR J BIOCHEM, V144, P497, DOI 10.1111/j.1432-1033.1984.tb08493.x; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; SWEZEY RR, 1988, P NATL ACAD SCI USA, V85, P812, DOI 10.1073/pnas.85.3.812; TAKIZAWA T, 1986, P NATL ACAD SCI USA, V83, P4157, DOI 10.1073/pnas.83.12.4157; TEEL JF, 1991, FASEB J, V5, pA424; TOMLINSON JE, 1988, J NUTR, V118, P408, DOI 10.1093/jn/118.3.408; TONIOLO D, 1991, GENE, V102, P197, DOI 10.1016/0378-1119(91)90078-P; URSINI MV, 1990, BIOCHEM BIOPH RES CO, V170, P1203, DOI 10.1016/0006-291X(90)90521-N; VALVERDE AM, 1991, EXP CELL RES, V194, P232, DOI 10.1016/0014-4827(91)90359-3; VALVERDE AM, 1992, EUR J BIOCHEM, V203, P313, DOI 10.1111/j.1432-1033.1992.tb19861.x; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; WHITE CW, 1989, J APPL PHYSIOL, V66, P1003, DOI 10.1152/jappl.1989.66.2.1003; WHITE CW, 1988, J APPL PHYSIOL, V65, P2607, DOI 10.1152/jappl.1988.65.6.2607; YOSHIMOTO K, 1983, J BIOL CHEM, V258, P2355; ZIMMER HG, 1992, CIRC RES, V71, P451, DOI 10.1161/01.RES.71.2.451	63	428	439	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					174	181		10.1096/fasebj.8.2.8119488	http://dx.doi.org/10.1096/fasebj.8.2.8119488			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119488				2022-12-28	WOS:A1994MY29900023
J	BROOKS, CC; TOLAN, DR				BROOKS, CC; TOLAN, DR			A PARTIALLY ACTIVE MUTANT ALDOLASE-B FROM A PATIENT WITH HEREDITARY FRUCTOSE INTOLERANCE	FASEB JOURNAL			English	Note						GLUCONEOGENESIS; SINGLE-STRAND CONFORMATIONAL POLYMORPHISM; PROTEIN STRUCTURE	AMINO-ACID-SEQUENCE; MOLECULAR ANALYSIS; ESCHERICHIA-COLI; SENSITIVE METHOD; MAIZE ALDOLASE; LIVER ALDOLASE; GENE; DNA; MUTATIONS; IDENTIFICATION	Hereditary fructose intolerance (HFI) is a potentially fatal autosomal recessive disease of carbohydrate metabolism. HFI patients are deficient in aldolase B, the isozyme expressed in fructose-metabolizing tissues. The eight protein coding exons, including splicing signals, of the aldolase B gene from one American HFI patient were amplified by the polymerase chain reaction (PCR). Single-strand conformational polymorphism (SSCP) analysis and direct sequence determination were applied to the amplified fragments. The mutations in the patient's alleles were identified as a nonsense mutation (R59op) in exon 3 and a missense mutation (C134R) in exon 5. These mutations were confirmed by sequence determination of cloned PCR-amplified exons 3 and 5 from the patient. Allele specific oligonucleotide (ASO) hybridizations of amplified exons 3 and 5 showed the Mendelian inheritance of both mutations. Site-directed mutagenesis was used to generate an expression plasmid for the C134R mutation, and the mutant enzyme was expressed in bacteria. Assays of partially purified enzyme preparations showed that this missense mutation results in an apparently unstable enzyme that retains partial activity. This is the first evidence for a partially active aldolase B from an HFI individual with an identified mutation, and supports the hypothesis that adequate gluconeogenesis/glycolysis is maintained in HFI patients by the presence of partially active enzymes.	BOSTON UNIV,DEPT CELL BIOL,25 SHATTUCK ST,BOSTON,MA 02215	Boston University				Tolan, Dean/0000-0002-0598-7241	NIDDK NIH HHS [DK-43521, DK-38821] Funding Source: Medline; NIGMS NIH HHS [GM-08291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043521, R29DK038821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAERLOCHER K, 1971, HELV PAEDIATR ACTA, V26, P489; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BEERNINK PT, 1992, PROTEIN EXPRES PURIF, V3, P332, DOI 10.1016/1046-5928(92)90009-L; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BERTHIAUME L, 1989, ARCH BIOCHEM BIOPHYS, V272, P281, DOI 10.1016/0003-9861(89)90221-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS CC, 1991, AM J HUM GENET, V49, P1075; BROOKS CC, 1993, AM J HUM GENET, V52, P835; BROOKS CC, 1994, THESIS BOSTON U BOST; CHAMBERS RA, 1956, LANCET, V2, P340; Cox T M, 1983, Mol Biol Med, V1, P393; COX TM, 1983, J CLIN INVEST, V72, P201, DOI 10.1172/JCI110958; COX TM, 1988, Q J MED, V256, P585; CROSS NCP, 1990, AM J HUM GENET, V47, P101; CROSS NCP, 1990, LANCET, V335, P306, DOI 10.1016/0140-6736(90)90603-3; CROSS NCP, 1990, NUCLEIC ACIDS RES, V18, P1925, DOI 10.1093/nar/18.7.1925; CROSS NCP, 1988, CELL, V53, P881, DOI 10.1016/S0092-8674(88)90349-2; DAZZO C, 1990, AM J HUM GENET, V46, P1194; EAGLES PAM, 1973, BIOCHEM J, V133, P429, DOI 10.1042/bj1330429; FROESCH ER, 1963, AM J MED, V34, P151, DOI 10.1016/0002-9343(63)90050-0; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; GITZELMANN R, 1908, METABOLIC BASIS INHE, P399; GITZELMANN R, 1974, BIOCHEM BIOPH RES CO, V598, P1270; GREGORI C, 1982, ANN HUM GENET, V46, P281, DOI 10.1111/j.1469-1809.1982.tb01579.x; Hayashi K, 1991, PCR Methods Appl, V1, P34; HENRY I, 1985, ANN HUM GENET, V49, P173, DOI 10.1111/j.1469-1809.1985.tb01691.x; HERS H. G., 1961, ENZYMOL BIOL ET CLIN, V1, P4; HERS HG, 1953, BIOCHIM BIOPHYS ACTA, V11, P427, DOI 10.1016/0006-3002(53)90062-6; KAJIHARA S, 1990, AM J HUM GENET, V47, P562; KOSTER JF, 1975, BIOCHEM BIOPH RES CO, V64, P289, DOI 10.1016/0006-291X(75)90251-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LAMEIRE N, 1978, AM J MED, V65, P416, DOI 10.1016/0002-9343(78)90767-2; LEBO RV, 1985, CYTOMETRY, V6, P478, DOI 10.1002/cyto.990060513; MOCK DM, 1983, NEW ENGL J MED, V309, P764, DOI 10.1056/NEJM198309293091305; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; NORDMANN Y, 1968, BIOCHEM BIOPH RES CO, V31, P884, DOI 10.1016/0006-291X(68)90534-2; ODIEVRE M, 1978, AM J DIS CHILD, V132, P605, DOI 10.1001/archpedi.1978.02120310069014; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PODUSLO SE, 1991, AM J HUM GENET, V49, P106; ROTTMANN WH, 1984, P NATL ACAD SCI-BIOL, V81, P2738, DOI 10.1073/pnas.81.9.2738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAKIBARA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P334, DOI 10.1016/0167-4781(89)90156-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAPIRA F, 1963, NATURE, V200, P995, DOI 10.1038/200995a0; SCHAPIRA F, 1974, ENZYME, V18, P73, DOI 10.1159/000459415; SCHULTE MJ, 1977, LANCET, V2, P188; SEBASTIO G, 1990, J MED GENET, V28, P241; STEINMANN B, 1981, HELV PAEDIATR ACTA, V36, P267; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOLAN DR, 1992, BIOCHEM MED METAB B, V48, P19, DOI 10.1016/0885-4505(92)90043-X; TOLAN DR, 1986, MOL BIOL MED, V3, P245; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	56	15	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					107	113		10.1096/fasebj.8.1.8299883	http://dx.doi.org/10.1096/fasebj.8.1.8299883			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299883				2022-12-28	WOS:A1994MV28200016
J	GAMETCHU, B; WATSON, CS; WU, SH				GAMETCHU, B; WATSON, CS; WU, SH			USE OF RECEPTOR ANTIBODIES TO DEMONSTRATE MEMBRANE GLUCOCORTICOID RECEPTOR IN CELLS FROM HUMAN LEUKEMIC PATIENTS	FASEB JOURNAL			English	Article						MEMBRANE GLUCOCORTICOID RECEPTOR; LEUKEMIA; LYMPHOCYTOLYSIS; STEROID	S-49 LYMPHOMA-CELLS; ESTROGEN-RECEPTOR; STEROID-BINDING; RAT-LIVER; PROGESTERONE-RECEPTOR; DEOXYRIBONUCLEIC-ACID; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; BREAST-CANCER; IDENTIFICATION	Anti-peptide antibody to the human glucocorticoid receptor (GR) was produced and used to demonstrate that a subset of the GR population resides in the plasma membrane of human leukemic cells. Characterization of the antibody with intracellular GR (iGR) showed its ability to shift [H-3]triamcinolone acetonide-labeled GR (4S protein) from two human leukemic cell lines to a higher density in sucrose gradients; Western and autoradiographic analysis of affinity-labeled ([H-3]dexamethasone 21-mesylate) receptor revealed an immunoreactive and competitively labeled band of 94 kDa. CCRF-CEM cell membrane GR (mGR) resolved as a >7S protein on density gradients and immunoselected cell surface protein labeled by whole cell biotinylation or affinity-labeling with [H-3]dexamethasone 21-mesylate was approximately 145 kDa, demonstrating that mGR was larger in size than iGR, as has been shown previously for the mGR of mouse lymphoma cells. Analysis of mGR in lymphocytes of leukemic patients and the CCRF-CEM cell line indicated differences in levels of expression as shown by FACS and immunocytochemical analyses. We are currently using this system to study the correlation between the quantity of membrane-resident GRs and the glucocorticoid-induced lytic response, a relationship previously shown in the murine (S-49 cell) system.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	GAMETCHU, B (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226, USA.							Ausubel FM, 1988, MOL REPROD DEV; BERGER U, 1991, CANCER RES, V51, P239; CARLSTEDTDUKE J, 1982, P NATL ACAD SCI-BIOL, V79, P4260, DOI 10.1073/pnas.79.14.4260; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GAMETCHU B, 1984, FED PROC, V43, P1572; GOLDIN A, 1976, CANCER CHEMOTH REP, V55, P309; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOMODELARCHE F, 1984, CANCER RES, V44, P431; HOUSLEY PR, 1982, J BIOL CHEM, V257, P8615; IBARROLA I, 1992, J MEMBRANE BIOL, V125, P185; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P638; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; MCBLAIN WA, 1980, J BIOL CHEM, V255, P3884; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIRAS ME, 1979, J STEROID BIOCHEM, V11, P1129, DOI 10.1016/0022-4731(79)90163-8; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; SCHREK R, 1961, P SOC EXP BIOL MED, V108, P328; SHERMAN MR, 1983, J BIOL CHEM, V258, P366; SHIH CY, 1987, PROGR CLIN BIOL RES, P439; SHIMADA A, 1985, P NATL ACAD SCI USA, V82, P4803, DOI 10.1073/pnas.82.14.4803; SHYMALA G, 1967, J BIOL CHEM, V244, P1097; SOYUM A, 1968, SCAND J CLIN LAB I S, V21, P77; STEVENS J, 1985, HORMONALLY RESPONSIV, P156; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; SUYEMITSU T, 1975, ENDOCRINOLOGY, V96, P1499, DOI 10.1210/endo-96-6-1499; SZEGO CM, 1981, BIOCHEM ACTION HORM, P307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018	40	106	107	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1283	1292		10.1096/fasebj.7.13.8405814	http://dx.doi.org/10.1096/fasebj.7.13.8405814			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405814				2022-12-28	WOS:A1993MB37600013
J	KUBES, P; KANWAR, S; NIU, XF; GABOURY, JP				KUBES, P; KANWAR, S; NIU, XF; GABOURY, JP			NITRIC-OXIDE SYNTHESIS INHIBITION INDUCES LEUKOCYTE ADHESION VIA SUPEROXIDE AND MAST-CELLS	FASEB JOURNAL			English	Article						INFLAMMATION; ENDOTHELIUM; MICROCIRCULATION	ENDOTHELIAL-CELLS; RELAXING FACTOR; L-ARGININE; REPERFUSION INJURY; OXYGEN RADICALS; ADHERENCE; NEUTROPHILS; INFLAMMATION; MESENTERY; PLATELET	Recent work has demonstrated that inhibition of nitric oxide production with various nitric oxide synthesis inhibitors (L-NAME, L-NMMA) initiate leukocyte adhesion to postcapillary venules. The objective of this study was to elucidate the mechanism (or mechanisms) that promote the L-NAME-induced leukocyte response. Intravital microscopy was used to examine 25-40 mum venules in the rat mesentery. Nitric oxide synthesis was inhibited with L-NAME and leukocyte adhesion was observed over the first 60 min. The fourfold increase in leukocyte adhesion was independent of alterations in venular red blood cell velocity. The adhesion was superoxide-mediated inasmuch as superoxide dismutase (SOD) abolished the rise in leukocyte adhesion associated with nitric oxide synthesis inhibition. Ketotifen, a mast cell stabilizer, also abolished the rise in leukocyte adhesion induced by L-NAME. Histology revealed that mast cell degranulation occurred only in animals treated with L-NAME but not in animals pretreated with SOD or ketotifen. This observation suggests that mast cells become activated in the absence of nitric oxide production and superoxide contributes to the mast cell activation. The L-NAME-induced leukocyte adhesion could be reproduced by infusing hypoxanthine/xanthine oxidase (a superoxide generating system) or compound 48/80 (an activator of mast cells) and both responses were attenuated by ketotifen. These data suggest that inhibition of nitric oxide synthesis results in a superoxide and mast cell-dependent leukocyte adhesion.			KUBES, P (corresponding author), UNIV CALGARY, FAC MED, DEPT MED PHYSIOL, GASTROINTESTINAL RES GRP, CALGARY T2N 4N1, AB, CANADA.		Kanwar, Shamsher S/F-6096-2019					ARNDT H, 1993, IN PRESS GASTROENTER; ASAKO H, 1992, INFLAMMATION, V16, P45, DOI 10.1007/BF00917514; Chance B., 1973, OXIDASES RELATED RED, P350; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DVORAK AM, 1980, HUM PATHOL, V11, P606, DOI 10.1016/S0046-8177(80)80072-4; FEIGL EO, 1988, NATURE, V331, P490, DOI 10.1038/331490a0; GABOURY J, 1993, IN PRESS AM J PHYSL; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HOGABOAM C M, 1992, Gastroenterology, V102, pA926; HOGABOAM CM, 1992, BRIT J PHARMACOL, V105, P87, DOI 10.1111/j.1476-5381.1992.tb14215.x; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; INAUEN W, 1990, AM J PHYSIOL, V259, pH925, DOI 10.1152/ajpheart.1990.259.3.H925; JOHNS RA, 1990, CIRC RES, V67, P979, DOI 10.1161/01.RES.67.4.979; KANWAR S, 1993, GASTROENTEROLOGY, V104, pA1044; KELLER AM, 1988, CIRC RES, V63, P1044, DOI 10.1161/01.RES.63.6.1044; KOCH AE, 1991, LAB INVEST, V64, P313; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1990, AM J PHYSIOL, V259, pG859, DOI 10.1152/ajpgi.1990.259.5.G859; KUBES P, 1991, AM J PHYSIOL, V261, pH1872, DOI 10.1152/ajpheart.1991.261.6.H1872; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MAY GR, 1991, BRIT J PHARMACOL, V102, P759, DOI 10.1111/j.1476-5381.1991.tb12246.x; MCCALL T, 1988, BRIT J PHARMACOL, V95, pP517; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAUD J, 1989, ACTA PHYSIOL SCAND, V135, P95, DOI 10.1111/j.1748-1716.1989.tb08556.x; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SALVEMINI D, 1991, J CARDIOVASC PHARM, V17, pS258, DOI 10.1097/00005344-199117003-00047; SCHMIDT HHHW, 1990, J PHARMACOL EXP THER, V254, P591; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SUZUKI M, 1991, MICROVASC RES, V42, P125, DOI 10.1016/0026-2862(91)90081-L; SUZUKI M, 1989, AM J PHYSIOL, V257, pH1740, DOI 10.1152/ajpheart.1989.257.5.H1740; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; VANDEVOORDE J, 1987, CIRC RES, V60, P517, DOI 10.1161/01.RES.60.4.517; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WALLACE JL, 1992, ANN NY ACAD SCI, V664, P400, DOI 10.1111/j.1749-6632.1992.tb39778.x; WASSERMAN SI, 1984, ARTHRITIS RHEUM, V27, P841, DOI 10.1002/art.1780270801; WOLIN MS, 1991, KLIN WOCHENSCHR, V69, P1046, DOI 10.1007/BF01645156	45	324	327	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1993	7	13					1293	1299		10.1096/fasebj.7.13.8405815	http://dx.doi.org/10.1096/fasebj.7.13.8405815			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405815				2022-12-28	WOS:A1993MB37600014
J	WOLF, LE; LAPPE, M; PETERSON, RD; EZRAILSON, EG				WOLF, LE; LAPPE, M; PETERSON, RD; EZRAILSON, EG			HUMAN IMMUNE-RESPONSE TO POLYDIMETHYLSILOXANE (SILICONE) - SCREENING STUDIES IN A BREAST IMPLANT POPULATION	FASEB JOURNAL			English	Article						SILICONE; IMMUNOGLOBULIN-G; ANTI-SILICONE ANTIBODIES; SILOXANE; BREAST IMPLANTS		Although initially it was thought that polydimethylsiloxane (silicone) was biologically inert, recent published studies have demonstrated varying levels of IgG antibody reactive with this structure in humans. The objective of our study was to determine whether silicone implanted in humans results in a measurable immune response directed against a 3700 mol wt hydroxyl terminated silicone molecule and whether that response could be correlated with the level of presumed silicone exposure as inferred by clinical history. In a blind study, sera from 111 patients, with and without breast implants, were sent to a laboratory using an enzyme-linked immunosorbent assay to determine specific anti-silicone IgG antibody levels. Test results showed that patients with implants demonstrated statistically significant elevation in anti-silicone antibodies compared with the unimplanted control, groups. The highest anti-silicone antibody levels were measured in implanted women with either frank implant ruptures or leakage of their silicone gel implants.	PLAZA MED CTR,HOUSTON,TX 77004; UNIV ILLINOIS,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; HEGGERS JP, 1983, ANN PLAS SURG, V11, P38, DOI 10.1097/00000637-198307000-00006; HEGGERS JP, 1992, FEB TOX FOR  WASH; KOSSOVSKY N, 1987, J BIOMED MATER RES, V21, P1125, DOI 10.1002/jbm.820210906; LAPPE MA, 1993, IN PRESS MED HYPOTHE; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011	8	73	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1265	1268		10.1096/fasebj.7.13.8405812	http://dx.doi.org/10.1096/fasebj.7.13.8405812			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405812				2022-12-28	WOS:A1993MB37600010
J	COLLINS, VP; JAMES, CD				COLLINS, VP; JAMES, CD			GENE AND CHROMOSOMAL ALTERATIONS ASSOCIATED WITH THE DEVELOPMENT OF HUMAN GLIOMAS	FASEB JOURNAL			English	Review						TUMOR SUPPRESSOR GENES; MALIGNANT GLIOMA	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR GENE; HUMAN-BRAIN-TUMORS; HUMAN-MALIGNANT ASTROCYTOMA; HUMAN GLIOBLASTOMAS; MONOCLONAL-ANTIBODY; SUPPRESSOR GENE; P53 MUTATIONS; CELL-LINES; HETEROZYGOSITY	The development of a malignant tumor generally entails a series of events that damage the genome of a somatic cell and result in the malignant phenotype. These events chronicle the malignant progression of a tumor; a dynamic process in which more aggressive and growth-deregulated cell populations are constantly evolving. Gliomas, the most common primary tumors of brain, are known to become increasingly malignant with time. Within recent years, several details of the molecular genetic events associated in their progression have been determined. The earliest events of glioma progression include loss of genetic information from the long arms of chromosomes 13 or 22, or the short arm of chromosome 17 for which targeting of the TP53 (p53) gene has been indicated. Loss of a single complement of type I interferon (IFN) genes from 9p and loss of genetic information from 19q are seen in the tumors of intermediate malignancy grade. Events associated with the most malignant of glial tumors include loss of the second, type I IFN gene complement, loss of genetic information from chromosome 10, and gene amplification (most commonly the epidermal growth factor receptor, in 40% of cases). These findings have helped elucidate the events associated with glial tumorigenesis, and through the identification of specific genes, have provided a starting point for investigating the molecular biology of central nervous system neoplasia.	SAHLGRENS UNIV HOSP,DEPT PATHOL,S-41345 GOTHENBURG,SWEDEN; EMORY UNIV,SCH MED,DEPT NEUROSURG,ATLANTA,GA 30322	Sahlgrenska University Hospital; Emory University	COLLINS, VP (corresponding author), KAROLINSKA HOSP,LUDWIG INST CANC RES,BOX 60004,S-10401 STOCKHOLM 60,SWEDEN.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER; NCI NIH HHS [CA55728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1988, J NEUROPATH EXP NEUR, V47, P191, DOI 10.1097/00005072-198805000-00001; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BRADY LW, 1992, INT J RADIAT ONCOL, V22, P225, DOI 10.1016/0360-3016(92)91009-C; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; DUMANSKI JP, 1990, CANCER RES, V50, P5863; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GODBOUT R, 1992, ONCOGENE, V7, P1879; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1991, CANCER RES, V51, P1684; JAMES CD, 1990, CANCER SURV, V9, P631; KALOFONOS HP, 1989, J NUCL MED, V30, P1636; KARLBOM AE, 1993, IN PRESS HUM GENET; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIZUNO M, 1990, CANCER RES, V50, P7826; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NOWELL PC, 1986, CANCER RES, V46, P2203; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; SCHERER JH, 1940, AM J CANCER, V40, P159; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VENTER DJ, 1991, BRIT J CANCER, V63, P753, DOI 10.1038/bjc.1991.168; VENTER DJ, 1991, ONCOGENE, V6, P445; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WATANABE K, 1990, ACTA NEUROPATHOL, V80, P251, DOI 10.1007/BF00294641; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; ZULCH KJ, 1979, INT HISTOLOGICAL CLA, V21	51	115	119	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					926	930		10.1096/fasebj.7.10.8344489	http://dx.doi.org/10.1096/fasebj.7.10.8344489			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344489				2022-12-28	WOS:A1993LQ33700016
J	LONG, DM; UHLENBECK, OC				LONG, DM; UHLENBECK, OC			SELF-CLEAVING CATALYTIC RNA	FASEB JOURNAL			English	Article						SELF-CLEAVING RNA; RIBOZYMES; CATALYTIC RNA	HEPATITIS DELTA-VIRUS; CLEAVAGE REACTION; HAMMERHEAD RIBOZYMES; SATELLITE RNA; SEQUENCE; SITES; PLUS	We describe the structures and catalytic properties of several naturally occurring self-cleaving RNA motifs that give 2', 3' cyclic phosphate products. The hammerhead and hairpin motifs are derived from plant pathogenic RNAs and the delta motif is part of the human hepatitis delta element. A fourth motif from Neurospora is less well characterized. By assembling the self-cleaving RNAs from more than one oligoribonucleotide, the cleavage reaction can be examined under a variety of conditions and catalytic turnover can be demonstrated. Mutagenesis and chemical methods to introduce modified nucleotides allowed the structural requirements to be deduced. The role of divalent cations in the catalytic mechanism is discussed.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder								BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; BUZAYAN JM, 1986, P NATL ACAD SCI USA, V83, P8859, DOI 10.1073/pnas.83.23.8859; CHOWRIRA BM, 1992, NUCLEIC ACIDS RES, V20, P2835, DOI 10.1093/nar/20.11.2835; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; EPSTEIN LM, 1987, CELL, V48, P535, DOI 10.1016/0092-8674(87)90204-2; FEDOR M, 1992, IN PRESS BIOCHEMISTR; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FU DJ, 1992, P NATL ACAD SCI USA, V89, P3985, DOI 10.1073/pnas.89.9.3985; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, FASEB J, V7, P90; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; JEFFRIES AC, 1989, NUCLEIC ACIDS RES, V17, P1371, DOI 10.1093/nar/17.4.1371; KEESE P, 1987, VIROIDS VIROID LIKE, P1; KOIZUMI M, 1988, FEBS LETT, V239, P285, DOI 10.1016/0014-5793(88)80935-9; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; MODRICH P, 1976, J BIOL CHEM, V251, P5866; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SLIM G, 1992, BIOCHEM BIOPH RES CO, V183, P605, DOI 10.1016/0006-291X(92)90525-P; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; UHLENBECK OC, 1993, ANTISENSE RES APPLIC; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; YARUS MJ, 1992, FASEB J, V7, P31	43	89	120	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					25	30		10.1096/fasebj.7.1.8422971	http://dx.doi.org/10.1096/fasebj.7.1.8422971			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422971				2022-12-28	WOS:A1993KH88000005
J	CARMELIET, P; COLLEN, D				CARMELIET, P; COLLEN, D			GENE TARGETING AND GENE-TRANSFER STUDIES OF THE PLASMINOGEN/PLASMIN SYSTEM - IMPLICATIONS IN THROMBOSIS, HEMOSTASIS, NEOINTIMA FORMATION, AND ATHEROSCLEROSIS	FASEB JOURNAL			English	Review						FIBRINOLYTIC SYSTEM; THROMBOLYSIS; HEMOSTASIS; NEOINTIMA FORMATION	ACTIVATOR INHIBITOR-1 GENE; MUSCLE CELL-MIGRATION; MYOCARDIAL-INFARCTION; TRANSGENIC MICE; DEFICIENT MICE; TYPE-1; UROKINASE; ARTERIES; INJURY; THROMBOLYSIS	The plasminogen/plasmin or fibrinolytic system with its physiological triggers, tissue-type plasminogen activator, and urokinase-type plasminogen activator has been presumed to participate in normal and pathological processes of the vessel wall such as blood clot dissolution (thrombolysis), hemostasis, aneurysm formation, neovasoularization, restenosis, and atherosclerosis, The implied role of the fibrinolytic system in vivo is, however, deduced from correlations between fibrinolytic activity and (patho)physiological phenomena, which does not allow establishing a cause/consequence relationship. Gene targeting and gene transfer technologies allow establishment of the in vivo role of gene products more conclusively, This article reviews briefly the findings of such studies on thrombolysis/thrombosis, hemostasis, neointima formation, atherosclerosis, and associated effects on survival.	VLAAMS INTERUNIV INST BIOTECHNOL,CTR TRANSGENE TECHNOL & GENE THERAPY,B-3000 LOUVAIN,BELGIUM				Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				ANIDJAR A, 1992, ANN VASC SURG, V6, P298; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CARMELIET P, 1994, FIBRINOLYSIS, V8, pA280; CARMELIET P, 1995, IN PRESS VASCULAR CO; CARMELIET P, 1994, FIBRINOLYSIS S1, V8, pA282; CHOMIKI N, 1994, THROMB HAEMOSTASIS, V72, P44; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; COLLEN D, 1991, BLOOD, V78, P3114; DEWERCHIN M, 1994, FIBRINOLYSIS S1, V8, pA142; ELLIOTT MJ, 1992, J IMMUNOL, V149, P3678; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1994, FIBRINOLYSIS, V8, P253, DOI 10.1016/0268-9499(94)90723-4; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HERBERT JM, 1994, J BIOL CHEM, V269, P3076; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; JACKSON CL, 1993, ARTERIOSCLER THROMB, V13, P1218, DOI 10.1161/01.ATV.13.8.1218; LIU AC, 1994, TRENDS CARDIOVAS MED, V46, P40; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; PLOPLIS V, 1994, IN PRESS THROMB HAEM; REILLY JM, 1994, J VASC SURG, V196, P865; SAWA H, 1992, ARTERIOSCLER THROMB, V12, P1507, DOI 10.1161/01.ATV.12.12.1507; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHNEIDERMAN J, 1991, TRENDS CARDIOVAS MED, V1, P99, DOI 10.1016/1050-1738(91)90001-U; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SMOKOVITIS A, 1988, HAEMOSTASIS, V18, P146; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; YORIMITSU K, 1993, HEART VESSELS, V8, P160, DOI 10.1007/BF01744801	36	80	83	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					934	938		10.1096/fasebj.9.10.7615162	http://dx.doi.org/10.1096/fasebj.9.10.7615162			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615162				2022-12-28	WOS:A1995RK89900015
J	PLOW, EF; HERREN, T; REDLITZ, A; MILES, LA; HOOVERPLOW, JL				PLOW, EF; HERREN, T; REDLITZ, A; MILES, LA; HOOVERPLOW, JL			THE CELL BIOLOGY OF THE PLASMINOGEN SYSTEM	FASEB JOURNAL			English	Review						LIPOPROTEIN(A); FIBRINOLYSIS; PROTEOLYSIS; PLASMINOGEN RECEPTORS; UROKINASE	HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; UROKINASE-TYPE; FIBRINOLYTIC COMPONENTS; RECEPTOR EXPRESSION; BOUND PLASMIN; TUMOR-CELLS; BINDING; ACTIVATION; LIPOPROTEIN(A)	The plasminogen system plays a pivotal role in maintaining vascular patency and in cell migration, Binding of plasminogen to surfaces (i.e., fibrin or cells) is of crucial importance in regulating the function of this system, Plasmin(ogen) binds to cells with low affinity and high capacity via its lysine binding sites, which are associated with its kringle domains and recognize carboxy-terminal lysines of cell surface proteins, Upon binding to cellular receptors, plasminogen is more readily activated; bound plasmin has increased enzymatic activity and is protected from inactivation by inhibitors, Plasminogen receptors are modulated by numerous factors, including proteases, steroid hormones, cytokines and the adhesive state of the cells, The apoprotein(a) moiety of lipoprotein(a) is remarkably similar in amino acid sequence to plasminogen. Shared binding sites for Lipoprotein(a) and plasmin(ogen) on cell surfaces and in the subendothelial matrix may contribute to the pathogenetic risks associated with elevated levels of lipoprotein(a).	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	PLOW, EF (corresponding author), CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ADELMAN B, 1988, BLOOD, V72, P1530; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAUER PI, 1984, BIOCHEM J, V218, P119, DOI 10.1042/bj2180119; BURTIN P, 1987, INT J CANCER, V39, P170, DOI 10.1002/ijc.2910390208; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; COHEN RL, 1991, BLOOD, V78, P479; CONFORTI G, 1994, BLOOD, V83, P994; DEGUCHI K, 1985, THROMB RES, V40, P853, DOI 10.1016/0049-3848(85)90321-4; DUVALJOBE C, 1994, J BIOL CHEM, V269, P21353; EDELBERT JM, 1989, BIOCHEMISTRY-US, V28, P2370, DOI 10.1021/bi00432a004; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GANZ PR, 1991, BIOCHEM CELL BIOL, V69, P442, DOI 10.1139/o91-067; GONIAS SL, 1989, BLOOD, V75, P729; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GONZALEZGRONOW M, 1994, J BIOL CHEM, V269, P4360; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HALL SW, 1991, J BIOL CHEM, V266, P12329; HOOVERPLOW JL, 1993, BIOCHEMISTRY-US, V32, P13681, DOI 10.1021/bi00212a037; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; KARIKO K, 1993, CANCER RES, V53, P3109; KIM BS, 1992, CIRICULATION, V86, pA148; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; LIU JN, 1993, BIOCHEMISTRY-US, V32, P9694, DOI 10.1021/bi00088a022; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; LU H, 1993, THROMB RES, V69, P353, DOI 10.1016/0049-3848(93)90034-L; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEISSAUER A, 1992, EXP CELL RES, V199, P179, DOI 10.1016/0014-4827(92)90423-6; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1995, THROMB HAEMOSTASIS, V73, P458; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1986, J CLIN INVEST, V77, P2001, DOI 10.1172/JCI112529; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, BLOOD, V72, P628; MILES LA, 1988, J BIOL CHEM, V263, P11928; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MORIMOTO K, 1993, THROMB HAEMOSTASIS, V69, P387; NAKAJIMA K, 1993, FEBS LETT, V333, P223, DOI 10.1016/0014-5793(93)80658-H; NAKAJIMA K, 1994, J NEUROCHEM, V63, P2048; NIEDBALA MJ, 1990, CANCER COMMUN, V2, P189; NIEDBALA MJ, 1992, BLOOD, V79, P678; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1989, J BIOL CHEM, V264, P5628; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; RYAN TJ, 1992, J CELL PHYSIOL, V151, P255, DOI 10.1002/jcp.1041510206; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SCANU AM, 1993, J CLIN INVEST, V91, P283, DOI 10.1172/JCI116182; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SHEA TB, 1992, FEBS LETT, V307, P190, DOI 10.1016/0014-5793(92)80765-9; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; STRICKER RB, 1986, BLOOD, V68, P275; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WONG AP, 1992, AM J PHYSIOL, V263, pF1112, DOI 10.1152/ajprenal.1992.263.6.F1112	67	370	380	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					939	945		10.1096/fasebj.9.10.7615163	http://dx.doi.org/10.1096/fasebj.9.10.7615163			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615163				2022-12-28	WOS:A1995RK89900016
J	HOFER, AM; SCHLUE, WR; CURCI, S; MACHEN, TE				HOFER, AM; SCHLUE, WR; CURCI, S; MACHEN, TE			SPATIAL-DISTRIBUTION AND QUANTITATION OF FREE LUMINAL [CA] WITHIN THE INSP(3)-SENSITIVE INTERNAL STORE OF INDIVIDUAL BHK-21-CELLS - ION DEPENDENCE OF INSP(3)-INDUCED CA RELEASE AND RELOADING	FASEB JOURNAL			English	Article						RATIO IMAGING; THAPSIGARGIN; CA IONOPHORES	CYTOSOLIC FREE MAGNESIUM; INDUCED CALCIUM RELEASE; ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; PERMEABILIZED HEPATOCYTES; GOLGI-APPARATUS; FLUORESCENT INDICATOR; CHANNEL BLOCKERS; CA-2+ RELEASE; PC12 CELLS	Free [Ga] within organelles of permeabilized BHK-21 cells was measured using ratio imaging of compartmentalized mag-fura-2. In BHK-21 cells, this dye monitors free [Ca] in principally one type of ATP-dependent Ca-sequestering organelle in which intrastore Ca was released uniformly and entirely by 100 nM thapsigargin or removal of ATP or Ca from the bath, and was reduced by 85% upon treatment with a supramaximal dose of InsP(3) (6 mu M). Examination of the spatial distribution of InsP(3)-sensitive Ca stores showed that InsP(3) released Ca throughout all regions of the cell, although we often noted a perinuclear region (which we speculate may correspond to the Golgi apparatus) with reduced responsiveness to InsP(3). InsP(3)-induced changes of intraluminal Mg could not be detected. Cyclic ADP-ribose, ryanodine, caffeine, mitochondrial inhibitors, and GTP, agents known to influence intraorganellar Ca sequestration in other cell types, were all without effect on the mag-fura-2 ratio. In situ calibration of the mag-fura-2 ratio with Ca ionophores revealed that the average free intraorganellar [Ca] was initially 188 +/- 21 mu M in the presence of 170 nM free Ca and 3 mM ATP, and was reduced to 25 +/- 5 mu M upon stimulation with 6 mu M InsP(3). The ionic dependence of the release and reloading process was also investigated. The presence of either K, Na, or Cl could consistently support both InsP(3)-induced release and the refilling of stores with Ca, but physiological concentrations of HCO3 were effective in sustaining the response in only 24% of cells examined.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV CELL & DEV BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHANDRA S, 1991, J CELL SCI, V100, P747; CHANDRA S, 1994, J BIOL CHEM, V269, P15186; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOEGER DE, 1989, BIOCHEM PHARMACOL, V38, P3995, DOI 10.1016/0006-2952(89)90679-5; GUILLEMETTE G, 1991, CELL CALCIUM, V12, P51, DOI 10.1016/0143-4160(91)90084-R; GUNTER TE, 1993, AM J PHYSIOL, V258, pC755; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HODSON S, 1978, J CELL SCI, V30, P117; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; KEMMER TP, 1987, J BIOL CHEM, V262, P13758; KOCH GLE, 1987, J CELL SCI, V87, P491; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1985, P NATL ACAD SCI USA, V82, P4433, DOI 10.1073/pnas.82.13.4433; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; OZAWA M, 1993, J BIOL CHEM, V268, P699; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALADE P, 1989, MOL PHARMACOL, V36, P664; QUAMME GA, 1990, BIOCHEM BIOPH RES CO, V167, P1406, DOI 10.1016/0006-291X(90)90679-H; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SHAH J, 1988, BIOCHEM J, V250, P617, DOI 10.1042/bj2500617; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; ZHANG GH, 1990, CELL CALCIUM, V11, P397, DOI 10.1016/0143-4160(90)90051-U	49	51	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1995	9	9					788	798		10.1096/fasebj.9.9.7601343	http://dx.doi.org/10.1096/fasebj.9.9.7601343			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601343				2022-12-28	WOS:A1995RH98200012
J	HENIN, N; VINCENT, MF; GRUBER, HE; VANDENBERGHE, G				HENIN, N; VINCENT, MF; GRUBER, HE; VANDENBERGHE, G			INHIBITION OF FATTY-ACID AND CHOLESTEROL-SYNTHESIS BY STIMULATION OF AMP-ACTIVATED PROTEIN-KINASE	FASEB JOURNAL			English	Article						ACETYL-COA CARBOXYLASE; HMG-COA REDUCTASE; AICARIBOSIDE; ZMP	ACETYL-COA CARBOXYLASE; ISOLATED RAT HEPATOCYTES; COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; REVERSIBLE PHOSPHORYLATION; CYCLIC-AMP; INACTIVATION; PURIFICATION; LIPOGENESIS	AMP-activated protein kinase is a multisubstrate protein kinase that, in liver, inactivates both acetyl-CoA carboxylase, the rate-limiting enzyme of fatty acid synthesis, and 3-hydroxy-3-methyl-glutaryl-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, AICAR (5-amino 4-imidazolecarboxamide ribotide, ZMP) was found to stimulate up to 10-fold rat liver AMP-activated protein kinase, with a half-maximal effect at approximately 5 mM. In accordance with previous observations, addition to suspensions of isolated rat hepatocytes of 50-500 mu M AICAriboside, the nucleoside corresponding to ZMP, resulted in the accumulation of millimolar concentrations of the latter. This was accompanied by a dose-dependent inactivation of both acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA reductase. Addition of 50-500 mu M AICAriboside to hepatocyte suspensions incubated in the presence of various substrates, including glucose and lactate/pyruvate, caused a parallel inhibition of both fatty acid and cholesterol synthesis, With lactate/pyruvate (10/1 mM), half-maximal inhibition was obtained at approximately 100 mu M, and near-complete inhibition at 500 mu M AICAriboside. These findings open new perspectives for the simultaneous control of triglyceride and cholesterol synthesis by pharmacological stimulators of AMP-activated protein kinase.	INT INST CELLULAR & MOLEC PATHOL,PHYSIOL CHEM LAB,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; GENSIA INC,SAN DIEGO,CA 92121	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BEG ZH, 1981, CURR TOP CELL REGUL, V20, P139; BEG ZH, 1985, J BIOL CHEM, V260, P1682; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P274, DOI 10.1016/0005-2760(87)90231-1; BROWN MS, 1975, J BIOL CHEM, V250, P2502; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1972, EUR J BIOCHEM, V203, P615; EASOM RA, 1984, BIOCHEM J, V220, P739, DOI 10.1042/bj2200739; EVANS RD, 1990, BIOCHEM J, V269, P269, DOI 10.1042/bj2690269; GEELEN MJH, 1991, BIOCHEM BIOPH RES CO, V180, P525, DOI 10.1016/S0006-291X(05)81096-4; GIBBONS GF, 1979, BIOCHEM J, V177, P255, DOI 10.1042/bj1770255; GIBBONS GF, 1986, BIOCHEM J, V239, P617, DOI 10.1042/bj2390617; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARRIS RA, 1975, ARCH BIOCHEM BIOPHYS, V169, P168, DOI 10.1016/0003-9861(75)90330-6; HAVEL RJ, 1988, J CLIN INVEST, V81, P1653, DOI 10.1172/JCI113501; JAVAUX F, 1995, BIOCHEM J, V305, P913, DOI 10.1042/bj3050913; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; LOPESVIRELLA MF, 1987, DIABETES METAB REV, V3, P691, DOI 10.1002/dmr.5610030305; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; NISHINA PM, 1990, J NUTR, V120, P668, DOI 10.1093/jn/120.7.668; SABINA RL, 1984, SCIENCE, V223, P1193, DOI 10.1126/science.6199843; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x	36	217	233	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					541	546		10.1096/fasebj.9.7.7737463	http://dx.doi.org/10.1096/fasebj.9.7.7737463			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737463				2022-12-28	WOS:A1995QX14800012
J	DELACADENA, RA; STADNICKI, A; UKNIS, AB; SARTOR, RB; KETTNER, CA; ADAM, A; COLMAN, RW				DELACADENA, RA; STADNICKI, A; UKNIS, AB; SARTOR, RB; KETTNER, CA; ADAM, A; COLMAN, RW			INHIBITION OF PLASMA KALLIKREIN PREVENTS PEPTIDOGLYCAN-INDUCED ARTHRITIS IN THE LEWIS RAT	FASEB JOURNAL			English	Article						KININOGEN; CONTACT SYSTEM; FACTOR XI; PROTEASE INHIBITORS; INFLAMMATORY JOINT DISEASE	STREPTOCOCCAL CELL-WALL; NORMAL-FLORA BACTERIA; HAGEMAN-FACTOR; FACTOR-XII; POLYSACCHARIDE POLYMERS; ARTHROPATHIC PROPERTIES; NEUTROPHIL ELASTASE; CONTACT ACTIVATION; MOLECULAR-WEIGHT; KININ SYSTEM	We investigate whether the previously shown contact system activation plays a pathogenetic role in a rat model of acute inflammation induced by peptido-glycan-polysaccharide (PG-APS) using a new specific plasma kallikrein inhibitor, Bz-Pro-Phe-boroArg-OH (P8720). Group I(control) received neither PG-APS nor inhibitor. Group II (disease-treated) received PG-APS intraperitoneally (IF) and P8720 orally. Group III(disease-untreated) received PG-APS IP. Anemia was evident at 49 h in group III but was not present (P < 0.01) in groups I and II. Spleen weight was significantly decreased in group II compared to group III. Acute arthritis progressively developed in group III from 27 to 49 h, but P8720 decreased the joint swelling in group II by 61% (P < 0.0005). We observed a significant fall in prekallikrein and factor XI (P < 0.01) in groups II and III but not in group I. The decrease in the functional levels of high molecular weight kininogen (P < 0.05) observed in group III were prevented by P8720 in group II. The changes in T-kininogen and alpha(1)-inhibitor 3 acute-phase proteins were partially prevented by P8720. We conclude that the inflammatory reactions leading to arthritis and anemia, as well as the acute-phase reaction, are due in part to contact activation, and that specific kallikrein inhibitors may have therapeutic potential.	TEMPLE UNIV,SCH MED,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; UNIV N CAROLINA,DEPT DIGEST DIS & NUTR,CHAPEL HILL,NC 27599; DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880; UNIV MONTREAL,DEPT PHARM,MONTREAL,PQ H3C 3J7,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of North Carolina; University of North Carolina Chapel Hill; DuPont; Universite de Montreal	DELACADENA, RA (corresponding author), TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL02681-04] Funding Source: Medline; NIDDK NIH HHS [DK45735, DK40249] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM A, 1989, BIOCHEM PHARMACOL, V38, P1569, DOI 10.1016/0006-2952(89)90303-1; BEDI GS, 1983, BIOCHEM PHARMACOL, V32, P2061, DOI 10.1016/0006-2952(83)90427-6; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CHETTY C, 1983, J EXP MED, V157, P1089, DOI 10.1084/jem.157.4.1089; COLMAN RW, 1978, J CLIN INVEST, V61, P287, DOI 10.1172/JCI108938; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; COLMAN RW, 1988, AM J PATHOL, V130, P418; DALLDORF FG, 1988, AM J PATHOL, V132, P258; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; DELACADENA RA, 1993, BLOOD, V81, P3313; DELACADENA RA, 1991, AM J PHYSIOL, V260, pG213, DOI 10.1152/ajpgi.1991.260.2.G213; DELACADENA RA, 1993, HEMOSTASIS THROMBOSI, P219; FOX A, 1982, INFECT IMMUN, V35, P1003, DOI 10.1128/IAI.35.3.1003-1010.1982; GERATZ JD, 1991, AM J PATHOL, V139, P921; GERATZ JD, 1990, AM J PATHOL, V136, P909; GINSBERG MH, 1980, J LAB CLIN MED, V95, P497; HEYMER B, 1977, MICROBIOLOGY 1977, P344; JANSEN PM, 1993, BLOOD, V82, pA66; JANUSZ MJ, 1987, INFLAMMATION, V11, P73, DOI 10.1007/BF00917773; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; KETTNER C, 1980, ARCH BIOCHEM BIOPHYS, V202, P420, DOI 10.1016/0003-9861(80)90446-4; KETTNER C, 1990, J BIOL CHEM, V265, P18289; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KNABB RM, 1992, THROMB HAEMOSTASIS, V67, P56; LAMBRIS JD, 1982, INFECT IMMUN, V35, P377, DOI 10.1128/IAI.35.1.377-380.1982; LIPSKY PE, 1989, SPRINGER SEMIN IMMUN, V11, P123; MASON JW, 1970, ANN INTERN MED, V73, P545, DOI 10.7326/0003-4819-73-4-545; MATTESON DS, 1981, J AM CHEM SOC, V103, P5241, DOI 10.1021/ja00407a051; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PIXLEY RA, 1995, CRIT CARE MED, V23, P41, DOI 10.1097/00003246-199501000-00010; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO AK, 1988, NEW ENGL J MED, V318, P1021, DOI 10.1056/NEJM198804213181603; REVAK SD, 1978, J EXP MED, V147, P719, DOI 10.1084/jem.147.3.719; SARTOR RB, 1989, INFECT IMMUN, V57, P1177, DOI 10.1128/IAI.57.4.1177-1185.1989; SARTOR RB, 1994, INFLAMM BOWEL DIS, P210; SARTOR RB, 1994, GASTROENTEROLOGY, V100, pA613; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHWAB JH, 1993, INFECT IMMUN, V61, P4535, DOI 10.1128/IAI.61.11.4535-4539.1993; SCHWAB JH, 1991, INFECT IMMUN, V59, P4436, DOI 10.1128/IAI.59.12.4436-4442.1991; SCOTT CF, 1988, J LAB CLIN MED, V111, P708; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; STIMPSON SA, 1986, INFECT IMMUN, V51, P240, DOI 10.1128/IAI.51.1.240-249.1986; STIMPSON SA, 1989, PHARM METHODS CONTRO, P381; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TOOSSI Z, 1992, P NATL ACAD SCI USA, V89, P11969, DOI 10.1073/pnas.89.24.11969; VELOSO D, 1987, BLOOD, V70, P1053; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; Williams J W, 1979, Methods Enzymol, V63, P437	49	33	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					446	452		10.1096/fasebj.9.5.7896018	http://dx.doi.org/10.1096/fasebj.9.5.7896018			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896018				2022-12-28	WOS:A1995QP45100021
J	MONONEN, I; HEISTERKAMP, N; DUNDER, U; ROMPPANEN, EL; NORONKOSKI, T; KURONEN, I; GROFFEN, J				MONONEN, I; HEISTERKAMP, N; DUNDER, U; ROMPPANEN, EL; NORONKOSKI, T; KURONEN, I; GROFFEN, J			RECOMBINANT GLYCOSYLASPARAGINASE AND IN-VITRO CORRECTION OF ASPARTYLGLYCOSAMINURIA	FASEB JOURNAL			English	Article						LYSOSOMAL STORAGE DISEASE; GLYCOPROTEINOSIS; LYSOSOMAL ENZYMES; MEMBRANE RECEPTORS; ENZYME THERAPY	PHOSPHOMANNOSYL RECEPTOR; HUMAN FIBROBLASTS; LYSOSOMAL ENZYME; MAMMALIAN-CELLS; PINOCYTOSIS; DISEASE; CDNA; ASPARTYLGLUCOSAMINIDASE; GLYCOASPARAGINASE; IDURONIDASE	Aspartylglycosaminuria (AGU) is the most common disorder of glycoprotein degradation. AGU patients are deficient in glycosylasparaginase (GA), which results in accumulation of aspartylglucosamine in body fluids and tissues. Human glycosylasparaginase was stably overexpressed in NIH-3T3 mouse fibroblasts, in which the unusual posttranslational processing and maturation of the enzyme occurred in a high degree. The recombinant enzyme was isolated as two isoforms, which were both phosphorylated, and actively transported into AGU fibroblasts and lymphoblasts through mannose-6-phosphate receptor-mediated endocytosis. The rate of uptake into fibroblasts was half-maximal when the concentration of GA in the medium was 5 x 10(-8) M. Immunofluorescence microscopy suggested compartmentalization of the recombinant enzyme in the lysosomes. Supplementation of culture medium with either isoform cleared AGU lymphoblasts of stored aspartylglucosamine when glycosylasparaginase activity in the cells reached 3-4% of that in normal lymphoblasts. A relatively small amount of recombinant GA in the culture medium was sufficient to reverse pathology in the target cells, indicating high corrective quality of the enzyme preparations. The combined evidence indicates that enzyme replacement therapy with the present recombinant glycosylasparaginase might reverse pathology at least in somatic cells of AGU patients.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	MONONEN, I (corresponding author), KUOPIO UNIV HOSP,DEPT CLIN CHEM,POB 1777,SF-70211 KUOPIO,FINLAND.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273				AULA P, 1982, GENETIC ERRORS GLYCO, P123; BACH G, 1972, P NATL ACAD SCI USA, V69, P2048, DOI 10.1073/pnas.69.8.2048; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELIAHU R, 1981, AM J HUM GENET, V33, P576; FISCHER HD, 1983, J CELL BIOCHEM, V22, P69, DOI 10.1002/jcb.240220202; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KAARTINEN V, 1989, J CHROMATOGR-BIOMED, V490, P293, DOI 10.1016/S0378-4347(00)82787-5; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KOKKO H, 1992, ANAL BIOCHEM, V201, P311, DOI 10.1016/0003-2697(92)90344-7; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1994, LANCET, V343, P1297, DOI 10.1016/S0140-6736(94)92187-3; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; TALKAD V, 1983, J BIOL CHEM, V258, P7345; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006	26	16	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					428	433		10.1096/fasebj.9.5.7896015	http://dx.doi.org/10.1096/fasebj.9.5.7896015			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896015				2022-12-28	WOS:A1995QP45100018
J	OCONNOR, PJ; MERRILL, GF				OCONNOR, PJ; MERRILL, GF			VENTRICULAR ARRHYTHMIAS CAUSED BY REPEAT EXPOSURE TO HYPOXIA ARE DEPENDENT ON DURATION OF REOXYGENATION	FASEB JOURNAL			English	Article						PRECONDITIONING; ADRENERGIC; PROPRANOLOL	ADENOSINE-DEAMINASE; CORONARY VASODILATION; MYOCARDIAL HYPOXIA	The three objectives of this study were: 1) to determine whether an initial exposure to systemic hypoxia could affect the ventricular ectopy caused by a second period of hypoxia, 2) to see whether the duration of the intervening period of reoxygenation was important, and 3) to determine whether propranolol could produce results similar to those caused by an inadequate period of reoxygenation. Anesthetized instrumented beagles of either sex weighing 10.2 +/- 0.4 kg (n = 25) were exposed to dual periods of hypoxia (4 min each, PO2 similar to 15 +/- 3 mmHg). Dogs were divided into four groups according to the duration of reoxygenation and propranolol treatment: group 1 (n = 7), 20 min of reoxygenation; group 2 (n = 7), 40 min of reoxygenation; group 3 (n = 6), 60 min of reoxygenation; group 4 (n = 5), 50 min of reoxygenation plus propranolol. Dogs in groups 1 and 4 experienced a significant reduction in percent ectopy during their second exposure to hypoxia [group 1; 47 +/- 9% vs. 11 +/- 6%, group 4; 50 +/- 1% vs, 1 +/- 2%, (P < 0.05)], There were no significant differences in percent ectopy between the two periods of hypoxia in either group 2 or group 3 dogs (e.g., group 2; 50 +/- 1% vs. 51 +/- 11%). The results show that a first exposure to hypoxia can precondition the myocardium against arrhythmogenic effects of a second period of hypoxia.	RUTGERS STATE UNIV, DEPT BIOL SCI, NEW BRUNSWICK, NJ 08903 USA; RUTGERS STATE UNIV, GRAD PROGRAM PHYSIOL & NEUROBIOL, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			O'Connor, Patrick/HII-2987-2022					BENSOREK ESW, 1993, ARCH INTERN MED, V153, P2701, DOI 10.1001/archinte.153.23.2701; DALY MDB, 1963, J PHYSIOL-LONDON, V165, P179; DALY MDB, 1964, J PHYSL, V73, P201; HERRMANN SC, 1992, CIRC RES, V70, P1203, DOI 10.1161/01.RES.70.6.1203; LASLEY RD, 1993, CARDIOVASC RES, V27, P565, DOI 10.1093/cvr/27.4.565; LAWSON CS, 1993, CARDIOVASC RES, V27, P681, DOI 10.1093/cvr/27.4.681; LEONE RJ, 1993, J APPL PHYSIOL, V74, P1543, DOI 10.1152/jappl.1993.74.4.1543; LEONE RJ, 1993, FASEB J, V7, pA97; LUCCHESI BR, 1961, J PHARMACOL EXP THER, V132, P372; MALOOTIAN A, 1992, CAN J PHYSIOL PHARM, V70, P94, DOI 10.1139/y92-013; MERRILL GF, 1988, CARDIOVASC RES, V22, P345, DOI 10.1093/cvr/22.5.345; MERRILL GF, 1986, AM J PHYSIOL, V250, pH579, DOI 10.1152/ajpheart.1986.250.4.H579; O'Connor P. J., 1993, BIOMED LETT, V48, P163; PELLEG A, 1993, CORONARY ARTERY DIS, V4, P109, DOI 10.1097/00019501-199301000-00010; SCHAAL SF, 1969, CARDIOVASC RES, V3, P241, DOI 10.1093/cvr/3.3.241; SHIZUKUDA Y, 1992, CARDIOVASC RES, V26, P534, DOI 10.1093/cvr/26.5.534; SHIZUKUDA Y, 1993, CARDIOVASC RES, V27, P559, DOI 10.1093/cvr/27.4.559; SOKAL RR, 1969, BIOMETRY, P127; SZEKERES L, 1993, CARDIOVASC RES, V27, P593, DOI 10.1093/cvr/27.4.593; TODOROV L, 1994, FASEB J, V8, pA375; TSUCHIDA A, 1993, CARDIOVASC RES, V27, P652, DOI 10.1093/cvr/27.4.652; VEGH A, 1993, CARDIOVASC RES, V27, P638, DOI 10.1093/cvr/27.4.638; VEGH A, 1992, BRIT J PHARMACOL, V107, P648, DOI 10.1111/j.1476-5381.1992.tb14501.x; WALKER MJA, 1988, CARDIOVASC RES, V22, P447, DOI 10.1093/cvr/22.7.447; WEI HM, 1989, AM J PHYSIOL, V257, pH1043, DOI 10.1152/ajpheart.1989.257.4.H1043; WEI HM, 1988, AM J PHYSIOL, V254, pH1004, DOI 10.1152/ajpheart.1988.254.5.H1004; WESTFALL DP, 1994, FASEB J, V8, pA375	27	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					387	391		10.1096/fasebj.9.5.7896008	http://dx.doi.org/10.1096/fasebj.9.5.7896008			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896008				2022-12-28	WOS:A1995QP45100011
J	SOTHERN, RB; SMAALAND, R; MOORE, JG				SOTHERN, RB; SMAALAND, R; MOORE, JG			CIRCANNUAL RHYTHM IN DNA-SYNTHESIS (S-PHASE) IN HEALTHY-HUMAN BONE-MARROW AND RECTAL MUCOSA	FASEB JOURNAL			English	Article						GASTROINTESTINAL; BIOLOGICAL RHYTHMS; CIRCANNUAL VARIATIONS; CIRCADIAN CYCLES	METASTATIC TUMOR-GROWTH; SEASONAL-VARIATION; CIRCADIAN STAGE; ANTIBODY-FORMATION; BREAST-CANCER; PROLIFERATION; PERIODICITY; MELANOMA; DISEASE; MOUSE	Cytotoxic anti-cancer drugs are meant to interact with tumor cells to impair the replicative and/or transcriptional functions of DNA in order to reduce proliferative rate and cause cell death. These drugs also affect rapidly proliferating healthy tissues such as the bone marrow and the gastrointestinal tract, thereby resulting in toxicity-related dose reductions and/or delays in treatment. We previously demonstrated a circadian rhythm in DNA synthesis (S-phase) of total bone marrow (BM) nucleated cells in 16 healthy, diurnally active men sampled every 4 h for 24 h (19 series). Highest values determined by flow cytometry were found near midday. We also reported a circadian rhythm in DNA synthesis of the rectal mucosa (RM) in 16 healthy men sampled every 2-3 h for 24 h under fed and fasting conditions (24 series). Highest proliferative activity as reflected by in vitro [H-3]Tdr uptake, was found near the time of awakening, Circannual (about yearly) rhythmicity in cell division rates may also influence treatment effects. Our BM and RM DNA data, which were collected over several years, were reanalyzed for seasonality by ANOVA and for circannual rhythm by the least-squares fit of a 1 year cosine. Characteristics of circadian amplitudes and acrophases were also compared between seasons. In addition to a significant circadian rhythm, a significant circannual rhythm in cell proliferation in healthy BM (P = 0.008) and RM (P < 0.001) could be established on the basis of these serially independent data. The range between the lowest and highest points of the fitted 1 year cosine (circannual double amplitude) was comparable to the circadian range for BM (25%); it was at least doubled for RM (70%). Highest values occurred in the late summer for BM and mid-fall for RM. Based on limited data in some seasons, the circadian patterns were more prominent in the fall and winter, with larger amplitudes and later acrophases, when compared with summer for BM and spring and summer for RM. Thus, in addition to time of day, time of year may influence chemo- and immunotherapeutic strategies and should be considered in the design of preclinical and clinical treatment regimens and other procedures.	ST PAUL RAMSEY MED CTR, RHYTHMOMETRY LAB, MINNEAPOLIS, MN 55455 USA; UNIV BERGEN, HAUKELAND HOSP, DEPT ONCOL, BERGEN, NORWAY; UNIV UTAH, SCH MED, DEPT INTERNAL MED, DIV GASTROENTEROL, SALT LAKE CITY, UT 84148 USA	Saint Paul Ramsey Medical Center; University of Bergen; Haukeland University Hospital; Utah System of Higher Education; University of Utah	SOTHERN, RB (corresponding author), UNIV MINNESOTA, CHRONOBIOL LABS, RHYTHMOMETRY LAB, BOX 609 UMHC, MINNEAPOLIS, MN 55455 USA.		Smaaland, Rune/AAH-2149-2021					AKSLEN LA, 1989, CHRONOBIOLOGIA, V16, P257; AKSLEN LA, 1991, INVAS METAST, V11, P58; BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BJARNASON GA, 1994, CIRCADIAN CANC THERA, P241; BLANK MA, 1992, WORKSHOP COMPUTER ME, P245; BUCHI KN, 1991, GASTROENTEROLOGY, V101, P410, DOI 10.1016/0016-5085(91)90019-H; COHEN P, 1983, CANCER RES, V43, P892; DOUPE J, 1957, CAN J BIOCHEM PHYS, V35, P203; GODFREY HP, 1975, INT ARCH ALLER A IMM, V49, P411, DOI 10.1159/000231422; HALBERG F, 1983, International Journal of Chronobiology, V8, P225; HALBERG FE, 1990, PROG CLIN BIOL RES, V341, P567; HARTVEIT F, 1992, CLIN EXP METASTAS, V10, P329, DOI 10.1007/BF00058172; HAUS E, 1992, CHRONOBIOL INT, V9, P393; HAUS E, 1987, Chronobiologia, V14, P184; Haus E, 1988, ANN REV CHRONOPHARMA, V4, P333; HERMIDA RC, 1993, CHRONOBIOL INT, V10, P54, DOI 10.3109/07420529309064482; HOSTMARK JG, 1984, SCAND J UROL NEPHROL, V18, P107, DOI 10.3109/00365598409182176; HRUSHESKY WJM, 1982, ANN NY ACAD SCI, V397, P293, DOI 10.1111/j.1749-6632.1982.tb43441.x; HRUSHESKY WJM, 1985, CHRONOBIOLOGY 1981 1, P493; HRUSHESKY WJM, 1993, CANCER PRINCIPLES PR, P2666; KLEMFUSS H, 1993, J INTERDISCIPL CYCLE, V24, P1, DOI 10.1080/09291019309360191; KOMADA H, 1989, J INTERDISCIPL CYCLE, V20, P107; LAERUM CD, 1988, CHRONOBIOL INT, V5, P19, DOI 10.3109/07420528809078549; LEVI F, 1988, EXP HEMATOL, V16, P696; LEVI F, 1989, BIOL RHYTHMS CLIN PR, P99; MACMURRAY JP, 1983, LIFE SCI, V32, P2363, DOI 10.1016/0024-3205(83)90767-1; MASON BH, 1985, BREAST CANCER RES TR, V5, P171, DOI 10.1007/BF01805991; MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Mormont C, 1989, CHRONOPHARMACOLOGY C, P395; NEWELL GR, 1985, JNCI-J NATL CANCER I, V74, P53; NICOLAU G Y, 1984, Chronobiology International, V1, P301, DOI 10.3109/07420528409063911; POLLMANN L, 1982, J INTERDISCIPL CYCLE, V13, P249; RATAJCZAK HV, 1993, CHRONOBIOL INT, V10, P383, DOI 10.3109/07420529309064492; RATAJCZAK HV, 1991, CHRONOBIOL INT, V8, P44, DOI 10.3109/07420529109063918; REINBERG A, 1978, ENV ENDOCRINOLOGY, P113; ROBERTSON WG, 1977, CLIN CHIM ACTA, V80, P347, DOI 10.1016/0009-8981(77)90043-2; SCHEVING LE, 1989, CHRONOPHARMACOLOGY C, P317; SHIFRINE M, 1982, J INTERDISCIPL CYCLE, V13, P157, DOI 10.1080/09291018209359774; SMAALAND R, 1993, CANCER RES, V53, P3129; SMAALAND R, 1992, BLOOD, V79, P2281; SMAALAND R, 1991, BLOOD, V77, P2603; SMAALAND R, 1994, CIRCADIAN CANCER THE, P119; Sothern R., 1972, PHYSIOL TEACH, V1, P1; SOTHERN RB, 1993, CHRONOBIOL INT, V10, P364, DOI 10.3109/07420529309064491; SOTHERN RB, 1994, CHRONOBIOLOGIA, V21, P7; SOTHERN RB, 1994, FASEB J, V8, pA927; SWERDLOW AJ, 1985, BRIT J CANCER, V52, P893, DOI 10.1038/bjc.1985.274	48	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					397	403		10.1096/fasebj.9.5.7896010	http://dx.doi.org/10.1096/fasebj.9.5.7896010			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896010				2022-12-28	WOS:A1995QP45100013
J	HEIDARAN, MA; MAHADEVAN, D; LAROCHELLE, WJ				HEIDARAN, MA; MAHADEVAN, D; LAROCHELLE, WJ			BETA-PDGFR-IGG CHIMERA DEMONSTRATES THAT HUMAN BETA-PDGFR IG-LIKE DOMAIN-1 TO DOMAIN-3 ARE SUFFICIENT FOR HIGH-AFFINITY PDGF-BB BINDING	FASEB JOURNAL			English	Article						FUSION PROTEINS; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; SURAMIN	GROWTH-FACTOR RECEPTORS; SIMIAN SARCOMA-VIRUS; MONOCLONAL-ANTIBODY; HUMAN-ALPHA; EXTRACELLULAR DOMAIN; FUSION PROTEINS; LIGAND-BINDING; V-SIS; EXPRESSION; INHIBITION	To localize human beta PDGFR binding determinants, we constructed a fusion protein comprising beta PDGFR Ig-like domains 1 to 3 and an IgG(1) Fc domain (beta PDGFR-HFc). beta PDGFR-HFc was expressed as a 200 kDa dimeric molecule and contained Fc epitopes as demonstrated by anti-mouse Fc antibody recognition. Scatchard analysis revealed that PDGF BB possessed a dissociation constant of 1.5 nM for beta PDGFR-HFc. Thus, beta PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding. We exploited this fusion protein technology to identify and characterize beta PDGFR antagonists using a sensitive beta PDGFR immunosorbent assay. In this assay, beta PDGFR-HFc half-maximally bound to PDGF BB with an affinity of around 150 pM. Suramin, as well as bacterially expressed and refolded human alpha PDGFR domains 1-3, inhibited beta PDGFR-HFc binding to PDGF BB half-maximally at 25 mu M and 10 nM respectively. Therefore, alpha PDGFR D1-3, like beta PDGFR D1-3, are sufficient for high affinity PDGF BB binding. Furthermore, the beta PDGFR-HFc immunosorbent assay will be useful to identify beta PDGFR antagonists as well as to study alpha and beta PDGFR substitution mutants which further map receptor binding determinants.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COGNE M, 1992, BLOOD, V79, P2181; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1992, CANCER RES, V52, P4550; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HERREN B, 1993, J BIOL CHEM, V268, P15088; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LIU YC, 1993, BIOCHEM BIOPH RES CO, V197, P1094, DOI 10.1006/bbrc.1993.2590; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; NISTER M, 1991, J BIOL CHEM, V266, P16755; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; ROONEY BC, 1994, FEBS LETT, V339, P181, DOI 10.1016/0014-5793(94)80411-7; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SMITS A, 1992, AM J PATHOL, V140, P639; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	45	22	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					140	145		10.1096/fasebj.9.1.7821753	http://dx.doi.org/10.1096/fasebj.9.1.7821753			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821753				2022-12-28	WOS:A1995QD20200022
J	PUTNAM, FW				PUTNAM, FW			MILESTONES IN STRUCTURAL IMMUNOLOGY	FASEB JOURNAL			English	Editorial Material							ANTIBODY				PUTNAM, FW (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.							DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; KABAT EA, 1991, NIH913242 PUBL; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; PUTNAM FW, 1967, COLD SPRING HARB SYM, V32, P9, DOI 10.1101/SQB.1967.032.01.006; PUTNAM FW, 1977, PLASMA PROTEINS, V3, P1; PUTNAM FW, 1987, PLASMA PROTEINS, V5, P49	9	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					146	147		10.1096/fasebj.9.1.7821754	http://dx.doi.org/10.1096/fasebj.9.1.7821754			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821754				2022-12-28	WOS:A1995QD20200023
J	YOUNG, ACM; NATHENSON, SG; SACCHETTINI, JC				YOUNG, ACM; NATHENSON, SG; SACCHETTINI, JC			STRUCTURAL STUDIES OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX PROTEINS - INSIGHTS INTO ANTIGEN PRESENTATION	FASEB JOURNAL			English	Review						ANTIGEN PRESENTATION; PEPTIDE BINDING; PROTEIN CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE	TOXIC LYMPHOCYTES-T; PEPTIDE BINDING; INFLUENZA NUCLEOPROTEIN; VIRAL PEPTIDES; MHC MOLECULES; TRANSPLANTATION ANTIGENS; SYNTHETIC PEPTIDES; H-2K(B) MOLECULE; CELL EPITOPE; SIDE-CHAINS	The three-dimensional structures of three human and two murine class I molecules, in complex with single peptides and with mixtures of endogenous peptides, have now been determined to high resolution. These structures have afforded important insights into the way in which antigenic peptides are bound by an MHC class I molecule, and how a given MHC molecule can bind a large number and variety of peptides, for presentation to a T cell receptor. Peptides are bound in a cleft located in the alpha(2)/alpha(2) domain of a class I molecule. They are tethered by an array of hydrogen bonding interactions many of which are conserved among the different structures. Binding is also accomplished through van der Waals interactions between two or three peptide residues and complementary pockets in the cleft. The location and the characteristics of its pockets are unique to a given MHC class I molecule, and so determine the identity of the anchor residues of the set of peptides that bind. The antigenic epitope recognized by the TCR consists of residues on the MHC as well as the side chains of those peptide residues that point out from the cleft. The various strategies used to expand the repertoire of peptides bound and presented are discussed.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI007289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30 CA 13330] Funding Source: Medline; NIAID NIH HHS [5 R37 AI-07289] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM-45859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BUXTON SE, 1992, J EXP MED, V175, P809, DOI 10.1084/jem.175.3.809; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; COSSINS J, 1993, VIROLOGY, V193, P289, DOI 10.1006/viro.1993.1124; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULD KG, 1991, J VIROL, V65, P5401, DOI 10.1128/JVI.65.10.5401-5409.1991; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NATHENSON SG, 1986, ANNU REV IMMUNOL, V4, P471, DOI 10.1146/annurev.iy.04.040186.002351; NATHENSON SG, 1981, ANNU REV BIOCHEM, V50, P1025, DOI 10.1146/annurev.bi.50.070181.005113; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7; ROHREN EM, 1993, J EXP MED, V177, P1713, DOI 10.1084/jem.177.6.1713; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STEINMETZ M, 1983, SCIENCE, V222, P727, DOI 10.1126/science.6356354; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; van Bleek G M, 1992, Trends Cell Biol, V2, P202, DOI 10.1016/0962-8924(92)90247-K; VANBLEEK GM, 1990, NATURE, V348, P213; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	54	56	56	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					26	36		10.1096/fasebj.9.1.7821756	http://dx.doi.org/10.1096/fasebj.9.1.7821756			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821756				2022-12-28	WOS:A1995QD20200006
J	JAVITT, NB				JAVITT, NB			BILE-ACID SYNTHESIS FROM CHOLESTEROL - REGULATORY AND AUXILIARY PATHWAYS	FASEB JOURNAL			English	Article						CHOLESTEROL 7-ALPHA-HYDROXYLASE; STEROL 27-HYDROXYLASE; LIVER; 27-HYDROXYCHOLESTEROL; METABOLIC PATHWAYS; 27-HYDROXYCHOLESTEROL 7-ALPHA-HYDROXYLASE; ATHEROSCLEROSIS; CEREBROTENDINOUS XANTHOMATOSIS (CTX); OXYSTEROL HYPOTHESIS	HMG-COA REDUCTASE; CEREBROTENDINOUS XANTHOMATOSIS; 7-ALPHA-HYDROXYLASE ACTIVITY; BIOSYNTHETIC ENZYME; HYDROXYLASE GENE; LDL RECEPTOR; CLONING; 26-HYDROXYCHOLESTEROL; METABOLISM; LIVER	Bile acid synthesis from cholesterol can occur via two pathways, one initiated by sterol 27-hydroxylase activity or one initiated by that of cholesterol 7 alpha-hydroxylase. In contrast to cholesterol 7 alpha-hydroxylase, which is found in the liver, sterol 27-hydroxylase is a widely distributed mitochondrial enzyme with high activity in vascular endothelial cells. Although both pathways lead to the production of chenodeoxycholic and cholic acids, the key step, 7 alpha-hydroxylation, is governed by two different enzymes. Both 27-hydroxycholesterol and 3 beta-hydroxy-5-cholestenoic acid, the metabolites of cholesterol occurring via sterol 27-hydroxylase activity, normally circulate in plasma. After their uptake by the liver they are metabolized mostly to chenodeoxycholic acid, which downregulates the activity of cholesterol 7 alpha-hydroxylase, the rate-limiting step for the production of bile acids in the liver. Because of this relationship and also in view of the accelerated atherosclerosis and cholesterol deposition in tissues that occur as a consequence of genetically determined sterol 27-hydroxylase deficiency and of the potent biologic effect of 27-hydroxycholesterol in cell culture, it is proposed that this metabolic pathway serves a regulatory function. The pathway beginning with cholesterol 7 alpha-hydroxylation is modulated by genetic, hormonal, and probably dietary factors, and becomes most prominent with the interruption of the enterohepatic circulation of bile acids.-Javitt, N. B. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways.			JAVITT, NB (corresponding author), NYU,MED CTR,DIV HEPAT DIS,550 1ST AVE,NEW YORK,NY 10016, USA.			Javitt, Norman B/0000-0001-9265-3508	NIDDK NIH HHS [DK-32995] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELSON M, 1988, J LIPID RES, V29, P629; AXELSON M, 1992, J BIOL CHEM, V267, P101; BERGINER VM, 1984, NEW ENGL J MED, V311, P1649, DOI 10.1056/NEJM198412273112601; Bergstrom S, 1959, CIBA F S BIOSYNTHESI, P185; Bloch K, 1943, J BIOL CHEM, V149, P511; CALI JJ, 1991, J BIOL CHEM, V266, P7779; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DECAPRIO J, 1992, J LIPID RES, V33, P441; DUANE WC, 1993, J CLIN INVEST, V92, P911, DOI 10.1172/JCI116666; EINARSSON K, 1992, J LIPID RES, V33, P1591; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; FEARS R, 1986, CHOLESTERL 7ALPHA HY; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KARAM WG, 1992, BIOCHEM BIOPH RES CO, V185, P588, DOI 10.1016/0006-291X(92)91665-D; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LAVY U, 1977, J LIPID RES, V18, P232; LEE YH, 1994, J BIOL CHEM, V269, P14681; MARTIN KO, 1993, J LIPID RES, V34, P581; NASEEM SM, 1987, BIOCHEM INT, V14, P71; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; OKUDA K, 1988, J BIOL CHEM, V263, P18138; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; REIHNER E, 1991, J LIPID RES, V32, P469; REIHNER E, 1989, GASTROENTEROLOGY, V97, P1498, DOI 10.1016/0016-5085(89)90395-8; REISS AB, 1994, J LIPID RES, V35, P1026; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; SALEN G, 1985, J CLIN INVEST, V76, P744, DOI 10.1172/JCI112030; SULD HM, 1962, J BIOL CHEM, V237, P338; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; WATERREUS RJ, 1987, CLIN NEUROL NEUROSUR, V89, P169, DOI 10.1016/S0303-8467(87)80050-1	38	152	152	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1308	1311		10.1096/fasebj.8.15.8001744	http://dx.doi.org/10.1096/fasebj.8.15.8001744			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001744				2022-12-28	WOS:A1994PY20900015
J	STRAHLE, U; BLADER, P				STRAHLE, U; BLADER, P			EARLY NEUROGENESIS IN THE ZEBRAFISH EMBRYO	FASEB JOURNAL			English	Review						NEURAL TUBE FORMATION; FLOOR PLATE; SONIC HEDGEHOG; AXIAL	CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; XENOPUS-LAEVIS; SPINAL-CORD; BRACHYDANIO-RERIO; PATHWAY SELECTION; SPT-1 MUTATION; POLARITY GENE; NEURAL PLATE; GROWTH CONES	Zebrafish embryos represent an attractive system for the study of early vertebrate neurogenesis. The embryos develop outside of the mother and are transparent allowing analysis at the cellular level in the living embryo during all phases of early neurogenesis. The teleostean neural tube is generated by a mechanism different from that of other vertebrates. A massive keel is formed first and the central canal appears by subsequent cavitation. Despite this, however, the organization of the neural plate and the neural keel resembles that of other vertebrates in many aspects. Oriented cell divisions coupled with oriented cell intercalations appear to be involved in the morphogenesis of the neural keel. Embryos mutant in the cyclops gene show deficiencies in the ventral neural tube. They lack the floor plate and the ventral parts of the diencephalon. Two recently cloned genes, axial and sonic hedgehog, have been implicated in the development of the ventral midline of the neural tube.;Expression of axial and sonic hedgehog is impaired by the cyclops mutation in the midline of the neural plate. This, together with the effects of ectopic expression of the two cloned genes, suggests that axial, sonic hedgehog, and cyclops are part of the regulatory cascade leading to floor plate formation.			STRAHLE, U (corresponding author), UNIV OXFORD, DEPT ZOOL, IMPERIAL CANC RES FUND, DEV BIOL UNIT, S PARK RD, OXFORD OX1 3PS, ENGLAND.		Straehle, Uwe/K-7054-2013	Blader, Patrick/0000-0003-3299-6108				ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; EASTER SS, 1992, NERVE GROWTH CONE, P337; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EISEN JS, 1991, NEURON, V6, P767, DOI 10.1016/0896-6273(91)90173-W; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EISEN JS, 1991, DEVELOPMENT, P141; EISEN JS, 1993, DEV BIOL, V159, P50, DOI 10.1006/dbio.1993.1220; GATCHALIAN CL, 1992, NEURON, V9, P105, DOI 10.1016/0896-6273(92)90225-3; Ginsburg AS, 1991, ANIMAL SPECIES DEV S, P15; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HALPERN ME, 1963, CELL, V75, P1; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HATTA K, 1993, PERSP DEV NEUROBIOL, V1, P256; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HISOAKA KK, 1960, J MORPHOL, V107, P205; HISOAKA KK, 1958, J MORPHOL, V102, P311; Ho R.K., 1992, Seminars in Developmental Biology, V3, P53; HO RK, 1993, SCIENCE, V261, P109, DOI 10.1126/science.8316841; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; KELLER R, 1992, DEVELOPMENT, P81; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KIMMEL CB, 1993, ANNU REV NEUROSCI, V16, P707, DOI 10.1146/annurev.ne.16.030193.003423; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LUTHER WOLFGANG, 1935, BIOL ZENTRALBL, V55, P114; MOHLER J, 1988, GENETICS, V120, P1061; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PAPAN C, 1994, ROUX ARCH DEV BIOL, V203, P178, DOI 10.1007/BF00636333; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; PUSCHEL AW, 1992, MECH DEVELOP, V38, P197, DOI 10.1016/0925-4773(92)90053-M; REICHENBACH A, 1990, J HIRNFORSCH, V31, P152; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V119, P579; SCHMITZ B, 1993, ROUX ARCH DEV BIOL, V202, P250, DOI 10.1007/BF00363214; SCHOENWOLF GC, 1989, DEVELOPMENT, V106, P427; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TABATA T, 1992, GENE DEV, V7, P1436; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WARGA RM, 1990, DEVELOPMENT, V108, P569; Westerfield M, 1993, ZEBRAFISH BOOK; WILSON SW, 1991, DEVELOPMENT, V112, P723; WILSON SW, 1990, DEVELOPMENT, V108, P121; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	70	39	40	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1994	8	10					692	698		10.1096/fasebj.8.10.8050667	http://dx.doi.org/10.1096/fasebj.8.10.8050667			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050667				2022-12-28	WOS:A1994NY35000005
J	HAREL, R; TANZER, ML				HAREL, R; TANZER, ML			EXTRACELLULAR-MATRIX .3. EVOLUTION OF THE EXTRACELLULAR-MATRIX IN INVERTEBRATES	FASEB JOURNAL			English	Review						COLLAGEN; PROTEOGLYCAN; LAMININ; FIBRONECTIN; DOPA PROTEIN; HYDROLYTIC ENZYMES	SEA-URCHIN EMBRYO; FIBRILLAR COLLAGEN GENE; SPONGE MICROCIONA-PROLIFERA; ARG-GLY-ASP; CHONDROITIN SULFATE; RECOGNITION SIGNAL; AGGREGATION FACTOR; BASEMENT-MEMBRANE; HATCHING ENZYME; SERINE PROTEASE	Invertebrates comprise about 95% of animal species, yet most studies of extracellular matrices have centered on vertebrates. Comparative studies of invertebrates will enhance comprehension of evolutionary processes and appreciation of the diversity of extracellular matrices. Moreover, new functions and new structures will be revealed over a wide range of organismic needs. Another important perspective is that several invertebrate species have provided insight into developmental processes, and those processes often have direct relevance to vertebrate development. Thus, studies of fruit flies, nematodes, and sea urchins have revealed common features of cell biology, embryonic development, and matrix properties that pertain throughout the animal kingdom. The advantages of invertebrates arc their rapid rates of embryonic development, their amenability to genetic manipulation, availability of innumerable mutants, and their ease of study in the laboratory. Extracellular matrices themselves are readily compared. Invertebrates display a wide diversity of such matrices, at the levels of both tissue architecture and molecular anatomy. Knowledge of that diversity leads to an appreciation of evolutionary variety and eventually to comprehension of the organization of extracellular matrices and of the properties of their constituent macromolecules. The expanding knowledge of unique matrix molecules from invertebrates also has economic potential and is beginning to provide new materials for biotechnology.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; HEBREW UNIV JERUSALEM,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL	University of Connecticut; Hebrew University of Jerusalem					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR012683, R01AR012683, R01AR017220] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-17220, AR-12683] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON H, 1988, DEVELOPMENT, V104, P601; BAIRATI A, 1985, BIOL INVERTEBRATE LO, P1; Barrett D, 1976, Methods Enzymol, V45, P354; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BECK K, 1989, CYTOSKELETAL EXTRACE, P102; BENSON S, 1990, EXP CELL RES, V188, P141, DOI 10.1016/0014-4827(90)90289-M; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BROWER DL, 1987, DEV BIOL, V119, P373, DOI 10.1016/0012-1606(87)90042-X; CAMPBELL AG, 1987, J BIOL CHEM, V262, P17605; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; CASSARO CMF, 1977, J BIOL CHEM, V252, P2254; CHI HC, 1989, J BIOL CHEM, V264, P1543; CHIQUET M, 1988, J CELL BIOL, V107, P1189, DOI 10.1083/jcb.107.3.1189; COX GN, 1992, J PARASITOL, V78, P1, DOI 10.2307/3283678; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; EDWARDS BF, 1977, ARCH BIOCHEM BIOPHYS, V182, P696, DOI 10.1016/0003-9861(77)90551-3; EISEN AZ, 1973, BIOCHEMISTRY-US, V12, P1814, DOI 10.1021/bi00733a024; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; EXPOSITO JY, 1990, EUR J BIOCHEM, V190, P401, DOI 10.1111/j.1432-1033.1990.tb15589.x; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; FIELDS C, 1988, J MOL EVOL, V28, P55, DOI 10.1007/BF02143497; FRANSSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P5657, DOI 10.1073/pnas.81.18.5657; GAILL F, 1991, J MOL BIOL, V221, P209, DOI 10.1016/0022-2836(91)80215-G; GRATECOS D, 1988, EMBO J, V7, P215, DOI 10.1002/j.1460-2075.1988.tb02802.x; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; GROSS J, 1985, BIOL INVERTEBRATE LO, P1; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HURION N, 1979, ARCH BIOCHEM BIOPHYS, V192, P438, DOI 10.1016/0003-9861(79)90113-9; Hynes RO, 1990, FIBRONECTINS; IWATA M, 1981, ROUX ARCH DEV BIOL, V190, P83, DOI 10.1007/BF00848399; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; Keildlouha V, 1978, BIOCHIM BIOPHYS ACTA, V522, P218, DOI 10.1016/0005-2744(78)90337-6; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LEPAGE T, 1989, J BIOL CHEM, V264, P4787; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LEPTIN M, 1987, EMBO J, V6, P1037, DOI 10.1002/j.1460-2075.1987.tb04856.x; Mathews M. B., 1975, CONNECTIVE TISSUE MA; MATHEWS MB, 1985, BIOL INVERTEBRATE LO, P545; MCCARTHY RA, 1987, EMBO J, V6, P1587, DOI 10.1002/j.1460-2075.1987.tb02404.x; MEYER MR, 1988, DEV BIOL, V130, P374, DOI 10.1016/0012-1606(88)90443-5; MISEVIC GN, 1990, J CELL BIOCHEM, V43, P307, DOI 10.1002/jcb.240430403; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MURRAY LW, 1985, BIOL INVERTEBRATE LO, P243; NAIDET C, 1987, NATURE, V325, P348, DOI 10.1038/325348a0; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SARRAS MP, 1991, DEV BIOL, V148, P481, DOI 10.1016/0012-1606(91)90266-6; SELLOS D, 1992, FEBS LETT, V309, P219, DOI 10.1016/0014-5793(92)80777-E; SHIMIZU K, 1990, BIOCHIM BIOPHYS ACTA, V1038, P39, DOI 10.1016/0167-4838(90)90007-3; SPIEGEL E, 1983, EXP CELL RES, V144, P47, DOI 10.1016/0014-4827(83)90440-8; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TANZER ML, 1978, TRENDS BIOCHEM SCI, V3, P15, DOI 10.1016/S0968-0004(78)92588-4; TILLET BE, 1992, EUR J BIOCHEM, V203, P179; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VARNER JA, 1988, J BIOL CHEM, V263, P8498; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; WAITE JH, 1992, BIOPOLYMERS, P27; WANG WC, 1993, J BIOL CHEM, P1448; WELGUS HG, 1982, BIOCHEMISTRY-US, V21, P5183, DOI 10.1021/bi00264a012; WESSEL GM, 1991, DEV BIOL, V148, P261, DOI 10.1016/0012-1606(91)90335-Z; Willmer P., 1990, INVERTEBRATE RELATIO	68	75	76	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1115	1123		10.1096/fasebj.7.12.8375610	http://dx.doi.org/10.1096/fasebj.7.12.8375610			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375610				2022-12-28	WOS:A1993LW81700003
J	GIORDANO, M; VERMEULEN, M; PALERMO, MS				GIORDANO, M; VERMEULEN, M; PALERMO, MS			SEASONAL-VARIATIONS IN ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY REGULATION BY MELATONIN	FASEB JOURNAL			English	Article						PINEAL GLAND; MELATONIN; ADCC; SEASONALITY	NATURAL-KILLER ACTIVITY; PINEAL-GLAND; RHYTHM; MICE	Data collected over a period of 4 years show that melatonin (two daily i.v. injections of 0.1 mg/kg body wt. given at 16:00 h) was able to enhance antibody-dependent cellular cytotoxicity (ADCC) in summer, but not in winter. Dose-response curves carried out in January, May, July, and October suggest that the seasonal effects reported are related to differences in the sensitivity of mice to melatonin during the course of the year. These results show seasonal variations in the immune modulatory action of melatonin.			GIORDANO, M (corresponding author), ACAD NACL MED BUENOS AIRES,IIHEMA,IMMUNOL LAB,SECC INMUNOL,PACHECO MELO 3081,RA-1425 BUENOS AIRES,ARGENTINA.							ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; BROCK MA, 1983, J IMMUNOL, V130, P2586; CAROLEO MC, 1991, 11TH M EUR FED IMM S, P32; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; FAMILARI M, 1988, JPN J EXP MED, V58, P73; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; Goldman B. D., 1983, Pineal Research Reviews, V1, P145; Maestromi G. J. M., 1989, Pineal Research Reviews, V7, P203; MAESTRONI GJM, 1987, ANN NY ACAD SCI, V496, P67, DOI 10.1111/j.1749-6632.1987.tb35747.x; MAESTRONI GJM, 1988, IMMUNOLOGY, V63, P465; PATI AK, 1987, CELL IMMUNOL, V108, P227, DOI 10.1016/0008-8749(87)90207-3; Perlmann P, 1970, Cell Immunol, V1, P300, DOI 10.1016/0008-8749(70)90051-1; REITER RJ, 1991, ENDOCR REV, V12, P152; TAMARKIN L, 1976, ENDOCRINOLOGY, V99, P1534, DOI 10.1210/endo-99-6-1534; VERMEULEN M, 1993, IN PRESS J NEUROIMMU; VRIEND J, 1983, NEUROENDOCRINOLOGY, V36, P68, DOI 10.1159/000123439; YU ZH, 1991, NEUROSCI LETT, V125, P175, DOI 10.1016/0304-3940(91)90021-K	17	27	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1052	1054		10.1096/fasebj.7.11.8370475	http://dx.doi.org/10.1096/fasebj.7.11.8370475			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370475				2022-12-28	WOS:A1993LT83900011
J	LIN, XL; DASHTI, A; SCHINAZI, RF; TANG, J				LIN, XL; DASHTI, A; SCHINAZI, RF; TANG, J			INTRACELLULAR DIVERSION OF GLYCOPROTEIN-GP160 OF HUMAN-IMMUNODEFICIENCY-VIRUS TO LYSOSOMES AS A STRATEGY OF AIDS GENE-THERAPY	FASEB JOURNAL			English	Article						AIDS; HIV; GENE THERAPY; LYSOSOME TARGETING; HIV GP160	HTLV-III/LAV ENVELOPE; CATHEPSIN-D; ACID-PHOSPHATASE; SOLUBLE CD4; MEMBRANE-GLYCOPROTEINS; HUMAN-FIBROBLASTS; CYTOPLASMIC TAIL; TYPE-1; PROTEIN; BIOSYNTHESIS	A potential gene therapy strategy against human immunodeficiency virus (HIV-1) is to disrupt the intracellular transport of viral proteins. We report here the binding and transporting of HIV-1 glycoprotein gp160 to lysosomes as a result of the expression of fusion genes consisting of soluble CD4 and lysosome targeting domains. The effective lysosome targeting domain tested includes a lysosomal protease zymogen, procathepsin D, and the COOH-terminal domains of three lysosome membrane proteins: lamp-1, lamp-2, and lysosomal acid phosphatase. We demonstrated that cell fusion (syncytium), caused by the transport of gp160 to the surface of HeLa-CD4+ cells, was completely abolished by the expression of these fusion genes. The lysosomal localization of gp160 in HeLa cells coexpressing CD4-fusion genes was also established. From pulse-chase experiments, we observed that gp160 and the fusion proteins were degraded, as expected of lysosomal activities. Additionally, T lymphoblastoid cells transiently and permanently expressing these fusion genes strongly retarded the propagation of human immunodeficiency virus type 1. Thus, these fusion genes can deprive HIV of newly synthesized envelope protein gp160 for the assembly of new virions and are potentially useful in gene therapy against AIDS.	OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; EMORY UNIV,SCH MED,ATLANTA,GA 30322; VET ADM MED CTR,DEPT PEDIAT,DECATUR,GA 30033	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Schinazi, Raymond F/B-6777-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCOVINI A, 1990, TECHNIQUES HIV RES, P155; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; ASHKENAZI A, 1992, P NATL ACAD SCI USA, V89, P1517, DOI 10.1073/pnas.89.4.1517; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HUANG JS, 1979, J BIOL CHEM, V254, P1405; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kriegler M., 1990, GENE TRANSFER EXPRES; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; ROSSI JJ, 1990, ANN NY ACAD SCI, V616, P184; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WHITT MA, 1991, FOCUS, V13, P8; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	20	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1070	1080		10.1096/fasebj.7.11.8370478	http://dx.doi.org/10.1096/fasebj.7.11.8370478			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370478				2022-12-28	WOS:A1993LT83900014
J	TAI, IT; SUN, AM				TAI, IT; SUN, AM			MICROENCAPSULATION OF RECOMBINANT CELLS - A NEW DELIVERY SYSTEM FOR GENE-THERAPY	FASEB JOURNAL			English	Article						GENE THERAPY; RECOMBINANT FIBROBLASTS; HUMAN GROWTH HORMONE GENE; MICROENCAPSULATION; XENOGRAFTS	HUMAN ADENOSINE-DEAMINASE; HEMATOPOIETIC STEM-CELLS; HUMAN GROWTH-HORMONE; SKIN FIBROBLASTS; EXPRESSION; TRANSPLANTATION; MOUSE; MYOBLASTS; MICE; LONG	The therapeutic potential of somatic gene therapy has been extensively investigated in recent years, yet its slow progression into the clinical setting can be attributed to problems associated with the inability to achieve efficient gene transfers, to obtain sustained level of expression of the transfected gene, and the necessity to avoid immunorejection after transplantation. Here we report on an alternate strategy in gene therapy that overcomes all three problems by immunoisolating genetically modified cells in a biocompatible membrane, thereby introducing a system that can provide sustained delivery of the desired gene product. As a model, mouse fibroblasts transformed with the human growth hormone gene (Ltk-GH) were encapsulated with an alginate-poly-L-lysine-alginate membrane. Long-term in vitro studies showed that the encapsulation of the cells was physiologically compatible with growth and survival of the cells. Furthermore, there was a unique pattern of secretion of the human protein by the encapsulated cells: there was a phase of steady increase in the secretion of the human growth hormone by each cell, followed by a plateau phase. The most convincing evidence of the feasibility of this strategy was provided by the in vivo study: Balb-c mice transplanted with encapsulated Ltk-GH cells had detectable serum levels of human growth hormone (hGH) for the duration of the study (115 days). Moreover, encapsulated cells recovered from a recipient 1 year after the transplantation continued to secrete high levels of hGH in culture.	UNIV TORONTO,DEPT PHYSIOL,1 KINGS COLL CIRCLE,MED SCI BDG,ROOM 3256,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto			Tai, Isabella T/E-8035-2012					BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; CHANG PL, 1990, MOL BIOL MED, V7, P461; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; CULVER KW, 1991, TRANSPLANT P, V23, P170; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; FLOWERS MED, 1990, P NATL ACAD SCI USA, V87, P2349, DOI 10.1073/pnas.87.6.2349; GARVER RI, 1987, P NATL ACAD SCI USA, V84, P1050, DOI 10.1073/pnas.84.4.1050; GOOSEN MFA, 1985, BIOTECHNOL BIOENG, V27, P146, DOI 10.1002/bit.260270207; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; LI CL, 1990, P NATL ACAD SCI USA, V87, P4349, DOI 10.1073/pnas.87.11.4349; LUM ZP, 1991, DIABETES, V40, P1511, DOI 10.2337/diabetes.40.11.1511; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PALMER TD, 1987, P NATL ACAD SCI USA, V84, P1055, DOI 10.1073/pnas.84.4.1055; SCANGOS G, 1981, GENE, V14, P1, DOI 10.1016/0378-1119(81)90143-8; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEAD RB, 1988, BLOOD, V71, P742; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; SUN AM, 1988, METHOD ENZYMOL, V137, P575; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439	28	72	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1061	1069		10.1096/fasebj.7.11.8370477	http://dx.doi.org/10.1096/fasebj.7.11.8370477			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370477				2022-12-28	WOS:A1993LT83900013
J	LUDLOW, JW				LUDLOW, JW			INTERACTIONS BETWEEN SV40 LARGE-TUMOR ANTIGEN AND THE GROWTH SUPPRESSOR PROTEIN-PRB AND PROTEIN-P53	FASEB JOURNAL			English	Review						ONCOPROTEINS; TRANSFORMATION; CELL CYCLE REGULATION	LARGE-T-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; CELL-CYCLE; P53 PROTEIN; COMPLEX-FORMATION; BINDING; PRODUCT; TRANSFORMATION; PHOSPHORYLATION	The oncogenic property of simian virus 40 depends in large part on the function of the virus-coded T-antigen. Although the precise mechanism of how T functions during neoplastic transformation is not clear, some answers to this question may lie in our understanding the nature of the proteins found to complex with T. The cellular protein p53 is perhaps the most extensively studied protein in this regard. Recently, p53 was defined as a growth suppressor protein. At about this same time, T was found to complex with another cell growth suppressor protein, the product of the retinoblastoma susceptibility gene. It has since become apparent that complex formation between these proteins affects their individual growth-modulating activities. Quite often this alteration of activity correlates with an uncontrolled proliferative state of the cell. Thus, transformation by SV40 is thought to involve complex formation between the viral T oncoprotein and cellular growth suppressor proteins. This complex formation is believed to result in nullification of the growth suppressor protein properties, thus increasing the propensity of the cell toward uncontrolled growth, the hallmark of neoplastic transformation.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	LUDLOW, JW (corresponding author), UNIV ROCHESTER,SCH MED & DENT,CTR CANC,DIV TUMOR BIOL,ROCHESTER,NY 14642, USA.				NCI NIH HHS [CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1992, ONCOGENE, V7, P1011; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MONTENARH M, 1992, ONCOGENE, V7, P1673; NEVINS JR, 1992, SCIENCE, V258, P424; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PRIVES C, 1977, P NATL ACAD SCI USA, V74, P457, DOI 10.1073/pnas.74.2.457; SAVOYSKY E, 1993, ONCOGENE, V8, P319; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEGTMEYER P, 1974, COLD SPRING HARB SYM, V39, P9, DOI 10.1101/SQB.1974.039.01.004; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; VANROY F, 1990, ONCOGENE, V5, P207; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	51	169	173	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					866	871		10.1096/fasebj.7.10.8344486	http://dx.doi.org/10.1096/fasebj.7.10.8344486			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344486				2022-12-28	WOS:A1993LQ33700008
J	RAUSCHER, FJ				RAUSCHER, FJ			THE WT1 WILMS-TUMOR GENE-PRODUCT - A DEVELOPMENTALLY-REGULATED TRANSCRIPTION FACTOR IN THE KIDNEY THAT FUNCTIONS AS A TUMOR-SUPPRESSOR	FASEB JOURNAL			English	Review						ONCOGENESIS; KIDNEY DEVELOPMENT; TRANSCRIPTION	DENYS-DRASH SYNDROME; ZINC FINGER PROTEIN; FACTOR-II GENE; FACTOR-A-CHAIN; FAMILIAL PREDISPOSITION; UROGENITAL DEVELOPMENT; HUMAN CHROMOSOME-11; DNA RECOGNITION; MESSENGER-RNA; GROWTH	Alteration of transcription factor function is becoming a common theme in molecular mechanisms of oncogenesis. A recent example of this trend is the isolation and characterization of the chromosome 11p13 Wilms tumor suppressor gene, WT1. The WT1 protein contains a DNA binding domain consisting of four zinc fingers of the Cys2-His2 class and a proline-glutamine rich region capable of regulating transcription. Deletions of the WT1 gene or point mutations which destroy the DNA binding activity of the protein are associated with the development of the pediatric nephroblastoma Wilms tumor and Denys-Drash syndrome. This article reviews the role of WT1 in normal kidney development processes, the known biochemical functions of the protein and the status of identifying target genes regulated by this potentially oncogenic transcription factor.			RAUSCHER, FJ (corresponding author), WISTAR INST ANAT & BIOL, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA47983, CA52009, CA 10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Ekblom P, 1984, ROLE EXTRACELLULAR M, P173; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HARBER DA, 1990, CELL, V61, P1257; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HOLST C, 1993, HUM MOL GENET, V2, P367, DOI 10.1093/hmg/2.4.367; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MADDEN SL, 1993, ZINC FINGER PROTEINS, V684, P75; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAW MA, 1992, CANCER RES, V52, P3094; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAIK S, 1989, LAB INVEST, V61, P522; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SHARMA PM, 1992, CANCER RES, V52, P6407; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VANHEYNINGEN V, 1992, TRENDS GENET, V8, P16, DOI 10.1016/0168-9525(92)90019-Z; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU J, 1993, IN PRESS DIFFERENTIA	67	228	235	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					896	903		10.1096/fasebj.7.10.8393820	http://dx.doi.org/10.1096/fasebj.7.10.8393820			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393820				2022-12-28	WOS:A1993LQ33700012
J	BLACKMAN, CF; BENANE, SG; HOUSE, DE				BLACKMAN, CF; BENANE, SG; HOUSE, DE			EVIDENCE FOR DIRECT EFFECT OF MAGNETIC-FIELDS ON NEURITE OUTGROWTH	FASEB JOURNAL			English	Note						PC-12 CELLS; NERVE GROWTH FACTOR; MAGNETIC FIELDS; ELECTRIC FIELDS; 50 HZ	BRAIN-TISSUE INVITRO; NERVE GROWTH-FACTOR; ELECTRIC-FIELDS; ELECTROMAGNETIC-FIELDS; PHEOCHROMOCYTOMA CELLS; CALCIUM-IONS; PC12 CELLS; LINE; RADIATION; EFFLUX	Electric fields can cause changes in cell responses both in vitro and in vivo. Alternating magnetic fields have been proposed to act through the electric fields induced in the conducting medium surrounding the cells. We have used a simple exposure system to test the relative contribution of magnetic fields compared to induced electric fields in a standard PC-12 cell culture assay, in which cells respond to nerve growth factor by producing neurites. This response to stimulation by nerve growth factor is inhibited by sinusoidal, 50-Hz magnetic fields at field strengths below 10 muT (100 mG). A standard procedure to distinguish magnetic- vs. electric-field effects demonstrates that the induced electric field is not involved. Additional work is necessary to identify the critical reaction site (or sites), and to establish the molecular mechanisms responsible for these results.			BLACKMAN, CF (corresponding author), US EPA,HLTH EFFECTS RES LAB,MD-68,RES TRIANGLE PK,NC 27711, USA.		Blackman, Carl/O-1951-2016	Blackman, Carl/0000-0003-3267-5224				ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; ADAIR RK, 1992, PHYS REV A, V46, P2185, DOI 10.1103/PhysRevA.46.2185; BASSETT CAL, 1982, JAMA-J AM MED ASSOC, V247, P623, DOI 10.1001/jama.247.5.623; BASSETT CAL, 1974, ANN NY ACAD SCI, V238, P242, DOI 10.1111/j.1749-6632.1974.tb26794.x; BLACKMAN CF, 1988, BIOELECTROMAGNETICS, V9, P129, DOI 10.1002/bem.2250090204; BLACKMAN CF, 1988, BIOELECTROMAGNETICS, V9, P215, DOI 10.1002/bem.2250090303; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P327, DOI 10.1002/bem.2250060402; BLACKMAN CF, 1989, BIOELECTROMAGNETICS, V10, P115, DOI 10.1002/bem.2250100202; BLACKMAN CF, 1990, BIOELECTROMAGNETICS, V11, P159, DOI 10.1002/bem.2250110207; BLACKMAN CF, 1992, IN PRESS BIOELECTROM; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; DIXEY R, 1982, NATURE, V296, P253, DOI 10.1038/296253a0; GREENE JJ, 1991, BIOCHEM BIOPH RES CO, V174, P742, DOI 10.1016/0006-291X(91)91480-Z; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; JAFFE LF, 1979, SCIENCE, V206, P569, DOI 10.1126/science.573921; KIRSCHVINK JL, 1992, PHYS REV A, V46, P2178, DOI 10.1103/PhysRevA.46.2178; KIRSCHVINK JL, 1989, BIOELECTROMAGNETICS, V10, P239, DOI 10.1002/bem.2250100304; KIRSCHVINK JL, 1992, P NATL ACAD SCI USA, V89, P7683, DOI 10.1073/pnas.89.16.7683; LEVI A, 1988, MOL NEUROBIOL, V2, P201, DOI 10.1007/BF02935346; LIBURDY RP, 1992, FEBS LETT, V301, P53, DOI 10.1016/0014-5793(92)80209-Y; MAZZOLENI AP, 1986, BIOELECTROMAGNETICS, V7, P95, DOI 10.1002/bem.2250070111; MISAKIAN M, 1990, BIOELECTROMAGNETICS, V11, P251, DOI 10.1002/bem.2250110306; NAKAE H, 1991, BRAIN RES, V558, P348, DOI 10.1016/0006-8993(91)90791-S; PATEL N, 1982, J NEUROSCI, V2, P483; PATEL NB, 1984, J NEUROSCI, V4, P2939; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806	27	68	68	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					801	806		10.1096/fasebj.7.9.8330687	http://dx.doi.org/10.1096/fasebj.7.9.8330687			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330687				2022-12-28	WOS:A1993LK43000013
J	ZIMMERMAN, JK; BOYER, RF				ZIMMERMAN, JK; BOYER, RF			ASBMB EDUCATIONAL AFFAIRS COMMITTEE STUDIES UNDERGRADUATE BIOCHEMISTRY AND MOLECULAR-BIOLOGY DEGREES	FASEB JOURNAL			English	Article									HOPE COLL,DEPT CHEM,HOLLAND,MI 49422	Hope College	ZIMMERMAN, JK (corresponding author), CLEMSON UNIV,DEPT BIOL SCI,CLEMSON,SC 29634, USA.							Boyer R., 1992, BIOCHEM EDUC, V20, P144; BOYER RF, 1992, COUNCIL UNDERGRAD RE, V12, P20; BOYER RF, 1991, FASEB J, V5, P1; BOYER RF, 1992, ASBMB NEWS, V1, P10; ZIMMERMAN JK, 1992, COUNCIL UNDERGRAD RE, V13, P18; ZIMMERMAN JK, 1993, IN PRESS BIOCH ED; ZIMMERMAN JK, 1993, ASBMB NEWS, V2, P1	7	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					733	734		10.1096/fasebj.7.9.8330679	http://dx.doi.org/10.1096/fasebj.7.9.8330679			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330679				2022-12-28	WOS:A1993LK43000003
J	SALDANHA, R; MOHR, G; BELFORT, M; LAMBOWITZ, AM				SALDANHA, R; MOHR, G; BELFORT, M; LAMBOWITZ, AM			GROUP-I AND GROUP-II INTRONS	FASEB JOURNAL			English	Article						CATALYTIC RNA; MOBILE INTRON; SITE-SPECIFIC ENDONUCLEASE; REVERSE TRANSCRIPTASE; EVOLUTION	COMPLEMENTARY-STRAND RNA; SELF-SPLICING RNA; ACTIVE-SITE; CATALYTIC INTRONS; SEQUENCE; TETRAHYMENA; RIBOZYME; PROTEIN; ORIGIN; RETROVIRUSES	Group I and group II introns arc two types of RNA enzymes, ribozymes, that catalyze their own splicing by different mechanisms. In this review, we summarize current information about the structures of group I and group II introns, their RNA-catalyzed reactions, the facilitation of RNA-catalyzed splicing by protein factors, and the ability of the introns to function as mobile elements. The RNA-based enzymatic reactions and intron mobility provide a framework for considering the role of primordial catalytic RNAs in evolution and the origin of introns in higher organisms.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; State University of New York (SUNY) System; Wadsworth Center	SALDANHA, R (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210, USA.			Belfort, Marlene/0000-0002-1592-5618; Mohr, Georg/0000-0002-6411-0685	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044844, R37GM039422, R01GM037949, R01GM039422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39422, GM44844, GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BELFORT M, 1991, CELL, V64, P9, DOI 10.1016/0092-8674(91)90201-9; BELFORT M, 1990, ANNU REV GENET, V24, P363; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTOPHER DA, 1989, NUCLEIC ACIDS RES, V17, P7591, DOI 10.1093/nar/17.19.7591; COPERTINO DW, 1991, NUCLEIC ACIDS RES, V19, P6491, DOI 10.1093/nar/19.23.6491; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GRIVELL LA, 1990, NATURE, V344, P110, DOI 10.1038/344110a0; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MADHANI HD, 1992, IN PRESS CELL; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUCHY M, 1991, J MOL BIOL, V222, P179, DOI 10.1016/0022-2836(91)90204-J; TURCQ B, 1992, P NATL ACAD SCI USA, V89, P1676, DOI 10.1073/pnas.89.5.1676; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; YARUS M, 1992, J MOL BIOL, V225, P945, DOI 10.1016/0022-2836(92)90095-2; YARUS M, 1991, NEW BIOL, V3, P183; YARUS M, 1993, FASEB J, V7; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	65	204	216	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					15	24		10.1096/fasebj.7.1.8422962	http://dx.doi.org/10.1096/fasebj.7.1.8422962			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422962				2022-12-28	WOS:A1993KH88000004
J	ASO, T; CONAWAY, JW; CONAWAY, RC				ASO, T; CONAWAY, JW; CONAWAY, RC			THE RNA-POLYMERASE-II ELONGATION COMPLEX	FASEB JOURNAL			English	Review						TRANSCRIPTION FACTOR; GENE REGULATION; TRANSCRIPTIONAL ARREST; NUCLEOTIDE EXCISION REPAIR	FACILITATED TRANSCRIPT CLEAVAGE; TERMINAL-DOMAIN KINASE; INITIATION-FACTOR; DEPENDENT TRANSCRIPTION; FACTOR-DELTA; FACTOR-SIII; RAT-LIVER; FACTOR-B; DNA; PURIFICATION	The initiation stage of transcription by RNA polymerase II has long been regarded as the primary site for regulation of eukaryotic gene expression, Nevertheless, a growing body of evidence reveals that the RNA polymerase II elongation complex is also a major target for regulation. Biochemical studies are implicating an increasing number of transcription factors in the regulation of elongation, and these transcription factors are being found to function by a diverse collection of mechanisms. Moreover, unexpected features of the structure and catalytic mechanism of RNA polymerase II are forcing a reconsideration of long-held views on the mechanics of some of the most basic: aspects of polymerase function, In this review, we will describe recent insights into the structures and functions of RNA polymerase II and the transcription factors that control its activity during the elongation stage of eukaryotic messenger RNA synthesis.	OKLAHOMA MED RES FDN,CELL & MOLEC BIOL PROGRAM,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1994, J BIOL CHEM, V269, P26575; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GERARD M, 1991, J BIOL CHEM, V266, P20940; GU W, 1995, J BIOL CHEM, V270, P12238; GU WG, 1993, J BIOL CHEM, V268, P25604; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; QUIAN X, 1993, NATURE, V365, P277; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THOMPSON CM, 1993, CELL, V73, P136; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU C, 1995, TRANSCRIPTION MECHAN, P459; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	79	57	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1419	1428		10.1096/fasebj.9.14.7589983	http://dx.doi.org/10.1096/fasebj.9.14.7589983			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589983				2022-12-28	WOS:A1995TF67800006
J	GASSNER, GT; LUDWIG, ML; GATTI, DL; CORRELL, CC; BALLOU, DP				GASSNER, GT; LUDWIG, ML; GATTI, DL; CORRELL, CC; BALLOU, DP			FLAVOPROTEIN STRUCTURE AND MECHANISM .7. STRUCTURE AND MECHANISM OF THE IRON-SULFUR FLAVOPROTEIN PHTHALATE DIOXYGENASE REDUCTASE	FASEB JOURNAL			English	Review						IRON-SULFUR PROTEIN; ELECTRON TRANSPORT; PYRIDINE NUCLEOTIDE	NAPHTHALENE DIOXYGENASE; PSEUDOMONAS-CEPACIA; ELECTRON-TRANSFER; ENZYME-SYSTEM; OXYGENASE COMPONENT; PURIFICATION; 1,2-DIOXYGENASE; STRAIN; NADP+; SEQUENCES	Transfer of electrons between pyridine nucleotides (obligatory two-electron carriers) and hemes or [2Fe-2S] centers (obligatory one-electron carriers) is an essential step mediated by flavins in respiration, photosynthesis, and many oxygenase systems, Phthalate dioxygenase reductase (PDR), a soluble iron-sulfur flavoprotein from Pseudomonas cepacia, is a convenient model for the study of this type of electron transfer, PDR is folded into three domains; the NH2-terminal FMN binding and central NAD(H) binding domains are closely related to ferredoxin-NADP(+) reductase (FNR), The COOH-terminal [2Fe-2S] domain is similar to plant ferredoxins, and can be removed by proteolysis without significantly altering the reactivity of the FNR-like domains, Kinetic studies have identified sequential steps in the reaction of PDR with NADH that involve pyridine nucleotide binding, hydride transfer to FMN, and intramolecular electron transfer from the reduced flavin to the [2Fe-2S] cluster, Crystal structures of reduced and liganded PDR correspond to some of the intermediates formed during reduction by NADH, Small structural changes that are observed in the vicinity of the cofactors upon reduction or NAD(H) binding may provide part of the reorganization energy or contribute to the gating mechanism that controls intramolecular electron transfer.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dballou@umich.edu, David P/A-1298-2007		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020877, R01GM020877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20877, GM16429] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; AXCELL BC, 1975, BIOCHEM J, V146, P173, DOI 10.1042/bj1460173; Ballou D, 1994, FLAVINS AND FLAVOPROTEINS 1993, P639; BATIE CJ, 1990, METHOD ENZYMOL, V188, P61; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BATIE CJ, 1992, CHEM BIOCH FLAVOENZY, V3, P543; BATIE CJ, 1986, J BIOL CHEM, V259, P11976; BERTRAND P, 1995, J AM CHEM SOC, V117, P1807, DOI 10.1021/ja00111a020; BRUNEL F, 1988, J BACTERIOL, V170, P4942; BUNZ PV, 1993, J BACTERIOL, V175, P6467; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Correll CC, 1994, FLAVINS AND FLAVOPROTEINS 1993, P649; CORRELL CC, 1993, PROTEIN SCI, V12, P2112; CORRELL CC, 1992, THESIS U MICHIGAN; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; GASSNER G, 1995, IN PRESS BIOCHEMISTR; GASSNER GT, 1995, THESIS U MICHIGAN; GASSNERG, 1994, BIOCHEMISTRY-US, V33, P12184; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KEIMS JJ, 1972, J BIOL CHEM, V247, P7374; LAMBETH JD, 1976, J BIOL CHEM, V251, P4299; LOCHER HH, 1991, J BACTERIOL, V173, P3741, DOI 10.1128/JB.173.12.3741-3748.1991; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NEIDLE EL, 1991, J BACTERIOL, V173, P5385, DOI 10.1128/jb.173.17.5385-5395.1991; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; ROMANOV V, 1994, J BACTERIOL, V176, P3368, DOI 10.1128/jb.176.11.3368-3374.1994; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SAUBER K, 1973, EUR J BIOCHEM, V741, P89; SCHWEIZER D, J BIOL CHEM, V262, P9340; SIMON MJ, 1993, GENE, V127, P31, DOI 10.1016/0378-1119(93)90613-8; SUEN WC, 1993, J BACTERIOL, V175, P5877, DOI 10.1128/JB.175.18.5877-5881.1993; TAKANO T, 1993, FLAVINS FLAVOPROTEIN, P407; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P5058; YEH WK, 1977, BIOCHEM BIOPH RES CO, V78, P401, DOI 10.1016/0006-291X(77)91268-2; [No title captured]	41	53	53	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1411	1418		10.1096/fasebj.9.14.7589982	http://dx.doi.org/10.1096/fasebj.9.14.7589982			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589982	Green Submitted			2022-12-28	WOS:A1995TF67800005
J	SIMONEAU, JA; BOUCHARD, C				SIMONEAU, JA; BOUCHARD, C			GENETIC DETERMINISM OF FIBER-TYPE PROPORTION IN HUMAN SKELETAL-MUSCLE	FASEB JOURNAL			English	Article						MUSCLE FIBER TYPE; HERITABILITY; EXERCISE TRAINING	HEAVY-CHAIN COMPOSITION; ENZYME-ACTIVITIES; MEN; ADAPTATION; INHERITANCE; EXERCISE; HEREDITY; WOMEN	Skeletal muscle fiber type distribution is quite heterogeneous, with about 25% of North American Caucasian men and women having either less than 35% or more than 65% of type I fiber in their vastus lateralis muscle. To what extent human skeletal muscle fiber type proportion is under the control of genetic factors is examined in this paper. The results summarized here suggest that about 15% of the total variance in the proportion of type I muscle fibers in human is explained by the error component related to muscle sampling and technical variance, that about 40% of the phenotype variance is influenced by environmental factors, and the remaining variance (about 45%) is associated with inherited factors. These estimates suggest that a difference of about 30% in type I fibers among individuals could be explained exclusively by differences in the local environment and level of muscular contractile activity. However, unidentified genetic factors would have to be invoked to account for the observation that the skeletal muscle of about 25% of the North American Caucasian population have either less than 35% or more than 65% of type I fibers.			SIMONEAU, JA (corresponding author), UNIV LAVAL, PEPS, PHYS ACT SCI LAB, ST FOY, PQ G1K 7P4, CANADA.		Bouchard, Claude/AAE-2035-2019; Bouchard, Claude/A-7637-2009	Bouchard, Claude/0000-0002-0048-491X				BASSETT DR, 1994, MED SCI SPORT EXER, V26, P957; BLOMSTRAND E, 1982, ACTA PHYSIOL SCAND, V116, P437, DOI 10.1111/j.1748-1716.1982.tb07163.x; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BOUCHARD C, 1986, CAN J PHYSIOL PHARM, V64, P1245, DOI 10.1139/y86-210; BOUCHARD C, 1983, EXERCISE SPORT SCI R, P275; Boulay MR, 1986, SPORT HUMAN GENETICS, P173; BROOKS GA, 1984, EXERCISE PHYSL HUMAN, P354; EDGERTON VR, 1975, HISTOCHEM J, V7, P259, DOI 10.1007/BF01003594; FALCONER DS, 1960, INTRO QUANTITATIVE G, P165; FRISKHOLMBERG M, 1983, ACTA MED SCAND, V213, P21, DOI 10.1111/j.0954-6820.1983.tb03683.x; FRY AC, 1994, EUR J APPL PHYSIOL O, V68, P246, DOI 10.1007/BF00376773; FUGLMEYER AR, 1982, ACTA PHYSIOL SCAND, V114, P277, DOI 10.1111/j.1748-1716.1982.tb06983.x; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; GLENMARK B, 1992, ACTA PHYSIOL SCAND, V146, P251, DOI 10.1111/j.1748-1716.1992.tb09414.x; GOLLNICK PD, 1972, J APPL PHYSIOL, V33, P312, DOI 10.1152/jappl.1972.33.3.312; HAGGMARK T, 1986, ORTHOPEDICS, V9, P181; HAMEL P, 1986, MED SCI SPORT EXER, V18, P690; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; KLITGAARD H, 1990, PFLUG ARCH EUR J PHY, V416, P470, DOI 10.1007/BF00370757; KOMI PV, 1977, ACTA PHYSIOL SCAND, V100, P385; LARSSON L, 1985, MUSCLE NERVE, V8, P714, DOI 10.1002/mus.880080815; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MAHON M, 1984, J NEUROL SCI, V63, P85, DOI 10.1016/0022-510X(84)90111-4; MCARDLE WD, 1991, EXERCISE PHYSL, P362; NAKAMURA T, 1993, EUR J APPL PHYSIOL O, V66, P85, DOI 10.1007/BF00863405; NIMMO MA, 1985, COMP BIOCHEM PHYS A, V81, P109, DOI 10.1016/0300-9629(85)90275-0; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PETTE D, 1992, REV PHYSL BIOCH PHAR, V116, P1; PRUDHOMME D, 1984, MED SCI SPORT EXER, V16, P489, DOI 10.1249/00005768-198410000-00012; REISER PJ, 1985, J BIOL CHEM, V260, P9077; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; SALE DG, 1990, J APPL PHYSIOL, V68, P260, DOI 10.1152/jappl.1990.68.1.260; Saltin B, 2010, COMPR PHYSIOL, P555; SIMONEAU JA, 1985, EUR J APPL PHYSIOL O, V54, P250, DOI 10.1007/BF00426141; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; SIMONEAU JA, 1986, INT J SPORTS MED, V7, P167, DOI 10.1055/s-2008-1025756; SIMONEAU JA, 1986, CLIN PHYSIOL, V6, P347, DOI 10.1111/j.1475-097X.1986.tb00240.x; SJOSTROM M, 1991, EUR J APPL PHYSIOL O, V62, P301, DOI 10.1007/BF00634963; STARON RS, 1991, HISTOCHEMISTRY, V96, P21, DOI 10.1007/BF00266756; STARON RS, 1994, J APPL PHYSIOL, V76, P1247, DOI 10.1152/jappl.1994.76.3.1247; THERIAULT R, 1994, J APPL PHYSIOL, V77, P1885, DOI 10.1152/jappl.1994.77.4.1885; THORSTENSSON A, 1976, ACTA PHYSL SCAND   S, V443, P1; WADE AJ, 1990, LANCET, V335, P805, DOI 10.1016/0140-6736(90)90933-V; WILMORE JH, 1994, PHYSL SPORT EXERCISE, P146	44	185	189	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1091	1095		10.1096/fasebj.9.11.7649409	http://dx.doi.org/10.1096/fasebj.9.11.7649409			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649409				2022-12-28	WOS:A1995RP99600014
J	WEINHOUSE, S				WEINHOUSE, S			THE ACETYL GROUP IN FATTY-ACID METABOLISM	FASEB JOURNAL			English	Article											WEINHOUSE, S (corresponding author), JEFFERSON MED COLL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.							FLOYD NF, 1947, J BIOL CHEM, V171, P633; LYNEN F, 1951, ANGEW CHEM-GER EDIT, V63, P47, DOI 10.1002/ange.19510630207; Weinhouse S, 1944, J BIOL CHEM, V155, P143; Weinhouse S, 1944, J BIOL CHEM, V153, P689	4	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					820	821		10.1096/fasebj.9.9.7601346	http://dx.doi.org/10.1096/fasebj.9.9.7601346			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601346				2022-12-28	WOS:A1995RH98200016
J	FISHELL, G; BLAZESKI, R; GODEMENT, P; RIVAS, R; WANG, LC; MASON, CA				FISHELL, G; BLAZESKI, R; GODEMENT, P; RIVAS, R; WANG, LC; MASON, CA			OPTICAL MICROSCOPY .3. TRACKING FLUORESCENTLY LABELED NEURONS IN DEVELOPING BRAIN	FASEB JOURNAL			English	Review						VIDEO TIME LAPSE MICROSCOPY; DYE LABELING; NEURONAL MIGRATION; AXON GUIDANCE; MAMMALIAN BRAIN	CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; TIME-LAPSE; FILOPODIAL CONTACTS; SYMPATHETIC NEURONS; OPTIC CHIASM; SINGLE AXONS; CULTURE; INVITRO; FIBERS	For decades, time-lapse microscopy has been used to track dynamic events associated with biological phenomena. Time-lapse studies of the developing nervous system have been restricted to analysis of dissociated cell cultures or of a series of static images from living organisms. The advent of new fluorescent dyes and video imaging technology has produced novel views of the behavior of neurons in the context of the developing nervous tissue, such as migrations within and away from proliferative zones and navigation of axonal processes to synaptic targets, After fixation of the tissue preparation, time-lapse monitoring can be followed by other analytical techniques and forms of microscopy, e.g., immunocytochemistry or electron microscopy, producing information on the interactions of individual cells whose behavioral histories are known. The power of video time-lapse microscopy of living brain tissue lies in the firsthand documentation of developmental patterning, which in turn can serve as an experimental assay.	COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10031; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT ANAT,NEW YORK,NY 10031; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT CELL BIOL,NEW YORK,NY 10031; CNRS,INST ALFRED FESSARD,UPR 2212,F-91198 GIF SUR YVETTE,FRANCE; ROCKEFELLER UNIV,DEV NEUROBIOL LAB,NEW YORK,NY 10021	Columbia University; Columbia University; Columbia University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Rockefeller University				Fishell, Gordon/0000-0002-9640-9278	NINDS NIH HHS [NS/EY 15429, NS/EY 39181, NS30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532, R01NS015429] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; BAIRD DH, 1992, J NEUROSCI, V12, P619; BAIRD DH, 1994, NEUROPROTOCOLS, V4, P106; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; BRAY D, 1973, J CELL BIOL, V56, P702, DOI 10.1083/jcb.56.3.702; BRELJE TC, 1991, METHODS CELL BIOL, V38; BUNGE MB, 1973, J CELL BIOL, V56, P713, DOI 10.1083/jcb.56.3.713; BURMEISTER DW, 1988, J NEUROSCI, V8, P3151; CAUDY M, 1986, J NEUROSCI, V6, P364; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COOPER MW, 1992, J NEUROBIOL, V23, P814, DOI 10.1002/neu.480230704; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FISHELL G, 1991, DEVELOPMENT, V113, P755; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; Fishell G., 1993, Society for Neuroscience Abstracts, V19, P614; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; GASSER UE, 1990, P NATL ACAD SCI USA, V87, P4543, DOI 10.1073/pnas.87.12.4543; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GODEMENT P, 1994, J NEUROSCI, V14, P7024; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HALLORAN MC, 1994, J NEUROSCI, V14, P2161; HARRIS WA, 1987, DEVELOPMENT, V101, P23; Harrison RG, 1910, J EXP ZOOL, V9, P787, DOI 10.1002/jez.1400090405; Inouye S., 1986, VIDEO MICROSCOPY; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; KAETHNER RJ, 1992, J NEUROSCI, V12, P3257, DOI 10.1523/JNEUROSCI.12-08-03257.1992; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOMURO H, 1992, SCIENCE, V260, P95; LETOURNEAU PC, 1975, DEV BIOL, V44, P92, DOI 10.1016/0012-1606(75)90379-6; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; MASON CA, 1984, J NEUROSCI, V4, P1715; MASON CA, 1995, IN PRESS J NEUROSCI; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; OAKLEY RA, 1993, J NEUROSCI, V13, P3773; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; Ramon y Cajal S., 1911, HISTOLOGIE SYSTEME N; RIVAS RJ, 1992, NEURON, V8, P107, DOI 10.1016/0896-6273(92)90112-Q; RIVAS RJ, 1995, IN PRESS J NEUROSCI; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SNOW DM, 1991, DEV BIOL, V138, P359; Speidel CC, 1933, AM J ANAT, V52, P1, DOI 10.1002/aja.1000520102; SPRING KR, 1991, SCANNING MICROSCOPY, V5, P63; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; Wang L.-C., 1992, Society for Neuroscience Abstracts, V18, P222; WESSELLS NK, 1978, EXP CELL RES, V115, P111, DOI 10.1016/0014-4827(78)90408-1; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653	55	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					324	334		10.1096/fasebj.9.5.7896001	http://dx.doi.org/10.1096/fasebj.9.5.7896001			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896001				2022-12-28	WOS:A1995QP45100003
J	AIZENBERG, J; HANSON, J; ILAN, M; LEISEROWITZ, L; KOETZLE, TF; ADDADI, L; WEINER, S				AIZENBERG, J; HANSON, J; ILAN, M; LEISEROWITZ, L; KOETZLE, TF; ADDADI, L; WEINER, S			MORPHOGENESIS OF CALCITIC SPONGE SPICULES - A ROLE FOR SPECIALIZED PROTEINS INTERACTING WITH GROWING CRYSTALS	FASEB JOURNAL			English	Article						BIOMINERALIZATION; CALCISPONGES; X-RAY DIFFRACTION; CALCITE; CRYSTAL MORPHOLOGY	MACROMOLECULES	Crystals formed in biological tissues often adopt remarkable morphologies that are thought to be determined mainly by the shapes of the confined spaces in which they grow. Another possible way of controlling crystal shape, demonstrated only in vitro, is by means of specialized proteins preferentially interacting with certain crystal faces. In so doing, they reduce the rate of growth in these directions and consequently change the overall crystal shape. In an X-ray diffraction study of the distribution of defects within the lattice of calcite crystals produced by certain sponges, we show that a remarkable correlation exists between the defect patterns or crystal texture and the macroscopic morphology of the spicules. This was observed in two cases in which proteins are present within the spicule crystal, but not in a third case where such intracrystalline proteins are absent. Furthermore, one of the spicules exhibited marked differences in texture even within families of structurally identical crystal planes, demonstrating that the organisms exert exquisite control over the microenvironment in which crystals grow. We conclude that highly controlled intercalation of specialized proteins inside the crystals is an additional means by which organisms control spicule growth.	WEIZMANN INST SCI,DEPT MAT & INTERFACES,REHOVOT,ISRAEL; TEL AVIV UNIV,DEPT ZOOL,TEL AVIV,ISRAEL; BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY	Weizmann Institute of Science; Tel Aviv University; United States Department of Energy (DOE); Brookhaven National Laboratory	AIZENBERG, J (corresponding author), WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL.		Ilan, Micha/ABG-4106-2020; Hanson, jonathan C/E-3517-2010	Ilan, Micha/0000-0002-4188-4573; Hanson, Jonathan/0000-0003-0686-3985				ADDADI L, 1994, MOL CRYST LIQ CRYS A, V248, P185, DOI 10.1080/10587259408027179; AIZENBERG J, 1994, J CRYST GROWTH, V142, P156, DOI 10.1016/0022-0248(94)90283-6; ALBECK S, 1993, J AM CHEM SOC, V115, P11691, DOI 10.1021/ja00078a005; BERMAN A, 1993, SCIENCE, V259, P776, DOI 10.1126/science.259.5096.776; BERMAN A, 1990, SCIENCE, V250, P664, DOI 10.1126/science.250.4981.664; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; GOLDSMITH JR, 1961, AM MINERAL, V46, P453; Guinier A., 1963, XRAY DIFFRACTION; Haeckel E., 1872, KALKSCHWAMME; Jones W. C., 1970, Symp. zool. Soc. Lond., VNo. 25, P91; JONES WC, 1955, Q J MICROSC SCI, V96, P129; JONES WC, 1970, CALC TISS RES, V4, P314; LEDGER PW, 1975, TISSUE CELL, V7, P13, DOI 10.1016/S0040-8166(75)80004-8; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1989, BIOMINERALIZATION CH, P189; Minchin E.A., 1898, Q J MICROSC SCI, V40, P469; Simkiss K, 1986, BIOMINERALIZATION LO, P19; Simkiss K, 1989, BIOMINERALIZATION CE; TSURNAMAL M, 1975, ISRAEL J ZOOL, V24, P137; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G	20	103	104	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					262	268		10.1096/fasebj.9.2.7781928	http://dx.doi.org/10.1096/fasebj.9.2.7781928			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781928				2022-12-28	WOS:A1995QJ24900015
J	WHELAN, WJ				WHELAN, WJ			THE ADVENT OF PAPER-CHROMATOGRAPHY	FASEB JOURNAL			English	Editorial Material											WHELAN, WJ (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,POB 016129,MIAMI,FL 33101, USA.							COUSDEN R, 1944, BIOCHEM J, V38, P224; Gordon A. H., 1943, BIOCHEM JOUR, V37, pxiii; JAMES AT, 1952, BIOCHEM J, V50, P670; LATHE GH, 1956, BIOCHEM J, V62, P665, DOI 10.1042/bj0620665; Martin AJP, 1941, BIOCHEM J, V35, P1358, DOI 10.1042/bj0351358; MARTIN AJP, 1952, NATURE, V170, P826; MOULD DL, 1954, BIOCHEM J, V58, P571, DOI 10.1042/bj0580571	7	9	9	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					287	288		10.1096/fasebj.9.2.7781933	http://dx.doi.org/10.1096/fasebj.9.2.7781933			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781933				2022-12-28	WOS:A1995QJ24900020
J	GUDDAT, LW; SHAN, L; FAN, ZC; ANDERSEN, KN; ROSAUER, R; LINTHICUM, DS; EDMUNDSON, AB				GUDDAT, LW; SHAN, L; FAN, ZC; ANDERSEN, KN; ROSAUER, R; LINTHICUM, DS; EDMUNDSON, AB			INTRAMOLECULAR SIGNALING UPON COMPLEXATION	FASEB JOURNAL			English	Article						INDUCED FIT; ALLOSTERIC MESSAGES	BENCE-JONES DIMER; CRYSTALLOGRAPHIC REFINEMENT; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGES; INTACT IMMUNOGLOBULIN; EFFECTOR FUNCTIONS; PROTEIN STRUCTURES; ANTIGEN-BINDING; ATOMIC MODELS; ANTIBODY	Crystal habits can be used as indicators of conformational changes in their constituent proteins. As in the conversion of unliganded hemoglobin to the oxygenated form, the addition of a small hapten to a suspension of platy crystals of an unliganded Fab (NC6.8) results in the immediate disintegration of the plates and their replacement with prisms of the ligand-protein complex. Examination of the native and liganded forms by Xray crystallography reveals that the space groups and protein structures are different. During complexation there are ligand-induced conformational changes both in the antigen combining site (local alterations) and in more distal portions of the molecule (allosteric changes). There is an extension of the light chain (10 Angstrom increase in length), a commensurate shortening of the heavy chain (by flexing), and a decrease in the ''elbow bend'' angle of 31 degrees (184 degrees to 153 degrees). Relative to the variable domains, the constant domain pair moves mainly as a unit in such a way that the carboxyl end of the heavy chain is displaced by 19 Angstrom. In an intact antibody this displacement may be relayed as a tug (by tensile forces) on the segment connecting the Fab to the Fc region, perhaps altering the orientations of the constituents responsible for such effector functions as complement activation.	TEXAS A&M UNIV,DEPT VET PATHOBIOL,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station	GUDDAT, LW (corresponding author), HARRINGTON CANC CTR,1500 WALLACE BLVD,AMARILLO,TX 79106, USA.		Guddat, Luke/AAI-2930-2021	Guddat, Luke/0000-0002-8204-8408				Anchin J M, 1991, J Mol Recognit, V4, P7, DOI 10.1002/jmr.300040103; ANCHIN JM, 1992, J CLIN IMMUNOASSAY, V15, P35; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BREKKE OH, 1993, NATURE, V363, P628, DOI 10.1038/363628a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DROUPADI PR, 1992, J MOL RECOGNIT, V5, P1173; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; EDMUNDSON AB, 1993, PROTEINS, V16, P246, DOI 10.1002/prot.340160304; EDMUNDSON AB, 1989, MOL IMMUNOL, V26, P207, DOI 10.1016/0161-5890(89)90074-6; EDMUNDSON AB, 1984, MOL IMMUNOL, V21, P561, DOI 10.1016/0161-5890(84)90041-5; ELY KR, 1978, BIOCHEMISTRY-US, V17, P158, DOI 10.1021/bi00594a023; ELY KR, 1978, BIOCHEMISTRY-US, V17, P820, DOI 10.1021/bi00598a011; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FETT JW, 1973, IMMUNOCHEMISTRY, V10, P115, DOI 10.1016/0019-2791(73)90238-3; FIRCA JR, 1978, BIOCHEMISTRY-US, V17, P148, DOI 10.1021/bi00594a022; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Kabat EA, 1991, SEQUENCES PROTEINS I; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; KOSSIAKOFF AA, 1992, PROTEINS, V14, P65, DOI 10.1002/prot.340140108; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; Metzger H, 1978, Contemp Top Mol Immunol, V7, P119; MIZUTANI R, 1993, J IMMUNOL, V150, P131; MULLER GW, 1992, J MED CHEM, V35, P740, DOI 10.1021/jm00082a015; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROWLAND RS, 1990, USE OF X-RAY CRYSTALLOGRAPHY IN THE DESIGN OF ANTIVIRAL AGENTS, P261; SHOPES B, 1993, MOL IMMUNOL, V30, P603, DOI 10.1016/0161-5890(93)90035-A; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; WALTERS DE, 1991, ACS SYM SER, V450, P214; 1989, INSIGHT USERS MANUAL	37	34	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					101	106		10.1096/fasebj.9.1.7821748	http://dx.doi.org/10.1096/fasebj.9.1.7821748			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821748				2022-12-28	WOS:A1995QD20200016
J	HULTMAN, P; JOHANSSON, U; TURLEY, SJ; LINDH, U; ENESTROM, S; POLLARD, KM				HULTMAN, P; JOHANSSON, U; TURLEY, SJ; LINDH, U; ENESTROM, S; POLLARD, KM			ADVERSE IMMUNOLOGICAL EFFECTS AND AUTOIMMUNITY INDUCED BY DENTAL AMALGAM AND ALLOY IN MICE	FASEB JOURNAL			English	Article						MERCURY; SILVER; FIBRILLARIN; ANTINUCLEAR ANTIBODIES; IMMUNE COMPLEX DEPOSITS	IMMUNE-COMPLEX DEPOSITS; CELL-STIMULATORY FACTOR; MERCURIC-CHLORIDE; ANTINUCLEAR ANTIBODIES; MURINE SUSCEPTIBILITY; AUTOANTIBODY PROFILES; LYMPHOCYTES-T; HEAVY-METALS; B-CELLS; FILLINGS	Dental amalgam fillings are the most important source of mercury exposure in the general population, but their potential to cause systemic health consequences is disputed. In this study, inbred mice genetically susceptible to mercury-induced immune aberrations were used to examine whether dental amalgam may interfere with the immune system and cause autoimmunity. Female SJL/N mice were implanted in the peritoneal cavity with 8-100 mg silver amalgam or silver alloy for 10 weeks or 6 months. Chronic hyperimmunoglobulinemia, serum IgG autoantibodies targeting the nucleolar protein fibrillarin, and systemic immune-complex deposits developed in a time- and dose-dependent manner after implantation of amalgam or alloy. Splenocytes from mice implanted with amalgam or alloy showed an increased expression of class II molecules. The functional capacity of splenic T and B cells was affected in a dose-dependent way: 10 weeks of low-dose and 6 months of high-dose amalgam implantation strongly increased mitogen-induced T and B cell proliferation, whereas 10 weeks of high-dose implantation decreased the proliferation. Not only mercury but also silver accumulated in the spleen and kidneys after amalgam implantation. In conclusion, dental amalgam implantation in a physiological body milieu causes chronic stimulation of the immune system with induction of systemic autoimmunity in genetically sensitive mice. Implantation of silver alloy not containing mercury also induced autoimmunity, suggesting that other elements, especially silver, have the potential to induce autoimmunity in genetically susceptible vertebrates. Accumulation of heavy metals, from dental amalgam and other sources, may lower the threshold of an individual metal to elicit immunological aberrations. We hypothesize that under appropriate conditions of genetic susceptibility and adequate body burden, heavy metal exposure from dental amalgam may contribute to immunological aberrations, which could lead to overt autoimmunity.	SCRIPPS RES INST, DEPT EXPTL MED, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; UPPSALA UNIV, CTR METAL BIOL, UPPSALA, SWEDEN	Scripps Research Institute; Uppsala University	HULTMAN, P (corresponding author), LINKOPING UNIV, DEPT PATHOL, LINKOPING, SWEDEN.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32155] Funding Source: Medline; NIAMS NIH HHS [AR 40770] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P469, DOI 10.1002/eji.1830200303; APOSHIAN HV, 1992, FASEB J, V6, P2472, DOI 10.1096/fasebj.6.7.1563599; ATEN J, 1988, AM J PATHOL, V133, P127; BARR RD, 1990, E AFR MED J, V67, P381; Berlin M, 1992, Lakartidningen, V89, P2918; BIGAZZI PE, 1992, CLIN IMMUNOL IMMUNOP, V65, P81, DOI 10.1016/0090-1229(92)90210-F; BOLEWSKA J, 1990, J ORAL PATHOL MED, V19, P39, DOI 10.1111/j.1600-0714.1990.tb00779.x; BROWN LJ, 1991, J AM DENT ASSOC, V122, P73, DOI 10.14219/jada.archive.1991.0258; BRUNE D, 1984, SCAND J DENT RES, V92, P165; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T; DIETER MP, 1983, TOXICOL APPL PHARM, V68, P218, DOI 10.1016/0041-008X(83)90006-6; DUBEY C, 1991, CLIN EXP IMMUNOL, V86, P118; EGGLESTON DW, 1984, J PROSTHET DENT, V51, P617, DOI 10.1016/0022-3913(84)90404-9; EGGLESTON DW, 1987, J PROSTHET DENT, V58, P704, DOI 10.1016/0022-3913(87)90424-0; Eybl V, 1992, Arch Toxicol Suppl, V15, P160; FURCHNER JE, 1968, HEALTH PHYS, V15, P505, DOI 10.1097/00004032-196812000-00005; GAWORSKI CL, 1978, TOXICOL APPL PHARM, V46, P305, DOI 10.1016/0041-008X(78)90076-5; GLEICHMANN E, 1989, ARCH TOXICOL, V63, P257, DOI 10.1007/BF00278639; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; HAHN LJ, 1989, FASEB J, V3, P2641, DOI 10.1096/fasebj.3.14.2636872; HANSON M, 1991, EXPERIENTIA, V47, P9, DOI 10.1007/BF02041243; Hickel R, 1991, Dtsch Zahnarztl Z, V46, P542; HULTMAN P, 1989, J CLIN LAB IMMUNOL, V28, P143; HULTMAN P, 1988, CLIN EXP IMMUNOL, V71, P269; HULTMAN P, 1993, CLIN IMMUNOL IMMUNOP, V68, P9, DOI 10.1006/clin.1993.1088; HULTMAN P, 1987, CLIN EXP IMMUNOL, V67, P283; HULTMAN P, 1989, CLIN EXP IMMUNOL, V78, P470; HULTMAN P, 1989, BRIT J EXP PATHOL, V70, P227; HULTMAN P, 1992, CLIN IMMUNOL IMMUNOP, V65, P98, DOI 10.1016/0090-1229(92)90212-7; HULTMAN P, 1991, FOOD CHEM TOXICOL, V29, P633, DOI 10.1016/0278-6915(91)90146-X; HULTMAN P, 1994, CLIN EXP IMMUNOL, V96, P285; LANGWORTH S, 1988, SWED DENT J, V12, P69; LANGWORTH S, 1993, SCAND J WORK ENV HEA, V19, P405, DOI 10.5271/sjweh.1454; LAWRENCE DA, 1981, TOXICOL APPL PHARM, V57, P439, DOI 10.1016/0041-008X(81)90241-6; Lentz D L, 1989, Am J Dent, V2, P171; MACKERT JR, 1991, J AM DENT ASSOC, V122, P49, DOI 10.14219/jada.archive.1991.0095; MADRENAS J, 1991, KIDNEY INT, V39, P273, DOI 10.1038/ki.1991.33; MAGOS L, 1987, ARCH TOXICOL, V60, P422, DOI 10.1007/BF00302384; MCCABE MJ, 1990, J IMMUNOL, V145, P671; MCCLUSKEY RT, 1983, PATHOLOGY KIDNEY, P301; NYLANDER M, 1987, SWED DENT J, V11, P179; OCHEL M, 1991, J IMMUNOL, V146, P3006; PIETSCH P, 1989, INT ARCH ALLER A IMM, V90, P47, DOI 10.1159/000234999; POLLARD KM, 1993, 3RD P INT WORKSH MOL, P65; REARDON CL, 1987, IMMUNOBIOLOGY, V175, P455, DOI 10.1016/S0171-2985(87)80073-6; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; REUTER R, 1989, P NATL ACAD SCI USA, V86, P237, DOI 10.1073/pnas.86.1.237; ROGER J, 1992, EUR J DERMAT, V2, P168; RUBIN RL, 1986, MANUAL CLIN LABORATO, P744; RUNGBY J, 1987, ARCH TOXICOL, V61, P40, DOI 10.1007/BF00324546; SCHRALLHAMMERBENKLER K, 1992, ACTA DERM-VENEREOL, V72, P294; Skare I, 1992, Lakartidningen, V89, P1299; SNAPP KR, 1989, J DENT RES, V68, P780, DOI 10.1177/00220345890680050501; SNYDER CA, 1991, J TOXICOL ENV HEALTH, V34, P127, DOI 10.1080/15287399109531553; TURLEY SJ, 1993, BIOCHIM BIOPHYS ACTA, V1216, P119, DOI 10.1016/0167-4781(93)90046-G; WATANABE C, 1993, B ENVIRON CONTAM TOX, V51, P24; Wilhelm M, 1991, Dtsch Zahnarztl Z, V46, P544; ZDOLSEK J, 1994, IN PRESS IMMUNOPHARM; 1989, J AM DENT ASSOC, V120, P395; [No title captured]; 1991, ENV HLTH CRITERIA, V118	63	64	67	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1183	1190		10.1096/fasebj.8.14.7958626	http://dx.doi.org/10.1096/fasebj.8.14.7958626			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958626				2022-12-28	WOS:A1994PT12800015
J	YUAN, D; KOH, CY; WILDER, JA				YUAN, D; KOH, CY; WILDER, JA			INTERACTIONS BETWEEN B-LYMPHOCYTES AND NK CELLS	FASEB JOURNAL			English	Review						IFN-GAMMA; IMMUNOGLOBULIN; ISOTYPES; CYTOTOXICITY	NATURAL-KILLER-CELLS; NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; DIFFERENTIATION FACTORS; ANTIBODY-PRODUCTION; ACTIVATION; EXPRESSION; INVITRO; CLONES; IGG2A	The ability of natural killer (NK) cells to secrete lymphokines confers upon them the potential to regulate cell types via mechanisms other than direct cytotoxicity. During the past few years increasing evidence has been accumulating to show that NK and B cells can interact productively. First, NK cells cocultured with B cells can induce them to initiate polyclonal Ig secretion. This help is mediated by a soluble factor (or factors) that appears to be different from any known cytokine. Second, preactivated B lymphocytes can induce NK cells to produce greater amounts of IFN-gamma via an interaction that requires direct cell contact. Third, in contrast to previous suggestions, NK cells do not have the ability to kill primary B lymphocytes regardless of their stage of differentiation. Evaluation of the in vivo relevance of these interactions revealed that activated NK cells can increase the IgG2a response to a specific protein antigen. Without activation, NK cells neither enhance nor inhibit B cell responses to antigens. The deviation of the isotype distribution may allow increased NK cell specificity for certain pathogens by enhancing antibody-dependent cytotoxicity.			YUAN, D (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOLEC PATHOL LAB, DALLAS, TX 75235 USA.		Koh, Crystal/D-9986-2013		NATIONAL CANCER INSTITUTE [R01CA051426] Funding Source: NIH RePORTER; NCI NIH HHS [CA51426] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABKEN H, 1992, J IMMUNOL, V149, P2785; ABRUZZO LV, 1986, CELL IMMUNOL, V98, P266, DOI 10.1016/0008-8749(86)90287-X; ABRUZZO LV, 1983, SCIENCE, V222, P581, DOI 10.1126/science.6685343; AMIGORENA S, 1990, EUR J IMMUNOL, V20, P1781, DOI 10.1002/eji.1830200824; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; ARAI S, 1983, J IMMUNOL, V131, P651; BECKER JC, 1990, SCAND J IMMUNOL, V32, P153, DOI 10.1111/j.1365-3083.1990.tb02905.x; BENNETT M, 1987, ADV IMMUNOL, V41, P333, DOI 10.1016/S0065-2776(08)60034-6; BRENNER MK, 1987, EUR J IMMUNOL, V17, P43, DOI 10.1002/eji.1830170108; BRIEVA JA, 1984, J IMMUNOL, V132, P611; BROOKS K, 1983, NATURE, V302, P825, DOI 10.1038/302825a0; CHARLEY MR, 1985, J INVEST DERMATOL, V85, pS121, DOI 10.1111/1523-1747.ep12275630; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; HERBERMAN RB, 1976, PROG CLIN BIOL RES, V58, P33; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KATZ P, 1989, CELL IMMUNOL, V119, P130, DOI 10.1016/0008-8749(89)90229-3; KHATER M, 1986, J EXP MED, V164, P1505, DOI 10.1084/jem.164.5.1505; KIMATA H, 1988, J CLIN IMMUNOL, V8, P381, DOI 10.1007/BF00917154; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1985, J MOL CELL IMMUNOL, V2, P155; LEBMAN DA, 1994, INT IMMUNOL, V6, P113, DOI 10.1093/intimm/6.1.113; MARKOWITZ JS, 1993, J IMMUNOL, V150, P1223; MICHAEL A, 1989, J IMMUNOL, V142, P1095; MIKHAEL A, 1991, NAT IMMUN CELL GROW, V218, P71; MOORE BB, 1993, NUCLEIC ACIDS RES, V21, P1481, DOI 10.1093/nar/21.6.1481; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOELLE R, 1992, CURR OPIN IMMUNOL, V4, P333, DOI 10.1016/0952-7915(92)90085-S; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; PAIGE CJ, 1978, J IMMUNOL, V121, P641; ROBLES CP, 1986, J IMMUNOL, V137, P2418; ROBLES CP, 1989, NAT IMMUN CELL GROW, V8, P209; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1993, J IMMUNOL, V151, P5251; SPLAWSKI JB, 1989, J IMMUNOL, V142, P1569; STEVENS TL, 1990, J IMMUNOL, V144, P869; STORKUS WJ, 1986, J IMMUNOL, V136, P1542; TARGAN S, 1985, J IMMUNOL, V134, P666; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; VYAKARNAM A, 1985, EUR J IMMUNOL, V15, P606, DOI 10.1002/eji.1830150614; WELSH RM, 1986, NAT IMMUN CELL GROW, V5, P169; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YUAN D, 1992, INT IMMUNOL, V4, P1373, DOI 10.1093/intimm/4.12.1373	44	53	55	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1012	1018		10.1096/fasebj.8.13.7926365	http://dx.doi.org/10.1096/fasebj.8.13.7926365			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926365				2022-12-28	WOS:A1994PN06900004
J	MAIA, JCD				MAIA, JCD			HEXOSAMINE AND CELL-WALL BIOGENESIS IN THE AQUATIC FUNGUS BLASTOCLADIELLA-EMERSONII	FASEB JOURNAL			English	Review						HEXOSAMINE; BIOSYNTHESIS; CHITIN; AMIDOTRANSFERASE; PROTEIN PHOSPHORYLATION	CHITIN SYNTHESIS; FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; ASPERGILLUS-NIDULANS; ESCHERICHIA-COLI; S-CEREVISIAE; GLUTAMINE; BIOSYNTHESIS; INHIBITION; SEQUENCE; CLONING	Chitin, a beta-(1-->4) polymer of N-acetylglucosamine, is an important constituent of fungal cell walls. This polymer is synthesized by the incorporation of N-acetyl-D-glucosamine units from the precursor UDP-N-acetyl-D-glucosamine (UDP-GlcNAc) in a reaction catalyzed by chitin synthase. In the aquatic fungus Blastocladiella emersonii, chitin, the major component of the cell wall, is synthesized and incorporated in the cell surface of the free-swimming zoospore during the abrupt transition from this wall-less cell to the sessile, wall-containing cyst. Studies with cycloheximide indicate that chitin synthesis occurs in the apparent absence of protein synthesis, and thus posttranslational controls presumably regulate the cell wall biogenesis during encystment. Glutamine: fructose 6-phosphate amidotransferase, first enzyme of the hexosamine biosynthetic pathway, was found to play a central role in the regulation of chitin synthesis in this fungus. This enzyme exists in two forms, which are interconvertible by phosphorylation or dephosphorylation of serine residues. It is allosterically inhibited in the phosphorylated form, as it is in the zoospore, by UDP-GlcNAc. In addition, UDP-GlcNAc inhibits the dephosphorylation of amidotransferase catalyzed by protein phosphatases 2A and 2C. Thus, UDP-GlcNAc plays a dual role in hexosamine and chitin synthesis in zoospore: it not only inhibits the phosphorylated form of the enzyme but also prevents its dephosphorylation. The available data suggest that substrate availability plays a role in the control of chitin synthesis during zoospore differentiation.			MAIA, JCD (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498970 SAO PAULO,BRAZIL.							BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BATES CJ, 1966, J BIOL CHEM, V241, P1705; BATNICKIGARCIA S, 1979, FUNGAL WALLS HYPHAL, P149; BORGIA PT, 1992, J BACTERIOL, V174, P377, DOI 10.1128/jb.174.2.377-383.1992; BORGIA PT, 1992, J BACTERIOL, V174, P384, DOI 10.1128/jb.174.2.384-389.1992; BOWEN AR, 1992, P NATL ACAD SCI USA, V89, P519, DOI 10.1073/pnas.89.2.519; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CABIB E, 1987, ADV ENZYMOL RAMB, V59, P59; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1979, FUNGAL WALLS HYPHAL, P189; Cabib E, 1990, BIOCH CELL WALLS MEM, P31; CAMARGO EP, 1967, J BIOL CHEM, V242, P3121; CHIEW YY, 1980, ARCH MICROBIOL, V125, P97, DOI 10.1007/BF00403204; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DALLEY NE, 1982, BIOCHIM BIOPHYS ACTA, V686, P65, DOI 10.1016/0005-2736(82)90152-3; DAVIDSON EA, 1957, J BIOL CHEM, V226, P125; ETCHEBEHERE LC, 1989, ARCH BIOCHEM BIOPHYS, V272, P301, DOI 10.1016/0003-9861(89)90223-3; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FRISA PS, 1982, P NATL ACAD SCI-BIOL, V79, P6289, DOI 10.1073/pnas.79.20.6289; GHOSH S, 1960, J BIOL CHEM, V235, P1265; GOMES SL, 1890, CELL DIFFER, V9, P169; Gooday GW, 1979, FUNGAL WALLS HYPHAL, P203; GOTTSCHALK WK, 1982, DEV BIOL, V93, P165, DOI 10.1016/0012-1606(82)90250-0; HOHN TM, 1984, J BACTERIOL, V158, P253, DOI 10.1128/JB.158.1.253-263.1984; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LELOIR LF, 1953, BIOCHIM BIOPHYS ACTA, V12, P15, DOI 10.1016/0006-3002(53)90119-X; LOVETT JS, 1975, BACTERIOL REV, V39, P345, DOI 10.1128/MMBR.39.4.345-404.1975; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; MILLS GL, 1981, ARCH MICROBIOL, V130, P72, DOI 10.1007/BF00527075; Myers R B, 1974, Monogr Dev Biol, V8, P1; NORRMAN J, 1975, PHYTOCHEMISTRY, V14, P1271, DOI 10.1016/S0031-9422(00)98608-4; ORLEAN P, 1985, FEBS LETT, V184, P313, DOI 10.1016/0014-5793(85)80629-3; PLUMBRIDGE JA, 1993, J BACTERIOL, P4951; REISSIG JL, 1956, J BIOL CHEM, V219, P753; SELITRENNIKOFF CP, 1980, P NATL ACAD SCI-BIOL, V77, P5998, DOI 10.1073/pnas.77.10.5998; SELITRENNIKOFF CP, 1976, DEV BIOL, V54, P37, DOI 10.1016/0012-1606(76)90284-0; SELITRENNIKOFF CP, 1976, P NATL ACAD SCI USA, V73, P534, DOI 10.1073/pnas.73.2.534; SHEKMAN R, 1979, P NATL ACAD SCI USA, V76, P645; SIKEMA WD, 1984, EXP MYCOL, V8, P225; SILVERMAN PM, 1975, MICROBIOLOGY, P484; SILVERMAN SJ, 1989, YEAST, V5, P459, DOI 10.1002/yea.320050605; SOLL DR, 1969, DEV BIOL, V20, P183, DOI 10.1016/0012-1606(69)90012-8; Truesdell L C, 1971, Curr Top Dev Biol, V6, P1, DOI 10.1016/S0070-2153(08)60636-5; TRUESDELL LC, 1970, ARCH MIKROBIOL, V70, P378, DOI 10.1007/BF00425421; VANDERCAMMEN A, 1990, J GEN MICROBIOL, V136, P137, DOI 10.1099/00221287-136-1-137; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATZELE G, 1989, J BIOL CHEM, V264, P8753; YAMAMOTO K, 1976, AGR BIOL CHEM TOKYO, V40, P2275, DOI 10.1080/00021369.1976.10862393	51	17	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					848	853		10.1096/fasebj.8.11.8070634	http://dx.doi.org/10.1096/fasebj.8.11.8070634			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070634				2022-12-28	WOS:A1994PC88500007
J	ROBBINS, FC				ROBBINS, FC			POLIOMYELITIS ERADICATION - A CONTINUING STORY .38.	FASEB JOURNAL			English	Article											ROBBINS, FC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106, USA.							Brodie M, 1936, AM J PUBLIC HEALTH N, V26, P119, DOI 10.2105/AJPH.26.2.119; ENDERS JF, 1949, SCIENCE, V109, P85, DOI 10.1126/science.109.2822.85; Francis Thomas, 1957, EVALUATION 1954 FIEL; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P7135; Kolmer JA, 1936, AM J PUBLIC HEALTH N, V26, P126, DOI 10.2105/AJPH.26.2.126; Leake JP, 1935, J AMER MED ASSOC, V105, P2152; MELNICK JL, 1988, VACCINES, P115; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; NATHANSON N, 1963, AM J HYG, V78, P16, DOI 10.1093/oxfordjournals.aje.a120327; NATHANSON N, 1963, AM J HYG, V78, P29, DOI 10.1093/oxfordjournals.aje.a120328; NATHANSON N, 1963, AM J HYG, V78, P61, DOI 10.1093/oxfordjournals.aje.a120329; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; ROBBINS FC, 1950, P SOC EXP BIOL MED, V75, P370; ROBBINS FC, 1951, AM J HYG, V54, P286, DOI 10.1093/oxfordjournals.aje.a119486; ROBBINS FC, 1993, JAMA-J AM MED ASSOC, V270, P1857, DOI 10.1001/jama.270.15.1857; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P105	16	2	2	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1994	8	9					665	666		10.1096/fasebj.8.9.8005394	http://dx.doi.org/10.1096/fasebj.8.9.8005394			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005394				2022-12-28	WOS:A1994NR90600015
J	SMITH, TK; MEISTER, A				SMITH, TK; MEISTER, A			ACTIVE DEGLYCOSYLATED MAMMALIAN GAMMA-GLUTAMYL-TRANSPEPTIDASE	FASEB JOURNAL			English	Article						CARBOHYDRATE; GLUTATHIONE; PROTEASE; KIDNEY; SUBUNITS	ESCHERICHIA-COLI K-12; TRANSFERASE TRANSPEPTIDASE; RAT-KIDNEY; SUBUNIT; PRECURSOR; FORMS	gamma-Glutamyl transpeptidase, a highly glycosylated heterodimeric enzyme that is usually attached to the external surface of cell membranes, is of major importance in the metabolism of glutathione. The enzyme, which has been isolated from many animal sources, contains a large amount of carbohydrate, which is linked to both protein subunits. Previous work has not shown whether such carbohydrate is needed for enzyme activity nor indicated its functional role. Notably, gamma-glutamyl transpeptidase isolated from Escherichia coli, which exhibits about 80% amino acid sequence homology with the rat enzyme, has only about 0.1% of its specific enzymatic activity and is not glycosylated. Here we treated the highly glycosylated gamma-glutamyl transpeptidases isolated from rat and pig kidneys with a mixture of glycosidases and then separated two completely active gamma-glutamyl transpeptidase fractions from each species. One fraction was completely devoid of carbohydrate and was fully active as compared with the respective isolated enzymes, but differed in solubility and stability. The other fraction, which contained 10-20% of the initially bound carbohydrate, exhibited a marked increase in susceptibility to proteases. The oligosaccharide chains of gamma-glutamyl transpeptidase may protect against protease action (including self-destruction by the inherent protease activity of the light subunit) during synthesis of the active enzyme from its single chain precursor, as well as after enzyme synthesis.	CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA	Cornell University					NIDDK NIH HHS [2 R37 DK 12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; COLOMA J, 1986, BIOCHEM BIOPH RES CO, V135, P304, DOI 10.1016/0006-291X(86)90977-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GARDELL SJ, 1979, J BIOL CHEM, V254, P4942; HAMOS J, 1987, FASEB J, V1, P143, DOI 10.1096/fasebj.1.2.3609611; KUNO T, 1983, BIOCHEM BIOPH RES CO, V114, P889, DOI 10.1016/0006-291X(83)90864-1; LAPERCHE Y, 1989, P NATL ACAD SCI USA, V86, P3159; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; NASH B, 1982, J BIOL CHEM, V257, P585; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PAPANDRIKOPOULOU A, 1989, EUR J BIOCHEM, V183, P693, DOI 10.1111/j.1432-1033.1989.tb21100.x; SMITH TK, 1991, THESIS U SURREY SURR; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; SZEWCZUK A, 1964, BIOCHIM BIOPHYS ACTA, V83, P218, DOI 10.1016/0926-6526(64)90038-2; Tate S.S., 1980, ENZYMATIC BASIS DETO, VII, P95; TATE SS, 1988, BIOCHEM BIOPH RES CO, V154, P1167, DOI 10.1016/0006-291X(88)90263-X; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1976, P NATL ACAD SCI USA, V73, P2599, DOI 10.1073/pnas.73.8.2599; TATE SS, 1985, METHOD ENZYMOL, V113, P400; TATE SS, 1986, BIOCHEM BIOPH RES CO, V141, P1189, DOI 10.1016/S0006-291X(86)80170-X; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1986, J BIOCHEM-TOKYO, V99, P55, DOI 10.1093/oxfordjournals.jbchem.a135479; YAMASHITA K, 1983, J BIOCHEM-TOKYO, V93, P135, DOI 10.1093/oxfordjournals.jbchem.a134147	30	13	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					661	664		10.1096/fasebj.8.9.7911768	http://dx.doi.org/10.1096/fasebj.8.9.7911768			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	7911768				2022-12-28	WOS:A1994NR90600014
J	PARKER, J				PARKER, J			HELP FROM PHILOSOPHY - RESPONDING TO THE ANIMAL RIGHTS CHALLENGE	FASEB JOURNAL			English	Article						RESEARCH; ANIMALS; ETHICS; UTILITARIANISM; CONTRACTUALISM		The chasm that C. P. Snow noted between the two cultures of science and the humanities may be part of an explanation for the success of the animal rights movement. Many philosophers, who represent the culture of the humanities, take an animal liberation position in the ethical debate about the use of animals in research. One who does not is Peter Carruthers. He presents a valuable critique of two important animal liberation ethicists, Tom Regan and Peter Singer, analyzing their thinking on the origins of ethical ideas and the source of ethical motivation. He identifies problems in their theories leading to conclusions that defy common sense about the value of human life. As an alternative, Carruthers introduces John Rawls' theory of contractualism. This theory provides a framework within which medical researchers and the public at large can defend the humane use of animals in research. His work promises to help bridge the gap between scientists and representatives of the humanities.			PARKER, J (corresponding author), OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006, USA.							CARRUTHERS P, 1992, ANIMALS ISSUE MORAL, pR11; COMROE JH, 1976, SCIENCE, V192, P105, DOI 10.1126/science.769161; FRANKLIN J, 1991, COALITION ANIMALS AN, V4, P1; HEARNE V, 1991, HARPERS MAGAZINE, V283, P59; KANT I, 1964, GROUNDWORK METAPHYSI, P96; REGAN T, 1983, CASE ANIMAL RIGHTS, P34; Singer P, 1975, ANIMAL LIBERATION, P1	7	1	1	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					375	377		10.1096/fasebj.8.6.8168687	http://dx.doi.org/10.1096/fasebj.8.6.8168687			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168687				2022-12-28	WOS:A1994NH25000002
J	VANSCHAFTINGEN, E; DETHEUX, M; DACUNHA, MV				VANSCHAFTINGEN, E; DETHEUX, M; DACUNHA, MV			SHORT-TERM CONTROL OF GLUCOKINASE ACTIVITY - ROLE OF A REGULATORY PROTEIN	FASEB JOURNAL			English	Review						GLUCOKINASE; GLYCOLYSIS; FRUCTOSE; REGULATORY PROTEIN	ISOLATED RAT HEPATOCYTES; HEXOKINASE-D GLUCOKINASE; LIVER GLUCOKINASE; FRUCTOSE 1-PHOSPHATE; GLUCOSE PHOSPHORYLATION; CO-OPERATIVITY; MECHANISM; 6-PHOSPHATE; EXPRESSION; GLYCOLYSIS	Glucokinase is one of the four hexokinases present in mammalian tissues. It is expressed in two cell types that have to respond to changes in the blood glucose concentration, the liver parenchymal cell and the P-cells of pancreatic islets. The former are responsible for the metabolism and storage of an important part of the ingested glucose, whereas the latter secrete insulin in response to an increase in the blood glucose level. One major characteristic of glucokinase is that it has a relatively low affinity for glucose and displays positive cooperativity for this substrate, despite the fact that it is a monomeric enzyme. Furthermore, unlike other hexokinases, it is not inhibited by micromolar (physiological) concentrations of glucose 6-phosphate but by a regulatory protein that transduces the effect of fructose 6-phosphate and of fructose 1-phosphate. The purpose of this review is to describe these aspects of the regulation of glucokinase.			VANSCHAFTINGEN, E (corresponding author), UNIV CATHOLIQUE LOUVAIN,INT INST CELLULAR & MOLEC PATHOL,CHIM PHYSIOL LAB,7539,AVE HIPPOCRATE 75,B-1200 BRUSSELS,BELGIUM.		Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647				BELL GI, 1993, TRENDS ENDOCRIN MET, V4, P86, DOI 10.1016/1043-2760(93)90084-R; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CARDENAS ML, 1984, EUR J BIOCHEM, V145, P163, DOI 10.1111/j.1432-1033.1984.tb08536.x; CLARK DG, 1979, BIOCHEM J, V184, P501, DOI 10.1042/bj1840501; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; CORNISHBOWDEN A, 1986, BIOCHEM J, V240, P293, DOI 10.1042/bj2400293; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; DAWSON CM, 1969, BIOCHIM BIOPHYS ACTA, V176, P657, DOI 10.1016/0005-2760(69)90238-0; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; DETHEUX M, 1993, FEBS LETT, V321, P111, DOI 10.1016/0014-5793(93)80089-D; FILLAT C, 1993, ARCH BIOCHEM BIOPHYS, V300, P564, DOI 10.1006/abbi.1993.1078; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATZ J, 1975, EUR J BIOCHEM, V60, P91, DOI 10.1111/j.1432-1033.1975.tb20979.x; LIN SX, 1990, J BIOL CHEM, V265, P9670; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MALAISSE WJ, 1990, EUR J BIOCHEM, V190, P539, DOI 10.1111/j.1432-1033.1990.tb15607.x; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIDDLETON RJ, 1990, BIOCHEM SOC T, V18, P180, DOI 10.1042/bst0180180; MIKKELSEN J, 1987, BIOCHEM J, V248, P709, DOI 10.1042/bj2480709; PERMUTT MA, 1992, DIABETES, V41, P1367, DOI 10.2337/diabetes.41.11.1367; POLLARDKNIGHT D, 1982, MOL CELL BIOCHEM, V44, P71; POLLARDKNIGHT D, 1987, BIOCHEM J, V245, P625, DOI 10.1042/bj2450625; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TOPPING DL, 1971, NUTR METAB, V13, P331; Van den Berghe G, 1986, Prog Biochem Pharmacol, V21, P1; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1992, BIOCHEM J, V286, P253, DOI 10.1042/bj2860253; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1992, EUR J BIOCHEM, V204, P363; VANSCHAFTINGEN E, 1991, FASEB J, V5, P326, DOI 10.1096/fasebj.5.3.2001793; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	40	203	203	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					414	419		10.1096/fasebj.8.6.8168691	http://dx.doi.org/10.1096/fasebj.8.6.8168691			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168691				2022-12-28	WOS:A1994NH25000008
J	LANOUE, KF; MARTIN, LF				LANOUE, KF; MARTIN, LF			ABNORMAL-A(1) ADENOSINE RECEPTOR FUNCTION IN GENETIC OBESITY	FASEB JOURNAL			English	Review						INSULIN; SYMPATHETIC NERVOUS SYSTEM; HYPERPHAGIA	ADENYLATE-CYCLASE ACTIVITY; NUCLEOTIDE REGULATORY COMPONENT; DEPENDENT PROTEIN-KINASE; ISLET-ACTIVATING PROTEIN; ZUCKER FA/FA RATS; ADIPOSE-TISSUE; FAT-CELLS; MEDIATED INHIBITION; ADIPOCYTE MEMBRANES; ADIPSIN EXPRESSION	Obesity is increasingly recognized as an important health problem in developed, industrialized countries. As a large proportion of the variance in individual adiposity is based on genetic factors (1-3), recent efforts have focused on identifying genes involved in regulating the percentage of body fat in a given individual. This effort is helped by the existence of rodent models of genetic obesity. Many strains of mice and at least three rat strains have been identified thus far that exhibit inherited obesity accompanied by a similar set of endocrine abnormalities (4). Although the symptoms of the disease are similar in different strains, different genes appear to be involved in causing the syndrome, as the mutation responsible for the obesity maps to different chromosomal sites in the different strains. Efforts to find the products of the mutated genes over the past 30 years have generally been unsuccessful. However, the available data imply that many obesity mutations may involve genes that code for proteins in a single signal transduction pathway or one particular cascade of covalent modification. Reasonable theories are plentiful about the identity of such a pathway, but current studies in the laboratories of the authors suggest that the A1 adenosine receptor signaling pathway may be involved. Evidence of abnormal A1 receptor function has been obtained from studies of Zucker rats and obese (ob/ob) mice (5-7). These strains are obese because of a single recessive mutation. Measurements of adenylyl cyclase activity and regulation in isolated adipocytes and isolated plasma membranes suggest that the receptor is unusually and tonically active in obese rats. Because signaling from this receptor inhibits lipolysis in white and brown fat, induces insulin resistance in skeletal muscle (8, 9), but increases insulin sensitivity in adipose tissue (10, 11), the possibility arises that the excessive activity of the A1 adenosine receptor may induce obesity. Data from human volunteers are also compatible with the possibility that the activity of the receptor is unusually high in vivo in obese individuals (12).	LOUISIANA STATE UNIV,MED CTR,DEPT SURG,NEW ORLEANS,LA 70112	Louisiana State University System	LANOUE, KF (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033, USA.							ARASE K, 1989, PHYSIOL BEHAV, V45, P5365; ARNER P, 1979, METABOLISM, V28, P198, DOI 10.1016/0026-0495(79)90065-9; ARNER P, 1987, EUR J CLIN INVEST, V17, P58, DOI 10.1111/j.1365-2362.1987.tb01226.x; BEGINHEICK N, 1985, J BIOL CHEM, V260, P6187; BEGINHEICK N, 1990, BIOCHEM J, V268, P83, DOI 10.1042/bj2680083; BESSESEN DH, 1991, AM J PHYSIOL, V261, pE246, DOI 10.1152/ajpendo.1991.261.2.E246; BRAY GA, 1987, NUTR REV, V45, P33; BRAY GA, 1982, P NUTR SOC, V41, P95, DOI 10.1079/PNS19820018; BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; BRAY GA, 1992, PROG BRAIN RES, V93, P333; CHALLIS RAJ, 1984, BIOCHEM J, V221, P915, DOI 10.1042/bj2210915; CHALLISS RAJ, 1992, EUR J PHARM-MOLEC PH, V226, P121, DOI 10.1016/0922-4106(92)90172-R; CONNACHER AA, 1991, CLIN SCI, V81, P635, DOI 10.1042/cs0810635; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; DABENT A, 1987, AM J PHYSIOL, V252, pE273; DALY JW, 1987, TOPICS PERSPECTIVES, P23; DEHAYE JP, 1985, HORM METAB RES, V17, P333, DOI 10.1055/s-2007-1013536; DORFLINGER LJ, 1985, ENDOCRINOLOGY, V117, P2330, DOI 10.1210/endo-117-6-2330; DUGAIL I, 1990, J BIOL CHEM, V265, P1831; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; EBERT R, 1973, N-S ARCH PHARMACOL, V278, P247, DOI 10.1007/BF00500286; FAIN JN, 1973, MOL PHARMACOL, V9, P595; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FREDHOLM BB, 1987, NAUYN SCHMIEDBERGS A, V337, P477; FRIED SK, 1991, AM J PHYSIOL, V261, pE653, DOI 10.1152/ajpendo.1991.261.5.E653; Garn S M, 1976, Pediatrics, V57, P443; GAWLER D, 1987, NATURE, V327, P229, DOI 10.1038/327229a0; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GREEN A, 1987, J BIOL CHEM, V262, P15702; GREENBERG AS, 1987, J BIOL CHEM, V262, P4564; GREENWOOD MRC, 1993, ANN NY ACAD SCI, V676, P253; GREENWOOD MRC, 1983, CONT ISSUES CLIN NUT, V4, P193; HOFFMAN BB, 1984, J CLIN INVEST, V74, P1750, DOI 10.1172/JCI111593; HOGAN S, 1981, AM J PHYSIOL, V241, pE436, DOI 10.1152/ajpendo.1981.241.6.E436; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; JACOBSON KA, 1992, J MED CHEM, V35, P4143, DOI 10.1021/jm00100a020; JOHNSON PR, 1991, ANNU REV NUTR, V11, P325, DOI 10.1146/annurev.nu.11.070191.001545; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAARTINEN JM, 1991, BIOCHEM J, V279, P17, DOI 10.1042/bj2790017; KURODA M, 1987, J BIOL CHEM, V262, P245; LANOUE K, 1986, MITOCHONDRIAL PHYSL, P1; LANOUE KF, 1993, FASEB J, V7, pA607; LANOUE KF, 1991, ROLE ADENOSINE ADENI, P487; LEE HT, 1992, FASEB J, V6, pA1859; LEVIN BE, 1983, AM J PHYSIOL, V245, pE87, DOI 10.1152/ajpendo.1983.245.1.E87; LEVIN BE, 1980, PHARMACOL BIOCHEM BE, V13, P107, DOI 10.1016/0091-3057(80)90128-8; LIANG BT, 1990, CIRC RES, V67, P406, DOI 10.1161/01.RES.67.2.406; LIBERT F, 1991, GENOMICS, V11, P225, DOI 10.1016/0888-7543(91)90125-X; LILLIOJA S, 1986, METABOLISM, V35, P505, DOI 10.1016/0026-0495(86)90006-5; LINDEN J, 1985, CIRC RES, V56, P728, DOI 10.1161/01.RES.56.5.728; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LOHSE MJ, 1987, J NEUROCHEM, V49, P89; LONDOS C, 1985, J BIOL CHEM, V260, P5139; LONDOS C, 1981, ADV CYCLIC NUCLEOTID, V14; LOWELL BB, 1990, ENDOCRINOLOGY, V126, P1514, DOI 10.1210/endo-126-3-1514; LUTHIN DR, 1993, FASEB J, V7, pA607; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; MALBON CC, 1978, J BIOL CHEM, V253, P8820; MALBON CC, 1985, J BIOL CHEM, V260, P2558; MARTIN LF, 1990, SURGERY, V108, P228; Medlund P, 1976, Acta Med Scand Suppl, V600, P1; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; OHISALO JJ, 1989, BIOCHEM J, V260, P843, DOI 10.1042/bj2600843; OHISALO JJ, 1986, METABOLISM, V35, P143, DOI 10.1016/0026-0495(86)90115-0; OHISALO JJ, 1992, CLIN SCI, V83, P589, DOI 10.1042/cs0830589; PLANCHE E, 1983, AM J PHYSIOL, V245, pE107, DOI 10.1152/ajpendo.1983.245.2.E107; PLATT KA, 1989, P NATL ACAD SCI USA, V86, P7490, DOI 10.1073/pnas.86.19.7490; PRICE RA, 1990, HUM BIOL, V62, P747; RICHELSEN B, 1988, METABOLISM, V37, P268, DOI 10.1016/0026-0495(88)90107-2; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SCHIMMEL RJ, 1985, AM J PHYSIOL, V246, pC456; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SMOLLER JM, 1993, AM J PHYSIOL, V33, pR8; SMOLLER JW, 1993, AM J PHYSIOL, V264, pR12, DOI 10.1152/ajpregu.1993.264.1.R12; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; TURKENKOPF IJ, 1982, AM J PHYSIOL, V242, pE220, DOI 10.1152/ajpendo.1982.242.4.E220; TURKENKOPF IJ, 1987, INT J OBESITY, V12, P515; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; VANNUCCI SJ, 1990, INT J OBESITY, V14, P125; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; WALKER CD, 1992, ENDOCRINOLOGY, V131, P2629, DOI 10.1210/en.131.6.2629; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093	90	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					72	80		10.1096/fasebj.8.1.8299893	http://dx.doi.org/10.1096/fasebj.8.1.8299893			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299893				2022-12-28	WOS:A1994MV28200011
J	ROSSI, AD; LARSSON, O; MANZO, L; ORRENIUS, S; VAHTER, M; BERGGREN, PO; NICOTERA, P				ROSSI, AD; LARSSON, O; MANZO, L; ORRENIUS, S; VAHTER, M; BERGGREN, PO; NICOTERA, P			MODIFICATIONS OF CA2+ SIGNALING BY INORGANIC MERCURY IN PC12 CELLS	FASEB JOURNAL			English	Note						SIGNAL TRANSDUCTION; CA2+ CHANNELS; INOSITOL POLYPHOSPHATES	NERVE GROWTH-FACTOR; PROTEIN KINASE-C; RAT PHEOCHROMOCYTOMA CELLS; CALCIUM CHANNELS; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; HEAVY-METALS; RELEASE; BRAIN; OSCILLATIONS	The effects of different levels of inorganic mercury (Hg2+) on depolarization- or agonist-stimulated Ca2+ signals were studied in PC12 cells. Exposure to 50-300 nM Hg2+ did not alter the resting cytosolic free Ca2+ concentration ([Ca2+]i), but enhanced the Ca2+ response to KCl-induced depolarization. Patch-clamp experiments revealed that these Hg2+ concentrations increased the voltage-dependent Ca2+ current through L-type channels. Also, Hg2+ treatment amplified the intracellular [Ca2+]i transients elicited by extracellular ATP. In contrast, the Ca2+ increase stimulated by bradykinin was unaffected. At slightly higher concentrations (1 to 2 muM), Hg2+ caused a sustained rise of the resting [Ca2+]i. This increase did not occur in Ca2+-free medium and was prevented by pretreatment with NiCl2 or with the L-type Ca2+ channel blockers, verapamil and nifedipine. Hg2+ did not mobilize Ca2+ from intracellular stores sensitive to thapsigargin, 2,5-di-(tert-butyl)-benzohydroquinone, or caffeine. At 2 muM, Hg2+ inhibited the [Ca2+]i transients elicited by bradykinin, ATP, or KCl-induced depolarization. The loss of the intracellular Ca2+ response to bradykinin was independent from the Ca2+ overload elicited by Hg2+; instead, it was associated with inhibition of polyphosphoinositide generation. Exposure to the lower Hg2+ concentrations (0.3-0.5 muM) greatly potentiated NGF-induced PC12 cell differentiation. Conversely, treatment with 2 muM Hg2+ caused cell death. Our results show that inorganic mercury has selective and different effects on Ca2+ signaling in PC12 cells depending on the concentration, within a narrow range.	KAROLINSKA INST, INST ENVIRONM MED, DEPT TOXICOL, BOX 60 400, S-10401 STOCKHOLM 60, SWEDEN; KAROLINSKA INST, INST ENVIRONM MED, DEPT ENDOCRINOL, S-10401 STOCKHOLM, SWEDEN; UNIV PAVIA, TOXICOL UNIT, I-27100 PAVIA, ITALY; LAVORO MED CTR CLIN, PAVIA, ITALY	Karolinska Institutet; Karolinska Institutet; University of Pavia			Vahter, Marie/HGB-1674-2022	Berggren, Per-Olof/0000-0001-8991-413X				ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ATCHISON WD, 1982, NEUROTOXICOLOGY, V3, P37; ATZORI L, 1990, J CELL PHYSIOL, V143, P165, DOI 10.1002/jcp.1041430123; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BELLOMO G, 1987, J BIOL CHEM, V262, P1530; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P3; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOW SC, 1992, ARCH BIOCHEM BIOPHYS, V298, P143, DOI 10.1016/0003-9861(92)90105-6; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS CC, 1991, CANCER RES, V51, pS5023; HEWETT SJ, 1992, TOXICOL APPL PHARM, V113, P267, DOI 10.1016/0041-008X(92)90124-B; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; INOUE Y, 1988, PHARMACOL TOXICOL, V62, P278, DOI 10.1111/j.1600-0773.1988.tb01887.x; ISLAM MS, 1993, FEBS LETT, V319, P128, DOI 10.1016/0014-5793(93)80051-U; JANIGRO D, 1989, FEBS LETT, V255, P398, DOI 10.1016/0014-5793(89)81131-7; JUNG KY, 1990, BIOCHEM BIOPH RES CO, V173, P606, DOI 10.1016/S0006-291X(05)80078-6; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; MAGOS L, 1972, J ASSOC OFF ANA CHEM, V55, P966; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MILLER RJ, 1988, TRENDS NEUROSCI, V11, P415, DOI 10.1016/0166-2236(88)90191-9; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY BJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P33; NAKAE H, 1991, BRAIN RES, V558, P348, DOI 10.1016/0006-8993(91)90791-S; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; Rosen J F, 1993, TOXICOLOGIST, V13, P1630; ROSSI A, 1991, PHARMACOL TOXICOL, V68, P424, DOI 10.1111/j.1600-0773.1991.tb01265.x; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Sarkar B, 1983, BIOL ASPECTS METALS, P183; SHAFER TJ, 1991, J PHARMACOL EXP THER, V258, P149; SHAPIRO IM, 1982, LANCET, V1, P1147; SINGER R, 1987, ARCH ENVIRON HEALTH, V42, P181; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	53	61	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1507	1514		10.1096/fasebj.7.15.8262335	http://dx.doi.org/10.1096/fasebj.7.15.8262335			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262335				2022-12-28	WOS:A1993ML74000014
J	NODA, M				NODA, M			MECHANISMS OF REVERSION	FASEB JOURNAL			English	Review						TRANSFORMATION; ONCOGENES; RAS; KINASES; PHOSPHATASES; CELL ADHESION	GTPASE-ACTIVATING PROTEIN; NERVE GROWTH-FACTOR; SOMATIC-CELL HYBRIDS; HA-RAS ONCOGENE; TYROSINE KINASE; TRANSFORMED-CELLS; SACCHAROMYCES-CEREVISIAE; FLAT REVERTANTS; SARCOMA-VIRUS; MONOCLONAL-ANTIBODIES	Reversion of transformed cells provides biological system useful in multiple areas of cancer research. First, reversion can be induced by inhibiting the activities of specific oncogenes or replacing intact tumor suppressor genes, and such experiments yield important insights into the roles of these genes in carcinogenesis and normal growth regulation as well as the functional relationships between these genes and other known genes. Second, novel genes involved in growth regulation can be discovered by isolating revertants from transformed cells after mutagenesis or DNA transfection and then characterizing the genes responsible for the non-transformed phenotype. Third, potential anti-cancer drugs can be screened by reversion assay using cells transformed by specific oncogenes. The novel genes and chemicals discovered through these studies serve as valuable tools that help our understanding of how cells regulate their growth and differentiation.			NODA, M (corresponding author), JAPANESE FDN CANC RES, DEPT VIRAL ONCOL, KAMI IKEBUKURO, TOSHIMA KU, TOKYO 170, JAPAN.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BOS JL, 1989, CANCER RES, V49, P4682; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CUTLER ML, 1993, IN PRESS MOL CELL BI, V12; DEAN NM, 1991, CARCINOGENESIS, V12, P665, DOI 10.1093/carcin/12.4.665; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Endo A, 1981, Methods Enzymol, V72, P684; FAGAN JB, 1981, J BIOL CHEM, V256, P520; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GRIDLEY T, 1987, TRENDS GENET, V3, P162, DOI 10.1016/0168-9525(87)90218-6; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATA Y, 1990, J BIOL CHEM, V265, P7104; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HYNES RO, 1976, BIOCHIM BIOPHYS ACTA, V458, P73, DOI 10.1016/0304-419X(76)90015-9; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ITOH O, 1989, CANCER RES, V49, P996; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Kriegler M., 1990, GENE TRANSFER EXPRES; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWON HJ, 1992, CANCER RES, V52, P6926; KYPRIANOU N, 1992, ONCOGENE, V7, P57; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1990, MOL CARCINOGEN, V3, P251, DOI 10.1002/mc.2940030502; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NODA M, 1993, IN PRESS BIOCH BIOPH; NODA M, 1987, ONCOGENES CANCER, P261; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Ozer H L, 1977, Adv Cancer Res, V25, P53, DOI 10.1016/S0065-230X(08)60632-6; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANBRIDGE EJ, 1988, CANCER SURV, V7, P317; STEEL DM, 1989, J CELL SCI, V93, P515; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAPLEY P, 1992, ONCOGENE, V7, P371; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; UEHARA Y, 1989, CANCER RES, V49, P780; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; VARMUS HE, 1981, CELL, V25, P23, DOI 10.1016/0092-8674(81)90228-2; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	103	24	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					834	846		10.1096/fasebj.7.10.8344483	http://dx.doi.org/10.1096/fasebj.7.10.8344483			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344483				2022-12-28	WOS:A1993LQ33700004
J	ARNOLD, FH				ARNOLD, FH			ENGINEERING PROTEINS FOR NONNATURAL ENVIRONMENTS	FASEB JOURNAL			English	Review						RANDOM MUTAGENESIS; STABILITY; METAL ION BINDING; SUBTILISIN	ORGANIC-SOLVENTS; ALPHA-HELICES; SUBTILISIN; DESIGN; SITES	The ability to use proteins in nonnatural environments greatly expands their potential applications in biotechnology. Because nature has not paid much attention to optimizing proteins for in vitro applications under conditions that differ substantially from their natural surroundings, there is generally room for improvement through alterations in the amino acid sequence. The most effective approach to this protein engineering task depends on the level to which the molecular basis for the desired property is understood. Consistently successful ''rational design using site-directed mutagenesis requires a high level of understanding of structure and mechanisms or, alternatively, a particularly simple strategy for obtaining the desired feature. An example of a generally applicable and easy-to-implement protein stabilization strategy is metal ion chelation by specific surface dihistidine sites, which can affect thermal stability as well as the protein's ability to withstand denaturants such as guanidinium chloride. Random mutagenesis, on the other hand, can be effective even when structure or mechanisms are poorly understood, provided one can conveniently screen or select for the property of interest. This approach is illustrated by the sequential accumulation of random mutations that greatly enhance the catalytic activity of a serine protease, subtilisin E, in polar organic solvents. The random mutagenesis approach, which mimics the natural evolutionary refinement process, can be used to ''coax'' enzymes into tolerating nonnatural environments.			ARNOLD, FH (corresponding author), CALTECH, DEPT CHEM & CHEM ENGN, PASADENA, CA 91125 USA.			Arnold, Frances H./0000-0002-4027-364X				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BRYAN P N, 1986, Proteins Structure Function and Genetics, V1, P326; CHATTERJEE S, 1992, BIOTECHNOL BIOENG, V40, P1069, DOI 10.1002/bit.260400910; CHEN K, 1993, IN PRESS P NATL ACAD; CHEN KQ, 1991, BIO-TECHNOL, V9, P1073, DOI 10.1038/nbt1191-1073; CUNNINGHAM BC, 1987, PROTEIN ENG, V1, P319, DOI 10.1093/protein/1.4.319; DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X; GHADIRI MR, 1990, J AM CHEM SOC, V112, P9633, DOI 10.1021/ja00182a030; GHADIRI MR, 1990, J AM CHEM SOC, V112, P1630, DOI 10.1021/ja00160a054; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; Haymore Barry L., 1992, Methods (Orlando), V4, P25, DOI 10.1016/1046-2023(92)90054-C; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; KELLIS JT, 1991, BIO-TECHNOL, V9, P994, DOI 10.1038/nbt1091-994; KLIBANOV AM, 1990, ACCOUNTS CHEM RES, V23, P114, DOI 10.1021/ar00172a004; LIAO H, 1986, P NATL ACAD SCI USA, V83, P576, DOI 10.1073/pnas.83.3.576; MUHEIM A, 1993, IN PRESS J AM CHEMS; OFAGAIN C, 1991, BIOTECHNOL ADV, V9, P351, DOI 10.1016/0734-9750(91)90865-S; OLIPHANT AR, 1989, P NATL ACAD SCI USA, V86, P9094, DOI 10.1073/pnas.86.23.9094; Pantoliano M.W, 1992, CURR OPIN STRUC BIOL, V2, P559; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SUH SS, 1991, PROTEIN ENG, V4, P301, DOI 10.1093/protein/4.3.301; UMANA P, 1993, ACS SYM SER, V516, P102; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILKS HM, 1992, ANN NY ACAD SCI, V672, P80; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059	26	57	71	3	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					744	749		10.1096/fasebj.7.9.8330682	http://dx.doi.org/10.1096/fasebj.7.9.8330682			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330682				2022-12-28	WOS:A1993LK43000006
J	LIN, CQ; BISSELL, MJ				LIN, CQ; BISSELL, MJ			MULTIFACETED REGULATION OF CELL-DIFFERENTIATION BY EXTRACELLULAR-MATRIX	FASEB JOURNAL			English	Review						FUNCTIONAL DIFFERENTIATION; CELL BEHAVIOR; MAMMARY GLAND; HEPATOCYTES; KERATINOCYTES	HUMAN EPIDERMAL-KERATINOCYTES; FLOATING COLLAGEN MEMBRANES; MAMMARY EPITHELIAL-CELLS; ADULT-RAT-HEPATOCYTES; ACIDIC PROTEIN GENE; TERMINAL DIFFERENTIATION; BASEMENT-MEMBRANE; ALBUMIN GENE; PRIMARY CULTURES; EXPRESSION	Extracellular matrix (ECM) is an intricate network composed of an array of macromolecules, the importance of which is becoming increasingly apparent. The ECM is an integral part of the machinery that regulates cell function; its role in cell differentiation and tissue-specific gene expression, although essential, is not yet understood. It can act as a positive as well as a negative regulator of functional differentiation depending on the cell type and the genes studied. It also acts in a hierarchical fashion, exacting higher and higher degrees of stringency to achieve full functional differentiation. Regulation by ECM is closely interrelated with the action of other regulators of cellular function, such as growth factors and hormones. But ECM may exert its regulation of gene expression by mechanisms distinct from those known for soluble transcription factors. In this short review, we describe three systems in which ECM has been shown to play a crucial role in functional differentiation, but we emphasize mainly the work from our own laboratory to provide a more in-depth analysis of one system. The three systems are: mouse mammary epithelial cells, rat hepatocytes, and human keratinocytes. The crucial role of ECM in normal cell differentiation implies that its alteration may have serious consequences in malignancies and other diseases. The current functional cell culture models could provide powerful tools not only for understanding regulation of normal cell function but also for the studies of tumorigenesis and possibly cancer therapy.			LIN, CQ (corresponding author), LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA.							ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BISSELL DM, 1990, MOL BIOL MED, V7, P187; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BISSELL DM, 1979, PROGR LIVER DISEASE, P69; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BURDON T, 1991, J BIOL CHEM, V266, P6909; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; DALE TC, 1992, MOL CELL BIOL, V12, P905, DOI 10.1128/MCB.12.3.905; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; EMERMAN JT, 1977, P NATL ACAD SCI USA, V74, P4466, DOI 10.1073/pnas.74.10.4466; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; GOODMAN HS, 1990, MOL ENDOCRINOL, V4, P1661, DOI 10.1210/mend-4-11-1661; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUBLER MD, 1991, J CELL SCI, V100, P153; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MICHALOPOULOS G, 1976, SCIENCE, V193, P907, DOI 10.1126/science.948753; NAWA K, 1986, J BIOL CHEM, V261, P6883; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROSKELLEY CD, 1993, IN PRESS ADV MOL CEL, V8; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; Stoker AW, 1990, CURR OPIN CELL BIOL, V2, P864, DOI 10.1016/0955-0674(90)90085-S; STREULI C, 1992, 5TH INT C CELL BIOL, P178; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TALHOUK RS, 1993, IN PRESS EPITHELIAL; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	47	526	544	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					737	743		10.1096/fasebj.7.9.8330681	http://dx.doi.org/10.1096/fasebj.7.9.8330681			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330681				2022-12-28	WOS:A1993LK43000005
J	REICHEL, RR; JACOB, ST				REICHEL, RR; JACOB, ST			CONTROL OF GENE-EXPRESSION BY LIPOPHILIC HORMONES	FASEB JOURNAL			English	Review						STEROID HORMONE RECEPTOR SUPERFAMILY; LIPOPHILIC HORMONES; POL-I GENE EXPRESSION; POL-II GENE EXPRESSION; ONCOGENESIS	RETINOIC ACID RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; CHICKEN PROGESTERONE-RECEPTOR; PROMYELOCYTIC LEUKEMIA FUSES; HUMAN ESTROGEN-RECEPTOR; MAMMARY-TUMOR VIRUS; A ONCOGENE PRODUCT; RIBOSOMAL-RNA GENE; THYROID-HORMONE; TRANSCRIPTION FACTOR	Regulation of gene expression in response to steroids, thyroid hormone, and retinoids is mediated by an impressive array of intracellular receptors. Sequence analysis showed that the hormone receptors comprise a large superfamily of ligand-responsive transcription factors. Upon binding to hormones, the receptors interact with specific hormone response elements located in the promoters of numerous genes. Promoter-bound receptors communicate with distinct receptors and/or additional members of the transcriptional machinery, frequently evoking protein-protein interactions. Ultimately, this results in the induction of complex gene systems that control hormone-induced processes such as differentiation, cell growth, and homeostasis. In addition to the genes transcribed by RNA polymerase II, the lipophilic hormones, particularly glucocorticoids, can also modulate RNA polymerase I-directed transcription of the ribosomal gene. For both transcription systems, activation and repression of genes in response to hormones have been reported. Finally, the involvement of hormone receptors in tumorigenesis has been discussed. It is likely that receptor studies will have major implications in the diagnosis and therapy of diseases such as leukemia.	CHICAGO MED SCH, DEPT PHARMACOL & MOLEC BIOL, 3333 GREEN BAY RD, N CHICAGO, IL 60064 USA	Chicago Medical School					NCI NIH HHS [CA 31894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BROWN TA, 1990, J BIOL CHEM, V265, P10025; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FORMAN B M, 1990, New Biologist, V2, P587; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JACOB ST, 1986, MOL CELL BIOCHEM, V70, P11; JACOB ST, 1969, EUR J BIOCHEM, V7, P449; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MISSEYANNI A, 1991, J STEROID BIOCHEM, V39, P409, DOI 10.1016/0960-0760(91)90234-V; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOUDGIL VK, 1990, BIOCHIM BIOPHYS ACTA, V1055, P243, DOI 10.1016/0167-4889(90)90040-K; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SAJDEL EM, 1971, BIOCHEM BIOPH RES CO, V45, P707, DOI 10.1016/0006-291X(71)90474-8; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEBB ML, 1989, MOL ENDOCRINOL, V3, P1861, DOI 10.1210/mend-3-11-1861; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; WRANGE O, 1978, J BIOL CHEM, V253, P856; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	76	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					427	436		10.1096/fasebj.7.5.8385039	http://dx.doi.org/10.1096/fasebj.7.5.8385039			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8385039				2022-12-28	WOS:A1993KV35100007
J	BERKHOUT, B; ESSINK, BBO; SCHONEVELD, I				BERKHOUT, B; ESSINK, BBO; SCHONEVELD, I			INVITRO DIMERIZATION OF HIV-2 LEADER RNA IN THE ABSENCE OF PUGGAPUA MOTIFS	FASEB JOURNAL			English	Article						HIV-2; INVITRO DIMERIZATION; RETROVIRAL LEADER RNA; RNA-RNA INTERACTION	MURINE LEUKEMIA-VIRUS; DIMER FORMATION; REVERSE TRANSCRIPTION; CIS ELEMENTS; PROTEIN; RETROVIRUS; MUTATIONS; CONSTRUCTION; SEQUENCES; MUTANTS	Retroviral particles contain a dimeric genome consisting of two full-length, noncovalently linked RNA molecules. Linkage of the two genomes is thought to be critical for a productive reverse transcription reaction and may increase genetic recombination rates. The molecular nature of the dimer linkage structure (DLS) is poorly understood. It was recently shown that in vitro synthesized retroviral transcripts can dimerize in the absence of protein factors. We studied in vitro dimerization of human immunodeficiency virus type 2 (HIV-2) RNA. Specific dimerization of HIV-2 RNAs was observed upon incubation at 37-degrees-C in high-salt buffer. Previously, physical and biochemical studies have mapped dimer linkage structures in retroviral leader RNA close to the gag open reading frame. In this study, we found efficient dimerization of HIV-2 RNAs containing only the 5' terminal 255 nucleotides of the leader RNA. Therefore, it seems likely that multiple dimerization signals are present in retroviral leader RNA. The implications for genome dimerization and genome packaging are discussed.			BERKHOUT, B (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.							ADAM MA, 1988, J VIROL, V62, P3802, DOI 10.1128/JVI.62.10.3802-3806.1988; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BERKHOUT B, 1992, NUCLEIC ACIDS RES, V20, P27, DOI 10.1093/nar/20.1.27; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BRAHIC M, 1975, J VIROL, V15, P1222, DOI 10.1128/JVI.15.5.1222-1230.1975; CANAANI E, 1973, P NATL ACAD SCI USA, V72, P401; CHEUNG KS, 1972, VIROLOGY, V50, P851, DOI 10.1016/0042-6822(72)90439-4; CHIEN YH, 1980, MOL BIOL RNA TUMOR V, P395; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COFFIN JM, 1984, RNA TUMOR VIRUSES 1, P261; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; HASELTINE WA, 1977, P NATL ACAD SCI USA, V74, P989, DOI 10.1073/pnas.74.3.989; LINIAL M, 1984, RNA TUMOR VIRUSES, P649; MANGEL WF, 1974, P NATL ACAD SCI USA, V71, P4541, DOI 10.1073/pnas.71.11.4541; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MURPHY JE, 1989, J VIROL, V63, P319, DOI 10.1128/JVI.63.1.319-327.1989; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; ROY C, 1990, NUCLEIC ACIDS RES, V18, P7287, DOI 10.1093/nar/18.24.7287; STOLTZFUS CM, 1975, J VIROL, V16, P1161, DOI 10.1128/JVI.16.5.1161-1170.1975; TOUNEKTI N, 1992, J MOL BIOL, V223, P205, DOI 10.1016/0022-2836(92)90726-Z; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; WATERS LC, 1982, BIOCHIM BIOPHYS ACTA, V696, P201, DOI 10.1016/0167-4781(82)90029-X; Weissmann C, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 2, P1043; Wyke J A, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 2, P897	32	44	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					181	187		10.1096/fasebj.7.1.8422965	http://dx.doi.org/10.1096/fasebj.7.1.8422965			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422965				2022-12-28	WOS:A1993KH88000028
J	CREMASCHI, G; ZWIRNER, NW; GORELIK, G; MALCHIODI, EL; CHIARAMONTE, MG; FOSSATI, CA; STERINBORDA, L				CREMASCHI, G; ZWIRNER, NW; GORELIK, G; MALCHIODI, EL; CHIARAMONTE, MG; FOSSATI, CA; STERINBORDA, L			MODULATION OF CARDIAC PHYSIOLOGY BY AN ANTI-TRYPANOSOMA CRUZI MONOCLONAL-ANTIBODY AFTER INTERACTION WITH MYOCARDIUM	FASEB JOURNAL			English	Article						ADENYLATE CYCLASE; MYOCARDIOPATHY; CHAGAS DISEASE MUSCARINIC CHOLINERGIC RECEPTOR	CHAGAS-DISEASE; CHOLINERGIC RECEPTORS; SURFACE-ANTIGEN; ANTILAMININ IGG; INFECTED MICE; PROTEIN; BINDING; CONTRACTILITY; PARTICIPATION; CARDIOPATHY	Circulating antibodies from human and murine chagasic sera are able to interact with myocardium, activating neurotransmitter receptors, Here, we studied the effects of a monoclonal antibody (Mab CAK20.12), which recognizes a 150 kilodalton antigen of Trypanosoma cruzi and reacts with normal human and murine striated muscles and with cardiac tissue, The MAb CAK20.12 binds to purified cardiac membranes and interferes with the binding of beta-adrenergic receptor radioligand ([I-125]CYP) and muscarinic cholinergic receptor (mAChR) radioligand ([H-3]QNB) in a noncompetitive way, As a consequence of this interaction, beta-adrenergic receptor and mAChR were activated, leading to increased intracellular levels of cyclic AMP as a result of beta-adrenergic receptor-coupled adenylate cyclase triggering, When its sympathetic action was abrogated, it also induced an mAChR-mediated increase in cyclic GMP. Furthermore, cardiac physiology was modified by MAb CAK20.12, as it was able to increase cardiac contractility through beta-adrenoceptor activation and to decrease atrial frequency as a result of mAChR activation, The fact that this MAb modalates and modifies the mechanical and biochemical activity of normal murine heart established an important basis for future research and understanding of how the host's humoral immune response acts on the course and development of the chronic chagasic myocardiopathy.	CONSEJO NACL INVEST CIENT & TECN, CTR ESTUDIOS FARMACOL & BOT, RA-1414 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, CONICET, INST ESTUDIOS INMUNIDAD HUMORAL, BUENOS AIRES, DF, ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires			Zwirner, Norberto/AAI-8961-2020	Zwirner, Norberto/0000-0001-7098-359X; Cremaschi, Graciela/0000-0002-1131-1723; Malchiodi, Emilio/0000-0001-7501-3330				ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255; ALCINA A, 1988, MOL BIOCHEM PARASIT, V29, P181, DOI 10.1016/0166-6851(88)90073-4; Andrade ZA, 1979, TRYPANOSOMA CRUZI DO, P199; BACMAN S, 1989, BRIT J PHARMACOL, V97, P377, DOI 10.1111/j.1476-5381.1989.tb11964.x; BACMAN S, 1990, CAN J PHYSIOL PHARM, V68, P539, DOI 10.1139/y90-078; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brener Z., 1980, Advances in Parasitology, V18, P247, DOI 10.1016/S0065-308X(08)60401-7; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; COSSIO PM, 1977, AM J PATHOL, V86, P533; COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13; CREMASCHI G, 1990, BIOCHEM PHARMACOL, V39, P1861, DOI 10.1016/0006-2952(90)90602-H; CREMASCHI G, 1992, BIOCHEM PHARMACOL, V43, P2493, DOI 10.1016/0006-2952(92)90136-7; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; DEBRACCO MMD, 1984, CLIN EXP IMMUNOL, V55, P405; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOLDBAUM FA, 1993, J CLIN MICROBIOL, V31, P2141, DOI 10.1128/JCM.31.8.2141-2145.1993; GOLL DE, 1967, J FOOD SCI, V32, P323, DOI 10.1111/j.1365-2621.1967.tb01322.x; GORELIK G, 1992, J MOL CELL CARDIOL, V24, P9, DOI 10.1016/0022-2828(92)91155-X; Hudson L., 1985, Parasitology Today, V1, P6, DOI 10.1016/0169-4758(85)90099-7; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; KOBERLE F, 1961, Bol Oficina Sanit Panam, V51, P404; Koberle F., 1974, CIBA F SYMP, P137; MARGNI RA, 1982, IMMUNOLOGIA IMMUNOQU, P451; MARTIN JM, 1987, J PHARMACOL EXP THER, V240, P683; MIRKIN GA, 1994, CLIN IMMUNOL IMMUNOP, V73, P69, DOI 10.1006/clin.1994.1171; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; PAULIN JJ, 1988, J PROTOZOOL, V35, P123, DOI 10.1111/j.1550-7408.1988.tb04091.x; SADIGURSKY M, 1982, AM J TROP MED HYG, V31, P934, DOI 10.4269/ajtmh.1982.31.934; SCHMUNIS G A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P287, DOI 10.1590/S0074-02761987000500011; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617; STERINBORDA L, 1990, FASEB J, V4, P1661, DOI 10.1096/fasebj.4.6.2156743; STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; SZARFMAN A, 1982, J EXP MED, V155, P1161, DOI 10.1084/jem.155.4.1161; VANVOORHIS WC, 1989, J EXP MED, V169, P641, DOI 10.1084/jem.169.3.641; ZWIRNER NW, 1994, INFECT IMMUN, V62, P2483, DOI 10.1128/IAI.62.6.2483-2489.1994	40	15	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1995	9	14					1482	1488		10.1096/fasebj.9.14.7589990	http://dx.doi.org/10.1096/fasebj.9.14.7589990			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589990				2022-12-28	WOS:A1995TF67800013
J	STANLEY, P; IOFFE, E				STANLEY, P; IOFFE, E			GLYCOSYLTRANSFERASE MUTANTS - KEY TO NEW INSIGHTS IN GLYCOBIOLOGY	FASEB JOURNAL			English	Review						MAMMALIAN MUTANTS; CELL SURFACE; CARBOHYDRATE FUNCTION; GLYCOSYLATION	HAMSTER OVARY CELLS; MOLECULAR-BASIS; OLIGOSACCHARIDES; GENE	Glycosyltransferases (Glyc-T's) catalyze the synthesis of the carbohydrate portions of glycoproteins, glycolipids, and proteoglycans, Most Glyc-T's transfer one sugar in one Linkage and are encoded by a unique gene, Thus, synthesis of a branched carbohydrate may require expression of at least 30 Glyc-T genes, Mutations that alter Glyc-T activity therefore provide an approach to identifying functions for carbohydrates. These fall into two general categories: 1) intramolecular functions pertaining to the physical and biochemical properties of a glycoconjugate; and 2) intermolecular functions that involve recognition of sugar (or sugars) by another molecule, such as the selectins that bind to specific sugar sequences at the cell surface, In this review, the origin, nature, and uses of Glyc-T mutants that have been used to study both types of carbohydrate function will be summarized, Many Glyc-T genes are now cloned, so transgenic and gene disruption techniques are the latest strategies for identifying new functions for carbohydrates, It is already apparent that the consequences of altering the spectrum of carbohydrates expressed by a cell or an organism range from ''none'' to ''death.'' A key challenge for the future is to identify molecular bases for the complex phenotypes created by glycosylation engineering, Equally important Hill be to understand factors that regulate Glyc-T genes, a new class of genes whose study may reveal novel mechanisms of biological regulation.			STANLEY, P (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R37 30645, R01 36434, P01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRADY RO, 1994, J INHERIT METAB DIS, V17, P510, DOI 10.1007/BF00711365; BRILES EB, 1982, INT REV CYTOL, V75, P101, DOI 10.1016/S0074-7696(08)61003-7; CARTRON JP, 1995, BLOOD CELL BIOCH MOL, V6; CHARUK JHM, 1995, EUR J BIOCHEM, V230, P797; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSS PE, 1994, CANCER RES, V54, P1450; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; IKEMATSU S, 1993, GLYCOBIOLOGY, V3, P575, DOI 10.1093/glycob/3.6.575; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; JAEKEN J, 1993, GLYCOBIOLOGY, V3, P423, DOI 10.1093/glycob/3.5.423; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Liener I.E., 1986, LECTINS; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; POTVIN B, 1990, J BIOL CHEM, V265, P1615; POWELL LD, 1994, J CLIN INVEST, V94, P1901, DOI 10.1172/JCI117540; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCOCCA JR, 1988, BIOCHEM BIOPH RES CO, V156, P1063, DOI 10.1016/S0006-291X(88)80740-X; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1993, CELL SURFACE EXTRACE, P181; TAN J, 1995, GLYCOCONJUGATE J, V12, P478; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; YAMADA N, 1995, BLOOD, V85, P885, DOI 10.1182/blood.V85.4.885.bloodjournal854885; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; Yeh E T, 1994, Semin Immunol, V6, P73, DOI 10.1006/smim.1994.1011; YOMTOVIAN R, 1993, TRANSFUSION, V33, P852, DOI 10.1046/j.1537-2995.1993.331094054626.x; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T	48	78	93	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1995	9	14					1436	1444		10.1096/fasebj.9.14.7589985	http://dx.doi.org/10.1096/fasebj.9.14.7589985			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589985				2022-12-28	WOS:A1995TF67800008
J	HANKS, SK; HUNTER, T				HANKS, SK; HUNTER, T			PROTEIN KINASES .6. THE EUKARYOTIC PROTEIN-KINASE SUPERFAMILY - KINASE (CATALYTIC) DOMAIN-STRUCTURE AND CLASSIFICATION	FASEB JOURNAL			English	Review						PROTEIN-TYROSINE KINASE; PROTEIN-SERINE KINASE; PROTEIN PHOSPHORYLATION; AMP-DEPENDENT PROTEIN KINASE		The eukaryotic protein kinases make up a large superfamily of homologous proteins. They are related by virtue of their kinase domains (also known as catalytic domains), which consist of approximate to 250-300 amino acid residues. The kinase domains that define this group of enzymes contain 12 conserved subdomains that fold into a common catalytic core structure, as revealed by the 3-dimensional structures of several protein-serine kinases. There are two main subdivisions within the superfamily: the protein-serine/threonine kinases and the protein-tyrosine kinases. A classification scheme can be founded on a kinase domain phylogeny, which reveals families of enzymes that have related substrate specificities and modes of regulation.	SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Salk Institute; Vanderbilt University								HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0	1	2187	2446	9	178	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					576	596		10.1096/fasebj.9.8.7768349	http://dx.doi.org/10.1096/fasebj.9.8.7768349			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768349				2022-12-28	WOS:A1995RC10600003
J	KLEINNULEND, J; VANDERPLAS, A; SEMEINS, CM; AJUBI, NE; FRANGOS, JA; NIJWEIDE, PJ; BURGER, EH				KLEINNULEND, J; VANDERPLAS, A; SEMEINS, CM; AJUBI, NE; FRANGOS, JA; NIJWEIDE, PJ; BURGER, EH			SENSITIVITY OF OSTEOCYTES TO BIOMECHANICAL STRESS IN-VITRO	FASEB JOURNAL			English	Article						HYDROSTATIC COMPRESSION; FLUID FLOW; FLUID SHEAR STRESS; PROSTAGLANDINS	BONE LOADING INVIVO; FUNCTIONAL STRAINS; SHEAR-STRESS; PROSTAGLANDIN-E2; CELLS; FLOW	It has been known for more than a century that bone tissue adapts to functional stress by changes in structure and mass, However, the mechanism by which stress is translated into cellular activities of bone formation and resorption is unknown, We studied the response of isolated osteocytes derived from embryonic chicken calvariae to intermittent hydrostatic compression as well as pulsating fluid flow, and compared their response to osteoblasts and periosteal fibroblasts. Osteocytes, but not osteoblasts or periosteal fibroblasts, reacted to 1 h pulsating fluid flow with a sustained release of prostaglandin E(2). Intermittent hydrostatic compression stimulated prostaglandin production to a lesser extent: after 6 and 24 h in osteocytes and after 6 h in osteoblasts. These data provide evidence that osteocytes are the most mechanosensitive cells in bone involved in the transduction of mechanical stress into a biological response. The results support the hypothesis that stress on bone causes fluid flow in the lacunar-canalicular system, which stimulates the osteocytes to produce factors that regulate bone metabolism.	LEIDEN UNIV,DEPT CELL BIOL,LEIDEN,NETHERLANDS; PENN STATE UNIV,DEPT CHEM ENGN,UNIVERSITY PK,PA 16802	Leiden University; Leiden University - Excl LUMC; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	KLEINNULEND, J (corresponding author), FREE UNIV AMSTERDAM,ACTA,DEPT ORAL CELL BIOL,VAN BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.							BASSETT CAL, 1991, ELECTROMAGNETICS IN MEDICINE AND BIOLOGY, P1; BASSETT CAL, 1962, SCIENCE, V137, P1063, DOI 10.1126/science.137.3535.1063; BERTRAM JEA, 1991, BIOL REV, V66, P245, DOI 10.1111/j.1469-185X.1991.tb01142.x; BURGER EH, 1993, BONE, V0007, P00037; Cowin, 1991, ADV BIOENGIN, V20, P313; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5; KLEINNULEND J, 1986, ARTHRITIS RHEUM-US, V29, P1002, DOI 10.1002/art.1780290809; KRUYT HR, 1960, INTRO PHYSICAL CHEM; KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021-9290(90)90350-C; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NIJWEIDE PJ, 1981, CALCIFIED TISSUE INT, V33, P529, DOI 10.1007/BF02409485; Pauwels F, 1980, BIOMECHANICS LOCOMOT; PEAD MJ, 1988, CALCIFIED TISSUE INT, V43, P92, DOI 10.1007/BF02555153; PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1990, J BIOMECH, V23, P43, DOI 10.1016/0021-9290(90)90040-A; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; SALZSTEIN RA, 1987, J BIOMECH, V20, P271, DOI 10.1016/0021-9290(87)90294-6; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9; THOMPSON DD, 1988, J BONE MINER RES, V3, P409; TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANDERPLAS A, 1994, J BONE MINER RES, V9, P1697; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Wolff J, 1892, GESETZ TRANSFORMATIO	32	577	596	2	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					441	445		10.1096/fasebj.9.5.7896017	http://dx.doi.org/10.1096/fasebj.9.5.7896017			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896017				2022-12-28	WOS:A1995QP45100020
J	WARREN, JB; LOI, RK				WARREN, JB; LOI, RK			CAPTOPRIL INCREASES SKIN MICROVASCULAR BLOOD-FLOW SECONDARY TO BRADYKININ, NITRIC-OXIDE, AND PROSTAGLANDINS	FASEB JOURNAL			English	Article						ANGIOTENSIN CONVERTING ENZYME; CYCLOOXYGENASE; HEART FAILURE; VASODILATION; ENDOTHELIUM	ANGIOTENSIN-CONVERTING ENZYME; ENDOTHELIUM-DERIVED BRADYKININ; MOLECULAR-WEIGHT KININOGEN; VASCULAR-RESPONSES; HEART-FAILURE; RABBIT SKIN; INHIBITION; CELLS; MICROCIRCULATION; POTENT	Angiotensin converting enzyme inhibitors (ACEIs) are a cornerstone of treatment of hypertension and heart failure yet their mechanism of action is still debated. This study was designed to test whether the ACEI captopril increases skin microvascular blood flow by a bradykinin-dependent mechanism. Local changes in microvascular blood flow were measured in the skin of rabbits and of human volunteers using a laser Doppler flow probe. Captopril injected intradermally increased skin blood flow over the dose range of 10(-12)-10(-8) mol site in rabbits and humans. In both species the response was abolished by coinjecting either a nitric oxide synthase (NOS) inhibitor or a cyclooxygenase inhibitor. Intradermal bradykinin also increased rabbit skin microvascular blood flow; at 10(-11) mol site it increased mean +/- SE basal blood flow by 88 +/- 12%. The responses to bradykinin or captopril were abolished by coinjecting a bradykinin antagonist, a specific bradykinin B-2 receptor antagonist, or inhibitors of NOS or cyclooxygenase. Injecting a specific angiotensin II receptor antagonist at a dose that antagonized the constrictor effects of exogenous angiotensin II did not cause a significant increase in rabbit skin blood flow. This suggests that endogenous angiotensin II does not influence microvascular blood flow in this model. The results indicate that captopril increases skin microvascular blood flow in rabbits and humans secondary to an increase in endogenous tissue bradykinin; this stimulates B-2 receptors with subsequent release of prostaglandins and nitric oxide, ACEIs may increase microvascular perfusion by a bradykinin-dependent mechanism.			WARREN, JB (corresponding author), NATL HEART & LUNG INST, DEPT APPL PHARMACOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.							BENJAMIN N, 1989, J PHYSIOL-LONDON, V412, P543, DOI 10.1113/jphysiol.1989.sp017630; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; CHATTERJEE K, 1987, Cardiovascular Drugs and Therapy, V1, P1, DOI 10.1007/BF02125827; CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; EDWARDS RM, 1983, AM J PHYSIOL, V244, pF526, DOI 10.1152/ajprenal.1983.244.5.F526; FERREIRA SH, 1965, BRIT J PHARM CHEMOTH, V24, P163, DOI 10.1111/j.1476-5381.1965.tb02091.x; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P88, DOI 10.1111/j.1365-2125.1987.tb03014.x; GERRITSEN ME, 1983, J CLIN INVEST, V72, P1658, DOI 10.1172/JCI111125; HILDITCH A, 1994, BRIT J PHARMACOL, V111, P137, DOI 10.1111/j.1476-5381.1994.tb14035.x; KALEY G, 1989, AM J PHYSIOL, V256, pH720, DOI 10.1152/ajpheart.1989.256.3.H720; KIOWSKI W, 1992, CIRCULATION, V85, P1; KOLLER A, 1989, AM J PHYSIOL, V257, pH1966, DOI 10.1152/ajpheart.1989.257.6.H1966; LAMMEK B, 1990, PEPTIDES, V11, P1041, DOI 10.1016/0196-9781(90)90031-Y; LAMONTAGNE D, 1992, J CARDIOVASC PHARM, V20, P652, DOI 10.1097/00005344-199210000-00020; LINZ W, 1990, J CARDIOVASC PHARM, V15, pS99, DOI 10.1097/00005344-199015061-00018; MACFADYEN RJ, 1991, BRIT J CLIN PHARMACO, V31, P1; MANINTVELD AJ, 1979, BRIT MED J, V2, P1110, DOI 10.1136/bmj.2.6198.1110; Messina E J, 1980, Adv Prostaglandin Thromboxane Res, V7, P719; MOORE TJ, 1981, HYPERTENSION, V3, P168, DOI 10.1161/01.HYP.3.2.168; MOOSER V, 1990, J CARDIOVASC PHARM, V15, P276, DOI 10.1097/00005344-199002000-00015; MORAVEC CS, 1990, CIRCULATION, V82, P1973, DOI 10.1161/01.CIR.82.6.1973; NISHIMURA H, 1989, AM HEART J, V117, P100, DOI 10.1016/0002-8703(89)90662-5; NUSSBERGER J, 1985, HYPERTENSION, V7, pI1, DOI 10.1161/01.HYP.7.3_Pt_2.I1; PONS F, 1993, EUR J PHARMACOL, V239, P23, DOI 10.1016/0014-2999(93)90971-J; PORSTI I, 1994, BRIT J PHARMACOL, V111, P652; RIVERS RJ, 1990, AM J PHYSIOL, V258, pH606, DOI 10.1152/ajpheart.1990.258.2.H606; ROBERTSON MJ, 1992, BRIT J PHARMACOL, V107, P1173, DOI 10.1111/j.1476-5381.1992.tb13425.x; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SWARTZ SL, 1980, J CLIN INVEST, V65, P1257, DOI 10.1172/JCI109788; SWARTZ SL, 1982, AM J CARDIOL, V49, P1405, DOI 10.1016/0002-9149(82)90351-4; TONEY GM, 1993, NEUROPHARMACOLOGY, V32, P581, DOI 10.1016/0028-3908(93)90054-7; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WARREN JB, 1993, FASEB J, V7, P1394, DOI 10.1096/fasebj.7.14.7693536; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; WARREN JB, 1994, AM J PHYSIOL, V266, pH1846, DOI 10.1152/ajpheart.1994.266.5.H1846; WIEMER G, 1992, AGENT ACTION SUPPL, V38, P196; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; WIEMER G, 1994, CARDIOVASC RES, V28, P166, DOI 10.1093/cvr/28.2.166; WILSON AJ, 1993, BRIT J PHARMACOL, V110, P633, DOI 10.1111/j.1476-5381.1993.tb13858.x; WOLIN MS, 1990, J PHARMACOL EXP THER, V254, P872	44	42	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					411	418		10.1096/fasebj.9.5.7896012	http://dx.doi.org/10.1096/fasebj.9.5.7896012			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896012				2022-12-28	WOS:A1995QP45100015
J	PRONCZUK, A; KHOSLA, P; HAYES, KC				PRONCZUK, A; KHOSLA, P; HAYES, KC			DIETARY MYRISTIC, PALMITIC, AND LINOLEIC CHOLESTEROLEMIA IN GERBILS	FASEB JOURNAL			English	Article						FATTY ACIDS; PLASMA CHOLESTEROL; REGRESSION ANALYSIS; THRESHOLD	LOW-DENSITY-LIPOPROTEIN; ESSENTIAL FATTY-ACID; PLASMA-CHOLESTEROL; LDL-CHOLESTEROL; SERUM-LIPIDS; METABOLISM; MONKEYS; REQUIREMENT; SATURATION; RECEPTOR	Previous studies with cebus monkeys and review of published human data indicated that 85% to 90% of the variation in plasma cholesterol (TC) could be explained on the basis of dietary myristic (14:0) and linoleic (18:2) acid intake in the absence of cholesterol, and that 16:0 contributed to cholesterolemia as dietary cholesterol was increased. Because monkeys are a limited resource, a more convenient, sensitive model was sought for investigating these dietary fatty acid and plasma lipid relationships. Accordingly this report describes the results of multiple regression analysis bf the TC response to dietary fatty acids based on 319 young, male Mongolian gerbils fed a total of 59 purified diets supplying about 40% energy as fat from single or blended fat sources. Gerbils (6-16 animals per dietary group) were fed purified diets (21 with 0.01 to 0.08% cholesterol and 38 cholesterol-free) for 4-week periods. When cholesterol-free diets were fed, dietary 14:0 and 18:2 together accounted for 89% of the observed variation in TC. Although 14:0 consumption increased TC in a linear manner, the independent ability of 18:2 to lower cholesterol was nonlinear and exhibited a threshold effect at 5-6% dietary energy above which further lowering of TC was less remarkable. In gerbils consuming cholesterol-supplemented diets, 87% of the observed variation in TC could be accounted for by a regression equation that included 14:0, palmitic acid (16:0), and a log function of 18:2 plus dietary cholesterol itself. These results demonstrate the applicability of gerbils for such studies and confirm previous observations in monkeys and humans that dietary 14:0 and 18:2 are the main fatty acids modulating plasma cholesterol under normocholesterolemic circumstances when consuming low-cholesterol diets and lipoprotein metabolism is normal) whereas 16:0 also appears modestly hypercholesterolemic when LDL receptors are compromised (i.e., when dietary cholesterol or certain metabolic factors have encumbered lipoprotein metabolism).	BRANDEIS UNIV,FOSTER BIOMED RES LAB,WALTHAM,MA 02254	Brandeis University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRONTESTEWART B, 1956, LANCET, V1, P521; CHRISTOPHE A, 1978, ARCH INT PHYSL BIOCH, V86, P414; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DIFRANCESCO I, 1990, ACTA CARDIOL, V45, P233; DUPONT J, 1990, J AM COLL NUTR, V9, P272; FIELDING CJ, 1992, FASEB J, V6, P3162, DOI 10.1096/fasebj.6.13.1327930; FUNGWE TV, 1992, J LIPID RES, V33, P179; GRUNDY SM, 1989, J NUTR, V119, P529, DOI 10.1093/jn/119.4.529; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HAYES KC, 1991, AM J CLIN NUTR, V53, P491, DOI 10.1093/ajcn/53.2.491; HAYES KC, 1992, FASEB J, V6, P2600, DOI 10.1096/fasebj.6.8.1592210; HAYES KC, 1992, J NUTR, V122, P374, DOI 10.1093/jn/122.2.374; HAYES KC, 1994, IN PRESS J NUTR BIOC; HAYES KC, 1990, NEW ENGL J MED, V321, P402; Hegsted D. M., 1991, Health effects of dietary fatty acids., P50; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1967, J LIPID RES, V8, P210; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; IP C, 1985, CANCER RES, V45, P1997; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1957, LANCET, V2, P959; KHOSLA P, 1993, BIOCHIM BIOPHYS ACTA, V1210, P13, DOI 10.1016/0005-2760(93)90043-9; KHOSLA P, 1992, AM J CLIN NUTR, V55, P51, DOI 10.1093/ajcn/55.1.51; KHOSLA P, 1991, BIOCHIM BIOPHYS ACTA, V1083, P46, DOI 10.1016/0005-2760(91)90123-Y; Khosla P, 1993, Metabolism, V42, P915, DOI 10.1016/0026-0495(93)90070-5; KRISETHERTON PM, 1993, METABOLISM, V42, P121, DOI 10.1016/0026-0495(93)90182-N; KRITCHEVSKY D, 1988, NUTR REV, V46, P177, DOI [10.1111/j.1753-4887.1988.tb05419.x, 10.1301/nr.2004.may.177-203]; Lands W. E. M., 1991, Health effects of dietary fatty acids., P21; LEPAGE G, 1986, J LIPID RES, V27, P114; MATTSON FH, 1985, J LIPID RES, V26, P194; MCGANDY RB, 1970, AM J CLIN NUTR, V23, P1288; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MERCER NJH, 1979, LIPIDS, V14, P1009, DOI 10.1007/BF02533438; MUKHERJEE S, 1969, J ATHEROSCLER RES, V10, P51, DOI 10.1016/S0368-1319(69)80081-5; NG TKW, 1992, J AM COLL NUTR, V11, P383; NICOLOSI RJ, 1981, ATHEROSCLEROSIS, V38, P359, DOI 10.1016/0021-9150(81)90052-6; NICOLOSI RJ, 1990, ARTERIOSCLEROSIS, V10, P119, DOI 10.1161/01.ATV.10.1.119; PRONCZUK A, 1991, LIPIDS, V26, P213, DOI 10.1007/BF02543974; RASSIAS G, 1991, EUR J CLIN NUTR, V45, P315; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SUNDRAM K, 1994, AM J CLIN NUTR, V59, P841, DOI 10.1093/ajcn/59.4.841; THOLSTRUP T, 1994, AM J CLIN NUTR, V59, P371, DOI 10.1093/ajcn/59.2.371; WEINGAND KW, 1990, CLIN CHEM, V36, P575; ZOCK PL, 1994, ARTERIOSCLER THROMB, V14, P567, DOI 10.1161/01.ATV.14.4.567; 1989, IMPLICATIONS REDUCIN	45	47	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1191	1200		10.1096/fasebj.8.14.7958627	http://dx.doi.org/10.1096/fasebj.8.14.7958627			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958627				2022-12-28	WOS:A1994PT12800016
J	NEUBIG, RR				NEUBIG, RR			MEMBRANE ORGANIZATION IN G-PROTEIN MECHANISMS	FASEB JOURNAL			English	Review						ADRENERGIC RECEPTOR; DIFFUSION; FLUORESCENCE; CYTOSKELETON; MEMBRANE FLUIDITY; PLECKSTRIN HOMOLOGY	BETA-ADRENERGIC-RECEPTOR; GTP-BINDING PROTEINS; RECONSTITUTED PHOSPHOLIPID-VESICLES; NUCLEOTIDE REGULATORY PROTEINS; TERNARY COMPLEX MODEL; ADENYLATE-CYCLASE; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; PLASMA-MEMBRANE; EPITHELIAL-CELLS	A prevailing view of receptor and G-protein function in cells includes random collisions between the proteins with a great specificity at the sites of protein-protein interaction. Recent evidence suggests that receptors, G-proteins, and effecters may be less mobile and that these systems are more highly organized than previously appreciated. Several types of evidence suggest that receptors do not have free access to all G-protein with which they are capable of coupling. Also, the specificity of signaling in intact cells appears to be significantly greater than in reconstituted systems. The distribution and mobility of G-proteins in cells are restricted to a surprising degree. Thus, complex interactions of the receptors and G-proteins with their effecters and cell membrane machinery appear to play an important role in their function. A full understanding of G-protein-coupled receptors must include a better description of the organization of these systems in cell membranes. Possible roles for noncoated pits (caveolae) and a novel pleckstrin homology domain need to be examined.	UNIV MICHIGAN, DEPT INTERNAL MED HYPERTENS, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	NEUBIG, RR (corresponding author), UNIV MICHIGAN, DEPT PHARMACOL, M6322 MED SCI BLDG 1, ANN ARBOR, MI 48109 USA.			Neubig, Richard/0000-0003-0501-0008	NIGMS NIH HHS [GM 39561] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONIN N, 1992, J NEUROSCI, V12, P3435; ASANO T, 1989, J NEUROCHEM, V53, P1195, DOI 10.1111/j.1471-4159.1989.tb07414.x; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5467, DOI 10.1021/bi00318a014; ATLAS D, 1980, BIOCHIM BIOPHYS ACTA, V597, P64, DOI 10.1016/0005-2736(80)90150-9; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; AXELROD D, 1983, J MEMBRANE BIOL, V75, P1, DOI 10.1007/BF01870794; Birnbaumer L, 1970, Adv Biochem Psychopharmacol, V3, P185; BOURGUIGNON LYW, 1990, J IMMUNOL, V144, P2242; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAUN S, 1979, BIOCHEMISTRY-US, V18, P2134, DOI 10.1021/bi00577a045; BROWN AM, 1991, FASEB J, V5, P2175, DOI 10.1096/fasebj.5.8.1708737; BRUNSKILL N, 1991, KIDNEY INT, V40, P997, DOI 10.1038/ki.1991.307; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CARLSON KE, 1986, MOL PHARMACOL, V30, P463; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CERIONE RA, 1991, METHOD ENZYMOL, V195, P329; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V1071, P473, DOI 10.1016/0304-4157(91)90007-J; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHIN GJ, 1990, BRAIN RES, V508, P265, DOI 10.1016/0006-8993(90)90405-Z; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DASSO LLT, 1992, MOL PHARMACOL, V42, P453; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GANTZOS RD, 1988, BIOCHEM PHARMACOL, V37, P2815, DOI 10.1016/0006-2952(88)90045-7; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GROSS W, 1991, MOL PHARMACOL, V39, P524; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENIS YI, 1989, TRENDS PHARMACOL SCI, V10, P95, DOI 10.1016/0165-6147(89)90201-0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; HOUSLAY MD, 1986, BIOCHEM J, V238, P109, DOI 10.1042/bj2380109; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; KWON G, 1994, IN PRESS CELL SIGNAL; LEFKOWITZ RJ, 1986, CURR TOP CELL REGUL, V28, P209; LEVITZKI A, 1985, BIOCHIM BIOPHYS ACTA, V822, P127, DOI 10.1016/0304-4157(85)90005-X; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MAY DC, 1985, J BIOL CHEM, V260, P5829; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUELLER H, 1991, J BIOL CHEM, V266, P12939; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKAMURA SI, 1991, P NATL ACAD SCI USA, V88, P7150, DOI 10.1073/pnas.88.16.7150; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBIG RR, 1985, MOL PHARMACOL, V28, P475; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; NEUBIG RR, 1987, MEMBRANE PROTEINS, P619; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ORLY J, 1976, P NATL ACAD SCI USA, V73, P4410, DOI 10.1073/pnas.73.12.4410; PERALDI S, 1989, J NEUROSCI, V9, P806; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POSNER RG, 1994, MOL PHARMACOL, V45, P65; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RASENICK MM, 1988, J NEUROCHEM, V51, P300, DOI 10.1111/j.1471-4159.1988.tb04870.x; RASENICK MM, 1990, ADV SEC MESS PHOSPH, V24, P381; RASENICK MM, 1985, MICROTUBULES MICROTU, P313; REMMERS AE, 1993, BIOCHEMISTRY-US, V32, P2409, DOI 10.1021/bi00060a036; RIMON G, 1978, NATURE, V276, P394, DOI 10.1038/276394a0; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; SCHULZE W, 1991, EUR HEART J, V12, P132, DOI 10.1093/eurheartj/12.suppl_F.132; SCHURMANN A, 1992, BIOCHEM J, V283, P795, DOI 10.1042/bj2830795; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SHINOHARA H, 1992, ACTA ANAT, V144, P167; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SIMMONS MA, 1991, J NEUROSCI, V11, P2130; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214	105	328	333	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					939	946		10.1096/fasebj.8.12.8088459	http://dx.doi.org/10.1096/fasebj.8.12.8088459			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088459	Green Submitted			2022-12-28	WOS:A1994PG29300006
J	MORTON, ME; CASSIDY, TN; FROEHNER, SC; GILMOUR, BP; LAURENS, RL				MORTON, ME; CASSIDY, TN; FROEHNER, SC; GILMOUR, BP; LAURENS, RL			ALPHA(1) AND ALPHA(2) CA2+ CHANNEL SUBUNIT EXPRESSION IN HUMAN NEURONAL AND SMALL-CELL CARCINOMA-CELLS	FASEB JOURNAL			English	Article						LAMBERT-EATON SYNDROME; CALCIUM CHANNEL; NEUROBLASTOMA	EATON MYASTHENIC SYNDROME; SENSITIVE CALCIUM-CHANNEL; MEMBRANE ACTIVE ZONES; MOTOR-NERVE TERMINALS; LUNG-CARCINOMA; MONOCLONAL-ANTIBODY; OMEGA-CONOTOXIN; TUMOR-CELLS; IGG; ALPHA-1-SUBUNIT	Monoclonal antibodies that recognize skeletal muscle dihydropyridine-sensitive calcium channel subunits were used to identify similar proteins in neuronal and small cell carcinoma cell lines. alpha(1)-related proteins were detected by FACS analysis on the surface of human neuroblastoma (IMR 32) and small cell carcinoma (DMS 273 and DMS 114) cell lines. alpha(1)-like polypeptides from these cells were isolated and partially characterized. The polypeptides exhibit an M(r) similar to that of the L-type channel alpha(1) subunit and are recognized by two distinct anti-alpha(1) mAbs. The data provide biochemical evidence for structural similarities between the alpha(1) subunit of small cell carcinoma and neuronal cell lines. Similarly, an alpha(2)-like protein was characterized from these cells. Because alpha(2) is a subunit shared by many subtypes of calcium channels, these data suggest that subunits other than the pore-forming alpha(1) subunit may play an important role in etiology of Lambert-Eaton syndrome. We demonstrate directly that small cell carcinoma and a cell line derived from peripheral neurons share L-type calcium channel-related proteins and a protein common to many voltage-gated calcium channel subtypes. These data support a model that proposes that cross-reactivity of anti-tumor cell antibodies with presynaptic elements, possibly calcium channels, plays a role in the development of Lambert-Eaton syndrome.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03756; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	Dartmouth College; University of North Carolina; University of North Carolina Chapel Hill	MORTON, ME (corresponding author), COLL HOLY CROSS,DEPT BIOL,WORCESTER,MA 01610, USA.							BALL ED, 1987, CANCER RES, V47, P6556; BERGH J, 1985, AM J CLIN PATHOL, V84, P1; COHEN MW, 1991, J NEUROSCI, V11, P1032; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; FUKUNAGA H, 1982, MUSCLE NERVE, V5, P686, DOI 10.1002/mus.880050905; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LAMBERT EH, 1982, MUSCLE NERVE, V5, pS39; LAMBERT EH, 1971, ANN NY ACAD SCI, V183, P183, DOI 10.1111/j.1749-6632.1971.tb30750.x; LANG B, 1981, LANCET, V2, P224; LANG B, 1989, ANN NEUROL, V25, P265, DOI 10.1002/ana.410250310; LANG B, 1983, J PHYSIOL-LONDON, V344, P335, DOI 10.1113/jphysiol.1983.sp014943; LOGIN IS, 1987, ANN NEUROL, V22, P610, DOI 10.1002/ana.410220509; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MORTON ME, 1987, J BIOL CHEM, V262, P11904; MORTON ME, 1988, J BIOL CHEM, V263, P613; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; PANCRAZIO JJ, 1989, CANCER RES, V49, P5901; PEERS C, 1990, J PHYSIOL-LONDON, V421, P293, DOI 10.1113/jphysiol.1990.sp017945; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SEAGAR MJ, 1993, BIOCHEM SOC T, V21, P423, DOI 10.1042/bst0210423; SHER E, 1990, CANCER RES, V50, P3892; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; TAPIA FJ, 1981, LANCET, V1, P808; TISCHLER AS, 1977, J PATHOL, V122, P153, DOI 10.1002/path.1711220306; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4	32	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					884	888		10.1096/fasebj.8.11.8070639	http://dx.doi.org/10.1096/fasebj.8.11.8070639			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070639				2022-12-28	WOS:A1994PC88500013
J	TURNER, CH; FORWOOD, MR; OTTER, MW				TURNER, CH; FORWOOD, MR; OTTER, MW			MECHANOTRANSDUCTION IN BONE - DO BONE-CELLS ACT AS SENSORS OF FLUID-FLOW	FASEB JOURNAL			English	Article						FREQUENCY; BONE ADAPTATION; HISTOMORPHOMETRY; RATS	ELECTROMECHANICAL POTENTIALS; STREAMING POTENTIALS; MECHANICAL STRAIN; CORTICAL BONE; STRESS; MASS; RAT	When compact bone is subjected to bending loads, interstitial fluid in the bone matrix flows away from regions of high compressive stress. The amount of interstitial fluid flow is strongly influenced by the loading rate in a dose-dependent fashion. We hypothesize that interstitial fluid flow affects bone formation, and we tested this hypothesis indirectly by measuring the effect of different loading frequencies on bone formation rate in vivo. The right tibiae of adult female rats were subjected to applied bending at frequencies of 0.05, 0.1, 0.2, 0.5, 1.0, and 2.0 Hz for a 2-wk period. The rats were then killed and histomorphometric measurements of bone formation were made of the midshaft of the tibia. Bending of the tibia increased bone formation rate in the higher-frequency (0.5 to 2.0 Hz) loading groups as much as fourfold, yet no increase in bone formation rate was observed for loading frequencies below 0.5 Hz. In a separate experiment, we found stress-generated potentials (SGP) in the rat tibia to increase monotonically with increasing loading frequency. The dose-response relationship between loading frequency and the bone formation response closely resembles the relationship between loading frequency and SGP within bone. The qualitative similarity between these two relationships suggests that increased bone formation is associated with increased SGP, which are caused by interstitial fluid flow. Bone cells are known to be sensitive to electric fields and may respond directly to SGP. Also, fluid shear forces have been shown to stimulate bone cells in culture, so it is possible that increased interstitial fluid flow directly affects bone formation.	HELEN HAYES HOSP,ORTHOPAED ENGN & RES CTR,W HAVERSTRAW,NY 10993		TURNER, CH (corresponding author), INDIANA UNIV,MED CTR,DEPT ORTHOPAED SURG,541 CLIN DR,RM 600,INDIANAPOLIS,IN 46202, USA.		Forwood, Mark/ABA-9040-2021	Forwood, Mark/0000-0002-9963-1616	NIAMS NIH HHS [AR40688] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040688] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arnaud SB, 1988, J BONE MINER RES, V3, pS119; BERTRAM JEA, 1991, BIOL REV, V66, P245, DOI 10.1111/j.1469-185X.1991.tb01142.x; BINDERMAN I, 1984, CALCIFIED TISSUE INT, V36, pS82, DOI 10.1007/BF02406139; BURGER EH, 1993, BONE, V0007, P00037; BURR DB, 1989, BONE, V10, P223, DOI 10.1016/8756-3282(89)90057-4; DILLAMAN RM, 1991, J BIOMECH, V24, P163, DOI 10.1016/0021-9290(91)90386-2; DONALDSON C L, 1970, Metabolism Clinical and Experimental, V19, P1071, DOI 10.1016/0026-0495(70)90032-6; ERIKSSON C, 1974, ANN NY ACAD SCI, V238, P321, DOI 10.1111/j.1749-6632.1974.tb26801.x; FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104; GROSS TS, 1992, T ORTHOP RES SOC, V17, P96; HARRIGAN TP, 1993, J BIOMECH, V26, P183, DOI 10.1016/0021-9290(93)90048-J; HERT J, 1969, FOLIA MORPHOL PRAGUE, V27, P389; JAWORSKI ZFG, 1986, BONE, V7, P431, DOI 10.1016/8756-3282(86)90003-7; JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021-9290(84)90003-4; LI XJ, 1990, ANAT RECORD, V227, P12, DOI 10.1002/ar.1092270103; MACK PB, 1967, AM J CLIN NUTR, V20, P1194, DOI 10.1093/ajcn/20.11.1194; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; OTTER MW, 1992, J ORTHOPAED RES, V10, P710, DOI 10.1002/jor.1100100513; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; ROER RD, 1990, J APPL PHYSIOL, V68, P13, DOI 10.1152/jappl.1990.68.1.13; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; SALZSTEIN RA, 1987, J BIOMECH, V20, P271, DOI 10.1016/0021-9290(87)90294-6; SALZSTEIN RA, 1987, J BIOMECH, V20, P261, DOI 10.1016/0021-9290(87)90293-4; SCOTT GC, 1990, J BIOMECH, V23, P127, DOI 10.1016/0021-9290(90)90347-6; SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9; TURNER CH, 1994, J BONE MINER RES, V9, P87; TURNER CH, 1991, BONE, V12, P203, DOI 10.1016/8756-3282(91)90043-I; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Wolff J, 1892, GESETZ TRANSFORMATIO	31	292	301	1	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					875	878		10.1096/fasebj.8.11.8070637	http://dx.doi.org/10.1096/fasebj.8.11.8070637			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070637				2022-12-28	WOS:A1994PC88500011
J	ROSE, JR; SALTO, R; CRAIK, CS				ROSE, JR; SALTO, R; CRAIK, CS			REGULATION OF AUTOPROTEOLYSIS OF HIV PROTEASES WITH ENGINEERED AMINO-ACID SUBSTITUTIONS	FASEB JOURNAL			English	Meeting Abstract									UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Abrams, William R/A-5782-2008; Salto, Rafael/A-6486-2011	Salto, Rafael/0000-0002-7044-3611	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, R01AR041474] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26499] Funding Source: Medline; NIAMS NIH HHS [AR41474, AR20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))			0	475	493	2	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 20	1993	7	7					A1208	A1208		10.1096/fasebj.7.13.8405806	http://dx.doi.org/10.1096/fasebj.7.13.8405806			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY848	8405806				2022-12-28	WOS:A1993KY84800985
J	PINARD, R; PAYANT, C; MELANCON, P; BRAKIERGINGRAS, L				PINARD, R; PAYANT, C; MELANCON, P; BRAKIERGINGRAS, L			THE 5' PROXIMAL HELIX OF 16S RIBOSOMAL-RNA IS INVOLVED IN THE BINDING OF STREPTOMYCIN TO THE RIBOSOME	FASEB JOURNAL			English	Article						16S RIBOSOMAL-RNA; STREPTOMYCIN; CONFORMATIONAL SWITCHES	ESCHERICHIA-COLI; DIHYDROSTREPTOMYCIN BINDING; CROSS-LINKING; 915 REGION; RNA GENES; MUTATIONS; SUBUNITS; MODEL; SITE	Single mutations at the end of the 5' proximal helix and in the 915 region (13U --> A or C; 914A --> U or G), and double mutations (13U --> A and 914A --> U; 13U --> C and 914A --> G) were constructed into Escherichia coli 16S ribosomal RNA. The mutations were introduced into an expression plasmid containing the rrnB operon under the transcriptional control of the temperature-inducible lambdaP(L) promoter. None of the mutant 16S rRNAs affected cell growth when expressed. Ribosomes extracted after induction of expression of the mutant 16S rRNAs were assayed for their capacity to bind the error-inducing drug streptomycin and for translational misreading in the presence of streptomycin. All mutations impaired the binding of streptomycin, and consequently its capacity to stimulate misreading. Our results demonstrate the involvement of the 5' proximal helix of 16S rRNA in the binding of streptomycin and confirm the participation of the 915 region. They do not support a previous suggestion [Leclerc, D. and Brakier-Gingras, L. (1991) FEBS Lett., Vol. 279, pp. 171-174] that base pairing between nucleotides 13 and 914 stabilizes the binding of streptomycin.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; BISWAS DK, 1972, P NATL ACAD SCI USA, V69, P2141, DOI 10.1073/pnas.69.8.2141; BOCK A, 1979, FEBS LETT, V104, P317, DOI 10.1016/0014-5793(79)80842-X; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GARVIN RT, 1974, P NATL ACAD SCI USA, V71, P3814, DOI 10.1073/pnas.71.10.3814; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRAVEL M, 1987, BIOCHEMISTRY-US, V26, P6227, DOI 10.1021/bi00393a041; HARRIS EH, 1989, GENETICS, V123, P281; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P376; LECLERC D, 1991, BIOCHIMIE, V73, P1431, DOI 10.1016/0300-9084(91)90175-Z; LECLERC D, 1990, BIOCHEM CELL BIOL, V68, P169, DOI 10.1139/o90-023; LECLERC D, 1991, FEBS LETT, V279, P171, DOI 10.1016/0014-5793(91)80141-O; LECLERC D, 1991, NUCLEIC ACIDS RES, V19, P3973, DOI 10.1093/nar/19.14.3973; MELANCON P, 1984, BIOCHEMISTRY-US, V23, P6697, DOI 10.1021/bi00321a064; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1986, STRUCTURE FUNCTION G, P143; OCONNOR M, 1991, BIOCHIMIE, V73, P1493, DOI 10.1016/0300-9084(91)90183-2; OZAKI M, 1969, NATURE, V222, P333, DOI 10.1038/222333a0; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; Sambrook J, 1989, MOL CLONING LABORATO; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; [No title captured]	28	33	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					173	176		10.1096/fasebj.7.1.7678560	http://dx.doi.org/10.1096/fasebj.7.1.7678560			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678560				2022-12-28	WOS:A1993KH88000026
J	SANDBERG, JA; SLIKKER, W				SANDBERG, JA; SLIKKER, W			DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY OF ANTI-HIV THERAPEUTIC AGENTS - DIDEOXYNUCLEOSIDES	FASEB JOURNAL			English	Article						FETAL EXPOSURE; PLACENTAL PERFUSION; PREGNANCY	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; CELLULAR PHARMACOLOGY; ZIDOVUDINE AZT; REVERSE-TRANSCRIPTASE; COMBINATION THERAPY; AZIDOTHYMIDINE AZT; NUCLEOSIDE ANALOGS	As the incidence of human immunodeficiency virus (HIV) infection has increased in women over the past decade, the need for safe, effective therapy during pregnancy has increased concomitantly, Although dideoxynucleosides such as 3'-deoxy-3'-azidothymidine (AZT), 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), and 2',3'-didehydro-3'-deoxythymidine have been approved for use in the general population, the administration, efficacy, and toxicity of these compounds during pregnancy and development are now being investigated. Initial human studies suggest that maternal use of AZT during pregnancy is well tolerated by both mother and child and provides a promising degree of protection from vertical HIV transmission to the infant. In vitro and animal models have greatly increased our understanding of the distribution and toxicity resulting from fetal dideoxynucleoside exposure. AZT, ddI, and ddC rapidly cross the placenta by simple diffusion but with different rates of transfer. In vivo data confirm the differential transfer of these compounds with AZT fetal exposure approximately twice that of ddI or ddC. Active phosphorylated metabolites have been detected in placental tissue after in vitro perfusion with AZT. The active triphosphate has not been detected in placental perfusion studies or in the fetal rhesus monkey 3 h after maternal exposure to ddI or ddC. Although in vitro and in vivo laboratory animal studies suggest the potential for toxicity with preimplantation exposure, the risk for teratogenic events after postimplantational exposure appears to be low at therapeutically effective concentrations of these dideoxynucleosides.			SANDBERG, JA (corresponding author), US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,HFT 132,JEFFERSON,AR 72079, USA.				NIEHS NIH HHS [Y01-ES-10187] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010187] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHLUWALIA G, 1993, DRUG METAB DISPOS, V21, P369; AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; AHLUWALJA G, 1988, P AM ASSOC CANC RES, V29, P349; BAWDON RE, 1992, AM J OBSTET GYNECOL, V167, P1570, DOI 10.1016/0002-9378(92)91742-S; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOUCHER FD, 1993, J PEDIATR-US, V122, P137, DOI 10.1016/S0022-3476(05)83507-3; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; BUI T, 1993, J ACQ IMMUN DEF SYND, V6, P120; CHAVANET P, 1989, NEW ENGL J MED, V22, P1348; CHEN MS, 1987, BIOCHEM PHARMACOL, V36, P4361, DOI 10.1016/0006-2952(87)90685-X; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X; DANCIS J, 1993, J ACQ IMMUN DEF SYND, V6, P2; DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOERSTER M, 1992, ARCH TOXICOL, V66, P688, DOI 10.1007/BF01972619; FORD H, 1991, J LIQ CHROMATOGR, V14, P3365, DOI 10.1080/01483919108049396; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GUSTAVSON LE, 1990, J ACQ IMMUN DEF SYND, V3, P28; HA JC, 1994, J ACQ IMMUN DEF SYND, V7, P154; HARTMAN NR, 1990, CLIN PHARMACOL THER, V47, P647, DOI 10.1038/clpt.1990.86; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; KATZ SL, 1989, NEW ENGL J MED, V320, P1687, DOI 10.1056/NEJM198906223202509; KELLEY JA, 1987, DRUG METAB DISPOS, V15, P595; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; KLECKER RW, 1988, J CLIN PHARMACOL, V28, P837, DOI 10.1002/j.1552-4604.1988.tb03225.x; KLUG S, 1991, ARCH TOXICOL, V65, P283, DOI 10.1007/BF01968962; KUMAR RM, 1994, J ACQ IMMUN DEF SYND, V7, P1034; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAMBERT JS, 1994, TROPHOBLAST RES, V8, P97; LIEBES L, 1993, AIDS, V7, P590, DOI 10.1097/00002030-199304000-00022; LIEBES L, 1990, J INFECT DIS, V161, P203, DOI 10.1093/infdis/161.2.203; LINDSTROM P, 1990, TERATOLOGY, V42, P131, DOI 10.1002/tera.1420420204; LIPMAN JM, 1993, TOXICOL APPL PHARM, V123, P137, DOI 10.1006/taap.1993.1230; LOPEZANAYA A, 1991, J ACQ IMMUN DEF SYND, V4, P64; LOPEZANAYA A, 1990, J ACQ IMMUN DEF SYND, V3, P1052; LOPEZANAYA A, 1991, J ACQ IMMUN DEF SYND, V3, P959; MANSURI MM, 1989, J MED CHEM, V32, P461, DOI 10.1021/jm00122a029; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; OSULLIVAN MJ, 1993, AM J OBSTET GYNECOL, V168, P1510, DOI 10.1016/S0002-9378(11)90791-1; PEREIRA CM, 1994, ANTIMICROB AGENTS CH, V38, P787, DOI 10.1128/AAC.38.4.787; PEREIRA CM, 1994, ANTIMICROB AGENTS CH, V38, P781, DOI 10.1128/AAC.38.4.781; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PLESSINGER M, 1992, TERATOLOGY, V45, P484; PLESSINGER MA, 1992, PLACENTA, V13, pA72; PONS JC, 1991, LANCET, V337, P732, DOI 10.1016/0140-6736(91)90313-E; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROGERS MF, 1988, PEDIATR ANN, V17, P324, DOI 10.3928/0090-4481-19880501-06; ROGERS MF, 1987, PEDIATRICS, V79, P1008; SANDBERG JA, 1994, TOXICOLOGIST, V14, P434; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SIEH E, 1992, AIDS RES HUM RETROV, V8, P639, DOI 10.1089/aid.1992.8.639; SINGLAS E, 1992, ANTIMICROB AGENTS CH, V36, P1519, DOI 10.1128/AAC.36.7.1519; SPRECHER S, 1986, LANCET, V2, P288; STARNES MC, 1987, J BIOL CHEM, V262, P988; TOLTZIS P, 1991, J INFECT DIS, V163, P1212, DOI 10.1093/infdis/163.6.1212; TOLTZIS P, 1994, J INFECT DIS, V169, P1100, DOI 10.1093/infdis/169.5.1100; TRANG JM, 1993, DRUG METAB DISPOS, V21, P189; UKWU HN, 1992, OBSTET GYNECOL, V80, P458; WATTS DH, 1991, J INFECT DIS, V163, P226, DOI 10.1093/infdis/163.2.226; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1988, LANCET, V1, P76; ZHU Z, 1990, BIOCHEM PHARMACOL, V39, pR15; 1994, HIV AIDS SURVEILLANC, V6, P1; 1989, MMWR-MORBID MORTAL W, V38, P229; 1994, MMWR-MORBID MORTAL W, V43, P286; 1991, PHYSICIANS DESK REFE	70	26	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1157	1163		10.1096/fasebj.9.12.7672508	http://dx.doi.org/10.1096/fasebj.9.12.7672508			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672508				2022-12-28	WOS:A1995RU81600005
J	FOLETTI, D; GUERINI, D; CARAFOLI, E				FOLETTI, D; GUERINI, D; CARAFOLI, E			SUBCELLULAR TARGETING OF THE ENDOPLASMIC-RETICULUM AND PLASMA-MEMBRANE CA2+ PUMPS - A STUDY USING RECOMBINANT CHIMERAS	FASEB JOURNAL			English	Article						CHIMERIC PROTEINS; PUMP EXPRESSION; MEMBRANE TARGETING	SARCOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; CALCIUM-PUMP; CA-2+ PUMP; INTRACELLULAR MEMBRANES; MONOCLONAL-ANTIBODIES; TRYPSIN PROTEOLYSIS; HUMAN-ERYTHROCYTES; GOLGI RETENTION; CA-2+-ATPASE	ATP-powered Ca2+ pumps are located in the plasma membrane (PMCA) and the sarco(endo)plasmic reticulum (SERCA). The two pump types share numerous structural and functional features; nevertheless, they are strictly targeted to different cell compartments. Chimeric SERCA/PMCA pumps were constructed to investigate the structural determinants responsible for their specific cellular location. The level of expression of the chimeric constructs and of the wild-type pumps in COS-7 and Sf9 cells was the same and so was their stability. One exception was chimera D, which showed special propensity to degradation. The chimeric constructs had no Ca2+-dependent ATPase activity, although in one trace amounts of the Ca2+-dependent phosphoenzyme intermediate were detected. Thus, the exchange of the regions encompassing the (NHP2-terminal) transmembrane domains apparently is incompatible with the activity of the pump. The immunofluorescence experiments showed that the 85 NH2-terminal residues of the SERCA pump, encompassing the first transmembrane domain, contain a signal-promoting retention of chimeric constructs otherwise consisting of the PMCA pump structure in the endoplasmic reticulum. Additional structural determinants most likely also contribute to the retention of the SERCA pump in the endoplasmic reticulum: one chimeric construct (E) composed of the first two transmembrane domains of the PMCA pump, followed by the remainder of the SERCA pump structure, was still retained, even if not completely in the endoplasmic reticulum.	SWISS FED INST TECHNOL,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V20, P1; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012; ZVARITCH E, 1995, J BIOL CHEM, V270, P1280	51	37	37	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					670	680		10.1096/fasebj.9.8.7768360	http://dx.doi.org/10.1096/fasebj.9.8.7768360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768360				2022-12-28	WOS:A1995RC10600014
J	OBRIEN, JS; CARSON, GS; SEO, HC; HIRAIWA, M; WEILER, S; TOMICH, JM; BARRANGER, JA; KAHN, M; AZUMA, N; KISHIMOTO, Y				OBRIEN, JS; CARSON, GS; SEO, HC; HIRAIWA, M; WEILER, S; TOMICH, JM; BARRANGER, JA; KAHN, M; AZUMA, N; KISHIMOTO, Y			IDENTIFICATION OF THE NEUROTROPHIC FACTOR SEQUENCE OF PROSAPOSIN	FASEB JOURNAL			English	Article						NEURITE OUTGROWTH; RECEPTOR; SAPOSIN PEPTIDE	SPHINGOLIPID ACTIVATOR PROTEINS; SAPOSIN PROTEINS; GAUCHER DISEASE; SERTOLI CELLS; GANGLIOSIDES; DEFICIENCY; PRECURSOR; PATIENT	Prosaposin, recently identified as a neurotrophic factor (1), is the precursor of saposins A, B, C, and D. The neurotrophic activity of prosaposin resides in the saposin C domain. We have pinpointed the active sequence to a linear 12-mer located in the NH2-terminal sequence of saposin C (LIDNNKTEKEIL). Nanomolar concentrations of a 22-mer peptide encompassing this region stimulated neurite outgrowth and choline acetyltransferase activity, and prevented cell death in neuroblastoma cells. In primary cerebellar granule cells, the 22-mer also stimulated neurite outgrowth. Studies of the neuroblastoma line NS20Y using a radiolabeled 18-mer from the neurotrophic region identified a high-affinity (K-d = 70 pM) binding site indicative of receptor-ligand interaction. The 22-mer stimulated protein phosphorylation of several proteins, some of which were tyrosine-phosphorylated after brief exposure similar to saposin C. Circular dichroism studies demonstrated that the 22-mer was converted from a random to a helical structure by addition of ganglioside GM(1). The results are consistent with receptor-ligand binding by the peptide initiating a signal transduction cascade and resulting in neuronal differentiation.	NHLBI,BETHESDA,MD 20892; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506; UNIV PITTSBURGH,DEPT HUMAN GENET,GENET MOLEC LAB,PITTSBURGH,PA 15261; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOBIOL,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kansas State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle	OBRIEN, JS (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT NEUROSCI,LA JOLLA,CA 92093, USA.			TOMICH, JOHN M./0000-0001-7848-8307	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013559] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43709] Funding Source: Medline; NINDS NIH HHS [NS08682, NS13559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MORIMOTO S, 1990, ANAL BIOCHEM, V190, P154, DOI 10.1016/0003-2697(90)90173-7; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SANO A, 1989, J BIOL CHEM, V263, P19597; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SPRECHERLEVY H, 1993, CELL MOL BIOL, V39, P287; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; THANGNIPON W, 1992, NEUROCHEM RES, V17, P45, DOI 10.1007/BF00966864; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WEILER S, 1993, J MOL NEUROSCI, V4, P161, DOI 10.1007/BF02782499; WEILER S, 1994, IN PRESS PROTEIN RES	27	112	116	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					681	685		10.1096/fasebj.9.8.7768361	http://dx.doi.org/10.1096/fasebj.9.8.7768361			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768361				2022-12-28	WOS:A1995RC10600015
J	LINS, L; BRASSEUR, R				LINS, L; BRASSEUR, R			THE HYDROPHOBIC EFFECT IN PROTEIN-FOLDING	FASEB JOURNAL			English	Review						HYDROPHOBICITY; SOLVATION ENERGY	APOLIPOPROTEIN-A-I; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; PREDICTION; SEQUENCES; BINDING; PROGRAM; FAMILY; MODEL	In this review of protein folding we consider the noncovalent interactions existing between atoms or molecules at the molecular level. The electrostatic, Van der Waals, hydrogen bonding, and hydrophobic interactions are described and their contribution to protein conformation is discussed. The growing interest in the hydrophobic effect arises from its importance in the protein folding process, and a semiempirical simulation of the free energy of solvation is proposed. In most proteins, the different forces we describe contribute to the stability of the protein conformation in a complex way. However, in the case of the apolipoproteins and cytochrome C-551, the energetic contributions are easily distinguished. For this reason, these proteins are used to illustrate the importance of the different energy fields.	FAC UNIV GEMBLOUX, CTR BIOPHYS MOLEC NUMER, B-5030 GEMBLOUX, BELGIUM	University of Liege			LINS, LAURENCE/Y-1661-2019; lins, laurence/E-3953-2012	LINS, LAURENCE/0000-0001-7772-6748; 				ALMASSY RJ, 1978, P NATL ACAD SCI USA, V75, P2674, DOI 10.1073/pnas.75.6.2674; BOGUSKI MS, 1985, P NATL ACAD SCI USA, V82, P992, DOI 10.1073/pnas.82.4.992; BRASSEUR R, 1986, BIOCHEM J, V238, P1; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BRASSEUR R, 1992, PROTEIN-STRUCT FUNCT, P246; CHAN HS, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881371; COLONNACESARI F, 1990, BIOPHYS J, V57, P1103, DOI 10.1016/S0006-3495(90)82630-8; CORIJN J, 1993, BIOCHIM BIOPHYS ACTA, V1170, P8, DOI 10.1016/0005-2760(93)90169-A; Creighton T. E., 1993, PROTEINS STRUCTURES; DANDEKAR T, 1994, J MOL BIOL, V236, P44; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAUCHERE, 1983, EUR J MED CHEM, V18, P368; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HAYNIE DT, 1993, PROTEINS, V16, P115, DOI 10.1002/prot.340160202; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; ISREALACHVILI J, 1982, NATURE, V300, P341; JONAS A, 1984, EXP LUNG RES, V6, P255, DOI 10.3109/01902148409109252; Jonas A., 1992, STRUCTURE FUNCTION A, P217; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P303; LI WH, 1988, J LIPID RES, V29, P245; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; MUNOZ V, 1994, IN PRESS NATURE STRU; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; PERROT G, 1992, J COMPUT CHEM, V13, P1, DOI 10.1002/jcc.540130102; ROSE GD, 1980, P NATL ACAD SCI-BIOL, V77, P4643, DOI 10.1073/pnas.77.8.4643; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; ROSSENEU M, 1992, INT CONGR SER, V1001, P105; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; VILA J, 1991, PROTEINS, V10, P199, DOI 10.1002/prot.340100305; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; XIE D, 1994, IN PRESS PROTEINS ST	34	116	120	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					535	540		10.1096/fasebj.9.7.7737462	http://dx.doi.org/10.1096/fasebj.9.7.7737462			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737462				2022-12-28	WOS:A1995QX14800011
J	MARTINUS, RD; RYAN, MT; NAYLOR, DJ; HERD, SM; HOOGENRAAD, NJ; HOJ, PB				MARTINUS, RD; RYAN, MT; NAYLOR, DJ; HERD, SM; HOOGENRAAD, NJ; HOJ, PB			ROLE OF CHAPERONES IN THE BIOGENESIS AND MAINTENANCE OF THE MITOCHONDRION	FASEB JOURNAL			English	Review						MITOCHONDRIAL DNA; MOLECULAR CHAPERONE; MITOCHONDRIAL PROTEIN; DNA METABOLISM	HEAT-SHOCK PROTEIN; TRANSCRIPTION FACTOR; MOLECULAR CHAPERONES; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; RAT-LIVER; HSP70; IMPORT; TRANSLOCATION; ACTIVATION	All cells depend on correctly folded proteins for optimal function. A central question in cellular biology is how such folded structures are formed and maintained, a process that is now recognized to rely heavily on a group of proteins called molecular chaperones. Molecular chaperones constitute distinct families of proteins that are ubiquitous and highly conserved from bacteria to humans, They appear to bind nonnative conformations of most, if not all, proteins, thereby preventing their aggregation and subsequent inactivation. The chaperones not only protect newly synthesized proteins during transport and folding, but also serve to maintain the cell in a healthy state during exposure to a multitude of stress conditions. Accordingly, chaperones are expressed constitutively, but their synthesis is further enhanced during stress conditions. Detailed insights into the role of molecular chaperones have come from studies of mitochondrial protein biogenesis, a process in which chaperones act as unfoldases, pulling devices, and foldases. In this review we summarize these developments and further discuss the potential role of chaperones in mitochondrial DNA metabolism and human mitochondrial disease states.	LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA	La Trobe University			Ryan, Michael T/C-6673-2011; martinus, ryan d/J-5937-2015; Ryan, Michael/X-2152-2019; Hoogenraad, Nicholas J/C-7505-2011; Hoj, Peter B/E-8526-2011	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829; martinus, ryan/0000-0002-5954-8770				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AGSTERIBBE E, 1993, BIOCHEM BIOPH RES CO, V193, P146, DOI 10.1006/bbrc.1993.1602; ALCONADA A, 1994, J BIOL CHEM, V269, P13670; ANATHAN J, 1986, SCIENCE, V232, P252; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANFINSEN CB, 1993, SCIENCE, V181, P223; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENJAMIN IJ, 1994, BIOL HEAT SHOCK PROT, P533; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; DEGRAEFFMEEDER ER, 1993, PEDIATR RES, V34, P425; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FOX TD, 1986, TRENDS GENET, V2, P97, DOI 10.1016/0168-9525(86)90192-7; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; Holbrook NJ, 1994, BIOL HEAT SHOCK PROT, P577; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LIAO X, 1993, CELL, V74, P61; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1993, FEBS LETT, V332, P277, DOI 10.1016/0014-5793(93)80649-F; LIU XK, 1992, CIRCULATION, V86, P358; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MADVENO F, 1993, PLANT CELL, V5, P1865; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MEZGER V, 1987, DEV BIOL, V124, P544, DOI 10.1016/0012-1606(87)90507-0; MORI K, 1993, CELL, V74, P743; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; Nagley Phillip, 1993, P137; NAYLOR DJ, 1995, IN PRESS BIOCH BIOPH; OZAWA T, 1991, BIOCHEM BIOPH RES CO, V176, P938, DOI 10.1016/S0006-291X(05)80276-1; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHINOHARA H, 1994, J NEUROL SCI, V119, P203; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WEBSTER T, 1994, IN PRESS DNA CELL BI; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	72	42	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					371	378		10.1096/fasebj.9.5.7896006	http://dx.doi.org/10.1096/fasebj.9.5.7896006			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896006				2022-12-28	WOS:A1995QP45100009
J	FORSDYKE, DR				FORSDYKE, DR			THE ORIGINS OF THE CLONAL SELECTION THEORY OF IMMUNITY AS A CASE-STUDY FOR EVALUATION IN SCIENCE	FASEB JOURNAL			English	Article								Evaluation of high achievement forms part of an evaluation continuum operating throughout the scientific enter prise. Correct evaluation of individuals and their work means that the best work is published and the most able individuals obtain research grants and awards. It is important that evaluations be carried out fairly and objectively. This paper reviews evaluations of the roles of Ehrlich, Jerne, Talmage, and Burnet in the conception and development of the clonal selection theory. These evaluations show varying degrees of bias; in particular, the major role of Ehrlich tends to be overlooked. The objective record shows that Talmage first conceived clonal selection. The proclivity of evaluation in science toward error suggests that our evaluation processes should be redesigned to take this into account.			FORSDYKE, DR (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA.		Forsdyke, Donald R/A-1182-2012	Forsdyke, Donald R/0000-0002-4844-1417				ADA GL, 1989, IMMUNOLOGY 1930 1980, P33; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; Burnet F. Macfarlane, 1956, ENZYME ANTIGEN VIRUS; BURNET FM, 1967, COLD SPRING HARB SYM, V32, P1; BURNET FM, 1959, CLONAL SELECTION THE; Burnet Frank Macfarlane, 1968, CHANGING PATTERNS; COHN M, 1994, ANNU REV IMMUNOL, V12, P1; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; CRUSE JM, 1994, J IMMUNOL, V153, P919; Ehrlich P., 1906, COLLECTED STUDIES IM; FORSDYKE DR, 1993, FASEB J, V7, P619, DOI 10.1096/fasebj.7.8.8500686; FORSDYKE DR, 1995, IMMUNOL TODAY, V16, P105, DOI 10.1016/0167-5699(95)80097-2; FORSDYKE DR, 1989, LANCET, V2, P1382; FORSDYKE DR, 1968, LANCET, V1, P281; FORSDYKE DR, 1994, ACCOUNTABILITY RES, V3, P269; FORSDYKE DR, 1993, ACCOUNTABILITY RES, V2, P237; Jerne Niels K., 1966, PHAGE ORIGINS MOL BI, P301; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; PUTNAM FW, 1953, J BIOL CHEM, V202, P727; Sexton Christopher, 1991, SEEDS TIME LIFE M BU; SIlverstein AM., 1989, HIST IMMUNOLOGY; TALMAGE DW, 1957, ANNU REV MED, V8, P239, DOI 10.1146/annurev.me.08.020157.001323; WITEBSKY E, 1954, Ann N Y Acad Sci, V59, P168, DOI 10.1111/j.1749-6632.1954.tb45929.x	23	21	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					164	166		10.1096/fasebj.9.2.7781918	http://dx.doi.org/10.1096/fasebj.9.2.7781918			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781918				2022-12-28	WOS:A1995QJ24900003
J	HOLT, JM; ACKERS, GK				HOLT, JM; ACKERS, GK			THE PATHWAY OF ALLOSTERIC CONTROL AS REVEALED BY HEMOGLOBIN INTERMEDIATE STATES	FASEB JOURNAL			English	Review						COOPERATIVITY; MUTANT HYBRID HEMOGLOBINS; OXYGEN BINDING; DIMER TETRAMER ASSEMBLY; THERMODYNAMIC LINKAGE	LINKED SUBUNIT INTERACTIONS; COBALT HYBRID HEMOGLOBINS; COOPERATIVE FREE-ENERGIES; EXPERIMENTAL RESOLUTION; OXYGEN-EQUILIBRIUM; ESCHERICHIA-COLI; LIGATION STATES; MOLECULAR CODE; BINDING; MODEL	The energetics of hemoglobin cooperativity has been analyzed through the use of stable, partially-ligated intermediates. These studies revealed that the two dimeric halves of the tetramer are autonomous, leading to a Symmetry Rule that governs the relationship between ligand-binding and the T --> R quaternary switch: the R structure is favored over T only when ligands are bound to both dimers within the tetramer. A major feature of the Symmetry Rule mechanism is the generation of cooperative free energy by tertiary conformational constraints, which are formed within one dimeric half of the T-tetramer and released during the quaternary structure change to R. These rules of tertiary and quaternary molecular switching also govern the roles of the heterotropic allosteric effecters (e.g. Bohr protons).	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)								ACKERS GK, 1981, J MOL BIOL, V147, P559, DOI 10.1016/0022-2836(81)90400-9; ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; BLOUGH NV, 1980, J AM CHEM SOC, V102, P5683, DOI 10.1021/ja00537a050; Bohr C., 1904, SKAND ARCH PHYSIOL, V16, P401; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; DAUGHERTY MA, 1991, P NATL ACAD SCI USA, V88, P1110, DOI 10.1073/pnas.88.4.1110; DAUGHERTY MA, 1994, BIOCHEMISTRY-US, V33, P10345, DOI 10.1021/bi00200a015; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DICKERSON RE, 1983, HEMOGLOBIN, P43; DICRISTOFARO R, 1992, BIOCHEMISTRY-US, V31, P1147; DOYLE ML, 1991, BIOCHEMISTRY-US, V30, P7263, DOI 10.1021/bi00243a031; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P11182, DOI 10.1021/bi00160a032; DOYLE ML, 1992, PROTEINS, V14, P351, DOI 10.1002/prot.340140304; EDSALL JT, 1980, FED PROC, V39, P226; HERZFELD J, 1974, J MOL BIOL, V82, P231, DOI 10.1016/0022-2836(74)90343-X; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; HOFFMAN BM, 1970, P NATL ACAD SCI USA, V67, P637, DOI 10.1073/pnas.67.2.637; HUANG Y, 1995, IN PRESS BIOCHEMISTR; HUANG YW, 1993, BIOCHEMISTRY-US, V32, P9329, DOI 10.1021/bi00087a011; IMAI K, 1980, J MOL BIOL, V138, P635, DOI 10.1016/S0022-2836(80)80021-0; JOHNSON JL, 1992, BIOCHEMISTRY-US, V31, P11510, DOI 10.1021/bi00161a032; JOHNSON ML, 1984, P NATL ACAD SCI-BIOL, V81, P1093, DOI 10.1073/pnas.81.4.1093; JOHNSON ML, 1976, BIOCHEMISTRY-US, V15, P5363, DOI 10.1021/bi00669a024; KIGER L, 1993, BIOPHYS J, V65, P1050, DOI 10.1016/S0006-3495(93)81164-0; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LEE AWM, 1983, P NATL ACAD SCI-BIOL, V80, P7055, DOI 10.1073/pnas.80.23.7055; LICATA VJ, 1990, BIOCHEMISTRY-US, V29, P9771, DOI 10.1021/bi00494a003; LICATA VJ, 1993, PROTEINS, V17, P279, DOI 10.1002/prot.340170306; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; MOFFAT K, 1976, J MOL BIOL, V104, P669, DOI 10.1016/0022-2836(76)90128-5; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1989, MECHANISMS COOPERATI, P1; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1987, P NATL ACAD SCI USA, V84, P7089, DOI 10.1073/pnas.84.20.7089; SPEROS PC, 1991, BIOCHEMISTRY-US, V30, P7254, DOI 10.1021/bi00243a030; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Turner B W, 1981, Methods Enzymol, V76, P596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YONETANI T, 1974, J BIOL CHEM, V249, P682	47	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					210	218		10.1096/fasebj.9.2.7781923	http://dx.doi.org/10.1096/fasebj.9.2.7781923			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781923				2022-12-28	WOS:A1995QJ24900009
J	PAN, Y; YUHASZ, SC; AMZEL, LM				PAN, Y; YUHASZ, SC; AMZEL, LM			ANTIIDIOTYPIC ANTIBODIES - BIOLOGICAL FUNCTION AND STRUCTURAL STUDIES	FASEB JOURNAL			English	Review						ANTI-IDOTYPE; MIMICRY; EPITOPES	HEAVY-CHAIN GENES; ANTIIDIOTYPIC ANTIBODY; IMMUNE-RESPONSE; ANGIOTENSIN-II; 3-DIMENSIONAL STRUCTURE; IDIOTOPE VACCINE; INFLUENZA-VIRUS; INTERNAL IMAGE; RECEPTOR; INDUCTION	Under a variety of circumstances antibodies can be elicited against the variable region of other antibody molecules (anti-idotypic antibodies, anti-ids). Some of the antibodies are directed against the binding sites of the eliciting antibodies. Of particular interest are the antibodies that recognize epitopes of the original antibody that are in contact with antigen. Antibodies of this kind have been produced and used in a variety of situations including attempts at using them as therapeutic agents. In recent years structural data at the atomic level have emerged for anti-idiotypic antibodies from X-ray diffraction studies. These studies provided structural basis for molecular mimicry of anti-ids. For a large globular antigen (lysozyme), where epitope is noncontinuguous, molecular mimicry is not present at the atomic level. In this case, idiotopes are largely composed of CDR residues, but framework residues are also used. For an epitope that is sequence-specific (anti-FIPV system), molecular mimicry appears to be present as evidenced by the sequence homology between the CDR loops of the anti-id and the epitope of the original antigen. In the case of a small hormone antigen (angiotensin II), an internal image of the eliciting antigen appears to be represented in a single CDR loop of the antiiodiotypic antibody.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Johns Hopkins University			Yuhasz, Stacieann/B-5428-2011	Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERS EM, 1989, J VIROL, V63, P2758, DOI 10.1128/JVI.63.6.2758-2767.1989; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BANIYASH M, 1987, EUR J IMMUNOL, V17, P1337, DOI 10.1002/eji.1830170918; BARRY MM, M58456 GENB ACC; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CHANH TC, 1990, J IMMUNOL, V144, P4721; CLARKE SH, 1990, J IMMUNOL, V144, P2795; CZOP JK, 1990, J IMMUNOL, V145, P995; FONS GCM, 1985, J IMMUNOL, V134, P1225; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GLASEL JA, 1985, LIFE SCI, V36, P2523, DOI 10.1016/0024-3205(85)90149-3; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GRIEDER FB, 1990, J IMMUNOL, V144, P2627; HUANG JH, 1986, J IMMUNOL, V137, P770; IRIBE H, 1988, J IMMUNOL, V140, P4151; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KENNEDY RC, 1986, SCIENCE, V232, P220, DOI 10.1126/science.3952505; KOFLER R, 1988, J IMMUNOL, V140, P4031; KRESINA TF, 1989, J CLIN INVEST, V83, P912, DOI 10.1172/JCI113976; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LAMARRE A, 1991, J IMMUNOL, V147, P4256; LAMBRIS JD, 1982, J EXP MED, V155, P1400, DOI 10.1084/jem.155.5.1400; LASSOUED K, 1991, EUR J IMMUNOL, V21, P1959, DOI 10.1002/eji.1830210826; MARASCO WA, 1982, J IMMUNOL, V128, P963; MCNAMARA MK, 1984, SCIENCE, V226, P1325, DOI 10.1126/science.6505692; MONAFO WJ, 1987, J IMMUNOL, V139, P2702; REAGAN KJ, 1983, J VIROL, V48, P660, DOI 10.1128/JVI.48.3.660-666.1983; ROUX KH, 1987, P NATL ACAD SCI USA, V84, P4984, DOI 10.1073/pnas.84.14.4984; SACKS DL, 1982, J EXP MED, V155, P1108, DOI 10.1084/jem.155.4.1108; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SCHREIBER JR, 1991, J IMMUNOL, V146, P188; SPITSIN SV, 1991, J IMMUNOL, V147, P2001; SU S, 1992, J IMMUNOL, V148, P234; VELGEROUSSEL F, 1989, J IMMUNOL, V142, P2527	40	62	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					43	49		10.1096/fasebj.9.1.7821758	http://dx.doi.org/10.1096/fasebj.9.1.7821758			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821758	Bronze			2022-12-28	WOS:A1995QD20200008
J	HOOK, VYH; AZARYAN, AV; HWANG, SR; TEZAPSIDIS, N				HOOK, VYH; AZARYAN, AV; HWANG, SR; TEZAPSIDIS, N			PROTEASES AND THE EMERGING ROLE OF PROTEASE INHIBITORS IN PROHORMONE PROCESSING	FASEB JOURNAL			English	Review						PROPROTEIN PROCESSING; NEUROENDOCRINE PEPTIDES	OPIOMELANOCORTIN-CONVERTING ENZYME; MEDULLARY CHROMAFFIN GRANULES; CARBOXYPEPTIDASE-H GENE; ENKEPHALIN PRECURSOR; THIOL PROTEASE; SECRETORY VESICLES; SERINE PROTEASE; RAT PITUITARY; FUNCTIONAL-PROPERTIES; ASPARTYL PROTEASE	Peptide hormones and neurotransmitters constitute a large class of neurohumoral agents that mediate cell-cell communication in neuroendocrine systems. Their biosynthesis requires proteolytic processing of inactive protein precursors into active neuropeptides. Elucidation of the proteolytic components required for prohormone processing is important for identifying key proteases that may control the production of neuropeptides. This article compares the subtilisin-like PC1/3 and PC2 processing enzymes identified through molecular biological approaches, and several candidate processing enzymes identified biochemically, including the 'pro-opiomelanocortin converting enzyme' (PCE) and the 'prohormone thiol protease' (PTP), as well as others of different classes (aspartyl, cysteine, metallo, and serine proteases). A role for PTP in cellular proenkephalin processing is suggested by blockade of forskolin-stimulated (Met)enkephalin production by Ep453 that is converted intracellularly to E-64c, a selective cysteine protease inhibitor that potently inhibits PTP A possible role for endogenous protease inhibitors in prohormone processing represents a new aspect of cellular mechanisms that may regulate neuropeptide biosynthesis. Future studies of the enzymology and molecular biology of processing enzymes and endogenous protease inhibitors will be necessary to elucidate mechanisms of prohormone processing.-Hook, V. Y. H., Azaryan, A. V., Hwang, S.-R., Tezapsidis, N. Proteases and the emerging role of protease inhibitors in prohormone processing.	UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	HOOK, VYH (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, 200 W ARBOR SR, 8227, SAN DIEGO, CA 92103 USA.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALARCON C, 1993, J BIOL CHEM, V268, P4276; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Azaryan A. V., 1992, Society for Neuroscience Abstracts, V18, P269; AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; BEINFELD MC, 1989, BIOCHEM BIOPH RES CO, V160, P968, DOI 10.1016/0006-291X(89)92530-8; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BONDY CA, 1989, MOL ENDOCRINOL, V3, P2086, DOI 10.1210/mend-3-12-2086; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Brownstein M. J, 1983, BRAIN PEPTIDES; BUTTLE DJ, 1992, BIOCHEM J, V281, P175, DOI 10.1042/bj2810175; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CLAMAGIRAND C, 1987, BIOCHEMISTRY-US, V26, P6018, DOI 10.1021/bi00393a011; DAS B, 1992, J NEUROCHEM, V59, P2263; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEVI L, 1986, J NEUROCHEM, V47, P154; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GAINER H, 1984, FEBS LETT, V175, P135, DOI 10.1016/0014-5793(84)80586-4; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; GOMEZ S, 1988, P NATL ACAD SCI USA, V85, P5468, DOI 10.1073/pnas.85.15.5468; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOOK VYH, 1990, BIOCHEM BIOPH RES CO, V167, P722, DOI 10.1016/0006-291X(90)92085-E; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1984, FEBS LETT, V172, P212, DOI 10.1016/0014-5793(84)81128-X; HOOK VYH, 1990, J NEUROSCI, V10, P3219; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; HWANG SR, 1994, MOL BRAIN RES, V25, P135, DOI 10.1016/0169-328X(94)90288-7; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JUNG YK, 1991, MOL ENDOCRINOL, V5, P1257, DOI 10.1210/mend-5-9-1257; JUNG YK, 1992, MOL ENDOCRINOL, V6, P2027, DOI 10.1210/me.6.12.2027; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LOH YP, 1988, FEBS LETT, V238, P142, DOI 10.1016/0014-5793(88)80244-8; LOH YP, 1982, P NATL ACAD SCI-BIOL, V79, P108, DOI 10.1073/pnas.79.1.108; LOH YP, 1985, J BIOL CHEM, V260, P7194; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MERCHENTHALER I, 1986, NEUROSCIENCE, V17, P325, DOI 10.1016/0306-4522(86)90250-2; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PARISH DC, 1986, J BIOL CHEM, V261, P4392; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; RUBIN H, 1990, J BIOL CHEM, V265, P1199; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, FEBS LETT, V310, P235, DOI 10.1016/0014-5793(92)81339-N; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; SMITH DR, 1992, MOL ENDOCRINOL, V6, P713, DOI 10.1210/me.6.5.713; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; WILSON JD, 1992, TXB ENDOCRINOLOGY; WYPIJ DM, 1988, J BIOL CHEM, V263, P7079; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	86	104	104	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1994	8	15					1269	1278		10.1096/fasebj.8.15.8001739	http://dx.doi.org/10.1096/fasebj.8.15.8001739			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001739				2022-12-28	WOS:A1994PY20900010
J	GELB, MH; JAIN, MK; BERG, OG				GELB, MH; JAIN, MK; BERG, OG			INHIBITION OF PHOSPHOLIPASE A(2)	FASEB JOURNAL			English	Review						LIPASES; INHIBITORS; ARACHIDONIC ACID; EICOSANOIDS; PROTEIN-LIPID INTERACTIONS	GROUP-II PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; HUMAN-PLATELET PHOSPHOLIPASE-A2; MOUSE PERITONEAL-MACROPHAGES; PRODUCT-CONTAINING VESICLES; ARTHRITIC SYNOVIAL-FLUID; TIGHT-BINDING INHIBITORS	Phospholipases A(2) are involved in inflammatory processes such as the liberation of free arachidonic acid from the membrane pool for the biosynthesis of eicosanoids. Inhibitors of these enzymes are proving useful in determining the biological roles of phospholipases A(2) in complex cellular processes and may also have therapeutic potential. Inhibition of these lipolytic enzymes is more difficult to characterize as the enzymatic reaction occurs at a lipid/water interface. This review focuses on the description of a number of classes of rationally designed phospholipase A(2) inhibitors. The development of a theoretical framework for the proper analysis of inhibitors is presented. Structural studies of phospholipase A(2)-inhibitor complexes suggest how the lipolysis reaction is catalyzed. Finally, some recent results on the use of phospholipase A(2) inhibitors in living cells and tissues are revealed.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV DELAWARE, DEPT CHEM & BIOCHEM, NEWARK, DE 19716 USA; UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, UPPSALA, SWEDEN	University of Washington; University of Washington Seattle; University of Delaware; Uppsala University	GELB, MH (corresponding author), UNIV WASHINGTON, DEPT CHEM, BG-19, SEATTLE, WA 98195 USA.			gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline; NIGMS NIH HHS [GM562, GM29703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEHDI AB, 1993, BIOCHIM BIOPHYS ACTA, V1167, P56, DOI 10.1016/0005-2760(93)90217-W; [Anonymous], 1987, PHOSPHOLIPASES; APITZCASTRO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P349, DOI 10.1016/0005-2736(82)90346-7; ARITA H, 1993, J LIPID MEDIATOR, V6, P217; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BELL JD, 1992, J BIOL CHEM, V267, P11046; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; BUCHLER M, 1989, KLIN WOCHENSCHR, V67, P217, DOI 10.1007/BF01711357; BUKOWSKI T, 1986, BIOCHEMISTRY-US, V25, P8024, DOI 10.1021/bi00372a035; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DIJKMAN R, 1993, BIOCHIM BIOPHYS ACTA, V1167, P281; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; FREMONT DH, 1993, P NATL ACAD SCI USA, V90, P342, DOI 10.1073/pnas.90.1.342; GELB MH, 1992, BIOORG MED CHEM LETT, V2, P1335, DOI 10.1016/S0960-894X(00)80508-9; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; Jain M K, 1992, Mediators Inflamm, V1, P85, DOI 10.1155/S0962935192000164; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7340, DOI 10.1021/bi00243a039; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11319, DOI 10.1021/bi00093a008; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P8360, DOI 10.1021/bi00083a040; JAIN MK, 1985, BIOCHIM BIOPHYS ACTA, V814, P319, DOI 10.1016/0005-2736(85)90451-1; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; JAIN MK, 1994, IN PRESS METHODS ENZ; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAUSE H, 1991, EUR J BIOCHEM, V199, P355, DOI 10.1111/j.1432-1033.1991.tb16131.x; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MORGAN BP, 1991, J AM CHEM SOC, V113, P297, DOI 10.1021/ja00001a043; MORI H, 1991, AGENTS ACTIONS, V32, P266, DOI 10.1007/BF01980884; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; PLESNIAK LA, 1993, BIOCHEMISTRY-US, V32, P5009, DOI 10.1021/bi00070a006; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; RANSAC S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P57, DOI 10.1016/0005-2760(90)90110-J; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROGERS J, 1992, BIOCHEMISTRY-US, V31, P6056, DOI 10.1021/bi00141a014; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TOMOO K, 1992, BIOCHEM BIOPH RES CO, V184, P137, DOI 10.1016/0006-291X(92)91169-Q; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; VADAS P, 1993, CIRC SHOCK, V39, P160; VANDENBERGH CJ, 1989, J CELL BIOCHEM, V39, P379, DOI 10.1002/jcb.240390404; VANEIJK JH, 1983, EUR J BIOCHEM, V132, P183; VANOORT MG, 1985, BIOCHEMISTRY-US, V24, P7993, DOI 10.1021/bi00348a023; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WESTERLUND B, 1992, FEBS LETT, V301, P159, DOI 10.1016/0014-5793(92)81238-H; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; YU L, 1991, METHOD ENZYMOL, V197, P65; YU L, 1991, P NATL ACAD SCI USA, V88, P9325, DOI 10.1073/pnas.88.20.9325; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028; YUAN W, 1988, J AM CHEM SOC, V110, P2665, DOI 10.1021/ja00216a059	93	97	102	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					916	924		10.1096/fasebj.8.12.8088457	http://dx.doi.org/10.1096/fasebj.8.12.8088457			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088457				2022-12-28	WOS:A1994PG29300003
J	NAGAO, A; OLSON, JA				NAGAO, A; OLSON, JA			ENZYMATIC FORMATION OF 9-CIS, 13-CIS, AND ALL-TRANS RETINALS FROM ISOMERS OF BETA-CAROTENE	FASEB JOURNAL			English	Note						9-CIS BETA-CAROTENE; CAROTENOID DIOXYGENASE; LIVER; INTESTINE	RETINOIC ACID; VITAMIN-A; CONVERSION; ALPHA	9-cis Retinoic acid is a highly preferred ligand for the nuclear retinoic acid receptor RXR. Although 9-cis retinoic acid can be formed from all-trans retinoic acid in vivo and in vitro, the nature isomerization process has not been defined. Retinoic acid might also be formed biologically from 9-cis beta-carotene, an isomer of beta-carotene commonly found in foods. We have observed that enzyme preparations of rat liver and intestine convert highly purified 9-cis beta-carotene (99.8%) to a mixture of 9-cis, all-trans, and 13-cis retinals. Highly purified all-trans beta-carotene (99.7%) and 13-cis beta-carotene (99%) are primarily converted to all-trans retinal. Several aldehyde dehydrogenases in tissues can convert retinal to retinoic acid. Although the rates of cleavage of 9-cis and 13-cis beta-carotenes are slower than that of the all-trans isomer, the oxidative conversion of 9-cis beta-carotene to 9-cis and all-trans retinals is the first identified enzymatic reaction for the formation of 9-cis retinal in animal tissues.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NCI NIH HHS [CA 46406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA046406, R01CA046406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWAY RJ, 1986, J AGR FOOD CHEM, V34, P409, DOI 10.1021/jf00069a006; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GROENENDIJK GWT, 1980, EUR J BIOCHEM, V106, P119; Hofmann Clementine, 1994, P387; Kouyama T, 1988, Adv Biophys, V24, P123, DOI 10.1016/0065-227X(88)90006-8; KRINSKY NI, 1993, ANN NY ACAD SCI, V691, P167, DOI 10.1111/j.1749-6632.1993.tb26168.x; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1987, AM J CLIN NUTR, V45, P704, DOI 10.1093/ajcn/45.4.704; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; OLSON JA, 1994, MODERN NUTR HLTH DIS, P287; ONEIL CA, 1991, J ASSOC OFF ANA CHEM, V74, P36; RANDO RR, 1994, PURE APPL CHEM, V66, P989, DOI 10.1351/pac199466050989; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; SCHWARTZ SJ, 1992, J CHROMATOGR, V624, P235; THALLER C, 1993, DEVELOPMENT, V118, P957; Underwood BA, 1984, RETINOIDS, P281; VANVLIET T, 1992, NETH J NUTR, V53, P186; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A	24	100	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1994	8	12					968	973		10.1096/fasebj.8.12.8088462	http://dx.doi.org/10.1096/fasebj.8.12.8088462			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088462				2022-12-28	WOS:A1994PG29300009
J	GELEZIUNAS, R; BOUR, S; WAINBERG, MA				GELEZIUNAS, R; BOUR, S; WAINBERG, MA			CELL-SURFACE DOWN-MODULATION OF CD4 AFTER INFECTION	FASEB JOURNAL			English	Review						GP160-CD4 COMPLEX; VPU GENE; NEF GENE; CD4; ANTIGEN	HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VPU PROTEIN; MURINE LEUKEMIA-VIRUS; ENVELOPE GLYCOPROTEIN; T-CELL; MESSENGER-RNA; CYTOPLASMIC DOMAIN; ENDOPLASMIC-RETICULUM; HIV-INFECTION; NEF GENE	Entry of HIV-1 into host cells is generally mediated by the cell surface CD4 receptor after specific interaction with the viral envelope glycoprotein gp120. Infection by HIV-1 commonly leads to the disappearance of CD4 from the plasma membrane, a phenomenon referred to as receptor down-modulation, This, in turn, renders cells refractory to subsequent infection by the same or other viruses that use the CD4 receptor for entry, creating a state of superinfection immunity. CD4 down-modulation is a complex process involving a variety of viral gene products, the effects of which may be manifest at different stages within the viral replication cycle. CD4 disappearance from the cell surface occurs in each of the CD4 + lymphocytes, T-cell lines, monocytic cell lines, and monocyte-derived macrophages. Internalization of CD4 can occur after binding of either gp120 alone of gp120 antigen-antibody complexes, and may also be mediated by the HIV-1 Nef gene. Other factors that cause cell surface CD4 depletion include reductions in CD4 transcript levels, impaired translation of CD4 mRNA, formation of CD4-gp160 intracellular complexes, and degradation of CD4 mediated by the HIV-1 Vpu gene.	SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, MCGILL AIDS CTR, MONTREAL H3T 1E2, PQ, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ, CANADA	Lady Davis Institute; McGill University; McGill University				Bour, Stephan/0000-0002-0211-0110				AMADORI A, 1992, J IMMUNOL, V148, P2709; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; BUTERA ST, 1991, J VIROL, V65, P4645, DOI 10.1128/JVI.65.9.4645-4653.1991; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CEFAI D, 1992, J IMMUNOL, V149, P285; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GELEZIUNAS R, 1991, AIDS, V5, P29, DOI 10.1097/00002030-199101000-00004; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRANOWITZ C, 1991, VIROLOGY, V183, P545, DOI 10.1016/0042-6822(91)90983-I; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HART AR, 1990, VIROLOGY, V177, P1, DOI 10.1016/0042-6822(90)90454-Y; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; KOGA Y, 1990, J IMMUNOL, V144, P94; KOGA Y, 1991, J VIROL, V65, P5609, DOI 10.1128/JVI.65.10.5609-5612.1991; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARSHALL WL, 1992, J VIROL, V66, P5492, DOI 10.1128/JVI.66.9.5492-5499.1992; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MITCHELL T, 1992, J VIROL, V66, P5696, DOI 10.1128/JVI.66.9.5696-5702.1992; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; REPKE H, 1992, J IMMUNOL, V149, P2585; RIVAS A, 1988, J IMMUNOL, V140, P2912; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SALMON P, 1988, J EXP MED, V168, P1953, DOI 10.1084/jem.168.6.1953; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SCHWARTZ S, 1992, MOL CELL BIOL, V12, P207, DOI 10.1128/MCB.12.1.207; SHAHABUDDIN M, 1992, J VIROL, V66, P6802, DOI 10.1128/JVI.66.11.6802-6805.1992; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; TEMIN HM, 1988, REV INFECT DIS, V10, P399; WEISS RA, 1985, RNA TUMOR VIRUSES, V1, P209; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992; YUILLE MAR, 1988, J ACQ IMMUN DEF SYND, V1, P131; ZAZOPOULOS E, 1993, J VIROL, V67, P1676, DOI 10.1128/JVI.67.3.1676-1680.1993	66	69	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					593	600		10.1096/fasebj.8.9.8005387	http://dx.doi.org/10.1096/fasebj.8.9.8005387			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005387				2022-12-28	WOS:A1994NR90600006
J	MAXFIELD, FR				MAXFIELD, FR			INTRODUCTION - OPTICAL MICROSCOPY IN PHYSIOLOGICAL INVESTIGATIONS	FASEB JOURNAL			English	Editorial Material							IMAGING MICROSCOPY; FLUORESCENCE; METABOLISM		COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University	MAXFIELD, FR (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA.		Maxfield, Fred/A-1718-2011	Maxfield, Frederick/0000-0003-4396-8866				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BALLARD SG, 1993, J HISTOCHEM CYTOCHEM, V41, P1755, DOI 10.1177/41.12.8245423; CAJAL SRY, 1909, HISTOLOGIE SYSTEME N, V1, P657; CARRINGTON WA, 1994, IN PRESS FASEB J; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; FISHELL G, 1994, IN PRESS FASEB J; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haugland R.P., 1992, HDB FLUORESCENT PROB; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; MAXFIELD FR, 1989, METHOD CELL BIOL, V29, P13; Metchnikoff E, 1892, LECONS PATHOLOGIE CO; POOL R, 1990, SCIENCE, V247, P634, DOI 10.1126/science.247.4943.634; REID T, 1992, P NATL ACAD SCI USA, V89, P1388; SALMON ED, 1994, IN PRESS FASEB J; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; WILLIAMS RM, 1994, IN PRESS FASEB J, V8	19	0	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					571	572		10.1096/fasebj.8.9.8005384	http://dx.doi.org/10.1096/fasebj.8.9.8005384			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005384	Bronze			2022-12-28	WOS:A1994NR90600003
J	SERREZE, DV				SERREZE, DV			AUTOIMMUNE DIABETES RESULTS FROM GENETIC-DEFECTS MANIFEST BY ANTIGEN-PRESENTING CELLS	FASEB JOURNAL			English	Article						AUTOIMMUNITY; DIABETES; IMMUNOGENETICS; NOD; T-CELL	MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREATIC-ISLET CELLS; RECEPTOR ALPHA-CHAIN; EMBRYONIC STEM-CELLS; BONE-MARROW CHIMERAS; T-CELLS; NOD MICE; CLASS-I; INTERFERON-GAMMA; CLONAL DELETION	In most cases, insulin-dependent diabetes results from autoimmune elimination of pancreatic beta cells by T lymphocytes that are generated as a result of complex polygenic interactions between particular MHC haplotypes and non-MHC linked susceptibility modifiers. Immature T cells with potential autoreactivity are normally destroyed in the thymus when they are highly activated after ligation of the T cell receptor (TCR) with ''self'' peptides bound to MHC molecules on antigen presenting cells (APC) such as macrophages. Here the hypothesis is put forth that non-MHC linked diabetes susceptibility genes contribute to subtle defects in the maturation of macrophages, and in synergy with a diabetogenic MHC haplotype generate APC that are unable to trigger autoreactive T cells to an activation state high enough to induce their destruction.			SERREZE, DV (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.							BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BOHME J, 1990, SCIENCE, V249, P293, DOI 10.1126/science.2115690; BOYER PD, 1989, J IMMUNOL, V142, P4121; BURTLES SS, 1992, J IMMUNOL, V149, P2185; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; EISENBARTH GS, 1986, DIABETES, V36, P355; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FONDELL JD, 1990, J IMMUNOL, V144, P1094; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GASKINS HR, 1992, SCIENCE, V256, P1826, DOI 10.1126/science.1352067; GERLING IC, 1992, DIABETES, V41, P1672, DOI 10.2337/diabetes.41.12.1672; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HUE I, 1990, J IMMUNOL, V144, P4410; ISHIKURA H, 1989, J IMMUNOL, V143, P414; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JARPE A, 1991, REG IMMUNOL, V3, P305; KAY TWH, 1991, DIABETOLOGIA, V34, P779, DOI 10.1007/BF00408350; KAYE J, 1992, J IMMUNOL, V148, P3342; KELLER RJ, 1989, IMMUNOTHERAPY DIABET, P1; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Leiter Edward H., 1992, Regional Immunology, V4, P263; LEITER EH, 1989, J EXP MED, V170, P1243, DOI 10.1084/jem.170.4.1243; LIVINGSTONE A, 1991, J IMMUNOL, V146, P529; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAEDA T, 1991, DIABETES, V40, P1580, DOI 10.2337/diabetes.40.12.1580; MAKINO S, 1991, Diabetes Research and Clinical Practice, V14, pS40; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MCDUFFIE M, 1988, J IMMUNOL, V141, P1840; MILICH DR, 1989, J IMMUNOL, V143, P3148; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA M, 1989, J IMMUNOL, V143, P1155; PANKEWYCZ O, 1991, EUR J IMMUNOL, V21, P873, DOI 10.1002/eji.1830210403; PROCHAZKA M, 1989, DIABETES, V38, P1446, DOI 10.2337/diabetes.38.11.1446; PROCHAZKA M, 1992, DIABETES, V41, P98, DOI 10.2337/diabetes.41.1.98; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; REICH EP, 1989, DIABETES, V38, P1647, DOI 10.2337/diabetes.38.12.1647; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SADELAIN MWJ, 1990, DIABETES, V39, P583, DOI 10.2337/diabetes.39.5.583; SERREZE DV, 1990, DIABETOLOGIA, V33, P84, DOI 10.1007/BF00401045; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SERREZE DV, 1993, J IMMUNOL, V150, P2534; SERREZE DV, 1991, J IMMUNOL, V147, P1222; SERREZE DV, 1988, DIABETES, V37, P252, DOI 10.2337/diabetes.37.2.252; SERREZE DV, 1990, J AUTOIMMUN, V2, P759; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHEEHY MJ, 1992, DIABETES, V41, P123, DOI 10.2337/diabetes.41.2.123; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SUZUKI G, 1989, J IMMUNOL, V142, P1463; TAKI T, 1991, DIABETES, V40, P1203, DOI 10.2337/diabetes.40.9.1203; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; UCKER DS, 1992, J IMMUNOL, V149, P1583; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WATERS SH, 1992, DIABETES, V41, P308, DOI 10.2337/diabetes.41.3.308; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1988, J EXP MED, V167, P1801, DOI 10.1084/jem.167.6.1801; WICKER LS, 1989, J IMMUNOL, V142, P781; WITSELL AL, 1991, P NATL ACAD SCI USA, V88, P1963, DOI 10.1073/pnas.88.5.1963; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	70	46	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1092	1096		10.1096/fasebj.7.11.8370480	http://dx.doi.org/10.1096/fasebj.7.11.8370480			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370480				2022-12-28	WOS:A1993LT83900016
J	ALTMAN, S; KIRSEBOM, L; TALBOT, S				ALTMAN, S; KIRSEBOM, L; TALBOT, S			RECENT STUDIES OF RIBONUCLEASE-P	FASEB JOURNAL			English	Review						TRANSFER RNA BIOSYNTHESIS; CATALYTIC RNA; RNA-PROTEIN INTERACTIONS; PHYLOGENETIC COMPARISONS	TRANSFER-RNA PRECURSORS; CATALYTIC M1 RNA; 4.5 S-RNA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SUBUNIT; COMPONENT; CLEAVAGE; ENZYME; PROTEIN	RNase P is an essential enzyme that is required for the biosynthesis of tRNA. It is composed of RNA and protein subunits. The RNA subunit of the enzyme derived from eubacterial sources can carry out the catalytic function by itself in vitro. Current studies of RNase P focus on structure-function relationships with respect to interactions of the RNA subunit with its substrates and with respect to the determination of the kinetic parameters of the reaction, the role of the protein component, and the rules governing recognition of substrates.	UNIV UPPSALA, DEPT MICROBIOL, S-75105 UPPSALA, SWEDEN	Uppsala University	ALTMAN, S (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA.				NIGMS NIH HHS [GM-19422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019422, R01GM019422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; ALTMAN S, 1979, NONSENSE MUTATIONS T, P173; BAER MF, 1988, J BIOL CHEM, V263, P2344; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DARR SC, 1992, BIOCHEMISTRY-US, V31, P328, DOI 10.1021/bi00117a003; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FUJITA MQ, 1990, GENE, V93, P73, DOI 10.1016/0378-1119(90)90138-H; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1992, P NATL ACAD SCI USA, V89, P1266, DOI 10.1073/pnas.89.4.1266; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; HOLM PS, 1992, NUCLEIC ACIDS RES, V20, P421, DOI 10.1093/nar/20.3.421; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KAHLE D, 1990, NUCLEIC ACIDS RES, V18, P837, DOI 10.1093/nar/18.4.837; KAZAKOV S, 1991, P NATL ACAD SCI USA, V88, P9193, DOI 10.1073/pnas.88.20.9193; KIRSEBOM LA, 1988, J MOL BIOL, V204, P879, DOI 10.1016/0022-2836(88)90048-4; KIRSEBOM LA, 1992, NUCLEIC ACIDS RES, V20, P425, DOI 10.1093/nar/20.3.425; KNAP AK, 1990, BIOCHIMIE, V72, P779, DOI 10.1016/0300-9084(90)90187-L; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LI Y, 1992, P NATL ACAD SCI USA, V89, P3185, DOI 10.1073/pnas.89.8.3185; LUMELSKY N, 1988, J MOL BIOL, V202, P443, DOI 10.1016/0022-2836(88)90277-X; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; REILLY RM, 1986, J BIOL CHEM, V261, P2928; SAKANO H, 1974, NUCLEIC ACIDS RES, V1, P355, DOI 10.1093/nar/1.3.355; SHIRAISHI H, 1986, EMBO J, V5, P3673, DOI 10.1002/j.1460-2075.1986.tb04698.x; SHIRAISHI H, 1988, EMBO J, V7, P3817, DOI 10.1002/j.1460-2075.1988.tb03266.x; SKOVGAARD O, 1990, GENE, V93, P27, DOI 10.1016/0378-1119(90)90131-A; Smith J D, 1976, Prog Nucleic Acid Res Mol Biol, V16, P25, DOI 10.1016/S0079-6603(08)60755-2; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; SVARD SG, 1992, IN PRESS J MOL BIOL; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; WANG MJ, 1988, EMBO J, V7, P1567, DOI 10.1002/j.1460-2075.1988.tb02981.x; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WISE CA, 1991, J BIOL CHEM, V266, P19154; YUAN Y, 1992, IN PRESS P NAT ACAD; ZIMMERLY S, 1990, FEBS LETT, V271, P189, DOI 10.1016/0014-5793(90)80403-6	60	155	160	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					7	14		10.1096/fasebj.7.1.7916700	http://dx.doi.org/10.1096/fasebj.7.1.7916700			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7916700				2022-12-28	WOS:A1993KH88000003
J	STACKEBRANDT, E; LIESACK, W; GOEBEL, BM				STACKEBRANDT, E; LIESACK, W; GOEBEL, BM			BACTERIAL DIVERSITY IN A SOIL SAMPLE FROM A SUBTROPICAL AUSTRALIAN ENVIRONMENT AS DETERMINED BY 16S RDNA ANALYSIS	FASEB JOURNAL			English	Article						PHYLOGENETIC ANALYSIS; GENETIC DIVERSITY	RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; GENE CLONING; COMMUNITY; DNA; BACTERIOPLANKTON; MICROORGANISMS; PURIFICATION; EVOLUTION; SEDIMENTS	In order to investigate the genetic diversity of streptomycetes in an acid forested soil sample from Mt. Coot-tha, Brisbane, Australia, cells were mechanically lysed within the soil matrix and genomic DNA was isolated and purified. 16S ribosomal (r)DNA was amplified by the polymerase chain reaction (PCR) method using one primer conserved for members of the domain Bacteria and a second designed specifically for streptomycetes and related taxa. PCR amplification products were cloned into phage vector M13 mp19 and the diversity of 16S rDNA genes was determined by sequence analysis and oligonucleotide probing of the resultant clone library. Comparison of partial 16S rDNA sequences with published sequences revealed that few sequences originated from streptomycetes. The majority of sequences belonged to members of the alpha subclass of Proteobacteria. Other clones were related to planctomycetes, actinomycetes, or represented novel lines of descent. Bacteria that are customarily isolated from soil of pH 4-7 such as thiobacilli, bacilli, spore- and nonsporeforming actinomycetes, and pseudomonads are represented in the clone library in small numbers or were not detected at all. Parameters influencing the recovery, amplification, quantification, and interpretation of genetic information from natural sites are discussed.	UNIV QUEENSLAND,CTR BACTERIAL DIVERS & IDENTIFICAT,DEPT MICROBIOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland				Stackebrandt, Erko/0000-0002-6130-760X; Liesack, Werner/0000-0002-9533-1552				Alexander M, 1961, INTRO SOIL MICROBIOL; BAKKEN LR, 1985, APPL ENVIRON MICROB, V49, P1482, DOI 10.1128/AEM.49.6.1482-1487.1985; BRIERLEY JA, 1978, APPL ENVIRON MICROB, V36, P523, DOI 10.1128/AEM.36.3.523-525.1978; BRITSCHGI TB, 1991, APPL ENVIRON MICROB, V57, P1707, DOI 10.1128/AEM.57.6.1707-1713.1991; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DESOETE G, 1983, PSYCHOMETRIKA, V48, P621, DOI 10.1007/BF02293884; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; Goodfellow, 1991, NUCL ACID TECHNIQUES, P177; HARRISON AP, 1984, ANNU REV MICROBIOL, V38, P265, DOI 10.1146/annurev.mi.38.100184.001405; HOLBEN WE, 1988, APPL ENVIRON MICROB, V54, P703, DOI 10.1128/AEM.54.3.703-711.1988; JANNASCH HW, 1959, LIMNOL OCEANOGR, V4, P128, DOI 10.4319/lo.1959.4.2.0128; JUKES T H, 1969, P21; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LANE DJ, 1992, J BACTERIOL, V174, P269, DOI 10.1128/jb.174.1.269-278.1992; LIESACK W, 1991, MICROBIAL ECOL, V21, P191, DOI 10.1007/BF02539153; LIESACK W, 1992, J BACTERIOL, V174, P5072, DOI 10.1128/JB.174.15.5072-5078.1992; LIESACK W, 1992, IN PRESS BIODIV CONS; MENZIES NW, 1991, AUST J SOIL RES, V29, P223, DOI 10.1071/SR9910223; OGRAM A, 1987, J MICROBIOL METH, V7, P57, DOI 10.1016/0167-7012(87)90025-X; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; PACE NR, 1986, ADV MICROB ECOL, V9, P1; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; SEEWALDT E, 1982, ARCH MICROBIOL, V131, P287, DOI 10.1007/BF00405895; STEFFAN RJ, 1988, APPL ENVIRON MICROB, V54, P2908, DOI 10.1128/AEM.54.12.2908-2915.1988; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WARD DM, 1990, FEMS MICROBIOL LETT, V75, P105, DOI 10.1016/0378-1097(90)90525-U; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WOESE CR, 1984, SYST APPL MICROBIOL, V5, P315, DOI 10.1016/S0723-2020(84)80034-X; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; [No title captured]	33	218	229	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					232	236		10.1096/fasebj.7.1.8422969	http://dx.doi.org/10.1096/fasebj.7.1.8422969			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422969				2022-12-28	WOS:A1993KH88000035
J	KORNBERG, A				KORNBERG, A			50 YEARS AGO - THE STATE OF BIOCHEMISTRY	FASEB JOURNAL			English	Item About an Individual											KORNBERG, A (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1497	1498		10.1096/fasebj.9.14.7589992	http://dx.doi.org/10.1096/fasebj.9.14.7589992			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589992				2022-12-28	WOS:A1995TF67800017
J	TODD, R; MCBRIDE, J; TSUJI, T; DONOFF, RB; NAGAI, M; CHOU, MY; CHIANG, T; WONG, DTW				TODD, R; MCBRIDE, J; TSUJI, T; DONOFF, RB; NAGAI, M; CHOU, MY; CHIANG, T; WONG, DTW			DELETED IN ORAL CANCER-1 (DOC-1), A NOVEL ORAL TUMOR-SUPPRESSOR GENE	FASEB JOURNAL			English	Article						CHEMICAL CARCINOGENS; SUBTRACTIVE HYBRIDIZATION	HUMAN CHORIONIC-GONADOTROPIN; POUCH KERATINOCYTES; DOWN-REGULATION; HA-RAS; CELLS; EXPRESSION; ONCOGENES; CARCINOGENESIS; ANGIOGENESIS; CARCINOMA	We have identified, isolated, and partially characterized doc-1, a novel cDNA sequence whose activity is consistent with a suppressor of hamster oral carcinogenesis. Doc-1 is an evolutionarily conserved gene exhibiting loss of heterozygosity and marked reduction in expression in malignant hamster oral keratinocytes. The full-length doc-1 cDNA encodes an 87 amino acid product that shows a significant homology to one of the seven novel genes induced in mouse fibroblasts by TNF-alpha. Transfection of the full-length doc-1 cDNA into malignant hamster oral keratinocytes alters the behavior of the recipients in terms of morphology, growth rate, and anchorage-independent growth, suggesting reversion of transformation phenotypes. We propose that doc-1 is a novel tumor suppressor gene in oral cancer development.	HARVARD UNIV, SCH DENT MED, DEPT ORAL MED & DIAGNOST SCI, DIV ORAL PATHOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ORAL & MAXILLOFACIAL SURG, BOSTON, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital			Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008680, R29DE008680, R03DE010208] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10208, DE-08680, DE-00275] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUSTRUY E, 1993, CANCER RES, V53, P2888; BOUCK N, 1986, CANCER RES, V46, P5101; BOUCK NP, 1989, RECESSIVE ONCOGENE T; BOYD NM, 1988, J ORAL PATHOL MED, V17, P193, DOI 10.1111/j.1600-0714.1988.tb01524.x; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHIANG T, 1991, CARCINOGENESIS, V12, P529; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD JK, 1994, ORAL ONCOL, V288, P67; Freshney RI, 1994, CULTURE ANIMAL CELLS; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; GIMENEZCONTI IB, 1903, J CELL BIOCHEM, P83; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU LC, 1993, CANCER RES, V53, P5766; HUSAIN Z, 1989, P NATL ACAD SCI USA, V86, P1264, DOI 10.1073/pnas.86.4.1264; ISSING WJ, 1993, ANTICANCER RES, V13, P2541; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JIN YS, 1993, ORAL ONCOL, V29B, P257, DOI 10.1016/0964-1955(93)90045-G; KLICKSTEIN LB, 1987, CURRENT PROTOCOLS MO; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LIN MH, 1994, ORAL ONCOL, V30B, P252, DOI 10.1016/0964-1955(94)90007-8; MOROCO JR, 1990, LAB INVEST, V63, P298; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; ODUKOYA O, 1983, J NATL CANCER I, V71, P1253; ONO M, 1985, J VIROL, V55, P387, DOI 10.1128/JVI.55.2.387-394.1985; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PARTRIDGE M, 1994, ORAL ONCOL, V30B, P248, DOI 10.1016/0964-1955(94)90006-X; POLVERINI PJ, 1986, LAB INVEST, V54, P432; POLVERINI PJ, 1988, CARCINOGENESIS, V9, P117, DOI 10.1093/carcin/9.1.117; POLVERINI PJ, 1988, J ORAL PATHOL MED, V17, P522, DOI 10.1111/j.1600-0714.1988.tb01328.x; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SAGER R, 1992, Current Opinion in Cell Biology, V4, P155, DOI 10.1016/0955-0674(92)90026-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCULLY C, 1993, J ORAL PATHOL MED, V22, P337, DOI 10.1111/j.1600-0714.1993.tb01086.x; Shklar G, 1984, ORAL CANCER, P41; SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082; SLAGA TJ, 1992, NATL CANCER I MONOGR, V13, P55; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; TADOKORO K, 1989, ONCOGENE, V4, P499; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WONG DTW, 1985, J CELL BIOL, V101, P2245, DOI 10.1083/jcb.101.6.2245; WONG DTW, 1984, J BIOL CHEM, V259, P738; WONG DTW, 1993, ORAL ONCOL, V29B, P3, DOI 10.1016/0964-1955(93)90003-W; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360	53	76	86	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1995	9	13					1362	1370		10.1096/fasebj.9.13.7557027	http://dx.doi.org/10.1096/fasebj.9.13.7557027			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557027				2022-12-28	WOS:A1995TA37000016
J	CHEN, JK; CHAO, HH; YANG, VC				CHEN, JK; CHAO, HH; YANG, VC			INHIBITION OF THE GROWTH OF A HUMAN NASOPHARYNGEAL CARCINOMA CELL-LINE BY BFGF IS MEDIATED VIA FGFR-1	FASEB JOURNAL			English	Article						FIBROBLAST GROWTH FACTORS; CARCINOMA CELLS; GROWTH INHIBITION; FGF RECEPTOR SUBTYPES; HEPARIN-LIKE MOLECULES	IMMUNOGLOBULIN DOMAIN; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; FIBROBLAST; GENE; EXPRESSION; IDENTIFICATION; SPECIFICITY; CLONING; FAMILY	The growth of CG-1 human nasopharyngeal carcinoma cell line and five of its randomly selected, single cell-derived subline cells is inhibited by bFGF in an autocrine and paracrine manner. In contrast, aFGF, which has a 55% homology in amino acid sequence with bFGF, stimulates cell growth. Basic FGF binds to specific cell surface high-affinity receptor sites with an apparent K-d of 105 pM. Of the two lines examined, the high-affinity binding sites for bFGF are calculated to be 1200 and 2600 per cell. The biological effect of bFGF is conveyed through its binding to the high-affinity receptor sites and the binding is dependent on the presence of cell surface heparin-like molecules, as treatment of cells with heparitinase or sodium chlorate abolishes high-affinity binding and growth inhibition. In contrast, similar treatment has no obvious effect on the growth-stimulatory effect of aFGF. Experimental results are also presented showing that the growth inhibition by bFGF is mediated through type I FGF receptors. These results suggest that bFGF and aFGF act via distinct receptor types to oppositely regulate the growth of CG-1 and subline cells.	TUNGHAI UNIV, INST BIOL GRAD, TAICHUNG 40704, TAIWAN	Tunghai University	CHEN, JK (corresponding author), CHANG GUNG COLL MED & TECHNOL, DEPT PHYSIOL, TAYUAN 333, TAIWAN.							AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BECKER D, 1992, ONCOGENE, V7, P2303; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG YS, 1989, CANCER RES, V49, P6752; CHAO HH, 1993, INT J CANCER, V54, P807, DOI 10.1002/ijc.2910540515; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN JK, 1992, IN VITRO CELL DEV-AN, V28A, P561, DOI 10.1007/BF02631020; CHEN JK, 1994, J CELL PHYSIOL, V160, P401, DOI 10.1002/jcp.1041600302; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EHRLICH R, 1979, J IMMUNOL METHODS, V26, P345, DOI 10.1016/0022-1759(79)90180-7; EISEMANN A, 1991, ONCOGENE, V6, P1195; GLEAVE M, 1991, CANCER RES, V51, P3753; HOSHI H, 1988, IN VITRO CELL DEV B, V24, P309; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAMATA N, 1986, CANCER RES, V46, P1648; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MAIER JAM, 1990, EXP CELL RES, V186, P354, DOI 10.1016/0014-4827(90)90316-3; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NEW BA, 1992, J CELL PHYSIOL, V150, P320, DOI 10.1002/jcp.1041500215; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RAZ V, 1991, ONCOGENE, V6, P753; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TORU M, 1992, P NATL ACAD SCI USA, V89, P246; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	38	5	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1995	9	12					1211	1219		10.1096/fasebj.9.12.7672514	http://dx.doi.org/10.1096/fasebj.9.12.7672514			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672514				2022-12-28	WOS:A1995RU81600011
J	SATO, K; KASHIWAYA, Y; KEON, CA; TSUCHIYA, N; KING, MT; RADDA, GK; CHANCE, B; CLARKE, K; VEECH, RL				SATO, K; KASHIWAYA, Y; KEON, CA; TSUCHIYA, N; KING, MT; RADDA, GK; CHANCE, B; CLARKE, K; VEECH, RL			INSULIN, KETONE-BODIES, AND MITOCHONDRIAL ENERGY TRANSDUCTION	FASEB JOURNAL			English	Article						TRICARBOXYLIC ACID CYCLE INTERMEDIATES; MITOCHONDRIAL REDOX STATES; DELTA-PH; E(MITO/CYTO), DELTA-G(ATP)	PHOSPHATE-TRANSPORT; TISSUES; RESPIRATION; METABOLISM; MECHANISM; MEMBRANE; KINETICS; PLASMA; CELLS	Addition of insulin or a physiological ratio of ketone bodies to buffer with 10 mM glucose increased efficiency (hydraulic work/energy from O-2 consumed) of working rat heart by 25%, and the two in combination increased efficiency by 36%. These additions increased the content of acetyl CoA by 9- to 18-fold, increased the contents of metabolites of the first third of the tricarboxylic acid (TCA) cycle 2- to 5-fold, and decreased succinate, oxaloacetate, and aspartate 2- to 3-fold. Succinyl CoA, fumarate, and malate were essentially unchanged. The changes in content of TCA metabolites resulted from a reduction of the free mitochondrial NAD couple by 2- to 10-fold and oxidation of the mitochondrial coenzyme Q couple by 2- to 4-fold. Cytosolic pH, measured using P-31-NMR spectra, was invariant at about 7.0. The total intracellular bicarbonate indicated an increase in mitochondrial pH from 7.1 with glucose to 7.2, 7.5, and 7.4 with insulin, ketones, and the combination, respectively. The decrease in Eh(7) of the mitochondrial NAD couple, Eh(NAD+/NADH)(7), from -280 to -300 mV and the increase in Eh(7) of the coenzyme Q couple, Eh(Q/QH2)(7), from -4 to +12 mV was equivalent to an increase from -53 kJ to -60 kJ/2 mol e in the reaction catalyzed by the mitochondrial NADH dehydrogenase multienzyme complex (EC 1.6.5.3). The increase in the redox energy of the mitochondrial cofactor couples paralleled the increase in the free energy of cytosolic ATP hydrolysis, Delta G(ATP). The potential of the mitochondrial relative to the cytosolic phases, E(mito/cyto), calculated from Delta G(ATP) and Delta pH on the assumption of a 4 H+ transfer for each ATP synthesized, was -143 mV during perfusion with glucose or glucose plus insulin, and decreased to -120 mV on addition of ketones. Viewed in this light, the moderate ketosis characteristic of prolonged fasting or type II diabetes appears to be an elegant compensation for the defects in mitochondrial energy transduction associated with acute insulin deficiency or mitochondrial senescence.	NIAAA, METAB & MOLEC BIOL LAB, ROCKVILLE, MD 20852 USA; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Oxford; University of Pennsylvania								ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; Altman PL, 1971, RESP CIRC, P16; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; BURTON K, 1953, BIOCHEM J, V54, P94, DOI 10.1042/bj0540094; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHANCE B, 1961, J BIOL CHEM, V236, P1577; CHRISTOF.C, 1969, J APPL PHYSIOL, V26, P56, DOI 10.1152/jappl.1969.26.1.56; CLARK WM, 1960, OXIDATION REDUCTION, P349; CLARKE K, 1987, AM J PHYSIOL, V253, pH412, DOI 10.1152/ajpheart.1987.253.2.H412; CORNELL NW, 1979, ANAL BIOCHEM, V95, P524, DOI 10.1016/0003-2697(79)90766-8; COTY WA, 1974, J BIOL CHEM, V249, P2593; DAVIS RJ, 1981, BIOCHEM J, V196, P133, DOI 10.1042/bj1960133; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1987, BIOCHEM SOC SYMP, P127; DOBSON GP, 1991, ANAL BIOCHEM, V195, P232, DOI 10.1016/0003-2697(91)90322-K; ENGEL PC, 1969, BIOCHEM J, V115, P621, DOI 10.1042/bj1150621; FELIG P, 1970, NEW ENGL J MED, V282, P166; FOLBERGROVA J, 1969, J NEUROCHEM, V16, P191, DOI 10.1111/j.1471-4159.1969.tb05937.x; GOLDBERG ND, 1966, J BIOL CHEM, V241, P3997; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GUYNN RW, 1973, J BIOL CHEM, V248, P6957; HAGLER HK, 1986, J MICROSC-OXFORD, V141, P311, DOI 10.1111/j.1365-2818.1986.tb02725.x; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KING MT, 1988, METHOD ENZYMOL, V166, P70; Klingenberg M, 1970, Essays Biochem, V6, P119; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NEELY JR, 1967, AM J PHYSIOL, V212, P804; NEELY JR, 1967, AM J PHYSIOL, V212, P815; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PETTE D, 1962, BIOCHEM BIOPH RES CO, V7, P425, DOI 10.1016/0006-291X(62)90328-5; REYNAFARJE B, 1978, P NATL ACAD SCI USA, V75, P4788, DOI 10.1073/pnas.75.10.4788; Sendroy J, 1934, J BIOL CHEM, V105, P597; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLATER EC, 1969, ENERGY LEVEL METABOL, P1; SRERE PA, 1981, TRENDS BIOCHEM SCI, V6, P4, DOI 10.1016/0968-0004(81)90003-7; UMBREIT WW, 1972, MANOMETRIC BIOCH TEC, P6; Veech R L, 1986, Adv Exp Med Biol, V194, P617; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	51	307	315	3	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					651	658		10.1096/fasebj.9.8.7768357	http://dx.doi.org/10.1096/fasebj.9.8.7768357			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768357				2022-12-28	WOS:A1995RC10600011
J	LORSCHEIDER, FL; VIMY, MJ; SUMMERS, AO				LORSCHEIDER, FL; VIMY, MJ; SUMMERS, AO			MERCURY EXPOSURE FROM SILVER TOOTH FILLINGS - EMERGING EVIDENCE QUESTIONS A TRADITIONAL DENTAL PARADIGM	FASEB JOURNAL			English	Review						MERCURY TOXICITY; DENTAL AMALGAM	ALZHEIMERS-DISEASE; AMALGAM FILLINGS; TRACE-ELEMENT; BETA-TUBULIN; BRAIN; GLUTATHIONE; PRIMATES; METALS; VAPOR; AIR	For more than 160 years dentistry has used silver amalgam, which contains approximately 50% Hg metal, as the preferred tooth filling material. During the past decade medical research has demonstrated that this Hg is continuously released as vapor into mouth air; then it is inhaled, absorbed into body tissues, oxidized to ionic Hg, and finally covalently bound to cell proteins. Animal and human experiments demonstrate that the uptake, tissue distribution, and excretion of amalgam Hg is significant, and that dental amalgam is the major contributing source to Hg body burden in humans. Current research on the pathophysiological effects of amalgam Hg has focused upon the immune system, renal system, oral and intestinal bacteria, reproductive system, and the central nervous system. Research evidence does not support the notion of amalgam safety.	UNIV CALGARY,FAC MED,DEPT MED,CALGARY,AB T2N 4N1,CANADA; UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	University of Calgary; University System of Georgia; University of Georgia	LORSCHEIDER, FL (corresponding author), UNIV CALGARY,FAC MED,DEPT MED PHYSIOL,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.			Summers, Anne/0000-0003-4258-9696				APOSHIAN HV, 1992, FASEB J, V6, P272; Aronsson A M, 1989, Biol Met, V2, P25, DOI 10.1007/BF01116197; BERRY TG, 1994, J AM DENT ASSOC, V125, P392, DOI 10.14219/jada.archive.1994.0053; Bloomfield V. A., 1974, PHYSICAL CHEM NUCLEI, P420; BOYD ND, 1991, AM J PHYSIOL, V261, pR1010, DOI 10.1152/ajpregu.1991.261.4.R1010; BREMNER MDK, 1954, STORY DENTISTRY; CLARKSON TW, 1988, BIOL MONITORING TOXI, P199; DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T; DARIEL MP, 1994, POWDER METALL, V37, P88; DEXTER JE, 1876, HIST DENTAL ORAL SCI; DRASCH G, 1994, EUR J PEDIATR, V153, P607, DOI 10.1007/s004310050200; DRUET P, 1982, ARCH TOXICOL, V50, P187, DOI 10.1007/BF00310850; DUHR E, 1991, FASEB J, V5, pA456; DUHR EF, 1993, TOXICOL APPL PHARM, V122, P273, DOI 10.1006/taap.1993.1196; ESCHEVERRIA D, 1995, NEUROTOXICOL TERATOL, V17, P161; FALCONER MM, 1994, NEUROTOXICOLOGY, V15, P109; GILBERT MP, 1988, PLASMID, V20, P127, DOI 10.1016/0147-619X(88)90015-7; GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I; GONZALEZRAMIREZ D, 1995, J PHARMACOL EXP THER, V272, P264; GROSS MJ, 1989, J APPL ELECTROCHEM, V19, P301, DOI 10.1007/BF01015227; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; HAHN LJ, 1989, FASEB J, V3, P2641, DOI 10.1096/fasebj.3.14.2636872; HIRSCH F, 1986, J IMMUNOL, V136, P3272; HULTMAN P, 1994, FASEB J, V8, P1183, DOI 10.1096/fasebj.8.14.7958626; INGALLS TH, 1983, AM J FOREN MED PATH, V4, P55, DOI 10.1097/00000433-198303000-00006; KHATOON S, 1989, ANN NEUROL, V26, P210, DOI 10.1002/ana.410260205; KLAASSEN CD, 1990, PHARMACOL BASIS THER, P1598; Lorscheider F. L., 1994, Neurotoxicology (Little Rock), V15, P955; LORSCHEIDER FL, 1993, FASEB J, V7, P1432, DOI 10.1096/fasebj.7.15.8262327; MAGOS L, 1978, BIOCHEM PHARMACOL, V27, P1373, DOI 10.1016/0006-2952(78)90122-3; MASI JV, 1995, STATUS QUO PERSPECTI; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOLIN M, 1990, ACTA ODONTOL SCAND, V48, P189, DOI 10.3109/00016359009005875; NYLANDER M, 1987, SWED DENT J, V11, P179; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PALK, 1994, J NEUROCHEM, V62, P2049; PATTERSON JE, 1985, B ENVIRON CONTAM TOX, V34, P459, DOI 10.1007/BF01609761; REINHARDT JW, 1988, J PUBLIC HEALTH DENT, V48, P172, DOI 10.1111/j.1752-7325.1988.tb03188.x; Ring M, 1985, DENT ILLUSTRATED HIS; ROWAND AS, 1994, OCCUP ENVIRON MED, V51, P28; SKARE I, 1994, ARCH ENVIRON HEALTH, V49, P384, DOI 10.1080/00039896.1994.9954991; SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825; SVARE CW, 1981, J DENT RES, V60, P1668, DOI 10.1177/00220345810600090601; THOMPSON CM, 1988, NEUROTOXICOLOGY, V9, P1; VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111; VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001; VIMY MJ, 1990, AM J PHYSIOL, V258, pR939, DOI 10.1152/ajpregu.1990.258.4.R939; VIMY MJ, 1985, J DENT RES, V6, P1069; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P; ZALUPS RK, 1990, TOXICOL APPL PHARM, V106, P245, DOI 10.1016/0041-008X(90)90244-O; ZALUPS RK, 1991, TOXICOL APPL PHARM, V54, P10; 1990, J AM DENT ASSN, V120, P395; [No title captured]; 1991, ENV HLTH CRITERIA, V118	54	138	145	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					504	508		10.1096/fasebj.9.7.7737458	http://dx.doi.org/10.1096/fasebj.9.7.7737458			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737458				2022-12-28	WOS:A1995QX14800007
J	MIHM, S; GALTER, D; DROGE, W				MIHM, S; GALTER, D; DROGE, W			MODULATION OF TRANSCRIPTION FACTOR NF-KAPPA-B ACTIVITY BY INTRACELLULAR GLUTATHIONE LEVELS AND BY VARIATIONS OF THE EXTRACELLULAR CYSTEINE SUPPLY	FASEB JOURNAL			English	Article						TNF-ALPHA; DNA-BINDING ACTIVITY; MOLT-4 CELLS; NF-KAPPA-B CONTROLS	HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; OXIDATION-REDUCTION; REDOX REGULATION; BUTHIONINE SULFOXIMINE; ENDOPLASMIC-RETICULUM; ACTIVATION; PROTEIN; INVITRO; LYMPHOCYTES	HIV-infected individuals and SIV-infected rhesus macaques have, on the average, decreased plasma cysteine and cystine concentrations and decreased intracellular glutathione levels. We now show that a depletion of intracellular glutathione in a human T cell line (Molt-4) inhibits the activation and nuclear translocation of the transcription factor NF kappa B, whereas incubation with increasing extracellular concentrations of cysteine inhibits the DNA-binding and transactivating activity of NF kappa B. Because inhibition of DNA-binding activity is associated with increasing intracellular glutathione disulfide levels and GSSG can be shown to inhibit the DNA-binding activity directly in cell-free systems, our studies suggest that GSSG is a physiologically relevant inhibitor in intact cells also, NF kappa B controls many immunologically important genes, so our studies suggest that the immune system may be sensitive not only against a cysteine and glutathione deficiency but also against an excess of cysteine.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT IMMUNOCHEM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Galter, Dagmar/C-4826-2011	Galter, Dagmar/0000-0001-6485-6244				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BUHL R, 1989, LANCET, V2, P1294; CACERES J, 1990, ONCOGENE, V5, P59; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; DROGE W, 1986, IMMUNOBIOLOGY, V172, P151; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ECK HP, 1992, INT IMMUNOL, V4, P7, DOI 10.1093/intimm/4.1.7; FEDORCSAK I, 1977, EXP CELL RES, V108, P331, DOI 10.1016/S0014-4827(77)80040-2; FRAME MC, 1991, ONCOGENE, V6, P205; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GMUNDER H, 1991, EUR J BIOCHEM, V201, P113, DOI 10.1111/j.1432-1033.1991.tb16263.x; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GMUNDER H, 1991, CELL IMMUNOL, V138, P229, DOI 10.1016/0008-8749(91)90147-4; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISHII T, 1985, J CELL PHYSIOL, V125, P151, DOI 10.1002/jcp.1041250119; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MESTDAGH N, 1992, BIOCHEM PHARMACOL, V43, P1529, DOI 10.1016/0006-2952(92)90211-Z; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLITOR JA, 1991, NEW BIOL, V3, P987; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEXTON DJ, 1992, COMP BIOCHEM PHYS B, V103, P897, DOI 10.1016/0305-0491(92)90211-9; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	49	147	148	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					246	252		10.1096/fasebj.9.2.7781927	http://dx.doi.org/10.1096/fasebj.9.2.7781927			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781927				2022-12-28	WOS:A1995QJ24900013
J	MILLER, N; VILE, R				MILLER, N; VILE, R			TARGETED VECTORS FOR GENE-THERAPY	FASEB JOURNAL			English	Review						TARGETING; RETROVIRUS; ADENOVIRUS; LIPOSOME	MURINE LEUKEMIA-VIRUS; RECEPTOR-MEDIATED ENDOCYTOSIS; HOST RANGE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; ADENOASSOCIATED VIRUS; RETROVIRAL VECTORS; CELL SPECIFICITY; GLIOMA-CELLS; EXPRESSION; DNA	Successful gene therapy requires not only the identification of an appropriate therapeutic gene for treatment of the disease, but also a delivery system by which that gene can be delivered to the desired cell type both efficiently and accurately. Reductions in accuracy will inevitably also reduce efficiency since fewer particles will be available for delivery to the correct cells if many are sequestered into nontarget cells. In addition, the therapy will have net benefit to the patient only if gene delivery is sufficiently restricted such that normal cells are left unaffected by any detrimental affects of bystander cell transduction. Here we review how currently available delivery systems, both plasmid and viral, can be manipulated to improve their targeting to specific cell types. Currently, targeting is achieved by engineering of the surface components of viruses and liposomes to achieve discrimination at the level of target cell recognition and/or by incorporating transcriptional elements into plasmid or viral genomes such that the therapeutic gene is expressed only in certain target cell types. In addition, we discuss emerging vectors and suggest how gene therapy delivery systems of the future will be composites of the best features of diverse vectors already in use.	ST THOMAS HOSP, RAYNE INST, IMPERIAL CANC RES FUND, CANC GENE THERAPY LAB, LONDON SE1 7EH, ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; ARBONES ML, 1994, NAT GENET, V6, P90, DOI 10.1038/ng0194-90; BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z; BATRA RK, 1994, GENE THER, V1, P255; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BRADY HJM, 1994, P NATL ACAD SCI USA, V91, P365, DOI 10.1073/pnas.91.1.365; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BURNS NR, 1992, EMBO J, V11, P1155, DOI 10.1002/j.1460-2075.1992.tb05156.x; CALAFAT J, 1983, J GEN VIROL, V64, P1241, DOI 10.1099/0022-1317-64-6-1241; CHAKRABORTY AK, 1993, FASEB J, V7, P971, DOI 10.1096/fasebj.7.10.8393821; CHEN JB, 1994, FEBS LETT, V338, P167, DOI 10.1016/0014-5793(94)80357-9; CHIORINI JA, 1994, J VIROL, V68, P797, DOI 10.1128/JVI.68.2.797-804.1994; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; DUPONT F, 1994, J VIROL, V68, P1397, DOI 10.1128/JVI.68.3.1397-1406.1994; ETIENNEJULAN M, 1992, J GEN VIROL, V73, P3251, DOI 10.1099/0022-1317-73-12-3251; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GOUD B, 1988, VIROLOGY, V163, P251, DOI 10.1016/0042-6822(88)90261-9; GUETTA E, 1986, J NATL CANCER I, V76, P1177; HARRIS JD, 1994, GENE THER, V1, P170; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HUXLEY C, 1994, GENE THER, V1, P7; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LOZIER JN, 1994, HUM GENE THER, V5, P313, DOI 10.1089/hum.1994.5.3-313; MAXWELL IH, 1991, CANCER RES, V51, P4299; MAYOR HD, 1993, PROG MED VIROL, V40, P193; MCDONALD JF, 1993, CURR OPIN GENET DEV, V3, P855, DOI 10.1016/0959-437X(93)90005-A; MICHAEL SI, 1993, J BIOL CHEM, V268, P6866; MICHAEL SI, 1994, GENE THER, V1, P223; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MIYAO Y, 1993, J NEUROSCI RES, V36, P472, DOI 10.1002/jnr.490360413; MIZUNO M, 1990, CANCER RES, V50, P7826; MORGAN RA, 1993, J VIROL, V67, P4712, DOI 10.1128/JVI.67.8.4712-4721.1993; MORISHITA R, 1993, HYPERTENSION, V21, P894, DOI 10.1161/01.HYP.21.6.894; MOULLIER P, 1994, KIDNEY INT, V45, P1220, DOI 10.1038/ki.1994.162; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NEDA H, 1991, J BIOL CHEM, V266, P14143; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROSENKRANZ AA, 1992, EXP CELL RES, V199, P323, DOI 10.1016/0014-4827(92)90441-A; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2; SCHREIER H, 1993, J CONTROL RELEASE, V24, P209, DOI 10.1016/0168-3659(93)90180-D; SHELLING AN, 1994, GENE THER, V1, P165; STAVRIDIS JC, 1986, EXP CELL RES, V164, P568, DOI 10.1016/0014-4827(86)90056-X; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TAKEUCHI Y, 1992, VIROLOGY, V186, P792, DOI 10.1016/0042-6822(92)90049-U; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; VILE R, 1994, GENE THER, V1, P88; VILE RG, 1993, CANCER RES, V53, P3860; VILE RG, 1991, VIROLOGY, V180, P420, DOI 10.1016/0042-6822(91)90050-L; VOYTAS DF, 1993, TRENDS GENET, V9, P421, DOI 10.1016/0168-9525(93)90105-Q; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WALTHER FJ, 1993, AM J PHYSIOL, V265, pL330, DOI 10.1152/ajplung.1993.265.4.L330; Weiss RA, 1993, RETROVIRIDAE, P1; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WU GY, 1994, J BIOL CHEM, V269, P11542; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YOUNG JAT, 1990, SCIENCE, V250, P1421, DOI 10.1126/science.2175047; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; ZHU ZH, 1990, J ACQ IMMUN DEF SYND, V3, P215	71	150	386	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					190	199		10.1096/fasebj.9.2.7781922	http://dx.doi.org/10.1096/fasebj.9.2.7781922			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781922	Bronze			2022-12-28	WOS:A1995QJ24900007
J	TICHER, A; ASHKENAZI, IE; REINBERG, AE				TICHER, A; ASHKENAZI, IE; REINBERG, AE			PRESERVATION OF THE FUNCTIONAL ADVANTAGE OF HUMAN TIME STRUCTURE	FASEB JOURNAL			English	Article						BIOLOGICAL RHYTHMS; HUMAN TEMPORAL ORDER; ADAPTIVE VALUE	CIRCADIAN-RHYTHMS	Upon exposure to sustained and synchronized diurnal activity, most human variables exhibit rhythms with a 24 h period. The best-fitting cosine curve to the data with a selected period (24 h) may yield parameters like acrophase (estimated peak time), amplitude, and mesor (rhythm adjusted mean). The sequential array of the rhythms' acrophases constructs the temporal order. Analyzing 168 different human rhythms revealed a time-dependent distribution with regard to the number of acrophases/h and to the clustering of variables according to function. Rhythms' amplitude/mesor ratios yielded a five modal distribution. The modes occurred at those clock times where repetitive habitual signals are anticipated. It is assumed that these specific features evolved to optimize the adaptive value of the temporal order.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,CHRONOBIOL UNIT,IL-69978 TEL AVIV,ISRAEL; FDN A ROTHSCHILD,CHRONOBIOL UNIT,F-75940 PARIS 19,FRANCE	Tel Aviv University; Sackler Faculty of Medicine								ANDLAUER P, 1979, J PHYSIOL-PARIS, V75, P507; ASCHOFF J, 1982, BIOL TIMEKEEPING, P143; ASCHOFF J, 1992, CIRCADIAN RHYTHMS DI, V7, P16; DEPRINS J, 1986, ANN REV CHRONOPHARMA, V2, P7; GOI G, 1989, CHRONOBIOLOGIA, V16, P63; GUIGNARD MM, 1980, ACTA ENDOCRINOL-COP, V94, P536, DOI 10.1530/acta.0.0940536; HALBERG F, 1967, J PHYSIOLOGY PARIS, V59, P117; HAUS E, 1990, ANN R CHRON, V7, P153; Haus E, 1988, ANN REV CHRONOPHARMA, V4, P333; KLEIN KE, 1977, VIGILANCE THEORY OPE, P111; MILLS JN, 1978, CHRONOBIOLOGIA, V5, P14; MINORS DS, 1989, CHRONOBIOL INT, V6, P29, DOI 10.3109/07420528909059140; MINORS DS, 1990, OCCUP MED, V5, P165; MINORS DS, 1989, BIOL RHYTHMS CLIN PR, P272; Monk T H, 1989, Clin Geriatr Med, V5, P331; Moore-Ede MC., 1982, CLOCKS TIME US; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1961, HARVEY LECT, V56, P93; REINBERG A, 1988, EUR J APPL PHYSIOL O, V57, P15, DOI 10.1007/BF00691232; Reinberg A, 1983, BIOL RHYTHMS MED; Reinberg A.E., 1992, BIOL RHYTHMS CLIN LA, P243; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; WINGET CM, 1985, MED SCI SPORT EXER, V17, P498; 1985, SAS USERS GUIDE STAT	24	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					269	272		10.1096/fasebj.9.2.7781929	http://dx.doi.org/10.1096/fasebj.9.2.7781929			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781929				2022-12-28	WOS:A1995QJ24900016
J	LU, CY; KHAIRELDIN, TA; DAWIDSON, IA; BUTLER, TM; BRASKY, KM; VAZQUEZ, MA; SICHER, SC				LU, CY; KHAIRELDIN, TA; DAWIDSON, IA; BUTLER, TM; BRASKY, KM; VAZQUEZ, MA; SICHER, SC			XENOTRANSPLANTATION	FASEB JOURNAL			English	Review						TRANSPLANTATION; PRIMATE; NATURAL ANTIBODY; COMPLEMENT; SWINE	XENOGRAFT HYPERACUTE REJECTION; ANTIGEN-PRESENTING CELLS; NATURAL ANTIBODIES; ENDOTHELIAL-CELLS; HEPARAN-SULFATE; T-CELLS; COMPLEMENT; MODEL; SYSTEM; IGM	Transplantation of solid organs (heart, lung, liver, and kidney) from swine to humans would solve the current critical shortage of cadaver organs needed by patients with end-stage disease of these organs. In addition, transplantation between distant species (discordant xenografting) will require an understanding of a number of unique immunologic features. Discordant xenografts are rejected within minutes to hours after transplantation. This rejection is due to natural immunity by recipients never before exposed to the xenografts. In some species combinations, this fulminant rejection is due to naturally occurring pre-existing antibodies against the xenograft endothelium. In other species combinations, the xenograft activates the alternative pathway of complement. The swine to human species combination is the most clinically relevant. In this combination, natural human and private antibodies recognize alpha-galactosyl residues of glycoproteins and glycolipids. Potential future therapeutic measures to prevent natural immunity include the genetic engineering of human complement inhibitors into swine cell membranes or genetic ''knock out'' of the enzymes responsible for placing alpha-galactosyl residues on swine cell surfaces. There are also special considerations in acquired immunity against xenografts. Cytokines and adhesion molecules may not work across species lines. Xenograft antigens may have to be processed by host antigen-presenting cells in order to effectively stimulate the immune system.	UNIV TEXAS,SW MED SCH,DEPT SURG,DIV TRANSPLANTAT,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,DEPT INTERNAL MED,DIV NEPHROL,DALLAS,TX 75235; SW FDN BIOMED RES,DEPT LAB ANIM MED,SAN ANTONIO,TX 78228; UNIV TEXAS,PARKLAND MEM HOSP,TRANSPLANT PROGRAM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Texas Biomedical Research Institute; University of Texas System; University of Texas Dallas					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043634] Funding Source: NIH RePORTER; NICHD NIH HHS [KO4-HD-00862, R0-1 HD242792] Funding Source: Medline; NIDDK NIH HHS [R0-1 DK43634] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexandre GP, 1991, TRANSPLANT REV-ORLAN, V5, P230; ALEXANDRE GPJ, 1989, XENOGRAFT, V25, P259; ALTER BJ, 1990, J EXP MED, V171, P333, DOI 10.1084/jem.171.1.333; ATKINSON JP, 1987, IMMUNOL TODAY, V8, P212, DOI 10.1016/0167-5699(87)90167-8; AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; AVRAMEAS S, 1993, MOL IMMUNOL, V30, P1133, DOI 10.1016/0161-5890(93)90160-D; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACH FH, 1991, TRANSPL P, V23, P205; BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; CALNE RY, 1989, XENOGRAFT, V25, P3; COOPER DKC, 1993, TRANSPLANT P, V25, P377; COOPER DKC, 1993, TRANSPLANTATION, V56, P769, DOI 10.1097/00007890-199310000-00001; COOPER DKC, 1988, J HEART TRANSPLANT, V7, P238; DALMASSO AP, 1993, TRANSPLANTATION, V56, P1171, DOI 10.1097/00007890-199311000-00024; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; EBELING SB, 1993, J IMMUNOL, V151, P6891; FISCHEL RJ, 1992, J HEART LUNG TRANSPL, V11, P965; FRANK MM, 1989, FUNDAMENTAL IMMUNOLO, P679; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GELLER RL, 1993, TRANSPLANTATION, V55, P168, DOI 10.1097/00007890-199301000-00031; GELLER RL, 1992, J AM SOC NEPHROL, V3, P1189; GOOD AH, 1992, TRANSPL P, V24, P559; HAMMER C, 1987, TRANSPL P, V19, P4443; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HAUGHTON G, 1993, IMMUNOL TODAY, V14, P84, DOI 10.1016/0167-5699(93)90064-R; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; INVERARDI L, 1992, TRANSPLANT P, V24, P459; JOHNSTON PS, 1992, TRANSPLANTATION, V54, P573, DOI 10.1097/00007890-199210000-00001; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KIRK AD, 1993, TRANSPLANTATION, V55, P924, DOI 10.1097/00007890-199304000-00043; KIRKMAN RL, 1989, XENOGRAFT, V25, P125; KOREN E, 1992, TRANSPLANT P, V24, P598; LEVENTHAL JR, 1994, TRANSPLANT REV, V8, P80; LEXER G, 1986, Journal of Heart Transplantation, V5, P411; LUCAS PJ, 1990, J IMMUNOL, V144, P4548; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; MOSES RD, 1990, J EXP MED, V172, P567, DOI 10.1084/jem.172.2.567; PERPER ROBERT J., 1966, TRANSPLANTATION, V4, P377, DOI 10.1097/00007890-196607000-00002; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; PLATT JL, 1991, TRANSPLANTATION, V52, P214, DOI 10.1097/00007890-199108000-00006; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; PLATT JL, 1991, TRANSPLANTATION, V52, P937, DOI 10.1097/00007890-199112000-00001; POTTER KN, 1993, J EXP MED, V1419, P1428; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; REEMTSMA K, 1964, ANN SURG, V160, P384, DOI 10.1097/00000658-196409000-00006; RICE HE, 1993, J SURG RES, V54, P355, DOI 10.1006/jsre.1993.1057; ROSE AG, 1991, J HEART LUNG TRANSPL, V10, P223; ROSS JR, 1993, TRANSPLANTATION, V55, P1144, DOI 10.1097/00007890-199305000-00040; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SANZ I, 1989, J IMMUNOL, V142, P4054; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; STARZL TE, 1989, XENOGRAFT, V25, P17; STREILEIN JW, 1991, TRANSPLANTATION, V52, P1, DOI 10.1097/00007890-199107000-00001; TURMAN MA, 1991, TRANSPLANTATION, V52, P710, DOI 10.1097/00007890-199110000-00024; TWEARDY DJ, 1982, CLIN RES, V30, pA359; WHITE D, 1993, LANCET, V342, P879, DOI 10.1016/0140-6736(93)91939-J; Wood L, 1986, J Clin Apher, V3, P124, DOI 10.1002/jca.2920030209; WORTIS H, 1993, IMMUNOL TODAY, V14, P89, DOI 10.1016/0167-5699(93)90067-U; ZHAO J, 1991, J BIOL CHEM, V266, P13418	61	45	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1122	1130		10.1096/fasebj.8.14.7958617	http://dx.doi.org/10.1096/fasebj.8.14.7958617			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958617				2022-12-28	WOS:A1994PT12800006
J	GIBEAUT, DM; CARPITA, NC				GIBEAUT, DM; CARPITA, NC			BIOSYNTHESIS OF PLANT-CELL WALL POLYSACCHARIDES	FASEB JOURNAL			English	Review						CELLULOSE; CALLOSE; (1-]3)-BETA-D-GLUCAN; (1-]4)-BETA-D-GLUCAN; (1-]3), (1-]4)-BETA-D-GLUCAN; GLUCOMANNAN; GLUCURONO(ARABINO)XYLAN; GLYCOSYLTRANSFERASE; GLYCAN SYNTHASE; XYLOGLUCAN	(1,3)-BETA-GLUCAN CALLOSE SYNTHASE; CYCLIC DIGUANYLIC ACID; BETA-VULGARIS L; DEPENDENT CELLULOSE SYNTHASE; DAUCUS-CAROTA L; UDP-GLUCOSE; ACETOBACTER-XYLINUM; GLUCAN SYNTHASE; 1,3-BETA-GLUCAN SYNTHASE; GOLGI-APPARATUS	The cell wall is the principal structural element of plant form. Cellulose, long crystals of several dozen glucan chains, forms the microfibrillar foundation of plant cell walls and is synthesized at the plasma membrane. Except for callose, all other noncellulosic components are secreted to the cell surface and form a porous matrix assembled around the cellulose microfibrils. These diverse noncellulosic polysaccharides and proteins are made in the endomembrane system. Many questions about the biosynthesis and modification within the Golgi apparatus and integration of cell components at the cell surface remain unanswered. The lability of synthetic complexes upon isolation is one reason for slow progress. However, with new methods of membrane isolation and analysis of products in vitro, recent advances have been made in purifying active synthases from plasma membrane and Golgi apparatus. Likely synthase polypeptides have been identified by affinity-labeling techniques, but we are just beginning to understand the unique features of the coordinated assembly of complex polysaccharides. Nevertheless, such progress renews hope that the first gene of a synthase for a wall polysaccharide from higher plants is within our grasp.	PURDUE UNIV, DEPT BOT & PLANT PATHOL, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus								ALONI Y, 1983, J BIOL CHEM, V258, P4419; AMOR Y, 1991, PLANT CELL, V3, P989, DOI 10.1105/tpc.3.9.989; BACIC A, 1981, PLANTA, V152, P346, DOI 10.1007/BF00388260; BAYDOUN EAH, 1989, BIOCHEM J, V257, P853, DOI 10.1042/bj2570853; BLANTON RL, 1990, PLANTA, V180, P324, DOI 10.1007/BF00198783; BRUMMELL DA, 1990, J CELL SCI, V96, P705; BULONE V, 1990, PLANT PHYSIOL, V94, P1748, DOI 10.1104/pp.94.4.1748; CAMIRAND A, 1987, PLANT PHYSIOL, V84, P753, DOI 10.1104/pp.84.3.753; CAMPBELL RE, 1988, BIOCHEM J, V253, P795, DOI 10.1042/bj2530795; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CARPITA NC, 1980, PLANT PHYSIOL, V66, P911, DOI 10.1104/pp.66.5.911; DELMER DP, 1993, PLANT PHYSIOL, V103, P307, DOI 10.1104/pp.103.2.307; DELMER DP, 1982, P NATL ACAD SCI-BIOL, V79, P5282, DOI 10.1073/pnas.79.17.5282; DELMER DP, 1991, PLANT PHYSIOL, V95, P556, DOI 10.1104/pp.95.2.556; DELMER DP, 1991, CYTOSKELETAL BASIS P, P101; DHUGGA KS, 1991, J BIOL CHEM, V266, P21977; DHUGGA KS, 1991, PLANT PHYSIOL, V95, P1302, DOI 10.1104/pp.95.4.1302; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; DRIOUICH A, 1993, TRENDS BIOCHEM SCI, V18, P210, DOI 10.1016/0968-0004(93)90191-O; EDWARDS M, 1989, PLANTA, V178, P41, DOI 10.1007/BF00392525; EIBERGER LL, 1987, PLANT PHYSIOL, V83, P982, DOI 10.1104/pp.83.4.982; EMONS AMC, 1991, BIOSYNTHESIS BIODEGR, P71; FARKAS V, 1988, ARCH BIOCHEM BIOPHYS, V264, P48, DOI 10.1016/0003-9861(88)90568-1; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; FINCHER GB, 1981, ENCY PLANT PHYSL B, V13, P68; FINK J, 1990, PLANTA, V181, P343, DOI 10.1007/BF00195886; FREDRIKSON K, 1991, PHYSIOL PLANTARUM, V81, P289, DOI [10.1111/j.1399-3054.1991.tb08734.x, 10.1034/j.1399-3054.1991.810301.x]; FROST DJ, 1990, J BIOL CHEM, V265, P2162; FRY SC, 1983, PLANT PHYSIOL, V73, P1055, DOI 10.1104/pp.73.4.1055; GALBRAITH DW, 1982, PHYSIOL PLANTARUM, V55, P25, DOI 10.1111/j.1399-3054.1982.tb00279.x; GIBEAUT DM, 1993, P NATL ACAD SCI USA, V90, P3850, DOI 10.1073/pnas.90.9.3850; GIBEAUT DM, 1990, PROTOPLASMA, V156, P82, DOI 10.1007/BF01666509; GIBEAUT DM, 1994, PROTOPLASMA, V180, P92, DOI 10.1007/BF01379227; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; GIRARD V, 1992, PLANT SCI, V82, P145, DOI 10.1016/0168-9452(92)90216-9; GIRARD V, 1991, FEMS MICROBIOL LETT, V82, P293; GORDON R, 1989, PLANT PHYSIOL, V91, P373, DOI 10.1104/pp.91.1.373; HANNA R, 1991, ARCH BIOCHEM BIOPHYS, V290, P7, DOI 10.1016/0003-9861(91)90584-6; HAYASHI T, 1981, PLANT CELL PHYSIOL, V22, P1571, DOI 10.1093/oxfordjournals.pcp.a076310; HAYASHI T, 1988, PLANT PHYSIOL, V87, P341, DOI 10.1104/pp.87.2.341; HAYASHI T, 1981, J BIOL CHEM, V256, P1117; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; HEINIGER U, 1983, PLANT SCI LETT, V32, P35, DOI 10.1016/0304-4211(83)90096-2; HENRY RJ, 1982, PLANT PHYSIOL, V69, P632, DOI 10.1104/pp.69.3.632; HENRY RJ, 1985, CARBOHYD POLYM, V5, P1, DOI 10.1016/0144-8617(85)90015-3; HOBBS MC, 1991, BIOCHEM J, V277, P653, DOI 10.1042/bj2770653; IIYAMA K, 1993, FORAGE CELL WALL STRUCTURE AND DIGESTIBILITY, P621; IIYAMA K, 1994, PLANT PHYSIOL, V104, P315, DOI 10.1104/pp.104.2.315; JARVIS MC, 1984, PLANT CELL ENVIRON, V7, P153, DOI 10.1111/1365-3040.ep11614586; KAKIMOTO T, 1992, PLANT CELL PHYSIOL, V33, P353; KNOX JP, 1990, PLANTA, V181, P512, DOI 10.1007/BF00193004; LAWSON SG, 1989, PLANT PHYSIOL, V90, P101, DOI 10.1104/pp.90.1.101; LI LK, 1993, PLANT PHYSIOL, V101, P1149, DOI 10.1104/pp.101.4.1149; LI LK, 1993, PLANT PHYSIOL, V101, P1143, DOI 10.1104/pp.101.4.1143; LIN FC, 1990, J BIOL CHEM, V265, P4782; LIN FC, 1985, SCIENCE, V230, P822, DOI 10.1126/science.230.4727.822; MA SX, 1991, PLANT PHYSIOL, V96, P664, DOI 10.1104/pp.96.2.664; MASON TL, 1990, PHYSIOL PLANTARUM, V79, P439, DOI 10.1111/j.1399-3054.1990.tb02100.x; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; MCCANN MC, 1992, J MICROSC-OXFORD, V166, P123, DOI 10.1111/j.1365-2818.1992.tb01511.x; MCCANN MC, 1992, CYTOSKELETAL BASIS P, P109; Meier H., 1982, Encyclopedia of plant physiology. New series. Volume 13 A. Plant carbohydrates. I. Intracellular carbohydrates [Loewus, F.A.; Tanner, W. (Editors)], P418; MEIKLE PJ, 1991, J BIOL CHEM, V266, P22569; MINEYUKI Y, 1990, J CELL SCI, V97, P527; MORI M, 1980, CARBOHYD RES, V84, P125, DOI 10.1016/S0008-6215(00)85436-1; NISHITANI K, 1992, J BIOL CHEM, V267, P21058; NORTHCOTE DH, 1985, BIOSYNTHESIS BIODEGR, P87; OHANA P, 1991, J BIOL CHEM, V266, P13742; OHANA P, 1992, PLANT PHYSIOL, V98, P708, DOI 10.1104/pp.98.2.708; OKUDA K, 1993, PLANT PHYSIOL, V101, P1131, DOI 10.1104/pp.101.4.1131; PHILIPPI ML, 1981, PLANTA, V152, P59, DOI 10.1007/BF00384986; PIRO G, 1993, PLANTA, V190, P206, DOI 10.1007/BF00196613; PONTLEZICA R, 1986, ADV CARBOHYD CHEM BI, V44, P341; QUENTMEIER H, 1987, PLANTA, V171, P483, DOI 10.1007/BF00392295; RAY PM, 1969, P NATL ACAD SCI USA, V64, P605, DOI 10.1073/pnas.64.2.605; RAY PM, 1980, BIOCHIM BIOPHYS ACTA, V629, P431, DOI 10.1016/0304-4165(80)90149-X; READ SM, 1987, PLANT PHYSIOL, V85, P1008, DOI 10.1104/pp.85.4.1008; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; RODGERS MW, 1992, BIOCHEM J, V288, P817, DOI 10.1042/bj2880817; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; SAXENA IM, 1991, PLANT MOL BIOL, V16, P947, DOI 10.1007/BF00016067; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SCHLUPMANN H, 1993, PLANTA, V191, P470, DOI 10.1007/BF00195748; SCHNEIDER B, 1986, PROTOPLASMA, V131, P142, DOI 10.1007/BF01285036; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SLOAN ME, 1987, PLANT PHYSIOL, V85, P516, DOI 10.1104/pp.85.2.516; THELEN MP, 1986, PLANT PHYSIOL, V81, P913, DOI 10.1104/pp.81.3.913; WALDRON KW, 1985, SEB SEMINAR SERIES, V28, P79; WASSERMAN BP, 1986, PLANT PHYSIOL, V82, P396, DOI 10.1104/pp.82.2.396; WHITE AR, 1993, BIOCHEM J, V294, P231, DOI 10.1042/bj2940231; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130; WOODWARD WR, 1985, NEW IDEAS PSYCHOL, V3, P207, DOI 10.1016/0732-118X(85)90012-1; WU A, 1993, PLANT J, V4, P683, DOI 10.1046/j.1365-313X.1993.04040683.x; WU AY, 1991, PLANT PHYSIOL, V97, P684, DOI 10.1104/pp.97.2.684; Wyatt Sarah E., 1993, Trends in Cell Biology, V3, P413, DOI 10.1016/0962-8924(93)90022-S	99	110	120	2	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					904	915		10.1096/fasebj.8.12.8088456	http://dx.doi.org/10.1096/fasebj.8.12.8088456			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088456				2022-12-28	WOS:A1994PG29300002
J	SIMPSON, P				SIMPSON, P			MODEL SYSTEMS FOR THE STUDY OF DEVELOPMENT AND PATTERNING OF THE NERVOUS-SYSTEM	FASEB JOURNAL			English	Review											SIMPSON, P (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.							ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; KESHISHIAN H, 1994, FASEB J, V8, P731, DOI 10.1096/fasebj.8.10.8050672; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; LUSKIN MB, 1994, FASEB J, V8, P722, DOI 10.1096/fasebj.8.10.8050671; SCHEETZ JA, 1994, FASEB J, V8, P745; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STERN CD, 1994, FASEB J, V8, P687, DOI 10.1096/fasebj.8.10.8050666; STRAHLE U, 1994, FASEB J, V8, P692, DOI 10.1096/fasebj.8.10.8050667	10	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					684	686		10.1096/fasebj.8.10.8050665	http://dx.doi.org/10.1096/fasebj.8.10.8050665			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050665				2022-12-28	WOS:A1994NY35000003
J	WRIGHT, SC; ZHONG, J; LARRICK, JW				WRIGHT, SC; ZHONG, J; LARRICK, JW			INHIBITION OF APOPTOSIS AS A MECHANISM OF TUMOR PROMOTION	FASEB JOURNAL			English	Article						TUMOR NECROSIS FACTOR; PHORBOL MYRISTATE ACETATE; CARCINOGENESIS; DNA FRAGMENTATION	PROGRAMMED CELL-DEATH; PROTEIN-KINASE-C; DNA FRAGMENTATION; MOUSE SKIN; THYMOCYTE NUCLEI; CARCINOGENESIS; FOS; TRANSCRIPTION; ENDONUCLEASE; STIMULATION	Recent evidence supports the concept that tumor growth in vivo depends on evasion of normal homeostatic control mechanisms that operate through induction of cell death by apoptosis. This study tested the hypothesis that a common property shared by known or suspected tumor promoters is the ability to block the process of apoptosis. A total of 10 tumor promoters were tested and all. were found to inhibit DNA fragmentation and cell death of 7 different cell lines triggered into apoptosis by diverse agents. Resistance to apoptosis could be induced rapidly (within 1 h) by treating with relatively high concentrations of promoters. However, low physiological concentrations of promoters could also induce complete resistance to apoptosis after prolonged exposure (5-15 days of culture). Like tumor promotion in vivo, promoter-induced resistance to apoptosis was reversible after culturing in the absence of promoter. These findings provide new insight into the mechanism of tumor promotion and suggest a novel in vitro screening assay to detect new tumor-promoting agents in the environment.			WRIGHT, SC (corresponding author), PALO ALTO INST MOLEC MED,2462 WYANDOTTE ST,MT VIEW,CA 94043, USA.							BRANDES LJ, 1992, CANCER RES, V52, P3796; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; BURSCH W, 1992, TIPS, V13, P243; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN JJ, 1984, J IMMUNOL, V132, P38; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EPSTEIN JH, 1992, CANCER RES, V52, P4053; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; ITO N, 1987, JPN J CANCER RES, V78, P1011; KIZAKI H, 1989, J BIOCHEM-TOKYO, V105, P673, DOI 10.1093/oxfordjournals.jbchem.a122724; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LOCHCARUSO R, 1985, CRC CR REV TOXICOL, V16, P157, DOI 10.3109/10408448509056269; LOTEM J, 1991, BLOOD, V78, P953; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; PITOT HC, 1993, CANCER-AM CANCER SOC, V72, P962, DOI 10.1002/1097-0142(19930801)72:3+<962::AID-CNCR2820721303>3.0.CO;2-H; PITOT HC, 1982, CANCER, V49, P1206, DOI 10.1002/1097-0142(19820315)49:6<1206::AID-CNCR2820490623>3.0.CO;2-7; PITOT HC, 1989, CANCER PRINCIPLES PR, V1, pCH8; POMMIER Y, 1992, CANCER RES, V52, P1907; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROSEJOHN S, 1988, CARCINOGENESIS, V9, P831, DOI 10.1093/carcin/9.5.831; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; WRIGHT SC, 1993, FASEB J, V7, P1045, DOI 10.1096/fasebj.7.11.8370474; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; 1993, PHYSICIANS DESK REFE, P2372	37	185	194	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1994	8	9					654	660		10.1096/fasebj.8.9.8005393	http://dx.doi.org/10.1096/fasebj.8.9.8005393			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005393				2022-12-28	WOS:A1994NR90600013
J	ALBELDA, SM; SMITH, CW; WARD, PA				ALBELDA, SM; SMITH, CW; WARD, PA			ADHESION MOLECULES AND INFLAMMATORY INJURY	FASEB JOURNAL			English	Review						ADHESION MOLECULES; INFLAMMATION; ENDOTHELIAL CELLS; LEUKOCYTES; INTEGRINS; SELECTINS; IMMUNOGLOBULIN SUPERFAMILY; NEUTROPHILS; CELL ADHESION	LEUKOCYTE ADHESION; NEUTROPHIL ADHERENCE; LUNG INJURY; ENDOTHELIAL-CELLS; BETA-2 INTEGRINS; INVIVO; MAC-1; LFA-1; GMP-140; INVITRO	Neutrophil-endothelial cell interactions are mediated by interacting sets of cell adhesion molecules (CAMs) and chemoattractant/activator molecules to form an ''adhesion cascade.'' The initial phase of inflammation, a transient slowing of neutrophils in postcapillary venules, is mediated by selectins. Subsequently, firm adhesion of neutrophils to the vessel wall occurs via interaction of the CD11/CD18 (beta(2)) integrins to endothelial ligands such as intercellular adhesion molecule-1 (ICAM-1). This binding requires activation of CD11/CD18 by exposure of the neutrophil to a variety of activating/chemoattractant molecules, such as platelet-activating factor or interleukin-8. Finally, transmigration into tissues occurs, a process that requires both a chemotactic stimulus and engagement of platelet-endothelial cell adhesion molecule-1 (PECAM-1). Several approaches have been used to probe the role of CAMs in vivo. These include the use of blocking antibodies, chimeric selectin-immunoglobulin proteins, sialyl Lewis(x) oligosaccharides and peptides, along with the study of humans and animals with genetically determined adhesion deficiencies. These studies demonstrate that CAM blockade can effectively inhibit inflammation; however, there appear to be clear differences in the adhesion requirements for particular types of inflammation. By understanding the CAM/chemoattractant profiles involved in specific disease states, it may be possible to precisely and effectively target therapy to a wide variety of inflammatory diseases.	UNIV PENN,MED CTR,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Pennsylvania; Baylor College of Medicine; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL49591, HL31963, HL46311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046311, P01HL031963, R29HL046311, R01HL049591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1986, J IMMUNOL, V137, P15; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BENNETT CF, 1994, J CELL BIOCH A S, V18, P262; BENNETT CF, 1994, IN PRESS J IMMUNOL; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOOTH SA, 1992, J INVEST DERMATOL, V98, P135, DOI 10.1111/1523-1747.ep12555654; BURCH RM, 1993, J IMMUNOL, V150, P3397; BURCH RM, 1991, P NATL ACAD SCI USA, V88, P355, DOI 10.1073/pnas.88.2.355; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTTRUM SM, 1993, BLOOD, V82, P1165; CHOPRA J, 1988, AM REV RESPIR DIS, V138, P915, DOI 10.1164/ajrccm/138.4.915; COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; DeLisser H M, 1993, Curr Top Microbiol Immunol, V184, P37; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; FIGDOR CG, 1989, LEUKOCYTE ADHESION M, P159; FISCHER A, 1986, LANCET, V2, P1058; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1991, J BIOL CHEM, V266, P22313; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; HUANG AJ, 1992, ENDOTHELIAL CELL DYS, P201; HUBER AR, 1991, SCIENCE, V253, P1; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, CAN J PHYSIOL PHARM, V71, P88, DOI 10.1139/y93-013; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEY K, 1991, BLOOD, V77, P2553; LO SK, 1989, J IMMUNOL, V143, P3325; LOBB RR, 1991, J IMMUNOL, V147, P124; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLIGAN MS, 1993, J CLIN INVEST, V91, P577, DOI 10.1172/JCI116237; MULLIGAN MS, 1992, J IMMUNOL, V148, P3086; MULLIGAN MS, 1992, J IMMUNOL, V148, P1847; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; MULLIGAN MS, 1993, J IMMUNOL, V150, P2401; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKERLJ, 1992, ANNU REV IMMUNOL, V10, P561; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; ROSENGREN S, 1991, J APPL PHYSIOL, V71, P1322, DOI 10.1152/jappl.1991.71.4.1322; ROSS L, 1992, J BIOL CHEM, V267, P8537; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SATO D, 1993, CELL, V75, P1; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76, DOI 10.1139/y93-012; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; WILSON RW, 1993, J IMMUNOL, V151, P1571; WINN RK, 1993, J CLIN INVEST, V92, P2042, DOI 10.1172/JCI116799; WINN RK, 1993, J CLIN INVEST, V92, P1168, DOI 10.1172/JCI116686; WOLITZKY BA, 1994, J CELL BIOCH S A, V18, P300; WRIGHT SD, 1990, LEUKOCYTE ADHESION MOLECULES, P190; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320; YAN HC, 1994, J IMMUNOL, V152, P3063; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	80	881	936	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					504	512		10.1096/fasebj.8.8.8181668	http://dx.doi.org/10.1096/fasebj.8.8.8181668			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181668	Green Submitted			2022-12-28	WOS:A1994NM36400007
J	RIETSCHEL, ET; KIRIKAE, T; SCHADE, FU; MAMAT, U; SCHMIDT, G; LOPPNOW, H; ULMER, AJ; ZAHRINGER, U; SEYDEL, U; DIPADOVA, F; SCHREIER, M; BRADE, H				RIETSCHEL, ET; KIRIKAE, T; SCHADE, FU; MAMAT, U; SCHMIDT, G; LOPPNOW, H; ULMER, AJ; ZAHRINGER, U; SEYDEL, U; DIPADOVA, F; SCHREIER, M; BRADE, H			BACTERIAL, ENDOTOXIN - MOLECULAR RELATIONSHIPS OF STRUCTURE TO ACTIVITY AND FUNCTION	FASEB JOURNAL			English	Review						LIPOPOLYSACCHARIDE; LIPID A; TUMOR NECROSIS FACTOR; INTERLEUKIN 1; ANTI-LPS ANTIBODIES; LPS ANTAGONISTS; MONOCYTES; SPHINGOGLYCOLIPID	GRAM-NEGATIVE BACTEREMIA; LIPID-A; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; EPITOPE SPECIFICITY; CHEMICAL-STRUCTURE; CLINICAL-TRIAL; SEPTIC SHOCK; CORE REGION; LIPOPOLYSACCHARIDE	Endotoxins of Gram-negative microbes fulfill as components of the outer membrane a vital function for bacterial viability and, if set free, induce in mammalians potent pathophysiological effects. Chemically, they are lipopolysaccharides (LPS) consisting of an O-specific chain, a core oligosaccharide, and a lipid component, termed lipid A. The latter determines the endotoxic activities and, together with the core constituent Kdo, essential functions for bacteria. The primary structure of lipid A of various bacterial origin has been elucidated and lipid A of Escherichia coli has been chemically synthesized. The biological analysis of synthetic lipid A partial structures proved that the expression of endotoxic activity depends on a unique primary structure and a peculiar endotoxic conformation. The biological lipid A effects are mediated by macrophage-derived bioactive peptides such as tumor necrosis factor alpha (TNF). Macrophages possess LPS receptors, and the lipid A regions involved in specific binding and cell activation have been characterized. Synthetic lipid A partial structures compete the specific binding of LPS or lipid A and antagonistically inhibit the production of LPS-induced TNF. LPS toxicity, in general, and the ability of LPS to induce TNF are also suppressed by a recently developed monoclonal antibody (IgG2a), which is directed against an epitope located in the core oligosaccharide. At present we determine molecular and submolecular details of the specificity of the interaction of lipid A with responsive host cells with the ultimate aim to provide pharmacological or immunological therapeutics that reduce or abolish the fatal inflammatory consequences of endotoxicosis.	SANDOZ,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	RIETSCHEL, ET (corresponding author), FORSCHUNGSINST BORSTEL,INST EXPTL BIOL & MED,PARKALLEE 22,D-23845 BORSTEL,GERMANY.							ALVING CR, 1993, IMMUNOBIOLOGY, V187, P430, DOI 10.1016/S0171-2985(11)80355-4; ARDITI M, 1993, IN PRESS INFECT IMMU; BAUMGARTNER JD, 1993, IMMUNOBIOLOGY, V187, P464, DOI 10.1016/S0171-2985(11)80357-8; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BRADE H, 1988, ZBL BAKT-INT J MED M, V268, P151; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COLWELL DE, 1984, J IMMUNOL, V133, P950; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; DIPADOVA FE, 1993, ENDOTOXIN RES SERIES, V2, P325; ERWIN AL, 1992, BACTERIAL ENDOTOXIC, V1, P405; FLAD HD, 1993, IMMUNOBIOLOGY, V187, P303, DOI 10.1016/S0171-2985(11)80346-3; FLEISCHER B, 1991, J IMMUNOL, V146, P11; FRANK S, 1977, J IMMUNOL, V119, P855; FUJIHARA Y, 1993, INFECT IMMUN, V61, P910, DOI 10.1128/IAI.61.3.910-918.1993; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; Galanos C., 1992, BACT ENDOTOXIC LIPOP, VII, P75; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GRIFFISS JM, 1988, REV INFECT DIS, V10, pS287; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HOLLINGSWORTH RI, 1990, ENDOTOXIN RES SERIES, V1, P73; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; KASTOWSKY M, 1992, J BACTERIOL, V174, P4798, DOI 10.1128/JB.174.14.4798-4806.1992; KAWAHARA K, 1991, FEBS LETT, V292, P107, DOI 10.1016/0014-5793(91)80845-T; KIESEL B, 1989, Wissenschaftliche Zeitschrift der Karl-Marx-Universitaet Leipzig Mathematisch-Naturwissenschaftliche Reihe, V38, P287; KIRIKAE T, 1992, J CELL BIOCHEM, V16, P161; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KUHN HM, 1992, INFECT IMMUN, V60, P2201, DOI 10.1128/IAI.60.6.2201-2210.1992; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; KUSUMOTO S, 1992, BACTERIAL ENDOTOXIC, V1, P81; LEBBARD S, 1983, EUR J IMMUNOL, V16, P87; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LOPPNOW H, 1993, ENDOTOXIN RES SERIES, V2, P337; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MAMAT U, 1991, Immunobiology, V183, P251; MAYER H, 1990, ENDOTOXIN RES SERIES, V1, P111; MORRISON DC, 1993, IMMUNOBIOLOGY, V187, P212, DOI 10.1016/S0171-2985(11)80340-2; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; NOWOTNY A, 1987, REV INFECT DIS, V9, pS503; POLLACK M, 1990, PRINCIPLES PRACTICE, P1; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RIETSCHEL ET, 1993, IMMUNOBIOLOGY, V187, P169, DOI 10.1016/S0171-2985(11)80338-4; RIETSCHEL ET, 1992, SCI AM, V267, P26; RIETSCHLE E T, 1988, P1; ROZALSKI A, 1989, CARBOHYD RES, V193, P257, DOI 10.1016/0008-6215(89)85124-9; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SCHUTT C, 1988, IMMUNOL LETT, V19, P321, DOI 10.1016/0165-2478(88)90162-9; SEYDEL U, 1993, IMMUNOBIOLOGY, V187, P191, DOI 10.1016/S0171-2985(11)80339-6; SMITH H, 1990, J GEN MICROBIOL, V136, P377, DOI 10.1099/00221287-136-3-377; SONESSON A, 1993, FEMS MICROBIOL LETT, V106, P315, DOI 10.1016/0378-1097(93)90421-W; TAKAYAMA K, 1992, BACTERIAL ENDOTOXIC, V1, P43; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; TSANG RSW, 1992, ZBL BAKT-INT J MED M, V276, P330, DOI 10.1016/S0934-8840(11)80539-6; ULMER AJ, 1992, INFECT IMMUN, V60, P5145, DOI 10.1128/IAI.60.12.5145-5152.1992; VOGEL SN, 1990, IMMUNOPHYSIOLOGY ROL, P238; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; Westphal O, 1978, MICROBIOLOGY 1977, P221; YOUNG LS, 1991, INFECTIOUS DISEASE C, V5; ZAHRINGER U, 1994, IN PRESS ADV CARBOHY; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; [No title captured]	67	1263	1332	23	198	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					217	225		10.1096/fasebj.8.2.8119492	http://dx.doi.org/10.1096/fasebj.8.2.8119492			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119492				2022-12-28	WOS:A1994MY29900028
J	WATFORD, M				WATFORD, M			HEPATIC GLUTAMINASE EXPRESSION - RELATIONSHIP TO KIDNEY-TYPE GLUTAMINASE AND TO THE UREA CYCLE	FASEB JOURNAL			English	Review						GLUTAMINASE; GLUTAMINE; LIVER; GLUCONEOGENESIS; UREA SYNTHESIS	PHOSPHATE-DEPENDENT GLUTAMINASE; MESSENGER-RNA; AMINO-ACID; RAT-KIDNEY; PHOSPHOENOLPYRUVATE CARBOXYKINASE; NITROGEN-METABOLISM; SYNTHETASE; HEPATOCYTES; AMMONIA; TISSUES	Glutamine functions as a major transport form of nitrogen and carbon within the body. In the liver, glutamine is hydrolyzed by a unique liver-type, phosphate-activated glutaminase, and the end products of hepatic glutamine catabolism are glucose and urea. Other tissues possess a different, kidney-type, glutaminase isozyme. The predicted amino acid sequences for the two glutaminases show a high degree of identity, indicating that they are products of different but related genes. Hepatic glutaminase activity is increased during diabetes, starvation, and on feeding high-protein diets, and decreased on feeding low-protein diets, whereas renal glutaminase appears to be regulated only by changes in acid-base status. Changes in the rate of gene transcription are the principal mechanism responsible for the long-term regulation of hepatic glutaminase, but the renal enzyme is regulated at the level of mRNA turnover. The pattern of regulation of hepatic glutaminase parallels that seen for genes encoding key enzymes of gluconeogenesis and urea synthesis, and indicates coordinate regulation of expression in keeping with the role of hepatic glutamine catabolism in these pathways.			WATFORD, M (corresponding author), RUTGERS UNIV,COOK COLL,DEPT NUTR SCI,NEW BRUNSWICK,NJ 08903, USA.				NIDDK NIH HHS [R01 DK37301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANNER C, 1988, MOL BRAIN RES, V3, P247, DOI 10.1016/0169-328X(88)90047-2; CERSOSIMO E, 1989, AM J PHYSIOL, V257, pE514, DOI 10.1152/ajpendo.1989.257.4.E514; CHAN KC, 1993, NUTRITION GENE EXPRE, P353; CHARLES R, 1968, THESIS U AMSTERDAM R; CURTHOYS NP, 1976, ARCH BIOCHEM BIOPHYS, V174, P82, DOI 10.1016/0003-9861(76)90326-X; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; CURTHOYS NP, 1976, ARCH BIOCHEM BIOPHYS, V172, P162, DOI 10.1016/0003-9861(76)90062-X; ENGLEHARDT JG, 1991, J BIOL CHEM, V266, P752; ERBELDING EJ, 1986, BIOCHEM SOC T, V14, P1058; Folin O, 1905, AM J PHYSIOL, V13, P66, DOI 10.1152/ajplegacy.1905.13.1.66; FRAYN KN, 1991, CLIN SCI, V80, P471, DOI 10.1042/cs0800471; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GRILL V, 1992, METABOLISM, V41, P28, DOI 10.1016/0026-0495(92)90186-E; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; KOWALSKI T, 1993, FASEB J, V7, pA387; Krebs H., 1980, GLUTAMINE METABOLISM, P319; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; KVAMME E, 1970, J BIOL CHEM, V245, P1871; LACEY JM, 1990, NUTR REV, V48, P297, DOI 10.1111/j.1753-4887.1990.tb02967.x; Lund P., 1976, UREA CYCLE, P479; MCGIVAN JD, 1991, BIOCHEM J, V274, P103, DOI 10.1042/bj2740103; MCGIVAN JD, 1988, GLUTAMINE GLUTAMATE, P183; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; NEWSHOLME EA, 1985, Q J EXP PHYSIOL CMS, V70, P473, DOI 10.1113/expphysiol.1985.sp002935; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; POGSON CI, 1991, A BENZON S, V30, P262; QUESADA A, 1987, BIOCHEM J, V255, P1031; SCHIMKE RT, 1970, ANNU REV BIOCHEM, V39, P929, DOI 10.1146/annurev.bi.39.070170.004433; SHAPIRO RA, 1987, BIOCHEM J, V242, P743, DOI 10.1042/bj2420743; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SMITH EM, 1990, J BIOL CHEM, V265, P10631; SMITH EM, 1988, ARCH BIOCHEM BIOPHYS, V260, P740, DOI 10.1016/0003-9861(88)90504-8; SOUBA WW, 1991, ANNU REV NUTR, V11, P285, DOI 10.1146/annurev.nu.11.070191.001441; SQUIRES EJ, 1983, BIOCHEM J, V210, P277, DOI 10.1042/bj2100277; SVENNEBY G, 1973, J NEUROCHEM, V120, P1217; TANNEN RL, 1978, AM J PHYSIOL, V235, pF265, DOI 10.1152/ajprenal.1978.235.4.F265; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TONG J, 1987, BIOCHEMISTRY-US, V26, P2773, DOI 10.1021/bi00384a018; ULBRIGHT C, 1993, ARCH BIOCHEM BIOPHYS, V301, P237, DOI 10.1006/abbi.1993.1139; VINCENT N, 1993, FASEB J, V7, pA387; VINCENT N, 1992, FASEB J, V6, pA72; WATFORD M, 1984, BIOCHEM J, V224, P207, DOI 10.1042/bj2240207; Watford M, 1985, Contrib Nephrol, V47, P140; WATFORD M, 1990, BIOCHEM J, V267, P265, DOI 10.1042/bj2670265; WATFORD M, 1991, CONTRIB NEPHROL, V92, P211; WATFORD M, 1993, NUTRITION GENE EXPRE, P335; Welbourne T C, 1988, Contrib Nephrol, V63, P178; WELBOURNE TC, 1987, AM J PHYSIOL, V253, pF1069, DOI 10.1152/ajprenal.1987.253.6.F1069; WINDMUELLER HG, 1974, J BIOL CHEM, V249, P5070; ZALKIN H, 1985, J BIOL CHEM, V260, P3350	57	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1468	1474		10.1096/fasebj.7.15.8262331	http://dx.doi.org/10.1096/fasebj.7.15.8262331			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262331	Bronze			2022-12-28	WOS:A1993ML74000009
J	RING, CS; COHEN, FE				RING, CS; COHEN, FE			MODELING PROTEIN STRUCTURES - CONSTRUCTION AND THEIR APPLICATIONS	FASEB JOURNAL			English	Review						INTERLEUKIN-4; INHIBITOR DESIGN; HOMOLOG MODELING; SERINE PROTEASES; CYSTEINE PROTEASES	HOMOLOGOUS PROTEINS; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; PREDICTION; SEQUENCES; PACKING; CONFORMATIONS; HELICES; RULES	Although no general solution to the protein folding problem exists, the three-dimensional structures of proteins are being successfully predicted when experimentally derived constraints are used in conjunction with heuristic methods. In the case of interleukin-4, mutagenesis data and CD spectroscopy were instrumental in the accurate assignment of secondary structure. In addition, the tertiary structure was highly constrained by six cysteines separated by many residues that formed three disulfide bridges. Although the correct structure was a member of a short list of plausible structures, the ''best'' structure was the topological enantiomer of the experimentally determined conformation. For many proteases, other experimentally derived structures can be used as templates to identify the secondary structure elements. In a procedure called modeling by homology, the structure of a known protein is used as a scaffold to predict the structure of another related protein. This method has been used to model a serine and a cysteine protease that are important in the schistosome and malarial life cycles, respectively. The model structures were then used to identify putative small molecule enzyme inhibitors computationally. Experiments confirm that some of these nonpeptidic compounds are active at concentrations of less than 10 muM.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM39900, GM07175] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN FE, 1986, BIOCHEMISTRY-US, V25, P266, DOI 10.1021/bi00349a037; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; COHEN FE, 1986, SCIENCE, V234, P349, DOI 10.1126/science.3489989; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; COHEN FE, 1987, PROTEINS, V2, P162, DOI 10.1002/prot.340020209; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARNIER J, 1990, BIOCHIMIE, V72, P513, DOI 10.1016/0300-9084(90)90115-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; GREER J, 1991, METHOD ENZYMOL, V202, P239; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GREGORET LM, 1991, J MOL BIOL, V219, P109, DOI 10.1016/0022-2836(91)90861-Y; HURLE MR, 1987, PROTEINS, V2, P210, DOI 10.1002/prot.340020306; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MOULT J, 1986, Proteins Structure Function and Genetics, V1, P146, DOI 10.1002/prot.340010207; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; RING CS, 1992, J MOL BIOL, V224, P685, DOI 10.1016/0022-2836(92)90553-V; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; ROOMAN MJ, 1990, J MOL BIOL, V213, P327, DOI 10.1016/S0022-2836(05)80194-9; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9	43	46	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					783	790		10.1096/fasebj.7.9.8330685	http://dx.doi.org/10.1096/fasebj.7.9.8330685			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330685				2022-12-28	WOS:A1993LK43000011
J	STEER, CJ				STEER, CJ			LIVER-REGENERATION	FASEB JOURNAL			English	Editorial Material							RAT-LIVER; C-FOS; HEPATOCYTES; GROWTH; GENES; EXPRESSION; HEPATECTOMY; INDUCTION; PROTEINS; DEFINE		UNIV MINNESOTA,SCH MED,DEPT CELL BIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	STEER, CJ (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455, USA.							BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BILIR BM, 1993, J BIOL CHEM, V268, P19776; BUCHER NLR, 1963, INT REV CYTOL, P245; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; Fausto Nelson, 1994, P1059; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; KREN BT, 1993, J CELL BIOL, V123, P707, DOI 10.1083/jcb.123.3.707; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MARTINEZHERNAND.A, 1993, EXTRACELLULAR MATRIX, P255; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MORELLO D, 1993, ONCOGENE, V8, P1921; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RETTINGER SD, 1994, P NATL ACAD SCI USA, V91, P1460, DOI 10.1073/pnas.91.4.1460; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; ROSENBERG E, 1992, EUR J CELL BIOL, V59, P21; STAMATOGLOU SC, 1992, J CELL BIOL, V116, P1507, DOI 10.1083/jcb.116.6.1507; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; WOODMAN AC, 1992, J CELL PHYSIOL, V151, P405, DOI 10.1002/jcp.1041510222; ZAMEGAR R, 1995, J CELL BIOL, V129, P1177	28	169	182	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1396	1400		10.1096/fasebj.9.14.7589980	http://dx.doi.org/10.1096/fasebj.9.14.7589980			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589980				2022-12-28	WOS:A1995TF67800003
J	SILVERSTEIN, SC				SILVERSTEIN, SC			ADVOCACY FOR BASIC BIOMEDICAL-RESEARCH	FASEB JOURNAL			English	Editorial Material											SILVERSTEIN, SC (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.							CLINT WJ, 1994, SCI NATIONAL INTERES; KIRSCHNER MW, 1994, SCIENCE, V266, P49, DOI 10.1126/science.7939643; LEE KB, 1994, 9TH BIOT IND ANN REP; MANSFIELD E, 1991, RES POLICY, V20, P1, DOI 10.1016/0048-7333(91)90080-A; SILVERSTEIN SC, 1993, FASEB J, V7, P1309, DOI 10.1096/fasebj.7.14.8224603; TALESNIK G, 1994, CHRONICLE HIGHE 1102, pB1; 1994, DEC CONS C FY 1996 F; 1993, NIH933109 PUBL	8	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					160	161		10.1096/fasebj.9.2.7781917	http://dx.doi.org/10.1096/fasebj.9.2.7781917			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781917				2022-12-28	WOS:A1995QJ24900002
J	LUSKIN, MB				LUSKIN, MB			NEURONAL CELL LINEAGE IN THE VERTEBRATE CENTRAL-NERVOUS-SYSTEM	FASEB JOURNAL			English	Review						MIGRATION; PROGENITOR CELL; PROLIFERATION; RETROVIRUS	DEVELOPING CEREBRAL-CORTEX; FETAL MONKEY NEOCORTEX; MEDIATED GENE-TRANSFER; CLONALLY RELATED CELLS; RECOMBINANT RETROVIRUS; SUBVENTRICULAR ZONE; COMMON PROGENITOR; OPTIC TECTUM; MIGRATION; OLIGODENDROCYTES	Fundamental, yet unresolved, issues in developmental neurobiology concern the relative influence of genetic vs. epigenetic factors in determining cell phenotype and establishing positional relationships among clonally related cells in the developing and mature vertebrate central nervous system (CNS). Advances in our understanding of how cells acquire their identity awaited a means to introduce lineage tracers into dividing cells of the developing CNS where the progenitor cells, which are situated in a neuroepithelial layer adjacent to the ventricles, generally are small and inaccessible. The technique of retroviral-mediated gene transfer, whereby a heritable, easily detectable marker such as the gene for lacZ is integrated into the DNA of individual progenitor cells, has been used to analyze the lineage relationships of cells in the CNS and to derive the types of progenitor cells in the proliferative zones at different developmental stages. Collectively, these studies indicate that the CNS uses more than one strategy to achieve cell diversity. The analysis of the phenotypic composition of the cells within a clone indicates that there are predominantly separate progenitor cells for each of the main cell types comprising the cerebral cortex by the onset of cortical neurogenesis, although in other systems mostly multipotential progenitor cells persist throughout neurogenesis. Here I will compare and contrast the inferred role of cell lineage in the developing cerebral cortex and olfactory bulb, where postmitotic neurons migrate relatively long distances from their site of generation to their final destination, with that in other regions of the CNS in which the displacement of postmitotic neurons from their birthplace is significantly less.			LUSKIN, MB (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.				NINDS NIH HHS [NS28380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BERNARD O, 1992, NEURON, V9, P1217, DOI 10.1016/0896-6273(92)90079-S; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CARNOW TB, 1991, GLIA, V4, P256, DOI 10.1002/glia.440040303; FARBMAN AI, 1991, SMELL TASTE HLTH DIS, pCH2; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; GROVE EA, 1993, DEVELOPMENT, V117, P553; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; JONES EG, 1970, PHILOS T ROY SOC B, V257, P1, DOI 10.1098/rstb.1970.0003; KIRKWOOD TBL, 1992, SCIENCE, V258, P317, DOI 10.1126/science.1411530; KISHI K, 1990, ARCH HISTOL CYTOL, V53, P219, DOI 10.1679/aohc.53.219; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; LING EA, 1973, J COMP NEUROL, V149, P43, DOI 10.1002/cne.901490104; LUBETZKI C, 1992, GLIA, V6, P289, DOI 10.1002/glia.440060407; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; LUSKIN MB, 1994, IN PRESS GLIA; LUSKIN MB, 1992, VISUAL SYSTEM GENESI, P111; LUSKIN MB, 1994, STRUCTURE FUNCTION N, P1; LUSKIN MB, 1993, J NIH RES, V5, P60; MARTINEZ S, 1992, DEV BRAIN RES, V66, P153, DOI 10.1016/0165-3806(92)90076-9; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MENEZES JRL, 1994, IN PRESS NEUR ABSTR, V20; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; Parnavelas JG, 1991, CEREB CORTEX, V1, P463, DOI 10.1093/cercor/1.6.463; Peters A., 1991, FINE STRUCTURE NERVO; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PRIVAT A, 1975, INT REV CYTOL, V40, P281, DOI 10.1016/S0074-7696(08)60955-9; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; SANES JR, 1989, TRENDS NEUROSCI, V12, P21, DOI 10.1016/0166-2236(89)90152-5; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHWOB JE, 1994, 17 M ASS CHEM SCI; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VAYSSE PJJ, 1990, NEURON, V4, P833; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WILLIAMS BP, 1992, BIOESSAYS, V14, P693, DOI 10.1002/bies.950141010; WILLIAMS BP, 1985, DEV BIOL, V112, P126, DOI 10.1016/0012-1606(85)90126-5; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; 1970, ANAT REC, V166, P257	58	57	57	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					722	730		10.1096/fasebj.8.10.8050671	http://dx.doi.org/10.1096/fasebj.8.10.8050671			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050671				2022-12-28	WOS:A1994NY35000009
J	TULLY, DB; ALLGOOD, VE; CIDLOWSKI, JA				TULLY, DB; ALLGOOD, VE; CIDLOWSKI, JA			MODULATION OF STEROID RECEPTOR-MEDIATED GENE-EXPRESSION BY VITAMIN-B-6	FASEB JOURNAL			English	Review						PYRIDOXAL PHOSPHATE; TRANSCRIPTION; GLUCOCORTICOID	MAMMARY-TUMOR VIRUS; AVIAN PROGESTERONE RECEPTOR; GLUCOCORTICOID-RECEPTOR; PYRIDOXAL-PHOSPHATE; TRANSCRIPTION FACTORS; HORMONE RECEPTORS; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; DNA-SEQUENCES; BINDING-SITE	Gene transcription mediated by steroid hormones has become one of the most extensively characterized model systems for studying the regulation of gene expression in eukaryotic cells. However, specific details of gene regulation by steroid hormones are often complex and may be unique in specific cell types. Diverse regulatory mechanisms leading to either activation or repression of particular genes frequently involve interactions between steroid hormone receptors and other ubiquitous and/or cell-specific transcription factors that act on the complex promoter of the regulated gene. Interplay between steroid receptor-mediated and other signal transduction pathways may also be involved. In addition, recent novel results indicate that moderate variations in the intracellular concentration of pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B-6, can have pronounced modulatory effects on steroid-induced gene expression. Specifically, elevation of intracellular PLP levels leads to decreased transcriptional responses to glucocorticoid, progesterone, androgen, or estrogen hormones. Conversely, cells in a vitamin B-6-deficient state exhibit enhanced responsiveness to steroid hormones. One aspect of the mechanism by which these transcriptional modulatory effects of PLP occur has recently been shown to involve interruption of functional interactions between steroid hormone receptors and the nuclear transcription factor NF1. These findings-that the vitamin B-6 nutritional status of cells modulates their capacity to respond to steroid hormones-impose an additional level of cell-specitic control over steroid hormone regulation of gene expression and will serve as the focal point for this review.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT NUTR, CHAPEL HILL, NC USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK 32459] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032459] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1990, ANN NY ACAD SCI, V585, P452, DOI 10.1111/j.1749-6632.1990.tb28076.x; ALLGOOD VE, 1991, J NUTR BIOCHEM, V2, P523, DOI 10.1016/0955-2863(91)90052-7; ALLGOOD VE, 1992, J BIOL CHEM, V267, P3819; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; ALLGOOD VE, 1991, THESIS U N CAROLINA; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BRIN M, 1976, HUMAN VITAMIN B6 REQ, P1; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; BURNSTEIN KL, 1993, J CELL BIOCHEM, V51, P130, DOI 10.1002/jcb.240510203; CAKE MH, 1978, J BIOL CHEM, V253, P4886; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHANDRA RK, 1984, VITAMIN B6 ITS ROLE, P163; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CIDLOWSKI JA, 1978, BIOCHEM BIOPH RES CO, V82, P1140, DOI 10.1016/0006-291X(78)90305-4; CIDLOWSKI JA, 1980, BIOCHEMISTRY-US, V19, P6162, DOI 10.1021/bi00567a033; CIDLOWSKI JA, 1977, NATURE, V266, P643, DOI 10.1038/266643a0; COMPTON MM, 1986, ENDOCR REV, V7, P140, DOI 10.1210/edrv-7-2-140; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EBADI M, 1978, INT J BIOCHEM, V9, P607, DOI 10.1016/0020-711X(78)90122-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEHRING H, 1984, CHEM BIOL ASPECTS B, P223; GEHRING U, 1984, MOL CELL ENDOCRINOL, V36, P107, DOI 10.1016/0303-7207(84)90089-3; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRIFFIN MJ, 1969, J CELL BIOL, V40, P297, DOI 10.1083/jcb.40.2.297; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARUTYUNYAN EG, 1984, CHEM BIOL ASPECTS B, P205; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HIIPAKKA RA, 1980, J STEROID BIOCHEM, V13, P841, DOI 10.1016/0022-4731(80)90156-9; HORWITZ KB, 1977, CANCER RES, V37, P1733; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; ING NH, 1992, J BIOL CHEM, V267, P17617; JANSONIUS JN, 1984, CHEM BIOL ASPECTS B, P195; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAHLSON G, 1965, ANNU REV PHARMACOLOG, V5, P305, DOI 10.1146/annurev.pa.05.040165.001513; KALINYAK JE, 1989, J CLIN INVEST, V84, P1843, DOI 10.1172/JCI114370; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; Leklem J.E., 1991, HDB VITAMINS, P341; LITTLEFIELD BA, 1984, ENDOCRINOLOGY, V114, P566, DOI 10.1210/endo-114-2-566; LOVENBERG W, 1962, J BIOL CHEM, V237, P89; Lumeng L, 1980, VITAMIN B6 METABOLIS, P27; MCCORMICK DB, 1989, PHYSIOL REV, V69, P1170, DOI 10.1152/physrev.1989.69.4.1170; MERRILL AH, 1987, ANNU REV NUTR, V7, P137, DOI 10.1146/annurev.nu.07.070187.001033; MERRILL AH, 1984, J NUTR, V114, P1664, DOI 10.1093/jn/114.9.1664; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MULDOON TG, 1980, J BIOL CHEM, V255, P3100; NISHIGORI H, 1978, BIOCHEM BIOPH RES CO, V80, P112, DOI 10.1016/0006-291X(78)91111-7; NISHIGORI H, 1979, J BIOL CHEM, V254, P9155; OBRIEN JM, 1981, J STEROID BIOCHEM, V14, P9, DOI 10.1016/0022-4731(81)90186-2; ROBERTS E, 1950, J BIOL CHEM, V187, P55; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAYLOR JE, 1990, ANN NY ACAD SCI, V585, P58, DOI 10.1111/j.1749-6632.1990.tb28041.x; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; TULLY DB, 1993, NUTRITION GENE EXPRE, P547; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VICEPSMADORE D, 1983, J BIOL CHEM, V258, P2689; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHANG YL, 1990, MOL ENDOCRINOL, V4, P1219, DOI 10.1210/mend-4-8-1219	70	67	69	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1994	8	3					343	349		10.1096/fasebj.8.3.8143940	http://dx.doi.org/10.1096/fasebj.8.3.8143940			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	8143940	Bronze			2022-12-28	WOS:A1994NB62300009
J	LANE, TF; SAGE, EH				LANE, TF; SAGE, EH			THE BIOLOGY OF SPARC, A PROTEIN THAT MODULATES CELL-MATRIX INTERACTIONS	FASEB JOURNAL			English	Review						ANGIOGENESIS; BM-40; CALCIUM BINDING; COLLAGEN BINDING; DEVELOPMENT; EXTRACELLULAR MATRIX; OSTEONECTIN	AORTIC ENDOTHELIAL-CELLS; CALCIUM-BINDING; INSITU HYBRIDIZATION; PLATELET OSTEONECTIN; EXTRACELLULAR-MATRIX; MESSENGER-RNA; GROWTH-FACTOR; DEVELOPMENTAL EXPRESSION; TRANSCRIPTIONAL CONTROL; ANGIOGENESIS INVITRO	An extracellular matrix-associated glycoprotein expressed in a variety of tissues during embryogenesis and repair, SPARC contains modular domains that can function independently to bind cells and matrix components. Because SPARC can selectively disrupt cellular contacts with matrix and thereby effect changes in cell shape, it has been referred to as an antiadhesin. Inhibition of the expression of SPARC altered axial development in frogs, and deregulated expression in nematode worms resulted in a derangement of muscle attachment and embryonic lethality. SPARC also inhibits cell cycle progression in vitro, in part through a cationic, disulfide-bonded region that is homologous to a repeated domain in the cytokine inhibitor, follistatin. Moreover, SPARC binds specifically to the B chain of platelet-derived growth factor and alters the response of cells to several cytokines. Although information concerning the expression, biochemical properties, and cellular activities of SPARC has increased significantly over the last decade, the precise function of the protein has not been resolved. Goals of future studies include characterization of cell-surface receptors for SPARC and the interactions with morphogens and growth factors that regulate specific activities during animal development.	UNIV WASHINGTON,SCH MED,DEPT BIOL STRUCT,SEATTLE,WA 98195; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Lane, Timothy F./0000-0002-0210-970X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; BERGSON C, 1993, MOL CELL NEUROSCI, V4, P64, DOI 10.1006/mcne.1993.1008; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P2919, DOI 10.1073/pnas.85.9.2919; BRETONGORIUS J, 1992, BLOOD, V79, P936; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CLEZARDIN P, 1988, EUR J BIOCHEM, V175, P275, DOI 10.1111/j.1432-1033.1988.tb14194.x; CLEZARDIN P, 1991, J BONE MINER RES, V6, P1059; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; DOMINGUEZ P, 1991, J BONE MINER RES, V6, P1127; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; EVERITT EA, 1993, BIOCH CELL BIOL, V70, P1368; FEDARKO NS, 1992, J BONE MINER RES, V7, P921; FINDLAY DM, 1988, BIOCHEMISTRY-US, V27, P1483, DOI 10.1021/bi00405a013; FLOEGE J, 1992, LAB INVEST, V67, P486; FORD R, 1993, EXP CELL RES, V206, P261, DOI 10.1006/excr.1993.1146; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GOLDBLUM SE, 1994, IN PRESS P NATL ACAD; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; HASSELAAR P, 1991, J BIOL CHEM, V266, P13178; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; HASTBACKA J, 1991, GENOMICS, V11, P968, DOI 10.1016/0888-7543(91)90021-6; HIROTA S, 1993, AM J PATHOL, V143, P1003; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HOWE CC, 1990, EXP CELL RES, V188, P185, DOI 10.1016/0014-4827(90)90158-7; HUGHES RC, 1987, EUR J BIOCHEM, V163, P57, DOI 10.1111/j.1432-1033.1987.tb10736.x; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; JOHNSTON IG, 1990, NEURON, V2, P165; KELM RJ, 1992, BLOOD, V80, P3112; KELM RJ, 1991, J BIOL CHEM, V266, P9632; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANKAT-BUTTGEREIT B, 1991, Journal of Dermatological Science, V2, P300, DOI 10.1016/0923-1811(91)90054-2; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MALAVAL L, 1991, J BONE MINER RES, V6, P315; MANN K, 1987, FEBS LETT, V218, P167, DOI 10.1016/0014-5793(87)81040-2; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NAGATA T, 1991, MATRIX, V11, P86, DOI 10.1016/S0934-8832(11)80212-X; NERI M, 1992, EUR J BIOCHEM, V205, P569, DOI 10.1111/j.1432-1033.1992.tb16814.x; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NOMURA S, 1989, J BIOL CHEM, V264, P12201; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OSHIMA O, 1989, CALCIFIED TISSUE INT, V45, P182, DOI 10.1007/BF02556062; OTSUKA K, 1984, J BIOL CHEM, V259, P9805; PAGE AE, 1993, INT J BIOCHEM, V25, P545, DOI 10.1016/0020-711X(93)90662-X; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; PURCELL L, 1993, J EXP ZOOL, V265, P153, DOI 10.1002/jez.1402650207; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; RINGUETTE M, 1992, ROUX ARCH DEV BIOL, V202, P4, DOI 10.1007/BF00364591; ROMBERG RW, 1985, J BIOL CHEM, V260, P2728; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P579, DOI 10.1139/o92-089; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P56, DOI 10.1139/o92-008; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; SAGE H, 1981, ARTERIOSCLEROSIS, V1, P427, DOI 10.1161/01.ATV.1.6.427; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; SHIMONAKA M, 1991, ENDOCRINOLOGY, V128, P3313, DOI 10.1210/endo-128-6-3313; Swaroop A, 1988, GENOMICS, V2, P37, DOI 10.1016/0888-7543(88)90107-3; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TRACY RP, 1988, INT J BIOCHEM, V20, P653, DOI 10.1016/0020-711X(88)90159-0; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; TYREE B, 1989, J BONE MINER RES, V4, P877; VERNON RB, 1989, BIOL REPROD, V40, P1329, DOI 10.1095/biolreprod40.6.1329; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049; VUORIO T, 1991, J RHEUMATOL, V18, P247; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; YOST JC, 1993, J BIOL CHEM, V268; YOUNG MF, 1989, J BIOL CHEM, V264, P450	88	465	485	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					163	173		10.1096/fasebj.8.2.8119487	http://dx.doi.org/10.1096/fasebj.8.2.8119487			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119487				2022-12-28	WOS:A1994MY29900022
J	KINOSHITA, M; ROSS, AC				KINOSHITA, M; ROSS, AC			VITAMIN-A STATUS AND IMMUNOGLOBULIN-G SUBCLASSES IN RATS IMMUNIZED WITH TETANUS TOXOID	FASEB JOURNAL			English	Article						RETINOL; IMMUNODEFICIENCY; RAT; IGG ISOTYPES; B-LYMPHOCYTES; MEMORY CELLS	MEMORY T-CELLS; IFN-GAMMA; DEFICIENT MICE; LECTIN BINDING; B-CELLS; DIFFERENTIATION; CHILDREN; GLYCOSYLATION; GLYCOPROTEIN; RETINOIDS	Vitamin A deficiency severely compromises the magnitude of the primary and secondary antibody response to tetanus toxoid (TT) but does not impair the development of immunologic memory. To further characterize this immunodeficiency in antibody production, we have quantified the immunoglobulin G (IgG) subclasses (IgG1, IgG2a, IgG2b, and IgG2c) during the primary and secondary response to TT in normal, vitamin A-deficient, and retinol-repleted rats. In the primary response in normal rats, anti-TT IgG1 and IgG2b predominated. In vitamin A-deficient rats the production of anti-TT IgG2b was severely impaired, with little change in either IgG1 or IgG2a. In the secondary response vitamin A-deficient rats produced low levels of all anti-TT IgG subclasses. However, when vitamin A-deficient rats were repleted with retinol 2 days before reimmunization their secondary anti-TT IgG response was normal both in magnitude and IgG subclass distribution. This result implies that although vitamin A deficiency during the primary antibody response impaired anti-TT IgG2b production, it did not inhibit Ig heavy chain recombination or the differentiation of lymphocytes that formed memory B cells for each subclass; furthermore, these cells were activated in the secondary response after vitamin A status was improved. Thus, these experiments further support the concept that memory cell formation remains normal during vitamin A deficiency despite low levels of antibody production.	MED COLL PENN,DEPT BIOCHEM,DIV EDUC,2900 QUEEN LANE,PHILADELPHIA,PA 19129	Drexel University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK041479, R01 DK-41479] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSIE A, 1991, CELL IMMUNOL, V135, P95, DOI 10.1016/0008-8749(91)90257-C; BOWMAN TA, 1990, J NUTR, V120, P1264, DOI 10.1093/jn/120.10.1264; BROWN KH, 1980, AM J CLIN NUTR, V33, P212, DOI 10.1093/ajcn/33.2.212; BRUGGEMANN M, 1988, EUR J IMMUNOL, V18, P317, DOI 10.1002/eji.1830180222; BRUGGEMANN M, 1988, GENE, V74, P473, DOI 10.1016/0378-1119(88)90180-1; CAI DC, 1991, EXP CELL RES, V192, P366, DOI 10.1016/0014-4827(91)90053-W; CARMAN JA, 1991, J IMMUNOL, V147, P1247; CARMAN JA, 1989, J IMMUNOL, V142, P388; CLEMENT LT, 1992, J CLIN IMMUNOL, V12, P1, DOI 10.1007/BF00918266; DE LUCA LM, 1991, FASEB J, V5, P2924; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HENDERSON RH, 1988, B WORLD HEALTH ORGAN, V66, P535; KINOSHITA M, 1993, J IMMUNOASSAY, V14, P149, DOI 10.1080/15321819308019846; KINOSHITA M, 1991, FASEB J, V5, P2473, DOI 10.1096/fasebj.5.10.2065894; KIRVEN MJ, 1991, MOL CELL BIOCHEM, V101, P101; LOTAN R, 1987, CANCER BIOCHEM BIOPH, V9, P211; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MERKENSCHLAGER M, 1989, NATURE, V341, P392, DOI 10.1038/341392b0; MILER I, 1983, IMMUNITY HUMAN FOETU; MINCHIN SA, 1990, J IMMUNOL, V145, P2427; Nauss KM, 1986, VITAMIN A DEFICIENCY, P207; REYNOLDS CW, 1981, J IMMUNOL, V126, P1581; Ross A. Catharine, 1994, P521; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; STEINMETZ JE, 1981, BEHAV RES METH INSTR, V13, P702, DOI 10.3758/BF03202100; 1989, OPPORTUNITIES BIOL, P224	29	9	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1277	1282		10.1096/fasebj.7.13.8405813	http://dx.doi.org/10.1096/fasebj.7.13.8405813			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405813				2022-12-28	WOS:A1993MB37600012
J	BOKOCH, GM; DER, CJ				BOKOCH, GM; DER, CJ			EMERGING CONCEPTS IN THE RAS SUPERFAMILY OF GTP-BINDING PROTEINS	FASEB JOURNAL			English	Review						SMALL GTP-BINDING PROTEINS; RAS-RELATED; SIGNAL TRANSDUCTION; RAS SUPERFAMILY; LOW MOLECULAR WEIGHT GTP-BINDING PROTEINS	NUCLEOTIDE EXCHANGE; ACTIVATION; OXIDASE	The Ras superfamily of GTP-binding proteins (> 50 members) regulates a diverse spectrum of intracellular processes. These include cellular proliferation and differentiation, intracellular vesicular trafficking, cytoskeletal control, NADPH oxidase function, as well as others. In this review, we describe recent progress and emerging themes in the action and regulation of these important cellular regulatory molecules. Structural studies have provided insight into the function of low molecular weight GTP-binding proteins (LMWGs) as molecular switches, and are defining modes of interaction with associated regulatory molecules. Details of the enzymatic processes involved in the posttranslational processing of LMWGs, and how this processing is important for protein function, are being elucidated. A variety of GTPase activating proteins, GDP/GTP dissociation stimulators, and GDP dissociation inhibitors have been identified, and their ability to determine the activity of LMWG-regulated systems is being worked out. The discovery of multifunctional regulatory molecules has indicated that substantial ''crosstalk'' between various LMWG may occur. The continuing emergence of additional cellular functions that are regulated by LMWGs, and particularly the recent availability of in vitro analytical systems for studies of the mechanism (or mechanisms) of action of LMWGs, is resulting in a wealth of information about the regulation and integration of cellular signaling, form, and function.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill	BOKOCH, GM (corresponding author), Scripps Clinic, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CHUNG HH, 1993, IN PRESS SCIENCE; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DOWNWARD J, 1992, Current Biology, V2, P329, DOI 10.1016/0960-9822(92)90897-J; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MCCAFFREY M, 1991, J CELL BIOL, V115, P309, DOI 10.1083/jcb.115.2.309; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PAWSON T, 1992, CELL, V71, P759; PAZAN MJ, 1992, TIBS, V17, P374; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEABRA MC, 1992, CELL, V70, P1048; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAI Y, 1992, INT REV CYTOL, V133, P178; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; WITTINGHOFER F, 1992, CANCER BIOL, V3, P189	48	208	214	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					750	759		10.1096/fasebj.7.9.8330683	http://dx.doi.org/10.1096/fasebj.7.9.8330683			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330683				2022-12-28	WOS:A1993LK43000007
J	GAUDRY, M; CAON, AC; NACCACHE, PH				GAUDRY, M; CAON, AC; NACCACHE, PH			MODULATION OF THE ACTIVITY AND SUBCELLULAR-DISTRIBUTION OF PROTEIN-TYROSINE KINASES IN HUMAN NEUTROPHILS BY PHORBOL ESTERS	FASEB JOURNAL			English	Note						PROTEIN KINASE-C; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; PHORBOL 12,13-DIBUTYRATE; PP60(SRC); PP93(FCS)	COLONY-STIMULATING FACTOR; HL-60 LEUKEMIA-CELLS; RABBIT PERITONEAL NEUTROPHILS; POTENT SELECTIVE INHIBITORS; SIGNAL TRANSDUCTION; MONOCYTIC DIFFERENTIATION; 12-MYRISTATE 13-ACETATE; MYRISTATE ACETATE; RESPIRATORY BURST; OXIDATIVE BURST	Although several tyrosine kinases are present in human neutrophils, little is known regarding the biochemical basis for their activation. We have identified two tyrosine kinase activities in 0.1 and 1% Triton cell extracts of human neutrophils using a non-denaturing gel assay. The first protein tyrosine kinase activity of a faster mobility was associated exclusively with the 0.1% Triton cell extract. The second activity, of slower mobility, was mainly associated with the 0.1% Triton cell extract and to a lesser extent with the 1% Triton cell extract. A modulation of the activities and the distribution of these two tyrosine kinase activities was observed upon stimulation of neutrophils with PDBu (phorbol 12,13-dibutyrate), a direct PKC (protein kinase C) activator. The addition of 1 muM PDBu induced a time-dependent decrease of both tyrosine kinases in the 0.1% Triton cell extract. Although the fast mobility tyrosine kinase activity disappeared completely, the slow mobility tyrosine activity decreased only partially. Concomitantly, an increase in the latter activity was detected in the 1% Triton cell extract. The pattern of tyrosine phosphorylation upon PDBu stimulation was also examined and the results showed that the phorbol ester induced time-dependent increases in the level of phosphotyrosine-containing proteins in at least 10 distinct bands. Two lines of evidence indicated that the effects of PDBu were mediated by PKC: 1) The stereo-isomer of PDBu, 4alpha-PDBu, did not affect the activities and distribution of the tyrosine kinases, and 2) The PKC inhibitor, RO 318220, prevented the redistribution of the tyrosine kinase activities and inhibited the stimulation of tyrosine phosphorylation induced by PDBu. These results show that the activity and distribution of at least two human neutrophil tyrosine kinases are modulated after the activation of PKC and that the low mobility tyrosine kinase activity is the most sensitive to PDBu. Based on previous studies, the fast mobility tyrosine kinase activity was likely to be a member of the pp60src tyrosine kinase family and the slower one may be related to the pp93fes. Furthermore, these results begin to define the nature of the relationships among the PKC- and the tyrosine kinase-signaling pathways.	UNIV LAVAL,FAC MED,DEPT MED,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University	GAUDRY, M (corresponding author), CHUL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,LOCAL 9800,2705 BLVD LAURIER,ST FOY G1V 4G2,PQ,CANADA.		Gaudry, Murielle/N-5934-2018	Gaudry, Murielle/0000-0002-9281-2334				BERKOW RL, 1990, BLOOD, V75, P2445; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BERKOW RL, 1987, J LEUKOCYTE BIOL, V41, P441, DOI 10.1002/jlb.41.5.441; BERKOW RL, 1991, J LEUKOCYTE BIOL, V49, P599, DOI 10.1002/jlb.49.6.599; BERRIDGE MJ, 1988, COLD SPRING HARB SYM, V53, P927, DOI 10.1101/SQB.1988.053.01.107; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GAUDRY M, 1990, IMMUNOPHARMACOLOGY, V20, P45, DOI 10.1016/0162-3109(90)90006-Z; GAUDRY M, 1990, IMMUNOPHARMACOLOGY, V19, P23, DOI 10.1016/0162-3109(90)90023-8; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V140, P908, DOI 10.1016/0006-291X(86)90721-7; GLAZER RI, 1987, ANAL BIOCHEM, V164, P214, DOI 10.1016/0003-2697(87)90388-5; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MCCOLL SR, 1991, BLOOD, V78, P1842; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NACCACHE PH, 1990, BLOOD, V76, P2098; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; TAUBER AI, 1987, BLOOD, V69, P711; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WHITE JR, 1984, J BIOL CHEM, V259, P8605; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YU G, 1988, MOL PHARMACOL, V33, P384; YU G, 1987, J BIOL CHEM, V262, P17543	47	25	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					687	693		10.1096/fasebj.7.8.7684713	http://dx.doi.org/10.1096/fasebj.7.8.7684713			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	7684713				2022-12-28	WOS:A1993LE29000011
J	THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A				THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A			MODULATION OF DOXORUBICIN RESISTANCE IN MULTIDRUG-RESISTANT CELLS BY LIPOSOMES	FASEB JOURNAL			English	Note						DRUG RESISTANCE; DOXORUBICIN; LIPOSOMES; P-GLYCOPROTEIN; DRUG INTRACELLULAR DISTRIBUTION	P-GLYCOPROTEIN EXPRESSION; BREAST CANCER-CELLS; PLASMA-MEMBRANE; HL-60 CELLS; ENCAPSULATED DOXORUBICIN; GLUTATHIONE TRANSFERASE; VINCRISTINE BINDING; DRUG ACCUMULATION; K562 CELLS; ADRIAMYCIN	In this study, we have confirmed the ability of liposome-encapsulated doxorubicin to modulate drug resistance, as previously observed in CH LZ cells (Thierry et al., Cancer Commun. 1, 311-316, 1989), in two human multidrug-resistant (MDR) cell lines, the breast cancer MCF-7/ADR cell line, and the ovarian carcinoma SKVLB cell line. This effect was specific to MDR cells, as liposomally encapsulated doxorubicin did not enhance cell sensitivity to the drug in the parental cell lines. Cytotoxicity assays demonstrated that empty liposomes in the presence of free doxorubicin (Dox) reversed resistance to the drug at a level that may be higher than that observed when liposome-encapsulated Dox is used. This effect seems to be due to the high affinity of Dox for cardiolipin, one of the liposome components, which leads to the association of the drug and the cardiolipin-containing liposomes in the culture medium before entry into the cells. Neither pretreatment of empty liposomes before drug treatment nor combined incubation of vincristine and empty liposomes alter MDR in CH LZ cells, suggesting that the drug must be encapsulated or complexed to the liposomes to overcome MDR. Because MDR in CH LZ cells does not seem to be related to GSH level, MDR modulation by liposome-encapsulated Dox apparently may not be effected by altering the GSH function. These results suggest that the enhancement of sensitivity of MDR cells using Dox encapsulated in liposomes or complexed with liposomes may be explained by an increase in cell drug incorporation and by an intracellular drug redistribution. Fluorescence confocal microscopy study indicated that Dox is transported and distributed mainly in intracytoplasmic vesicles in SKVLB and MCF-7/ADR cells, whereas in parental cells the drug is located mainly in the nucleus. In addition, presentation of Dox in liposomes modifies the drug distribution pattern in MDR cells by partially shifting the drug to nuclear compartments. Thus, liposome-associated Dox may bypass the vesicular drug transport in MDR cells, resulting in the enhancement of the drug biological activity.	GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,LOMBARDI CANC RES CTR,BIOSTAT & EPIDEMIOL UNIT,WASHINGTON,DC 20007; UNIV TEXAS,MED BRANCH,DEPT RADIAT THERAPY,GALVESTON,TX 77550	Georgetown University; Georgetown University; University of Texas System; University of Texas Medical Branch Galveston	THIERRY, AR (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT RADIAT MED,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		thierry, alain/F-9492-2014					BATIST G, 1986, J BIOL CHEM, V261, P5544; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BRADLEY G, 1989, CANCER RES, V49, P2790; CHABNER BA, 1989, J NATL CANCER I, V81, P910, DOI 10.1093/jnci/81.12.910; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEFFIE AM, 1988, CANCER RES, V48, P3595; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN D, 1990, CANCER RES, V50, P3619; FOJO A, 1985, CANCER RES, V45, P3002; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOTTESMAN MM, 1989, J CLIN ONCOL, V7, P409, DOI 10.1200/JCO.1989.7.4.409; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; HARRIS JR, 1979, INT J RADIAT ONCOL, V5, P1235, DOI 10.1016/0360-3016(79)90645-X; HINDENBURG AA, 1989, CANCER RES, V49, P4607; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOWELL N, 1984, CANCER RES, V44, P4023; KEIZER HG, 1989, CANCER RES, V49, P2988; KLOHS WD, 1988, CANCER RES, V48, P3025; LIU DX, 1989, BIOCHIM BIOPHYS ACTA, V981, P254, DOI 10.1016/0005-2736(89)90035-7; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; NAITO M, 1989, CANCER RES, V49, P1452; NAITO M, 1988, J BIOL CHEM, V263, P11887; NOGAE I, 1989, BIOCHEM PHARMACOL, V38, P519; OUDARD S, 1991, CANCER CHEMOTH PHARM, V28, P259; PAPAHADJ.D, 1974, NATURE, V252, P163, DOI 10.1038/252163a0; QUIAN XD, 1990, CANCER RES, V50, P1132; Roninson, 1991, MOL CELLULAR BIOL MU, P263; SADASIVAN R, 1991, CANCER LETT, V57, P165, DOI 10.1016/0304-3835(91)90211-Y; SEHESTED M, 1989, BRIT J CANCER, V60, P809, DOI 10.1038/bjc.1989.371; SHUMAN H, 1989, BIOTECHNIQUES, V7, P154; SHUURHUIS GJ, 1989, J NATL CANCER I, V81, P1887; Thierry A R, 1989, Cancer Commun, V1, P311; Thierry A. R., 1992, Gene regulation: biology of antisense RNA and DNA., P147; THIERRY AR, 1992, BIOCHEM BIOPH RES CO, V187, P1098, DOI 10.1016/0006-291X(92)91310-M; TREAT J, 1990, J NATL CANCER I, V82, P1706, DOI 10.1093/jnci/82.21.1706; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VERELLE P, 1991, J NATL CANCER I, V83, P111; YANOVICH S, 1989, CANCER RES, V49, P4499	40	101	106	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					572	579		10.1096/fasebj.7.6.8097173	http://dx.doi.org/10.1096/fasebj.7.6.8097173			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8097173				2022-12-28	WOS:A1993KY00900011
J	DUFAU, ML; TINAJERO, JC; FABBRI, A				DUFAU, ML; TINAJERO, JC; FABBRI, A			CORTICOTROPIN-RELEASING FACTOR - AN ANTIREPRODUCTIVE HORMONE OF THE TESTIS	FASEB JOURNAL			English	Review						CORTICOTROPIN-RELEASING FACTOR; RECEPTORS/ACTIONS; BETA-ENDORPHIN; OPIOIDS; TESTIS; LEYDIG CELLS; SEROTONERGIC REGULATION; SEROTONIN RECEPTORS ACTION; SIGNALING PATHWAYS; TESTOSTERONE; SEXUAL DYSFUNCTION	RAT LEYDIG-CELLS; PROOPIOMELANOCORTIN-DERIVED PEPTIDES; PITUITARY-TESTICULAR AXIS; BETA-ENDORPHIN; RESTRAINT STRESS; ACTH-SECRETION; SERTOLI CELLS; RECEPTORS; SEROTONIN; LOCALIZATION	Corticotropin-releasing factor (CRF), the key neuropeptide in the stress cascade, has major inhibitory actions on testicular function in addition to its known antireproductive effects at the central level (inhibition of sexual behavior and LH secretion). CRF is secreted by the Leydig cells of the testis and acts through high-affinity receptors at the Leydig cell membrane as a potent negative regulator of LH action, inhibiting gonadotropin-induced cAMP generation and androgen production. CRF is also a primary stimulus of beta-endorphin secretion by the Leydig cells, which in turn exerts paracrine inhibition of FSH action in the tubular compartment of the testis through high-affinity receptors in the Sertoli cells. CRF action in the Leydig cells involves a pertussis toxin-insensitive guanyl nucleotide regulatory unit. In contrast to CRF receptors in the brain, pituitary, and other peripheral tissues, those in the Leydig cell are not coupled to G(s). The inhibitory action of CRF in the Leydig cell is exerted through protein kinase C, at the level of the catalytic subunit of adenylate cyclase. The secretion of CRF by the Leydig cell is stimulated by LH, acting via release of serotonin (5HT) and autocrine activation of 5HT2 receptors. Serotonin acts on 5HT2 receptors in the Leydig cell to stimulate CRF secretion via a pertussis toxin insensitive G-protein and presumably through activation of phosphoinositide hydrolysis. The diversity of the biochemical responses to CRF and 5HT2 receptor activation (i.e., inhibition of adenylate cyclase at the cytoplasmic aspect of the cell membrane vs. stimulation of CRF release from secretion granules) may reflect the stimulation of different protein kinase C isoenzymes. The LH --> 5HT --> CRF inhibitory loop serves to continuously buffer the stimulation of androgen production by gonadotropin. 5HT, the immediate stimulus of testicular CRF secretion, is released during stress and is locally increased in the testis in pathological conditions associated with impaired testicular function (i.e., orchitis, varicocele). Also, propranolol, the beta-adrenergic antagonist frequently used in the control of blood pressure in patients with hypertension and often associated with impotence, acts via a serotonergic mechanism to stimulate CRF secretion and causes marked inhibition of LH-induced cAMP production and steroidogenesis in cultured Leydig cells. These basic studies of 5HT and CRF are relevant to the pathogenesis of testicular dysfunction and for the development of antagonist therapies to block CRF production and its local antireproductive effects.			DUFAU, ML (corresponding author), NICHHD, MOLEC ENDOCRINOL SECT, ENDOCRINOL & REPROD RES BRANCH, BLDG 10, RM B1-L400, BETHESDA, MD 20892 USA.							ADELL A, 1988, J NEUROCHEM, V50, P1678, DOI 10.1111/j.1471-4159.1988.tb02462.x; AGUILERA G, 1983, J BIOL CHEM, V258, P8039; ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358; AUDHYA T, 1989, BIOCHIM BIOPHYS ACTA, V995, P10, DOI 10.1016/0167-4838(89)90226-4; BARDIN CW, 1987, RECENT PROG HORM RES, V43, P1; BAUHN T, 1984, NEUROENDOCRINOLOGY, V39, P170; BELDHUIS JD, 1986, J CLIN INVEST, V72, P2035; BELLVE AR, 1989, J REPROD FERTIL, V85, P771, DOI 10.1530/jrf.0.0850771; BLANK MS, 1986, ENDOCRINOLOGY, V118, P2097, DOI 10.1210/endo-118-5-2097; BRUHN TO, 1987, ENDOCRINOLOGY, V120, P25, DOI 10.1210/endo-120-1-25; CALDAMONE AA, 1980, J UROLOGY, V123, P683, DOI 10.1016/S0022-5347(17)56091-7; CALOGERO AE, 1989, PEPTIDES, V10, P189, DOI 10.1016/0196-9781(89)90096-X; CAMPOS MB, 1990, J REPROD FERTIL, V88, P475, DOI 10.1530/jrf.0.0880475; COCKETT ATK, 1970, FERTIL STERIL, V21, P610; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; DUFAU ML, 1992, SERONO SYM, V86, P169; ELLIS LC, 1972, ENDOCRINOLOGY, V90, P1610, DOI 10.1210/endo-90-6-1610; ESKELAND NL, 1989, ENDOCRINOLOGY, V124, P2914, DOI 10.1210/endo-124-6-2914; ESKELAND NL, 1992, ENDOCRINOLOGY, V130, P1173, DOI 10.1210/en.130.3.1173; FABBRI A, 1985, ENDOCRINOLOGY, V117, P2544, DOI 10.1210/endo-117-6-2544; FABBRI A, 1988, ENDOCRINOLOGY, V122, P749, DOI 10.1210/endo-122-2-749; FABBRI A, 1988, J STEROID BIOCHEM, V30, P347, DOI 10.1016/0022-4731(88)90121-5; FABBRI A, 1990, ENDOCRINOLOGY, V127, P1541, DOI 10.1210/endo-127-3-1541; FABBRI A, 1990, HORMONAL COMMUNICATI, V70, P95; FABBRI A, 1990, TEM              JAN, P117; GERENDAI I, 1986, ENDOCRINOLOGY, V118, P2039, DOI 10.1210/endo-118-5-2039; GLENNON RA, 1988, J MED CHEM, V31, P5, DOI 10.1021/jm00396a003; HARRISON KL, 1987, FERTIL STERIL, V48, P633; HARTIG PR, 1989, TRENDS PHARMACOL SCI, V10, P64, DOI 10.1016/0165-6147(89)90080-1; HOLMES MC, 1982, J ENDOCRINOL, V93, P151, DOI 10.1677/joe.0.0930151; KENNETT GA, 1981, NEUROPHARMACOLOGY, V20, P39, DOI 10.1016/0028-3908(81)90039-3; KHANUM A, 1988, J BIOL CHEM, V263, P5070; KRUSEMAN ACN, 1982, LANCET, V2, P1245; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LEBOUILLE JLM, 1986, ENDOCRINOLOGY, V118, P372, DOI 10.1210/endo-118-1-372; MADDOCKS S, 1990, J REPROD IMMUNOL, V18, P33, DOI 10.1016/0165-0378(90)90023-Y; MANN DR, 1990, LIFE SCI, V46, P1601; MASTORAKOS G, 1992, ENDOCRINOLOGY, V130, P778; MCGRADY AV, 1984, ARCH ANDROLOGY, V13, P1; MORRIS PL, 1987, BIOCHEM BIOPH RES CO, V148, P1513, DOI 10.1016/S0006-291X(87)80303-0; MOSS HB, 1982, GEN HOSP PSYCHIAT, V4, P121, DOI 10.1016/0163-8343(82)90041-X; NIES AS, 1975, CIRCULATION, V52, P6, DOI 10.1161/01.CIR.52.1.6; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; PALKOVITS M, 1987, ANN NY ACAD SCI, V512, P139, DOI 10.1111/j.1749-6632.1987.tb24956.x; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; PETRAGLIA F, 1987, ENDOCRINOLOGY, V120, P1083, DOI 10.1210/endo-120-3-1083; PETRUSZ P, 1992, P129; RAJFER J, 1987, BIOL REPROD, V36, P933, DOI 10.1095/biolreprod36.4.933; RIVIER C, 1986, SCIENCE, V231, P607, DOI 10.1126/science.3003907; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; SHARPE RM, 1990, CLIN ENDOCRINOL, V33, P787, DOI 10.1111/j.1365-2265.1990.tb03916.x; SHARPE RM, 1990, AM J ANAT, V188, P3, DOI 10.1002/aja.1001880103; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SIRINATHSINGHJI DJS, 1983, NATURE, V305, P232, DOI 10.1038/305232a0; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SPARK FR, 1988, INFERTILE MALE, P221; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; SUDA T, 1984, J CLIN ENDOCR METAB, V59, P861, DOI 10.1210/jcem-59-5-861; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; TANAKA H, 1986, J ENDOCRINOL INVEST, V9, P97, DOI 10.1007/BF03348075; THOMPSON RC, 1987, ANN NY ACAD SCI, V512, P1, DOI 10.1111/j.1749-6632.1987.tb24947.x; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; TINAJERO J, 1992, CLIN RES, V40, pA263; TINAJERO JC, 1992, ENDOCRINOLOGY, V130, P1780, DOI 10.1210/en.130.4.1780; ULISSE S, 1990, J BIOL CHEM, V265, P1964; ULISSE S, 1989, J BIOL CHEM, V264, P2156; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALENCA MM, 1986, ENDOCRINOLOGY, V118, P32, DOI 10.1210/endo-118-1-32; Verbeuren TJ, 1989, PERIPHERAL ACTIONS 5, P1; VERHOEVEN G, 1992, BAILLIERE CLIN ENDOC, V6, P313, DOI 10.1016/S0950-351X(05)80152-1; WYNN PC, 1984, PEPTIDES, V5, P1077, DOI 10.1016/0196-9781(84)90174-8; WYNN PC, 1983, BIOCHEM BIOPH RES CO, V110, P602, DOI 10.1016/0006-291X(83)91192-0; YOON DJ, 1988, ENDOCRINOLOGY, V122, P759, DOI 10.1210/endo-122-2-759	73	101	102	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					299	307		10.1096/fasebj.7.2.8382638	http://dx.doi.org/10.1096/fasebj.7.2.8382638			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8382638				2022-12-28	WOS:A1993KN88500005
J	MARTINEZHERNANDEZ, A; AMENTA, PS				MARTINEZHERNANDEZ, A; AMENTA, PS			LIVER REGENERATION .1. THE EXTRACELLULAR-MATRIX IN HEPATIC REGENERATION	FASEB JOURNAL			English	Review						BASEMENT MEMBRANES; CIRRHOSIS; COLLAGEN; FIBRONECTIN; ITO CELLS; LAMININ; LIVER; SINUSOIDS	HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE COMPONENTS; COLLAGEN TYPE-III; NORMAL RAT-LIVER; ULTRASTRUCTURAL-LOCALIZATION; CONNECTIVE-TISSUE; FIBRONECTIN GENE; CELL-ADHESION; LAMININ; IV	After partial hepatectomy, as a consequence of hepatocyte proliferation, cell clusters containing 10-14 hepatocytes are formed, These clusters are devoid of sinusoids and extracellular matrix; therefore, many hepatocytes are two to three cells removed from the vascular spaces, Four days after hepatectomy, Ito cells send delicate cell processes between the hepatocytes in the clusters, This ''invasion'' of the clusters coincides with the activation in Ito cells of genes encoding for several laminin chains, The penetration of Ito cells into the clusters is followed by fenestrated endothelial cells, and in this manner the normal hepatocyte vascular relationship is restored, As soon as the normal vascular structure is reestablished, the laminin genes are turned off, This chain of events is similar to the one taking place during hepatogenesis when continuous capillaries are converted into sinusoids, This similarity in hepatogensis and regeneration suggests that the secreted laminin chains may be signals for the vascularization of the clusters by fenestrated sinusoids, During this process neither entactin nor laminin a chains are secreted, The vascularization of the regenerating clusters contrasts sharply to the vascularization of cirrhotic nodules, In the latter ease, entactin and perhaps laminin al chains are secreted, and the final result is the formation of basement membranes and continuous capillaries rather than fenestrated sinusoids, We suggest that entactin and specific laminin chains play a crucial role in determining the outcome of hepatic injury, Definition of the roles of entactin and laminin chains in vascularization and modulation of the endothelial phenotype will not only elucidate important aspects of regeneration, but may provide a better understanding of cirrhosis and even suggest therapeutic approaches.	UNIV TENNESSEE,COLL MED,DEPT PATHOL,MEMPHIS,TN 38104; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL & LAB MED,NEW BRUNSWICK,NJ 08903	University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	MARTINEZHERNANDEZ, A (corresponding author), VET ADM MED CTR,PATHOL & LAB MED SERV,1030 JEFFERSON AVE,MEMPHIS,TN 38104, USA.		Sano, Michael/E-1715-2011					ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AMENTA PS, 1988, J HISTOCHEM CYTOCHEM, V36, P1167, DOI 10.1177/36.9.3403967; AMENTA PS, 1983, J CELL BIOL, V96, P104, DOI 10.1083/jcb.96.1.104; AMENTA PS, 1986, COLLAGEN REL RES, V6, P125; BALOCH Z, 1992, DIFFERENTIATION, V51, P209, DOI 10.1111/j.1432-0436.1992.tb00698.x; BIEMPICA L, 1980, AM J PATHOL, V98, P591; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHUNG AE, 1993, KIDNEY INT, V43, P13, DOI 10.1038/ki.1993.4; CLEMENT B, 1986, HEPATOLOGY, V6, P225, DOI 10.1002/hep.1840060212; CLEMENT B, 1985, J HISTOCHEM CYTOCHEM, V33, P407, DOI 10.1177/33.5.3886779; CRIMAUD JA, 1980, J HISTOCHEM CYTOCHEM, V28, P1145; DUBOIS RN, IN PRESS MOL ASPECTS; FAUSTO N, 1994, LIVER BIOL PATHOBIOL, P365; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1990, SEMIN LIVER DIS, P20; GRESSNER AM, 1990, SEMIN LIVER DIS, P30; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HOFFMAN AL, 1994, SEMIN LIVER DIS, V14, P190, DOI 10.1055/s-2007-1007311; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INZZO RV, 1985, LAB INVEST, V53, P373; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; IOZZO RV, 1991, BIOCHEM J, V302, P625; JEFFERSON DM, 1985, HEPATOLOGY, V5, P14, DOI 10.1002/hep.1840050105; KARKAVELAS G, 1988, J ULTRA MOL STRUCT R, V100, P137, DOI 10.1016/0889-1605(88)90021-3; KOKKO LA, 1987, BIOCHEM J, V244, P75; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MARTINEZHERNAND.A, 1993, VIRCHOWS ARCH A, V423, P77; MARTINEZHERNAND.A, 1991, HEPATOLOGY, V14, P864; MARTINEZHERNAND.A, 1987, METHODS ENZYMOLOGY S, P145; MARTINEZHERNAND.A, 1985, LAB INVEST, V53, P166; MARTINEZHERNAND.A, 1983, LAB INVEST, V48, P656; MARTINEZHERNAND.A, 1981, COLLAGEN REL RES, V1, P405; MARTINEZHERNAND.A, 1993, VIRCHOWS ARCH A, V423, P1; MARTINEZHERNAND.A, 1985, BASEMENT MEMBRANES; MARTINEZHERNAND.A, 1984, LAB INVEST, V51, P57; MARTINEZHERNAND.A, 1984, J HISTOCHEM CYTOCHEM, V32, P289; MARTINEZHERNAND.A, 1993, EXTRACELLULAR MATRIX, P255; MARTINEZHERNANDEZ, 1991, LAB INVEST, V64, P157; MODIS L, 1991, LAB INVEST, V65, P661; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MYNDERSE LA, 1983, LAB INVEST, V48, P292; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OLDBERG A, 1986, J BIOL CHEM, V261, P2113; Olsen Bjorn Reino, 1993, P32; PORTO LC, 1990, ANAT RECORD, V228, P392, DOI 10.1002/ar.1092280405; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; ROJKIND M, 1986, LIVER ANN, P210; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; SCHUPPAN D, 1986, CELL TISSUE RES, V243, P535; SCHWOEGLER S, 1994, LAB INVEST, V70, P525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TANAKA Y, 1990, J PATHOL, V160, P129, DOI 10.1002/path.1711600206; Timpl R, 1977, Curr Probl Clin Biochem, V8, P20; VANEYKEN P, 1990, J HEPATOL, V11, P43, DOI 10.1016/0168-8278(90)90270-2; WEWER UM, 1992, LAB INVEST, V66, P378; WOESSNER JF, 1993, FASEB J, V7, P735, DOI 10.1096/fasebj.7.9.8330680; YAMADA KM, 1985, J CELL BIOCHEM, V28, P79, DOI 10.1002/jcb.240280202; YURCHENCO PD, 1988, AM J PATHOL, V132, P278	60	251	262	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1401	1410		10.1096/fasebj.9.14.7589981	http://dx.doi.org/10.1096/fasebj.9.14.7589981			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589981				2022-12-28	WOS:A1995TF67800004
J	IPPOLITI, R; LENDARO, E; DAGOSTINO, I; FIANI, ML; GUIDARINI, D; VESTRI, S; BENEDETTI, PA; BRUNORI, M				IPPOLITI, R; LENDARO, E; DAGOSTINO, I; FIANI, ML; GUIDARINI, D; VESTRI, S; BENEDETTI, PA; BRUNORI, M			A CHIMERIC SAPORIN-TRANSFERRIN CONJUGATE COMPARED TO RICIN TOXIN - ROLE OF THE CARRIER IN INTRACELLULAR-TRANSPORT AND TOXICITY	FASEB JOURNAL			English	Article						ENDOCYTOSIS; TOXIC CONJUGATES	RIBOSOME-INACTIVATING PROTEINS; EUKARYOTIC RIBOSOMES; K562 CELLS; A-CHAIN; RECEPTOR; IMMUNOTOXINS; MECHANISM; CYCLE	Human transferrin (Tf) and saporin-6 (Sap), a ribosome inactivating protein from Saponaria officinalis, were chemically conjugated: the reaction generated two chimeras (called Tf-Sap) that proved to be cytotoxic to HepG2 cells. Electrophoretic and chromatographic analysis revealed that the two conjugates contained saporin and Tf in a 2:1 or 1:1 molar ratio (140 and 110 KDa, respectively). Free saporin is essentially nontoxic, whereas Tf-Sap efficiently kills HepG2 cells, although its ID50 (= 6 nM) is 1000-fold greater than that of ricin. Intracellular transport of these toxins was followed by in vivo fluorescence video microscopy, preparing the conjugates starting from rhodamine isothiocyanate-labeled saporin. Image analysis of living HepG2 cells exposed to fluorescent Tf-Sap revealed that the endocytotic path way involving passage through secondary endosomes is dictated by Tf and is different from that of ricin (the dimeric toxin from Ricinus communis), which is delivered to the Golgi apparatus, the probable site of activation. We discuss whether differences in toxicity between ricin and Tf-Sap can be attributed to the different mechanisms of transport and activation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM,FDN CENCI BOLOGNETTI,IST PASTEUR,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY; IST SUPER SANITA,I-00161 ROME,ITALY; CNR,IST BIOFIS,PISA,ITALY	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)			Fiani, Maria Luisa/G-9369-2016	Fiani, Maria Luisa/0000-0003-2997-0767; Brunori, Maurizio/0000-0002-7795-1635; IPPOLITI, RODOLFO/0000-0003-0652-3470				AISEN P, 1980, ANN REV BIOCH, V49, P359; BARBIERI L, 1987, J CHROMATOGR, V408, P235, DOI 10.1016/S0021-9673(01)81806-9; BARBIERI L, 1989, EUR J HAEMATOL, V42, P238; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BELLELLI A, 1990, BIOCHEM BIOPH RES CO, V169, P602, DOI 10.1016/0006-291X(90)90373-U; BELLELLI A, 1994, BIOCHEM MOL BIOL INT, V33, P289; BERGAMASCHI G, 1988, BRIT J HAEMATOL, V68, P379, DOI 10.1111/j.1365-2141.1988.tb04218.x; BLUM JS, 1991, J BIOL CHEM, V266, P22091; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FANLK WP, 1980, LANCET, V2, P390; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; KILLISCH I, 1992, J CELL SCI, V103, P211; LENDARO E, 1994, FEBS LETT, V344, P99, DOI 10.1016/0014-5793(94)00255-X; RAMAKRISHNAN S, 1992, ANN REV PHARM TOXICO, V32, P571; RASO V, 1984, J BIOL CHEM, V259, P1143; SALLUSTIO S, 1990, J BIOL CHEM, V265, P582; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; SINGH V, 1989, INT J PEPT PROT RES, V33, P22; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TONEVITSKY AG, 1993, BIOCHEM MOL BIOL INT, V31, P1059; VITETTA ES, 1985, ANNU REV IMMUNOL, V3, P197; WELLHONER HH, 1991, J BIOL CHEM, V266, P4309; YOSHIDA T, 1981, EXP CELL RES, V192, P389	29	33	40	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1220	1225		10.1096/fasebj.9.12.7672515	http://dx.doi.org/10.1096/fasebj.9.12.7672515			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672515				2022-12-28	WOS:A1995RU81600012
J	LOHR, D; VENKOV, P; ZLATANOVA, J				LOHR, D; VENKOV, P; ZLATANOVA, J			TRANSCRIPTIONAL REGULATION IN THE YEAST GAL GENE FAMILY - A COMPLEX GENETIC NETWORK	FASEB JOURNAL			English	Review						GAL4P; GALACTOSE; NUCLEOSOMES; REGULATORY GENE CONTROL; SACCHAROMYCES-CEREVISIAE	SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; GLUCOSE REPRESSION; PROTEIN-BINDING; ACTIVATOR GAL4; CONTROL REGION; DNA-BINDING; INVIVO; EXPRESSION; NUCLEOSOME	Regulation of the GAL structural genes in the yeast Saccharomyces cerevisiae is implemented by the products of GAL-specific (GAL4, GAL80, GAL3) and general (GAL11, SWI1, 2, 3, SNF5, 6, numerous glucose repression) genes. Recent work; has 1) yielded significant new insights on the DNA binding and transcription activation/Gal80 protein binding functions of the Gal4 activator protein, 2) described the characterization of purified Gal4 protein-Gal80 protein complexes, 3) deconvoluted the multiple and complex glucose repression pathways acting on GAL genes, 4) suggested a new mechanism for the Gal3 protein-mediated induction of GAL structural gene expression, 5) introduced Gal1 protein, a structural gene product, into the regulation scheme, and 6) extended our already substantial understanding of GAL regulatory gene control. The mechanisms which control structural and regulatory gene expression in the GAL family are compared and GAL structural/regulatory gene chromatin structure is discussed.	ARIZONA STATE UNIV,MOLEC CELLULAR BIOL PROGRAM,TEMPE,AZ 85287; BULGARIAN ACAD SCI,INST MOLEC BIOL,BU-1113 SOFIA,BULGARIA; OREGON STATE UNIV,DEPT BIOCHEM BIOPHYS,CORVALLIS,OR 97371; BULGARIAN ACAD SCI,INST GENET,BU-1113 SOFIA,BULGARIA	Arizona State University; Arizona State University-Tempe; Bulgarian Academy of Sciences; Oregon State University; Bulgarian Academy of Sciences	LOHR, D (corresponding author), ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,BOX 871604,TEMPE,AZ 85287, USA.		Zlatanova, Jordanka/B-3273-2009					AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CIRILLO VP, 1968, J BACTERIOL, V95, P1727, DOI 10.1128/JB.95.5.1727-1731.1968; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; FLICK JS, 1992, GENETICS, V130, P295; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HUIBREGTSE JM, 1993, J BIOL CHEM, V268, P22219; IGARASHI M, 1987, MOL GEN GENET, V207, P273, DOI 10.1007/BF00331589; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; LAUGHON A, 1982, P NATL ACAD SCI-BIOL, V79, P6827, DOI 10.1073/pnas.79.22.6827; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MEYER J, 1991, MOL CELL BIOL, V11, P5454, DOI 10.1128/MCB.11.11.5454; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NOGI Y, 1989, MOL CELL BIOL, V9, P3009, DOI 10.1128/MCB.9.7.3009; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PARTHUN MR, 1992, MOL CELL BIOL, V12, P5683, DOI 10.1128/MCB.12.12.5683; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; POSTBEITTENMILL.MA, 1984, MOL CELL BIOL, V4, P1238; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; RAMOS J, 1989, J BACTERIOL, V171, P3539, DOI 10.1128/jb.171.6.3539-3544.1989; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SALMERON JM, 1990, GENETICS, V125, P21; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SHIMADA H, 1985, GENE, V39, P1; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TSCHOPP JF, 1986, J BACTERIOL, V166, P313, DOI 10.1128/jb.166.1.313-318.1986; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YOCUM RR, 1987, CRC BIOL RES IND YEA, V3, P61; ZLATANOVA J, 1992, ENCY MICROBIOLOGY, V4, P265	59	322	337	5	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					777	787		10.1096/fasebj.9.9.7601342	http://dx.doi.org/10.1096/fasebj.9.9.7601342			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601342				2022-12-28	WOS:A1995RH98200011
J	DENG, GE; PODACK, ER				DENG, GE; PODACK, ER			DEOXYRIBONUCLEASE INDUCTION IN APOPTOTIC CYTOTOXIC T-LYMPHOCYTES	FASEB JOURNAL			English	Article						APOPTOSIS; NUCLEASE; GROWTH FACTOR DEPRIVATION; CELL DEATH; DNA FRAGMENTATION	PROGRAMMED CELL-DEATH; ENDONUCLEASE; IDENTIFICATION; PURIFICATION; EXPRESSION; THYMOCYTES; SURVIVAL; NUCLEASE; BCL-2; LINES	IL-2-dependent CTLL2 cells, upon IL-2 deprivation, die by apoptosis, which is accompanied by the fragmentation of genomic DNA. Two major deoxyribonuclease activities were detected in the extract of IL-2-deprived CTLL2 cells in a zymographic assay. They were designated nuc-58 and nuc-40, based on their apparent molecular mass of 58 and 40 kDa. The activity of both DNases was greatly induced in CTLL2 cells deprived of IL-2 or treated with the kinase inhibitor staurosporine. Deregulated expression of bcl-2 cDNA suppressed the induction of both nuclease activities. Nuc-58 was dependent on both Ca2+ and Mg2+ ions whereas nuc-40 was also active in the presence of Mg2+ ions alone. Nuc-40 showed a preferential nuclear localization over that of nuc-58, which was found primarily in the cytoplasm, Optimal activity of both DNases required neutral pH and was inhibited by zinc ions. The physicochemical characteristics of the nucleases indicate that they are novel DNases associated with apoptosis in CTLL2 cells.	UNIV MIAMI, SCH MED, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33136 USA	University of Miami								BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDES RS, 1993, ANTICANCER RES, V13, P1253; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GILLIS S, 1977, J EXP MED, V146, P468, DOI 10.1084/jem.146.2.468; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	27	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					665	669		10.1096/fasebj.9.8.7768359	http://dx.doi.org/10.1096/fasebj.9.8.7768359			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768359				2022-12-28	WOS:A1995RC10600013
J	ENTSCH, B; VANBERKEL, WJH				ENTSCH, B; VANBERKEL, WJH			FLAVOPROTEIN STRUCTURE AND MECHANISM .1. STRUCTURE AND MECHANISM OF PARA-HYDROXYBENZOATE HYDROXYLASE	FASEB JOURNAL			English	Review						MECHANISM OF HYDROXYLATION; ENZYME STRUCTURE; FLAVIN MOVEMENT IN CATALYSIS; H-BOND CHAIN IN CATALYSIS	PSEUDOMONAS-FLUORESCENS; CRYSTAL-STRUCTURE; PHENOL HYDROXYLASE; SUBSTRATE COMPLEX; ENZYME-SUBSTRATE; INTERMEDIATE-II; GENE CLONING; BINDING-SITE; ACTIVE-SITE; PURIFICATION	Para-hydroxybenzoate hydroxylase (EC 1.14.13.2) is a flavoprotein involved in degradation of aromatic compounds, and it has become a model for enzymes involved in the oxygenation of a substrate. The chemical and kinetic mechanisms of this enzyme are described and integrated with an outline of the structure of the protein from crystallographic analysis. The structure is unusual because there is no recognizable domain for the binding of NADPH involved in the reaction. Recently, mechanistic studies of site-directed mutants, combined with structural analyses, have provided some exciting discoveries about protein function. The substrate during catalysis is largely isolated from solvent in the active site, a necessary condition for successful product formation. The flavin ring structure moves substantially in the active site, probably to enable substrate and product exchange into this site and possibly to regulate the reduction of the flavin by NADPH. A chain of H-bonds can connect p-hydroxybenzoate in the active site of the enzyme with the protein surface. This chain is responsible for the reversible formation of substrate phenolate anion observed in the active site and partly responsible for the reactivity of this substrate.	AGR UNIV WAGENINGEN,DEPT BIOCHEM,WAGENINGEN,NETHERLANDS	Wageningen University & Research	ENTSCH, B (corresponding author), UNIV NEW ENGLAND,DEPT BIOCHEM & MICROBIOL,ARMIDALE,NSW 2351,AUSTRALIA.		van Berkel, Willem J.H./O-2431-2014	van Berkel, Willem J.H./0000-0002-6551-2782				BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BEADLE CA, 1982, EUR J BIOCHEM, V123, P323, DOI 10.1111/j.1432-1033.1982.tb19771.x; BRUICE TC, 1994, FLAVINS FLAVOPROTEIN, P45; CHEN YCJ, 1988, J BACTERIOL, V170, P781, DOI 10.1128/jb.170.2.781-789.1988; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DIMARCO AA, 1993, GENE, V125, P25, DOI 10.1016/0378-1119(93)90741-K; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; Entsch B, 1994, FLAVINS AND FLAVOPROTEINS 1993, P211; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, 1988, GENE, V71, P279, DOI 10.1016/0378-1119(88)90044-3; Entsch B, 1976, FLAVINS FLAVOPROTEIN, P111; ESCHRICH K, 1993, EUR J BIOCHEM, V216, P137, DOI 10.1111/j.1432-1033.1993.tb18125.x; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; Husain M, 1978, Methods Enzymol, V53, P543; HUSAIN M, 1980, J BIOL CHEM, V255, P4189; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; KALIN M, 1992, J BACTERIOL, V174, P7112; Lah MS, 1994, FLAVINS AND FLAVOPROTEINS 1993, P221; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; March J, 1992, ADV ORG CHEM, P501; MERENYI G, 1991, J AM CHEM SOC, V113, P9371, DOI 10.1021/ja00024a054; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; MULLER F, 1982, EUR J BIOCHEM, V128, P21; PALFEY BA, 1994, BIOCHEMISTRY-US, V33, P1545, DOI 10.1021/bi00172a035; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SHOUN H, 1979, J BIOL CHEM, V254, P899; SHUMAN B, 1993, J BIOL CHEM, V268, P17057; van Berkel W.J.H., 1991, CHEM BIOCH FLAVOENZY, P1; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANBERKEL WJH, 1994, FEMS MICROBIOL LETT, V121, P207, DOI 10.1016/0378-1097(94)90128-7; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANBERKEL WJH, 1988, EUR J BIOCHEM, V176, P449; VANBERKEL WJH, 1995, PROTEIN SCI, V3, P2245; VANDERLAAN JM, 1989, EUR J BIOCHEM, V179, P715, DOI 10.1111/j.1432-1033.1989.tb14605.x; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8062, DOI 10.1021/bi00372a040; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WONG CM, 1994, MICROBIOL-SGM, V140, P2775, DOI 10.1099/00221287-140-10-2775; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	50	174	177	1	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					476	483		10.1096/fasebj.9.7.7737455	http://dx.doi.org/10.1096/fasebj.9.7.7737455			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737455				2022-12-28	WOS:A1995QX14800004
J	EARNSHAW, WC; MACKAY, AM				EARNSHAW, WC; MACKAY, AM			ROLE OF NONHISTONE PROTEINS IN THE CHROMOSOMAL EVENTS OF MITOSIS	FASEB JOURNAL			English	Review						TOPOISOMERASE II; CHROMOSOME PASSENGER PROTEINS; CHROMOSOME CONDENSATION; INCENPS; CYTOSKELETON; METAPHASE-ANAPHASE; TRANSITION	DNA TOPOISOMERASE-II; YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE CONTROL; MITOTIC CHROMOSOMES; DROSOPHILA-MELANOGASTER; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CHROMATID SEGREGATION; CENTROMERE PROTEINS; MONOCLONAL-ANTIBODY	This review is concerned with the role of chromosomal nonhistone proteins in three important aspects of mitotic events: chromosome condensation, sister chromatid separation at the metaphase:anaphase transition, and interactions between the chromosomes and cytoskeleton that occur during construction of the mitotic spindle and cleavage furrow. Emphasis will be given to the potential roles of topoisomerase II and the chromosome passenger proteins in these events. Other important aspects of mitotic events such as the regulation of the G(2)-->M transition, the structural changes that affect the nuclear envelope and other organelles during mitosis, and the mechanism of chromosome movement will not be considered here. Despite long histories of often elegant experimentation, all three of our chosen subjects remain areas of lively, ongoing controversy. Thus, although recent advances appear to have taken us many steps closer to an understanding of the underlying mechanisms, we suspect that final answers will be some time in coming.			EARNSHAW, WC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212, R01GM030985] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30985, GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ANDREASSEN PR, 1991, J CELL SCI, V99, P523; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BERNAT RL, 1991, CELL, V66, P1229, DOI 10.1016/0092-8674(91)90045-Z; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BUCHENAU P, 1993, J CELL SCI, V104, P1175; CARDENAS ME, 1993, J CELL SCI, V104, P533; CASIANO CA, 1993, J CELL SCI, V106, P1045; CLARKE DJ, 1993, J CELL SCI, V105, P563; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DANG Q, 1994, IN PRESS J MOL BIOL; DAWSON IA, 1993, DEVELOPMENT, V117, P359; DOMBRADI V, 1990, FEBS LETT, V275, P39, DOI 10.1016/0014-5793(90)81434-P; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOMES R, 1993, J CELL SCI, V104, P583; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; GUACCI V, 1994, IN PRESS J CELL BIOL; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; KINGWELL B, 1987, CELL MOTIL CYTOSKEL, V8, P360, DOI 10.1002/cm.970080408; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAZIA D, 1961, CELL, V3, P77; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; MOLEBAJER J, 1958, CHROMOSOMA, V9, P332, DOI 10.1007/BF02568085; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PANKOV R, 1990, CHROMOSOMA, V99, P95, DOI 10.1007/BF01735324; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PHILP AV, 1993, J CELL SCI, V106, P87; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RATTNER JB, 1992, CHROMOSOMA, V101, P625, DOI 10.1007/BF00360540; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; SAMEJIMA I, 1993, J CELL SCI, V105, P135; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SLUDER G, 1983, J CELL BIOL, V97, P877, DOI 10.1083/jcb.97.3.877; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUMNER AT, 1992, J CELL SCI, V103, P105; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TODA T, 1981, J CELL SCI, V52, P271; TOMKIEL JE, 1994, IN PRESS J CELL BIOL; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; UMESONO K, 1983, CURR GENET, V7, P123, DOI 10.1007/BF00365637; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F; ZIRKLE RE, 1970, J CELL BIOL, V47, pA235; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	99	74	77	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					947	956		10.1096/fasebj.8.12.8088460	http://dx.doi.org/10.1096/fasebj.8.12.8088460			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088460				2022-12-28	WOS:A1994PG29300007
J	JANS, DA				JANS, DA			NUCLEAR SIGNALING PATHWAYS FOR POLYPEPTIDE LIGANDS AND THEIR MEMBRANE-RECEPTORS	FASEB JOURNAL			English	Review						SIGNAL TRANSDUCTION; NUCLEAR LOCALIZATION SIGNALS; TYROSINE KINASE RECEPTORS; GROWTH FACTORS	DEPENDENT PROTEIN-KINASE; GROWTH-HORMONE RECEPTOR; RENAL EPITHELIAL-CELLS; SV40 T-ANTIGEN; FACTOR A-CHAIN; ADENYLATE-CYCLASE; VASOPRESSIN V2-RECEPTOR; INTERLEUKIN-1 RECEPTOR; LOCALIZATION SEQUENCE; AUTOCRINE STIMULATION	Classical signal transduction theory revolves around the premise that the role of membrane receptors is to transfer the signal represented by ligand binding from the external cell surface across the membrane to within the cell. Other components of the signaling cascade such as second-messenger molecules and kinases then convey the signal from the cytoplasm to the nucleus to effect changes in gene expression. Membrane receptor endocytosis is seen as part of the cellular down-regulation and desensitization apparatus rather than as having an active signaling function. Evidence is mounting, however, that polypeptide ligands and their membrane receptors may have an important additional signaling role within the cell including the nucleus. Several ligands such as those of the platelet-derived and fibroblast growth factor classes have been found not only to localize in the nucleus, but also to possess sequences similar to the nuclear localization signal of the simian virus SV40 large T antigen. In most cases where they have been examined, these sequences appear to be both functional in nuclear targeting and essential for full signaling activity. The implication is that subsequent to internalization, polypeptide ligands and/or their receptors may translocate to the nucleus and participate directly in regulating gene expression.			JANS, DA (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,NUCL SIGNALING LAB,POB 334,CANBERRA,ACT 2601,AUSTRALIA.							ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BOUCHE G, 1989, NUCLEIC ACIDS RES, V17, P6625; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GRENFELL S, 1991, BIOCHEM J, V280, P111, DOI 10.1042/bj2800111; HANNINK M, 1986, MOL CELL BIOL, V6, P1343, DOI 10.1128/MCB.6.4.1343; HANSKI E, 1979, BIOCHEMISTRY-US, V18, P846, DOI 10.1021/bi00572a017; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1991, J CELL BIOL, V114, P53, DOI 10.1083/jcb.114.1.53; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; JAYA M, 1988, EMBO J, V7, P963; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KUNO K, 1993, J BIOL CHEM, V268, P13510; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MOLL T, 1991, CELL, V66, P1; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROSENKRANZ AA, 1992, EXP CELL RES, V199, P323, DOI 10.1016/0014-4827(92)90441-A; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAMIGUCHI T, 1993, CELL, V73, P5; TOLKOVSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P213, DOI 10.1073/pnas.79.2.213; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; TOWNSEND PV, 1993, GROWTH FACTORS, V9, P2130; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG KY, 1988, BIOCHEMISTRY-US, V27, P375, DOI 10.1021/bi00401a056; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269; ZU XW, 1991, J BIOL CHEM, V266, P6023	63	129	137	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					841	847		10.1096/fasebj.8.11.8070633	http://dx.doi.org/10.1096/fasebj.8.11.8070633			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070633				2022-12-28	WOS:A1994PC88500006
J	KESHISHIAN, H; CHANG, TN; JARECKI, J				KESHISHIAN, H; CHANG, TN; JARECKI, J			PRECISION AND PLASTICITY DURING DROSOPHILA NEUROMUSCULAR DEVELOPMENT	FASEB JOURNAL			English	Review						SYNAPTOGENESIS; NEUROMUSCULAR JUNCTION; CELL RECOGNITION; SYNAPTIC PLASTICITY	CELL-ADHESION MOLECULE; ACTIVITY-DEPENDENT DEVELOPMENT; ACETYLCHOLINE-RECEPTORS; EMBRYONIC-DEVELOPMENT; SYNAPTIC TERMINALS; PRECURSOR CELLS; NERVOUS-SYSTEM; FASCICLIN-III; MUSCLE-CELLS; MOTOR AXONS	Synaptogenesis can be analyzed in a simple array of motoneurons and muscle fibers of the embryos and larvae of Drosophila melanogaster. Each abdominal hemisegment contains a stereotypic array of 30 muscle fibers. During middle to late embryogenesis, motoneurons exit the central nervous system to make precise synaptic connections with specific muscle fibers. Target recognition has been tested using both genetic and microsurgical manipulations, which indicate that motoneurons actively recognize specific muscle fibers. The molecular basis of target recognition has been examined by screens for mutations that disrupt both guidance events and correct innervation. In addition, the motoneurons and muscle fibers both express an array of putative cell adhesion molecules whose functions may contribute to normal connectivity. Postsynaptic specializations, including glutamate receptor distribution, depend on innervation and neural activity. The neuromuscular system is not ''hardwired,'' as motoneurons are capable of altering both their branch arborizations and connectivity in response to local denervation and blockade of synaptic function. Collectively, these studies show that the Drosophila motor innervation is a powerful model system for testing at the cellular and molecular level the mechanisms that govern synaptic development.	YALE UNIV,INTERDEPT NEUROSCI PROGRAM,NEW HAVEN,CT 06520; YALE UNIV,DEPT GENET,NEW HAVEN,CT 06520	Yale University; Yale University	KESHISHIAN, H (corresponding author), YALE UNIV,DEPT BIOL,ROOM 640 KBT,POB 208103,NEW HAVEN,CT 06520, USA.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; ANDERSON MS, 1988, J NEUROSCI, V8, P242; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BATE M, 1990, DEVELOPMENT, V110, P791; Bate Michael, 1993, P1013; BENTLEY D, 1992, NERVE GROWTH CONE, P265; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BROADIE K, 1993, NEURON, V11, P607, DOI 10.1016/0896-6273(93)90073-Z; BROADIE K, 1993, NATURE, V361, P350, DOI 10.1038/361350a0; BROADIE KS, 1993, J NEUROSCI, V13, P144; BROWN MC, 1977, NATURE, V265, P459, DOI 10.1038/265459a0; BUDNIK V, 1992, J NEUROBIOL, V23, P1054, DOI 10.1002/neu.480230810; BUDNIK V, 1990, J NEUROSCI, V10, P3754; CAMPANELLI JT, 1992, COLD SPRING HARB SYM, V57, P461, DOI 10.1101/SQB.1992.057.01.051; CANTERA R, 1992, CELL TISSUE RES, V269, P459, DOI 10.1007/BF00353901; CASH S, 1992, J NEUROSCI, V12, P2051; Chang T. N., 1993, Society for Neuroscience Abstracts, V19, P645; CHIBA A, 1993, J NEUROSCI, V13, P714; Chiba A., 1992, Society for Neuroscience Abstracts, V18, P1273; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; DRYSDALE R, 1993, ROUX ARCH DEV BIOL, V202, P276, DOI 10.1007/BF00363217; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOOD, 1992, GOODMAN CS, P283; Goodman Corey S., 1993, P1131; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; JACOBS JR, 1989, J NEUROSCI, V9, P12; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Jarecki J. E., 1993, Society for Neuroscience Abstracts, V19, P645; JIA XX, 1993, J NEUROBIOL, V24, P1025, DOI 10.1002/neu.480240804; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; Lin D., 1992, Society for Neuroscience Abstracts, V18, P36; LNENICKA GA, 1986, J NEUROSCI, V6, P2252; LNENICKA GA, 1991, J NEUROSCI, V11, P1040; MCALLISTER L, 1992, DEVELOPMENT, V115, P267; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SCHUSTER CM, 1991, SCIENCE, V254, P112, DOI 10.1126/science.1681587; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; Truman James W., 1993, P1245; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VOLK T, 1994, DEVELOPMENT, V120, P59; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; ZHONG Y, 1992, J NEUROSCI, V12, P644	60	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					731	737		10.1096/fasebj.8.10.8050672	http://dx.doi.org/10.1096/fasebj.8.10.8050672			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050672				2022-12-28	WOS:A1994NY35000010
J	KLIP, A; TSAKIRIDIS, T; MARETTE, A; ORTIZ, PA				KLIP, A; TSAKIRIDIS, T; MARETTE, A; ORTIZ, PA			REGULATION OF EXPRESSION OF GLUCOSE TRANSPORTERS BY GLUCOSE - A REVIEW OF STUDIES IN-VIVO AND IN CELL-CULTURES	FASEB JOURNAL			English	Review						GLYCEMIA; GLUT1; GLUT4; DIABETES; INSULIN	L6 MUSCLE-CELLS; HEXOSE-TRANSPORT; SKELETAL-MUSCLE; SUGAR-TRANSPORT; DIFFERENTIAL REGULATION; INSULIN RESISTANCE; MURINE FIBROBLASTS; PLASMA-MEMBRANE; SMALL-INTESTINE; MESSENGER-RNA	Glucose transporters are membrane-embedded proteins that mediate the uptake of glucose from the surrounding medium into the cell. Glucose is the main fuel for most cells, and its uptake is rate-limiting for glucose utilization. For this reason, it is expected that glucose transport is tightly regulated. Whereas rapid regulation of glucose transporters by hormones has been known for some time, the regulation of glucose transporters by substrate availability (i.e., by glucose itself) is less well understood. This question has been approached by scientists from two angles: one, by measuring the consequence of diabetic states (in which there is surplus of glucose availability) on the expression of glucose transporter genes, and another one, by measuring the effect of glucose availability and glucose deprivation in cell cultures on glucose transporter gene expression. The results from both camps are unfortunately not coincident, due in part to the coexistence of other variables in the diabetic animals, and to the lack of ideal cell cultures. In spite of these caveats, the profuse literature on both approaches propelled us to find commonalities within each approach. This review concludes that in animal studies, one isoform of glucose transporters, the GLUT4 type, is down-regulated by high levels of circulating glucose in muscle but not in fat cells. This down-regulation of the protein is independent of regulation of transcription. In contrast, in fat cells, high glucose levels depress GLUT4 mRNA levels. In cell culture studies, high glucose levels lead to lower expression of the GLUT1 transporter isoform relative to glucose-deprived cultures. Glucose levels do not affect the amount of GLUT4 transporter isoform. The down-regulation of the GLUT1 transporter protein is caused by pre- and post-transcriptional mechanisms, the prevalence of each being cell-type specific. No glucose-responsive elements have been identified on either the GLUT1 or GLUT4 genes, and no information is available on the glucose metabolites that mediate the response of glucose transporter gene expression to glucose availability.	SKIDMORE COLL,DEPT BIOL,SARATOGA SPRINGS,NY 12866	Skidmore College	KLIP, A (corresponding author), HOSP SICK CHILDREN,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Marette, Andre/E-9342-2013					ANDREJCHYSHYN S, 1991, AM J PHYSIOL, V261, P973; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHRISTOPHER CW, 1976, J CELL PHYSIOL, V89, P683, DOI 10.1002/jcp.1040890427; DIMITRAKOUDIS D, 1992, J AM SOC NEPHROL, V3, P1078; DIMITRAKOUDIS D, 1992, BIOCHEM J, V284, P341, DOI 10.1042/bj2840341; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FAIK P, 1989, BIOCHEM J, V260, P153, DOI 10.1042/bj2600153; FAIK P, 1984, BIOCHEM SOC T, V12, P230; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GERMINARIO RJ, 1985, BIOCHEM BIOPH RES CO, V128, P1418, DOI 10.1016/0006-291X(85)91098-8; GERMINARIO RJ, 1990, J CELL PHYSIOL, V145, P318, DOI 10.1002/jcp.1041450217; GERMINARIO RJ, 1989, J CELL PHYSIOL, V138, P300, DOI 10.1002/jcp.1041380211; GERMINARIO RJ, 1982, J CELL PHYSL, V111, P367; GERRITS PM, 1993, J BIOL CHEM, V268, P640; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HASPEL HC, 1991, MOL ENDOCRINOL, V5, P61, DOI 10.1210/mend-5-1-61; HUNDAL HS, 1992, BIOCHEM J, V286, P339, DOI 10.1042/bj2860339; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAHN BB, 1993, ENDOCRINOLOGY, V132, P13, DOI 10.1210/en.132.1.13; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; KALCKAR HM, 1979, P NATL ACAD SCI USA, V76, P6453, DOI 10.1073/pnas.76.12.6453; KALCKAR HM, 1984, CELL MEMBRANE, P253; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; MARETTE A, 1993, DIABETES, V42, P1195, DOI 10.2337/diabetes.42.8.1195; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MORGAN MJ, 1980, CELL BIOL INT REP, V4, P121, DOI 10.1016/0309-1651(80)90066-1; MORGAN MJ, 1981, BIOSCIENCE REP, V1, P669, DOI 10.1007/BF01116465; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NEUFER NP, 1993, J BIOL CHEM, V268, P13824; ORTIZ PA, 1993, BIOCHEM J, V295, P67, DOI 10.1042/bj2950067; ORTIZ PA, 1992, BIOCHEMISTRY-US, V31, P5386, DOI 10.1021/bi00138a021; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; PASTERNAK CA, 1991, J CELL PHYSIOL, V149, P324, DOI 10.1002/jcp.1041490221; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SARIER MH, 1989, MICROBIOL REV, V53, P109; SHEPHERD PR, 1992, DIABETES, V41, P1360, DOI 10.2337/diabetes.41.10.1360; SIMMONS RA, 1993, ENDOCRINOLOGY, V132, P2312, DOI 10.1210/en.132.6.2312; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; TAKAKURA Y, 1991, BIOCHIM BIOPHYS ACTA, V1070, P1, DOI 10.1016/0005-2736(91)90139-Y; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; ULLREY DB, 1982, P NATL ACAD SCI-BIOL, V79, P3777, DOI 10.1073/pnas.79.12.3777; ULLREY DB, 1978, J CELL PHYSIOL, V96, P23, DOI 10.1002/jcp.1040960104; ULLREY DB, 1991, P NATL ACAD SCI USA, V88, P1504, DOI 10.1073/pnas.88.4.1504; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WERTHEIMER E, 1990, J CELL PHYSIOL, V143, P330, DOI 10.1002/jcp.1041430217	60	258	269	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					43	53		10.1096/fasebj.8.1.8299889	http://dx.doi.org/10.1096/fasebj.8.1.8299889			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299889				2022-12-28	WOS:A1994MV28200008
J	MATZ, JM; BLAKE, MJ; SAARI, JT; BODE, AM				MATZ, JM; BLAKE, MJ; SAARI, JT; BODE, AM			DIETARY COPPER DEFICIENCY REDUCES HEAT-SHOCK PROTEIN EXPRESSION IN CARDIOVASCULAR TISSUES	FASEB JOURNAL			English	Note						METABOLIC STRESSORS; CATECHOLAMINE METABOLISM; CARDIAC MITOCHONDRIA	CARDIAC-HYPERTROPHY; MESSENGER-RNAS; RATS; MITOCHONDRIAL; STRESS; IRON; ENLARGEMENT; MEMBRANE; COMPLEX; LIVER	Dietary copper deficiency impairs cardiovascular function by depression of catecholamine metabolism, and alteration of the structure and function of cardiac mitochondria. Heat shock proteins (HSPs) are a group of cellular homeostatic proteins that are induced in vascular tissue by catecholaminergic transmission after exposure to stress. We investigated the effects of dietary copper deficiency on the induction and accumulation of HSPs in several cardiovascular tissues. Stress-induced levels of aortic HSP70 mRNA were reduced in copper-deficient (CuD) rats when compared with copper-adequate (CuA) controls. Cocaine-induced HSP70 mRNA accumulation was not different between CuA and CuD rats, suggesting that reduced HSP70 levels in restrained CuD animals may result from altered catecholaminergic neurotransmission. The level of HSP60 mRNA was specifically reduced in the atria of CuD rats, which may be associated with altered mitochondrial structure and function. These results describe a novel relationship between dietary copper deficiency and the expression of highly conserved cellular stress response proteins. Loss of these essential homeostatic proteins in vascular tissue may contribute to the impairment of cardiovascular function known to accompany copper deficiency.	UNIV N DAKOTA,SCH MED,DEPT PHYSIOL,BOX 9001,GRAND FORKS,ND 58202; UNIV N DAKOTA,SCH MED,DEPT PHARMACOL & TOXICOL,GRAND FORKS,ND 58202; USDA ARS,GRAND FORKS HUMAN NUTR RES CTR,GRAND FORKS,ND 58202	University of North Dakota Grand Forks; University of North Dakota Grand Forks; United States Department of Agriculture (USDA)					NIDDK NIH HHS [DK44439] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044439] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG D, 1991, J BIOL CHEM, V266, P24233; BENNETTS H. W., 1948, AUSTRALIAN VET JOUR, V24, P237, DOI 10.1111/j.1751-0813.1948.tb04683.x; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; BLAKE MJ, 1993, IN PRESS J PHARM EXP; BODE AM, 1992, J NUTR BIOCHEM, V3, P668, DOI 10.1016/0955-2863(92)90088-Z; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRIE RW, 1991, BIOCHEM CELL BIOL, V69, P375, DOI 10.1139/o91-057; DALLMAN PR, 1970, BLOOD-J HEMATOL, V35, P496, DOI 10.1182/blood.V35.4.496.496; DELCAYRE C, 1988, J CLIN INVEST, V82, P460, DOI 10.1172/JCI113619; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN S, 1965, J BIOL CHEM, V240, pPC552; GOODMAN JR, 1970, PEDIATR RES, V4, P244, DOI 10.1203/00006450-197005000-00003; GRAY RE, 1990, FEBS LETT, V265, P265; GUBLER CJ, 1957, J BIOL CHEM, V224, P553; HOWARD G, 1986, MOL CELL BIOCHEM, V69, P155; JOHNSON WT, 1987, J NUTR, V117, P1085, DOI 10.1093/jn/117.6.1085; KELLY WA, 1974, EXP MOL PATHOL, V20, P40, DOI 10.1016/0014-4800(74)90042-2; KITANO S, 1980, CIRC RES, V46, P681, DOI 10.1161/01.RES.46.5.681; KLEVAY LM, 1991, PHYSIOL BEHAV, V49, P309, DOI 10.1016/0031-9384(91)90048-S; KLEVAY LM, 1993, P SOC EXP BIOL MED, V203, P214, DOI 10.3181/00379727-203-43594; KNOWLTON AA, 1991, J CLIN INVEST, V88, P2018, DOI 10.1172/JCI115529; KOHANE DS, 1990, AM J PHYSIOL, V258, pH1699, DOI 10.1152/ajpheart.1990.258.6.H1699; LAI YK, 1986, BIOCHEM BIOPH RES CO, V135, P857, DOI 10.1016/0006-291X(86)91007-7; LUIS AM, 1990, J BIOL CHEM, V265, P7713; MEDEIROS DM, 1993, BIOL TRACE ELEM RES, V36, P271, DOI 10.1007/BF02783961; MEDEIROS DM, 1991, J NUTR, V121, P815, DOI 10.1093/jn/121.6.815; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; MORIMOTO R I, 1990, P1; NIELSEN FH, 1982, BIOL TRACE ELEM RES, V4, P125, DOI 10.1007/BF02783253; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PROHASKA JR, 1990, J NUTR BIOCHEM, V1, P149, DOI 10.1016/0955-2863(90)90015-D; PROHASKA JR, 1982, J NUTR, V112, P2142; SEIDEL KE, 1991, J NUTR, V121, P474, DOI 10.1093/jn/121.4.474; SHIELDS GS, 1962, AM J PATHOL, V41, P603; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; UDELSMAN R, 1991, SURGERY, V110, P1125; VIESTENZ KE, 1982, AM J CLIN NUTR, V35, P258, DOI 10.1093/ajcn/35.2.258; [No title captured]	41	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					97	102		10.1096/fasebj.8.1.8299895	http://dx.doi.org/10.1096/fasebj.8.1.8299895			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299895				2022-12-28	WOS:A1994MV28200014
J	HUBER, PW				HUBER, PW			CHEMICAL NUCLEASES - THEIR USE IN STUDYING RNA STRUCTURE AND RNA-PROTEIN INTERACTIONS	FASEB JOURNAL			English	Review						METAL COMPLEXES; NUCLEOTIDES; CHEMICAL PROBES; NUCLEIC ACIDS; RIBOSOMAL RNA	TERTIARY STRUCTURE; MESSENGER-RNA; RIBOSOMAL-RNA; NMR-SPECTROSCOPY; NUCLEIC-ACIDS; BINDING-SITE; DNA; RECOGNITION; COMPLEXES; CLEAVAGE	Metal complexes that cleave nucleic acids provide a new means to study RNA structure and RNA-protein interactions. Methods that use these chemical nucleases help compensate for the limitations of other techniques used to determine structure. Because the ligands that coordinate the metal generally control the cleavage selectivity of these complexes, it has become possible to design nucleolytic reagents that target specific higher-order structures. In combination with site-directed mutagenesis these conformation-specific probes can be used to delineate long-range interactions. Alternatively, complexes that cut irrespective of sequence and secondary structure have been used in protection (foot-printing) experiments to locate protein binding sites. Because each position of the nucleic acid is susceptible to cleavage, the protection pattern yields a highly resolved definition of the contact site between the protein and RNA. In other applications, metal complexes have been conjugated to functional moieties such as oligonucleotides, peptides, or substrate analogs to direct their binding to a distinct site on a specific RNA molecule. This latter strategy holds significant therapeutic promise for the destruction of pathogenic RNAs.			HUBER, PW (corresponding author), UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHEN CHB, 1987, SCIENCE, V237, P1197, DOI 10.1126/science.2820056; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CHOW CS, 1992, METHOD ENZYMOL, V212, P219; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P5423, DOI 10.1021/bi00139a001; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; DARSILLO P, 1991, J BIOL CHEM, V266, P21075; DOAN TL, 1986, BIOCHEMISTRY-US, V25, P6736; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JAYASENA SD, 1992, P NATL ACAD SCI USA, V89, P3526, DOI 10.1073/pnas.89.8.3526; KEAN JM, 1985, BIOCHEMISTRY-US, V24, P5062, DOI 10.1021/bi00340a016; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LIN SB, 1989, BIOCHEMISTRY-US, V28, P1054, DOI 10.1021/bi00429a020; MARUSAK RA, 1993, IN PRESS REACTIVE SP; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MODAK AS, 1991, J AM CHEM SOC, V113, P283, DOI 10.1021/ja00001a041; MORROW JR, 1992, J AM CHEM SOC, V114, P1903, DOI 10.1021/ja00031a067; MURAKAWA GJ, 1989, BIOCHEMISTRY-US, V28, P8067, DOI 10.1021/bi00446a015; MURAKAWA GJ, 1989, NUCLEIC ACIDS RES, V17, P5361, DOI 10.1093/nar/17.13.5361; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NAZAR RN, 1991, J BIOL CHEM, V266, P4562; NIELSEN PE, 1990, NUCLEIC ACIDS RES, V18, P3847, DOI 10.1093/nar/18.13.3847; NIKONOWICZ EP, 1992, NATURE, V355, P184, DOI 10.1038/355184a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SMITH J, 1993, J AM CHEM SOC, V115, P362, DOI 10.1021/ja00054a062; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TANNER NK, 1985, NUCLEIC ACIDS RES, V13, P7759, DOI 10.1093/nar/13.21.7759; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; VARY CPH, 1984, P NATL ACAD SCI-BIOL, V81, P6978, DOI 10.1073/pnas.81.22.6978; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WU HN, 1987, BIOCHEMISTRY-US, V26, P8221, DOI 10.1021/bi00399a030	57	20	20	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1993	7	14					1367	1375		10.1096/fasebj.7.14.7693534	http://dx.doi.org/10.1096/fasebj.7.14.7693534			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693534				2022-12-28	WOS:A1993MH00800009
J	CONRAD, KP; VILL, M; MCGUIRE, PG; DAIL, WG; DAVIS, AK				CONRAD, KP; VILL, M; MCGUIRE, PG; DAIL, WG; DAVIS, AK			EXPRESSION OF NITRIC-OXIDE SYNTHASE BY SYNCYTIOTROPHOBLAST IN HUMAN PLACENTAL VILLI	FASEB JOURNAL			English	Article						NADPH DIAPHORASE; IN-SITU HYBRIDIZATION; MICHAELIS-MENTEN KINETICS; PLACENTAL CIRCULATION	URINARY-EXCRETION; ENDOTHELIUM; CALMODULIN; ADHESION; PREGNANCY; INVITRO; CELLS; CGMP	The endogenous biosynthesis of nitric oxide (NO) is increased during gestation. To begin our investigation of a possible tissue source (or sources), we examined the placenta. We postulated that analogous to the endothelium of blood vessels, the syncytiotrophoblast (STr) cell layer that lines the intervillous blood space of the human placenta would express NO synthase. Our results show that human placental villi express a calcium- and calmodulin-sensitive form of NO synthase, located mainly in the microsomal cell fraction. By in situ hybridization using a riboprobe generated from human endothelial NO synthase cDNA, we observe NO synthase mRNA expression in STr. The STr also shows NADPH-diaphorase staining, indicating the presence of NO synthase, and most likely other flavin-containing enzymes involved in sex steroid metabolism. NO synthase activity was also detected in the villi of a complete mole placenta (which lacks fetal vessels), further supporting a trophoblastic origin. Our findings suggest a previously unrecognized role for STr-derived NO in placental function.	UNIV NEW MEXICO, SCH MED, DEPT OBSTET & GYNECOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT ANAT, ALBUQUERQUE, NM 87131 USA	University of New Mexico; University of New Mexico	CONRAD, KP (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT PHYSIOL, 915 STANFORD NE, ALBUQUERQUE, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046865] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46865] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; Benirschke K, 1990, PATHOLOGY HUMAN PLAC; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; Casey ML, 1992, WILLIAMS TXB ENDOCRI, P977; CONRAD KP, 1989, AM J PHYSIOL, V257, pR847, DOI 10.1152/ajpregu.1989.257.4.R847; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; HOWARD RB, 1987, MED HYPOTHESES, V23, P51, DOI 10.1016/0306-9877(87)90180-0; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; KOPP L, 1977, J CLIN ENDOCR METAB, V44, P590, DOI 10.1210/jcem-44-3-590; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MYATT L, 1992, AM J OBSTET GYNECOL, V166, P224, DOI 10.1016/0002-9378(92)91863-6; MYATT L, 1992, PORTL PR P, V1, P347; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; Reid E, 1974, Methods Enzymol, V31, P713; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169	24	144	147	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1269	1276		10.1096/fasebj.7.13.7691671	http://dx.doi.org/10.1096/fasebj.7.13.7691671			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	7691671				2022-12-28	WOS:A1993MB37600011
J	BRADDOCK, M; POWELL, R; BLANCHARD, AD; KINGSMAN, AJ; KINGSMAN, SM				BRADDOCK, M; POWELL, R; BLANCHARD, AD; KINGSMAN, AJ; KINGSMAN, SM			HIV-1 TAR RNA-BINDING PROTEINS CONTROL TAT ACTIVATION OF TRANSLATION IN XENOPUS OOCYTES	FASEB JOURNAL			English	Article						XENOPUS OOCYTES; HIV-1; TAT; TAR; TRANSLATION	HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATION; TRANSCRIPTION; INVITRO; REGION; LOOP; TRANSACTIVATION; RECOGNITION; ELONGATION; REQUIRES	Human immunodeficiency virus (HIV-1) gene expression is activated by the viral TAT protein that interacts with an RNA sequence, TAR, located at the 5' end of all viral mRNAs. TAT functions primarily as a transcriptional activator in mammalian cells. However, in Xenopus oocytes TAT functions primarily as a translational activator. TAR is an RNA structure comprising a partially base-paired stem, a tripyrimidine bulge in the upper stem, and an unpaired six-nucleotide loop. In vitro, TAT binds directly to the bulge with no requirement for the loop. In vivo, however, mutations in the loop abolish TAT activation of transcription and translation, implying a requirement for TAR-binding cellular factors. We now provide genetic evidence for the presence of two TAR-specific cellular factors in Xenopus oocytes. These factors display independent and mutually exclusive interactions with either the loop or the bulge region of TAR. Furthermore, by using in vivo RNA competition assays we show that the cellular factors regulate the accessibility of the TAT binding site. The fact that Xenopus oocytes contain factors that specifically interact with a human viral RNA sequence might indicate that the TAT/TAR interaction is subverting a conserved pathway in the cell.	UNIV OXFORD,DEPT BIOCHEM,S PARKS RD,OXFORD OX1 3QU,ENGLAND	University of Oxford								BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRADDOCK M, 1991, NATURE, V350, P439, DOI 10.1038/350439a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; COLVIN RA, 1992, J VIROL, V66, P930, DOI 10.1128/JVI.66.2.930-935.1992; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DELLING U, 1992, J VIROL, V66, P3018, DOI 10.1128/JVI.66.5.3018-3025.1992; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P353; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KINGSMAN SM, 1991, GENETIC STRUCTURE RE; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	36	29	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					214	222		10.1096/fasebj.7.1.8422967	http://dx.doi.org/10.1096/fasebj.7.1.8422967			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422967				2022-12-28	WOS:A1993KH88000033
J	BRIMACOMBE, R; MITCHELL, P; OSSWALD, M; STADE, K; BOCHKARIOV, D				BRIMACOMBE, R; MITCHELL, P; OSSWALD, M; STADE, K; BOCHKARIOV, D			CLUSTERING OF MODIFIED NUCLEOTIDES AT THE FUNCTIONAL CENTER OF BACTERIAL RIBOSOMAL-RNA	FASEB JOURNAL			English	Article						MODIFIED NUCLEOTIDE; RIBOSOMAL RNA; SITE-DIRECTED CROSS-LINKING; TRANSFER RNA BINDING; RIBOSOME STRUCTURE	ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; MESSENGER-RNA; DECODING SITE; A-SITES; P-SITES; TERTIARY STRUCTURE; 23S RNA; 16S RNA; 3' END	An aryl trifluoromethyl diazirine photoreactive derivative was attached to the 2-thiocytidine residue at position 32 of tRNA(I)Arg and this derivatized tRNA was bound to Escherichia coli 70S ribosomes. After irradiation at 350 nm the site of cross-linking to the 16S RNA was analyzed by our standard procedures and found to lie within the secondary structural element comprising bases 956-983; this region contains two modified nucleotides at positions 966 and 967. Similarly, an aryl azido photoreactive derivative was attached to the phenylalanine residue of Phe-tRNA(Phe), and the derivatized aminoacyl tRNA was bound to the ribosome either at the A- or the P-site. In both cases, after irradiation at 250 nm, the cross-link site was localized to position 2439 of the 23S RNA; in the secondary structure of the latter the neighboring nucleotide 2442 is base-paired to a modified nucleotide at position 2069. Taken together with other cross-linking data, these results now directly implicate a total of 27 out of the 29 modified nucleotides in E. coli 16S and 23S RNA as lying within or close to the functional center of the ribosome.			BRIMACOMBE, R (corresponding author), MAX PLANCK INST MOLEC GENET, IHNESTR 73, W-1000 BERLIN 33, GERMANY.			Mitchell, Phil/0000-0002-3178-0439				BOCHKARIOV DE, 1992, ANAL BIOCHEM, V204, P90, DOI 10.1016/0003-2697(92)90144-V; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; CARBON P, 1979, EUR J BIOCHEM, V100, P399, DOI 10.1111/j.1432-1033.1979.tb04183.x; CHEN JK, 1985, BIOCHEMISTRY-US, V24, P4777, DOI 10.1021/bi00339a011; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; DORING T, 1991, NUCLEIC ACIDS RES, V19, P3517, DOI 10.1093/nar/19.13.3517; DORING T, 1992, NUCLEIC ACIDS RES, V20, P1593, DOI 10.1093/nar/20.7.1593; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; HASELMAN T, 1989, NUCLEIC ACIDS RES, V17, P2215, DOI 10.1093/nar/17.6.2215; KUECHLER E, 1988, METHOD ENZYMOL, V164, P361; LARSEN N, 1992, P NATL ACAD SCI USA, V89, P5044, DOI 10.1073/pnas.89.11.5044; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MITCHELL P, 1990, NUCLEIC ACIDS RES, V18, P4325, DOI 10.1093/nar/18.15.4325; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; PODKOWINSKI J, 1989, NUCLEIC ACIDS RES, V17, P8767, DOI 10.1093/nar/17.21.8767; PRESCOTT C, 1991, NUCLEIC ACIDS RES, V19, P5281, DOI 10.1093/nar/19.19.5281; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; SHEN ZH, 1989, NUCLEIC ACIDS RES, V17, P4535, DOI 10.1093/nar/17.12.4535; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STIEGE W, 1988, NUCLEIC ACIDS RES, V16, P2369, DOI 10.1093/nar/16.6.2369; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; VANCHARLDORP R, 1981, NUCLEIC ACIDS RES, V9, P2717, DOI 10.1093/nar/9.12.2717; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	41	116	116	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					161	167		10.1096/fasebj.7.1.8422963	http://dx.doi.org/10.1096/fasebj.7.1.8422963			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422963				2022-12-28	WOS:A1993KH88000024
J	PIOTROWICZ, RS; WEBER, LA; HICKEY, E; LEVIN, EG				PIOTROWICZ, RS; WEBER, LA; HICKEY, E; LEVIN, EG			ACCELERATED-GROWTH AND SENESCENCE OF ARTERIAL ENDOTHELIAL-CELLS EXPRESSING THE SMALL MOLECULAR-WEIGHT HEAT-SHOCK PROTEIN HSP27	FASEB JOURNAL			English	Article						WILD-TYPE HSP27; MUTANT GENE; ESTRADIOL TREATMENT; CHINESE HAMSTER CELLS	HUMAN-BREAST-CANCER; PHOSPHORYLATION; ORGANIZATION; RESISTANCE; MODULATION; INDUCTION; CARCINOMA; GENE	Bovine arterial endothelial cells were stably transfected with the human wild-type (wt) HSP27 or a mutant gene (mu) encoding a nonphosphorylatable form of the protein. At early passage both cultural and cellular morphology were similar, although the vacuole content in wtHSP27 was much higher than muHSP27 cells. As the cultures aged, wtHSP27 cells became large, polymorphic, highly vacuolated, and reached senescence before muHSP27 transfected cultures, which remained small and polygonal with few detectable vacuoles. Vector control cells showed an intermediate phenotype. Tritiated thymidine incorporation studies were performed with multiple wtHSP27 and muHSP27 clones and the results compared with 11 vector control clones. The results showed an average increase in growth rate for the wtHSP27 cells of 3.0 +/- 0.6 times. The growth rate of eight muHSP27 clones showed a slight decrease. Estradiol treatment of endothelial cells resulted in an increase in both bovine and human HSP27, with peak expression at 100 nM. Treatment of the vector-transfected cells with 100 nM estradiol resulted in a 1.44 +/- 0.18 fold increase in growth rate, which was blocked by expression of muHSP27. These data demonstrate a role for HSP27 in controlling the growth rate of endothelial cells in an estrogen-responsive manner.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV NEVADA, RENO, NV 89557 USA	Scripps Research Institute; Nevada System of Higher Education (NSHE); University of Nevada Reno								ADAMS DJ, 1983, CANCER RES, V43, P4297; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FAUCHER C, 1993, J BIOL CHEM, V268, P15168; FUQUA SAW, 1989, CANCER RES, V49, P4126; GEIGER B, 1983, DIFFERENTIATION, V23, P189; GUESDON F, 1991, J IMMUNOL, V147, P3402; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HOVER L, 1991, HEAT SHOCK RESPONSE, P41; INGBER DE, 1987, IN VITRO CELL DEV B, V23, P387; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LEVIN EG, 1991, J BIOL CHEM, V266, P174; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TORREY RJ, 1994, AM J REPROD IMMUNOL, V27, P171; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	22	35	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1079	1084		10.1096/fasebj.9.11.7649407	http://dx.doi.org/10.1096/fasebj.9.11.7649407			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649407				2022-12-28	WOS:A1995RP99600012
J	RISAU, W				RISAU, W			DIFFERENTIATION OF ENDOTHELIUM	FASEB JOURNAL			English	Review						ENDOTHELIAL CELLS; VASCULAR REGRESSION; CELL SURFACE MOLECULES; BLOOD-BRAIN BARRIER	BLOOD-BRAIN-BARRIER; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; CAPILLARY MORPHOGENESIS; FGF-RECEPTOR; EXTRACELLULAR-MATRIX; CELL DIFFERENTIATION; LYMPH-NODES; EXPRESSION; VASCULOGENESIS	Vascular endothelial cells cover the entire inner surface of blood vessels in the body, They play an important role in tissue homeostasis, fibrinolysis and coagulation, blood-tissue exchange, vasotonus regulation, the vascularization of normal and neoplastic tissues, and blood cell activation and migration during physiological and pathological processes, It is therefore important to define the basic: determinants of the endothelial phenotype and its modulation in response to different signals, Signal recognition, transduction, and processing are likely to be complex events dependent on the status of the target endothelial cell in a given organ or tissue, This status is a consequence of inductive and permissive interactions of a pluripotent cell with soluble and insoluble signaling molecules of the environment during embryonic and postnatal development, This review will focus on the biological mechanisms involved in the differentiation of endothelial cells from the mesoderm and their subsequent functional heterogeneity in different organs and tissues under physiological as well as pathological conditions.			RISAU, W (corresponding author), MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, MOLEK ZELLBIOL ABT, PK STR 1, D-61231 BAD NAUHEIM, GERMANY.							ACHEN MG, 1995, IN PRESS DIFFERENTIA; AGER A, 1987, J CELL SCI, V87, P133; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; AUSPRUNK DH, 1975, AM J PATHOL, V79, P597; AZAR Y, 1979, J EMBRYOL EXP MORPH, V52, P79; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BAR T, 1984, CELL TISSUE RES, V235, P99; Bar T., 1980, ADV ANAT EMBRYOL CEL, V59, P1, DOI DOI 10.1007/978-3-642-67432-7_1; BENNETT HS, 1959, AM J PHYSIOL, V196, P381, DOI 10.1152/ajplegacy.1959.196.2.381; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, IN PRESS DEV DYN; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; COOMBER BL, 1987, J NEURO-ONCOL, V5, P299, DOI 10.1007/BF00148386; CORMIER F, 1988, DEVELOPMENT, V102, P279; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FINA L, 1990, BLOOD, V75, P2417; FLAMME I, 1992, DEVELOPMENT, V116, P435; FLAMME I, 1995, IN PRESS DEV BIOL; GAFFNEY J, 1985, J CELL SCI, V79, P317; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOERDT S, 1991, J CELL BIOL, V113, P1425, DOI 10.1083/jcb.113.6.1425; HALLMANN R, 1987, DIFFERENTIATION, V34, P98, DOI 10.1111/j.1432-0436.1987.tb00055.x; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HIRAKOW R, 1981, ANAT EMBRYOL, V163, P299, DOI 10.1007/BF00315706; HOLASH JA, 1993, DEV DYNAM, V197, P14, DOI 10.1002/aja.1001970103; IMAI Y, 1993, NATURE, V361, P555; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KUMAR S, 1987, DIFFERENTIATION, V36, P57, DOI 10.1111/j.1432-0436.1987.tb00181.x; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LATKER CH, 1981, INVEST OPHTH VIS SCI, V21, P689; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEVICK JR, 1987, MICROVASC RES, V33, P233, DOI 10.1016/0026-2862(87)90020-3; LOMBARDI T, 1986, J CELL BIOL, V102, P1965, DOI 10.1083/jcb.102.5.1965; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MAHER PA, 1992, J CELL PHYSIOL, V151, P549, DOI 10.1002/jcp.1041510314; MAJNO G, 1965, ULTRASTRUCTURE VASCU, P2293; MEBIUS RE, 1993, INT IMMUNOL, V5, P443, DOI 10.1093/intimm/5.5.443; MILICI AJ, 1985, P NATL ACAD SCI USA, V82, P6181, DOI 10.1073/pnas.82.18.6181; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; NODEN DM, 1991, DEVELOPMENT, V111, P867; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PETERS KG, 1992, DEVELOPMENT, V114, P233; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; QIN Y, 1995, DEV DYNAM, V202, P172, DOI 10.1002/aja.1002020209; RISAU W, 1988, DEVELOPMENT, V102, P471; RISAU W, 1991, ANN NY ACAD SCI, V633, P405; RISAU W, 1986, EMBO J, V5, P3179, DOI 10.1002/j.1460-2075.1986.tb04627.x; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Risau W., 1991, DEV VASCULAR SYSTEM, P58; ROBERTS WG, 1995, IN PRESS J CELL SCI, V109; ROSENQUIST GC, 1970, ANAT RECORD, V168, P351, DOI 10.1002/ar.1091680303; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Sabin FR, 1917, CONTRIB EMBRYOL, V6, P63; SARIOLA H, 1983, DEV BIOL, V96, P427, DOI 10.1016/0012-1606(83)90180-X; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SIMIONESCU M, 1982, J CELL BIOL, V95, P425, DOI 10.1083/jcb.95.2.425; SINNING AR, 1992, ANAT REC, V232, P285, DOI 10.1002/ar.1092320213; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; WILT FH, 1965, SCIENCE, V147, P1588, DOI 10.1126/science.147.3665.1588; WOLBURG H, 1994, J CELL SCI, V107, P1347; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YANG JT, 1993, DEVELOPMENT, V119, P1093; YOSHIDA Y, 1988, DEV BRAIN RES, V44, P211, DOI 10.1016/0165-3806(88)90219-2; [No title captured]	92	485	506	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1995	9	10					926	933		10.1096/fasebj.9.10.7615161	http://dx.doi.org/10.1096/fasebj.9.10.7615161			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615161				2022-12-28	WOS:A1995RK89900014
J	MASSEY, V				MASSEY, V			FLAVOPROTEIN STRUCTURE AND MECHANISM - INTRODUCTION	FASEB JOURNAL			English	Review							ACYL-COA DEHYDROGENASE; CRYSTAL-STRUCTURE; RESOLUTION; OXIDASE; FLAVINS				MASSEY, V (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.							CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; ENTSCH B, 1965, FASEB J, V9; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; GHISLA S, 1986, BIOCHEM J, V239, P1; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; KARPLUS PA, 1990, SCIENCE, V251, P60; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; LEDERER F, 1992, CHEM BIOCH FLAVOENZY, V3, P153; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; MANSTEIN DJ, 1988, BIOCHEMISTRY-US, V27, P2300, DOI 10.1021/bi00407a009; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; Mathews FS, 1991, CURR OPIN STRUC BIOL, V1, P954, DOI 10.1016/0959-440X(91)90091-7; MIZZER JP, 1982, FLAVINS FLAVOPROTEIN, P637; NARHI LO, 1986, J BIOL CHEM, V261, P7160; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	21	90	91	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					473	475		10.1096/fasebj.9.7.7737454	http://dx.doi.org/10.1096/fasebj.9.7.7737454			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737454	Green Submitted			2022-12-28	WOS:A1995QX14800003
J	PADLAN, EA; ABERGEL, C; TIPPER, JP				PADLAN, EA; ABERGEL, C; TIPPER, JP			IDENTIFICATION OF SPECIFICITY-DETERMINING RESIDUES IN ANTIBODIES	FASEB JOURNAL			English	Article						COMPLEMENTARITY-DETERMINING REGIONS; HUMANIZATION	3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; ANTIGEN COMPLEX; BINDING-SITE; LIGHT-CHAINS; COMPLEMENTARITY; PROTEIN; MOUSE; NEURAMINIDASE; RESOLUTION	The successful identification of the residues that contact ligand has important implications, especially in view of the increasing use of antibodies in various medical and industrial applications. Analysis of the crystallographically derived, three-dimensional Structures of five antibody-antigen complexes and of the available amino acid sequence data on antibody variable regions reveals that the residues that contact antigen are in the main also the most variable. It is proposed that a good first guess of the identity of the specificity-determining residues can be made from an examination of the variability values at sequence positions. New boundaries for the complementarity-determining regions are proposed.			PADLAN, EA (corresponding author), NIDDKD,MOLEC BIOL LAB,BLDG 5,ROOM 303,BETHESDA,MD 20892, USA.			Abergel, Chantal/0000-0003-1875-4049				ABERGEL C, 1994, RES IMMUNOL, V145, P49, DOI 10.1016/S0923-2494(94)80043-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E A, 1978, Adv Protein Chem, V32, P1, DOI 10.1016/S0065-3233(08)60574-4; KABAT EA, 1977, J BIOL CHEM, V252, P6609; KABAT EA, 1991, PHS NIH913242 PUBL; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1977, P NATL ACAD SCI USA, V74, P2551, DOI 10.1073/pnas.74.6.2551; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PADLAN EA, 1992, IMMUNOMETHODS, V1; PADLAN EA, 1994, IN PRESS ANTIBODY AN; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PRASAD L, 1988, J BIOL CHEM, V263, P2571; SCHLOM J, 1991, BIOL THERAPY CANCER, P464; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; [No title captured]	31	112	350	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					133	139		10.1096/fasebj.9.1.7821752	http://dx.doi.org/10.1096/fasebj.9.1.7821752			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821752				2022-12-28	WOS:A1995QD20200021
J	ROBERTS, VA; GETZOFF, ED				ROBERTS, VA; GETZOFF, ED			METALLOANTIBODY DESIGN	FASEB JOURNAL			English	Article						METALLOPROTEIN; PROTEIN DESIGN; PROTEIN ENGINEERING; ZINC	METAL-BINDING SITES; 3-DIMENSIONAL STRUCTURE; CATALYTIC ANTIBODIES; PROTEINS; SEQUENCE; ANTIGEN; FAB	Metal-binding sites were designed within the antigen-binding pocket of the catalytic antibody 43C9 based on a 3-dimensional antibody model and crystallographic structures of Zn-binding metalloenzymes. These tetrahedral Zn-binding sites were designed to mimic both secondary and tertiary structural characteristics of catalytic metal sites in enzymes. Each site was planned to have two His ligands across from each other on adjacent antiparallel beta-strands. Sites were selected to sequester the metal ion from bulk solvent and place an open metal coordination position next to the antigen or potential substrates. Three distinct metal-site designs, with ligands in the variable light domain, in the variable heavy domain, and in both domains, were later implemented experimentally and shown spectroscopically to bind metal ions as predicted. These results demonstrate the success of our design approach, the versatility of the antibody structure for metalloprotein design, and the validity of the 3-dimensional model. The ability to predictably design multiple metal sites in the ordered antigen-recognition region at the bottom of the pocket allows tuning of metal ion placement and enhances the likelihood of interaction with putative substrates.			ROBERTS, VA (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, MB4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM 48495, GM 48877] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048877, P01GM048495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROWNER MF, 1994, NAT STRUCT BIOL, V1, P327, DOI 10.1038/nsb0594-327; CHEN C, 1992, J EXP MED, V176, P855, DOI 10.1084/jem.176.3.855; FRIEDMAN AR, 1994, PROTEINS, V20, P15, DOI 10.1002/prot.340200104; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; IRVING H, 1953, J CHEM SOC, P3192, DOI 10.1039/jr9530003192; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JANDA KD, 1991, J AM CHEM SOC, V113, P291, DOI 10.1021/ja00001a042; KAAT EA, 1991, SEQUENCES PROTEINS I; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KIEFER LL, 1993, BIOCHEMISTRY-US, V32, P9896, DOI 10.1021/bi00089a004; KIEFER LL, 1993, J AM CHEM SOC, V115, P12581, DOI 10.1021/ja00079a046; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MUHEIM A, 1993, J AM CHEM SOC, V115, P5312, DOI 10.1021/ja00065a060; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; Stewart J D, 1993, Int Rev Immunol, V10, P229, DOI 10.3109/08830189309061698; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1994, DOI 10.1021/bi00174a004; STEWART JD, 1994, J AM CHEM SOC, V116, P415, DOI 10.1021/ja00080a065; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; TAINER JA, 1991, CURR OPIN BIOTECH, V2, P582, DOI 10.1016/0958-1669(91)90084-I; WADE WS, 1993, J AM CHEM SOC, V115, P4449, DOI 10.1021/ja00064a005; WADE WS, 1993, J AM CHEM SOC, V115, P4906, DOI 10.1021/ja00064a068; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	35	14	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					94	100		10.1096/fasebj.9.1.7821766	http://dx.doi.org/10.1096/fasebj.9.1.7821766			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821766				2022-12-28	WOS:A1995QD20200015
J	CARAFOLI, E				CARAFOLI, E			BIOGENESIS - PLASMA-MEMBRANE CALCIUM-ATPASE - 15 YEARS OF WORK ON THE PURIFIED ENZYME	FASEB JOURNAL			English	Article						CALCIUM PUMP; CALCIUM TRANSPORT; TRANSPORT ATPASES; ISOFORM DIVERSITY; ALTERNATIVE SPLICING; CALMODULIN	CALMODULIN-BINDING DOMAIN; HUMAN-ERYTHROCYTE MEMBRANES; AMINO-ACID-SEQUENCE; CAMP-DEPENDENT PHOSPHORYLATION; CA2+ PUMP CONTAINS; PIG SMOOTH-MUSCLE; C-TERMINAL DOMAIN; PROTEIN-KINASE-C; RED-CELL GHOSTS; CA-2+ PUMP	The plasma membrane calcium pump is the system that ejects Ca2+ out of eukaryotic cells: this is documented in all animal and plant cells, although knowledge on the latter is only now beginning to be established. Information on lower eukaryotic cells, e.g., yeast, is still scarce, but it also is beginning to develop. The pump shares the catalytic properties of ion-motive ATPases of the P-type family, but has distinctive regulation properties: it is modulated by calmodulin, acidic phospholipids, a number of protein kinases, possibly by the interaction of calcium with its COOH-terminal region, and by aggregation (dimerization) through the calmodulin binding domain. The latter acts as an endogenous inhibitor of pump activity, much as phospholamban does for the sarcoplasmic reticulum pump. The analogy of the regulation mechanisms of the two pumps is heightened by the finding that phosphorylation of the calmodulin binding domain by protein kinase C removes its autoinhibiting function, as other kinases do in the case of phospholamban. The pump is the product of a family of four genes located on different human chromosomes. The isoform diversity is dramatically enhanced by alternative splicing of the transcripts, occurring at ''hot spot'' A (NH2-terminal) and C (COOH-terminal). At present more than 20 different transcripts with striking tissue and developmental specificity have been detected.			CARAFOLI, E (corresponding author), ETH ZENTRUM,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; AU KS, 1986, BIOCHIM BIOPHYS ACTA, V905, P273; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1982, BIOCHIM BIOPHYS ACTA, V683, P279, DOI 10.1016/0304-4173(82)90004-0; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CARONI P, 1981, J BIOL CHEM, V256, P3263; CARONI P, 1981, J BIOL CHEM, V256, P9371; CAVIERES JD, 1984, BIOCHIM BIOPHYS ACTA, V771, P241, DOI 10.1016/0005-2736(84)90539-X; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHIESI M, 1991, BIOCHEMISTRY-US, V30, P7978, DOI 10.1021/bi00246a015; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; DEJAEGERE S, 1990, BIOCHEM J, V271, P655, DOI 10.1042/bj2710655; ENYEDI A, 1994, J BIOL CHEM, V269, P41; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; GARRAHAN PJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P59, DOI 10.1016/0005-2736(78)90111-6; GIETZEN K, 1980, BIOCHEM J, V189, P81, DOI 10.1042/bj1890081; GMAJ P, 1982, FEBS LETT, V131, P60; GRAF E, 1981, ARCH BIOCHEM BIOPHYS, V210, P257, DOI 10.1016/0003-9861(81)90187-9; GRAF E, 1982, BIOCHEMISTRY-US, V21, P4511, DOI 10.1021/bi00261a049; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; HAO LN, 1994, J BIOL CHEM, V269, P14268; HASSELBACH W, 1982, ANN NY ACAD SCI, V402, P459, DOI 10.1111/j.1749-6632.1982.tb25768.x; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HOWARD A, 1993, AM J PHYSIOL, V264, P91; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; KAHN I, 1991, BIOCHEM J, V277, P345; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1990, J BIOL CHEM, V265, P16012; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KNAUF PA, 1974, J GEN PHYSIOL, V63, P324, DOI 10.1085/jgp.63.3.324; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KUMAR R, 1993, J BONE MINER RES, V8, P505; LATIF F, 1993, CANCER RES, V53, P861; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAGOCSI M, 1992, AM J PHYSIOL, V263, pF7, DOI 10.1152/ajprenal.1992.263.1.F7; MAMYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MICHALAK M, 1984, J BIOL CHEM, V259, P5540; NIGGLI V, 1982, CELL CALCIUM, V3, P131, DOI 10.1016/0143-4160(82)90010-0; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; OLSON S, 1991, GENOMICS, V9, P629, DOI 10.1016/0888-7543(91)90356-J; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENNISTON JT, 1982, ANN NY ACAD SCI, V402, P296, DOI 10.1111/j.1749-6632.1982.tb25751.x; RONNER P, 1977, ARCH BIOCHEM BIOPHYS, V179, P578, DOI 10.1016/0003-9861(77)90146-1; ROSSI JPFC, 1982, J PHYSIOL-LONDON, V327, P1; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SZASZ I, 1978, MOL CELL BIOCHEM, V22, P147, DOI 10.1007/BF00496240; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WAISMAN DM, 1981, J BIOL CHEM, V256, P420; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; WUYTACK F, 1981, BIOCHEM J, V198, P265, DOI 10.1042/bj1980265; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	91	350	357	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					993	1002		10.1096/fasebj.8.13.7926378	http://dx.doi.org/10.1096/fasebj.8.13.7926378			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926378				2022-12-28	WOS:A1994PN06900002
J	PERL, E				PERL, E			THE 1944 NOBEL-PRIZE TO ERLANGER AND GASSER .39.	FASEB JOURNAL			English	Editorial Material											PERL, E (corresponding author), UNIV N CAROLINA,DEPT PHILOSOPHY,CB 7545,MED SCI RES BLDG,CHAPEL HILL,NC 27599, USA.							Bernstein J., 1912, ELEKTROBIOLOGIE LEHR, DOI 10.1007/978-3-663-01627-4; Erlanger J, 1924, AM J PHYSIOL, V70, P624, DOI 10.1152/ajplegacy.1924.70.3.624; ERLANGER J, 1937, ELECTRICAL SIGNS NER; Gasser HS, 1921, AM J PHYSIOL, V57, P1, DOI 10.1152/ajplegacy.1921.57.1.1; GASSER HS, 1960, J GEN PHYSIOL, V43, P927, DOI 10.1085/jgp.43.5.927; Gasser HS, 1927, AM J PHYSIOL, V80, P522, DOI 10.1152/ajplegacy.1927.80.3.522; Gasser HS, 1922, AM J PHYSIOL, V62, P496, DOI 10.1152/ajplegacy.1922.62.3.496; GASSER HS, 1950, J GEN PHYSIOL, V33, P651, DOI 10.1085/jgp.33.6.651; GASSER HS, 1955, J GEN PHYSIOL, V38, P709, DOI 10.1085/jgp.38.5.709; Gasser HS, 1939, AM J PHYSIOL, V127, P393, DOI 10.1152/ajplegacy.1939.127.2.393; HUNT CC, 1994, IN PRESS P NATL ACAD; SCHOEPFLE GM, 1951, AM J PHYSIOL, V167, P134, DOI 10.1152/ajplegacy.1951.167.1.134	12	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					782	783		10.1096/fasebj.8.10.8050679	http://dx.doi.org/10.1096/fasebj.8.10.8050679			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050679				2022-12-28	WOS:A1994NY35000018
J	GARTY, H				GARTY, H			MOLECULAR-PROPERTIES OF EPITHELIAL, AMILORIDE-BLOCKABLE NA+ CHANNELS	FASEB JOURNAL			English	Review						ALDOSTERONE; AMILORIDE; EPITHELIAL TRANSPORT; NA+ CHANNELS; VASOPRESSIN	CORTICAL COLLECTING TUBULE; SODIUM-TRANSPORTING EPITHELIA; TOAD URINARY-BLADDER; CATION CHANNEL; DUCT CELLS; ALDOSTERONE ACTION; APICAL MEMBRANE; BINDING-PROTEIN; REGULATORY MECHANISMS; XENOPUS OOCYTES	The apical membrane of many tight contains Na+ channels that are primarily characterized by their high affinity to the diuretic blocker amiloride. These channels mediate the first step of active Na+ reabsorption essential for the maintenance of body salt and water homeostasis. They are regulated by mineralocorticoids, antidiuretic peptides, atrial natriuretic peptides, and other factors. The molecular events that mediate the hormonal actions are poorly understood. In addition, patch clamp studies have established that amiloride-sensitive channels in different epithelia may differ in their regulatory mechanisms and biophysical properties. Several groups have reported the biochemical purification and/or molecular cloning of putative channel components. Of particular importance is the recent cloning of three cDNAs, whose coexpression in Xenopus oocytes evokes a large amiloride-blockable Na+ specific conductance (Canesa et al. (1994) Nature (London), 367, 463-467. This review summarizes existing data on properties, regulatory mechanisms, and diversity of amiloride-blockable channels, describes the different putative channel components identified, and examines possible relationships among them.			GARTY, H (corresponding author), WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; ASHER C, 1987, J BIOL CHEM, V262, P8566; ASHER C, 1992, AM J PHYSIOL, V262, pG244, DOI 10.1152/ajpgi.1992.262.2.G244; ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; ASHER C, 1992, J BIOL CHEM, V267, P16061; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; AUSIELLO DA, 1987, KIDNEY INT, V31, P521, DOI 10.1038/ki.1987.31; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BASTL CP, 1992, KIDNEY INT, V42, P250, DOI 10.1038/ki.1992.284; BENO, 1991, BENOS DJ, P261; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1976, J GEN PHYSIOL, V68, P43, DOI 10.1085/jgp.68.1.43; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; COX M, 1984, CURR TOP MEMBR TRANS, V20, P271; DAVID P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P59, DOI 10.1016/0005-2736(93)90338-Z; DAVID P, 1992, J BIOL CHEM, V267, P1141; FRINDT G, 1993, AM J PHYSIOL, V264, pF565, DOI 10.1152/ajprenal.1993.264.3.F565; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1989, AM J PHYSIOL, V256, pF965, DOI 10.1152/ajprenal.1989.256.5.F965; GARTY H, 1992, SEMIN NEPHROL, V12, P24; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GARTY H, 1986, J MEMBRANE BIOL, V90, P193, DOI 10.1007/BF01870126; GARTY H, 1987, J MEMBRANE BIOL, V95, P151, DOI 10.1007/BF01869160; GOLDSTEIN O, 1993, J BIOL CHEM, V268, P7856; HAMILL OP, 1992, TRENDS PHARMACOL SCI, V13, P373, DOI 10.1016/0165-6147(92)90115-M; HAMILTON KL, 1986, FASEB J, V45, P2713; HINTON CF, 1989, AM J PHYSIOL, V257, pC825, DOI 10.1152/ajpcell.1989.257.4.C825; JORIS L, 1989, PFLUG ARCH EUR J PHY, V414, P369, DOI 10.1007/BF00584641; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KIPNOWSKI J, 1983, AM J PHYSIOL, V245, pF726, DOI 10.1152/ajprenal.1983.245.6.F726; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1992, J BIOL CHEM, V267, P9622; KNEPPER MA, 1991, CAN J PHYSIOL PHARM, V69, P1537, DOI 10.1139/y91-229; KOEFOEDJOHNSEN V, 1958, ACTA PHYSIOL SCAND, V42, P298, DOI 10.1111/j.1748-1716.1958.tb01563.x; LEWIS SA, 1986, P NATL ACAD SCI USA, V83, P5345, DOI 10.1073/pnas.83.14.5345; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; LIGHT DB, 1989, J CLIN INVEST, V84, P352, DOI 10.1172/JCI114162; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LIN CS, 1993, IN PRESS J BIOL CHEM; LINDEMANN B, 1984, ANNU REV PHYSIOL, V46, P497, DOI 10.1146/annurev.ph.46.030184.002433; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MATALON S, 1992, AM J PHYSIOL, V262, pC1228, DOI 10.1152/ajpcell.1992.262.5.C1228; OH Y, 1993, AM J PHYSIOL, V264, pC1489, DOI 10.1152/ajpcell.1993.264.6.C1489; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PALMER LG, 1982, J MEMBRANE BIOL, V64, P91, DOI 10.1007/BF01870771; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1987, AM J PHYSIOL, V253, pF333, DOI 10.1152/ajprenal.1987.253.2.F333; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; SILVER RB, 1993, AM J PHYSIOL, V264, pF557, DOI 10.1152/ajprenal.1993.264.3.F557; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; Stanton B. A., 1993, Journal of the American Society of Nephrology, V4, P880; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; SZERLIP H, 1991, J AM SOC NEPHROL, V2, P1108; TOUSSON A, 1989, J CELL SCI, V93, P349; VERRIER B, 1989, EUR J BIOCHEM, V183, P499, DOI 10.1111/j.1432-1033.1989.tb21077.x; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WEHLING M, 1993, TRENDS PHARMACOL SCI, V14, P1, DOI 10.1016/0165-6147(93)90104-R	77	112	116	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					522	528		10.1096/fasebj.8.8.8181670	http://dx.doi.org/10.1096/fasebj.8.8.8181670			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181670				2022-12-28	WOS:A1994NM36400009
J	HAMMES, A; OBERDORF, S; STREHLER, EE; STAUFFER, T; CARAFOLI, E; VETTER, H; NEYSES, L				HAMMES, A; OBERDORF, S; STREHLER, EE; STAUFFER, T; CARAFOLI, E; VETTER, H; NEYSES, L			DIFFERENTIATION-SPECIFIC ISOFORM MESSENGER-RNA EXPRESSION OF THE CALMODULIN-DEPENDENT PLASMA-MEMBRANE CA2+-ATPASE	FASEB JOURNAL			English	Article						PLASMA MEMBRANE CA2+ PUMP; CA2+ TRANSPORT; ISOFORMS; ALTERNATIVE SPLICING; DIFFERENTIATION; MUSCLE CELLS; NEURONAL CELLS; MYOGENIN; MYOGENIC DETERMINATION	CA2+ PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; SKELETAL-MUSCLE; MESSENGER-RNAS; CALCIUM-PUMP; RAT-HEART; DOMAIN; CELL; BINDING	The functional significance of the isoform diversity of the calmodulin-dependent plasma membrane Ca2+-ATPase (PMCA) is largely unknown. To determine whether the mRNA synthesis of different isoforms of the enzyme is regulated in a differentiation-specific manner, we investigated the expression of isoform-specific mRNAs in muscle and neuronal cells during differentiation by reverse transcription PCR. In the rat, the ubiquitous PMCA splicing variants 1b and 4b formed the typical PMCA isoform pattern of L6 myoblasts, the heart-derived cell line H9c2(2-1), two different fibroblast cell lines (FR and NRK-49F), smooth muscle, and endothelial cells. In addition to these two enzymes, novel expression of the splicing variants 1c, 1d, and 4a was induced during myogenic differentiation of L6 and H9c2(2-1) cells. A similar isoform subtype switch could be detected during differentiation of the neuronal PC-12 cells induced by nerve growth factor (NGF). The isoform-specific mRNAs 1c, 1d, and 4a were not expressed in cells other than myocytes and neurons, and therefore may be specific for excitable cells. The mRNA for isoform 1d was heart- and skeletal muscle-specific. To determine whether expression of a differentiation-specific PMCA mRNA pattern is under control of a myogenic determination factor, myogenin was constitutively expressed in rat fibroblasts. These cells converted to multinucleated myotubes, which displayed the PMCA isoform-specific mRNAs 1c, 1d, and 4a, typical of differentiated muscle cells. We conclude that: 1) the distribution of the various PMCA isoform-specific mRNAs and their splicing variants is cell type- and development-specific 2) expression of the myogenic determination factor myogenin is sufficient to direct alternative splicing generating muscle-specific PMCA mRNA species; and 3) PMCA isoforms and/or splicing variants may play a role in determining functions of terminally differentiated muscle and neuronal cells and possibly during the differentiation process itself.	UNIV BONN, MED POLICLIN, W-5300 BONN 1, GERMANY; ETH ZENTRUM, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA	University of Bonn; Swiss Federal Institutes of Technology Domain; ETH Zurich; Mayo Clinic			Carafoli, Ernesto/K-5192-2016; Neyses, Ludwig/AGY-7446-2022	Carafoli, Ernesto/0000-0002-7826-0094; Hammes-Lewin, Annette/0000-0003-1663-8378				ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARONI P, 1980, P NATL ACAD SCI-BIOL, V77, P6354, DOI 10.1073/pnas.77.11.6354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; EWTON DZ, 1981, DEV BIOL, V86, P31, DOI 10.1016/0012-1606(81)90312-2; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KNOLL G, 1991, J CELL BIOL, V113, P1295, DOI 10.1083/jcb.113.6.1295; MANGIACAPRA FJ, 1992, MOL ENDOCRINOL, V6, P2038, DOI 10.1210/me.6.12.2038; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; NEYSES L, 1985, J BIOL CHEM, V260, P283; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; POWELL T, 1988, BIOL ADULT CARDIAC M, P9; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; ROSE H, 1986, PFLUG ARCH EUR J PHY, V407, P116, DOI 10.1007/BF00580731; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Strehler E E, 1990, Semin Cell Biol, V1, P283; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WUYTACK F, 1992, 8TH INT S CALC BIND; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZURINI M, 1984, J BIOL CHEM, V259, P618	43	74	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					428	435		10.1096/fasebj.8.6.8168693	http://dx.doi.org/10.1096/fasebj.8.6.8168693			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168693				2022-12-28	WOS:A1994NH25000010
J	LORD, JM; ROBERTS, LM; ROBERTUS, JD				LORD, JM; ROBERTS, LM; ROBERTUS, JD			RICIN - STRUCTURE, MODE OF ACTION, AND SOME CURRENT APPLICATIONS	FASEB JOURNAL			English	Review						RICIN; RIBOSOME INACTIVATING PROTEIN; LECTIN; DEPURINATION ENDOCYTOSIS	28-S RIBOSOMAL-RNA; A-CHAIN; B-CHAIN; GALACTOSE-BINDING; COMMUNIS AGGLUTININ; INTRACELLULAR-TRANSPORT; ESCHERICHIA-COLI; STORAGE PROTEIN; LECTIN ACTIVITY; RECOMBINANT	Ricin is an abundant protein component of Ricinus communis seeds (castor beans) that is exquisitely toxic to mammalian cells. It consists of an enzymic polypeptide that catalyzes the N-glycosidic cleavage of a specific adenine residue from 28S ribosomal RNA, joined by a single disulfide bond to a galactose (cell)-binding lectin. The enzymatic activity renders ribosomes containing depurinated 28S RNA incapable of protein synthesis. The bipartite molecular structure of ricin allows it to bind to the mammalian cell surface, enter via endocytic uptake, and deliver the catalytically active polypeptide into the cell cytosol where it irreversibly inhibits protein synthesis causing cell death. Because of its cytotoxic potency, modified ricin is being used for the selective killing of unwanted cells and for the toxigenic ablation of cell lineages in transgenic organisms.	UNIV TEXAS, DEPT CHEM, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	LORD, JM (corresponding author), UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.							CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; CHANG MS, 1987, P NATL ACAD SCI USA, V84, P5640, DOI 10.1073/pnas.84.16.5640; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FRANKEL A, 1990, MOL CELL BIOL, V10, P6257, DOI 10.1128/MCB.10.12.6257; HALLING KC, 1985, NUCLEIC ACIDS RES, V13, P8019, DOI 10.1093/nar/13.22.8019; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; KERNAN NA, 1988, JAMA-J AM MED ASSOC, V259, P3154, DOI 10.1001/jama.259.21.3154; KIM Y, 1992, PROTEIN ENG, V5, P775, DOI 10.1093/protein/5.8.775; KIM YS, 1992, BIOCHEMISTRY-US, V31, P3294, DOI 10.1021/bi00127a035; KNIGHT B, 1979, BRIT MED J, V1, P350; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LADIN BF, 1987, PLANT MOL BIOL, V9, P287, DOI 10.1007/BF00166464; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LANDEL CP, 1988, GENE DEV, V2, P1168, DOI 10.1101/gad.2.9.1168; Lord J M, 1991, Semin Cell Biol, V2, P15; LORD JM, 1985, EUR J BIOCHEM, V146, P403, DOI 10.1111/j.1432-1033.1985.tb08666.x; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; LORD JM, 1993, SOC EXP BIOL SEMIN S, V53, P243, DOI 10.1017/CBO9780511600401.017; MISNA D, 1993, PROTEIN SCI, V2, P429; MOFFAT KG, 1992, DEVELOPMENT, V114, P681; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; O'Kane CJ, 1992, CURR OPIN GENET DEV, V2, P602, DOI 10.1016/S0959-437X(05)80179-0; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; OHARE M, 1992, FEBS LETT, V299, P209, DOI 10.1016/0014-5793(92)80116-X; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PETER F, 1992, J BIOL CHEM, V267, P10631; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; RICHARDSON PT, 1991, CARBOHYD RES, V213, P19, DOI 10.1016/S0008-6215(00)90594-9; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; RICHARDSON PT, 1988, BIO-TECHNOL, V6, P565, DOI 10.1038/nbt0588-565; RICHARDSON PT, 1988, BIOCHIM BIOPHYS ACTA, V950, P385, DOI 10.1016/0167-4781(88)90135-2; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; Stillmark H., 1888, THESIS U DORPAT ESTO; TREGEAR JW, 1992, PLANT MOL BIOL, V18, P515, DOI 10.1007/BF00040667; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; Vitetta E S, 1991, Semin Cell Biol, V2, P47; VITETTA ES, 1986, J IMMUNOL, V136, P1880; VITETTA ES, 1990, BIOCHIM BIOPHYS ACTA, V1049, P151, DOI 10.1016/0167-4781(90)90035-Z; WALES R, 1991, J BIOL CHEM, V266, P19172; WALES R, 1992, ARCH BIOCHEM BIOPHYS, V294, P291, DOI 10.1016/0003-9861(92)90171-R; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1982, J BIOL CHEM, V257, P1598	55	374	394	3	60	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					201	208		10.1096/fasebj.8.2.8119491	http://dx.doi.org/10.1096/fasebj.8.2.8119491			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119491				2022-12-28	WOS:A1994MY29900026
J	DREON, DM; FERNSTROM, HA; MILLER, B; KRAUSS, RM				DREON, DM; FERNSTROM, HA; MILLER, B; KRAUSS, RM			LOW-DENSITY-LIPOPROTEIN SUBCLASS PATTERNS AND LIPOPROTEIN RESPONSE TO A REDUCED-FAT DIET IN MEN	FASEB JOURNAL			English	Note						LOW-DENSITY LIPOPROTEINS; CHOLESTEROL; TRIGLYCERIDES; GENETICS	CARBOHYDRATE-INDUCED HYPERTRIGLYCERIDEMIA; PARTICLE-SIZE; CHOLESTEROL RESPONSE; APOLIPOPROTEIN-E; PLASMA; SUSCEPTIBILITY; FRAMINGHAM; PHENOTYPE; DISEASE; LIPIDS	Low-density lipoprotein (LDL) subclass pattern B is a common genetically influenced lipoprotein profile characterized by a predominance of small, dense LDL particles, and associated with increased levels of triglyceride-rich lipoproteins, reductions in high-density lipoprotein cholesterol (HDL-C), and increased risk of coronary artery disease compared to individuals with a predominance of larger LDL (pattern A). We sought to determine whether LDL subclass patterns are associated with response of plasma lipoprotein levels to changes in dietary fat and carbohydrate content. In a randomized cross-over study, 105 men consumed, for six weeks each, high-fat (46%) and low-fat (24%) solid food diets, with replacement of fat by carbohydrate. Diet-induced changes in subjects who exhibited pattern B (n = 18) following the high-fat diet differed significantly from those in subjects with pattern A (n = 87): in pattern B subjects LDL cholesterol (LDL-C) reductions were two-fold greater and plasma apolipoprotein (apo) B levels decreased significantly. These differences remained significant after adjustment for levels of plasma LDL-C, apo B, HDL-C, and body mass index. Thus, LDL subclass pattern is a factor that contributes significantly to interindividual variation of plasma lipoprotein response to a low-fat, high-carbohydrate diet.			DREON, DM (corresponding author), LAWRENCE BERKELEY LAB,DONNER LAB,ROOM 465,1 CYCLOTRON RD,BERKELEY,CA 94720, USA.				NHLBI NIH HHS [HL-18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbey M., 1991, NUTR METAB CARDIOVAS, V1, P10; AUSTIN MA, 1993, ARTERIOSCLER THROMB, V13, P687, DOI 10.1161/01.ATV.13.5.687; AUSTIN MA, 1988, AM J HUM GENET, V43, P838; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; AUSTIN MA, 1988, ARTERIOSCLEROSIS, V8, pA615; AUSTIN MA, 1986, LANCET, V2, P592; BOERWINKLE E, 1991, AM J HUM GENET, V49, P1145; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; BU XD, 1992, CIRCULATION, V86, P552; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P1410, DOI 10.1161/01.ATV.12.12.1410; CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1089, DOI 10.1161/01.ATV.11.4.1089; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; COBB MM, 1992, CIRCULATION, V86, P849, DOI 10.1161/01.CIR.86.3.849; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DENKE MA, 1993, AM J MED, V94, P626, DOI 10.1016/0002-9343(93)90215-B; DREON DM, 1992, MONOGR HUM GENET, V14, P325; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG H, 1976, J CLIN ENDOCR METAB, V42, P729, DOI 10.1210/jcem-42-4-729; GONEN B, 1981, METABOLISM, V30, P1125, DOI 10.1016/0026-0495(81)90058-5; JACKSON B, 1986, J AM DIET ASSOC, V86, P1531; JACOBS DR, 1983, ATHEROSCLEROSIS, V48, P1161; KATZEL LI, 1991, ARTERIOSCLER THROMB, V11, pA1513; KEIDAR S, 1990, METABOLISM, V39, P281, DOI 10.1016/0026-0495(90)90048-H; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1991, AM J MED S, V90, pS38; KUUSI T, 1985, J LIPID RES, V26, P360; MANTTARI M, 1991, METABOLISM, V40, P217, DOI 10.1016/0026-0495(91)90179-Z; MATA P, 1992, CIRCULATION, V86, P405; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; NICHOLS A. V., 1957, Geriatrics, V12, P7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1992, P NATL ACAD SCI USA, V89, P708, DOI 10.1073/pnas.89.2.708; OUCHERONY O, 1978, HDB EXPT IMMUNOLOGYK; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; RUDERMAN NB, 1971, J CLIN INVEST, V50, P1355, DOI 10.1172/JCI106615; SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268; TIKKANEN MJ, 1990, ARTERIOSCLEROSIS, V10, P285, DOI 10.1161/01.ATV.10.2.285; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; ULLMANN D, 1991, ARTERIOSCLER THROMB, V11, P1059, DOI 10.1161/01.ATV.11.4.1059; WARNICK GR, 1985, CLIN CHEM, V31, P217; 1985, SAS USERS GUIDE STAT; 1985, SAS USERS GUIDE BASI	48	153	164	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					121	126		10.1096/fasebj.8.1.8299884	http://dx.doi.org/10.1096/fasebj.8.1.8299884			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299884				2022-12-28	WOS:A1994MV28200018
J	VAULONT, S; KAHN, A				VAULONT, S; KAHN, A			TRANSCRIPTIONAL CONTROL OF METABOLIC-REGULATION GENES BY CARBOHYDRATES	FASEB JOURNAL			English	Review						GLYCOLYSIS; GLUCOSE RESPONSE ELEMENT; L-PK GENE; GENIC PATHWAY; GENE TRANSCRIPTION	PYRUVATE-KINASE GENE; PHOSPHOENOLPYRUVATE-CARBOXYKINASE GENE; HELIX ZIPPER PROTEIN; RAT HEPATOCYTES; CYCLIC-AMP; RESPONSE ELEMENT; PRIMARY CULTURES; TRANSGENIC MICE; DNA-BINDING; FACTOR USF	Glucose can modulate the transcription of many genes, particularly those encoding enzymes of liver metabolism. The transcriptional effect of glucose can be indirect, being mediated in vivo b hormonal variations, especially increase in insulin and decrease in glucagon secretion. Whereas the transcription of the glucokinase gene, for example, is stimulated by insulin without the aid of glucose, the transcriptional activation of most glycolytic and lipogenic genes in hepatocytes requires the presence of both glucose and insulin. The role of insulin in the activation of these genes seems mainly to stimulate glucokinase synthesis, and thus to permit glucose phosphorylation. In some cells in which hexokinase activity is constitutive, the glucose-dependent activation of the same genes does not require insulin and, in addition, can be produced by the nonmetabolisable analog, 2-deoxyglucose. In hepatocytes, the insulin effect on the glucose-dependent activation of the L-pyruvate kinase gene can be reproduced by fructose at low concentrations. Fructose probably acts through the fructose 1-phosphate dependent deinhibition of glucokinase activity. A glucose/carbohydrate element has been identified on the L-type pyruvate kinase and spot 14 gene promoters. It is able to bind, in vitro, transcriptional factors of the MLTF/USF family and could act in cooperation with tissue-specific contiguous elements, such as the HNF4 binding site in the L-type pyruvate kinase gene.	INSERM,U29,INST COCHIN GENET MOLEC,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Vaulont, Sophie/O-6732-2017					ALEXANDERBRIDGE.M, 1991, J CELL BIOCHEM, V48, P129; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DIAZGUERRA MJM, 1993, IN PRESS MOL CELL BI; EXTON JH, 1991, DIABETES, V40, P521, DOI 10.2337/diabetes.40.5.521; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; GOTO Y, 1992, DIABETES, V41, P339, DOI 10.2337/diabetes.41.3.339; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JENKINS AB, 1986, INT J BIOCHEM, V18, P311, DOI 10.1016/0020-711X(86)90036-4; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MARIE S, 1993, IN PRESS J BIOL CHEM; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MATSUDA T, 1990, J BIOCHEM, V107, P655, DOI 10.1093/oxfordjournals.jbchem.a123103; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MEYER S, 1991, EUR J BIOCHEM, V202, P985, DOI 10.1111/j.1432-1033.1991.tb16460.x; MIKSICEK RJ, 1982, J BIOL CHEM, V257, P1829; MONTMINY MR, 1990, METABOLISM, V39, P6, DOI 10.1016/0026-0495(90)90198-L; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NISCH D, 1993, MOL CELL BIOL, V13, P4494; NOGUCHI T, 1993, FEBS LETT, V318, P269, DOI 10.1016/0014-5793(93)80526-Z; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Sirito Mario, 1992, Gene Expression, V2, P231; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P178; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1984, BIOCHEM BIOPH RES CO, V125, P135, DOI 10.1016/S0006-291X(84)80345-9	63	179	179	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					28	35		10.1096/fasebj.8.1.8299888	http://dx.doi.org/10.1096/fasebj.8.1.8299888			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299888				2022-12-28	WOS:A1994MV28200006
J	PUISIEUX, A; GALVIN, K; TROALEN, F; BRESSAC, B; MARCAIS, C; GALUN, E; PONCHEL, F; YAKICIER, C; JI, JW; OZTURK, M				PUISIEUX, A; GALVIN, K; TROALEN, F; BRESSAC, B; MARCAIS, C; GALUN, E; PONCHEL, F; YAKICIER, C; JI, JW; OZTURK, M			RETINOBLASTOMA AND P53-TUMOR SUPPRESSOR GENES IN HUMAN HEPATOMA-CELL LINES	FASEB JOURNAL			English	Note						HEPATOCELLULAR CARCINOMA; RB GENE; IMMUNOCHEMICAL STUDIES; ANTI-RB PROTEIN ANTIBODIES; P53	HUMAN HEPATOCELLULAR-CARCINOMA; P53 GENE; EXPRESSION; MUTATION; TUMORS; DNA; PHOSPHORYLATION; INACTIVATION; SARCOMAS; SEGMENT	We analyzed the status of retinoblastoma and p53 genes in 10 human hepatoma cell lines. Polyclonal anti-peptide antibodies generated against peptides homologous to COOH-terminal and leucine-zipper domains of the retinoblastoma protein allowed us to identify two cell lines (Hep 3B and FOCUS) with abnormal expression. The same cell lines have both lacked p53 expression. In contrast to the retinoblastoma gene, the expression of the p53 gene was abnormal in six additional cell lines. Indeed, only the Hep G2 hepatoblastoma cell line (and its derivative Hep G2/2215) appeared to have normal p53 and retinoblastoma gene expression. Our studies indicate that p53 abnormalities are common but retinoblastoma gene aberrations are rare in human hepatoma cell lines.	MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129; INST GUSTAVE ROUSSY,SERV IMMUNOL MOLEC,F-94805 VILLEJUIF,FRANCE; HADASSAH MED CTR,JERUSALEM,ISRAEL	UNICANCER; Gustave Roussy; Hebrew University of Jerusalem; Hadassah University Medical Center	PUISIEUX, A (corresponding author), CTR LEON BERARD,MOLEC ONCOL LAB,28 RUE LAENNEC,F-69008 LYON,FRANCE.		Galun, Eithan/AAD-9117-2022; ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021; Paillerets, Brigitte Bressac-de/D-8954-2018	Galun, Eithan/0000-0002-6243-6702; OZTURK, MEHMET/0000-0002-6092-9706; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; PUISIEUX, Alain/0000-0002-9938-3798	NCI NIH HHS [CA-54567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1984, ADV HEPATITIS RES, P190; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DOERR R, 1989, CANCER RES, V49, P384; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KNOWLES BB, 1984, ADV HEPATITIS RES; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCNAB GM, 1976, BRIT J CANCER, V34, P509; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NISHIDA N, 1993, CANCER RES, V53, P368; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; OZTURK M, 1992, BONE MARROW TRANSPL, V9, P164; REISSMANN PT, 1989, ONCOGENE, V4, P839; Sambrook J, 1989, MOL CLONING LABORATO; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SLAGLE BL, 1991, CANCER RES, V51, P49; STEVENSON D, 1987, HEPATOLOGY, V7, P1291, DOI 10.1002/hep.1840070619; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YOKOTA J, 1988, ONCOGENE, V3, P471	44	132	142	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1407	1413		10.1096/fasebj.7.14.8224613	http://dx.doi.org/10.1096/fasebj.7.14.8224613			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224613				2022-12-28	WOS:A1993MH00800015
J	COLLI, W				COLLI, W			TRANS-SIALIDASE - A UNIQUE ENZYME-ACTIVITY DISCOVERED IN THE PROTOZOAN TRYPANOSOMA-CRUZI	FASEB JOURNAL			English	Review						CHAGAS DISEASE; SIALIC ACIDS; TRANS-SIALIDASE	SURFACE-ANTIGEN GENE; BACTERIAL NEURAMINIDASES; TRYPOMASTIGOTE FORMS; MAMMALIAN-CELLS; FAMILY; ACID; EXPRESSION; SIALOGLYCOLIPIDS; INVASION; SEQUENCE	Trypanosoma cruzi, the agent of Chagas' disease, an ailment characterized by a progressive chronic fibrotic myocarditis and degeneration of tissues that are innervated by the autonomic nervous system, is a voracious sialic acid eater from glycoconjugates of the surrounding medium. This is accomplished through an active trans-sialidase residing on the surface membrane of the trypomastigote stage, which is the parasite form that invades vertebrate cells. The existence of the enzyme was proposed and established only 7 years ago and yet a flood of information on the subject is already available. Transsialidase is able to reversibly transfer sialic acid alpha(2-->3)-linked to an external Galbeta from the host cell surface sialoglycoconjugates to a terminal Galbeta of an appropriate acceptor on the parasite surface. In the absence of an acceptor, the enzyme acts as a hydrolase transferring sialic acid to water. Trans-sialidase belongs to a highly heterogeneous gene family of surface molecules sharing with each other and with bacterial neuraminidases variable degrees of nucleotide sequence homology and common motifs. It has been proposed that sialylation of the parasite surface catalyzed by trans-sialidase is necessary for successful invasion of the host cell, but the evidence available is still indirect. Another function could be a protection from lysis by the alternative pathway of complement while the parasite is circulating in the acute phase of the disease.			COLLI, W (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498-970 SAO PAULO,BRAZIL.		Colli, Walter/AAW-7649-2021; Colli, Walter/ABA-5440-2021; Colli, Walter/G-1188-2012	Colli, Walter/0000-0001-7305-4673; 				ABUIN G, 1989, MOL BIOCHEM PARASIT, V35, P229, DOI 10.1016/0166-6851(89)90209-0; AFFRANCHINO JL, 1991, FEBS LETT, V280, P316, DOI 10.1016/0014-5793(91)80320-3; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BARRETOBERGTER E, 1992, MOL BIOCHEM PARASIT, V51, P263, DOI 10.1016/0166-6851(92)90076-V; CAMPETELLA O, 1992, PARASITOL TODAY, V8, P378, DOI 10.1016/0169-4758(92)90175-2; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; COLLI W, 1992, S RELAB RED LAT CIEN, V2, P259; CONFALONIERI AN, 1983, BIOCHEM INT, V7, P215; COUTO AS, 1985, EXPERIENTIA, V41, P736, DOI 10.1007/BF02012572; COUTO AS, 1990, MOL BIOCHEM PARASIT, V39, P101, DOI 10.1016/0166-6851(90)90012-B; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; EISEN H, 1992, CURR OPIN IMMUNOL, V3, P507; ENGSTLER M, 1992, MOL BIOCHEM PARASIT, V54, P21, DOI 10.1016/0166-6851(92)90091-W; FERREROGARCIA MA, 1993, IN PRESS EUR J BIOCH; FOUTS DL, 1991, MOL BIOCHEM PARASIT, V46, P189, DOI 10.1016/0166-6851(91)90043-6; FREVERT U, 1992, INFECT IMMUN, V60, P2349, DOI 10.1128/IAI.60.6.2349-2360.1992; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; HARTH G, 1987, P NATL ACAD SCI USA, V84, P8320, DOI 10.1073/pnas.84.23.8320; KAHN S, 1991, P NATL ACAD SCI USA, V88, P4481, DOI 10.1073/pnas.88.10.4481; KIPNIS TL, 1981, P NATL ACAD SCI-BIOL, V78, P602, DOI 10.1073/pnas.78.1.602; LEDERKREMER RM, 1985, BIOCH INT, V10, P79; ORTEGABARRIA E, 1992, INFECT AGENT DIS, V1, P136; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PEREIRA MEA, 1980, J EXP MED, V152, P1375, DOI 10.1084/jem.152.5.1375; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; POLLEVICK GD, 1993, IN PRESS MOL BIOCH P; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHENKMAN RPF, 1993, INFECT IMMUN, V61, P898, DOI 10.1128/IAI.61.3.898-902.1993; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCHENKMAN S, 1993, IN PRESS MOL BIOCH P; SOUTOPADRON T, 1985, BIOCHIM BIOPHYS ACTA, V814, P163, DOI 10.1016/0005-2736(85)90432-8; TAKLE GB, 1991, MOL BIOCHEM PARASIT, V48, P185, DOI 10.1016/0166-6851(91)90114-L; TAKLE GB, 1992, MOL BIOCHEM PARASIT, V56, P117, DOI 10.1016/0166-6851(92)90159-H; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; TOMLINSON S, 1992, GLYCOBIOLOGY, V2, P549, DOI 10.1093/glycob/2.6.549; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WENDEL S, 1992, CHAGAS DISEASE AM TR; YOSHIDA N, 1990, MOL BIOCHEM PARASIT, V39, P39, DOI 10.1016/0166-6851(90)90006-8; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	52	112	123	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1257	1264		10.1096/fasebj.7.13.8405811	http://dx.doi.org/10.1096/fasebj.7.13.8405811			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405811				2022-12-28	WOS:A1993MB37600009
J	HARGROVE, JL				HARGROVE, JL			MICROCOMPUTER-ASSISTED KINETIC MODELING OF MAMMALIAN GENE-EXPRESSION	FASEB JOURNAL			English	Article						GENE EXPRESSION; MESSENGER RNA; PROTEIN SYNTHESIS; MATHEMATICAL MODELING; COMPUTER SOFTWARE	RNA SPLICING INVITRO; MESSENGER-RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; EUKARYOTIC CELLS; INITIATION; TRANSCRIPTION; STABILITY; OVALBUMIN; STABILIZATION; PARAMETERS	New software for microcomputers enables predictive, quantitative models of genetic systems to be produced that can account for the elements of time, scale, and feedback control of hierarchical systems. The flow of genetic information during protein synthesis can be addressed by treating each intermediate as a kinetic element in a linked series of reactions. When the rate of transcription changes, the time required to achieve a new level of the encoded protein is expected to be a function of the conversion rates or half-lives of all intermediates. Kinetic modeling may be used to make predictions and integrate primary data concerning rates of transcription, nuclear mRNA dynamics, nucleocytoplasmic transport, translational control, and other processes that govern the rate of synthesis for specific proteins.			HARGROVE, JL (corresponding author), UNIV GEORGIA,DEPT FOODS & NUTR,ATHENS,GA 30602, USA.							BAILEY RC, 1974, BIOMETRICS, V30, P67, DOI 10.2307/2529618; BELLMAN K, 1983, MOL GENETIC INFORMAT; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CHRAPKIEWICZ NB, 1982, J BIOL CHEM, V257, P4428; CORNISHBOWDEN A, 1991, COMPUT APPL BIOSCI, V7, P89; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREENBERG JR, 1972, NATURE, V240, P102, DOI 10.1038/240102a0; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HARGROVE JL, 1993, IN PRESS BIOTECHNIQU; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Kafatos F C, 1972, Curr Top Dev Biol, V7, P125, DOI 10.1016/S0070-2153(08)60071-X; KILEDJIAN M, 1991, J BIOL CHEM, V266, P4207; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEE KL, 1970, J BIOL CHEM, V245, P5806; LEYS EJ, 1984, J CELL BIOL, V99, P180, DOI 10.1083/jcb.99.1.180; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LYNE A, 1992, COMPUT METH PROG BIO, V38, P117, DOI 10.1016/0169-2607(92)90082-I; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MONOD J, 1952, BIOCHIM BIOPHYS ACTA, V9, P648, DOI 10.1016/0006-3002(52)90227-8; MOORE RE, 1980, CANCER RES, V40, P1449; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PALMITER RD, 1975, CELL, V4, P189, DOI 10.1016/0092-8674(75)90167-1; PALMITER RD, 1973, J BIOL CHEM, V248, P8260; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PFISTER K, 1984, J BIOL CHEM, V259, P5816; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; SAVAGEAU M. A., 1972, CURR TOP CELL REGUL, V6, P63, DOI DOI 10.1016/B978-0-12-152806-5.50010-2; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SONG MKH, 1988, J BIOL CHEM, V263, P17970; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; Wong-Staal F, 1992, Mol Genet Med, V2, P189; Yagil G, 1975, Curr Top Cell Regul, V9, P183; YAGIL G, 1980, MATH MODELS MOL CELL, P68	49	38	39	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1163	1170		10.1096/fasebj.7.12.8375615	http://dx.doi.org/10.1096/fasebj.7.12.8375615			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375615				2022-12-28	WOS:A1993LW81700011
J	SHEPRO, D; MOREL, NML				SHEPRO, D; MOREL, NML			PERICYTE PHYSIOLOGY	FASEB JOURNAL			English	Review						BIOCHEMISTRY; ENDOTHELIUM; PERICYTES; PHYSIOLOGY; TISSUE CULTURE	RETINAL CAPILLARY PERICYTES; SMOOTH-MUSCLE CELLS; MICROVASCULAR ENDOTHELIAL-CELLS; CULTURED MESANGIAL CELLS; HYPERTENSIVE RAT BRAINS; GROWTH-FACTOR-BETA; CONTRACTILE PROTEINS; EXTRACELLULAR-MATRIX; BINDING-SITES; INVITRO	Endothelial cells are the primary physical barrier between blood and tissue in microvessels. The other capillary and post-capillary venule wall cell is the pericyte. The literature on the biology of endothelium is appreciable but less is known about pericytes. Pericytes are morphologically, biochemically, and physiologically heterogeneous. Some of pericyte functional characteristics observed in vivo and in vitro are that they: regulate endothelial proliferation and differentiation; contract in manners that either exacerbate or stem endothelial cell junctional inflammatory leakage; function as a progenitor cell; synthesize and secrete a wide variety of vasoactive autoregulating agonists; synthesize and release structural constituents of the basement membrane and extracellular matrix. Pericytes are also involved in specific microvascular diseases. This review focuses principally on nonmesangial pericytes and specific activities such as the posttranslational, short-term responses that affect microvascular perfusion and permeability, and on pericyte-endothelial cell interaction.			SHEPRO, D (corresponding author), BOSTON UNIV, MICROVASC RES LAB, BOSTON, MA 02215 USA.							ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BRAVERMAN MS, 1986, J INVEST DERMATOL, V86, P290, DOI 10.1111/1523-1747.ep12285445; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, V275, P287; BUCHANAN RA, 1990, MICROCIRC ENDOTH LYM, V6, P159; CANFIELD AE, 1990, J CELL SCI, V96, P159; CANFIELD AE, 1989, BIOCHEM J, V259, P529, DOI 10.1042/bj2590529; CANFIELD AE, 1991, FEBS LETT, V286, P171, DOI 10.1016/0014-5793(91)80967-8; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; COOMBER BL, 1991, EXP CELL RES, V194, P42, DOI 10.1016/0014-4827(91)90127-G; CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5; DAMORE PA, 1990, CELL CULTURE TECHNIQ, P299; DICTOR M, 1991, VIRCHOW ARCH PATHOL, V49, P35; DODGE AB, 1991, CELL MOTIL CYTOSKEL, V18, P180, DOI 10.1002/cm.970180304; DODGE AB, 1992, DIABETES CARE, V15, P1168, DOI 10.2337/diacare.15.9.1168; DODGE AB, 1991, THESIS BOSTON U BOST, P77; ESKENASY M, 1988, CELL BIOL INT REP, V12, P1055, DOI 10.1016/0309-1651(88)90030-6; FERRARIDILEO G, 1992, INVEST OPHTH VIS SCI, V33, P42; FERRARIDILEO G, 1991, BLOOD VESSELS, V28, P542; FRANKLIN WA, 1990, CANCER RES, V50, P6344; GITLIN JD, 1983, MICROVASC RES, V26, P74, DOI 10.1016/0026-2862(83)90056-0; HELBIG H, 1992, INVEST OPHTH VIS SCI, V33, P2105; HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43; HERMAN IM, 1987, TISSUE CELL, V19, P197, DOI 10.1016/0040-8166(87)90005-X; HERMAN IM, 1988, TISSUE CELL, V20, P1, DOI 10.1016/0040-8166(88)90002-X; HOLTHOFER H, 1990, CELL DIFFER DEV, V30, P181, DOI 10.1016/0922-3371(90)90138-M; HUDES GR, 1988, INVEST OPHTH VIS SCI, V29, P1511; ISHINO T, 1991, KIDNEY INT, V39, P1118, DOI 10.1038/ki.1991.142; JACKSON JA, 1992, AM J PHYSIOL, V263, pH634, DOI 10.1152/ajpheart.1992.263.2.H634; JOYCE NC, 1984, MICROVASC RES, V28, P206, DOI 10.1016/0026-2862(84)90018-9; JOYCE NC, 1985, J CELL BIOL, V100, P1379, DOI 10.1083/jcb.100.5.1379; JOYCE NC, 1985, J CELL BIOL, V100, P1387, DOI 10.1083/jcb.100.5.1387; KELLEY C, 1988, J MUSCLE RES CELL M, V9, P184, DOI 10.1007/BF01773740; KIMURA T, 1991, JPN J PSYCHIAT NEUR, V45, P671; KRAUSE D, 1988, CELL TISSUE RES, V252, P543, DOI 10.1007/BF00216641; LARSON DM, 1987, MICROVASC RES, V34, P184, DOI 10.1016/0026-2862(87)90052-5; LEE TS, 1989, DIABETES, V38, P1643, DOI 10.2337/diabetes.38.12.1643; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MENE P, 1992, J AM SOC NEPHROL, V2, pS100; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; Metchnikoff E., 1968, LECTURES COMP PATHOL; MILLER FN, 1992, MICROVASC RES, V44, P166, DOI 10.1016/0026-2862(92)90078-4; MIYAZATO M, 1991, ACTA PATHOL JAPON, V41, P133; MOREL NML, 1993, J CELL PHYSL BIOCH, V3, P127; MYOKEN Y, 1990, EXP CELL RES, V191, P299, DOI 10.1016/0014-4827(90)90018-6; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; RHODIN JAG, 1989, J SUBMICR CYTOL PATH, V21, P1; RISAU W, 1990, J CELL BIOL, V110, P1757, DOI 10.1083/jcb.110.5.1757; SAEKI T, 1991, AM J PATHOL, V139, P949; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; SCHOR AM, 1986, MICROVASC RES, V32, P21, DOI 10.1016/0026-2862(86)90041-5; SCHOR AM, 1991, IN VITRO CELL DEV B, V27, P651; SHEPRO D, 1984, HDB PHYSL 1 2, V4, P103; SHIN WK, 1992, MICROVASC RES, V44, P255, DOI 10.1016/0026-2862(92)90085-4; SHULTZ PJ, 1991, AM J KIDNEY DIS, V17, P8; SIMONSON MS, 1992, J AM SOC NEPHROL, V2, pS116; SIMS DE, 1991, CAN J CARDIOL, V7, P431; SINGHAL PC, 1986, KIDNEY INT, V30, P862, DOI 10.1038/ki.1986.266; TAKAHASHI K, 1989, DIABETES, V38, P1200, DOI 10.2337/diabetes.38.9.1200; TILTON RG, 1979, MICROVASC RES, V18, P325, DOI 10.1016/0026-2862(79)90041-4; Zimmermann K. W., 1923, Zeitschrift Ges Anat Munchen Abt 1, V68, P29, DOI 10.1007/BF02593544	63	537	553	3	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1993	7	11					1031	1038		10.1096/fasebj.7.11.8370472	http://dx.doi.org/10.1096/fasebj.7.11.8370472			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370472				2022-12-28	WOS:A1993LT83900008
J	VALERA, A; RODRIGUEZGIL, JE; YUN, JS; MCGRANE, MM; HANSON, RW; BOSCH, F				VALERA, A; RODRIGUEZGIL, JE; YUN, JS; MCGRANE, MM; HANSON, RW; BOSCH, F			GLUCOSE-METABOLISM IN TRANSGENIC MICE CONTAINING A CHIMERIC P-ENOLPYRUVATE CARBOXYKINASE BOVINE GROWTH-HORMONE GENE	FASEB JOURNAL			English	Note						BOVINE GROWTH HORMONE; P-ENOLPYRUVATE CARBOXYKINASE PROMOTER; TRANSGENIC MICE; GLUCOSE METABOLISM; GENE EXPRESSION	TYROSINE AMINOTRANSFERASE GENE; PROMOTER-REGULATORY REGION; HEPATIC GLYCOGEN-SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; RAT-LIVER; FACTOR-I; PROTEIN-KINASE; MESSENGER-RNA; INSULIN; ACTIVATION	Transgenic mice, containing the chimeric gene obtained by linking the promoter-regulatory region of P-enolpyruvate carboxykinase (PEPCK) gene to the bovine growth hormone structural gene (bGH), were used to investigate the long-term effects of bGH on glucose metabolism. Expression of the PEPCK/bGH gene was markedly enhanced by feeding a diet high in protein and inhibited by a high carbohydrate diet. All transgenic mice had normal levels of blood glucose but were hyperinsulinemic, indicating that they were insulin resistant. The glycogen synthase activity ratios in the muscle and liver of transgenic mice were lower than noted for control animals, and remained unchanged in liver after feeding a standard high carbohydrate or a high protein diet. Similar effects were detected in the activity of glycogen phosphorylase, except that a high carbohydrate diet activated this enzyme in the liver. The activation of glycogen phosphorylase in both muscle and liver correlated with the expression of their genes. These animals had a significant content of glycogen and glucose 6-phosphate, which was related to the levels of glucokinase mRNA in the liver. The concentration of fructose 2,6-bisphosphate in the liver of all fed transgenic mice was lower than noted in livers from fed animals. In addition, a decrease in the hepatic expression of the endogenous genes for PEPCK, tyrosine aminotransferase (TAT), and the glucose transporter GLUT-2 was observed and directly correlated with the expression of bGH. Thus, bGH can control glucose metabolism in vivo, at least in part, by modifying the expression of several genes coding for proteins of importance in carbohydrate metabolism. Taken together, these results indicate a state of insulin resistance caused by chronic exposure of the animals to an elevated concentration of bGH.	AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT BIOCHEM, E-08193 BARCELONA, SPAIN; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; OHIO UNIV, EDISON ANIM BIOTECHNOL CTR, ATHENS, OH 45701 USA; AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona; Case Western Reserve University; University System of Ohio; Ohio University; Autonomous University of Barcelona			Rodriguez-Gil, Joan E./F-8748-2016	Rodriguez-Gil, Joan E./0000-0002-1112-9884; BOSCH, FATIMA/0000-0002-7705-5515	NIDDK NIH HHS [DK-24451, DK-21859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; Ausubel FM, 1988, MOL REPROD DEV; BAK JF, 1991, AM J PHYSIOL, V260, pE736, DOI 10.1152/ajpendo.1991.260.5.E736; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; BECK P, 1965, J LAB CLIN MED, V66, P366; BEHRINGER RR, 1990, ENDOCRINOLOGY, V127, P1033, DOI 10.1210/endo-127-3-1033; CAMERON CM, 1987, ENDOCRINOLOGY, V120, P1568, DOI 10.1210/endo-120-4-1568; CHISTIANSEN JS, 1991, ACTA ENDOCRINOL-COP, V125, P7; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; CIUDAD CJ, 1981, FEBS LETT, V129, P123, DOI 10.1016/0014-5793(81)80771-5; COATS WS, 1991, J BIOL CHEM, V266, P16113; CRETTAZ M, 1988, BIOCHEMISTRY-US, V27, P495, DOI 10.1021/bi00401a071; DANFORTH WH, 1965, J BIOL CHEM, V240, P588; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DOUGLAS RG, 1990, BRIT J SURG, V77, P785, DOI 10.1002/bjs.1800770722; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; HANSEN I, 1986, AM J PHYSIOL, V250, pE269, DOI 10.1152/ajpendo.1986.250.3.E269; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEE KL, 1986, ARCH BIOCHEM BIOPHYS, V248, P597, DOI 10.1016/0003-9861(86)90513-8; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Li CH, 1944, SCIENCE, V99, P183, DOI 10.1126/science.99.2566.183; LI CH, 1945, J BIOL CHEM, V159, P353; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maniatis T, 1989, MOL CLONING; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MILLER TB, 1973, J BIOL CHEM, V248, P3483; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PERET J, 1976, J NUTR, V106, P103, DOI 10.1093/jn/106.1.103; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; POSTELVINAY MC, 1990, HORM METAB RES, V22, P7, DOI 10.1055/s-2007-1004837; POSTELVINAY MC, 1982, MOL CELL ENDOCRINOL, V28, P657, DOI 10.1016/0303-7207(82)90153-8; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RABINOVITCH A, 1983, DIABETES, V32, P307, DOI 10.2337/diabetes.32.4.307; ROACH PJ, 1977, FEBS LETT, V80, P95, DOI 10.1016/0014-5793(77)80414-6; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMAL J, 1987, BIOCHEM BIOPH RES CO, V147, P1232, DOI 10.1016/S0006-291X(87)80202-4; SONENBERG M, 1954, ENDOCRINOLOGY, V55, P709; STEWART TA, 1992, ENDOCRINOLOGY, V130, P405, DOI 10.1210/en.130.1.405; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; THOMAS AP, 1985, J BIOL CHEM, V260, P5963; UHING RJ, 1981, FEBS LETT, V134, P185, DOI 10.1016/0014-5793(81)80598-4; VANDEWERVE G, 1977, BIOCHEM J, V162, P135, DOI 10.1042/bj1620135; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WALKER J, 1989, J CLIN ENDOCR METAB, V69, P253, DOI 10.1210/jcem-69-2-253; WANG P, 1972, ANAL BIOCHEM, V47, P495, DOI 10.1016/0003-2697(72)90143-1; WITTERS LA, 1978, BIOCHEMISTRY-US, V17, P406, DOI 10.1021/bi00596a004; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	80	41	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					791	800		10.1096/fasebj.7.9.8330686	http://dx.doi.org/10.1096/fasebj.7.9.8330686			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330686				2022-12-28	WOS:A1993LK43000012
J	LINCOLN, TM; CORNWELL, TL				LINCOLN, TM; CORNWELL, TL			INTRACELLULAR CYCLIC-GMP RECEPTOR PROTEINS	FASEB JOURNAL			English	Review						PROTEIN KINASE; CALCIUM; ION CHANNELS; SMOOTH MUSCLE; NEUTROPHILS; PLATELETS; CYCLIC AMP	SMOOTH-MUSCLE CELLS; PEPTIDE-STIMULATED NEUTROPHILS; NITRIC-OXIDE; NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PHOSPHORYLATION; OLFACTORY EPITHELIUM; ROD PHOTORECEPTORS; MOLECULAR-CLONING; HUMAN PLATELETS; BINDING-SITES	Cyclic GMP is recognized as an important intracellular mediator of extracellular signals such as nitric oxide and natriuretic peptides. Cyclic GMP interacts with three types of intracellular receptor proteins: cGMP-dependent protein kinases, cGMP-regulated ion channels, and cGMP-regulated cyclic nucleotide phosphodiesterases. This means that cGMP can alter cell function through protein phosphorylation or through mechanisms not directly related to protein phosphorylation. Cyclic GMP appears to regulate a number of intracellular processes, such as vascular smooth muscle relaxation and neutrophil activation, through these receptor proteins in the cell. It is also becoming clear that the localization of these cGMP receptor proteins in the cell is an important factor in the regulation of cell function by cGMP.			LINCOLN, TM (corresponding author), UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR PATHOL, BIRMINGHAM, AL 35294 USA.				NHLBI NIH HHS [HL34646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; CHEN GF, 1992, CIRC RES, V70, P257, DOI 10.1161/01.RES.70.2.257; CHEN XL, 1992, AM J PHYSIOL, V263, pC468, DOI 10.1152/ajpcell.1992.263.2.C468; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; ECKER T, 1989, CIRC RES, V65, P1361, DOI 10.1161/01.RES.65.5.1361; FELBEL J, 1988, J BIOL CHEM, V263, P16764; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; FRANCIS SH, 1989, SEC MESS PHOSPHOPROT, V12, P301; GARG UC, 1989, AM J PHYSIOL, V257, pF60, DOI 10.1152/ajprenal.1989.257.1.F60; GARLAND CJ, 1992, BRIT J PHARMACOL, V105, P429, DOI 10.1111/j.1476-5381.1992.tb14270.x; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GERZER R, 1985, J CLIN ENDOCR METAB, V61, P1217, DOI 10.1210/jcem-61-6-1217; Gillespie P.G., 1990, CYCLIC NUCLEOTIDE PH, P163; GOLDBERG ND, 1969, J BIOL CHEM, V244, P4458; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HAMET P, 1986, J HYPERTENS, V4, pS49; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HIRATA M, 1990, J BIOL CHEM, V265, P1268; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JIANG H, 1992, J BIOL CHEM, V267, P1015; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; JOYCE NC, 1986, J CYCLIC NUCL PROT, V11, P191; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KAPLAN SS, 1989, BLOOD, V74, P1885; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KIRSCH GE, 1988, AM J PHYSIOL, V254, pH1200, DOI 10.1152/ajpheart.1988.254.6.H1200; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1981, BIOCHIM BIOPHYS ACTA, V676, P230, DOI 10.1016/0304-4165(81)90192-6; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MACPHEE CH, 1986, P NATL ACAD SCI USA, V83, P6660, DOI 10.1073/pnas.83.17.6660; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P87; MCDANIEL NL, 1992, AM J PHYSIOL, V263, pC461, DOI 10.1152/ajpcell.1992.263.2.C461; MEISHERI KD, 1986, AM J PHYSIOL, V250, pC171, DOI 10.1152/ajpcell.1986.250.1.C171; MEISHERI KD, 1991, J CARDIOVASC PHARM, V17, P903, DOI 10.1097/00005344-199106000-00007; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MILLER WH, 1983, ADV CYCL NUCL RES<D>, V15, P495; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; MOLLEMAN A, 1991, J BIOL CHEM, V266, P5658; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURASHIMA S, 1990, BIOCHEMISTRY-US, V29, P5285, DOI 10.1021/bi00474a010; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; ONO K, 1991, J PHYSIOL-LONDON, V443, P387, DOI 10.1113/jphysiol.1991.sp018839; PARKS TP, 1987, ARCH BIOCHEM BIOPHYS, V255, P361, DOI 10.1016/0003-9861(87)90404-8; PAUPARDINTRITSCH D, 1986, NATURE, V323, P812, DOI 10.1038/323812a0; PAWSON T, 1988, ONCOGENE, V3, P491; PRYZWANSKY KB, 1990, BLOOD, V76, P612; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; ROSKOSKI R, 1987, J NEUROCHEM, V48, P840, DOI 10.1111/j.1471-4159.1987.tb05593.x; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SOUNESS JE, 1990, BIOCHEM J, V266, P127, DOI 10.1042/bj2660127; STANTON BA, 1992, FASEB J, V6, pA1808; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THORNBURY KD, 1991, AM J PHYSIOL, V261, pG553, DOI 10.1152/ajpgi.1991.261.3.G553; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALDMANN R, 1986, EUR J BIOCHEM, V158, P203, DOI 10.1111/j.1432-1033.1986.tb09739.x; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1981, EUR J BIOCHEM, V118, P339; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WHALIN ME, 1991, MOL PHARMACOL, V39, P711; WHALIN ME, 1988, BIOCHIM BIOPHYS ACTA, V972, P79; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WYATT TA, 1991, J BIOL CHEM, V266, P21274; WYATT TA, 1993, IN PRESS AM J PHYSL; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	106	528	536	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					328	338		10.1096/fasebj.7.2.7680013	http://dx.doi.org/10.1096/fasebj.7.2.7680013			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	7680013				2022-12-28	WOS:A1993KN88500008
J	OLSEN, GJ; WOESE, CR				OLSEN, GJ; WOESE, CR			RIBOSOMAL-RNA - A KEY TO PHYLOGENY	FASEB JOURNAL			English	Article						MOLECULAR PHYLOGENY; MAXIMUM PARSIMONY; MAXIMUM LIKELIHOOD; LEAST SQUARES DISTANCE	SECONDARY STRUCTURE; ARCHAEBACTERIAL PHYLOGENY; EVOLUTIONARY PARSIMONY; RIBONUCLEASE-P; SEQUENCES; EUKARYOTES; ORIGIN; TREES; EUBACTERIA; ORGANISMS	As molecular phylogeny increasingly shapes our understanding of organismal relationships, no molecule has been applied to more questions than have ribosomal RNAs. We review this role of the rRNAs and some of the insights that have been gained from them. We also offer some of the practical considerations in extracting the phylogenetic information from the sequences. Finally, we stress the importance of comparing results from multiple molecules, both as a method for testing the overall reliability of the organismal phylogeny and as a method for more broadly exploring the history of the genome.			OLSEN, GJ (corresponding author), UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRIL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA.							ACHENBACHRICHTER L, 1987, NATURE, V327, P348, DOI 10.1038/327348a0; ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BAYLEY ST, 1964, J MOL BIOL, V9, P654, DOI 10.1016/S0022-2836(64)80173-X; Buchanan R.E, 1974, BERGEYS MANUAL DETER, V8th ed., DOI 10.1007/bergeysoutline200405; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P358, DOI 10.1016/S0723-2020(11)80310-3; CAMMARANO P, 1992, J MOL EVOL, V34, P396, DOI 10.1007/BF00162996; CRETI R, 1991, J MOL EVOL, V33, P332, DOI 10.1007/BF02102864; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FOSTER I, 1991, AUTOMATED REASONING, P231; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOUY M, 1989, NATURE, V339, P145, DOI 10.1038/339145a0; HOLMQUIST R, 1988, MOL BIOL EVOL, V5, P201; HORI H, 1987, MOL BIOL EVOL, V4, P445; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JIN L, 1990, MOL BIOL EVOL, V7, P82; JUKES T H, 1969, P21; KAINE BP, 1990, MOL GEN GENET, V221, P315, DOI 10.1007/BF00259394; Kimura M., 1983, NEUTRAL THEORY MOL E; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; KURLAND CG, 1990, RIBOSOME, P513; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1987, MOL BIOL EVOL, V4, P167; LANE DJ, 1992, J BACTERIOL, V174, P269, DOI 10.1128/jb.174.1.269-278.1992; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; MATHESON AT, 1985, BACTERIA, V8, P345; NEI M, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P90; OLSEN GJ, 1989, CAN J MICROBIOL, V35, P119, DOI 10.1139/m89-018; OLSEN GJ, 1992, NUCLEIC ACIDS RES, V20, P2199, DOI 10.1093/nar/20.suppl.2199; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; PACE NR, 1990, J BIOL CHEM, V265, P3587; PENNY D, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P155; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REICH C, 1986, J BIOL CHEM, V261, P7888; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SOGIN ML, 1989, INT CONGR SER, V824, P133; STANIER RY, 1962, ARCH MIKROBIOL, V42, P17, DOI 10.1007/BF00425185; Stanier RY, 1941, J BACTERIOL, V42, P437, DOI 10.1128/JB.42.4.437-466.1941; SUEOKA N, 1961, P NATL ACAD SCI USA, V47, P1141, DOI 10.1073/pnas.47.8.1141; Swofford David L., 1990, P411; VANNIEL CB, 1946, COLD SPRING HARB SYM, V11, P285; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WHITTAKER RH, 1969, SCIENCE, V163, P150, DOI 10.1126/science.163.3863.150; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1986, SYST APPL MICROBIOL, V7, P161; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1976, J MOL EVOL, V8, P143, DOI 10.1007/BF01739100; WOESE CR, 1991, SYST APPL MICROBIOL, V14, P364, DOI 10.1016/S0723-2020(11)80311-5; WOESE CR, 1992, PROKARYOTES, V1, P3; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	61	505	533	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					113	123		10.1096/fasebj.7.1.8422957	http://dx.doi.org/10.1096/fasebj.7.1.8422957			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422957				2022-12-28	WOS:A1993KH88000017
J	SCHMID, SL; DAMKE, H				SCHMID, SL; DAMKE, H			COATED VESICLES - A DIVERSITY OF FORM AND FUNCTION	FASEB JOURNAL			English	Review						CLATHRIN-COATED VESICLES; VESICLE BUDDING; COP-COATED VESICLES	ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES; TRANSPORT VESICLES; MEDIATED ENDOCYTOSIS; A431 CELLS; CLATHRIN; PROTEIN; PITS; DROSOPHILA; DYNAMIN	In every well-characterized example, the small transport vesicles that mediate membrane trafficking between intracellular organelles are encased in a protein coat. In general, the coat proteins assemble from cytosolic pools onto the membrane and play a critical role in vesicle formation, Recent reviews have emphasized the clear similarities in the mechanisms that drive vesicle budding at distinct cellular locations. Here we focus on the diversity of solutions to an apparently related biological task, These mechanistic differences are likely to be physiologically important determinants of the diversity in form and function of coated transport vesicles.			SCHMID, SL (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Schmid, Sandra/0000-0002-1690-7024				BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DAMKE H, 1994, J CELL BIOL, V127, P9151; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HINSHAW JE, 1994, MOL BIOL CELL, V5, pA435; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LAMAZE C, 1993, MOL BIOL CELL, V3, P1181; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OREI L, 1986, CELL, V46, P171; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; Prasad K., 1994, Molecular Biology of the Cell, V5, p329A; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	70	66	68	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1445	1453		10.1096/fasebj.9.14.7589986	http://dx.doi.org/10.1096/fasebj.9.14.7589986			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589986				2022-12-28	WOS:A1995TF67800009
J	SNEYD, J; KEIZER, J; SANDERSON, MJ				SNEYD, J; KEIZER, J; SANDERSON, MJ			MECHANISMS OF CALCIUM OSCILLATIONS AND WAVES - A QUANTITATIVE-ANALYSIS	FASEB JOURNAL			English	Review						CALCIUM WAVES; MATHEMATICAL MODELS; INOSITOL TRISPHOSPHATE RECEPTOR	XENOPUS-LAEVIS OOCYTES; BULLFROG SYMPATHETIC NEURONS; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; <CA2+>I OSCILLATIONS; CA2+ OSCILLATIONS; EXCITABLE MEDIA; POOL MODEL; RELEASE; TRISPHOSPHATE	Oscillations and waves of increased intracellular free calcium concentration ([Ca2+]i) are observed in a wide range of cell types, Because of their inherent nonlinear nature and the consequent unreliability of intuitive approaches, mathematical modeling has an important role to play in the study of these phenomena, One important class of oscillations and waves is dependent on the presence of inositol (1,4,5)-trisphosphate (IP3), which releases Ca2+ from internal stores via the IP3 receptor/Ca2+ channel, With the minimum possible mathematical formalism, we review mechanistic models for IP3-dependent Ca2+ oscillations and waves, These models are based on the regulation of the IP3 receptor by both IP3 and Ca2+, and incorporate experimental data on the steady-state and kinetic properties of the receptor, The extension of the models to describe intracellular and intercellular Ca2+ waves is considered.	UNIV CALIF DAVIS,INST THEORET DYNAM,DAVIS,CA 95616; UNIV CALIF DAVIS,NEUROBIOL PHYSIOL & BEHAV SECT,DAVIS,CA 95616; UNIV MASSACHUSETTS,MED CTR,DEPT PHYSIOL,WORCESTER,MA 01655	University of California System; University of California Davis; University of California System; University of California Davis; University of Massachusetts System; University of Massachusetts Worcester	SNEYD, J (corresponding author), UNIV CANTERBURY,DEPT MATH & STAT,CHRISTCHURCH,NEW ZEALAND.		Sneyd, James/C-8995-2009	Sneyd, James/0000-0001-7305-2862	NHLBI NIH HHS [HL 49288] Funding Source: Medline; NIGMS NIH HHS [GM 48682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Amundson J, 1993, Curr Opin Neurobiol, V3, P375, DOI 10.1016/0959-4388(93)90131-H; ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Chay T R, 1993, Adv Biophys, V29, P75, DOI 10.1016/0065-227X(93)90006-Q; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DUPONT C, 1995, IN PRESS BIOPHYS J; DUPONT G, 1993, CELL CALCIUM, V14, P311, DOI 10.1016/0143-4160(93)90052-8; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1994, MOL CELL ENDOCRINOL, V98, P141, DOI 10.1016/0303-7207(94)90132-5; IRVING M, 1990, BIOPHYS J, V57, P717, DOI 10.1016/S0006-3495(90)82592-3; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; JAFRI MS, 1992, BIOPHYS J, V63, P235, DOI 10.1016/S0006-3495(92)81583-7; JAFRI MS, 1994, P NATL ACAD SCI USA, V91, P9485, DOI 10.1073/pnas.91.20.9485; JAFRI MS, 1995, IN PRESS BIOPHYS J; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KEENER JP, 1980, SIAM J APPL MATH, V39, P528, DOI 10.1137/0139043; KEIZER J, 1993, CELL CALCIUM, V14, P397, DOI 10.1016/0143-4160(93)90044-7; KOPELL N, 1973, SCIENCE, V180, P1171, DOI 10.1126/science.180.4091.1171; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LI YX, 1994, J THEOR BIOL, V166, P461, DOI 10.1006/jtbi.1994.1041; LI YX, 1994, P NATL ACAD SCI USA, V91, P58, DOI 10.1073/pnas.91.1.58; LYTTON J, 1992, J BIOL CHEM, V267, P14183; MARSHALL ICB, 1993, J EXP BIOL, V184, P161; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MIRONOV SL, 1990, J THEOR BIOL, V146, P87, DOI 10.1016/S0022-5193(05)80045-1; OTHMER HG, 1994, EXPT THEORETICAL ADV; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1992, P R SOC LONDON B, V246, P269; PARYS JB, 1992, J BIOL CHEM, V267, P18776; POLEDNA J, 1993, GEN PHYSIOL BIOPHYS, V12, P381; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SNEYD J, 1993, B MATH BIOL, V55, P315; SNEYD J, 1993, PHYSICA D, V65, P365, DOI 10.1016/0167-2789(93)90062-6; SNEYD J, 1994, AM J PHYSIOL, V266, pC293, DOI 10.1152/ajpcell.1994.266.1.C293; SNEYD J, 1994, CELL CALCIUM, V15, P289, DOI 10.1016/0143-4160(94)90068-X; SNEYD J, 1995, IN PRESS AM J PHYSL; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STUCKI JW, 1994, BBA-BIOENERGETICS, V1183, P453, DOI 10.1016/0005-2728(94)90073-6; THOM P, 1993, CELL, V74, P661; TSE A, 1991, SCIENCE, V255, P462; TYSON JJ, 1988, PHYSICA D, V32, P327, DOI 10.1016/0167-2789(88)90062-0; WAGNER J, 1994, BIOPHYS J, V67, P447, DOI 10.1016/S0006-3495(94)80500-4; YAO Y, 1994, J PHYSIOL-LONDON, V476, P17; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	59	156	161	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1463	1472		10.1096/fasebj.9.14.7589988	http://dx.doi.org/10.1096/fasebj.9.14.7589988			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589988				2022-12-28	WOS:A1995TF67800011
J	SPECTOR, A				SPECTOR, A			OXIDATIVE STRESS-INDUCED CATARACT - MECHANISM OF ACTION	FASEB JOURNAL			English	Review						REDOX; H2O2; DNA; EPITHELIAL CELL DEATH; TRANSPORT	LENS EPITHELIAL-CELLS; CULTURED RABBIT LENS; HYDROGEN-PEROXIDE; AQUEOUS-HUMOR; DNA DAMAGE; TRANSPORT-SYSTEMS; ALPHA-CRYSTALLIN; SENILE CATARACTS; CHELATED IRON; FREE-RADICALS	This review examines the hypothesis that oxidative stress is an initiating factor for the development of maturity onset cataract and describes the events leading to lens opacification. Data are reviewed that indicate that extensive oxidation of lens protein and lipid is associated with human cataract found in older individuals whereas little oxidation (and only in membrane components) is found in control subjects of similar age, A significant proportion of lenses and aqueous humor taken from cataract patients have elevated H2O2 levels. Because H2O2, at concentrations found in cataract, can cause lens opacification and produces a pattern of oxidation similar to that found in cataract, it is concluded that H2O2 is the major oxidant involved in cataract formation. This viewpoint is further supported by experiments showing that cataract formation in organ culture caused by photochemically generated superoxide radical, H2O2, and hydroxyl radical is completely prevented by the addition of a GSH peroxidase mimic. The damage caused by oxidative stress does not appear to be reversible and there is an inverse relationship between the stress period and the time required for loss of transparency and degeneration of biochemical parameters such as ATP, GPD, nonprotein thiol, and hydration, After exposure to oxidative stress, the redox set point of the single layer of the lens epithelial cells (but not the remainder of the lens) quickly changes, going from a strongly reducing to an oxidizing environment. Almost concurrent with this change is extensive damage to DNA and membrane pump systems, followed by loss of epithelial cell viability and death by necrotic and apoptotic mechanisms. The data suggest that the epithelial cell layer is the initial site of attack by oxidative stress and that involvement of the lens fibers follows, leading to cortical cataract.			SPECTOR, A (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT OPHTHALMOL,BIOCHEM & MOLEC BIOL LAB,630 W 168TH ST,NEW YORK,NY 10032, USA.							BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X; BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776; BONTING SL, 1963, ARCH BIOCHEM BIOPHYS, V101, P47, DOI 10.1016/0003-9861(63)90532-0; CHIOU SH, 1980, BIOCHEM BIOPH RES CO, V95, P894, DOI 10.1016/0006-291X(80)90871-2; CHYLACK LT, 1994, PRINCIPLES PRACTICE, V1, P591; CUI XL, 1993, EXP EYE RES, V57, P156; DEJONG WW, 1988, ADV POSTTRANSLATIONA, P95; DEVRIES ACJ, 1991, EXP EYE RES, V53, P519, DOI 10.1016/0014-4835(91)90169-F; DILLON J, 1976, NATURE, V259, P422, DOI 10.1038/259422a0; DILLON J, 1990, PHOTOCHEM PHOTOBIOL, V51, P849; FOOTE CS, 1976, FREE RAD BIOL, P85; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592; GARNER M H, 1982, Investigative Ophthalmology and Visual Science, V22, P34; GARNER MH, 1980, EXP EYE RES, V31, P361, DOI 10.1016/S0014-4835(80)80044-3; GARNER MH, 1980, P NATL ACAD SCI USA, V77, P174; GARNER WH, 1983, P NATL ACAD SCI-BIOL, V80, P2044, DOI 10.1073/pnas.80.7.2044; GARNER WH, 1978, P NATL ACAD SCI USA, V75, P3618, DOI 10.1073/pnas.75.8.3618; GARRIELI Y, 1992, J CELL BIOL, V119, P493; GEIGER T, 1987, J BIOL CHEM, V262, P785; GIBLIN F, 1987, INVEST OPHTH VIS SCI, V22, P330; GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8; GIBLIN FJ, 1988, INVEST OPHTH VIS SCI, V29, P1312; GIBLIN FJ, 1990, EXP EYE RES, V50, P795, DOI 10.1016/0014-4835(90)90130-M; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDING JJ, 1984, EYE, V1; HEJTMANCIK JF, 1994, PRINCIPLES PRACTICE, V1, P168; HIGHTOWER KR, 1995, CURR EYE RES, V14, P71, DOI 10.3109/02713689508999916; HIGHTOWER KR, 1991, INVEST OPHTH VIS SCI, V32, P406; HOCKWIN O, 1984, GERIATRICS, P343; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HORWIITZ J, 1992, TXB OPHTHALMOLOGY, V3; ITO K, 1993, J BIOL CHEM, V268, P13221; JERNIGAN HM, 1981, EXP EYE RES, V32, P461, DOI 10.1016/S0014-4835(81)80025-5; KIM H, 1993, PHOTOCHEM PHOTOBIOL, V57, P777, DOI 10.1111/j.1751-1097.1993.tb09210.x; KINOSHITA JH, 1974, INVEST OPHTHALMOL, V713, P713; KLEIMAN NJ, 1993, CURR EYE RES, V12, P423, DOI 10.3109/02713689309024624; KLEIMAN NJ, 1990, MUTAT RES, V240, P35, DOI 10.1016/0165-1218(90)90006-N; KOBAYASHI S, 1983, CURR EYE RES, V2, P327; KRISHNA CM, 1991, PHOTOCHEM PHOTOBIOL, V54, P51, DOI 10.1111/j.1751-1097.1991.tb01984.x; KUPFER C, 1994, PRINCIPLES PRACTICE, P1249; KUPFER C, 1984, T OPHTHAL SOC UK, V104, P1; KWAN M, 1972, INVEST OPHTH VISUAL, V11, P108; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; LI WC, 1994, EXP EYE RES, V59, P170; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MATSUDA H, 1981, EXP EYE RES, V33, P253, DOI 10.1016/S0014-4835(81)80049-8; MOLL HR, 1991, Patent No. 5030651; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; PADGAONKAR V, 1989, EXP EYE RES, V49, P887, DOI 10.1016/S0014-4835(89)80047-8; PANDE A, 1979, BIOCHEM BIOPH RES CO, V89, P1260, DOI 10.1016/0006-291X(79)92144-2; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; RATHBUN WB, 1968, CURR EYE RES, V5, P381; REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G; REDDY VN, 1979, INVEST OPHTH VIS SCI, V18, P1000; SCHMITZ GG, 1991, ANAL BIOCHEM, V192, P222, DOI 10.1016/0003-2697(91)90212-C; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6; SPECTOR A, 1993, EXP EYE RES, V57, P659, DOI 10.1006/exer.1993.1174; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1987, EXP EYE RES, V45, P453, DOI 10.1016/S0014-4835(87)80130-6; SPECTOR A, 1993, P NATL ACAD SCI USA, V90, P7485, DOI 10.1073/pnas.90.16.7485; SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6; SPECTOR A, 1995, EXP EYE RES, V60, P72; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VARMA SD, 1979, P NATL ACAD SCI USA, V76, P3504, DOI 10.1073/pnas.76.7.3504; WANNEMACHER CF, 1968, EXP EYE RES, V7, P623, DOI 10.1016/S0014-4835(68)80018-1; Wendel A., 1985, European Patent, Patent No. [0165534, 0-165-534]; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; Worgul B V, 1989, Lens Eye Toxic Res, V6, P559; WORGUL BV, 1981, CURR EYE RES, V1, P275, DOI 10.3109/02713688108999447; WORGUL BV, 1976, ARCH OPHTHALMOL-CHIC, V94, P996, DOI 10.1001/archopht.1976.03910030506013; YU CCK, 1990, DEVELOPMENT, V110, P131; ZHANG WZ, 1994, EXP EYE RES, V59, P91, DOI 10.1006/exer.1994.1084; Zigler J. S., 1994, PRINCIPLES PRACTICE, P97; ZIGLER JS, 1985, ARCH BIOCHEM BIOPHYS, V241, P163, DOI 10.1016/0003-9861(85)90372-8; ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499; Zigman S., 1985, OCULAR LENS STRUCTUR, P301	89	732	773	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1173	1182		10.1096/fasebj.9.12.7672510	http://dx.doi.org/10.1096/fasebj.9.12.7672510			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672510				2022-12-28	WOS:A1995RU81600007
J	KAMTEKAR, S; HECHT, MH				KAMTEKAR, S; HECHT, MH			PROTEIN MOTIFS .7. THE 4-HELIX BUNDLE - WHAT DETERMINES A FOLD	FASEB JOURNAL			English	Review						ALPHA HELIX; 4-HELIX BUNDLE; PROTEIN FOLDING DE NOVO PROTEIN DESIGN; PROTEIN STABILITY	ASSEMBLED SYNTHETIC PROTEINS; 4-HELIX BUNDLE; ALPHA-HELIX; DESIGNED PROTEIN; COILED COILS; PRINCIPLES; PEPTIDE; DIPOLE; STABILIZATION; RESOLUTION	The four-helix bundle motif occurs in many structural contexts and in proteins that are functionally diverse. The motif can be classified into individual folds on the basis of topological and geometric properties. It has been thoroughly investigated structurally by both nuclear magnetic resonance and x-ray crystallography. Many mutants of four-helix bundles have been generated, and the motif has also been the target of de novo design studies. Taken together, these studies provide an opportunity to examine many of the forces governing protein folding. In this article we consider the relative importance of the burial of hydrophobic residues, loss of conformational entropy, packing interactions, interhelical turn composition, and helical dipole interactions all within the context of a single folding motif. We conclude by examining why de novo designed four-helix bundle proteins possess flexible interiors, and possible mechanisms by which natural proteins may lock their cores into rigid structures.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University; Princeton University				Hecht, Michael/0000-0002-5538-9813				AKERFELDT KS, 1992, J AM CHEM SOC, V114, P9656, DOI 10.1021/ja00050a054; ARGOS P, 1977, BIOCHEM BIOPH RES CO, V75, P83, DOI 10.1016/0006-291X(77)91292-X; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; CHOMA CT, 1994, J AM CHEM SOC, V116, P856, DOI 10.1021/ja00082a005; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CHOU KC, 1992, BIOPHYS J, V63, P682, DOI 10.1016/S0006-3495(92)81653-3; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Creighton T. E., 1993, PROTEINS STRUCTURES; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; FENG Y, 1994, STRUCT BIOL, V1, P30; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1524, DOI 10.1073/pnas.86.5.1524; GROVE A, 1993, J AM CHEM SOC, V115, P5919, DOI 10.1021/ja00067a004; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL TM, 1993, J AM CHEM SOC, V115, P4457, DOI 10.1021/ja00064a006; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KAISER ET, 1987, TRENDS BIOCHEM SCI, V12, P305, DOI 10.1016/0968-0004(87)90147-2; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REDFIELD C, 1992, BIOCHEMISTRY-US, V31, P10431, DOI 10.1021/bi00158a003; REDFIELD C, 1994, STRUCT BIOL, V1, P23; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; ROBINSON CR, 1993, PROTEIN SCI, V2, P826, DOI 10.1002/pro.5560020512; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SANDER C, 1994, TRENDS BIOTECHNOL, V12, P163, DOI 10.1016/0167-7799(94)90077-9; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SCHAFMEISTER CE, 1993, SCIENCE, V262, P734, DOI 10.1126/science.8235592; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SMITH LJ, 1994, NAT STRUCT BIOL, V1, P301, DOI 10.1038/nsb0594-301; VLASSI M, 1994, STRUCT BIOL, V1, P706; Wada A, 1976, Adv Biophys, P1; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; ZINK T, 1994, BIOCHEMISTRY-US, V33, P8453, DOI 10.1021/bi00194a009	64	105	106	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1013	1022		10.1096/fasebj.9.11.7649401	http://dx.doi.org/10.1096/fasebj.9.11.7649401			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649401				2022-12-28	WOS:A1995RP99600005
J	POU, S; BHAN, A; BHADTI, VS; WU, SY; HOSMANE, RS; ROSEN, GM				POU, S; BHAN, A; BHADTI, VS; WU, SY; HOSMANE, RS; ROSEN, GM			THE USE OF FLUOROPHORE-CONTAINING SPIN TRAPS AS POTENTIAL PROBES TO LOCALIZE FREE-RADICALS IN CELLS WITH FLUORESCENCE IMAGING METHODS	FASEB JOURNAL			English	Article						HYDROXYL RADICAL; SPIN TRAPS	BIOLOGICAL-SYSTEMS; TRAPPING EVIDENCE; SUPEROXIDE; HYDROXYL	Central to the study of free radical processes is the ability to identify and localize their cellular site of formation. Under the best of experimental conditions, spin trapping/ESR spectroscopy can only characterize intracellular production of specific free radicals and confocal microscopy can only localize the site of their formation. In this article, we report on the development of a fluorophore-containing nitrone, alpha-[4-[5-((2-carboxy)phenyl)-5-hydroxy-4-oxo-3-phenyl)-2-pyrrolin-1-yl]phenyl]-N-(tert-butyl)nitrone sodium salt (4).(3) This nitrone (4) reacts with alpha-hydroxyethyl radical with a second order rate constant of 1.7 x 10(5) M(-1) s(-1) to give a characteristic ESR spectrum. However, we were unable to decrease the fluorescence emission, due in part to the small concentration of nitroxide generated from the reaction of alpha-hydroxyethyl radical with nitrone (4). Using the fluorophore-containing nitroxide (7) as a model, we found that only 12% of the nitroxide needs to be reduced to give an almost 400% increase in the fluorescent emission of (7). Our findings suggest new approaches to the development of various fluorophore-containing nitrones that can both characterize specific free radicals and localize their site of intracellular formation.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM,CHEM DYNAM LAB,BALTIMORE,MD 21228; VET AFFAIRS MED CTR,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-33550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1989, J APPL PHYSIOL, V66, P102, DOI 10.1152/jappl.1989.66.1.102; BLOUGH NV, 1987, J AM CHEM SOC, V110, P1915; BRITIGAN BE, 1990, J BIOL CHEM, V265, P2650; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FINKELSTEIN E, 1985, ADV FREE RADICAL BIO, V1, P345; FOSKETT JK, 1990, NONINVASIVE TECHNIQU; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GERLOCK JL, 1990, FREE RADICAL RES COM, V10, P119, DOI 10.3109/10715769009145941; GREEN SA, 1990, J AM CHEM SOC, V112, P7337, DOI 10.1021/ja00176a038; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; JANZEN EG, 1980, FREE RAD BIOL, P116; KIEBER DJ, 1990, FREE RADICAL RES COM, V10, P109, DOI 10.3109/10715769009145940; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; MARRIOTT PR, 1980, CAN J CHEM, V58, P803, DOI 10.1139/v80-125; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; POU S, 1994, ANAL BIOCHEM, V217, P76, DOI 10.1006/abio.1994.1085; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; POYER JL, 1971, J BIOL CHEM, V246, P263; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; SAMUNI A, 1989, FREE RADICAL BIO MED, V6, P141, DOI 10.1016/0891-5849(89)90111-1; TAYLOR DL, 1989, METHODS CELL BIOL, V30	23	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1085	1090		10.1096/fasebj.9.11.7649408	http://dx.doi.org/10.1096/fasebj.9.11.7649408			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649408				2022-12-28	WOS:A1995RP99600013
J	PRATO, FS; CARSON, JJL; OSSENKOPP, KP; KAVALIERS, M				PRATO, FS; CARSON, JJL; OSSENKOPP, KP; KAVALIERS, M			POSSIBLE MECHANISMS BY WHICH EXTREMELY-LOW-FREQUENCY MAGNETIC-FIELDS AFFECT OPIOID FUNCTION	FASEB JOURNAL			English	Article						SNAIL; ELECTRIC FIELDS; OPIOID PEPTIDES; MAGNETIC FIELD DETECTION MECHANISMS	MORPHINE-INDUCED ANALGESIA; CEPAEA-NEMORALIS; ENKEPHALINASE INHIBITOR; ELECTROMAGNETIC-FIELDS; LAND SNAIL; EXPOSURE; MICE; ORIENTATION; INVOLVEMENT; SYSTEMS	Although extremely low frequency (ELF, <300 Hz) magnetic fields exert a variety of biological effects, the magnetic field sensing/transduction mechanism (or mechanisms) remain to be identified. Using the well-defined inhibitory effects that magnetic fields have on opioid peptide mediated antinociception or ''analgesial' in the land snail Cepaea nemoralis, we show that these actions only occur for certain frequency and amplitude combinations of time-varying sinusoidal magnetic fields in a manner consistent with a direct influence of these fields. We exposed snails with augmented opioid activity to ELF magnetic fields, which were varied in both amplitude and frequency, along with a parallel static magnetic field, When the peak amplitude (0-547 mu T) of a magnetic field of 60 Hz was varied systematically, we observed a nonlinear response, i.e., a nonlinear reduction in analgesia as measured by the latency of a defined response by the snails to a thermal stimulus. When frequency (10-240 Hz) was varied, keeping the amplitude constant (141 mu T), we saw significant inhibitory effects between 30 and 35 Hz, 60 and 90 Hz and at 120 and 240 Hz. Finally, when the static field was varied but the amplitude and frequency of the time-varying field were held constant, we observed significant inhibition at almost all amplitudes. This amplitude/frequency ''resonance-like'' dependence of the magnetic field effects suggests that the mechanism (or mechanisms) of response to weak ELF fields likely involves a direct magnetic field detection mechanism rather than an induced current phenomenon. We examined the implications of our findings for several models proposed for the direct sensing of ELF magnetic fields.	UNIV WESTERN ONTARIO, DEPT MED BIOPHYS, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT PSYCHOL, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, FAC DENT, DIV ORAL BIOL, LONDON, ON N6A 5C1, CANADA; LAWSON RES INST, LONDON, ON N6A 4L6, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	PRATO, FS (corresponding author), ST JOSEPHS HLTH CTR, DEPT NUCL MED & MAGNET RESONANCE, 268 GROSVENOR ST, LONDON, ON N6A 4V2, CANADA.		Carson, Jeffrey JL/C-7785-2014; Ossenkopp, Klaus-Peter/A-4810-2008; Prato, Frank S/C-9117-2014	Carson, Jeffrey JL/0000-0003-0683-6004; Ossenkopp, Klaus-Peter/0000-0001-7391-3239; Prato, Frank/0000-0002-4592-2522				ADAIR RK, 1994, P NATL ACAD SCI USA, V91, P2925, DOI 10.1073/pnas.91.8.2925; ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; BATES MN, 1991, ENVIRON HEALTH PERSP, V95, P147, DOI 10.2307/3431121; BETANCUR C, 1994, NEUROSCI LETT, V182, P147, DOI 10.1016/0304-3940(94)90784-6; Bevington P. R, 1969, DATA REDUCTION ERROR; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; CARSON JJL, 1990, AM J PHYSIOL, V259, pC687, DOI 10.1152/ajpcell.1990.259.4.C687; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V245, P829; CHIPKIN RE, 1991, PHARMACOL BIOCHEM BE, V38, P21, DOI 10.1016/0091-3057(91)90584-O; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FREY AH, 1993, FASEB J, V7, P272, DOI 10.1096/fasebj.7.2.8440406; FREY AH, 1994, NATURE ELECTROMAGNET, P9; GRUNDLER W, 1992, NATURWISSENSCHAFTEN, V79, P551, DOI 10.1007/BF01131411; HAMILTON CA, 1988, MOL PHYS, V65, P423, DOI 10.1080/00268978800101141; HARKINS TT, 1994, SCIENCE, V263, P958, DOI 10.1126/science.8310292; Herz A., 1993, OPIOIDS; Herz A., 1993, OPIOIDS; KAVALIERS M, 1991, BIOL BULL, V180, P301, DOI 10.2307/1542401; KAVALIERS M, 1988, J COMP PHYSIOL A, V162, P551, DOI 10.1007/BF00612520; KAVALIERS M, 1987, N-S ARCH PHARMACOL, V336, P308; KAVALIERS M, 1986, BRAIN RES, V379, P30, DOI 10.1016/0006-8993(86)90252-0; KAVALIERS M, 1983, SCIENCE, V220, P99, DOI 10.1126/science.6298941; KAVALIERS M, 1984, PHYSIOL BEHAV, V32, P261, DOI 10.1016/0031-9384(84)90139-2; KAVALIERS M, 1993, J COMP PHYSIOL A, V173, P241; KAVALIERS M, 1986, PSYCHOPHARMACOLOGY, V89, P440, DOI 10.1007/BF02412118; KAVALIERS M, 1990, BRAIN RES, V517, P276, DOI 10.1016/0006-8993(90)91038-I; KAVALIERS M, 1991, BRAIN RES, V554, P65, DOI 10.1016/0006-8993(91)90172-R; KAVALIERS M, 1994, NATURE ELECTROMAGNET, P181; KIRSCHVINK JL, 1992, P NATL ACAD SCI USA, V89, P7683, DOI 10.1073/pnas.89.16.7683; KORALL H, 1988, J COMP PHYSIOL A, V162, P279, DOI 10.1007/BF00606116; LEASK MJM, 1977, NATURE, V267, P144, DOI 10.1038/267144a0; LEDNEV VV, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P550; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LEDNEV VV, 1994, NATURE ELECTROMAGNET, P59; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; OSSENKOPP KP, 1978, NEUROSCI BIOBEHAV R, V2, P255, DOI 10.1016/0149-7634(78)90034-9; OSSENKOPP KP, 1987, BRAIN RES, V418, P356, DOI 10.1016/0006-8993(87)90103-X; PHILLIPS JB, 1993, J COMP PHYSIOL A, V172, P303, DOI 10.1007/BF00216612; PHILLIPS JB, 1992, NATURE, V359, P142, DOI 10.1038/359142a0; POLK C, 1994, BIOELECTROMAGNETICS, V15, P261, DOI 10.1002/bem.2250150308; POLK C, 1992, BIOELECTROMAGNETICS, P209, DOI 10.1002/bem.2250130720; PRATO F S, 1987, Magnetic Resonance Imaging, V5, P9, DOI 10.1016/0730-725X(87)90478-4; PRATO FS, 1992, ANN NY ACAD SCI, V649, P44, DOI 10.1111/j.1749-6632.1992.tb49595.x; REITER RJ, 1992, FASEB J, V6, P2283, DOI 10.1096/fasebj.6.6.1544540; SAKHAROV D, 1993, BRAIN RES, V620, P114, DOI 10.1016/0006-8993(93)90276-S; SAKSIDA LM, 1993, PEPTIDES, V14, P763, DOI 10.1016/0196-9781(93)90110-3; SCAIANO JC, 1994, PHOTOCHEM PHOTOBIOL, V59, P585; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; STEINER UE, 1989, CHEM REV, V89, P51, DOI 10.1021/cr00091a003; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550, DOI 10.1093/oxfordjournals.aje.a117046; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WILTSCHKO W, 1993, NATURE, V364, P525, DOI 10.1038/364525a0	53	87	90	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1995	9	9					807	814		10.1096/fasebj.9.9.7601344	http://dx.doi.org/10.1096/fasebj.9.9.7601344			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601344				2022-12-28	WOS:A1995RH98200014
J	SIMONEAU, JA; COLBERG, SR; THAETE, FL; KELLEY, DE				SIMONEAU, JA; COLBERG, SR; THAETE, FL; KELLEY, DE			SKELETAL-MUSCLE GLYCOLYTIC AND OXIDATIVE ENZYME CAPACITIES ARE DETERMINANTS OF INSULIN SENSITIVITY AND MUSCLE COMPOSITION IN OBESE WOMEN	FASEB JOURNAL			English	Article						COMPUTED TOMOGRAPHY; LIMB BALANCE METHODS; MUSCLE METABOLISM	COMPUTED-TOMOGRAPHY; FAT; RESISTANCE; WEIGHT; FIBERS; MEN	Regional fat distribution is an important determinant of insulin resistance in obesity. In the current study, the relationship between skeletal muscle insulin sensitivity, mid-thigh muscle composition, and the metabolic profile of muscle was investigated. Muscle composition was assessed by computed tomography of the mid-thigh, and by activities of marker enzymes of aerobic-oxidative and glycolytic pathways and muscle fiber typing using biopsies of the vastus lateralis muscle. Muscle with reduced Hounsfield attenuation on computed tomography scans was increased in proportion to obesity, and was strongly related to insulin resistance, reduced muscle oxidative capacity, and increased anaerobic and glycolytic capacities by muscle. These findings suggest that as part of its expression of insulin resistance, skeletal muscle of obese individuals is also poorly equipped for substrate oxidation and manifests increased storage of fat.	UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15261 USA; VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, DEPT RADIOL, PITTSBURGH, PA 15261 USA; UNIV LAVAL, PHYS ACT SCI LAB, Ste Foy, PQ, CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University			Colberg, Sheri R/A-9793-2017	Colberg, Sheri R/0000-0001-7574-2533	NCRR NIH HHS [5MO1RR00056] Funding Source: Medline; NIDDK NIH HHS [1P30DK46204] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046204] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; BULCKE D, 1987, J AM DIET ASSOC, V87, P196; BULCKE JA, 1981, MUSCLE NERVE, V4, P67, DOI 10.1002/mus.880040112; COLBERG SR, 1995, IN PRESS J CLIN INVE; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DESPRES JP, 1993, NUTRITION, V9, P452; DOUGLAS AR, 1988, J APPL PHYSIOL, V65, P473; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FERRARO RT, 1993, J CLIN INVEST, V92, P441, DOI 10.1172/JCI116586; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; HOPPELER H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P567; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; KELLEY DE, 1991, AM J CLIN NUTR, V54, P509, DOI 10.1093/ajcn/54.3.509; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; LINDGARDE F, 1982, ACTA MED SCAND, V212, P99; LOWRY CV, 1978, J BIOL CHEM, V253, P8269; Newsholme E.A., 1983, BIOCH MED SCI; OLEFSKY JM, 1976, J CLIN INVEST, V57, P1165, DOI 10.1172/JCI108384; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; REICHMANN H, 1982, HISTOCHEMISTRY, V74, P27, DOI 10.1007/BF00495049; SIMONEAU JA, 1985, CAN J PHYSIOL PHARM, V63, P30, DOI 10.1139/y85-005; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	25	282	285	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					273	278		10.1096/fasebj.9.2.7781930	http://dx.doi.org/10.1096/fasebj.9.2.7781930			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781930				2022-12-28	WOS:A1995QJ24900017
J	RAAG, R; WHITLOW, M				RAAG, R; WHITLOW, M			SINGLE-CHAIN FVS	FASEB JOURNAL			English	Review						MULTIVALENT FV; CRYSTAL; NMR; STRUCTURE; AGGREGATION	MONOCLONAL-ANTIBODY CC49; ESCHERICHIA-COLI; RECOMBINANT IMMUNOTOXIN; IMMUNOGLOBULIN FORMS; BINDING-AFFINITY; FUSION PROTEINS; FRAGMENTS; STABILITY; LINKER; SITES	Single-chain Fvs (sFvs) are recombinant antibody fragments consisting of only the variable light chain (V-L) and variable heavy chain (V-H) domains covalently connected to one another by a polypeptide linker. Due to their small size, sFvs have rapid pharmacokinetics and tumor penetration in vivo. Single-chain Fvs also show a concentration-dependent tendency to oligomerize. Bivalent sFvs are formed when the variable domains of a sFv disassociate from one another and reassociate with the variable domains of a second sFv. Similar rearrangement and reassociation of variable domains from different sFvs can result in the formation of trimers or higher multimeric oligomers. Each Fv in a bivalent or multivalent Fv is composed of the V-L domain from one sFv and the V-H domain from a second sFv. Modifying linker length or the inclusion of antigen may stabilize the V-L/V-H interface against rearrangement such that specific multimeric or monomeric forms of sFvs may be isolated. Nuclear magnetic resonance studies have shown that McPC603-derived Fv and sFvs have similar structures, and that the sFv linker is a rapidly moving, highly flexible peptide with a random coil-like structure. In X-ray crystallographic investigations of three different sFvs, linkers have also been found to be disordered. Indirect evidence suggests that a monomeric sFv has been crystallized in one case, and dimeric sFvs in the other two.	BERLEX BIOSCI INC, PROT BIOPHYS, RICHMOND, CA 94804 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley								BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; COLMAN PM, 1989, PHILOS T R SOC B, V323, P511, DOI 10.1098/rstb.1989.0028; CUMBER AJ, 1992, J IMMUNOL, V149, P120; DESPLANCQ D, 1994, PROTEIN ENG, V7, P1027, DOI 10.1093/protein/7.8.1027; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; ESSIG NZ, 1993, J MOL BIOL, V234, P897, DOI 10.1006/jmbi.1993.1638; FISCHER PH, 1994, ADV ENZYME REGUL, V34, P119, DOI 10.1016/0065-2571(94)90012-4; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; FREUND C, 1994, BIOCHEMISTRY-US, V33, P3296, DOI 10.1021/bi00177a021; FRIEDMAN PN, 1993, J IMMUNOL, V150, P3054; GIBBS RA, 1991, P NATL ACAD SCI USA, V88, P4001, DOI 10.1073/pnas.88.9.4001; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HANISCH FG, 1989, BIOL CHEM H-S, V370, P21, DOI 10.1515/bchm3.1989.370.1.21; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; LILLEY GG, 1994, J IMMUNOL METHODS, V171, P211, DOI 10.1016/0022-1759(94)90041-8; MALBY RL, 1993, PROTEINS, V16, P57, DOI 10.1002/prot.340160107; MALLENDER WD, 1994, J BIOL CHEM, V269, P199; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILENIC DE, 1991, CANCER RES, V51, P6363; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHOTT ME, 1992, CANCER RES, V52, P6413; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; WADE WS, 1993, J AM CHEM SOC, V115, P4449, DOI 10.1021/ja00064a005; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; WYLIE DE, 1992, P NATL ACAD SCI USA, V89, P4104, DOI 10.1073/pnas.89.9.4104; YOKOTA T, 1993, CANCER RES, V53, P3776; YOKOTA T, 1992, CANCER RES, V52, P3402; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	47	125	208	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					73	80		10.1096/fasebj.9.1.7821762	http://dx.doi.org/10.1096/fasebj.9.1.7821762			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821762				2022-12-28	WOS:A1995QD20200012
J	BALSARI, AL; MORELLI, D; MENARD, S; VERONESI, U; COLNAGHI, MI				BALSARI, AL; MORELLI, D; MENARD, S; VERONESI, U; COLNAGHI, MI			PROTECTION AGAINST DOXORUBICIN-INDUCED ALOPECIA IN RATS BY LIPOSOME-ENTRAPPED MONOCLONAL-ANTIBODIES	FASEB JOURNAL			English	Article						DOXORUBICIN; ALOPECIA; MONOCLONAL ANTIBODIES; LIPOSOMES	CHEMOTHERAPY-INDUCED ALOPECIA; INTERLEUKIN-1 PROTECTS; INVIVO; DRUG; MODEL; CELLS; GENE	Alopecia is a common side effect of several anti-cancer drugs, including doxorubicin. Based on our recent observation that a monoclonal antibody (MADl1) directed against this anthracycline inhibits the systemic toxic effect of the drug in mice, we investigated the possibility that MAD11 administered topically might protect against doxorubicin-induced alopecia. In 31 of 45 young rats treated intraperitoneally with doxorubicin, alopecia was completely prevented by topical treatment of the skin with liposome-incorporated anti-doxorubicin monoclonal antibody. This type of treatment might find relevance in preventing anthracycline-induced alopecia in cancer patients. Our findings also provide the first demonstration that liposome-entrapped monoclonal antibodies are capable of penetrating the stratum corneum of the skin without losing their function.	IST NAZL TUMORI,DIV EXPTL ONCOL E,I-20133 MILAN,ITALY; UNIV MILAN,FAC MED,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan			Morelli, Daniele/I-4113-2017; balsari, andrea/M-5657-2016	Morelli, Daniele/0000-0002-1823-3764; balsari, andrea/0000-0002-3250-2668				ALINO SF, 1992, LAB INVEST, V66, P671; BALSARI A, 1988, INT J CANCER, V42, P798, DOI 10.1002/ijc.2910420528; BALSARI A, 1991, INT J CANCER, V47, P889, DOI 10.1002/ijc.2910470617; Baxley K O, 1984, Cancer Nurs, V7, P499; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; CHEN HSG, 1979, CANCER CHEMOTH PHARM, V2, P85; Cline B W, 1984, Cancer Nurs, V7, P221; CROUNSE RG, 1960, J INVEST DERMATOL, V35, P83, DOI 10.1038/jid.1960.88; HUNTER MM, 1982, J IMMUNOL, V129, P1165; HUSSEIN AM, 1990, SCIENCE, V249, P1564, DOI 10.1126/science.2218498; JIMENEZ JJ, 1992, CANCER RES, V52, P5123; JIMENEZ JJ, 1992, CANCER INVEST, V10, P271, DOI 10.3109/07357909209032751; JIMENEZ JJ, 1991, FASEB J, V5, P2456, DOI 10.1096/fasebj.5.10.2065892; JIMENEZ JJ, 1992, FASEB J, V6, P911, DOI 10.1096/fasebj.6.3.1740239; KORTING HC, 1991, J AM ACAD DERMATOL, V25, P1068, DOI 10.1016/0190-9622(91)70309-P; OBRIEN R, 1970, NEW ENGL J MED, V283, P1469; SCHAFERKORTING M, 1989, J AM ACAD DERMATOL, V21, P1271, DOI 10.1016/S0190-9622(89)70342-X; SEIPP CA, 1983, ONCOLOGY NURSING FOR, V10, P12; SORIANO P, 1983, P NATL ACAD SCI-BIOL, V80, P7128, DOI 10.1073/pnas.80.23.7128; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WITMAN G, 1981, CANCER TREAT REP, V65, P507	22	50	52	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					226	230		10.1096/fasebj.8.2.8119493	http://dx.doi.org/10.1096/fasebj.8.2.8119493			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119493				2022-12-28	WOS:A1994MY29900029
J	BEINERT, H; KENNEDY, MC				BEINERT, H; KENNEDY, MC			ACONITASE, A 2-FACED PROTEIN - ENZYME AND IRON REGULATORY FACTOR	FASEB JOURNAL			English	Article						IRON-SULFUR PROTEIN; IRON-SULFUR CLUSTER LABILITY; IRON-SULFUR CLUSTER INTERCONVERSIONS; APO-ACONITASE	ELEMENT BINDING-PROTEIN; BEEF-HEART ACONITASE; ELECTRON-PARAMAGNETIC-RES; GIGAS FERREDOXIN-II; SULFUR CLUSTER; RNA-BINDING; DESULFOVIBRIO-GIGAS; ACTIVE-SITE; AZOTOBACTER-VINELANDII; <4FE-4S>+ CLUSTER	In this brief survey, the path of development of our knowledge of the iron-sulfur enzyme aconitase [citrate(isocitrate)hydrolyase EC4.2.1.3.] is traced from its discovery in 1937. Particular emphasis is on developments in the past decade, when EPR, Mossbauer and electron nuclear double resonance spectroscopies, X-ray crystallography, and mutational analysis were applied to the problem. More recently discovered was the significant amino acid sequence identity between mitochondrial aconitase and the iron regulatory factor or iron-responsive element binding protein (IRE-BP). This has led to the realization that IRE-BP is an alternative form of cytosolic (not of mitochondrial) aconitase that is devoid of its cubane Fe-S cluster.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	Medical College of Wisconsin	BEINERT, H (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226, USA.							ANTONIO MR, 1982, J BIOL CHEM, V257, P6646; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; DICKMAN SR, 1951, J BIOL CHEM, V188, P379; EANES RZ, 1974, MOL PHARMACOL, V10, P130; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; ENGLARD S, 1960, J BIOL CHEM, V235, P1510; GAHAN LR, 1985, J AM CHEM SOC, V107, P6231, DOI 10.1021/ja00308a015; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GAWRON O, 1961, J AM CHEM SOC, V83, P3634, DOI 10.1021/ja01478a021; GLUSKER JP, 1968, J MOL BIOL, V38, P149, DOI 10.1016/0022-2836(68)90403-8; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; KENNEDY C, 1972, BIOCHEM BIOPH RES CO, V47, P740; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1993, J INORG BIOCHEM, V51, P442; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KENT TA, 1982, ELECTRON TRANSPORT O, P371; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; Martius C, 1937, Z PHYSL CHEM, V247, P104; MARTIUS C, 1939, Z PHYSL CHEM, V257, P29; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; OGSTON AG, 1948, NATURE, V162, P963, DOI 10.1038/162963b0; PLANK DW, 1988, J BIOL CHEM, V263, P8184; ROBBINS AH, 1985, J BIOL CHEM, V260, P2328; ROSE IA, 1967, J BIOL CHEM, V242, P1870; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; RUZICKA FJ, 1978, J BIOL CHEM, V253, P2514; RUZICKA FJ, 1974, BIOCHEM BIOPH RES CO, V58, P556, DOI 10.1016/S0006-291X(74)80456-0; RYDEN L, 1984, J BIOL CHEM, V259, P3141; SPEYER JF, 1956, J BIOL CHEM, V220, P193; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1980, J BIOL CHEM, V255, P1797; STOUT CD, 1979, NATURE, V279, P83, DOI 10.1038/279083a0; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; VILLAFRANCA JJ, 1971, J BIOL CHEM, V246, P772; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016; WONG JY, 1977, J BIOL CHEM, V252, P7424; ZHENG L, 1992, J BIOL CHEM, V267, P7895; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	49	212	219	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1442	1449		10.1096/fasebj.7.15.8262329	http://dx.doi.org/10.1096/fasebj.7.15.8262329			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262329				2022-12-28	WOS:A1993ML74000006
J	LEVINE, RL				LEVINE, RL			ISCHEMIA - FROM ACIDOSIS TO OXIDATION	FASEB JOURNAL			English	Review						SHOCK; ACIDOSIS; ISCHEMIA; REPERFUSION INJURY; METAL-CATALYZED OXIDATION; IRON; RETINOPATHY OF PREMATURITY	METAL-CATALYZED OXIDATION; GLUTAMINE-SYNTHETASE; FREE-RADICALS; CARDIAC RESUSCITATION; REPERFUSION; INJURY; OXYGEN; PROTEINS; CONSEQUENCES; BICARBONATE	Organ damage can occur quickly when blood flow is compromised. Lactic acidosis has long been associated with such ischemia, and many physicians assume that organ damage is caused by this acidosis. However, reviewing the literature related to hypoxia and ischemia reveals little data to support the concept of acidosis as damaging to tissue. In contrast, recent studies indicate that the acidosis is actually protective, even during reperfusion when cellular damage may occur. Reperfusion is accompanied by generation of free radicals and other reactive species that can damage proteins, membranes, and nucleic acids, supporting an emerging view that implicates these reactive species in the actual tissue damage. The critical targets of the damaging species are not known, but reaction with key enzymes and structural proteins could certainly disrupt organ function. Cellular proteins are oxidatively modified during reperfusion, in part by metal-catalyzed oxidation in which cellular iron plays a key role. Metal-catalyzed oxidation of proteins may be important in the pathogenesis of other disorders, including the potentially blinding disease, retinopathy of the premature.			LEVINE, RL (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,ROOM 106,BETHESDA,MD 20892, USA.		Levine, Rodney L/D-9885-2011					ALVAREZ JC, 1992, BIOCHEMISTRY-US, V31, P8315, DOI 10.1021/bi00150a027; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; AUST SD, 1985, ADV FREE RADICAL BIO, V1, P1; Bloom, 1987, TXB NEONATAL RESUSCI; BOND JM, 1991, BIOCHEM BIOPH RES CO, V179, P798, DOI 10.1016/0006-291X(91)91887-I; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; Das D.K., 1992, PATHOPHYSIOLOGY REPE; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FERGUSON WW, 1972, AM J PHYSIOL, V222, P450, DOI 10.1152/ajplegacy.1972.222.2.450; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLYNN JT, 1992, NEW ENGL J MED, V326, P1050, DOI 10.1056/NEJM199204163261603; FOLBERGROVA J, 1993, J CEREBR BLOOD F MET, V13, P145, DOI 10.1038/jcbfm.1993.17; GRAF H, 1985, SCIENCE, V227, P754, DOI 10.1126/science.3969564; GUERCI AD, 1986, CIRCULATION, V74, P75; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; KETTE F, 1991, JAMA-J AM MED ASSOC, V266, P2121, DOI 10.1001/jama.266.15.2121; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001; KINSEY VE, 1949, JAMA-J AM MED ASSOC, V139, P572, DOI 10.1001/jama.1949.02900260018005; KITAKAZE M, 1988, J CLIN INVEST, V82, P920, DOI 10.1172/JCI113699; LANGLEY SC, 1993, PEDIATR RES, V33, P247, DOI 10.1203/00006450-199303000-00008; Levine R, 1944, AM J PHYSIOL, V141, P0209; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LUCEY JF, 1984, PEDIATRICS, V73, P82; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENTHAL RE, 1992, FREE RADICAL BIO MED, V12, P29, DOI 10.1016/0891-5849(92)90055-L; Silverman W. A., 1980, RETROLENTAL FIBROPLA; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; USHER R, 1963, PEDIATRICS, V32, P966; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353	36	66	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1242	1246		10.1096/fasebj.7.13.8405809	http://dx.doi.org/10.1096/fasebj.7.13.8405809			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405809				2022-12-28	WOS:A1993MB37600007
J	ROSENBLOOM, J; ABRAMS, WR; MECHAM, R				ROSENBLOOM, J; ABRAMS, WR; MECHAM, R			EXTRACELLULAR-MATRIX .4. THE ELASTIC FIBER	FASEB JOURNAL			English	Review						ELASTIN; TROPOELASTIN; CROSS-LINKING; FIBRILLIN; MICROFIBRIL-ASSOCIATED PROTEINS	MICROFIBRIL-ASSOCIATED GLYCOPROTEIN; COMPLEMENTARY-DNA CLONING; DEVELOPING CHICK AORTA; GROWTH-FACTOR-BETA; MARFAN-SYNDROME; MESSENGER-RNA; GENE-EXPRESSION; BINDING-PROTEIN; POSTTRANSCRIPTIONAL MECHANISM; TROPOELASTIN EXPRESSION	The clastic properties of many tissues such as the lung, dermis, and large blood vessels are due to the presence of elastic fibers in the extracellular space. These fibers have been shown by biochemical and ultrastructural analysis to be composed of two distinct components, a more abundant amorphous component and a 10-12 nm microfibrillar component, which is located primarily around the periphery of the amorphous component. The protein elastin makes up the highly insoluble amorphous component and is responsible for the elastic properties. Elastin is found throughout the vertebrate kingdom and possesses an unusual chemical composition rich in glycine, proline, and hydrophobic amino acids, consonant with its characteristic physical properties. The 72-kDa biosynthetic precursor, tropoelastin, is secreted into the extracellular space where it becomes highly cross-linked into a rubber-like network through the activity of the copper-requiring enzyme lysyl oxidase. Analysis of the elastin gene has demonstrated that hydrophobic and cross-linking domains are encoded in separate exons and that there is significant alternative splicing, resulting in multiple isoforms of tropoelastin. The elastin gene promoter contains many potential binding sites for various modulating factors indicative of a complex pattern of transcriptional regulation. The microfibrils contain several proteins, including fibrillin, and probably act as an organizing scaffold in the formation of the elastin network. There appears to be a fibrillin gene family in which each protein contains multiple repeats of a motif previously found in epidermal growth factor and a second motif observed in transforming growth factor beta1-binding protein. Mutations in the fibrillin gene located on human chromosome 15 have been strongly implicated as the cause of the Marfan syndrome.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)	ROSENBLOOM, J (corresponding author), UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104, USA.		Abrams, William R/A-5782-2008; Salto, Rafael/A-6486-2011	Salto, Rafael/0000-0002-7044-3611	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, R01AR041474] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26499] Funding Source: Medline; NIAMS NIH HHS [AR41474, AR20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN SO, 1971, COMPREHENSIVE BIOCH, P633; BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; BRESSAN GM, 1987, BIOCHEMISTRY-US, V26, P1497, DOI 10.1021/bi00380a001; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; BURNETT W, 1982, J BIOL CHEM, V257, P1569; CALABRETTA B, 1982, NATURE, V296, P219, DOI 10.1038/296219a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DAMIANO V, 1984, COLLAGEN REL RES, V4, P153; DAVIDSON JM, 1984, BIOCHEM J, V220, P653, DOI 10.1042/bj2200653; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; EICHNER R, 1979, ARCH BIOCHEM BIOPHYS, V198, P414, DOI 10.1016/0003-9861(79)90515-0; FAHRENBACH WH, 1966, ANAT RECORD, V155, P563, DOI 10.1002/ar.1091550409; FAZIO MJ, 1991, AM J HUM GENET, V48, P696; FLEMING WW, 1980, BIOPOLYMERS, V19, P597, DOI 10.1002/bip.1980.360190311; FOSTER JA, 1976, BIOPOLYMERS, V15, P833, DOI 10.1002/bip.1976.360150503; FOSTER JA, 1973, J BIOL CHEM, V248, P2876; FRANZBLAU C, 1989, J BIOL CHEM, V264, P15116; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GODFREY M, 1990, AM J HUM GENET, V46, P652; GOTTE L, 1967, S FIBROUS PROTEINS, P236; Gray W R, 1977, Adv Exp Med Biol, V79, P285; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HOEVE CAJ, 1974, BIOPOLYMERS, V13, P677, DOI 10.1002/bip.1974.360130404; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; Kagan HM, 1986, REGULATION MATRIX AC, P321; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KARRER HE, 1961, J ULTRASTRUCT RES, V4, P420; KELLY RE, 1967, SCIENCE, V155, P208, DOI 10.1126/science.155.3759.208; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; LANSING AI, 1952, ANAT RECORD, V114, P555, DOI 10.1002/ar.1091140404; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LIU J, 1989, BIOCHEM BIOPH RES CO, V154, P895; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; MECHAM RP, 1985, J BIOL CHEM, V260, P3255; MECHAM RP, 1984, J BIOL CHEM, V259, P2414; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; PEREJDA AJ, 1985, J LAB CLIN MED, V106, P376; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; RAJU K, 1987, J BIOL CHEM, V262, P5755; RICH CB, 1992, AM J PHYSIOL, V263, pL276, DOI 10.1152/ajplung.1992.263.2.L276; RICH CB, 1984, BIOCHEM J, V217, P581, DOI 10.1042/bj2170581; ROSENBLOOM J, 1986, COLLAGEN REL RES, V6, P423; ROSENBLOOM J, 1976, BIOCHEM BIOPH RES CO, V69, P6143; ROSS R, 1969, J CELL BIOL, V40, P366, DOI 10.1083/jcb.40.2.366; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANDBERG LB, 1969, BIOCHEMISTRY-US, V8, P2940, DOI 10.1021/bi00835a037; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SERAFINIFRACASS.A, 1984, ULTRASTRUCTURE CONNE, P140; SERAFINIFRACASSINI A, 1981, BIOCHEMISTRY-US, V20, P5424, DOI 10.1021/bi00522a011; SHADWICK RE, 1981, SCIENCE, V213, P759, DOI 10.1126/science.7256277; STARCHER BC, 1976, ANAL BIOCHEM, V74, P441, DOI 10.1016/0003-2697(76)90224-4; SYKES B, 1993, NAT GENET, V3, P99, DOI 10.1038/ng0293-99; UITTO J, 1976, ARCH BIOCHEM BIOPHYS, V173, P187, DOI 10.1016/0003-9861(76)90249-6; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; WRENN DS, 1987, J BIOL CHEM, V262, P2244; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; YOON K, 1984, BIOCHEM BIOPH RES CO, V118, P261, DOI 10.1016/0006-291X(84)91095-7	79	475	493	2	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1208	1218		10.1096/fasebj.7.13.8405806	http://dx.doi.org/10.1096/fasebj.7.13.8405806			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405806				2022-12-28	WOS:A1993MB37600003
J	IYENGAR, R				IYENGAR, R			MOLECULAR AND FUNCTIONAL DIVERSITY OF MAMMALIAN G(S)-STIMULATED ADENYLYL CYCLASES	FASEB JOURNAL			English	Review						CELLULAR SIGNALING; CROSS TALK; EFFECTORS	BETA-GAMMA-SUBUNITS; G-PROTEINS; HETEROLOGOUS DESENSITIZATION; BRAIN; PURIFICATION; EXPRESSION; INHIBITION; FORSKOLIN; SEQUENCE; ENZYMES	Receptor-regulated adenylyl cyclase in mammalian systems is among the best-studied of the cell surface signaling pathways that utilize G-proteins as transducers. In addition to the multiplicity of receptors and G(s) proteins that function in this pathway, recent studies have shown that substantial molecular diversity exists in the effector as well. Full-length cDNAs encoding six different G-protein-regulated adenylyl cyclases have been isolated, and partial sequences identifying two more are known. These eight mammalian adenylyl cyclases can be grouped into five distinct families. The different types share some common properties such as stimulation by G(s) and the diterpene forskolin. They show very distinct patterns of regulation by the betagamma-subunits of G-proteins and protein kinases such as protein kinase C. The different types also appear to be localized in a tissue-specific manner. This diversity of regulatory features indicates that the effector can play an important role in determining the routing of signals to the cAMP pathway. The tissue and cell type-specific localization of the individual forms suggests that effectors such as adenylyl cyclase could be potential targets for a new generation of cell and tissue-specific drugs.			IYENGAR, R (corresponding author), CUNY MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRD IM, 1993, ENDOCRINOLOGY, V132, P932, DOI 10.1210/en.132.2.932; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GORDON LM, 1980, J BIOL CHEM, V255, P4519; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOHNSON JA, 1991, J PHARMACOL EXP THER, V39, P539; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PFEUFFER E, 1991, METHOD ENZYMOL, V195, P83; PFEUFFER T, 1982, FEBS LETT, V146, P369, DOI 10.1016/0014-5793(82)80955-1; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; SEAMON KB, 1987, ISI ATLAS-PHARMACOL, V1, P250; SIMMOTEIT RR, 1991, FEBS LETT, V249, P189; STENGEL D, 1992, HUM GENET, V90, P126; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	48	295	306	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					768	775		10.1096/fasebj.7.9.8330684	http://dx.doi.org/10.1096/fasebj.7.9.8330684			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330684				2022-12-28	WOS:A1993LK43000009
J	SADOWSKI, PD				SADOWSKI, PD			SITE-SPECIFIC GENETIC-RECOMBINATION - HOPS, FLIPS, AND FLOPS	FASEB JOURNAL			English	Review						TRANSPOSONS; SITE-SPECIFIC RECOMBINATION; TARGET SEQUENCE	BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; TN3 RESOLVASE; TARGET SITE; MECHANISM; DNA; PROTEIN; LAMBDA; DOMAIN; REPLICATION	Genetic recombination plays a key role in the life of organisms as diverse as bacteriophages and humans. Contrary to our idea that chromosomes are stable structures, studies of recombination over the past few decades have shown that in fact DNA replicons are remarkably plastic, undergoing frequent recombination-induced rearrangements. This review summarizes our recent knowledge of the biochemistry of the two major classes of site-specific recombination: 1) transpositional recombination, and 2) conservative site-specific recombination.			SADOWSKI, PD (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA.							ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BENJAMIN HW, 1985, CELL, V40, P147, DOI 10.1016/0092-8674(85)90318-6; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BURGIN AB, 1992, P NATL ACAD SCI USA, V89, P9642, DOI 10.1073/pnas.89.20.9642; CAMPBELL AM, 1962, ADV GENET, V11, P101; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CLARK AJ, 1971, ANNU REV MICROBIOL, V25, P437, DOI 10.1146/annurev.mi.25.100171.002253; Cox M. M., 1989, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; FUTCHER AB, 1983, J BACTERIOL, V154, P612, DOI 10.1128/JB.154.2.612-622.1983; GELLERT M, 1992, ANNU REV GENET, V22, P425; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GRIFFITH JD, 1985, P NATL ACAD SCI USA, V82, P3124, DOI 10.1073/pnas.82.10.3124; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; HAGEMANN AT, 1993, GENETICS, V133, P9; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KLECKNER N, 1990, ANNU REV CELL BIOL, V6, P297, DOI 10.1146/annurev.cb.06.110190.001501; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; Morgan TH, 1911, J EXP ZOOL, V11, P365, DOI 10.1002/jez.1400110404; MURRAY JAH, 1988, J MOL BIOL, V200, P601, DOI 10.1016/0022-2836(88)90546-3; NASH HA, 1975, P NATL ACAD SCI USA, V72, P1072, DOI 10.1073/pnas.72.3.1072; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PAN G, 1993, IN PRESS MOL CELL BI; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN H, 1991, J BIOL CHEM, V266, P11347; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SAUER B, 1990, New Biologist, V2, P441; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; STAHL FW, 1979, COLD SPRING HARB SYM, V43, P1353, DOI 10.1101/SQB.1979.043.01.154; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; 1992, TRENDS GENET, V8, P403	54	105	164	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1993	7	9					760	767		10.1096/fasebj.7.9.8392474	http://dx.doi.org/10.1096/fasebj.7.9.8392474			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8392474				2022-12-28	WOS:A1993LK43000008
J	MCCONKEY, DJ; ORRENIUS, S; OKRET, S; JONDAL, M				MCCONKEY, DJ; ORRENIUS, S; OKRET, S; JONDAL, M			CYCLIC-AMP POTENTIATES GLUCOCORTICOID-INDUCED ENDOGENOUS ENDONUCLEASE ACTIVATION IN THYMOCYTES	FASEB JOURNAL			English	Note						APOPTOSIS; PROGRAMMED CELL DEATH; CALCIUM; GLUCOCORTICOID RECEPTOR	DNA FRAGMENTATION; CELL-DEATH; DEPENDENT PHOSPHORYLATION; IMMATURE THYMOCYTES; RECEPTOR; APOPTOSIS; PROTEIN; MODULATION; CLEAVAGE; NUCLEI	The present study was undertaken to determine whether specific interactions between cAMP and glucocorticoids regulate apoptosis in thymocytes. Incubation of murine thymocytes with agents that elevate the cAMP level resulted in enhancement of glucocorticoid-induced Ca2+ increases, DNA fragmentation, and cell death compared to levels observed in thymocytes treated with steroid alone. cAMP did not affect DNA fragmentation in thymocytes treated with Ca2+ ionophore, a compound that induces endonuclease activation via an independent mechanism. Treatment with cAMP also increased glucocorticoid potency by lowering the concentration of steroid required for induction of apoptosis. The mechanism of cAMP action appeared to involve the glucocorticoid receptor, since the glucocorticoid antagonist RU-486 abrogated the cAMP response in animals treated with the adenosine analog NECA in vivo. Analysis of cellular glucocorticoid binding and receptor protein levels revealed modest cAMP-stimulated increases that appeared insufficient to account for the effects of cAMP on endogenous endonuclease activation, suggesting the possible involvement of a posttranslational mechanism in the response. These results demonstrate that cAMP and glucocorticoids synergize to promote apoptosis in thymocytes via a mechanism that appears to involve modification of glucocorticoid receptor activity.	KAROLINSKA INST,DEPT TOXICOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT MED NUTR,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet								BASILE DV, 1975, P NATL ACAD SCI USA, V70, P3055; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COHEN JJ, 1984, J IMMUNOL, V132, P38; DICKEN ES, 1992, MOL CELL BIOL, V12, P589; DONG Y, 1989, J BIOL CHEM, V264, P13679; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; GRANDICS P, 1984, BIOCHEM BIOPH RES CO, V120, P59, DOI 10.1016/0006-291X(84)91413-X; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOMODELARCHE F, 1985, J IMMUNOL, V135, P506; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; ORTI E, 1989, J BIOL CHEM, V264, P9728; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; SHI YF, 1990, J IMMUNOL, V144, P3326; SINGH VB, 1985, J BIOL CHEM, V260, P3684; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	32	57	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					580	585		10.1096/fasebj.7.6.8386120	http://dx.doi.org/10.1096/fasebj.7.6.8386120			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8386120				2022-12-28	WOS:A1993KY00900012
J	WAUGH, DS; PACE, NR				WAUGH, DS; PACE, NR			GAP-SCAN DELETION ANALYSIS OF BACILLUS-SUBTILIS RNASE P-RNA	FASEB JOURNAL			English	Article						RNASE-P; RIBOZYME; TRANSFER RNA PROCESSING; DELETION ANALYSIS	RIBONUCLEASE-P; RIBONUCLEOPROTEIN ENZYME; SECONDARY STRUCTURE; COMPONENT; MUTATIONS; SUBSTRATE; SUBUNIT; PROTEIN; MOIETY; SITE	We carried out an exhaustive deletion analysis of Bacillus subtilis ribonuclease P (RNase P) RNA, seeking sequences that are essential for its catalytic activity. A collection of partially deleted RNase P RNA genes was used to construct templates for synthesis, by in vitro transcription, of circularly permuted RNA molecules that lack various wild-type sequences. The mutant RNAs were assayed for catalytic activity in vitro, using a precursor of B. subtilis tRNA(Asp) as a substrate. Gap-scan deletion analysis revealed that most of the RNase P RNA sequence is important for activity; only two substantive deletions did not dramatically inhibit pre-tRNA processing in vitro. One part of the molecule (nucleotides 225-270) seemed particularly sensitive to deletion, but considering a collection of mutants with overlapping deletion gaps, it was possible to remove every residue in the RNase P RNA without completely abolishing its catalytic activity. Thus, the catalytic mechanism of RNase P does not depend absolutely on a single, particular nucleotide or local sequence for activity.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, INST MOLEC & CELLULAR BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034527, R01GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; GARDINER K, 1980, J BIOL CHEM, V255, P7507; GUERRIERTAKADA C, 1986, CELL, V45, P177, DOI 10.1016/0092-8674(86)90381-8; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HASSUR SM, 1974, ANAL BIOCHEM, V59, P162, DOI 10.1016/0003-2697(74)90020-7; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KIRSEBOM LA, 1988, J MOL BIOL, V204, P879, DOI 10.1016/0022-2836(88)90048-4; LAWRENCE NP, 1986, J MOL BIOL, V191, P163, DOI 10.1016/0022-2836(86)90253-6; LUMELSKY N, 1988, J MOL BIOL, V202, P443, DOI 10.1016/0022-2836(88)90277-X; PACE NR, 1990, J BIOL CHEM, V265, P3587; REICH C, 1986, J BIOL CHEM, V261, P7888; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAISHI H, 1986, EMBO J, V5, P3673, DOI 10.1002/j.1460-2075.1986.tb04698.x; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; WAUGH DS, 1989, MOL BIOL RNA, P67; WAUGH DS, 1989, THESIS INDIANA U BLO	23	30	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					188	195		10.1096/fasebj.7.1.7678561	http://dx.doi.org/10.1096/fasebj.7.1.7678561			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678561				2022-12-28	WOS:A1993KH88000029
J	LIN, M; HULTQUIST, KL; OH, DH; BAUER, EA; HOEFFLER, WK				LIN, M; HULTQUIST, KL; OH, DH; BAUER, EA; HOEFFLER, WK			INHIBITION OF COLLAGENASE TYPE-I EXPRESSION BY PSORALEN ANTISENSE OLIGONUCLEOTIDES IN DERMAL FIBROBLASTS	FASEB JOURNAL			English	Article						COLLAGENASE I; SKIN; ULTRAVIOLET LIGHT	HUMAN IMMUNODEFICIENCY VIRUS; GLOBIN MESSENGER-RNA; MATRIX METALLOPROTEINASES; CROSS-LINKING; EPIDERMOLYSIS-BULLOSA; TRANSLATION; INVITRO; AGENTS; DNA	Type I collagenase plays an important role in both tumor metastasis and the remodeling of connective tissue in normal human skin, during wound healing, for example, and may participate in the pathophysiology of some dermatological diseases such as skin cancer and a chronic blistering disease, recessive dystrophic epidermolysis bullosa. In an effort specifically to inhibit collagenase expression, we have designed phosphorothioate antisense oligonucleotides, linked at the 5' ends with photoreactive 4'-(hydroxyethoxymethyl)-4,5',8-trimethylpsoralen (HMT), and directed them against the 5' end of the collagenase mRNA, Two antisense-HMT molecules targeting a region overlapping the initiation codon were compared. Only one contained the HMT moiety targeting a 5'TpA on its complementary sense strand, and we observed greater than 50-fold improvement on the cross-linking of this antisense oligonucleotide to its target sequence after ultraviolet A (WA) irradiation. Likewise, sequence complementary to the 5'TpA target was also required to demonstrate specific inhibition of in vitro translation of collagenase mRNA, Tissue culture experiments, conducted by incubation of collagenase-specific antisense-HMT oligonucleotides with fibroblasts in monolayer or in 3-dimensional dermal equivalents, showed lowered collagenase levels 24 h after UVA irradiation as compared to controls. Initial screening of antisense oligomers for specific hybridization and photo-cross-linking is a useful step in the design of antisense oligonucleotides, and allowed us to design an HMT-linked antisense phosphorothioate oligonucleotide that specifically inhibits the expression of fibroblastic collagenase.	STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305	Stanford University				Hoeffler, Warren/0000-0001-8656-6651	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019537, R01AR019537] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR19537] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; DENK W, 1990, SCIENCE, V248, P43; ECKES B, 1993, FEBS LETT, V318, P129, DOI 10.1016/0014-5793(93)80006-G; EMONARD H, 1990, CELL MOL BIOL, V36, P131; GASPARRO FP, 1988, PSORALEN DNA PHOTOBI, V2; GASPARRO FP, 1988, PSORALEN DNA PHOTOBI, V1; GHOSH MK, 1993, ANTI-CANCER DRUG DES, V8, P15; GOLDBERG GI, 1988, ARCH DERMATOL, V124, P737, DOI 10.1001/archderm.124.5.737; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HEARST JE, 1981, ANNU REV BIOPHYS BIO, V10, P691; HELENE C, 1994, EUR J CANCER, V30A, P1721, DOI 10.1016/0959-8049(93)E0352-Q; KEAN JM, 1988, BIOCHEMISTRY-US, V27, P9113, DOI 10.1021/bi00426a008; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LEE BL, 1987, BIOCHEMISTRY-US, V27, P3197; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MILLIGAN JF, 1994, ANN NY ACAD SCI, V716, P228, DOI 10.1111/j.1749-6632.1994.tb21715.x; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; PETERSEN MJ, 1992, J INVEST DERMATOL, V99, P440, DOI 10.1111/1523-1747.ep12616142; PIELES U, 1989, NUCLEIC ACIDS RES, V17, P285, DOI 10.1093/nar/17.1.285; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P1434; UHLMANN E, 1990, CHEM REV, V90, P544; UITTO J, 1992, J INVEST DERMATOL, V98, P391, DOI 10.1111/1523-1747.ep12499822; UNEMORI EN, 1994, EXP CELL RES, V211, P212, DOI 10.1006/excr.1994.1080; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WEBB TR, 1986, NUCLEIC ACIDS RES, V14, P7661, DOI 10.1093/nar/14.19.7661; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	33	13	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1995	9	13					1371	1377		10.1096/fasebj.9.13.7557028	http://dx.doi.org/10.1096/fasebj.9.13.7557028			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557028				2022-12-28	WOS:A1995TA37000017
J	MELCHIORRI, D; REITER, RJ; SEWERYNEK, E; CHEN, LD; NISTICO, G				MELCHIORRI, D; REITER, RJ; SEWERYNEK, E; CHEN, LD; NISTICO, G			MELATONIN REDUCES KAINATE-INDUCED LIPID-PEROXIDATION IN HOMOGENATES OF DIFFERENT BRAIN-REGIONS	FASEB JOURNAL			English	Article						OXIDATIVE STRESS; FREE RADICALS; NEUROPROTECTION; MALONALDEHYDE; EXCITATORY NEUROTRANSMITTER	FREE-RADICAL FORMATION; KAINIC ACID; GLUTAMATE RECEPTOR; OXYGEN RADICALS; AMINO-ACIDS; CELLS; INVITRO; RELEASE; RATS	Melatonin protection against in vitro kainic acid-induced oxidative damage in homogenates from different rat brain regions is shown. Brain-disrupted cell homogenates from cerebral cortex, cerebellum, hippocampus, hypothalamus, and corpus striatum were incubated with kainate (11.7 mM) with or without different concentrations of melatonin (0.1-4 mM). The concentration of malonaldehyde and 4-hydroxyalkenals was measured as an index of Lipid peroxidation. Wistar and Sprague-Dawley rats were used. When administered with kainate, melatonin markedly reduced lipid peroxidation in every brain region of both rat strains. The reduction in lipid peroxidation by melatonin Tvas concentration-dependent and varied from 10% to 100%. The protection conferred by melatonin is likely due, at least in part, to its newly discovered, free radical scavenging ability.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; UNIV ROMA TOR VERGATA,DEPT BIOL,ROME,ITALY	University of Texas System; University of Texas Health San Antonio; University of Rome Tor Vergata								BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERDICHEVSKY E, 1983, NEUROSCI LETT, V36, P75, DOI 10.1016/0304-3940(83)90489-5; BIZIERE K, 1978, J NEUROCHEM, V31, P513, DOI 10.1111/j.1471-4159.1978.tb02666.x; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BOSE R, 1992, TOXICOL LETT, V60, P211, DOI 10.1016/0378-4274(92)90276-P; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V66, P289; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; DYKENS JA, 1987, J NEUROCHEM, V409, P122; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FERKANY JW, 1983, J PHARMACOL EXP THER, V225, P399; GEBICKI JM, 1976, CHEM PHYS LIPIDS, V16, P142, DOI 10.1016/0009-3084(76)90006-2; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; HALL JG, 1978, NEUROSCI LETT, V8, P171, DOI 10.1016/0304-3940(78)90192-1; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Hardeland R., 1993, CHRONOBIOLOGY CHRONO, P113; HICKS M, 1986, FEBS LETT, V199, P92, DOI 10.1016/0014-5793(86)81230-3; KENNAWAY DJ, 1988, J PINEAL RES, V5, P455, DOI 10.1111/j.1600-079X.1988.tb00788.x; Kohler C, 1984, EXCITOTOXINS, P99; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARANI E, 1987, EXPERIENTIA, V43, P305, DOI 10.1007/BF01945560; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Melchiorri Daniela, 1995, Life Sciences, V56, P83, DOI 10.1016/0024-3205(94)00417-Q; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MORI A, 1994, NEUROCHEM INT, V24, P201, DOI 10.1016/0197-0186(94)90076-0; NARANJORODRIGUE.E, 1994, SOC NEUR ABSTR, V20, P1603; NARANJORODRIGUE.EB, 1991, BRAIN RES BULL, V27, P595; PELLEGRINIGIAMP.DE, 1990, J NEUROSCI, V10, P1035; Pierre C., 1994, LIFE SCI, V55, P271; POEGGELER B, 1994, J PINEAL RES, V17, P1, DOI 10.1111/j.1600-079X.1994.tb00106.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; SHIDA CS, 1994, J PINEAL RES, V16, P198, DOI 10.1111/j.1600-079X.1994.tb00102.x; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; TAN DX, 1994, CARCINOGENESIS, V15, P215, DOI 10.1093/carcin/15.2.215; Tan DX, 1993, ENDOCR J, V1, P57	38	164	164	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1205	1210		10.1096/fasebj.9.12.7672513	http://dx.doi.org/10.1096/fasebj.9.12.7672513			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672513				2022-12-28	WOS:A1995RU81600010
J	SILVERSTEIN, SC; GARRISON, HH; HEINIG, SJ				SILVERSTEIN, SC; GARRISON, HH; HEINIG, SJ			A FEW BASIC ECONOMIC FACTS ABOUT RESEARCH IN THE MEDICAL AND RELATED LIFE SCIENCES	FASEB JOURNAL			English	Article									FEDERAT AMER SOC EXPTL BIOL,OFF POLICY ANAL & RES,BETHESDA,MD 20814		SILVERSTEIN, SC (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.			Garrison, Howard/0000-0001-9455-3527				MANSFIELD E, 1991, RES POLICY, V20, P1, DOI 10.1016/0048-7333(91)90080-A; 1993, NIH931261 PUBL; 1990, ASSESSMENT MASSACHUS; 1994, IMPACT NATIONAL I HL; 1991, BANK BOSTON STUDY JO; 1993, CONSENSUS C FY 1996; 1992, NEW YORK ACADEMY MED; 3RD ANN STUDY EC IMP; 1994, BIOTECH 95 REFORM RE; 1993, HLTH CARE TECHNOLOGY	10	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					833	840		10.1096/fasebj.9.10.7615152	http://dx.doi.org/10.1096/fasebj.9.10.7615152			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615152				2022-12-28	WOS:A1995RK89900002
J	VILLALOBOS, C; GARCIASANCHO, J				VILLALOBOS, C; GARCIASANCHO, J			GLUTAMATE INCREASES CYTOSOLIC CALCIUM IN GH(3) PITUITARY-CELLS ACTING VIA A HIGH-AFFINITY GLUTAMATE TRANSPORTER	FASEB JOURNAL			English	Article						GLUTAMATE RECEPTORS; CA2+ CHANNELS; GH(3) PITUITARY CELLS; PROLACTIN SECRETION	THYROTROPIN-RELEASING-HORMONE; AMINO-ACID RECEPTORS; PROLACTIN SECRETION; ACTION-POTENTIALS; CA-2+; RAT; THAPSIGARGIN; STIMULATION; ANTAGONISTS; RESISTANT	Hormone secretion by GH(3) pituitary cells is regulated by oscillations of the cytosolic Ca2+ concentration ([Ca2+](i)), which are driven by electrical activity and modulated by hypothalamic releasing factors. We find that micromolar concentrations of L-gIutamate and other acidic amino acids, but not selective excitatory amino acid receptor agonists, increase [Ca2+](i) in GH(3) cells. Activation by glutamate is blocked by dihydropyridines or removal of extracellular Ca2+ or Na+, but not by tetrodotoxin or excitatory amino acid receptor antagonists. Glutamate mate also accelerated the entry of Mn2+ used as a Ca2+ surrogate for Ca2+ channels. L-Glutamate and other acidic amino acids were taken up into GH(3) cells by an Na+-dependent high-affinity transporter. The half-maximal effect of glutamate [Ca2+](i) was reached at concentrations similar to the K-m for the glutamate transporter. Moreover, only those amino acids taken up through this transporter were able to increase [Ca2+](i). We propose that electrogenic entry of Na+-glutamate depolarizes the plasma membrane, thus causing an increase of action potentials firing and Ca2+ entry through voltage-gated channels. Our results suggest that glutamate may cooperate to the modulation of pituitary hormone secretion by an unconventional mechanism involving a high-affinity glutamate transporter rather than excitatory amino acid receptors.	UNIV VALLADOLID,FAC MED,DEPT BIOCHIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Villalobos, Carlos/M-9839-2017; Garcia-Sancho, Javier/K-2975-2014	Villalobos, Carlos/0000-0002-0429-3846; Garcia-Sancho, Javier/0000-0003-4573-7930				ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALONSO MT, 1989, BIOCHEM BIOPH RES CO, V162, P24, DOI 10.1016/0006-291X(89)91956-6; BARROS F, 1994, PFLUG ARCH EUR J PHY, V426, P221, DOI 10.1007/BF00374775; BJORO T, 1990, BIOSCIENCE REP, V10, P189, DOI 10.1007/BF01116578; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; KIYAMA H, 1993, MOL BRAIN RES, V19, P262, DOI 10.1016/0169-328X(93)90039-R; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LOGIN IS, 1990, LIFE SCI, V47, P2269, DOI 10.1016/0024-3205(90)90158-N; MATTESON DR, 1986, J GEN PHYSIOL, V83, P371; MEEKER RB, 1994, ENDOCRINOLOGY, V134, P621, DOI 10.1210/en.134.2.621; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROBINSON MB, 1993, J NEUROCHEM, V60, P167, DOI 10.1111/j.1471-4159.1993.tb05835.x; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; TERRY LC, 1981, BRAIN RES, V217, P129; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161	32	29	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					815	819		10.1096/fasebj.9.9.7601345	http://dx.doi.org/10.1096/fasebj.9.9.7601345			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601345				2022-12-28	WOS:A1995RH98200015
J	YEH, JY; BEILSTEIN, MA; ANDREWS, JS; WHANGER, PD				YEH, JY; BEILSTEIN, MA; ANDREWS, JS; WHANGER, PD			TISSUE DISTRIBUTION AND INFLUENCE OF SELENIUM STATUS ON LEVELS OF SELENOPROTEIN-W	FASEB JOURNAL			English	Article						WESTERN BLOTS; POLYCLONAL ANTIBODIES; RATS; RABBITS; SHEEP; CATTLE	PLASMA GLUTATHIONE-PEROXIDASE; IODOTHYRONINE 5'-DEIODINASE; PARENTERAL-NUTRITION; RAT MUSCLE; CDNA; SELENOENZYME; PROTEINS; ENZYME; PURIFICATION; EXPRESSION	Rabbits were immunized with two synthetic peptides based on hydrophilic regions of selenoprotein W from rat muscle, The resulting polyclonal antibodies were used in Western blots to determine the compartmentation and tissue distribution of selenoprotein W, and to determine the influence of selenium on the levels of this selenoprotein in rat muscle. Selenoprotein W exists mainly in cytosol, but very small amounts were associated with membranes, Western blots revealed selenoprotein W in muscle, spleen, testis, and brain of rats. Rats were fed diets of either no addition of selenium (0 ppm Se) or additions of 0.1 and 4.0 mg selenium/g (0.1 ppm Se and 4.0 ppm Se) diet for 6 wk. Selenoprotein W was undetectable in skeletal muscle of rats fed the basal diet, detectable in those fed 0.1 ppm selenium in the diet, and much higher in muscle from rats fed 4 ppm selenium diet. In a species comparison, Western blots indicated the presence of selenoprotein W in muscle of rabbits, sheep, and cattle.	OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR GENE RES & BIOTECHNOL, CORVALLIS, OR 97331 USA	Oregon State University; Oregon State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEILSTEIN MA, 1984, J NUTR, V114, P929, DOI 10.1093/jn/114.5.929; BEILSTEIN MA, 1993, FASEB J, V7, pA289; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODT P, 1983, ANNU REV MICROBIOL, V37, P447, DOI 10.1146/annurev.mi.37.100183.002311; BROWN MR, 1986, AM J CLIN NUTR, V43, P549, DOI 10.1093/ajcn/43.4.549; CHEN XS, 1980, BIOL TRACE ELEM RES, V2, P91, DOI 10.1007/BF02798589; CHU FF, 1993, J BIOL CHEM, V268, P2571; DEAGEN JT, 1993, ANAL BIOCHEM, V208, P176, DOI 10.1006/abio.1993.1025; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; FIELDS C G, 1991, Peptide Research, V4, P95; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HAWKES WC, 1985, J INORG BIOCHEM, V23, P77, DOI 10.1016/0162-0134(85)83011-7; HILL KE, 1991, J BIOL CHEM, V266, P10050; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; KARIMPOUR I, 1992, DNA CELL BIOL, V11, P693, DOI 10.1089/dna.1992.11.693; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OH SH, 1974, BIOCHEMISTRY-US, V13, P1825, DOI 10.1021/bi00706a008; POND FR, 1983, J REPROD FERTIL, V69, P411, DOI 10.1530/jrf.0.0690411; READ R, 1990, J BIOL CHEM, V265, P17899; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHUBERT JR, 1961, FED PROC, V20, P689; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; VANRIJ AM, 1981, JPEN-PARENTER ENTER, V5, P120, DOI 10.1177/0148607181005002120; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; WHANGER PD, 1987, SELENIUM BIOL MED, P197; WHANGER PD, 1993, SOME BIOCH PROPERTIE, P119; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	40	80	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					392	396		10.1096/fasebj.9.5.7896009	http://dx.doi.org/10.1096/fasebj.9.5.7896009			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896009				2022-12-28	WOS:A1995QP45100012
J	NEWCOMER, ME				NEWCOMER, ME			RETINOID-BINDING PROTEINS - STRUCTURAL DETERMINANTS IMPORTANT FOR FUNCTION	FASEB JOURNAL			English	Review						VITAMIN-A; X-RAY STRUCTURE	P2 MYELIN PROTEIN; MANDUCA-SEXTA L; ESCHERICHIA-COLI; CRABP-I; 3-DIMENSIONAL STRUCTURE; TERATOCARCINOMA CELLS; MOLECULAR-CLONING; RAT EPIDIDYMIS; DNA-BINDING; VITAMIN-A	The transport and functions of biologically active naturally occurring retinoids (Vitamin A, retinol, and its metabolites) are mediated by extracellular, intracellular, and nuclear proteins. X-ray crystallographic studies to date on the extra- and intracellular proteins have helped to define distinct protein retinoid recognition mechanisms, each with a characteristic structural motif. The extracellular proteins (serum retinol-binding protein and a retinoic acid-binding protein from rat epididymis) bind retinoids with a hand-in-glove like fit in deep, hydrophobic-binding cavities. The intracellular proteins (cellular retinol-binding proteins types I and II) encapsulate the ligand in an aqueous internal cavity. The details of the mechanisms of retinoid recognition, and how they result as a consequence of the different protein structures, are described in this review.			NEWCOMER, ME (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041891] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41891] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTROM A, 1991, J BIOL CHEM, V266, P17662; BANASZAK L, 1993, ADV PROTEIN CHEM, V45, P89; BENNING MM, 1992, J MOL BIOL, V228, P208; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GOODMAN DS, 1984, RETINOIDS, V2, P1; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; JAMISON RS, 1994, BIOCHEMISTRY-US, V33, P2873, DOI 10.1021/bi00176a017; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KATO M, 1985, BIOL REPROD, V32, P173, DOI 10.1095/biolreprod32.1.173; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LI E, 1991, J BIOL CHEM, V266, P3622; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MANGELSDORF DJ, 1994, RETINOIDS, P283; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; NEWCOMER ME, 1990, J BIOL CHEM, V265, P12876; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; NILSSON MHL, 1988, EUR J BIOCHEM, V173, P45, DOI 10.1111/j.1432-1033.1988.tb13964.x; NISHIWAKI S, 1991, J NUTR SCI VITAMINOL, V37, P461, DOI 10.3177/jnsv.37.461; Ong David E., 1994, P283; ONG DE, 1988, ARCH BIOCHEM BIOPHYS, V267, P474, DOI 10.1016/0003-9861(88)90053-7; ONG DE, 1987, J BIOL CHEM, V262, P2729; PAPPAS RS, 1993, BIOL REPROD, V48, P235, DOI 10.1095/biolreprod48.2.235; PORTER SB, 1985, J ANDROL, V6, P197; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STONER CM, 1989, CANCER RES, V49, P1497; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TILBEURGH HV, 1993, NATURE, V362, P814; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V248, P10728; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202; ZWAIN IH, 1992, ENDOCRINOLOGY, V131, P1511, DOI 10.1210/en.131.3.1511	48	80	88	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					229	239		10.1096/fasebj.9.2.7781925	http://dx.doi.org/10.1096/fasebj.9.2.7781925			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781925				2022-12-28	WOS:A1995QJ24900011
J	RATTAN, SIS				RATTAN, SIS			GERONTOGENES - REAL OR VIRTUAL	FASEB JOURNAL			English	Article						AGING; LIFE SPAN; HOMEOSTASIS; VIRTUAL GENES	DIETARY RESTRICTION; CAENORHABDITIS-ELEGANS; PROTEIN-SYNTHESIS; LIFE-SPAN; OXIDATIVE DAMAGE; DNA-POLYMERASES; REPAIR; AGE; DROSOPHILA; LIVER	The view that the life span of an organism is intrinsically limited and is largely species-specific necessarily involves certain notions of genetic elements of regulation. The term gerontogenes refers to any such genetic elements that are involved in the regulation of aging and life span. The existence of genes for programmed aging is generally discounted on the basis of evolutionary arguments against the notion of the adaptive nature of aging. It is suggested here that the concept of gerontogenes be linked with the idea of genes involved in homeostasis and longevity assurance, which is not contradictory to the nonadaptive nature of aging. Because these genes were not originally selected as real genes for aging, their involvement in aging is an emergent property making them virtual gerontogenes. Some experimental evidence is available that suggests that sets of genes involved in the maintenance and repair of various cellular functions are the primary candidates qualifying as virtual gerontogenes.			RATTAN, SIS (corresponding author), AARHUS UNIV, DEPT CHEM, CELLULAR AGING LAB, DK-8000 AARHUS C, DENMARK.			Rattan, Suresh I.S./0000-0002-3478-1381				ARKING R, 1988, EXP GERONTOL, V23, P59, DOI 10.1016/0531-5565(88)90020-4; ARKING R, 1988, EXP AGING RES, V14, P125, DOI 10.1080/03610738808259737; CHATTERJEE B, 1989, FASEB J, V3, P169, DOI 10.1096/fasebj.3.2.2464518; CUTLER RG, 1985, MOL BIOL AGING GENE, P307; FRIEDMAN DB, 1988, GENETICS, V118, P75; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; HART RW, 1981, NATURWISSENSCHAFTEN, V68, P552, DOI 10.1007/BF00401663; HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S; Holland Barbara, 1985, SOVIET SISTERHOOD BR, P15, DOI DOI 10.2307/2499207; HOLLIDAY R, 1988, PERSPECT BIOL MED, V32, P109; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HOLLIDAY R, 1992, NEWS PHYSIOL SCI, V7, P38; ISHIGAMI A, 1990, ARCH BIOCHEM BIOPHYS, V283, P362, DOI 10.1016/0003-9861(90)90655-I; JOHNSON TE, 1988, J GERONTOL, V43, pB87, DOI 10.1093/geronj/43.4.B87; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; Kirkwood Thomas B. L., 1992, P35; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LUCKINBILL LS, 1993, ARCH GERONTOL GERIAT, V16, P17, DOI 10.1016/0167-4943(93)90023-B; MACIEIRACOELHO A, 1993, EXP GERONTOL, V28, P1, DOI 10.1016/0531-5565(93)90016-7; Martin George M., 1992, P41; MCFARLAND GA, 1994, EXP CELL RES, V212, P167, DOI 10.1006/excr.1994.1132; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MERRY BJ, 1991, MECH AGEING DEV, V58, P139, DOI 10.1016/0047-6374(91)90088-H; MERRY BJ, 1992, EXP GERONTOL, V27, P191, DOI 10.1016/0531-5565(92)90043-Y; MERRY BJ, 1991, COMP BIOCHEM PHYS A, V98, P559, DOI 10.1016/0300-9629(91)90446-J; NUELL MJ, 1989, EXP GERONTOL, V24, P469, DOI 10.1016/0531-5565(89)90053-3; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RATTAN SIS, 1988, TRENDS BIOTECHNOL, V6, P58, DOI 10.1016/0167-7799(88)90092-3; RATTAN SIS, 1994, BIOCHEM BIOPH RES CO, V201, P665, DOI 10.1006/bbrc.1994.1752; RATTAN SIS, 1989, INT REV CYTOL, V116, P47; RATTAN SIS, 1991, PERSPECT BIOL MED, V34, P526; RATTAN SIS, 1985, BIOESSAYS, V2, P226, DOI 10.1002/bies.950020511; ROOSE MR, 1991, EVOLUTIONARY BIOL AG; SACHER GA, 1982, PERSPECT BIOL MED, V25, P339; SMITH JR, 1992, EXP GERONTOL, V27, P409, DOI 10.1016/0531-5565(92)90073-9; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SRIVASTAVA V, 1992, EXP GERONTOL, V27, P593, DOI 10.1016/0531-5565(92)90014-Q; SRIVASTAVA VK, 1991, EXP GERONTOL, V26, P453, DOI 10.1016/0531-5565(91)90034-J; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6; WHITEHEAD I, 1993, J GERONTOL, V48, pB124, DOI 10.1093/geronj/48.4.B124; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; YOUNGMAN LD, 1993, MUTAT RES, V295, P165, DOI 10.1016/0921-8734(93)90018-X; YU BP, 1990, REV BIOL RES AGING, V4, P349; [No title captured]	50	33	35	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					284	286		10.1096/fasebj.9.2.7781932	http://dx.doi.org/10.1096/fasebj.9.2.7781932			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781932				2022-12-28	WOS:A1995QJ24900019
J	BRADEN, BC; POLJAK, RJ				BRADEN, BC; POLJAK, RJ			STRUCTURAL FEATURES OF THE REACTIONS - BETWEEN ANTIBODIES AND PROTEIN ANTIGENS	FASEB JOURNAL			English	Review						3-DIMENSIONAL STRUCTURE; MONOCLONAL ANTIBODIES; ANTIGEN-ANTIBODY COMPLEXES; ANTIBODY SPECIFICITY	INFLUENZA-VIRUS NEURAMINIDASE; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; THERMODYNAMIC ANALYSIS; MONOCLONAL-ANTIBODY; COMPUTER-SIMULATION; FAB FRAGMENTS; COMPLEX; BINDING	Antibodies bind protein antigens over large sterically and electrostatically complementary surfaces. Van der Waals forces, hydrogen bonds, and occasionally ion pairs provide stability to antibody-antigen complexes. In addition, water molecules contribute hydrogen bonds linking antigen and antibody, and increase the complementarity of antigen-antibody interfaces. In qualification to a strict 'lock and key' mechanism, evidence of conformational changes between free and complexed antibodies indicate some accommodation to the antigen. Antibody-protein antigen reactions are enthalpically driven with varying degrees of entropic compensation, often dependent on the magnitude of the enthalpy of the reaction. In the case of two antibody-combining sites studied by X-ray diffraction, the relative arrangements of the variable domains of the light and heavy chains of the antibody change slightly from the free to the antigen-bound state. Furthermore, the contacting residues of both antibodies exhibit similar reduced mobilities when complexed to antigen, suggesting that differences in 'solvent entropy' rather than in conformational freedom may be the source of different entropic compensation factors. In concert, data from structural studies, reaction rates, calorimetric measurements, molecular dynamics simulations, and site-directed mutagenesis are beginning to detail the nature of antibody-protein antigen interactions.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA									ALARY F, 1993, J PHYS CHEM-US, V97, P13864, DOI 10.1021/j100153a069; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; CHANG CYY, 1994, J MOL BIOL, V239, P154, DOI 10.1006/jmbi.1994.1358; CHERFILS J, 1991, PROTEINS, V11, P271, DOI 10.1002/prot.340110406; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COLMAN PM, 1989, PHILOS T R SOC B, V323, P511, DOI 10.1098/rstb.1989.0028; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; DAVIES DR, 1989, COLD SH Q B, V54, P233; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; ITO W, 1993, J BIOL CHEM, V268, P16639; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JIANG F, 1991, J MOL BIOL, V219, P79, DOI 10.1016/0022-2836(91)90859-5; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KENETT D, 1987, MOL IMMUNOL, V24, P313, DOI 10.1016/0161-5890(87)90150-7; KODANDAPANI RM, 1993, ACTA CRYSTALLOGR D, V49, P234; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KOZACK RE, 1993, PROTEIN SCI, V2, P915, DOI 10.1002/pro.5560020605; LATTMAN EE, 1994, PROTEINS, V18, P103, DOI 10.1002/prot.340180203; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LESCAR J, 1993, PROTEINS, V15, P209, DOI 10.1002/prot.340150211; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PELLEGRINI M, 1993, PROTEINS, V15, P436, DOI 10.1002/prot.340150410; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RAMAN CS, 1992, BIOCHEMISTRY-US, V31, P10370, DOI 10.1021/bi00157a027; RAMANADHAM M, 1990, ACTA CRYSTALLOGR B, V46, P63, DOI 10.1107/S0108768189009195; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108; TOTROV M, 1994, NAT STRUCT BIOL, V1, P259, DOI 10.1038/nsb0494-259; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; TULIP WR, 1991, J MOL BIOL, V221, P487, DOI 10.1016/0022-2836(91)80069-7; WALLS PH, 1992, J MOL BIOL, V228, P277, DOI 10.1016/0022-2836(92)90506-F; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON KP, 1992, J BIOL CHEM, V267, P10842; YSERN X, 1994, J MOL BIOL, V238, P496	63	172	182	2	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					9	16		10.1096/fasebj.9.1.7821765	http://dx.doi.org/10.1096/fasebj.9.1.7821765			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821765				2022-12-28	WOS:A1995QD20200004
J	SCHERF, T; HILLER, R; ANGLISTER, J				SCHERF, T; HILLER, R; ANGLISTER, J			NMR OBSERVATION OF INTERACTIONS IN THE COMBINING SITE REGION OF AN ANTIBODY USING A SPIN-LABELED PEPTIDE ANTIGEN AND NOESY DIFFERENCE SPECTROSCOPY	FASEB JOURNAL			English	Article						PROTEIN NMR; ANTIBODY STRUCTURE	3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; MAGNETIC-RESONANCE; PROTEINS; SEQUENCES; COMPLEXES; RESIDUES; LIGANDS; HAPTEN	A spin-labeled peptide antigen (TEMPO-VEVPGSQHIDSQ) was used to measure NOESY difference spectra that show interactions in the binding site region of the Fab fragment of the anti-cholera toxin peptide antibody TE33. In addition to identification of peptide-Fab interactions and interactions within the bound peptide, these difference spectra show well-resolved cross peaks due to interactions within the large Fab fragment (50 kDa). These difference spectra indicate that the conformational changes in the Fab upon peptide binding are confined to the combining site region of the antibody. The NOESY difference spectra of selectively deuterated Fab molecules were used in combination with HOHAHA measurements to assign the interactions to amino acid type and to identify the interactions within the Fab as either inter- or intraresidue interactions. The assignment of interactions within the Fab to corresponding aromatic residues in the Fab sequence was facilitated by an earlier NMR-derived model calculated on the basis of NOE restraints on Fab-peptide and intra-bound-peptide distances. The new restraints on distances within the Fab, combined with the previously obtained restraints, were used to generate a refined NMR-derived model for the TE33-peptide complex.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ANGLISTER J, 1984, BIOCHEMISTRY-US, V23, P5372, DOI 10.1021/bi00317a041; ANGLISTER J, 1984, BIOCHEMISTRY-US, V23, P1138, DOI 10.1021/bi00301a016; ANGLISTER J, 1989, BIOCHEMISTRY-US, V28, P3360, DOI 10.1021/bi00434a035; ANGLISTER J, 1990, BIOCHEMISTRY-US, V29, P921, DOI 10.1021/bi00456a011; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1989, METHOD ENZYMOL, V176, P151; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COHN M, 1971, ACCOUNTS CHEM RES, V4, P214, DOI 10.1021/ar50042a004; DEJONG EAM, 1988, J MAGN RESON, V80, P197, DOI 10.1016/0022-2364(88)90291-0; DWEK RA, 1975, EUR J BIOCHEM, V53, P25, DOI 10.1111/j.1432-1033.1975.tb04038.x; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; Kabat EA, 1991, SEQUENCES PROTEINS I, P647; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; MOONEN CTW, 1984, EUR J BIOCHEM, V141, P323, DOI 10.1111/j.1432-1033.1984.tb08195.x; NAKAYAMA T, 1993, BIOCHEMISTRY-US, V32, P13961, DOI 10.1021/bi00213a028; ODAKA A, 1992, BIOCHEMISTRY-US, V31, P10686, DOI 10.1021/bi00159a007; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; WAGNER G, 1993, J BIOMOL NMR, V3, P375; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; ZILBER B, 1990, BIOCHEMISTRY-US, V29, P10032, DOI 10.1021/bi00495a004	25	10	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					120	126		10.1096/fasebj.9.1.7821751	http://dx.doi.org/10.1096/fasebj.9.1.7821751			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821751				2022-12-28	WOS:A1995QD20200019
J	DINARELLO, CA				DINARELLO, CA			THE INTERLEUKIN-1 FAMILY - 10 YEARS OF DISCOVERY	FASEB JOURNAL			English	Review						CYTOKINES; TUMOR NECROSIS FACTOR; RECEPTOR ANTAGONIST; APOPTOSIS; INFLAMMATION	TUMOR-NECROSIS-FACTOR; IL-1 RECEPTOR ANTAGONIST; HUMAN MONOCYTE INTERLEUKIN-1; BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE-C; DEATH GENE CED-3; NF-KAPPA-B; SIGNAL TRANSDUCTION; II RECEPTOR; SOLUBLE RECEPTOR	Ten years ago the cloning of two interleukin-l molecules (IL-1 alpha and IL-1 beta) resolved the question of whether a single polypeptide could evoke a wide variety of biological effects. During the past decade, the biology of IL-1 has greatly expanded our understanding of how the host responds to external challenges, such as injury and infection, as well as its role in several diseases. We learned of the remarkable potency of IL-1 in the femtomolar range and of its ability to induce a response by triggering only one or two receptors per cell. Unexpectedly, the IL-1 family of genes, receptors and associated molecules have been linked to those of Drosophila, nematodes, and microorganisms and IL-1 signal transduction is similar to that observed after cellular stress. The cloning of IL-1 opened other avenues of fundamental biological interest. For example, in addition to the two agonist molecules IL-1 alpha and IL-1 beta, a third member of the IL-1 gene family is a specific, high affinity receptor antagonist (IL-I receptor antagonist). That this third member of the IL-1 family inhibits the other two is characteristic of the tight control over production and activity exerted on IL-1. Although IL-1 contributes to the pathogenesis of many diseases, a small amount appears to be needed to combat infection and inititate healing processes. This article highlights 10 years of discoveries on IL-1.-Dinarello, C.A. The interleukin-l family: 10 years of discovery.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA	Tufts University	DINARELLO, CA (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, 750 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015614, R01AI015614, R37AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAHOSHI T, 1988, J CLIN INVEST, V82, P1219, DOI 10.1172/JCI113719; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ANTONI G, 1986, J IMMUNOL, V137, P3201; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BAKOUCHE O, 1987, J IMMUNOL, V138, P4249; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; BERGHOLDT R, 1994, EUR J ENDOCRINOL S1, V130, P17; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOMALASKI JS, 1992, J IMMUNOL, V148, P155; BORASCHI D, 1990, EUR J IMMUNOL, V20, P317, DOI 10.1002/eji.1830200213; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHENSUE SW, 1993, J IMMUNOL, V151, P3654; CHIN J, 1988, J CLIN INVEST, V82, P420, DOI 10.1172/JCI113614; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Cominelli F., 1993, Lymphokine and Cytokine Research, V12, P340; DIDONATO JA, 1994, IN PRESS MOL CELL BI; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; Dower S K, 1994, Ther Immunol, V1, P113; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EVANS RJ, 1994, IN PRESS J BIOL CHEM; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FISCHER E, 1992, BLOOD, V79, P2196; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GALLIS B, 1989, J IMMUNOL, V143, P3235; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWITZ EV, 1992, BLOOD, V79, P2356; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRUETER MG, 1994, IN PRESS PROTEIN ENG; GUENARD V, 1991, J NEUROSCI RES, V29, P396, DOI 10.1002/jnr.490290315; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1994, IN PRESS BIOCH J, V304; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HENRICSON BE, 1991, INFECT IMMUN, V59, P1188, DOI 10.1128/IAI.59.3.1188-1191.1991; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KASPAR RL, 1994, J IMMUNOL, V153, P277; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KOCH KC, 1992, EUR J IMMUNOL, V22, P153, DOI 10.1002/eji.1830220123; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRACHT M, 1994, IN PRESS J EXP MED, V180; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; LAMBRIOLATOMKIN.E, 1993, PROTEIN ENG, V6, P535; LIU J, 1994, J BIOL CHEM, V269, P3047; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MANCILLA J, 1993, INFECT IMMUN, V61, P926, DOI 10.1128/IAI.61.3.926-932.1993; MANDRUPPOULSEN T, 1987, J IMMUNOL, V139, P4077; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATSUSHIMA K, 1987, J IMMUNOL, V139, P3367; MATSUSHIMA K, 1986, J IMMUNOL, V137, P3183; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZEL SB, 1987, J IMMUNOL, V138, P2906; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; Moldawer L L, 1990, Nutr Clin Pract, V5, P187, DOI 10.1177/0115426590005005187; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUNOZ E, 1990, J IMMUNOL, V144, P964; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NANDURI VB, 1991, BIOCHIM BIOPHYS ACTA, V1118, P25, DOI 10.1016/0167-4838(91)90437-5; NETA R, 1987, J IMMUNOL, V139, P1861; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROSOFF PM, 1989, LYMPHOKINE RES, V8, P407; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHINDLER R, 1990, J IMMUNOL, V144, P2216; SCHINDLER R, 1990, BLOOD, V76, P1631; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432-1033.1993.tb17754.x; SHINTANI F, 1994, IN PRESS J NEUROSCI; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SIMS JE, 1994, CLIN IMMUNOL IMMUNOP, V72, P9, DOI 10.1006/clin.1994.1100; SIMS JE, 1995, IN PRESS CYTOKINE; SLACK J, 1993, J BIOL CHEM, V268, P2513; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; SPINAS GA, 1986, ACTA ENDOCRINOL-COP, V113, P551, DOI 10.1530/acta.0.1130551; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; Symons J. A., 1993, Lymphokine and Cytokine Research, V12, P381; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TARLOW JK, 1993, HUM GENET, V91, P403; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TILG H, 1994, CYTOKINE, V6, P215, DOI 10.1016/1043-4666(94)90044-2; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; WEBB AC, 1986, LYMPHOKINE RES, V5, P77; WEIZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YAMAYOSHI M, 1990, LYMPHOKINE RES, V9, P405; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; YE K, 1992, IMMUNOLOGY, V75, P427; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	128	711	773	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1994	8	15					1314	1325		10.1096/fasebj.8.15.8001745	http://dx.doi.org/10.1096/fasebj.8.15.8001745			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001745				2022-12-28	WOS:A1994PY20900016
J	HOLVOET, P; COLLEN, D				HOLVOET, P; COLLEN, D			OXIDIZED LIPOPROTEINS IN ATHEROSCLEROSIS AND THROMBOSIS	FASEB JOURNAL			English	Review						LDL OXIDATION; ATHEROGENESIS; ANTIOXIDANT	LOW-DENSITY-LIPOPROTEIN; VITAMIN-E CONSUMPTION; OXIDATIVE MODIFICATION; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; FOAM CELLS; MACROPHAGE; LDL; DEGRADATION; MONOCYTE	Oxidized low density lipoproteins (LDL) and autoimmune antibodies against oxidized LDL have been demonstrated in human atherosclerotic lesions; they may enhance the progression of these lesions by 1) enhancing monocyte adhesion and macrophage foam cell generation; 2) inducing smooth muscle cell migration, proliferation, and foam cell generation; 3) enhancing platelet adhesion and aggregation, which may stimulate macrophage foam cell generation and smooth muscle cell proliferation; 4) triggering thrombosis; and 5) impairing vasodilation, which results in increased shear stress. The oxidation of LDL probably occurs in the arterial wall, where it is sequestered from circulating antioxidants. Atherosclerotic arterial walls contain increased levels of redox-active metal ions, and the LDL of patients with atherosclerotic cardiovascular disease are more susceptible to oxidation, possibly as a result of reduced endogenous antioxidants such as vitamin E. Dietary supplementation with vitamin E (up to 1,000 IU/day) or administration of probucol reduce the oxidation rate of LDL and may significantly decrease the risk of coronary heart disease.-Holvoet, P., Collen, D. Oxidized lipoproteins in atherosclerosis and thrombosis.			HOLVOET, P (corresponding author), UNIV LOUVAIN,CTR MOLEC & VASC BIOL,CAMPUS GASTHUISBERG,O&N,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772				ARBUSTINI E, 1991, AM J CARDIOL, V68, pB36; ARMSTRONG DA, 1992, MED HYPOTHESES, V38, P244, DOI 10.1016/0306-9877(92)90103-J; AVIRAM M, 1993, J CLIN INVEST, V91, P1942, DOI 10.1172/JCI116413; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; DAVIES MJ, 1993, BRIT HEART J, V69, P377; ESTERBAUER H, 1991, ANN MED, V23, P573, DOI 10.3109/07853899109150520; ESTERBAUER H, 1987, J LIPID RES, V28, P495; GERRITY RG, 1981, AM J PATHOL, V103, P181; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAMSTEN A, 1987, LANCET, V2, P3; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOLLAND JA, 1992, AM J PATHOL, V140, P551; HOLVOET P, 1994, J CLIN INVEST, V93, P89, DOI 10.1172/JCI116988; HUGHES DA, 1992, CLIN EXP IMMUNOL, V87, P279, DOI 10.1111/j.1365-2249.1992.tb02988.x; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; JORIS I, 1983, AM J PATHOL, V113, P341; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; LEHR HA, 1992, ARTERIOSCLER THROMB, V12, P824, DOI 10.1161/01.ATV.12.7.824; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REAVEN P, 1991, AM J CLIN NUTR, V54, P701, DOI 10.1093/ajcn/54.4.701; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHNEIDER JE, 1993, CIRCULATION, V88, P628, DOI 10.1161/01.CIR.88.2.628; SHIMANO H, 1991, J LIPID RES, V32, P763; SIMON BC, 1993, J CARDIOVASC PHARM, V21, P893, DOI 10.1097/00005344-199306000-00007; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STEMME S, 1994, CORONARY ARTERY DIS, V5, P216, DOI 10.1097/00019501-199403000-00006; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; WALLDIUS G, 1993, AM J CARDIOL, V71, pB15, DOI 10.1016/0002-9149(93)90140-8; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WEISSER B, 1992, ARTERIOSCLER THROMB, V12, P231, DOI 10.1161/01.ATV.12.2.231; WOOLF N, 1982, PATHOLOGY ATHEROSCLE, P261; XIU RJ, 1994, J CLIN INVEST, V93, P2732, DOI 10.1172/JCI117288; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	53	176	182	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1279	1284		10.1096/fasebj.8.15.8001740	http://dx.doi.org/10.1096/fasebj.8.15.8001740			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001740				2022-12-28	WOS:A1994PY20900011
J	CARONLESLIE, LAM; EVANS, RB; CIDLOWSKI, JA				CARONLESLIE, LAM; EVANS, RB; CIDLOWSKI, JA			BCL-2 INHIBITS GLUCOCORTICOID-INDUCED APOPTOSIS BUT ONLY PARTIALLY BLOCKS CALCIUM IONOPHORE OR CYCLOHEXIMIDE-REGULATED APOPTOSIS IN S49 CELLS	FASEB JOURNAL			English	Article						DEXAMETHASONE; PROGRAMMED CELL DEATH; STEROID; ANTIPROLIFERATION; BCL-2 EXPRESSION; INTERNUCLEOSOMAL DNA DEGRADATION	DNA FRAGMENTATION; THYMOCYTE APOPTOSIS; PROTEIN-SYNTHESIS; DEATH APOPTOSIS; LYMPHOMA-CELLS; GENE; INVOLVEMENT; EXPRESSION; SELECTION; SURVIVAL	Many non-Hodgkins B-cell lymphomas possess a deregulated bcl-2 gene resulting in a phenotype that is apparently resistant to programmed eel death (apoptosis). We have used a mouse lymphoma cell line (S49.1) that undergoes apoptosis in response to a variety of stimuli to determine the effect of bcl-2 expression on induction of apoptosis. S49 cells were stably transfected with recombinant amphotrophic retroviruses carrying either a G418 antibiotic resistance gene alone (S49-NEO) or this gene in combination with a bcl-2 complementary DNA (S49-Bcl-2). Three different agents previously shown to activate apoptosis by different pathways in S49 cells (dexamethasone, the calcium ionophore A23187, and cycloheximide) were used to examine the effect of bcl-2 expression on cell growth and apoptosis caused by multiple signal transduction pathways. Dexamethasone (DEX) treatment inhibited cell growth and stimulated cell death in S49-NEO cells. Although S49-Bcl-2 cells exhibited a similar antiproliferative response, they failed to die in response to steroid treatment. Western blot analysis revealed no difference in the levels of glucocorticoid receptor protein in the two cell lines, and both responded to glucocorticoid with a profound inhibition of protein synthesis. Cycloheximide (CX) and A23187 also had antiproliferative and cell killing effects in both cell types, although higher concentrations of each agent were needed to kill S49-Bcl-2 cells. To determine whether the loss of viability in response to these drugs was due to apoptosis, cells were examined morphologically and DNA integrity was examined by gel electrophoresis. The presence of condensed chromatin and an internucleosomal pattern of DNA degradation was used as an index of apoptosis. The S49-NEO cells exhibited internucleosomal DNA degradation and an apoptotic morphology in response to DEX, A23187, and CX treatment, indicating that these compounds cause apoptotic death in this cell type. Similar internucleosomal DNA degradation and cellular morphology were observed in A23187- and CX-treated S49-Bcl-2 cells, but not in the DEX-treated S49-Bcl-2 cells. These data indicate that Bcl-2 does not interfere with the mechanisms responsible for apoptosis, but rather alters signaling pathways controlling its activation.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK-32078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; CARONLESLIE LM, 1994, OVARIAN CELL INTERAC, P1; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; COLLINS RJ, 1991, BRIT J CANCER, V64, P518, DOI 10.1038/bjc.1991.341; COMPTON MM, 1992, TRENDS ENDOCRIN MET, V3, P17, DOI 10.1016/1043-2760(92)90087-H; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DISTELHORST CW, 1988, BLOOD, V72, P1305; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HARRIS AW, 1970, EXP CELL RES, V60, P341, DOI 10.1016/0014-4827(70)90527-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; MARTIN SJ, 1990, BIOCHEM SOC T, V18, P634, DOI 10.1042/bst0180634; MIYASHITA T, 1992, CANCER RES, V52, P5407; Munck A., 1977, RECEPTORS MECHANIS 2, P311; NUNEZ G, 1990, J IMMUNOL, V144, P3602; REED JC, 1991, CANCER RES, V51, P6529; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIEGEL RM, 1992, P NATL ACAD SCI USA, V89, P7003, DOI 10.1073/pnas.89.15.7003; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THOMPSON EA, 1991, CANCER RES, V51, P5551; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; WARING P, 1990, J BIOL CHEM, V265, P14476	29	69	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1994	8	9					639	645		10.1096/fasebj.8.9.8005391	http://dx.doi.org/10.1096/fasebj.8.9.8005391			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005391				2022-12-28	WOS:A1994NR90600011
J	NOWELL, PC				NOWELL, PC			CYTOGENETIC APPROACHES TO HUMAN CANCER GENES	FASEB JOURNAL			English	Article						CHROMOSOMES; CANCER; ONCOGENES; SUPPRESSOR GENES; LEUKEMIA; LYMPHOMA; CLONAL EVOLUTION	CHRONIC MYELOGENOUS LEUKEMIA; C-MYC ONCOGENE; BREAST-CANCER; EXPRESSION; RECEPTOR; PROTEIN; DOMAIN; BCR; P53; TRANSLOCATIONS	Chromosome studies of human tumors have provided important clues to the location of relevant genes and the mechanisms by which their growth regulatory functions have been altered. In the last decade, molecular dissection of chromosome translocations in hematopoietic tumors and chromosomal deletions in solid tumors have been particularly helpful in demonstrating the involvement of a few previously known oncogenes and a wide variety of previously unknown ''cancer genes'' which often differ from one type of tumor to another, and normally may either stimulate or inhibit cell growth. These studies have also helped to clarify the importance of multiple genetic lesions in the development of most tumors, and the recently acquired information is already being used in clinical diagnosis and management. In addition, new specific treatments will ultimately result from these findings, but the work to date also clearly indicates that no single, simple answer to human cancer will be forthcoming.			NOWELL, PC (corresponding author), UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CLARKSON B, 1991, CANCER CELL-MON REV, V3, P211; CLEARY ML, 1993, NEW ENGL J MED, V329, P958, DOI 10.1056/NEJM199309233291311; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; GEBHART E, 1987, BIOL ZBL, V106, P191; GERMAN J, 1983, CHROMOSOME MUTATION; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HEIM S, 1987, CANCER CYTOGENETICS; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORAK E, 1991, ONCOGENE, V6, P2277; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOPROWSKI H, 1985, SOMAT CELL MOLEC GEN, V11, P297, DOI 10.1007/BF01534687; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOEB LA, 1991, CANCER RES, V51, P3075; MARX J, 1993, SCIENCE, V261, P1385, DOI 10.1126/science.8367721; MINNA J, 1991, ACCOMPLISHMENTS CANC, P243; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NOWELL PC, 1988, CANCER GENET CYTOGEN, V33, P155, DOI 10.1016/0165-4608(88)90025-8; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; OOKAWA K, 1993, ONCOGENE, V8, P2175; PARMITER AH, 1993, J INVEST DERMATOL, V100, pS254, DOI 10.1038/jid.1993.46; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROTH MS, 1992, BLOOD, V79, P276; ROWLEY JD, 1990, CANCER RES, V50, P3816; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	41	17	17	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					408	413		10.1096/fasebj.8.6.8168690	http://dx.doi.org/10.1096/fasebj.8.6.8168690			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168690				2022-12-28	WOS:A1994NH25000007
J	SUGDEN, MC; HOLNESS, MJ				SUGDEN, MC; HOLNESS, MJ			INTERACTIVE REGULATION OF THE PYRUVATE-DEHYDROGENASE COMPLEX AND THE CARNITINE PALMITOYLTRANSFERASE SYSTEM	FASEB JOURNAL			English	Review						PYRUVATE DEHYDROGENASE; KINASE; CARNITINE; PALMITOYLTRANSFERASE; LIPOPROTEIN LIPASE; GLUCOSE FATTY ACID CYCLE	RAT-LIVER MITOCHONDRIA; FATTY-ACID OXIDATION; TO-FED TRANSITION; LONGER-TERM REGULATION; BROWN ADIPOSE-TISSUE; MALONYL-COA; SKELETAL-MUSCLE; GLUCOSE-UTILIZATION; STARVED TRANSITION; HEART-MITOCHONDRIA	The review examines the mechanisms regulating the activities of the two kev enzymes determining rates of glucose and fatty acid oxidation, i.e. the pyruvate dehydrogenase (PDH) complex and the carnitine palmitoyltransferase (CPT) system. The review also evaluates the regulatory importance of gene expression in the control of tissue fuel selection within the context of substrate competition between glucose and fatty acids. It identifies a strong indirect input of nutrient-gene interactions in the control of pyruvate oxidation through the regulated provision of pyruvate as a substrate for PDH and as an inhibitor of PDH kinase. Nutrient-gene interactions are also identified in relation to the regulation of CPT I activity by malonyl-CoA (inhibitor) and by the provision of long-chain acyl-CoA (substrate/activator), the latter via the hydrolysis of plasma or tissue triacylglycerol (by lipoprotein lipase and hormone-sensitive lipase, respectively). We discuss how such regulation is reinforced by long-term modulation of PDH kinase-specific activity and CPT I maximal activity. We also explore the role of mechanisms operating at the levels of the PDH complex and the CPT system that act to promote and accelerate a switch in fuel utilization once a committed change in nutrient supply has been established. In particular, we discuss the regulatory influences exerted by altered sensitivities of PDH kinase to inhibition by pyruvate and CPT I to inhibition by malonyl-CoA, respectively.			SUGDEN, MC (corresponding author), UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT BIOCHEM BASIC MED SCI, MILE END RD, LONDON EL 4NS, ENGLAND.							BELFRAGE P, 1985, NEW PERSPECTIVES ADI, P121; BRADY PS, 1989, BIOCHEM J, V258, P677, DOI 10.1042/bj2580677; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; BROWNSEY RW, 1987, ENZYMES B, V18, P123, DOI DOI 10.1016/S1874-6047(08)60256-5; CATERSON ID, 1982, BIOCHEM J, V208, P53, DOI 10.1042/bj2080053; CHEN MT, 1992, METABOLISM, V41, P564, DOI 10.1016/0026-0495(92)90221-U; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; COPLPACK SW, 1992, METABOLISM, V41, P264; COPPACK SW, 1990, CLIN SCI, V79, P339, DOI 10.1042/cs0790339; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; DENYER GS, 1989, FEBS LETT, V250, P464, DOI 10.1016/0014-5793(89)80777-X; DENYER GS, 1991, PFLUG ARCH EUR J PHY, V419, P115, DOI 10.1007/BF00372995; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FATANIA HR, 1986, BIOCHEM J, V234, P233, DOI 10.1042/bj2340233; FRAYN KN, 1992, P NUTR SOC, V51, P409, DOI 10.1079/PNS19920054; FRENCH TJ, 1988, BIOCHEM J, V250, P773, DOI 10.1042/bj2500773; FULLER SJ, 1984, BIOCHEM J, V219, P635, DOI 10.1042/bj2190635; FULLER SJ, 1992, BIOCHEM J, V281, P121, DOI 10.1042/bj2810121; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HOLNESS MJ, 1990, BIOCHEM J, V268, P77, DOI 10.1042/bj2680077; HOLNESS MJ, 1986, BIOCHEM J, V235, P441, DOI 10.1042/bj2350441; HOLNESS MJ, 1990, BIOCHEM J, V270, P245, DOI 10.1042/bj2700245; HOLNESS MJ, 1989, BIOCHEM J, V264, P771, DOI 10.1042/bj2640771; HOLNESS MJ, 1989, BIOCHEM J, V258, P529, DOI 10.1042/bj2580529; HOLNESS MJ, 1988, BIOCHEM J, V252, P325, DOI 10.1042/bj2520325; HOLNESS MJ, 1991, BIOCHEM J, V273, P233, DOI 10.1042/bj2730233; HUTSON NJ, 1978, FEBS LETT, V92, P73, DOI 10.1016/0014-5793(78)80724-8; HUTSON NJ, 1978, BIOCHEM J, V173, P669, DOI 10.1042/bj1730669; JENKINS AB, 1988, J CLIN INVEST, V82, P293, DOI 10.1172/JCI113586; JONES BS, 1992, BIOCHIM BIOPHYS ACTA, V1134, P164, DOI 10.1016/0167-4889(92)90040-I; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KERBEY AL, 1982, BIOCHEM J, V206, P103, DOI 10.1042/bj2060103; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; MARCHINGTON DR, 1990, BIOCHEM J, V267, P245, DOI 10.1042/bj2670245; MARCHINGTON DR, 1987, BIOCHEM J, V246, P233, DOI 10.1042/bj2460233; MCGARRY JD, 1973, J BIOL CHEM, V248, P270; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1987, ANNU REV NUTR, V7, P51, DOI 10.1146/annurev.nu.07.070187.000411; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MILLIGAN G, 1990, BIOCHEM J, V270, P765, DOI 10.1042/bj2700765; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; MITCHELL FM, 1989, BIOCHEM J, V262, P403, DOI 10.1042/bj2620403; MOIR AMB, 1992, BIOCHEM J, V283, P145, DOI 10.1042/bj2830145; MOIR AMB, 1993, BIOCHEM J, V289, P49, DOI 10.1042/bj2890049; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; PARK OJ, 1992, BIOCHEM J, V282, P753, DOI 10.1042/bj2820753; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PEGORIER JP, 1988, BIOCHEM J, V249, P801, DOI 10.1042/bj2490801; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; Randle P J, 1981, Curr Top Cell Regul, V18, P107; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; ROBINSON IN, 1982, BIOCHEM J, V206, P177, DOI 10.1042/bj2060177; RUSSELL RR, 1992, AM J PHYSIOL, V263, pE556, DOI 10.1152/ajpendo.1992.263.3.E556; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAGGERSON D, 1986, BIOCHEM SOC T, V14, P679, DOI 10.1042/bst0140679; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; SALE GJ, 1981, BIOCHEM J, V193, P935, DOI 10.1042/bj1930935; SALE GJ, 1982, BIOCHEM J, V203, P99, DOI 10.1042/bj2030099; SMALL CA, 1989, BIOCHEM J, V258, P67, DOI 10.1042/bj2580067; STACE PB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P201, DOI 10.1016/0167-4889(92)90137-Z; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Sugden Mary C., 1993, Biochemical Society Transactions, V21, p313S; SUGDEN MC, 1993, ADV ENZYME REGUL, V33, P71; SUGDEN MC, 1989, ANN NY ACAD SCI, V573, P314, DOI 10.1111/j.1749-6632.1989.tb15008.x; SUGDEN MC, 1989, BIOCHEM J, V263, P313, DOI 10.1042/bj2630313; SUGDEN MC, 1993, BIOCHEM J, V295, P171, DOI 10.1042/bj2950171; SUGDEN MC, 1993, FEBS LETT, V321, P121, DOI 10.1016/0014-5793(93)80091-8; SUGDEN MC, 1993, BIOCHEM J, V292, P113, DOI 10.1042/bj2920113; SUGDEN MC, 1990, BIOCHEM SOC T, V18, P847, DOI 10.1042/bst0180847; SUGDEN MC, 1989, BIOCHEM J, V262, P669, DOI 10.1042/bj2620669; SUGDEN PH, 1978, BIOCHEM J, V169, P433, DOI 10.1042/bj1690433; VANSCHAFTINGEN E, 1993, DIABETOLOGIA, V36, P581, DOI 10.1007/BF00404065; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; Vernon RG, 1985, NEW PERSPECTIVES ADI, P65; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZAMMIT VA, 1986, BIOCHEM SOC T, V14, P676, DOI 10.1042/bst0140676; ZAMMIT VA, 1989, BIOCHEM J, V263, P89, DOI 10.1042/bj2630089; ZAMMIT VA, 1988, BIOCHEM J, V250, P415, DOI 10.1042/bj2500415	88	103	104	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1994	8	1					54	61		10.1096/fasebj.8.1.8299890	http://dx.doi.org/10.1096/fasebj.8.1.8299890			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299890	Bronze			2022-12-28	WOS:A1994MV28200009
J	WEBB, EC				WEBB, EC			ENZYME NOMENCLATURE - A PERSONAL RETROSPECTIVE	FASEB JOURNAL			English	Editorial Material																		[Anonymous], 1961, REPORT COMMISSION EN; [Anonymous], 1979, ENZYMES; Haldane JBS, 1930, ENZYMES; HOFFMAN-OSTENHOF O., 1950, ENZYMOLOGIA [HAGUE], V14, P72; HOFFMANNOSTENHOF O, 1953, ADV ENZYMOL REL S BI, V14, P219; HOFFMANNOSTENHOF O, 1958, NATURE, V181, P452; 1964, RECOMMENDATIONS INT; 1992, RECOMMENDATIONS INT	8	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1192	1194		10.1096/fasebj.7.12.8375619	http://dx.doi.org/10.1096/fasebj.7.12.8375619			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375619				2022-12-28	WOS:A1993LW81700017
J	FERKOL, T; LINDBERG, GL; CHEN, J; PERALES, JC; CRAWFORD, DR; RATNOFF, OD; HANSON, RW				FERKOL, T; LINDBERG, GL; CHEN, J; PERALES, JC; CRAWFORD, DR; RATNOFF, OD; HANSON, RW			REGULATION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE HUMAN FACTOR-IX GENE INTRODUCED INTO THE LIVERS OF ADULT-RATS BY RECEPTOR-MEDIATED GENE-TRANSFER	FASEB JOURNAL			English	Article						ASIALOGLYCOPROTEIN RECEPTOR; HUMAN COAGULATION FACTOR-IX; PHOSPHOENOLPYRUVATE CARBOXYKINASE PROMOTER; GENE THERAPY; LIVER	GROWTH-HORMONE GENE; HEMOPHILIA-B; ASIALOGLYCOPROTEIN RECEPTOR; EXPRESSION INVIVO; DEFICIENT RABBITS; SKIN FIBROBLASTS; TRANSGENIC MICE; THERAPY; CELLS; DNA	Gene transfer systems targeting the asialoglycoprotein receptor have been developed to introduce functional genes into cells in culture and livers of intact animals. A synthetic neoglycoprotein carrier was constructed and complexed to a chimeric gene containing the cDNA for human factor IX ligated to the promoter-regulatory region of the gene for phosphoenolpyruvate carboxykinase from the rat. The complex was used to transfect human hepatoma cells that express the asialoglycoprotein receptor. Human factor IX DNA sequences were found in cells 10 days after treatment. A 1.4 kB mRNA transcript was detected by Northern blot hybridization, which was inducible by treatment with dexamethasone or cAMP with theophylline. Western blot hybridization of proteins secreted into the culture medium detected human factor IX. The chimeric gene was also transferred into livers of rats using the neoglycoprotein carrier system after partial hepatectomy. Although the results were variable, the exogenous gene was transcribed in livers of several animals, and maximal levels of expression of the fully processed human factor IX were detected 30 days after introduction. The concentration of factor IX in the blood returned to control levels 60 days after transfection. Factor IX production was induced as late as 96 days after treatment by feeding transfected animals a diet high in protein but devoid of carbohydrates. This DNA carrier system can be used to introduce functional genes into the livers of rats, and may be a useful technique for gene therapy targeting the liver.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; RAINBOW BABIES & CHILDRENS HOSP,DEPT PEDIAT,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University Hospitals of Cleveland; Case Western Reserve University			PERALES, JOSE C. C/D-5586-2012; PERALES, JOSE C/J-7457-2017; PERALES, JOSE C./AAC-3156-2019	PERALES, JOSE C. C/0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; PERALES, JOSE C./0000-0001-7363-2226	NHLBI NIH HHS [HL01661] Funding Source: Medline; NIDDK NIH HHS [DK21859, DK24451] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, R37DK021859] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AACH RD, 1978, VIRAL HEPATITIS; ANDERSON WF, 1992, SCIENCE, V256, P809; ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; AXELROD JH, 1990, P NATL ACAD SCI USA, V87, P5173, DOI 10.1073/pnas.87.13.5173; Battey, 1986, BASIC METHODS MOL BI; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CLARKE BL, 1989, BIOCHEM J, V262, P277, DOI 10.1042/bj2620277; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; EVANS JP, 1989, BLOOD, V74, P207; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GEBARA MM, 1987, MOL CELL BIOL, V7, P1459, DOI 10.1128/MCB.7.4.1459; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWARD DJ, 1982, J BIOL CHEM, V257, P2856; JAFFE HW, 1985, JAMA-J AM MED ASSOC, V254, P770; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Maniatis T, 1989, DECONTAMINATION DILU; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MILLAND J, 1991, FEBS LETT, V279, P184, DOI 10.1016/0014-5793(91)80144-R; MILLER AD, 1990, BLOOD, V76, P271; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PALMER TD, 1989, BLOOD, V73, P438; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; RATNOFF OD, 1962, BIOCHEMISTRY-US, V1, P967, DOI 10.1021/bi00912a005; RATNOFF OD, 1968, TREATMENT HEMORRHAGI; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SELDEN RF, 1987, NEW ENGL J MED, V317, P1067; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; THOMPSON AR, 1986, BLOOD, V67, P565; VERMEER C, 1986, HAEMOSTASIS, V16, P239; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	49	52	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1081	1091		10.1096/fasebj.7.11.8370479	http://dx.doi.org/10.1096/fasebj.7.11.8370479			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370479				2022-12-28	WOS:A1993LT83900015
J	MEYER, HE; EISERMANN, B; HEBER, M; HOFFMANNPOSORSKE, E; KORTE, H; WEIGT, C; WEGNER, A; HUTTON, T; DONELLADEANA, A; PERICH, JW				MEYER, HE; EISERMANN, B; HEBER, M; HOFFMANNPOSORSKE, E; KORTE, H; WEIGT, C; WEGNER, A; HUTTON, T; DONELLADEANA, A; PERICH, JW			STRATEGIES FOR NONRADIOACTIVE METHODS IN THE LOCALIZATION OF PHOSPHORYLATED AMINO-ACIDS IN PROTEINS	FASEB JOURNAL			English	Review						PHOSPHOTYROSINE; PHOSPHOSERINE; PHOSPHOPROTEIN; PHOSPHOTHREOUINE; MASS SPECTROMETRY; SEQUENCE ANALYSIS	PHOSPHOTYROSINE-CONTAINING PEPTIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; SEQUENCE-ANALYSIS; CAPILLARY ELECTROPHORESIS; S-ETHYLCYSTEINE; KINASE; SITES; PHOSPHOSERINE; IDENTIFICATION; RECEPTOR	Identification of O-phosphorylated amino acids within the primary structure of regulatory proteins is important in understanding the mechanisms by which their functions are regulated. In many cases radioactive labeling with [P-32]phosphate is tedious or sometimes impossible. Therefore, we have established a series of new non-radioactive methods that permit the localization of phosphoserine, phosphothreonine, and phosphotyrosine. After partial hydrolysis of a phosphopeptide or phosphoprotein, phosphoserine, phosphothreonine, or phosphotyrosine are determined by capillary electrophoresis as their dabsyl-derivatives. Chemical modification transforms phosphoserine or phosphothreonine to S-ethyl-cysteine or beta-methyl-S-ethyl-cysteine, respectively, allowing their localization during sequence analysis. We apply solid-phase sequencing to overcome the limitations of the gas-phase sequenator in the case of phosphotyrosine-containing peptides. Liquid chromatography on-line connected to an electrospray mass spectrometer is a powerful new method of increasing importance in the protein chemistry field. It is especially well suited for identification of phosphoserine- or phosphothreonine-containing peptides in a proteolytic digest of a phosphoprotein. In this article we will describe how to work with these new methods practically.	FISONS INSTRUMENTS VG BIOTECH, ALTRINCHAM WA14 5RZ, CHESHIRE, ENGLAND; UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY; UNIV MELBOURNE, SCH CHEM, PARKVILLE, VIC 3052, AUSTRALIA	University of Padua; University of Melbourne	MEYER, HE (corresponding author), RUHR UNIV BOCHUM, BIOCHEM SUPRAMOLEK SYST ABT, INST PHYSIOL CHEM 1, W-4630 BOCHUM, GERMANY.							ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; BANDI HR, 1993, IN PRESS J BIOLC HEM; BANDI HR, 1991, CELLULAR REGULATION, P245; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; CHENG YF, 1988, SCIENCE, V242, P562, DOI 10.1126/science.3140381; CRAIG AG, 1991, BIOL MASS SPECTROM, V20, P565, DOI 10.1002/bms.1200200910; CRAIG AG, 1991, ADV LIF SCI, P275; DEDNER N, 1988, FEBS LETT, V236, P77, DOI 10.1016/0014-5793(88)80288-6; GUSKE N, 1992, FEBS LETT, V307, P199; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HEBER M, 1992, CHROMATOGRAPHIA, V33, P347, DOI 10.1007/BF02275916; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MEYER HE, 1987, J CHROMATOGR, V397, P113, DOI 10.1016/S0021-9673(01)84994-3; MEYER HE, 1990, CHROMATOGRAPHIA, V30, P691, DOI 10.1007/BF02269745; MEYER HE, 1990, EUR J BIOCHEM, V188, P367, DOI 10.1111/j.1432-1033.1990.tb15413.x; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MEYER HE, 1993, IN PRESS PROTEIN SEQ; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SCHRODER W, 1991, CELLULAR REGULATION, P79; SCHROEDER W, 1991, BIOCHEMISTRY-US, V30, P3583, DOI 10.1021/bi00228a032; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; VOORTER CEM, 1989, FEBS LETT, V259, P50; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; [No title captured]	33	29	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					776	782		10.1096/fasebj.7.9.7687226	http://dx.doi.org/10.1096/fasebj.7.9.7687226			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	7687226				2022-12-28	WOS:A1993LK43000010
J	BELINSKY, MG; BRITTON, E; DINTERGOTTLIEB, G				BELINSKY, MG; BRITTON, E; DINTERGOTTLIEB, G			MODIFICATION INTERFERENCE ANALYSIS OF A SELF-CLEAVING RNA FROM HEPATITIS-DELTA VIRUS	FASEB JOURNAL			English	Article						HEPATITIS-DELTA VIRUS; RIBOZYME; RNA STRUCTURE	ANTIGENOMIC RNA; CLEAVAGE; RIBOZYMES; SEQUENCES; GENOME	A chemical modification-interference as say was used to evaluate the sequence requirements for self-cleavage of a 73-nucleotide self-cleaving RNA from the genomic hepatitis delta virus (HDV). Twenty-two nucleotides were categorized as individually essential for self-cleavage, shown by loss of activity when modified. All of these required nucleotides fell within 38 nucleotides downstream of the cleavage site, suggesting an essential structural or functional role for this region. Lesser effects were seen for nucleotides further 3' of the cleavage site. and a small number of nucleotides had a negligible effect on the extent of self-cleavage when modified. Several modifications increased the extent of self-cleavage, suggesting these nucleotides may act to inhibit the reaction when unmodified. The functional requirements for certain nucleotides are discussed in the light of structural probing data and conventional mutational analysis available for other HDV RNAs.	DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, 32ND & CHESTNUT ST, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19104 USA	Drexel University; University of Pennsylvania					NIAID NIH HHS [AI 31821] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031821] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELINSKY MG, 1991, NUCLEIC ACIDS RES, V19, P559, DOI 10.1093/nar/19.3.559; BELINSKY MG, 1992, HEPATITIS DELTA VIRU; BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; BROWN DM, 1967, METHODS ENZYMOL    A, V12, P31; CASHMORE AR, 1978, NUCLEIC ACIDS RES, V5, P2485, DOI 10.1093/nar/5.7.2485; CHEN PJ, 1986, P NATL ACAD SCI USA, V83, P8774, DOI 10.1073/pnas.83.22.8774; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; PRASAD Y, 1992, ANTISENSE STRATEGIES, V660, P277; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SMITH JB, 1991, NUCLEIC ACIDS RES, V19, P1285, DOI 10.1093/nar/19.6.1285; SUH YA, 1992, NUCLEIC ACIDS RES, V20, P747, DOI 10.1093/nar/20.4.747; THILL G, 1991, NUCLEIC ACIDS RES, V19, P6519, DOI 10.1093/nar/19.23.6519; VINCZE A, 1973, J AM CHEM SOC, V95, P2677, DOI 10.1021/ja00789a045; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	26	24	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					130	136		10.1096/fasebj.7.1.8422959	http://dx.doi.org/10.1096/fasebj.7.1.8422959			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422959				2022-12-28	WOS:A1993KH88000019
J	BURKE, JM; BERZALHERRANZ, A				BURKE, JM; BERZALHERRANZ, A			INVITRO SELECTION AND EVOLUTION OF RNA - APPLICATIONS FOR CATALYTIC RNA, MOLECULAR RECOGNITION, AND DRUG DISCOVERY	FASEB JOURNAL			English	Article						RNA REPLICATION; RIBOZYME; RNA STRUCTURE; RNA BINDING	SELF-SPLICING RNA; DNA-POLYMERASE; TETRAHYMENA; AMPLIFICATION; SEQUENCE; LIGANDS; BINDING	In vitro selection and in vitro evolution methods represent powerful tools for isolating functional RNA molecules, and are proving to have wide applications in biology. Selection in the absence of living cells is possible because some RNA molecules possess a selectable ''phenotype'' (catalytic activity or ligand binding) as well as a ''genotype'' (nucleotide sequence). This review discusses the basic principles of in vitro selection technology and the application of these methods to isolate RNA molecules with interesting and novel properties. Selection techniques have been used to analyze the structure and function of catalytic RNA molecules (ribozymes), and to isolate novel catalytic structures not found in nature. They are also useful for studying protein-RNA interactions and for isolating RNA molecules that bind specifically to peptides and other ligands. The isolation of RNA molecules with new binding functionalities (aptamers) for both large and small molecules has exciting potential for discovery of new drugs and diagnostic reagents.			BURKE, JM (corresponding author), UNIV VERMONT, VERMONT CANC CTR, MARKEY CTR MOLEC GENET, BURLINGTON, VT 05405 USA.		, John/AAB-5945-2021; Berzal-Herranz, Alfredo/K-8614-2014	Berzal-Herranz, Alfredo/0000-0003-3722-7973				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; HICKE BJ, 1989, EMBO J, V8, P3843, DOI 10.1002/j.1460-2075.1989.tb08562.x; JOSEPH S, 1993, IN PRESS GENES DEV; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; NOMURA M, 1990, TRENDS BIOCHEM SCI, V15, P244, DOI 10.1016/0968-0004(90)90038-D; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	24	50	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					106	112		10.1096/fasebj.7.1.8422956	http://dx.doi.org/10.1096/fasebj.7.1.8422956			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422956				2022-12-28	WOS:A1993KH88000016
J	JAKUBOWSKI, H				JAKUBOWSKI, H			ENERGY-COST OF PROOFREADING INVIVO - THE CHARGING OF METHIONINE TRANSFER-RNAS IN ESCHERICHIA-COLI	FASEB JOURNAL			English	Article						TRANSLATIONAL ACCURACY; DEACYLATION OF AMINOACYL-TRANSFER RNA; S-METHYL-HOMOCYSTEINE THIOLACTONE; METHIONYL-TRANSFER RNA SYNTHETASE	AMINO-ACIDS; SYNTHETASE; HOMOCYSTEINE; MECHANISM; BINDING; MET	Previous in vitro work has shown that Escherichia coli methionyl-tRNA synthetase has a limited ability to discriminate against cognate methionine in the editing site designed for noncognate homocysteine. As a result, a small fraction of the correct product Met-tRNA is deacylated with the formation of a cyclic sulfonium compound, S-methyl-homocysteine thiolactone. This is exploited here to estimate energy costs associated with the destruction of a correct product by methionyl-tRNA synthetase in bacterial cells. In vivo measurements of S-methyl-homocysteine thiolactone indicate that in Escherichia coli 3.3 molecules of Met-tRNA are destroyed by deacylation per 10,000 molecules of Met-tRNA successfully transferring methionine to protein. This number of destroyed molecules of a correct product. Met-tRNA, is 30 times lower than the number of destroyed molecules of an incorrect product, homocysteinyl adenylate. Thus, most of the energy cost of proofreading in vivo is due to editing of the noncognate amino acid.			JAKUBOWSKI, H (corresponding author), UMDNJ, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; BLANQUET S, 1973, EUR J BIOCHEM, V36, P213, DOI 10.1111/j.1432-1033.1973.tb02903.x; BLANQUET S, 1976, J MOL BIOL, V103, P765, DOI 10.1016/0022-2836(76)90208-4; DEV IK, 1984, J BIOL CHEM, V259, P8402; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1988, J THEOR BIOL, V133, P363, DOI 10.1016/S0022-5193(88)80327-8; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JAKUBOWSKI H, 1992, IN PRESS J BIOL CHEM; JAKUBOWSKI HZ, 1977, ANAL BIOCHEM, V82, P29, DOI 10.1016/0003-2697(77)90130-0; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P4507, DOI 10.1073/pnas.76.9.4507; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23	17	11	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					168	172		10.1096/fasebj.7.1.8422964	http://dx.doi.org/10.1096/fasebj.7.1.8422964			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422964				2022-12-28	WOS:A1993KH88000025
J	VANKEULEN, H; GUTELL, RR; GATES, MA; CAMPBELL, SR; ERLANDSEN, SL; JARROLL, EL; KULDA, J; MEYER, EA				VANKEULEN, H; GUTELL, RR; GATES, MA; CAMPBELL, SR; ERLANDSEN, SL; JARROLL, EL; KULDA, J; MEYER, EA			UNIQUE PHYLOGENETIC POSITION OF DIPLOMONADIDA BASED ON THE COMPLETE SMALL SUBUNIT RIBOSOMAL-RNA SEQUENCE OF GIARDIA-ARDEAE, G-MURIS, G-DUODENALIS AND HEXAMITA SP	FASEB JOURNAL			English	Article						RIBOSOMAL RNA; DIPLOMONADIDA; GIARDIA; HEXAMITA; PHYLOGENETIC RELATIONSHIP	DOMAINS ARCHAEA; EVOLUTION; BACTERIA; LAMBLIA; EUCARYA	Complete small-subunit rRNA (SSU-rRNA) coding region sequences were determined for two species of the intestinal parasite Giardia: G. ardeae and G. muris, both belonging to the order Diplomonadida, and a free-living member of this order, Hexamita sp. These sequences were compared to published SSU-rDNA sequences from a third member of the genus Giardia, G. duodenalis (often called G. intestinalis or G. lamblia) and various representative organisms from other taxa. Of the three Giardia sequences analyzed, the SSU-rRNA from G. muris is the smallest (1432 bases as compared to 1435 and 1453 for G. ardeae and G. duodenalis, respectively) and has the lowest G + C content (58.9%). The Hexamita SSU-rRNA is the largest in this group, containing 1550 bases. Because the sizes of the SSU-rRNA are prokaryotic rather than typically eukaryotic, the secondary structures of the SSU-rRNAs were constructed. These structures show a number of typically eukaryotic signature sequences. Sequence alignments based on constraints imposed by secondary structure were used for construction of a phylogenetic tree for these four taxa. The results show that of the four diplomonads represented, the Giardia species form a distinct group. The other diplomonad Hexamita and the microsporidium Vairimorpha necatrix appear to be distinct from Giardia.	OREGON HLTH SCI UNIV, DEPT MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; UNIV COLORADO, BOULDER, CO 80309 USA; UNIV MINNESOTA, SCH MED, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; CHARLES UNIV, DEPT PARASITOL, CS-12844 PRAGUE, CZECHOSLOVAKIA	Oregon Health & Science University; University of Colorado System; University of Colorado Boulder; University of Minnesota System; University of Minnesota Twin Cities; Charles University Prague	VANKEULEN, H (corresponding author), CLEVELAND STATE UNIV, DEPT BIOL, 1983 E 24TH ST, CLEVELAND, OH 44115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048207] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48207] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON S A, 1984, Biotechniques, V2, P66; CAMPBELL SR, 1990, EXP PARASITOL, V71, P470, DOI 10.1016/0014-4894(90)90073-L; CAVALIERSMITH T, 1989, NATURE, V339, P100, DOI 10.1038/339100a0; DEBRY RW, 1992, MOL BIOL EVOL, V9, P537; ERLANDSEN SL, 1990, J PARASITOL, V76, P717, DOI 10.2307/3282988; ERLANDSEN SL, 1987, J PARASITOL, V73, P623, DOI 10.2307/3282146; FILICE FRANCIS P., 1952, UNIV CALIFORNIA PUBL ZOOL, V57, P53; GUTELL RR, 1993, IN PRESS RIBOSOMAL R; HEALEY A, 1990, NUCLEIC ACIDS RES, V18, P4006, DOI 10.1093/nar/18.13.4006; Maniatis T., 1982, MOL CLONING; MEYER EA, 1976, EXP PARASITOL, V39, P101, DOI 10.1016/0014-4894(76)90016-3; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; NEI M, 1990, GENETICS, V125, P873; NEI M, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P90; NICKRENT DL, 1991, NUCLEIC ACIDS RES, V19, P227, DOI 10.1093/nar/19.2.227; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; ROBERTSTHOMSON IC, 1976, GASTROENTEROLOGY, V71, P57; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHLEGEL M, 1991, J MOL EVOL, V32, P64, DOI 10.1007/BF02099930; SIDDALL ME, 1992, J PROTOZOOL, V39, P361, DOI 10.1111/j.1550-7408.1992.tb01465.x; SOGAYAR MIL, 1989, REV I MED TROP, V31, P242, DOI 10.1590/S0036-46651989000400006; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Thompson R. C. A., 1990, Protozoological Abstracts, V14, P1; VANKEULEN H, 1991, MOL BIOCHEM PARASIT, V46, P275, DOI 10.1016/0166-6851(91)90051-7; WENMAN WM, 1986, CAN J MICROBIOL, V32, P926, DOI 10.1139/m86-171; WINKER S, 1991, SYST APPL MICROBIOL, V14, P305, DOI 10.1016/S0723-2020(11)80303-6; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983	30	63	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					223	231		10.1096/fasebj.7.1.8422968	http://dx.doi.org/10.1096/fasebj.7.1.8422968			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422968				2022-12-28	WOS:A1993KH88000034
J	THORPE, C; KIM, JJP				THORPE, C; KIM, JJP			FLAVOPROTEIN STRUCTURE AND MECHANISM .3. STRUCTURE AND MECHANISM OF ACTION OF THE ACYL-COA DEHYDROGENASES	FASEB JOURNAL			English	Review						FLAVOPROTEIN; CRYSTAL STRUCTURE; FATTY ACID OXIDATION DISORDERS; ELECTRON-TRANSFERRING FLAVOPROTEIN	COENZYME-A DEHYDROGENASE; ELECTRON-TRANSFERRING FLAVOPROTEIN; REDUCTIVE HALF-REACTION; PIG-LIVER MITOCHONDRIA; MEDIUM-CHAIN; BUTYRYL-COA; ESCHERICHIA-COLI; SITE MUTANT; WILD-TYPE; KIDNEY	Mitochondrial beta-oxidation involves a family of flavoproteins that introduce a C-C double bond into their fatty acyl-CoA substrates, Deficiencies of these acyl-CoA dehydrogenases lead to fatty acid oxidation disorders involving life-threatening episodes of metabolic derangement. This review focuses on the medium chain acyl-CoA dehydrogenase as the best-understood member of its class. The crystal structure of the enzyme and salient features of its substrate specificity and mechanism of action are summarized, The surprising observation of a catalytically essential amino acid residue that nevertheless is not conserved in the acyl-CoA dehydrogenase family is discussed.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin	THORPE, C (corresponding author), UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076, R01GM026643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26643, GM29076] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1994, J BIOL CHEM, V269, P19088; BECKER DF, 1993, BIOCHEMISTRY-US, V32, P10736, DOI 10.1021/bi00091a026; BECKER DF, 1994, BIOCHEMISTRY-US, V33, P7082, DOI 10.1021/bi00189a010; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; Beinert H., 1963, ENZYMES, P447; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; BROSS P, 1990, J BIOL CHEM, V265, P7116; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; COATES PM, 1992, NEW DEV FATTY ACID O, P271; CRANE FL, 1956, J BIOL CHEM, V218, P717; CUMMINGS JG, 1992, BIOCHEMISTRY-US, V31, P8523, DOI 10.1021/bi00151a020; DJORDJEVIC S, 1994, BIOCHEMISTRY-US, V33, P4258, DOI 10.1021/bi00180a021; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; Engel P. C., 1992, CHEM BIOCH FLAVOENZY, P597; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11945; Ghisla S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P283; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; HERRICK KR, 1994, J BIOL CHEM, V269, P32239; IKEDA Y, 1985, J BIOL CHEM, V260, P1326; JOHNSON BD, 1993, BIOCHEMISTRY-US, V32, P10799; JOHNSON JK, 1992, BIOCHEMISTRY-US, V31, P10564, DOI 10.1021/bi00158a020; KIM JJ, 1992, NEW DEV FATTY ACID O; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; KOLVRAA S, 1982, CLIN CHIM ACTA, V126, P53, DOI 10.1016/0009-8981(82)90361-8; LAI MT, 1993, J AM CHEM SOC, V115, P1619, DOI 10.1021/ja00058a001; LAU SM, 1988, BIOCHEMISTRY-US, V27, P5089, DOI 10.1021/bi00414a021; LAU SM, 1989, BIOCHEMISTRY-US, V28, P8255, DOI 10.1021/bi00446a043; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LENN ND, 1990, BIOCHEMISTRY-US, V29, P3709, DOI 10.1021/bi00467a017; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mayhew S.G., 1975, ENZYMES, V12, P57; MCKEAN MC, 1979, J BIOL CHEM, V254, P2730; Muller F., 1975, REACTIVITY FLAVINS, P51; MURFIN WW, 1974, THESIS WASHINGTON U; Nandy A, 1994, FLAVINS AND FLAVOPROTEINS 1993, P327; NISHINA Y, 1992, J BIOCHEM-TOKYO, V111, P699, DOI 10.1093/oxfordjournals.jbchem.a123822; POWELL PJ, 1988, BIOCHEMISTRY-US, V27, P8022, DOI 10.1021/bi00421a008; POWELL PJ, 1987, BIOCHEMISTRY-US, V26, P3704, DOI 10.1021/bi00386a066; REINSCH J, 1980, J BIOL CHEM, V255, P9093; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; SAIJO T, 1994, J BIOL CHEM, V269, P4401; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SCHOPFER LM, 1988, BIOCHEMISTRY-US, V27, P6599, DOI 10.1021/bi00417a059; STEENKAMP DJ, 1987, BIOCHEM J, V243, P519, DOI 10.1042/bj2430519; TANAKA K, 1992, NEW DEV FATTY ACID O, P95; THORPE C, 1983, BIOCHEMISTRY-US, V22, P2972, DOI 10.1021/bi00281a029; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; WANG R, 1991, BIOCHEMISTRY-US, V30, P7895, DOI 10.1021/bi00246a004; WENZ A, 1981, J BIOL CHEM, V256, P9809; WHITE SA, 1994, J MOL BIOL, V240, P265, DOI 10.1006/jmbi.1994.1440; WILLIAMSON G, 1982, J BIOL CHEM, V257, P4314; YOKOTA I, 1992, J BIOL CHEM, V267, P26004	55	164	179	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					718	725		10.1096/fasebj.9.9.7601336	http://dx.doi.org/10.1096/fasebj.9.9.7601336			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601336				2022-12-28	WOS:A1995RH98200005
J	YODER, MD; JURNAK, F				YODER, MD; JURNAK, F			PROTEIN MOTIFS .3. THE PARALLEL BETA-HELIX AND OTHER COILED FOLDS	FASEB JOURNAL			English	Review						BETA ROLL; PARALLEL BETA DOMAINS; PECTATE LYASES; ALKALINE PROTEASES	3-DIMENSIONAL STRUCTURE; PROTEIN-STRUCTURE; LIPOVITELLIN; RESOLUTION; COMPLEX; MOTIF; ROLL	A new type of structural domain, composed of all parallel beta strands, has been observed within the last year. An analysis of the basic types suggests that there are two distinct classes: the parallel beta helices, which belong to a tri beta-strand category, and the beta roll, which belongs to a di beta-strand category. The novel structural features of each class are described and the proteins belonging to each category are summarized. Proteins with the parallel beta helix fold include three pectate lyases and the tailspike protein from P22 phage. Proteins with the beta roll fold include two alkaline proteases. Although the parallel beta composition is emphasized, the same set of proteins share another common structural feature with several other proteins containing alpha helices: the polypeptide backbone is folded into a coiled structure in which each coil has the same 3-dimensional arrangement of a group of secondary structural elements, In addition to parallel beta domains, the other groups include the alpha/beta coiled fold, as represented by ribonuclease inhibitor, and the alpha/alpha coiled fold, as represented by lipovitellin and soluble lytic transglycoslyase. Novel features of the alpha/beta and alpha/alpha coiled folds are summarized.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV MISSOURI,SCH BIOL SCI,DIV CELL BIOL & BIOPHYS,KANSAS CITY,MO 64110	University of California System; University of California Riverside; University of Missouri System; University of Missouri Kansas City								BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, IN PRESS J MOL BIOL; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CHOTHIA C, 1993, STRUCTURE, V1, P217, DOI 10.1016/0969-2126(93)90010-E; COLLOCH N, 1991, J MOL BIOL, V221, P603, DOI 10.1016/0022-2836(91)80075-6; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; HENRISSAT B, IN PRESS PLANT PHYSL; KOBE B, 1993, NATURE, V266, P751; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; MAKHOV AM, 1994, J MOL BIOL, V241, P110, DOI 10.1006/jmbi.1994.1478; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; SPRANG SR, 1993, TRENDS BIOCHEM SCI, V18, P313; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	27	87	87	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					335	342		10.1096/fasebj.9.5.7896002	http://dx.doi.org/10.1096/fasebj.9.5.7896002			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896002				2022-12-28	WOS:A1995QP45100004
J	WEIR, EK; ARCHER, SL				WEIR, EK; ARCHER, SL			THE MECHANISM OF ACUTE HYPOXIC PULMONARY VASOCONSTRICTION - THE TALE OF 2 CHANNELS	FASEB JOURNAL			English	Article						HYPOXIA; PULMONARY VASCULAR SMOOTH MUSCLE; REDOX; POTASSIUM CHANNEL; CALCIUM CHANNEL	PERFUSED RAT LUNG; VASCULAR TONE; K+ CHANNELS; POTASSIUM CHANNELS; REDOX STATE; INHIBITION; ARTERIES; CELLS; RESPONSES; CALCIUM	Hypoxia causes constriction in small pulmonary arteries and dilatation in systemic arteries. Hypoxic pulmonary vasoconstriction (HPV) is an important mechanism by which pulmonary blood flow is controlled in the fetus and by which local lung perfusion is matched to ventilation in the adult. HPV reduces the flow of desaturated blood through underventilated areas of lung. Even though many vasoactive substances have been examined as possible mediators of HPV, these appear more likely to be modulators than mediators. Hypoxic contraction has been demonstrated in single pulmonary vascular smooth muscle cells (PVSMC). The ability to sense changes in oxygen tension is observed in PVSMC and type 1 cells of the carotid body. In both cells, hypoxia has been shown to inhibit an outward potassium current, thus causing membrane depolarization and calcium entry through the voltage-dependent calcium channels. In both cells there is evidence to suggest that changes in the redox status of the oxygen-sensitive potassium channel or channels may control current flow, so that the channel is open when oxidized and closed when reduced. The redox status may be determined by the effects of hypoxia on mitochondrial/peroxisomal function or on the activity of an oxidase similar to NAD(P)H oxidase. More studies are needed to precisely define the individual potassium channels responsive to hypoxia and to confirm the gating mechanism. In systemic arteries hypoxia causes an increased current through ATP-dependent potassium channels and vasodilatation, whereas in the pulmonary arteries hypoxia inhibits potassium current vasoconstriction.	UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN	University of Minnesota System; University of Minnesota Twin Cities	WEIR, EK (corresponding author), VET ADM MED CTR 111C,1 VET DR,MINNEAPOLIS,MN 55417, USA.		Archer, Stephen L/C-3621-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; ARCHER S, 1993, CIRCULATION, V88, P1; ARCHER SL, 1986, HERZ, V11, P127; ARCHER SL, 1989, BIOCHEM BIOPH RES CO, V164, P1198, DOI 10.1016/0006-291X(89)91796-8; ARCHER SL, 1989, J APPL PHYSIOL, V67, P1903, DOI 10.1152/jappl.1989.67.5.1903; ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; ARCHER SL, 1989, PULMONARY CIRCULATIO, P87; Bradford J R, 1894, J Physiol, V16, P34; BUCKLER KJ, 1994, J PHYSIOL-LONDON, V476, P423, DOI 10.1113/jphysiol.1994.sp020143; BUESCHER PC, 1991, J APPL PHYSIOL, V70, P1874, DOI 10.1152/jappl.1991.70.4.1874; CHANG SW, 1992, AM J PHYSIOL, V263, P6446; CLAPP LH, 1991, EXP PHYSIOL, V76, P677, DOI 10.1113/expphysiol.1991.sp003535; CORNFIELD D, 1993, AM J PHYSIOL, V265, pL1; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; DEMIERA EV, 1992, BIOCHEM BIOPH RES CO, V186, P1681; Euler Us V, 1946, ACTA PHYSL SCAND, V12, P301, DOI [10.1111/j.1748-1716.1946.tb00389.x, DOI 10.1111/J.1748-1716.1946.TB00389.X]; FARRUKH IS, 1992, AM REV RESPIR DIS, V145, P1389, DOI 10.1164/ajrccm/145.6.1389; FISHER AB, 1976, AM J PHYSIOL, V230, P1198, DOI 10.1152/ajplegacy.1976.230.5.1198; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; HARDER DR, 1985, J APPL PHYSIOL, V59, P1389, DOI 10.1152/jappl.1985.59.5.1389; HASUNUMA K, 1991, AM REV RESPIR DIS, V144, P884, DOI 10.1164/ajrccm/144.4.884; HYMAN AL, 1991, AM J PHYSIOL, V260, pH586, DOI 10.1152/ajpheart.1991.260.2.H586; ISAACSON TC, 1994, J APPL PHYSIOL, V76, P933, DOI 10.1152/jappl.1994.76.2.933; JENSEN KS, 1992, J APPL PHYSIOL, V72, P2018, DOI 10.1152/jappl.1992.72.5.2018; JIN NJ, 1992, AM J PHYSIOL, V263, pL73, DOI 10.1152/ajplung.1992.263.1.L73; KUO SS, 1993, P NATL ACAD SCI USA, V90, P908, DOI 10.1073/pnas.90.3.908; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; LEE S, 1994, PFLUG ARCH EUR J PHY, V427, P378, DOI 10.1007/BF00374548; LOPEZBARNEO J, 1993, NEWS PHYSIOL SCI, V8, P191; MADDEN JA, 1985, J APPL PHYSIOL, V59, P113, DOI 10.1152/jappl.1985.59.1.113; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; MCDONNELL TJ, 1990, AM J PHYSIOL, V259, pH751, DOI 10.1152/ajpheart.1990.259.3.H751; MCMURTRY IF, 1985, AM J PHYSIOL, V249, pH741, DOI 10.1152/ajpheart.1985.249.4.H741; MCMURTRY IF, 1976, CIRC RES, V38, P99, DOI 10.1161/01.RES.38.2.99; MEURY J, 1990, ARCH MICROBIOL, V154, P475, DOI 10.1007/BF00245231; OMAR HA, 1992, AM J PHYSIOL, V262, pL560, DOI 10.1152/ajplung.1992.262.5.L560; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; POST JM, 1993, ION FLUX PULMONARY V, P189; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROUNDS S, 1981, CIRC RES, V48, P393, DOI 10.1161/01.RES.48.3.393; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SALVATERRA CG, 1993, AM J PHYSIOL, V264, pL323, DOI 10.1152/ajplung.1993.264.3.L323; SHEEHAN DW, 1994, AM J RESP CRIT CARE, V149, pA293; SHIRAI M, 1986, J APPL PHYSIOL, V61, P440, DOI 10.1152/jappl.1986.61.2.440; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; STANBROOK HS, 1983, J APPL PHYSIOL, V55, P1467, DOI 10.1152/jappl.1983.55.5.1467; SYLVESTER JT, 1978, CIRC RES, V43, P429, DOI 10.1161/01.RES.43.3.429; THOMAS HM, 1991, BIOCHEM PHARMACOL, V42, pR9, DOI 10.1016/0006-2952(91)90440-G; TOLINS M, 1986, J APPL PHYSIOL, V60, P942, DOI 10.1152/jappl.1986.60.3.942; VADULA MS, 1993, AM J PHYSIOL, V265, pL591, DOI 10.1152/ajplung.1993.265.6.L591; VOELKEL NF, 1986, AM REV RESPIR DIS, V133, P1186; WEIR EK, 1994, J APPL PHYSIOL, V76, P2611, DOI 10.1152/jappl.1994.76.6.2611; WEIR EK, 1982, B EUR PHYSIOPATH RES, V18, P81; WEIR EK, 1983, P SOC EXP BIOL MED, V173, P96; WIENER CM, 1991, J CLIN INVEST, V88, P500, DOI 10.1172/JCI115331; WYATT CN, 1994, NEUROSCI LETT, V172, P63, DOI 10.1016/0304-3940(94)90663-7; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; YUAN XJ, 1994, AM J PHYSIOL, V267, pL52, DOI 10.1152/ajplung.1994.267.1.L52; YUAN XJ, 1990, AM J PHYSIOL, V259, pH281, DOI 10.1152/ajpheart.1990.259.2.H281; YUAN XJ, 1993, AM J PHYSIOL, V264, pL107, DOI 10.1152/ajplung.1993.264.2.L107; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	65	379	384	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					183	189		10.1096/fasebj.9.2.7781921	http://dx.doi.org/10.1096/fasebj.9.2.7781921			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781921				2022-12-28	WOS:A1995QJ24900006
J	CLORE, GM; GRONENBORN, AM				CLORE, GM; GRONENBORN, AM			3-DIMENSIONAL STRUCTURES OF ALPHA-CHEMOKINES AND BETA-CHEMOKINES	FASEB JOURNAL			English	Review						TERTIARY STRUCTURE; QUATERNARY STRUCTURE; NMR; X-RAY CRYSTALLOGRAPHY	3-DIMENSIONAL STRUCTURE; FUNCTIONAL EXPRESSION; RECEPTOR-BINDING; CYTOKINE FAMILY; INTERLEUKIN-8; BIOLOGY	Members of the chemokine family of proteins play a key role in the orchestration of the immune response. This family has been further divided into two subfamilies, alpha and beta, based on sequence, function, and chromosomal location. To date, the three-dimensional structures of two members of the alpha subfamily, interleukin-8 (IL-8) and platelet factor 4, and one member of the beta subfamily, human macrophage inflammatory protein-1 beta (hMIP-1 beta), have been solved by either NMR or X-ray crystallography. In this review, we discuss their three-dimensional structures and their possible relationship to function. The structures of the monomers are very similar, as expected from the significant degree of sequence identity between these proteins. The quaternary structures of the alpha and beta chemokines, however, are entirely distinct and the dimer interface is formed by a completely different set of residues. Whereas the IL-8 dimer is globular, the hMIP-1 beta dimer is elongated and cylindrical. Platelet factor 4 is a tetramer comprising a dimer of dimers of the IL-8 type. The IL-8 dimer comprises a six stranded anti-parallel beta-sheet, three strands contributed by each subunit, on top of which lie two antiparallel helices separated by approximately 14 Angstrom, and the symmetry axis is located between residues 26 and 26' (equivalent to residue 29 of hMIP-1 beta) at the center of strands beta(1) and beta(1)'. In contrast, in the hMIP-1 beta dimer the symmetry axis is located between residues 10 and 10' which are part of an additional mini-antiparallel beta-sheet formed by strands beta(0) and beta(0)'; the two helices are 46 Angstrom apart on opposite sides of the molecule; and strands beta(1) and beta(1)' are about 30 Angstrom apart and located on the exterior of the protein. Calculation of the solvation free energies of dimerization and analysis of hydrophobic clusters strongly suggests that the formation and stabilization of the two different types of dimers arise from the burial of hydrophobic residues, and that the distinct quaternary structures are preserved throughout the two subfamilies. The implications with regard to receptor recognition and the absence of cross-binding between the two subfamilies are discussed.			CLORE, GM (corresponding author), NIDDKD,CHEM PHYS LAB,BLDG 5,BETHESDA,MD 20892, USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; COVELL DG, 1994, IN PRESS PROTEIN SCI; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1992, J BIOL CHEM, V268, P7283; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HERBERT CA, 1991, J BIOL CHEM, V266, P18989; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1993, J BIOL CHEM, V268, P7125; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	26	112	114	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					57	62		10.1096/fasebj.9.1.7821760	http://dx.doi.org/10.1096/fasebj.9.1.7821760			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821760				2022-12-28	WOS:A1995QD20200010
J	LEA, S; STUART, D				LEA, S; STUART, D			ANALYSIS OF ANTIGENIC SURFACES OF PROTEINS	FASEB JOURNAL			English	Article						EVOLUTION; IMMUNE SYSTEM; PROTEIN-PROTEIN INTERACTIONS	MOUTH-DISEASE VIRUS; 3-DIMENSIONAL STRUCTURE; ANTIBODY-BINDING; 2.8-A RESOLUTION; 3.0-A RESOLUTION; 2.0-A RESOLUTION; POLIOVIRUS; REFINEMENT; DETERMINANTS; CHEMISTRY	The processes underlying molecular evolution have proved difficult to understand due to the complexity and obscurity of the selective pressures at work. The strong selective pressure to optimize antigen recognition means that antibody paratopes are more favorable systems than most in which to investigate these processes, as are viral epitopes, which evolve under an inverse pressure, rapidly changing to avoid recognition. Because recognition is a property of the surfaces of these molecules we expect that their evolutionary development may be read in the changes in the 3-dimensional array of chemical groups displayed on their surface. We have analyzed the bulk properties of these surfaces and find that there are significant differences in exposed amino acid preferences among 1) a control group of immunologically secluded proteins, 2) binding surfaces of immunoglobulins, and 3) the outer surfaces of picornaviruses. Compared to the control group, the immunoglobulin complementarity determining regions possess a relative excess of serine residues whereas picornaviruses suppress serine but overuse threonine residues, suggesting that the differing selective pressure has led to perturbations in the population of amino acid types on the surface of these proteins. Although these changes may be rationalized in terms of the structure and chemistry of the different side chains, we suggest that there may be a further, genetic component behind the observations: point mutations in the respective codons for serine and threonine lead to markedly different forms of structural variability. The high rate of reselection observed for these residues is in line with this second mechanism.	UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford			Lea, Susan M/B-7678-2009	Lea, Susan M/0000-0001-9287-8053; Stuart, David/0000-0002-3426-4210				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DAVIES DR, 1989, COLD SH Q B, V54, P233; ENGH R, 1989, PROTEIN ENG, V2, P407, DOI 10.1093/protein/2.6.407; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOGLE JM, 1989, PHILOS T ROY SOC B, V323, P467, DOI 10.1098/rstb.1989.0024; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KITSON JDA, 1990, VIROLOGY, V179, P26, DOI 10.1016/0042-6822(90)90269-W; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MALE D, 1987, ADV IMMUNOLOGYY, P34; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MARTINEZ MA, 1992, J VIROL, V66, P3557; MORGUNOVA EY, 1994, FEBS LETT, V338, P267, DOI 10.1016/0014-5793(94)80281-5; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; OVERINGTON J, 1992, PROTEIN SCI, V1, P216; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; ROSSMANN MG, 1976, J MOL BIOL, V105, P75, DOI 10.1016/0022-2836(76)90195-9; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; TAUSSIG MJ, 1984, PROCESSES PATHOLOGY; TULIP WR, 1991, J MOL BIOL, V221, P487, DOI 10.1016/0022-2836(91)80069-7; 1991, PROGRAM MANUAL GCG P	38	16	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					87	93		10.1096/fasebj.9.1.7821764	http://dx.doi.org/10.1096/fasebj.9.1.7821764			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821764				2022-12-28	WOS:A1995QD20200014
J	ZLATANOVA, J; DOENECKE, D				ZLATANOVA, J; DOENECKE, D			HISTONE H1-DEGREES - A MAJOR PLAYER IN CELL-DIFFERENTIATION	FASEB JOURNAL			English	Review						CHROMATIN; PROLIFERATION; MALIGNANT TRANSFORMATION	MURINE ERYTHROLEUKEMIA-CELLS; IMMEDIATE EARLY RESPONSE; H1(0) MESSENGER-RNA; TERMINAL DIFFERENTIATION; RAT-BRAIN; H10 ACCUMULATION; XENOPUS-LAEVIS; LEUKEMIA CELLS; EXPRESSION; CHROMATIN	Histone H1 degrees was initially described as a member of the lysine-rich histone class, typically present in nondividing mammalian cells. Since then it has been found in almost every animal or plant species studied. The protein accumulates in terminally differentiated cells that have stopped dividing. It has also been implicated in changes in chromatin structure and function accompanying malignant transformation. Despite its involvement in these fundamental cellular processes, its precise role remains elusive, as do the molecular mechanisms via which it acts. This review is an attempt to summarize and critically discuss the huge relevant literature, trying to highlight the problems that still await answers.-Zlatanova, J., Doenecke, D., Histone H1 degrees: a major player in cell differentiation?	BULGARIAN ACAD SCI,INST GENET,BU-1113 SOFIA,BULGARIA; UNIV GOTTINGEN,INST BIOCHEM & MOLEC CELL BIOL,D-37073 GOTTINGEN,GERMANY	Bulgarian Academy of Sciences; University of Gottingen	ZLATANOVA, J (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.		Zlatanova, Jordanka/B-3273-2009					ADOLF GR, 1988, COMPT REND ACAD BULG, V41, P137; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BALLAL NR, 1973, CANCER RES, V33, P2737; BANCHEV T, 1988, EXP CELL RES, V177, P1, DOI 10.1016/0014-4827(88)90019-5; BANCHEV TB, 1990, MOL CELL BIOCHEM, V95, P167; BOIX J, 1992, EXP CELL RES, V201, P531, DOI 10.1016/0014-4827(92)90306-S; BOUTERFA H, 1990, EXP CELL RES, V188, P160, DOI 10.1016/0014-4827(90)90292-I; BOUTERFA HL, 1993, EUR J BIOCHEM, V217, P353, DOI 10.1111/j.1432-1033.1993.tb18253.x; BRENEMAN JW, 1993, EXP CELL RES, V206, P16, DOI 10.1006/excr.1993.1115; BREUER B, 1993, NUCLEIC ACIDS RES, V21, P927, DOI 10.1093/nar/21.4.927; CARY PD, 1981, EUR J BIOCHEM, V120, P371, DOI 10.1111/j.1432-1033.1981.tb05714.x; CASTIGLIA D, 1993, NUCLEIC ACIDS RES, V21, P1674, DOI 10.1093/nar/21.7.1674; CESTELLI A, 1992, CELL MOL NEUROBIOL, V12, P33, DOI 10.1007/BF00711637; CHABANAS A, 1985, J MOL BIOL, V183, P141, DOI 10.1016/0022-2836(85)90208-6; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; DANISH R, 1992, ONCOGENE, V7, P901; DAVIE JR, 1987, CANCER RES, V47, P5407; DELABAR JM, 1985, J BIOL CHEM, V260, P2622; DILIEGRO I, 1990, CELL MOL NEUROBIOL, V10, P267, DOI 10.1007/BF00734579; DOENECKE D, 1994, J CELL BIOCHEM, V54, P423, DOI 10.1002/jcb.240540409; DOMINGUEZ V, 1992, DEVELOPMENT, V115, P181; EISEN H, 1981, CELLULAR CONTROLS DI, P215; GABRIELLI F, 1986, MOL CELL BIOCHEM, V71, P129, DOI 10.1007/BF00214771; GABRIELLI F, 1985, MOL CELL BIOCHEM, V65, P57; GARCIAIGLESIAS MJ, 1993, DIFFERENTIATION, V55, P27, DOI 10.1111/j.1432-0436.1993.tb00030.x; GARCIASEGURA LM, 1993, DEV BRAIN RES, V73, P63, DOI 10.1016/0165-3806(93)90046-D; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIRARDET JL, 1988, BIOPHYS CHEM, V31, P275, DOI 10.1016/0301-4622(88)80033-4; GJERSET R, 1981, BIOCHEM BIOPH RES CO, V99, P349, DOI 10.1016/0006-291X(81)91752-6; GJERSET R, 1982, P NATL ACAD SCI-BIOL, V79, P2333, DOI 10.1073/pnas.79.7.2333; GORKA C, 1993, EXP CELL RES, V205, P152, DOI 10.1006/excr.1993.1069; GRUNWALD D, 1991, EXP CELL RES, V194, P174, DOI 10.1016/0014-4827(91)90350-4; HALL JM, 1986, J BIOL CHEM, V261, P5168; HOCHHUTH C, 1990, DIFFERENTIATION, V43, P212, DOI 10.1111/j.1432-0436.1990.tb00448.x; HOCHHUTH C, 1992, J CELL BIOCHEM, V50, P316, DOI 10.1002/jcb.240500312; JAMI J, 1975, TERATOMAS DIFFERENTI, P221; KHOCHBIN S, 1991, FEBS LETT, V283, P65, DOI 10.1016/0014-5793(91)80554-G; KHOCHBIN S, 1993, GENE, V128, P173, DOI 10.1016/0378-1119(93)90560-P; KREIMEYER A, 1985, BIOL CHEM H-S, V366, P537, DOI 10.1515/bchm3.1985.366.1.537; KRESS H, 1986, NUCLEIC ACIDS RES, V14, P7189, DOI 10.1093/nar/14.18.7189; LEA MA, 1987, CANCER BIOCHEM BIOPH, V9, P199; LINDNER H, 1990, BIOCHEM J, V269, P359, DOI 10.1042/bj2690359; LINDNER H, 1993, ELECTROPHORESIS, V14, P480, DOI 10.1002/elps.1150140174; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MANNIRONI C, 1988, CANCER RES, V48, P3670; MANNIRONI C, 1987, BLOOD, V70, P1203; MEDVEDEV ZA, 1990, EXP GERONTOL, V25, P189, DOI 10.1016/0531-5565(90)90050-C; MEDVEDEV ZA, 1982, INT J CANCER, V30, P87, DOI 10.1002/ijc.2910300115; MENDELSON E, 1986, EUR J BIOCHEM, V160, P253, DOI 10.1111/j.1432-1033.1986.tb09964.x; MOORMAN AFM, 1987, DIFFERENTIATION, V35, P100, DOI 10.1111/j.1432-0436.1987.tb00156.x; ORTIZCARO J, 1988, DEV BRAIN RES, V42, P229, DOI 10.1016/0165-3806(88)90241-6; OSBORNE HB, 1984, EXP CELL RES, V152, P449, DOI 10.1016/0014-4827(84)90646-3; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; PEHRSON J, 1980, NATURE, V285, P43, DOI 10.1038/285043a0; PERKINS PS, 1987, DEV BRAIN RES, V33, P161, DOI 10.1016/0165-3806(87)90150-7; PRASAD KN, 1976, IN VITRO CELL DEV B, V12, P125; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; ROUSSEAU D, 1992, EUR J BIOCHEM, V208, P775, DOI 10.1111/j.1432-1033.1992.tb17247.x; ROUSSEAU D, 1991, J MOL BIOL, V217, P85, DOI 10.1016/0022-2836(91)90613-B; RUTLEDGE RG, 1988, GENE, V70, P117, DOI 10.1016/0378-1119(88)90110-2; SMITH BJ, 1984, EUR J BIOCHEM, V138, P309, DOI 10.1111/j.1432-1033.1984.tb07916.x; STAMBOLOVA M, 1984, DIFFERENTIATION, V28, P191, DOI 10.1111/j.1432-0436.1984.tb00283.x; TSANEV R, 1975, P197; VANHEMERT FJ, 1992, MOL BIOL REP, V16, P33, DOI 10.1007/BF00788751; YANEVA J, 1990, FEBS LETT, V263, P225, DOI 10.1016/0014-5793(90)81379-3; ZLATANOVA J, 1992, J CELL SCI, V103, P889; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E; ZLATANOVA J, 1980, IN VIVO IN VITRO ERY, P297; ZLATANOVA JS, 1990, MOL CELL BIOCHEM, V92, P1; ZLATANOVA JS, 1980, FEBS LETT, V112, P19	72	106	110	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1994	8	15					1260	1268		10.1096/fasebj.8.15.8001738	http://dx.doi.org/10.1096/fasebj.8.15.8001738			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PY209	8001738				2022-12-28	WOS:A1994PY20900009
J	MOSCKOVITZ, R; UDENFRIEND, S; FELIX, A; HEIMER, E; TATE, SS				MOSCKOVITZ, R; UDENFRIEND, S; FELIX, A; HEIMER, E; TATE, SS			MEMBRANE TOPOLOGY OF THE RAT-KIDNEY NEUTRAL AND BASIC-AMINO-ACID TRANSPORTER	FASEB JOURNAL			English	Article						BRUSH BORDER MEMBRANES; ANTIPEPTIDE ANTIBODIES; IMMUNOFLUORESCENCE; LIMITED PROTEOLYSIS	EXPRESSION CLONING; PROTEINS; CDNA; CYSTINE; LOCALIZATION; BIOSYNTHESIS; ANTIBODIES; PEPTIDASES; SYSTEM	A recently cloned rat kidney protein (NBAT) mediates the sodium-independent transport of neutral as well as basic amino acids and cystine when expressed in Xenopus laevis oocytes. The human equivalent of this transporter may be the one that is defective in cystinuria. Immunocytochemical studies have indicated that NBAT is primarily localized in the brush border membranes of rat kidney and intestinal epithelial cells, a localization consistent with its proposed role in amino acid transport. Two contrasting topological models have been proposed for NBAT: a four membrane-spanning domain (MSD) Nin-Cin model and a single MSD Nin-Cout model. We have investigated the topology of this membrane protein using two different approaches. One method was an immunofluorescent labeling technique in which intact or membrane-permeabilized cells expressing NBAT were probed with antibodies directed against putative extracellular and intracellular domains of the protein. In the second method, fragments generated by limited surface proteolysis of intact brush border membrane vesicles were subjected to immunoblot analysis using several site-specific antibodies. Both approaches yielded results consistent with a four MSD Nin-Cin topological model for NBAT.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT PEPTIDE RES,NUTLEY,NJ 07110	Cornell University; Roche Holding; Roche Holding								BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TATE SS, 1985, METHOD ENZYMOL, V113, P471; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	17	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1069	1074		10.1096/fasebj.8.13.7926373	http://dx.doi.org/10.1096/fasebj.8.13.7926373			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926373				2022-12-28	WOS:A1994PN06900012
J	SAXENA, R; SAKSA, BA; HAWKINS, KS; GANZ, MB				SAXENA, R; SAKSA, BA; HAWKINS, KS; GANZ, MB			PROTEIN-KINASE-C BETA(I) AND BETA(II) ARE DIFFERENTIALLY EXPRESSED IN THE DEVELOPING GLOMERULUS	FASEB JOURNAL			English	Article						MESANGIAL CELLS; DEVELOPMENT; MESANGIUM; THY 1.1	PROXIMAL TUBULAR CELLS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; MESANGIAL CELLS; ANGIOTENSIN-II; DEVELOPMENTAL EXPRESSION; EPITHELIAL-CELLS; MESSENGER-RNAS; NPKC-EPSILON; PKC-ALPHA	In the pre- and postnatal period of kidney development, proliferation with subsequent functional maturation of intrinsic glomerular mesangial cells (MCs) continues within the existing framework. Recent work has suggested that PKC beta isoform is responsible for the proliferation observed during maturation. We sought to ascertain whether PKC beta isoform expression is altered during the development of the mesangium. MCs were subcultured from glomerular explants of Sprague-Dawley rat kidneys, days 1, 3, 5, 8, 15 postnatally, and adult. MCs from rat kidneys postnatally days 1-5 proliferated at a significantly greater rate than adult [>1.169-fold, P < 0.01] but term day 8 cells did not [<1.34-fold, not significant)] as assessed by [H-3]thymidine incorporation. Western blot analysis using isoform specific antibodies was performed on confluent neonatal and adult MC. We observed that all neonatal and adult MC express beta(I) PKC (n = 8 kidneys from separate primaries for each date and adult). However, unlike adult MCs, neonatal MC express beta(II) in postnatal days 1-5 and none thereafter. Immunofluorescent staining of postnatal kidneys confirmed that PKC beta(II) is present in neonatal MC up to day 5. By day 8, staining of mesangium with PKC beta(II) begins to disappear and assumes a parietal epithelial pattern. In adult kidneys, there was only PKC beta(II) staining of the parietal epithelial cells. Our results demonstrate that differential expression of PKC beta(II) closely parallels the proliferative behavior of the MCs of the maturing glomerulus. Therefore, PKC beta(II) expression and activation may play a critical role in development.	CASE WESTERN RESERVE UNIV,VET ADM MED CTR,DEPT MED,NEPHROL SECT,CLEVELAND,OH 44106	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BARR LF, 1991, CANCER RES, V51, P5514; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CELSI G, 1991, AM J PHYSIOL, V260, pF192, DOI 10.1152/ajprenal.1991.260.2.F192; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEVALIA V, 1992, BLOOD, V80, P68; DEVAVAL E, 1990, J DEV PHYSL, V14, P1; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EKBLAD H, 1991, TXB CLIN NEPHROLOGY; EKBLOM P, 1981, MED BIOL, V59, P139; ELDHAR SS, 1993, AM J PHYSIOL, V265, pF146; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GANZ MB, 1988, AM J PHYSIOL, V254, pF787, DOI 10.1152/ajprenal.1988.254.6.F787; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GRAIZER GE, 1987, J CELL PHYSL, V133, P169; GUPTAROY B, 1992, J BIOL CHEM, V267, P15326; HATA A, 1993, J BIOL CHEM, V268, P9122; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIEH LL, 1989, J CELL BIOCHEM, V41, P179, DOI 10.1002/jcb.240410403; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JOHNSON RJ, 1993, J AM SOC NEPHROL, V4, P119; KREISBERG JI, 1978, KIDNEY INT, V14, P21, DOI 10.1038/ki.1978.86; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON SH, 1990, ACTA PHYSIOL SCAND, V138, P243, DOI 10.1111/j.1748-1716.1990.tb08841.x; LARSSON SH, 1988, ACTA PHYSIOL SCAND, V132, P129, DOI 10.1111/j.1748-1716.1988.tb08309.x; LARSSON SH, 1990, ACTA PHYSIOL SCAND, V138, P99, DOI 10.1111/j.1748-1716.1990.tb08819.x; LOVETT DH, 1983, J IMMUNOL, V131, P2830; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MOINZ C, 1990, J MOL ENDOCRINOL, V5, P259; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1987, SCIENCE, V236, P116; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; PABST R, 1983, KIDNEY INT, V24, P626, DOI 10.1038/ki.1983.203; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; SAXENA R, 1993, AM J PHYSIOL, V265, pF53, DOI 10.1152/ajprenal.1993.265.1.F53; SECHI LA, 1992, AM J PHYSIOL, V262, pF236, DOI 10.1152/ajprenal.1992.262.2.F236; SHEARMAN MS, 1993, J CELL SCI, V104, P173; SPITZER A, 1971, AM J PHYSIOL, V221, P1431, DOI 10.1152/ajplegacy.1971.221.5.1431; SPITZER A, 1974, J CLIN INVEST, V53, P279, DOI 10.1172/JCI107548; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WINTERS TA, 1993, BIOL REPROD, V48, P1395, DOI 10.1095/biolreprod48.6.1395; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	56	30	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1994	8	9					646	653		10.1096/fasebj.8.9.8005392	http://dx.doi.org/10.1096/fasebj.8.9.8005392			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NR906	8005392				2022-12-28	WOS:A1994NR90600012
J	BARRANTES, FJ				BARRANTES, FJ			STRUCTURAL-FUNCTIONAL CORRELATES OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR AND ITS LIPID MICROENVIRONMENT	FASEB JOURNAL			English	Review						CHOLINERGIC RECEPTOR; LIPID-PROTEIN INTERACTIONS; ION CHANNELS; STRUCTURE-FUNCTION RELATIONSHIPS	MARMORATA ELECTRIC ORGAN; TSCHUDII ELECTROCYTE MEMBRANES; TORPEDO-MARMORATA; RICH MEMBRANES; RECONSTITUTED MEMBRANES; PROTEIN INTERACTIONS; ACTIVATED CHANNELS; LOCAL-ANESTHETICS; NATIVE MEMBRANES; FATTY-ACIDS	Among the proteins specialized in signal transduction, the nicotinic acetylcholine receptor (AChR) is the best-characterized member of the superfamily of ligand-gated ion channels. Since the early finding of a motionally restricted shell of lipids (annulus) encircling the protein in its native membrane (1), there is growing experimental evidence supporting the notion that this interface region is the locus of a variety of pharmacologically relevant processes, including some of the actions of local anesthetics, steroids, and other lipophilic compounds. Biochemical data on the composition and metabolism of AChR-rich membranes and cells, combined with biophysical data on their structure and dynamics, are beginning to provide information on the nature of the annulus itself Patch-clamp data on cells expressing the AChR protein add another dimension to this knowledge, enabling correlations to be established between the chemical composition of lipid-modified cells and the functional properties of the receptor protein in situ at the single-channel level. The effect of free fatty acids, alcohols, phospholipids, cholesterol, and steroid glucocorticoid hormones on the function of the AChR is reviewed. In the case of steroids, their effects at the single-channel level bear a relationship to their use in pathological conditions of medical relevance, e.g., in the treatment of the disease myasthenia gravis.	UNIV NACL SUR, RA-8000 BAHIA BLANCA, ARGENTINA	National University of the South	BARRANTES, FJ (corresponding author), CONSEJO NACL INVEST CIENT & TECN, INST INVEST BIOQUIM, CC 857, RA-8000 BAHIA BLANCA, ARGENTINA.		Barrantes, Francisco J./HCH-0258-2022	Barrantes, Francisco J./0000-0002-4745-681X				ANDREASEN TJ, 1980, BIOCHEMISTRY-US, V19, P4719, DOI 10.1021/bi00561a027; ARIAS HR, 1987, COMP BIOCHEM PHYS B, V86, P623, DOI 10.1016/0305-0491(87)90458-5; ARIAS HR, 1990, BIOCHIM BIOPHYS ACTA, V1027, P287, DOI 10.1016/0005-2736(90)90320-N; ARIAS HR, 1987, NEUROCHEM INT, V11, P101, DOI 10.1016/0197-0186(87)90155-0; ARTIGUES A, 1989, BIOCHIM BIOPHYS ACTA, V985, P325, DOI 10.1016/0005-2736(89)90420-3; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P437, DOI 10.3109/10409238909086961; BARRANTES FJ, 1983, INT REV NEUROBIOL, V24, P259, DOI 10.1016/S0074-7742(08)60224-X; BARRANTES FJ, 1992, MOL NEUROBIOL, V6, P463, DOI 10.1007/BF02757947; BARRANTES FJ, 1993, NEW COMPREHENSIVE BI, V26; BENOIT E, 1988, BRIT J PHARMACOL, V94, P635, DOI 10.1111/j.1476-5381.1988.tb11570.x; BERTRAND D, 1991, NEUROREPORT, V2, P277, DOI 10.1097/00001756-199105000-00016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOLOTINA V, 1989, PFLUG ARCH EUR J PHY, V415, P262, DOI 10.1007/BF00370875; BOUZAT C, 1991, NEUROREPORT, V2, P681, DOI 10.1097/00001756-199111000-00012; BOUZAT C, 1993, NEUROREPORT, V4, P143, DOI 10.1097/00001756-199302000-00007; BOUZAT C, 1993, IN PRESS RECEPTORS C, V1; Bouzat Cecilia B., 1993, Molecular Neuropharmacology, V3, P109; BRAUN MS, 1991, PFLUG ARCH EUR J PHY, V418, P62, DOI 10.1007/BF00370452; CHANGEUX JP, 1986, J PHYSIOL-LONDON, V378, P497, DOI 10.1113/jphysiol.1986.sp016232; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; CRIADO M, 1984, J BIOL CHEM, V259, P9188; DALZIEL AW, 1980, FEBS LETT, V122, P193, DOI 10.1016/0014-5793(80)80435-2; DEROMANELLI ICB, 1990, INT J BIOCHEM, V22, P785, DOI 10.1016/0020-711X(90)90016-V; DEROMANELLI ICB, 1987, BIOCHEM J, V245, P111, DOI 10.1042/bj2450111; DILGER JP, 1991, ANN NY ACAD SCI, V625, P616, DOI 10.1111/j.1749-6632.1991.tb33896.x; DILGER JP, 1992, MOL PHARMACOL, V41, P127; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; ERULKAR SD, 1989, J NEUROPHYSIOL, V61, P1036, DOI 10.1152/jn.1989.61.5.1036; FFRENCHMULLEN JMH, 1991, EUR J PHARMACOL, V202, P269, DOI 10.1016/0014-2999(91)90303-8; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; HORVATH LI, 1990, BIOCHEMISTRY-US, V29, P8707, DOI 10.1021/bi00489a029; INOUE M, 1989, AM J PHYSIOL, V257, pC906, DOI 10.1152/ajpcell.1989.257.5.C906; JONES OT, 1988, BIOCHEMISTRY-US, V27, P3733, DOI 10.1021/bi00410a032; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; MARSH D, 1981, BIOCHIM BIOPHYS ACTA, V645, P97, DOI 10.1016/0005-2736(81)90516-2; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MCNAMEE MG, 1982, BIOPHYS J, V37, P103, DOI 10.1016/S0006-3495(82)84622-5; MIDDLEMAS DS, 1987, BIOCHEMISTRY-US, V26, P1219, DOI 10.1021/bi00379a003; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; OGDEN DC, 1981, NATURE, V289, P596, DOI 10.1038/289596a0; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; ORTELLS MO, 1992, JERUS SYM Q, V25, P185; PEDICONI MF, 1992, LIPIDS, V27, P669, DOI 10.1007/BF02536022; POPOT JL, 1978, EUR J BIOCHEM, V85, P27, DOI 10.1111/j.1432-1033.1978.tb12209.x; RENAUD JF, 1986, P NATL ACAD SCI USA, V83, P8007, DOI 10.1073/pnas.83.20.8007; ROTSTEIN NP, 1987, J NEUROCHEM, V49, P1341, DOI 10.1111/j.1471-4159.1987.tb00997.x; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SINE SM, 1988, CURR TOP MEMBR TRANS, V33, P133; SPENCE KT, 1991, LIFE SCI, V49, pPL235, DOI 10.1016/0024-3205(91)90649-V; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; WOOD SC, 1991, MOL PHARMACOL, V39, P332	53	63	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1993	7	15					1460	1467		10.1096/fasebj.7.15.8262330	http://dx.doi.org/10.1096/fasebj.7.15.8262330			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262330				2022-12-28	WOS:A1993ML74000008
J	KREPS, DM; WHITTLE, SM; HOFFMAN, JM; TOEWS, ML				KREPS, DM; WHITTLE, SM; HOFFMAN, JM; TOEWS, ML			LYSOPHOSPHATIDIC ACID MIMICS SERUM-INDUCED SENSITIZATION OF CYCLIC-AMP ACCUMULATION	FASEB JOURNAL			English	Note						GLIAL CELLS; PHOSPHATIDIC ACID; PHOSPHOLIPASE-C; MITOGENESIS; PERTUSSIS TOXIN	PROTEIN-KINASE-C; HUMAN ASTROCYTOMA-CELLS; ADENYLATE-CYCLASE; PHOSPHATIDIC-ACID; XENOPUS OOCYTES; PHORBOL-ESTER; NEURITE RETRACTION; CAMP ACCUMULATION; MEMBRANE CURRENTS; PHOSPHOLIPASE-C	Pretreatment of 1321N1 human astrocytoma cells with serum induces a pronounced increase in subsequent stimulation by forskolin and other agents of intracellular cyclic AMP accumulation, a phenomenon referred to as sensitization (Mol. Pharmacol. 39, 399-406, 1991). Pretreatment of these cells with lysophosphatidic acid induced sensitization to a similar extent as that with serum (approximately fivefold for forskolin stimulation and twofold for isoproterenol and prostaglandin E1 stimulation), with half-maximal effects at approximately 30 nm lysophosphatidic acid. Phosphatidic acid was effective but less potent whereas other lipids were ineffective. Sensitization by serum and by lysophosphatidic acid were almost completely inhibited by pertussis toxin pretreatment and partially inhibited by prolonged phorbol ester exposure to induce protein kinase C down-regulation. Among nine cell lines tested, those that exhibited sensitization with serum showed comparable sensitization with lysophosphatidic acid. The effects of both lysophosphatidic acid and serum were markedly inhibited by treatment with phospholipase B but only minimally altered with phospholipases A2, D, and C. Exposure of cells to phospholipase C alone induced approximately threefold sensitization, but both serum and lysophosphatidic acid were able to induce further three- to fourfold sensitization above that induced by phospholipase C alone. In contrast, the effects of serum and lysophosphatidic acid were not additive with each other. Together these results suggest that lysophosphatidic acid or a closely related compound present in serum is the factor responsible for sensitization of the cyclic AMP pathway.	UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, 600 S 42ND ST, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center					NIGMS NIH HHS [GM34500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL RL, 1990, J BIOL CHEM, V265, P12836; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; DYER D, 1992, MOL BRAIN RES, V14, P293, DOI 10.1016/0169-328X(92)90096-T; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HOFFMAN JM, 1992, FASEB J, V6, pA1921; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; JALINK K, 1990, J BIOL CHEM, V265, P12232; JOHNSON JA, 1986, J CYCLIC NUCL PROT, V11, P199; JOHNSON RA, 1990, MOL PHARMACOL, V37, P296; JOHNSON RA, 1991, MOL PHARMACOL, V39, P399; JONES SB, 1987, P NATL ACAD SCI USA, V84, P1294, DOI 10.1073/pnas.84.5.1294; LUTTRELL DK, 1992, CELL SIGNAL, V4, P531, DOI 10.1016/0898-6568(92)90022-Z; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MEEKER RB, 1983, MOL PHARMACOL, V23, P384; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MURAYAMA T, 1989, J BIOL CHEM, V264, P15186; PROLL MA, 1985, MOL PHARMACOL, V28, P331; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TOEWS ML, 1992, J PHARMACOL EXP THER, V262, P471; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	30	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1993	7	14					1376	1380		10.1096/fasebj.7.14.8224610	http://dx.doi.org/10.1096/fasebj.7.14.8224610			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224610				2022-12-28	WOS:A1993MH00800010
J	POLLOCK, DM; KEITH, TL; HIGHSMITH, RF				POLLOCK, DM; KEITH, TL; HIGHSMITH, RF			ENDOTHELIN RECEPTORS AND CALCIUM SIGNALING	FASEB JOURNAL			English	Article						CALCIUM; ENDOTHELIAL CELLS; VASCULAR SMOOTH MUSCLE; SIGNAL TRANSDUCTION	VASCULAR SMOOTH-MUSCLE; PULMONARY TISSUES; ANESTHETIZED RAT; CELLS; SUBTYPES; VASOCONSTRICTION; ACTIVATION; RESPONSES; MECHANISM; RELEASE	Endothelin (ET) is a potent vasoactive peptide produced by endothelial cells that elicits prolonged constriction in most smooth mascle preparations and dilation in others, Of three isopeptides, ET-1 is the only form constitutively released and may modulate vascular tone via binding to one of several receptor subtypes in smooth muscle. Activation of the ET(A) receptor is associated with pronounced vasoconstriction whereas ET(B) receptor occupation is linked to vasodilation. In addition, other subtypes of the ET(B) receptor exist, one mediating vasodilation (ET(B1)) and the other eliciting constriction (ET(B2)). An additional receptor subtype, ET(c), has been identified although its physiological significance is uncertain. Distribution of these receptors varies between species and among tissue types, although it has been generally observed that ETA receptors predominate in arterial vessels whereas ET(B) receptors predominate on the low pressure side of the circulation. In vascular smooth muscle, an increase in intracellular Ca2+ is a common feature occurring after activation of all receptor subtypes, Upon binding of ET-1 to ET(A), phospholipase C is activated and inositol triphosphate is generated, Ca2+ is then released from intracellular stores accompanied by the influx of extracellular Ca2+ and activation of the contractile machinery. The precise mechanism by which ET-1 affects intracellular Ca2+ regalation is not fully understood, but most likely involves multiple ion channels, protein kinases, and other intracellular mediators. The events coupled to non-ET(A) receptor signaling are poorly understood.	UNIV CINCINNATI,COLL MED,DEPT MOLEC & CELLULAR PHYSIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	POLLOCK, DM (corresponding author), ABBOTT LABS,PHARMACEUT DISCOVERY,D46R,AP9,100 ABBOTT PK RD,ABBOTT PK,IL 60064, USA.							ABRAHAM WM, 1993, J APPL PHYSIOL, V74, P2537, DOI 10.1152/jappl.1993.74.5.2537; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BIGAUD M, 1992, BRIT J PHARMACOL, V107, P912, DOI 10.1111/j.1476-5381.1992.tb13385.x; BOUSSOMITTLER D, 1991, BIOCHEM BIOPH RES CO, V178, P921, DOI 10.1016/0006-291X(91)90979-H; CHEN C, 1991, CIRC RES, V69, P447, DOI 10.1161/01.RES.69.2.447; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; COLIGORSKY M, 1994, J CELL PHYSL, V158, P485; CRISTOL JP, 1993, BRIT J PHARMACOL, V108, P776, DOI 10.1111/j.1476-5381.1993.tb12877.x; DAVENPORT AP, 1993, J CARDIOVASC PHARM, V22, pS22, DOI 10.1097/00005344-199322008-00008; EDANO T, 1994, BIOL PHARM BULL, V17, P376; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FUKURODA T, 1994, J APPL PHYSIOL, V76, P1976, DOI 10.1152/jappl.1994.76.5.1976; GARDINER SM, 1990, BRIT J PHARMACOL, V100, P158, DOI 10.1111/j.1476-5381.1990.tb12069.x; GARDNER JP, 1992, AM J PHYSIOL, V262, pC148, DOI 10.1152/ajpcell.1992.262.1.C148; GOTO K, 1989, P NATL ACAD SCI USA, V86, P3915, DOI 10.1073/pnas.86.10.3915; GRAY GA, 1994, BRIT J PHARMACOL, V112, pU62; HAY DWP, 1993, BRIT J PHARMACOL, V110, P1175, DOI 10.1111/j.1476-5381.1993.tb13938.x; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HORI M, 1993, BRIT J PHARMACOL, V110, P1527, DOI 10.1111/j.1476-5381.1993.tb13996.x; HUBEL CA, 1993, FASEB J, V7, pA332; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISENBERG G, 1993, NONSELECTIVE CATION, P247; KARNE S, 1993, J BIOL CHEM, V268, P1916; KASUYA Y, 1992, BRIT J PHARMACOL, V107, P456, DOI 10.1111/j.1476-5381.1992.tb12767.x; KENT A, 1994, BRIT J PHARMACOL, V122, pU62; KOBAYASHI S, 1994, J UROLOGY, V151, P763, DOI 10.1016/S0022-5347(17)35083-8; KUKOVETZ WR, 1992, JPN J PHARM S2, V58, P213; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LIU Y, 1992, AM J PHYSIOL, V262, pC941, DOI 10.1152/ajpcell.1992.262.4.C941; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; MASAKI T, 1994, PHARMACOL REV, V46, P137; MEYERLEHNERT H, 1989, BIOCHEM BIOPH RES CO, V163, P458, DOI 10.1016/0006-291X(89)92158-X; MINAMI K, 1994, PFLUG ARCH EUR J PHY, V426, P254, DOI 10.1007/BF00374779; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; MORELAND S, 1994, BRIT J PHARMACOL, V112, P704, DOI 10.1111/j.1476-5381.1994.tb13133.x; NAKAMICHI K, 1992, BIOCHEM BIOPH RES CO, V182, P144, DOI 10.1016/S0006-291X(05)80123-8; NAMBI P, 1994, J PHARMACOL EXP THER, V268, P202; POLLOCK DM, 1994, BRIT J PHARMACOL, V111, P729, DOI 10.1111/j.1476-5381.1994.tb14798.x; POLLOCK DM, 1993, AM J PHYSIOL, V264, pR222, DOI 10.1152/ajpregu.1993.264.1.R222; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUHMANN K, 1994, FEBS LETT, V341, P208, DOI 10.1016/0014-5793(94)80458-3; SHIMAMOTO H, 1992, BRIT J PHARMACOL, V107, P282, DOI 10.1111/j.1476-5381.1992.tb12739.x; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; STANIMIROVIC DB, 1994, EUR J PHARM-MOLEC PH, V288, P1, DOI 10.1016/0922-4106(94)90003-5; TELEMAQUE S, 1993, EUR J PHARMACOL, V237, P275, DOI 10.1016/0014-2999(93)90279-Q; VANRENTERGHEM C, 1988, BIOCHEM BIOPH RES CO, V157, P977, DOI 10.1016/S0006-291X(88)80970-7; VANRENTERGHEM C, 1993, PFLUG ARCH EUR J PHY, V425, P156, DOI 10.1007/BF00374516; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WARNER TD, 1993, BRIT J PHARMACOL, V110, P777, DOI 10.1111/j.1476-5381.1993.tb13879.x; XUAN YT, 1994, AM J PHYSIOL, V266, pC1560, DOI 10.1152/ajpcell.1994.266.6.C1560; YAMASHITA Y, 1991, J PHARMACOL EXP THER, V259, P1256; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zagulova D V, 1993, Biull Eksp Biol Med, V116, P258	55	229	233	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1196	1204		10.1096/fasebj.9.12.7672512	http://dx.doi.org/10.1096/fasebj.9.12.7672512			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672512				2022-12-28	WOS:A1995RU81600009
J	DYSON, HJ; WRIGHT, PE				DYSON, HJ; WRIGHT, PE			ANTIGENIC PEPTIDES	FASEB JOURNAL			English	Review						ANTIPEPTIDE ANTIBODY; ANTIGEN-ANTIBODY INTERACTIONS; NMR; PEPTIDE CONFORMATIONS	PRINCIPAL NEUTRALIZING DETERMINANT; FOLDING INITIATION SITES; SECONDARY STRUCTURE; SYNTHETIC PEPTIDES; CONFORMATIONAL PREFERENCES; IMMUNODEFICIENCY-VIRUS; IMMUNODOMINANT SITE; CIRCULAR-DICHROISM; COMPLETE SEQUENCE; AQUEOUS-SOLUTION	Although most short, linear peptide fragments of proteins are unstructured in aqueous solution, a number of immunogenic and antigenic peptides have been shown to have conformational preferences for structured forms. By using mainly NMR and CD spectroscopy, it has been possible to detect and quantify quite small populations of beta-turn, helical, and nascent helical conformations. Recent studies have been published indicating that the presence of structured forms is correlated with the location of T cell and/or B cell epitopes in peptide sequences. X-ray crystal structures of complexes between peptides and anti-peptide antibodies frequently show the peptides bound in beta-turn conformations, and the presence of helix in one peptide-antibody complex has been shown by NMR spectroscopy. Studies of peptides free in solution and bound to anti-peptide antibodies in the crystal indicate that the structure of the principal neutralizing determinant of HIV-1 probably includes at least one beta-turn in a highly conserved region. These results can potentially be used in the design of peptide-based vaccines.			DYSON, HJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Dyson, Jane/D-4160-2011	Dyson, Jane/0000-0001-6855-3398; Wright, Peter/0000-0002-1368-0223	NCI NIH HHS [CA 27498] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler A J, 1973, Methods Enzymol, V27, P675; BERKOWER I, 1986, J IMMUNOL, V136, P2498; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1992, BIOCHEMISTRY-US, V31, P1458, DOI 10.1021/bi00120a024; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P7828, DOI 10.1021/bi00486a008; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GRASMASSE H, 1988, MOL IMMUNOL, V25, P673, DOI 10.1016/0161-5890(88)90102-2; KEMMINK J, 1993, J MOL BIOL, V230, P312, DOI 10.1006/jmbi.1993.1144; KIEFFER B, 1993, J BIOMOL NMR, V3, P91; LACZKO I, 1992, BIOCHEMISTRY-US, V31, P4282, DOI 10.1021/bi00132a019; LAMTHANH H, 1993, BIOCHIM BIOPHYS ACTA, V1203, P191, DOI 10.1016/0167-4838(93)90082-3; LAROSA GJ, 1990, SCIENCE, V24, P9932; LERNER RA, 1982, NATURE, V299, P592, DOI 10.1038/299592a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCINNES C, 1993, BIOCHEMISTRY-US, V32, P13432, DOI 10.1021/bi00212a008; OHERN PA, 1991, MOL IMMUNOL, V28, P1047, DOI 10.1016/0161-5890(91)90019-G; PRECHEUR B, 1994, EUR J BIOCHEM, V220, P415, DOI 10.1111/j.1432-1033.1994.tb18639.x; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SATTERTHWAIT AC, 1989, PHILOS T ROY SOC B, V323, P565, DOI 10.1098/rstb.1989.0036; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6348, DOI 10.1021/bi00076a007; SPOUGE JL, 1987, J IMMUNOL, V138, P204; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TSANG P, 1992, BIOCHEMISTRY-US, V31, P3862, DOI 10.1021/bi00130a018; WALTHO JP, 1989, FEBS LETT, V250, P400, DOI 10.1016/0014-5793(89)80764-1; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WILLIAMSON MP, 1986, EUR J BIOCHEM, V158, P527, DOI 10.1111/j.1432-1033.1986.tb09786.x; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015	43	78	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					37	42		10.1096/fasebj.9.1.7821757	http://dx.doi.org/10.1096/fasebj.9.1.7821757			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821757				2022-12-28	WOS:A1995QD20200007
J	SCHEETZ, AJ; CONSTANTINEPATON, M				SCHEETZ, AJ; CONSTANTINEPATON, M			MODULATION OF NMDA RECEPTOR FUNCTION - IMPLICATIONS FOR, VERTEBRATE NEURAL DEVELOPMENT	FASEB JOURNAL			English	Review						GLUTAMATE RECEPTOR; NEURONAL ACTIVITY; SYNAPSE REFINEMENT; VISUAL SYSTEM; NEURONAL PLASTICITY	KITTEN VISUAL-CORTEX; LONG-TERM POTENTIATION; ACETYLCHOLINE-RECEPTOR; SYNAPTIC TRANSMISSION; ASPARTATE RECEPTORS; SENSITIVITY; CAT; PLASTICITY; CHANNEL; SYNAPTOGENESIS	The NMDA subtype of glutamate receptor is hypothesized to mediate synaptic competition in the developing brain by stabilizing converging synapses that have correlated activity patterns. Disruption of NMDA receptor function during development interferes with synapse elimination and sensory map formation. Moreover, many studies indicate that NMDA receptor function is high during times of synaptic rearrangement. In this review, a corollary of the NMDA receptor hypothesis for activity-dependent synapse stabilization is proposed. As developing inputs increase in number and strength, the increasing excitatory synaptic activity in young neurons should lead to increases in postsynaptic Ca2+ influx through NMDA receptors. This Ca2+ flux is postulated to trigger a feedback system that changes the subunit composition of the NMDA receptor complex so that less Ca2+ enters postsynaptic cells upon NMDA receptor activation. Changes in NMDA receptor effectiveness resulting from manipulations of activity are consistent with the idea that NMDA receptor function is under the control of activity. This postulate of activity-dependent control of NMDA receptor expression has implications for the control of brain plasticity. If particular combinations of NMDA receptor subunits typically expressed in young animals are better than adult receptor types at maintaining synapses in regions where they are not well correlated with other inputs, then expression of these juvenile subunit combinations could facilitate synaptic rearrangements in the mature brain after the normal end of synaptic plasticity. Thus, understanding the regulation of NMDA receptor function during development could provide a novel approach to restructuring circuitry in the adult brain to compensate for damage produced by trauma or disease.			SCHEETZ, AJ (corresponding author), YALE UNIV,DEPT BIOL,KLINE BIOL TOWER,NEW HAVEN,CT 06511, USA.							BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CLINE HT, 1990, J NEUROSCI, V10, P11907; CONSTANTINEPATON M, 1990, COLD SPRING HARB SYM, V55, P431; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COX JA, 1990, NEURON, V4, P941, DOI 10.1016/0896-6273(90)90147-8; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DEBSKI EA, 1991, J NEUROSCI, V11, P2947; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; FIELDS RD, 1991, J NEUROSCI, V11, P134; FOX K, 1992, J NEUROSCI, V12, P2672; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FOX K, 1989, J NEUROSCI, V9, P2443; GORDON B, 1991, DEV BRAIN RES, V62, P61, DOI 10.1016/0165-3806(91)90190-T; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Hickmott Peter W., 1993, Society for Neuroscience Abstracts, V19, P452; HOFER M, 1994, IN PRESS PROG BRAIN; HOFER M, 1994, IN PRESS J NEUROCHEM; HOLLMAN M, 1993, NEURON, V11, P943; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; ISHII T, 1993, J BIOL CHEM, V268, P2836; KELEKNER NW, 1991, MOL BRAIN RES, V11, P151; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEVAY S, 1978, J COMP NEUROL, V179, P233; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LUND RD, 1976, J COMP NEUROL, V169, P133, DOI 10.1002/cne.901690202; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISOND V, 1991, ANN REV NEUROSCI, V14, P379; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1990, NEUROSCIENCE, V38, P103, DOI 10.1016/0306-4522(90)90377-G; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORRISETT RA, 1990, DEV BRAIN RES, V56, P257, DOI 10.1016/0165-3806(90)90090-L; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; OKADA K, 1992, FEBS LETT, V313, P34; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; REH TA, 1984, J NEUROSCI, V4, P442; REYNOLDS IJ, 1991, EXP BRAIN RES, V85, P611; Schnupp W. J. H., 1993, Society for Neuroscience Abstracts, V19, P887; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SIMON DK, 1990, DEV BIOL, V137, P125, DOI 10.1016/0012-1606(90)90013-9; SIMON DK, 1992, J NEUROSCI, V12, P1212; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WARTON SS, 1989, SYNAPSE, V3, P136, DOI 10.1002/syn.890030205; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1992, MOL PHARMACOL, V42, P147; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	61	244	249	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1994	8	10					745	752		10.1096/fasebj.8.10.8050674	http://dx.doi.org/10.1096/fasebj.8.10.8050674			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	8050674				2022-12-28	WOS:A1994NY35000012
J	SAFFITZ, JE; NASH, JA; GREEN, KG; LUKE, RA; RANSNAS, LA; INSEL, PA				SAFFITZ, JE; NASH, JA; GREEN, KG; LUKE, RA; RANSNAS, LA; INSEL, PA			IMMUNOELECTRON MICROSCOPIC IDENTIFICATION OF CYTOPLASMIC AND NUCLEAR G(S-ALPHA) IN S49 LYMPHOMA-CELLS	FASEB JOURNAL			English	Article						IMMUNOELECTRON MICROSCOPY; G(S-ALPHA); S49 CELLS; CONFOCAL MICROSCOPY	GTP-BINDING PROTEIN; ISLET-ACTIVATING PROTEIN; PERTUSSIS TOXIN; ALPHA-SUBUNIT; PLASMA-MEMBRANE; GS-ALPHA; RECEPTOR; PATHWAYS; G(S); ASIALOGLYCOPROTEIN	The subcellular distribution of G(s alpha) was characterized in S49 lymphoma cells with two polyclonal antisera directed against specific COOH- and NH2-terminal epitopes. Nonspecific binding was determined in each subcellular compartment by incubating cyc(-) S49 cells, known to be deficient in G(s alpha) and its mRNA, with primary and secondary antisera. Small proportions of total specific binding sites were localized to the plasmalemma as well as the nuclear envelope. Because of their small size, these compartments contained a high concentration of G(s alpha). However, most of the specific binding sites were found in nonstructured cytoplasm and within the nucleus. Specific binding was abolished or significantly reduced by preincubating primary antisera with their peptide immunogens but not with an irrelevant peptide. Intracellular G(s alpha) immunoreactive binding sites did not colocalize with gold-conjugated transferrin in cells preincubated with this ligand to mark a classical endocytotic pathway. The intracellular and intranuclear location of G(s alpha) was confirmed with confocal microscopy of S49 cells immunostained with specific primary and fluorescently labeled secondary antibodies. G(s alpha) was also detected with immunoblots of proteins extracted from purified S49 cell. nuclei. Thus, G(s alpha) is abundantly distributed in intracellular and intranuclear sites in S49 cells and occurs in loci distinct from organelles of the transferrin pathway. The substantial intracellular distribution of G(s alpha) suggests that G(s) may subserve intracellular and, perhaps, intranuclear functions that may be important in proliferating cells.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093	Washington University (WUSTL); University of California System; University of California San Diego; University of California System; University of California San Diego	SAFFITZ, JE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL-17646, HL-17682] Funding Source: Medline; NIGMS NIH HHS [GM40781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017646, P50HL017682, P60HL017646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; BERRYMAN M A, 1988, Journal of Cell Biology, V107, p111A; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FUGINAGA Y, 1989, FEBS LETT, V245, P117; GERARDYSCHAN R, 1989, J BIOL CHEM, V266, P6942; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; ROTH DA, 1992, FEBS LETT, V296, P46, DOI 10.1016/0014-5793(92)80400-B; ROTROSEN D, 1988, J BIOL CHEM, V263, P10958; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STIRLING JW, 1990, J HISTOCHEM CYTOCHEM, V38, P145, DOI 10.1177/38.2.2405054; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TOHKIN M, 1989, FEBS LETT, V255, P187, DOI 10.1016/0014-5793(89)81088-9; VEDIA LMY, 1989, P NATL ACAD SCI USA, V86, P868, DOI 10.1073/pnas.86.3.868; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG N, 1990, J BIOL CHEM, V265, P1239	32	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					252	258		10.1096/fasebj.8.2.8119495	http://dx.doi.org/10.1096/fasebj.8.2.8119495			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119495				2022-12-28	WOS:A1994MY29900033
J	OPDENAKKER, G; RUDD, PM; PONTING, CP; DWEK, RA				OPDENAKKER, G; RUDD, PM; PONTING, CP; DWEK, RA			CONCEPTS AND PRINCIPLES OF GLYCOBIOLOGY	FASEB JOURNAL			English	Review						N-GLYCOSYLATION; ENZYMES; RECOGNITION; GLYCOFORM	TISSUE PLASMINOGEN-ACTIVATOR; EPIDERMAL GROWTH-FACTOR; N-LINKED GLYCOSYLATION; 3-DIMENSIONAL STRUCTURE; FC-FRAGMENT; PROTEIN-A; OLIGOSACCHARIDE; IGG; CARBOHYDRATE; RECOGNITION	In biological systems oligosaccharides are normally conjugated to proteins or lipids. The heterogeneity and branching of oligosaccharides allow glyco-conjugates to display a further level of structural and functional diversity compared with linear proteins and nucleic acids or with lipids. This review summarizes some general principles that are emerging from the new field of glycobiology which, by addressing the molecular interactions of glycoconjugates in biological systems, spans the classical physicochemical, biological, and biochemical sciences. We discuss the genesis of glycoforms, the functional roles for glycosylation, and some general aspects of structure/function relationships with reference to N-glycosylated animal glycoproteins including the enzymes ribonuclease and tissue plasminogen activator, IgG, the family of C-type lectins, and receptor ligands.	CATHOLIC UNIV LEUVEN, FAC MED, REGA INST MED RES, B-3000 LOUVAIN, BELGIUM; UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND	KU Leuven; University of Oxford	OPDENAKKER, G (corresponding author), UNIV OXFORD, INST GLYCOBIOL, DEPT BIOCHEM, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Opdenakker, Ghislain/V-8562-2019; Ponting, Chris/AAV-2621-2021; Opdenakker, Ghislain/Q-3130-2017	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Ponting, Chris/0000-0003-0202-7816				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAHL KD, 1988, SCIENCE, V239, P72, DOI 10.1126/science.3122320; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DWEK RA, 1984, BIOCHEM SOC SYMP, P123; GOOCHEE CF, 1992, FRONTIERS BIOPROCESS, V2, P199; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HASEGAWA M, 1992, EUR J BIOCHEM, V210, P9, DOI 10.1111/j.1432-1033.1992.tb17384.x; HOWARD S C, 1991, Glycobiology, V1, P411, DOI 10.1093/glycob/1.4.411; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; LEATHERBARROW RJ, 1983, FEBS LETT, V164, P227, DOI 10.1016/0014-5793(83)80290-7; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LIVI GP, 1991, J BIOL CHEM, V266, P15348; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OPDENAKKER G, 1986, P SOC EXP BIOL MED, V182, P248; PAREKH R, 1988, J EXP MED, V167, P1731, DOI 10.1084/jem.167.5.1731; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROOK GAW, 1991, J AUTOIMMUN, V4, P779, DOI 10.1016/0896-8411(91)90173-A; RUDD PM, 1991, MOL IMMUNOL, V28, P1369, DOI 10.1016/0161-5890(91)90039-M; RUDD PM, 1992, GLYCOCONJUGATE J, V9, P86, DOI 10.1007/BF00731704; SAVVIDOU G, 1984, BIOCHEMISTRY-US, V23, P3736, DOI 10.1021/bi00311a026; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Welply J K, 1991, Biotechnology, V17, P59; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x	40	190	194	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1993	7	14					1330	1337		10.1096/fasebj.7.14.8224606	http://dx.doi.org/10.1096/fasebj.7.14.8224606			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224606				2022-12-28	WOS:A1993MH00800004
J	CABANAC, M				CABANAC, M			SELECTIVE BRAIN COOLING IN HUMANS - FANCY OR FACT	FASEB JOURNAL			English	Article						TEMPERATURE REGULATION; BRAIN TEMPERATURE; HYPERTHERMIA	BLOOD-FLOW; THERMOREGULATORY RESPONSES; TYMPANIC TEMPERATURES; EMISSARY VEINS; HUMAN HEAD; EXERCISE; HYPERTHERMIA; VENTILATION; PERFORMANCE; MONKEY	A mechanism that selectively cools the brain during hyperthermia is a well-accepted fact in animals. Selective brain cooling (SBC) during hyperthermia has also been proposed in humans, but this suggestion has met with considerable debate. Several authors have rejected the idea of human SBC for the following reasons: 1) SBC is illogical because this mechanism removes the error signal activating the defense against hyperthermia; 2) unlike other animals, humans do not pant and thus do not possess a powerful heat sink at a short distance from the brain; 3) humans do not have a carotid rete, the countercurrent heat exchanger between the arterial and venous bloods flowing in and out of the brain; 4) the high and constant arterial blood flow of the brain is sufficient to cool the brain under all conditions; and 5) the relatively low tympanic temperature (T(ty)) recorded in hyperthermic humans is not a sign of SBC, but rather is the sign of contamination of T(ty) by a low head skin temperature. These arguments are reviewed and rejected and results of several recent experiments are summarized. Finally, recent experimental articles that contradict the existence of human SBC or the validity of T(ty) are discussed and their conclusions refuted. This review points to overwhelming evidence in favor of human SBC.			CABANAC, M (corresponding author), UNIV LAVAL,FAC MED,DEPT PHYSIOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA.							Baker M.A., 1979, Scientific American, V240, P114; BAKER MA, 1972, J APPL PHYSIOL, V32, P739, DOI 10.1152/jappl.1972.32.6.739; Benzinger T.H., 1963, TEMPERATURE ITS MEAS, P111; Brengelmann G.L., 1987, MAN STRESSFUL ENV TH, P5; BRENGELMANN GL, 1990, BEHAV BRAIN SCI, V13, P349, DOI 10.1017/S0140525X00079036; BRINNEL H, 1989, J THERM BIOL, V14, P47, DOI 10.1016/0306-4565(89)90029-6; BRINNEL H, 1989, ARCH DERMATOL RES, V282, P66; Brinnel H, 1987, MAIN STRESSFUL ENV T, P87; Brinnel H., 1987, HEAT STRESS PHYS EXE, P209; BRISSON GR, 1989, EUR J APPL PHYSIOL O, V58, P816, DOI 10.1007/BF02332212; BRISSON GR, 1987, INT J SPORTS MED, V8, P387, DOI 10.1055/s-2008-1025691; BROWN GA, 1982, AVIAT SPACE ENVIR MD, V53, P583; CABANAC M, 1988, EUR J APPL PHYSIOL, V58, P39, DOI 10.1007/BF00636601; CABANAC M, 1985, EUR J APPL PHYSIOL O, V54, P172, DOI 10.1007/BF02335925; CABANAC M, 1979, J PHYSIOL-LONDON, V289, P163, DOI 10.1113/jphysiol.1979.sp012730; CABANAC M, 1987, EUR J APPL PHYSIOL O, V56, P534, DOI 10.1007/BF00635366; CABANAC M, 1986, NEWS PHYSIOL SCI, V1, P41; CAPUTA M, 1991, J THERM BIOL, V16, P19, DOI 10.1016/0306-4565(91)90046-5; CAPUTA M, 1983, J THERM BIOL, V8, P265, DOI 10.1016/0306-4565(83)90007-4; CAPUTA M, 1977, B ACAD POL SCI BIOL, V25, P695; CAPUTA M, 1988, EUR J APPL PHYSIOL, V57, P611, DOI 10.1007/BF00418471; CAPUTA M, 1980, J APPL PHYSIOL, V48, P1020, DOI 10.1152/jappl.1980.48.6.1020; CAPUTA M, 1981, CONTRIBUTIONS THERMA, P183; CAPUTA M, 1978, CR ACAD SCI D NAT, V87, P1011; CHMIELOWA M, 1980, ROCZN A M POZNAN, P157; DEKLUNDER G, 1991, EUR J APPL PHYSIOL O, V62, P342, DOI 10.1007/BF00634970; DMIEL R, 1986, J THERM BIOL, V11, P157, DOI 10.1016/0306-4565(86)90040-9; FAITHFULL NS, 1984, EUR J APPL PHYSIOL O, V53, P274, DOI 10.1007/BF00776602; FULLER CA, 1983, AM J PHYSIOL, V245, pR293, DOI 10.1152/ajpregu.1983.245.2.R293; GREENLEAF JE, 1980, AVIAT SPACE ENVIR MD, V51, P747; HALES JRS, 1986, LANCET, V1, P1495; HART GR, 1982, MEDICINE, V61, P189, DOI 10.1097/00005792-198205000-00005; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; HIRATA K, 1988, EUR J APPL PHYSIOL O, V57, P735, DOI 10.1007/BF01075996; HIRATA K, 1987, EUR J APPL PHYSIOL, V56, P43, DOI 10.1007/BF00696374; JESSEN C, 1992, J APPL PHYSIOL, V72, P664, DOI 10.1152/jappl.1992.72.2.664; Khogali M, 1984, THERMAL PHYSL, P503; KISCH R, 1966, AKTUELLE PROBLEME GE, P53; MACDOUGALL JD, 1974, J APPL PHYSIOL, V36, P538, DOI 10.1152/jappl.1974.36.5.538; MARON MB, 1977, J APPL PHYSIOL, V42, P909, DOI 10.1152/jappl.1977.42.6.909; MCCAFFREY TV, 1975, J APPL PHYSIOL, V39, P114, DOI 10.1152/jappl.1975.39.1.114; Mekjavic IB, 1992, 5TH P INT C ENV ERG, P42; MITCHELL D, 1987, S AFR J SCI, V83, P598; NADEL ER, 1987, NEWS PHYSIOL SCI, V2, P33; NAGASAKA T, 1989, HYPERTHERMIC ONCOLOG, V2, P322; NAGASAKA T, 1990, JPN J BIOMETEOROL, V27, P113; NAREBSKI J, 1985, ACTA NEUROBIOL EXP, V45, P63; NIELSEN B, 1992, PFLUG ARCH EUR J PHY, V422, P168, DOI 10.1007/BF00370416; NIELSEN B, 1988, PFLUG ARCH EUR J PHY, V411, P456, DOI 10.1007/BF00587727; NUNNELY SA, 1992, 5TH P INT C ENV ERG, P134; OGAWA T, 1988, JPN J PHYSIOL, V38, P479, DOI 10.2170/jjphysiol.38.479; RASCH W, 1991, J APPL PHYSIOL, V71, P590, DOI 10.1152/jappl.1991.71.2.590; RASCH W, 1993, IN PRESS J APPL PHYS; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482, DOI 10.1152/jappl.1988.65.1.482; SMINIA P, 1989, INT J HYPERTHER, V5, P115, DOI 10.3109/02656738909140438; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744, DOI 10.1152/jappl.1989.67.2.744; WENGER CB, 1987, NEWS PHYSIOL SCI, V2, P150; WHITBY JD, 1971, BRIT J ANAESTH, V43, P673, DOI 10.1093/bja/43.7.673	58	100	111	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1143	1146		10.1096/fasebj.7.12.8375612	http://dx.doi.org/10.1096/fasebj.7.12.8375612			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375612				2022-12-28	WOS:A1993LW81700006
J	ROSE, RC; BODE, AM				ROSE, RC; BODE, AM			BIOLOGY OF FREE-RADICAL SCAVENGERS - AN EVALUATION OF ASCORBATE	FASEB JOURNAL			English	Review						ASCORBATE; FREE RADICAL; ANTIOXIDANT	CENTRAL NERVOUS-SYSTEM; DEHYDROASCORBIC ACID; LIQUID-CHROMATOGRAPHY; REDUCTION POTENTIALS; CORNEAL ENDOTHELIUM; ALPHA-TOCOPHEROL; GUINEA-PIG; URIC-ACID; METABOLISM; TRANSPORT	Reactive free radical species (R.) arc associated with several forms of tissue damage and disease, and also with the process of aging. Protection is thought to be available in the form of endogenous compounds that react with and thereby ''scavenge'' the R.. Because many R. are reactive forms of oxygen, an effective scavenger is often referred to as an antioxidant. To be an effective antioxidant physiologically, a substance must have certain chemical and biological properties: it must be present in adequate amounts in the body; it must react with a variety of R.; it must be suitable for compartmentation; it must be readily available; it might be suitable for regeneration; it must be conserved by the kidneys; and it must have tolerable toxicity. Several water-soluble candidates are mentioned, with most having no more than one or two of the attributes listed. Ascorbic acid is discussed in detail, and an analysis is made of whether it has the properties mentioned.	UNIV N DAKOTA,DEPT PHYSIOL,GRAND FORKS,ND 58202	University of North Dakota Grand Forks	ROSE, RC (corresponding author), UNIV HLTH SCI CHICAGO MED SCH,DEPT PHYSIOL & BIOPHYS,3333 GREEN BAY RD,N CHICAGO,IL 60064, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020398] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007320] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05 407-22] Funding Source: Medline; NEI NIH HHS [EY 07320] Funding Source: Medline; NICHD NIH HHS [NICHHD HD 20398] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; BENSCH KG, 1985, P NATL ACAD SCI USA, V82, P7193, DOI 10.1073/pnas.82.21.7193; BIANCHI J, 1985, BIOCHIM BIOPHYS ACTA, V819, P75, DOI 10.1016/0005-2736(85)90197-X; BIANCHI J, 1986, TOXICOLOGY, V40, P75, DOI 10.1016/0300-483X(86)90047-8; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; BIANCHI J, 1986, AM J PHYSIOL, V250, pG461, DOI 10.1152/ajpgi.1986.250.4.G461; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BODE AM, 1990, CLIN CHEM, V36, P1807; BODE AM, 1991, INVEST OPHTH VIS SCI, V32, P2266; BODE AM, 1993, IN PRESS CURR EYE RE; Borg D. C., 1993, OXYGEN FREE RADICALS, P12; BORG DC, 1989, CRC HDB FREE RADICAL, V1, P12; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CARPENTER KJ, 1986, HIST SCURVY VITAMIN, P288; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CAVALIERI EL, 1984, FREE RAD BIOL, V1, P323; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; CHOI JL, 1989, P SOC EXP BIOL MED, V190, P369; COHEN AI, 1987, ADLERS PHYSL EYE CLI, V8, P458; COTLIER E, 1987, ADLERS PHYSL EYE, P268; CRANE RK, 1962, FED PROC, V21, P891; CUTLER RG, 1984, ARCH GERONTOL GERIAT, V3, P321, DOI 10.1016/0167-4943(84)90033-5; CUTLER RG, 1984, FREE RADICAL BIO MED, V6, P371, DOI DOI 10.1016/B978-0-12-566506-3.50019-4; DIMATTIO J, 1989, INVEST OPHTH VIS SCI, V30, P2320; DREYER R, 1993, P SOC EXP BIOL MED, V202, P212, DOI 10.3181/00379727-202-43529; EDGAR JA, 1970, NATURE, V227, P2426; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; Friedman GJ, 1940, J CLIN INVEST, V19, P685, DOI 10.1172/JCI101171; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GREENBERG DAE, 1992, EYE CARE DIGEST, V10, P45; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; HORNIG D, 1971, CLIN CHIM ACTA, V33, P187, DOI 10.1016/0009-8981(71)90267-1; JOVANOVIC SV, 1990, J PHYS CHEM-US, V94, P3583, DOI 10.1021/j100372a041; KOPPENOL WH, 1990, FEBS LETT, V264, P165, DOI 10.1016/0014-5793(90)80239-F; KOPPENOL WH, 1989, FOCUS MEMBRANE LIPID, V1, P1; LEVINE M, 1985, VITAM HORM, V42, P1; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; LOHMANN W, 1987, ANN NY ACAD SCI, V498, P402, DOI 10.1111/j.1749-6632.1987.tb23777.x; Lunec J, 1985, Free Radic Res Commun, V1, P31, DOI 10.3109/10715768509056534; MAPLES KR, 1988, J BIOL CHEM, V263, P1709; MAROTTI T, 1990, ADV EXP MED BIOL, V264, P271; MARTIN M, 1983, AM J PHYSIOL, V244, pF335, DOI 10.1152/ajprenal.1983.244.3.F335; McCord, 1986, PHYSL OXYGEN RADICAL; MEKHJIAN HS, 1971, J CLIN INVEST, V50, P1569, DOI 10.1172/JCI106644; MELHORN RJ, 1991, J BIOL CHEM, V266, P2724; MONNIER VM, 1982, CLIN ENDOCRINOL META, V11, P431, DOI 10.1016/S0300-595X(82)80023-6; NIKI E, 1990, METHOD ENZYMOL, V186, P330; NIKI E, 1987, ANN NY ACAD SCI, V498, P186, DOI 10.1111/j.1749-6632.1987.tb23761.x; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; OKE AF, 1987, ANN NY ACAD SCI, V498, P1, DOI 10.1111/j.1749-6632.1987.tb23747.x; OMAYE ST, 1987, ANN NY ACAD SCI, V498, P389, DOI 10.1111/j.1749-6632.1987.tb23776.x; ORGANISCIAK DT, 1990, INVEST OPHTH VIS SCI, V31, P1195; PATTERSON JW, 1950, J BIOL CHEM, V183, P81; PENCE LA, 1979, TOXICOL APPL PHARM, V50, P578; PERLY B, 1985, BIOCHIM BIOPHYS ACTA, V819, P131, DOI 10.1016/0005-2736(85)90203-2; PIETRONIGRO DD, 1985, BRAIN RES, V333, P161, DOI 10.1016/0006-8993(85)90138-6; PRABHAKARAM M, 1991, EXP EYE RES, V53, P261, DOI 10.1016/0014-4835(91)90082-P; REISS GR, 1986, ARCH OPHTHALMOL-CHIC, V104, P753; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; RICHTER HE, 1988, CAN J MICROBIOL, V34, P822, DOI 10.1139/m88-140; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; ROSE RC, 1986, AM J PHYSIOL, V250, pF627, DOI 10.1152/ajprenal.1986.250.4.F627; ROSE RC, 1991, COMP BIOCHEM PHYS A, V100, P273, DOI 10.1016/0300-9629(91)90470-W; ROSE RC, 1992, ENZYME, V46, P196, DOI 10.1159/000468788; ROSE RC, 1992, LIFE SCI, V50, P1543, DOI 10.1016/0024-3205(92)90145-F; ROSE RC, 1989, NEWS PHYSIOL SCI, V4, P190; ROSE RC, 1990, AM J PHYSIOL, V258, pR1238, DOI 10.1152/ajpregu.1990.258.5.R1238; ROSE RC, 1991, HDB PHYSL 6, V4, P421; Selkurt EE, 1944, AM J PHYSIOL, V141, P0423, DOI 10.1152/ajplegacy.1944.141.3.423; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; SPECTOR R, 1977, NEW ENGL J MED, V296, P1393, DOI 10.1056/NEJM197706162962409; STAHL RL, 1985, BIOCHIM BIOPHYS ACTA, V839, P119, DOI 10.1016/0304-4165(85)90189-8; Stein WD, 1967, MOVEMENT MOL CELL ME; STOCKER R, 1990, METHOD ENZYMOL, V186, P301; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V881, P391, DOI 10.1016/0304-4165(86)90031-0; SURDHAR PS, 1986, J PHYS CHEM-US, V90, P5915, DOI 10.1021/j100280a091; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TABOR MW, 1991, ADV EXP MED BIOL, V283, P833; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P422; VARMA SD, 1987, ANN NY ACAD SCI, V498, P280, DOI 10.1111/j.1749-6632.1987.tb23768.x; VARMA SD, 1988, OPHTHALMIC RES, V20, P164, DOI 10.1159/000266579; WILLIAMS NH, 1982, AUST J CHEM, V35, P1133, DOI 10.1071/CH9821133	82	389	401	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1135	1142		10.1096/fasebj.7.12.8375611	http://dx.doi.org/10.1096/fasebj.7.12.8375611			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375611				2022-12-28	WOS:A1993LW81700005
J	KLEIN, G				KLEIN, G			GENES THAT CAN ANTAGONIZE TUMOR-DEVELOPMENT	FASEB JOURNAL			English	Review							RETINOBLASTOMA; EXPRESSION				KLEIN, G (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.							ALI AA, 1993, FASEB J, V7, P931, DOI 10.1096/fasebj.7.10.8344490; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANDERSON MJ, FASEB J, V7, P826; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAKRABORTY AK, 1993, FASEB J, V7, P971, DOI 10.1096/fasebj.7.10.8393821; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DAMM K, 1993, FASEB J, V7, P904, DOI 10.1096/fasebj.7.10.8102105; ENG C, 1993, FASEB J, V7, P910, DOI 10.1096/fasebj.7.10.8102106; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HARRIS H, 1993, FASEB J, V7, P978, DOI 10.1096/fasebj.7.10.8344496; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEIN G, 1989, GENE CHROMOSOME CANC, V1, P3, DOI 10.1002/gcc.2870010103; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NODA M, 1993, FASEB J, V7, P834, DOI 10.1096/fasebj.7.10.8344483; NUSSE R, 1986, TRENDS GENET, V2, P244, DOI 10.1016/0168-9525(86)90247-7; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1993, IN PRESS P NATL ACAD, P53; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	33	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					821	825		10.1096/fasebj.7.10.8344481	http://dx.doi.org/10.1096/fasebj.7.10.8344481			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344481				2022-12-28	WOS:A1993LQ33700002
J	WIMAN, KG				WIMAN, KG			THE RETINOBLASTOMA GENE - ROLE IN CELL-CYCLE CONTROL AND CELL-DIFFERENTIATION	FASEB JOURNAL			English	Review						RB; TUMOR SUPPRESSOR GENE; CELL CYCLE CONTROL; DIFFERENTIATION	RB GENE; SUSCEPTIBILITY GENE; TUMOR SUPPRESSOR; C-MYC; CARCINOMA-CELLS; ADENOVIRUS E1A; PROTEIN; PRODUCT; EXPRESSION; PHOSPHORYLATION	The retinoblastoma (RB) gene is the prototype tumor suppressor gene. It encodes a nuclear protein that acts as a cell cycle control checkpoint at the G1 phase. Deletion or inactivation of both RB alleles plays an essential, rate-limiting role in retinoblastoma and in the osteosarcomas that arise within families that carry a mutated RB gene. RB inactivation is also found in other sarcomas, small cell carcinoma of the lung, and in carcinoma of the breast, bladder, and prostate. Transforming proteins encoded by SV40, and the transforming or tumor-associated subtypes of adenoviruses and human papilloma viruses (HPV) can bind RB, thereby blocking its normal function. The EBNA-5 protein of Epstein-Barr virus (EBV) is also able to bind RB in vitro. In addition, RB can interact with several cellular proteins, including the transcription factor E2F. RB gene knock-out mice die in utero around day 14 of gestation. The embryos show disturbed neural and hematopoietic differentiation, indicating that RB is vitally important for these processes. This notion is further supported by studies demonstrating that RB expression in mouse embryo tissues is highest in cells undergoing differentiation, and that RB is required for MyoD-induced muscle differentiation.			WIMAN, KG (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				BANERJEE A, 1992, CANCER RES, V52, P6297; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P117; GU W, 1993, CELL, V72, P1; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUEN DS, 1988, ONCOGENE, V3, P729; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG WQ, 1991, EXP CELL RES, V197, P314, DOI 10.1016/0014-4827(91)90438-Z; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MADREPERLA SA, 1991, CANCER RES, V51, P6381; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; SZEKELY L, 1993, IN PRESS J CELL PHYS; SZEKELY L, 1993, IN PRESS P NATL ACAD, P53; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VENTER DJ, 1991, ONCOGENE, V6, P445; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471	50	112	115	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					841	845		10.1096/fasebj.7.10.8393817	http://dx.doi.org/10.1096/fasebj.7.10.8393817			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393817				2022-12-28	WOS:A1993LQ33700005
J	HEIDENREICH, O; PIEKEN, W; ECKSTEIN, F				HEIDENREICH, O; PIEKEN, W; ECKSTEIN, F			CHEMICALLY MODIFIED RNA - APPROACHES AND APPLICATIONS	FASEB JOURNAL			English	Article						PHOSPHOROTHIOATE RNA; HAMMERHEAD RIBOZYMES; 2'-MODIFIED RNA	HAMMERHEAD RIBOZYMES; NUCLEOSIDE PHOSPHOROTHIOATES; TETRAHYMENA RIBOZYME; CLEAVAGE REACTION; NUCLEIC-ACIDS; OLIGORIBONUCLEOTIDES; POLYMERASE; BINDING; DNA; OLIGODEOXYRIBONUCLEOTIDES	The modification of phosphate into phosphorothioate internucleotidic linkages in various RNAs and their usefulness in identifying phosphate positions essential for function are described. Several modifications of the 2'-hydroxyl group of the ribose, particularly the replacement by fluorine atoms and amino groups, is discussed. These studies have been concentrated on hammerhead ribozymes in order to determine hydroxyl groups important for the catalytic activity. In addition these derivatives have been instrumental in rendering ribozymes more stable toward nucleases.	MAX PLANCK INST EXPTL MED,HERMANN REIN STR 3,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CARMOFONCESA M, 1992, EMBO J, V10, P195; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; COSSTICK R, 1984, NUCLEIC ACIDS RES, V12, P1791, DOI 10.1093/nar/12.4.1791; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; COTTEN M, 1991, NUCLEIC ACIDS RES, V19, P2629, DOI 10.1093/nar/19.10.2629; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ECKSTEIN F, 1970, EUR J BIOCHEM, V13, P558, DOI 10.1111/j.1432-1033.1970.tb00961.x; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; FU DJ, 1992, P NATL ACAD SCI USA, V89, P3985, DOI 10.1073/pnas.89.9.3985; GAIT MJ, 1991, OLIGONUCLEOTIDES ANA, P25; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GISH G, 1989, TIBS, V14, P97; GRIFFITHS AD, 1987, NUCLEIC ACIDS RES, V15, P4145, DOI 10.1093/nar/15.10.4145; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KONARSKA MM, 1990, CELL, V63, P609, DOI 10.1016/0092-8674(90)90456-O; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MASCHHOFF KL, 1992, NUCLEIC ACIDS RES, V20, P1949, DOI 10.1093/nar/20.8.1949; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MORVAN F, 1990, TETRAHEDRON LETT, V31, P7149, DOI 10.1016/S0040-4039(00)97264-2; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; OGILVIE KK, 1988, P NATL ACAD SCI USA, V85, P5764, DOI 10.1073/pnas.85.16.5764; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; OTT J, 1987, BIOCHEMISTRY-US, V26, P8237, DOI 10.1021/bi00399a032; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROSSI JJ, 1992, HUMAN RETROVIR, V8, P183; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SHIBAHARA S, 1989, NUCLEIC ACIDS RES, V17, P239, DOI 10.1093/nar/17.1.239; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; USMAN N, 1992, TRENDS BIOCHEM SCI, V17, P334, DOI 10.1016/0968-0004(92)90306-T; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WARING RB, 1989, NUCLEIC ACIDS RES, V17, P10281, DOI 10.1093/nar/17.24.10281; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; ZHANGKECK ZY, 1988, J BIOL CHEM, V263, P9550; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	57	92	133	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					90	96		10.1096/fasebj.7.1.7678566	http://dx.doi.org/10.1096/fasebj.7.1.7678566			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678566				2022-12-28	WOS:A1993KH88000014
J	WEITZMANN, CJ; CUNNINGHAM, PR; NURSE, K; OFENGAND, J				WEITZMANN, CJ; CUNNINGHAM, PR; NURSE, K; OFENGAND, J			CHEMICAL EVIDENCE FOR DOMAIN ASSEMBLY OF THE ESCHERICHIA-COLI 30S RIBOSOME	FASEB JOURNAL			English	Article						INVITRO TRANSCRIPT; RIBOSOMAL PROTEINS; 5' DOMAIN; 16S RNA; RIBOSOME ASSEMBLY	DECODING SITE C1400; 16S-RIBOSOMAL RNA; SUBUNIT; TRANSCRIPTION; REGION; MODEL	A fragment of 16S RNA corresponding to most of the 5'-domain (residues 1-526) was prepared by in vitro run-off transcription. When this fragment was incubated with a mixture of 30S proteins under conditions known to result in the in vitro assembly of a complete, functional 30S ribosome from a full-length transcript, a discrete 16S particle was formed. This particle contained near stoichiometric amounts of ribosomal proteins S4, S16, S17, and S20. These four proteins are the same, and only, ones that have been shown to interact with the 5' domain of 16S RNA in the intact 30S ribosome in the footprinting studies of Noller and co-workers. We conclude that the 5' fragment 1-526 is capable of folding independently of the rest of the molecule so as to generate the protein binding sites for the same four proteins with which the corresponding segment of full-length 16S RNA normally interacts. These sites not only include those for S4, S17, and S20 that are known to bind directly to the RNA, but also the site for S16, which requires the prior binding of S4 and S20.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; BRIMACOMBE R, 1985, BIOCHEM J, V229, P1; CORMACK RS, 1991, J BIOL CHEM, V266, P18525; CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P7629, DOI 10.1021/bi00148a026; CUNNINGHAM PR, 1990, RIBOSOME, P243; CUNNINGHAM PR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P18, DOI 10.1016/0167-4781(90)90135-O; DENMAN R, 1989, BIOCHEMISTRY-US, V28, P1002, DOI 10.1021/bi00429a013; DENMAN R, 1989, BIOCHEMISTRY-US, V28, P1012, DOI 10.1021/bi00429a014; DRAPER DE, 1990, RIBOSOME, P160; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HELD WA, 1974, J BIOL CHEM, V249, P3103; HUBBARD JM, 1991, J MOL BIOL, V221, P889, DOI 10.1016/0022-2836(91)80182-T; KRZYZOSIAK WJ, 1988, ANAL BIOCHEM, V175, P373, DOI 10.1016/0003-2697(88)90560-X; MACKIE GA, 1978, J MOL BIOL, V121, P17, DOI 10.1016/0022-2836(78)90260-7; MANDIYAN V, 1991, P NATL ACAD SCI USA, V88, P8174, DOI 10.1073/pnas.88.18.8174; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; NOWOTNY V, 1988, BIOCHEMISTRY-US, V27, P7051, DOI 10.1021/bi00418a057; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1986, J MOL BIOL, V192, P101, DOI 10.1016/0022-2836(86)90467-5; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	28	69	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					177	180		10.1096/fasebj.7.1.7916699	http://dx.doi.org/10.1096/fasebj.7.1.7916699			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7916699				2022-12-28	WOS:A1993KH88000027
